PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chou, FL; Hill, JM; Hsieh, JC; Pouyssegur, J; Brunet, A; Glading, A; Uberall, F; Ramos, JW; Werner, MH; Ginsberg, MH				Chou, FL; Hill, JM; Hsieh, JC; Pouyssegur, J; Brunet, A; Glading, A; Uberall, F; Ramos, JW; Werner, MH; Ginsberg, MH			PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH EFFECTOR DOMAIN; PROTEIN-KINASE-C; CRYSTAL-STRUCTURE; ERK2; IDENTIFICATION; SUBSTRATE; COMMON; P38; PHOSPHOPROTEIN; RECOGNITION	Activation of Raf-1 suppresses integrin activation, potentially through the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2). However, bulk ERK1/2 activation does not correlate with suppression. PEA-15 reverses suppression of integrin activation and binds ERK1/2. Here we report that PEA-15 reversal of integrin suppression depends on its capacity to bind ERK1/2, indicating that ERK1/2 function is indeed required for suppression. Mutations in either the death effector domain or C-terminal tail of PEA-15 that block ERK1/2 binding abrogated the reversal of integrin suppression. Furthermore, we used ERK/p38 chimeras and site-directed mutagenesis to identify ERK1/2 residues required for binding PEA-15. Mutations of residues that precede the alphaG helix and within the mitogen-activated protein kinase insert blocked ERK2 binding to PEA-15, but not activation of ERK2. These ERK2 mutants blocked the ability of PEA-15 to reverse suppression of integrin activation. Thus, PEA-15 regulation of integrin activation depends on its binding to ERK1/2. To directly test the role of ERK1/2 localization in suppression, we enforced membrane association of ERK1 and 2 by joining a membrane-targeting CAAX box sequence to them. Both ERK1-CAAX and ERK2-CAAX were membrane-localized and suppressed integrin activation. In contrast to suppression by membrane-targeted Raf-CAAX, suppression by ERK1/2-CAAX was not reversed by PEA-15. Thus, ERK1/2 are the Raf effectors for suppression of integrin activation, and PEA-15 reverses suppression by binding ERK1/2.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Rutgers State Univ, Nelson Biol Labs, Piscataway, NJ 08854 USA; CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA	Scripps Research Institute; Rockefeller University; Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Innsbruck; Rockefeller University	Werner, MH (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mwerner@portugal.rockefeller.edu; ginsberg@scripps.edu	Hill, Justine M/C-5781-2009; Glading, Angela/AAI-3455-2020; Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115; Glading, Angela/0000-0002-1830-6601	NATIONAL CANCER INSTITUTE [R01CA093849, R56CA093849] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, P01HL057900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060614] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA093849-05, R01 CA093849, CA93849-01] Funding Source: Medline; NHLBI NIH HHS [HL-48728, HL-57900] Funding Source: Medline; NIGMS NIH HHS [GM-60614] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Hughes PE, 2002, MOL BIOL CELL, V13, P2256, DOI 10.1091/mbc.01-10-0480; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1996, J CELL BIOL, V134, P227, DOI 10.1083/jcb.134.1.227; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	36	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52587	52597		10.1074/jbc.M309322200	http://dx.doi.org/10.1074/jbc.M309322200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14506247	hybrid			2022-12-25	WOS:000187480700077
J	Lee, DJ; Busby, SJW; Lloyd, GS				Lee, DJ; Busby, SJW; Lloyd, GS			Exploitation of a chemical nuclease to investigate the location and orientation of the Escherichia coli RNA polymerase alpha subunit C-terminal domains at simple promoters that are activated by cyclic AMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION; DEPENDENT PROMOTERS; CONTACT DOMAIN; MINOR-GROOVE; DNA-BINDING; CAMP-CRP; ELEMENT; COMPLEX; DETERMINANTS; ORGANIZATION	The C-terminal domain of the alpha subunit (alphaCTD) of bacterial RNA polymerase plays an important role in promoter recognition. It is known that alphaCTD binds to the DNA minor groove at different locations at different promoters via a surface-exposed determinant, the 265 determinant. Here we describe experiments that permit us to determine the location and orientation of binding of alphaCTD at any promoter. In these experiments, a DNA cleavage reagent is attached to specific locations on opposite faces of the RNA polymerase alpha subunit. After incorporation of the tagged alpha subunits into holo-RNA polymerase, patterns of DNA cleavage due to the reagent are determined in open complexes. The locations of DNA cleavage due to the reagent attached at different positions allow the position and orientation of alphaCTD to be deduced. Here we present data from experiments with simple Escherichia coli promoters that are activated by the cyclic AMP receptor protein.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Lloyd, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	G.S.Lloyd@bham.ac.uk	Busby, Stephen/C-2712-2015	Busby, Stephen/0000-0003-2148-1758; Lee, David/0000-0003-2395-351X; Lloyd, Georgina/0000-0002-8104-4878				Belyaeva TA, 1996, NUCLEIC ACIDS RES, V24, P2243, DOI 10.1093/nar/24.12.2243; Benoff B, 2002, SCIENCE, V297, P1562, DOI 10.1126/science.1076376; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Boucher PE, 2003, MOL CELL, V11, P163, DOI 10.1016/S1097-2765(03)00007-8; BUCKLE M, 1992, EMBO J, V11, P2619, DOI 10.1002/j.1460-2075.1992.tb05327.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Chen H, 2003, MOL CELL, V11, P1621, DOI 10.1016/S1097-2765(03)00201-6; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Eichenberger P, 1996, BIOCHEMISTRY-US, V35, P15302, DOI 10.1021/bi961377d; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; Gourse RL, 2000, MOL MICROBIOL, V37, P687, DOI 10.1046/j.1365-2958.2000.01972.x; Greiner DP, 1997, BIOCONJUGATE CHEM, V8, P44, DOI 10.1021/bc9600731; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; Jeon YH, 1997, J MOL BIOL, V267, P953, DOI 10.1006/jmbi.1997.0902; Jessee J., 1986, FOCUS, V8, P9; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Law EC, 1999, BIOCHEM J, V337, P415, DOI 10.1042/0264-6021:3370415; Lee DJ, 2000, MOL MICROBIOL, V37, P1032, DOI 10.1046/j.1365-2958.2000.02086.x; Lloyd GS, 2002, GENE DEV, V16, P2557, DOI 10.1101/gad.237502; Murakami K, 1997, P NATL ACAD SCI USA, V94, P11274, DOI 10.1073/pnas.94.21.11274; Murakami K, 1997, P NATL ACAD SCI USA, V94, P1709, DOI 10.1073/pnas.94.5.1709; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Ozoline ON, 2000, J BIOL CHEM, V275, P1119, DOI 10.1074/jbc.275.2.1119; Ozoline ON, 2001, NUCLEIC ACIDS RES, V29, P4909, DOI 10.1093/nar/29.24.4909; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Ross W, 2003, GENE DEV, V17, P1293, DOI 10.1101/gad.1079403; Ross W, 2001, GENE DEV, V15, P491, DOI 10.1101/gad.870001; Savery NJ, 1998, EMBO J, V17, P3439, DOI 10.1093/emboj/17.12.3439; Savery NJ, 2002, J BACTERIOL, V184, P2273, DOI 10.1128/JB.184.8.2273-2280.2002; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Yasuno K, 2001, J MOL BIOL, V306, P213, DOI 10.1006/jmbi.2000.4369	39	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52944	52952		10.1074/jbc.M308300200	http://dx.doi.org/10.1074/jbc.M308300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530288	hybrid			2022-12-25	WOS:000187480700117
J	Zhang, YM; Wu, BN; Zheng, J; Rock, CO				Zhang, YM; Wu, BN; Zheng, J; Rock, CO			Key residues responsible for acyl carrier protein and beta-ketoacyl-acyl carrier protein reductase (FabG) interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; SYNTHASE III FABH; ESCHERICHIA-COLI; MOLECULAR-PROPERTIES; SUBSTRATE-BINDING; SITE; NMR; ASSIGNMENT; DYNAMICS; REVEAL	Fatty acid synthesis in bacteria is catalyzed by a set of individual enzymes collectively known as type II fatty-acid synthase. Each enzyme interacts with acyl carrier protein (ACP), which shuttles the pathway intermediates between the proteins. The type II enzymes do not possess primary sequence similarity that defines a common ACP-binding site, but rather are hypothesized to possess an electropositive/hydrophobic surface feature that interacts with the electronegative/hydrophobic residues along helix alpha2 of ACP (Zhang, Y.-M., Marrakchi, H., White, S. W., and Rock, C. O. (2003) J. Lipid Res. 44, 1-10). We tested this hypothesis by mutating two surface residues, Arg-129 and Arg-172, located in a hydrophobic patch adjacent to the active site entrance on beta-ketoacyl-ACP reductase (FabG). Enzymatic analysis showed that the mutant enzymes were compromised in their ability to utilize ACP thioester substrates but were fully active in assays with a substrate analog. Direct binding assays and competitive inhibition experiments showed that the FabG mutant proteins had reduced affinities for ACP. Chemical shift perturbation protein NMR experiments showed that FabG-ACP interactions occurred along the length of ACP helix alpha2 and extended into the adjacent loop-2 region to involve Ile-54. These data confirm a role for the highly conserved electronegative/hydrophobic residues along ACP helix alpha2 in recognizing a constellation of Arg residues embedded in a hydrophobic patch on the surface of its partner enzymes, and reveal a role for the loop-2 region in the conformational change associated with ACP binding. The specific FabG-ACP interactions involve the most conserved ACP residues, which accounts for the ability of ACPs and the type II proteins from different species to function interchangeably.	St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, Prot Sci Div, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org	wu, bainan/C-2071-2012		NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [R01 GM061739, R01 GM069916, GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069916, R37GM034496, R01GM034496, R01GM061739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beaudet L, 2001, GENOME RES, V11, P600, DOI 10.1101/gr.172501; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CRONAN JE, 1982, J BIOL CHEM, V257, P5013; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; GODDARD TD, 1998, SPARKY 3 0; Gong H, 2003, BIOCHEM BIOPH RES CO, V302, P35, DOI 10.1016/S0006-291X(03)00108-6; Heath R. J., 2002, BIOCH LIPIDS LIPOPRO, P55, DOI DOI 10.1016/S0167-7306(02)36005-8; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; Keatinge-Clay AT, 2003, STRUCTURE, V11, P147, DOI 10.1016/S0969-2126(03)00004-2; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; KIM YM, 1990, BIOCHEM PHARMACOL, V40, P7; KIM YM, 1991, PROTEIN-STRUCT FUNCT, V8, P377; Li Q, 2003, BIOCHEMISTRY-US, V42, P4648, DOI 10.1021/bi0274120; Liu GH, 2002, J BIOMOL NMR, V23, P75, DOI 10.1023/A:1015371216689; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Pellecchia M, 1999, NAT STRUCT BIOL, V6, P336; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; Price AC, 2001, BIOCHEMISTRY-US, V40, P12772, DOI 10.1021/bi010737g; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Rock CO, 2002, BIOCHEM BIOPH RES CO, V292, P1155, DOI 10.1006/bbrc.2001.2022; Roujeinikova A, 2002, STRUCTURE, V10, P825, DOI 10.1016/S0969-2126(02)00775-X; TSAY JT, 1992, J BIOL CHEM, V267, P6807; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Worsham LAS, 2003, BIOCHEMISTRY-US, V42, P167, DOI 10.1021/bi0261950; Xu GY, 2001, STRUCTURE, V9, P277, DOI 10.1016/S0969-2126(01)00586-X; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Zhang YM, 2003, J LIPID RES, V44, P1, DOI 10.1194/jlr.R200016-JLR200; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	42	55	57	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52935	52943		10.1074/jbc.M309874200	http://dx.doi.org/10.1074/jbc.M309874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527946	hybrid			2022-12-25	WOS:000187480700116
J	Hemelaar, J; Lelyveld, VS; Kessler, BM; Ploegh, HL				Hemelaar, J; Lelyveld, VS; Kessler, BM; Ploegh, HL			A single protease, Apg4B, is specific for the autophagy-related ubiquitin-like proteins GATE-16, MAP1-LC3, GABARAP, and Apg8L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED PROTEIN; MEMBRANE-TRANSPORT MODULATOR; GABA(A) RECEPTORS; CRYSTAL-STRUCTURE; GABA(A)-RECEPTOR-ASSOCIATED PROTEIN; DEUBIQUITINATING ENZYME; CONJUGATION SYSTEM; ACTIVATING ENZYME; BINDING; CYTOPLASM	Apg8 is a ubiquitin-like protein involved in autophagy in yeast. Apg8 is covalently but transiently attached to membrane lipids through the actions of activating, conjugating, and processing/deconjugating enzymes. The mammalian Apg8 homologues GATE-16, GARARAP, and MAP1-LC3 have been implicated in intra-Golgi transport, receptor sorting, and autophagy, respectively. All are served by a single set of activating and conjugating enzymes. Here we identify a novel mammalian Apg8 homologue, which we name Apg8L, and describe the synthesis of electrophilic probes based on the GATE-16, GARARAP, MAP1-LC3, and Apg8L proteins. These probes not only form specific adducts in crude cell lysates,but also allow identification of the cellular proteases specific for the C termini of these Apg8 homologues. We find a single protease, Apg4B/autophagin-1, capable of acting on GATE-16, GABARAP, MAP1-LC3, and Apg8L. The Apg4B/autophagin-1 protease thus serves as a processing/deconjugating enzyme for these four highly divergent mammalian Apg8 homologues.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Kessler, Benedikt/AAY-8614-2021	Kessler, Benedikt/0000-0002-8160-2446; /0000-0002-3890-0288; Hemelaar, Joris/0000-0003-3523-7457				Bavro VN, 2002, EMBO REP, V3, P183, DOI 10.1093/embo-reports/kvf026; Becher P, 2002, J VIROL, V76, P13069, DOI 10.1128/JVI.76.24.13069-13076.2002; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; HE H, 2003, J BIOL CHEM, V11, P11; HEMELAAR J, 2003, IN PRESS MOL CELL BI; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; MARINO G, 2002, J BIOL CHEM, V21, P21; Meyers G, 1998, J VIROL, V72, P4139, DOI 10.1128/JVI.72.5.4139-4148.1998; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Scherz-Shouval R, 2003, J BIOL CHEM, V278, P14053, DOI 10.1074/jbc.M212108200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Vernier-Magnin S, 2001, BIOCHEM BIOPH RES CO, V284, P118, DOI 10.1006/bbrc.2001.4908; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; [No title captured]	41	200	211	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51841	51850		10.1074/jbc.M308762200	http://dx.doi.org/10.1074/jbc.M308762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530254	hybrid			2022-12-25	WOS:000187206300120
J	Izaguirre, G; Zhang, WQ; Swanson, R; Bedsted, T; Olson, ST				Izaguirre, G; Zhang, WQ; Swanson, R; Bedsted, T; Olson, ST			Localization of an antithrombin exosite that promotes rapid inhibition of factors Xa and IXa dependent on heparin activation of the serpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; CONFORMATIONAL-CHANGE; BETA-ANTITHROMBIN; BINDING EXOSITE; BASIC RESIDUES; AUTOLYSIS LOOP; HIGH-AFFINITY; THROMBIN; MECHANISM; PENTASACCHARIDE	We have previously shown that exosites in antithrombin outside the P6-P3' reactive loop region become available upon heparin activation to promote rapid inhibition of the target proteases, factor Xa and factor IXa. To identify these exosites, we prepared six antithrombin-alpha(1)-proteinase inhibitor chimeras in which antithrombin residues 224-286 and 310-322 that circumscribe a region surrounding the reactive loop on the inhibitor surface were replaced in 10-16-residue segments with the homologous segments of alpha(1)-proteinase inhibitor. All chimeras bound heparin with a high affinity similar to wild-type, underwent heparin-induced fluorescence changes indicative of normal conformational activation, and were able to form SDS-stable complexes with thrombin, factor Xa, and factor IXa and inhibit these proteases with stoichiometries minimally altered from those of wild-type antithrombin. With only one exception, conformational activation of the chimeras with a heparin pentasaccharide resulted in normal similar to 100-300-fold enhancements in reactivity with factor Xa and factor IXa. The exception was the chimera in which residues 246-258 were replaced, corresponding to strand 3 of beta-sheet C, which showed little or no enhancement of its reactivity with these proteases following pentasaccharide activation. By contrast, all chimeras including the strand 3C chimera showed essentially wild-type reactivities with thrombin after pentasaccharide activation as well as normal full-length heparin enhancements in reactivity with all proteases due to heparin bridging. These findings suggest that antithrombin exosites responsible for enhancing the rates of factor Xa and factor IXa inhibition in the conformationally activated inhibitor lie in strand 3 of beta-sheet C of the serpin.	Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Rm 530E Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.				NHLBI NIH HHS [P01-HL-64013, R01-HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arocas V, 2001, J BIOL CHEM, V276, P43809, DOI 10.1074/jbc.M105294200; Backovic M, 2002, J PROTEOME RES, V1, P367, DOI 10.1021/pr025515z; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; Chen VC, 2000, J BIOL CHEM, V275, P40371, DOI 10.1074/jbc.M005691200; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; ERSDALBADJU E, 1995, BIOCHEM J, V310, P323, DOI 10.1042/bj3100323; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jairajpuri MA, 2003, J BIOL CHEM, V278, P15941, DOI 10.1074/jbc.M212319200; Jairajpuri MA, 2002, J BIOL CHEM, V277, P24460, DOI 10.1074/jbc.M203127200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; McCoy AJ, 2003, J MOL BIOL, V326, P823, DOI 10.1016/S0022-2836(02)01382-7; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PICARD V, 1995, BIOCHEMISTRY-US, V34, P8433, DOI 10.1021/bi00026a026; Pike RN, 1997, J BIOL CHEM, V272, P19652, DOI 10.1074/jbc.272.32.19652; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Yang LK, 2003, J BIOL CHEM, V278, P25032, DOI 10.1074/jbc.M302174200; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51433	51440		10.1074/jbc.M309266200	http://dx.doi.org/10.1074/jbc.M309266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532267	hybrid			2022-12-25	WOS:000187206300072
J	Surks, HK; Richards, CT; Mendelsohn, ME				Surks, HK; Richards, CT; Mendelsohn, ME			Myosin phosphatase-Rho interacting protein - A new member of the myosin phosphatase complex that directly binds RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; SMOOTH-MUSCLE CONTRACTION; CORONARY-ARTERY SPASM; SERINE/THREONINE KINASE; NEOINTIMAL FORMATION; CA2+ SENSITIZATION; PUTATIVE TARGET; PHOSPHORYLATION; SUBUNIT; INHIBITION	Regulation of vascular smooth muscle cell contractile state is critical for the maintenance of blood vessel tone. Abnormal vascular smooth muscle cell contractility plays an important role in the pathogenesis of hypertension, blood vessel spasm, and atherosclerosis. Myosin phosphatase, the key enzyme controlling myosin light chain dephosphorylation, regulates smooth muscle cell contraction. Vasoconstrictor and vasodilator pathways inhibit and activate myosin phosphatase, respectively. G-protein-coupled receptor agonists can inhibit myosin phosphatase and cause smooth muscle cell contraction by activating RhoA/Rho kinase, whereas NO/cGMP can activate myosin phosphatase and cause smooth muscle cell relaxation by activation of cGMP-dependent protein kinase. We have used yeast two-hybrid screening to identify a 116-kDa human protein that interacts with both myosin phosphatase and RhoA. This myosin phosphatase-RhoA interacting protein, or M-RIP, is highly homologous to murine p116(RIP3), is expressed in vascular smooth muscle, and is localized to actin myofilaments. M-RIP binds directly to the myosin binding subunit of myosin phosphatase in vivo in vascular smooth muscle cells by an interaction between coiled-coil and leucine zipper domains in the two proteins. An adjacent domain of M-RIP directly binds RhoA in a nucleotide-independent manner. M-RIP copurifies with RhoA and Rho kinase, colocalizes on actin stress fibers with RhoA and MBS, and is associated with Rho kinase activity in vascular smooth muscle cells. M-RIP can assemble a complex containing both RhoA and MBS, suggesting that M-RIP may play a role in myosin phosphatase regulation by RhoA.	Tufts Univ, New England Med Ctr, Div Cardiol, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Surks, HK (corresponding author), Tufts Univ, New England Med Ctr, Div Cardiol, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	Hsurks@tufts-nemc.org			NHLBI NIH HHS [HL55309] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Araki S, 2001, PFLUG ARCH EUR J PHY, V441, P596, DOI 10.1007/s004240000462; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; DIEKMANN D, 1995, METHOD ENZYMOL, V256, P207; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Eto Y, 2000, AM J PHYSIOL-HEART C, V278, pH1744, DOI 10.1152/ajpheart.2000.278.6.H1744; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GOLDBERG ID, 1979, SCIENCE, V205, P920, DOI 10.1126/science.472713; GONG MC, 1992, J BIOL CHEM, V267, P21492; Harlow E., 1988, ANTIBODIES LAB MANUA; Hartshorne DJ, 1998, ACTA PHYSIOL SCAND, V164, P483; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kandabashi T, 2000, CIRCULATION, V101, P1319, DOI 10.1161/01.CIR.101.11.1319; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; Masumoto A, 2002, CIRCULATION, V105, P1545, DOI 10.1161/hc1002.105938; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Mohri M, 2003, J AM COLL CARDIOL, V41, P15, DOI 10.1016/S0735-1097(02)02632-3; Mulder J, 2003, J BIOL CHEM, V278, P27216, DOI 10.1074/jbc.M302399200; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; SHEPHERD JT, 1985, MAYO CLIN PROC, V60, P33, DOI 10.1016/S0025-6196(12)65280-X; Shibata R, 2001, CIRCULATION, V103, P284; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Somlyo AP, 1998, ACTA PHYSIOL SCAND, V164, P437; STARY HC, 1989, ARTERIOSCLEROSIS, V9, pI19; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752	51	70	76	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51484	51493		10.1074/jbc.M305622200	http://dx.doi.org/10.1074/jbc.M305622200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506264	hybrid			2022-12-25	WOS:000187206300079
J	Baert, F; Bodart, JF; Bocquet-Muchembled, B; Lescuyer-Rousseau, A; Vilain, JP				Baert, F; Bodart, JF; Bocquet-Muchembled, B; Lescuyer-Rousseau, A; Vilain, JP			Xp42(Mpk1) activation is not required for germinal vescicle breakdown but for Raf complete phosphorylation in insulin-stimulated Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B/AKT; MOS MESSENGER-RNA; MEIOTIC MATURATION; MAP KINASE; C-MOS; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOPLASMIC POLYADENYLATION; MOLECULAR-CLONING; SIGNALING PATHWAY; CDC2 ACTIVATION	Fully grown G(2)-arrested Xenopus oocytes resume meiosis in vitro upon exposure to hormonal stimulation. Progesterone triggers oocyte meiosis resumption through a Ras-independent pathway that involves a p39(Mos)-dependent activation of the mitogen-activated protein (MAP) kinases. Insulin also triggers meiosis resumption through a tyrosine kinase receptor that activates a Ras-dependent pathway leading to the MAP kinases activation. Antisense phosphorothioate oligonucleotides were used to prevent p39(Mos) accumulation and Erk-like Xp42(Mpk1) activation during insulin-induced Xenopus oocytes maturation. In contrast to previous works, prevention of p39(Mos)-induced activation of Xp42(Mpk1) in insulin-treated oocytes did not inhibit but delayed meiotic resumption, like in progesterone-stimulated oocytes. Activations of Xp42(Mpk1), the unique Erk of the oocyte, and of its downstream target p90(Rsk), were impaired and phosphorylation of the MAPKK kinase Raf was partially inhibited. Similarly, oocytes treated with the MEK inhibitor U0126, stimulated by insulin exhibited delayed germinal vesicle breakdown, absence of Xp42(Mpk1) activation, and partial phosphorylation of Raf. To summarize, whereas p39(Mos)-induced activation of MEK/MAPK pathway is dispensable for insulin-induced germinal vesicle breakdown, Xp42(Mpk1) activation induced by insulin is dependent upon p39(Mos) synthesis. Raf complete phosphorylation appears to require the MEK/MAPK pathway activation both in progesterone and insulin-stimulated oocytes.	Univ Sci & Technol Lille, Dev Biol Lab, UPRES EA1033, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille	Bodart, JF (corresponding author), Univ Sci & Technol Lille, Dev Biol Lab, UPRES EA1033, Batiment SN3,IFR118, F-59655 Villeneuve Dascq, France.		Bodart, Jean-François Laurent/AAZ-2075-2021; Bocquet, Beatrice/AAY-8447-2020	Bodart, Jean-François Laurent/0000-0002-6113-7700; Bocquet, Beatrice/0000-0002-6369-4818				Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; Andersen CB, 2003, BIOCHEM J, V369, P227, DOI 10.1042/BJ20021243; AZZI L, 1994, J BIOL CHEM, V269, P13279; Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; Barkoff A, 1998, EMBO J, V17, P3168, DOI 10.1093/emboj/17.11.3168; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; Bodart JF, 2002, MOL REPROD DEV, V61, P570, DOI 10.1002/mrd.10112; Bodart JF, 1999, EXP CELL RES, V253, P413, DOI 10.1006/excr.1999.4662; Bodart JFL, 2002, DEV BIOL, V245, P348, DOI 10.1006/dbio.2002.0647; Cailliau K, 2001, BBA-MOL CELL RES, V1538, P228, DOI 10.1016/S0167-4889(01)00074-X; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Chesnel F, 1997, DEV BIOL, V188, P122, DOI 10.1006/dbio.1997.8631; Chie L, 2000, CANCER CHEMOTH PHARM, V45, P441, DOI 10.1007/s002800051017; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 2001, J BIOL CHEM, V276, P46099, DOI 10.1074/jbc.C100496200; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; Hehl S, 2001, BIOCHEM J, V360, P691, DOI 10.1042/0264-6021:3600691; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Howard EL, 1999, MOL CELL BIOL, V19, P1990; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; Lopez-Hernandez E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Peter M, 2002, DEVELOPMENT, V129, P2129; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; Radziwill G, 1996, BIOCHEM BIOPH RES CO, V227, P20, DOI 10.1006/bbrc.1996.1461; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; Shibuya EK, 1996, CELL GROWTH DIFFER, V7, P235; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; TRAVERSE S, 1993, ONCOGENE, V8, P3175; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhu L, 1998, ENDOCRINOLOGY, V139, P949, DOI 10.1210/en.139.3.949	54	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49714	49720		10.1074/jbc.M308067200	http://dx.doi.org/10.1074/jbc.M308067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14507918	hybrid			2022-12-25	WOS:000187068200011
J	Park, MT; Choi, JA; Kim, MJ; Um, HD; Bae, S; Kang, CM; Cho, CK; Kang, SM; Chung, HY; Lee, YS; Lee, SJ				Park, MT; Choi, JA; Kim, MJ; Um, HD; Bae, S; Kang, CM; Cho, CK; Kang, SM; Chung, HY; Lee, YS; Lee, SJ			Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8-and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; PROTEIN-KINASE; SPHINGOSINE 1-PHOSPHATE; CYTOCHROME-C; T-CELLS; ANTAGONIZES APOPTOSIS; BAX TRANSLOCATION; GROWTH-FACTOR; HL-60 CELLS; STRESS	We previously demonstrated that the phytosphingosine-induced apoptosis was accompanied by the concomitant induction of both the caspase- 8- mediated and mitochondrial activation- mediated apoptosis pathways. In the present study, we investigated the role of mitogen-activated protein kinases ( MAPKs) in the activation of these two distinct cell death pathways induced by phytosphingosine in human cancer cells. Phytosphingosine caused strong induction of caspase- 8 activity and caspase- independent Bax translocation to the mitochondria. A rapid decrease of phosphorylated ERK1/ 2 and a marked increase of p38 MAPK phosphorylation were observed within 10 min after phytosphingosine treatment. Activation of ERK1/ 2 by pretreatment with phorbol 12- myristate 13- acetate or forced expression of ERK1/ 2 attenuated phytosphingosine- induced caspase- 8 activation. However, Bax translocation and caspase- 9 activation was unaffected, indicating that down- regulation of the ERK activity is specifically required for the phytosphingosine- induced caspase- 8- dependent cell death pathway. On the other hand, treatment with SB203580, a p38 MAPK- specific inhibitor, or expression of a dominant negative form of p38 MAPK suppressed phytosphingosine- induced translocation of the proapoptotic protein, Bax, from the cytosol to mitochondria, cytochrome c release, and subsequent caspase- 9 activation but did not affect caspase- 8 activation, indicating that activation of p38 MAPK is involved in the mitochondrial activation- mediated cell death pathway. Our results suggest that phytosphingosine can utilize two different MAPK signaling pathways for amplifying the apoptosis cascade, enhancing the understanding of the molecular mechanisms utilized by naturally occurring metabolites to regulate cell death. Molecular dissection of the signaling pathways that activate the apoptotic cell death machinery is critical for both our understanding of cell death events and development of cancer therapeutic agents.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Expt Pathol, Seoul 139706, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea.	sjlee@kcch.re.kr	Um, Hong-Duk/AAH-3733-2021	Chung, Hee Yong/0000-0001-7580-0537				Alessenko A V, 2000, Membr Cell Biol, V13, P303; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Edsall LC, 1997, J NEUROSCI, V17, P6952; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gate L, 2003, BIOCHEM PHARMACOL, V65, P1611, DOI 10.1016/S0006-2952(03)00152-7; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Green DR, 1998, NATURE, V396, P629, DOI 10.1038/25248; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844; Kim JY, 2002, J CELL PHYSIOL, V190, P29, DOI 10.1002/jcp.10049; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kleuser B, 1998, CANCER RES, V58, P1817; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koh YH, 2001, J BIOCHEM-TOKYO, V130, P351, DOI 10.1093/oxfordjournals.jbchem.a002993; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee JS, 2001, FEBS LETT, V499, P82, DOI 10.1016/S0014-5793(01)02527-3; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; LEONIDAS C, 2003, BLOOD, V101, P4667; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Martin DSD, 2002, J BIOL CHEM, V277, P34239, DOI 10.1074/jbc.M205289200; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; OHTA H, 1995, CANCER RES, V55, P691; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Ouwens DM, 2001, BBA-MOL CELL RES, V1540, P97, DOI 10.1016/S0167-4889(01)00126-4; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; Perez GI, 1997, NAT MED, V3, P1228, DOI 10.1038/nm1197-1228; Persons DL, 1999, CLIN CANCER RES, V5, P1007; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakakura C, 1998, BIOCHEM BIOPH RES CO, V246, P827, DOI 10.1006/bbrc.1998.8719; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yan CYI, 1998, J NEUROSCI, V18, P4042; Yoshino T, 2001, EUR J IMMUNOL, V31, P2702, DOI 10.1002/1521-4141(200109)31:9<2702::AID-IMMU2702>3.0.CO;2-8; Zhang JP, 2000, CLIN EXP IMMUNOL, V122, P20, DOI 10.1046/j.1365-2249.2000.01344.x; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	67	103	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50624	50634		10.1074/jbc.M309011200	http://dx.doi.org/10.1074/jbc.M309011200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522966	hybrid			2022-12-25	WOS:000187068200117
J	Sebulsky, MT; Shilton, BH; Speziali, CD; Heinrichs, DE				Sebulsky, MT; Shilton, BH; Speziali, CD; Heinrichs, DE			The role of FhuD2 in iron(III)-hydroxamate transport in Staphylococcus aureus - Demonstration that FhuD2 binds iron(III)-hydroxamates but with minimal conformational change and implication of mutations on transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN FHUD; SYNCHROTRON RADIATION; PERIPLASMIC RECEPTORS; MALTOSE-BINDING; LIGAND-BINDING; SIDEROPHORES; CHEMOTAXIS; SCATTERING; SOFTWARE	The fhuD2 gene encodes a lipoprotein that has previously been shown to be important for the utilization of iron(III)-hydroxamates by Staphylococcus aureus. We have studied the function of the FhuD2 protein in greater detail, and demonstrate here that the protein binds several iron(III)-hydroxamates. Mutagenesis of FhuD2 identified several residues that were important for the ability of the protein to function in iron(III)-hydroxamate transport. Several residues, notably Tyr-191, Trp-197, and Glu-202, were found to be critical for ligand binding. Moreover, mutation of two highly conserved glutamate residues, Glu-97 and Glu-231, had no affect on ligand binding, but did impair iron(III)-hydroxamate transport. Interestingly, the transport defect was not equivalent for all iron(III)-hydroxamates. We modeled FhuD2 against the high resolution structures of Escherichia coli FhuD and BtuF, two structurally related proteins, and showed that the three proteins share a similar overall structure. FhuD2 Glu-97 and Glu-231 were positioned on the surface of the N and C domains, respectively. Characterization of E97A, E231A, or E97A/E231A mutants suggests that these residues, along with the ligand itself, play a cumulative role in recognition by the ABC transporter FhuBGC(2). In addition, small angle x-ray scattering was used to demonstrate that, in solution, FhuD2 does not undergo a detectable change in conformation upon binding iron(III)-hydroxamates. Therefore, the mechanism of binding and transport of ligands for binding proteins within this family is significantly different from that of other well studied binding protein families, such as that represented by maltose-binding protein.	Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Lawson Hlth Res Inst, London, ON N6A 4V2, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Heinrichs, DE (corresponding author), Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada.		Heinrichs, David/ABD-5702-2021; Shilton, Brian H/A-6667-2011	Speziali, Craig/0000-0002-6401-0174; Heinrichs, David/0000-0002-7217-2456	NCRR NIH HHS [RR-08630] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; Clarke TE, 2002, J BIOL CHEM, V277, P13966, DOI 10.1074/jbc.M109385200; Clarke TE, 2002, BIOMETALS, V15, P121, DOI 10.1023/A:1015249530156; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guinier A., 1955, SMALL ANGLE SCATTERI; Hammersley AP, 1996, HIGH PRESSURE RES, V14, P235, DOI 10.1080/08957959608201408; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Karpowich NK, 2003, J BIOL CHEM, V278, P8429, DOI 10.1074/jbc.M212239200; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; KREISWIRTH BN, 1983, NATURE, V305, P680; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Meyer JM, 1997, MICROBIOL-UK, V143, P35, DOI 10.1099/00221287-143-1-35; MILLER DM, 1983, J BIOL CHEM, V258, P3665; PAYNE SM, 1994, METHOD ENZYMOL, V235, P329; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; Sambrook J., 2002, MOL CLONING LAB MANU; Sebulsky MT, 2000, J BACTERIOL, V182, P4394, DOI 10.1128/JB.182.16.4394-4400.2000; Sebulsky MT, 2001, J BACTERIOL, V183, P4994, DOI 10.1128/JB.183.17.4994-5000.2001; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Telmer PG, 2003, J BIOL CHEM, V278, P34555, DOI 10.1074/jbc.M301004200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	32	66	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49890	49900		10.1074/jbc.M305073200	http://dx.doi.org/10.1074/jbc.M305073200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514690	hybrid			2022-12-25	WOS:000187068200031
J	Yaglom, JA; Ekhterae, D; Gabai, VL; Sherman, MY				Yaglom, JA; Ekhterae, D; Gabai, VL; Sherman, MY			Regulation of necrosis of H9c2 myogenic cells upon transient energy deprivation - Rapid deenergization of mitochondria precedes necrosis and is controlled by reactive oxygen species, stress kinase JNK, Hsp72, and ARC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; HEAT-SHOCK-PROTEIN; N-TERMINAL KINASE; PERMEABILITY TRANSITION; CYTOCHROME-C; CYCLOSPORINE-A; APOPTOSIS REPRESSOR; GENE-TRANSFER; REPERFUSION; INHIBITION	Subjecting myogenic H9c2 cells to transient energy deprivation leads to a caspase-independent death with typical features of necrosis. Here we show that the rupture of cytoplasmic membrane, the terminal event in necrosis, is shortly preceded by rapid depolarization of mitochondrial membranes. The rapid deenergization of mitochondria critically depended upon prior generation of reactive oxygen species (ROS) during ATP depletion stage. Accordingly, expression of catalase prevented mitochondrial depolarization and averted subsequent necrosis. Interestingly, trifluoperazine, a compound that protects cells from ischemic insults, prevented necrosis of H9c2 cells through inhibition of ROS production. Other factors that regulated the mitochondrial membrane depolarization and subsequent loss of plasma membrane integrity include a stress kinase JNK activated at early steps of recovery from ATP depletion, as well as an apoptotic inhibitory protein ARC. Accordingly, inhibition of JNK or overexpression of ARC prevented mitochondrial depolarization and rescued H9c2 cells from necrosis. ROS and JNK affected mitochondrial deenergization and necrosis independently of each other since inhibition of ROS production did not prevent activation of JNK, whereas inhibition of JNK did not suppress ROS accumulation. Therefore, JNK activation and ROS production represent two independent pathways that control mitochondrial depolarization and subsequent necrosis of cells subjected to transient energy deprivation. Overexpression of ARC, although preventing mitochondrial depolarization, did not affect either JNK activation or production of ROS. The major heat shock protein Hsp72 inhibited JNK-related steps of necrotic pathway but did not affect ROS accumulation. Interestingly, mitochondrial depolarization and subsequent necrosis can be suppressed by an Hsp72 mutant Hsp72DeltaEEVD, which lacks chaperone function but can efficiently suppress JNK activation. Thus, Hsp72 is directly implicated in a signaling pathway, which leads to necrotic death.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	Boston University; Jefferson University	Gabai, VL (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	gabai@biochem.bumc.bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Yaglom, Julia/0000-0002-8723-3506; Sherman, Michael/0000-0003-3345-073X				Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Ekhterae D, 2003, AM J PHYSIOL-CELL PH, V284, pC1405, DOI 10.1152/ajpcell.00279.2002; Ekhterae D, 1999, CIRC RES, V85, pE70; Elimadi A, 1997, FUNDAM CLIN PHARM, V11, P440, DOI 10.1111/j.1472-8206.1997.tb00206.x; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gabai VL, 2000, J BIOL CHEM, V275, P38088, DOI 10.1074/jbc.M006632200; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; Khan SZ, 2001, CELL SIGNAL, V13, P57, DOI 10.1016/S0898-6568(00)00140-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuroda S, 1997, STROKE, V28, P2539, DOI 10.1161/01.STR.28.12.2539; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Piper HM, 1998, CARDIOVASC RES, V38, P291, DOI 10.1016/S0008-6363(98)00033-9; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; SCHWERTSCHLAG U, 1986, J PHARMACOL EXP THER, V238, P119; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692	50	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50483	50496		10.1074/jbc.M306903200	http://dx.doi.org/10.1074/jbc.M306903200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523009	hybrid			2022-12-25	WOS:000187068200101
J	Choi, JK; Choi, S; Choi, JW; Cha, MK; Kim, IH; Shin, W				Choi, JK; Choi, S; Choi, JW; Cha, MK; Kim, IH; Shin, W			Crystal structure of Escherichia coli thiol peroxidase in the oxidized state - Insights into intramolecular disulfide formation and substrate binding in atypical 2-Cys peroxiredoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; MAMMALIAN PEROXIREDOXIN; HYDROGEN-PEROXIDE; SCAVENGASE P20; ANTIOXIDANT; FAMILY; MECHANISM; MUTATION; REVEALS; PROGRAM	Thioredoxin-dependent thiol peroxidase (Tpx) from Escherichia coli represents a group of antioxidant enzymes that are widely distributed in pathogenic bacterial species and which belong to the peroxiredoxin (Prx) family. Bacterial Tpxs are unique in that the location of the resolving cysteine (C-R) is different from those of other Prxs. E. coli Tpx (EcTpx) shows substrate specificity toward alkyl hydroperoxides over H2O2 and is the most potent reductant of alkyl hydroperoxides surpassing AhpC and BCP, the other E. coli Prx members. Here, we present the crystal structure of EcTpx in the oxidized state determined at 2.2-Angstrom resolution. The structure revealed that Tpxs are the second type of atypical 2-Cys Prxs with an intramolecular disulfide bond formed between the peroxidatic (C-P, Cys(61)) and resolving (Cys(95)) cysteine residues. The extraordinarily long N-terminal chain of EcTpx folds into a beta-hairpin making the overall structure very compact. Modeling suggests that, in atypical 2-Cys Prxs, the C-R-loop as well as the C-P-loop may alternately assume the fully folded or locally unfolded conformation depending on redox states, as does the C-P-loop in typical 2-Cys Prxs. EcTpx exists as a dimer stabilized by hydrogen bonds. Its substrate binding site extends to the dimer interface. A modeled structure of the reduced EcTpx in complex with 15-hydroperoxyeicosatetraenoic acid suggests that the size and shape of the binding site are particularly suited for long fatty acid hydroperoxides consistent with its greater reactivity.	Seoul Natl Univ, Sch Chem, Seoul 151742, South Korea; Seoul Natl Univ, Ctr Mol Catalysis, Seoul 151742, South Korea; Univ Suwon, Dept Chem, Suwon 445743, South Korea; Paichai Univ, Dept Biochem, Natl Creat Res Initiat Ctr Antioxidant Prot, Taejon 302735, South Korea	Seoul National University (SNU); Seoul National University (SNU); Suwon University; Pai Chai University	Shin, W (corresponding author), Seoul Natl Univ, Sch Chem, Seoul 151742, South Korea.	nswcshin@plaza.snu.ac.kr	Kim, Il-Han/W-1401-2019					Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Case D. A., 2002, AMBER 7; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Cho SW, 2001, J MOL BIOL, V311, P863, DOI 10.1006/jmbi.2001.4919; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Choi J, 2003, ACTA CRYSTALLOGR D, V59, P1064, DOI 10.1107/S0907444903006930; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Forman HJ, 1997, OXIDATIVE STRESS SIG; Fujii J, 2002, REDOX REP, V7, P123, DOI 10.1179/135100002125000352; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim SJ, 2003, J BIOL CHEM, V278, P10790, DOI 10.1074/jbc.M209553200; Kong W, 2000, BIOCHEM J, V351, P107, DOI 10.1042/0264-6021:3510107; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhou Y, 1997, BIOCHEM BIOPH RES CO, V233, P848, DOI 10.1006/bbrc.1997.6564	40	55	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49478	49486		10.1074/jbc.M309015200	http://dx.doi.org/10.1074/jbc.M309015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506251	hybrid			2022-12-25	WOS:000186829000116
J	Harvey, KJ; Newport, J				Harvey, KJ; Newport, J			Metazoan origin selection - Origin recognition complex chromatin binding is regulated by Cdc6 recruitment and ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CELL-CYCLE; XENOPUS-LAEVIS; MCM PROTEINS; EGG EXTRACTS; ASSOCIATION; INITIATION; SPECIFICATION; CDK2	Using a plasmid competition assay, we have measured the stability of origin recognition complex (ORC) associated with sperm chromatin under physiological conditions. Under conditions in which pre-RCs are formed, both ORC and CDC6 dissociate from sperm chromatin with a relatively fast t(1/2) of 15 min. ORC dissociation from chromatin is regulated through the recruitment of CDC6 and MCM proteins as well as ATP hydrolysis. The t(1/2) for ORC alone in the absence of Cdc6 is 40 min and increases 8-fold to > 2 h when Cdc6 is present. Strikingly, the presence of a non-hydrolyzable ATP derivative, ATPgammaS, not only increases both ORC and CDC6 t(1/2) but also inhibits the loading of MCM. The very stable association of ORC and Cdc6 with chromatin in this sequence-independent replication system suggests that origin selection in metazoans cannot be strictly dependent on the interaction of ORCs with specific DNA binding sequences.	Univ Calif San Diego, Dept Cell & Dev Biol, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Newport, J (corresponding author), Univ Calif San Diego, Dept Cell & Dev Biol, Div Biol Sci, Bonner Hall 4202,M-C 0349,9500 Gilmann Dr, La Jolla, CA 92093 USA.	jnewport@ucsd.edu		Harvey, Kevin/0000-0002-4479-1575	NIGMS NIH HHS [GM33523, F32GM20633-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033523, F32GM020633, R01GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Frolova NS, 2002, MOL BIOL CELL, V13, P1298, DOI 10.1091/mbc.01-08-0382; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mizushima T, 2000, GENE DEV, V14, P1631; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Rowles A, 1999, J CELL SCI, V112, P2011; Sasaki T, 1999, MOL CELL BIOL, V19, P547; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101	31	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48524	48528		10.1074/jbc.M307661200	http://dx.doi.org/10.1074/jbc.M307661200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506278	hybrid			2022-12-25	WOS:000186829000003
J	Tejero, J; Martinez-Julvez, M; Mayoral, T; Luquita, A; Sanz-Aparicio, J; Hermoso, JA; Hurley, JK; Tollin, G; Gomez-Moreno, C; Medina, M				Tejero, J; Martinez-Julvez, M; Mayoral, T; Luquita, A; Sanz-Aparicio, J; Hermoso, JA; Hurley, JK; Tollin, G; Gomez-Moreno, C; Medina, M			Involvement of the pyrophosphate and the 2 '-phosphate binding regions of ferredoxin-NADP(+) reductase in coenzyme specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER; NADP+ REDUCTASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; COMPLEX-FORMATION; ANABAENA; DEHYDROGENASE; FLAVODOXIN; MECHANISM	Previous studies indicated that the determinants of coenzyme specificity in ferredoxin-NADP(+) reductase (FNR) from Anabaena are situated in the 2'-phosphate (2'-P) NADP(+) binding region, and also suggested that other regions must undergo structural rearrangements of the protein backbone during coenzyme binding. Among the residues involved in such specificity could be those located in regions where interaction with the pyrophosphate group of the coenzyme takes place, namely loops 155 - 160 and 261 - 268 in Anabaena FNR. In order to learn more about the coenzyme specificity determinants, and to better define the structural basis of coenzyme binding, mutations in the pyrophosphate and 2'-P binding regions of FNR have been introduced. Modification of the pyrophosphate binding region, involving residues Thr-155, Ala-160, and Leu-263, indicates that this region is involved in determining coenzyme specificity and that selected alterations of these positions produce FNR enzymes that are able to bind NAD(+). Thus, our results suggest that slightly different structural rearrangements of the backbone chain in the pyrophosphate binding region might determine FNR specificity for the coenzyme. Combined mutations at the 2'-P binding region, involving residues Ser-223, Arg-224, Arg-233, and Tyr-235, in combination with the residues mentioned above in the pyrophosphate binding region have also been carried out in an attempt to increase the FNR affinity for NAD(+)/H. However, in most cases the analyzed mutants lost the ability for NADP(+)/H binding and electron transfer, and no major improvements were observed with regard to the efficiency of the reactions with NAD(+)/H. Therefore, our results confirm that determinants for coenzyme specificity in FNR are also situated in the pyrophosphate binding region and not only in the 2'-P binding region. Such observations also suggest that other regions of the protein, yet to be identified, might also be involved in this process.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; CSIC, Inst Quim Fis Rocasolano, Grp Cristalog Macromol & Biol Estructural, E-28006 Madrid, Spain; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Arizona	Medina, M (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	mmedina@unizar.es	Tejero, Jesus/G-3953-2017; Martinez-Julvez, Marta/G-3839-2017; Hermoso, Juan/J-3433-2012; Sanz-Aparicio, Julia/F-6201-2013; Martinez-Julvez, Marta M/G-5392-2012; Medina, Milagros/F-8310-2012	Tejero, Jesus/0000-0003-3245-9978; Martinez-Julvez, Marta/0000-0001-9047-0046; Hermoso, Juan/0000-0002-1862-8950; Sanz-Aparicio, Julia/0000-0002-6849-8621; Martinez-Julvez, Marta M/0000-0001-9047-0046; Medina, Milagros/0000-0001-8743-0182	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015057] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adak S, 2002, P NATL ACAD SCI USA, V99, P13516, DOI 10.1073/pnas.192283399; Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Carrillo N, 2003, EUR J BIOCHEM, V270, P1900, DOI 10.1046/j.1432-1033.2003.03566.x; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; CHEN RD, 1995, P NATL ACAD SCI USA, V92, P11666, DOI 10.1073/pnas.92.25.11666; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Didierjean C, 1997, J MOL BIOL, V268, P739, DOI 10.1006/jmbi.1997.0998; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; Elmore CL, 2002, J BIOL CHEM, V277, P48960, DOI 10.1074/jbc.M210173200; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; Hermoso JA, 2002, J MOL BIOL, V319, P1133, DOI 10.1016/S0022-2836(02)00388-1; Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; Hurley JK, 2002, BBA-BIOENERGETICS, V1554, P5, DOI 10.1016/S0005-2728(02)00188-3; Hurley JK, 1996, J AM CHEM SOC, V118, P5526, DOI 10.1021/ja953662a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Medina M, 2001, J BIOL CHEM, V276, P11902, DOI 10.1074/jbc.M009287200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Perozich J, 2000, EUR J BIOCHEM, V267, P6197, DOI 10.1046/j.1432-1327.2000.01697.x; Piubelli L, 2000, J BIOL CHEM, V275, P10472, DOI 10.1074/jbc.275.14.10472; PUEYO JJ, 1991, PREP BIOCHEM, V21, P191, DOI 10.1080/10826069108018571; SANCHO J, 1991, ARCH BIOCHEM BIOPHYS, V288, P231, DOI 10.1016/0003-9861(91)90189-P; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; SIMONDSEN RP, 1982, BIOCHEMISTRY-US, V21, P6366, DOI 10.1021/bi00268a008; SIMONDSEN RP, 1983, BIOCHEMISTRY-US, V22, P3008, DOI 10.1021/bi00281a034; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100	34	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49203	49214		10.1074/jbc.M307934200	http://dx.doi.org/10.1074/jbc.M307934200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500716	hybrid			2022-12-25	WOS:000186829000085
J	Figueroa, C; Tarras, S; Taylor, J; Vojtek, AB				Figueroa, C; Tarras, S; Taylor, J; Vojtek, AB			Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; MIXED LINEAGE KINASE-3; CELL-SURVIVAL; SH3 DOMAINS; ACTIVATION; RAF; APOPTOSIS; SCAFFOLD; PHOSPHORYLATION; INHIBITION	We demonstrate that POSH, a scaffold for the JNK signaling pathway, binds to Akt2. A POSH mutant that is unable to bind Akt2 ( POSH W489A) exhibits enhanced-binding to MLK3, and this increase in binding is accompanied by increased activation of the JNK signaling pathway. In addition, we show that the association of MLK3 with POSH is increased upon inhibition of the endogenous phosphatidylinositol 3-kinase/Akt signaling pathway. Thus, the assembly of an active JNK signaling complex by POSH is negatively regulated by Akt2. Further, the level of Akt-phosphorylated MLK3 is reduced in cells expressing the Akt2 binding domain of POSH, which acts as a dominant interfering protein. Taken together, our results support a model in which Akt2 binds to a POSH-MLK-MKK-JNK complex and phosphorylates MLK3; phosphorylation of MLK3 by Akt2 results in the disassembly of the JNK complex bound to POSH and down-regulation of the JNK signaling pathway.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, 3323 MSRB III,Box 0606, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190				Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Ghose R, 2001, NAT STRUCT BIOL, V8, P998, DOI 10.1038/nsb1101-998; Guan KL, 2000, J BIOL CHEM, V275, P27354; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Lambert JM, 2002, J BIOL CHEM, V277, P4770, DOI 10.1074/jbc.M109379200; Mayer BJ, 2001, J CELL SCI, V114, P1253; Okishio N, 2001, BIOCHEMISTRY-US, V40, P119, DOI 10.1021/bi001607v; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	30	59	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47922	47927		10.1074/jbc.M307357200	http://dx.doi.org/10.1074/jbc.M307357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504284	hybrid			2022-12-25	WOS:000186731400070
J	Kadare, G; Toutant, M; Formstecher, E; Corvol, JC; Carnaud, M; Boutterin, MC; Girault, JA				Kadare, G; Toutant, M; Formstecher, E; Corvol, JC; Carnaud, M; Boutterin, MC; Girault, JA			PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SRC-FAMILY KINASES; SUMO-1 MODIFICATION; NUCLEOCYTOPLASMIC TRAFFICKING; DIFFERENTIAL REGULATION; NUCLEAR TRANSLOCATION; GENE ACTIVATION; CELL-MIGRATION; PIAS PROTEINS; P53 ACTIVITY	Focal adhesion kinase (FAK) is a protein tyrosine kinase enriched in focal adhesions, which plays a critical role in integrin-dependent cell motility and survival. The crucial step in its activation is autophosphorylation on Tyr-397, which promotes the recruitment of several enzymes including Src family kinases and the activation of multiple signaling pathways. We found in a yeast two-hybrid screen that the N-terminal domain of FAK interacted with protein inhibitor of activated STAT1 (PIAS1). This interaction was confirmed and shown to be direct using in vitro assays. PIAS1 was co-immunoprecipitated with FAK from transfected cells and brain extracts. PIAS1 has recently been recognized as a small ubiquitin-like modifier ( SUMO) ligase. In the presence of PIAS1 and SUMO-1, FAK was sumoylated in intact cells, whereas PYK2, a closely related enzyme, was not. Sumoylation occurred on Lys-152, a residue conserved in FAK during evolution. Sumoylated FAK, like PIAS1, was recovered predominantly from the nuclear fraction. Sumoylation did not require the catalytic activity or autophosphorylation of FAK. In contrast, sumoylation increased dramatically the ability of FAK to autophosphorylate in intact cells and in immune precipitate kinase assays. Endogenous FAK was sumoylated in the presence of PIAS1 and SUMO-1 independently of cell adhesion, and autophosphorylation of sumoylated FAK was persistently increased in suspended cells. These observations show that sumoylation controls the activity of a protein kinase and suggest that FAK may play a novel role in signaling between the plasma membrane and the nucleus.	Univ Paris 06, INSERM, U536, F-75005 Paris, France; Univ Paris 06, Inst Fer Moulin, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Girault, JA (corresponding author), Univ Paris 06, INSERM, U536, 17 Rue Fer Moulin, F-75005 Paris, France.		Corvol, Jean-Christophe/F-2124-2017; Girault, Jean-Antoine/F-7518-2013; corvol, jean-christophe/I-6387-2012	Corvol, Jean-Christophe/0000-0001-7325-0199; Girault, Jean-Antoine/0000-0002-7900-1705; corvol, jean-christophe/0000-0001-7325-0199; Kadare, Gress/0000-0002-8865-5743; FORMSTECHER, Etienne/0000-0002-6410-4365				Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Aoto H, 2002, CELL STRUCT FUNCT, V27, P47, DOI 10.1247/csf.27.47; Aplin AE, 2003, FEBS LETT, V534, P11, DOI 10.1016/S0014-5793(02)03840-1; Aplin AE, 2001, J CELL BIOL, V155, P187, DOI 10.1083/jcb.200107116; Burgaya F, 1997, J BIOL CHEM, V272, P28720, DOI 10.1074/jbc.272.45.28720; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Farsshori PQ, 2003, J STEROID BIOCHEM, V85, P337, DOI 10.1016/S0960-0760(03)00226-7; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Sieg DJ, 1999, J CELL SCI, V112, P2677; SOBEL A, 1989, J BIOL CHEM, V264, P3765; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; Stewart A, 2002, BIOCHEM BIOPH RES CO, V299, P62, DOI 10.1016/S0006-291X(02)02547-0; Toutant M, 2000, BIOCHEM J, V348, P119, DOI 10.1042/0264-6021:3480119; Toutant M, 2002, MOL CELL BIOL, V22, P7731, DOI 10.1128/MCB.22.22.7731-7743.2002; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; Yi XP, 2003, HYPERTENSION, V41, P1317, DOI 10.1161/01.HYP.0000072772.74183.5F	62	84	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47434	47440		10.1074/jbc.M308562200	http://dx.doi.org/10.1074/jbc.M308562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500712	hybrid			2022-12-25	WOS:000186731400013
J	Takagi, Y; Komori, H; Chang, WH; Hudmon, A; Erdjument-Bromage, H; Tempst, P; Kornberg, RD				Takagi, Y; Komori, H; Chang, WH; Hudmon, A; Erdjument-Bromage, H; Tempst, P; Kornberg, RD			Revised subunit structure of yeast transcription factor IIH (TFIIH) and reconciliation with human TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; CDK-ACTIVATING KINASE; DNA-DEPENDENT ATPASE; SACCHAROMYCES-CEREVISIAE; HELICASE; PROTEIN; COMPLEX; RAD3; GENE	Tfb4 is identified as a subunit of the core complex of yeast RNA polymerase II general transcription factor IIH (TFIIH) by affinity purification, by peptide sequence analysis, and by expression of the entire complex in insect cells. Tfb3, previously identified as a component of the core complex, is shown instead to form a complex with cdk and cyclin subunits of TFIIH. This reassignment of subunits resolves a longstanding discrepancy between yeast and human TFIIH complexes.	Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Sch Med, Stanford, CA 94305 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Stanford University; Stanford University; Memorial Sloan Kettering Cancer Center	Kornberg, RD (corresponding author), Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA.		Chang, Wei-Hau/F-1965-2015	Chang, Wei-Hau/0000-0002-2612-850X; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; Chang WH, 2000, CELL, V102, P609, DOI 10.1016/S0092-8674(00)00083-0; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Feaver WJ, 1999, J BIOL CHEM, V274, P29564, DOI 10.1074/jbc.274.41.29564; FLORES O, 1992, J BIOL CHEM, V267, P2786; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Schultz P, 2000, CELL, V102, P599, DOI 10.1016/S0092-8674(00)00082-9; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0	33	32	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43897	43900		10.1074/jbc.C300417200	http://dx.doi.org/10.1074/jbc.C300417200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	14500720	hybrid			2022-12-25	WOS:000186306700004
J	Bernhard, D; Pfister, G; Huck, CW; Kind, M; Salvenmoser, W; Bonn, GK; Wick, G				Bernhard, D; Pfister, G; Huck, CW; Kind, M; Salvenmoser, W; Bonn, GK; Wick, G			Disruption of vascular endothelial homeostasis by tobacco smoke - impact on atherosclerosis	FASEB JOURNAL			English	Article						smoking; cell death; statin; aging	POLYCYCLIC AROMATIC-HYDROCARBONS; CIGARETTE-SMOKING; APOPTOSIS; CELL; MECHANISMS; NICOTINE; INHIBITION; EXPRESSION; NECROSIS; DISEASE	The World Health Organization (WHO) predicts that by 2020 tobacco will become the largest single health problem worldwide and will cause an estimated 8.4 million deaths annually (http://www5.who.int/tobacco/). Although the impact of smoking on human health is well defined from the medical point of view, surprisingly little is known about the mechanisms by which tobacco smoke mediates its disastrous effects. Here, we demonstrate that tobacco smoke dramatically changes vascular endothelial cell and tissue morphology, leading to a loss of endothelial barrier function within minutes. Long-term exposure of endothelial cells to tobacco smoke extracts induces necrosis that may trigger a pro-inflammatory status of the vessel wall. Pre-incubation of the extracts without cells for 6 h at 37degreesC led to a complete loss of activity. Further, the endothelium could be rescued by changing to fresh medium even at times when the extracts had lost their activity. Finally, we show that N-acetyl cysteine and statins inhibit the adverse tobacco smoke effects.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Leopold Franzens Univ Innsbruck, Inst Analyt Chem & Radiochem, A-6020 Innsbruck, Austria; Leopold Franzens Univ Innsbruck, Inst Zool & Limnol, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck; University of Innsbruck	Bernhard, D (corresponding author), Univ Innsbruck, Inst Pathophysiol, Fritz Pregel Str 3-4OG, A-6020 Innsbruck, Austria.	David.Bernhard@uibk.ac.at		Bernhard, David/0000-0002-2383-6607; Pfister, Gerald/0000-0003-4928-6612; Huck, Christian/0000-0002-6272-3242				Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; American Hospital Association, 2002, HEART DIS STROK STAT, P1; BAKKER S, 2000, CARIOVASC RES, V45, P486; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bernhard D, 2003, CANCER LETT, V195, P193, DOI 10.1016/S0304-3835(03)00157-5; Bialous SA, 2001, TOB CONTROL, V10, P96, DOI 10.1136/tc.10.2.96; DAVIS JW, 1990, ADV EXP MED BIOL, V273, P107; DAWBER TR, 1960, CIRCULATION, V22, P164; DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Hoshino Y, 2001, AM J PHYSIOL-LUNG C, V281, pL509, DOI 10.1152/ajplung.2001.281.2.L509; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Ishii T, 2001, AM J PHYSIOL-LUNG C, V280, pL1189, DOI 10.1152/ajplung.2001.280.6.L1189; Jarvis MJ, 2001, JNCI-J NATL CANCER I, V93, P134, DOI 10.1093/jnci/93.2.134; Jousilahti P, 1996, CIRCULATION, V93, P1372, DOI 10.1161/01.CIR.93.7.1372; Kita T, 2001, ANN NY ACAD SCI, V947, P199; LEHR HA, 1993, ANN NY ACAD SCI, V686, P112, DOI 10.1111/j.1749-6632.1993.tb39163.x; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Milionis HJ, 2001, ANGIOLOGY, V52, P575, DOI 10.1177/000331970105200901; Nagy J, 1997, ENDOTHELIUM-J ENDOTH, V5, P251, DOI 10.3109/10623329709052590; Nathe TJ, 2002, ARTERIOSCL THROM VAS, V22, P1293, DOI 10.1161/01.ATV.0000023428.69244.49; Nia AB, 2002, BIOMARKERS, V7, P209, DOI 10.1080/13547500110120000; NORONHADUTRA AA, 1993, CARDIOVASC RES, V27, P774, DOI 10.1093/cvr/27.5.774; Penn A, 1996, ENVIRON HEALTH PERSP, V104, P1108, DOI 10.2307/3433125; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Shen YM, 1996, AM J PHYSIOL-HEART C, V270, pH1624, DOI 10.1152/ajpheart.1996.270.5.H1624; Stone PCW, 2002, BIOCHEM BIOPH RES CO, V295, P1150, DOI 10.1016/S0006-291X(02)00800-8; Tithof PK, 2002, FASEB J, V16, P1463, DOI 10.1096/fj.02-0092fje; Tithof PK, 2001, AM J PHYSIOL-HEART C, V281, pH1946, DOI 10.1152/ajpheart.2001.281.5.H1946; Vayssier M, 1998, AM J PHYSIOL-LUNG C, V275, pL771, DOI 10.1152/ajplung.1998.275.4.L771; Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293; Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081; Wick G, 2001, TRENDS IMMUNOL, V22, P665, DOI 10.1016/S1471-4906(01)02089-0; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; ZUCCARO P, 1993, J CHROMATOGR-BIOMED, V621, P257, DOI 10.1016/0378-4347(93)80103-B	41	75	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2302	+		10.1096/fj.03-0312fje	http://dx.doi.org/10.1096/fj.03-0312fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525940				2022-12-25	WOS:000186343300003
J	Lavenburg, KR; Ivey, J; Hsu, T; Muise-Helmericks, RC				Lavenburg, KR; Ivey, J; Hsu, T; Muise-Helmericks, RC			Coordinated functions of Akt/PKB and ETS1 in tubule formation	FASEB JOURNAL			English	Article						angiogenesis; Drosophila; tubulogenesis; tracheal development	ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GENETIC-CONTROL; CELL-MIGRATION; AKT; ANGIOGENESIS; PROTEIN; EXPRESSION; PATHWAY	We investigated the inter-relationship between two downstream effectors of vascular endothelial growth factor (VEGF), the serine threonine kinase Akt (also known as protein kinase B) and the transcription factor ETS1, during tubulogenesis. Human endothelial cell culture and the in vivo Drosophila tracheal systems are employed in comparative analysis. We show that VEGF stimulates the expression of ETS1 through a phosphatidylinositol-3-kinase (PI3K)/Akt-dependent pathway in primary endothelial cells. Activation of Akt results in vessel formation in vitro, a process that is blocked by expression of antisense ETS1. The functional relationship between ETS and Akt was then tested in the homologous tubular system in Drosophila. Contrary to expectation, ETS1 and Akt did not form a linear positive regulatory pathway in vivo. Instead, genetic analyses suggest that the Drosophila ETS 1 homologue Pointed is required for cell motility per se while Drosophila Akt (Dakt1) is responsible for organized and restricted cell movement that is essential for tubule formation. Taken together, our results show that ETS1 and Akt control different aspects of cell motility that are integrated in the precise regulation of vascular tubule formation.	Med Univ S Carolina, Lab Canc Genom, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hsu, T (corresponding author), Med Univ S Carolina, Lab Canc Genom, Hollings Canc Ctr, Rm 333,86 Jonathon Lucas St, Charleston, SC 29425 USA.	hsut@musc.edu; musehelm@musc.edu		Hsu, Tien/0000-0003-2308-4297	NCI NIH HHS [P01 CA078582-080005, R01 CA109860, P01 CA078582, R21 CA095888, R01 CA109860-04] Funding Source: Medline; NCRR NIH HHS [P20 RR016434] Funding Source: Medline; NIGMS NIH HHS [R01 GM057843, R01 GM057843-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582, R01CA109860, R21CA095888] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Affolter M, 2000, CURR OPIN CELL BIOL, V12, P731, DOI 10.1016/S0955-0674(00)00160-5; Arias A.M., 1993, DEV DROSOPHILA, P609; Bagni C, 2002, MECH DEVELOP, V117, P265, DOI 10.1016/S0925-4773(02)00176-4; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen ZQ, 1997, CANCER RES, V57, P2013; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jin J, 2001, DEV CELL, V1, P817, DOI 10.1016/S1534-5807(01)00090-9; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUISEHELMERICKS RC, 1995, J BIOL CHEM, V270, P27538, DOI 10.1074/jbc.270.46.27538; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Perrimon N, 1996, GENETICS, V144, P1681; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Ribeiro C, 2002, DEV CELL, V2, P677, DOI 10.1016/S1534-5807(02)00171-5; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Veikkola T, 2000, CANCER RES, V60, P203; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	39	21	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2278	+		10.1096/fj.03-0040fje	http://dx.doi.org/10.1096/fj.03-0040fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525946	Green Accepted			2022-12-25	WOS:000186343300013
J	Ahuja, U; Thony-Meyer, L				Ahuja, U; Thony-Meyer, L			Dynamic features of a heme delivery system for cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; N-OXIDE REDUCTASE; CHAPERONE CCME; MUTATIONAL ANALYSIS; BIOGENESIS; BACTERIA; GENE; PATHWAY; PROTEIN; IDENTIFICATION	In Escherichia coli, heme is delivered to cytochrome c in a process involving eight proteins encoded by the ccmABCDEFGH operon. Heme is transferred to the periplasmic heme chaperone CcmE by CcmC and from there to apocytochrome c. The role of CcmC was investigated by random as well as site-directed mutagenesis. Important amino acids were all located in periplasmic domains of the CcmC protein that has six membrane-spanning helices. Besides the tryptophan-rich motif and two conserved histidines, new residues were identified as functionally important. Mutants G111S and H184Y had a clear defect in CcmC-CcmE interaction, did not transfer heme to CcmE, and lacked c-type cytochromes. Conversely, mutants D47N, R55P, and S176Y were affected neither in interaction with nor in delivery of heme to CcmE but produced less than 10% c-type cytochromes. A strain carrying a CcmCE fusion had a similar phenotype, suggesting that CcmC is important not only for heme transfer to CcmE but also for its delivery to cytochrome c. Co-immunoprecipitation of CcmC with CcmF was not detectable although CcmE co-precipitated individually with CcmC and CcmF. This contradicts the idea of CcmCEF supercomplex formation. Our results favor a model that predicts CcmE to shuttle between CcmC and CcmF for heme delivery.	ETH, Inst Mikrobiol, CH-8092 Zurich, Switzerland	ETH Zurich	Thony-Meyer, L (corresponding author), ETH, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.		Ahuja, Umesh/ABC-2954-2020					BONNEFOY V, 1994, ANTON LEEUW INT J G, V66, P47, DOI 10.1007/BF00871632; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHOE M, 1993, J BACTERIOL, V175, P1165, DOI 10.1128/JB.175.4.1165-1172.1993; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; FABIANEK RA, 1999, THESIS EIDGENOSSISCH; Gaballa A, 1998, MOL MICROBIOL, V30, P547, DOI 10.1046/j.1365-2958.1998.01085.x; Gaballa A, 1996, MOL MICROBIOL, V21, P777, DOI 10.1046/j.1365-2958.1996.391399.x; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Gon S, 2000, J BACTERIOL, V182, P5779, DOI 10.1128/JB.182.20.5779-5786.2000; Greener A., 1994, STRATEGIES, V7, P32; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Miller J. H., 1992, SHORT COURSE BACTERI, P263; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Page MD, 1999, MICROBIOL-UK, V145, P3047, DOI 10.1099/00221287-145-11-3047; Pommier J, 1998, J BIOL CHEM, V273, P16615, DOI 10.1074/jbc.273.26.16615; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Tanapongpipat S, 1998, BIOCHEM J, V334, P355, DOI 10.1042/bj3340355; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1996, EUR J BIOCHEM, V235, P754, DOI 10.1111/j.1432-1033.1996.00754.x; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Viswanathan VK, 2002, INFECT IMMUN, V70, P1842, DOI 10.1128/IAI.70.4.1842-1852.2002; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632	40	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52061	52070		10.1074/jbc.M310077200	http://dx.doi.org/10.1074/jbc.M310077200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532274	hybrid			2022-12-25	WOS:000187480700012
J	Mould, AP; Barton, SJ; Askari, JA; Craig, SE; Humphries, MJ				Mould, AP; Barton, SJ; Askari, JA; Craig, SE; Humphries, MJ			Role of ADMIDAS cation-binding site in ligand recognition by integrin alpha(5)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; A-DOMAIN; EXTRACELLULAR SEGMENT; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; BETA(2) SUBUNIT; ACTIVATION; MECHANISM; SEQUENCE; CA2+	Integrin-ligand interactions are regulated in a complex manner by divalent cations, and multiple cation-binding sites are found in both alpha and beta integrin subunits. A key cation-binding site that lies in the beta subunit A-domain is known as the metal-ion dependent adhesion site (MIDAS). Recent x-ray crystal structures of integrin alpha(V)beta(3) have identified a novel cation binding site in this domain, known as the ADMIDAS (adjacent to MIDAS). The role of this novel site in ligand recognition has yet to be elucidated. Using the interaction between alpha(5)beta(1) and fibronectin as a model system, we show that mutation of residues that form the ADMIDAS site inhibits ligand binding but this effect can be partially rescued by the use of activating monoclonal antibodies. The ADMIDAS mutants had decreased expression of activation epitopes recognized by 12G10, 15/7, and HUTS-4, suggesting that the ADMIDAS is important for stabilizing the active conformation of the integrin. Consistent with this suggestion, the ADMIDAS mutations markedly increased the dissociation rate of the integrin-fibronectin complex. Mutation of the ADMIDAS residues also reduced the allosteric inhibition of Mn2+-supported ligand binding by Ca2+, suggesting that the ADMIDAS is a Ca2+-binding site involved in the inhibition of Mn2+-supported ligand binding. Mutations of the ADMIDAS site also perturbed transduction of a conformational change from the MIDAS through the C-terminal helix region of the betaA domain to the underlying hybrid domain, implying an important role for this site in receptor signaling.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228				BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELGOVA N, 2002, NAT STRUCT BIOL, V9, P282; Brower DL, 1997, P NATL ACAD SCI USA, V94, P9182, DOI 10.1073/pnas.94.17.9182; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Labadia ME, 1998, J IMMUNOL, V161, P836; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; SMITH JW, 1994, J BIOL CHEM, V269, P960; Springer TA, 2000, CELL, V102, P275, DOI 10.1016/S0092-8674(00)00033-7; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200	32	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51622	51629		10.1074/jbc.M306655200	http://dx.doi.org/10.1074/jbc.M306655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532288	hybrid			2022-12-25	WOS:000187206300096
J	Schmalisch, MH; Bachem, S; Stulke, J				Schmalisch, MH; Bachem, S; Stulke, J			Control of the Bacillus subtilis antiterminator protein GlcT by phosphorylation - Elucidation of the phosphorylation chain leading to inactivation of GlcT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SIGNAL-TRANSDUCING PROTEIN; SITE-DIRECTED MUTAGENESIS; SUGAR PHOSPHOTRANSFERASE SYSTEM; RNA-BINDING DOMAIN; ESCHERICHIA-COLI; TRANSCRIPTIONAL ANTITERMINATOR; ENZYME-I; CATALYZED PHOSPHORYLATION; MULTIPLE PHOSPHORYLATION	Bacillus subtilis transports glucose by the phosphotransferase system (PTS). The genes for this system are encoded in the ptsGHI operon, which is induced by glucose and depends on a termination/antitermination mechanism involving a riboswitch and the RNA-binding antitermination protein GlcT. In the absence of glucose, GlcT is inactive, and a terminator is formed in the leader region of the ptsG mRNA. If glucose is present, GlcT can bind to its RNA target and prevent transcription termination. The GlcT protein is composed of three domains, an N-terminal RNA binding domain and two PTS regulation domains, PTS regulation domain (PRD) I and PRD-II. In this work, we demonstrate that GlcT can be phosphorylated by two PTS proteins, HPr and the glucose-specific enzyme II (EIIGlc). HPr-dependent phosphorylation occurs on PRD-II and has a slight stimulatory effect on GlcT activity. In contrast, EIIGlc phosphorylates the PRD-I of GlcT, and this phosphorylation inactivates GlcT. This latter phosphorylation event links the availability of glucose to the expression of the ptsGHI operon via the phosphorylation state of EIIGlc and GlcT. This is the first in vitro demonstration of a direct phosphorylation of an antiterminator of the BglG family by the corresponding PTS permease.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany	University of Erlangen Nuremberg	Stulke, J (corresponding author), Univ Gottingen, Abt Allgemeine Mikrobiol, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.		Stülke, Jörg/AAD-1600-2021	Stulke, Jorg/0000-0001-5881-5390				AmsterChoder O, 1997, J BACTERIOL, V179, P5621, DOI 10.1128/jb.179.17.5621-5624.1997; AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Arnaud M, 1996, J BIOL CHEM, V271, P18966, DOI 10.1074/jbc.271.31.18966; Bachem S, 1998, J BACTERIOL, V180, P5319, DOI 10.1128/JB.180.20.5319-5326.1998; Bachem S, 1997, FEMS MICROBIOL LETT, V156, P233, DOI 10.1016/S0378-1097(97)00430-8; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; Darbon E, 2002, MOL MICROBIOL, V43, P1039, DOI 10.1046/j.1365-2958.2002.02800.x; Faires Niki, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P141; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; GONZYTREBOUL G, 1987, J BACTERIOL, V169, P2287, DOI 10.1128/jb.169.5.2287-2290.1987; Gorke B, 1999, EMBO J, V18, P3370, DOI 10.1093/emboj/18.12.3370; Gorke B, 2001, J MOL BIOL, V308, P131, DOI 10.1006/jmbi.2001.4590; Gosalbes MJ, 2002, MICROBIOL-SGM, V148, P695, DOI 10.1099/00221287-148-3-695; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; Greenberg DB, 2002, RES MICROBIOL, V153, P519, DOI 10.1016/S0923-2508(02)01362-1; Henstra SA, 2000, J BIOL CHEM, V275, P7037, DOI 10.1074/jbc.275.10.7037; Kruger S, 1996, J BACTERIOL, V178, P2637; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; Langbein I, 1999, J MOL BIOL, V293, P795, DOI 10.1006/jmbi.1999.3176; LECOQ D, 1995, J BACTERIOL, V177, P1527, DOI 10.1128/jb.177.6.1527-1535.1995; Lindner C, 2002, J BACTERIOL, V184, P4819, DOI 10.1128/JB.184.17.4819-4828.2002; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; Ludwig H, 2002, MOL MICROBIOL, V45, P543, DOI 10.1046/j.1365-2958.2002.03034.x; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; Monedero V, 2001, EMBO J, V20, P3928, DOI 10.1093/emboj/20.15.3928; Parche S, 1999, EUR J BIOCHEM, V265, P308, DOI 10.1046/j.1432-1327.1999.00727.x; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; Peterkofsky A, 2001, J MOL MICROB BIOTECH, V3, P347; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; Reizer J, 1999, MICROBIOL-UK, V145, P3419, DOI 10.1099/00221287-145-12-3419; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Sambrook J., 2002, MOL CLONING LAB MANU; Schauder S, 1998, J MOL BIOL, V276, P591, DOI 10.1006/jmbi.1997.1544; Schirmer F, 1997, J BACTERIOL, V179, P1329, DOI 10.1128/jb.179.4.1329-1336.1997; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; STULKE J, 1995, J BACTERIOL, V177, P6928; Stulke J, 1998, MOL MICROBIOL, V28, P865, DOI 10.1046/j.1365-2958.1998.00839.x; Stulke J, 1997, MOL MICROBIOL, V25, P65, DOI 10.1046/j.1365-2958.1997.4351797.x; Stulke J, 2000, ANNU REV MICROBIOL, V54, P849, DOI 10.1146/annurev.micro.54.1.849; Tobisch S, 1999, J BACTERIOL, V181, P4995, DOI 10.1128/JB.181.16.4995-5003.1999; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635	55	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51108	51115		10.1074/jbc.M309972200	http://dx.doi.org/10.1074/jbc.M309972200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527945	hybrid			2022-12-25	WOS:000187206300035
J	Chung, SW; Arnott, JA; Yang, YZ; Wong, PMC				Chung, SW; Arnott, JA; Yang, YZ; Wong, PMC			Presence of prepackaged mRNA in virions of DNA adenovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-THERAPY; IN-VIVO; VECTORS; EXPRESSION; RESPONSES; MACROPHAGES; ENTRY; INTERNALIZATION; TRANSCRIPTS; LPS(D)/RAN	Ran GTPase has been shown to be involved in host innate immune response, and two alleles, RanT/ n and RanC/ d, which differ from each other by a single nucleotide, have opposite effects on host innate immune response. In this study, we showed that although intravenous administration in mice with either Ran cDNA using an identical adenovirus ( Ad) vector resulted in no significant difference in vector tissue distribution, intraperitoneal administration resulted in effective vector transduction into peritoneal macrophages, coupled with a striking difference in vector tissue distribution in 2 h or less. We further demonstrated the presence of prepackaged RNA in virions of Ad vectors, in cells actively producing Ad virus particles, and in cells very shortly after Ad infection. Real- time PCR analysis confirmed the presence of prepackaged RNA and estimated the copy number to be one per viral genome. The prepackaged viral mRNA could be used for translation into proteins, as shown by experiments in which the transcriptional inhibitor actinomycin- D was used. Hence, translation of Ran proteins from prepackaged viral mRNA immediately after virus uncoating in the cytoplasm is one mechanism that would account for an early difference in Ad- vector tissue distribution after efficient gene transfer into macrophages.	Temple Univ, Sch Med, Dept Pathol & Lab Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Wong, PMC (corresponding author), 3307 N Broad St,Room 552,AHB, Philadelphia, PA 19140 USA.				NCI NIH HHS [R01-CA70854] Funding Source: Medline; NIAID NIH HHS [R01-AI39159, R01-AI45951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039159, R01AI045951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Brenner M, 1999, BLOOD, V94, P3965, DOI 10.1182/blood.V94.12.3965.424k42_3965_3967; Bresnahan WA, 2000, SCIENCE, V288, P2373, DOI 10.1126/science.288.5475.2373; Cullen BR, 2001, CELL, V105, P697, DOI 10.1016/S0092-8674(01)00392-0; GLENN GM, 1988, VIRUS RES, V9, P73, DOI 10.1016/0168-1702(88)90051-2; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037; Li E, 2001, J VIROL, V75, P5405, DOI 10.1128/JVI.75.11.5405-5409.2001; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Muruve DA, 1999, HUM GENE THER, V10, P965, DOI 10.1089/10430349950018364; Schnell MA, 2001, MOL THER, V3, P708, DOI 10.1006/mthe.2001.0330; St George JA, 2003, GENE THER, V10, P1135, DOI 10.1038/sj.gt.3302071; Sung RS, 2001, MOL THER, V3, P757, DOI 10.1006/mthe.2001.0318; Suomalainen M, 1999, J CELL BIOL, V144, P657, DOI 10.1083/jcb.144.4.657; Thorne PS, 1999, AM J RESP CELL MOL, V20, P1155, DOI 10.1165/ajrcmb.20.6.3632; Whittaker GR, 2000, ANNU REV CELL DEV BI, V16, P627, DOI 10.1146/annurev.cellbio.16.1.627; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wolff G, 1997, J VIROL, V71, P624, DOI 10.1128/JVI.71.1.624-629.1997; Wong PMC, 1999, P NATL ACAD SCI USA, V96, P11543, DOI 10.1073/pnas.96.20.11543; Wong PMC, 2003, J BIOMED SCI, V10, P468, DOI 10.1159/000072374; Wong PMC, 2001, J BIOL CHEM, V276, P33129, DOI 10.1074/jbc.M105400200; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Yuan Q, 2000, P NATL ACAD SCI USA, V97, P2852, DOI 10.1073/pnas.040567797; Zhang Y, 2001, MOL THER, V3, P697, DOI 10.1006/mthe.2001.0329; Zhao FP, 2001, J ENDOTOXIN RES, V7, P53, DOI 10.1179/096805101101532549; Zsengeller Z, 2000, J VIROL, V74, P9655, DOI 10.1128/JVI.74.20.9655-9667.2000	28	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50635	50640		10.1074/jbc.M309945200	http://dx.doi.org/10.1074/jbc.M309945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522982	hybrid			2022-12-25	WOS:000187068200118
J	Fornaro, M; Plescia, J; Chheang, S; Tallini, G; Zhu, YM; King, M; Altieri, DC; Languino, LR				Fornaro, M; Plescia, J; Chheang, S; Tallini, G; Zhu, YM; King, M; Altieri, DC; Languino, LR			Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED APOPTOSIS; CELLULAR-SURVIVAL; EPITHELIAL-CELLS; GENE-EXPRESSION; INTEGRIN; BETA(1C); VARIANTS; AKT	Integrins are cell surface heterodimeric transmembrane receptors that, in addition to mediating cell adhesion to extracellular matrix proteins modulate cell survival. This mechanism may be exploited in cancer where evasion from apoptosis invariably contributes to cellular transformation. The molecular mechanisms responsible for matrix-induced survival signals begin to be elucidated. Here we report that the inhibitor of apoptosis survivin is expressed in vitro in human prostate cell lines with the highest levels present in aggressive prostate cancer cells such as PC3 and LNCaP-LN3 as well as in vivo in prostatic adenocarcinoma. We also show that interference with survivin in PC3 prostate cancer cells using a Cys(84)-->Ala dominant negative mutant or survivin antisense cDNA causes nuclear fragmentation, hypodiploidy, cleavage of a 32-kDa proform caspase-3 to active caspase-3, and proteolysis of the caspase substrate poly( ADP-ribose) polymerase. We demonstrate that in the aggressive PC3 cell line, adhesion to fibronectin via beta(1) integrins results in up-regulation of survivin and protection from apoptosis induced by tumor necrosis factor-alpha (TNF-alpha). In contrast, survivin is not up-regulated by cell adhesion in the non-tumorigenic LNCaP cell line. Dominant negative survivin counteracts the ability of fibronectin to protect cells from undergoing apoptosis, whereas wild-type survivin protects non-adherent cells from TNF-alpha-induced apoptosis. Evidence is provided that expression of beta(1A) integrin is necessary to protect non-adherent cells transduced with survivin from TNF-alpha-induced apoptosis. In contrast, the beta(1C) integrin, which contains a variant cytoplasmic domain, is not able to prevent apoptosis induced by TNF-alpha in non-adherent cells transduced with survivin. Finally, we show that regulation of survivin levels by integrins are mediated by protein kinase B/AKT. These findings indicate that survivin is required to maintain a critical anti-apoptotic threshold in prostate cancer cells and identify integrin signaling as a crucial survival pathway against death receptor-mediated apoptosis.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Yale University	Languino, LR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	lucia.languino@umassmed.edu	Tallini, Giovanni/F-7850-2013	Tallini, Giovanni/0000-0003-0113-6682	NCI NIH HHS [CA90917, R29 CA71870, R01 CA78810, R01 CA89720] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071870, R01CA078810, R01CA089720, R01CA090917] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Astier AL, 2003, BLOOD, V101, P1118, DOI 10.1182/blood-2002-05-1519; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; Fornaro M, 1998, AM J PATHOL, V153, P1079, DOI 10.1016/S0002-9440(10)65652-0; Fornaro M, 1997, MATRIX BIOL, V16, P185, DOI 10.1016/S0945-053X(97)90007-X; Fortugno P, 2002, J CELL SCI, V115, P575; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gewies A, 2000, CANCER RES, V60, P2163; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 2002, CANCER RES, V62, P3093; Hemler ME, 1995, INTEGRINS BIOL PROBL, P1, DOI 10.1201/9780203711644-1; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Keledjian K, 2003, J UROLOGY, V169, P1150, DOI 10.1097/01.ju.0000042453.12079.77; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; McKay TR, 2003, ONCOGENE, V22, P3539, DOI 10.1038/sj.onc.1206417; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; Tamm I, 1998, CANCER RES, V58, P5315; Temme A, 2003, MOL BIOL CELL, V14, P78, DOI 10.1091/mbc.E02-04-0182; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Webber MM, 1997, PROSTATE, V30, P136, DOI 10.1002/(SICI)1097-0045(19970201)30:2<136::AID-PROS9>3.0.CO;2-M; WITKOWSKI CM, 1993, J CANCER RES CLIN, V119, P637, DOI 10.1007/BF01215981; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zheng DQ, 1999, CANCER RES, V59, P1655	57	125	134	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50402	50411		10.1074/jbc.M307627200	http://dx.doi.org/10.1074/jbc.M307627200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523021	hybrid			2022-12-25	WOS:000187068200091
J	Georlette, D; Blaise, V; Dohmen, C; Bouillenne, F; Damien, B; Depiereux, E; Gerday, C; Uversky, VN; Feller, G				Georlette, D; Blaise, V; Dohmen, C; Bouillenne, F; Damien, B; Depiereux, E; Gerday, C; Uversky, VN; Feller, G			Cofactor binding modulates the conformational stabilities and unfolding patterns of NAD(+)-dependent DNA ligases from Escherichia coli and Thermus scotoductus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIALLY FOLDED CONFORMATIONS; BLUNT-END LIGATION; NUCLEOTIDE-SEQUENCE; MOLTEN GLOBULE; ZYMOMONAS-MOBILIS; FLUORESCENCE; PROTEIN; STATE; PURIFICATION; RESIDUES	DNA ligases are important enzymes required for cellular processes such as DNA replication, recombination, and repair. NAD(+)-dependent DNA ligases are essentially restricted to eubacteria, thus constituting an attractive target in the development of novel antibiotics. Although such a project might involve the systematic testing of a vast number of chemical compounds, it can essentially gain from the preliminary deciphering of the conformational stability and structural perturbations associated with the formation of the catalytically active adenylated enzyme. We have, therefore, investigated the adenylation-induced conformational changes in the mesophilic Escherichia coli and thermophilic Thermus scotoductus NAD(+)-DNA ligases, and the resistance of these enzymes to thermal and chemical (guanidine hydrochloride) denaturation. Our results clearly demonstrate that anchoring of the cofactor induces a conformational rearrangement within the active site of both mesophilic and thermophilic enzymes accompanied by their partial compaction. Furthermore, the adenylation of enzymes increases their resistance to thermal and chemical denaturation, establishing a thermodynamic link between cofactor binding and conformational stability enhancement. Finally, guanidine hydrochloride-induced unfolding of NAD(+)-dependent DNA ligases is shown to be a complex process that involves accumulation of at least two equilibrium intermediates, the molten globule and its precursor.	Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium; Univ Liege, Inst Chem B6, Enzymol Lab, B-4000 Liege, Belgium; Univ Liege, Inst Chem B6, Ctr Ingn Prot, B-4000 Liege, Belgium; Fac Univ Notre Dame Paix, Dept Biol, Unite Biol Mol, B-5000 Namur, Belgium; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of Liege; University of Liege; University of Liege; University of Namur; Russian Academy of Sciences; University of California System; University of California Santa Cruz	Feller, G (corresponding author), Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium.	gfeller@ulg.ac.be	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P3819, DOI 10.1021/bi0116700; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; Brandes HK, 1998, ARCH BIOCHEM BIOPHYS, V352, P130, DOI 10.1006/abbi.1998.0580; Brannigan JA, 1999, BBA-PROTEIN STRUCT M, V1432, P413, DOI 10.1016/S0167-4838(99)00122-3; Brotz-Oesterhelt H, 2003, J BIOL CHEM, V278, P39435, DOI 10.1074/jbc.M306479200; BURSTEIN EA, 1976, SERIES BIOPHYSICS, V7; Bushmarina NA, 2001, CHEMBIOCHEM, V2, P813, DOI 10.1002/1439-7633(20011105)2:11<813::AID-CBIC813>3.0.CO;2-W; Candy JM, 1996, BIOCHEM J, V315, P745, DOI 10.1042/bj3150745; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Ciarrocchi G, 1999, ANTIMICROB AGENTS CH, V43, P2766, DOI 10.1128/AAC.43.11.2766; D'Auria S, 1999, BIOCHEM BIOPH RES CO, V263, P550, DOI 10.1006/bbrc.1999.1330; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Favilla R, 2002, BBA-PROTEIN STRUCT M, V1597, P42, DOI 10.1016/S0167-4838(02)00278-9; Georlette D, 2003, J BIOL CHEM, V278, P37015, DOI 10.1074/jbc.M305142200; Georlette D, 2000, EUR J BIOCHEM, V267, P3502, DOI 10.1046/j.1432-1327.2000.01377.x; Goenka S, 2001, BIOCHEM J, V359, P547, DOI 10.1042/0264-6021:3590547; Goldberg, 1995, Fold Des, V1, P21; Gupta GS, 1997, INDIAN J BIOCHEM BIO, V34, P307; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; Kaczorowski T, 1996, GENE, V179, P189, DOI 10.1016/S0378-1119(96)00324-1; KUBE D, 1987, Biokhimiya, V52, P179; Kuznetsova IM, 2002, BBA-PROTEIN STRUCT M, V1596, P138, DOI 10.1016/S0167-4838(02)00212-1; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Martin IV, 2002, GENOME BIOL, V3; MAYR LM, 1993, BIOCHEMISTRY-US, V32, P7994, DOI 10.1021/bi00082a021; MODRICH P, 1973, J BIOL CHEM, V248, P7495; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P779, DOI 10.1111/j.1432-1033.1995.0779m.x; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; Murataliev MB, 2000, BIOCHEMISTRY-US, V39, P12699, DOI 10.1021/bi001068u; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Pace C N, 1986, Methods Enzymol, V131, P266; PANASENKO SM, 1978, J BIOL CHEM, V253, P4590; PERMYAKOV EA, 1980, EUR J BIOCHEM, V109, P307, DOI 10.1111/j.1432-1033.1980.tb04796.x; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHEPHERD GB, 1976, BIOCHEMISTRY-US, V15, P311, DOI 10.1021/bi00647a011; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sinha KM, 1999, BIOCHEM J, V339, P667, DOI 10.1042/0264-6021:3390667; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; TAKAHASHI M, 1986, J BIOCHEM-TOKYO, V100, P123, DOI 10.1093/oxfordjournals.jbchem.a121684; Tang CK, 2001, ARCH BIOCHEM BIOPHYS, V392, P110, DOI 10.1006/abbi.2001.2396; THORBJARNARDOTTIR SH, 1995, GENE, V161, P1, DOI 10.1016/0378-1119(95)00286-F; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2003, J PHARM SCI, V92, P847, DOI 10.1002/jps.10355; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; Uversky VN, 2002, FEBS LETT, V514, P181, DOI 10.1016/S0014-5793(02)02359-1; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; Uversky VN, 1997, PROTEIN PEPTIDE LETT, V4, P355; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; Vassilenko KS, 2002, BBA-PROTEIN STRUCT M, V1594, P168, DOI 10.1016/S0167-4838(01)00303-X; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x; Zhang YL, 1996, BBA-PROTEIN STRUCT M, V1295, P239, DOI 10.1016/0167-4838(96)00044-1; ZIMMERMAN SB, 1983, P NATL ACAD SCI-BIOL, V80, P5852, DOI 10.1073/pnas.80.19.5852	65	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49945	49953		10.1074/jbc.M307761200	http://dx.doi.org/10.1074/jbc.M307761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523019	hybrid, Green Published			2022-12-25	WOS:000187068200037
J	Iavarone, C; Catania, A; Marinissen, MJ; Visconti, R; Acunzo, M; Tarantino, C; Carlomagno, MS; Bruni, CB; Gutkind, JS; Chiariello, M				Iavarone, C; Catania, A; Marinissen, MJ; Visconti, R; Acunzo, M; Tarantino, C; Carlomagno, MS; Bruni, CB; Gutkind, JS; Chiariello, M			The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; JUN NH2-TERMINAL KINASE; KAPPA-B; CELLULAR-TRANSFORMATION; TRANSCRIPTION; JNK; SURVIVAL; PDGF; GENE	Pro-inflammatory cytokines, environmental stresses, as well as receptor tyrosine kinases regulate the activity of JNK. In turn, JNK phosphorylates Jun members of the AP-1 family of transcription factors, thereby controlling processes as different as cell growth, differentiation, and apoptosis. Still, very few targets of the JNK-Jun pathway have been identified. Here we show that JNK is required for the induction of c-myc expression by PDGF. Furthermore, we identify a phylogenetically conserved AP-1-responsive element in the promoter of the c-myc proto-oncogene that recruits in vivo the c-Jun and JunD AP-1 family members and controls the PDGF-dependent transactivation of the c-myc promoter. These findings suggest the existence of a novel biochemical route linking tyrosine kinase receptors, such as those for PDGF, and c-myc expression through JNK activation of AP-1 transcription factors. They also provide a novel potential mechanism by which both JNK and Jun proteins may exert either their proliferative or apoptotic potential by stimulating the expression of the c-myc proto-oncogene.	CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Chiariello, M (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	chiariel@unina.it	Gutkind, J. Silvio/J-1201-2016; Visconti, Roberta/C-5299-2009; Chiariello, Mario/O-3642-2014; Acunzo, Mario/ABE-1739-2020; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Chiariello, Mario/0000-0001-8434-5177; Tarantino, Carolina/0000-0003-2470-3803; Acunzo, Mario/0000-0002-3942-9061; Visconti, Roberta/0000-0001-7613-3801	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Chiariello M, 2002, METHOD ENZYMOL, V345, P437; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WONG KK, 1995, MOL CELL BIOL, V15, P6535	37	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50024	50030		10.1074/jbc.M308617200	http://dx.doi.org/10.1074/jbc.M308617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523011	hybrid			2022-12-25	WOS:000187068200045
J	Kozaki, T; Matsui, Y; Gu, JG; Nishiuchi, R; Sugiura, N; Kimata, K; Ozono, K; Yoshikawa, H; Sekiguchi, K				Kozaki, T; Matsui, Y; Gu, JG; Nishiuchi, R; Sugiura, N; Kimata, K; Ozono, K; Yoshikawa, H; Sekiguchi, K			Recombinant expression and characterization of a novel fibronectin isoform expressed in cartilaginous tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; SPLICED EDA SEGMENT; CELL-BINDING DOMAIN; CHONDROITIN SULFATE; PLASMA FIBRONECTIN; MAMMALIAN-CELLS; MATRIX; ADHESION; INTEGRIN; IDENTIFICATION	A novel fibronectin ( FN) isoform lacking the segment from IIICS ( type III connecting segment) through the I- 10 module is expressed predominantly in normal cartilaginous tissues. We expressed and purified recombinant cartilage- type FN using a mammalian expression system and characterized its molecular and biological properties. Although FNs have been shown to be secreted as disulfide- bonded dimers, cartilage- type FN was secreted mainly as a monomer. It was less potent than plasma- type FN in promoting cell adhesion and binding to integrin alpha(5)beta(1), although it was more active than plasma- type FN in binding to chondroitin sulfate E. When added exogenously, cartilage- type FN was poorly assembled into the fibrillar FN matrix, mostly because of its monomeric structure. Given that cartilage is characterized by its non- fibrillar matrix with abundant chondroitin sulfate- containing proteoglycans, it is likely that cartilage- type FN has evolved to adapt itself to the non- fibrillar structure of the cartilage matrix through acquisition of a novel mechanism of alternative pre- mRNA splicing.	Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Orthoped Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan	Osaka University; Osaka University; Osaka University; Aichi Medical University; Seikagaku Corporation	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Gu, Jianguo/ABC-9257-2020					AOTA S, 1991, J BIOL CHEM, V266, P15938; BARKALOW FJ, 1994, J BIOL CHEM, V269, P3957; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Burton-Wurster N, 1999, BIOCHEM J, V341, P555, DOI 10.1042/0264-6021:3410555; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen H, 2002, J BIOL CHEM, V277, P20095, DOI 10.1074/jbc.M201238200; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Fukuda T, 2002, CANCER RES, V62, P5603; Gendelman R, 2003, J BIOL CHEM, V278, P11175, DOI 10.1074/jbc.M211799200; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1992, FEBS LETT, V299, P155, DOI 10.1016/0014-5793(92)80236-A; ICHIHARATANAKA K, 1995, J CELL SCI, V108, P907; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; KATAYAMA M, 1989, EXP CELL RES, V185, P229, DOI 10.1016/0014-4827(89)90051-7; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200; MacLeod JN, 1996, J BIOL CHEM, V271, P18954, DOI 10.1074/jbc.271.31.18954; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; Matsui Y, 2001, ANTICANCER RES, V21, P1103; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P4359; SOTTILE J, 1993, BIOCHEMISTRY-US, V32, P1641, DOI 10.1021/bi00057a031; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOLFF C, 1989, ARCH BIOCHEM BIOPHYS, V268, P536, DOI 10.1016/0003-9861(89)90320-2; WOLFF CE, 1990, BIOCHEMISTRY-US, V29, P3354, DOI 10.1021/bi00465a030; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	41	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50546	50553		10.1074/jbc.M307432200	http://dx.doi.org/10.1074/jbc.M307432200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525997	Green Published, hybrid			2022-12-25	WOS:000187068200108
J	Matos, P; Collard, JG; Jordan, P				Matos, P; Collard, JG; Jordan, P			Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; FACTOR-KAPPA-B; EPITHELIAL-CELLS; CDC42 GTPASES; MDCK CELLS; ACTIVATION; PROTEINS; COMPLEX; BINDING; GTP	Rac1 is a member of the Rho family of small GTPases, which control signaling pathways that regulate actin cytoskeletal dynamics and gene transcription. Rac1 is activated by guanine nucleotide exchange factors and inactivated by GTPase-activating proteins. In addition, Rho-GDP dissociation inhibitors (Rho-GDIs) can inhibit Rac1 by sequestering it in the cytoplasm. We have found previously that colorectal tumors express an alternatively spliced variant, Rac1b, containing 19 additional amino acids following the switch II region. Here we characterized the regulation and downstream signaling of Rac1b. Although little Rac1b protein is expressed in cells, the amount of activated Rac1b protein often exceeds that of activated Rac1, suggesting that Rac1b contributes significantly to the downstream signaling of Rac in cells. The regulation of both Rac1 and Rac1b activities is dependent on guanine nucleotide exchange factors and GTPase-activating proteins, but the difference in their activation is mainly determined by the inability of Rac1b to interact with Rho-GDI. As a consequence, most Rac1b remains bound to the plasma membrane and is not sequestered by Rho-GDI in the cytoplasm. Unlike Rac1, activated Rac1b is unable to induce lamellipodia formation and is unable to bind and activate p21-activated protein kinase nor activate the downstream protein kinase JNK. However, both Rac1 and Rac1b are able to activate NFkappaB to the same extent. These data suggest that alternative splicing of Rac1 leads to a highly active Rac variant that differs in regulation and downstream signaling.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	Instituto Nacional de Saude Dr. Ricardo Jorge; Netherlands Cancer Institute	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Ave Padre Cruz, P-1649016 Lisbon, Portugal.		Jordan, Peter/G-9335-2012; Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019	Jordan, Peter/0000-0002-1425-9211; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696				Akhtar N, 2000, CELL ADHES COMMUN, V7, P465, DOI 10.3109/15419060009040304; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gildea JJ, 2002, CANCER RES, V62, P6418; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matos P, 2000, BIOCHEM BIOPH RES CO, V277, P741, DOI 10.1006/bbrc.2000.3743; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Rihet S, 2001, J CANCER RES CLIN, V127, P733; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	48	100	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50442	50448		10.1074/jbc.M308215200	http://dx.doi.org/10.1074/jbc.M308215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506233	hybrid			2022-12-25	WOS:000187068200096
J	McCulloch, SD; Gu, LY; Li, GM				McCulloch, SD; Gu, LY; Li, GM			Nick-dependent and -independent processing of large DNA loops in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERODUPLEX PLASMID DNA; WERNER-SYNDROME PROTEIN; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; NUCLEAR EXTRACTS; RECOMBINATION; TRANSFORMATION; INSTABILITY; SPECIFICITY	DNA loop heterologies are products of normal DNA metabolism and can lead to severe genomic instability if unrepaired. To understand how human cells process DNA loop structures, a set of circular heteroduplexes containing a 30-nucleotide loop were constructed and tested for repair in vitro by human cell nuclear extracts. We demonstrate here that, in addition to the previously identified 5' nick-directed loop repair pathway (Littman, S. J., Fang, W. H., and Modrich, P. (1999) J. Biol. Chem. 274, 7474-7481), human cells can process large DNA loop heterologies in a loop-directed manner. The loop-directed repair specifically removes the loop structure and occurs only in the looped strand, and appears to require limited DNA synthesis. Like the nick-directed loop repair, the loop-directed repair is independent of many known DNA repair pathways, including DNA mismatch repair and nucleotide excision repair. In addition, our data also suggest that an aphidicolin- sensitive DNA polymerase is involved in the excision step of the nick-directed loop repair pathway.	Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Li, GM (corresponding author), Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lucille P Markey Canc Ctr, 800 Rose St, Lexington, KY 40536 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R29CA072956, R01CA085377] Funding Source: NIH RePORTER; NCI NIH HHS [CA72956, CA85377] Funding Source: Medline; NIEHS NIH HHS [ES-07266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; Bill CA, 2001, MUTAT RES-DNA REPAIR, V485, P255, DOI 10.1016/S0921-8777(01)00065-9; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; Corrette-Bennett SE, 2001, NUCLEIC ACIDS RES, V29, P4134, DOI 10.1093/nar/29.20.4134; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Kearney HM, 2001, GENETICS, V158, P1457; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kornberg A., 1992, DNA REPLICATION; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; Loeb LA, 2001, CANCER RES, V61, P3230; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; McCulloch SD, 2003, J BIOL CHEM, V278, P3891, DOI 10.1074/jbc.M210687200; MEYER TF, 1979, J BIOL CHEM, V254, P2642; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU SS, 1988, J BIOL CHEM, V263, P6829; Taghian DG, 1998, GENETICS, V148, P1257; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	31	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50803	50809		10.1074/jbc.M309025200	http://dx.doi.org/10.1074/jbc.M309025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522965	hybrid			2022-12-25	WOS:000187068200136
J	Miller, BM; Nyitrai, M; Bernstein, SI; Geeves, MA				Miller, BM; Nyitrai, M; Bernstein, SI; Geeves, MA			Kinetic analysis of Drosophila muscle myosin isoforms suggests a novel mode of mechanochemical coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNLOADED SHORTENING VELOCITY; HEAVY-CHAIN; SMOOTH-MUSCLE; ADP RELEASE; MOTOR DOMAIN; ACTOMYOSIN SUBFRAGMENT-1; MICROGRAM QUANTITIES; FUNCTIONAL DOMAINS; ALTERNATIVE EXONS; SLIDING VELOCITY	The molecular mechanism of myosin function was addressed by measuring transient kinetic parameters of naturally occurring and chimeric Drosophila muscle myosin isoforms. We assessed the native embryonic isoform, the native indirect flight muscle isoform, and two chimeric isoforms containing converter domains exchanged between the indirect flight muscle and embryonic isoforms. Myosin was purified from the indirect flight muscles of transgenic flies, and S1 was produced by alpha-chymotryptic digestion. Previous studies in vertebrate and scallop myosins have shown a correlation between actin filament velocity in motility assays and cross-bridge detachment rate, specifically the rate of ADP release. In contrast, our study showed no correlation between the detachment rate and actin filament velocity in Drosophila myosin isoforms and further that the converter domain does not significantly influence the biochemical kinetics governing the detachment of myosin from actin. We suggest that evolutionary pressure on a single muscle myosin gene may maintain a fast detachment rate in all isoforms. As a result, the attachment rate and completion of the power stroke or the equilibrium between actin . myosin . ADP states may define actin filament velocity for these myosin isoforms.	Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; Univ Pecs, Fac Med, Dept Biophys,Res Grp Fluorescence Spect, Off Acad Res Grp, H-7601 Pecs, Hungary	University of Kent; California State University System; San Diego State University; California State University System; San Diego State University; University of Pecs	Geeves, MA (corresponding author), Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England.	m.a.geeves@ukc.ac.uk	Geeves, Michael/F-7583-2011	Geeves, Michael/0000-0002-9364-8898; Bernstein, Sanford/0000-0001-7094-5390; Nyitrai, Miklos/0000-0002-6229-4337	FIC NIH HHS [3 T37 TW000067] Funding Source: Medline; NIGMS NIH HHS [GM32443] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032443] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker JE, 2002, BIOPHYS J, V82, P2134, DOI 10.1016/S0006-3495(02)75560-4; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Clark RJ, 2003, J MUSCLE RES CELL M, V24, P315; COLLIER VL, 1990, GENE DEV, V4, P885, DOI 10.1101/gad.4.6.885; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Conibear PB, 1999, J MUSCLE RES CELL M, V20, P727, DOI 10.1023/A:1005696017544; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Josephson RK, 2000, J EXP BIOL, V203, P2713; KRONERT WA, 1991, EMBO J, V10, P2479, DOI 10.1002/j.1460-2075.1991.tb07787.x; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; Littlefield KP, 2003, AM J PHYSIOL-CELL PH, V284, pC1031, DOI 10.1152/ajpcell.00474.2002; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; Maughan D, 1998, ADV EXP MED BIOL, V453, P471; NORBY JG, 1971, ACTA CHEM SCAND, V25, P2717, DOI 10.3891/acta.chem.scand.25-2717; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; Pereira JS, 2001, J BIOL CHEM, V276, P4409, DOI 10.1074/jbc.M006441200; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SILVA R, IN PRESS J MUSCLE RE; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Swank DM, 2000, MICROSC RES TECHNIQ, V50, P430, DOI 10.1002/1097-0029(20000915)50:6<430::AID-JEMT2>3.0.CO;2-E; Swank DM, 2002, NAT CELL BIOL, V4, P312, DOI 10.1038/ncb776; Swank DM, 2001, J BIOL CHEM, V276, P15117, DOI 10.1074/jbc.M008379200; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Thedinga E, 1999, J MUSCLE RES CELL M, V20, P785, DOI 10.1023/A:1005658825375; Tyska MJ, 2002, CELL MOTIL CYTOSKEL, V51, P1, DOI 10.1002/cm.10014; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Webb MR, 2001, BIOPHYS J, V81, P1562, DOI 10.1016/S0006-3495(01)75810-9; Weiss S, 2000, J MUSCLE RES CELL M, V21, P423, DOI 10.1023/A:1005690106951; Weiss S, 2001, J BIOL CHEM, V276, P45902, DOI 10.1074/jbc.M107434200; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x; WEST JJ, 1967, BIOCHEM BIOPH RES CO, V29, P611, DOI 10.1016/0006-291X(67)90530-X; WHITE DCS, 1986, J MUSCLE RES CELL M, V7, P179, DOI 10.1007/BF01753419; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Zhang SX, 2001, MECH DEVELOP, V101, P35, DOI 10.1016/S0925-4773(00)00549-9	49	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50293	50300		10.1074/jbc.M308318200	http://dx.doi.org/10.1074/jbc.M308318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506231	hybrid			2022-12-25	WOS:000187068200077
J	Thomas, G; Moffatt, P; Salois, P; Gaumond, MH; Gingras, R; Godin, E; Miao, DS; Goltzman, D; Lanctot, C				Thomas, G; Moffatt, P; Salois, P; Gaumond, MH; Gingras, R; Godin, E; Miao, DS; Goltzman, D; Lanctot, C			Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PARATHYROID-HORMONE; VITAMIN-D; TRANSGENIC MICE; OSTEOCLAST DIFFERENTIATION; PROGRESSIVE DEVELOPMENT; PROHORMONE CONVERTASE; PRECURSOR PROTEINS; OSTEOCALCIN GENE; LONG-BONE	Although a number of secreted factors have been demonstrated to be bone regulators, none of these are unique to bone. Using a viral- based signal- trap strategy we have identified a novel gene we have termed " osteocrin." A 1280- bp mRNA encodes osteocrin producing a mature protein of 103 amino acids with a molecular mass of 11.4 kDa. Osteocrin shows no homology with any known gene except for two conserved sequence motifs reminiscent of dibasic cleavage sites found in peptide hormone precursors. Immunofluorescence and Western blot analysis confirmed the secretory nature of osteocrin. Two protein species were identified in the medium of cells overexpressing osteocrin, a full- length 11.4 kDa species and a processed similar to 5 kDa species. Mutation of the (KKKR79)-K-76 dibasic cleavage site abolished the appearance of this smaller osteocrin fragment. By in situ hybridization in mouse embryos, osteocrin was expressed specifically in Cbfa- 1- positive, osteocalcin- negative osteoblasts. Immunohistochemistry on adult mouse bone showed osteocrin localization in osteoblasts and young osteocytes. By Northern blot analysis, osteocrin expression was only detected in bone, expression peaking just after birth and decreasing markedly with age. In primary osteoblastic cell cultures osteocrin expression coincided with matrix formation then decreased in very mature cultures. Treatment of cultures with 1,25- dihydroxyvitamin D-3 resulted in a rapid dose- dependent down- regulation of osteocrin expression, suggesting direct regulation. Chronic treatment of primary cultures with osteocrin- conditioned media inhibited mineralization and reduced osteocalcin and alkaline phosphatase expression. These results suggest that osteocrin represents a novel, unique vitamin D- regulated bone- specific protein that appears to act as a soluble osteoblast regulator.	Phenogene Therapeut Inc, Montreal, PQ H3A 1L2, Canada; McGill Univ, Ctr Hlth, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada	McGill University	Thomas, G (corresponding author), Phenogene Therapeut Inc, 416 Maisonneuve W,Suite 1020, Montreal, PQ H3A 1L2, Canada.	gthomas@phenogene.com	Thomas, Gethin P/A-3624-2011	Moffatt, Pierre/0000-0002-5793-1944; Lanctot, Christian/0000-0003-3211-3061; Thomas, Gethin/0000-0001-9081-3686; Miao, Dengshun/0000-0002-2682-3502				Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200; Amling M, 2001, ADV EXP MED BIOL, V496, P85; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Baron Roland, 1993, P3; Boardman PE, 2002, CURR BIOL, V12, P1965, DOI 10.1016/S0960-9822(02)01296-4; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BRADBURY AF, 1987, BIOSCIENCE REP, V7, P907, DOI 10.1007/BF01122123; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Creemers JWM, 1998, SEMIN CELL DEV BIOL, V9, P3, DOI 10.1006/scdb.1997.0195; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Everts V, 1999, FASEB J, V13, P1219, DOI 10.1096/fasebj.13.10.1219; Feldman D, 1999, AM J MED, V107, P637, DOI 10.1016/S0002-9343(99)00283-1; Frenkel B, 1997, ENDOCRINOLOGY, V138, P2109, DOI 10.1210/en.138.5.2109; Frost HM, 2000, J BONE MINER METAB, V18, P305, DOI 10.1007/s007740070001; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201, DOI 10.1177/10454411980090020401; HARRIS RB, 1989, ARCH BIOCHEM BIOPHYS, V275, P315, DOI 10.1016/0003-9861(89)90379-2; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Karaplis A C, 2000, Rev Endocr Metab Disord, V1, P331, DOI 10.1023/A:1026526703898; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; Kobayashi Y, 1998, CALCIFIED TISSUE INT, V62, P426, DOI 10.1007/s002239900455; Kodaira K, 1999, GENE, V230, P121, DOI 10.1016/S0378-1119(99)00025-6; Lanctot C, 1997, DEVELOPMENT, V124, P2807; LEE AV, 1994, MOL CELL ENDOCRINOL, V99, P211, DOI 10.1016/0303-7207(94)90010-8; LIAN JB, 1978, FED PROC, V37, P2615; LIANG CT, 1992, BONE, V13, P435, DOI 10.1016/8756-3282(92)90087-D; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; LIU B, 1995, AM J PHYSIOL-ENDOC M, V268, pE832, DOI 10.1152/ajpendo.1995.268.5.E832; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MACDONALD BR, 1993, BAILLIERE CLIN RHEUM, V7, P421, DOI 10.1016/S0950-3579(05)80071-8; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; MARUYAMA K, 1994, GENE, V138, P171; McCarthy TL, 2000, CRIT REV ORAL BIOL M, V11, P409, DOI 10.1177/10454411000110040201; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756-3282(00)00346-X; Meyer RA, 2000, CALCIFIED TISSUE INT, V66, P282, DOI 10.1007/s002230010057; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Moffatt P, 2002, NUCLEIC ACIDS RES, V30, P4285, DOI 10.1093/nar/gkf542; Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756-3282(00)00355-0; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishida S, 1999, J BONE MINER METAB, V17, P171, DOI 10.1007/s007740050081; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN A W, 1992, Current Opinion in Rheumatology, V4, P375; Oberbauer AM, 2001, GROWTH DEVELOP AGING, V65, P3; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Parfitt AM, 2001, J BONE MINER RES, V16, P1583, DOI 10.1359/jbmr.2001.16.9.1583; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PFEIFFER S, 1995, AM J PHYS ANTHROPOL, V96, P89, DOI 10.1002/ajpa.1330960110; POSER JW, 1980, J BIOL CHEM, V255, P8685; Robey PG, 1996, CONNECT TISSUE RES, V35, P131, DOI 10.3109/03008209609029183; Robson H, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000023494.70201.1C; Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; Sodek KL, 2000, BONE, V26, P189, DOI 10.1016/S8756-3282(99)00251-3; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051; SUTHERLAND MSK, 1995, OSTEOPOROSIS INT, V5, P335, DOI 10.1007/BF01622255; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; TURNER CH, 1992, BONE, V13, P403, DOI 10.1016/8756-3282(92)90082-8; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674	76	88	100	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50563	50571		10.1074/jbc.M307310200	http://dx.doi.org/10.1074/jbc.M307310200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523025	hybrid			2022-12-25	WOS:000187068200110
J	Yao, N; Coryell, L; Zhang, D; Georgescu, RE; Finkelstein, J; Coman, MM; Hingorani, MM; O'Donnell, M				Yao, N; Coryell, L; Zhang, D; Georgescu, RE; Finkelstein, J; Coman, MM; Hingorani, MM; O'Donnell, M			Replication factor C clamp loader subunit arrangement within the circular pentamer and its attachment points to proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DELTA-SUBUNIT; ACCESSORY PROTEINS; SLIDING CLAMPS; GAMMA-COMPLEX; ATP-BINDING; BETA-CLAMP; OVERPRODUCTION	Replication factor C (RFC) is a heteropentameric AAA+ protein clamp loader of the proliferating cell nuclear antigen ( PCNA) processivity factor. The prokaryotic homologue, gamma complex, is also a heteropentamer, and structural studies show the subunits are arranged in a circle. In this report, Saccharomyces cerevisiae RFC protomers are examined for their interaction with each other and PCNA. The data lead to a model of subunit order around the circle. A characteristic of AAA+ oligomers is the use of bipartite ATP sites in which one subunit supplies a catalytic arginine residue for hydrolysis of ATP bound to the neighboring subunit. We find that the RFC(3/4) complex is a DNA-dependent ATPase, and we use this activity to determine that RFC3 supplies a catalytic arginine to the ATP site of RFC4. This information, combined with the subunit arrangement, defines the composition of the remaining ATP sites. Furthermore, the RFC(2/3) and RFC(3/4) subassemblies bind stably to PCNA, yet neither RFC2 nor RFC4 bind tightly to PCNA, indicating that RFC3 forms a strong contact point to PCNA. The RFC1 subunit also binds PCNA tightly, and we identify two hydrophobic residues in RFC1 that are important for this interaction. Therefore, at least two subunits in RFC make strong contacts with PCNA, unlike the Escherichia coli gamma complex in which only one subunit makes strong contact with the beta clamp. Multiple strong contact points to PCNA may reflect the extra demands of loading the PCNA trimeric ring onto DNA compared with the dimeric beta ring.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA; Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Rockefeller University; Howard Hughes Medical Institute; Wesleyan University	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave,Box 228, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu	Georgescu, Roxana/B-9943-2011	O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839, GM64514-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839, R01GM064514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Finkelstein J, 2003, ANAL BIOCHEM, V319, P78, DOI 10.1016/S0003-2697(03)00273-2; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; INDIANI C, 2003, IN PRESS J BIOL CHEM; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Venclovas C, 2002, PROTEIN SCI, V11, P2403, DOI 10.1110/ps.0214302; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	36	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50744	50753		10.1074/jbc.M309206200	http://dx.doi.org/10.1074/jbc.M309206200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14530260				2022-12-25	WOS:000187068200130
J	Fujita, N; Sato, S; Tsuruo, T				Fujita, N; Sato, S; Tsuruo, T			Phosphorylation of p27(Kip1) at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; CELL-CYCLE PROGRESSION; INHIBITOR P27(KIP1); TUMOR-SUPPRESSOR; DEPENDENT PHOSPHORYLATION; NUCLEAR-LOCALIZATION; SIGNALING PATHWAY; BREAST-CANCER; P27; COMPLEX	The cyclin-dependent kinase inhibitor p27(Kip1) plays an important role in cell cycle regulation. The cyclin-dependent kinase-inhibitory activity of p27(Kip1) is regulated by changes in its concentration and its subcellular localization. Several reports suggest that phosphorylation of p27(Kip1) at serine 10, threonine 157, and threonine 187 regulate its localization. We have previously identified that carboxyl-terminal threonine 198 (Thr(198)) in p27(Kip1) is a novel phosphorylation site and that Akt is associated with the phosphorylation at the site (Fujita, N., Sato, S., Katayama, K., and Tsuruo, T. (2002) J. Biol. Chem. 277, 28706 - 28713). We show herein that activation of the Ras/Raf/mitogen-activated protein kinase kinase (MAPK kinase/MEK) pathway also regulates phosphorylation of p27(Kip1) at Thr(198). MAPKs were not directly associated with p27(Kip1) phosphorylation at Thr198, but the p90 ribosomal protein S6 kinases (RSKs) could bind to and directly phosphorylate p27(Kip1) at Thr(198) in a Ras/ Raf/MEK-dependent manner. RSK-dependent phosphorylation promoted the p27(Kip1) binding to 14-3-3 and its cytoplasmic localization. To prove the direct relationship between 14-3-3 binding and cytoplasmic localization, we constructed a p27(Kip1)-R18 fusion protein in which the R18 peptide was fused to the carboxyl-terminal region of p27(Kip1). The R18 peptide is known to interact with 14-3-3 independent of phosphorylation. The p27(Kip1)-R18 distributed mainly in the cytosol, whereas mutant p27(Kip1)-R18 (p27(Kip1)- R18-K2) that had no 14-3-3 binding capability existed mainly in the nucleus. These results indicate that RSKs play a crucial role in cell cycle progression through translocation of p27(Kip1), in addition to Akt, to the cytoplasm in a phosphorylation- and 14-3-3 binding-dependent manner.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.			Fujita, Naoya/0000-0002-9631-9264				Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Zeng Y, 2000, BIOCHEM BIOPH RES CO, V274, P37, DOI 10.1006/bbrc.2000.3098; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	53	159	170	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49254	49260		10.1074/jbc.M306614200	http://dx.doi.org/10.1074/jbc.M306614200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504289	hybrid			2022-12-25	WOS:000186829000091
J	Ivic, L; Sands, TTJ; Fishkin, N; Nakanishi, K; Kriegstein, AR; Stromgaard, K				Ivic, L; Sands, TTJ; Fishkin, N; Nakanishi, K; Kriegstein, AR; Stromgaard, K			Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA(A) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY NEOCORTICAL DEVELOPMENT; GLUTAMIC-ACID DECARBOXYLASE; RADIAL GLIAL-CELLS; SECO-PREZIZAANE; SESQUITERPENE; PICROTOXININ; HIPPOCAMPUS; CHANNELS; LEAVES; SLICES	Glycine and gamma-aminobutyric acid, type A (GABA(A)) receptors are members of the ligand-gated ion channel superfamily that mediate inhibitory synaptic transmission in the adult central nervous system. During development, the activation of these receptors leads to membrane depolarization. Ligands for the two receptors have important implications both in disease therapy and as pharmacological tools. Terpene trilactones (ginkgolides and bilobalide) are unique constituents of Ginkgo biloba extracts that have various effects on the central nervous system. We have investigated the relative potency of these compounds on glycine and GABA(A) receptors. We find that most of the ginkgolides are selective and potent antagonists of the glycine receptor. Bilobalide, the single major component in G. biloba extracts, also reduces glycine-induced currents, although to a lesser extent. Both ginkgolides and bilobalide inhibit GABA(A) receptors, with bilobalide demonstrating a more potent effect. Additionally, we provide evidence that open channels are required for glycine receptor inhibition by ginkgolides. Finally, we employ molecular modeling to elucidate the similarities and differences in the structure of the terpene trilactones to account for the pharmacological properties of these compounds and demonstrate a striking similarity between ginkgolides and picrotoxinin, a GABA(A) and recombinant glycine alpha-homomeric receptor antagonist.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University; Columbia University; Columbia University	Kriegstein, AR (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.		Stromgaard, Kristian/E-3380-2010	Stromgaard, Kristian/0000-0003-2206-4737	NINDS NIH HHS [NS 38658] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS038658] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS PR, 1983, AUST J CHEM, V36, P2219, DOI 10.1071/CH9832219; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; BETZ H, 2001, HDB EXPT PHARM, P150; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeFeudis F.V., 1998, GINKGO BILOBA EXTRAC; DUPONT L, 1986, ACTA CRYSTALLOGR C, V42, P1759, DOI 10.1107/S0108270186090662; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; Granger AS, 2001, AGE AGEING, V30, P523, DOI 10.1093/ageing/30.6.523; HARIHARAN PC, 1974, MOL PHYS, V27, P209, DOI 10.1080/00268977400100171; Huang SH, 2003, EUR J PHARMACOL, V464, P1, DOI 10.1016/S0014-2999(03)01344-X; Jones FA, 2002, AMINO ACIDS, V22, P369, DOI 10.1007/s007260200021; KLUNK WE, 1983, MOL PHARMACOL, V23, P511; Kondratskaya EL, 2002, NEUROCHEM INT, V40, P647, DOI 10.1016/S0197-0186(01)00109-7; Kuriyama T, 2002, BIOORGAN MED CHEM, V10, P1873, DOI 10.1016/S0968-0896(02)00011-1; Leite JF, 2001, MOL CELL NEUROSCI, V17, P777, DOI 10.1006/mcne.2001.0984; Lichtblau D, 2002, J NAT PROD, V65, P1501, DOI 10.1021/np0201974; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; Malatesta P, 2000, DEVELOPMENT, V127, P5253; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Mori M, 2002, J PHYSIOL-LONDON, V539, P191, DOI 10.1113/jphysiol.2001.013147; NAKANISHI K, 1971, J AM CHEM SOC, V93, P3544, DOI 10.1021/ja00743a051; NAKANISHI KOJI, 1967, PURE APPL CHEM, V14, P89, DOI 10.1351/pac196714010089; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Owens DF, 1999, J NEUROPHYSIOL, V82, P570, DOI 10.1152/jn.1999.82.2.570; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Sasaki K, 1999, EUR J PHARMACOL, V367, P165, DOI 10.1016/S0014-2999(98)00968-6; Sasaki K, 2000, LIFE SCI, V67, P709, DOI 10.1016/S0024-3205(00)00657-3; Sasaki K, 1999, COMP BIOCHEM PHYS C, V124, P315, DOI 10.1016/S0742-8413(99)00082-1; Schmidt TJ, 1999, BIOORGAN MED CHEM, V7, P2857, DOI 10.1016/S0968-0896(99)00240-0; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; vanBeek TA, 1997, J NAT PROD, V60, P735, DOI 10.1021/np970060r; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	33	93	97	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49279	49285		10.1074/jbc.M304034200	http://dx.doi.org/10.1074/jbc.M304034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504293	hybrid			2022-12-25	WOS:000186829000094
J	Jiang, JH; Cyr, D; Babbitt, RW; Sessa, WC; Patterson, C				Jiang, JH; Cyr, D; Babbitt, RW; Sessa, WC; Patterson, C			Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; IN-VITRO; PROTEASOME PATHWAY; NO RELEASE; HSP90; DEGRADATION; CELLS; GELDANAMYCIN; DOMAIN	Endothelial nitric-oxide synthase (eNOS), the enzyme responsible for production of endothelial NO, is under tight and complex regulation. Proper cellular localization of eNOS is critical for optimal coupling of extracellular stimulation with NO production. In addition, the molecular chaperone Hsp90 interacts with eNOS and positively regulates eNOS activity. Hsp90 is modulated by physical interaction with its co-chaperones. CHIP ( carboxyl terminus of Hsp70-interacting protein) is such a co-chaperone that remodels the Hsp90 heterocomplex and causes protein degradation of some Hsp90 substrates through the ubiquitin-protein isopeptide ligase activity of CHIP. Here we show that CHIP incorporated into the eNOS . Hsp90 complex and specifically decreased soluble eNOS levels in transiently transfected COS cells. Surprisingly, in contrast to the effects of the Hsp90 inhibitor geldanamycin, which induces eNOS ubiquitylation and its subsequent protein degradation, CHIP did not target eNOS for ubiquitylation and proteasome-dependent degradation. Instead, CHIP partitioned soluble eNOS into an insoluble and inactive cellular compartment, presumably through its co-chaperone activity. This effect seems to be due to displacement of eNOS from the Golgi apparatus, which is otherwise required for trafficking of eNOS to the plasmalemma and subsequent activation. Consistent with observations from overexpression studies, eNOS localization to the membrane and activity were increased in mouse lung endothelial cells lacking CHIP. Taken together, these results demonstrate a novel co-chaperone-dependent mechanism through which eNOS trafficking is regulated and suggest a potentially generalized role for CHIP in protein trafficking through the Golgi compartment.	Univ N Carolina, Carolina Cardiovasc Biol Ctr, Div Cardiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Boyer Ctr Mol Med, Program Vasc Cell Signaling & Therapeut, New Haven, CT 06536 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Patterson, C (corresponding author), Univ N Carolina, Carolina Cardiovasc Biol Ctr, Div Cardiol, 324 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.		Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Cyr, Douglas/0000-0002-4928-3414	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065619, R01HL057665, R37HL061371, R01HL061371, R01HL064793, R37HL065619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981, R01GM061728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57665, HL61371, HL64793, HL65619] Funding Source: Medline; NIGMS NIH HHS [GM56981, GM61728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dedio J, 2001, FASEB J, V15, P79, DOI 10.1096/fj.00-0078com; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	47	83	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49332	49341		10.1074/jbc.M304738200	http://dx.doi.org/10.1074/jbc.M304738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507928	hybrid, Green Published			2022-12-25	WOS:000186829000101
J	Ramachandran, A; Omar, M; Cheslock, P; Schnitzler, GR				Ramachandran, A; Omar, M; Cheslock, P; Schnitzler, GR			Linker histone H1 modulates nucleosome remodeling by human SWI/SNF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; RNA-POLYMERASE-II; HUMAN SWI-SNF; CHROMATIN-STRUCTURE; GENE-TRANSCRIPTION; POSITIONED NUCLEOSOMES; DNA; DISRUPTION; COMPLEX; BINDING	Chromatin, a combination of nucleosomes and linker histones, inhibits transcription by blocking polymerase movement and access of factors to DNA. ATP-dependent remodeling complexes such as SWI/SNF and RSC alter chromatin structure to increase or decrease this repression. To further our understanding of how human SWI/ SNF (hSWI/SNF) "remodels" chromatin we examined the octamer location, nature, and template specificity of hSWI/SNF-remodeled mononucleosomes when free or bound by linker histone H1. We find that, in the absence of H1, hSWI/SNF consistently moves nucleosomes to DNA ends, regardless of template sequence. On some sequences the repositioned histone octamer appears to be moved similar to 45 bp off the DNA edge, whereas on others it appears to be normal, suggesting that the nature of the remodeled nucleosome can be influenced by DNA sequence. By contrast, in the presence of histone H1, hSWI/SNF slides octamers to more central positions and does not promote nucleosome movement off the ends of the DNA. Our results indicate that the nature and position of hSWI/SNF products may be influenced both by DNA sequence and linker histone, and shed light on the roles of H1 and hSWI/SNF in modulating chromatin structure.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Schnitzler, GR (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.				NCI NIH HHS [K01CA88835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA088835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoyagi S, 2002, MOL CELL BIOL, V22, P7484, DOI 10.1128/MCB.22.21.7484-7490.2002; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO, V4; Bonaldi T, 2002, EMBO J, V21, P6865, DOI 10.1093/emboj/cdf692; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Fitzgerald DJ, 1998, NUCLEIC ACIDS RES, V26, P2526, DOI 10.1093/nar/26.11.2526; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Guyon JR, 2001, MOL CELL BIOL, V21, P1132, DOI 10.1128/MCB.21.4.1132-1144.2001; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; Hellauer K, 2001, J BIOL CHEM, V276, P13587, DOI 10.1074/jbc.M011196200; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; Kang JG, 2002, EMBO J, V21, P1406, DOI 10.1093/emboj/21.6.1406; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Koop R, 2003, EMBO J, V22, P588, DOI 10.1093/emboj/cdg052; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee KM, 1998, BIOCHEMISTRY-US, V37, P8622, DOI 10.1021/bi980499y; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Lorch Y, 2001, MOL CELL, V7, P89, DOI 10.1016/S1097-2765(01)00157-5; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; ROBERTS MS, 1995, BIOCHEMISTRY-US, V34, P12470, DOI 10.1021/bi00038a046; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schnitzler GR, 2001, MOL CELL BIOL, V21, P8504, DOI 10.1128/MCB.21.24.8504-8511.2001; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Studitsky VM, 1999, METH MOL B, V119, P17; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Travers A, 1999, TRENDS BIOCHEM SCI, V24, P4, DOI 10.1016/S0968-0004(98)01339-5; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Utley RT, 1996, METHOD ENZYMOL, V274, P276; Vicent GP, 2002, J MOL BIOL, V324, P501, DOI 10.1016/S0022-2836(02)01101-4; Wolffe AP, 2001, ESSAYS BIOCHEM, V37, P45, DOI 10.1042/bse0370045; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; Zlatanova J, 2000, FASEB J, V14, P1697, DOI 10.1096/fj.99-0869rev	54	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48590	48601		10.1074/jbc.M309033200	http://dx.doi.org/10.1074/jbc.M309033200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512420	hybrid			2022-12-25	WOS:000186829000011
J	Dupre, DJ; Chen, ZG; Le Gouill, C; Theriault, C; Parent, JL; Rola-Pleszczynski, M; Stankova, J				Dupre, DJ; Chen, ZG; Le Gouill, C; Theriault, C; Parent, JL; Rola-Pleszczynski, M; Stankova, J			Trafficking, ubiquitination, and down-regulation of the human platelet-activating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-INDUCED INTERNALIZATION; DELTA-OPIOID RECEPTORS; HAMSTER OVARY CELLS; BETA(2)-ADRENERGIC RECEPTOR; PLASMA-MEMBRANE; BETA-2-ADRENERGIC RECEPTOR; INTRACELLULAR TRAFFICKING; ENDOCYTIC PATHWAY; EARLY ENDOSOMES	Platelet-activating factor (PAF) is a potent phospholipid mediator involved in various disease states such as allergic asthma, atherosclerosis and psoriasis. The human PAF receptor (PAFR) is a member of the G protein-coupled receptor family. Following PAF stimulation, cells become rapidly desensitized; this refractory state can be maintained for hours and is dependent on PAFR phosphorylation, internalization, and down-regulation. In this report, we characterized ligand-induced, long term PAFR desensitization, and pathways leading to its degradation. Some GPCRs are known to be targeted to proteasomes for degradation while others traffic via the early/late endosomes toward lysosomes. Specific inhibitors of lysosomal proteases and inhibitors of the proteasome were effective in reducing the ligand-induced PAFR down-regulation by 40 and 25%, respectively, indicating the importance of receptor targeting to both lysosomes and proteasomes in long term cell desensitization to PAF. The effects of the proteasome and lysosomal protease inhibitors were additive and, together, completely blocked ligand-induced degradation of PAFR. Using dominant-negative Rab5 and 7 and colocalization of the PAFR with the early endosome autoantigen I (EEAI) or transferrin, we confirmed that ligand-induced PAFR down-regulation was Rab5/7-dependent and involved lysosomal degradation. In addition, we also demonstrated that PAFR was ubiquitinated in an agonist-independent manner. However, a dominant negative ubiquitin ligase (NCbl) reduced PAFR ubiquitination and inhibited ligand-induced but not basal receptor degradation. Our results indicate that PAFR degradation can occur via both the proteasome and lysosomal pathways and ligand-stimulated degradation is ubiquitin-dependent.	Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Med, Div Rheumatol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Stankova, J (corresponding author), Univ Sherbrooke, Fac Med, Dept Pediat, Div Immunol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.		Dupre, Denis J/AAI-2631-2021; Chen, Zhangguo/AAW-2032-2021	Dupre, Denis J/0000-0001-6401-6157; Chen, Zhangguo/0000-0002-2741-0080				ALI H, 1994, J BIOL CHEM, V269, P24557; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; Brocheriou I, 2000, CIRCULATION, V102, P2569; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FRANKLIN RA, 1995, BIOCHEM BIOPH RES CO, V209, P1111, DOI 10.1006/bbrc.1995.1612; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GHOSH RN, 1994, J CELL SCI, V107, P2177; HEIN L, 1994, J BIOL CHEM, V269, P27719; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Houle S, 2003, BIOCHEM J, V375, P151, DOI 10.1042/BJ20030872; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LAW PY, 1984, J BIOL CHEM, V259, P4096; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MERESSE S, 1995, J CELL SCI, V108, P3349; Moore RH, 1999, J CELL SCI, V112, P329; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Subtil A, 1998, J BIOL CHEM, V273, P29424, DOI 10.1074/jbc.273.45.29424; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Vitelli R, 1997, J BIOL CHEM, V272, P4391, DOI 10.1074/jbc.272.7.4391; Volpicelli LA, 2001, J BIOL CHEM, V276, P47590, DOI 10.1074/jbc.M106535200; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	62	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48228	48235		10.1074/jbc.M304082200	http://dx.doi.org/10.1074/jbc.M304082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500726	hybrid			2022-12-25	WOS:000186731400106
J	Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG				Ribatti, D; Guidolin, D; Conconi, MT; Nico, B; Baiguera, S; Parnigotto, PP; Vacca, A; Nussdorfer, GG			Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo	ONCOGENE			English	Article						adrenomedullin; angiogenesis; antiangiogenesis; chorioallantoic membrane; Matrigel; vinblastine	MICE LACKING; ANTIANGIOGENESIS; ABNORMALITIES; GROWTH	Adrenomedullin (ADM) is protumorigenic by stimulating tumor cell growth and angiogenesis. In this context, ADM is identified as a novel target for antiangiogenic therapy. In this study, we addressed the possibility that vinblastine (VBL), as demonstrated in other experimental conditions, may act as an angiostatic molecule in the angiogenic response induced by ADM in two assays, such as Matrigel tube formation in vitro and angiogenesis in the chick embryo chorioallantoic membrane (CAM) in vivo. When tested on Matrigel, ADM caused a morphogenetic effect. In fact, endothelial cells spread and aligned with each other to form branching anastomosing tubes with multicentric junctions that gave rise to a meshwork of capillary-like structures. When ADM was administered in the presence of VBL, the capillary-like tubes were interrupted, most cells were spherical, either isolated or aggregated in small clumps. In the CAM assay, ADM induced a strong angiogenic response, which was counteracted by the treatment with VBL. Overall, these observations implicate ADM as a promoter of tumor growth and a possible target for anticancer strategies, such as the use of VBL at very low, nontoxic doses. Nevertheless, the antiangiogenic acitivity of low-dose VBL deserves further investigation, alone or together with other antiangiogenic agents for the treatment of tumors characterized by enhanced angiogenesis.	Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Padua, Sch Med, Sect Anat, Dept Human Anat & Physiol, Padua, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Sect Internal Med & Clin Oncol, Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Padua; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Policlin, Dept Human Anat & Histol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022; Baiguera, Silvia/AAC-4738-2022	Vacca, Angelo/0000-0002-4567-8216; Baiguera, Silvia/0000-0002-6669-7061; Guidolin, Diego/0000-0003-2133-3552				Belloni AS, 2001, HISTOL HISTOPATHOL, V16, P1263, DOI 10.14670/HH-16.1263; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; ElHafny B, 1997, BIOCHEM PHARMACOL, V53, P1735, DOI 10.1016/S0006-2952(97)00093-2; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Hague S, 2000, CLIN CANCER RES, V6, P2808; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Martinez A, 2002, J NATL CANCER I, V94, P1226; Minamino N, 2000, CLIN HEMORHEOL MICRO, V23, P95; Nikitenko LL, 2002, TRENDS PHARMACOL SCI, V23, P101, DOI 10.1016/S0165-6147(00)01983-0; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Presta M, 2002, LEUKEMIA, V16, P1490, DOI 10.1038/sj.leu.2402646; Presta M, 1999, CANCER RES, V59, P2417; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti Domenico, 1999, Neoplasia (New York), V1, P293, DOI 10.1038/sj.neo.7900038; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155; Vacca A, 2002, J HEMATOTH STEM CELL, V11, P103, DOI 10.1089/152581602753448577; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	20	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6458	6461		10.1038/sj.onc.1206789	http://dx.doi.org/10.1038/sj.onc.1206789			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508526				2022-12-25	WOS:000185535300016
J	Brunelli, R; Greco, G; Barteri, M; Krasnowska, EK; Mei, G; Natella, F; Pala, A; Rotella, S; Ursini, F; Zichella, L; Parasassi, T				Brunelli, R; Greco, G; Barteri, M; Krasnowska, EK; Mei, G; Natella, F; Pala, A; Rotella, S; Ursini, F; Zichella, L; Parasassi, T			One site on the apoB-100 specifically binds 17-beta-estradiol and regulates the overall structure of LDL	FASEB JOURNAL			English	Article						electronegative LDL; equilibrium dialysis; circular dichroism; SAXS	LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN B-100; OXIDATION; RECEPTOR; EXPRESSION; PARTICLES; AROMATASE; ESTROGEN; BEHAVIOR	The major protein component (apoB-100) of low-density lipoprotein (LDL) is known as a multipotential molecule the several functional regions of which can all be affected by key structural modifications driven by specific domains. Based on our previous report on structural and conformational modifications of apoB-100 in the presence of 17-beta-estradiol (E-2), we characterized the interaction between E-2 and the apoB-100 and further explored the induced alterations in terms of the structural arrangement of the whole LDL particle. We report evidence for the existence on apoB-100 of a single specific and saturable binding site for E-2, the occupancy of which modifies the overall structure of the protein, inducing an increase in the alpha-helix fraction. As a consequence, the structure of the LDL particle is deeply perturbed, with a change in the arrangement of both the outer shell and lipid core and an overall volume shrinkage. The evidence of a regulation of apoB-100 structure by a physiological ligand opens new perspectives in the study of the biological addressing of the LDL particle and suggests a novel rationale in the search for mechanisms underlying the beneficial role of E-2 in decreasing the risk of early lesions in atherosclerosis.	CNR, Ist Neurobiol & Med Mol, I-00137 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol & Puericultura, Rome, Italy; Univ Roma La Sapienza, Dipartimento Chim, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, Rome, Italy; Ist Nazl Ric Alimenti & Nutr, Rome, Italy; Univ Padua, Dipartimento Chim Biol, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; University of Rome Tor Vergata; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Padua	Parasassi, T (corresponding author), CNR, Ist Neurobiol & Med Mol, Viale Marx 15-43, I-00137 Rome, Italy.	t.parasassi@in.rm.cnr.it	fausta, natella/AGR-5829-2022	fausta, natella/0000-0002-1999-9817; Parasassi, Tiziana/0000-0002-9795-0568				BENVENGA S, 1990, ENDOCRINOLOGY, V127, P2241, DOI 10.1210/endo-127-5-2241; BENVENGA S, 1988, J CLIN ENDOCR METAB, V67, P6, DOI 10.1210/jcem-67-1-6; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; Brunelli R, 2000, BIOCHEMISTRY-US, V39, P13897, DOI 10.1021/bi000341p; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; Ettelaie C, 1997, BBA-LIPID LIPID MET, V1345, P237, DOI 10.1016/S0005-2760(96)00185-3; Glatter O., 1982, SMALL ANGLE XRAYS SC; Guevara J, 1996, J PROTEIN CHEM, V15, P17, DOI 10.1007/BF01886807; Guevara JG, 1999, J PROTEIN CHEM, V18, P845, DOI 10.1023/A:1020627212272; Harada N, 1999, CIRC RES, V84, P1285, DOI 10.1161/01.RES.84.11.1285; Harada N, 1999, ONCOLOGY-BASEL, V57, P7, DOI 10.1159/000055270; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; HOFF HF, 1995, CURR OPIN LIPIDOL, V6, P317, DOI 10.1097/00041433-199510000-00012; LESZCZYNSKI D E, 1989, Steroids, V54, P37, DOI 10.1016/0039-128X(89)90074-3; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Lund-Katz S, 1998, BIOCHEMISTRY-US, V37, P12867, DOI 10.1021/bi980828m; Meyer DF, 1996, BIOCHEM J, V319, P217, DOI 10.1042/bj3190217; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; Nielsen LB, 1996, ATHEROSCLEROSIS, V123, P1, DOI 10.1016/0021-9150(96)05802-9; OLSSON U, 1993, BIOCHEMISTRY-US, V32, P1858, DOI 10.1021/bi00058a020; Parasassi T, 2000, FREE RADICAL BIO MED, V28, P1589, DOI 10.1016/S0891-5849(00)00275-6; Pentikainen MO, 2001, J LIPID RES, V42, P916; PRASSL R, 1995, BIOCHEMISTRY-US, V34, P3795, DOI 10.1021/bi00011a037; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; Rutledge JC, 1997, CIRC RES, V80, P819; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 2001, J LIPID RES, V42, P1346; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Shwaery GT, 1998, ATHEROSCLEROSIS, V138, P255, DOI 10.1016/S0021-9150(98)00020-3; SINGH S, 1986, BIOCHIM BIOPHYS ACTA, V876, P460, DOI 10.1016/0005-2760(86)90032-9; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Tang M, 1997, J LAB CLIN MED, V129, P447, DOI 10.1016/S0022-2143(97)90078-0; Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; Xu SH, 1998, BIOCHEMISTRY-US, V37, P9284, DOI 10.1021/bi9729662	36	13	13	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2127	+		10.1096/fj.02-1181fje	http://dx.doi.org/10.1096/fj.02-1181fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500554				2022-12-25	WOS:000185925100001
J	Adhikari, A; Sprang, SR				Adhikari, A; Sprang, SR			Thermodynamic characterization of the binding of activator of G protein signaling 3 (AGS3) and peptides derived from AGS3 with G alpha(i1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; G-ALPHA SUBUNITS; RECEPTOR-INDEPENDENT ACTIVATORS; CAENORHABDITIS-ELEGANS EMBRYOS; NUCLEOTIDE EXCHANGE FACTOR; CIRCULAR-DICHROISM; TETRATRICOPEPTIDE REPEAT; DISSOCIATION INHIBITOR; REGULATORY MOTIF; IDENTIFICATION	Activator of G protein signaling 3 (AGS3) is a guanine nucleotide dissociation inhibitor (GDI) that contains four G protein regulatory (GPR) or GoLoco motifs in its C-terminal domain. The entire C-terminal domain (AGS3-C) as well as certain peptides corresponding to individual GPR motifs of AGS3 bound to Galpha(i1) and inhibited the binding of GTP by stabilizing the GDP-bound conformation of Galpha(i1). The stoichiometry, free energy, enthalpy, and dissociation constant for binding of AGS3-C to Galpha(i1) were determined using isothermal titration calorimetry. AGS3-C possesses two apparent high affinity (K(d)similar to 20 nM) and two apparent low affinity (K-d similar to 300 nM) binding sites for Galpha(i1). Upon deletion of the C-terminal GPR motif from AGS3-C, the remaining sites were approximately equivalent with respect to their affinity (K-d similar to 400 nM) for Galpha(i1). Peptides corresponding to each of the four GPR motifs of AGS3 (referred to as GPR1, GPR2, GPR3, and GPR4, respectively, going from N to C terminus) bound to Galpha(i1) with K-d values in the range of 1-8 muM. Although GPR1, GPR2, and GPR4 inhibited the binding of the fluorescent GTP analog BODIPY-FL-guanosine 5'-3-O-(thio)triphosphate to Galpha(i1), GPR3 did not. However, addition of N- and C-terminal flanking residues to the GPR3 GoLoco core increased its affinity for Galpha(i1) and conferred GDI activity similar to that of AGS3-C itself. Similar increases were observed for extended GPR2 and extended GPR1 peptides. Thus, while the tertiary structure of AGS3 may affect the affinity and activity of the GPR motifs contained within its sequence, residues outside of the GPR motifs strongly potentiate their binding and GDI activity toward Galpha(i1) even though the amino acid sequences of these residues are not conserved among the GPR repeats.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, Mol Biophys Grad Program, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046371, R01DK046371] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK046371, DK46371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LEE E, 1994, METHOD ENZYMOL, V237, P146; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; *MICR, 1998, ITC DAT AN OR; Miller KG, 2000, GENETICS, V156, P1649; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sreerama N, 1999, PROTEIN SCI, V8, P370; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	35	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51825	51832		10.1074/jbc.M306300200	http://dx.doi.org/10.1074/jbc.M306300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530282	hybrid			2022-12-25	WOS:000187206300118
J	Absalom, NL; Lewis, TM; Kaplan, W; Pierce, KD; Schofield, PR				Absalom, NL; Lewis, TM; Kaplan, W; Pierce, KD; Schofield, PR			Role of charged residues in coupling ligand binding and channel activation in the extracellular domain of the glycine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; GABA(A) RECEPTOR; AGONIST BINDING; NICOTINIC RECEPTORS; ALPHA-1 SUBUNIT; SPASMODIC MOUSE; M2-M3 LOOP; MUTATION; HYPEREKPLEXIA; ACCESSIBILITY	The glycine receptor is a member of the ligand-gated ion channel receptor superfamily that mediates fast synaptic transmission in the brainstem and spinal cord. Following ligand binding, the receptor undergoes a conformational change that is conveyed to the transmembrane regions of the receptor resulting in the opening of the channel pore. Using the acetylcholine-binding protein structure as a template, we modeled the extracellular domain of the glycine receptor alpha1-subunit and identified the location of charged residues within loops 2 and 7 ( the conserved Cys-loop). These loops have been postulated to interact with the M2-M3 linker region between the transmembrane domains 2 and 3 as part of the receptor activation mechanism. Charged residues were substituted with cysteine, resulting in a shift in the concentration-response curves to the right in each case. Covalent modification with 2-(trimethylammonium) ethyl methanethiosulfonate was demonstrated only for K143C, which was more accessible in the open state than the closed state, and resulted in a shift in the EC50 toward wild-type values. Charge reversal mutations (E53K, D57K, and D148K) also impaired channel activation, as inferred from increases in EC50 values and the conversion of taurine from an agonist to an antagonist in E53K and D57K. Thus, each of the residues Glu-53, Asp-57, Lys-143, and Asp-148 are implicated in channel gating. However, the double reverse charge mutations E53K: K276E, D57K: K276E, and D148K: K276E did not restore glycine receptor function. These results indicate that loops 2 and 7 in the extracellular domain play an important role in the mechanism of activation of the glycine receptor although not by a direct electrostatic mechanism.	Garvan Inst Med Res, Neurobiol Res Program, Darlinghurst, NSW, Australia; Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Darlinghurst, NSW, Australia; Univ New S Wales, St Vincents Hosp, Sch Med, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Schofield, PR (corresponding author), Garvan Inst Med Res, 384 Victoria St, Sydney, NSW 2010, Australia.		Lewis, Trevor/A-2939-2011; Pierce, Kerrie D/O-7300-2018; Schofield, Peter/C-9669-2011	Lewis, Trevor/0000-0003-1864-6806; Pierce, Kerrie D/0000-0003-0636-4836; Schofield, Peter/0000-0003-2967-9662				AMIN J, 1994, MOL PHARMACOL, V45, P317; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Croxen R, 1997, HUM MOL GENET, V6, P767, DOI 10.1093/hmg/6.5.767; Dougherty DA, 2001, NATURE, V411, P252, DOI 10.1038/35077192; Elmslie FV, 1996, J MED GENET, V33, P435, DOI 10.1136/jmg.33.5.435; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAUL B, 1994, FEBS LETT, V350, P71, DOI 10.1016/0014-5793(94)00736-5; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VANDENBERG RJ, 1993, MOL PHARMACOL, V44, P198	24	65	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50151	50157		10.1074/jbc.M305357200	http://dx.doi.org/10.1074/jbc.M305357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525990	hybrid			2022-12-25	WOS:000187068200060
J	Bellido, T; Ali, AA; Plotkin, LI; Fu, Q; Gubrij, I; Roberson, PK; Weinstein, RS; O'Brien, CA; Manolagas, SC; Jilka, RL				Bellido, T; Ali, AA; Plotkin, LI; Fu, Q; Gubrij, I; Roberson, PK; Weinstein, RS; O'Brien, CA; Manolagas, SC; Jilka, RL			Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANT; ELEMENT-BINDING PROTEIN; RESPONSE ELEMENT; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; GROWTH-FACTORS; BH3 DOMAIN; C-FOS; CELLS; RECEPTOR	It is unknown why sustained elevation of parathyroid hormone (PTH) stimulates bone resorption, whereas intermittent administration stimulates bone formation. We show in mice that daily injections of PTH attenuate osteoblast apoptosis, thereby increasing osteoblast number, bone formation rate, and bone mass, but do not affect osteoclast number. In contrast, sustained elevation of PTH, achieved either by infusion or by raising endogenous hormone secretion with a calcium-deficient diet, does not affect osteoblast apoptosis but increases osteoclast number. Attenuation of apoptosis by PTH in cultured osteoblastic cells requires protein kinase A-mediated phosphorylation and inactivation of the pro-apoptotic protein Bad as well as transcription of survival genes, like Bcl-2, mediated by CREB ( cAMP response element-binding protein) and Runx2. But, PTH also increases proteasomal proteolysis of Runx2. Moreover, the anti-apoptotic effect of PTH is prolonged by inhibition of proteasomal activity, by overexpressing a dominant negative form of the E3 ligase (ubiquitin-protein isopeptide ligase) that targets Runx2 for degradation (Smurf1), or by overexpressing Runx2 itself. The duration of the anti-apoptotic effect of PTH, thus, depends on the level of Runx2, which in turn is decreased by PTH via Smurf1-mediated proteasomal proteolysis. The self-limiting nature of PTH-induced survival signaling might explain why intermittent administration of the hormone is required for bone anabolism.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Jilka, RL (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Cent Arkansas Vet Healthcare Syst, Slot 587,4301 W Markham, Little Rock, AR 72205 USA.		O'Brien, Charles A./AAL-5078-2020; Plotkin, Lilian/H-7188-2019	Plotkin, Lilian/0000-0002-9537-4544	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002127, R01AR046823] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR46823, K02 AR02127] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Arora K, 2001, DEV CELL, V1, P441, DOI 10.1016/S1534-5807(01)00067-3; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Baron R.A., 1983, BONE HISTOMORPHOMETR, P13; BELCHETZ PE, 1978, SCIENCE, V202, P631, DOI 10.1126/science.100883; Boyce BF, 2002, PRINCIPLES BONE BIOL, V1, P151; BROWN PH, 1994, ONCOGENE, V9, P791; Cheng ZQ, 2000, J ENDOCRINOL, V167, P175, DOI 10.1677/joe.0.1670175; CHOREV M, 2002, PRINCIPLES BONE BIOL, P423; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683; Gubrij I, 2003, J BONE MINER RES, V18, pS136; Guo CY, 1996, J CLIN ENDOCR METAB, V81, P3487, DOI 10.1210/jc.81.10.3487; Heersche JN., 2001, PARATHYROIDS, P199; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KENDALL M, 1987, KENDALLS ADV THEORY, P324; Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002-0225; LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Parfitt AM, 2002, J BONE MINER RES, V17, P1741, DOI 10.1359/jbmr.2002.17.10.1741; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Pompeiano M, 1998, CELL DEATH DIFFER, V5, P702, DOI 10.1038/sj.cdd.4400403; PRAGER D, 1992, J CLIN INVEST, V90, P2117, DOI 10.1172/JCI116096; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shenolikar S, 2000, PRINCIPLES OF MOLECULAR REGULATION, P311; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wilk S, 1997, MOL BIOL REP, V24, P119, DOI 10.1023/A:1006851428691; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WRONSKI TJ, 1994, BONE, V15, P51, DOI 10.1016/8756-3282(94)90891-5; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	58	303	326	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50259	50272		10.1074/jbc.M307444200	http://dx.doi.org/10.1074/jbc.M307444200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523023	hybrid			2022-12-25	WOS:000187068200074
J	Diveu, C; Lelievre, E; Perret, D; Lak-Hal, AHL; Froger, J; Guillet, C; Chevalier, S; Rousseau, F; Wesa, A; Preissner, L; Chabbert, M; Gauchat, JF; Galy, A; Gascan, H; Morel, A				Diveu, C; Lelievre, E; Perret, D; Lak-Hal, AHL; Froger, J; Guillet, C; Chevalier, S; Rousseau, F; Wesa, A; Preissner, L; Chabbert, M; Gauchat, JF; Galy, A; Gascan, H; Morel, A			GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; MULTIPLE SEQUENCE ALIGNMENT; IMMUNOGLOBULIN-LIKE DOMAIN; ONCOSTATIN-M RECEPTOR; LIGAND-BINDING SITE; ALPHA-COMPONENT; CNTF RECEPTOR; INTERLEUKIN-6 RECEPTOR	We describe a novel cytokine receptor named GP130 Like receptor, or GPL, that displays similarities with the interleukin-6 and interleukin-12 family of signaling receptors. Four different isoforms diverging in their carboxyl terminus were isolated, corresponding to proteins encompassing 560, 610, 626, and 745 amino acids. Sequences included a signal peptide of 32 amino acids, followed by a cytokine binding domain containing four conserved cysteines, a WSDWS motif, and a region consisting of three fibronectin type III domain repeats. No immunoglobulin-like module was identified in the GPL sequences. The intracellular part of longer isoforms contained a proline-rich region defining a box1 motif for interaction with the Janus kinases. The Gpl gene is organized in 15 exons and is located on 5q11.2 in tandem with the gp130 gene. Both genes were only separated by 24 kilobases, with opposite transcriptional orientations. The GPL receptor displayed a 28% identity with gp130. Specific GPL transcripts were observed in tissues involved in reproduction. Transcripts were also found in blood cells and in bone marrow, revealing expression of GPL in all of the myelomonocytic lineage, from hematopoietic stem cells to activated dendritic cells. In monocytes and dendritic cells, expression of GPL was strongly up-regulated by interferon-gamma, indicating a possible involvement of GPL in Th1-type immune responses. The molecular basis of cell signaling mediated by GPL was studied using chimeric receptors where external portions of alpha or beta interleukin-5 receptor subunits were fused to the internal portion of GPL or of related receptors. Results indicated that association of GPL to the intracellular portions of gp130, or LIF receptor, allowed the signaling cascade.	CHU Angers, INSERM, U564, F-49033 Angers, France; Wayne State Univ, Barbara Ann Karamanos Canc Inst, Detroit, MI 48201 USA; Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Wayne State University; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Gascan, H (corresponding author), CHU Angers, INSERM, U564, 4 Rue Larrey, F-49033 Angers, France.	gascan@univ-angers.fr	Chabbert, Marie/K-1245-2015; Morel, Alain/AAU-7496-2021; Lelievre, Eric/M-2878-2015; Galy, Anne HM/J-4439-2013	Galy, Anne HM/0000-0002-0153-4392; morel, alain/0000-0003-0125-1883; lelievre, eric/0000-0002-4132-4023				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; Barton VA, 2000, J BIOL CHEM, V275, P36197, DOI 10.1074/jbc.M004648200; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Boulay JL, 2003, IMMUNITY, V19, P159, DOI 10.1016/S1074-7613(03)00211-5; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; Brombacher F, 2003, TRENDS IMMUNOL, V24, P207, DOI 10.1016/S1471-4906(03)00067-X; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; CHUA AO, 1994, J IMMUNOL, V153, P128; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Ferlazzo G, 1999, J IMMUNOL, V163, P3597; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; Gupta Ramneek, 2002, Pac Symp Biocomput, P310; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hermanns HM, 1999, J IMMUNOL, V163, P6651; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Hombria JCG, 2002, CURR BIOL, V12, pR569, DOI 10.1016/S0960-9822(02)01057-6; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; KIDD VJ, 1992, SOMAT CELL MOLEC GEN, V18, P477, DOI 10.1007/BF01233087; Kobari L, 2001, J HEMATOTH STEM CELL, V10, P273, DOI 10.1089/15258160151134980; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; LELIEVRE E, 2002, J INTERFERON CYTOKIN, V22, pS91; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MICHENER CD, 1957, EVOLUTION, V11, P130, DOI 10.2307/2406046; MIYAJIMA A, 1993, BLOOD, V82, P1960; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nicholas K.B., 1997, EMBNEW NEWS, V4, P1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pagni M, 2001, NUCLEIC ACIDS RES, V29, P148, DOI 10.1093/nar/29.1.148; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Plun-Favreau H, 2003, J BIOL CHEM, V278, P27169, DOI 10.1074/jbc.M303168200; Plun-Favreau H, 2001, EMBO J, V20, P1692, DOI 10.1093/emboj/20.7.1692; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Robinson DS, 2002, IMMUNITY, V16, P755, DOI 10.1016/S1074-7613(02)00331-X; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sprecher CA, 1998, BIOCHEM BIOPH RES CO, V246, P82, DOI 10.1006/bbrc.1998.8576; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; WARD LD, 1994, J BIOL CHEM, V269, P23286; Wesa AK, 2001, INT IMMUNOL, V13, P1053, DOI 10.1093/intimm/13.8.1053; Yoon C, 2000, EMBO J, V19, P3530, DOI 10.1093/emboj/19.14.3530; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	76	61	95	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49850	49859		10.1074/jbc.M307286200	http://dx.doi.org/10.1074/jbc.M307286200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14504285	hybrid			2022-12-25	WOS:000187068200026
J	Gong, YP; Duvvuri, M; Krise, JP				Gong, YP; Duvvuri, M; Krise, JP			Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR P-GLYCOPROTEIN; ACUTE MYELOID-LEUKEMIA; VACUOLAR H+-ATPASE; TUMOR-CELLS; GLUTATHIONE; TRANSPORT; VESICLES; ACCUMULATION; EXPRESSION; PROTEIN	The sequestration of drugs away from cellular target sites into cytoplasmic organelles of multidrug-resistant (MDR) cancer cells has been recently shown to be a cause for ineffective drug therapy. This process is poorly understood despite the fact that it has been observed in a large number of MDR cancer cell lines. Analysis of drug sequestration in these cells has traditionally been done using fluorescent anthracycline antibiotics (i.e. daunorubicin, doxorubicin). This narrow selection of substrates has resulted in a limited understanding of sequestration mechanisms and the intracellular compartments that are involved. To better characterize this phenotype, we chose to examine the sequestration of molecules having different acid/base properties in the MDR HL-60 human leukemic cell line. Here we show that weakly basic drug daunorubicin is sequestered into lysosomes according to a pH partitioning type mechanism, whereas sulforhodamime 101, a zwitterionic molecule, is sequestered into the Golgi apparatus through a drug transporter-mediated process. Quantitative intracellular pH measurements reveal that the lysosome-to-cytosol pH gradient is expanded in the MDR line. Moreover, the MDR cells overexpress the multidrug resistance-related protein (MRP1), which is localized to the Golgi apparatus. These results demonstrate, for the first time, that two distinct mechanisms for intracellular compartmentalization are operational in a single MDR cell line.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Krise, JP (corresponding author), Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA.	krise@unc.edu						Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Belhoussine R, 1999, INT J CANCER, V81, P81, DOI 10.1002/(SICI)1097-0215(19990331)81:1<81::AID-IJC15>3.0.CO;2-P; Benderra Z, 2000, EUR J CANCER, V36, P428, DOI 10.1016/S0959-8049(99)00288-9; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Ferrao P, 2001, LEUKEMIA RES, V25, P395, DOI 10.1016/S0145-2126(00)00156-9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P483; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; Lage H, 2000, Lancet Oncol, V1, P169, DOI 10.1016/S1470-2045(00)00032-2; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Litman T, 1998, CELL PHYSIOL BIOCHEM, V8, P138, DOI 10.1159/000016277; LUTZKY J, 1989, CANCER RES, V49, P4120; MA LD, 1992, BIOCHEM BIOPH RES CO, V182, P675, DOI 10.1016/0006-291X(92)91785-O; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.3.CO;2-W; Moriyama Y, 1996, J EXP BIOL, V199, P1447; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; Shapiro AB, 1998, INT J CANCER, V76, P857, DOI 10.1002/(SICI)1097-0215(19980610)76:6<857::AID-IJC15>3.0.CO;2-#; Sharma R, 2003, CURR CANCER DRUG TAR, V3, P89, DOI 10.2174/1568009033482047; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; SKOVSGAARD T, 1990, PEZ FDN SYM, P209; THIEBAUT F, 1990, J HISTOCHEM CYTOCHEM, V38, P685, DOI 10.1177/38.5.1692055; Van Der Kolk DM, 2002, LEUKEMIA LYMPHOMA, V43, P685, DOI 10.1080/10428190290016773; Van Luyn MJA, 1998, INT J CANCER, V76, P55, DOI 10.1002/(SICI)1097-0215(19980330)76:1<55::AID-IJC10>3.3.CO;2-O	31	78	83	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50234	50239		10.1074/jbc.M306606200	http://dx.doi.org/10.1074/jbc.M306606200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522995	Green Published, hybrid			2022-12-25	WOS:000187068200071
J	Morosinotto, T; Breton, J; Bassi, R; Croce, R				Morosinotto, T; Breton, J; Bassi, R; Croce, R			The nature of a chlorophyll ligand in Lhca proteins determines the far red fluorescence emission typical of photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; MUTATION ANALYSIS; HIGHER-PLANTS; BINDING; IDENTIFICATION; SUBUNITS; PIGMENTS; FORMS	Photosystem I of higher plants is characterized by a typically long wavelength fluorescence emission associated to its light-harvesting complex I moiety. The origin of these low energy chlorophyll spectral forms was investigated by using site-directed mutagenesis of Lhca1-4 genes and in vitro reconstitution into recombinant pigment-protein complexes. We showed that the red-shifted absorption originates from chlorophyll-chlorophyll (Chl) excitonic interactions involving Chl A5 in each of the four Lhca antenna complexes. An essential requirement for the presence of the red-shifted absorption/ fluorescence spectral forms was the presence of asparagine as a ligand for the Chl a chromophore in the binding site A5 of Lhca complexes. In Lhca3 and Lhca4, which exhibit the most red-shifted red forms, its substitution by histidine maintains the pigment binding and, yet, the red spectral forms are abolished. Conversely, in Lhca1, having very low amplitude of red forms, the substitution of Asn for His produces a red shift of the fluorescence emission, thus confirming that the nature of the Chl A5 ligand determines the correct organization of chromophores leading to the excitonic interaction responsible for the red-most forms. The red-shifted fluorescence emission at 730 nm is here proposed to originate from an absorption band at similar to 700 nm, which represents the low energy contribution of an excitonic interaction having the high energy band at 683 nm. Because the mutation does not affect Chl A5 orientation, we suggest that coordination by Asn of Chl A5 holds it at the correct distance with Chl B5.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, Fac Sci Luminy, Dept Biol, Lab Genet & Biophys Plantes, F-13288 Marseille, France; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France; CNR, Ist Biofis, I-38050 Trento, Italy	University of Verona; CEA; UDICE-French Research Universities; Aix-Marseille Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, Str Grazie 15, I-37134 Verona, Italy.	bassi@sci.univr.it	Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/ABG-3595-2021; Morosinotto, Tomas/AAC-3188-2019	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1987, EUR J BIOCHEM, V163, P221, DOI 10.1111/j.1432-1033.1987.tb10791.x; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1996, BIOCHEMISTRY-US, V35, P8572, DOI 10.1021/bi960214m; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; GOBETS B, 1994, BBA-BIOENERGETICS, V1188, P75, DOI 10.1016/0005-2728(94)90024-8; Gobets B, 2001, BBA-BIOENERGETICS, V1507, P80, DOI 10.1016/S0005-2728(01)00203-1; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V679, P428, DOI 10.1016/0005-2728(82)90164-5; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; Ihalainen JA, 2003, J PHYS CHEM B, V107, P9086, DOI 10.1021/jp034778t; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; MOROSINOTTO T, 2003, IN PRESS PHYSL PLANT; Mukerji I, 1990, CURRENT RES PHOTOSYN, VII, P321; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rivadossi A, 1999, PHOTOSYNTH RES, V60, P209, DOI 10.1023/A:1006236829711; SAUER K, 1966, J AM CHEM SOC, V88, P2681, DOI 10.1021/ja00964a011; Savikhin S, 1999, BIOPHYS J, V76, P3278, DOI 10.1016/S0006-3495(99)77480-1; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, BIOCHEMISTRY-US, V41, P9126, DOI 10.1021/bi016042x; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; VANAMERONGEN H, 2000, PHOTOSYNTHETIC EXCIT, P52	31	136	140	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49223	49229		10.1074/jbc.M309203200	http://dx.doi.org/10.1074/jbc.M309203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504274	hybrid			2022-12-25	WOS:000186829000087
J	Rychlik, JL; Gerbasi, V; Lewis, EJ				Rychlik, JL; Gerbasi, V; Lewis, EJ			The interaction between dHAND and Arix at the dopamine beta-hydroxylase promoter region is independent of direct dHAND binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEIN; REGULATES TRANSCRIPTION; GENE-TRANSCRIPTION; BRANCHIAL ARCH; CAMP-RESPONSE; LIMB BUD; EXPRESSION; EXTRADENTICLE; SPECIFICATION	Dopamine beta-hydroxylase (DBH) catalyzes the production of norepinephrine, and its expression defines the noradrenergic phenotype. Transcription factors dHAND, a basic helix-loop-helix protein, and Arix/ Phox2a, a homeoprotein, have been demonstrated to play a role in the differentiation and maintenance of catecholaminergic neurons. Three Arix regulatory sites have been identified in the DBH promoter proximal region, but there is no such evidence for dHAND. Cotransfection with a DBH promoter-luciferase reporter construct plus dHAND or dHAND-E12 expression plasmids did not alter luciferase activity, whereas transfection with Arix resulted in a 2.5-fold stimulation of luciferase activity. However, a 5.5-fold increase was observed when Arix and dHAND were combined, and an 8-fold level of expression was observed when Arix was transfected with a dHAND mutant lacking the basic DNA-binding domain. When the homeodomain sites in the DBH promoter proximal region were mutated, all activity was lost, demonstrating dependence upon Arix-DNA interaction for transcriptional activation. In electrophoretic mobility shift assays, the addition of dHAND decreased the amount of Arix needed to elicit a mobility shift with the DBH homeodomain sites, and the dHAND basic mutant potentiated Arix binding in a manner similar to wild-type dHAND. The dHAND-Arix complex was dissociated upon the addition of an unlabeled competitor containing a homeodomain, but not upon the addition of a competitor containing E-boxes. Arix coprecipitated with antisera directed against recombinant dHAND, demonstrating direct protein-protein interactions. These results indicate that the activation of the DBH promoter by Arix is potentiated by dHAND via a mechanism independent of a direct interaction of dHAND with DNA.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Rychlik, JL (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.			Gerbasi, Robert/0000-0001-5573-0578	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038696, R29GM038696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2000, DNA CELL BIOL, V19, P539, DOI 10.1089/104454900439773; Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Angelo S, 2000, MECH DEVELOP, V95, P231, DOI 10.1016/S0925-4773(00)00334-8; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Charite J, 2000, DEVELOPMENT, V127, P2461; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; Gestblom C, 1999, LAB INVEST, V79, P67; Goridis C, 2002, NAT REV NEUROSCI, V3, P531, DOI 10.1038/nrn871; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hong SJ, 2002, BIOTECHNIQUES, V33, P1236, DOI 10.2144/02336bm11; Howard M, 1999, DEV BIOL, V215, P62, DOI 10.1006/dbio.1999.9450; Howard MJ, 2000, DEVELOPMENT, V127, P4073; Kim HS, 1998, J NEUROSCI, V18, P8247; Lewis AL, 1999, J BIOL CHEM, V274, P14188, DOI 10.1074/jbc.274.20.14188; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; MOKENTIN JD, 1995, CELL, V83, P1125; Muller F, 2002, DEVELOPMENT, V129, P5707, DOI 10.1242/dev.00165; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1999, TRENDS CARDIOVAS MED, V9, P11, DOI 10.1016/S1050-1738(98)00033-4; Swanson DJ, 1998, J BIOL CHEM, V273, P24065, DOI 10.1074/jbc.273.37.24065; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; Thattaliyath BD, 2002, J MOL CELL CARDIOL, V34, P1335, DOI 10.1006/jmcc.2002.2085; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Welscher PT, 2002, GENE DEV, V16, P421, DOI 10.1101/gad.219202; Yamagishi H, 2000, J CLIN INVEST, V105, P261, DOI 10.1172/JCI8856; Yanagisawa H, 2003, DEVELOPMENT, V130, P1069, DOI 10.1242/dev.00337; Zellmer E, 1995, J NEUROSCI, V15, P8109	31	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49652	49660		10.1074/jbc.M308577200	http://dx.doi.org/10.1074/jbc.M308577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506227	hybrid			2022-12-25	WOS:000186829000137
J	Sherbet, DP; Tiosano, D; Kwist, KM; Hochberg, Z; Auchus, RJ				Sherbet, DP; Tiosano, D; Kwist, KM; Hochberg, Z; Auchus, RJ			CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; TESTICULAR MICROSOMAL CYTOCHROME-P-450; HUMAN P450C17; MOLECULAR-CLONING; OXYGEN ACTIVATION; GENE CYP17; AMINO-ACID; 17-ALPHA-HYDROXYLASE; B(5); TESTIS	Cytochrome P450c17 (CYP17) converts the C-21 steroids pregnenolone and progesterone to the C-19 androgen precursors dehydroepiandrosterone ( DHEA) and androstenedione, respectively, via sequential 17alpha-hydroxylase and 17,20-lyase reactions. Disabling mutations in CYP17 cause combined 17alpha-hydroxylase/17,20-lyase deficiency, but rare missense mutations cause isolated loss of 17,20-lyase activity by disrupting interactions of redox partner proteins with CYP17. We studied an adolescent male with clinical and biochemical features of isolated 17,20- lyase deficiency, including micropenis, hypospadias, and gynecomastia, who is homozygous for CYP17 mutation E305G, which lies in the active site. When expressed in HEK-293 cells or Saccharomyces cerevisiae, mutation E305G retains 17alpha-hydroxylase activities, converting pregnenolone and progesterone to 17alpha-hydroxysteroids. However, mutation E305G lacks 17,20- lyase activity for the conversion of 17alpha-hydroxypregnenolone to DHEA, which is the dominant pathway to C19 steroids catalyzed by human CYP17 ( the Delta(5)-steroid pathway). In contrast, mutation E305G exhibits 11-fold greater catalytic efficiency (k(cat)/K-m) for the cleavage of 17alpha-hydroxyprogesterone to androstenedione compared with wild-type CYP17. We conclude that mutation E305G selectively impairs 17,20- lyase activity for DHEA synthesis despite an increased capacity to form androstenedione. Mutation E305G provides genetic evidence that androstenedione formation from 17alpha-hydroxyprogesterone via the minor alpha(4)-steroid pathway alone is not sufficient for complete formation of the male phenotype in humans.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Dallas, TX 75390 USA; Meyer Childrens Hosp, Rambam Med Ctr, Div Endocrinol, IL-31096 Haifa, Israel	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Rambam Health Care Campus; Technion Israel Institute of Technology	Auchus, RJ (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Endocrinol & Metab, POB 8857,5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NIDDK NIH HHS [R03DK56641, K08DK02387] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002387, R03DK056641] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Arlt W, 2002, ENDOCRINOLOGY, V143, P4665, DOI 10.1210/en.2002-220456; Auchus RJ, 1999, MOL ENDOCRINOL, V13, P1169, DOI 10.1210/me.13.7.1169; Auchus RJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P134, DOI 10.1016/S0003-9861(02)00491-5; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Auchus RJ, 2001, ENDOCRIN METAB CLIN, V30, P101, DOI 10.1016/S0889-8529(08)70021-5; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; BIGLIERI EG, 1966, J CLIN INVEST, V15, P1945; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; COSTASANTOS M, 2003, IN PRESS J CLIN ENDO; Dealwis CG, 1995, PROTEIN ENG, V8, P865, DOI 10.1093/protein/8.9.865; FEVOLD HR, 1989, MOL ENDOCRINOL, V3, P968, DOI 10.1210/mend-3-6-968; Fluck CE, 2003, J CLIN ENDOCR METAB, V88, P3762, DOI 10.1210/jc.2003-030143; Geller DH, 1999, MOL ENDOCRINOL, V13, P167, DOI 10.1210/me.13.1.167; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOTOH O, 1992, J BIOL CHEM, V267, P83; Graham SE, 2002, METHOD ENZYMOL, V357, P15; Griffin JE, 2003, WILLIAMS TXB ENDOCRI, P709; Gupta MK, 2001, J CLIN ENDOCR METAB, V86, P4416, DOI 10.1210/jc.86.9.4416; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P319; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; Lee-Robichaud P, 1999, BIOCHEM J, V342, P309, DOI 10.1042/0264-6021:3420309; Lee-Robichaud P, 1998, BIOCHEM J, V330, P967, DOI 10.1042/bj3300967; LEEROBICHAUD P, 1995, BIOCHEM J, V308, P901, DOI 10.1042/bj3080901; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Miura K, 1996, J CLIN ENDOCR METAB, V81, P3797, DOI 10.1210/jc.81.10.3797; NAKAJIN S, 1981, J BIOL CHEM, V256, P6134; NAKAJIN S, 1981, BIOCHEMISTRY-US, V20, P4037, DOI 10.1021/bi00517a014; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; Shimada H, 1999, J BIOL CHEM, V274, P9363, DOI 10.1074/jbc.274.14.9363; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Szczebara FM, 2003, NAT BIOTECHNOL, V21, P143, DOI 10.1038/nbt775; TREMBLAY Y, 1994, DNA CELL BIOL, V13, P1199, DOI 10.1089/dna.1994.13.1199; Van Den Akker ELT, 2002, J CLIN ENDOCR METAB, V87, P5714, DOI 10.1210/jc.2001-011880; YANAGIBASHI K, 1986, J BIOL CHEM, V261, P8429; YANASE T, 1992, BIOCHIM BIOPHYS ACTA, V1139, P275, DOI 10.1016/0925-4439(92)90100-2; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; Yang WH, 2003, J BIOL CHEM, V278, P9552, DOI 10.1074/jbc.M212027200; YOUNGBLOOD GL, 1992, MOL ENDOCRINOL, V6, P927, DOI 10.1210/me.6.6.927; ZHOU D, 1992, J BIOL CHEM, V267, P762	45	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48563	48569		10.1074/jbc.M307586200	http://dx.doi.org/10.1074/jbc.M307586200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504283	hybrid			2022-12-25	WOS:000186829000008
J	Watcharasit, P; Bijur, GN; Song, L; Zhu, JH; Chen, XB; Jope, RS				Watcharasit, P; Bijur, GN; Song, L; Zhu, JH; Chen, XB; Jope, RS			Glycogen synthase kinase-3 beta (GSK3 beta) binds to and promotes the actions of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; FUNCTIONAL DOMAINS; INDUCED APOPTOSIS; TERMINAL DOMAIN; KINASE 3-BETA; CYTOCHROME-C; DNA-BINDING; PROTEIN; ACTIVATION; MITOCHONDRIA	The recent discovery of direct interactions between two important regulators of cell fate, the tumor suppressor p53 and glycogen synthase kinase-3beta (GSK3beta), led us to examine the mechanism and outcomes of this interaction. Two regions of p53 were identified that regulate its binding to GSK3beta. Deletion of the p53 activation domain-1 (AD1), but not mutations that prevent MDM2 binding through the AD1 domain, enhanced GSK3beta binding to p53, indicating that the AD1 domain interferes with p53 binding to GSK3beta. Deletion of the p53 basic domain (BD) abrogated GSK3beta binding, and a ten amino acid region within the C-terminal BD domain was identified as necessary for binding to GSK3beta. GSK3beta activity was not required for p53 binding, but inhibition of GSK3beta stabilized the association, suggesting a transient interaction during which active GSK3beta promotes actions of p53. This regulatory role of GSK3beta was demonstrated by large reductions of p53-induced increases in the levels of MDM2, p21, and Bax when GSK3beta was inhibited. Besides promoting p53-mediated transcription, GSK3beta also contributed to mitochondrial p53 apoptotic signaling. After DNA damage, mitochondrial GSK3beta co-immunoprecipitated with p53 and was activated, and inhibition of GSK3beta blocked cytochrome c release and caspase-3 activation. Thus, GSK3beta interacts with p53 in both the nucleus and mitochondria and promotes its actions at both sites.	Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Jope, RS (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,Sparks Ctr 1057, Birmingham, AL 35294 USA.		Watcharasit, Piyajit/N-4408-2016		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021045] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG021045] Funding Source: Medline; NIMH NIH HHS [R01 MH038752] Funding Source: Medline; NINDS NIH HHS [R01 NS037768] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Naerum L, 2002, BIOORG MED CHEM LETT, V12, P1525, DOI 10.1016/S0960-894X(02)00169-5; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Song L, 1999, J BIOL CHEM, V274, P29689, DOI 10.1074/jbc.274.42.29689; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	39	223	232	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48872	48879		10.1074/jbc.M305870200	http://dx.doi.org/10.1074/jbc.M305870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14523002	hybrid, Green Accepted			2022-12-25	WOS:000186829000044
J	Jost, MM; Ninci, E; Meder, B; Kempf, C; van Royen, N; Hua, J; Berger, B; Hoefer, I; Modolell, M; Buschmann, N				Jost, MM; Ninci, E; Meder, B; Kempf, C; van Royen, N; Hua, J; Berger, B; Hoefer, I; Modolell, M; Buschmann, N			Divergent effects of GM-CSF and TGF beta(1) on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix-metalloproteinase-12: a potential role during arteriogenesis	FASEB JOURNAL			English	Article						blood vessels; bone marrow cells; cell adhesion; cytokines; gene expression	COLONY-STIMULATING FACTOR; L-ARGININE TRANSPORT; COLLATERAL GROWTH; IN-VIVO; CELLS; ARTERY; ANGIOGENESIS; GENE; TRANSPLANTATION; PROTEOLYSIS	Granulocyte/macrophage-colony stimulating factor (GM-CSF) and transforming growth factor (TGF)beta(1) induce arteriogenesis in a nonischemic model of femoral artery ligation. Moreover, clinical trials demonstrated an improved collateralization after injection of bone marrow cells. In the present study, the expression of arteriogenic factors in bone marrow-derived macrophages (BMDM) was measured to verify the potential of these cells to influence collateral artery growth. GM-CSF induced in BMDM the expression of monocyte chemoattractive protein (MCP)-1, matrix-metalloproteinase (MMP)-12, and arginase-1-the latter also showing a remarkable increase in activity. During in vivo induced arteriogenesis, the accumulation rate of macrophages around proliferating collaterals was significantly increased. We also show that MCP-1 is found to be mainly expressed in the media of the vessel wall, MMP-12 in macrophages of the adventitia, and arginase at both locations. This study provides for the first time a comprehensive analysis of GM-CSF/TGFbeta(1)-regulated arteriogenic factors in BMDM and supports the hypothesis that arteriogenesis is a multistage mechanism, including monocyte/macrophage adhesion and transmigration, pro-arteriogenic cytokine expression, degradation of connective tissue, and collagen synthesis regulation. Selective modulation of these mechanisms as well as cell-based therapies supplying arteriogenic factors in vivo point toward new strategies to influence collateral artery growth.	Univ Freiburg, Dept Internal Med Cardiol & Angiol 3, Res Grp Expt & Clin Arteriogenesis, D-79106 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Jost, MM (corresponding author), Univ Freiburg, Dept Internal Med 3, Res Grp Expt & Clin Arteriogenesis, Breisacher Str 66 ZKF, D-79106 Freiburg, Germany.	meyer@med1.ukl.uni-freiburg.de	van Royen, Niels/Q-1097-2017					Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Ballermann BJ, 1998, KIDNEY INT, V54, pS100, DOI 10.1046/j.1523-1755.1998.06720.x; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; Buschmann IR, 2003, CIRCULATION, V108, P610, DOI 10.1161/01.CIR.0000074209.17561.99; Buschmann Ivo, 1999, Journal of the American College of Cardiology, V33, p318A; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; Durante W, 2000, FASEB J, V14, P1775, DOI 10.1096/fj.99-0960com; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E; Epstein SE, 2001, CARDIOVASC RES, V49, P532, DOI 10.1016/S0008-6363(00)00217-0; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Greaves DR, 2002, TRENDS IMMUNOL, V23, P535, DOI 10.1016/S1471-4906(02)02331-1; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Hoefer IE, 2002, CIRCULATION, V105, P1639, DOI 10.1161/01.CIR.0000014987.32865.8E; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Kosaki K, 1998, CIRC RES, V82, P794, DOI 10.1161/01.RES.82.7.794; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Li H, 2002, AM J PHYSIOL-REG I, V282, pR64, DOI 10.1152/ajpregu.2002.282.1.R64; Lijnen HR, 1999, THROMB HAEMOSTASIS, V81, P799; LIN EY, 1993, J IMMUNOL, V151, P1979; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; Malik N, 1996, J IMMUNOL, V156, P3952; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Rozen S., 1998, PRIMER3; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje; van Royen N, 2003, CIRC RES, V92, P218, DOI 10.1161/01.RES.0000052313.23087.3F	41	51	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2281	+		10.1096/fj.03-0071fje	http://dx.doi.org/10.1096/fj.03-0071fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525945				2022-12-25	WOS:000186343300007
J	Rosenfeldt, HM; Amrani, Y; Watterson, KR; Murthy, KS; Panettieri, RA; Spiegel, S				Rosenfeldt, HM; Amrani, Y; Watterson, KR; Murthy, KS; Panettieri, RA; Spiegel, S			Sphingosine-l-phosphate stimulates contraction of human airway smooth muscle cells	FASEB JOURNAL			English	Article						asthma; airway smooth muscle cells; sphingosine-1-phosphate; contractility	COLLAGEN-MATRIX CONTRACTION; SIGNAL-TRANSDUCTION; RECEPTOR EDG-1; STRESS FIBERS; RHO-KINASE; G-PROTEINS; IN-VITRO; 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; PHOSPHORYLATION	The bioactive sphingolipid sphingosine-1-phosphate (SIP) that is increased in airways of asthmatic subjects markedly induced contraction of human airway smooth muscle (HASM) cells embedded in collagen matrices in a G; independent manner. Dihydro-S1P, which binds to SIP receptors, also stimulated contractility. SIP induced formation of stress fibers, contraction of individual HASM cells, and stimulated myosin light chain phosphorylation, which was inhibited by the Rho-associated kinase inhibitor Y-27632. S1P-stimulated HASM cell contractility was independent of the ERK1/2 and PKC signaling pathways, important regulators of airway smooth muscle contraction. However, removal of extracellular calcium completely blocked S1P-mediated contraction and Y-27632 reduced it. SIP also induced calcium mobilization that was not desensitized by repeated additions. Pretreatment with thapsigargin to deplete InsP3 sensitive calcium stores partially blocked increases in [Ca2+](i) induced by SIP, yet did not inhibit S1P-stimulated contraction. In sharp contrast, the L-type calcium channel blocker verapamil markedly decreased S1P-induced HASM cell contraction, supporting a role for calcium influx from extracellular sources. Collectively, our results suggest that SIP may regulate HASM contractility, important in the pathobiology of asthma.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Dept Physiol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; University of Pennsylvania; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,2-011 Sanger Hall,1101 E, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Amrani, Yassine/Q-6323-2019	Amrani, Yassine/0000-0002-7042-6926	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, P50HL067663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67663, P01 HL067663, P50 HL067663] Funding Source: Medline; NIAID NIH HHS [AI50094, R01 AI050094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Amrani Y, 2002, CURR OPIN ALLERGY CL, V2, P39, DOI 10.1097/00130832-200202000-00007; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BURRIDGE K, 1981, NATURE, V294, P691, DOI 10.1038/294691a0; Cain AE, 2002, HYPERTENSION, V39, P543, DOI 10.1161/hy0202.103129; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Formigli L, 2002, AM J PHYSIOL-CELL PH, V282, pC1361, DOI 10.1152/ajpcell.00378.2001; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Hirshman CA, 1999, LIFE SCI, V64, P443, DOI 10.1016/S0024-3205(98)00586-4; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hori M, 1998, LIFE SCI, V62, P1629, DOI 10.1016/S0024-3205(98)00119-2; Ishihata A, 2002, EUR J PHARMACOL, V445, P247, DOI 10.1016/S0014-2999(02)01790-9; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Meacci E, 2002, BIOCHEM J, V362, P349, DOI 10.1042/0264-6021:3620349; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; Oishi K, 2000, AM J PHYSIOL-CELL PH, V279, pC1432, DOI 10.1152/ajpcell.2000.279.5.C1432; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Roux E, 1998, GEN PHARMACOL, V31, P349, DOI 10.1016/S0306-3623(98)00007-X; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Tornquist K, 1997, ENDOCRINOLOGY, V138, P4049, DOI 10.1210/en.138.10.4049; Tosaka M, 2001, STROKE, V32, P2913, DOI 10.1161/hs1201.099525; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Zhong JM, 2001, J PHYSIOL-LONDON, V531, P105, DOI 10.1111/j.1469-7793.2001.0105j.x	41	104	108	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1789	1799		10.1096/fj.02-0836com	http://dx.doi.org/10.1096/fj.02-0836com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519658				2022-12-25	WOS:000186343300033
J	Desai, AA; Innocenti, F; Ratain, MJ				Desai, AA; Innocenti, F; Ratain, MJ			Pharmacogenomics: road to anticancer therapeutics nirvana?	ONCOGENE			English	Review						pharmacogenomics; cancer chemotherapy; EGFR; irinotecan; thymidylate synthase	EPIDERMAL-GROWTH-FACTOR; THYMIDYLATE-SYNTHASE GENE; HUMAN UDP-GLUCURONOSYLTRANSFERASES; ACTIVE METABOLITE; REPEATED SEQUENCES; IRINOTECAN CPT-11; COLORECTAL-CANCER; REGULATORY REGION; UGT1A1 PROMOTER; ENHANCER REGION	Interindividual differences in the toxicity and response to anticancer therapies are currently observed for essentially all available treatment regimens. Such 'unpredictable' drug responses are particularly dangerous in the context of anticancer agents that have narrow therapeutic indices. Pharmacogenomics attempts to elucidate the inherited basis of interindividual differences in drug response, with the eventual goal of minimizing such variability through the use of 'individualized' treatments. There are several emerging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug targets that have been shown to influence the toxicity and efficacy of anticancer treatment. This review discusses the role of genetic variants of UGT1A1, TS and EGFR to exemplify the potential impact of phramacogenomics on the field of anticancer therapeutics.	Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Ratain, MJ (corresponding author), Univ Chicago, Canc Res Ctr, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	mratain@medicine.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER; NIGMS NIH HHS [U01GM61393] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acuna Gonzalo, 2002, Pharmacogenomics Journal, V2, P327, DOI 10.1038/sj.tpj.6500123; ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; Akaba K, 1998, BIOCHEM MOL BIOL INT, V46, P21; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Ando Y, 2000, CANCER RES, V60, P6921; ARAKI E, 1993, JPN J CANCER RES, V84, P697, DOI 10.1111/j.1349-7006.1993.tb02031.x; Aschele C, 1999, J CLIN ONCOL, V17, P1760, DOI 10.1200/JCO.1999.17.6.1760; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BRUNO R, 2003, P ASCO, V22; BURCHELL B, 1995, LIFE SCI, V57, P1819, DOI 10.1016/0024-3205(95)02073-R; Burchell B, 1999, J GASTROEN HEPATOL, V14, P960, DOI 10.1046/j.1440-1746.1999.01984.x; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen Z, 2000, ANTICANCER RES, V20, P899; Chi D. D., 1992, Human Molecular Genetics, V1, P135, DOI 10.1093/hmg/1.2.135; CHRYSOGELOS SA, 1993, NUCLEIC ACIDS RES, V21, P5736, DOI 10.1093/nar/21.24.5736; Chu E, 1999, CANC DRUG DISC DEV, P397; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; CLARK GM, 2003, P ASCO, V22; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Dolnick BJ, 2000, CANCER J, V6, P215; EVANS DAP, 1968, ANN NY ACAD SCI, V151, P723, DOI 10.1111/j.1749-6632.1968.tb11933.x; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Fuchs CS, 2003, J CLIN ONCOL, V21, P807, DOI 10.1200/JCO.2003.08.058; Fukuoka M, 2002, P AN M AM SOC CLIN, V21, p298a; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; GRAU JJ, 2003, P ASCO, V22; GUPTA E, 1994, CANCER RES, V54, P3723; HALEY JD, 1991, J BIOL CHEM, V266, P1746; Hidalgo M, 2001, J CLIN ONCOL, V19, P3267, DOI 10.1200/JCO.2001.19.13.3267; HORIE N, 1995, CELL STRUCT FUNCT, V20, P191, DOI 10.1247/csf.20.191; Huang CS, 2000, PHARMACOGENETICS, V10, P539, DOI 10.1097/00008571-200008000-00007; Humerickhouse R, 2000, CANCER RES, V60, P1189; Innocenti F, 2002, PHARMACOGENETICS, V12, P725, DOI 10.1097/00008571-200212000-00006; Innocenti F, 2002, EUR J CANCER, V38, P639, DOI 10.1016/S0959-8049(01)00434-8; INNOCENTI F, 2003, P ASCO, V22; Innocenti F, 2002, PHARMACOGENOMICS SEA; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Iyer L, 1998, CANCER CHEMOTH PHARM, V42, pS31, DOI 10.1007/s002800051077; Iyer L., 2002, Pharmacogenomics Journal, V2, P43, DOI 10.1038/sj.tpj.6500072; Iyer L, 1998, J CLIN INVEST, V101, P847, DOI 10.1172/JCI915; JOHNSTON PG, 1994, J CLIN ONCOL, V12, P2640, DOI 10.1200/JCO.1994.12.12.2640; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1995, CANCER RES, V55, P1407; KALOW W, 1956, LANCET, V271, P576; KANEDA S, 1987, NUCLEIC ACIDS RES, V15, P1259, DOI 10.1093/nar/15.3.1259; KAWABE S, 2003, P AM SOC CLIN ONCOLO, V22; Kawakami K., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P436; Kohn EC, 1997, J CLIN ONCOL, V15, P1985, DOI 10.1200/JCO.1997.15.5.1985; Korn EL, 2001, J CLIN ONCOL, V19, P265, DOI 10.1200/JCO.2001.19.1.265; Kornmann M, 1997, CANCER LETT, V118, P29, DOI 10.1016/S0304-3835(97)00220-6; KRIS MG, 2002, P ASCO, V21; Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; Liu WQ, 2003, CLIN CANCER RES, V9, P1009; Luo HR, 2002, BIOCHEM GENET, V40, P41, DOI 10.1023/A:1014589105977; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Mandola MV, 2003, CANCER RES, V63, P2898; Marsh S, 2000, Hum Mutat, V16, P528; Marsh S, 2001, INT J ONCOL, V19, P383; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Monaghan G, 1997, PHARMACOGENETICS, V7, P153, DOI 10.1097/00008571-199704000-00010; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Nagasubramanian R, 2003, ANNU REV MED, V54, P437, DOI 10.1146/annurev.med.54.101601.152352; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; PESTALOZZI BC, 1995, BRIT J CANCER, V71, P1151, DOI 10.1038/bjc.1995.225; Peus D, 1997, J INVEST DERMATOL, V109, P751, DOI 10.1111/1523-1747.ep12340759; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65; Ratain MJ, 2001, NAT MED, V7, P283, DOI 10.1038/85414; Reardon David A, 2003, Oncology (Williston Park), V17, P9; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALTZ L, 2002, P ASCO, V21; Saltz LB, 2003, P ASCO, V22, p817a; Sampietro M, 1999, HAEMATOLOGICA, V84, P150; Santos A, 2000, CLIN CANCER RES, V6, P2012; Sato H, 1996, LANCET, V347, P557, DOI 10.1016/S0140-6736(96)91266-0; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SOONG R, 2003, P ASCO, V22; Stadler WM, 2000, INVEST NEW DRUG, V18, P7, DOI 10.1023/A:1006371512390; Sugatani J, 2002, BIOCHEM BIOPH RES CO, V292, P492, DOI 10.1006/bbrc.2002.6683; Sung T, 2000, BRAIN PATHOL, V10, P249, DOI 10.1111/j.1750-3639.2000.tb00258.x; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Villafranca E, 2001, J CLIN ONCOL, V19, P1779, DOI 10.1200/JCO.2001.19.6.1779	90	41	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6621	6628		10.1038/sj.onc.1206958	http://dx.doi.org/10.1038/sj.onc.1206958			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528287				2022-12-25	WOS:000185700700019
J	Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE				Iyengar, P; Combs, TP; Shah, SJ; Gouon-Evans, V; Pollard, JW; Albanese, C; Flanagan, L; Tenniswood, MP; Guha, C; Lisanti, MP; Pestell, RG; Scherer, PE			Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization	ONCOGENE			English	Review						stromal cells; heterotypic signaling; breast cancer; adipocytes; Type VI collagen	HUMAN-BREAST-CANCER; BETA-CATENIN; EPITHELIAL-CELL; GENE-EXPRESSION; ADIPOSE-TISSUE; GROWTH-FACTOR; MALIGNANT-TRANSFORMATION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MESSENGER-RNA	Mammary epithelial cells are embedded in a unique extracellular environment to which adipocytes and other stromal cells contribute. Mammary epithelial cells are critically dependent on this milieu for survival. However, it remains unknown which adipocyte-secreted factors are required for the survival of the mammary epithelia and what role these adipokines play in the process of ductal carcinoma tumorigenesis. Here, we take a systematic molecular approach to investigate the multiple ways adipocytes and adipokines can uniquely influence the characteristics and phenotypic behavior of malignant breast ductal epithelial cells. Microarray analysis and luciferase reporter assays indicate that adipokines specifically induce several transcriptional programs involved in promoting tumorigenesis, including increased cell proliferation (IGF2, FOS, JUN, cyclin D1), invasive potential (MMP1, ATF3), survival (A20, NFkappaB), and angiogenesis. One of the key changes in the transformed ductal epithelial cells associated with the cell cycle involves the induction of NFkappaB (five-fold) and cyclin D1 (three-fold). We show that by regulating the transcription of these molecules, the synergistic activity of adipocyte-derived factors can potentiate MCF-7 cell proliferation. Furthermore, compared to other stromal cell-secreted factors, the full complement of adipokines shows an unparalleled ability to promote increased cell motility, migration, and the capacity for angiogenesis. Adipocyte-secreted factors can affect tumorigenesis by increasing the stabilization of pro-oncogenic factors such as beta-catenin and CDK6 as a result of a reduction in the gene expression of their inhibitors (i.e. p18). An in vivo coinjection system using 3T3-L1 adipocytes and SUM159PT cells effectively recapitulates the host-tumor interactions in primary tumors. Type VI collagen, a soluble extracellular matrix protein abundantly expressed in adipocytes, is further upregulated in adipocytes during tumorigenesis. It promotes GSK3beta phosphorylation, beta-catenin stabilization, and increased beta-catenin activity in breast cancer cells and may critically contribute towards tumorigenesis when not counterbalanced by other factors.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; Univ Notre Dame, Galvin Life Sci Ctr, Notre Dame, IN 46556 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Georgetown University; University of Notre Dame; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Gouon-Evans, Valerie/0000-0001-5424-6573; Shah, Shalin/0000-0002-1622-8443	NATIONAL CANCER INSTITUTE [R01CA094173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [CA94173] Funding Source: Medline; NIDDK NIH HHS [1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achison M, 2001, J BIOL CHEM, V276, P3167, DOI 10.1074/jbc.M007186200; Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Atkinson JC, 1996, EXP CELL RES, V228, P283, DOI 10.1006/excr.1996.0328; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BATSAKIS JG, 1983, HEAD NECK SURG, V5, P222, DOI 10.1002/hed.2890050307; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berking C, 2001, CANCER RES, V61, P8306; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bickel PE, 2000, BIOTECHNOL GENET ENG, V17, P417, DOI 10.1080/02648725.2000.10648000; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; Chamras H, 1998, NUTR CANCER, V32, P59, DOI 10.1080/01635589809514719; Charpentier AH, 2000, CANCER RES, V60, P5977; Cheng YC, 2001, MOL BRAIN RES, V92, P193, DOI 10.1016/S0169-328X(01)00147-4; CHRISTIANSEN NO, 1992, ACTA BIOCHIM BIOPHYS, V26, P1; Codd JD, 1999, J PATHOL, V187, P549; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Cunha GR, 2000, ADV EXP MED BIOL, V480, P93; de la Guardia C, 2001, HEAD NECK-J SCI SPEC, V23, P104; Dieudonne MN, 2002, BIOCHEM BIOPH RES CO, V293, P622, DOI 10.1016/S0006-291X(02)00205-X; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; ELLIOTT BE, 1992, INT J CANCER, V51, P416, DOI 10.1002/ijc.2910510314; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FIDLER I, 2001, J NATL CANC I MONOGR, V28, P10; Fidler I J, 2001, Surg Oncol Clin N Am, V10, P257; Fidler IJ, 2001, JNCI-J NATL CANCER I, V93, P1040, DOI 10.1093/jnci/93.14.1040; Flanagan L, 1999, BREAST CANCER RES TR, V58, P193, DOI 10.1023/A:1006331716981; FRIDMAN R, 1991, JNCI-J NATL CANCER I, V83, P769, DOI 10.1093/jnci/83.11.769; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen RK, 2000, ENDOCR-RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Hayward SW, 2001, CANCER RES, V61, P8135; Heber D, 1996, ADV EXP MED BIOL, V399, P41; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; Huss FRM, 2001, CELLS TISSUES ORGANS, V169, P361, DOI 10.1159/000047903; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; JOHNSTON PG, 1992, CANCER RES, V52, P6860; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lapointe J, 1996, CANCER RES, V56, P4586; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1983, LAB INVEST, V49, P636; Liu SC, 2000, ORAL ONCOL, V36, P145, DOI 10.1016/S1368-8375(99)00076-7; Matrisian LM, 2001, CANCER RES, V61, P3844; McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123; McKeon F, 1999, Breast Cancer Res, V1, P8, DOI 10.1186/bcr4; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; O'Brien SN, 1999, BIOCHEM BIOPH RES CO, V259, P695, DOI 10.1006/bbrc.1999.0843; Oh Y, 1997, ENDOCRINE, V7, P111, DOI 10.1007/BF02778076; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Pentecost BT, 1998, J STEROID BIOCHEM, V64, P25, DOI 10.1016/S0960-0760(97)00140-4; Perks CM, 2000, J MAMMARY GLAND BIOL, V5, P75, DOI 10.1023/A:1009519400591; PEYRAT JP, 1988, CANCER RES, V48, P6429; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1998, IN VITRO CELL DEV-AN, V34, P412; Rasmussen AA, 1998, BREAST CANCER RES TR, V47, P219, DOI 10.1023/A:1005903000777; Ross JS, 2001, ANN NY ACAD SCI, V947, P271; Ruhl M, 1999, J BIOL CHEM, V274, P34361, DOI 10.1074/jbc.274.48.34361; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SHERR CJ, 1994, STEM CELLS, V12, P47; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shigeishi H, 2001, PATHOBIOLOGY, V69, P24, DOI 10.1159/000048754; SILVERMAN KJ, 1988, BIOCHEM BIOPH RES CO, V153, P347, DOI 10.1016/S0006-291X(88)81229-4; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; Tani M, 1997, GENOMICS, V39, P30, DOI 10.1006/geno.1996.4483; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; Wagenaar RA, 2001, CANCER RES, V61, P2097; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Ye S, 2001, CANCER RES, V61, P1296; Zangani D, 1999, EXP CELL RES, V247, P399, DOI 10.1006/excr.1998.4373; Zhang JY, 2001, CLIN EXP IMMUNOL, V125, P3, DOI 10.1046/j.1365-2249.2001.01585.x	105	263	282	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6408	6423		10.1038/sj.onc.1206737	http://dx.doi.org/10.1038/sj.onc.1206737			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508521				2022-12-25	WOS:000185535300011
J	Becker, KP; Hannun, YA				Becker, KP; Hannun, YA			CPKC-dependent sequestration of membrane-recycling components in a subset of recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3T3 FIBROBLASTS; PHOSPHOLIPASE-D; PHORBOL ESTERS; BREFELDIN-A; RECEPTOR; CELLS; GOLGI; TRANSLOCATION; LOCALIZATION	In addition to the classical role of protein kinase C (PKC) as a mediator of transmembrane signals initiated at the plasma membrane, there is also significant evidence to suggest that a more sustained PKC activity is necessary for a variety of long term cellular responses. To date, the subcellular localization of PKC during sustained activation has not been extensively studied. We report here that long term activation of PKC (1 h) leads to the selective translocation of classical PKC isoenzymes, alpha and betaII, to a juxtanuclear compartment. Juxtanuclear translocation of PKC required an intact C1 and C2 domain, and occurred in a microtubule-dependent manner. This juxtanuclear compartment was localized close to the Golgi complex but displayed no overlap with Golgi markers, and was resistant to dispersal with Golgi disrupting agents, brefeldin A and nocodazole. Further characterization revealed that PKCalpha and betaII translocated to a compartment that colocalized with the small GTPase, rab11, which is a marker for the subset of recycling endosomes concentrated around the microtubule-organizing center/centrosome. Analysis of the functional consequence of cPKC translocation on membrane recycling demonstrated a cPKC-dependent sequestration of transferrin, a marker of membrane recycling, in the cPKC compartment. These results identify a novel site for cPKC translocation and define a novel function for the sustained activation of PKCalpha and betaII in regulation of recycling components.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL 43707] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BOUVIER M, 1991, FEBS LETT, V279, P243, DOI 10.1016/0014-5793(91)80159-Z; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P1344, DOI 10.1016/S0006-291X(89)80151-2; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOOY J, 1992, J BIOL CHEM, V267, P20255; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MIRANDA AF, 1974, J CELL BIOL, V62, P406, DOI 10.1083/jcb.62.2.406; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Song Y, 1999, MOL BIOL CELL, V10, P1609, DOI 10.1091/mbc.10.5.1609; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; WELSH CJ, 1991, IN VITRO CELL DEV B, V27, P425; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Widmann C, 1996, J BIOL CHEM, V271, P19957, DOI 10.1074/jbc.271.33.19957; Wigley WC, 1999, J CELL BIOL, V145, P481; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8	49	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52747	52754		10.1074/jbc.M305228200	http://dx.doi.org/10.1074/jbc.M305228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527960	hybrid			2022-12-25	WOS:000187480700093
J	Kuberan, B; Beeler, DL; Lech, M; Wu, ZLL; Rosenberg, RD				Kuberan, B; Beeler, DL; Lech, M; Wu, ZLL; Rosenberg, RD			Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HERPES-SIMPLEX-VIRUS; HEPARIN/HEPARAN SULFATE; CAPSULAR POLYSACCHARIDE; N-SULFOTRANSFERASE; HIGH-AFFINITY; ANTITHROMBIN; BINDING; BIOSYNTHESIS; EXPRESSION	Heparan sulfate (HS) polysaccharides interact with numerous proteins at the cell surface and orchestrate many different biological functions. Though many functions of HS are well established, only a few specific structures can be attributed to HS functions. The extreme diversity of HS makes chemical synthesis of specific bioactive HS structures a cumbersome and tedious undertaking that requires laborious and careful functional group manipulations. Now that many of the enzymes involved in HS biosynthesis are characterized, we show in this study how one can rapidly and easily assemble bioactive HS structures with a set of cloned enzymes. We have demonstrated the feasibility of this new approach to rapidly assemble antithrombin III-binding classical and non-classical anticoagulant polysaccharide structures for the first time.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Mol Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, 31 Ames St,68-480, Cambridge, MA 02142 USA.	rdrrosen@mit.edu		Balagurunathan, Kuberan/0000-0001-9203-8118; Wu, Zhengliang/0000-0002-0700-0906	NHLBI NIH HHS [P01HL41484, P01HL66105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL066105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; JEMTH P, 2003, J BIOL CHEM, V278, P30567; Kuberan B, 2003, NAT BIOTECHNOL, V21, P1343, DOI 10.1038/nbt885; Kuberan B, 2003, J AM CHEM SOC, V125, P12424, DOI 10.1021/ja036737g; Kuberan B, 2002, J AM CHEM SOC, V124, P8707, DOI 10.1021/ja0178867; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIVELY JE, 1970, BIOCHEMISTRY-US, V9, P33, DOI 10.1021/bi00803a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SINAY P, 1984, CARBOHYD RES, V132, pC5, DOI 10.1016/0008-6215(84)85236-2; Stephan D, 1997, FUND CLIN PHARMACOL, V11, P97, DOI 10.1111/j.1472-8206.1997.tb00175.x; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200	42	40	43	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52613	52621		10.1074/jbc.M305029200	http://dx.doi.org/10.1074/jbc.M305029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14519763	hybrid			2022-12-25	WOS:000187480700079
J	Gong, CL; Martins, A; Shuman, S				Gong, CL; Martins, A; Shuman, S			Structure-function analysis of Trypanosoma brucei RNA triphosphatase and evidence for a two-metal mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO FUNCTION; MESSENGER-RNA; MUTATIONAL ANALYSIS; CAPPING APPARATUS; GUANYLYLTRANSFERASE COMPONENT; NUCLEOSIDE TRIPHOSPHATASE; CAP STRUCTURE; DRUG TARGET; ACTIVE-SITE; YEAST	Trypanosoma brucei RNA triphosphatase TbCet1 is a 252- amino acid polypeptide that catalyzes the first step in mRNA cap formation. By performing an alanine scan of TbCet1, we identified six amino acids that are essential for triphosphatase activity ( Glu- 52, Arg- 127, Glu- 168, Arg- 186, Glu- 216, and Glu- 218). These results consolidate the proposal that protozoan, fungal, and Chlorella virus RNA triphosphatases belong to a single family of metal-dependent NTP phosphohydrolases with a unique tunnel active site composed of eight beta strands. Limited proteolysis of TbCet1 suggests that the hydrophilic N terminus is surface- exposed, whereas the catalytic core domain is tightly folded with the exception of a protease-sensitive loop ( (76)WKGRRARKT(84)) between two of the putative tunnel strands. The catalytic domain of TbCet1 is extraordinarily thermostable. It remains active after heating for 2 h at 75 degrees C. Analysis by zonal velocity sedimentation indicates that TbCet1 is a monomeric enzyme, unlike fungal RNA triphosphatases, which are homodimers. We show that tripolyphosphate is a potent competitive inhibitor of TbCet1 ( K-i 1.4 muM) that binds more avidly to the active site than the ATP substrate ( K-m 25 muM). We present evidence of synergistic activation of the TbCet1 triphosphatase by manganese and magnesium, consistent with a two- metal mechanism of catalysis. Our findings provide new insight to the similarities ( in active site tertiary structure and catalytic mechanism) and differences ( in quaternary structure and thermal stability) among the different branches of the tunnel enzyme family.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGS JD, 1992, J BIOL CHEM, V267, P9805; Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gong CL, 2002, J BIOL CHEM, V277, P15317, DOI 10.1074/jbc.M200532200; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hausmann S, 2003, J BIOL CHEM, V278, P30487, DOI 10.1074/jbc.M303060200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lehman K, 2001, J BIOL CHEM, V276, P14996, DOI 10.1074/jbc.M100588200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Mair G, 2000, J BIOL CHEM, V275, P28994, DOI 10.1074/jbc.M004193200; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; Martins A, 2001, J BIOL CHEM, V276, P45522, DOI 10.1074/jbc.M107615200; MARTINS A, 2001, NUCLEIC ACIDS RES, V31, P145; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; Takagi T, 2001, MOL BIOCHEM PARASIT, V114, P239, DOI 10.1016/S0166-6851(01)00254-7; Tock MR, 2003, EMBO J, V22, P995, DOI 10.1093/emboj/cdg098; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1995, J BIOL CHEM, V270, P20365, DOI 10.1074/jbc.270.35.20365	33	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50843	50852		10.1074/jbc.M309188200	http://dx.doi.org/10.1074/jbc.M309188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525979	hybrid			2022-12-25	WOS:000187206300003
J	Lynch, AM; Moore, M; Craig, S; Lonergan, PE; Martin, DS; Lynch, MA				Lynch, AM; Moore, M; Craig, S; Lonergan, PE; Martin, DS; Lynch, MA			Analysis of interleukin-1 beta-induced cell signaling activation in rat hippocampus following exposure to gamma irradiation - Protective effect of eicosapentaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PROINFLAMMATORY CYTOKINE PRODUCTION; RADIATION-INDUCED APOPTOSIS; DENTATE GYRUS; BRAIN IRRADIATION; HUMAN KERATINOCYTES; PROTEIN-KINASES; UV IRRADIATION; GRANULE CELLS; CYTOCHROME-C	Among the many reported effects of irradiation in cells is activation of the stress-activated protein kinase, c-Jun N-terminal kinase (JNK), which has been shown to result in apoptotic cell death. The trigger that leads to JNK activation has not been identified, although, in rat hippocampus at least, irradiation-induced apoptosis has been coupled with increased accumulation of reactive oxygen species (ROS). Significantly, irradiation-induced changes in hippocampus are abrogated by treatment of rats with the polyunsaturated fatty acid, eicosapentaenoic acid (EPA). A close coupling between ROS accumulation and concentration of the pro-inflammatory cytokine, interleukin-1beta (IL-1beta) in hippocampus has been reported, and the evidence suggests that IL-1beta may be responsible for the enhanced ROS production. Here we set out to assess the possibility that whole body gamma-irradiation increases IL-1beta concentration in hippocampus and to investigate the consequences of such a change. We present evidence that reveals that the irradiation-induced increase in IL-1beta concentration in hippocampus is accompanied by increased expression of IL-1 type I receptor and IL-1 accessory protein and increased activation of IL-1 receptor-activated kinase. These changes, which were coupled with increased activation of JNK and evidence of apoptotic cell death, were absent in hippocampus of rats that received EPA treatment. Significantly, EPA treatment enhanced hippocampal IL-10 concentration that was inversely correlated with IL-1beta concentration. The data are consistent with the idea that EPA exerts anti-inflammatory and neuroprotective effects in the central nervous system.	Trinity Coll Dublin, Dept Physiol, Inst Neurosci, Dublin 2, Ireland	Trinity College Dublin	Lynch, AM (corresponding author), Trinity Coll Dublin, Dept Physiol, Inst Neurosci, Dublin 2, Ireland.		Lonergan, Peter E/B-4544-2008	Lonergan, Peter E/0000-0001-7233-8156; Lynch, Marina/0000-0002-4631-0499				Anderson CNG, 1999, J NEUROSCI, V19, P664; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Armstrong CL, 2000, NEUROPSY NEUROPSY BE, V13, P101; Babcock T, 2000, NUTRITION, V16, P1116, DOI 10.1016/S0899-9007(00)00392-0; BALDIE G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P125, DOI 10.1016/0167-4889(93)90133-A; Bessis N, 1998, CLIN EXP IMMUNOL, V111, P391; Bradbury J, 2002, LANCET ONCOL, V3, P521, DOI 10.1016/S1470-2045(02)00861-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaillan FA, 1997, EUR J NEUROSCI, V9, P884, DOI 10.1111/j.1460-9568.1997.tb01439.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chiang CS, 1997, INT J RADIAT BIOL, V72, P45, DOI 10.1080/095530097143527; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; Czeh B, 1998, HIPPOCAMPUS, V8, P548; Field CJ, 2001, LIPIDS, V36, P1025, DOI 10.1007/s11745-001-0813-6; Foitzik T, 2002, JPEN-PARENTER ENTER, V26, P351, DOI 10.1177/0148607102026006351; French RA, 1999, J NEUROIMMUNOL, V93, P194, DOI 10.1016/S0165-5728(98)00224-0; Grewe M, 1996, J INVEST DERMATOL, V107, P865; Gridley DS, 1998, CANCER DETECT PREV, V22, P20, DOI 10.1046/j.1525-1500.1998.00010.x; Hayashi H, 1999, CURR MED RES OPIN, V15, P177, DOI 10.1185/03007999909114089; Hodges H, 1998, BEHAV BRAIN RES, V91, P99, DOI 10.1016/S0166-4328(97)00108-3; Hong JH, 1999, INT J RADIAT BIOL, V75, P1421, DOI 10.1080/095530099139287; Kelly A, 2001, J BIOL CHEM, V276, P45564, DOI 10.1074/jbc.M108757200; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Leon LR, 1998, ANN NY ACAD SCI, V856, P69, DOI 10.1111/j.1749-6632.1998.tb08314.x; Lonergan PE, 2002, J BIOL CHEM, V277, P20804, DOI 10.1074/jbc.M202387200; Lynch AM, 2002, EUR J NEUROSCI, V15, P1779, DOI 10.1046/j.1460-9568.2002.02012.x; LYNCH AM, 2003, IN PRESS J NEUROCHEM; Marionnet AV, 1997, EXP DERMATOL, V6, P22, DOI 10.1111/j.1600-0625.1997.tb00141.x; Martin DSD, 2002, J BIOL CHEM, V277, P34239, DOI 10.1074/jbc.M205289200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Morita Y, 2001, RHEUMATOL INT, V20, P49, DOI 10.1007/s002960000074; Nagai R, 2000, SURG NEUROL, V53, P503, DOI 10.1016/S0090-3019(00)00214-7; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Parent JM, 1999, J NEUROSCI, V19, P4508; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; PELLMAR TC, 1993, RADIAT RES, V136, P255, DOI 10.2307/3578619; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Tappia PS, 1996, MOL CELL BIOCHEM, V165, P135, DOI 10.1007/BF00229475; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002; Vereker E, 2001, EUR J NEUROSCI, V14, P1809, DOI 10.1046/j.0953-816x.2001.01809.x; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Wan YS, 2001, CELL SIGNAL, V13, P139, DOI 10.1016/S0898-6568(00)00146-7; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	35	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51075	51084		10.1074/jbc.M307970200	http://dx.doi.org/10.1074/jbc.M307970200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525971	hybrid			2022-12-25	WOS:000187206300031
J	Pfeiffer, M; Kirscht, S; Stumm, R; Koch, T; Wu, DF; Laugsch, M; Schroder, H; Hollt, V; Schulz, S				Pfeiffer, M; Kirscht, S; Stumm, R; Koch, T; Wu, DF; Laugsch, M; Schroder, H; Hollt, V; Schulz, S			Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA-ARRESTIN; MICE LACKING; SPINAL-CORD; OLIGOMERIZATION; SUBTYPES; INTERNALIZATION; MORPHINE; NK1; HOMODIMERIZATION	The mu-opioid receptor (MOR1) and the substance P receptor (NK1) coexist and functionally interact in nociceptive brain regions; however, a molecular basis for this interaction has not been established. Using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET), we show that MOR1 and NK1 can form heterodimers in HEK 293 cells coexpressing the two receptors. Although NK1-MOR1 heterodimerization did not substantially change the ligand binding and signaling properties of these receptors, it dramatically altered their internalization and resensitization profile. Exposure of the NK1-MOR1 heterodimer to the MOR1-selective ligand [D-Ala(2), Me-Phe(4), Gly(5)-ol] enkephalin (DAMGO) promoted cross-phosphorylation and cointernalization of the NK1 receptor. Conversely, exposure of the NK1-MOR1 heterodimer to the NK1-selective ligand substance P (SP) promoted cross-phosphorylation and cointernalization of the MOR1 receptor. In cells expressing MOR1 alone, beta-arrestin directs the receptors to clathrin-coated pits, but does not internalize with the receptor. In cells expressing NK1 alone, beta-arrestin internalizes with the receptor into endosomes. Interestingly, in cells coexpressing MOR1 and NK1 both DAMGO and SP induced the recruitment of beta-arrestin to the plasma membrane and cointernalization of NK1-MOR1 heterodimers with beta-arrestin into the same endosomal compartment. Consequently, resensitization of MOR1-dependent receptor functions was severely delayed in coexpressing cells as compared with cells expressing MOR1 alone. Together, our findings indicate that MOR1 by virtue of its physical interaction with NK1 is sequestered via an endocytotic pathway with delayed recycling and resensitization kinetics.	Otto von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Schulz, S (corresponding author), Otto von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Stefan.Schulz@Medizin.Uni-Magdeburg.de	Schulz, Stefan/A-6928-2017; Laugsch, Magdalena/AAH-8170-2021	Schulz, Stefan/0000-0002-5997-8885; 				Aicher SA, 2000, J NEUROSCI, V20, P4345; Aicher SA, 2000, SYNAPSE, V36, P12, DOI 10.1002/(SICI)1098-2396(200004)36:1<12::AID-SYN2>3.0.CO;2-E; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Foran SE, 2000, P NATL ACAD SCI USA, V97, P7621, DOI 10.1073/pnas.130181897; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Hanyaloglu AC, 2002, J BIOL CHEM, V277, P50422, DOI 10.1074/jbc.M209340200; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Jasmin L, 2002, P NATL ACAD SCI USA, V99, P1029, DOI 10.1073/pnas.012598599; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Luttrell LM, 2002, J CELL SCI, V115, P455; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2001, J CELL SCI, V114, P1265; Murtra P, 2000, NATURE, V405, P180, DOI 10.1038/35012069; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Ripley TL, 2002, NEUROPHARMACOLOGY, V43, P1258, DOI 10.1016/S0028-3908(02)00295-2; Schulz S, 1998, NEUROSCIENCE, V82, P613; Spike RC, 2002, EUR J NEUROSCI, V15, P1306, DOI 10.1046/j.1460-9568.2002.01969.x; Stumm RK, 2002, J NEUROSCI, V22, P5865; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	39	114	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51630	51637		10.1074/jbc.M307095200	http://dx.doi.org/10.1074/jbc.M307095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532289	hybrid			2022-12-25	WOS:000187206300097
J	Yadav, SP; Kundu, B; Ghosh, JK				Yadav, SP; Kundu, B; Ghosh, JK			Identification and characterization of an amphipathic leucine zipper-like motif in Escherichia coli toxin hemolysin E - Plausible role in the assembly and membrane destabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENDAI-VIRUS FUSION; THURINGIENSIS DELTA-ENDOTOXIN; FLUORESCENCE ENERGY-TRANSFER; PORE-FORMING DOMAIN; PHOSPHOLIPID-MEMBRANES; SOLID-PHASE; TRANSMEMBRANE HELIX; BACTERIAL TOXIN; LIPID-BILAYERS; HEPTAD REPEAT	Hemolysin E ( HlyE) is a 34 kDa protein toxin, recently isolated from a pathogenic strain of Escherichia coli, which is believed to exert its toxic activity via formation of pores in the target cell membrane. With the goal of understanding the involvement of different segments of hemolysin E in the membrane interaction and assembly of the toxin, a conserved, amphipathic leucine zipper-like motif has been identified. In order to evaluate the possible structural and functional roles of this segment in HlyE, a 30- residue peptide ( H- 205) corresponding to the leucine zipper motif ( amino acid 205 - 234) and two mutant peptides of the same size were synthesized and labeled by fluorescent probes at their N termini. The results show that the wild- type H- 205 binds to both zwitterionic ( PC/ Chol) and negatively charged ( PC/ PG/ Chol) phospholipid vesicles and also self- assemble therein. Detailed membrane- binding experiments revealed that this synthetic motif ( H- 205) formed large aggregates and inserted into the bilayer of only negatively charged lipid vesicles but not of zwitterionic membrane. Although both the mutants bound to zwitterionic and negatively charged lipid vesicles, neither of them inserted into the lipid bilayers nor assembled in any of these lipid vesicles. Furthermore, H- 205 adopted a significant helical structure in membrane mimetic environments and induced the permeation of monovalent ions and release of entrapped calcein across the phospholipid vesicles more efficiently than the mutant peptides. The results presented here indicate that this H- 205 ( amino acid 205 234) segment may be an important structural element in hemolysin E, which could play a significant role in the binding and assembly of the toxin in the target cell membrane and its destabilization.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Cent Drug Res Inst, Div Med Chem, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Ghosh, JK (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India.	jighosh@yahoo.com						ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; Atkins A, 2000, J BIOL CHEM, V275, P41150, DOI 10.1074/jbc.M005420200; BAIDIN G, 1990, FEBS LETT, V259, P254; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Ben-Efraim I, 1999, J MOL BIOL, V285, P609, DOI 10.1006/jmbi.1998.2370; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; Bonev BB, 2001, J BIOL CHEM, V276, P5714, DOI 10.1074/jbc.M005126200; Bouchayer E, 2001, J PEPT RES, V57, P39, DOI 10.1034/j.1399-3011.2001.00792.x; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Choma C, 2000, NAT STRUCT BIOL, V7, P161; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P3429, DOI 10.1021/bi00064a029; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Ghosh JK, 1998, J BIOL CHEM, V273, P7252, DOI 10.1074/jbc.273.13.7252; Ghosh JK, 1998, J BIOL CHEM, V273, P27182, DOI 10.1074/jbc.273.42.27182; Ghosh JK, 1997, BIOCHEMISTRY-US, V36, P15451, DOI 10.1021/bi971152i; Ghosh JK, 1999, J MOL BIOL, V292, P531, DOI 10.1006/jmbi.1999.3097; GomezGomez JM, 1996, MOL MICROBIOL, V19, P909, DOI 10.1046/j.1365-2958.1996.443955.x; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; INOUYE M, 1974, P NATL ACAD SCI USA, V71, P2396, DOI 10.1073/pnas.71.6.2396; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Oscarsson J, 1999, MOL MICROBIOL, V32, P1226, DOI 10.1046/j.1365-2958.1999.01435.x; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1991, J BIOL CHEM, V266, P22346; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; Therien AG, 2002, J MOL BIOL, V322, P583, DOI 10.1016/S0022-2836(02)00781-7; UHLIN BE, 1994, J CELL BIOCH S A, V18, P71; VOJKOVSKY T, 1995, PEPTIDE RES, V8, P236; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; WELCH RA, 1984, INFECT IMMUN, V43, P156, DOI 10.1128/IAI.43.1.156-160.1984; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	63	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51023	51034		10.1074/jbc.M310052200	http://dx.doi.org/10.1074/jbc.M310052200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525984	hybrid			2022-12-25	WOS:000187206300025
J	Forne, I; Carrascal, M; Martinez-Lostao, L; Abian, J; Rodriguez-Sanchez, JL; Juarez, C				Forne, I; Carrascal, M; Martinez-Lostao, L; Abian, J; Rodriguez-Sanchez, JL; Juarez, C			Identification of the autoantigen HB as the barrier-to-autointegration factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; HIV TYPE-1 INTEGRATION; PREINTEGRATION COMPLEXES; POLYACRYLAMIDE-GELS; MASS-SPECTROMETRY; HISTONES H2A; AUTOANTIBODIES; BAF; ANTIBODIES; SCLERODERMA	The HB autoantigen, a 10- kDa DNA- binding protein recognized by autoantibodies only when bound to DNA, was identified by two- dimensional electrophoresis. Silver-stained protein spots corresponding to the antigen were excised from two- dimensional electrophoresis gels, digested with trypsin, and analyzed by matrix- assisted laser desorption/ ionization- reflectron time of flight and nano- electrospray ionization- ion trap/ mass spectrometry. Data base search identified the HB antigen as the barrier- to- autointegration factor, a cellular protein implicated in the cellular cycle that blocks autointegration and promotes intermolecular integration of retrovirus such as the Moloney murine leukemia and the human immunodeficiency type 1 virus. The physicochemical characteristics described for these proteins, their ability to bind double- stranded DNA but not single-stranded DNA, and their nuclear localization confirm that HB and barrier- to- autointegration factor are the same protein.	Univ Autonoma Barcelona, Hosp Sant Pau, Dept Immunol, Barcelona 08025, Spain; CSIC, IDIBAPS, IIBB,Dept Expt Pathol, Struct & Biol Mass Spectrometry Unit, Barcelona, Spain	Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Juarez, C (corresponding author), Univ Autonoma Barcelona, Hosp Sant Pau, Dept Immunol, Avda Sant Antoni Maria Claret 167, Barcelona 08025, Spain.	cjuarez@hsp.santpau.es	Martinez-Lostao, Luis/AAI-3090-2021; Carrascal, Montserrat/M-1913-2014; Forne, Ignasi/B-3837-2016; Abian, Joaquin/M-1965-2014	Carrascal, Montserrat/0000-0002-0205-2176; Abian, Joaquin/0000-0003-2823-5429; Juarez, Candido/0000-0003-2235-9893; Martinez-Lostao, Luis/0000-0003-3043-147X				BUSTIN M, 1982, SCIENCE, V215, P1245, DOI 10.1126/science.6460317; Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345; Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270; Furukawa K, 1999, J CELL SCI, V112, P2485; Haraguchi T, 2001, J CELL SCI, V114, P4575; HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; JUAREZ C, 1994, CLIN IMMUNOL IMMUNOP, V72, P248, DOI 10.1006/clin.1994.1138; JUAREZ C, 1988, J IMMUNOL, V141, P3841; Lee KK, 2001, J CELL SCI, V114, P4567; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003; LOSMAN MJ, 1992, J IMMUNOL, V148, P1561; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Monestier M, 1996, MOL IMMUNOL, V33, P89, DOI 10.1016/0161-5890(95)00115-8; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; REKVIG OP, 1980, J EXP MED, V152, P1720, DOI 10.1084/jem.152.6.1720; RODRIGUEZSANCHEZ JL, 1987, J IMMUNOL, V139, P2579; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Suzuki Y, 2002, J VIROL, V76, P12376, DOI 10.1128/JVI.76.23.12376-12380.2002; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; Umland TC, 2000, BIOCHEMISTRY-US, V39, P9130, DOI 10.1021/bi000572w; WALKER DH, 1986, ACTA TROP, V43, P175; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	31	14	14	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50641	50644		10.1074/jbc.M308531200	http://dx.doi.org/10.1074/jbc.M308531200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523012	hybrid			2022-12-25	WOS:000187068200119
J	Krebs, A; Edwards, PC; Villa, C; Li, JD; Schertler, GFX				Krebs, A; Edwards, PC; Villa, C; Li, JD; Schertler, GFX			The three-dimensional structure of bovine rhodopsin determined by electron cryomicroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DISULFIDE BOND FORMATION; STATE TERTIARY STRUCTURE; LIGHT-DEPENDENT CHANGES; TRANSMEMBRANE HELICES; CYSTEINE RESIDUE-110; PROJECTION STRUCTURE; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; ARRANGEMENT	G-protein-coupled receptors are integral membrane proteins that respond to environmental signals and initiate signal transduction pathways, which activate cellular processes. Rhodopsin, a well known member of the G-protein-coupled receptor family, is located in the disk membranes of the rod outer segment, where it is responsible for the visualization of dim light. Rhodopsin is the most extensively studied G-protein-coupled receptor, and knowledge about its structure serves as a template for other related receptors. We have gained detailed structural knowledge from the crystal structure ( 1), which was solved by x-ray crystallography in 2000 using three-dimensional crystals. Here we report a three-dimensional density map of bovine rhodopsin determined by electron cryomicroscopy of two-dimensional crystals with p22(1)2(1) symmetry. The usage of relatively small and disordered crystals made the process of structure determination challenging. Special attention was paid to the extraction of amplitudes and phases, since usable raw data were limited to a maximum tilt of 45degrees. In the refinement process, an improved unbending procedure was applied. This led to a final resolution of 5.5 Angstrom in the membrane plane and similar to 13 Angstrom perpendicular to it, making our electron density map the most accurate map of a G-protein-coupled receptor currently available by electron microscopy. Most important is the information we gain about the center of the membrane plane and the orientation of the molecule relative to the bilayer. This information cannot be retrieved from the three-dimensional crystals. In our electron density map, all seven transmembrane helices were identified, and their arrangement is in agreement with the arrangement known from the crystal structure ( 1). In the retinal binding pocket, a density peak adjacent to helix 3 suggests the position of the beta-ionine ring of the chromophore, and in its vicinity several of the bigger amino acids can be identified.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; European Mol Biol Lab, D-69117 Heidelberg, Germany	MRC Laboratory Molecular Biology; European Molecular Biology Laboratory (EMBL)	Krebs, A (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	krebs@embl-heidelberg.de; gfx@mrc-lmb.cam.ac.uk	Schertler, Gebhard/M-9512-2014	Schertler, Gebhard F.X./0000-0002-5846-6810				Albert AD, 1997, BBA-BIOMEMBRANES, V1328, P74, DOI 10.1016/S0005-2736(97)00100-4; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bockaert J, 2002, INT REV CYTOL, V212, P63; Cai KW, 2001, BIOCHEMISTRY-US, V40, P12479, DOI 10.1021/bi010747h; Chopra A, 2000, BBA-BIOMEMBRANES, V1463, P1, DOI 10.1016/S0005-2736(99)00212-6; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; Eilers M, 2002, METHOD ENZYMOL, V343, P212; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV BIOPH BIOM, V32, P375, DOI 10.1146/annurev.biophys.32.110601.142520; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GREER J, 1985, METHOD ENZYMOL, V115, P206; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1977, BIOCHIM BIOPHYS ACTA, V492, P83, DOI 10.1016/0005-2795(77)90216-1; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Herzyk P, 1998, J MOL BIOL, V281, P741, DOI 10.1006/jmbi.1998.1981; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; Klein-Seetharaman J, 2001, BIOCHEMISTRY-US, V40, P12472, DOI 10.1021/bi010746p; Krebs A, 1998, J MOL BIOL, V282, P991, DOI 10.1006/jmbi.1998.2070; Kunji ERS, 2000, P NATL ACAD SCI USA, V97, P4637, DOI 10.1073/pnas.080064697; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Sakmar TP, 2002, CURR OPIN CELL BIOL, V14, P189, DOI 10.1016/S0955-0674(02)00306-X; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Shichida Y, 1998, CELL MOL LIFE SCI, V54, P1299, DOI 10.1007/s000180050256; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Vaughan M, 1998, J BIOL CHEM, V273, P17297, DOI 10.1074/jbc.273.28.17297; Watson S., 1994, G PROTEIN LINKED REC; Yeagle PL, 2001, BIOCHEMISTRY-US, V40, P11932, DOI 10.1021/bi015543f	54	42	42	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50217	50225		10.1074/jbc.M307995200	http://dx.doi.org/10.1074/jbc.M307995200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514682	hybrid			2022-12-25	WOS:000187068200069
J	Ueta, R; Fukunaka, A; Yamaguchi-Iwai, Y				Ueta, R; Fukunaka, A; Yamaguchi-Iwai, Y			Pse1p mediates the nuclear import of the iron-responsive transcription factor Aft1p in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAN-BINDING-PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT; YEAST; EXPORT; LOCALIZATION; RECEPTOR; EXPRESSION; RESISTANCE; FAMILY; AFT2P	In Saccharomyces cerevisiae, the iron-responsive transcription factor Aft1p plays a critical role in maintaining iron homeostasis. The activity of Aft1p is induced in response to iron starvation and as a consequence the expression of the iron-regulon is increased. We have shown previously that Aft1p is localized to the cytoplasm under iron-replete conditions but that it is localized to the nucleus under iron-depleted conditions. In this study, we identified the transport receptor that mediates the import of Aft1p into the nucleus, located the nuclear localization signal (NLS) sequences of Aft1p, and examined whether the nuclear import of Aft1p is affected by iron status. In pse1-1 cells, which bear a temperature-sensitive mutation of PSE1, Aft1p was misdirected to the cytoplasm during iron starvation at the restrictive temperature. Aft1p could also directly bind to Pse1p and was dissociated from the complex by RanGTP in vitro. These results indicate that Aft1p is imported into the nucleus by Pse1p. Supporting this is that the induction of an Aft1p target gene, FTR1, in response to iron starvation was greatly reduced in pse1-1 cells. Furthermore, we demonstrated that the nuclear localization of a mutant Aft1 protein that contains an NLS derived from SV40 was regulated by iron status regardless of whether Pse1p could interact with Aft1p. This suggests that the interaction between Aft1p and Pse1p is not a critical step that controls the iron-regulated nucleocytoplasmic transport of Aft1p.	Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Yamaguchi-Iwai, Y (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan.							Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Chaves SR, 2001, J BIOL CHEM, V276, P17712, DOI 10.1074/jbc.M010760200; De Freitas J, 2003, BIOMETALS, V16, P185, DOI 10.1023/A:1020771000746; Delahodde A, 2001, MOL MICROBIOL, V39, P304, DOI 10.1046/j.1365-2958.2001.02182.x; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Isoyama T, 2001, J BIOL CHEM, V276, P21863, DOI 10.1074/jbc.M009258200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Leslie DM, 2002, MOL CELL BIOL, V22, P2544, DOI 10.1128/MCB.22.8.2544-2555.2002; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Strom AC, 2001, GENOME BIOL, V2; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729	40	37	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50120	50127		10.1074/jbc.M305046200	http://dx.doi.org/10.1074/jbc.M305046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523005	hybrid			2022-12-25	WOS:000187068200056
J	Kukkola, L; Hieta, R; Kivirikko, KI; Myllyharju, J				Kukkola, L; Hieta, R; Kivirikko, KI; Myllyharju, J			Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; PEPTIDE-BINDING DOMAIN; ALPHA-SUBUNIT; CAENORHABDITIS-ELEGANS; BACULOVIRUS EXPRESSION; ENZYME TETRAMER; HIF-ALPHA; CLONING; HYPOXIA; CELLS	Collagen prolyl 4-hydroxylases (C-P4Hs) catalyze the formation of 4-hydroxyproline by the hydroxylation of -X-Pro-Gly-triplets. The vertebrate enzymes are alpha(2)beta(2) tetramers, the beta-subunit being identical to protein-disulfide isomerase (PDI). Two isoforms of the catalytic alpha-subunit, which combine with PDI to form [alpha(I)](2)beta(2) and [alpha(II)](2)beta(2) tetramers, have been known up to now. We report here on the cloning and characterization of a third vertebrate C-P4H alpha-subunit isoform, alpha(III). The processed human, rat and mouse alpha(III) polypeptides consist of 520-525 residues, all three having signal peptides of 19-22 additional residues. The sequence of the processed human alpha(III) polypeptide is 35-37% identical to those of human alpha(I) and alpha(II), the highest identity being found within the catalytically important C-terminal region and all five critical residues at the cosubstrate binding sites being conserved. The sequence within a region corresponding to the peptide-substrate binding domain is less conserved, but all five alpha helices constituting this domain can be predicted to be located in identical positions in alpha(I), alpha(II), and alpha(III) and to have essentially identical lengths. The alpha(III) mRNA is expressed in many human tissues, but at much lower levels than the alpha(I) and alpha(II) mRNAs. In contrast to alpha(I) and alpha(II), no evidence was found for alternative splicing of the alpha(III) transcripts. Coexpression of a recombinant human alpha(III) polypeptide with PDI in human embryonic kidney cells led to the formation of an active enzyme that hydroxylated collagen chains and a collagen-like peptide and appeared to be an [alpha(III)](2)beta(2) tetramer. The catalytic properties of the recombinant enzyme were very similar to those of the type I and II C-P4Hs, with the exception that its peptide binding properties were intermediate between those of the type I and type II enzymes.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POb 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi		Hieta, Reija/0000-0001-5724-6253				Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Elkins JM, 2003, J BIOL CHEM, V278, P1802, DOI 10.1074/jbc.C200644200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; HELAAKOSKI T, 1994, J BIOL CHEM, V269, P27847; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JOHN DCA, 1994, BIOCHEMISTRY-US, V33, P14018, DOI 10.1021/bi00251a009; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LANE D, 1988, ANTIBODIES LAB MANUA, P90; Lee C, 2003, J BIOL CHEM, V278, P7558, DOI 10.1074/jbc.M210385200; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 2003, MATRIX BIOL, V22, P15, DOI 10.1016/S0945-053X(03)00006-4; Myllyharju J, 2002, J BIOL CHEM, V277, P29187, DOI 10.1074/jbc.M203824200; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Nokelainen M, 2001, EUR J BIOCHEM, V268, P5300, DOI 10.1046/j.0014-2956.2001.02464.x; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pekkala M, 2003, ACTA CRYSTALLOGR D, V59, P940, DOI 10.1107/S0907444903005420; Riihimaa P, 2002, J BIOL CHEM, V277, P18238, DOI 10.1074/jbc.M200895200; Rost B, 1996, METHOD ENZYMOL, V266, P525; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; Veijola J, 1996, BIOCHEM J, V315, P613, DOI 10.1042/bj3150613; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X	42	91	95	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47685	47693		10.1074/jbc.M306806200	http://dx.doi.org/10.1074/jbc.M306806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500733	hybrid			2022-12-25	WOS:000186731400043
J	Hastrup, H; Sen, N; Javitch, JA				Hastrup, H; Sen, N; Javitch, JA			The human dopamine transporter forms a tetramer in the plasma membrane - Cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER MICROSCOPY; RAT GABA TRANSPORTER-1; SEROTONIN TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; ESCHERICHIA-COLI; LIVING CELLS; GXXXG MOTIF; OLIGOMERIZATION; PROTEIN; ACCESSIBILITY	Using cysteine cross-linking, we demonstrated previously that the dopamine transporter (DAT) is at least a homodimer, with the extracellular end of transmembrane segment (TM) 6 at a symmetrical dimer interface. We have now explored the possibility that DAT exists as a higher order oligomer in the plasma membrane. Cysteine cross-linking of wild type DAT resulted in bands on SDS-PAGE consistent with dimer, trimer, and tetramer, suggesting that DAT forms a tetramer in the plasma membrane. A cysteine-depleted DAT (CD-DAT) into which only Cys(243) or Cys(306) was reintroduced was cross-linked to dimer, suggesting that these endogenous cysteines in TM4 and TM6, respectively, were crosslinked at a symmetrical dimer interface. Reintroduction of both Cys(243) and Cys(306) into CD-DAT led to a pattern of cross-linking indistinguishable from that of wild type, with dimer, trimer, and tetramer bands. This indicated that the TM4 interface and the TM6 interface are distinct and further suggested that DAT may exist in the plasma membrane as a dimer of dimers, with two symmetrical homodimer interfaces. The cocaine analog MFZ 2-12 and other DAT inhibitors, including benztropine and mazindol, protected Cys(243) against cross-linking. In contrast, two substrates of DAT, dopamine and tyramine, did not significantly impact cross-linking. We propose that the impairment of cross-linking produced by the inhibitors results from a conformational change at the TM4 interface, further demonstrating that these compounds are not neutral blockers but by themselves have effects on the structure of the transporter.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, P&S 11-401,630 W 168th St,Box 7, New York, NY 10032 USA.			Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, R01DA011495] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11495, DA12408] Funding Source: Medline; NIMH NIH HHS [MH57324] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; BONNET JJ, 1994, EUR J PHARM-MOLEC PH, V266, P87, DOI 10.1016/0922-4106(94)90213-5; Carneiro AM, 2002, J NEUROSCI, V22, P7045; Chang AS, 1998, BIOCHEM BIOPH RES CO, V249, P416, DOI 10.1006/bbrc.1998.9158; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; KANNER BI, 1994, J EXP BIOL, V196, P237; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; Newman AH, 2001, BIOORG MED CHEM LETT, V11, P1659, DOI 10.1016/S0960-894X(01)00271-2; Norgaard-Nielsen K, 2002, FEBS LETT, V524, P87, DOI 10.1016/S0014-5793(02)03008-9; Norregaard L, 2003, J BIOL CHEM, V278, P30587, DOI 10.1074/jbc.M303854200; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Robbins AK, 1998, BIOTECHNIQUES, V25, P240, DOI 10.2144/98252st04; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shvetsov A, 2002, BIOCHEMISTRY-US, V41, P10787, DOI 10.1021/bi020205f; Sonders MS, 1997, J NEUROSCI, V17, P960; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Soskine M, 2002, P NATL ACAD SCI USA, V99, P12043, DOI 10.1073/pnas.192392899; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; WANG JB, 1995, J NEUROCHEM, V64, P1416; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558	43	97	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45045	45048		10.1074/jbc.C300349200	http://dx.doi.org/10.1074/jbc.C300349200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	14519759	hybrid			2022-12-25	WOS:000186452300002
J	Parrilla-Castellar, E; Karnitz, LM				Parrilla-Castellar, E; Karnitz, LM			Cut5 is required for the binding of Atr and DNA polymerase alpha to genotoxin-damaged chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; REPLICATION CHECKPOINT; CONTAINING PROTEIN; KINASE; REPAIR; ACTIVATION; INITIATION; COMPLEXES; CLASPIN; TOPBP1	DNA damage triggers the assembly of checkpoint signaling proteins on chromatin that activate the Chk1 signaling pathway and block S-phase progression. Here we show that genotoxin-induced Chk1 activation requires Cut5 (Mus101/TopBP1) in a process that is independent of the role of Cut5 in DNA replication. Analysis of the role of Cut5 in checkpoint activation revealed that it associated with chromatin following DNA damage in a process that required RPA. Additionally, Cut5 was required for the recruitment of Atr, DNA polymerase alpha, and Rad1 but not RPA to chromatin following DNA damage. Taken together, these results demonstrate that Cut5 plays an integral role in the recruitment and assembly of the Chk1 signaling cascade components following DNA damage.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu			NCI NIH HHS [T32 CA75926, F31 CA99940] Funding Source: Medline; NIGMS NIH HHS [R25 GM5525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075926, F31CA099940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BOYD JB, 1976, GENETICS, V84, P485; DARPA P, 1990, CANCER RES, V50, P6919; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Melo JA, 2001, GENE DEV, V15, P2809; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sarkaria JN, 1999, CANCER RES, V59, P4375; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1999, PRACT APPROACH SER, V199, P201; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45507	45511		10.1074/jbc.C300418200	http://dx.doi.org/10.1074/jbc.C300418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	14525986	hybrid			2022-12-25	WOS:000186452300057
J	Rodriguez, P; Bhogal, MS; Colyer, J				Rodriguez, P; Bhogal, MS; Colyer, J			Stoichiometric phosphorylation of cardiac ryanodine receptor on serine 2809 by calmodulin-dependent kinase II and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; PHOSPHOLAMBAN PHOSPHORYLATION; SKELETAL-MUSCLE; FAILING HEARTS; CA2+ RELEASE; SITE; ANTIBODIES; MG2+	The ryanodine receptor of cardiac muscle performs a central role in excitation-contraction coupling. Phosphorylation of the channel on serine 2809 ( in rabbit or the corresponding serine 2808 in man) alters function in vitro, although the impact of this in vivo has not been established. We have produced a pair of antisera to the serine 2809 phosphorylation site to aid description of the incidence and consequence of phosphorylation of this receptor. One of these antisera is specific for the serine 2809 phosphorylated form of the cardiac ryanodine receptor; the other antiserum is specific for the serine 2809 dephosphorylated receptor. These antibodies have been used to demonstrate that both protein kinase A and calmodulin-dependent kinase II are capable of phosphorylating serine 2809 in vitro. Both kinases phosphorylate serine 2809 to full stoichiometry, but this is accompanied by the incorporation of more ( radioactive) phosphate into the receptor by calmodulin-dependent kinase II than by protein kinase A. These data suggest that calmodulin-dependent kinase II phosphorylates at least four sites in addition to serine 2809 in vitro.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Colyer, J (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.							Al-Hillawi E, 1998, EUR J BIOCHEM, V256, P535, DOI 10.1046/j.1432-1327.1998.2560535.x; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Carter J. Mark, 1996, P693, DOI 10.1007/978-1-60327-259-9_119; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Hagemann D, 2002, TRENDS CARDIOVAS MED, V12, P51, DOI 10.1016/S1050-1738(01)00145-1; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; HUDSON L, 1980, PRACTICAL INMUNOLOGY, P348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CF, 1990, BIOCHEMISTRY-US, V29, P4535, DOI 10.1021/bi00471a005; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; OTSU K, 1990, J BIOL CHEM, V265, P13472; PUCEAT M, 1990, CIRC RES, V67, P517, DOI 10.1161/01.RES.67.2.517; Reiken S, 2003, J BIOL CHEM, V278, P444, DOI 10.1074/jbc.M207028200; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	29	135	136	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38593	38600		10.1074/jbc.C301180200	http://dx.doi.org/10.1074/jbc.C301180200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	14514795				2022-12-25	WOS:000185575100063
J	Akyol, Z; Bartos, JA; Merrill, MA; Faga, LA; Jaren, OR; Shea, MA; Hell, JW				Akyol, Z; Bartos, JA; Merrill, MA; Faga, LA; Jaren, OR; Shea, MA; Hell, JW			Apo-calmodulin binds with its C-terminal domain to the N-methyl-D-aspartate receptor NR1 C0 region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ION-CHANNEL REGULATION; CALCIUM-BINDING; CA2+-DEPENDENT INACTIVATION; TARGET RECOGNITION; NMDA RECEPTORS; ALPHA-ACTININ; MUTANTS SHOW; CALCIUM/CALMODULIN; POTENTIATION	Calmodulin (CaM) is the major Ca2+ sensor in eukaryotic cells. It consists of four EF-hand Ca2+ binding motifs, two in its N-terminal domain and two in its C-terminal domain. Through a negative feedback loop, CaM inhibits Ca2+ influx through N-methyl-D-aspartate-type glutamate receptors in neurons by binding to the C0 region in the cytosolic tail of the NR1 subunit. Ca2+-depleted (apo) CaM is pre-associated with a variety of ion channels for fast and effective regulation of channel activities upon Ca2+ influx. Using the NR1 C0 region for fluorescence and circular dichroism spectroscopy studies we found that not only Ca2+-saturated CaM but also apoCaM bound to NR1 C0. In vitro interaction assays showed that apoCaM also binds specifically to full-length NR1 solubilized from rat brain and to the complete C terminus of the NR1 splice form that contains the C0 plus C2' domain. The Ca2+-independent interaction of CaM was also observed with the isolated C- but not N-terminal fragment of calmodulin in the independent spectroscopic assays. Fluorescence polarization studies indicated that apoCaM associated via its C- terminal domain with NR1 C0 in an extended conformation and collapsed to adopt a more compact conformation of faster rotational mobility in its complex with NR1 C0 upon addition of Ca2+. Our results indicate that apoCaM is associated with NR1 and that the complex of CaM bound to NR1 C0 undergoes a dramatic conformational change when Ca2+ binds to CaM.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Shea, MA (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	madeline-shea@uiowa.edu; johannes-hell@uiowa.edu	Shea, Madeline A/F-5798-2010; Hell, Johannes W./P-5085-2019	Bartos, Jason/0000-0003-0113-5305; Shea, Madeline/0000-0003-0814-7069	NIGMS NIH HHS [R01 GM 57001] Funding Source: Medline; NINDS NIH HHS [R01 NS 35563] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jaren OR, 2000, BIOCHEMISTRY-US, V39, P6881, DOI 10.1021/bi000037w; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupp JJ, 1999, J NEUROSCI, V19, P1165; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; KUNG C, 1992, CELL CALCIUM, V13, P413, DOI 10.1016/0143-4160(92)90054-V; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Leonard AS, 2002, J BIOL CHEM, V277, P48441, DOI 10.1074/jbc.M205164200; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P10676, DOI 10.1021/bi00033a044; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; RAO ST, 1993, PROTEIN SCI, V2, P436; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; Saimi Y, 2002, ANNU REV PHYSIOL, V64, P289, DOI 10.1146/annurev.physiol.64.100301.111649; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sorensen BR, 1998, BIOCHEMISTRY-US, V37, P4244, DOI 10.1021/bi9718200; Sorensen BR, 2001, BIOCHEMISTRY-US, V40, P896, DOI 10.1021/bi0023091; Vanscyoc WS, 2001, PROTEIN SCI, V10, P1758, DOI 10.1110/ps.11601; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Zhang HW, 2003, J BIOL CHEM, V278, P8348, DOI 10.1074/jbc.M209565200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	50	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2166	2175		10.1074/jbc.M302542200	http://dx.doi.org/10.1074/jbc.M302542200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14530275	hybrid			2022-12-25	WOS:000188005700073
J	Choe, JY; Nelson, SW; Arienti, KL; Axe, FU; Collins, TL; Jones, TK; Kimmich, RDA; Newman, MJ; Norvell, K; Ripka, WC; Romano, SJ; Short, KM; Slee, DH; Fromm, HJ; Honzatko, RB				Choe, JY; Nelson, SW; Arienti, KL; Axe, FU; Collins, TL; Jones, TK; Kimmich, RDA; Newman, MJ; Norvell, K; Ripka, WC; Romano, SJ; Short, KM; Slee, DH; Fromm, HJ; Honzatko, RB			Inhibition of fructose-1,6-bisphosphatase by a new class of allosteric effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; STRUCTURE REFINEMENT; AMP COOPERATIVITY; PRODUCT COMPLEXES; CRYSTAL-STRUCTURE; DYNAMIC LOOP; 2,6-BISPHOSPHATE; MECHANISM	A highly constrained pseudo-tetrapeptide (OC252-324) further defines a new allosteric binding site located near the center of fructose-1,6-bisphosphatase. In a crystal structure, pairs of inhibitory molecules bind to opposite faces of the enzyme tetramer. Each ligand molecule is in contact with three of four subunits of the tetramer, hydrogen bonding with the side chain of Asp(187) and the backbone carbonyl of residue 71, and electrostatically interacting with the backbone carbonyl of residue 51. The ligated complex adopts a quaternary structure between the canonical R- and T-states of fructose-1,6-bisphosphatase, and yet a dynamic loop essential for catalysis (residues 52-72) is in a conformation identical to that of the T-state enzyme. Inhibition by the pseudo-tetrapeptide is cooperative (Hill coefficient of 2), synergistic with both AMP and fructose 2,6-bisphosphate, noncompetitive with respect to Mg2+, and uncompetitive with respect to fructose 1,6-bisphosphate. The ligand dramatically lowers the concentration at which substrate inhibition dominates the kinetics of fructose-1,6-bisphosphatase. Elevated substrate concentrations employed in kinetic screens may have facilitated the discovery of this uncompetitive inhibitor. Moreover, the inhibitor could mimic an unknown natural effector of fructose-1,6-bisphosphatase, as it interacts strongly with a conserved residue of undetermined functional significance.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Ontogen Corp, Carlsbad, CA 92009 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.		Short, Kieran/O-4476-2019	Short, Kieran/0000-0001-9137-008X	NIDDK NIH HHS [R43-DK57342-01, R44 DK57342-02] Funding Source: Medline; NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R44DK057342, R43DK057342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; Choe JY, 2003, J BIOL CHEM, V278, P16015, DOI 10.1074/jbc.M212395200; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON JWR, 1976, GLUCONEOGENESIS ITS, P481; LIU F, 1988, J BIOL CHEM, V263, P9122; LU G, 1997, J BIOL CHEM, V297, P5076; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; MACGREGOR JS, 1980, P NATL ACAD SCI-BIOL, V77, P3889, DOI 10.1073/pnas.77.7.3889; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOORHEAD GBG, 1994, ARCH BIOCHEM BIOPHYS, V312, P326, DOI 10.1006/abbi.1994.1316; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; PONTREMOLI S, 1983, BIOCHEM SOC T, V11, P241; Rakus D, 2000, BIOCHEM BIOPH RES CO, V275, P611, DOI 10.1006/bbrc.2000.3308; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1997, J BIOL CHEM, V272, P26295, DOI 10.1074/jbc.272.42.26295; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; Wen J, 2001, PHOTOCHEM PHOTOBIOL, V74, P679, DOI 10.1562/0031-8655(2001)074<0679:EOTIPF>2.0.CO;2; Wright SW, 2002, J MED CHEM, V45, P3865, DOI 10.1021/jm010496a; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	40	36	37	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51176	51183		10.1074/jbc.M308396200	http://dx.doi.org/10.1074/jbc.M308396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530289	hybrid			2022-12-25	WOS:000187206300043
J	Gilchrist, D; Rexach, M				Gilchrist, D; Rexach, M			Molecular basis for the rapid dissociation of nuclear localization signals from karyopherin alpha in the nucleoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORTIN-ALPHA; YEAST NUCLEOPORIN; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; EXPORT; NUP2P; RANGTP; SRP1P/IMPORTIN-ALPHA; IDENTIFICATION; RECOGNITION	The yeast karyopherin heterodimer Kap60p . Kap95p facilitates nuclear import of proteins bearing a classic nuclear localization signal (NLS). The alpha subunit Kap60p binds to the NLS of cargo molecules in the cytoplasm, forming stable complexes that must ultimately dissociate in the nucleoplasm. Although Kap60p can release NLSs on its own using an autoinhibitory sequence (AIS) motif that can occupy the NLS binding site, that mechanism is too slow to support rapid nuclear import. We previously showed that the nuclear basket nucleoporin Nup2p and the exportin complex Cse1p . Gsp1p . GTP function as karyopherin release factors (KaRFs) because they can accelerate the rate of dissociation of NLSs from Kap60p. Here we dissect the molecular mechanics of their KaRF activity. We show that Cse1p accelerates dissociation of Kap60p . NLS-cargo complexes and Kap60p . Nup2p complexes by increasing the affinity of Kap60p for its AIS motif. In contrast, Nup2p uses a conserved sequence motif (VMXXRKIA) coupled to an AIS-like motif to accelerate dissociation of Kap60p . NLS complexes in a vectorial reaction mechanism. Mutation of either motif in Nup2p leads to a loss of KaRF activity and to the accumulation of Kap60p . NLS- cargo complexes in the nucleoplasm of yeast. We discuss a model whereby Nup2p, Cse1p, and Gsp1p cooperate to establish directionality in the movement of Kap60p and NLS-cargos across the nuclear pore complex.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	rexach@stanford.edu		Gilchrist, Daniel/0000-0003-1668-2790				Allen NPC, 2002, MOL CELL PROTEOMICS, V1, P930, DOI 10.1074/mcp.T200012-MCP200; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Barry DM, 2000, ESSAYS BIOCHEM, V36, P89, DOI 10.1042/bse0360089; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Lindsay ME, 2002, CELL, V110, P349, DOI 10.1016/S0092-8674(02)00836-X; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moroianu J, 1997, P NATL ACAD SCI USA, V94, P9699, DOI 10.1073/pnas.94.18.9699; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5	37	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51937	51949		10.1074/jbc.M307371200	http://dx.doi.org/10.1074/jbc.M307371200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14514698	hybrid			2022-12-25	WOS:000187206300130
J	Hartness, ME; Brazier, SP; Peers, C; Bateson, AN; Ashford, MLJ; Kemp, PJ				Hartness, ME; Brazier, SP; Peers, C; Bateson, AN; Ashford, MLJ; Kemp, PJ			Post-transcriptional control of human maxiK potassium channel activity and acute oxygen sensitivity by chronic hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED K+ CHANNELS; LARGE-CONDUCTANCE; CAROTID-BODY; PULMONARY VASOCONSTRICTION; CHEMORECEPTOR CELLS; MESSENGER-RNA; BETA-SUBUNITS; CALCIUM; INHIBITION; AIRWAY	Various cardiorespiratory diseases (e.g. congestive heart failure, emphysema) result in systemic hypoxia and patients consequently demonstrate adaptive cellular responses which predispose them to conditions such as pulmonary hypertension and stroke. Central to many affected excitable tissues is activity of large conductance, Ca2+-activated K+ (maxiK) channels. We have studied maxiK channel activity in HEK293 cells stably co-expressing the most widely distributed of the human alpha- and beta-subunits that constitute these channel following maneuvers which mimic severe hypoxia. At all [Ca2+](i), chronic hypoxia (similar to18 mm Hg, 72 h) increased K+ current density, most markedly at physiological [Ca2+](i). K+ currents in cells cultured in normoxia showed a [Ca2+](i)-dependent sensitivity to acute hypoxic inhibition (similar to25 mm Hg, 3 min). However, chronic hypoxia dramatically changed the Ca2+ sensitivity of this acute hypoxic inhibitory profile such that low [Ca2+](i) could sustain an acute hypoxic inhibitory response. Chronic hypoxia caused no change in alpha-subunit immunoreactivity with Western blotting but evoked a 3-fold increase in beta-subunit expression. These observations were fully supported by immunocytochemistry, which also suggested that chronic hypoxia augmented alpha/beta-subunit co-localization at the plasma membrane. Using a novel nuclear run-on assay and RNase protection we found that chronic hypoxia did not alter mRNA production rates or steady-state levels, which suggests that this important environmental cue modulates maxiK channel function via post-transcriptional mechanisms.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Pharmacol & Neurosci, Dundee DD1 9SY, Scotland	University of Leeds; University of Leeds; University of Dundee	Kemp, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	p.z.kemp@leeds.ac.uk	Hartness, Matthew/ABE-6961-2021; Kemp, Paul/A-4634-2010	Kemp, Paul/0000-0003-2773-973X; Peers, Chris/0000-0002-8354-346X; Ashford, Michael/0000-0002-0861-7676				Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; Coppock EA, 2001, AM J PHYSIOL-LUNG C, V281, pL1, DOI 10.1152/ajplung.2001.281.1.L1; Cutz E, 1999, RESP PHYSIOL, V115, P201, DOI 10.1016/S0034-5687(99)00018-3; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; EDEN GJ, 1987, J PHYSIOL-LONDON, V392, P11, DOI 10.1113/jphysiol.1987.sp016766; EDEN GJ, 1987, J PHYSIOL-LONDON, V392, P1; GARCIACALVO M, 1994, P NATL ACAD SCI USA, V91, P4718, DOI 10.1073/pnas.91.11.4718; Gurney AM, 2002, CLIN EXP PHARMACOL P, V29, P330, DOI 10.1046/j.1440-1681.2002.03653.x; Haddad GG, 1997, ANNU REV PHYSIOL, V59, P23, DOI 10.1146/annurev.physiol.59.1.23; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartness ME, 2001, J BIOL CHEM, V276, P26499, DOI 10.1074/jbc.M010357200; Hulme JT, 1999, CIRC RES, V85, P489, DOI 10.1161/01.RES.85.6.489; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; Kemp P, 2002, FASEB J, V16, pA61; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lanfranchi P, 2001, RESPIR RES, V2, P315, DOI 10.1186/rr79; Lewis A, 2002, J PHYSIOL-LONDON, V540, P771, DOI 10.1113/jphysiol.2001.013888; Liu HJ, 1999, J CLIN INVEST, V104, P577, DOI 10.1172/JCI7291; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; MONGE C, 1991, PHYSIOL REV, V71, P1135, DOI 10.1152/physrev.1991.71.4.1135; Munoz F, 2001, FEBS LETT, V492, P156, DOI 10.1016/S0014-5793(01)02247-5; O'Kelly I, 1998, AM J PHYSIOL-LUNG C, V275, pL709, DOI 10.1152/ajplung.1998.275.4.L709; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; O'Kelly I, 2000, J BIOL CHEM, V275, P7684, DOI 10.1074/jbc.275.11.7684; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Peers C, 2001, RESP RES, V2, P145, DOI 10.1186/rr51; Perez-Garcia MT, 2000, J NEUROSCI, V20, P5689, DOI 10.1523/JNEUROSCI.20-15-05689.2000; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Plant LD, 2002, STROKE, V33, P2324, DOI 10.1161/01.STR.0000027440.68031.B0; Pluger S, 2000, CIRC RES, V87, pE53, DOI 10.1161/01.RES.87.11.e53; Prabhakar NR, 2002, AM J RESP CRIT CARE, V165, P859, DOI 10.1164/ajrccm.165.7.2202030c; Prabhakar NR, 2001, J APPL PHYSIOL, V90, P1986, DOI 10.1152/jappl.2001.90.5.1986; Riesco-Fagundo AM, 2001, CIRC RES, V89, P430, DOI 10.1161/hh1701.095632; Rolfe FG, 1997, AM J RESP CELL MOL, V17, P243, DOI 10.1165/ajrcmb.17.2.2819; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; Soh H, 2001, NEUROSCI LETT, V298, P115, DOI 10.1016/S0304-3940(00)01737-7; STEA A, 1992, P NATL ACAD SCI USA, V89, P9469, DOI 10.1073/pnas.89.20.9469; STEA A, 1995, J NEUROSCI, V15, P2192, DOI 10.1523/JNEUROSCI.15-03-02192.1995; Tang XD, 2001, J GEN PHYSIOL, V117, P253, DOI 10.1085/jgp.117.3.253; Thompson RJ, 1998, J PHYSIOL-LONDON, V512, P421, DOI 10.1111/j.1469-7793.1998.421be.x; TristaniFirouzi M, 1996, J CLIN INVEST, V98, P1959, DOI 10.1172/JCI118999; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wang YW, 2002, J NEUROSCI, V22, P1550, DOI 10.1523/JNEUROSCI.22-05-01550.2002; Wanner SG, 1999, BIOCHEMISTRY-US, V38, P5392, DOI 10.1021/bi983040c; Ward JPT, 1999, RESP PHYSIOL, V115, P261, DOI 10.1016/S0034-5687(99)00025-0; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Yang SX, 2001, AM J RESP CELL MOL, V24, P527, DOI 10.1165/ajrcmb.24.5.4400; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	57	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51422	51432		10.1074/jbc.M309463200	http://dx.doi.org/10.1074/jbc.M309463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522958	hybrid			2022-12-25	WOS:000187206300071
J	Huwiler, A; Akool, ES; Aschrafi, A; Hamada, FMA; Pfeilschifter, J; Eberhardt, W				Huwiler, A; Akool, ES; Aschrafi, A; Hamada, FMA; Pfeilschifter, J; Eberhardt, W			ATP potentiates interleukin-1 beta-induced MMP-9 expression in mesangial cells via recruitment of the ELAV protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED MATRIX-METALLOPROTEINASE-9 EXPRESSION; AU-RICH ELEMENTS; MESSENGER-RNA; EXTRACELLULAR ATP; KINASE CASCADE; POSTTRANSCRIPTIONAL REGULATION; MATRIX METALLOPROTEINASES; BINDING-PROTEINS; GROWTH-FACTOR; RAT	Renal mesangial cells express high levels of matrix metalloproteinase 9 (MMP-9) in response to inflammatory cytokines such as interleukin (IL)-1beta. We demonstrate here that the stable ATP analog adenosine 5'-O-(thiotriphosphate) (ATPgammaS) potently amplifies the cytokine-induced gelatinolytic content of mesangial cells mainly by an increase in the MMP-9 steady-state mRNA level. A Luciferase reporter gene containing 1.3 kb of the MMP-9 5'-promoter region showed weak responses to ATPgammaS but confered a strong ATP-dependent increase in Luciferase activity when under the additional control of the 3'-untranslated region of MMP-9. By in vitro degradation assay and actinomycin D experiments we found that ATPgammaS potently delayed the decay of MMP-9 mRNA. Gel-shift and supershift assays demonstrated that three AU-rich elements (AREs) present in the 3'-untranslated region of MMP-9 are constitutively bound by complexes containing the mRNA stabilizing factor HuR. The RNA binding of these complexes was markedly increased by ATPgammaS. Mutation of each ARE element strongly impaired the RNA binding of the HuR containing complexes. Reporter gene assays revealed that mutation of one ARE did not affect the stimulatory effects by ATPgammaS, but mutation of all three ARE motifs caused a loss of ATP-dependent increase in luciferase activity without affecting IL-1beta-inducibility. By confocal microscopy we demonstrate that ATPgammaS increased the nucleo cytoplasmic shuttling of HuR and caused an increase in the cytosolic HuR level as shown by cell fractionation experiments. Together, our results indicate that the amplification of MMP-9 expression by extracellular ATP is triggered through mechanisms that likely involve a HuR-dependent rise in MMP-9 mRNA stability.	Univ Frankfurt Klinikum, Pharmazentrum, D-60590 Frankfurt, Germany; Al Azhar Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Egyptian Knowledge Bank (EKB); Al Azhar University	Eberhardt, W (corresponding author), Univ Frankfurt Klinikum, Pharmazentrum, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	w.eberhardt@em.uni-frankfurt.de	Aschrafi, Armaz/E-2202-2012; Akool, El-Sayed/ABB-7729-2021	Akool, El-Sayed/0000-0003-4216-5164; Aschrafi, Armaz/0000-0003-4089-0960				Akool ES, 2003, MOL CELL BIOL, V23, P4901, DOI 10.1128/MCB.23.14.4901-4916.2003; Antic D, 1998, J CELL SCI, V111, P183; Atasoy U, 1998, J CELL SCI, V111, P3145; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DAVIES M, 1992, KIDNEY INT, V41, P671, DOI 10.1038/ki.1992.103; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Eberhardt W, 2002, J BIOL CHEM, V277, P33518, DOI 10.1074/jbc.M202008200; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fogo AB, 2001, KIDNEY INT, V59, P804, DOI 10.1046/j.1523-1755.2001.059002804.x; Gao FB, 1996, J CELL SCI, V109, P579; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; Huwiler A, 2000, BRIT J PHARMACOL, V129, P612, DOI 10.1038/sj.bjp.0703077; Huwiler A, 2002, BRIT J PHARMACOL, V136, P520, DOI 10.1038/sj.bjp.0704748; HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x; Huwiler A, 1997, BRIT J PHARMACOL, V120, P807, DOI 10.1038/sj.bjp.0700979; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; King PH, 2000, GENE, V242, P125, DOI 10.1016/S0378-1119(99)00537-5; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; Lenz O, 2000, J AM SOC NEPHROL, V11, P574, DOI 10.1681/ASN.V113574; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Park JW, 2001, BIOCHEM BIOPH RES CO, V280, P244, DOI 10.1006/bbrc.2000.4105; PAVENSTADT H, 1993, BRIT J PHARMACOL, V109, P953, DOI 10.1111/j.1476-5381.1993.tb13713.x; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pfeilschifter J, 1996, J AUTON PHARMACOL, V16, P315, DOI 10.1111/j.1474-8673.1996.tb00043.x; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; PFEILSCHIFTER J, 1993, BRIT J PHARMACOL, V110, P847, DOI 10.1111/j.1476-5381.1993.tb13890.x; PFEILSCHIFTER J, 2003, NEPHRON, V93, P23; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POELSTRA K, 1992, LAB INVEST, V66, P555; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHULZELOHOFF E, 1998, AM J PHYSIOL, V275, P962; Simon C, 1998, CANCER RES, V58, P1135; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yokoo T, 1996, AM J PHYSIOL-RENAL, V270, pF123, DOI 10.1152/ajprenal.1996.270.1.F123; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	54	72	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51758	51769		10.1074/jbc.M305722200	http://dx.doi.org/10.1074/jbc.M305722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523003	hybrid			2022-12-25	WOS:000187206300111
J	Kulkarni, AA; Haworth, IS; Uchiyama, T; Lee, VHL				Kulkarni, AA; Haworth, IS; Uchiyama, T; Lee, VHL			Analysis of transmembrane segment 7 of the dipeptide transporter hPepT1 by cysteine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT1 GLUCOSE-TRANSPORTER; BRUSH-BORDER MEMBRANE; BINDING-SITE CREVICE; DOPAMINE D2 RECEPTOR; PEPTIDE TRANSPORTER; GLYCYLSARCOSINE TRANSPORT; OLIGOPEPTIDE TRANSPORTER; SPANNING SEGMENT; ACTIVE-TRANSPORT; IDENTIFICATION	To investigate the involvement of transmembrane segment 7 (TMS7) of hPepT1 in forming the putative central aqueous channel through which the substrate traverses, we individually mutated each of the 21 amino acids in TMS7 to a cysteine and analyzed the mutated transporters using the scanning cysteine accessibility method. Y287C- and M292C-hPepT1 did not express at the plasma membrane. Out of the remaining 19 transporters, three (F293C-, L296C-, and F297C-hPepT1) showed negligible glycyl-sarcosine (gly-sar) uptake activity and may play an important role in defining the overall hPepT1 structure. K278C-hPepT1 showed similar to40% activity and the 15 other transporters exhibited more than 50% gly-sar uptake when compared with wild type (WT)-hPepT1. Gly-sar uptake for the 16 active transporters containing cysteine mutations was then measured in the presence of 2.5 mM 2-aminoethyl methanethiosulfonate hydrobromide (MTSEA) or 1 mM [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET). Gly-sar uptake was significantly inhibited for each of the 16 single cysteine mutants in the presence of 2.5 mM MTSEA. In contrast, significant inhibition of uptake was only observed for K278C-, M279C-, V280C-, T281C-, M284C-, L286C-, P291C-, and D298C-hPepT1 in the presence of 1 mM MTSET. MTSET modification of R282C-hPepT1 resulted in a significant increase in gly-sar uptake. To investigate this further, we mutated WT-hPepT1 to R282A-, R282E-, and R282K-hPepT1. R282E-hPepT1 showed a 43% reduction in uptake activity, whereas R282A- and R282K-hPepT1 had activities comparable with WT-hPepT1, suggesting a role for the Arg-282 positive charge in substrate translocation. Most of the amino acids that were MTSET-sensitive upon cysteine mutation, including R282C, are located toward the intracellular end of TMS7. Hence, our results suggest that TMS7 of hPepT1 is relatively solvent-accessible along most of its length but that the intracellular end of the transmembrane domain is particularly so. From a structure-function perspective, we speculate that the extracellular end of TMS7 may shift following substrate binding, providing the basis for channel opening and substrate translocation.	Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA; Univ So Calif, Sch Pharm, Dept Ophthalmol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Haworth, IS (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, 1985 Zonal Ave, Los Angeles, CA 90089 USA.	ihaworth@usc.edu	Lee, Vincent HL/A-9439-2008	Lee, Vincent HL/0000-0001-7708-6269	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059297] Funding Source: NIH RePORTER; NIDDK NIH HHS [IP30 DK48522] Funding Source: Medline; NIGMS NIH HHS [GM59297] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand BS, 2003, J PHARMACOL EXP THER, V304, P781, DOI 10.1124/jpet.102.044313; Anand BS, 2002, EXPERT OPIN BIOL TH, V2, P607, DOI 10.1517/14712598.2.6.607; Bockman DE, 1997, INT J PANCREATOL, V22, P221; Bolger MB, 1998, J PHARM SCI-US, V87, P1286, DOI 10.1021/js980090u; Doring F, 1996, J PHYSIOL-LONDON, V497, P773; Fei YJ, 1998, BIOCHEM BIOPH RES CO, V246, P39, DOI 10.1006/bbrc.1998.8566; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; Han HK, 1998, PHARMACEUT RES, V15, P1154, DOI 10.1023/A:1011919319810; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; INUI KI, 1992, J PHARMACOL EXP THER, V260, P482; Javitch JA, 2000, BIOCHEMISTRY-US, V39, P12190, DOI 10.1021/bi001069m; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Kulkarni AA, 2003, BIOCHEM BIOPH RES CO, V306, P177, DOI 10.1016/S0006-291X(03)00926-4; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Martinez MN, 2002, J CLIN PHARMACOL, V42, P620, DOI 10.1177/00970002042006005; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; Temple CS, 1998, J BIOL CHEM, V273, P20, DOI 10.1074/jbc.273.1.20; Terada T, 2000, PHARM RES-DORDR, V17, P15, DOI 10.1023/A:1007554105597; Thamotharan M, 1997, J BIOL CHEM, V272, P11786, DOI 10.1074/jbc.272.18.11786; THWAITES DT, 1994, BRIT J PHARMACOL, V113, P1050, DOI 10.1111/j.1476-5381.1994.tb17099.x; TSUJI A, 1987, BIOCHEM PHARMACOL, V36, P565, DOI 10.1016/0006-2952(87)90369-8; TSUJI A, 1990, PHARMACEUT RES, V7, P308, DOI 10.1023/A:1015894617027; Yeung AK, 1998, BIOCHEM BIOPH RES CO, V250, P103, DOI 10.1006/bbrc.1998.9283; Zhang EY, 2002, DRUG METAB REV, V34, P709, DOI 10.1081/DMR-120015692; Zhang EY, 2002, ADV DRUG DELIVER REV, V54, P329, DOI 10.1016/S0169-409X(02)00007-8; Zhou XD, 2000, BBA-BIOMEMBRANES, V1466, P372, DOI 10.1016/S0005-2736(00)00201-7	33	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51833	51840		10.1074/jbc.M308356200	http://dx.doi.org/10.1074/jbc.M308356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532279	hybrid			2022-12-25	WOS:000187206300119
J	Myles, T; Nishimura, T; Yun, TH; Nagashima, M; Morser, J; Patterson, AJ; Pearl, RG; Leung, LLK				Myles, T; Nishimura, T; Yun, TH; Nagashima, M; Morser, J; Patterson, AJ; Pearl, RG; Leung, LLK			Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C; IN-VIVO; SECRETED PHOSPHOPROTEINS; CARBOXYPEPTIDASE-N; OSTEOPONTIN; FRAGMENT; SEQUENCE; PURIFICATION; MECHANISMS; ADHESION	The latent plasma carboxypeptidase thrombin-activable fibrinolysis inhibitor ( TAFI) is activated by thrombin/thrombomodulin on the endothelial cell surface, and functions in dampening fibrinolysis. In this study, we examined the effect of activated TAFI (TAFIa) in modulating the proinflammatory functions of bradykinin, complement C5a, and thrombin-cleaved osteopontin. Hydrolysis of bradykinin and C5a and thrombin-cleaved osteopontin peptides by TAFIa was as efficient as that of plasmin-cleaved fibrin peptides, indicating that these are also good substrates for TAFIa. Plasma carboxypeptidase N, generally regarded as the physiological regulator of kinins, was much less efficient than TAFIa. TAFIa abrogated C5a-induced neutrophil activation in vitro. Jurkat cell adhesion to osteopontin was markedly enhanced by thrombin cleavage of osteopontin. This was abolished by TAFIa treatment due to the removal of the C-terminal Arg(168) by TAFIa from the exposed SV-VYGLR alpha(4)beta(1) integrin-binding site in thrombin-cleaved osteopontin. Thus, thrombin cleavage of osteopontin followed by TAFIa treatment may sequentially up- and down-modulate the pro-inflammatory properties of osteopontin. An engineered anticoagulant thrombin, E229K, was able to activate endogenous plasma TAFI in mice, and E229K thrombin infusion effectively blocked bradykinin-induced hypotension in wild-type, but not in TAFI-deficient, mice in vivo. Our data suggest that TAFIa may have a broad anti-inflammatory role, and its function is not restricted to fibrinolysis.	Stanford Univ, Div Hematol, Dept Med, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Anesthesiol, Sch Med, Stanford, CA 94305 USA; Berlex Biosci, Cardiovasc Res, Richmond, CA 94806 USA	Stanford University; Stanford University	Myles, T (corresponding author), Stanford Univ, Div Hematol, Dept Med, Sch Med, 269 Campus Dr,CCSR,Rm 1155, Stanford, CA 94305 USA.	tmyles@stanford.edu			NHLBI NIH HHS [R01 HL57530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 2000, ARTERIOSCL THROM VAS, V20, P2511, DOI 10.1161/01.ATV.20.12.2511; Barry ST, 2000, EXP CELL RES, V258, P342, DOI 10.1006/excr.2000.4941; Bayless KJ, 2001, J BIOL CHEM, V276, P13483, DOI 10.1074/jbc.M011392200; Bayless KJ, 1998, J CELL SCI, V111, P1165; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; Campbell WD, 2002, MICROBIOL IMMUNOL, V46, P131, DOI 10.1111/j.1348-0421.2002.tb02669.x; COLLEN D, 1975, J BIOL CHEM, V250, P5808; Colman RW, 1999, THROMB HAEMOSTASIS, V82, P1568; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; EATON DL, 1991, J BIOL CHEM, V266, P21833; Esmon CT, 2002, J EXP MED, V196, P561, DOI 10.1084/jem.20021088; Green PM, 2001, FEBS LETT, V503, P75, DOI 10.1016/S0014-5793(01)02690-4; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; HENSON PM, 1978, J IMMUNOL, V121, P851; HUEY R, 1983, AM J PATHOL, V112, P48; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Koschinsky ML, 2001, CLIN GENET, V60, P345, DOI 10.1034/j.1399-0004.2001.600504.x; Nagashima M, 2002, J CLIN INVEST, V109, P101, DOI 10.1172/JCI12119; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1988, CANCER RES, V48, P5770; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Swaisgood CM, 2002, J CLIN INVEST, V110, P1275, DOI 10.1172/JCI200215082; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; Yokasaki Y, 2000, TRENDS CARDIOVAS MED, V10, P155, DOI 10.1016/S1050-1738(00)00055-4; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328	37	183	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51059	51067		10.1074/jbc.M306977200	http://dx.doi.org/10.1074/jbc.M306977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525995	hybrid			2022-12-25	WOS:000187206300029
J	Perez-Sala, D; Cernuda-Morollon, E; Canada, FJ				Perez-Sala, D; Cernuda-Morollon, E; Canada, FJ			Molecular basis for the direct inhibition of AP-1 DNA binding by 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; NITRIC-OXIDE; CYCLOPENTENONE PROSTAGLANDINS; CYCLOOXYGENASE-2 EXPRESSION; DEPENDENT REPRESSION; POTENTIAL INDUCERS; REDOX REGULATION; PROTEIN-KINASE; APOPTOSIS	Cyclopentenone prostaglandins may interfere with cellular functions by multiple mechanisms. The cyclopentenone 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d- PGJ(2)) has been reported to inhibit the activity of the transcription factor AP-1 in several experimental settings. We have explored the possibility of a direct interaction of 15d- PGJ(2) with AP-1 proteins. Here we show that 15d-PGJ(2) covalently modifies c-Jun and directly inhibits the DNA binding activity of AP-1. The modification of c-Jun occurs both in vitro and in intact cells as detected by labeling with biotinylated 15d- PGJ(2) and mass spectrometry analysis. Attachment of the cyclopentenone prostaglandin occurs at cysteine 269, which is located in the c-Jun DNA binding domain. In addition, 15d- PGJ(2) can promote the oligomerization of a fraction of c-Jun through the formation of intermolecular disulfide bonds or 15d-PGJ(2)-bonded dimers. Our results identify a novel site of interaction of 15d- PGJ(2) with the AP-1 activation pathway that may contribute to the complex effects of cyclopentenone prostaglandins on the cellular response to pro-inflammatory agents. They also show the first evidence for the induction of protein cross-linking by 15d- PGJ(2).	CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Perez-Sala, D (corresponding author), CSIC, Dept Estructura & Func Prot, Ctr Invest Biol, Ramiro Maeztui 9, Madrid 28040, Spain.	dperezsala@cib.csic.es	Perez-Sala, Dolores/L-5969-2014; Cañada, Francisco J./D-5837-2014	Perez-Sala, Dolores/0000-0003-0600-665X; Cañada, Francisco J./0000-0003-4462-1469				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Boyault S, 2001, FEBS LETT, V501, P24, DOI 10.1016/S0014-5793(01)02614-X; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2003, MOL CELL BIOL, V23, P1196, DOI 10.1128/MCB.23.4.1196-1208.2003; Cernuda-Morollon E, 2002, J AM SOC NEPHROL, V13, P2223, DOI 10.1097/01.ASN.0000025786.87646.B1; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Clay CE, 2001, J BIOL CHEM, V276, P47131, DOI 10.1074/jbc.C100339200; Cox B, 2002, BBA-MOL CELL BIOL L, V1584, P37, DOI 10.1016/S1388-1981(02)00267-6; Cuzzocrea S, 2002, MOL PHARMACOL, V61, P997, DOI 10.1124/mol.61.5.997; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diaz-Cazorla M, 1999, J AM SOC NEPHROL, V10, P943; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Jung KM, 2003, MOL PHARMACOL, V63, P607, DOI 10.1124/mol.63.3.607; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; Li LY, 2001, J BIOL CHEM, V276, P38152; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Maggi LB, 2000, DIABETES, V49, P346, DOI 10.2337/diabetes.49.3.346; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Reilly CM, 2000, J IMMUNOL, V164, P1498, DOI 10.4049/jimmunol.164.3.1498; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sawano H, 2002, KIDNEY INT, V61, P1957, DOI 10.1046/j.1523-1755.2002.00351.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Shibata T, 2003, J BIOL CHEM, V278, P26046, DOI 10.1074/jbc.M303690200; Simonin MA, 2002, AM J PHYSIOL-CELL PH, V282, pC125, DOI 10.1152/ajpcell.2002.282.1.C125; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001	48	130	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51251	51260		10.1074/jbc.M309409200	http://dx.doi.org/10.1074/jbc.M309409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532268	hybrid, Green Published			2022-12-25	WOS:000187206300051
J	Stevenson-Lindert, LM; Fowler, P; Lew, J				Stevenson-Lindert, LM; Fowler, P; Lew, J			Substrate specificity of CDK2-cyclin A - What is optimal?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; ACTIVATION MECHANISM; RECOGNITION MOTIF; KINETIC BASIS; PHOSPHORYLATION; P107; INHIBITORS; COMPLEXES; BINDING	The optimal amino acid sequence of substrates for recognition by the cyclin- dependent kinases is well established as - Ser/Thr(0)- Pro(+1)- Lys(+2)- Lys(+3)-. The catalytic efficiency of CDK2- cyclin A is impaired 2000-, 10-, and 150- fold, when Pro(+1), Lys(+2), or Lys(+3), respectively, is substituted with Ala in a short synthetic peptide substrate. Yet, in physiological substrates of both CDK2-cyclin A and CDK2- cyclin E, it is found that Lys(+2), and, occasionally, both Lys(+2) and Lys(+3) together are replaced with suboptimal determinants. Such suboptimal phosphorylation site motifs are invariably associated with a distinct cyclin- binding ( Cy) motif, which has been shown to compensate for otherwise poor catalysis. Here we have investigated the kinetic basis for substrate recognition by CDK2- cyclin A. In the optimal motif, Pro(+1) serves to dramatically enhance both substrate binding affinity as well as the rate of chemical phosphotransfer, whereas Lys(+2) and Lys(+3) both serve to enhance mainly substrate binding. When linked to a suboptimal phosphorylation site sequence ( Lys(+2) --> Pro) the Cy motif increases catalytic efficiency ( k(cat)/K-m) by increasing affinity without affecting turnover ( k(cat)). When fused to the optimal sequence, however, catalytic efficiency is only minimally enhanced, because the resulting high substrate affinity impedes the rate of the phosphoryl transfer reaction. Our results provide kinetic insight into the basis for selecting suboptimal specificity determinants for the phosphorylation of cellular substrates.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Mol Biosci & Engn, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Lew, J (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	lew@lifesci.ucsb.edu						ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P683; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Guida P, 1999, BIOCHEM BIOPH RES CO, V258, P596, DOI 10.1006/bbrc.1999.0656; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Holmes JK, 2001, EUR J BIOCHEM, V268, P4647, DOI 10.1046/j.1432-1327.2001.02392.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Lew J, 2003, BIOCHEMISTRY-US, V42, P849, DOI 10.1021/bi0269761; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nigg E A, 1991, Semin Cell Biol, V2, P261; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SRINIVASAN J, 1995, BIOCHEM J, V309, P927, DOI 10.1042/bj3090927; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; WALSH DA, 1990, PEPTIDES PROTEIN PHO, P44; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	36	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50956	50960		10.1074/jbc.M306546200	http://dx.doi.org/10.1074/jbc.M306546200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506259	hybrid			2022-12-25	WOS:000187206300017
J	Wu, KM; Yang, Y; Wang, CG; Davoli, MA; D'Amico, M; Li, AP; Cveklova, K; Kozmik, Z; Lisanti, MP; Russell, RG; Cvekl, A; Pestell, RG				Wu, KM; Yang, Y; Wang, CG; Davoli, MA; D'Amico, M; Li, AP; Cveklova, K; Kozmik, Z; Lisanti, MP; Russell, RG; Cvekl, A; Pestell, RG			DACH1 inhibits transforming growth factor-beta signaling through binding Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-DACHSHUND; GENE-EXPRESSION; ANDROGEN RECEPTOR; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR CLASSIFICATION; SKI ONCOPROTEIN; CYCLIN D1; EYE; MOUSE	The vertebrate homologues of Drosophila dachsund, DACH1 and DACH2, have been implicated as important regulatory genes in development. DACH1 plays a role in retinal and pituitary precursor cell proliferation and DACH2 plays a specific role in myogenesis. DACH proteins contain a domain (DS domain) that is conserved with the proto-oncogenes Ski and Sno. Since the Ski/Sno proto-oncogenes repress AP-1 and SMAD signaling, we hypothesized that DACH1 might play a similar cellular function. Herein, DACH1 was found to be expressed in breast cancer cell lines and to inhibit transforming growth factor-beta (TGF-beta)-induced apoptosis. DACH1 repressed TGF-beta induction of AP-1 and Smad signaling in gene reporter assays and repressed endogenous TGF-beta-responsive genes by microarray analyses. DACH1 bound to endogenous NCoR and Smad4 in cultured cells and DACH1 co-localized with NCoR in nuclear dotlike structures. NCoR enhanced DACH1 repression, and the repression of TGF-beta-induced AP-1 or Smad signaling by DACH1 required the DACH1 DS domain. The DS domain of DACH was sufficient for NCoR binding at a Smad4-binding site. Smad4 was required for DACH1 repression of Smad signaling. In Smad4 null HTB-134 cells, DACH1 inhibited the activation of SBE-4 reporter activity induced by Smad2 or Smad3 only in the presence of Smad4. DACH1 participates in the negative regulation of TGF-beta signaling by interacting with NCoR and Smad4.	Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20057 USA; Albert Einstein Coll Med, Dept Ophthalmol & Visual Sci & Mol Genet, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Georgetown University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Pestell, RG (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Res Bldg Rm E501,3970 Reservoir Rd NW,Box 571468, Washington, DC 20057 USA.		Lisanti, Michael P/C-6866-2013; Kozmik, Zbynek/I-8807-2014; Cvekl, Ales/B-2427-2013; Kozmik, Zbynek/G-3581-2014; Lisanti, Michael/B-6131-2018	Lisanti, Michael/0000-0003-2034-1382; wu, kongming/0000-0003-2499-1032; Kozmik, Zbynek/0000-0002-5850-2105	NATIONAL CANCER INSTITUTE [R01CA070896, R01CA075503, R01CA086072] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012200] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA70896, R01CA86072, R01CA86071, R01CA75503] Funding Source: Medline; NEI NIH HHS [EY12200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Ayres JA, 2001, GENOMICS, V77, P18, DOI 10.1006/geno.2001.6618; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Caubit X, 1999, DEV DYNAM, V214, P66, DOI 10.1002/(SICI)1097-0177(199901)214:1<66::AID-DVDY7>3.0.CO;2-7; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; D'Amico M, 2003, CANCER RES, V63, P3395; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Davis RJ, 2001, MOL CELL BIOL, V21, P1484, DOI 10.1128/MCB.21.5.1484-1490.2001; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hammond KL, 1998, MECH DEVELOP, V74, P121, DOI 10.1016/S0925-4773(98)00071-9; Hayes SA, 2001, CANCER RES, V61, P2112; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Heanue TA, 2002, MECH DEVELOP, V111, P75, DOI 10.1016/S0925-4773(01)00611-6; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horner A, 2002, DEV DYNAM, V225, P35, DOI 10.1002/dvdy.10132; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin L, 1997, AM J PATHOL, V151, P509; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim SS, 2002, STRUCTURE, V10, P787, DOI 10.1016/S0969-2126(02)00769-4; Kozmik Z, 1999, DEV GENES EVOL, V209, P537, DOI 10.1007/s004270050286; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li X, 2002, SCIENCE, V297, P1180; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MARDON G, 1994, DEVELOPMENT, V120, P3473; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; MASTUDA T, 2001, J BIOL CHEM, V276, P42908; NORMURA T, 1999, GENE DEV, V13, P412; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Szele FG, 2002, MECH DEVELOP, V112, P179, DOI 10.1016/S0925-4773(01)00641-4; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1997, J BIOL CHEM, V272, P20063, DOI 10.1074/jbc.272.32.20063; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	55	114	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51673	51684		10.1074/jbc.M310021200	http://dx.doi.org/10.1074/jbc.M310021200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525983	hybrid			2022-12-25	WOS:000187206300102
J	Yang, HP; Sadda, MR; Yu, V; Zeng, Y; Lee, TD; Ou, XP; Chen, LX; Lu, SC				Yang, HP; Sadda, MR; Yu, V; Zeng, Y; Lee, TD; Ou, XP; Chen, LX; Lu, SC			Induction of human methionine adenosyltransferase 2A expression by tumor necrosis factor alpha - Role of NF-kappa B and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; DIFFERENTIAL EXPRESSION; 5'-FLANKING REGION; CLONING; GLUTATHIONE; SUBUNIT; GROWTH; CDNA	Two genes ( MAT1A and MAT2A) encode for methionine adenosyltransferase ( MAT), an essential cellular enzyme responsible for S- adenosylmethionine biosynthesis. MAT1A is expressed mostly in the liver, whereas MAT2A is widely distributed. We showed a switch from MAT1A to MAT2A expression in human hepatocellular carcinoma ( HCC), which facilitates cancer cell growth. Using DNase I footprinting analysis, we previously identified a region in the MAT2A promoter protected from DNase I digestion in HCC. This region contains NF-kappaB and AP- 1 elements, and the present study examined whether they regulate MAT2A promoter activity. We found nuclear binding of NF-kappaB and AP- 1 to the MAT2A promoter increased in HCC. Tumor necrosis factor alpha ( TNFalpha), which activates both NF-kappaB and AP- 1, increased MAT2A expression in a dose- and time- dependent manner, binding of both NF-kappaB and AP- 1 to the MAT2A promoter and MAT2A promoter activity, with the latter effect blocked by site- directed mutagenesis of the NF-kappaB and AP- 1 binding sites. Blocking NF-kappaB with IkappaB super-repressor or AP- 1 with dominant- negative c- Jun led to decreased basal MAT2A expression and prevented the TNFalpha- induced increase in MAT2A expression. Although blocking NF-kappaB had no influence on the ability of TNFalpha to increase AP- 1 nuclear binding, blocking AP- 1 with dominant- negative c- Jun prevented the TNFalpha- mediated increase in NF-kappaB binding. In conclusion, both NF-kappaB and AP- 1 are required for basal MAT2A expression in HepG2 cells and mediate the increase in MAT2A expression in response to TNF alpha treatment. Increased trans-activation of these two sites also contributes to MAT2A up- regulation in HCC.	Univ So Calif, Keck Sch Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis,Dept Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Keck Sch Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis,Dept Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, Hoffman Med Res Bldg,415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@usc.edu	Lu, Shelly/AAH-5937-2021	Lu, Shelly/0000-0003-2128-5407	NCCIH NIH HHS [AT1576] Funding Source: Medline; NCI NIH HHS [5P30CA14089] Funding Source: Medline; NIAAA NIH HHS [AA12677, T32 AA07578] Funding Source: Medline; NIDDK NIH HHS [DK51719, DK48522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT001576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522, R01DK051719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007578, R01AA012677] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALVAREZ L, 1993, BIOCHEM J, V293, P481, DOI 10.1042/bj2930481; Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Gil B, 1996, HEPATOLOGY, V24, P876; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; HORIKAWA S, 1993, FEBS LETT, V330, P307, DOI 10.1016/0014-5793(93)80894-Z; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; Huang ZZ, 1999, HEPATOLOGY, V29, P1471, DOI 10.1002/hep.510290525; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Lu SC, 2000, AM J PHYSIOL-GASTR L, V279, pG178, DOI 10.1152/ajpgi.2000.279.1.G178; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; Mao ZB, 1998, BIOCHEM BIOPH RES CO, V248, P479, DOI 10.1006/bbrc.1998.8965; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; She HY, 2002, AM J PHYSIOL-GASTR L, V283, pG719, DOI 10.1152/ajpgi.00108.2002; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Tobena R, 1996, BIOCHEM J, V319, P929, DOI 10.1042/bj3190929; Yang HP, 2002, J BIOL CHEM, V277, P35232, DOI 10.1074/jbc.M203812200; Yang HP, 2001, FASEB J, V15, P1507, DOI 10.1096/fj.01-0040com; Yang HP, 2001, AM J PHYSIOL-GASTR L, V280, pG184; Zeng ZH, 2000, BIOCHEM J, V346, P475, DOI 10.1042/0264-6021:3460475	30	46	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50887	50896		10.1074/jbc.M307600200	http://dx.doi.org/10.1074/jbc.M307600200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530285	hybrid			2022-12-25	WOS:000187206300008
J	Nesper, J; Hill, CMD; Paiment, A; Harauz, G; Beis, K; Naismith, JH; Whitfield, C				Nesper, J; Hill, CMD; Paiment, A; Harauz, G; Beis, K; Naismith, JH; Whitfield, C			Translocation of group 1 capsular polysaccharide in Escherichia coli serotype K30 - Structural and functional analysis of the outer membrane lipoprotein Wza	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL SECRETORY PATHWAY; GRAM-NEGATIVE BACTERIA; PHAGE PIV MULTIMER; PROTEIN-KINASE WZC; C-TERMINAL DOMAIN; TYROSINE AUTOKINASE; POLYSIALIC ACID; K-ANTIGEN; 2-DIMENSIONAL CRYSTALLIZATION; NEISSERIA-MENINGITIDIS	The late steps in assembly of capsular polysaccharides (CPS) and their translocation to the bacterial cell surface are not well understood. The Wza protein was shown previously to be required for the formation of the prototype group 1 capsule structure on the surface of Escherichia coli serotype K30 (Drummelsmith, J., and Whitfield, C. (2000) EMBO J. 19, 57 - 66). Wza is a conserved outer membrane lipoprotein that forms multimers adopting a ringlike structure, and collective evidence suggests a role for these structures in the export of capsular polymer across the outer membrane. Wza was purified in the native form and with a C-terminal hexahistidine tag. Wza(His6) was acylated and functional in capsule assembly, although its efficiency was slightly reduced in comparison to the native Wza protein. Ordered two-dimensional crystals of Wza(His6) were obtained after reconstitution of purified multimers into lipids. Electron microscopy of negatively stained crystals and Fourier filtering revealed ringlike multimers with an average outer diameter of 8.84 nm and an average central cavity diameter of 2.28 nm. Single particle analysis yielded projection structures at an estimated resolution of 3 nm, favoring a structure for the WzaHis6 containing eight identical subunits. A derivative of Wza (Wza*) in which the original signal sequence was replaced with that from OmpF showed that the native acylated N terminus of Wza is critical for formation of normal multimeric structures and for their competence for CPS assembly, but not for targeting Wza to the outer membrane. In the presence of Wza*, CPS accumulated in the periplasm but was not detected on the cell surface. Chemical cross-linking of intact cells suggested formation of a transmembrane complex minimally containing Wza and the inner membrane tyrosine autokinase Wzc.	Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	University of Guelph; University of Guelph; University of St Andrews	Whitfield, C (corresponding author), Univ Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada.	cwhitfie@uoguelph.ca	Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Harauz, George/0000-0002-6114-9947; Beis, Konstantinos/0000-0001-5727-4721				Amer AO, 2000, J BACTERIOL, V182, P498, DOI 10.1128/JB.182.2.498-503.2000; Andersen C, 2002, P NATL ACAD SCI USA, V99, P11103, DOI 10.1073/pnas.162039399; Ast VM, 2002, MOL MICROBIOL, V44, P217, DOI 10.1046/j.1365-2958.2002.02870.x; Balakrishnan L, 2001, J MOL BIOL, V313, P501, DOI 10.1006/jmbi.2001.5038; BAYER ME, 1977, J BACTERIOL, V130, P911, DOI 10.1128/JB.130.2.911-936.1977; BAYER ME, 1991, J STRUCT BIOL, V107, P268, DOI 10.1016/1047-8477(91)90052-X; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; Brok R, 1999, J MOL BIOL, V294, P1169, DOI 10.1006/jmbi.1999.3340; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; Chen LY, 1996, J BIOL CHEM, V271, P2703, DOI 10.1074/jbc.271.5.2703; Cieslewicz M, 1997, MOL MICROBIOL, V26, P237, DOI 10.1046/j.1365-2958.1997.5651942.x; Collins RF, 2003, J BACTERIOL, V185, P2611, DOI 10.1128/JB.185.8.2611-2617.2003; Collins RF, 2001, J BACTERIOL, V183, P3825, DOI 10.1128/JB.183.13.3825-3832.2001; Crago AM, 1998, MOL MICROBIOL, V30, P47, DOI 10.1046/j.1365-2958.1998.01036.x; Daefler S, 1998, MOL MICROBIOL, V28, P1367, DOI 10.1046/j.1365-2958.1998.00908.x; Daefler S, 1997, MOL MICROBIOL, V24, P465, DOI 10.1046/j.1365-2958.1997.3531727.x; Doublet P, 2002, J BIOL CHEM, V277, P37339, DOI 10.1074/jbc.M204465200; Drummelsmith J, 1999, MOL MICROBIOL, V31, P1321, DOI 10.1046/j.1365-2958.1999.01277.x; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; Eswaran J, 2003, J MOL BIOL, V327, P309, DOI 10.1016/S0022-2836(03)00116-5; Feng JN, 1999, MOL MICROBIOL, V34, P745, DOI 10.1046/j.1365-2958.1999.01636.x; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; FLAIBANI A, 1994, INT J BIOL MACROMOL, V16, P65, DOI 10.1016/0141-8130(94)90016-7; GENIN S, 1994, MOL GEN GENET, V243, P112, DOI 10.1007/BF00283883; Gerard-Vincent M, 2002, MOL MICROBIOL, V44, P1651, DOI 10.1046/j.1365-2958.2002.02991.x; Grangeasse C, 2003, J BIOL CHEM, V278, P39323, DOI 10.1074/jbc.M305134200; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Guilvout I, 1999, J BACTERIOL, V181, P7212, DOI 10.1128/JB.181.23.7212-7220.1999; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Harauz G, 1998, MICRON, V29, P161, DOI 10.1016/S0968-4328(97)00069-3; Hardie KR, 1996, MOL MICROBIOL, V22, P967, DOI 10.1046/j.1365-2958.1996.01539.x; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOMONYLO MK, 1988, CAN J MICROBIOL, V34, P1159, DOI 10.1139/m88-204; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; JANN K, 1983, PROG ALLERGY, V33, P53; Klein G, 2003, MOL MICROBIOL, V48, P269, DOI 10.1046/j.1365-2958.2003.03449.x; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 2001, CURR OPIN STRUC BIOL, V11, P403, DOI 10.1016/S0959-440X(00)00224-4; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; KRONCKE KD, 1990, J BACTERIOL, V172, P3469; KRONCKE KD, 1990, J BACTERIOL, V172, P1085; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; Levy D, 2001, FEBS LETT, V504, P187, DOI 10.1016/S0014-5793(01)02748-X; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; MACLACHLAN PR, 1993, J BACTERIOL, V175, P7515, DOI 10.1128/JB.175.23.7515-7522.1993; Marciano DK, 2001, P NATL ACAD SCI USA, V98, P9359, DOI 10.1073/pnas.161170398; MCCALLUM KL, 1989, CAN J MICROBIOL, V35, P994, DOI 10.1139/m89-166; Morona R, 2000, MICROBIOL-UK, V146, P1, DOI 10.1099/00221287-146-1-1; Nouwen N, 2000, EMBO J, V19, P2229, DOI 10.1093/emboj/19.10.2229; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Opalka N, 2003, J MOL BIOL, V325, P461, DOI 10.1016/S0022-2836(02)01246-9; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; PAVELKA MS, 1994, J BIOL CHEM, V269, P20149; Rahn A, 2003, J BACTERIOL, V185, P5882, DOI 10.1128/JB.185.19.5882-5890.2003; Rahn A, 1999, J BACTERIOL, V181, P2307, DOI 10.1128/JB.181.7.2307-2313.1999; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; Schmidt SA, 2001, J BACTERIOL, V183, P4848, DOI 10.1128/JB.183.16.4848-4859.2001; Schuch R, 2001, J BACTERIOL, V183, P6991, DOI 10.1128/JB.183.24.6991-6998.2001; Shevchik VE, 1997, EMBO J, V16, P3007, DOI 10.1093/emboj/16.11.3007; Silver RP, 2001, RES MICROBIOL, V152, P357, DOI 10.1016/S0923-2508(01)01207-4; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WHITFIELD C, 1986, FEMS MICROBIOL LETT, V37, P351, DOI 10.1111/j.1574-6968.1986.tb01823.x; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	73	72	74	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49763	49772		10.1074/jbc.M308775200	http://dx.doi.org/10.1074/jbc.M308775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522970	hybrid			2022-12-25	WOS:000187068200016
J	Rigden, DJ; Jedrzejas, MJ				Rigden, DJ; Jedrzejas, MJ			Structures of Streptococcus pneumoniae hyaluronate lyase in complex with chondroitin and chondroitin sulfate disaccharides - Insights into specificity and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; CRYSTAL-STRUCTURE; TERTIARY STRUCTURES; EXTRACELLULAR MATRICES; VIRULENCE FACTORS; SURFACE-PROTEINS; AQUEOUS-SOLUTION; HEPARAN-SULFATE; ACTION PATTERN; CELL-WALL	Streptococcus pneumoniae hyaluronate lyase is a surface enzyme of this Gram- positive bacterium. The enzyme degrades hyaluronan and chondroitin/ chondroitin sulfates by cleaving the beta1,4- glycosidic linkage between the glycan units of these polymeric substrates. This degradation helps spreading of this bacterial organism throughout the host tissues and facilitates the disease process caused by pneumococci. The mechanism of this degradative process is based on beta- elimination, is termed proton acceptance and donation, and involves selected residues of a well defined catalytic site of the enzyme. The degradation of hyaluronan alone is thought to proceed through a processive mode of action. The structures of complexes between the enzyme and chondroitin as well as chondroitin sulfate disaccharides allowed for the first detailed insights into these interactions and the mechanism of action on chondroitins. This degradation of chondroitin/ chondroitin sulfates is nonprocessive and is selective for the chondroitin sulfates only with certain sulfation patterns. Chondroitin sulfation at the 4- position on the nonreducing site of the linkage to be cleaved or 2- sulfation prevent degradation due to steric clashes with the enzyme. Evolutionary studies suggest that hyaluronate lyases evolved from chondroitin lyases and still retained chondroitin/ chondroitin sulfate degradation abilities while being specialized in the degradation of hyaluronan. The more efficient processive degradation mechanism has come to be preferred for the unsulfated substrate hyaluronan.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; EMBRAPA, Cenargen, Embrapa Genet Resources & Biotechnol, Brasilia, DF, Brazil	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	MJedrzejas@chori.org		Rigden, Daniel/0000-0002-7565-8937	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Almond A, 1998, GLYCOBIOLOGY, V8, P973, DOI 10.1093/glycob/8.10.973; Almond A, 2000, J PHYS CHEM B, V104, P5634, DOI 10.1021/jp000402t; Almond A, 1998, J MOL BIOL, V284, P1425, DOI 10.1006/jmbi.1998.2245; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JR, 2000, BIOCHEM J, V348, P465, DOI 10.1042/0264-6021:3480465; Baker JR, 1997, BIOCHEM J, V327, P65, DOI 10.1042/bj3270065; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; Cowman MK, 1996, MACROMOLECULES, V29, P2894, DOI 10.1021/ma951701x; Cowman MK, 2001, MACROMOLECULES, V34, P110, DOI 10.1021/ma001082e; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DeAngelis PL, 2002, ANAT RECORD, V268, P317, DOI 10.1002/ar.10163; Delano W. L., 2003, PYMOL MOL GENETICS G; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Gribbon P, 2000, BIOCHEM J, V350, P329, DOI 10.1042/0264-6021:3500329; GU KN, 1995, BIOCHEM J, V312, P569, DOI 10.1042/bj3120569; Hamai A, 1997, J BIOL CHEM, V272, P9123; HOLMBECK SMA, 1994, BIOCHEMISTRY-US, V33, P14246, DOI 10.1021/bi00251a037; Huang WJ, 2003, J MOL BIOL, V328, P623, DOI 10.1016/S0022-2836(03)00345-0; Huang WJ, 2001, BIOCHEMISTRY-US, V40, P2359, DOI 10.1021/bi0024254; JANDIK KA, 1994, GLYCOBIOLOGY, V4, P289, DOI 10.1093/glycob/4.3.289; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2004, FRONT BIOSCI-LANDMRK, V9, P891, DOI 10.2741/1299; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JEDRZEJAS MJ, 2002, SCI HAYLURONAN TODAY; JEDRZEJAS MJ, 2002, RRD BIO BIO, V2, P197; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Kim YS, 1996, J BIOL CHEM, V271, P11750, DOI 10.1074/jbc.271.20.11750; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lauder RM, 2000, GLYCOBIOLOGY, V10, P393, DOI 10.1093/glycob/10.4.393; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 2003, SCI HAYLURONAN TODAY; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LIN B, 1994, J BIOL CHEM, V269, P30113; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LINKER A, 1956, J BIOL CHEM, V219, P13; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; McPherson A., 1999, CRYSTALLIZATION BIOL; Mello LV, 1998, BIOCHEMISTRY-US, V37, P3137, DOI 10.1021/bi971402v; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; OHYA T, 1970, BIOCH BIOPHYS ACTA, V198; OLIVEIRA FW, 1994, BBA-GEN SUBJECTS, V1200, P241, DOI 10.1016/0304-4165(94)90163-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; QUIOCHO FA, 1999, BIOORGANIC CHEM CARB, P441; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rigden DJ, 2003, PROTEINS, V52, P203, DOI 10.1002/prot.10405; Rigden DJ, 2003, CRIT REV BIOCHEM MOL, V38, P143, DOI 10.1080/713609215; Ruijssenaars HJ, 1999, APPL ENVIRON MICROB, V65, P2446; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCOTT JE, 1992, EUR J BIOCHEM, V209, P675, DOI 10.1111/j.1432-1033.1992.tb17335.x; Scott JE, 1998, J ANAT, V192, P391, DOI 10.1046/j.1469-7580.1998.19230391.x; Scott JE, 1999, P NATL ACAD SCI USA, V96, P4850, DOI 10.1073/pnas.96.9.4850; Scott JE, 2002, BIOMACROMOLECULES, V3, P547, DOI 10.1021/bm010170j; Scott JE, 2001, PATHOL BIOL, V49, P284, DOI 10.1016/S0369-8114(01)00152-3; SCOTT JE, 1995, BIOCHEMISTRY-US, V34, P15467, DOI 10.1021/bi00047a011; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P1015, DOI 10.1093/oxfordjournals.jbchem.a133052; SICINSKA W, 1993, CARBOHYD RES, V242, P29, DOI 10.1016/0008-6215(93)80020-F; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; TOFFANIN R, 1993, CARBOHYD RES, V245, P113, DOI 10.1016/0008-6215(93)80064-L; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; TURNER RE, 1988, ARCH BIOCHEM BIOPHYS, V265, P484, DOI 10.1016/0003-9861(88)90153-1; WINTER WT, 1975, J MOL BIOL, V99, P219, DOI 10.1016/S0022-2836(75)80142-2; WINTER WT, 1978, J MOL BIOL, V125, P1, DOI 10.1016/0022-2836(78)90251-6; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883; Yoon HJ, 2001, J MOL BIOL, V307, P9, DOI 10.1006/jmbi.2000.4509	83	43	45	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50596	50606		10.1074/jbc.M307596200	http://dx.doi.org/10.1074/jbc.M307596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523022	hybrid			2022-12-25	WOS:000187068200114
J	Bolger, GB; McCahill, A; Huston, E; Cheung, YF; McSorley, T; Baillie, GS; Houslay, MD				Bolger, GB; McCahill, A; Huston, E; Cheung, YF; McSorley, T; Baillie, GS; Houslay, MD			The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; AMP-SPECIFIC PHOSPHODIESTERASE; A-MEDIATED PHOSPHORYLATION; DEPENDENT PROTEIN-KINASE; ROLIPRAM INHIBITION; CROSS-TALK; MAP KINASE; ACTIVATION; RECEPTORS; CELLS	Isoproterenol challenge of Hek-B2 cells causes a transient recruitment of the endogenous PDE4D isoforms found in these cells, namely PDE4D3 and PDE4D5, to the membrane fraction. PDE4D5 provides around 80% of the total PDE4D protein so recruited, although it only comprises about 40% of the total PDE4D protein in Hek-B2 cells. PDE4D5 provides about 80% of the total PDE4D protein found associated with beta-arrestins immunopurified from Hek-B2, COS1, and A549 cells as well as cardiac myocytes, whereas its overall level in these cells is between 15 and 50% of the total PDE4D protein. Truncation analyses indicate that two sites in PDE4D5 are involved in mediating its interaction with beta-arrestins, one associated with the common PDE4 catalytic region and the other located within its unique amino-terminal region. Truncation analyses indicate that two sites in beta-arrestin 2 are involved in mediating its interaction with PDE4D5, one associated with its extreme amino-terminal region and the other located within the carboxylterminal domain of the protein. We suggest that the unique amino-terminal region of PDE4D5 allows it to preferentially interact with beta-arrestins. This specificity appears likely to account for the preferential recruitment of PDE4D5, compared with PDE4D3, to membranes of Hek-B2 cells and cardiac myocytes upon challenge with isoproterenol.	Univ Alabama Birmingham, Ctr Comprehens Canc, WTI 520, Birmingham, AL 35294 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Alabama System; University of Alabama Birmingham; University of Glasgow	Bolger, GB (corresponding author), Univ Alabama Birmingham, Ctr Comprehens Canc, WTI 520, 1530 3rd Ave S, Birmingham, AL 35294 USA.	Graeme.Bolger@ccc.uab.edu	Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058553] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM58553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baillie G, 2001, MOL PHARMACOL, V60, P1100, DOI 10.1124/mol.60.5.1100; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Berkman N, 1996, IMMUNOLOGY, V89, P363, DOI 10.1046/j.1365-2567.1996.d01-745.x; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2002, J NEUROSCI, V22, P10494; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; Bolger GB, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-24; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; Burnouf C, 2002, CURR PHARM DESIGN, V8, P1255, DOI 10.2174/1381612023394665; Clerk A, 2002, BIOCHEM J, V368, P101, DOI 10.1042/BJ20021083; Conner DA, 1997, CIRC RES, V81, P1021; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; HARLOW E, 1990, ANTIBODIES LAB MANUA, P685; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Huston E, 1997, BIOCHEM J, V328, P549, DOI 10.1042/bj3280549; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Sambrook J, 2001, MOL CLONING LAB MANU; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; THOMPSON WJ, 1971, J BIOL CHEM, V246, P3145; Torphy Theodore J., 2000, Trends in Pharmacological Sciences, V21, P157; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	54	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49230	49238		10.1074/jbc.M303772200	http://dx.doi.org/10.1074/jbc.M303772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500724	hybrid			2022-12-25	WOS:000186829000088
J	Coustou, V; Besteiro, S; Biran, M; Diolez, P; Bouchaud, V; Voisin, P; Michels, PAM; Canioni, P; Baltz, T; Bringaud, F				Coustou, V; Besteiro, S; Biran, M; Diolez, P; Bouchaud, V; Voisin, P; Michels, PAM; Canioni, P; Baltz, T; Bringaud, F			ATP generation in the Trypanosoma brucei procyclic form - Cytosolic substrate level phosphorylation is essential, but not oxidative phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BLOOD-STREAM FORMS; ENERGY-METABOLISM; PYRUVATE-KINASE; GENE-EXPRESSION; INTERFERENCE; COMPARTMENTATION; INHIBITION; THREONINE; PROMOTERS	Trypanosoma brucei is a parasitic protist responsible for sleeping sickness in humans. The procyclic form of this parasite, transmitted by tsetse flies, is considered to be dependent on oxidative phosphorylation for ATP production. Indeed, its respiration was 55% inhibited by oligomycin, which is the most specific inhibitor of the mitochondrial F-0/F-1-ATP synthase. However, a 10-fold excess of this compound did not significantly affect the intracellular ATP concentration and the doubling time of the parasite was only 1.5-fold increased, suggesting that oxidative phosphorylation is not essential for procyclic trypanosomes. To further investigate the sites of ATP production, we studied the role of two ATP producing enzymes, which are involved in the synthesis of pyruvate from phosphoenolpyruvate: the glycosomal pyruvate phosphate dikinase (PPDK) and the cytosolic pyruvate kinase (PYK). The parasite was not affected by PPDK gene knockout. In contrast, inhibition of PYK expression by RNA interference was lethal for these cells. In the absence of PYK activity, the intracellular ATP concentration was reduced by up to 2.3-fold, whereas the intracellular pyruvate concentration was not reduced. Furthermore, we show that this mutant cell line still excreted acetate from D-glucose metabolism, and both the wild type and mutant cell lines consumed pyruvate present in the growth medium with similar high rates, indicating that in the absence of PYK activity pyruvate is still present in the trypanosomes. We conclude that PYK is essential because of its ATP production, which implies that the cytosolic substrate level phosphorylation is essential for the growth of procyclic trypanosomes.	Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Biochem Lab, B-1200 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Universite Catholique Louvain; Universite Catholique Louvain	Bringaud, F (corresponding author), Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Fonct Trypanosomatides, 146 Leo Saignat, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr	Michels, Paul A/A-5637-2009; Besteiro, Sébastien/F-3622-2014	Michels, Paul A/0000-0003-3726-6104; Besteiro, Sébastien/0000-0003-1853-1494; Diolez, Philippe/0000-0002-7548-2070				ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; Bastin P, 2000, J CELL SCI, V113, P3321; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; Bochud-Allemann N, 2002, J BIOL CHEM, V277, P32849, DOI 10.1074/jbc.M205776200; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; CALLENS M, 1992, MOL BIOCHEM PARASIT, V50, P235, DOI 10.1016/0166-6851(92)90220-E; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; CROSS GAM, 1975, PARASITOLOGY, V71, P311, DOI 10.1017/S0031182000046758; CZOK R, 1974, METHOD ENZYMAT AN, V3, P1585; Denise H, 1999, EUR J BIOCHEM, V259, P339, DOI 10.1046/j.1432-1327.1999.00048.x; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Inoue N, 2002, MOL BIOCHEM PARASIT, V120, P309, DOI 10.1016/S0166-6851(02)00015-4; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lemasters J J, 1979, Methods Enzymol, V56, P530; LINSTEAD DJ, 1977, J GEN MICROBIOL, V101, P243, DOI 10.1099/00221287-101-2-243; LUMSDEN HR, 1976, BIOL KINETOPLASTIDA; MACOUILLARDPOUL.D, 1998, CYTOMETRY, V33, P333; Michels PAM, 2000, PARASITOL TODAY, V16, P482, DOI 10.1016/S0169-4758(00)01810-X; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; NOLAN DP, 1992, EUR J BIOCHEM, V209, P207, DOI 10.1111/j.1432-1033.1992.tb17278.x; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; SAMBOROK J, 1989, MOL CLONING LAB MANU; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0; Turrens J, 1999, PARASITOL TODAY, V15, P346, DOI 10.1016/S0169-4758(99)01479-9; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; VISSER N, 1981, EUR J BIOCHEM, V118, P521, DOI 10.1111/j.1432-1033.1981.tb05550.x; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WILLIAMS N, 1994, J BIOENERG BIOMEMBR, V26, P173, DOI 10.1007/BF00763066; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	43	78	80	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49625	49635		10.1074/jbc.M307872200	http://dx.doi.org/10.1074/jbc.M307872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506274	hybrid			2022-12-25	WOS:000186829000134
J	Manolson, MF; Yu, HS; Chen, WM; Yao, YQ; Li, KY; Lees, RL; Heersche, JNM				Manolson, MF; Yu, HS; Chen, WM; Yao, YQ; Li, KY; Lees, RL; Heersche, JNM			The a3 isoform of the 100-kDa V-ATPase subunit is highly but differentially expressed in large (>= 10 nuclei) and small (<= 5 nuclei) osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; INFANTILE MALIGNANT OSTEOPETROSIS; PROTON-TRANSLOCATING ATPASE; RENAL TUBULAR-ACIDOSIS; BONE-RESORPTION; MOLECULAR-CLONING; GENE ENCODES; IN-VIVO; MEMBRANE-PROTEIN; PUMP SUBUNIT	Osteoclasts dissolve bone through acidification of an extracellular compartment by means of a multimeric vacuolar type H+-ATPase (V-ATPase). In mammals, there are four isoforms of the 100-kDa V-ATPase "a" subunit. Mutations in the a3 isoform result in deficient bone resorption and osteopetrosis, suggesting that a3 has a unique function in osteoclasts. It is thus surprising that several studies show a basal level of a3 expression in most tissues. To address this issue, we have compared a3 expression in bone with expression in other tissues. RNA blots revealed that the a3 isoform was expressed highest in bone and confirmed its expression ( in decreasing order) in liver, kidney, brain, lung, spleen, and muscle. In situ hybridization on bone tissue sections revealed that the a3 isoform was highly expressed in multinucleated osteoclasts but not in mononuclear stromal cells, whereas the a1 isoform was expressed in both cell types at about the same level. We also found that a3 expression was greater in osteoclasts with 10 or more nuclei as compared with osteoclasts with five or fewer nuclei. We hypothesize that these differences in a3 expression may be associated with previously demonstrated differences between large and small osteoclasts with reference to their resorptive activity.	Univ Toronto, Fac Dent, Res Inst, Toronto, ON M5G 1G6, Canada	University of Toronto	Manolson, MF (corresponding author), Univ Toronto, Fac Dent, Res Inst, 124 Edward St,Rm 429, Toronto, ON M5G 1G6, Canada.			Manolson, Morris/0000-0001-8755-5460				Aota S, 1996, CALCIFIED TISSUE INT, V59, P385, DOI 10.1007/s002239900144; Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169-409X(00)00061-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Gagliardi S, 1998, J MED CHEM, V41, P1568, DOI 10.1021/jm9800144; Heinemann T, 1999, GENOMICS, V57, P398, DOI 10.1006/geno.1999.5751; KANEHISA J, 1988, BONE, V9, P73, DOI 10.1016/8756-3282(88)90106-8; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P17941, DOI 10.1074/jbc.M010790200; KAYE M, 1985, KIDNEY INT, V27, P574, DOI 10.1038/ki.1985.49; Komminoth P., 1996, NONRADIOACTIVE IN SI, P126; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; LAITALA T, 1994, J CLIN INVEST, V93, P2311, DOI 10.1172/JCI117235; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Landolt-Marticorena C, 1999, J BIOL CHEM, V274, P26057, DOI 10.1074/jbc.274.37.26057; Lees RL, 2001, BONE, V28, P187, DOI 10.1016/S8756-3282(00)00433-6; Lees RL, 2000, AM J PHYSIOL-CELL PH, V279, pC751, DOI 10.1152/ajpcell.2000.279.3.C751; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; MAKRIS GP, 1982, ARCH ORAL BIOL, V27, P965, DOI 10.1016/0003-9969(82)90104-2; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MANOLSON MF, 2000, OSTEOPOROSIS PRIMER, P36; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Michigami T, 2002, BONE, V30, P436, DOI 10.1016/S8756-3282(01)00684-6; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Okahashi N, 1997, J BONE MINER RES, V12, P1116, DOI 10.1359/jbmr.1997.12.7.1116; Pujol N, 2001, J BIOL CHEM, V276, P11913, DOI 10.1074/jbc.M009451200; Rasmussen Alan H., 1974, ETHNOL SCAND, V1974, P117; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756-3282(99)00278-1; Scimeca JC, 2003, HUM MUTAT, V21, P151, DOI 10.1002/humu.10165; Scott BB, 1998, EUR J PHARMACOL, V346, pR3, DOI 10.1016/S0014-2999(98)00163-0; Shibutani T, 1997, J PERIODONTOL, V68, P385, DOI 10.1902/jop.1997.68.4.385; Singer Frederick R., 1996, P969; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stover EH, 2002, J MED GENET, V39, P796, DOI 10.1136/jmg.39.11.796; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; SUNDQUIST KT, 1994, J BONE MINER RES, V9, P1575; THOMASCAVALLIN M, 1988, J HISTOCHEM CYTOCHEM, V36, P1335, DOI 10.1177/36.10.3138309; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074-7613(00)80634-2; Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145	50	83	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49271	49278		10.1074/jbc.M309914200	http://dx.doi.org/10.1074/jbc.M309914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504271	hybrid			2022-12-25	WOS:000186829000093
J	Ohama, T; Hori, M; Sato, K; Ozaki, H; Karaki, H				Ohama, T; Hori, M; Sato, K; Ozaki, H; Karaki, H			Chronic treatment with interleukin-1 beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; NITRIC-OXIDE SYNTHASE; RHO-ASSOCIATED KINASE; INTEGRIN-LINKED KINASE; RAT MYENTERIC PLEXUS; MYOSIN PHOSPHATASE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CALCIUM SENSITIZATION; CA2+ SENSITIZATION	Interleukin-1beta (IL-1beta) is a proinflammatory cytokine that plays a central role in inflammatory bowel disease (IBD). In order to elucidate the mechanism of motility disorders frequently observed in IBD, we investigated the long term effects of IL-1beta on rat ileal smooth muscle contractility by using an organ culture system. When ileal smooth muscle strips were cultured with IL-1beta (10 ng/ml), contractions elicited by high K+ and carbachol were inhibited in a time-dependent manner. IL-1beta more strongly inhibited the carbachol-induced contractions than high K+ with decreasing myosin light chain phosphorylation. In the alpha-toxin-permeabilized ileal muscle, carbachol with GTP or guanosine 5'-3-O-(thio) triphosphate increased the Ca2+ sensitivity of contractile elements, and this G protein-coupled Ca2+ sensitization was significantly reduced in the IL-1beta-treated ileum. Among the functional proteins involved in the smooth muscle Ca2+ sensitization, CPI-17 expression was significantly reduced after the culture with IL-1beta, whereas the expressions of RhoA, ROCK-I, ROCK-II, MYPT-1, myosin light chain kinase, and myosin phosphatase (PP1) were unchanged. The phosphorylation level of CPI-17 by carbachol was low in accordance with the decrease in CPI-17 expression due to IL-1beta treatment. In contrast, constitutively phosphorylated MYPT-1 was also decreased in the IL-1beta-treated muscles. These results suggest that long term treatment with IL-1beta decreases either CPI-17 expression or MYPT-1 phosphorylation, which may result in an increase in myosin phosphatase activity to reduce force generation. Based on these findings, we consider IL-1beta to be an important mediator of gastrointestinal motility disorders in IBD, and CPI-17 and MYPT-1 are key molecules in the decreased smooth muscle contractility due to IL-1beta.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Radioisotope Ctr, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Ozaki, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.							AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; Bauer Anthony J, 2002, Curr Opin Crit Care, V8, P152, DOI 10.1097/00075198-200204000-00011; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Hori M, 2001, AM J PHYSIOL-GASTR L, V280, pG930, DOI 10.1152/ajpgi.2001.280.5.G930; HORI M, 1993, BRIT J PHARMACOL, V110, P1527, DOI 10.1111/j.1476-5381.1993.tb13996.x; Hori M, 1998, LIFE SCI, V62, P1629, DOI 10.1016/S0024-3205(98)00119-2; HURST S, 1993, AM J PHYSIOL, V264, pG30, DOI 10.1152/ajpgi.1993.264.1.G30; HURST SM, 1993, GASTROENTEROLOGY, V105, P1754, DOI 10.1016/0016-5085(93)91073-Q; Jensen PE, 1996, BIOCHEM J, V318, P469, DOI 10.1042/bj3180469; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KANEDA T, 1995, JPN J PHARMACOL, V69, P195, DOI 10.1254/jjp.69.195; Karaki H, 1997, PHARMACOL REV, V49, P157; Kiss E, 2002, BIOCHEM J, V365, P79, DOI 10.1042/BJ20011295; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; Kitazawa T, 2003, J PHYSIOL-LONDON, V546, P879, DOI 10.1113/jphysiol.2002.029306; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Kuemmerle JF, 1998, AM J PHYSIOL-GASTR L, V274, pG178, DOI 10.1152/ajpgi.1998.274.1.G178; LESH RE, 1995, CIRC RES, V77, P220, DOI 10.1161/01.RES.77.2.220; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; LI XM, 1994, J BIOL CHEM, V269, P19653; Lodato RF, 1999, AM J PHYSIOL-GASTR L, V276, pG1356, DOI 10.1152/ajpgi.1999.276.6.G1356; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MAIN C, 1993, GASTROENTEROLOGY, V104, P1648, DOI 10.1016/0016-5085(93)90641-O; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MIKKELSEN HB, 1985, ANAT REC, V213, P77, DOI 10.1002/ar.1092130111; MILANO S, 1995, PROSTAG OTH LIPID M, V49, P105, DOI 10.1016/0090-6980(94)00004-G; Mita M, 2002, BIOCHEM J, V364, P431, DOI 10.1042/BJ20020191; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi A, 2001, FEBS LETT, V493, P80, DOI 10.1016/S0014-5793(01)02283-9; Niiro N, 2003, BIOCHEM J, V369, P117, DOI 10.1042/BJ20021040; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; Otto B, 1996, J PHYSIOL-LONDON, V496, P317, DOI 10.1113/jphysiol.1996.sp021687; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; Rogler G, 1998, WORLD J SURG, V22, P382, DOI 10.1007/s002689900401; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakamoto K, 2003, J PHARMACOL SCI, V92, P56; Sakurada S, 2003, CIRC RES, V93, P548, DOI 10.1161/01.RES.0000090998.08629.60; Sartore S, 1997, ARTERIOSCL THROM VAS, V17, P1210, DOI 10.1161/01.ATV.17.7.1210; SATO K, 1994, J PHYSIOL-LONDON, V481, P677, DOI 10.1113/jphysiol.1994.sp020473; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sward K, 2000, J PHYSIOL-LONDON, V522, P33, DOI 10.1111/j.1469-7793.2000.0033m.x; Sward K, 1997, AM J PHYSIOL-CELL PH, V273, pC77, DOI 10.1152/ajpcell.1997.273.1.C77; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Torihashi S, 2000, HISTOCHEM CELL BIOL, V113, P73, DOI 10.1007/s004180050009; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VERMILLION DL, 1993, GASTROENTEROLOGY, V104, P1692, DOI 10.1016/0016-5085(93)90647-U; Vrees MD, 2002, ARCH SURG-CHICAGO, V137, P439, DOI 10.1001/archsurg.137.4.439; Weisbrodt NW, 1996, AM J PHYSIOL-GASTR L, V271, pG454, DOI 10.1152/ajpgi.1996.271.3.G454; WORD RA, 1991, AM J PHYSIOL, V260, pC861, DOI 10.1152/ajpcell.1991.260.4.C861; Yamawaki H, 2000, LIFE SCI, V67, P807, DOI 10.1016/S0024-3205(00)00675-5	61	75	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48794	48804		10.1074/jbc.M310166200	http://dx.doi.org/10.1074/jbc.M310166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512413	hybrid			2022-12-25	WOS:000186829000036
J	Pastor-Soler, N; Beaulieu, V; Litvin, TN; Da Silva, N; Chen, YQ; Brown, D; Buck, J; Levin, LR; Breton, S				Pastor-Soler, N; Beaulieu, V; Litvin, TN; Da Silva, N; Chen, YQ; Brown, D; Buck, J; Levin, LR; Breton, S			Bicarbonate-regulated adenylyl cyclase (sAC) is a sensor that regulates pH-dependent V-ATPase recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE REPRODUCTIVE-TRACT; RAT EPIDIDYMIS; PROTON SECRETION; VAS-DEFERENS; POSTNATAL-DEVELOPMENT; H+-ATPASE; CELLS; TRANSPORT; COLOCALIZATION; ACIDIFICATION	Modulation of environmental pH is critical for the function of many biological systems. However, the molecular identity of the pH sensor and its interaction with downstream effector proteins remain poorly understood. Using the male reproductive tract as a model system in which luminal acidification is critical for sperm maturation and storage, we now report a novel pathway for pH regulation linking the bicarbonate activated soluble adenylyl cyclase (sAC) to the vacuolar H+ ATPase (V-ATPase). Clear cells of the epididymis and vas deferens contain abundant V-ATPase in their apical pole and are responsible for acidifying the lumen. Proton secretion is regulated via active recycling of V-ATPase. Here we demonstrate that this recycling is regulated by luminal pH and bicarbonate. sAC is highly expressed in clear cells, and apical membrane accumulation of V-ATPase is triggered by a sAC-dependent rise in cAMP in response to alkaline luminal pH. As sAC is expressed in other acid/base transporting epithelia, including kidney and choroid plexus, this cAMP-dependent signal transduction pathway may be a widespread mechanism that allows cells to sense and modulate extracellular pH.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Program Membrane Biol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cornell University	Breton, S (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 13th St 149-8000, Charlestown, MA 02129 USA.	sbreton@receptor.mgh.harvard.edu	Da Silva, Nicolas/T-3528-2019	Levin, Lonny/0000-0002-5204-6356	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD040793] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038722, F32HD008684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042956, P01DK038452, P30DK057521, R37DK042956, P30DK043351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062328] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD040793, F32 HD008684, HD42060, HD38722, R01 HD038722, HD40793] Funding Source: Medline; NIDDK NIH HHS [P30 DK057521, DK57521, DK43351, P30 DK043351, R37 DK042956, R01 DK042956, DK38452, DK42956, P01 DK038452] Funding Source: Medline; NIGMS NIH HHS [GM62328, R01 GM062328] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN T, 1990, P SOC EXP BIOL MED, V194, P58; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Breton S, 1999, HISTOCHEM CELL BIOL, V111, P97, DOI 10.1007/s004180050339; Breton S, 1998, AM J PHYSIOL-CELL PH, V275, pC1134, DOI 10.1152/ajpcell.1998.275.4.C1134; Breton S, 2000, AM J PHYSIOL-RENAL, V278, pF717, DOI 10.1152/ajprenal.2000.278.5.F717; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; BROWN D, 1988, J CLIN INVEST, V82, P2114, DOI 10.1172/JCI113833; BROWN D, 1992, AM J PHYSIOL, V263, pC913, DOI 10.1152/ajpcell.1992.263.4.C913; Brown D, 1996, J EXP BIOL, V199, P2345; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Buck J, 2002, METHOD ENZYMOL, V345, P95; Carlin RW, 2003, BIOL REPROD, V68, P1027, DOI 10.1095/biolreprod.102.009381; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Fisher JS, 2002, BIOL REPROD, V67, P1106, DOI 10.1095/biolreprod67.4.1106; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; HAYS S, 1986, J CLIN INVEST, V78, P1279, DOI 10.1172/JCI112712; HUDSON RL, 1993, AM J PHYSIOL, V264, pR946, DOI 10.1152/ajpregu.1993.264.5.R946; Isnard-Bagnis C, 2003, AM J PHYSIOL-CELL PH, V284, pC220, DOI 10.1152/ajpcell.00374.2001; Jaiswal BS, 2001, J BIOL CHEM, V276, P31698, DOI 10.1074/jbc.M011698200; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; LEVINE N, 1971, J PHYSIOL-LONDON, V213, P557, DOI 10.1113/jphysiol.1971.sp009400; LEVINE N, 1978, J REPROD FERTIL, V52, P333, DOI 10.1530/jrf.0.0520333; MADSEN KM, 1991, KIDNEY INT, V40, pS57; MITTAG TW, 1993, AM J PHYSIOL, V264, pF1060, DOI 10.1152/ajprenal.1993.264.6.F1060; Pushkin A, 2000, J ANDROL, V21, P708; Sedlacek RL, 2001, AM J PHYSIOL-RENAL, V281, pF557, DOI 10.1152/ajprenal.2001.281.3.F557; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; STEINMETZ PR, 1986, AM J PHYSIOL, V251, pF173, DOI 10.1152/ajprenal.1986.251.2.F173; WONG PYD, 1988, AM J PHYSIOL, V254, pF121, DOI 10.1152/ajprenal.1988.254.1.F121; Wuttke M S, 2001, JOP, V2, P154; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	34	192	195	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49523	49529		10.1074/jbc.M309543200	http://dx.doi.org/10.1074/jbc.M309543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512417	Green Accepted, hybrid			2022-12-25	WOS:000186829000122
J	Poelarends, GJ; Johnson, WH; Murzin, AG; Whitman, CP				Poelarends, GJ; Johnson, WH; Murzin, AG; Whitman, CP			Mechanistic characterization of a bacterial malonate semialdehyde decarboxylase - Identification of a new activity in the tautomerase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-3-CHLOROACRYLIC ACID DEHALOGENASE; SITE ARGININE RESIDUES; 4-OXALOCROTONATE TAUTOMERASE; ESCHERICHIA-COLI; ENZYMATIC DECARBOXYLATION; CRYSTAL-STRUCTURE; PH-DEPENDENCE; PK(A) VALUES; FPG PROTEIN; ENZYMES	Malonate semialdehyde decarboxylase (MSAD) has been identified as the protein encoded by the orf130 gene from Pseudomonas pavonaceae 170 on the basis of the genomic context of the gene as well as its ability to catalyze the decarboxylation of malonate semialdehyde to generate acetaldehyde. The enzyme is found in a degradative pathway for the xenobiotic nematocide trans-1,3-dichloropropene. MSAD has no sequence homology to previously characterized decarboxylases, but the presence of a conserved motif (Pro(1)-(X) 8-Gly-Arg(11)-X-AspX- Gln) in its N-terminal region suggested a relationship to the tautomerase superfamily. Sequence analysis identified Pro(1) and Arg(75) as potential active site residues that might be involved in the MSAD activity. The results of site-directed mutagenesis experiments confirmed the importance of these residues to activity and provided further evidence to implicate MSAD as a new member of the tautomerase superfamily. MSAD is the first identified decarboxylase in the superfamily and is possibly the first characterized member of a new and distinct family within this superfamily. Malonate semialdehyde is analogous to a beta-keto acid, and enzymes that catalyze the decarboxylation of these acids generally utilize metal ion catalysis, a Schiff base intermediate, or polarization of the carbonyl group by hydrogen bonding and/or electrostatic interactions. A mechanistic analysis shows that the rate of the reaction is not affected by the presence of a metal ion or EDTA while the incubation of MSAD with the substrate in the presence of sodium cyanoborohydride results in the irreversible inactivation of the enzyme. The site of modification is Pro1. These observations are consistent with the latter two mechanisms, but do not exclude the first mechanism. Based on the sequence analysis, the outcome of the mutagenesis and mechanistic experiments, and the roles determined for Pro(1) and the conserved arginine in all tautomerase superfamily members characterized thus far, two mechanistic scenarios are proposed for the MSAD-catalyzed reaction in which Pro(1) and Arg(75) play prominent roles.	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Texas System; University of Texas Austin; University of Cambridge	Whitman, CP (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.			Poelarends, Gerrit/0000-0002-6917-6368	NIGMS NIH HHS [GM 65324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065324] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2002, BIOCHEMISTRY-US, V41, P12010, DOI 10.1021/bi020271h; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; Czerwinski RM, 1999, BIOCHEMISTRY-US, V38, P12358, DOI 10.1021/bi9911177; Czerwinski RM, 1997, BIOCHEMISTRY-US, V36, P14551, DOI 10.1021/bi971545h; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Fitzgerald MC, 1996, P NATL ACAD SCI USA, V93, P6851, DOI 10.1073/pnas.93.14.6851; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; HAMILTON GA, 1959, J AM CHEM SOC, V81, P6332, DOI 10.1021/ja01532a058; HARAYAMA S, 1989, J BACTERIOL, V171, P6251, DOI 10.1128/jb.171.11.6251-6258.1989; Harris TK, 1999, BIOCHEMISTRY-US, V38, P12343, DOI 10.1021/bi991116e; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KOSICKI GW, 1968, BIOCHEMISTRY-US, V7, P4303, DOI 10.1021/bi00852a023; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LEBHERZ HG, 1973, J BIOL CHEM, V10, P1650; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; OLEARY MH, 1992, ENZYMES, V20, P235; Person MD, 2003, CHEM RES TOXICOL, V16, P598, DOI 10.1021/tx020109f; Poelarends GJ, 2000, J BACTERIOL, V182, P2725, DOI 10.1128/JB.182.10.2725-2731.2000; Poelarends GJ, 1998, APPL ENVIRON MICROB, V64, P2931; Poelarends GJ, 2000, J BACTERIOL, V182, P2191, DOI 10.1128/JB.182.8.2191-2199.2000; Poelarends GJ, 2001, J BACTERIOL, V183, P4269, DOI 10.1128/JB.183.14.4269-4277.2001; Sambrook J., 2002, MOL CLONING LAB MANU; SILVERMAN RB, 2000, ORGANIC CHEM ENZYME, P321; Smith B J, 1988, Methods Mol Biol, V3, P57, DOI 10.1385/0-89603-126-8:57; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P814, DOI 10.1021/bi9510789; Sugimoto H, 1999, BIOCHEMISTRY-US, V38, P3268, DOI 10.1021/bi982184o; TAMAKI N, 1982, METHOD ENZYMOL, V89, P469; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang SC, 2003, BIOCHEMISTRY-US, V42, P8762, DOI 10.1021/bi034598+; Whitman CP, 2002, ARCH BIOCHEM BIOPHYS, V402, P1, DOI 10.1016/S0003-9861(02)00052-8; WHITMAN CP, 1991, J AM CHEM SOC, V113, P3154, DOI 10.1021/ja00008a052; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	39	37	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48674	48683		10.1074/jbc.M306706200	http://dx.doi.org/10.1074/jbc.M306706200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506256	hybrid, Green Published			2022-12-25	WOS:000186829000021
J	Xie, ZL; Singh, M; Siwik, DA; Joyner, WL; Singh, K				Xie, ZL; Singh, M; Siwik, DA; Joyner, WL; Singh, K			Osteopontin inhibits interleukin-1 beta-stimulated increases in matrix metalloproteinase activity in adult rat cardiac fibroblasts - Role of protein kinase C-zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; B-MEDIATED INDUCTION; NF-KAPPA-B; MYOCARDIAL-INFARCTION; EXTRACELLULAR-MATRIX; HEART-FAILURE; TNF-ALPHA; ALPHA(V)BETA(3) INTEGRIN; SIGNAL-TRANSDUCTION; TISSUE INHIBITOR	We have shown that osteopontin (OPN), an extracellular matrix protein, plays an important role in post myocardial infarction (MI) remodeling by promoting collagen synthesis and accumulation. Interleukin-1beta (IL-1beta), increased in the heart following MI, increases matrix metalloproteinase (MMP) activity in cardiac fibroblasts in vitro. Here, we show that OPN alone has no effect on MMP activity or expression. However, it reduces IL-1beta-stimulated increases in MMP activity and expression in adult rat cardiac fibroblasts. Pretreatment with bovine serum albumin had no effect on MMP activity or protein content, whereas GRGDS (glycine-arginine-glycine-aspartic acid-serine)-pentapeptide ( which interrupts binding of RGD-containing proteins to cell surface integrins) and monoclonal antibody m7E3 (a rat beta(3) integrins antagonist) inhibited the effects of OPN. Inhibition of PKC using chelerythrine inhibited the activities of both MMP-2 and MMP-9. Stimulation of cells using IL-1beta increased phosphorylation and translocation of PKC to membrane fractions, which was inhibited by OPN. OPN inhibited IL-1beta-stimulated increases in translocation of PKC-zeta from cytosolic to membrane fractions. Furthermore, the levels of phospho-PKC-zeta were lower in the cytosolic fractions of OPN knock-out mice hearts as compared with wild type 6 days post-MI. Inhibition of PKC-zeta using PKC-zeta pseudosubstrate inhibited IL-1beta-stimulated increases in MMP-2 and MMP-9 activities. These observations suggest that OPN, acting via beta(3) integrins, inhibits IL-1beta-stimulated increases in MMP-2 and MMP-9 activity, at least in part, via the involvement of PKC-zeta. Thus, OPN may play a key role in collagen deposition during myocardial remodeling following MI by modulating cytokine-stimulated MMP activity.	E Tennessee State Univ, James H Quillen Vet Affairs Med Ctr, James H Quillen Coll Med, Dept Physiol, Johnson City, TN 37614 USA; Boston Univ, Sch Med, Boston, MA 02118 USA	East Tennessee State University; Boston University	Singh, K (corresponding author), E Tennessee State Univ, James H Quillen Vet Affairs Med Ctr, James H Quillen Coll Med, Dept Physiol, POB 70576, Johnson City, TN 37614 USA.			/0000-0002-7166-327X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071519, R01HL057947] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-071519, R01 HL071519, HL-057947] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashizawa N, 1996, J CLIN INVEST, V98, P2218, DOI 10.1172/JCI119031; Bendeck MP, 2001, J VASC RES, V38, P590, DOI 10.1159/000051095; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Carlyle WC, 1997, J MOL CELL CARDIOL, V29, P2451, DOI 10.1006/jmcc.1997.0482; Chang YC, 2002, J ENDODONT, V28, P90, DOI 10.1097/00004770-200202000-00010; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coker ML, 2001, AM J PHYSIOL-HEART C, V281, pH543, DOI 10.1152/ajpheart.2001.281.2.H543; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Danielsen CC, 1998, J MOL CELL CARDIOL, V30, P1431; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Deten A, 2001, J MOL CELL CARDIOL, V33, P1191, DOI 10.1006/jmcc.2001.1383; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; ETOH T, 2001, AM J PHYSIOL, V281, pG987; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; Graf K, 2000, HYPERTENSION, V35, P978, DOI 10.1161/01.HYP.35.4.978; Han YP, 2001, J CELL SCI, V114, P131; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Hussain S, 2002, J BIOL CHEM, V277, P27345, DOI 10.1074/jbc.M111890200; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Li YY, 2000, CARDIOVASC RES, V46, P214, DOI 10.1016/S0008-6363(00)00003-1; Liaw L, 1998, J CLIN INVEST, V101, P1468; Libby P, 2000, CIRCULATION, V102, P1874, DOI 10.1161/01.CIR.102.16.1874; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; MACKAY AR, 1992, INVAS METAST, V12, P168; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Ophascharoensuk V, 1999, KIDNEY INT, V56, P571, DOI 10.1046/j.1523-1755.1999.00580.x; Peterson JT, 2000, CARDIOVASC RES, V46, P307, DOI 10.1016/S0008-6363(00)00029-8; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Podesser BK, 2001, AM J PHYSIOL-HEART C, V280, pH984, DOI 10.1152/ajpheart.2001.280.3.H984; SINGH K, 1995, J BIOL CHEM, V270, P28471; Singh K, 1999, HYPERTENSION, V33, P663, DOI 10.1161/01.HYP.33.2.663; Siwik DA, 2000, CIRC RES, V86, P1259, DOI 10.1161/01.RES.86.12.1259; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Steffensen B, 2001, CRIT REV ORAL BIOL M, V12, P373, DOI 10.1177/10454411010120050201; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Takahashi K, 1999, INT J CANCER, V80, P387, DOI 10.1002/(SICI)1097-0215(19990129)80:3<387::AID-IJC9>3.0.CO;2-T; Trueblood NA, 2001, CIRC RES, V88, P1080, DOI 10.1161/hh1001.090842; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tyagi SC, 1996, J MOL CELL CARDIOL, V28, P1415, DOI 10.1006/jmcc.1996.0132; Uede T, 1997, MICROBIOL IMMUNOL, V41, P641, DOI 10.1111/j.1348-0421.1997.tb01906.x; Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250; Zhang YY, 2002, CANCER RES, V62, P3962; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	50	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48546	48552		10.1074/jbc.M302727200	http://dx.doi.org/10.1074/jbc.M302727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500723	hybrid			2022-12-25	WOS:000186829000006
J	Zhu, PP; Patterson, A; Lavoie, B; Stadler, J; Shoeb, M; Patel, R; Blackstone, C				Zhu, PP; Patterson, A; Lavoie, B; Stadler, J; Shoeb, M; Patel, R; Blackstone, C			Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT OPTIC ATROPHY; GTP-BINDING PROTEIN; TORSION DYSTONIA; DYNAMIN; MUTATION; CLASSIFICATION; INTERACTS; GTPASES; DISEASE; NEURONS	Hereditary spastic paraplegias comprise a group of clinically heterogeneous syndromes characterized by lower extremity spasticity and weakness, with distal axonal degeneration in the long ascending and descending tracts of the spinal cord. The early onset hereditary spastic paraplegia SPG3A is caused by mutations in the atlastin/human guanylate-binding protein-3 gene (renamed here atlastin-1), which codes for a 64-kDa member of the dynamin/Mx/guanylate-binding protein superfamily of large GTPases. The atlastin-1 protein is localized predominantly in brain, where it is enriched in pyramidal neurons in the cerebral cortex and hippocampus. In cultured cortical neurons, atlastin-1 colocalized most prominently with markers of the Golgi apparatus, and immunogold electron microscopy revealed a predominant localization of atlastin-1 to the cis-Golgi. Yeast two-hybrid analyses and co-immunoprecipitation studies demonstrated that atlastin-1 can self-associate, and gel-exclusion chromatography and chemical cross-linking studies indicated that atlastin-1 exists as an oligomer in vivo, most likely a tetramer. Membrane fractionation and protease protection assays revealed that atlastin-1 is an integral membrane protein with two predicted transmembrane domains; both the N-terminal GTP-binding and C-terminal domains are exposed to the cytoplasm. Together, these findings indicate that the SPG3A protein atlastin-1 is a multimeric integral membrane GTPase that may be involved in Golgi membrane dynamics or vesicle trafficking.	NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; George Washington Univ, NIH, Grad Partnerships Program Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); George Washington University; National Institutes of Health (NIH) - USA	Blackstone, C (corresponding author), NINDS, Cellular Neurol Unit, NIH, Bldg 36,Rm 5W21,9000 Rockville Pike, Bethesda, MD 20892 USA.		Patterson, Andrew/G-3852-2012; Patterson, Andrew/ABF-1575-2020	Patterson, Andrew/0000-0003-2073-0070; Patterson, Andrew/0000-0003-2073-0070	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002992, ZIANS002992] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Ciccarelli FD, 2003, GENOMICS, V81, P437, DOI 10.1016/S0888-7543(03)00011-9; Crosby AH, 2002, AM J HUM GENET, V71, P1009, DOI 10.1086/344206; Dalpozzo F, 2003, NEUROLOGY, V61, P580, DOI 10.1212/01.WNL.0000078189.73611.DF; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Di Paolo C, 1999, J BIOL CHEM, V274, P32071, DOI 10.1074/jbc.274.45.32071; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; Fink JK, 2002, ANN NEUROL, V51, P669, DOI 10.1002/ana.10258; Fink JK, 2002, NEUROL CLIN, V20, P711, DOI 10.1016/S0733-8619(02)00007-5; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; Haller O, 2002, TRAFFIC, V3, P710, DOI 10.1034/j.1600-0854.2002.31003.x; HARDING AE, 1983, LANCET, V1, P1151; Hewett J, 2000, HUM MOL GENET, V9, P1403, DOI 10.1093/hmg/9.9.1403; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Jackson CL, 2003, CURR BIOL, V13, pR174, DOI 10.1016/S0960-9822(03)00116-7; Jareb M, 1997, J NEUROSCI, V17, P8955; Kustedjo K, 2000, J BIOL CHEM, V275, P27933; Luan ZD, 2002, FEBS LETT, V530, P233, DOI 10.1016/S0014-5793(02)03467-1; Muglia M, 2002, ANN NEUROL, V51, P794, DOI 10.1002/ana.10185; Patel H, 2001, AM J HUM GENET, V69, P209, DOI 10.1086/321267; Patel H, 2002, NAT GENET, V31, P347, DOI 10.1038/ng937; Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Reid E, 2002, AM J HUM GENET, V71, P1189, DOI 10.1086/344210; Reid E, 2003, J MED GENET, V40, P81, DOI 10.1136/jmg.40.2.81; Rojo M, 2002, J CELL SCI, V115, P1663; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWARZ GA, 1956, ARCH NEURO PSYCHIATR, V75, P144, DOI 10.1001/archneurpsyc.1956.02330200038005; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Tallaksen CME, 2001, CURR OPIN NEUROL, V14, P457, DOI 10.1097/00019052-200108000-00005; Tessa A, 2002, NEUROLOGY, V59, P2002, DOI 10.1212/01.WNL.0000036902.21438.98; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; Zhao XP, 2001, NAT GENET, V29, P326, DOI 10.1038/ng758; Zheng YL, 2003, J BIOL CHEM, V278, P24026, DOI 10.1074/jbc.M303079200	42	116	130	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49063	49071		10.1074/jbc.M306702200	http://dx.doi.org/10.1074/jbc.M306702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506257	hybrid			2022-12-25	WOS:000186829000068
J	Tu, Z; Lee, FS				Tu, Z; Lee, FS			Subdomain VIII is a specificity-determining region in MEKK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B KINASE; ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; MAP KINASES; IKK-ALPHA; PATHWAYS; BINDING; IDENTIFICATION; COMPLEX	MAPK/ERK kinase kinase 1 (MEKK1) is a mitogen-activated protein kinase kinase kinase (MAP3K) of the stress-induced JNK pathway. Once activated, MEKK1 phosphorylates the MAP2K MKK4, which in turn phosphorylates JNK. MEKK1 also has the capacity to activate IKK, the central protein kinase of the NF-kappaB pathway. The molecular determinants responsible for the ability of MEKK1 to recognize specific substrates are poorly understood. We report here that select point mutations in subdomain VIII of the protein kinase domain of MEKK1 (MEKK1Delta) differentially affect its ability to activate MKK4 and IKK, and consequently AP1 and NF-kappaB reporter genes. Moreover, binding of MKK4 to MEKK1Delta protects the latter from cleavage at an engineered protease target site in subdomain VIII. Collectively these results provide evidence that subdomain VIII of MEKK1 is involved not only in binding to, but also in discrimination of, protein substrates.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, 422 Curie Blvd, Philadelphia, PA 19104 USA.	franklee@mail.med.upenn.edu		Lee, Frank/0000-0003-2511-1834	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055672] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55672] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chang CI, 2002, MOL CELL, V9, P1241, DOI 10.1016/S1097-2765(02)00525-7; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Huang JH, 2003, BIOCHEM BIOPH RES CO, V303, P532, DOI 10.1016/S0006-291X(03)00387-5; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tu Z, 2001, J IMMUNOL, V166, P6839, DOI 10.4049/jimmunol.166.11.6839; Tu Z, 2003, CELL SIGNAL, V15, P65, DOI 10.1016/S0898-6568(02)00056-6; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; [No title captured]	39	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48498	48505		10.1074/jbc.M304234200	http://dx.doi.org/10.1074/jbc.M304234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500727	hybrid			2022-12-25	WOS:000186731400136
J	Kamel-Reid, S; Zhang, T; Wells, RA				Kamel-Reid, S; Zhang, T; Wells, RA			Expression of NPM-RAR alpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis	ONCOGENE			English	Article						PPAR gamma; apoptosis; NPM-RAR alpha; acute myelogenous leukemia	PROLIFERATOR-ACTIVATED RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN BREAST-CANCER; RETINOID-X-RECEPTOR; PPAR-GAMMA; MONOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; CYTOSINE-ARABINOSIDE; GROWTH-INHIBITION; LUNG-CANCER	We have investigated the effects of acute promyelocytic leukemia (APL) fusion gene NPM-RARalpha on the function of PPARgamma using the monoblastic cell line U937. U937 cells were transduced using a retrovirus carrying NPM-RARalpha. While treatment with the synthetic PPARgamma ligand troglitazone (TG) had no effect on the viability of U937 cells, TG treatment of U937/NPM-RARalpha cells resulted in a dramatic decrease in cell viability, dependent upon both the concentration of TG and the level of expression of NPM-RARalpha. Analysis of the cell cycle pro. le and flow cytometry with annexin V confirmed that these effects of TG were due to induction of apoptosis. Induction of apoptosis was accompanied by caspase-8 and caspase-9 activation, and could be blocked by treatment with the caspase inhibitor Z-VAD-FMK. Cotreatment of U937/NPM-RARalpha cells with all-trans retinoic acid (atRA) abrogated the induction of apoptosis by TG. Induction of apoptosis was seen also in the PML-RARalpha-expressing APL cell line NB4, and in several other atRA-sensitive leukemia cell lines, demonstrating that this effect is limited neither to the monocyte lineage nor to the rare NPM-RARalpha fusion variant. RXRalpha/NPM-RARalpha heterodimers were found to interact directly with a PPARgamma-responsive element in vitro. We conclude that in the presence of X-RARalpha, TG induces cell death due to apoptosis via the caspase pathway. These observations suggest the investigation of PPARgamma ligands as therapeutic agents in acute leukemia.	Univ Toronto, Inst Med Sci, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Wells, RA (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Room 8-209,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rwells@uhnres.utoronto.ca		Kamel-Reid, Suzanne/0000-0002-4386-0292				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Asou H, 1999, INT J ONCOL, V15, P1027; ATSUMI Y, 1986, AM J MED SCI, V292, P152, DOI 10.1097/00000441-198609000-00006; BENITO A, 1995, AM J PATHOL, V146, P481; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chang TH, 2000, CANCER RES, V60, P1129; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fujimura S, 1998, INT J ONCOL, V13, P1263; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Greene M. E., 1995, Gene Expression, V4, P281; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hirase N, 1999, ONCOLOGY-BASEL, V57, P17, DOI 10.1159/000055271; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOISTINEN P, 1991, LEUKEMIA, V5, P704; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Padilla J, 2002, CLIN IMMUNOL, V103, P22, DOI 10.1006/clim.2001.5181; Pizzimenti S, 2002, FREE RADICAL BIO MED, V32, P233, DOI 10.1016/S0891-5849(01)00798-5; Rebel VI, 1999, BLOOD, V93, P2217, DOI 10.1182/blood.V93.7.2217.407a01_2217_2224; RIGBY WFC, 1984, BLOOD, V64, P1110; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; TESTA U, 1994, CANCER RES, V54, P4508; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG C, 1989, LEUKEMIA, V3, P699; YANG GS, 1993, LEUKEMIA, V7, P1012; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	48	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6424	6435		10.1038/sj.onc.1206696	http://dx.doi.org/10.1038/sj.onc.1206696			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508522				2022-12-25	WOS:000185535300012
J	El-Agnaf, OMA; Salem, SA; Paleologou, KE; Cooper, LJ; Fullwood, NJ; Gibson, MJ; Curran, MD; Court, JA; Mann, DMA; Ikeda, S; Cookson, MR; Hardy, J; Allsop, D				El-Agnaf, OMA; Salem, SA; Paleologou, KE; Cooper, LJ; Fullwood, NJ; Gibson, MJ; Curran, MD; Court, JA; Mann, DMA; Ikeda, S; Cookson, MR; Hardy, J; Allsop, D			alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma	FASEB JOURNAL			English	Article						amyloid; dementia with Lewy bodies; neurodegeneration	MULTIPLE-SYSTEM ATROPHY; ALZHEIMERS-DISEASE; LEWY BODIES; HUMAN BRAIN; CEREBROSPINAL-FLUID; MESSENGER-RNA; MOUSE MODEL; FATTY-ACIDS; PROTEIN; MUTATIONS	Parkinson's disease (PD) and other related disorders are characterized by the accumulation of fibrillar aggregates of alpha-synuclein protein (alpha-syn) inside brain cells. It is likely that the formation of alpha-syn aggregates plays a seminal role in the pathogenesis of at least some of these diseases, because two different mutations in the gene encoding alpha-syn have been found in inherited forms of PD. alpha-Syn is mainly expressed by neuronal cells and is generally considered to exist as a cytoplasmic protein. Here, we report the unexpected identification of alpha-syn in conditioned culture media from untransfected and alpha-syn-transfected human neuroblastoma cells, as well as in human cerebrospinal fluid and blood plasma. The method used was immunocapture by using anti-alpha-syn antibodies coupled to magnetic beads, followed by detection on Western blots. In all cases, alpha-syn was identified as a single 15 kDa band, which co-migrated with a recombinant form of the protein and reacted with five different antibodies to alpha-syn. Our findings suggest that cells normally secrete alpha-syn into their surrounding media, both in vitro and in vivo. The detection of extracellular alpha-syn and/or its modified forms in body fluids, particularly in human plasma, offers new opportunities for the development of diagnostic tests for PD and related diseases.	Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England; Belfast City Hosp, Movement Disorders Clin, Belfast BT9 7AD, Antrim, North Ireland; Belfast City Hosp, No Ireland Reg Histocompatibil & Immunogenet Lab, Belfast BT9 7AD, Antrim, North Ireland; Newcastle Gen Hosp, Joint MRC Newcastle Univ Dev Clin Brain Ageing, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Hope Hosp, Clin Neurosci Res Grp, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England; Shinshu Univ, Sch Med, Nagano, Japan; NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Lancaster University; Belfast City Hospital; Belfast City Hospital; Newcastle General Hospital; Shinshu University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	El-Agnaf, OMA (corresponding author), Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England.	o.el-agnaf@lancaster.ac.uk	Resource Center, NINDS Human Genetics/AGF-2474-2022; Allsop, David/B-9725-2008; Hardy, John/C-2451-2009; Cookson, Mark/AAW-2516-2021; Sander-Effron, Samuel/AAX-2231-2020	Allsop, David/0000-0002-0513-5575; Hardy, John/0000-0002-3122-0423; Cookson, Mark/0000-0002-1058-3831; Fullwood, Nigel James/0000-0002-9405-8515	NATIONAL INSTITUTE ON AGING [Z01AG000952] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V237, P611, DOI 10.1006/bbrc.1997.6978; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakowec MW, 1998, NEUROSCI LETT, V253, P13, DOI 10.1016/S0304-3940(98)00599-0; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li QX, 2002, J ALZHEIMERS DIS, V4, P309, DOI 10.3233/JAD-2002-4406; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353	44	452	479	1	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1945	+		10.1096/fj.03-0098fje	http://dx.doi.org/10.1096/fj.03-0098fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519670				2022-12-25	WOS:000185345100012
J	Haruta, N; Yu, XN; Yang, SX; Egelman, EH; Cox, MM				Haruta, N; Yu, XN; Yang, SX; Egelman, EH; Cox, MM			A DNA pairing-enhanced conformation of bacterial RecA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ATP-GAMMA-S; EXTREMELY RADIATION-RESISTANT; ESCHERICHIA-COLI; DEINOCOCCUS-RADIODURANS; HETERODUPLEX FORMATION; HELICAL FILAMENTS; NUCLEOSIDE TRIPHOSPHATE; BRANCH MIGRATION; BINDING PROTEIN	The RecA proteins of Escherichia coli (Ec) and Deinococcus radiodurans (Dr) both promote a DNA strand exchange reaction involving two duplex DNAs. The four-strand exchange reaction promoted by the DrRecA protein is similar to that promoted by EcRecA, except that key parts of the reaction are inhibited by Ec single-stranded DNA-binding protein (SSB). In the absence of SSB, the initiation of strand exchange is greatly enhanced by dsDNA-ssDNA junctions at the ends of DNA gaps. This same trend is seen with the EcRecA protein. The results lead to an expansion of published hypotheses for the pathway for RecA-mediated DNA pairing, in which the slow first order step (observed in several studies) involves a structural transition to a state we designate P. The P state is identical to the state found when RecA is bound to double-stranded (ds) DNA. The structural state present when the RecA protein is bound to single-stranded (ss) DNA is designated A. The DNA pairing model in turn facilitates an articulation of three additional conclusions arising from the present work. 1) When a segment of a RecA filament bound to ssDNA is forced into the P state (as RecA bound to the ssDNA immediately adjacent to dsDNA-ssDNA junction), the segment becomes "pairing enhanced." 2) The unusual DNA pairing properties of the D. radiodurans RecA protein can be explained by postulating this protein has a more stringent requirement to initiate DNA strand exchange from the P state. 3) RecA filaments bound to dsDNA (P state) have directly observable structural changes relative to RecA filaments bound to ssDNA (A state), involving the C-terminal domain.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Wisconsin System; University of Wisconsin Madison; University of Virginia	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu	yang, shixin/B-4015-2010; Egelman, Edward H/A-2488-2009	yang, shixin/0000-0002-3639-7818; Egelman, Edward/0000-0003-4844-5212; Haruta, Nami/0000-0002-4232-9635	NIGMS NIH HHS [GM35269, GM32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, R01GM035269] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Bazemore LR, 1997, J BIOL CHEM, V272, P14672, DOI 10.1074/jbc.272.23.14672; Bazemore LR, 1997, P NATL ACAD SCI USA, V94, P11863, DOI 10.1073/pnas.94.22.11863; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; CHOW SA, 1992, J MOL BIOL, V223, P79, DOI 10.1016/0022-2836(92)90717-X; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Egelman EH, 2000, ULTRAMICROSCOPY, V85, P225, DOI 10.1016/S0304-3991(00)00062-0; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Ferreira AC, 1997, INT J SYST BACTERIOL, V47, P939, DOI 10.1099/00207713-47-4-939; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KIM JI, 1992, J BIOL CHEM, V267, P16444; Kim JI, 2002, P NATL ACAD SCI USA, V99, P7917, DOI 10.1073/pnas.122218499; KIM JI, 1992, J BIOL CHEM, V267, P16438; Kim JI, 2002, J BACTERIOL, V184, P1649, DOI 10.1128/JB.184.6.1649-1660.2002; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; Lin JY, 1999, SCIENCE, V285, P1558, DOI 10.1126/science.285.5433.1558; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Nishinaka T, 1997, P NATL ACAD SCI USA, V94, P6623, DOI 10.1073/pnas.94.13.6623; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; STASIAK A, 1988, J MOL BIOL, V202, P659, DOI 10.1016/0022-2836(88)90293-8; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; STOLE E, 1994, J BIOL CHEM, V269, P7919; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; YANCEYWRONA JE, 1995, CURR BIOL, V5, P1149, DOI 10.1016/S0960-9822(95)00231-4; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	73	36	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52710	52723		10.1074/jbc.M308563200	http://dx.doi.org/10.1074/jbc.M308563200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530291	hybrid			2022-12-25	WOS:000187480700089
J	Krum, SA; Miranda, GA; Lin, CW; Lane, TF				Krum, SA; Miranda, GA; Lin, CW; Lane, TF			BRCA1 associates with processive RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; BREAST-CANCER; DNA-DAMAGE; EMBRYONIC LETHALITY; CELL-CYCLE; PROTEIN; EXPRESSION; ELONGATION; MUTATIONS	The human BRCA1 tumor suppressor interacts with transcriptional machinery, including RNA polymerase II (RNA pol II). We demonstrated that interaction with RNA pol II is a conserved feature of BRCA1 proteins from several species. We found that full-length BRCA1 proteins universally fail to activate transcription in classic GAL4-UAS one-hybrid assays and that the activity associated with the human BRCA1 C terminus was poorly conserved in closely related homologs of the gene. Fractionation studies demonstrated that BRCA1 proteins from all species tested interacted specifically with hyperphosphorylated pol II (IIO), in preference to hypophosphorylated RNA pol II (IIA) expected at promoters. BRCA1-RNA pol II complexes showed evidence of a multiply phosphorylated heptad repeat domain in the catalytic subunit (p220) of RNA pol II, and the complex was highly functional in transcriptional run-off assays. Interestingly, endogenous BRCA1 associated with a large fraction of the processive RNA pol II activity present in undamaged cells, and the interaction was disrupted by DNA-damaging agents. Preferential interaction with processive RNA pol II in undamaged cells places BRCA1 in position to link late events in transcription with repair processes in eukaryotic cells.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lane, TF (corresponding author), Jonsson Comprehens Canc Ctr, Div Gynecol Oncol, CHS 27-139,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Krum, Susan A./D-7282-2013	Krum, Susan A./0000-0002-6414-6397; Lane, Timothy F./0000-0002-0210-970X	NIGMS NIH HHS [GM07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173; Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Carvalho MA, 2002, CANCER BIOL THER, V1, P502, DOI 10.4161/cbt.1.5.165; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Krum SA, 2003, ONCOGENE, V22, P6032, DOI 10.1038/sj.onc.1206515; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Lane TF, 2000, ONCOGENE, V19, P4085, DOI 10.1038/sj.onc.1203760; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Malone KE, 2000, CANCER, V88, P1393, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Schlegel BP, 2003, ONCOGENE, V22, P983, DOI 10.1038/sj.onc.1206195; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sinclair CS, 2000, CANCER RES, V60, P1371; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; Tomlinson GE, 1998, CANCER RES, V58, P3237; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Worley T, 2002, CANCER BIOL THER, V1, P497, DOI 10.4161/cbt.1.5.164; YE Q, 2001, J BIOL CHEM, V1556, P911; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	69	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52012	52020		10.1074/jbc.M308418200	http://dx.doi.org/10.1074/jbc.M308418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14506230	hybrid			2022-12-25	WOS:000187480700007
J	Bowmaker, M; Yang, MY; Yasukawa, T; Reyes, A; Jacobs, HT; Huberman, JA; Holt, IJ				Bowmaker, M; Yang, MY; Yasukawa, T; Reyes, A; Jacobs, HT; Huberman, JA; Holt, IJ			Mammalian mitochondrial DNA replicates bidirectionally from an initiation zone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE DOMAIN; AGAROSE-GEL ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; YEAST CHROMOSOMES; ORIGINS; RECOMBINATION; DELETIONS; SITES; ORGANIZATION; PATTERNS	Previous data from our laboratory suggested that replication of mammalian mitochondrial DNA initiates exclusively at or near to the formerly designated origin of heavy strand replication, O-H, and proceeds unidirectionally from that locus. New results obtained using two-dimensional agarose gel electrophoresis of replication intermediates demonstrate that replication of mitochondrial DNA initiates from multiple origins across a broad zone. After fork arrest near O-H, replication is restricted to one direction only. The initiation zone of bidirectional replication includes the genes for cytochrome b and NADH dehydrogenase subunits 5 and 6.	Dunn Human Nutr Unit, Cambridge CB2 2XY, England; CNR, Ist Tecnol Biomed, Sez Bioinformat & Genom Bari, I-70126 Bari, Italy; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Univ Tampere, Tampere Univ Hosp, FIN-33014 Tampere, Finland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Tampere University; Tampere University; Tampere University Hospital; University of Glasgow; Roswell Park Cancer Institute	Holt, IJ (corresponding author), Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Jacobs, Howard T/G-2434-2011; Yasukawa, Takehiro/AAP-1335-2020; Yang, Mingyao/AAX-9927-2020	Yang, Mingyao/0000-0001-6508-2738; holt, ian/0000-0001-5468-0193; Yasukawa, Takehiro/0000-0001-9531-8780; Jacobs, Howard/0000-0003-1895-6003	Medical Research Council [MC_U105663140] Funding Source: Medline; NCI NIH HHS [CA84302, CA95908] Funding Source: Medline; NIGMS NIH HHS [GM49294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095908, R21CA084302] Funding Source: NIH RePORTER; MRC [MC_U105663140] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aladjem MI, 2002, MOL CELL BIOL, V22, P442, DOI 10.1128/MCB.22.2.442-452.2002; ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Belanger KG, 1996, NUCLEIC ACIDS RES, V24, P2166, DOI 10.1093/nar/24.11.2166; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Bidnenko V, 2002, EMBO J, V21, P3898, DOI 10.1093/emboj/cdf369; Biet E, 2003, NUCLEIC ACIDS RES, V31, P1006, DOI 10.1093/nar/gkg195; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CREWS S, 1979, NATURE, V277, P192, DOI 10.1038/277192a0; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; Dijkwel PA, 1999, METHODS, V18, P418, DOI 10.1006/meth.1999.0800; DIJKWEL PA, 1992, CHROMOSOMA, V102, pS17; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GILLUM AM, 1978, P NATL ACAD SCI USA, V75, P735; HAN ZY, 1994, CHROMOSOMA, V103, P162, DOI 10.1007/BF00368008; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Kajander OA, 2001, EMBO REP, V2, P1007, DOI 10.1093/embo-reports/kve233; Kalejta RF, 1996, MOL CELL BIOL, V16, P4915; Kalejta RF, 1996, MOL CELL BIOL, V16, P4923; KASAMATSU H, 1971, P NATL ACAD SCI USA, V68, P2252, DOI 10.1073/pnas.68.9.2252; Kuzminov A, 1997, J MOL BIOL, V268, P1, DOI 10.1006/jmbi.1997.0955; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LOCKSHON D, 1995, CELL, V81, P947, DOI 10.1016/0092-8674(95)90014-4; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MAYHOOK AG, 1992, P ROY SOC B-BIOL SCI, V248, P85, DOI 10.1098/rspb.1992.0046; Mesner LD, 2003, MOL CELL BIOL, V23, P804, DOI 10.1128/MCB.23.3.804-814.2003; MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; Preiser PR, 1996, EMBO J, V15, P684, DOI 10.1002/j.1460-2075.1996.tb00401.x; RAGHURAMAN MK, 1994, GENE DEV, V8, P554, DOI 10.1101/gad.8.5.554; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Rothstein R, 2000, GENE DEV, V14, P1; Santamaria D, 1998, J BIOL CHEM, V273, P33386, DOI 10.1074/jbc.273.50.33386; van Brabant AJ, 1998, ELECTROPHORESIS, V19, P1239, DOI 10.1002/elps.1150190803; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WANG S, 1998, P NATL ACAD SCI USA, V95, P14757; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9; Zhou J, 2002, P NATL ACAD SCI USA, V99, P13693, DOI 10.1073/pnas.212392399	46	149	152	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50961	50969		10.1074/jbc.M308028200	http://dx.doi.org/10.1074/jbc.M308028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506235	hybrid			2022-12-25	WOS:000187206300018
J	Jackson, MD; Schmidt, MT; Oppenheimer, NJ; Denu, JM				Jackson, MD; Schmidt, MT; Oppenheimer, NJ; Denu, JM			Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Biochemistry-and-Molecular-Biology	APR 12, 2003	SAN DIEGO, CA	Amer Soc Biochem & Mol Biol			GLYCOHYDROLASE-CATALYZED REACTIONS; PURINE NUCLEOSIDE PHOSPHORYLASE; SPLEEN NAD(+) GLYCOHYDROLASE; TRANSITION-STATE STRUCTURE; GAS-PHASE DISSOCIATION; SILENCING PROTEIN SIR2; ACETYL-ADP-RIBOSE; SACCHAROMYCES-CEREVISIAE; DEPENDENT DEACETYLASE; HISTONE DEACETYLASE	Silent information regulator 2 ( Sir2) enzymes catalyze NAD(+)- dependent protein/ histone deacetylation, where the acetyl group from the lysine epsilon- amino group is transferred to the ADP- ribose moiety of NAD(+), producing nicotinamide and the novel metabolite O- acetyl- ADPribose. Sir2 proteins have been shown to regulate gene silencing, metabolic enzymes, and life span. Recently, nicotinamide has been implicated as a direct negative regulator of cellular Sir2 function; however, the mechanism of nicotinamide inhibition was not established. Sir2 enzymes are multifunctional in that the deacetylase reaction involves the cleavage of the nicotinamide- ribosyl, cleavage of an amide bond, and transfer of the acetyl group ultimately to the 2'- ribose hydroxyl of ADP- ribose. Here we demonstrate that nicotinamide inhibition is the result of nicotinamide intercepting an ADP- ribosylenzyme- acetyl peptide intermediate with regeneration of NAD(+) ( transglycosidation). The cellular implications are discussed. A variety of 3- substituted pyridines was found to be substrates for enzyme- catalyzed transglycosidation. A Bronsted plot of the data yielded a slope of + 0.98, consistent with the development of a nearly full positive charge in the transition state, and with basicity of the attacking nucleophile as a strong predictor of reactivity. NAD(+) analogues including beta-2'-deoxy-2'- fluororibo-NAD(+) and a His- to- Ala mutant were used to probe the mechanism of nicotinamide- ribosyl cleavage and acetyl group transfer. We demonstrate that nicotinamide-ribosyl cleavage is distinct from acetyl group transfer to the 2'-OH ribose. The observed enzyme- catalyzed formation of a labile 1'- acetylated- ADP- fluororibose intermediate using beta-2'- deoxy-2'- fluororibo- NAD(+) supports a mechanism where, after nicotinamide- ribosyl cleavage, the carbonyl oxygen of acetylated substrate attacks the C-1' ribose to form an initial iminium adduct.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Oregon Health & Science University; University of California System; University of California San Francisco	Denu, JM (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	jmdenu@wisc.edu						Afshar G, 1999, GENE, V234, P161, DOI 10.1016/S0378-1119(99)00162-6; Allart B, 1998, EUR J BIOCHEM, V256, P155, DOI 10.1046/j.1432-1327.1998.2560155.x; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Berti PJ, 1997, J AM CHEM SOC, V119, P12079, DOI 10.1021/ja971317a; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buckley N, 1996, J ORG CHEM, V61, P2753, DOI 10.1021/jo951257w; BUCKLEY N, 1994, J ORG CHEM, V59, P3609, DOI 10.1021/jo00092a021; Buckley N, 1996, J ORG CHEM, V61, P7360, DOI 10.1021/jo960729j; Cakir-Kiefer C, 2000, BIOCHEM J, V349, P203, DOI 10.1042/0264-6021:3490203; Cakir-Kiefer I, 2001, BIOCHEM J, V358, P399, DOI 10.1042/bj3580399; Chang JH, 2002, J BIOL CHEM, V277, P34489, DOI 10.1074/jbc.M205460200; Denu JM, 2003, TRENDS BIOCHEM SCI, V28, P41, DOI 10.1016/S0968-0004(02)00005-1; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; HANDLON AL, 1994, J AM CHEM SOC, V116, P12087, DOI 10.1021/ja00105a073; Hilbert GE, 1930, J AM CHEM SOC, V52, P4489, DOI 10.1021/ja01374a045; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P79; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MCDONALD LJ, 1992, BIOCHEMISTRY-US, V31, P11881, DOI 10.1021/bi00162a029; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; MullerSteffner H, 1997, ADV EXP MED BIOL, V419, P399; MullerSteffner HM, 1996, J BIOL CHEM, V271, P23967, DOI 10.1074/jbc.271.39.23967; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; NIEDBALLA U, 1974, J ORG CHEM, V39, P3654, DOI 10.1021/jo00939a008; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; PASCAL M, 1976, FEBS LETT, V66, P107, DOI 10.1016/0014-5793(76)80596-0; Rafty LA, 2002, J BIOL CHEM, V277, P47114, DOI 10.1074/jbc.M208997200; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sandmeier JJ, 2002, GENETICS, V160, P877; Sauve AA, 1998, BIOCHEMISTRY-US, V37, P13239, DOI 10.1021/bi981248s; Sauve AA, 2003, BIOCHEMISTRY-US, V42, P9249, DOI 10.1021/bi034959l; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Sauve AA, 2002, BIOCHEMISTRY-US, V41, P8455, DOI 10.1021/bi0258795; Sauve AA, 2000, J AM CHEM SOC, V122, P7855, DOI 10.1021/ja001139c; Scheuring J, 1997, BIOCHEMISTRY-US, V36, P4526, DOI 10.1021/bi962841h; Scheuring J, 1997, BIOCHEMISTRY-US, V36, P8215, DOI 10.1021/bi970379a; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; SLEATH PR, 1991, J ORG CHEM, V56, P3608, DOI 10.1021/jo00011a029; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Starai VJ, 2003, GENETICS, V163, P545; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; WILSON BA, 1990, BIOCHEMISTRY-US, V29, P8643, DOI 10.1021/bi00489a021; ZATMAN LJ, 1953, J BIOL CHEM, V200, P197; Zhang QB, 2001, J AM CHEM SOC, V123, P6756, DOI 10.1021/ja010473l	65	212	220	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50985	50998		10.1074/jbc.M306552200	http://dx.doi.org/10.1074/jbc.M306552200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	752ZM	14522996	hybrid			2022-12-25	WOS:000187206300021
J	Lai, CY; Cronan, JE				Lai, CY; Cronan, JE			beta-ketoacyl-acyl carrier protein synthase III (FabH) is essential for bacterial fatty acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; COENZYME-A; THIOLACTOMYCIN RESISTANCE; VIBRIO-HARVEYI; GENE-CLUSTER; BIOSYNTHESIS; PURIFICATION; SYNTHETASE; PHOSPHOLIPIDS; COLLECTION	beta-Ketoacyl-acyl carrier protein (ACP) synthase III (KAS III, also called acetoacetyl-ACP synthase) encoded by the fabH gene is thought to catalyze the first elongation reaction (Claisen condensation) of type II fatty acid synthesis in bacteria and plant plastids. However, direct in vivo evidence that KAS III catalyzes an essential reaction is lacking, because no mutant organism deficient in this activity has been isolated. We report the first bacterial strain lacking KAS III, a fabH mutant constructed in the Gram-positive bacterium Lactococcus lactis subspecies lactis IL1403. The mutant strain carries an in-frame deletion of the KAS III active site region and was isolated by gene replacement using a medium supplemented with a source of saturated and unsaturated long-chain fatty acids. The mutant strain is devoid of KAS III activity and fails to grow in the absence of supplementation with exogenous long-chain fatty acids demonstrating that KAS III plays an essential role in cellular metabolism. However, the L. lactis fabH deletion mutant requires only long-chain unsaturated fatty acids for growth, a source of long-chain saturated fatty acids is not required. Because both saturated and unsaturated fatty acids are required for growth when fatty acid synthesis is blocked by biotin starvation ( which prevents the synthesis of malonyl-CoA), another pathway for saturated fatty acid synthesis must remain in the fabH deletion strain. Indeed, incorporation of [1-C-14] acetate into fatty acids in vivo showed that the fabH mutant retained about 10% of the fatty acid synthetic ability of the wild-type strain and that this residual synthetic capacity was preferentially diverted to the saturated branch of the pathway. Moreover, mass spectrometry showed that the fabH mutant retained low levels of palmitic acid upon fatty acid starvation. Derivatives of the fabH deletion mutant strain were isolated that were octanoic acid auxotrophs consistent with biochemical studies indicating that the major role of FabH is production of short-chain fatty acid primers. We also confirmed the essentiality of FabH in Escherichia coli by use of a plasmid-based gene insertion/deletion system. Together these results provide the first genetic evidence demonstrating that FabH conducts the major condensation reaction in the initiation of type II fatty acid biosynthesis in both Gram-positive and Gram-negative bacteria.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; Allen EE, 2000, J BACTERIOL, V182, P1264, DOI 10.1128/JB.182.5.1264-1271.2000; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; AXELROD AE, 1947, J BIOL CHEM, V169, P761; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bloch K., 1971, ENZYMES, V5, P441; Bolotin A, 1999, ANTON LEEUW INT J G, V76, P27, DOI 10.1023/A:1002048720611; BYERS DM, 1990, BIOCHEM CELL BIOL, V68, P1045, DOI 10.1139/o90-154; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Christie W. W., 2003, LIPID ANAL ISOLATION, V15; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; CRONAN JE, 1980, ANAL BIOCHEM, V103, P377, DOI 10.1016/0003-2697(80)90626-0; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; FICE D, 1993, J BACTERIOL, V175, P1865, DOI 10.1128/JB.175.7.1865-1870.1993; Haldimann A, 2001, J BACTERIOL, V183, P6384, DOI 10.1128/JB.183.21.6384-6393.2001; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; Jackowski S, 2002, ANTIMICROB AGENTS CH, V46, P1246, DOI 10.1128/AAC.46.5.1246-1252.2002; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; Kutchma AJ, 1999, J BACTERIOL, V181, P5498, DOI 10.1128/JB.181.17.5498-5504.1999; LAI CY, 2003, THESIS U ILLINOIS CH; Leenhouts Kees, 1998, Methods in Cell Science, V20, P35, DOI 10.1023/A:1009862119114; Miller J.H., 1972, EXPT MOL GENETICS; MORRIS LJ, 1965, J CHROMATOGR, V20, P27, DOI 10.1016/S0021-9673(01)97362-5; Nichols BP, 1998, J BACTERIOL, V180, P6408; POTTER RL, 1948, J BIOL CHEM, V172, P531; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; Revill WP, 2001, J BACTERIOL, V183, P3526, DOI 10.1128/JB.183.11.3526-3530.2001; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SILBERT DF, 1975, ANNU REV BIOCHEM, V44, P315, DOI 10.1146/annurev.bi.44.070175.001531; SINGER M, 1989, MICROBIOL REV, V53, P1; Sweetman G, 1996, MOL MICROBIOL, V20, P233, DOI 10.1111/j.1365-2958.1996.tb02504.x; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; WILLIAMS VR, 1945, IND ENG CHEM, V17, P127, DOI 10.1021/i560138a018; WILLIAMS WL, 1947, J BIOL CHEM, V170, P619; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang Y, 1998, J BACTERIOL, V180, P3295, DOI 10.1128/JB.180.13.3295-3303.1998	45	135	150	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51494	51503		10.1074/jbc.M308638200	http://dx.doi.org/10.1074/jbc.M308638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523010	hybrid			2022-12-25	WOS:000187206300080
J	Ram, S; Cox, AD; Wright, JC; Vogel, U; Getzlaff, S; Boden, R; Li, JJ; Plested, JS; Meri, S; Gulati, S; Stein, DC; Richards, JC; Moxon, ER; Rice, PA				Ram, S; Cox, AD; Wright, JC; Vogel, U; Getzlaff, S; Boden, R; Li, JJ; Plested, JS; Meri, S; Gulati, S; Stein, DC; Richards, JC; Moxon, ER; Rice, PA			Neisserial lipooligosaccharide is a target for complement component C4b - Inner core phosphoethanolamine residues define C4b linkage specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; HAEMOPHILUS-INFLUENZAE; BACTERICIDAL ACTIVITY; SHUTTLE MUTAGENESIS; MONOCLONAL-ANTIBODY; COVALENT BINDING; ESCHERICHIA-COLI; SERUM RESISTANCE; 4TH COMPONENT; SEROGROUP-B	We identified Neisseria meningitidis lipooligosaccharide ( LOS) as an acceptor for complement component C4b ( C4b). Phosphoethanolamine ( PEA) residues on the second heptose ( HepII) residue in the LOS core structure formed amide linkages with C4b. PEA at the 6- position of HepII ( 6- PEA) was more efficient than 3- PEA in binding C4b. Strains bearing 6- PEA bound more C4b than strains with 3- PEA and were more susceptible to complement-mediated killing in serum bactericidal assays. Deleting 3- PEA from a strain that expressed both 3- and 6- PEA simultaneously on HepII did not decrease C4b binding. Glycose chain extension of the first heptose residue ( HepI) influenced the nature of the C4b- LOS linkage. Predominantly ester C4b- LOS bonds were seen when lacto-N- neotetraose formed the terminus of the glycose chain extension of HepI with 3- PEA on HepII in the LOS core. Related LOS species with more truncated chain extensions from HepI bound C4b via amide linkages to 3- PEA on HepII. However, 6- PEA in the LOS core bound C4b even when the glycose chain from HepI bore lacto-N-neotetraose at the terminus. The C4A isoform exclusively formed amide linkages, whereas C4B bound meningococci preferentially via ester linkages. These data may serve to explain the preponderance of 3- PEA- bearing meningococci among clinical isolates, because 6- PEA enhances C4b binding that may facilitate clearance of 6- PEA- bearing strains resulting from enhanced serum killing by the classical pathway of complement.	Boston Univ, Med Ctr, Evans Biomed Res Ctr, Infect Dis Sect, Boston, MA 02118 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Oxford, John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England; Univ Wurzburg, Inst Hyg & Microbiol, D-97080 Wurzburg, Germany; Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki 00014, Finland; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	Boston University; National Research Council Canada; University of Oxford; University of Wurzburg; University of Helsinki; University System of Maryland; University of Maryland College Park	Ram, S (corresponding author), Boston Univ, Med Ctr, Evans Biomed Res Ctr, Infect Dis Sect, Boston, MA 02118 USA.		Peter, Silke/GQA-5104-2022	Peter, Silke/0000-0002-1355-3953; Stein, Daniel/0000-0003-3397-5720; Cox, Andrew/0000-0002-8397-9271	NIAID NIH HHS [AI32725, AI24452, AI054544] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI024452, R01AI054544, R29AI024452, R01AI032725, R01AI024452, R37AI032725] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberti S, 1996, INFECT IMMUN, V64, P4726; APICELLA MA, 1981, INFECT IMMUN, V34, P751, DOI 10.1128/IAI.34.3.751-756.1981; ATKINSON JP, 1989, CLIN EXP RHEUMATO S3, V7, P95; AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; BAKKALOGLU A, 1995, TURKISH J PEDIATR, V37, P147; BELLINGERKAWAHARA C, 1990, J EXP MED, V172, P1201, DOI 10.1084/jem.172.4.1201; BISHOF NA, 1990, J INFECT DIS, V162, P248, DOI 10.1093/infdis/162.1.248; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; Claus H, 1997, MOL GEN GENET, V257, P28, DOI 10.1007/s004380050620; Claus H, 1998, MOL GEN GENET, V259, P363, DOI 10.1007/s004380050823; Cox AD, 2002, CARBOHYD RES, V337, P1435, DOI 10.1016/S0008-6215(02)00161-1; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; Drogari-Apiranthitou M, 2002, INFECT IMMUN, V70, P3752, DOI 10.1128/IAI.70.7.3752-3758.2002; Edwards JL, 2002, CELL MICROBIOL, V4, P585, DOI 10.1046/j.1462-5822.2002.00212.x; Fijen CAP, 1999, CLIN INFECT DIS, V28, P98, DOI 10.1086/515075; FROSCH M, 1989, P NATL ACAD SCI USA, V86, P1669, DOI 10.1073/pnas.86.5.1669; GILES CM, 1991, CLIN EXP IMMUNOL, V84, P263; GODDARD EA, 1994, PEDIATR INFECT DIS J, V13, P661, DOI 10.1097/00006454-199407000-00017; HAAS R, 1993, GENE, V130, P23, DOI 10.1016/0378-1119(93)90342-Z; Hartmann D, 1997, J CLIN IMMUNOL, V17, P176, DOI 10.1023/A:1027334716982; HETHERINGTON SV, 1993, INFECT IMMUN, V61, P5157, DOI 10.1128/IAI.61.12.5157-5163.1993; HOLTEN E, 1979, J CLIN MICROBIOL, V9, P186; IIDA K, 1987, IMMUNOLOGY, V62, P413; INGWER I, 1978, J LAB CLIN MED, V92, P211; ISENMAN DE, 1986, J IMMUNOL, V136, P2542; Jennings MP, 1999, MICROBIOL-UK, V145, P3013, DOI 10.1099/00221287-145-11-3013; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JOINER KA, 1986, J IMMUNOL, V136, P710; JOINER KA, 1984, J IMMUNOL, V132, P369; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; LAW SK, 1980, J IMMUNOL, V125, P634; Levin JC, 1996, J BACTERIOL, V178, P4571, DOI 10.1128/jb.178.15.4571-4575.1996; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; MCQUILLEN DP, 1994, METHOD ENZYMOL, V236, P137; Minor SY, 2000, INFECT IMMUN, V68, P6526, DOI 10.1128/IAI.68.12.6526-6534.2000; NAGASAWA S, 1980, J IMMUNOL, V125, P578; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; RAM S, 2000, 12 INT PATH NIESS C, P38; Ross G.D., 1986, IMMUNOBIOLOGY COMPLE, P1; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; ROWE PC, 1989, J INFECT DIS, V160, P448, DOI 10.1093/infdis/160.3.448; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; Seppanen M, 2001, CLIN INFECT DIS, V33, P1604, DOI 10.1086/323462; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRJI M, 1991, MOL MICROBIOL, V5, P1831, DOI 10.1111/j.1365-2958.1991.tb00807.x; Vogel U, 1999, INFECT IMMUN, V67, P954, DOI 10.1128/IAI.67.2.954-957.1999; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; WANG RH, 1993, J CLIN INVEST, V92, P1326, DOI 10.1172/JCI116706; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; ZOLLINGER WD, 1983, INFECT IMMUN, V40, P257, DOI 10.1128/IAI.40.1.257-264.1983	55	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50853	50862		10.1074/jbc.M308364200	http://dx.doi.org/10.1074/jbc.M308364200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525973	hybrid			2022-12-25	WOS:000187206300004
J	Zhang, XM; Wang, XT; Yue, HW; Leung, SW; Thibodeau, PH; Thomas, PJ; Guggino, SE				Zhang, XM; Wang, XT; Yue, HW; Leung, SW; Thibodeau, PH; Thomas, PJ; Guggino, SE			Organic solutes rescue the functional defect in Delta F508 cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; NEPHROGENIC DIABETES-INSIPIDUS; CELL-SURFACE EXPRESSION; PROTEIN STABILIZATION; CHEMICAL CHAPERONES; EPITHELIAL-CELLS; ION-CHANNEL; CFTR; BETAINE; STABILITY	The most common defect in cystic fibrosis, deletion of phenylalanine from position 508 of the cystic fibrosis transmembrane conductance regulator (DeltaF508 CFTR), decreases the trafficking of this protein to the cell surface membrane. Previous studies have shown that low temperature and high concentrations of glycerol or trimethylamine N-oxide can partially counteract the processing defect of DeltaF508 CFTR. The present study investigates whether physiologically relevant concentrations of organic solutes, accumulated by cotransporter proteins, can rescue the misprocessing of DeltaF508 CFTR. Myoinositol alone or myoinositol, betaine, and taurine given sequentially increased the processing of core-glycosylated, endoplasmic reticulum-arrested DeltaF508 CFTR into the fully glycosylated form of CFTR in IB3 cells or NIH 3T3 cells stably expressing DeltaF508 CFTR. Pulse-chase experiments using transiently transfected COS7 cells demonstrated that organic solutes also increased the processing of the core-glycosylated form of green fluorescent protein-DeltaF508 CFTR. Moreover, the prolonged half-life of the complex-glycosylated form of GFP-DeltaF508 CFTR suggests that this treatment stabilized the mature form of the protein. In vitro studies of purified NBD1 stability and aggregation showed that myoinositol stabilized both the DeltaF508 and wild type CFTR and inhibited DeltaF508 misfolding. Most significantly, treatment of CF bronchial airway cells with these transportable organic solutes restores cAMP-stimulated single channel activity of both CFTR and outwardly rectifying chloride channel in the cell surface membrane and also restores a forskolin-stimulated macroscopic Cl-36(-) efflux. We conclude that organic solutes can repair CFTR functions by enhancing the processing of DeltaF508 CFTR to the plasma membrane by stabilizing the complex-glycosylated form of DeltaF508 CFTR.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Guggino, SE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Rm 929,Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	sguggino@jhmi.edu	Thomas, Philip J/F-7115-2012; Leung, Steve W/E-5624-2011	Leung, Steve W/0000-0003-2832-2258; Thibodeau, Patrick/0000-0002-6790-144X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK049835] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49835] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Barak AJ, 1997, ALCOHOL CLIN EXP RES, V21, P1100, DOI 10.1097/00000374-199709000-00024; Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; BORDEN LA, 1995, J NEUROCHEM, V64, P977; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Collins KD, 1997, BIOPHYS J, V72, P65, DOI 10.1016/S0006-3495(97)78647-8; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DARLING PB, 1985, PEDIATR RES, V19, P578, DOI 10.1203/00006450-198506000-00015; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gao L, 1999, AM J PHYSIOL-LUNG C, V277, pL113, DOI 10.1152/ajplung.1999.277.1.L113; GEKKO K, 1990, J BIOCHEM-TOKYO, V107, P572, DOI 10.1093/oxfordjournals.jbchem.a123088; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1633, DOI 10.1093/oxfordjournals.jbchem.a133638; GORDON RE, 1986, AM J PATHOL, V125, P585; GORDON RE, 1992, ADV EXP MED BIOL, V315, P319; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMOSH A, 1992, HUM MOL GENET, V1, P542, DOI 10.1093/hmg/1.7.542; HAWORTH JC, 1993, AM J MED GENET, V45, P572, DOI 10.1002/ajmg.1320450510; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KENDLER BS, 1989, PREV MED, V18, P79, DOI 10.1016/0091-7435(89)90056-X; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; NAKANISHI T, 1989, P NATL ACAD SCI USA, V86, P6002, DOI 10.1073/pnas.86.15.6002; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Rajesh D, 2003, J BIOL CHEM, V278, P35968, DOI 10.1074/jbc.M303280200; RASOLA A, 1995, FEBS LETT, V373, P229, DOI 10.1016/0014-5793(95)01052-G; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SONE M, 1993, AM J PHYSIOL, V264, pF722, DOI 10.1152/ajprenal.1993.264.4.F722; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; TAYLOR LS, 1995, BBA-PROTEIN STRUCT M, V1253, P39, DOI 10.1016/0167-4838(95)00142-H; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; van der Vliet A, 2000, Curr Opin Pulm Med, V6, P533, DOI 10.1097/00063198-200011000-00013; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WARD CL, 1994, J BIOL CHEM, V269, P25710; WHITESIDE CI, 1991, AM J PHYSIOL, V260, pF138, DOI 10.1152/ajprenal.1991.260.1.F138; Wimmer R, 1997, J BIOTECHNOL, V55, P85, DOI 10.1016/S0168-1656(97)00061-8; Yue HW, 2000, J BIOL CHEM, V275, P10030, DOI 10.1074/jbc.275.14.10030	59	73	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51232	51242		10.1074/jbc.M309076200	http://dx.doi.org/10.1074/jbc.M309076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532265	hybrid			2022-12-25	WOS:000187206300049
J	Gomez, D; Aouali, N; Londono-Vallejo, A; Lacroix, L; Megnin-Chanet, F; Lemarteleur, T; Douarre, C; Shin-ya, K; Mailliet, P; Trentesaux, C; Morjani, H; Mergny, JL; Riou, JF				Gomez, D; Aouali, N; Londono-Vallejo, A; Lacroix, L; Megnin-Chanet, F; Lemarteleur, T; Douarre, C; Shin-ya, K; Mailliet, P; Trentesaux, C; Morjani, H; Mergny, JL; Riou, JF			Resistance to the short term antiproliferative activity of the G-quadruplex ligand 12459 is associated with telomerase overexpression and telomere capping alteration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; IN-VITRO; SMALL-MOLECULE; DNA; INHIBITOR; SENESCENCE; EXPRESSION; APOPTOSIS; MUTANT; HTERT	Ligands that stabilize the telomeric G- rich single-stranded DNA overhang into G- quadruplex can be considered as potential antitumor agents that block telomere replication. Ligand 12459, a potent G- quadruplex ligand that belongs to the triazine series, has been previously shown to induce both telomere shortening and apoptosis in the human A549 cell line as a function of its concentration and time exposure. We show here that A549 clones obtained after mutagenesis and selected for resistance to the short term effect of ligand 12459 frequently displayed hTERT transcript overexpression ( 2 - 6- fold). Overexpression of hTERT was also characterized in two resistant clones ( JFD10 and JFD18) as an increase in telomerase activity, leading to an increase in telomere length. An increased frequency of anaphase bridges was also detected in JFD10 and JFD18, suggesting an alteration of telomere capping functions. Transfection of either hTERT or DN- hTERT cDNAs into A549 cells did not confer resistance or hypersensitivity to the short term effect of ligand 12459, indicating that telomerase expression is not the main determinant of the antiproliferative effect of ligand 12459. In contrast, transfection of DN- hTERT cDNA into resistant JFD18 cells restored sensitivity to apoptotic concentrations of ligand 12459, suggesting that telomerase does participate in the resistance to this G- quadruplex ligand. This work provides evidence that telomerase activity is not the main target for the 12459 G- quadruplex ligand but that hTERT functions contribute to the resistance phenotype to this class of agents.	Univ Reims, UFR Pharm, CNRS, UMR 642, F-51096 Reims, France; INSERM, U434, F-75010 Paris, France; CNRS, Museum Natl Hist Nat, INSERM, UMR 8466,U565,Lab Biophys, F-75005 Paris, France; Inst Curie, Inst Curie Rech, U350, INSERM,Ctr Univ, F-91405 Orsay, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Aventis Pharma SA, Ctr Rech Paris, F-94403 Vitry Sur Seine, France	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Tokyo; Sanofi-Aventis; Sanofi France	Riou, JF (corresponding author), Univ Reims, UFR Pharm, CNRS, UMR 642, 51 Rue Cognacq Jay,IFR53, F-51096 Reims, France.		Morjani, Hamid/AAJ-1260-2020; Mergny, Jean-Louis/E-2860-2013; Gomez Zamorano, Dennis Gomez/AAX-5182-2021; Chanet, Frédérique Megnin/M-1983-2018; Lacroix, Laurent/C-7024-2009; Londono-Vallejo, Arturo/ABH-5555-2020	Mergny, Jean-Louis/0000-0003-3043-8401; Gomez Zamorano, Dennis Gomez/0000-0001-9942-1451; Lacroix, Laurent/0000-0002-6382-9057; Londono-Vallejo, Arturo/0000-0003-3535-7563; riou, jean-francois/0000-0002-0055-6506				Akiyama M, 2002, CANCER LETT, V178, P187, DOI 10.1016/S0304-3835(01)00838-2; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn E, 1999, MT SINAI J MED, V66, P292; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Gomez D, 2003, CANCER RES, V63, P6149; Gomez D, 2002, CANCER RES, V62, P3365; Gowan SM, 2002, MOL PHARMACOL, V61, P1154, DOI 10.1124/mol.61.5.1154; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; GUPTA RS, 1988, CANCER RES, V48, P6404; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Izbicka E, 1999, ANTI-CANCER DRUG DES, V14, P355; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; Kim MY, 2003, CANCER RES, V63, P3247; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; MAILLIET P, 2001, Patent No. 0140218; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755; Phan AT, 2002, NUCLEIC ACIDS RES, V30, P4618, DOI 10.1093/nar/gkf597; Reichenbach P, 2003, CURR BIOL, V13, P568, DOI 10.1016/S0960-9822(03)00173-8; Rezler EM, 2002, CURR OPIN PHARMACOL, V2, P415, DOI 10.1016/S1471-4892(02)00182-0; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; RIOU JF, 1992, BIOCHEM BIOPH RES CO, V187, P164, DOI 10.1016/S0006-291X(05)81474-3; Schaffitzel C, 2001, P NATL ACAD SCI USA, V98, P8572, DOI 10.1073/pnas.141229498; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Stansel RM, 2001, EMBO J, V20, P5532; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yi XM, 2001, NUCLEIC ACIDS RES, V29, P4818, DOI 10.1093/nar/29.23.4818; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	45	52	56	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50554	50562		10.1074/jbc.M308440200	http://dx.doi.org/10.1074/jbc.M308440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525974	hybrid			2022-12-25	WOS:000187068200109
J	Guo, L; Groenendyk, J; Papp, S; Dabrowska, M; Knoblach, B; Kay, C; Parker, JMR; Opas, M; Michalak, M				Guo, L; Groenendyk, J; Papp, S; Dabrowska, M; Knoblach, B; Kay, C; Parker, JMR; Opas, M; Michalak, M			Identification of an N-domain histidine essential for chaperone function in calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; P-DOMAIN; PROTEIN; BINDING; SUBSTRATE; CALNEXIN; CELLS; ER	Calreticulin is an endoplasmic reticulum ( ER) luminal Ca2+- binding chaperone involved in folding of newly synthesized glycoproteins via the " calreticulin- calnexin cycle." We reconstituted ER of calreticulin- deficient cells with N- terminal histidine ( His(25), His(82), His(128), and His(153)) calreticulin mutants and carried out a functional analysis. In crt (-/-) cells bradykinin- dependent Ca2+ release is altered, and the reestablishment of bradykinin-dependent Ca2+ release was used as a marker for calreticulin function. Bradykinin- dependent Ca2+ release from the ER was rescued by wild type calreticulin and by the His(25), His(82), or His(128) mutant but not by the His(153) mutant. Wild type calreticulin and the His(25), His(82), and His(128) mutants all prevented in vitro thermal aggregation of malate dehydrogenase and IgY, whereas the His(153) mutant did not, indicating that His(153) chaperone function was impaired. Biophysical analysis of His(153) mutant revealed that conformation changes in calreticulin mutant may be responsible for the loss of its chaperone activity. We conclude that mutation of a single amino acid residue in calreticulin has devastating consequences for its chaperone function, indicating that mutations in chaperones may play a significant role in protein folding disorders.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Dept Pathol & Lab Med, Toronto, ON M5S 1A8, Canada	University of Alberta; University of Toronto	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Guo, Lei/E-9232-2011; Knoblach, Barbara/B-9454-2009	guo, lei/0000-0002-0402-4152				Andrin C, 2000, PROTEIN EXPRES PURIF, V20, P207, DOI 10.1006/prep.2000.1291; Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, FEBS LETT, V488, P69, DOI 10.1016/S0014-5793(00)02382-6; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Feltham JL, 2000, CELL, V100, P193, DOI 10.1016/S0092-8674(00)81557-3; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; Knee R, 2003, BIOCHEM BIOPH RES CO, V304, P661, DOI 10.1016/S0006-291X(03)00643-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schrag JD, 2003, TRENDS BIOCHEM SCI, V28, P49, DOI 10.1016/S0968-0004(02)00004-X; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WADA I, 1991, J BIOL CHEM, V266, P19599	34	64	71	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50645	50653		10.1074/jbc.M309497200	http://dx.doi.org/10.1074/jbc.M309497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522955	hybrid			2022-12-25	WOS:000187068200120
J	Oses-Prieto, JA; Bengoechea-Alonso, MT; Artigues, A; Iriarte, A; Martinez-Carrion, M				Oses-Prieto, JA; Bengoechea-Alonso, MT; Artigues, A; Iriarte, A; Martinez-Carrion, M			The nature of the rate-limiting steps in the refolding of the cofactor-dependent protein aspartate aminotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE HYDROGEN-EXCHANGE; ANTIBODY SCFV FRAGMENT; ESCHERICHIA-COLI; PROLINE ISOMERIZATION; PYRIDOXAL 5'-PHOSPHATE; RIBONUCLEASE-A; GUANIDINE-HYDROCHLORIDE; MASS-SPECTROMETRY; CYTOCHROME B(562); KINETIC TRAPS	The refolding of mitochondrial aspartate aminotransferase (mAAT; EC 2.6.1.1) has been studied following unfolding in 6 M guanidine hydrochloride for different periods of time. Whereas reactivation of equilibrium-unfolded mAAT is sigmoidal, reactivation of the short term unfolded protein displays a double exponential behavior consistent with the presence of fast and slow refolding species. The amplitude of the fast phase decreases with increasing unfolding times (k approximate to 0.75 min(-1) at 20 degreesC) and becomes undetectable at equilibrium unfolding. According to hydrogen exchange and stopped-flow intrinsic fluorescence data, unfolding of mAAT appears to be complete in less than 10 s, but hydrolysis of the Schiff base linking the coenzyme pyridoxal 5'-phosphate (PLP) to the polypeptide is much slower (k approximate to 0.08 min(-1)). This implies the existence in short term unfolded samples of unfolded species with PLP still attached. However, since the disappearance of the fast refolding phase is about 10-fold faster than the release of PLP, the fast refolding phase does not correspond to folding of the coenzyme-containing molecules. The fast refolding phase disappears more rapidly in the pyridoxamine and apoenzyme forms of mAAT, both of which lack covalently attached cofactor. Thus, bound PLP increases the kinetic stability of the fast refolding unfolding intermediates. Conversion between fast and slow folding forms also takes place in an early folding intermediate. The presence of cyclophilin has no effect on the reactivation of either equilibrium or short term unfolded mAAT. These results suggest that proline isomerization may not be the only factor determining the slow refolding of this cofactor-dependent protein.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.			Oses-Prieto, Juan/0000-0003-4759-2341	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Apiyo D, 2002, PROTEIN SCI, V11, P1129, DOI 10.1110/ps.3840102; Arnould S, 1998, BIOCHEMISTRY-US, V37, P12818, DOI 10.1021/bi980713i; ARRIODUPONT M, 1978, EUR J BIOCHEM, V91, P369, DOI 10.1111/j.1432-1033.1978.tb12689.x; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BERTLAND LH, 1968, BIOCHEMISTRY-US, V7, P134, DOI 10.1021/bi00841a018; Bettati S, 2000, J BIOL CHEM, V275, P40244, DOI 10.1074/jbc.M007015200; Bhat R, 2003, BIOCHEMISTRY-US, V42, P5722, DOI 10.1021/bi030024t; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; Birolo L, 2002, J BIOL CHEM, V277, P17428, DOI 10.1074/jbc.M200650200; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Chen JW, 2001, NAT STRUCT BIOL, V8, P721, DOI 10.1038/90443; CHENG S, 1972, J BIOL CHEM, V247, P6597; CHURCHICH JE, 1965, BIOCHEMISTRY-US, V4, P1405, DOI 10.1021/bi00883a027; Dalessio PM, 2000, BIOCHEMISTRY-US, V39, P860, DOI 10.1021/bi991937j; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; ENGLANDER JJ, 1985, ANAL BIOCHEM, V147, P234, DOI 10.1016/0003-2697(85)90033-8; Goedken ER, 2000, PROTEIN SCI, V9, P1914, DOI 10.1110/ps.9.10.1914; GROHA C, 1978, EUR J BIOCHEM, V92, P437, DOI 10.1111/j.1432-1033.1978.tb12764.x; HOURY WA, 1994, BIOCHEMISTRY-US, V33, P2516, DOI 10.1021/bi00175a022; Jager M, 2000, PROTEIN SCI, V9, P552; Jager M, 1997, FEBS LETT, V418, P106, DOI 10.1016/S0014-5793(97)01350-1; Jager M, 1999, J MOL BIOL, V285, P2005, DOI 10.1006/jmbi.1998.2425; JENKINS WT, 1966, BIOCHEM BIOPH RES CO, V22, P376, DOI 10.1016/0006-291X(66)90656-5; KERN G, 1995, J BIOL CHEM, V270, P740, DOI 10.1074/jbc.270.2.740; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIEHN ED, 1970, NATURE, V226, P544, DOI 10.1038/226544a0; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leckner J, 1997, BBA-PROTEIN STRUCT M, V1342, P19, DOI 10.1016/S0167-4838(97)00074-5; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; MATHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MUI PW, 1985, BIOCHEMISTRY-US, V24, P4481, DOI 10.1021/bi00337a033; Pertinhez TA, 2000, PROTEIN SCI, V9, P1466, DOI 10.1110/ps.9.8.1466; Pierce MM, 2000, J MOL BIOL, V298, P955, DOI 10.1006/jmbi.2000.3700; Pozdnyakova I, 2001, J BIOL INORG CHEM, V6, P182, DOI 10.1007/s007750000189; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; REYES AM, 1993, J BIOL CHEM, V268, P22281; Robinson CR, 1997, BIOCHEMISTRY-US, V36, P16141, DOI 10.1021/bi971470h; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; Wedemeyer WJ, 2002, BIOCHEMISTRY-US, V41, P14637, DOI 10.1021/bi020574b; Widmann M, 2000, J BIOL CHEM, V275, P18619, DOI 10.1074/jbc.C000156200; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; Wittung-Stafshede P, 1999, P NATL ACAD SCI USA, V96, P6587, DOI 10.1073/pnas.96.12.6587; Wu TH, 2003, BBA-PROTEINS PROTEOM, V1647, P315, DOI 10.1016/S1570-9639(03)00081-5; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522	60	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49988	49999		10.1074/jbc.M309922200	http://dx.doi.org/10.1074/jbc.M309922200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522984	hybrid			2022-12-25	WOS:000187068200042
J	Park, KH; Chhowalla, M; Iqbal, Z; Sesti, F				Park, KH; Chhowalla, M; Iqbal, Z; Sesti, F			Single-walled carbon nanotubes are a new class of ion channel blockers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; IMMOBILIZATION; PROTEINS; GROWTH; CELLS	Here we identify a novel class of biological membrane ion channel blockers called single-walled carbon nanotubes (SWNTs). SWNTs with diameter distributions peaked at similar to 0.9 and 1.3 nm, C-60 fullerenes, multi wall nanotubes (MWNTs), and hyperfullerenes (nano-"on-ions") were synthesized by several techniques and applied to diverse channel types heterologously expressed in mammalian cells. External as-fabricated and purified SWNTs blocked K+ channel subunits in a dose-dependent manner. Blockage was dependent on the shape and dimensions of the nanoparticles used and did not require any electrochemical interaction. SWNTs were more effective than the spherical fullerenes and, for both, diameter was the determining factor. These findings postulate new uses for SWNTs in biological applications and provide unexpected insights into the current view of mechanisms governing the interaction of ion channels with blocking molecules.	Rutgers State Univ, Dept Ceram & Mat Engn, Piscataway, NJ 08854 USA; New Jersey Inst Technol, Dept Chem & Environm Sci, Newark, NJ 07102 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; New Jersey Institute of Technology; Rutgers State University New Brunswick; Rutgers State University Medical Center	Chhowalla, M (corresponding author), Rutgers State Univ, Dept Ceram & Mat Engn, 607 Taylor Rd, Piscataway, NJ 08854 USA.		Park, Ki Ho/E-8921-2011; Park, Ki Ho/N-8153-2017	Park, Ki Ho/0000-0002-6193-9826	NIGMS NIH HHS [R01GM68581-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068581] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Davis JJ, 1998, INORG CHIM ACTA, V272, P261, DOI 10.1016/S0020-1693(97)05926-4; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 2001, IONIC CHANNELS EXCIT, P814; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Lan A, 2002, APPL PHYS LETT, V81, P433, DOI 10.1063/1.1492846; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; Mattson MP, 2000, J MOL NEUROSCI, V14, P175, DOI 10.1385/JMN:14:3:175; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Tomita S, 1999, CHEM PHYS LETT, V305, P225, DOI 10.1016/S0009-2614(99)00374-7; Tsang SC, 1997, ANGEW CHEM INT EDIT, V36, P2198, DOI 10.1002/anie.199721981; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhu XR, 1999, RECEPTOR CHANNEL, V6, P387	20	263	273	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50212	50216		10.1074/jbc.M310216200	http://dx.doi.org/10.1074/jbc.M310216200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522977	Green Submitted, hybrid			2022-12-25	WOS:000187068200068
J	Xiao, JQ; Jethanandani, P; Ziober, BL; Kramer, RH				Xiao, JQ; Jethanandani, P; Ziober, BL; Kramer, RH			Regulation of alpha(7) integrin expression during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-BINDING-PROTEIN; C-MYC; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; CODING ELEMENTS; MESSENGER-RNA; CELLS; GENE; PROMOTER; MYOD	Expression of the laminin-binding alpha(7) integrin is tightly regulated during myogenic differentiation, reflecting required functions that range from cell motility to formation of stable myotendinous junctions. However, the exact mechanism controlling alpha(7) expression in a tissue- and differentiation-specific manner is poorly understood. This report provides evidence that alpha(7) gene expression during muscle differentiation is regulated by the c-Myc transcription factor. In myoblasts, alpha(7) is expressed at basal levels, but following conversion to myotubes the expression of the integrin is strongly elevated. The increased alpha(7) mRNA and protein levels following myogenic differentiation are inversely correlated with c-Myc expression. Transfection of myoblasts with the c-Myc transcription factor down-regulated alpha(7) expression, whereas overexpression of Madmyc, a dominant-negative c-Myc chimera, induced elevated alpha(7) expression. Functional analysis with site-specific deletions identified a specific double E-box sequence in the upstream promoter region ( - 2.0 to - 2.6 kb) that is responsible for c-Myc-induced suppression of alpha(7) expression. DNA-protein binding assays and supershift analysis revealed that c-Myc forms a complex with this double E-box sequence. Our results suggest that the interaction of c-Myc with this promoter region is an important regulatory element controlling alpha(7) integrin expression during muscle development and myotendinous junction formation.	Univ Calif San Francisco, Dept Stomatol & Anat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Stomatol & Anat, Box 0422,Rm S-612, San Francisco, CA 94143 USA.				NIDCR NIH HHS [R01 DE 15404, R01 DE 13479] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013479, R01DE015404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAO ZZ, 1993, J CELL SCI, V106, P579; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bondurant MC, 1996, J CELL PHYSIOL, V168, P255, DOI 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO;2-O; BUCKLE RS, 1995, ONCOGENE, V10, P1249; Case SS, 1999, P NATL ACAD SCI USA, V96, P2988, DOI 10.1073/pnas.96.6.2988; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fujioka Y, 2001, J BIOL CHEM, V276, P45137, DOI 10.1074/jbc.M106127200; HANN SR, 1995, ADV EXP MED BIOL, V375, P107; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ishida Seiichi, 1997, Leukemia (Basingstoke), V11, P399; KI KW, 2002, J BIOL CHEM, V13, P13; La Rocca SA, 2002, ONCOGENE, V21, P4838, DOI 10.1038/sj.onc.1205586; LAROCCA SA, 1994, ONCOGENE, V9, P3499; Lopez-Rodriguez C, 2000, EUR J IMMUNOL, V30, P2465; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; ORIAN A, 2001, SCI STKE; Pegoraro E, 2002, AM J PATHOL, V160, P2135, DOI 10.1016/S0002-9440(10)61162-5; Rashtchian A, 1992, PCR Methods Appl, V2, P124; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SAMBROOK J, 2000, MOL CLONING LAB MANU, P152; Semov A, 2002, ANAL BIOCHEM, V302, P38, DOI 10.1006/abio.2001.5515; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; Vizirianakis IS, 2001, ARCH BIOCHEM BIOPHYS, V385, P108, DOI 10.1006/abbi.2000.2134; Xiao GS, 2001, CIRC RES, V89, P1122, DOI 10.1161/hh2401.100742; Xiao JQ, 1998, J VIROL, V72, P5994, DOI 10.1128/JVI.72.7.5994-6003.1998; Yao CC, 1997, J CELL SCI, V110, P1477; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Ziober BL, 1996, J BIOL CHEM, V271, P22915, DOI 10.1074/jbc.271.37.22915	38	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49780	49788		10.1074/jbc.M308542200	http://dx.doi.org/10.1074/jbc.M308542200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525975	hybrid			2022-12-25	WOS:000187068200018
J	Bae, SS; Cho, H; Mu, J; Birnbaum, MJ				Bae, SS; Cho, H; Mu, J; Birnbaum, MJ			Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; BROWN ADIPOCYTES; GLUT4-CONTAINING VESICLES; GLUT4 TRANSLOCATION; GROWTH; DIFFERENTIATION; STIMULATION; TRANSPORT; AKT1; ADIPOGENESIS	Recent data have implicated the serine/threonine protein kinase Akt/protein kinase B (PKB) in a diverse array of physiological pathways, raising the question of how biological specificity is maintained. Partial clarification derived from the observation that mice deficient in either of the two isoforms, Akt1/PKBalpha or Akt2/PKBbeta, demonstrate distinct abnormalities, i.e. reduced organismal size or insulin resistance, respectively. However, the question still persists as to whether these divergent phenotypes are due exclusively to tissue-specific differences in isoform expression or distinct capacities for signaling intrinsic to the two proteins. Here we show that Akt2/PKBbeta(-/-) adipocytes derived from immortalized mouse embryo fibroblasts display significantly reduced insulin-stimulated hexose uptake, clearly establishing that the partial defect in glucose disposal in these mice derives from lack of a cell autonomous function of Akt2/PKBbeta. Moreover, in adipocytes differentiated from primary fibroblasts or immortalized mouse embryo fibroblasts, and brown preadipocytes the absence of Akt2/PKBbeta resulted in reduction of insulin-induced hexose uptake and glucose transporter 4 (GLUT4) translocation, whereas Akt1/PKBalpha was dispensable for this effect. Most importantly, hexose uptake and GLUT4 translocation were completely restored after re-expression of Akt2/PKBbeta in Akt2/PKBbeta(-/-) adipocytes, but overexpression of Akt1/PKBalpha at comparable levels was ineffective at rescuing insulin action to normal. These results show that the Akt1/PKBalpha and Akt2/ PKBbeta isoforms are uniquely adapted to preferentially transmit distinct biological signals, and this property is likely to contribute significantly to the ability of Akt/ PKB to play a role in diverse processes.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Med, 415 Curie Blvd,Rm 322 CRB, Philadelphia, PA 19104 USA.			Mu, James/0000-0001-8081-2401; Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK39615] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039615] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Burcelin R, 2000, DIABETES, V49, P1635, DOI 10.2337/diabetes.49.10.1635; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hunter SJ, 1998, AM J MED, V105, P331, DOI 10.1016/S0002-9343(98)00300-3; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Klein J, 2002, BIOESSAYS, V24, P382, DOI 10.1002/bies.10058; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; Murthy SS, 2000, CYTOGENET CELL GENET, V88, P38, DOI 10.1159/000015481; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; TODARO GJ, 1966, P NATL ACAD SCI USA, V55, P302, DOI 10.1073/pnas.55.2.302; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071	34	251	261	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49530	49536		10.1074/jbc.M306782200	http://dx.doi.org/10.1074/jbc.M306782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522993	hybrid			2022-12-25	WOS:000186829000123
J	Karvinen, S; Pasonen-Seppanen, S; Hyttinen, JMT; Pienimaki, JP; Torronen, K; Jokela, TA; Tammi, MI; Tammi, R				Karvinen, S; Pasonen-Seppanen, S; Hyttinen, JMT; Pienimaki, JP; Torronen, K; Jokela, TA; Tammi, MI; Tammi, R			Keratinocyte growth factor stimulates migration and hyaluronan synthesis in the epidermis by activation of keratinocyte hyaluronan synthases 2 and 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; SKIN ORGAN-CULTURE; FACTOR EXPRESSION; IN-VITRO; CELL-MIGRATION; CHO-CELLS; DIFFERENTIATION; KGF; PROLIFERATION; METABOLISM	Keratinocyte growth factor (KGF) activates keratinocyte migration and stimulates wound healing. Hyaluronan, an extracellular matrix glycosaminoglycan that accumulates in wounded epidermis, is known to promote cell migration, suggesting that increased synthesis of hyaluronan might be associated with the KGF response in keratinocytes. Treatment of monolayer cultures of rat epidermal keratinocytes led to an elongated and lifted cell shape, increased filopodial protrusions, enhanced cell migration, accumulation of intermediate size hyaluronan in the culture medium and within keratinocytes, and a rapid increase of hyaluronan synthase 2 (Has2) mRNA, suggesting a direct influence on this gene. In stratified, organotypic cultures of the same cell line, both Has2 and Has3 with the hyaluronan receptor CD44 were up-regulated and hyaluronan accumulated in the epidermis, the spinous cell layer in particular. At the same time the expression of the early differentiation marker keratin 10 was inhibited, whereas filaggrin expression and epidermal permeability were less affected. The data indicate that Has2 and Has3 belong to the targets of KGF in keratinocytes, and support the idea that enhanced hyaluronan synthesis acts an effector for the migratory response of keratinocytes in wound healing, whereas it may delay keratinocyte terminal differentiation.	Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	University of Eastern Finland	Tammi, R (corresponding author), Univ Kuopio, Dept Anat, POB 1627, FIN-70211 Kuopio, Finland.		Tammi, Markku/AAQ-7878-2021; Jokela, Tiina/O-9206-2015	Jokela, Tiina/0000-0002-7521-3866; Hyttinen, Juha/0000-0002-3414-4032				AGREN UM, 1995, J CELL PHYSIOL, V164, P240, DOI 10.1002/jcp.1041640204; Andreadis ST, 2001, FASEB J, V15, P898, DOI 10.1096/fj.00-0324com; BADEN HP, 1983, J INVEST DERMATOL, V80, P124, DOI 10.1111/1523-1747.ep12532899; Beer HD, 2000, J INVEST DERM SYMP P, V5, P34, DOI 10.1046/j.1087-0024.2000.00009.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Collis L, 1998, FEBS LETT, V440, P444, DOI 10.1016/S0014-5793(98)01505-1; Dube B, 2001, BBA-MOL CELL RES, V1538, P283, DOI 10.1016/S0167-4889(01)00079-9; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; HAYDOCK PV, 1993, J INVEST DERMATOL, V101, P118, DOI 10.1111/1523-1747.ep12363609; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jeschke MG, 2002, GENE THER, V9, P1065, DOI 10.1038/sj.gt.3301732; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; MACCALLUM D K, 1990, Skin Pharmacology, V3, P86; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MCGUIRE PG, 1987, J CELL PHYSIOL, V133, P267, DOI 10.1002/jcp.1041330210; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Nabi IR, 1999, J CELL SCI, V112, P1803; Pasonen-Seppanen S, 2003, J INVEST DERMATOL, V120, P1038, DOI 10.1046/j.1523-1747.2003.12249.x; Pasonen-Seppanen S, 2001, HISTOCHEM CELL BIOL, V116, P287, DOI 10.1007/s004180100312; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; Rilla K, 2002, J CELL SCI, V115, P3633, DOI 10.1242/jcs.00042; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Spicer A P, 2001, Methods Mol Biol, V171, P373; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; Tammi R, 1998, J BIOL CHEM, V273, P28878, DOI 10.1074/jbc.273.44.28878; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; TAMMI R, 1988, J INVEST DERMATOL, V90, P412, DOI 10.1111/1523-1747.ep12456530; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Tammi RH, 2000, HISTOCHEM CELL BIOL, V113, P265, DOI 10.1007/s004180000128; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896	46	127	133	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49495	49504		10.1074/jbc.M310445200	http://dx.doi.org/10.1074/jbc.M310445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506240	hybrid			2022-12-25	WOS:000186829000118
J	Kawasaki, M; Maeda, T; Hanasawa, K; Ohkubo, I; Tani, T				Kawasaki, M; Maeda, T; Hanasawa, K; Ohkubo, I; Tani, T			Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS EXPERIMENTAL METASTASIS; ENDOTHELIAL-CELL APOPTOSIS; SITE-DIRECTED MUTAGENESIS; BINDING-PROTEIN; LIGHT-CHAIN; PLASMA PREKALLIKREIN; HEAVY-CHAIN; RECEPTOR; ADHESION; IDENTIFICATION	We have demonstrated previously that kinin-free high molecular weight kininogen, its domain 5 (D5(H), Gly(402) Lys(502)), and peptides derived from D5(H) inhibited vitronectin-mediated migration and invasion of cancer cells in vitro ( Kamiyama, F., Maeda, T., Yamane, T., Li, Y. H., Ogikubo, O., Otsuka, T., and Ohkubo, I. ( 2001) Biochem. Biophys. Res. Commun. 288, 975 - 980). In this study, we found that the amino acid sequence His-Gly-Lys (HGK) in D5(H) is the core motif for inhibition of adhesion and invasion of MDA-MB-231 cells in vitro. P-5m ((484)GHGKHKNK(491), Gly(484) - Lys(491)), an octapeptide including the HGK motif derived from D5(H), and HGK, a tripeptide, inhibited both cell adhesion and invasion in vitro. However, an octapeptide designated P-5m (K487R), in which Lys(487) was changed to Arg, did not inhibit either cell adhesion or invasion, and peptides HGR and HGG also had no inhibitory effect. Recombinant GST-D5(H) expressed in Escherichia coli had a stronger inhibitory effect on cell adhesion and invasion in vitro than did GST-D5(H) (K487R) in which Lys(487) was changed to Arg. Furthermore, P-5m (Gly(484) - Lys(491)) peptide clearly suppressed lung metastasis in mice experimentally induced by using B16-F10 cells, but P-5m (G487R) had no effect. These data strongly indicate that both the HGK motif and lysine residue (Lys(487)) play essential roles in inhibition of cell adhesion and invasion in vitro and in prevention of metastasis of cancer cells in vivo. We tried to identify the HGK motif binding protein on the surface of cancer cells. A 95-kDa surface biotin-labeled membrane protein was specifically detached from GST-D5(H) by P- 5 ( His(479)-Lys(493)) peptide but not by P-1 (Gly(402)-Lys(420)) peptide originating from the N-terminal region of D5(H).	Shiga Univ Med Sci, Dept Med Biochem, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Ohkubo, I (corresponding author), Shiga Univ Med Sci, Dept Med Biochem, Otsu, Shiga 5202192, Japan.	ionfox@belle.shiga-med.ac.jp						Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; Berger AC, 2000, MICROVASC RES, V60, P70, DOI 10.1006/mvre.2000.2249; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BUSHKINHARAV I, 1995, J BIOL CHEM, V270, P13422, DOI 10.1074/jbc.270.22.13422; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2002, J BIOL CHEM, V277, P23157, DOI 10.1074/jbc.M202529200; Chavakis T, 2002, J BIOL CHEM, V277, P32677, DOI 10.1074/jbc.M204010200; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; DeLa Cadena RA, 1998, THROMB HAEMOSTASIS, V79, P186; Feng XD, 2002, J IMMUNOL, V168, P2441, DOI 10.4049/jimmunol.168.5.2441; Guo YL, 2001, ARTERIOSCL THROM VAS, V21, P1427, DOI 10.1161/hq0901.095277; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JOHNSON MD, 1993, CANCER RES, V53, P873; Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kamiyama F, 2001, BIOCHEM BIOPH RES CO, V288, P975, DOI 10.1006/bbrc.2001.5864; Lambert PA, 1997, SURGERY, V122, P372, DOI 10.1016/S0039-6060(97)90029-5; Li YH, 2000, BIOCHEM BIOPH RES CO, V276, P553, DOI 10.1006/bbrc.2000.3519; Lin VCL, 2001, CLIN CANCER RES, V7, P2880; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; Nakazawa Y, 2002, INT IMMUNOPHARMACOL, V2, P1875, DOI 10.1016/S1567-5769(02)00182-0; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Ogikubo O, 1998, BIOCHEM BIOPH RES CO, V252, P257, DOI 10.1006/bbrc.1998.9614; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; Parrott MB, 2001, BIOCHEM BIOPH RES CO, V281, P993, DOI 10.1006/bbrc.2001.4437; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Shurety W, 2001, LAB INVEST, V81, P107, DOI 10.1038/labinvest.3780216; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Vasse M, 2001, BRIT J CANCER, V84, P802, DOI 10.1054/bjoc.2000.1648; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; Yamada KM, 1989, FIBRONECTIN, P47; Yang XH, 2001, CANCER RES, V61, P5284; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zhang JC, 2000, FASEB J, V14, P2589, DOI 10.1096/fj.99-1025com; Zhang JC, 2002, P NATL ACAD SCI USA, V99, P12224, DOI 10.1073/pnas.192668299	54	31	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49301	49307		10.1074/jbc.M308790200	http://dx.doi.org/10.1074/jbc.M308790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506238	hybrid			2022-12-25	WOS:000186829000097
J	Klein, CDP; Schiffmann, R; Folkers, G; Piana, S; Rothlisberger, U				Klein, CDP; Schiffmann, R; Folkers, G; Piana, S; Rothlisberger, U			Protonation states of methionine aminopeptidase and their relevance for inhibitor binding and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; INHOMOGENEOUS ELECTRON-GAS; DENSITY-FUNCTIONAL THEORY; ESCHERICHIA-COLI; CORRELATION-ENERGY; FUMAGILLIN; ANGIOGENESIS; APPROXIMATION; MECHANISM; PROTEINS	We have performed a computational study of different protomeric states of the methionine aminopeptidase active site using a combined quantum-mechanical/molecular mechanical simulation approach. The aim of this study was to clarify the native protonation state of the enzyme, which is needed for the development of novel irreversible inhibitors that can possibly be used as antiangiogenic and antibiotic drugs by virtual screening and other drug design methods. The results of the simulations indicated that two protonation states are possible without disturbing the overall geometry of the active site. We then verified experimentally the presence of the two protonation states by studying the substrate hydrolysis and inhibitor binding reactions at different pH values and come to the conclusion that one of the protomeric states is relevant for inhibitor binding, whereas the other is relevant for substrate hydrolysis. This result has implications for the development of other inhibitors of this class of enzymes and adds a new perspective to the pharmacological properties of the antiangiogenic drug fumagillin, which is an irreversible inhibitor of the human methionine aminopeptidase type II.	Univ Saarland, FR Pharmazeut & Med Chem 8 5, D-66041 Saarbrucken, Germany; Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Mol & Biol Chem, CH-1015 Lausanne, Switzerland	Saarland University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Klein, CDP (corresponding author), Univ Saarland, FR Pharmazeut & Med Chem 8 5, D-66041 Saarbrucken, Germany.	cdpk@mx.uni-saarland.de		Folkers, Gerd/0000-0002-3620-705X; Klein, Christian/0000-0003-3522-9182				BARNETT RN, 1993, PHYS REV B, V48, P2081, DOI 10.1103/PhysRevB.48.2081; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; Bertini I., 1994, BIOINORG CHEM, P37; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; Carloni P, 2002, ACCOUNTS CHEM RES, V35, P455, DOI 10.1021/ar010018u; CASE DA, 1999, AMBER6; Colombo MC, 2002, CHIMIA, V56, P13, DOI 10.2533/000942902777680865; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cosper NJ, 2001, BIOCHEMISTRY-US, V40, P13302, DOI 10.1021/bi010837m; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; HUTTER J, 1995, CPMD; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jorgensen AT, 2002, J COMPUT AID MOL DES, V16, P167, DOI 10.1023/A:1020119527789; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Laio A, 2002, J PHYS CHEM B, V106, P7300, DOI 10.1021/jp0143138; Laio A, 2002, J CHEM PHYS, V116, P6941, DOI 10.1063/1.1462041; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; Lowther WT, 1999, BIOCHEMISTRY-US, V38, P7678, DOI 10.1021/bi990684r; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; Reinhardt WP, 2001, ACCOUNTS CHEM RES, V34, P607, DOI 10.1021/ar950181n; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Rovira C, 2001, INORG CHEM, V40, P11, DOI 10.1021/ic000143m; Schurer G, 2002, J PHYS CHEM B, V106, P8815, DOI 10.1021/jp025575s; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Suarez D, 2002, J COMPUT CHEM, V23, P1587, DOI 10.1002/jcc.10157; TROULLIER N, 1991, PHYS REV B, V43, P1993, DOI 10.1103/PhysRevB.43.1993; Walker KW, 1998, PROTEIN SCI, V7, P2684, DOI 10.1002/pro.5560071224; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Yang G, 2001, BIOCHEMISTRY-US, V40, P10645, DOI 10.1021/bi010806r; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427	41	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47862	47867		10.1074/jbc.M305325200	http://dx.doi.org/10.1074/jbc.M305325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14514693	hybrid			2022-12-25	WOS:000186731400063
J	Pedersen, CB; Bross, P; Winter, VS; Corydon, TJ; Bolund, L; Bartlett, K; Vockley, J; Gregersen, N				Pedersen, CB; Bross, P; Winter, VS; Corydon, TJ; Bolund, L; Bartlett, K; Vockley, J; Gregersen, N			Misfolding, degradation, and aggregation of variant proteins - The molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; ETHYLMALONIC ACIDURIA; NEURODEGENERATIVE DISORDERS; CHAPERONES; STABILITY; MUTATIONS; PATIENT; IMPORT; GENE	Short chain acyl-CoA dehydrogenase (SCAD) deficiency is an inborn error of the mitochondrial fatty acid metabolism caused by rare variations as well as common susceptibility variations in the SCAD gene. Earlier studies have shown that a common variant SCAD protein (R147W) was impaired in folding, and preliminary experiments suggested that the variant protein displayed prolonged association with chaperonins and delayed formation of active enzyme. Accordingly, the molecular pathogenesis of SCAD deficiency may rely on intramitochondrial protein quality control mechanisms, including degradation and aggregation of variant SCAD proteins. In this study we investigated the processing of a set of disease-causing variant SCAD proteins (R22W, G68C, W153R, R359C, and Q341H) and two common variant proteins (R147W and G185S) that lead to reduced SCAD activity. All SCAD proteins, including the wild type, associate with mitochondrial hsp60 chaperonins; however, the variant SCAD proteins remained associated with hsp60 for prolonged periods of time. Biogenesis experiments at two temperatures revealed that some of the variant proteins (R22W, G68C, W153R, and R359C) caused severe misfolding, whereas others (R147W, G185S, and Q341H) exhibited a less severe temperature-sensitive folding defect. Based on the magnitude of in vitro defects, these SCAD proteins are characterized as folding-defective variants and mild folding variants, respectively. Pulse-chase experiments demonstrated that the variant SCAD proteins either triggered proteolytic degradation by mitochondrial proteases or, especially at elevated temperature, aggregation of non-native conformers. The latter finding may indicate that accumulation of aggregated SCAD proteins may play a role in the pathogenesis of SCAD deficiency.	Aarhus Univ Hosp, Skejby Sygehus, Res Unit Mol Med, DK-8200 Aarhus, Denmark; Univ Aarhus, Dept Human Genet, DK-8000 Aarhus, Denmark; Univ Newcastle Upon Tyne, Sch Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA	Aarhus University; Aarhus University; Newcastle University - UK; Mayo Clinic	Pedersen, CB (corresponding author), Univ Aarhus, Skejby Sygehus, Res Unit Mol Med, DK-8200 Aarhus N, Denmark.		Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016; Bross, Peter/B-7219-2013	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Bross, Peter/0000-0001-9526-8525; Corydon, Thomas Juhl/0000-0003-3588-6350				AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; Baerlocher KE, 1997, J INHERIT METAB DIS, V20, P427, DOI 10.1023/A:1005319120751; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; BHALA A, 1995, J PEDIATR-US, V126, P910, DOI 10.1016/S0022-3476(95)70207-5; BROSS P, 1995, J BIOL CHEM, V270, P10284, DOI 10.1074/jbc.270.17.10284; BROSS P, 2003, PROTEIN MISFOLDING D, P285; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; COATES PM, 1988, J CLIN INVEST, V81, P171, DOI 10.1172/JCI113290; Corydon MJ, 2001, PEDIATR RES, V49, P18; Corydon MJ, 1996, PEDIATR RES, V39, P1059, DOI 10.1203/00006450-199606000-00021; Corydon TJ, 1998, J BIOL CHEM, V273, P13065, DOI 10.1074/jbc.273.21.13065; DAWSON DB, 1995, J PEDIATR-US, V126, P69, DOI 10.1016/S0022-3476(95)70505-8; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; GREGERSEN N, 1979, PEDIATR RES, V13, P1227, DOI 10.1203/00006450-197911000-00005; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Gregersen N, 2001, J INHERIT METAB DIS, V24, P189, DOI 10.1023/A:1010319001722; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEGRE CS, 1959, J AM CHEM SOC, V84, P6526; Huang THJ, 2000, J BIOL CHEM, V275, P36436, DOI 10.1074/jbc.M005698200; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; Jorgensen MM, 2000, J BIOL CHEM, V275, P33861, DOI 10.1074/jbc.M004663200; Macheroux P, 1997, BIOL CHEM, V378, P1381, DOI 10.1515/bchm.1997.378.11.1381; Martin J, 1997, J BIOENERG BIOMEMBR, V29, P35, DOI 10.1023/A:1022407705182; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Matern D, 2001, J PEDIATR-US, V138, P585, DOI 10.1067/mpd.2001.111814; McCormack EA, 2001, J STRUCT BIOL, V135, P185, DOI 10.1006/jsbi.2001.4389; Milewski MI, 2002, J BIOL CHEM, V277, P34462, DOI 10.1074/jbc.M205420200; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; NAITO E, 1989, J CLIN INVEST, V84, P1671, DOI 10.1172/JCI114346; Nguyen TV, 2002, BIOCHEMISTRY-US, V41, P11126, DOI 10.1021/bi026030r; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Ribes A, 1998, EUR J PEDIATR, V157, P317, DOI 10.1007/s004310050819; Ritco-Vonsovici M, 2000, J MOL BIOL, V304, P81, DOI 10.1006/jmbi.2000.4177; Ryan MT, 1997, INT REV CYTOL, V174, P127, DOI 10.1016/S0074-7696(08)62117-8; SAIJO T, 1994, J BIOL CHEM, V269, P4401; Seidel J, 2003, J INHERIT METAB DIS, V26, P37, DOI 10.1023/A:1024019311933; SEWELL AC, 1993, EUR J PEDIATR, V152, P922, DOI 10.1007/BF01957531; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; Shinder GA, 2001, J BIOL CHEM, V276, P12791, DOI 10.1074/jbc.M010759200; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Tein I, 1999, NEUROLOGY, V52, P366, DOI 10.1212/WNL.52.2.366; WOOD PA, 1989, PEDIATR RES, V25, P38, DOI 10.1203/00006450-198901000-00010; YOKOTA I, 1992, J BIOL CHEM, V267, P26004; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	47	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47449	47458		10.1074/jbc.M309514200	http://dx.doi.org/10.1074/jbc.M309514200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506246	hybrid			2022-12-25	WOS:000186731400015
J	Senay, C; Ferrari, P; Rocher, C; Rieger, KJ; Winter, J; Platel, D; Bourne, Y				Senay, C; Ferrari, P; Rocher, C; Rieger, KJ; Winter, J; Platel, D; Bourne, Y			The Mtr2-Mex67 NTF2-like domain complex - Structural insights into a dual role of Mtr2 for yeast nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; MOLECULAR MECHANISM; BINDING-SITES; FG REPEAT; FXFG; MEX67P; GLFG; NUCLEOPORINS; TRAFFICKING	The formation of the Mtr2-Mex67 heterodimer is essential for yeast mRNA export as it constitutes a key nuclear component for shuttling mRNA between the nuclear and cytoplasm compartments through the nuclear pore complex. We report the crystal structures of apo-Mtr2 from the human pathogen Candida albicans and of its complex with the Mex67 NTF2-like domain. Compared with other members of the NTF2 fold family, Mtr2 displays novel structural features involved in the nuclear export of the large ribosomal subunit and consistent with a dual functional role of Mtr2 during yeast nuclear export events. The structure of the Mtr2-Mex67 NTF2-like domain complex, which overall is similar to those of the human and Saccharomyces cerevisiae homologs, unveils three putative Phe-Gly repeat binding sites, of which one contributes to the heterodimer interface. These structures exemplify an unrecognized adaptability of the NTF2 building block in evolution, identify novel structural determinants associated with key biological functions at the molecular surface of the yeast Mtr2-Mex67 complex, and suggest that the yeast and human mRNA export machineries may differ.	CNRS, UMR 6098, AFMB, F-13402 Marseille 20, France; Aventis Pharma, Infect Dis Grp, F-93235 Romainville, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Sanofi-Aventis; Sanofi France	Bourne, Y (corresponding author), CNRS, UMR 6098, AFMB, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	yves@afmb.cnrs-mrs.fr	Bourne, Yves/AAC-4635-2022	Bourne, Yves/0000-0003-3850-0548				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Bayliss R, 2002, EMBO J, V21, P2843, DOI 10.1093/emboj/cdf305; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; CHRISTOPHER JA, 1998, SPOCK; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Fribourg S, 2003, EMBO REP, V4, P699, DOI 10.1038/sj.embor.embor883; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Herold A, 2000, MOL CELL BIOL, V20, P8996, DOI 10.1128/MCB.20.23.8996-9008.2000; Hieronymus H, 2003, NAT GENET, V33, P155, DOI 10.1038/ng1080; KADOWAKI T, 1994, MOL BIOL CELL, V5, P1253, DOI 10.1091/mbc.5.11.1253; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Lamzin VS, 2000, NAT STRUCT BIOL, V7, P978, DOI 10.1038/80763; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; RIESENBERG D, 1991, J BIOTECHNOL, V20, P17, DOI 10.1016/0168-1656(91)90032-Q; ROUSSEL A, 1989, TURBO FRODO SILICON; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Stewart M, 2000, CELL STRUCT FUNCT, V25, P217, DOI 10.1247/csf.25.217; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X	41	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48395	48403		10.1074/jbc.M308275200	http://dx.doi.org/10.1074/jbc.M308275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504280	hybrid			2022-12-25	WOS:000186731400125
J	Wei, CC; Wang, ZQ; Hemann, C; Hille, R; Stuehr, DJ				Wei, CC; Wang, ZQ; Hemann, C; Hille, R; Stuehr, DJ			A tetrahydrobiopterin radical forms and then becomes reduced during N-omega-hydroxyarginine oxidation by nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-DIOXY REDUCTION; LOW-TEMPERATURE; L-ARGININE; DOMAIN; ACTIVATION; COMPLEX; MECHANISM; PTERIN; OXYGEN	Nitric-oxide synthases are flavoheme enzymes that catalyze two sequential monooxygenase reactions to generate nitric oxide (NO) from L-arginine. We investigated a possible redox role for the enzyme-bound cofactor 6R-tetrahydrobiopterin (H4B) in the second reaction of NO synthesis, which is conversion of N-hydroxy-L-arginine ( NOHA) to NO plus citrulline. We used stopped-flow spectroscopy and rapid-freeze EPR spectroscopy to follow heme and biopterin transformations during single-turnover NOHA oxidation reactions catalyzed by the oxygenase domain of inducible nitric-oxide synthase (iNOSoxy). Significant biopterin radical (> 0.5 per heme) formed during reactions catalyzed by iNOSoxy that contained either H4B or 5-methyl-H4B. Biopterin radical formation was kinetically linked to conversion of a heme-dioxy intermediate to a heme-NO product complex. The biopterin radical then decayed within a 200 300- ms time period just prior to dissociation of NO from a ferric heme-NO product complex. Measures of final biopterin redox status showed that biopterin radical decay occurred via an enzymatic one-electron reduction process that regenerated H4B ( or 5MeH(4)B). These results provide evidence of a dual redox function for biopterin during the NOHA oxidation reaction. The data suggest that H4B first provides an electron to a hemedioxy intermediate, and then the H4B radical receives an electron from a downstream reaction intermediate to regenerate H4B. The first one-electron transition enables formation of the heme-based oxidant that reacts with NOHA, while the second one-electron transition is linked to formation of a ferric heme-NO product complex that can release NO from the enzyme. These redox roles are novel and expand our understanding of biopterin function in biology.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol NB3, Cleveland, OH 44195 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol NB3, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stuehrd@ccf.org		Wei, Chin-Chuan/0000-0001-6453-9409; Hemann, Craig/0000-0002-7380-4072	NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058481] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53914] Funding Source: Medline; NIGMS NIH HHS [GM 58481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Roman LJ, 2002, CHEM REV, V102, P1179, DOI 10.1021/cr000661e; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350	29	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46668	46673		10.1074/jbc.M307682200	http://dx.doi.org/10.1074/jbc.M307682200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14504282	hybrid			2022-12-25	WOS:000186569400056
J	Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C				Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C			Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas	ONCOGENE			English	Article						HOX gene network; HOX C locus; chromosome 12q13; bladder cancer	HUMAN-MELANOMA; MUTANT MICE; EXPRESSION; CANCER; HOMEOBOX; PATTERN; HOXD-11; IDENTIFICATION; AMPLIFICATION; ORGANIZATION	Bladder carcinogenesis remains unclear despite the identification of chemical, environmental and genetic factors. It has recently been reported that the chromosomal region 12q13-q15, containing crucial cancer genes such as MDM2, CDK4 and GLI, is amplified in bladder cancer. In the same region are also located the genes of the locus HOX C, flanked by keratin genes whose protein product may be a prognostic marker of bladder cancer. The HOX genes constitute a network of transcription factors controlling embryonal development and play an important role in crucial adult eukaryotic cell functions. The molecular organization of this 39-gene network is unique in the genome and probably acts by regulating phenotypical cell identity. We have analysed the expression of the whole HOX gene network in pairs of normal tumour bladder and in tumoral biopsies. Comparison between normal urothelium and bladder tumour has identified dramatic variations of expression in a block of three genes (HOX C4, HOX C5 and HOX C6) localized in the HOX C locus on the chromosome 12q13 and in the paralogous group 11 HOX genes, involved during normal development in the formation of the urogenital system. These data suggest a key involvement of the HOX gene network, and especially the locus C, in bladder cancer.	Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, I-80131 Naples, Italy; Univ Naples Federico II, Sch Med, Dept Urol, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Cillo, C (corresponding author), Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.	clecillo@unina.it	Cindolo, Luca/Q-8342-2016	Vincenzo, Altieri/0000-0002-1321-2817; Cantile, Monica/0000-0001-7840-3369				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Adshead JM, 1999, BJU INT, V83, P1039; AKAM M, 1987, DEVELOPMENT, V101, P1; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Cantile M, 2003, EUR J CANCER, V39, P257, DOI 10.1016/S0959-8049(02)00599-3; Cantile M, 2003, J CELL PHYSIOL, V194, P225, DOI 10.1002/jcp.10210; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christoph F, 1999, INT J CANCER, V84, P169, DOI 10.1002/(SICI)1097-0215(19990420)84:2<169::AID-IJC13>3.0.CO;2-F; CILLO C, 1994, INVAS METAST, V14, P38; Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.0.CO;2-6; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; CILLO C, 1995, INT J ONCOL, V7, P1145; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; CILLO C, 1995, P 86 AACR; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DEKKER EJ, 1992, DEVELOPMENT, P195; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; FUJIMOTO K, 1992, CANCER RES, V52, P1393; Gazzaniga P, 2001, CLIN CANCER RES, V7, P4288; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; Hostikka SL, 1998, MECH DEVELOP, V70, P133, DOI 10.1016/S0925-4773(97)00182-2; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MOLL R, 1988, AM J PATHOL, V132, P123; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nocito A, 2001, INT J CANCER, V94, P1, DOI 10.1002/ijc.1385; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reed SI, 1997, CANCER SURV, V29, P7; Sandberg AA, 2002, AM J MED GENET, V115, P173, DOI 10.1002/ajmg.10693; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shinohara N, 2002, UROL RES, V30, P273, DOI 10.1007/s00240-002-0275-0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 2001, CANCER RES, V61, P4514; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; UICC/AJCC, 1997, TNM CLASS MAL TUM; Wada T, 2000, CLIN CANCER RES, V6, P610; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YOON SJ, 1994, GENOMICS, V24, P502, DOI 10.1006/geno.1994.1659	55	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6462	6468		10.1038/sj.onc.1206808	http://dx.doi.org/10.1038/sj.onc.1206808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508527				2022-12-25	WOS:000185535300017
J	Otaegui, PJ; Ferre, T; Riu, E; Bosch, F				Otaegui, PJ; Ferre, T; Riu, E; Bosch, F			Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice	FASEB JOURNAL			English	Article						diabetes mellitus; glucose tolerance; UCP3	DEPENDENT DIABETES-MELLITUS; HUMAN UNCOUPLING PROTEIN-3; GLUCOSE-TRANSPORT; GLYCOGEN-SYNTHASE; HEXOKINASE II; GENE LOCUS; NIDDM; SENSITIVITY; GLUT4; LIVER	In type 2 diabetes, glucose phosphorylation, a regulatory step in glucose utilization by skeletal muscle, is impaired. Since glucokinase expression in skeletal muscle of transgenic mice increases glucose phosphorylation, we examined whether such mice conteract the obesity and insulin resistance induced by 12 wk of a high-fad diet. When fed this diet, control mice became obese, whereas transgenic mice remained lean. Further more, high-fat fed control mice developed hyperglycemia and hyperinsulinemia (a 3-fold increase) indicating that they were insulin resistant. In contrast, transgenic mice were normoglycemic and showed only a mild increase in insulinemia (1.5-fold). They also showed improved whole body glucose tolerance and insulin sensitivity and increased intramuscular concentrations of glucose 6-phosphate and glycogen. A parallel increase in uncoupling protein 3 mRNA levels in skeletal muscle of glucokinase-expressing transgenic mice was also observed. These results suggest that the rise in glucose phosphorylation by glucokinase expression in skeletal muscle leads to increased glucose utilization and energy expenditure that counteracts weight gain and maintains insulin sensitivity.	Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, E-08193 Bellaterra, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain.	fatima.bosch@uab.es		BOSCH, FATIMA/0000-0002-7705-5515; Riu, Efren/0000-0002-2574-3578; Ferre, Tura/0000-0001-9713-0829				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; DELPRATO S, 1993, J CLIN INVEST, V91, P484, DOI 10.1172/JCI116226; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; Gutmann I, 1974, METHOD ENZYMAT AN, P1464; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Jimenez-Chillaron JC, 1999, FASEB J, V13, P2153, DOI 10.1096/fasebj.13.15.2153; JIMENEZCHILLARO.JC, 2000, METABOLISM, V51, P121; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; Kim JK, 2001, J CLIN INVEST, V108, P153, DOI 10.1172/JCI10294; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; Mathews ST, 2002, DIABETES, V51, P2450, DOI 10.2337/diabetes.51.8.2450; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; Morral N, 2002, HUM GENE THER, V13, P1561, DOI 10.1089/10430340260201653; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; ORahilly S, 1997, NAT MED, V3, P1080, DOI 10.1038/nm1097-1080; Otabe S, 1999, DIABETES, V48, P206; Otaegui PJ, 2000, HUM GENE THER, V11, P1543, DOI 10.1089/10430340050083270; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; PICKUP JC, 1994, CHRONIC COMPLICATION; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Seoane J, 1999, J BIOL CHEM, V274, P31833, DOI 10.1074/jbc.274.45.31833; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; Shulman RG, 1996, DIABETES, V45, pS93, DOI 10.2337/diab.45.1.S93; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YKIJARVINEN H, 1990, DIABETES, V39, P157, DOI 10.2337/diabetes.39.2.157; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a; Zimmet PZ, 1997, LANCET, V350, pSI1	51	8	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2097	+		10.1096/fj.03-0081fje	http://dx.doi.org/10.1096/fj.03-0081fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500548				2022-12-25	WOS:000185925100002
J	Serero, A; Giglione, C; Sardini, A; Martinez-Sanz, J; Meinnel, T				Serero, A; Giglione, C; Sardini, A; Martinez-Sanz, J; Meinnel, T			An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; NEW-GENERATION; ACTINONIN; AMINOPEPTIDASE; INHIBITORS; REQUIRES; UNIVERSALITY; RESISTANCE; PROTEINS; STRAINS	Dedicated machinery for N-terminal methionine excision (NME) was recently identified in plant organelles and shown to be essential in plastids. We report here the existence of mitochondrial NME in mammals, as shown by the identification of cDNAs encoding specific peptide deformylases (PDFs) and new methionine aminopeptidases (MAP1D). We cloned the two full-length human cDNAs and showed that the N-terminal domains of the encoded enzymes were specifically involved in targeting to mitochondria. In contrast to mitochondrial MAP1D, the human PDF sequence differed from that of known PDFs in several key features. We characterized the human PDF fully in vivo and in vitro. Comparison of the processed human enzyme with the plant mitochondrial PDF1A, to which it is phylogenetically related, showed that the human enzyme had an extra N-terminal domain involved in both mitochondrial targeting and enzyme stability. Mammalian PDFs also display non-random substitutions in the conserved motifs important for activity. Human PDF site-directed mutagenesis variants were studied and compared with the corresponding plant PDF1A variants. We found that amino acid substitutions in human PDF specifically altered its catalytic site, resulting in an enzyme intermediate between bacterial PDF1Bs and plant PDF1As. Because (i) human PDF was found to be active both in vitro and in vivo, (ii) the entire machinery is conserved and expressed in most animals, (iii) the mitochondrial genome expresses substrates for these enzymes, and (iv) mRNA synthesis is regulated, we conclude that animal mitochondria have a functional NME machinery that can be regulated.	CNRS, UPR 2355, Inst Sci Vegetal, Prot Maturat Grp, F-91198 Gif Sur Yvette, France; Imperial Coll Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Meinnel, T (corresponding author), CNRS, UPR 2355, Inst Sci Vegetal, Prot Maturat Grp, Batiment 23,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.	meinnel@isv.cnrs-gif.fr	Meinnel, Thierry/B-9813-2016	Meinnel, Thierry/0000-0001-5642-8637; Giglione, Carmela/0000-0002-7475-1558				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boisson B, 2003, J BIOL CHEM, V278, P43418, DOI 10.1074/jbc.M307321200; Bracchi-Ricard V, 2001, ARCH BIOCHEM BIOPHYS, V396, P162, DOI 10.1006/abbi.2001.2631; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Brown JR, 2003, NAT REV GENET, V4, P121, DOI 10.1038/nrg1000; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; Clements JM, 2001, ANTIMICROB AGENTS CH, V45, P563, DOI 10.1128/AAC.45.2.563-570.2001; DARDEL F, 1994, COMPUT APPL BIOSCI, V10, P273; Dardel F, 1998, J MOL BIOL, V280, P501, DOI 10.1006/jmbi.1998.1882; Davies SJ, 2003, BIOORG MED CHEM LETT, V13, P2715, DOI 10.1016/S0960-894X(03)00533-X; Giglione C, 2003, EMBO J, V22, P13, DOI 10.1093/emboj/cdg007; Giglione C, 2001, TRENDS PLANT SCI, V6, P566, DOI 10.1016/S1360-1385(01)02151-3; Giglione C, 2001, Expert Opin Ther Targets, V5, P41, DOI 10.1517/14728222.5.1.41; Giglione C, 2000, MOL MICROBIOL, V36, P1197, DOI 10.1046/j.1365-2958.2000.01908.x; Giglione C, 2000, EMBO J, V19, P5916, DOI 10.1093/emboj/19.21.5916; Groche D, 1998, BIOCHEM BIOPH RES CO, V246, P342, DOI 10.1006/bbrc.1998.8616; Grujic M, 2002, CANCER LETT, V182, P113, DOI 10.1016/S0304-3835(02)00086-1; Guilloteau JP, 2002, J MOL BIOL, V320, P951, DOI 10.1016/S0022-2836(02)00549-1; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Keeling PJ, 1996, TRENDS BIOCHEM SCI, V21, P285; KOZAK M, 1983, MICROBIOL REV, V47, P1; Kumar A, 2002, STRUCTURE, V10, P357, DOI 10.1016/S0969-2126(02)00719-0; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Lazennec C, 1997, ANAL BIOCHEM, V244, P180, DOI 10.1006/abio.1996.9910; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Margolis P, 2001, ANTIMICROB AGENTS CH, V45, P2432, DOI 10.1128/AAC.45.9.2432-2435.2001; MAZEL D, 1994, EMBO J, V13, P914, DOI 10.1002/j.1460-2075.1994.tb06335.x; MEINNEL T, 1995, J BACTERIOL, V177, P1883, DOI 10.1128/jb.177.7.1883-1887.1995; MEINNEL T, 1995, J MOL BIOL, V254, P175, DOI 10.1006/jmbi.1995.0609; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; Meinnel T, 1996, FEBS LETT, V385, P91, DOI 10.1016/0014-5793(96)00357-2; Meinnel T, 1999, BIOCHEMISTRY-US, V38, P4287, DOI 10.1021/bi982622r; Meinnel T, 1997, J MOL BIOL, V267, P749, DOI 10.1006/jmbi.1997.0904; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; Meinnel T, 2000, PARASITOL TODAY, V16, P165, DOI 10.1016/S0169-4758(99)01627-0; Miesel L, 2003, NAT REV GENET, V4, P442, DOI 10.1038/nrg1086; Nguyen KT, 2003, BIOCHEMISTRY-US, V42, P9952, DOI 10.1021/bi0346446; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Ragusa S, 1999, J MOL BIOL, V289, P1445, DOI 10.1006/jmbi.1999.2832; Ragusa S, 1998, J MOL BIOL, V280, P515, DOI 10.1006/jmbi.1998.1883; Rajagopalan PTR, 2000, BIOCHEMISTRY-US, V39, P779, DOI 10.1021/bi9919899; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Serero A, 2001, J MOL BIOL, V314, P695, DOI 10.1006/jmbi.2001.5175; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SINGER M, 1989, MICROBIOL REV, V53, P1; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Vetro JA, 2002, J CELL BIOCHEM, V85, P678, DOI 10.1002/jcb.10161; Waller AS, 2002, CURR OPIN DRUG DI DE, V5, P785; Wiesner J, 2001, TRENDS PARASITOL, V17, P7, DOI 10.1016/S1471-4922(00)01735-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xu Y, 1998, CLIN CANCER RES, V4, P171; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Yuan ZY, 2001, DRUG DISCOV TODAY, V6, P954, DOI 10.1016/S1359-6446(01)01925-0	61	109	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52953	52963		10.1074/jbc.M309770200	http://dx.doi.org/10.1074/jbc.M309770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532271	hybrid			2022-12-25	WOS:000187480700118
J	Nagafuku, M; Kabayama, K; Oka, D; Kato, A; Tani-ichi, S; Shimada, Y; Ohno-Iwashita, Y; Yamasaki, S; Saito, T; Iwabuchi, K; Hamaoka, T; Inokuchi, J; Kosugi, A				Nagafuku, M; Kabayama, K; Oka, D; Kato, A; Tani-ichi, S; Shimada, Y; Ohno-Iwashita, Y; Yamasaki, S; Saito, T; Iwabuchi, K; Hamaoka, T; Inokuchi, J; Kosugi, A			Reduction of glycosphingolipid levels in lipid rafts affects the expression state and function of glycosylphosphatidylinositol-anchored proteins but does not impair signal transduction via the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE RAFTS; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; PHOSPHOLIPASE-C; CHOLESTEROL; MICRODOMAINS; ACCUMULATION; ACTIVATION	Lipid rafts are highly enriched in cholesterol and sphingolipids. In contrast to many reports that verify the importance of cholesterol among raft lipid components, studies that address the role of sphingolipids in raft organization and function are scarce. Here, we investigate the role of glycosphingolipids (GSLs) in raft structure and raft-mediated signal transduction in T lymphocytes by the usage of a specific GSL synthesis inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino1- propanol (D-PDMP). Surface GM1 expression and the expression of GSLs in rafts were profoundly reduced by D-PDMP treatment, whereas the expression of other lipid and protein constituents, such as cholesterol, sphingomyelin, Lck, and linker for activation of T cells, was not affected. T cell receptor-mediated signal transduction induced by antigen stimulation or by antibody cross-linking was normal in D-PDMP-treated T cells. In contrast, the signal through glycosylphosphatidylinositol (GPI)-anchored proteins was clearly augmented by D-PDMP treatment. Moreover, GPI-anchored proteins became more susceptible to phosphatidylinositol-specific phospholipase C cleavage in D-PDMP-treated cells, demonstrating that GSL depletion from rafts primarily influences the expression state and function of GPI-anchored proteins. Finally, by comparing the effect of D-PDMP with that of methyl-beta-cyclodextrin, we identified that compared with cholesterol depletion, GSL depletion has the opposite effect on the phosphatidylinositol-specific phospholipase C sensitivity and signaling ability of GPI-anchored proteins. These results indicate a specific role of GSLs in T cell membrane rafts that is dispensable for T cell receptor signaling but is important for the signal via GPI-anchored proteins.	Osaka Univ, Dept Immunobiol Med Technol & Sci, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Dept Oncol, Grad Sch Med, Osaka 5650871, Japan; Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Tokyo Metropolitan Inst Gerontol, Biomembrane Res Grp, Tokyo 1730015, Japan; Chiba Univ, Dept Mol Genet, Grad Sch Med, Chiba 2608670, Japan; Hokkaido Univ, Div Immunobiol, Inst Med Genet, Sapporo, Hokkaido 0600815, Japan; Japan Sci & Technol Corp, Core Res, Evolut Sci & Technol Program, CREST, Saitama 3320012, Japan	Osaka University; Osaka University; Hokkaido University; Tokyo Metropolitan Institute of Gerontology; Chiba University; Hokkaido University; Japan Science & Technology Agency (JST)	Kosugi, A (corresponding author), Osaka Univ, Dept Immunobiol Med Technol & Sci, Grad Sch Med, 1-7 Yamada Oka, Osaka 5650871, Japan.		Kabayama, Kazuya/ABD-5748-2020; Inokuchi, Jin-ichi/AAW-9964-2020; Saito, Takashi/C-9684-2009	Kabayama, Kazuya/0000-0002-7583-5454; Inokuchi, Jin-ichi/0000-0002-0703-5746; Saito, Takashi/0000-0001-9495-3547; Tani-ichi, Shizue/0000-0003-2388-776X				Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Burack WR, 2002, J IMMUNOL, V169, P2837, DOI 10.4049/jimmunol.169.6.2837; Crespo PM, 2002, J BIOL CHEM, V277, P44731, DOI 10.1074/jbc.M204604200; DE MR, 1997, SCIENCE, V277, P1652; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Fukasawa M, 2000, J BIOL CHEM, V275, P34028, DOI 10.1074/jbc.M005151200; HANADA K, 1993, J BIOL CHEM, V268, P13820; HANSBURG D, 1983, J IMMUNOL, V131, P319; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Horejsi V, 2002, TRENDS IMMUNOL, V23, P562, DOI 10.1016/S1471-4906(02)02330-X; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Inokuchi J, 2000, GLYCOCONJUGATE J, V17, P239, DOI 10.1023/A:1026549525628; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; Kosugi A, 2001, IMMUNITY, V14, P669, DOI 10.1016/S1074-7613(01)00146-7; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lehto MT, 2002, BIOCHEMISTRY-US, V41, P1398, DOI 10.1021/bi011579w; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVIS GM, 1976, BIOCHEM J, V156, P103, DOI 10.1042/bj1560103; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOROI Y, 1991, JPN J CANCER RES, V82, P909, DOI 10.1111/j.1349-7006.1991.tb01920.x; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Simons M, 1999, MOL BIOL CELL, V10, P3187, DOI 10.1091/mbc.10.10.3187; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Tanimura N, 2003, J CELL BIOL, V160, P125, DOI 10.1083/jcb.200207096; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamasaki S, 2001, J BIOL CHEM, V276, P45175, DOI 10.1074/jbc.M105384200; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	45	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51920	51927		10.1074/jbc.M307674200	http://dx.doi.org/10.1074/jbc.M307674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506277	hybrid			2022-12-25	WOS:000187206300128
J	Qin, WP; Ho, L; Pompl, PN; Peng, YZ; Zhao, Z; Xiang, ZM; Robakis, NK; Shioi, J; Suh, J; Pasinetti, GM				Qin, WP; Ho, L; Pompl, PN; Peng, YZ; Zhao, Z; Xiang, ZM; Robakis, NK; Shioi, J; Suh, J; Pasinetti, GM			Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MOUSE MODEL; CELL-CYCLE ACTIVITY; ALZHEIMERS-DISEASE; HIPPOCAMPAL-FORMATION; CONTROLLED-TRIAL; CDNA CLONING; EXPRESSION; PROGRESSION; PLACEBO; NSAIDS	In previous studies we found that overexpression of the inducible form of cyclooxygenase, COX- 2, in the brain exacerbated beta- amyloid ( Abeta) neuropathology in a transgenic mouse model of Alzheimer's disease. To explore the mechanism through which COX may influence A beta amyloidosis, we used an adenoviral gene transfer system to study the effects of human ( h) COX- 1 and hCOX- 2 isoform expression on Abeta peptide generation. We found that expression of hCOXs in human amyloid precursor protein ( APP)- overexpressing ( Chinese hamster ovary ( CHO)- APP(swe)) cells or human neuroglioma ( H4- APP(751)) cells resulting in 10 - 25 nM prostaglandin ( PG)- E-2 concentration in the conditioned medium coincided with an similar to 1.8- fold elevation of Abeta- ( 1 - 40) and Abeta- ( 1 - 42) peptide generation and an similar to 1.8- fold induction of the C- terminal fragment ( CTF)-gamma cleavage product of the APP, an index of gamma- secretase activity. Treatment of APP-overexpressing cells with the non- selective COX inhibitor ibuprofen ( 1 muM, 48 h) or with the specific gamma-secretase inhibitor L- 685,458 significantly attenuated hCOX- 1-and hCOX- 2- mediated induction of A beta peptide generation and CTF-gamma cleavage product formation. Based on this evidence, we next tested the hypothesis that COX expression might promote A beta peptide generation via a PG-E-2-mediated mechanism. We found that exposure of CHO-APP(swe) or human embryonic kidney ( HEK- APP(swe)) cells to PG-E-2 ( 11- deoxy- PG-E-2) at a concentration ( 10 nM) within the range of PG- E-2 found in hCOX- expressing cells similarly promoted (similar to 1.8- fold) the generation of the CTF-gamma cleavage product of APP and commensurate Abeta- ( 1 - 40) and Abeta- ( 1 - 42) peptide elevation. The study suggests that expression of COXs may influence A beta peptide generation through mechanisms that involve PG-E-2-mediated potentiation of gamma- secretase activity, further supporting a role for COX- 2 and COX- 1 in Alzheimer's disease neuropathology.	Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu	Robakis, Nikolaos/AAA-1838-2021	Pasinetti, Giulio/0000-0002-1524-5196	NATIONAL INSTITUTE ON AGING [R01AG013799] Funding Source: NIH RePORTER; NIA NIH HHS [AG13799] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; Andreasson KI, 2001, J NEUROSCI, V21, P8198; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Bazan NG, 2002, PROSTAG OTH LIPID M, V68-9, P197, DOI 10.1016/S0090-6980(02)00031-X; Bazan NG, 2001, NAT MED, V7, P414, DOI 10.1038/86477; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Crider JY, 2000, PROSTAG LEUKOTR ESS, V62, P21, DOI 10.1054/plef.1999.0120; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; Ho L, 1999, J NEUROSCI RES, V57, P295; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; IWAMOTO N, 1989, J NEUROL, V236, P80, DOI 10.1007/BF00314401; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Launer LJ, 2003, DRUGS, V63, P731, DOI 10.2165/00003495-200363080-00001; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; Martin BK, 2002, CONTROL CLIN TRIALS, V23, P93, DOI 10.1016/S0197-2456(01)00189-1; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McLendon C, 2000, FASEB J, V14, P2383; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Montine TJ, 1999, NEUROLOGY, V53, P1495, DOI 10.1212/WNL.53.7.1495; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oka A, 1997, NEUROREPORT, V8, P1161, DOI 10.1097/00001756-199703240-00020; Pasinetti GM, 2002, LANCET NEUROL, V1, P403, DOI 10.1016/S1474-4422(02)00214-4; Pasinetti GM, 1998, J NEUROSCI RES, V54, P1; Pasinetti GM, 2001, ARCH GERONTOL GERIAT, V33, P13, DOI 10.1016/S0167-4943(01)00091-7; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Pompl PN, 2003, FASEB J, V17, P725, DOI 10.1096/fj.02-0876fje; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Tsuboi K, 2002, PROSTAG OTH LIPID M, V68-9, P535, DOI 10.1016/S0090-6980(02)00054-0; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Xiang ZM, 2002, NEUROBIOL AGING, V23, P327, DOI 10.1016/S0197-4580(01)00282-2; Yan Q, 2003, J NEUROSCI, V23, P7504; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; Yokota O, 2003, NEUROSCI LETT, V343, P175, DOI 10.1016/S0304-3940(03)00339-2; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	49	91	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50970	50977		10.1074/jbc.M307699200	http://dx.doi.org/10.1074/jbc.M307699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14507922	hybrid			2022-12-25	WOS:000187206300019
J	Casarosa, P; Gruijthuijsen, YK; Michel, D; Beisser, PS; Holl, J; Fitzsimons, CP; Verzijl, D; Bruggeman, CA; Mertens, T; Leurs, R; Vink, C; Smit, MJ				Casarosa, P; Gruijthuijsen, YK; Michel, D; Beisser, PS; Holl, J; Fitzsimons, CP; Verzijl, D; Bruggeman, CA; Mertens, T; Leurs, R; Vink, C; Smit, MJ			Constitutive signaling of the human cytomegalovirus-encoded receptor UL33 differs from that of its rat cytomegalovirus homolog R33 by promiscuous activation of G proteins of the G(q), G(i), and G(s) classes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; IMMEDIATE-EARLY GENE; COUPLED RECEPTOR; CHEMOKINE RECEPTOR; MURINE CYTOMEGALOVIRUS; KAPOSIS-SARCOMA; IMMUNE-SYSTEM; US28; EXPRESSION; IDENTIFICATION	The human cytomegalovirus (HCMV) UL33 gene is conserved among all beta-herpesviruses and encodes a protein that shows sequence similarity with chemokine receptors belonging to the family of G protein-coupled receptors. Here, we show that HCMV UL33 is predominantly transcribed as a spliced mRNA of which the 5' terminus is localized 55 bp upstream of the start codon. Like its homolog from rat cytomegalovirus (RCMV), R33, UL33 activates multiple signaling pathways in a ligand-independent manner. Although both receptors constitutively activate phospholipase C via G(q/11), and partially via G(i/o)-mediated pathways, they exhibit profound differences in the modulation of cAMP-responsive element (CRE) activation. R33 constitutively inhibits, whereas UL33 constitutively enhances CRE-mediated transcription. For R33, the inhibition of CRE-driven transcription is entirely G(i/o)-mediated. For UL33, however, CRE-mediated transcription is modulated not only through coupling to Galpha(i/o) but also through coupling to Galpha(s). In addition, UL33 was found to enhance CRE activation through the Rho/p38 pathway, via Gbetagamma. Interestingly, by studying chimeric UL33/R33 proteins, we found the C-terminal cytoplasmic tail of UL33, but not that of R33, to be responsible for the activation of G(i/o) proteins. A UL33-deficient variant of HCMV was generated to analyze UL33-signaling properties in a physiologically relevant model system. Data obtained with infected cells show that HCMV induces CRE activation, and this effect is, at least in part, dependent on UL33 expression. Taken together, our data indicate that constitutive signaling of UL33 differs from that of R33 by promiscuous activation of G proteins of the G(q), G(i/o), as well as G(s) class. Thus, HCMV may effectively use UL33 to orchestrate multiple signaling networks within infected cells.	Free Univ Amsterdam, Fac Chem, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands; Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands; Univ Ulm, Inst Microbiol, Dept Virol, D-89081 Ulm, Germany	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Maastricht University; Ulm University	Smit, MJ (corresponding author), Free Univ Amsterdam, Fac Chem, Div Med Chem, Leiden Amsterdam Ctr Drug Res, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.		Mertens, Thomas M/E-9826-2013; Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021	Leurs, Rob/0000-0003-1354-2848; Fitzsimons, Carlos P./0000-0002-1556-2650; Smit, Martine/0000-0003-2713-0238; Verzijl, Dennis/0000-0002-7716-9838				ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; Alewijnse AE, 1997, FEBS LETT, V419, P171, DOI 10.1016/S0014-5793(97)01440-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Atalay R, 2002, J VIROL, V76, P8596, DOI 10.1128/JVI.76.17.8596-8608.2002; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 2001, J VIROL, V75, P5949, DOI 10.1128/JVI.75.13.5949-5957.2001; Beisser PS, 1999, J VIROL, V73, P7218, DOI 10.1128/JVI.73.9.7218-7230.1999; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; Diviani D, 1996, J BIOL CHEM, V271, P5049; Fraile-Ramos A, 2002, TRAFFIC, V3, P218, DOI 10.1034/j.1600-0854.2002.030307.x; Goossens VJ, 2000, TRANSPLANT P, V32, P155, DOI 10.1016/S0041-1345(99)00917-3; Gruijthuijsen YK, 2002, J VIROL, V76, P1328, DOI 10.1128/JVI.76.3.1328-1338.2002; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; LEE SB, 1993, J BIOL CHEM, V268, P25952; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; Minisini R, 2003, J VIROL, V77, P4489, DOI 10.1128/JVI.77.8.4489-4501.2003; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; Nasman J, 2001, BIOCHEM PHARMACOL, V62, P913, DOI 10.1016/S0006-2952(01)00730-4; Oliveira SA, 2001, P NATL ACAD SCI USA, V98, P3237, DOI 10.1073/pnas.051629898; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rigoutsos I, 2003, J VIROL, V77, P4326, DOI 10.1128/JVI.77.7.4326-4344.2003; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sun B, 2001, J CELL BIOCHEM, V83, P563, DOI 10.1002/jcb.1251; SWEET C, 1990, TOPLEY WILSONS PRINC, V4, P105; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Vink C, 2001, J CLIN VIROL, V23, P43, DOI 10.1016/S1386-6532(01)00184-6; Wagner M, 2000, J VIROL, V74, P10729, DOI 10.1128/JVI.74.22.10729-10736.2000; Wagner M, 2002, TRENDS MICROBIOL, V10, P318, DOI 10.1016/S0966-842X(02)02394-6; WAGNER M, 2004, METHODS MOL BIOL, V23; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Yamauchi J, 2001, J BIOL CHEM, V276, P23362, DOI 10.1074/jbc.M011752200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	52	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50010	50023		10.1074/jbc.M306530200	http://dx.doi.org/10.1074/jbc.M306530200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522997	hybrid, Green Published			2022-12-25	WOS:000187068200044
J	Munoz, P; Navarro, MD; Pavon, EJ; Salmeron, J; Malavasi, F; Sancho, J; Zubiaur, M				Munoz, P; Navarro, MD; Pavon, EJ; Salmeron, J; Malavasi, F; Sancho, J; Zubiaur, M			CD38 signaling in T cells is initiated within a subset of membrane rafts containing Lck and the CD3-zeta subunit of the T cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; GPI-ANCHORED PROTEINS; CYCLIC ADP-RIBOSE; LIPID RAFTS; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 3-KINASE; H-RAS; ZETA-PHOSPHORYLATION; SURFACE ANTIGENS; ERK ACTIVATION	In this study we present data supporting that most CD38 is pre-assembled in a subset of Brij 98-resistant raft vesicles, which were stable at 37degreesC, and have relatively high levels of Lck and the CD3-zeta subunit of T cell antigen receptor-CD3 complex in contrast with a Brij 98-soluble pool, where CD38 is associated with CD3-zeta, and Lck is not detected. Our data further indicate that following CD38 engagement, LAT and Lck are tyrosine-phosphorylated exclusively in Brij 98-resistant rafts, and some key signaling components translocate into rafts (i.e. Sos and p85-phosphatidylinositol 3-kinase). Moreover, N-Ras results activated within rafts immediately upon CD38 ligation, whereas activated Erk was mainly found in soluble fractions with delayed kinetics respective to Ras activation. Furthermore, full phosphorylation of CD3-zeta and CD3-epsilon only occurs in rafts, whereas partial CD3-zeta tyrosine phosphorylation occurs exclusively in the soluble pool, which correlated with increased levels of c-Cbl tyrosine phosphorylation in the non-raft fractions. Taken together, these results suggest that, unlike the non-raft pool, CD38 in rafts is able to initiate and propagate several activating signaling pathways, possibly by facilitating critical associations within other raft subsets, for example, LAT rafts via its capacity to interact with Lck and CD3-zeta. Overall, these findings provide the first evidence that CD38 operates in two functionally distinct microdomains of the plasma membrane.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Hosp Univ San Cecilio, Granada 18012, Spain; Univ Turin, Sch Med, Immunogenet Lab, I-10126 Turin, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital Universitario San Cecilio; University of Turin	Zubiaur, M (corresponding author), CSIC, Inst Parasitol & Biomed, Ventanilla 11, Granada 18001, Spain.	mzubiaur@ipb.csic.es	Zubiaur, Mercedes/K-9390-2014; Sancho, Jaime/O-3228-2013; Munoz, Pilar/N-2277-2016; Sancho, Jaime/K-5989-2019; Zubiaur, Mercedes/AAC-5792-2021	Zubiaur, Mercedes/0000-0002-4127-3027; Sancho, Jaime/0000-0003-3852-7951; Munoz, Pilar/0000-0002-7985-9859; Sancho, Jaime/0000-0003-3852-7951; Zubiaur, Mercedes/0000-0002-4127-3027; MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)		Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buhl AM, 1997, IMMUNOL REV, V160, P127, DOI 10.1111/j.1600-065X.1997.tb01033.x; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Cheng PC, 2001, J IMMUNOL, V166, P3693, DOI 10.4049/jimmunol.166.6.3693; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Cho YS, 2000, J BIOL CHEM, V275, P1685, DOI 10.1074/jbc.275.3.1685; Deaglio S, 1996, J IMMUNOL, V156, P727; Deaglio S, 2000, CHEM IMMUNOL, V75, P99; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; EXLEY M, 1994, J BIOL CHEM, V269, P15140; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Franco L, 1998, FASEB J, V12, P1507; FUNARO A, 1993, EUR J IMMUNOL, V23, P2407, DOI 10.1002/eji.1830231005; Funaro A, 2000, CHEM IMMUNOL, V75, P256; Guirado M, 2002, BIOCHEM BIOPH RES CO, V291, P574, DOI 10.1006/bbrc.2002.6492; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hartgroves LC, 2003, J BIOL CHEM, V278, P20389, DOI 10.1074/jbc.M301212200; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Ilangumaran S, 1998, BLOOD, V91, P3901; Iyer SB, 1998, CYTOMETRY, V33, P206, DOI 10.1002/(SICI)1097-0320(19981001)33:2<206::AID-CYTO15>3.0.CO;2-Y; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jose ES, 1998, EUR J IMMUNOL, V28, P12; Kabouridis PS, 2003, BIOCHEM J, V371, P907, DOI 10.1042/BJ20021578; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MAKOVER D, 1991, ONCOGENE, V6, P455; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Millan J, 1999, TISSUE ANTIGENS, V53, P33, DOI 10.1034/j.1399-0039.1999.530104.x; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Morra M, 1998, FASEB J, V12, P581, DOI 10.1096/fasebj.12.7.581; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pitcher LA, 2003, IMMUNOL REV, V191, P47, DOI 10.1034/j.1600-065X.2003.00003.x; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; PONCELET P, 1985, J IMMUNOL METHODS, V85, P65, DOI 10.1016/0022-1759(85)90274-1; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Salojin KV, 2000, J BIOL CHEM, V275, P5966, DOI 10.1074/jbc.275.8.5966; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; Schade AE, 2002, J IMMUNOL, V168, P2233, DOI 10.4049/jimmunol.168.5.2233; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sun L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0705com; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; van Oers NSC, 2000, NAT IMMUNOL, V1, P322, DOI 10.1038/79774; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WANGE RL, 2000, SCIENCE STKE; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zubiaur M, 1999, J BIOL CHEM, V274, P20633, DOI 10.1074/jbc.274.29.20633; Zubiaur M, 1997, J IMMUNOL, V159, P193; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	84	64	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50791	50802		10.1074/jbc.M308034200	http://dx.doi.org/10.1074/jbc.M308034200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523017	hybrid			2022-12-25	WOS:000187068200135
J	Shin, DJ; Campos, JA; Gil, G; Osborne, TF				Shin, DJ; Campos, JA; Gil, G; Osborne, TF			PGC-1 alpha activates CYP7A1 and bile acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE; RECEPTOR-ALPHA; TRANSCRIPTIONAL COACTIVATOR; NUCLEAR RECEPTORS; RAT HEPATOCYTES; GLUCONEOGENESIS; GALLSTONES; ENZYMES; PGC-1; FXR	Cholesterol 7-alpha-hydroxylase (CYP7A1) is the key enzyme that commits cholesterol to the neutral bile acid biosynthesis pathway and is highly regulated. In the current studies, we have uncovered a role for the transcriptional co-activator PGC-1alpha in CYP7A1 gene transcription. PGC-1alpha plays a vital role in adaptive thermogenesis in brown adipose tissue and stimulates genes important to mitochondrial function and oxidative metabolism. It is also involved in the activation of hepatic gluconeogenesic gene expression during fasting. Because the mRNA for CYP7A1 was also induced in mouse liver by fasting, we reasoned that PGC-1alpha might be an important co-activator for CYP7A1. Here we show that PGC-1alpha and CYP7A1 are also co-induced in livers of mice in response to streptozotocin induced diabetes. Additionally, infection of cultured HepG2 cells with a recombinant adenovirus expressing PGC-1alpha directly activates CYP7A1 gene expression and increases bile acid biosynthesis as well. Furthermore, we show that PGC-1alpha activates the CYP7A1 promoter directly in transient transfection assays in cultured cells. Thus, PGC-1alpha is a key activator of CYP7A1 and bile acid biosynthesis and is likely responsible for the fasting and diabetes dependent induction of CYP7A1. PGC-1alpha has already been shown to be a critical activator of several other oxidative processes including adaptive thermogenesis and fatty acid oxidation. Our studies provide further evidence of the fundamental role played by PGC-1alpha in oxidative metabolism and define PGC-1alpha as a link between diabetes and bile acid metabolism.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA	University of California System; University of California Irvine; Virginia Commonwealth University	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Campos-Sandoval, José/I-7375-2018	Campos-Sandoval, José/0000-0002-2457-9884	NHLBI NIH HHS [HL48044] Funding Source: Medline; NIAAA NIH HHS [R01 AA026322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; DeSantis A, 1997, HEPATOLOGY, V25, P787, DOI 10.1002/hep.510250401; DUMASWALA R, 1994, AM J PHYSIOL-GASTR L, V267, pG836, DOI 10.1152/ajpgi.1994.267.5.G836; FOLCH J, 1957, J BIOL CHEM, V226, P497; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, MOL ENDOCRINOL, V17, P386, DOI 10.1210/me.2002-0246; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mathews C.K., 2000, BIOCHEMISTRY; Pacchioni M, 2000, DIGEST DIS SCI, V45, P2002, DOI 10.1023/A:1005544009372; Pandak WM, 2002, J BIOL CHEM, V277, P48158, DOI 10.1074/jbc.M205244200; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Stroup D, 2000, J LIPID RES, V41, P1; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; UCHIDA K, 1979, JPN J PHARMACOL, V29, P553, DOI 10.1254/jjp.29.553; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	22	87	95	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50047	50052		10.1074/jbc.M309736200	http://dx.doi.org/10.1074/jbc.M309736200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522988	hybrid			2022-12-25	WOS:000187068200048
J	Bitto, E; McKay, DB				Bitto, E; McKay, DB			The periplasmic molecular chaperone protein SurA binds a peptide motif that is characteristic of integral outer membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; PORINS; PARVULIN; GENE	The Escherichia coli SurA protein is a periplasmic molecular chaperone that facilitates correct folding of outer membrane porins. The peptide binding specificity of SurA has been characterized using phage display of heptameric peptides of random sequence. The consensus binding pattern of aromatic-polar-aromatic-nonpolarproline amino acids emerges for both SurA and a SurA "core domain," which remains after deletion of a peripheral peptidyl-proline isomerase domain. Isothermal titration calorimetry with a high affinity heptameric peptide of sequence WEYIPNV yields peptide affinities in the range of 1 - 14 muM for both SurA and its core domain. Although the peptide consensus aromatic-polar-aromatic- nonpolar-proline occurs infrequently in E. coli proteins, the less restrictive tripeptide motif aromatic-random- aromatic appears with greater-than-random frequency in outer membrane proteins and is prevalent in the " aromatic bands" of the porin beta barrel structures. Thus, SurA recognizes a peptide motif that is characteristic of integral outer membrane proteins.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	McKay, DB (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; TORMO A, 1990, J BACTERIOL, V172, P4339, DOI 10.1128/jb.172.8.4339-4347.1990; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Webb HM, 2001, J BIOL CHEM, V276, P45622, DOI 10.1074/jbc.M107508200	17	100	102	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49316	49322		10.1074/jbc.M308853200	http://dx.doi.org/10.1074/jbc.M308853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506253	hybrid			2022-12-25	WOS:000186829000099
J	Salazar, MA; Kwiatkowski, AV; Pellegrini, L; Cestra, G; Butler, MH; Rossman, KL; Serna, DM; Sondek, J; Gertler, FB; De Camilli, P				Salazar, MA; Kwiatkowski, AV; Pellegrini, L; Cestra, G; Butler, MH; Rossman, KL; Serna, DM; Sondek, J; Gertler, FB; De Camilli, P			Tuba, a novel protein containing Bin/amphiphysin/Rvs and Dbl homology domains, links dynamin to regulation of the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; N-WASP; ARP2/3 COMPLEX; ENA/VASP PROTEINS; RHO GTPASES; AMPHIPHYSIN; BINDING; REORGANIZATION; MECHANISM; MEMBRANE	Tuba is a novel scaffold protein that functions to bring together dynamin with actin regulatory proteins. It is concentrated at synapses in brain and binds dynamin selectively through four N-terminal Src homology-3 (SH3) domains. Tuba binds a variety of actin regulatory proteins, including N-WASP, CR16, WAVE1, WIRE, PIR121, NAP1, and Ena/VASP proteins, via a C-terminal SH3 domain. Direct binding partners include N-WASP and Ena/VASP proteins. Forced targeting of the C-terminal SH3 domain to the mitochondrial surface can promote accumulation of F-actin around mitochondria. A Dbl homology domain present in the middle of Tuba upstream of a Bin/amphiphysin/Rvs ( BAR) domain activates Cdc42, but not Rac and Rho, and may thus cooperate with the C terminus of the protein in regulating actin assembly. The BAR domain, a lipid-binding module, may functionally replace the pleckstrin homology domain that typically follows a Dbl homology domain. The properties of Tuba provide new evidence for a close functional link between dynamin, Rho GTPase signaling, and the actin cytoskeleton.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06519 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06519 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC 27599 USA	Yale University; Howard Hughes Medical Institute; Yale University; Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 295 Congress Ave,BCMM 236, New Haven, CT 06519 USA.	pietro.decamilli@yale.edu	cestra, gianluca/AAL-4736-2021	Sondek, John/0000-0002-1127-8310	Fondazione Telethon Funding Source: Custom; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058801, R01GM062299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036251, R37NS036251] Funding Source: NIH RePORTER; NCI NIH HHS [CA46128] Funding Source: Medline; NIGMS NIH HHS [GM62299, GM58801] Funding Source: Medline; NINDS NIH HHS [NS36251] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aspenstrom P, 2002, EXP CELL RES, V279, P21, DOI 10.1006/excr.2002.5576; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; ISHIKAWA R, 1994, J BIOL CHEM, V269, P29928; Kato M, 2002, BIOCHEM BIOPH RES CO, V291, P41, DOI 10.1006/bbrc.2002.6406; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lombardi R, 2001, J BIOL CHEM, V276, P6016, DOI 10.1074/jbc.M008735200; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; MASUR SK, 1990, J NEUROGENET, V6, P191, DOI 10.3109/01677069009107110; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Modregger J, 2000, J CELL SCI, V113, P4511; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soto MC, 2002, GENE DEV, V16, P620, DOI 10.1101/gad.955702; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tsuboi D, 2002, BIOCHEM BIOPH RES CO, V292, P697, DOI 10.1006/bbrc.2002.6717; Vignjevic D, 2003, J CELL BIOL, V160, P951, DOI 10.1083/jcb.200208059; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Zamanian JL, 2003, MOL BIOL CELL, V14, P1624, DOI 10.1091/mbc.E02-08-0494	72	127	136	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49031	49043		10.1074/jbc.M308104200	http://dx.doi.org/10.1074/jbc.M308104200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506234	hybrid, Green Published			2022-12-25	WOS:000186829000065
J	Ferguson, G; Mothe-Satney, I; Lawrence, JC				Ferguson, G; Mothe-Satney, I; Lawrence, JC			Ser-64 and Ser-111 in PHAS-I are dispensable for insulin-stimulated dissociation from eIF4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4E-BINDING PROTEIN-1; CAP-DEPENDENT TRANSLATION; SIGNALING PATHWAY; MAMMALIAN TARGET; (S/T)P SITES; FAT-CELLS; PHOSPHORYLATION; KINASE; RAPAMYCIN; REGULATOR	Insulin stimulates phosphorylation of multiple sites in the eIF4E-binding protein, PHAS-I, leading to dissociation of the PHAS-I.eIF4E complex and to an increase in cap-dependent translation. The Ser-64 and Ser-111 sites have been proposed to have key roles in controlling the association of PHAS-I and eIF4E. To determine whether the effects of insulin require these sites, we assessed the control of PHAS-I proteins having Ala-64 or Ala-111 mutations. The results indicate that phosphorylation of neither site is required for insulin to promote release of PHAS-I from eIF4E. Also, the mutation of Ser-111, which has been proposed to serve as a necessary priming site for the phosphorylation of other sites in PHAS- I, did not affect the phosphorylation of Thr-36/45, Ser-64, or Thr-69. Insulin promoted the release of eIF4E from PHAS-II, a PHAS isoform that lacks the Ser-111 site, but it was without effect on the amount of eIF4E bound to the third isoform, PHAS-III. The results demonstrate that contrary to widely accepted models, Ser-64 and Ser-111 are not required for the control of PHAS- I binding to eIF4E in cells, implicating phosphorylation of the Thr sites in dissociation of the PHAS- I . eIF4E complex. The findings also indicate that PHAS-II, but not PHAS-III, contributes to the control of protein synthesis by insulin.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu	MOTHE-SATNEY, ISABELLE/Q-6377-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385	NIDDK NIH HHS [DK52753, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM RT, 2003, GENE DEV, V15, P2177; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Denning G, 2001, J BIOL CHEM, V276, P22709, DOI 10.1074/jbc.C100144200; DIGGLE TA, 1991, BIOCHEM J, V279, P545, DOI 10.1042/bj2790545; Fadden P, 1998, FEBS LETT, V435, P105, DOI 10.1016/S0014-5793(98)01047-3; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; Karim MM, 2001, J BIOL CHEM, V276, P20750, DOI 10.1074/jbc.M011068200; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence J C Jr, 2001, Prog Mol Subcell Biol, V26, P1; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	34	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47459	47465		10.1074/jbc.M307949200	http://dx.doi.org/10.1074/jbc.M307949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14507920	hybrid			2022-12-25	WOS:000186731400016
J	Seeliger, S; Derian, CK; Vergnolle, N; Bunnett, NW; Nawroth, R; Schmelz, M; von der Weid, PY; Buddenkotte, J; Sunderkotter, C; Metze, D; Andrade-Gordon, P; Harms, E; Vestweber, D; Luger, TA; Steinhoff, M				Seeliger, S; Derian, CK; Vergnolle, N; Bunnett, NW; Nawroth, R; Schmelz, M; von der Weid, PY; Buddenkotte, J; Sunderkotter, C; Metze, D; Andrade-Gordon, P; Harms, E; Vestweber, D; Luger, TA; Steinhoff, M			Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo	FASEB JOURNAL			English	Article						proteinase-activated receptors; G-protein-coupled receptors; immune response; knockout mouse; skin	MAST-CELL TRYPTASE; TUMOR-NECROSIS-FACTOR; P-SELECTIN; HUMAN-SKIN; NITRIC-OXIDE; SUBSTANCE-P; RECEPTOR-2-ACTIVATING PEPTIDES; VASCULAR-PERMEABILITY; CONTACT SENSITIVITY; ENDOTHELIAL-CELLS	Proteinase-activated receptor-2 belongs to a new subfamily of G-protein-coupled receptors. Its precise role during inflammation and the underlying mechanisms is still unclear. Our study establishes that PAR-2 plays a direct proinflammatory role during cutaneous inflammation in mice and humans in vivo. In a model of experimentally induced allergic (ACD) and toxic (ICD) contact dermatitis (CD) we show that ear swelling responses, plasma extravasation, and leucocyte adherence were significantly attenuated in PAR-2 null mutant (PAR-2(-/-)) mice compared with wild-type (PAR-2(+/+)) mice, especially at early stages. The proinflammatory effects by PAR-2 activation were significantly diminished using nitric oxide-synthase inhibitors, while NF-kappaB and neuropeptides appear to play a minor role in these mechanisms. PAR-2-mediated upregulation of E-selectin and cell adhesion molecule ICAM-1; enhanced plasma extravasation was observed in humans and mice and of interleukin-6 in mice in vivo. Thus, PAR-2 may be a beneficial therapeutic target for the treatment of inflammatory skin diseases.	Univ Munster, Dept Dermatol, D-48129 Munster, Germany; Univ Munster, Dept Pediat, D-48129 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48129 Munster, Germany; Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA USA; Univ Calgary, Dept Pharmacol, Calgary, AB T2N 1N4, Canada; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA; Univ Munster, ZMBE, Dept Cell Biol, D-4400 Munster, Germany; Univ Erlangen Nurnberg, Dept Physiol, Erlangen, Germany; Univ Calgary, Dept Physiol, Calgary, AB T2N 1N4, Canada	University of Munster; University of Munster; University of Munster; Johnson & Johnson; Johnson & Johnson USA; University of Calgary; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster; University of Erlangen Nuremberg; University of Calgary	Steinhoff, M (corresponding author), Univ Munster, Dept Dermatol, von Esmarch Str 58, D-48129 Munster, Germany.	msteinho@uni-muenster.de	Schmelz, Martin/A-9327-2013; Vergnolle, Nathalie/C-7677-2018; Steinhoff, Martin/F-6312-2013	Schmelz, Martin/0000-0002-9736-7241; Vergnolle, Nathalie/0000-0003-1825-6015; Vestweber, Dietmar/0000-0002-3517-732X; Sunderkotter, Cord/0000-0002-2929-145X; Bunnett, Nigel W./0000-0003-3367-0644; Steinhoff, Martin/0000-0002-7090-2187	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R56DK043207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43207] Funding Source: Medline; PHS HHS [57840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; BAATZ H, 1995, INT J MICROCIRC, V15, P85, DOI 10.1159/000178955; Benitez-Bribiesca L, 2001, J HISTOCHEM CYTOCHEM, V49, P1061, DOI 10.1177/002215540104900816; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; BOGGEMEYER E, 1994, CELL ADHES COMMUN, V2, P145, DOI 10.3109/15419069409004433; Brain SD, 2000, NAT MED, V6, P134, DOI 10.1038/72218; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Cairns JA, 1996, J IMMUNOL, V156, P275; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2002, CAN J PHYSIOL PHARM, V80, P987, DOI 10.1139/Y02-125; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152; DERY O, 1998, AM J PHYSIOL, V274, pG1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; ENK AH, 1995, J INVEST DERMATOL, V105, pS80, DOI 10.1111/1523-1747.ep12316112; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; FRAKI JE, 1977, ACTA DERM-VENEREOL, V57, P393; Grabbe S, 1996, J IMMUNOL, V156, P473; Hamilton JR, 2001, J CARDIOVASC PHARM, V38, P108, DOI 10.1097/00005344-200107000-00012; Harari OA, 1999, J IMMUNOL, V163, P6860; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Hickey MJ, 1999, J IMMUNOL, V162, P1137; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Howells GL, 1997, J CELL SCI, V110, P881; Kanke T, 2001, J BIOL CHEM, V276, P31657, DOI 10.1074/jbc.M100377200; Kawabata A, 2002, LIFE SCI, V71, P2435, DOI 10.1016/S0024-3205(02)02044-1; Kawabata A, 2002, NEUROSCI LETT, V329, P349, DOI 10.1016/S0304-3940(02)00702-4; Kawabata A, 2001, J CLIN INVEST, V107, P1443, DOI 10.1172/JCI10806; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kawagoe J, 2002, JPN J PHARMACOL, V88, P77, DOI 10.1254/jjp.88.77; Klimuk SK, 2000, J PHARMACOL EXP THER, V292, P480; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631; KRUEGER GG, 1989, J INVEST DERMATOL, V92, pS32; Langer F, 1999, BRIT J HAEMATOL, V105, P542; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Liden C, 2001, CONTACT DERMATITIS, V44, P65, DOI 10.1034/j.1600-0536.2001.440201.x; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Michel JB, 1996, J CARDIOVASC PHARM, V28, P142, DOI 10.1097/00005344-199607000-00021; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; Quinlan KL, 1998, AM J PHYSIOL-CELL PH, V275, pC1580, DOI 10.1152/ajpcell.1998.275.6.C1580; Ribatti D, 2000, INT J CANCER, V85, P171, DOI 10.1002/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Sahin S, 2001, ARCH DERMATOL RES, V293, P214, DOI 10.1007/s004030100207; Saifeddine M, 1998, BRIT J PHARMACOL, V125, P1445, DOI 10.1038/sj.bjp.0702213; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Scholzen TE, 2001, J IMMUNOL, V166, P1285, DOI 10.4049/jimmunol.166.2.1285; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vila L, 2001, ALLERGY, V56, P568, DOI 10.1034/j.1398-9995.2001.056006568.x; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; von Stebut E, 2000, EUR J IMMUNOL, V30, P3498, DOI 10.1002/1521-4141(2000012)30:12&lt;3498::AID-IMMU3498&gt;3.0.CO;2-6; Wallengren J, 2001, ARCH DERMATOL RES, V293, P121, DOI 10.1007/s004030000198; Weidner C, 2000, J INVEST DERMATOL, V115, P1015, DOI 10.1046/j.1523-1747.2000.00142.x	82	105	117	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1871	1885		10.1096/fj.02-1112com	http://dx.doi.org/10.1096/fj.02-1112com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519665				2022-12-25	WOS:000186343300040
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH			The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; Alzheimer's disease	CLOSED-HEAD INJURY; MAO-B INHIBITOR; ENDOGENOUS NEUROTOXIN; BETA-PROTEIN; ALZHEIMERS-DISEASE; CHOLINESTERASE; APOPTOSIS; N-METHYL(R)SALSOLINOL; RIVASTIGMINE; PEPTIDE	Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 muM) significantly protected rat PC12 cells against beta-amyloid (Abeta(1-42)) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPa. was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 muM), suggesting that the effect is mediated via alpha-secretase activity. Rasagiline-induced sAPPa. release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 muM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 muM) and GF109203X (2.5 muM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPalpha-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPa. and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Pharmacol, NPF Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Akao Y, 1999, NEUROSCI LETT, V267, P153, DOI 10.1016/S0304-3940(99)00361-4; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Finberg J P, 1999, Adv Neurol, V80, P495; Grant SM, 1999, NEUROREPORT, V10, P41, DOI 10.1097/00001756-199901180-00008; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; KIEBURTZ K, 2001, PARK RELAT DISORD S, V60; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; Maruyama W, 2001, J NEURAL TRANSM, V108, P11, DOI 10.1007/s007020170093; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moreira PI, 2002, J NEUROSCI RES, V69, P257, DOI 10.1002/jnr.10282; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2003, IN PRESS BIOCH PHARM	44	107	122	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2325	+		10.1096/fj.03-0078fje	http://dx.doi.org/10.1096/fj.03-0078fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525944				2022-12-25	WOS:000186343300004
J	Sartipy, P; Loskutoff, DJ				Sartipy, P; Loskutoff, DJ			Expression profiling identifies genes that continue to respond to insulin in adipocytes made insulin-resistant by treatment with tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; OBESITY; OLIGONUCLEOTIDE; TRANSCRIPTION; RECEPTORS; DIFFERENTIATION; TRANSPORTERS; PATHOGENESIS; PROMOTER; REVEALS	We have employed microarray technology using RNA from normal 3T3-L1 adipocytes and from 3T3-L1 adipocytes made insulin-resistant by treatment with tumor necrosis factor-alpha to identify a new class of insulin-responsive genes. These genes continued to respond normally to insulin even though the adipocytes themselves were metabolically insulin-resistant, i.e. they displayed a significantly decreased rate of insulin-stimulated glucose uptake. Approximately 12,000 genes/expressed sequence tags (ESTs) were screened. Of these, 40 genes/ESTs were identified that became insulin-resistant as expected (e.g. Socs-3, junB, and matrix metalloproteinase-11). However, 61 genes/ESTs continued to respond normally to insulin. Although some of these genes were previously shown to be regulated by insulin (e.g. Glut-1 and beta(3)-adrenergic receptor), other novel insulin-sensitive genes were also identified (e.g. Egr-1, epiregulin, Fra-1, and ABCA1). Real-time reverse transcription-PCR analysis confirmed the expression patterns of several of the differentially expressed genes. One gene that remained insulin-sensitive in the insulin-resistant adipocytes is the transcription factor Egr-1. Using an antisense strategy, we show that tissue factor and macrophage colony-stimulating factor, two cardiovascular risk factors, are downstream EGR-1 target genes in the adipocyte. Taken together, these data support the hypothesis that some signaling pathways remain insulin-sensitive in metabolically insulin-resistant adipocytes. These pathways may promote abnormal gene expression in hyperinsulinemic states like obesity and type II diabetes and thus may contribute to pathologies associated with these conditions.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, 10550 N Torrey Pines Rd,VB-3, La Jolla, CA 92037 USA.	loskutof@scripps.edu			NHLBI NIH HHS [HL59459] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5; Albrektsen T, 2001, MOL PHARMACOL, V59, P567, DOI 10.1124/mol.59.3.567; ALIHAUD G, 2000, INT J OBES RELAT S2, V24, pS1; BECKNIELSEN H, 1992, DIABETES CARE, V15, P418, DOI 10.2337/diacare.15.3.418; Bjorntorp P, 1999, DIABETES-METAB RES, V15, P427; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Collins S, 1999, INT J OBESITY, V23, P669, DOI 10.1038/sj.ijo.0800894; Comuzzie AG, 1998, SCIENCE, V280, P1374, DOI 10.1126/science.280.5368.1374; Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Ferrannini E, 1999, EUR J CLIN INVEST, V29, P842; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; HAFFNER SM, 1988, NEW ENGL J MED, V319, P1297, DOI 10.1056/NEJM198811173192001; HAJDUCH E, 1995, ENDOCRINOLOGY, V136, P4782, DOI 10.1210/en.136.11.4782; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; Hida K, 2000, J LIPID RES, V41, P1615; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Juhan-Vague I, 2000, ANN MED, V32, P78; KIM SJ, 1994, J BIOL CHEM, V269, P11887; Levine JA, 1998, J CLIN INVEST, V101, P1557, DOI 10.1172/JCI2293; Li JY, 2002, J BIOL CHEM, V277, P9069, DOI 10.1074/jbc.M110467200; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mackman N, 1997, THROMB HAEMOSTASIS, V78, P747; MAMOUNAS M, 1991, P NATL ACAD SCI USA, V88, P3530, DOI 10.1073/pnas.88.9.3530; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Pratley RE, 2001, DIABETOLOGIA, V44, P929, DOI 10.1007/s001250100580; Rauch U, 2001, ANN INTERN MED, V134, P224, DOI 10.7326/0003-4819-134-3-200102060-00014; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Samad F, 1998, P NATL ACAD SCI USA, V95, P7591, DOI 10.1073/pnas.95.13.7591; Samad F, 2000, MOL MED, V6, P680, DOI 10.1007/BF03402048; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; Sartipy P, 1998, ARTERIOSCL THROM VAS, V18, P1934, DOI 10.1161/01.ATV.18.12.1934; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Stern MP, 2000, J CLIN INVEST, V106, P323, DOI 10.1172/JCI10725; Wurmbach E, 2001, J BIOL CHEM, V276, P47195, DOI 10.1074/jbc.M108716200; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zapala MA, 2002, GENOME BIOL, V3; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	53	57	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52298	52306		10.1074/jbc.M306922200	http://dx.doi.org/10.1074/jbc.M306922200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530283	hybrid			2022-12-25	WOS:000187480700039
J	Andag, U; Schmitt, HD				Andag, U; Schmitt, HD			Dsl1p, an essential component of the Golgi-endoplasmic reticulum retrieval system in yeast, uses the same sequence motif to interact with different subunits of the COPI vesicle coat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; CLATHRIN-BINDING; IN-VITRO; COMPLEX; ER; TRANSPORT; GAMMA; DOCKING; GENE; YPT1P	Dsl1p is required for Golgi-endoplasmic reticulum ( ER) retrograde transport in yeast. It interacts with the ER resident protein Tip20p and with delta-COP, a subunit of coatomer, the coat complex of COPI vesicles. To test the significance of these interactions, we mapped the different binding sites and created mutant versions of Dsl1p and delta-COP, which are unable to bind directly to each other. Three domains were identified in Dsl1p: a Tip20p binding region within the N-terminal 200 residues, a highly acidic region in the center of Dsl1p containing crucial tryptophan residues that is required for binding to delta-COP and essential for viability, and an evolutionarily well conserved domain at the C terminus. Most importantly, Dsl1p uses the same central acidic domain to interact not only with delta-COP but also with alpha-COP. Strong interaction with alpha-COP requires the presence of comparable amounts of epsilon-COP or beta'-COP. Thus, the binding characteristics of Dsl1p resemble those of many accessory factors of the clathrin coat. They interact with different layers of the vesicle coat by using tandemly arranged sequence motifs, some of which have dual specificity.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Schmitt, HD (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.	hschmit@gwdg.de						Andag U, 2001, J BIOL CHEM, V276, P39150, DOI 10.1074/jbc.M105833200; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Cosson P, 1997, EUR J CELL BIOL, V73, P93; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; Duden R, 1998, EMBO J, V17, P985, DOI 10.1093/emboj/17.4.985; Duncan MC, 2003, NAT CELL BIOL, V5, P77, DOI 10.1038/ncb901; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Eugster A, 2000, EMBO J, V19, P3905, DOI 10.1093/emboj/19.15.3905; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Frigerio G, 1998, YEAST, V14, P633, DOI 10.1002/(SICI)1097-0061(199805)14:7<633::AID-YEA267>3.0.CO;2-3; Haffner C, 2000, CURR BIOL, V10, P471, DOI 10.1016/S0960-9822(00)00446-2; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; James P, 1996, GENETICS, V144, P1425; Lanoix J, 2001, J CELL BIOL, V155, P1199, DOI 10.1083/jcb.200108017; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Lowe M, 1996, J BIOL CHEM, V271, P30725, DOI 10.1074/jbc.271.48.30725; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morsomme P, 2002, DEV CELL, V2, P307, DOI 10.1016/S1534-5807(02)00133-8; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Price A, 2000, J CELL BIOL, V148, P1223, DOI 10.1083/jcb.148.6.1223; Rehling P, 1999, NAT CELL BIOL, V1, P346, DOI 10.1038/14037; Reilly BA, 2001, MOL BIOL CELL, V12, P3783, DOI 10.1091/mbc.12.12.3783; Rein U, 2002, J CELL BIOL, V157, P395, DOI 10.1083/jcb.200112092; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Scheele U, 2003, J BIOL CHEM, V278, P25357, DOI 10.1074/jbc.M303738200; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Schledzewski K, 1999, J MOL EVOL, V48, P770, DOI 10.1007/PL00006521; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SenGupta M, 1997, YEAST, V13, P849, DOI 10.1002/(SICI)1097-0061(199707)13:9<849::AID-YEA106>3.0.CO;2-N; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sherman F., 1981, METHODS YEAST GENETI; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Starr DA, 1998, J CELL BIOL, V142, P763, DOI 10.1083/jcb.142.3.763; Starr DA, 1997, J CELL BIOL, V138, P1289, DOI 10.1083/jcb.138.6.1289; Suvorova ES, 2002, J CELL BIOL, V157, P631, DOI 10.1083/jcb.200111081; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; Takatsu H, 2001, BIOCHEM BIOPH RES CO, V284, P1083, DOI 10.1006/bbrc.2001.5081; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; VanRheenen SM, 2001, TRAFFIC, V2, P212, DOI 10.1034/j.1600-0854.2001.020307.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	76	71	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51722	51734		10.1074/jbc.M308740200	http://dx.doi.org/10.1074/jbc.M308740200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14504276	hybrid, Green Published			2022-12-25	WOS:000187206300107
J	Luciano, RL; Wilson, AC				Luciano, RL; Wilson, AC			HCF-1 functions as a coactivator for the zinc finger protein Krox20	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; HOST-CELL FACTOR; VP16 ACCESSORY PROTEIN; TRANSCRIPTIONAL ACTIVATION; VP16-INDUCED COMPLEX; TERMINAL SUBUNIT; C1 FACTOR; BINDING; FAMILY; DOMAIN	HCF-1 is a transcriptional cofactor required for activation of herpes simplex virus immediate-early genes by VP16 as well as less clearly defined roles in cell proliferation, cytokinesis, and spliceosome formation. It is expressed as a large precursor that undergoes proteolysis to yield two subunits that remain stably associated. VP16 uses a degenerate 4-amino acid sequence, known as the HCF-binding motif, to bind to a six-bladed beta-propeller domain at the N terminus of HCF-1. Functional HCF-binding motifs are also found in LZIP and Zhangfei, two cellular bZIP transcription factors of unknown function. Here we show that the HCF-binding motif occurs in a wide spectrum of DNA-binding proteins and transcriptional cofactors. Three well characterized examples were further analyzed for their ability to use HCF-1 as a coactivator. Krox20, a zinc finger transcription factor required for Schwann cell differentiation, and E2F4, a cell cycle regulator, showed a strong requirement for functional HCF-1 to activate transcription. In contrast, activation by estrogen receptor-alpha did not display HCF dependence. In Krox20, the HCF-binding motif lies within the N-terminal activation domain and mutation of this sequence diminishes both transactivation and association with the HCF-1 beta-propeller. The activation domain in the C-terminal subunit of HCF-1 contributes to activation by Krox20, possibly through recruitment of p300. These results suggest that HCF-1 is recruited by many different classes of cellular transcription factors and is therefore likely to be required for a variety of cellular processes including cell cycle progression and development.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	New York University; New York University	Wilson, AC (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	angus.wilson@med.nyu.edu	Wilson, Angus C/AAA-8153-2019	Wilson, Angus C/0000-0002-5016-4164	NIAID NIH HHS [AI07180-21, T32 AI007180] Funding Source: Medline; NIGMS NIH HHS [GM61139, R01 GM061139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuh P, 2002, EMBO J, V21, P6590, DOI 10.1093/emboj/cdf652; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Chan HM, 2001, J CELL SCI, V114, P2363; Coulthard VH, 2003, J BIOL CHEM, V278, P10942, DOI 10.1074/jbc.M212950200; FRATTINI A, 1994, GENOMICS, V23, P30, DOI 10.1006/geno.1994.1455; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Gattiker A, 2002, PROTEOMICS, V2, P1435, DOI 10.1002/1615-9861(200210)2:10<1435::AID-PROT1435>3.0.CO;2-9; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jessen KR, 2002, J ANAT, V200, P367, DOI 10.1046/j.1469-7580.2002.00046.x; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; LaBoissiere S, 1997, MOL CELL BIOL, V17, P7108, DOI 10.1128/MCB.17.12.7108; Lai JS, 1997, MOL CELL BIOL, V17, P3937, DOI 10.1128/MCB.17.7.3937; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Luciano RL, 2002, P NATL ACAD SCI USA, V99, P13403, DOI 10.1073/pnas.202200399; Mahajan SS, 2002, J BIOL CHEM, V277, P44292, DOI 10.1074/jbc.M205440200; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; OHARE P, 1993, SEMIN VIROL, V4, P145, DOI 10.1006/smvy.1993.1010; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reilly PT, 2002, EXP CELL RES, V277, P119, DOI 10.1006/excr.2002.5551; Reilly PT, 2002, MOL CELL BIOL, V22, P6767, DOI 10.1128/MCB.22.19.6767-6778.2002; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; Scarr RB, 2002, ONCOGENE, V21, P5245, DOI 10.1038/sj.onc.1205647; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Simmen KA, 1997, J VIROL, V71, P3886, DOI 10.1128/JVI.71.5.3886-3894.1997; Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Venken K, 2002, NEUROGENETICS, V4, P37, DOI 10.1007/s10048-001-0124-2; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WU TJ, 1994, MOL CELL BIOL, V14, P3484, DOI 10.1128/MCB.14.5.3484; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420	58	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51116	51124		10.1074/jbc.M303470200	http://dx.doi.org/10.1074/jbc.M303470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532282	hybrid, Green Accepted			2022-12-25	WOS:000187206300036
J	Wu, JM; Xiao, L; Cheng, XK; Cui, LX; Wu, NH; Shen, YF				Wu, JM; Xiao, L; Cheng, XK; Cui, LX; Wu, NH; Shen, YF			PKC epsilon is a unique regulator for hsp90 beta gene in heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; EXPRESSION; INHIBITION; ISOENZYMES; PROMOTER; SEQUENCE; HSP70	An early event in cellular heat shock response is the transmittance of stress signals from the cell surface into the nuclei, resulting in the induction of heat shock proteins (Hsps). Protein kinase C (PKC) has been implicated as a key player in transducing stress signals. However, mechanism(s) by which PKC regulates heat shock-induced events remains largely unknown. Here we present data that pan-PKC inhibitor GF109203X, but not classic PKC inhibitor Go6976, specifically repressed heat shock-induced accumulation of mRNA as well as promoter activity of hsp90beta, but not hsp90alpha, in Jurkat cells. Subcellular fractionation studies revealed that heat shock exclusively induced PKC-epsilon membrane translocation. Consistently, expression of a constitutively active PKC-epsilon(A159E) resulted in an enhanced promoter activity of hsp90beta upon heat shock, whereas a dominant-negative PKC-epsilon(K437R) abolished this effect. In contrast, constitutively active-PKC-alpha or dominant-negative-PKC-alpha had no effects on heat shock induction of the gene. The effect of PKC-epsilon on hsp90beta expression seems to be stimuli-specific, as phorbol myristate acetate-mediated hsp90beta expression was PKC-epsilon-independent. We conclude that PKC-epsilon is specifically required in the signaling pathway leading to the induction of hsp90beta gene in response to heat shock.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union Med Coll, Beijing 100005, Peoples R China; Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Xiao, L (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, 5 Dongdan Santiao, Beijing 100005, Peoples R China.	lxiao@ufl.edu; yfshen@imicams.ac.cn			NCI NIH HHS [R01-CA88815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERE HM, 2001, SCI STKE; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Ding L, 2002, J BIOL CHEM, V277, P35305, DOI 10.1074/jbc.M201460200; Elefant F, 1999, MOL BIOL CELL, V10, P2101, DOI 10.1091/mbc.10.7.2101; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Holmberg CI, 1998, J CELL SCI, V111, P3357; Hostein I, 2001, CANCER RES, V61, P4003; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LANG W, 2003, IN PRESS CELL SIGNAL; LeHoux JG, 2001, J BIOL CHEM, V276, P8021, DOI 10.1074/jbc.M009495200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mo ZC, 2002, PROG NAT SCI, V12, P742; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Nollen EAA, 2002, J CELL SCI, V115, P2809; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; RITZ MF, 1993, RECEPTOR, V3, P311; SAMBROOK J, 2000, MOL CLONING LAB MANU; Shen Y F, 1986, J Cell Physiol Suppl, V4, P35; Shen YF, 1997, FEBS LETT, V413, P92, DOI 10.1016/S0014-5793(97)00883-1; SHEN YF, 1999, ADV MED MOL BIOL, V2, P205; Slepko N, 1999, J NEUROSCI RES, V57, P33, DOI 10.1002/(SICI)1097-4547(19990701)57:1<33::AID-JNR4>3.0.CO;2-6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG YF, 1995, THESIS PEKING UNION; Wang YL, 1996, CHINESE SCI BULL, V41, P1730; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xiao L, 2000, CANCER RES, V60, P400; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zhang SL, 1999, FEBS LETT, V444, P130, DOI 10.1016/S0014-5793(99)00044-7	42	25	27	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51143	51149		10.1074/jbc.M305537200	http://dx.doi.org/10.1074/jbc.M305537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532285	hybrid			2022-12-25	WOS:000187206300039
J	Banci, L; Bertini, I; Ciofi-Baffoni, S; Gonnelli, L; Su, XC				Banci, L; Bertini, I; Ciofi-Baffoni, S; Gonnelli, L; Su, XC			Structural basis for the function of the N-terminal domain of the ATPase CopA from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; TORSION ANGLE DYNAMICS; MENKES-DISEASE; COPPER TRANSPORT; NMR STRUCTURE; COUPLING-CONSTANTS; BINDING DOMAIN; CANDIDATE GENE; N-15 NMR	The solution structure of the N-terminal region (151 amino acids) of a copper ATPase, CopA, from Bacillus subtilis, is reported here. It consists of two domains, CopAa and CopAb, linked by two amino acids. It is found that the two domains, which had already been separately characterized, interact one to the other through a hydrogen bond network and a few hydrophobic interactions, forming a single rigid body. The two metal binding sites are far from one another, and the short link between the domains prevents them from interacting. This and the surface electrostatic potential suggest that each domain receives copper from the copper chaperone, CopZ, independently and transfers it to the membrane binding site of CopA. The affinity constants of silver( I) and copper( I) are similar for the two sites as monitored by NMR. Because the present construct "domain-short link-domain" is shared also by the last two domains of the eukaryotic copper ATPases and several residues at the interface between the two domains are conserved, the conclusions of the present study have general validity for the understanding of the function of copper ATPases.	Univ Florence, CERM, Magnet Resonance Ctr, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy	University of Florence; University of Florence	Bertini, I (corresponding author), Univ Florence, CERM, Magnet Resonance Ctr, Via Luigi Sacconi 6, I-50019 Florence, Italy.	bertini@cerm.unifi.it	Ciofi-Baffoni, Simone/AAH-9778-2021; Su, Xun-Cheng/A-3182-2014	Ciofi Baffoni, Simone/0000-0002-2376-3321; , Xun-Cheng/0000-0003-3051-0047; BANCI, LUCIA/0000-0003-0562-5774				Andrews NC, 2002, CURR OPIN CHEM BIOL, V6, P181, DOI 10.1016/S1367-5931(02)00307-1; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Banci L, 2003, J MOL BIOL, V331, P473, DOI 10.1016/S0022-2836(03)00769-1; Banci L, 2003, BIOCHEMISTRY-US, V42, P1939, DOI 10.1021/bi027096p; Banci L, 2002, J MOL BIOL, V317, P415, DOI 10.1006/jmbi.2002.5430; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Cobine PA, 2000, BIOCHEMISTRY-US, V39, P6857, DOI 10.1021/bi000015+; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Einstein A, 1956, INVESTIGATIONS THEOR; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fatemi N, 2002, J BIOENERG BIOMEMBR, V34, P339, DOI 10.1023/A:1021245902195; Fatemi N, 2002, INORG CHIM ACTA, V339, P179, DOI 10.1016/S0020-1693(02)00949-0; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Gardner KH, 1996, J BIOMOL NMR, V8, P351, DOI 10.1007/BF00410333; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuhlbrandt W, 2002, SCIENCE, V297, P1692, DOI 10.1126/science.1072574; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lutsenko S, 2002, J BIOENERG BIOMEMBR, V34, P351, DOI 10.1023/A:1021297919034; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Maroney MJ, 1999, CURR OPIN CHEM BIOL, V3, P188, DOI 10.1016/S1367-5931(99)80032-5; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Opella SJ, 2002, CURR OPIN CHEM BIOL, V6, P217, DOI 10.1016/S1367-5931(02)00314-9; Pearlman DA, 1997, AMBER 5 0; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Radford DS, 2003, FEMS MICROBIOL LETT, V220, P105, DOI 10.1016/S0378-1097(03)00095-8; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rosen BP, 1999, ESSAYS BIOCHEM, V34, P1; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 2002, J BIOENERG BIOMEMBR, V34, P363, DOI 10.1023/A:1021250003104; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; WIDER G, 1989, J MAGN RESON, V85, P426, DOI 10.1016/0022-2364(89)90157-1; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; WISHART DS, 1994, J BIOMOL NMR, V4, P171	63	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50506	50513		10.1074/jbc.M307389200	http://dx.doi.org/10.1074/jbc.M307389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514665	hybrid			2022-12-25	WOS:000187068200103
J	Zhang, CF; Yan, HG; Burton, ZF				Zhang, CF; Yan, HG; Burton, ZF			Combinatorial control of human RNA polymerase II (RNAP II) pausing and transcript cleavage by transcription factor IIF, hepatitis delta antigen, and stimulatory factor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASCENT TRANSCRIPT; ELONGATION COMPLEX; RAP74 SUBUNIT; FACTORS GREA; VIRUS; INITIATION; IDENTIFICATION; TFIIS; DNA; REPLICATION	When RNA polymerase II (RNAP II) is forced to stall, elongation complexes (ECs) are observed to leave the active pathway and enter a paused state. Initially, ECs equilibrate between active and paused conformations, but with stalls of a long duration, ECs backtrack and become sensitive to transcript cleavage, which is stimulated by the EC rescue factor stimulatory factor II (TFIIS/SII). In this work, the rates for equilibration between the active and pausing pathways were estimated in the absence of an elongation factor, in the presence of hepatitis delta antigen (HDAg), and in the presence of transcription factor IIF (TFIIF), with or without addition of SII. Rates of equilibration between the active and paused states are not very different in the presence or absence of elongation factors HDAg and TFIIF. SII facilitates escape from stalled ECs by stimulating RNAP II backtracking and transcript cleavage and by increasing rates into and out of the paused EC. TFIIF and SII cooperate to merge the pausing and active pathways, a combinatorial effect not observed with HDAg and SII. In the presence of HDAg and SII, pausing is observed without stimulation of transcript cleavage, indicating that the EC can pause without backtracking beyond the pre-translocated state.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	burton@msu.edu			NIGMS NIH HHS [GM57461] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Chang JH, 2002, EMBO J, V21, P157, DOI 10.1093/emboj/21.1.157; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; Dunlap CA, 2002, BIOCHEMISTRY-US, V41, P11226, DOI 10.1021/bi025837g; Elmendorf BJ, 2001, J BIOL CHEM, V276, P23109, DOI 10.1074/jbc.M101445200; Filipovska J, 2000, RNA, V6, P41, DOI 10.1017/S1355838200991167; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; Funk JD, 2002, J BIOL CHEM, V277, P46998, DOI 10.1074/jbc.M206249200; Gnatt A, 2002, BBA-GENE STRUCT EXPR, V1577, P175, DOI 10.1016/S0167-4781(02)00451-7; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GUO HL, 1993, J BIOL CHEM, V268, P18762; Huang ZS, 1998, J BIOL CHEM, V273, P26455, DOI 10.1074/jbc.273.41.26455; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Jeng KS, 1996, J VIROL, V70, P4205, DOI 10.1128/JVI.70.7.4205-4209.1996; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Koulich D, 1998, J MOL BIOL, V276, P379, DOI 10.1006/jmbi.1997.1545; Koulich D, 1997, J BIOL CHEM, V272, P7201, DOI 10.1074/jbc.272.11.7201; Kulish D, 2000, J BIOL CHEM, V275, P12789, DOI 10.1074/jbc.275.17.12789; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; Lei L, 1999, MOL CELL BIOL, V19, P8372; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; Nedialkov YA, 2003, METHOD ENZYMOL, V371, P252; Nedialkov YA, 2003, J BIOL CHEM, V278, P18303, DOI 10.1074/jbc.M301103200; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; Ren DL, 1999, MOL CELL BIOL, V19, P7377; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TAN SY, 1994, J BIOL CHEM, V269, P25684; Taylor JM, 2003, TRENDS MICROBIOL, V11, P185, DOI 10.1016/S0966-842X(03)00045-3; Taylor JM, 1999, CURR TOP MICROBIOL, V239, P107; Ubukata T, 2003, J BIOL CHEM, V278, P8580, DOI 10.1074/jbc.M211384200; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Yamaguchi Y, 2001, SCIENCE, V293, P124, DOI 10.1126/science.1057925; Yamaguchi Y, 2002, MICROBES INFECT, V4, P1169, DOI 10.1016/S1286-4579(02)01641-6; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	55	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50101	50111		10.1074/jbc.M307590200	http://dx.doi.org/10.1074/jbc.M307590200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506279	hybrid			2022-12-25	WOS:000187068200054
J	Burgess, J; Hihi, AK; Benard, CY; Branicky, R; Hekimi, S				Burgess, J; Hihi, AK; Benard, CY; Branicky, R; Hekimi, S			Molecular mechanism of maternal rescue in the clk-1 mutants of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; C-ELEGANS; ESCHERICHIA-COLI; COENZYME-Q; MITOCHONDRIAL; UBIQUINONE; GENE; IDENTIFICATION; BIOSYNTHESIS; LONGEVITY	The clk-1 mutants of Caenorhabditis elegans display an average slowing down of physiological rates, including those of development, various behaviors, and aging. clk-1 encodes a hydroxylase involved in the biosynthesis of the redox-active lipid ubiquinone (co-enzyme Q), and in clk-1 mutants, ubiquinone is replaced by its biosynthetic precursor demethoxyubiquinone. Surprisingly, homozygous clk-1 mutants display a wild-type phenotype when issued from a heterozygous mother. Here, we show that this maternal effect is the result of the persistence of small amounts of maternally derived CLK-1 protein and that maternal CLK-1 is sufficient for the synthesis of considerable amounts of ubiquinone during development. However, gradual depletion of CLK-1 and ubiquinone, and expression of the mutant phenotype, can be produced experimentally by developmental arrest. We also show that the very long lifespan observed in daf-2 clk-1 double mutants is not abolished by the maternal effect. This suggests that, like developmental arrest, the increased lifespan conferred by daf-2 allows for depletion of maternal CLK-1, resulting in the expression of the synergism between clk-1 and daf-2. Thus, increased adult longevity can be uncoupled from the early mutant phenotypes, indicating that it is possible to obtain an increased adult lifespan from the late inactivation of processes required for normal development and reproduction.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.		Benard, Claire/I-7526-2015	Burgess, Jason/0000-0003-2909-3506				Braeckman BP, 2002, MECH AGEING DEV, V123, P1447, DOI 10.1016/S0047-6374(02)00085-4; Braeckman BP, 1999, CURR BIOL, V9, P493, DOI 10.1016/S0960-9822(99)80216-4; Branicky R, 2001, GENETICS, V159, P997; BRENNER S, 1974, GENETICS, V77, P71; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Ernster L., 1993, CLIN INVESTIGATOR, V71, P60; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Finch CE, 1990, LONGEVITY SENESCENCE; FORSMARK P, 1991, FEBS LETT, V285, P39, DOI 10.1016/0014-5793(91)80720-N; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; HEKIMI S, 1995, GENETICS, V141, P1351; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Hihi AK, 2003, J BIOL CHEM, V278, P41013, DOI 10.1074/jbc.M305034200; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Macinga DR, 1998, J BACTERIOL, V180, P128, DOI 10.1128/JB.180.1.128-135.1998; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Pearl R., 1928, RATE LIVING; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Rousseau G, 1998, J CHROMATOGR SCI, V36, P247, DOI 10.1093/chromsci/36.5.247; WONG A, 1995, GENETICS, V139, P1247	33	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49555	49562		10.1074/jbc.M308507200	http://dx.doi.org/10.1074/jbc.M308507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14517217	hybrid			2022-12-25	WOS:000186829000126
J	Devlin, GL; Carver, JA; Bottomley, SP				Devlin, GL; Carver, JA; Bottomley, SP			The selective inhibition of serpin aggregation by the molecular chaperone, alpha-crystallin, indicates a nucleation-dependent specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATES; CENTER LOOP LENGTH; B-CRYSTALLIN; A-CRYSTALLIN; IN-VIVO; ALPHA(1)-ANTITRYPSIN POLYMERIZATION; CONFORMATIONAL-CHANGES; REACTIVE LOOP; PROTEIN; MECHANISM	Small heat shock proteins (sHsps) are a ubiquitous family of molecular chaperones that prevent the misfolding and aggregation of proteins. However, specific details about their substrate specificity and mechanism of chaperone action are lacking. alpha(1)-Antichymotrypsin (ACT) and alpha(1)-antitrypsin (alpha(1)-AT) are two closely related members of the serpin superfamily that aggregate through nucleation-dependent and nucleation-independent pathways, respectively. The sHsp alpha-crystallin was unable to prevent the nucleation-independent aggregation of alpha(1)-AT, whereas alpha-crystallin inhibited ACT aggregation in a dose-dependent manner. This selective inhibition of ACT aggregation coincided with the formation of a stable high molecular weight alpha-crystallin-ACT complex with a stoichiometry of 1 on a molar subunit basis. The kinetics of this interaction occur at the same rate as the loss of ACT monomer, suggesting that the monomeric species is bound by the chaperone. 4,4'-Dianilino-1,1 -binaphthyl-5,5'-disulfonic acid (Bis-ANS) binding and far-UV circular dichroism data suggest that alpha-crystallin interacts specifically with a non-native conformation of ACT. The finding that alpha-crystallin does not interact with alpha(1)-AT under these conditions suggests that alpha-crystallin displays a specificity for proteins that aggregate through a nucleation-dependent pathway, implying that the dynamic nature of both the chaperone and its substrate protein is a crucial factor in the chaperone action of alpha-crystallin and other sHsps.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia	Monash University; University of Wollongong	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.		Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108				Abgar S, 2001, BIOPHYS J, V80, P1986, DOI 10.1016/S0006-3495(01)76168-1; Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; Bottomley SP, 1997, BIOCHEM BIOPH RES CO, V241, P264, DOI 10.1006/bbrc.1997.7805; Bottomley SP, 2000, BBA-PROTEIN STRUCT M, V1481, P11, DOI 10.1016/S0167-4838(00)00118-7; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; Crowther DC, 2003, BIOCHEMISTRY-US, V42, P2355, DOI 10.1021/bi0259305; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Devlin GL, 2002, J MOL BIOL, V324, P859, DOI 10.1016/S0022-2836(02)01088-4; Devlin GL, 2001, AM J RESP CELL MOL, V24, P727, DOI 10.1165/ajrcmb.24.6.4407; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Hatters DM, 2001, J BIOL CHEM, V276, P33755, DOI 10.1074/jbc.M105285200; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; James EL, 1999, J BIOL CHEM, V274, P9482, DOI 10.1074/jbc.274.14.9482; Lindner RA, 1997, J BIOL CHEM, V272, P27722, DOI 10.1074/jbc.272.44.27722; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; Lindner RA, 2001, BIOCHEM J, V354, P79, DOI 10.1042/0264-6021:3540079; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pearce MC, 2000, J BIOL CHEM, V275, P28513, DOI 10.1074/jbc.M004310200; Pike RN, 2002, IUBMB LIFE, V54, P1, DOI 10.1080/15216540213825; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; Rajaraman K, 2001, FEBS LETT, V497, P118, DOI 10.1016/S0014-5793(01)02451-6; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Santhoshkumar P, 2002, BBA-PROTEINS PROTEOM, V1598, P115, DOI 10.1016/S0167-4838(02)00356-4; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; SVEGER T, 1976, NEW ENGL J MED, V294, P1316, DOI 10.1056/NEJM197606102942404; Treweek TM, 2000, BBA-PROTEIN STRUCT M, V1481, P175, DOI 10.1016/S0167-4838(00)00109-6; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang KY, 2001, BIOCHEM BIOPH RES CO, V287, P642, DOI 10.1006/bbrc.2001.5636; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	56	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48644	48650		10.1074/jbc.M308376200	http://dx.doi.org/10.1074/jbc.M308376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500715	hybrid			2022-12-25	WOS:000186829000017
J	Furuhata, A; Ishii, T; Kumazawa, S; Yamada, T; Nakayama, T; Uchida, K				Furuhata, A; Ishii, T; Kumazawa, S; Yamada, T; Nakayama, T; Uchida, K			N-epsilon-(3-methylpyridinium) lysine, a major antigenic adduct generated in acrolein-modified protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LIPID-PEROXIDATION; CATALYZED OXIDATION; MODEL PEPTIDES; BOUND ACROLEIN; ALDEHYDES; PRODUCT; CONSEQUENCES; INCREASE; SMOKE	Acrolein, a representative carcinogenic aldehyde, that could be ubiquitously generated in biological systems under oxidative stress shows facile reactivity with a nucleophile such as a protein. In this study, to gain a better understanding of the molecular basis of acrolein modification of protein, we characterized the acrolein modification of a model peptide ( the oxidized B chain of insulin) by electrospray ionization-liquid chromatography/ mass spectrometry method and established a novel acrolein-lysine condensation reaction. In addition, we found that this condensation adduct represented the major antigenic adduct generated in acrolein-modified protein. To identify the modification site and structures of adducts generated in the acrolein-modified insulin B chain, both the acrolein-pretreated and untreated peptides were digested with V8 protease and the resulting peptides were subjected to electrospray ionization-liquid chromatography/ mass spectrometry. This technique identified nine peptides, which contained the acrolein adducts at Lys-29 and the N terminus, and revealed that the reaction of the insulin B chain with acrolein gave multiple adducts, including an unknown adduct containing two molecules of acrolein per lysine. To identify this adduct, we incubated N-alpha-acetyllysine with acrolein and isolated a product having the same molecular mass as the unknown acrolein-lysine adduct. On the basis of the chemical and spectroscopic evidence, the adduct was determined to be a novel pyridinium-type lysine adduct, N-epsilon-(3-methylpyridinium) lysine (MP-lysine). The formation of MP-lysine was confirmed by amino acid analysis of proteins treated with acrolein. More notably, this condensation adduct appeared to be an intrinsic epitope of a monoclonal antibody 5F6 that had been raised against acrolein-modified protein.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Univ Shizuoka, Sch Food & Nutr Sci, Lab Funct Food Sci, Shizuoka 4228526, Japan	Nagoya University; University of Shizuoka	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		Kumazawa, Shigenori/A-2067-2013	Uchida, Koji/0000-0003-3894-5299				ALAIZ M, 1995, CHEM PHYS LIPIDS, V75, P43, DOI 10.1016/0009-3084(94)02399-P; [Anonymous], 1995, IARC Monogr Eval Carcinog Risks Hum, V63, P337; Baker A, 1998, CHEM RES TOXICOL, V11, P730, DOI 10.1021/tx970167e; Baker AG, 1999, J AM SOC MASS SPECTR, V10, P613, DOI 10.1016/S1044-0305(99)00029-X; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; Carbone V, 1997, J PEPT RES, V49, P586; COHEN SM, 1992, CANCER RES, V52, P3577; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Furuhata A, 2002, J BIOL CHEM, V277, P27919, DOI 10.1074/jbc.M202794200; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; HOBERMAN HD, 1988, J BIOCHEM TOXICOL, V3, P105, DOI 10.1002/jbt.2570030205; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; IZARD C, 1978, Mutation Research, V47, P115, DOI 10.1016/0165-1110(78)90016-7; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nagai R, 2002, J BIOL CHEM, V277, P48905, DOI 10.1074/jbc.M205688200; Noiri E, 2002, FREE RADICAL BIO MED, V33, P1651, DOI 10.1016/S0891-5849(02)01138-3; Sakata K, 2003, BIOCHEM SOC T, V31, P371, DOI 10.1042/BST0310371; Sakata K, 2003, BIOCHEM BIOPH RES CO, V305, P143, DOI 10.1016/S0006-291X(03)00716-2; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tsukahara H, 2003, PEDIATR RES, V54, P419, DOI 10.1203/01.PDR.0000076662.72100.74; Tsukahara H, 2003, LIFE SCI, V72, P2509, DOI 10.1016/S0024-3205(03)00145-0; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X	32	95	98	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48658	48665		10.1074/jbc.M309401200	http://dx.doi.org/10.1074/jbc.M309401200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504272	hybrid			2022-12-25	WOS:000186829000019
J	Kang, SH; Han, JS; Park, JH; Skarstad, K; Hwang, DS				Kang, SH; Han, JS; Park, JH; Skarstad, K; Hwang, DS			SeqA protein stimulates the relaxing and decatenating activities of topoisomerase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION INITIATION; ESCHERICHIA-COLI; NUCLEOID SEGREGATION; CHROMOSOME-REPLICATION; SALMONELLA-TYPHIMURIUM; GATC SEQUENCES; ROLES; GYRASE; SEQUESTRATION; MECHANISM	The SeqA protein, which prevents overinitiation of chromosome replication, has been suggested to also participate in the segregation of chromosomes in Escherichia coli. Using a bacterial two-hybrid system, we found that SeqA interacts with the ParC subunit of topoisomerase IV (topo IV), a type II topoisomerase involved in decatenation of daughter chromosomes and relief of topological constraints generated by replication and transcription. We demonstrated that purified SeqA protein stimulates the activities of topo IV, both in relaxing supercoiled plasmid DNA and converting catenanes to monomers. The same moderate levels of SeqA protein did not affect the activities of DNA gyrase or topoisomerase I. At higher levels of SeqA, topo IV favored the formation of catenanes, caused by intermolecular strand exchange among plasmid DNA aggregates formed by SeqA. Excess SeqA inhibited the activity of all topoisomerases. We also found that stimulation of topo IV was dependent upon the affinity of SeqA for DNA. Our results suggest that this stimulation is mediated by the specific interaction of topo IV with SeqA. Some of the known phenotypes of mutant cells lacking SeqA, such as deficient chromosome segregation and increased negative superhelicity, support that the SeqA protein is required for topo IV-mediated relaxation and decatenation of chromosomes and plasmids, during and after their replication.	Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea; Norwegian Radium Hosp, Inst Canc Res, Dept Cell Biol, N-0310 Oslo, Norway	Seoul National University (SNU); University of Oslo	Hwang, DS (corresponding author), Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea.	dshwang@plaza.snu.ac.kr		Kang, Sukhyun/0000-0002-7567-0231				ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Bach T, 2003, EMBO J, V22, P315, DOI 10.1093/emboj/cdg020; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Boye E, 1996, P NATL ACAD SCI USA, V93, P12206, DOI 10.1073/pnas.93.22.12206; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Crisona NJ, 2000, GENE DEV, V14, P2881, DOI 10.1101/gad.838900; Espeli O, 2003, MOL CELL, V11, P189, DOI 10.1016/S1097-2765(03)00013-3; Fossum S, 2003, MOL MICROBIOL, V47, P619, DOI 10.1046/j.1365-2958.2003.t01-1-03329.x; Guarne A, 2002, NAT STRUCT BIOL, V9, P839, DOI 10.1038/nsb857; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Han JS, 2003, J BIOL CHEM, V278, P34983, DOI 10.1074/jbc.M304923200; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiraga S, 1998, MOL CELL, V1, P381, DOI 10.1016/S1097-2765(00)80038-6; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; Kornberg A., 1992, DNA REPLICATION; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; Lee H, 2001, J BIOL CHEM, V276, P34600, DOI 10.1074/jbc.M101339200; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; LUTTINGER AL, 1991, NEW BIOL, V3, P687; Miller JH., 1992, SHORT COURSE BACTERI, P72; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; Onogi T, 1999, MOL MICROBIOL, V31, P1775, DOI 10.1046/j.1365-2958.1999.01313.x; PENG H, 1993, J BIOL CHEM, V268, P24481; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; Skarstad K, 2000, MOL MICROBIOL, V36, P1319, DOI 10.1046/j.1365-2958.2000.01943.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Sogo JM, 1999, J MOL BIOL, V286, P637, DOI 10.1006/jmbi.1998.2510; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; Torheim NK, 1999, EMBO J, V18, P4882, DOI 10.1093/emboj/18.17.4882; von Freiesleben U, 2000, EMBO J, V19, P6240, DOI 10.1093/emboj/19.22.6240; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitao T, 2000, EMBO REP, V1, P494; Yigit H, 1999, J BACTERIOL, V181, P3185, DOI 10.1128/JB.181.10.3185-3192.1999; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	48	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48779	48785		10.1074/jbc.M308843200	http://dx.doi.org/10.1074/jbc.M308843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512422	hybrid			2022-12-25	WOS:000186829000034
J	Morishima, Y; Kanelakis, KC; Murphy, PJM; Lowe, ER; Jenkins, GJ; Osawa, Y; Sunahara, RK; Pratt, WB				Morishima, Y; Kanelakis, KC; Murphy, PJM; Lowe, ER; Jenkins, GJ; Osawa, Y; Sunahara, RK; Pratt, WB			The Hsp90 cochaperone p23 is the limiting component of the multiprotein Hsp90/Hsp70-based chaperone system in vivo where it acts to stabilize the client protein center dot Hsp90 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; ESTROGEN-RECEPTOR; LIGAND-BINDING; RECONSTITUTION; HYDROLYSIS; MACHINERY; STATES; HSP70; BAG-1	A variety of signaling proteins form heterocomplexes with and are regulated by the heat shock protein chaperone hsp90. These complexes are formed by a multiprotein machinery, including hsp90 and hsp70 as essential and abundant components and Hop, hsp40, and p23 as nonessential cochaperones that are present in much lower abundance in cells. Overexpression of signaling proteins can overwhelm the capacity of this machinery to properly assemble heterocomplexes with hsp90. Here, we show that the limiting component of this assembly machinery in vitro in reticulocyte lysate and in vivo in Sf9 cells is p23. Only a fraction of glucocorticoid receptors (GR) overexpressed in Sf9 cells are in heterocomplex with hsp90 and have steroid binding activity, with the majority of the receptors present as both insoluble and cytosolic GR aggregates. Coexpression of p23 with the GR increases the proportion of cytosolic receptors that are in stable GR . hsp90 heterocomplexes with steroid binding activity, a strictly hsp90-dependent activity for the GR. Coexpression of p23 eliminates the insoluble GR aggregates and shifts the cytosolic receptor from very large aggregates without steroid binding activity to similar to 600-kDa heterocomplexes with steroid binding activity. These data lead us to conclude that p23 acts in vivo to stabilize hsp90 binding to client protein.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.	ymo@umich.edu	Sunahara, Roger/AAJ-8667-2020		NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; HONORE B, 1992, J BIOL CHEM, V267, P8485; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Kanelakis KC, 2000, BIOCHEMISTRY-US, V39, P14314, DOI 10.1021/bi001671c; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Murphy PJM, 2003, J BIOL CHEM, V278, P34764, DOI 10.1074/jbc.M304469200; Oxelmark E, 2003, J BIOL CHEM, V278, P36547, DOI 10.1074/jbc.M305960200; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schmidt U, 2003, J BIOL CHEM, V278, P4926, DOI 10.1074/jbc.M212000200; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	33	67	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48754	48763		10.1074/jbc.M309814200	http://dx.doi.org/10.1074/jbc.M309814200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507910	hybrid			2022-12-25	WOS:000186829000031
J	Pandhare, J; Dash, C; Rao, M; Deshpande, V				Pandhare, J; Dash, C; Rao, M; Deshpande, V			Slow tight binding inhibition of proteinase K by a proteinaceous inhibitor - Conformational alterations responsible for conferring irreversibility to the enzyme-inhibitor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE PROTEASE INHIBITOR; TRITIRACHIUM-ALBUM-LIMBER; SERINE-PROTEASE; KINETIC-PARAMETERS; CHYMOTRYPSIN; RESOLUTION; CATALYSIS; MECHANISM; SUBSTRATE; AFFINITY	The kinetics of slow onset inhibition of Proteinase K by a proteinaceous alkaline protease inhibitor (API) from a Streptomyces sp. is presented. The kinetic analysis revealed competitive inhibition of Proteinase K by API with an IC50 value 5.5 +/- 0.5 x 10(-5) M. The progress curves were time-dependent, consistent with a two-step slow tight binding inhibition. The first step involved a rapid equilibrium for formation of reversible enzyme-inhibitor complex (EI) with a K-i value 5.2 +/- 0.6 x 10(-6) M. The EI complex isomerized to a stable complex (EI*) in the second step because of inhibitor-induced conformational changes, with a rate constant k(5) (9.2 +/- 1 x 10(-3) s(-1)). The rate of dissociation of EI* (k(6)) was slower (4.5 +/- 0.5 x 10(-5) s(-1)) indicating the tight binding nature of thew inhibitor. The overall inhibition constant K-i* for two-step inhibition of Proteinase K by API was 2.5 +/- 0.3 x 10(-7) M. Time-dependent dissociation of EI* revealed that the complex failed to dissociate after a time point and formed a conformationally altered, irreversible complex EI**. These conformational states of enzyme-inhibitor complexes were characterized by fluorescence spectroscopy. Tryptophanyl fluorescence of Proteinase K was quenched as a function of API concentration without any shift in the emission maximum indicating a subtle conformational change in the enzyme, which is correlated to the isomerization of EI to EI*. Time-dependent shift in the emission maxima of EI* revealed the induction of gross conformational changes, which can be correlated to the irreversible conformationally locked EI** complex. API binds to the active site of the enzyme as demonstrated by the abolished fluorescence of 5-iodoacetamidofluorescein-labeled Proteinase K. The chemoaffinity labeling experiments lead us to hypothesize that the inactivation of Proteinase K is because of the interference in the electronic microenvironment and disruption of the hydrogen-bonding network between the catalytic triad and other residues involved in catalysis.	Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Deshpande, V (corresponding author), Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India.			Dash, Chandravanu/0000-0003-4466-8355; Pandhare, Jui/0000-0002-0356-064X				BEITH JG, 1995, METHOD ENZYMOL, V248, P59; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; Betzel C, 2001, BIOCHEMISTRY-US, V40, P3080, DOI 10.1021/bi002538n; BIRK Y, 1987, PROTEINASE INHIBITOR, P257; BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004; BONE R, 1987, BIOCHEMISTRY-US, V26, P7609, DOI 10.1021/bi00398a012; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cleland W W, 1979, Methods Enzymol, V63, P103; Dash C, 2002, J BIOL CHEM, V277, P17978, DOI 10.1074/jbc.M111250200; Dash C, 2001, BIOCHEMISTRY-US, V40, P11525, DOI 10.1021/bi010594y; DELMAR EG, 1979, ANAL BIOCHEM, V99, P316, DOI 10.1016/S0003-2697(79)80013-5; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Kati WM, 1998, BIOCHEM BIOPH RES CO, V244, P408, DOI 10.1006/bbrc.1998.8282; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P180; LANGE G, 1994, EUR J BIOCHEM, V224, P507, DOI 10.1111/j.1432-1033.1994.00507.x; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MERKLER DJ, 1990, BIOCHEMISTRY-US, V29, P8358, DOI 10.1021/bi00488a023; MORISON JF, 1985, COMMENTS MOL CELL BI, V2, P347; Morisson J.F., 1988, ADV ENZYMOL RELAT AR, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; PEGG MS, 1994, BIOCHEM MOL BIOL INT, V32, P851; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; SIEZEN RJ, 1991, PROTEIN ENG, V4, P719, DOI 10.1093/protein/4.7.719; SIMONS SS, 1979, BIOCHEMISTRY-US, V18, P4915, DOI 10.1021/bi00589a020; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TAGUCHI S, 1992, FEMS MICROBIOL LETT, V99, P293, DOI 10.1016/0378-1097(92)90043-N; Tanksale AM, 2000, BIOCHEM BIOPH RES CO, V270, P910, DOI 10.1006/bbrc.2000.2494; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; Vernekar JV, 2001, BIOCHEM BIOPH RES CO, V285, P1018, DOI 10.1006/bbrc.2001.5257; Vernekar JV, 1999, BIOCHEM BIOPH RES CO, V262, P702, DOI 10.1006/bbrc.1999.1269; Williams J W, 1979, Methods Enzymol, V63, P437; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Yiallouros I, 1998, BIOCHEM J, V331, P375, DOI 10.1042/bj3310375	38	13	13	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48735	48744		10.1074/jbc.M308976200	http://dx.doi.org/10.1074/jbc.M308976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507912	hybrid			2022-12-25	WOS:000186829000029
J	Sola, S; Ma, XM; Castro, RE; Kren, BT; Steer, CJ; Rodrigues, CMP				Sola, S; Ma, XM; Castro, RE; Kren, BT; Steer, CJ; Rodrigues, CMP			Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta 1-induced apoptosis of rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RETINOBLASTOMA GENE-PRODUCT; BETA-MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR P53; TRANSCRIPTION FACTOR; CYTOCHROME-C; CELL-DEATH; IN-VIVO; PERMEABILITY TRANSITION; HEPATOMA-CELLS	Transforming growth factor beta1 (TGF-beta1)-induced hepatocyte apoptosis is associated with activation of E2F transcription factors and p53 stabilization through Mdm-2, thus potentially modulating a number of target genes. In previous studies, we have shown that ursodeoxycholic acid (UDCA) prevents TGF-beta1-induced hepatocyte apoptosis by inhibiting the mitochondrial pathway of cell death. In this study we examined the role of p53 in the induction of apoptosis by TGF-beta1, and identified additional antiapoptosis targets for UDCA. Our data show a significant transcriptional activation of E2F-1 in primary rat hepatocytes incubated with TGF-beta1 , as well as a 5-fold increase in p53 and a 2-fold decrease in its inhibitor, Mdm-2 (p < 0.05). In addition, bax mRNA expression was significantly induced at 36 h ( p < 0.01), resulting in increased levels of Bax protein. In contrast, Bcl-2 transcript and protein levels were decreased at all time points ( p < 0.01). Notably, UDCA inhibited E2F-1 transcriptional activation, p53 stabilization and Bcl-2 family expression (p < 0.05), in part, through a caspase-independent mechanism. Moreover, in the absence of TGF-beta1, UDCA prevented induction of p53 and Bax by overexpression of E2F-1 and p53, respectively ( p < 0.05). In addition, UDCA inhibited TGF-&beta;1-induced degradation of nuclear factor &kappa;B (NF-&kappa;B) and its inhibitor I&kappa;B (p < 0.05). In conclusion, these results demonstrate that UDCA inhibits E2F-1 transcriptional activation of hepatocyte apoptosis, thus modulating p53 stabilization, NF-kappaB degradation, and expression of Bcl-2 family members.	Univ Lisbon, Ctr Patogenese Mol, Fac Pharm, P-1600083 Lisbon, Portugal; Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA	Universidade de Lisboa; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Rodrigues, CMP (corresponding author), Av Forcas Armadas, P-1600083 Lisbon, Portugal.		Rodrigues, Cecilia MP/M-3572-2013; Castro, Rui E/AAG-4179-2021; iMed.ULisboa, CellFun/A-4244-2014; Solá, Susana/M-5251-2013; Solá, Susana/AAI-4580-2021; Castro, Rui E/I-2975-2013	Rodrigues, Cecilia MP/0000-0002-4829-754X; Castro, Rui E/0000-0002-7417-0091; Solá, Susana/0000-0003-2036-797X; Solá, Susana/0000-0003-2036-797X; Castro, Rui E/0000-0002-7417-0091				Ahmed MM, 2002, J BIOL CHEM, V277, P2234, DOI 10.1074/jbc.M110168200; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOTLA R, 1995, J PHARMACOL EXP THER, V272, P930; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan GS, 2002, J CELL SCI, V115, P3181; Fan GS, 1996, ONCOGENE, V12, P1909; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heathcote EJ, 2000, HEPATOLOGY, V31, P1005, DOI 10.1053/he.2000.5984; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang YL, 1998, J BIOMED SCI, V5, P185; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kim CN, 1997, CANCER RES, V57, P3115; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Paumgartner G, 2002, HEPATOLOGY, V36, P525, DOI 10.1053/jhep.2002.36088; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Regula KM, 2002, J BIOL CHEM, V277, P38676, DOI 10.1074/jbc.M206175200; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rodrigues CMP, 1998, J CLIN INVEST, V101, P2790, DOI 10.1172/JCI1325; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; Schrantz N, 1999, ONCOGENE, V18, P3511, DOI 10.1038/sj.onc.1202718; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	58	61	62	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48831	48838		10.1074/jbc.M300468200	http://dx.doi.org/10.1074/jbc.M300468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514686	hybrid			2022-12-25	WOS:000186829000040
J	Wang, L; Zeng, HY; Wang, P; Soker, S; Mukhopadhyay, D				Wang, L; Zeng, HY; Wang, P; Soker, S; Mukhopadhyay, D			Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; FACTOR VEGF; NERVOUS-SYSTEM; TUMOR-CELLS; FACTOR RECEPTOR-2; MEMBRANE-PROTEIN; SEMAPHORIN-III; NEUROPILIN; ANGIOGENESIS; EXPRESSION	Neuropilin-1 (NRP-1) has been found to be expressed by endothelial cells and tumor cells as an isoform-specific receptor for vascular permeability factor/vascular endothelial growth factor (VEGF). Previous studies were mainly focused on the extracellular domain of NRP-1 that can bind to VEGF(165) and, thus, enables NRP-1 to act as a co-receptor for VEGF(165), which enhances its binding to VEGFR-2 and its bioactivity. However, the exact functional roles and related signaling mechanisms of NRP-1 in angiogenesis are not well understood. In this study we constructed a chimeric receptor, EGNP-1, by fusing the extracellular domain of epidermal growth factor receptor to the transmembrane and intracellular domains of NRP-1 and transduced it into HUVECs with a retroviral expression vector. We observed that NRP-1/EGNP-1 mediates ligand-stimulated migration of human umbilical vein endothelial cells (HUVECs) but not proliferation. Our results show that NRP-1 alone can mediate HUVEC migration through its intracellular domain, and its C-terminal three amino acids (SEA-COOH) are essential for the process. We demonstrate that phosphatidylinositol 3-kinase inhibitor Ly294002 and the p85 dominant negative mutant can block NRP-1-mediated HUVEC migration. NRP-1-mediated migration can be significantly reduced by overexpression of the dominant negative mutant of RhoA (RhoA-19N). In addition, G(q) family proteins and Gbetagamma subunits are also required for NRP-1-mediated HUVEC migration. These results show for the first time that NRP-1 can independently promote cell signaling in endothelial cells and also demonstrate the importance of last three amino acids of NRP-1 for its function.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Urol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.	dmukhopa@bidmc.harvard.edu			NCI NIH HHS [CA78383, CA 45548] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, P01CA045548, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bachelder RE, 2001, CANCER RES, V61, P5736; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Cai HB, 1999, J NEUROSCI, V19, P6519; Datta K, 2001, CANCER RES, V61, P1768; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fuh G, 2000, J BIOL CHEM, V275, P26690; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Mamluk R, 2002, J BIOL CHEM, V277, P24818, DOI 10.1074/jbc.M200730200; Matthies AM, 2002, AM J PATHOL, V160, P289, DOI 10.1016/S0002-9440(10)64372-6; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Pavelock K, 2001, ENDOCRINOLOGY, V142, P613, DOI 10.1210/en.142.2.613; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200	42	175	191	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48848	48860		10.1074/jbc.M310047200	http://dx.doi.org/10.1074/jbc.M310047200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514674	hybrid			2022-12-25	WOS:000186829000042
J	Li, KW; Hornshaw, MP; Van der Schors, RC; Watson, R; Tate, S; Casetta, B; Jimenez, CR; Gouwenberg, Y; Gundelfinger, ED; Smalla, KH; Smit, AB				Li, KW; Hornshaw, MP; Van der Schors, RC; Watson, R; Tate, S; Casetta, B; Jimenez, CR; Gouwenberg, Y; Gundelfinger, ED; Smalla, KH; Smit, AB			Proteomics analysis of rat brain postsynaptic density - Implications of the diverse protein functional groups for the integration of synaptic physiology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; AMPA RECEPTOR TRAFFICKING; DOMAIN-CONTAINING PROTEIN; HEAT-SHOCK PROTEINS; E3 UBIQUITIN LIGASE; DENDRITIC SPINES; ACTIN-FILAMENTS; NMDA RECEPTOR; ELONGATION FACTOR-1-ALPHA; MOLECULAR-ORGANIZATION	The postsynaptic density contains multiple protein complexes that together relay the presynaptic neurotransmitter input to the activation of the postsynaptic neuron. In the present study we took two independent proteome approaches for the characterization of the protein complement of the postsynaptic density, namely 1) two-dimensional gel electrophoresis separation of proteins in conjunction with mass spectrometry to identify the tryptic peptides of the protein spots and 2) isolation of the trypsin-digested sample that was labeled with isotope-coded affinity tag, followed by liquid chromatography-tandem mass spectrometry for the partial separation and identification of the peptides, respectively. Functional grouping of the identified proteins indicates that the postsynaptic density is a structurally and functionally complex organelle that may be involved in a broad range of synaptic activities. These proteins include the receptors and ion channels for glutamate neurotransmission, proteins for maintenance and modulation of synaptic architecture, sorting and trafficking of membrane proteins, generation of anaerobic energy, scaffolding and signaling, local protein synthesis, and correct protein folding and breakdown of synaptic proteins. Together, these results imply that the postsynaptic density may have the ability to function (semi-)autonomously and may direct various cellular functions in order to integrate synaptic physiology.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Neurosci Res Inst, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands; Appl Biosyst Inc, Warrington WA3 7QH, Cheshire, England; Applera Italia, Appl Biosyst, I-20052 Monza, Italy; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; FAN GmbH, D-39120 Magdeburg, Germany	Vrije Universiteit Amsterdam; Thermo Fisher Scientific; Applied Biosystems; Thermo Fisher Scientific; Applied Biosystems; Leibniz Institut fur Neurobiologie (LIN)	Li, KW (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Neurosci Res Inst, Dept Mol & Cellular Neurobiol, Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.		Smit, August B/E-8410-2011; Jimenez, Connie/AAI-3763-2020; Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; tate, stephen/0000-0001-5508-0819; li, ka wan/0000-0001-6983-5055; Jimenez, Connie R/0000-0002-3103-4508				Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Bader GD, 2002, NAT BIOTECHNOL, V20, P991, DOI 10.1038/nbt1002-991; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; Blanpied TA, 2002, NEURON, V36, P435, DOI 10.1016/S0896-6273(02)00979-0; Bockmann J, 2002, J NEUROCHEM, V83, P1013, DOI 10.1046/j.1471-4159.2002.01204.x; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Burette A, 2002, J NEUROSCI, V22, P8961; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chang JS, 2002, J BIOL CHEM, V277, P19697, DOI 10.1074/jbc.M111206200; CHAPMAN AP, 1994, NEUROSCI LETT, V168, P238, DOI 10.1016/0304-3940(94)90459-6; Chew CS, 2000, J CELL SCI, V113, P2035; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Deneka M, 2002, NAT CELL BIOL, V4, pE33, DOI 10.1038/ncb0202-e33; Di Cunto F, 2003, BRAIN RES BULL, V60, P319, DOI 10.1016/S0361-9230(03)00058-3; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; El-Husseini AE, 2002, CELL, V108, P849, DOI 10.1016/S0092-8674(02)00683-9; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Griffin TJ, 2001, ANAL CHEM, V73, P978, DOI 10.1021/ac001169y; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Halpain S, 1998, J NEUROSCI, V18, P9835; Hansen KC, 2003, MOL CELL PROTEOMICS, V2, P299, DOI 10.1074/mcp.M300021-MCP200; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huntley GW, 2002, CELL, V108, P1, DOI 10.1016/S0092-8674(01)00631-6; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; HUSI H, 2002, FENS FOR 2002 PAR; Ishimoto T, 2002, BBA-GENE STRUCT EXPR, V1579, P189, DOI 10.1016/S0167-4781(02)00538-9; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jimenez CR, 2002, J NEUROCHEM, V81, P735, DOI 10.1046/j.1471-4159.2002.00873.x; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kaech S, 2001, P NATL ACAD SCI USA, V98, P7086, DOI 10.1073/pnas.111146798; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kim JH, 2003, J NEUROSCI, V23, P1119; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Koller A, 2002, P NATL ACAD SCI USA, V99, P11969, DOI 10.1073/pnas.172183199; Komiyama NH, 2002, J NEUROSCI, V22, P9721; Langnaese K, 1996, MOL BRAIN RES, V42, P118, DOI 10.1016/S0169-328X(96)00147-7; Lee HK, 2002, J NEUROCHEM, V81, P1338, DOI 10.1046/j.1471-4159.2002.00937.x; Lee SH, 2002, NEURON, V36, P661, DOI 10.1016/S0896-6273(02)01024-3; Lei SB, 2001, J NEUROSCI, V21, P8464, DOI 10.1523/JNEUROSCI.21-21-08464.2001; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; McClatchy DB, 2002, J BIOL CHEM, V277, P29268, DOI 10.1074/jbc.M203081200; McGee AW, 2003, CURR OPIN NEUROBIOL, V13, P111, DOI 10.1016/S0959-4388(03)00008-4; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Murphey RK, 2002, NEURON, V36, P5, DOI 10.1016/S0896-6273(02)00943-1; Nagle GT, 2001, EUR J BIOCHEM, V268, P1213, DOI 10.1046/j.1432-1327.2001.01972.x; Nimchinsky EA, 2002, ANNU REV PHYSIOL, V64, P313, DOI 10.1146/annurev.physiol.64.081501.160008; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Suzuki T, 1999, BRAIN RES, V816, P99, DOI 10.1016/S0006-8993(98)01083-X; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; Takahashi H, 2003, J NEUROSCI, V23, P6586; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takenawa T, 2001, J CELL SCI, V114, P1801; Tao WA, 2003, CURR OPIN BIOTECH, V14, P110, DOI 10.1016/S0958-1669(02)00018-6; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Walikonis RS, 2000, J NEUROSCI, V20, P4069; WALSH MJ, 1992, J NEUROCHEM, V59, P667, DOI 10.1111/j.1471-4159.1992.tb09421.x; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273; Wyneken U, 2001, NEUROSCIENCE, V102, P65, DOI 10.1016/S0306-4522(00)00469-3; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yuasa K, 2001, EUR J BIOCHEM, V268, P4440, DOI 10.1046/j.1432-1327.2001.02366.x; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999; Zhang WD, 2000, HIPPOCAMPUS, V10, P512, DOI 10.1002/1098-1063(2000)10:5<512::AID-HIPO2>3.0.CO;2-M; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	97	213	225	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					987	1002		10.1074/jbc.M303116200	http://dx.doi.org/10.1074/jbc.M303116200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14532281	hybrid, Green Published			2022-12-25	WOS:000187722800022
J	Lucau-Danila, A; Delaveau, T; Lelandais, G; Devaux, F; Jacq, C				Lucau-Danila, A; Delaveau, T; Lelandais, G; Devaux, F; Jacq, C			Competitive promoter occupancy by two yeast paralogous transcription factors controlling the multidrug resistance phenomenon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION DATA; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; GENOME-WIDE; OXIDATIVE STRESS; REGULATORS; ACTIVATION; PROTEIN; ELEMENTS; NETWORK	Highly flexible gene expression programs are required to allow cell growth in the presence of a wide variety of chemicals. We used genome-wide expression analyses coupled with chromatin immunoprecipitation experiments to study the regulatory relationships between two very similar yeast transcription factors involved in the control of the multidrug resistance phenomenon. Yrm1 (Yor172w) is a new zinc finger transcription factor, the overproduction of which decreases the level of transcription of the target genes of Yrr1, a zinc finger transcription factor controlling the expression of several membrane transporter-encoding genes. Surprisingly, the absence of YRR1 releases the transcriptional activity of Yrm1, which then up-regulates 23 genes, 14 of which are also direct target genes of Yrr1. Chromatin immunoprecipitation experiments confirmed that Yrm1 binds to the promoters of the up-regulated genes only in yeast strains from which YRR1 has been deleted. This sophisticated regulatory program can be associated with drug resistance phenotypes of the cell. The program-specific distribution of paired transcription factors throughout the genome may be a general mechanism by which similar transcription factors regulate overlapping gene expression programs in response to chemical stress.	Ecole Normale Super, Genet Mol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Jacq, C (corresponding author), Ecole Normale Super, Genet Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.		Lucau-Danila, Anca/AAE-7674-2021; DEVAUX, Frédéric/N-2288-2019	DEVAUX, Frédéric/0000-0002-0039-9096; LUCAU-DANILA, Anca/0000-0002-9379-6241				Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hallstrom TC, 1998, MOL CELL BIOL, V18, P1147, DOI 10.1128/MCB.18.3.1147; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Hiesinger M, 2001, CURR GENET, V39, P68, DOI 10.1007/s002940000182; Hikkel I, 2003, J BIOL CHEM, V278, P11427, DOI 10.1074/jbc.M208549200; JACQUET M, 2003, J CELL BIOL; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; Keller G, 2001, J BIOL CHEM, V276, P38697, DOI 10.1074/jbc.M107131200; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Mamnun YM, 2002, MOL MICROBIOL, V46, P1429, DOI 10.1046/j.1365-2958.2002.03262.x; Maniatis T., 1982, MOL CLONING LAB MANU; Marc P, 2002, BIOINFORMATICS, V18, P888, DOI 10.1093/bioinformatics/18.6.888; Moye-Rowley WS, 2002, ANTIOXID REDOX SIGN, V4, P123, DOI 10.1089/152308602753625915; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; RUTHERFORD JC, 2003, J BIOL CHEM; Sambrook J., 2002, MOL CLONING LAB MANU; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	35	40	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52641	52650		10.1074/jbc.M309580200	http://dx.doi.org/10.1074/jbc.M309580200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14512416	hybrid			2022-12-25	WOS:000187480700082
J	Nogues, G; Munoz, MJ; Kornblihtt, AR				Nogues, G; Munoz, MJ; Kornblihtt, AR			Influence of polymerase II processivity on alternative splicing depends on splice site strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN EDA EXON; RNA; TRANSCRIPTION; ELONGATION; ENHANCER; SEQUENCES; INCLUSION; EXPRESSION; MACHINES; SF2/ASF	Transcription and pre-mRNA splicing are coordinated temporally and spatially, and both processes can influence each other. In particular, control of transcriptional elongation by RNA polymerase II has proved to be important for alternative splicing regulation. In this report we demonstrate that the efficiency of exon recognition by the splicing machinery is crucial for the elongation control. Alternative splicing of the fibronectin extra domain I (EDI) is because the polypyrimidine tract of its 3'-splice site occurs suboptimal. By mutating the polypyrimidine tract of EDI in two different positions, individually or in combination, and by disrupting its exonic splicing silencer, we managed to generate minigenes with increasing degrees of exon recognition. Improvement of exon recognition is evidenced by independence from the splicing regulator SF2/ASF for inclusion. The mutated minigenes were used to transfect human cells in culture and study the responsiveness of EDI alternative splicing to activation or inhibition of pol II elongation. Our results revealed that responsiveness of exon skipping to elongation is inversely proportional to 3'-splice site strength, which means that the better the alternative exon is recognized by the splicing machinery, the less its degree of inclusion is affected by transcriptional elongation.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, Lab Fisiol & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, IFIBYNE, RA-1428 Buenos Aires, DF, Argentina	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Kornblihtt, AR (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Fisiol Biol Mol & Celular, Lab Fisiol & Biol Mol, Ciudad Univ,Pabellon 2, RA-1428 Buenos Aires, DF, Argentina.	ark@fbmc.fcen.uba.ar		Kornblihtt, Alberto/0000-0003-4322-0831; Munoz, Manuel J./0000-0002-1152-5449				Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Blau J, 1996, MOL CELL BIOL, V16, P2044; Buvoli M, 1997, EMBO J, V16, P7174, DOI 10.1093/emboj/16.23.7174; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Chandler DS, 2001, NUCLEIC ACIDS RES, V29, P3012, DOI 10.1093/nar/29.14.3012; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; de la Mata M, 2003, MOL CELL, V12, P525, DOI 10.1016/j.molcel.2003.08.001; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hatton AR, 1998, MOL CELL, V2, P787, DOI 10.1016/S1097-2765(00)80293-2; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; Howe KJ, 2003, RNA, V9, P993, DOI 10.1261/rna.5390803; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Muro AF, 1999, MOL CELL BIOL, V19, P2657; Muro AF, 1998, FEBS LETT, V437, P137, DOI 10.1016/S0014-5793(98)01201-0; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; Pagani F, 2003, J BIOL CHEM, V278, P1511, DOI 10.1074/jbc.M209676200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; TAMM I, 1980, BIOCHEMISTRY-US, V19, P2743, DOI 10.1021/bi00553a032; Zhang MQ, 1998, HUM MOL GENET, V7, P919, DOI 10.1093/hmg/7.5.919	33	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52166	52171		10.1074/jbc.M309156200	http://dx.doi.org/10.1074/jbc.M309156200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530256	hybrid			2022-12-25	WOS:000187480700024
J	Dalley, JA; Bulleid, NJ				Dalley, JA; Bulleid, NJ			The endoplasmic reticulum (ER) translocon can differentiate between hydrophobic sequences allowing signals for glycosylphosphatidylinositol anchor addition to be fully translocated into the ER lumen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEMS; MEMBRANE-PROTEINS; GPI ANCHOR; TERMINAL SIGNAL; ATTACHMENT; TRANSAMIDASE; COMPLEX; BIOSYNTHESIS; GAA1P; SUBSTRATE	The signal sequence within polypeptide chains that designates whether a protein is to be anchored to the membrane by a glycosylphosphatidylinositol (GPI) anchor is characterized by a carboxyl-terminal hydrophobic domain preceded by a short hydrophilic spacer linked to the GPI anchor attachment (omega) site. The hydrophobic domain within the GPI anchor signal sequence is very similar to a transmembrane domain within a stop transfer sequence. To investigate whether the GPI anchor signal sequence is translocated across or integrated into the endoplasmic reticulum membrane we studied the translocation, GPI anchor addition, and glycosylation of different variants of a model GPI-anchored protein. Our results unequivocally demonstrated that the hydrophobic domain within a GPI signal cannot act as a transmembrane domain and is fully translocated even when followed by an authentic charged cytosolic tail sequence. However, a single amino acid change within the hydrophobic domain of the GPI-signal converts it into a transmembrane domain that is fully integrated into the endoplasmic reticulum membrane. These results demonstrated that the translocation machinery can recognize and differentiate subtle changes in hydrophobic sequence allowing either full translocation or membrane integration.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Bulleid, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 2 205 Stopford Bldg, Manchester M13 9PT, Lancs, England.			Bulleid, Neil/0000-0002-9839-5279				BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; KODUKULA K, 1995, METHOD ENZYMOL, V250, P536; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Nilsson I, 2000, J BIOL CHEM, V275, P17338, DOI 10.1074/jbc.M002317200; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; UDENFRIEND S, 1991, CELL BIOL INT REP, V15, P739, DOI 10.1016/0309-1651(91)90030-M; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Wang JY, 1999, J MOL BIOL, V286, P1303, DOI 10.1006/jmbi.1999.2584; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wigley WC, 2002, NAT STRUCT BIOL, V9, P381, DOI 10.1038/nsb784; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; [No title captured]	31	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51749	51757		10.1074/jbc.M303978200	http://dx.doi.org/10.1074/jbc.M303978200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530277	hybrid			2022-12-25	WOS:000187206300110
J	Inagaki, T; Suzuki, S; Miyamoto, T; Takeda, T; Yamashita, K; Komatsu, A; Yamauchi, K; Hashizume, K				Inagaki, T; Suzuki, S; Miyamoto, T; Takeda, T; Yamashita, K; Komatsu, A; Yamauchi, K; Hashizume, K			The retinoic acid-responsive proline-rich protein is identified in promyeloleukemic HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; GENE-EXPRESSION; DIFFERENTIATION; RECEPTOR; ALPHA; INDUCTION; RXR	To identify new genes that retinoic acid activates, we employed an mRNA differential display technique and screened for genes that are differentially expressed in promyeloleukemic HL-60 cells incubated in the presence of all-trans-retinoic acid ( ATRA) compared with the absence of ATRA. We cloned the coding region of a retinoic acid-induced gene from a human thymus library, which was the mRNA encoding the 666-amino acid human homologue of mouse proline-rich protein 76. We have designated it RARP1 ( retinoic acid response proline-rich protein 1). Transcription of an similar to 2.4-kbp mRNA occurred mainly in organs with immune functions, such as thymus, spleen, and peripheral leukocytes. Cycloheximide blocked the ATRA-induced expression. In megakaryocyte-like human erythroleukemia HEL cells, the amount of RARP1 mRNA was high, but it was low in human T-lymphoblastoid Jurkat cells. A specific antibody against RARP1 recognized a 110-kDa protein, which accumulates after incubation of HL-60 cells with ATRA. In immunohistochemical experiments, strong RARP1 staining was observed in the megakaryocytes of bone marrow and spleen, and heterogeneous stain was seen in thymus. Transcriptional studies showed that RARP1 expression impaired the transactivation through activator protein1 and serum response-element in all cell lines we checked, whereas it did not affect the transactivation through cAMP-response element in the same cell lines. Further analysis demonstrated that proline-rich regions of RARP1 are the functional regions regulated for suppression of activator protein1 transactivation. These data suggest that ATRA-inducible RARP1 selectively affects signal transduction and may contribute to myeloid and megakaryocytic differentiation.	Shinshu Univ, Grad Sch, Dept Aging Med & Geriatr, Inst Aging & Adaptat,Div Med, Nagano 3908621, Japan	Shinshu University	Suzuki, S (corresponding author), Shinshu Univ, Grad Sch, Dept Aging Med & Geriatr, Inst Aging & Adaptat,Div Med, 3-1-1 Asahi, Nagano 3908621, Japan.		Inagaki, Takeshi/J-8802-2013	Inagaki, Takeshi/0000-0003-1711-8286				ANN DK, 1992, J BIOL CHEM, V267, P699; Battle TE, 2001, EUR J CELL BIOL, V80, P59, DOI 10.1078/0171-9335-00141; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; Breitman T R, 1986, Prog Clin Biol Res, V226, P215; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; DEVALIA V, 1992, BLOOD, V80, P68; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HSU HC, 1993, LEUKEMIA, V7, P458; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KATAGIRI K, 1991, J IMMUNOL, V146, P701; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Mori JI, 2002, ENDOCRINOLOGY, V143, P1538, DOI 10.1210/en.143.4.1538; Ohtsuki T, 1997, BIOCHEM BIOPH RES CO, V230, P81, DOI 10.1006/bbrc.1996.5887; Pessin Jeffrey E., 1999, Endocrine Journal, V46, pS11, DOI 10.1507/endocrj.46.Suppl_S11; PFAHL M, 1994, VITAM HORM, V49, P327; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; Suzuki S, 2003, EUR J ENDOCRINOL, V148, P259, DOI 10.1530/eje.0.1480259; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	21	10	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51685	51692		10.1074/jbc.M308016200	http://dx.doi.org/10.1074/jbc.M308016200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530287	hybrid			2022-12-25	WOS:000187206300103
J	Kronke, G; Bochkov, VN; Huber, J; Gruber, F; Bluml, S; Furnkranz, A; Kadl, A; Binder, BR; Leitinger, N				Kronke, G; Bochkov, VN; Huber, J; Gruber, F; Bluml, S; Furnkranz, A; Kadl, A; Binder, BR; Leitinger, N			Oxidized phospholipids induce expression of human heme oxygenase-1 involving activation of cAMP-responsive element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN-1; ISCHEMIA-REPERFUSION INJURY; LOW-DENSITY-LIPOPROTEIN; ZUCKER RAT LIVERS; TIME RT-PCR; ENDOTHELIAL-CELLS; CARBON-MONOXIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS	Heme oxygenase- 1 ( HO- 1) catalyzes the rate- limiting step in heme degradation, protects against oxidative stress, and shows potent anti- inflammatory effects. Oxidized phospholipids, which are generated during inflammation and apoptosis, modulate the inflammatory response by inducing the expression of several genes including HO- 1. Here we investigated the signaling pathways and transcriptional events involved in the induction of HO- 1 gene expression by oxidized 1- palmitoyl-2- arachidonoyl- sn- glycero- 3- phosphorylcholine ( OxPAPC) in human umbilical vein endothelial cells. OxPAPC up- regulated HO- 1 mRNA and protein in a time- and concentration- dependent manner, whereas pro- inflammatory agents like TNF-alpha and lipopolysaccharide did not significantly induce HO- 1 expression in human umbilical vein endothelial cells. Signaling pathways involved in the OxPAPC- mediated HO- 1 induction included protein kinases A and C, as well as the mitogen-activated protein kinases p38 and ERK. The cAMP-responsive element- binding protein ( CREB) was phosphorylated via these pathways in response to OxPAPC treatment and expression of a dominant- negative mutant of CREB inhibited OxPAPC- induced activity of a human heme oxygenase- 1 promoter- driven luciferase reporter construct. We identified a cAMP- responsive element and a Maf recognition element to be involved in the transcriptional activation of the HO- 1 promoter by OxPAPC. In gel shift assays we observed binding of CREB to the cAMP- responsive element after OxPAPC treatment. Induction of HO- 1 expression by lipid oxidation products via CREB may represent a feedback mechanism to limit inflammation and associated tissue damage.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria	University of Vienna	Leitinger, N (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Schwarzspanierstr 17, A-1090 Vienna, Austria.	norbert.leitinger@univie.ac.at	Krönke, Gerhard/C-6615-2014; Kadl, Alexandra/AAV-3395-2021	Krönke, Gerhard/0000-0002-7566-4325; Gruber, Florian/0000-0003-1094-5641; Bluml, Stephan/0000-0002-2758-4400				Alam J, 2000, J BIOL CHEM, V275, P27694; ALAM J, 2002, AM J PHYSIOL, V284, pF743; Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Bauer M, 2002, ANTIOXID REDOX SIGN, V4, P749, DOI 10.1089/152308602760598891; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; BROWN Z, 1994, AM J PATHOL, V145, P913; Camhi SL, 1998, AM J RESP CELL MOL, V18, P226, DOI 10.1165/ajrcmb.18.2.2910; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Casteel D, 1998, BLOOD, V91, P3193, DOI 10.1182/blood.V91.9.3193.3193_3193_3201; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209, DOI 10.1152/ajplung.2001.281.1.L209; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Coito AJ, 2002, TRANSPLANTATION, V74, P96, DOI 10.1097/00007890-200207150-00017; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Cristol JP, 1998, TRANSPLANTATION, V65, P1322, DOI 10.1097/00007890-199805270-00007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Girotti AW, 1998, J LIPID RES, V39, P1529; Gong PF, 2002, ARCH BIOCHEM BIOPHYS, V405, P265, DOI 10.1016/S0003-9861(02)00404-6; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; HILLKAPTURCZAK N, 2003, ARTERIOSCLER THROMB; Honda HM, 1999, ARTERIOSCL THROM VAS, V19, P680, DOI 10.1161/01.ATV.19.3.680; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Immenschuh S, 1998, MOL PHARMACOL, V53, P483, DOI 10.1124/mol.53.3.483; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Iuliano L, 2001, LIPIDS, V36, pS41, DOI 10.1007/s11745-001-0680-1; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kadl A, 2002, VASC PHARMACOL, V38, P219, DOI 10.1016/S1537-1891(02)00172-6; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; Kawashima A, 2002, HUM PATHOL, V33, P125, DOI 10.1053/hupa.2002.30217; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; KITAMURO T, 2003, J BIOL CHEM; Lang JD, 2002, CHEST, V122, p314S, DOI 10.1378/chest.122.6_suppl.314S; Lee H, 2000, CIRC RES, V87, P516; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Li N, 2000, J IMMUNOL, V165, P3393, DOI 10.4049/jimmunol.165.6.3393; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Onishi Y, 2003, J BIOL CHEM, V278, P8163, DOI 10.1074/jbc.M209612200; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rim JS, 2002, J BIOL CHEM, V277, P34589, DOI 10.1074/jbc.M108866200; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; RIZZARDINI M, 1994, BIOCHEM J, V304, P477, DOI 10.1042/bj3040477; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Seed MP, 1997, INFLAMM RES, V46, P279, DOI 10.1007/s000110050187; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shi WB, 2000, CIRCULATION, V102, P75, DOI 10.1161/01.CIR.102.1.75; Song RP, 2003, AM J PHYSIOL-LUNG C, V284, pL50, DOI 10.1152/ajplung.00212.2002; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Vachharajani TJ, 2000, AM J PHYSIOL-HEART C, V278, pH1613, DOI 10.1152/ajpheart.2000.278.5.H1613; VIGNE P, 1995, BIOCHEM BIOPH RES CO, V214, P1, DOI 10.1006/bbrc.1995.2248; Wang LJ, 1998, AM J PATHOL, V152, P711; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Wellmann S, 2001, CLIN CHEM, V47, P654; Willis D, 2000, J PATHOL, V190, P627; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; WILLIS D, 1995, INFLAMM RES S2, V44, P218; Willoughby DA, 2000, INT J IMMUNOPHARMACO, V22, P1131, DOI 10.1016/S0192-0561(00)00064-3; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yang G, 2001, BLOOD, V97, P1306, DOI 10.1182/blood.V97.5.1306; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	85	161	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51006	51014		10.1074/jbc.M304103200	http://dx.doi.org/10.1074/jbc.M304103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523007	hybrid			2022-12-25	WOS:000187206300023
J	Ohshima, T; Shimotohno, K				Ohshima, T; Shimotohno, K			Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-TALK; E3 LIGASE; GENE-EXPRESSION; C-JUN; UBIQUITIN; PROTEIN; RECEPTOR; CONJUGATION; PML; CELLS	Post- translational modifications such as ubiquitination, phosphorylation, and acetylation play important roles in the regulation of Smad- mediated functions. Here, we demonstrate that Smad4 is covalently modified by SUMO- 1, which was characterized recently as a key modulator of many transcription factors. Sumoylation of Smad4 mainly occurs at lysine 159, located in the linker region, and facilitates Smad- dependent transcriptional activation. Furthermore, we show that the PIAS family proteins, PIAS1 and PIASxbeta, function as E3 ligase factors for Smad4. Intriguingly, sumoylation of Smad4 was strongly enhanced by TGF-beta- induced activation of the p38 MAP kinase pathway but not the Smad pathway. Activation of p38 not only stabilized PIASxbeta protein but also enhanced PIASxbeta gene expression, suggesting that PIAS- mediated sumoylation of Smad4 is regulated by the p38 MAP kinase pathway. These findings illustrate a novel regulatory mechanism by which Smad- dependent transcriptional activation cooperatively modulates Smad proteins through receptor- mediated phosphorylation and sumoylation.	Kyoto Univ, Inst Virus Res, Dept Virol Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ohshima, T (corresponding author), Kyoto Univ, Inst Virus Res, Dept Virol Oncol, Sakyo Ku, Kyoto 6068507, Japan.			OHSHIMA, Takayuki/0000-0002-1501-6430				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chou WC, 2003, MOL BIOL CELL, V14, P1279, DOI 10.1091/mbc.E02-07-0375; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Marone M, 2002, LEUKEMIA, V16, P94, DOI 10.1038/sj.leu.2402334; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 2001, J CELL SCI, V114, P4359; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Piek E, 1999, J CELL SCI, V112, P4557; Pinsky BA, 2002, DEV CELL, V3, P4, DOI 10.1016/S1534-5807(02)00214-9; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sternsdorf T, 2003, CURR BIOL, V13, pR258, DOI 10.1016/S0960-9822(03)00193-3; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Wagers AJ, 2000, J IMMUNOL, V165, P5011, DOI 10.4049/jimmunol.165.9.5011; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	63	101	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50833	50842		10.1074/jbc.M307533200	http://dx.doi.org/10.1074/jbc.M307533200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14514699	hybrid			2022-12-25	WOS:000187206300002
J	Davie, JK; Edmondson, DG; Coco, CB; Dent, SYR				Davie, JK; Edmondson, DG; Coco, CB; Dent, SYR			Tup1-Ssn6 interacts with multiple class I histone deacetylases in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COREPRESSORS; CYC8-TUP1 COREPRESSOR; N-COR; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; GENE ACTIVITY; YEAST; COMPLEX; PROTEIN	The Tup1-Ssn6 corepressor complex in Saccharomyces cerevisiae represses the transcription of a diverse set of genes. Chromatin is an important component of Tup1-Ssn6-mediated repression. Tup1 binds to underacetylated histone tails and requires multiple histone deacetylases (HDACs) for its repressive functions. Here, we describe physical interactions of the corepressor complex with the class I HDACs Rpd3, Hos2, and Hos1. In contrast, no in vivo interaction was observed between Tup-Ssn6 and Hda1, a class II HDAC. We demonstrate that Rpd3 interacts with both Tup1 and Ssn6. Rpd3 and Hos2 interact with Ssn6 independently of Tup1 via distinct tetratricopeptide domains within Ssn6, suggesting that these two HDACs may contact the corepressor at the same time.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Box 117,1515 Holcombe Blvd, Houston, TX 77030 USA.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715	NIGMS NIH HHS [GM51189] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Edmondson DG, 1998, COLD SPRING HARB SYM, V63, P459, DOI 10.1101/sqb.1998.63.459; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Guenther MG, 2000, GENE DEV, V14, P1048; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang EY, 2000, GENE DEV, V14, P45; Huang L, 1997, MOL CELL BIOL, V17, P6555, DOI 10.1128/MCB.17.11.6555; Kao HY, 2000, GENE DEV, V14, P55; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198	37	82	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50158	50162		10.1074/jbc.M309753200	http://dx.doi.org/10.1074/jbc.M309753200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525981	hybrid			2022-12-25	WOS:000187068200061
J	Fernandez, J; Lopez, AB; Wang, CP; Mishra, R; Zhou, LY; Yaman, I; Snider, MD; Hatzolgou, M				Fernandez, J; Lopez, AB; Wang, CP; Mishra, R; Zhou, LY; Yaman, I; Snider, MD; Hatzolgou, M			Transcriptional control of the arginine/lysine transporter, Cat-1, by physiological stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; ASPARAGINE SYNTHETASE GENE; SITE-MEDIATED TRANSLATION; RIBOSOME ENTRY SITE; EUKARYOTIC INITIATION FACTOR-2-ALPHA; AMINO-ACID TRANSPORTERS; MESSENGER-RNA; MAMMALIAN-CELLS; MOLECULAR-BIOLOGY; EXPRESSION	Cells respond to physiological stress by phosphorylating the alpha subunit of the translation initiation factor eIF2. This adaptive response inhibits protein synthesis and up-regulates genes essential for cell survival. Cat-1, the transporter for the essential amino acids, arginine and lysine, is one of the up-regulated genes. We previously showed that stress increases cat-1 expression by coordinated stabilization of the mRNA and increased mRNA translation. This induction is triggered by amino acid depletion and the unfolded protein response (UPR), which is caused by unfolded proteins in the endoplasmic reticulum. We show here that cat-1 gene transcription is also increased by cellular stress. Our studies demonstrate that the cat-1 gene promoter/regulatory region is TATA-less and is located in a region that includes 94 bases of the first exon. Transcription from this promoter is stimulated 8-fold by cellular stress. An amino acid response element within the first exon is shown to be required for the response to amino acid depletion but not to the UPR. The stimulation of transcription by amino acid depletion requires activation of GCN2 kinase, which phosphorylates eIF2alpha. This phosphorylation also induces translation of the cat-1 mRNA, demonstrating that stress-induced transcriptional and translational control of cat-1 are downstream targets of a signaling pathway initiating with eIF2alpha phosphorylation. Our studies show that the increase in cat-1 gene expression by cellular stress involves at least three types of coordinate regulation: regulation of transcription, regulation of mRNA stability, and regulation of mRNA translation.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Hatzolgou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.		yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060596, T32DK007319, R01DK053307] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53307, 5T32-DK07319, R01-DK60596] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; Calkhoven CF, 2000, GENE DEV, V14, P1920; Clark JH, 2002, BIOCHEMISTRY-US, V41, P11847, DOI 10.1021/bi025600k; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HANSEN BS, 1972, J BIOL CHEM, V247, P3854; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Jefferson LS, 2001, J NUTR, V131, p2460S, DOI 10.1093/jn/131.9.2460S; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mykkanen J, 2003, BIOCHEM BIOPH RES CO, V301, P855, DOI 10.1016/S0006-291X(03)00054-8; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sood R, 2000, GENETICS, V154, P787; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076; Zhou TY, 2002, NUCLEIC ACIDS RES, V30, P4145, DOI 10.1093/nar/gkf537	41	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50000	50009		10.1074/jbc.M305903200	http://dx.doi.org/10.1074/jbc.M305903200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523001	hybrid			2022-12-25	WOS:000187068200043
J	Kent, OA; Reayi, A; Foong, L; Chilibeck, KA; MacMillan, AM				Kent, OA; Reayi, A; Foong, L; Chilibeck, KA; MacMillan, AM			Structuring of the 3 ' splice site by U2AF65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SEX-LETHAL; POLYPYRIMIDINE TRACT; BRANCH SITE; RECOGNITION; BINDING; PROTEINS; U2AF(65); DOMAIN	Recognition of the 3 ' splice site in mammalian introns is accomplished by association of the splicing factor U2AF with the precursor mRNA ( pre- mRNA) in a multiprotein splicing commitment complex. It is well established that this interaction involves binding of the large U2AF65 subunit to sequences upstream of the 3 ' splice site, but the orientation of the four domains of this protein with respect to the RNA and hence their role in structuring the commitment complex remain unclear and the basis of contradictory models. We have examined the interaction of U2AF65 with an RNA representing the 3 ' splice site using a series of U2AF deletion mutants modified at the N terminus with the directed hydroxyl radical probe iron- EDTA. These studies, combined with an analysis of extant high resolution x- ray structures of protein . RNA complexes, suggest a model whereby U2AF65 bends the pre- mRNA to juxtapose reactive functionalities of the pre- mRNA substrate and organize these structures for subsequent spliceosome assembly.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	MacMillan, AM (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	andrew.macmillan@ualberta.ca		Kent, Oliver/0000-0001-6494-4383				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Banerjee H, 2003, RNA, V9, P88, DOI 10.1261/rna.2131603; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Burge CB, 1999, RNA WORLD, P525; Chan RCC, 1997, MOL CELL BIOL, V17, P4667, DOI 10.1128/MCB.17.8.4667; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Erlanson DA, 1996, CHEM BIOL, V3, P981, DOI 10.1016/S1074-5521(96)90165-9; HAN HY, 1994, P NATL ACAD SCI USA, V91, P4955, DOI 10.1073/pnas.91.11.4955; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Ito T, 1999, EMBO J, V18, P4523, DOI 10.1093/emboj/18.16.4523; Kent OA, 2002, NAT STRUCT BIOL, V9, P576, DOI 10.1038/nsb822; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEE CG, 1993, J BIOL CHEM, V268, P13472; Liu ZH, 2001, SCIENCE, V294, P1098, DOI 10.1126/science.1064719; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Query CC, 1997, MOL CELL BIOL, V17, P2944, DOI 10.1128/MCB.17.5.2944; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rudner DZ, 1998, MOL CELL BIOL, V18, P4004, DOI 10.1128/MCB.18.7.4004; Selenko P, 2003, MOL CELL, V11, P965, DOI 10.1016/S1097-2765(03)00115-1; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	37	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50572	50577		10.1074/jbc.M307976200	http://dx.doi.org/10.1074/jbc.M307976200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506271	hybrid			2022-12-25	WOS:000187068200111
J	Streblow, DN; Vomaske, J; Smith, P; Melnychuk, R; Hall, L; Pancheva, D; Smit, M; Casarosa, P; Schlaepfer, DD; Nelson, JA				Streblow, DN; Vomaske, J; Smith, P; Melnychuk, R; Hall, L; Pancheva, D; Smit, M; Casarosa, P; Schlaepfer, DD; Nelson, JA			Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							US28; PHOSPHORYLATION; EXPRESSION; ENCODES; FAK; OVEREXPRESSION; IDENTIFICATION; ASSOCIATION; MOTILITY; INVASION	The human cytomegalovirus-encoded chemokine receptor US28 induces arterial smooth muscle cell (SMC) migration; however, the underlying mechanisms involved in this process are unclear. We have previously shown that US28-mediated SMC migration occurs by a ligand-dependent process that is sensitive to protein-tyrosine kinase inhibitors. We demonstrate here that US28 signals through the non-receptor protein-tyrosine kinases Src and focal adhesion kinase (FAK) and that this activity is necessary for US28-mediated SMC migration. In the presence of RANTES ( regulated on activation normal T cell expressed and secreted), US28 stimulates the production of a FAK . Src kinase complex. Interestingly, Src co-immunoprecipitates with US28 in a ligand-dependent manner. This association occurs earlier than the formation of the FAK . Src kinase complex, suggesting that US28 activates Src before FAK. US28 binding to RANTES also promotes the formation of a Grb2 . FAK complex, which is sensitive to treatment with the Src inhibitor PP2, further highlighting the critical role of Src in US28 activation of FAK. Human cytomegalovirus US28-mediated SMC migration is inhibited by treatment with PP2 and through the expression of either of two dominant negative inhibitors of FAK (F397Y and NH2-terminal amino acids 1 - 401). These findings demonstrate that activation of FAK and Src plays a critical role in US28-mediated signaling and SMC migration.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Free Univ Amsterdam, Fac Chem, Div Med Chem, Leiden Amsterdam Ctr Drug Res, NL-1081 HV Amsterdam, Netherlands; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Oregon Health & Science University; Oregon Health & Science University; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; Scripps Research Institute	Streblow, DN (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.	streblow@ohsu.edu	Totonchy, Jennifer/AAX-6900-2021	Totonchy, Jennifer/0000-0002-8444-8536; Smit, Martine/0000-0003-2713-0238	NCI NIH HHS [CA87083, CA75240] Funding Source: Medline; NHLBI NIH HHS [HL65754, HL71695] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075240, R01CA075240] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071695, R01HL065754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akter P, 2003, J GEN VIROL, V84, P1117, DOI 10.1099/vir.0.18952-0; ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 2001, J VIROL, V75, P5949, DOI 10.1128/JVI.75.13.5949-5957.2001; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Cary LA, 1996, J CELL SCI, V109, P1787; Casarosa P, 2003, J BIOL CHEM, V278, P5172, DOI 10.1074/jbc.M210033200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; Chee MS, 1990, CURR TOP MICROBIOL, P125, DOI 10.1007/978-3-642-74980-3_6; Cobbs CS, 2002, CANCER RES, V62, P3347; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Feniger-Barish R, 2003, BIOCHEMISTRY-US, V42, P2874, DOI 10.1021/bi026783d; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; GAO JL, 1994, J BIOL CHEM, V269, P28539; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; ILLC D, 1995, NATURE, V377, P539; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mellado M, 1998, J IMMUNOL, V161, P805; Melnick JL, 1998, INFECT MED, V15, P479; Miller WE, 2003, J BIOL CHEM, V278, P21663, DOI 10.1074/jbc.M303219200; Minisini R, 2003, J VIROL, V77, P4489, DOI 10.1128/JVI.77.8.4489-4501.2003; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Schneider GB, 2002, CANCER, V95, P2508, DOI 10.1002/cncr.10992; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200	39	79	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50456	50465		10.1074/jbc.M307936200	http://dx.doi.org/10.1074/jbc.M307936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506272	hybrid, Green Published			2022-12-25	WOS:000187068200098
J	Yamada-Inagawa, T; Okuno, T; Karata, K; Yamanaka, K; Ogura, T				Yamada-Inagawa, T; Okuno, T; Karata, K; Yamanaka, K; Ogura, T			Conserved pore residues in the AAA protease FtsH are important for proteolysis and its coupling to ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEASE; ESCHERICHIA-COLI; MEMBRANE ASSOCIATION; SUBSTRATE PROTEIN; TRANSLOCATION; DEGRADATION; MECHANISM; COMPLEX; BINDING; ATPASES	Like other AAA proteins, Escherichia coli FtsH, a membrane-bound AAA protease, contains highly conserved aromatic and glycine residues (Phe(228) and Gly(230)) that are predicted to lie in the central pore region of the hexamer. The functions of Phe(228) and Gly(230) were probed by site-directed mutagenesis. The results of both in vivo and in vitro assays indicate that these conserved pore residues are important for FtsH function and that bulkier, uncharged/apolar residues are essential at position 228. None of the point mutants, F228A, F228E, F228K, or G230A, was able to degrade sigma(32), a physiological substrate. The F228A mutant was able to degrade casein, an unfolded substrate, although the other three mutants were not. Mutation of these two pore residues also affected the ATPase activity of FtsH. The F228K and G230A mutations markedly reduced ATPase activity, whereas the F228A mutation caused a more modest decrease in this activity. The F228E mutant was actually more active ATPase. The substrates, sigma(32) and casein, stimulated the ATPase activity of wild type FtsH. The ATPase activity of the mutants was no longer stimulated by casein, whereas that of the three Phe(228) mutants, but not the G230A mutant, remained sigma(32)-stimulatable. These results suggest that Phe(228) and Gly(230) in the predicted pore region of the FtsH hexamer have important roles in proteolysis and its coupling to ATP hydrolysis.	Kumamoto Univ, Inst Mol Embryol & Genet, Div Mol Cell Biol, Kumamoto 8620976, Japan	Kumamoto University	Ogura, T (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Div Mol Cell Biol, Kumamoto 8620976, Japan.	ogura@gpo.kumamoto-u.ac.jp		Ogura, Teru/0000-0003-3784-0970				Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Akiyama Y, 2001, BIOCHEMISTRY-US, V40, P7687, DOI 10.1021/bi010039w; Akiyama Y, 2000, EMBO J, V19, P3888, DOI 10.1093/emboj/19.15.3888; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; De Mot R, 1999, TRENDS MICROBIOL, V7, P88, DOI 10.1016/S0966-842X(98)01432-2; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 2003, ANNU REV CELL DEV BI, V19, P565, DOI 10.1146/annurev.cellbio.19.110701.153228; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Herman C, 2003, MOL CELL, V11, P659, DOI 10.1016/S1097-2765(03)00068-6; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Huang HC, 1997, J BIOL CHEM, V272, P21364, DOI 10.1074/jbc.272.34.21364; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Karata K, 2001, MOL MICROBIOL, V39, P890, DOI 10.1046/j.1365-2958.2001.02301.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Makino S, 1999, FEBS LETT, V460, P554, DOI 10.1016/S0014-5793(99)01411-8; Makyio H, 2002, BIOCHEM BIOPH RES CO, V296, P8, DOI 10.1016/S0006-291X(02)00830-6; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Neuwald AF, 1999, GENOME RES, V9, P27; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ogura T, 2003, MOL CELL, V11, P3, DOI 10.1016/S1097-2765(03)00004-2; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Shotland Y, 1997, MOL MICROBIOL, V24, P1303, DOI 10.1046/j.1365-2958.1997.4231796.x; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	50	107	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50182	50187		10.1074/jbc.M308327200	http://dx.doi.org/10.1074/jbc.M308327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514680	hybrid			2022-12-25	WOS:000187068200064
J	Bradley, KA; Mogridge, J; Rainey, GJA; Batty, S; Young, JAT				Bradley, KA; Mogridge, J; Rainey, GJA; Batty, S; Young, JAT			Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 ICAM-1; LETHAL FACTOR CLEAVES; PROTECTIVE ANTIGEN; I-DOMAIN; A-DOMAIN; CRYSTAL-STRUCTURE; QUALITY-CONTROL; GUINEA-PIGS; INFECTION; IDENTIFICATION	The secreted protein toxin produced by Bacillus anthracis contributes to virulence of this pathogen and can cause many of the symptoms seen during an anthrax infection, including shock and sudden death. The cell-binding component of anthrax toxin, protective antigen, mediates entry of the toxin into cells by first binding directly to the extracellular integrin-like inserted ( I) domain of the cellular anthrax toxin receptor, ATR. Here we report that this interaction requires an intact metal ion-dependent adhesion site (MIDAS) in the receptor as well as the presence of specific divalent cations. Also, we demonstrate that the toxin-receptor interaction is critically dependent on the Asp-683 carboxylate group of protective antigen, which projects from the receptor binding surface. We propose that this carboxylate group completes the coordination of the MIDAS metal of ATR, mimicking integrin-ligand interactions.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of California System; University of California Los Angeles; University of Wisconsin System; University of Wisconsin Madison; University of Toronto	Bradley, KA (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 609 Charles E Young Dr E, Los Angeles, CA 90095 USA.			Young, John/0000-0003-1824-2561	NCI NIH HHS [T32-CA09075, CA-16042] Funding Source: Medline; NIAID NIH HHS [AI48489, AI-28697] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042, T32CA009075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697, R01AI048489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beedham RJ, 2001, VACCINE, V19, P4409, DOI 10.1016/S0264-410X(01)00197-9; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Flick-Smith HC, 2002, INFECT IMMUN, V70, P1653, DOI 10.1128/IAI.70.3.1653-1656.2002; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kobiler D, 2002, INFECT IMMUN, V70, P544, DOI 10.1128/IAI.70.2.544-550.2002; Koradi R, 1996, J MOL GRAPHICS, V14, P29; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Little SF, 1997, INFECT IMMUN, V65, P5171, DOI 10.1128/IAI.65.12.5171-5175.1997; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; OBRIEN J, 1985, INFECT IMMUN, V47, P306, DOI 10.1128/IAI.47.1.306-310.1985; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; ROSOVITZ MJ, 2003, J BIOL CHEM; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Varughese M, 1999, INFECT IMMUN, V67, P1860; Varughese M, 1998, MOL MED, V4, P87, DOI 10.1007/BF03401732; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Wesche J, 1998, BIOCHEMISTRY-US, V37, P15737, DOI 10.1021/bi981436i; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259	35	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49342	49347		10.1074/jbc.M307900200	http://dx.doi.org/10.1074/jbc.M307900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507921	hybrid			2022-12-25	WOS:000186829000102
J	Matsubara, M; Titani, K; Taniguchi, H; Hayashi, N				Matsubara, M; Titani, K; Taniguchi, H; Hayashi, N			Direct involvement of protein myristoylation in myristoylated alanine-rich C kinase substrate (MARCKS)-calmodulin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARCKS-RELATED PROTEIN; CALMODULIN-BINDING; N-MYRISTOYLATION; BOVINE BRAIN; PHOSPHOLIPID-VESICLES; DEPENDENT BINDING; CATALYTIC SUBUNIT; PEPTIDE COMPLEX; MAJOR SUBSTRATE; PHOSPHORYLATION	MARCKS, a major in vivo substrate of protein kinase C, interacts with plasma membranes in a phosphorylation, myristoylation-, and calmodulin-dependent manner. Although we have previously observed that myristoylated and non-myristoylated MARCKS proteins behave differently during calmodulin-agarose chromatography, the role of protein myristoylation in the MARCKS-calmodulin interaction remained to be elucidated. Here we demonstrate that the myristoyl moiety together with the N-terminal protein domain is directly involved in the MARCKS-calmodulin interaction. Both myristoylated and non-myristoylated recombinant MARCKS bound to calmodulin-agarose at low ionic strengths, but only the former retained the affinity at high ionic strengths. A quantitative analysis obtained with dansyl (5-dimethylaminonaphthalene-1-sulfonyl)calmodulin showed that myristoylated MARCKS has an affinity higher than the non-myristoylated protein. Furthermore, a synthetic peptide based on the N-terminal sequence was found to bind calmodulin only when it was myristoylated. Only the N-terminal peptide but not the canonical calmodulin-binding domain showed the ionic strength-independent calmodulin binding. A mutation study suggested that the importance of the positive charge in the N-terminal protein domain in the binding.	Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 4701192, Japan	Fujita Health University	Matsubara, M (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Div Biomed Polymer Sci, Aichi 4701192, Japan.		Hayashi, Nobuhiro/F-6088-2011; Matsubara, Mamoru/AAP-4016-2021; Taniguchi, Hisaaki/I-9171-2012	Hayashi, Nobuhiro/0000-0002-9950-094X; Matsubara, Mamoru/0000-0002-8893-0485; 				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hayashi N, 2000, PROTEIN SCI, V9, P1905, DOI 10.1110/ps.9.10.1905; Hayashi N, 2002, PROTEIN SCI, V11, P529, DOI 10.1110/ps.23702; HERGET T, 1992, EUR J BIOCHEM, V209, P7, DOI 10.1111/j.1432-1033.1992.tb17255.x; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; Kennedy MT, 1996, J BIOL CHEM, V271, P26517, DOI 10.1074/jbc.271.43.26517; KIM JY, 1994, J BIOL CHEM, V269, P28214; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MANENTI S, 1995, BIOCHEM SOC T, V23, P561, DOI 10.1042/bst0230561; Matsubara M, 1998, FEBS LETT, V421, P203, DOI 10.1016/S0014-5793(97)01557-3; Matsubara M, 1997, J BIOL CHEM, V272, P23050, DOI 10.1074/jbc.272.37.23050; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; NOBUHIRO H, 2002, RECENT RES DEV BIOPH, V2, P33; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; SENIN II, 1995, FEBS LETT, V376, P87, DOI 10.1016/0014-5793(95)01187-2; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; Takasaki A, 1999, J BIOL CHEM, V274, P11848, DOI 10.1074/jbc.274.17.11848; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TANIGUCHI H, 1994, J BIOL CHEM, V269, P22481; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Ulrich A, 2000, P NATL ACAD SCI USA, V97, P5191, DOI 10.1073/pnas.090500397; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	49	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48898	48902		10.1074/jbc.M305488200	http://dx.doi.org/10.1074/jbc.M305488200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506265	hybrid			2022-12-25	WOS:000186829000047
J	Petrovic, N; Bhagwat, SV; Ratzan, WJ; Ostrowski, MC; Shapiro, LH				Petrovic, N; Bhagwat, SV; Ratzan, WJ; Ostrowski, MC; Shapiro, LH			CD13/APN transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPEPTIDASE-N; PROTEIN INTERACTIONS; VASCULAR DEVELOPMENT; ANGIOGENIC SWITCH; RNA INTERFERENCE; GENE-EXPRESSION; TUBE FORMATION; CORE PROMOTER; IN-VITRO; FAMILY	CD13/aminopeptidase N (CD13/APN) is a potent regulator of angiogenesis both in vitro and in vivo and transcription of CD13/APN in endothelial cells is induced by angiogenic growth factors via the RAS/MAPK pathway. We have explored the nuclear effectors downstream of this pathway that are responsible for CD13/APN induction. The response to serum/angiogenic growth factors mapped to a 38-bp region of the CD13/APN promoter containing an Ets-core motif that specifically binds a protein complex from nuclear lysates from activated endothelial cells. This motif and the proteins that target it are functionally relevant because mutation of this sequence abrogates CD13/APN transcription. Analysis of endothelial Ets family members showed that Ets-2, and to a lesser extent Ets-1, transactivate CD13/APN promoter activity via the Ets-core motif, whereas Fli, Erg, and NERF are ineffective. We investigated the possibility that the induction of CD13/APN is mediated by phosphorylation of Ets-2 via RAS/MAPK. A phosphorylation-defective Ets-2 mutant, T72A, failed to transactivate CD13/APN, suggesting that Ets-2 phosphorylation is obligatory for CD13/APN induction. To confirm a role for endogenous Ets-2 in CD13/APN expression, we specifically abrogated Ets-2 mRNA and protein by siRNA knockdown that significantly inhibited CD13/APN transcription. Finally, to assess the relevance of Ets-2 in endothelial cell function, we induced endothelial cells containing Ets-2 siRNA oligonucleotides to form capillary networks. Cells containing the Ets-2 inhibitory small interfering RNAs were completely incapable of forming the organized networks characteristic of endothelial morphogenesis. Thus, the phosphorylation of Ets-2 by RAS/MAPK is a prerequisite for CD13/APN endothelial induction and Ets-2 and its targets play essential roles in endothelial cell function.	Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol MC3501, Farmington, CT 06030 USA; OSI Pharmaceut Inc, Farmingdale, NY 11735 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Connecticut; Astellas Pharmaceuticals; OSI Pharmaceuticals; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Shapiro, LH (corresponding author), Univ Connecticut, Ctr Hlth, Dept Physiol, Ctr Vasc Biol MC3501, 263 Farmington Ave, Farmington, CT 06030 USA.	lshapiro@neuron.uchc.edu	Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [R01 CA 85714, R01 CA53271, R01 CA085714] Funding Source: Medline; NHLBI NIH HHS [R01 HL 69442, R01 HL069442] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085714, R01CA053271] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069442] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bhagwat SV, 2003, BLOOD, V101, P1818, DOI 10.1182/blood-2002-05-1422; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FALK K, 1994, IMMUNOGENETICS, V39, P230; FISHER RJ, 1991, ONCOGENE, V6, P2249; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Ghosh D, 2003, MOL ENDOCRINOL, V17, P11, DOI 10.1210/me.2002-0223; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; Hegde SP, 1999, BLOOD, V94, P1578, DOI 10.1182/blood.V94.5.1578.417k18_1578_1589; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; HOGG N, 1987, LEUKOCYTE TYPING, V3; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Kappel A, 2000, BLOOD, V96, P3078; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lie-Venema H, 2003, CIRC RES, V92, P749, DOI 10.1161/01.RES.0000066662.70010.DB; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MATSAS R, 1984, FEBS LETT, V175, P124, DOI 10.1016/0014-5793(84)80583-9; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Miyamoto T, 2000, J BIOL CHEM, V275, P2825, DOI 10.1074/jbc.275.4.2825; PALMIERI FE, 1989, BIOCHEM PHARMACOL, V38, P173, DOI 10.1016/0006-2952(89)90165-2; Pasqualini R, 2000, CANCER RES, V60, P722; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; Slupsky CM, 1998, BIOCHEM CELL BIOL, V76, P379, DOI 10.1139/bcb-76-2-3-379; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TURNER AJ, 1987, MAMMALIAN ECTOENZYME; WERNERT N, 1992, AM J PATHOL, V140, P119; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	48	50	52	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49358	49368		10.1074/jbc.M308071200	http://dx.doi.org/10.1074/jbc.M308071200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507917	hybrid			2022-12-25	WOS:000186829000104
J	Dong, MQ; Li, ZJ; Zang, MQ; Pinon, DI; Lybrand, TP; Miller, LJ				Dong, MQ; Li, ZJ; Zang, MQ; Pinon, DI; Lybrand, TP; Miller, LJ			Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor - Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PARATHYROID-HORMONE-RECEPTOR; CHOLECYSTOKININ RECEPTOR; DIRECT IDENTIFICATION; SEQUENCE ALIGNMENTS; BINDING DOMAIN; DISTINCT SITE; EXOLOOP 3; PEPTIDE; ACTIVATION	Photoaffinity labeling of receptors by bound agonists can provide important spatial constraints for molecular modeling of activated receptor complexes. Secretin is a 27-residue peptide hormone with a diffuse pharmacophoric domain that binds to the secretin receptor, a prototypic member of the Class B family of G protein-coupled receptors. In this work, we have developed, characterized, and applied two new photolabile probes for this receptor, with sites for covalent attachment in peptide positions 12 and 14, surrounding the previously most informative site of affinity labeling of this receptor. The [Tyr(10),(BzBz) Lys(12)] rat secretin-27 probe covalently labeled receptor residue Val(6), whereas the [Tyr(10),(BzBz) Lys(14)] rat secretin-27 probe labeled receptor residue Pro(38). When combined with previous photoaffinity labeling data, there are now seven independent sets of constraints distributed throughout the peptide and receptor amino-terminal domain that can be used together to generate a new molecular model of the ligand-occupied secretin receptor. The amino-terminal domain of this receptor presented a stable platform for peptide ligand interaction, with the amino terminus of the peptide hormone extended toward the transmembrane helix domain of the receptor. This provides clear insights into the molecular basis of natural ligand binding and supplies testable hypotheses regarding the molecular basis of activation of this receptor.	Vanderbilt Univ, Dept Chem, Scottsdale, AZ 85259 USA; Vanderbilt Univ, Ctr Struct Biol, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Vanderbilt University; Vanderbilt University; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Lybrand, TP (corresponding author), Vanderbilt Univ, Dept Chem, 5142 Biosci MRB III, Scottsdale, AZ 85259 USA.	lybrand@structbio.vanderbilt.edu; miller@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NINDS NIH HHS [NS-33290] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Barton G J, 1994, Methods Mol Biol, V25, P327; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Behar V, 2000, J BIOL CHEM, V275, P9, DOI 10.1074/jbc.275.1.9; Berger AC, 2001, J CLIN ONCOL, V19, P3051, DOI 10.1200/JCO.2001.19.12.3051; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Case D. A., 2002, AMBER 7; Chauvin S, 2000, MOL PHARMACOL, V57, P625, DOI 10.1124/mol.57.3.625; *CHEM COMP GROUP I, 2001, 200101 MOE CHEM COMP; CLORE GM, 1988, EUR J BIOCHEM, V171, P479, DOI 10.1111/j.1432-1033.1988.tb13814.x; Di Paolo E, 1999, RECEPTOR CHANNEL, V6, P309; Ding WQ, 2002, GASTROENTEROLOGY, V122, P500, DOI 10.1053/gast.2002.31039; Ding WQ, 2002, CANCER RES, V62, P5223; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Frimurer TM, 1999, PROTEINS, V35, P375, DOI 10.1002/(SICI)1097-0134(19990601)35:4<375::AID-PROT1>3.0.CO;2-2; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GREGORET LM, 1990, J MOL BIOL, V211, P959, DOI 10.1016/0022-2836(90)90086-2; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Horn F, 1998, RECEPTOR CHANNEL, V5, P305; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Macke TJ, 1998, ACS SYM SER, V682, P379; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park CG, 2000, J PHARMACOL EXP THER, V295, P682; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sohn J, 2002, J BIOL CHEM, V277, P50165, DOI 10.1074/jbc.M207646200; SWANSON E, 1995, PSSHOW SILICON GRAPH; Taylor WR, 2003, COMPUT BIOL CHEM, V27, P103, DOI 10.1016/S1476-9271(03)00020-3; *TRIP INC, 2003, SYB 6 9; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; Vilardaga JP, 1996, BIOCHEM BIOPH RES CO, V218, P842, DOI 10.1006/bbrc.1996.0150; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993	61	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48300	48312		10.1074/jbc.M309166200	http://dx.doi.org/10.1074/jbc.M309166200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500709	hybrid			2022-12-25	WOS:000186731400115
J	Sommer, U; Liu, H; Doering, TL				Sommer, U; Liu, H; Doering, TL			An alpha-1,3-mannosyltransferase of Cryptococcus neoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULE-ASSOCIATED GENE; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; PROTEIN COMPLEXES; RNA INTERFERENCE; MUTANT STRAINS; O-ACETYLATION; POLYSACCHARIDE; VIRULENCE; YEAST	Cryptococcus neoformans is a pathogenic fungus, distinguished by an elaborate polysaccharide capsule that is essential for its virulence. As part of an effort to understand the biosynthesis of this important structure, we initiated purification of an alpha-1,3-mannosyltransferase with appropriate specificity for a role in building the main capsule polysaccharide, glucuronoxylomannan. A pool of proteins that was 5,000-fold enriched in this activity included several polypeptides, which acted potentially as the catalytic protein. These were analyzed using sequence information and double-stranded RNA interference. Interference that targeted a sequence corresponding to part of a 46 kDa protein in the enriched fraction abolished the activity of interest and reduced the capsule on the affected cells. This gene was cloned and expressed in active form in Saccharomyces cerevisiae to confirm function, and was termed CMT1, for cryptococcal mannosyltransferase 1. CMT1 has no confirmed homologs in GenBank(TM) other than CAP59, a cryptococcal gene encoding a protein of unknown function that is required for capsule synthesis and virulence. The Cmt1p protein also co-purifies with a homolog of CAP64, a gene whose product has similarly been implicated in capsule synthesis and virulence. A strain disrupted in CMT1 was generated in C. neoformans; this had no effect on virulence in an animal model of cryptococcosis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Doering, TL (corresponding author), Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	doering@borcim.wustl.edu			NIAID NIH HHS [R01 AI49173] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049173] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANUMULA KR, 1994, ANAL BIOCHEM, V220, P275, DOI 10.1006/abio.1994.1338; Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; Bose I, 2003, EUKARYOT CELL, V2, P655, DOI 10.1128/EC.2.4.655-663.2003; Buchanan KL, 1998, EMERG INFECT DIS, V4, P71, DOI 10.3201/eid0401.980109; Casadevall A, 1998, CRYPTOCOCCUS NEOFORM; Chang YC, 1999, J BACTERIOL, V181, P5636, DOI 10.1128/JB.181.18.5636-5643.1999; Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996; CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912; Chang YC, 1998, INFECT IMMUN, V66, P2230, DOI 10.1128/IAI.66.5.2230-2236.1998; Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cleare W, 1999, INFECT IMMUN, V67, P3096, DOI 10.1128/IAI.67.6.3096-3107.1999; Cottrell TR, 2003, TRENDS MICROBIOL, V11, P37, DOI 10.1016/S0966-842X(02)00004-5; Cox GM, 2000, INFECT IMMUN, V68, P443, DOI 10.1128/IAI.68.2.443-448.2000; Davidson RC, 2000, FUNGAL GENET BIOL, V29, P38, DOI 10.1006/fgbi.1999.1180; Davidson RC, 2002, MICROBIOL-SGM, V148, P2607, DOI 10.1099/00221287-148-8-2607; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Doering TL, 1999, J BACTERIOL, V181, P5482, DOI 10.1128/JB.181.17.5482-5488.1999; Duro RM, 2003, CLIN DIAGN LAB IMMUN, V10, P252, DOI 10.1128/CDLI.10.2.252-258.2003; Feldmesser M, 2000, INFECT IMMUN, V68, P3642, DOI 10.1128/IAI.68.6.3642-3650.2000; FRASER CG, 1973, CAN J BIOCHEM CELL B, V51, P219, DOI 10.1139/o73-027; FROMTLING RA, 1982, MYCOPATHOLOGIA, V79, P23, DOI 10.1007/BF00636177; Girrbach V, 2003, J BIOL CHEM, V278, P12554, DOI 10.1074/jbc.M212582200; Heitman J, 1999, MYCOPATHOLOGIA, V148, P1, DOI 10.1023/A:1007136602930; Hochstenbach F, 1998, P NATL ACAD SCI USA, V95, P9161, DOI 10.1073/pnas.95.16.9161; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; JACOBSON ES, 1982, J BACTERIOL, V152, P932; JACOBSON ES, 1982, J BACTERIOL, V150, P1292, DOI 10.1128/JB.150.3.1292-1296.1982; Janbon G, 2001, MOL MICROBIOL, V42, P453, DOI 10.1046/j.1365-2958.2001.02651.x; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Jungmann J, 1999, J BIOL CHEM, V274, P6579, DOI 10.1074/jbc.274.10.6579; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Korf I, 2001, Bioinformatics, V17 Suppl 1, pS140; Kozel TR, 2003, INFECT IMMUN, V71, P2868, DOI 10.1128/IAI.71.5.2868-2875.2003; Liu H, 2002, GENETICS, V160, P463; Moyrand F, 2002, MOL MICROBIOL, V45, P837, DOI 10.1046/j.1365-2958.2002.03059.x; MUKHERJEE S, 1994, INFECT IMMUN, V62, P1079, DOI 10.1128/IAI.62.3.1079-1088.1994; ORLEAN P, 1992, BIOCHEM CELL BIOL, V70, P438, DOI 10.1139/o92-067; ROBBINS PW, 1991, BIOCHEM SOC T, V19, P642, DOI 10.1042/bst0190642; Roncero C, 2002, CURR GENET, V41, P367, DOI 10.1007/s00294-002-0318-7; Sentandreu R, 1984, Subcell Biochem, V10, P193; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; TOFFALETTI DL, 1993, J BACTERIOL, V175, P1405, DOI 10.1128/JB.175.5.1405-1411.1993; Vaishnav VV, 1998, CARBOHYD RES, V306, P315, DOI 10.1016/S0008-6215(97)10058-1; VARKI A, 1999, ESSENTIALS GLYCOBIOL, P258; WHITE CW, 1993, CAN J MICROBIOL, V39, P129, DOI 10.1139/m93-019; WHITE CW, 1990, J MED VET MYCOL, V28, P289; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wilder JA, 2002, AM J RESP CELL MOL, V26, P306, DOI 10.1165/ajrcmb.26.3.4479; Wills EA, 2001, MOL MICROBIOL, V40, P610, DOI 10.1046/j.1365-2958.2001.02401.x	53	48	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47724	47730		10.1074/jbc.M307223200	http://dx.doi.org/10.1074/jbc.M307223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504286	hybrid			2022-12-25	WOS:000186731400048
J	Tateyama, M; Rivolta, I; Clancy, CE; Kass, RS				Tateyama, M; Rivolta, I; Clancy, CE; Kass, RS			Modulation of cardiac sodium channel gating by protein kinase A can be altered by disease-linked mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; CAMP-DEPENDENT PHOSPHORYLATION; RAT SKELETAL-MUSCLE; I-II LINKER; ALPHA-SUBUNIT; NA+-CHANNEL; ADENYLATE-CYCLASE; CALCIUM CHANNELS; XENOPUS OOCYTES; INACTIVATION	Mutations associated with sodium channel-linked inherited Long-QT syndrome often result in a gain of channel function by disrupting channel inactivation. A small fraction of channels fail to inactivate ( burst) at depolarized potentials where normal ( wild type) channels fully inactivate. These noninactivating channels give rise to a sustained macroscopic current. We studied the effects of protein kinase A stimulation on sustained current in wild type and three disease-linked C-terminal mutant channels (D1790G, Y1795C, and Y1795H). We show that protein kinase A stimulation differentially affects gating in the mutant channels. Wild type, Y1795C, and Y1795H channels are insensitive to protein kinase A stimulation, whereas "bursting" in the D1790G mutant is markedly enhanced by protein kinase A-dependent phosphorylation. Our results suggest that the charge at position 1790 of the C terminus of the channel modulates the response of the cardiac sodium channel to protein kinase A stimulation and that phosphorylation of residue 36 in the N terminus and residue 525 in the cytoplasmic linker joining domains I and II of the channel alpha subunit facilitate destabilization of inactivation and thereby increase sustained current.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Kass, RS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St PH 7W 318, New York, NY 10032 USA.		Clancy, Colleen/B-2528-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021922, R01HL056810] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01 HL 21922, 1R01 HL 56810, P01 HL 66170] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; ATTWELL D, 1979, PFLUG ARCH EUR J PHY, V379, P137, DOI 10.1007/BF00586939; Baroudi G, 2000, FEBS LETT, V487, P224, DOI 10.1016/S0014-5793(00)02360-7; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Cantrell AR, 1997, J NEUROSCI, V17, P7330; Cantrell AR, 2001, NAT REV NEUROSCI, V2, P397, DOI 10.1038/35077553; Catterall WA, 1997, ADV SEC MESS PHOSPH, V31, P159; Catterall WA, 1996, J BIOENERG BIOMEMBR, V28, P219, DOI 10.1007/BF02110697; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Chandra R, 1999, CARDIOVASC RES, V42, P490, DOI 10.1016/S0008-6363(99)00042-5; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Clancy CE, 1999, NATURE, V400, P566, DOI 10.1038/23034; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Deschenes I, 2001, J MEMBRANE BIOL, V183, P103, DOI 10.1007/s00232-001-0058-5; DOWNS RW, 1980, J BIOL CHEM, V255, P949; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Frohnwieser B, 1997, J PHYSIOL-LONDON, V498, P309, DOI 10.1113/jphysiol.1997.sp021859; INOUE M, 1995, J GEN PHYSIOL, V105, P249, DOI 10.1085/jgp.105.2.249; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; Murphy BJ, 1996, J BIOL CHEM, V271, P28837, DOI 10.1074/jbc.271.46.28837; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; Ono K, 1999, CELL CALCIUM, V26, P37, DOI 10.1054/ceca.1999.0050; Pinkse MWH, 1999, BIOCHEMISTRY-US, V38, P9926, DOI 10.1021/bi990446w; Rivolta I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/jbc.M104471200; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; Schreibmayer W, 1999, CELL PHYSIOL BIOCHEM, V9, P187, DOI 10.1159/000016316; Smith RD, 1996, J NEUROSCI, V16, P1965; Smith RD, 2000, AM J PHYSIOL-CELL PH, V278, pC638, DOI 10.1152/ajpcell.2000.278.4.C638; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Zhang H, 2000, BBA-BIOMEMBRANES, V1467, P406, DOI 10.1016/S0005-2736(00)00238-8	38	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46718	46726		10.1074/jbc.M308977200	http://dx.doi.org/10.1074/jbc.M308977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14500710	hybrid			2022-12-25	WOS:000186569400062
J	Rohde, HM; Cheong, FY; Konrad, G; Paiha, K; Mayinger, P; Boehmelt, G				Rohde, HM; Cheong, FY; Konrad, G; Paiha, K; Mayinger, P; Boehmelt, G			The human phosphatidylinositol phosphatase SAC1 interacts with the coatomer I complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELIMINATED REGION-1 C3CER1; MICROSOMAL ATP TRANSPORT; EARLY SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; PHOSPHOINOSITIDE PHOSPHATASE; TRANSCRIPTIONAL MAP; TUMOR-SUPPRESSOR; MEMBRANE-PROTEIN; YEAST SAC1; GOLGI	The Saccharomyces cerevisiae SAC1 gene encodes an integral membrane protein of the endoplasmic reticulum (ER) and the Golgi apparatus. Yeast SAC1 mutants display a wide array of phenotypes including inositol auxotrophy, cold sensitivity, secretory defects, disturbed ATP transport into the ER, or suppression of actin gene mutations. At present, it is not clear how these phenotypes relate to the finding that SAC1 displays polyphosphoinositide phosphatase activity. Moreover, it is still an open question whether SAC1 functions similarly in mammalian cells, since some phenotypes are yeast-specific. Potential protein interaction partners and, connected to that, possible regulatory circuits have not been described. Therefore, we have cloned human SAC1 (hSAC1), show that it behaves similar to ySac1p in terms of substrate specificity, demonstrate that the endogenous protein localizes to the ER and Golgi, and identify for the first time members of the coatomer I (COPI) complex as interaction partners of hSAC1. Mutation of a putative COPI interaction motif (KXKXX) at its C terminus abolishes interaction with COPI and causes accumulation of hSAC1 in the Golgi. In addition, we generated a catalytically inactive mutant, demonstrate that its lipid binding capacity is unaltered, and show that it accumulates in the Golgi, incapable of interacting with the COPI complex despite the presence of the KXKXX motif. These results open the possibility that the enzymatic function of hSAC1 provides a switch for accessibility of the COPI interaction motif.	Boehringer Ingelheim Austria GmbH, A-1121 Vienna, Austria; Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria	Boehringer Ingelheim; Ruprecht Karls University Heidelberg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Boehmelt, G (corresponding author), Boehringer Ingelheim Austria GmbH, Dr Boehringer Gasse 5-11, A-1121 Vienna, Austria.							Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Barlowe C, 1998, BBA-MOL CELL RES, V1404, P67, DOI 10.1016/S0167-4889(98)00047-0; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Chaudhary A, 1998, J BIOL CHEM, V273, P8344, DOI 10.1074/jbc.273.14.8344; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Dressman MA, 2000, J HISTOCHEM CYTOCHEM, V48, P179, DOI 10.1177/002215540004800203; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; Hudson RT, 1997, MOL BIOL CELL, V8, P1901, DOI 10.1091/mbc.8.10.1901; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hughes WE, 1999, YEAST, V15, P1111, DOI 10.1002/(SICI)1097-0061(199908)15:11<1111::AID-YEA440>3.0.CO;2-H; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kiss H, 2002, EUR J HUM GENET, V10, P52, DOI 10.1038/sj.ejhg.5200758; Kiss H, 2001, GENOMICS, V73, P10, DOI 10.1006/geno.2000.6498; Kochendorfer KU, 1999, EMBO J, V18, P1506, DOI 10.1093/emboj/18.6.1506; Konrad G, 2002, J BIOL CHEM, V277, P10547, DOI 10.1074/jbc.M200090200; Lambert C, 2001, J BIOL CHEM, V276, P22265, DOI 10.1074/jbc.M100956200; Laporte J, 2001, TRENDS GENET, V17, P221, DOI 10.1016/S0168-9525(01)02245-4; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Minagawa T, 2001, J BIOL CHEM, V276, P22011, DOI 10.1074/jbc.M101579200; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Nemoto Y, 2000, J BIOL CHEM, V275, P34293, DOI 10.1074/jbc.M003923200; Nickel W, 2002, J CELL SCI, V115, P3235; NOVICK P, 1989, GENETICS, V121, P659; Rivas MP, 1999, MOL BIOL CELL, V10, P2235, DOI 10.1091/mbc.10.7.2235; Rusk N, 2003, CURR BIOL, V13, P659, DOI 10.1016/S0960-9822(03)00241-0; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Schorr M, 2001, CURR BIOL, V11, P1421, DOI 10.1016/S0960-9822(01)00449-3; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Wicky S, 2003, FEBS LETT, V537, P35, DOI 10.1016/S0014-5793(03)00067-X; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	49	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52689	52699		10.1074/jbc.M307983200	http://dx.doi.org/10.1074/jbc.M307983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527956	hybrid			2022-12-25	WOS:000187480700087
J	Hamberg, M; Sanz, A; Rodriguez, MJ; Calvo, AP; Castresana, C				Hamberg, M; Sanz, A; Rodriguez, MJ; Calvo, AP; Castresana, C			Activation of the fatty acid alpha-dioxygenase pathway during bacterial infection of tobacco leaves - Formation of oxylipins protecting against cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VICIA-FABA L; LIPOXYGENASE PATHWAY; POTATO LEAVES; HIGHER-PLANTS; IDENTIFICATION; BIOSYNTHESIS; ARABIDOPSIS; OXYGENASE; ENZYME; OXIDATION	A pathogen-induced oxygenase showing homology to prostaglandin endoperoxide synthases-1 and -2 was recently characterized by in vitro experiments as a fatty acid alpha-dioxygenase catalyzing formation of unstable 2(R)-hydroperoxy fatty acids. To study the activity of this enzyme under in vivo conditions and to elucidate the fate of enzymatically produced 2-hydroperoxides, leaves of tobacco were analyzed for the presence of alpha-dioxygenase-enerated compounds as well as for lipoxygenase (LOX) products and free fatty acids. Low basal levels of 2-hydroxylinolenic acid (0.4 nmol/g leaves fresh weight) and 8,11,14-heptadecatrienoic acid (0.1 nmol/g) could be demonstrated. These levels increased strongly upon infection with the bacterium Pseudomonas syringae pv syringae (548 and 47 nmol/g, respectively). Transgenic tobacco plants overexpressing alpha-dioxygenase were developed, and incompatible infection of such plants led to a dramatic elevation of 2-hydroxylinolenic acid (1778 nmol/g) and 8,11,14-heptadecatrienoic acid (86 nmol/g), whereas the levels of LOX products were strongly decreased. Further analysis of oxylipins in infected leaves revealed the presence of a number of 2-hydroxy fatty acids differing with respect to chain length and degree of unsaturation as well as two new doubly oxygenated oxylipins identified as 2(R),9(S)-dihydroxy-10(E), 12(Z), 15(Z)-octadecatrienoic acid and 2(R),9(S)-dihydroxy-10(E),12(Z)-octadecadienoic acid. alpha-Dioxygenase-generated 2-hydroxylinolenic acid, and to a lesser extent lipoxygenase-generated 9-hydroxyoctadecatrienoic acid, exerted a tissue-protective effect in bacterially infected tobacco leaves.	Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Karolinska Institutet; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Hamberg, M (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden.		Sánchez, Arturo/L-3622-2019	Sánchez, Arturo/0000-0002-4946-1559; Hamberg, Mats/0000-0002-8910-7810				Akakabe Y, 1999, TETRAHEDRON LETT, V40, P1137, DOI 10.1016/S0040-4039(98)02547-7; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; Borge GIA, 1997, BBA-LIPID LIPID MET, V1344, P47; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; de Leon IP, 2002, PLANT J, V29, P61, DOI 10.1046/j.1365-313x.2002.01195.x; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Gobel C, 2002, BBA-MOL CELL BIOL L, V1584, P55, DOI 10.1016/S1388-1981(02)00268-8; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Hamberg M, 1999, LIPIDS, V34, P1131, DOI 10.1007/s11745-999-0464-7; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Hamberg M, 2002, PROSTAG OTH LIPID M, V68-9, P363, DOI 10.1016/S0090-6980(02)00040-0; HAMBERG M, 1992, PLANT PHYSIOL, V99, P987, DOI 10.1104/pp.99.3.987; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V283, P409, DOI 10.1016/0003-9861(90)90662-I; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; Koeduka T, 2002, J BIOL CHEM, V277, P22648, DOI 10.1074/jbc.M110420200; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LUMMERZHEIM M, 1993, MOL PLANT MICROBE IN, V6, P532, DOI 10.1094/MPMI-6-532; Saffert A, 2000, PLANT PHYSIOL, V123, P1545, DOI 10.1104/pp.123.4.1545; Sambrook J., 2002, MOL CLONING LAB MANU; Sanz A, 1998, PLANT CELL, V10, P1523, DOI 10.1105/tpc.10.9.1523; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Vidal S, 1997, PLANT J, V11, P115, DOI 10.1046/j.1365-313X.1997.11010115.x; Weber H, 2002, TRENDS PLANT SCI, V7, P217, DOI 10.1016/S1360-1385(02)02250-1; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49	27	90	93	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51796	51805		10.1074/jbc.M310514200	http://dx.doi.org/10.1074/jbc.M310514200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522973	hybrid			2022-12-25	WOS:000187206300115
J	Goenka, S; Marlar, C; Schindler, U; Boothby, M				Goenka, S; Marlar, C; Schindler, U; Boothby, M			Differential roles of C-terminal activation motifs in the establishment of Stat6 transcriptional specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSACTIVATION DOMAINS; FUNCTIONAL INTERACTION; COACTIVATOR PROTEINS; EPSILON PROMOTER; GENE-REGULATION; IFN-GAMMA; CBP; INHIBITION; P300/CBP	Members of the Stat transcription factor family are specifically activated by cytokines, and each Stat mediates its biological effects through the trans-activation of a unique profile of target genes. This specificity is achieved even when Stat proteins mediating opposite transcriptional effects bind to the same palindromic Stat sites in target genes. We show here that the nonconserved sequences of Stat transcription activation domains (TADs) contribute to specificity in promoter activation. Chimeric proteins in which the Stat6 TAD was replaced by that from Stat1alpha or Stat5 exhibited normal interleukin-4-inducible DNA binding activity, but at best modest trans-activation of reporters containing Stat6 binding sites, and a failure to activate the endogenous CD23 promoter in primary B cells. The p160 coactivator nuclear coactivator-1 (Src-1) was specifically recruited by and coactivated Stat6 but not the chimeric Stat6 molecules. Strikingly, transcriptional responses exhibited distinct requirements for the nuclear coactivator-1 interaction motif of the Stat6 C terminus. Together, these findings indicate that the Stat6 TAD contributes to promoter specificity by the differential recruitment of and requirement for a p160-class coactivator.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol, Nashville, TN 37232 USA; Tularik GmbH, D-93053 Regensburg, Germany	Vanderbilt University; Vanderbilt University	Boothby, M (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.				NCI NIH HHS [CA68485] Funding Source: Medline; NIAID NIH HHS [T32AI07474] Funding Source: Medline; NIDDK NIH HHS [P60 DK20593] Funding Source: Medline; NIGMS NIH HHS [GM42550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042550, R01GM042550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; CONRAD DH, 1988, J IMMUNOL, V141, P1091; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Goenka S, 1999, J IMMUNOL, V163, P4663; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Litterst CM, 2001, J BIOL CHEM, V276, P45713, DOI 10.1074/jbc.M108132200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Mak HY, 2001, MOL CELL BIOL, V21, P4379, DOI 10.1128/MCB.21.13.4379-4390.2001; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; Ohmori Y, 1997, J IMMUNOL, V159, P5474; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Park HJ, 1998, MOL IMMUNOL, V35, P239, DOI 10.1016/S0161-5890(98)00022-4; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Wang DZ, 1996, INT IMMUNOL, V8, P977, DOI 10.1093/intimm/8.7.977; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Youn J, 1998, J EXP MED, V188, P1803, DOI 10.1084/jem.188.10.1803; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	49	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50362	50370		10.1074/jbc.M305854200	http://dx.doi.org/10.1074/jbc.M305854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14519766	hybrid			2022-12-25	WOS:000187068200086
J	Liu, CL; Eriste, E; Sutton, S; Chen, JC; Roland, B; Kuei, C; Farmer, N; Jornvall, H; Sillard, R; Lovenberg, TW				Liu, CL; Eriste, E; Sutton, S; Chen, JC; Roland, B; Kuei, C; Farmer, N; Jornvall, H; Sillard, R; Lovenberg, TW			Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANIN-CONCENTRATING-HORMONE; HUMAN THYROTROPIN RECEPTOR; INSULIN-LIKE PEPTIDE; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; HUMAN RELAXIN; FAMILY; CDNA; GENE; NEUROPEPTIDE	GPCR135, publicly known as somatostatin- and angiotensin-like peptide receptor, is expressed in the central nervous system and its cognate ligand(s) has not been identified. We have found that both rat and porcine brain extracts stimulated S-35-labeled guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) incorporation in cells overexpressing GPCR135. Multiple rounds of extraction, purification, followed by N-terminal sequence analysis of the ligand from porcine brain revealed that the ligand is a product of the recently identified gene, relaxin-3 (aka insulin-7 or INSL7). Recombinant human relaxin-3 potently stimulates GTPgammaS binding and inhibits cAMP accumulation in GPCR135 overexpressing cells with EC50 values of 0.25 and 0.35 nM, respectively. I-125-Relaxin-3 binds GPCR135 at high affinity with a K-d value of 0.31 nM. Relaxin-3 is the only member of the insulin/relaxin superfamily that can activate GPCR135. In situ hybridization showed that relaxin-3 mRNA is predominantly expressed in the dorsomedial ventral tegmental nucleus of the brainstem (aka nucleus incertus), as well as in discrete cells in the lateral periaqueductal gray and in the central gray nucleus. GPCR135 is expressed abundantly in the hypothalamus with discrete expression in the paraventricular nucleus of the hypothalamus and supraoptic nucleus, as well as in the cortex, septal nucleus, and preoptical area. Relaxin-3 has previously been shown to bind and activate the LGR7 relaxin receptor. However, we believe that neuroanatomical colocalization of GPCR135 and relaxin-3, coupled with a clear high affinity interaction, suggest that GPCR135 is the receptor for relaxin-3. The identification of relaxin-3 as the ligand for GPCR135 provides the framework for the discovery of a new brainstem/hypothalamus circuitry.	Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Johnson & Johnson; Johnson & Johnson USA; Karolinska Institutet	Liu, CL (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA.							ADHAM IM, 1993, J BIOL CHEM, V268, P26668; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; Brezillon S, 2003, J BIOL CHEM, V278, P776, DOI 10.1074/jbc.M206396200; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; Feighner SD, 1999, SCIENCE, V284, P2184, DOI 10.1126/science.284.5423.2184; Fujii R, 2002, J BIOL CHEM, V277, P34010, DOI 10.1074/jbc.M205883200; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; Goto M, 2001, J COMP NEUROL, V438, P86, DOI 10.1002/cne.1303; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Koman A, 1996, J BIOL CHEM, V271, P20238, DOI 10.1074/jbc.271.34.20238; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Matsumoto M, 2000, GENE, V248, P183, DOI 10.1016/S0378-1119(00)00123-2; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SHERWOOD OD, 1994, PHYSL REPRODUCTION, V1, P861; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; Shimomura Y, 2002, J BIOL CHEM, V277, P35826, DOI 10.1074/jbc.M205337200; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	46	277	293	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50754	50764		10.1074/jbc.M308995200	http://dx.doi.org/10.1074/jbc.M308995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522968	hybrid			2022-12-25	WOS:000187068200131
J	McIninch, JK; McIninch, JD; May, SW				McIninch, JK; McIninch, JD; May, SW			Catalysis, stereochemistry, and inhibition of ureidoglycolate lyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLGLYCINE ALPHA-MONOOXYGENASE; TRYPTOPHAN INDOLE-LYASE; PEPTIDE AMIDATION; GLYOXYLIC ACID; 2 ENZYMES; PEPTIDYLAMIDOGLYCOLATE LYASE; HYDROXYGLYCINE DERIVATIVES; STREPTOCOCCUS ALLANTOICUS; CRYSTAL-STRUCTURE; DEGRADATION	Ureidoglycolate lyase (UGL, EC 4.3.2.3) catalyzes the breakdown of ureidoglycolate to glyoxylate and urea, which is the final step in the catabolic pathway leading from purines to urea. Although the sequence of enzymatic steps was worked out nearly 40 years ago, the stereochemistry of the uric acid degradation pathway and the catalytic properties of UGL have remained very poorly described. We now report the first direct investigation of the absolute stereochemistry of UGL catalysis. Using chiral chromatographic analyses with substrate enantiomers, we demonstrate that UGL catalysis is stereospecific for substrates with the (S)-hydroxyglycine configuration. The first potent competitive inhibitors for UGL are reported here. These inhibitors are compounds which contain a 2,4-dioxocarboxylate moiety, designed to mimic transient species produced during lyase catalysis. The most potent inhibitor, 2,4-dioxo-4-phenylbutanoic acid, exhibits a K-I value of 2.2 nM and is therefore among the most potent competitive inhibitors ever reported for a lyase enzyme. New synthetic alternate substrates for UGL, which are acyl-alpha-hydroxyglycine compounds, are described. Based on these alternate substrates, we introduce the first assay method for monitoring UGL activity directly. Finally, we report the first putative primary nucleotide and derived peptide sequence for UGL. This sequence exhibits a high level of similarity to the fumarylacetoacetate hydrolase family of proteins. Close mechanistic similarities can be visualized between the chemistries of ureidoglycolate lyase and fumarylacetoacetate hydrolase catalysis.	Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	May, SW (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	sheldon.may@chemistry.gatech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040540] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40540] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHT AM, 1962, ANAL CHEM, V34, P398, DOI 10.1021/ac60183a028; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMRHEIN N, 1977, PLANT SCI LETT, V8, P313, DOI 10.1016/0304-4211(77)90148-1; Bateman RL, 2001, J BIOL CHEM, V276, P15284, DOI 10.1074/jbc.M007621200; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P624; BONGAERTS GPA, 1976, J BACTERIOL, V125, P689, DOI 10.1128/JB.125.2.689-697.1976; Brincat MC, 2002, BIOTECHNOL PROGR, V18, P1149, DOI 10.1021/bp0256115; BRUNEL A, 1936, THESIS U PARIS P AND; CHOI KS, 1966, ANAL BIOCHEM, V17, P413, DOI 10.1016/0003-2697(66)90177-1; CHOI KS, 1968, ARCH BIOCHEM BIOPHYS, V126, P261, DOI 10.1016/0003-9861(68)90582-1; Christman AA, 1944, J BIOL CHEM, V155, P161; Clift FP, 1932, BIOCHEM J, V26, P1788, DOI 10.1042/bj0261788; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; DIXON GH, 1959, BIOCHEM J, V72, pP3; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; DOMNAS A, 1962, J BIOCHEM-TOKYO, V52, P149; Echevin R, 1937, CR HEBD ACAD SCI, V205, P294; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; ELZAINY TA, 1982, ZBL MIKROBIOL, V137, P133; FALKINHAM JO, 1983, J BACTERIOL, V155, P36, DOI 10.1128/JB.155.1.36-39.1983; GAUDY ET, 1965, J BACTERIOL, V90, P1531, DOI 10.1128/JB.90.6.1531-1536.1965; GAUDY ET, 1965, J BACTERIOL, V90, P1525, DOI 10.1128/JB.90.6.1525-1530.1965; Hartmann RW, 2000, J MED CHEM, V43, P4266, DOI 10.1021/jm001008m; Hartmann RW, 2000, J MED CHEM, V43, P4437, DOI 10.1021/jm991070n; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; Ideyama Y, 1998, PROSTATE, V37, P10; KASPARI H, 1986, ARCH MICROBIOL, V144, P67, DOI 10.1007/BF00454958; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KATOPODIS AG, 1988, BIOCHEM BIOPH RES CO, V151, P499, DOI 10.1016/0006-291X(88)90621-3; KAWAHARA T, 1992, J CHEM SOC CHEM COMM, P625, DOI 10.1039/c39920000625; KREBS HA, 1935, PROBL BIOL MED, P497; MACHIDA Y, 1982, AGR BIOL CHEM TOKYO, V46, P2135, DOI 10.1080/00021369.1982.10865395; MCFADDEN BA, 1960, ANAL BIOCHEM, V1, P240, DOI 10.1016/0003-2697(60)90051-8; McIninch JK, 1998, J CHROMATOGR A, V828, P191, DOI 10.1016/S0021-9673(98)00651-7; Mothes K., 1952, Flora, Jena, V139, P586; Mounier CE, 1997, J BIOL CHEM, V272, P5016, DOI 10.1074/jbc.272.8.5016; O'Carra P, 1974, Methods Enzymol, V34, P598; Paulsen IT, 2002, P NATL ACAD SCI USA, V99, P13148, DOI 10.1073/pnas.192319099; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1989, J AM CHEM SOC, V111, P727, DOI 10.1021/ja00184a051; Piedras P, 2000, ARCH BIOCHEM BIOPHYS, V378, P340, DOI 10.1006/abbi.2000.1833; PINEDA M, 1994, ANAL BIOCHEM, V222, P450, DOI 10.1006/abio.1994.1515; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; PING DS, 1995, J BIOL CHEM, V270, P29250, DOI 10.1074/jbc.270.49.29250; REINERT WR, 1975, ARCH BIOCHEM BIOPHYS, V166, P565, DOI 10.1016/0003-9861(75)90421-X; SGRAVENMADE EJ, 1970, BIOCHIM BIOPHYS ACTA, V198, P569, DOI 10.1016/0005-2744(70)90134-8; SODA K, 1973, AGR BIOL CHEM TOKYO, V37, P1393, DOI 10.1080/00021369.1973.10860828; SPIKNER JE, 1962, ANAL CHEM, V34, P1468, DOI 10.1021/ac60191a035; TAKADA Y, 1986, BIOCHEM J, V235, P391, DOI 10.1042/bj2350391; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; TRIJBELS F, 1966, BIOCHIM BIOPHYS ACTA, V113, P292, DOI 10.1016/S0926-6593(66)80068-1; TRIJBELS F, 1969, COMP BIOCHEM PHYSIOL, V30, P359, DOI 10.1016/0010-406X(69)90817-2; TRIJBELS F, 1967, BIOCHIM BIOPHYS ACTA, V132, P115, DOI 10.1016/0005-2744(67)90197-0; TRIJBELS F, 1966, BIOCHIM BIOPHYS ACTA, V118, P387, DOI 10.1016/S0926-6593(66)80047-4; VALENTINE R, 1961, BIOCHEM BIOPH RES CO, V5, P305, DOI 10.1016/0006-291X(61)90168-1; VALENTINE RC, 1962, J BIOL CHEM, V237, P2271; VANDERDRIFT C, 1967, BIOCHIM BIOPHYS ACTA, V139, P162, DOI 10.1016/0005-2744(67)90122-2; VANDERDRIFT C, 1970, BIOCHIM BIOPHYS ACTA, V198, P339, DOI 10.1016/0005-2744(70)90067-7; VANDERDRIFT C, 1981, A LEEUWENHOEK, V7, P565; VANDERWERF MJ, 1994, TRENDS BIOTECHNOL, V12, P95, DOI 10.1016/0167-7799(94)90112-0; VOGELS GD, 1969, RECL TRAV CHIM PAY-B, V88, P951; VOGELS GD, 1970, ANAL BIOCHEM, V33, P143, DOI 10.1016/0003-2697(70)90448-3; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; VOGELS GD, 1969, BIOCHIM BIOPHYS ACTA, V185, P186, DOI 10.1016/0005-2744(69)90294-0; YOSHIDA T, 1993, ANAL BIOCHEM, V208, P296, DOI 10.1006/abio.1993.1049; ZAREMBSK.PM, 1965, BIOCHEM J, V96, P218, DOI 10.1042/bj0960218	66	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50091	50100		10.1074/jbc.M303828200	http://dx.doi.org/10.1074/jbc.M303828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506266	hybrid			2022-12-25	WOS:000187068200053
J	Pilloff, DE; Leyh, TS				Pilloff, DE; Leyh, TS			Allosteric and catalytic functions of the PPi-binding motif in the ATP sulfurylase-GTPase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE ACTIVATION LOCUS; HEPARIN COFACTOR-II; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; BACILLUS-SUBTILIS; P-LOOP; SYNTHETASE; THROMBIN; SULFOTRANSFERASES; INHIBITION	ATP sulfurylase, from Escherichia coli K-12, catalyzes and couples the Gibbs potentials of two reactions, GTP hydrolysis and activated sulfate (APS, adenosine 5'-phosphosulfate) synthesis. Coupling these potentials requires that the catalytic cycle include reaction stage-dependent conformational changes that gate the activities of the two active sites. These interactions were probed in a mutagenesis study of a highly conserved pyrophosphate-binding motif (SXGXDS), which is located at the APS-forming active site. The motif appears to be unique to the N-type PPi synthetase family, and mutations in it are linked, in other systems, to citrullinemia, an often fatal orphan disease. The conserved sites in the motif were evaluated individually for their ability to activate GTP hydrolysis ( which reports interactions among the activator (AMP or Mg2+ . PPi), the enzyme, and GTP), to affect the energetic coupling of the two reactions, and to alter the kinetic constants of the adenylyl transfer reaction in the absence of guanine nucleotide. What emerges from this first mutagenic exploration of the PPi motif in any adenylyltransferase is that the residues of the motif participate differently, and in sometimes profoundly important ways, in the different functions of the enzyme.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Leyh, TS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054469] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54469] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; Cleland W W, 1979, Methods Enzymol, V63, P103; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; ISHIHARA M, 1993, GLYCOBIOLOGY, V3, P83, DOI 10.1093/glycob/3.1.83; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; Lemke CT, 2001, STRUCTURE, V9, P1153, DOI 10.1016/S0969-2126(01)00683-9; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P542; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIU CX, 1994, BIOCHEMISTRY-US, V33, P7309, DOI 10.1021/bi00189a036; NAGATA N, 1991, AM J MED GENET, V39, P228, DOI 10.1002/ajmg.1320390226; NESSI C, 1995, J BIOL CHEM, V270, P6181, DOI 10.1074/jbc.270.11.6181; ODOM JM, 1993, SULFATE REDUCING BAC, P1; PASQUALINI JR, 1992, J STEROID BIOCHEM, V41, P323, DOI 10.1016/0960-0760(92)90358-P; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Savage H, 1997, STRUCTURE, V5, P895, DOI 10.1016/S0969-2126(97)00244-X; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Sukal S, 2001, BIOCHEMISTRY-US, V40, P15009, DOI 10.1021/bi015735a; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG RX, 1995, BIOCHEMISTRY-US, V34, P490, DOI 10.1021/bi00002a013; Wei J, 1998, BIOCHEMISTRY-US, V37, P17163, DOI 10.1021/bi9817461; Wei J, 1999, BIOCHEMISTRY-US, V38, P6311, DOI 10.1021/bi990216h; Wei J, 2002, BIOCHEMISTRY-US, V41, P8493, DOI 10.1021/bi025953j; Yang M, 1997, BIOCHEMISTRY-US, V36, P3270, DOI 10.1021/bi962140k	33	2	2	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50435	50441		10.1074/jbc.M306897200	http://dx.doi.org/10.1074/jbc.M306897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506286	hybrid			2022-12-25	WOS:000187068200095
J	Wheeler, GL; Trotter, EW; Dawes, IW; Grant, CM				Wheeler, GL; Trotter, EW; Dawes, IW; Grant, CM			Coupling of the transcriptional regulation of glutathione biosynthesis to the availability of glutathione and methionine via the Met4 and Yap1 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; CENTROMERE-BINDING FACTOR-1; OXIDATIVE STRESS-RESPONSE; PROTEIN S-THIOLATION; HYDROGEN-PEROXIDE; GSH1 GENE; ACTIVATOR MET4; TARGET GENE; EXPRESSION	Depletion of the cellular pool of glutathione is detrimental to eukaryotic cells and in Saccharomyces cerevisiae leads to sensitivity to oxidants and xenobiotics and an eventual cell cycle arrest. Here, we show that the Yap1 and Met4 transcription factors regulate the expression of gamma-glutamylcysteine synthetase (GSH1), encoding the rate-limiting enzyme in glutathione biosynthesis to prevent the damaging effects of glutathione depletion. Transcriptional profiling of a gsh1 mutant indicates that glutathione depletion leads to a general activation of Yap1 target genes, but the expression of Met4-regulated genes remains unaltered. Glutathione depletion appears to result in Yap1 activation via oxidation of thioredoxins, which normally act to down-regulate the Yap1-mediated response. The requirement for Met4 in regulating GSH1 expression is lost in the absence of the centromere-binding protein Cbf1. In contrast, the Yap1-mediated effect is unaffected, indicating that Met4 acts via Cbf1 to regulate the Yap1-mediated induction of GSH1 expression in response to glutathione depletion. Furthermore, yeast cells exposed to the xenobiotic 1-chloro-2,4-dintrobenzene are rapidly depleted of glutathione, accumulate oxidized thioredoxins, and elicit the Yap1/Met4-dependent transcriptional response of GSH1. The addition of methionine, which promotes Met4 ubiquitination and inactivation, specifically represses GSH1 expression after 1-chloro-2,4-dintrobenzene exposure but does not affect Yap1 activation. These results indicate that the Yap1-dependant activation of GSH1 expression in response to glutathione depletion is regulated by the sulfur status of the cell through a specific Met4-dependant mechanism.	UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of Manchester; University of New South Wales Sydney	Grant, CM (corresponding author), UMIST, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.		Wheeler, Glen L/E-5034-2011	Grant, Chris/0000-0002-0616-6576				Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; Blaiseau PL, 1997, MOL CELL BIOL, V17, P3640, DOI 10.1128/MCB.17.7.3640; Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DEWINDE JH, 1992, MOL CELL BIOL, V12, P2872, DOI 10.1128/MCB.12.6.2872; Dormer UH, 2000, J BIOL CHEM, V275, P32611, DOI 10.1074/jbc.M004167200; Dormer UH, 2002, BBA-GENE STRUCT EXPR, V1576, P23, DOI 10.1016/S0167-4781(02)00248-8; DOUGLAS KT, 1987, ADV ENZYMOL RAMB, V59, P103; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Grant CM, 1996, REDOX REP, V2, P223, DOI 10.1080/13510002.1996.11747054; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; Harding CO, 1997, J BIOL CHEM, V272, P12560, DOI 10.1074/jbc.272.19.12560; Inoue Y, 1998, BBA-GENE STRUCT EXPR, V1395, P315, DOI 10.1016/S0167-4781(97)00199-1; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; KURAS L, 1995, FEBS LETT, V367, P15, DOI 10.1016/0014-5793(95)00528-H; Kuras L, 1997, EMBO J, V16, P2441, DOI 10.1093/emboj/16.9.2441; Kuras L, 1996, EMBO J, V15, P2519, DOI 10.1002/j.1460-2075.1996.tb00609.x; LARSSON A, 1990, GLUTATHIONE METABOLI, P359; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Lee MA, 2000, ARCH NEUROL-CHICAGO, V57, P65, DOI 10.1001/archneur.57.1.65; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LISOWSKY T, 1993, CURR GENET, V23, P408, DOI 10.1007/BF00312627; MARTENSSON J, 1991, P NATL ACAD SCI USA, V88, P9360, DOI 10.1073/pnas.88.20.9360; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moreau JL, 2003, MOL CELL, V11, P1609, DOI 10.1016/S1097-2765(03)00184-9; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Spector D, 2001, J BIOL CHEM, V276, P7011, DOI 10.1074/jbc.M009814200; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stephen DWS, 1996, FEMS MICROBIOL LETT, V141, P207, DOI 10.1111/j.1574-6968.1996.tb08386.x; Sugiyama K, 2000, J BIOL CHEM, V275, P15535, DOI 10.1074/jbc.275.20.15535; Takeuchi T, 1997, FEBS LETT, V416, P339, DOI 10.1016/S0014-5793(97)01233-7; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; Westwater J, 2002, YEAST, V19, P233, DOI 10.1002/yea.835; Wheeler GL, 2002, MOL MICROBIOL, V46, P545, DOI 10.1046/j.1365-2958.2002.03174.x; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	62	55	55	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49920	49928		10.1074/jbc.M310156200	http://dx.doi.org/10.1074/jbc.M310156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514673	hybrid			2022-12-25	WOS:000187068200034
J	Alves, ID; Salamon, Z; Varga, E; Yamamura, HI; Tollin, G; Hruby, VJ				Alves, ID; Salamon, Z; Varga, E; Yamamura, HI; Tollin, G; Hruby, VJ			Direct observation of G-protein binding to the human delta-opioid receptor using plasmon-waveguide resonance spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BILAYER-MEMBRANES; BETA(2) ADRENERGIC-RECEPTOR; MULTIPLE G-PROTEINS; COUPLED RECEPTORS; DRUG EFFICACY; AGONISTS; SYSTEM; ACTIVATION; CONFORMATIONS; INTERACT	Using a recently developed method (Salamon, Z., Macleod, H. A., and Tollin, G. (1997) Biophys. J. 73, 2791 - 2797), plasmon-waveguide resonance spectroscopy, we have been able, for the first time, to directly measure the binding between the human brain delta-opioid receptor (hDOR) and its G-protein effectors in real-time. We have found that the affinity of the G-proteins toward the receptor is highly dependent on the nature of the ligand pre-bound to the receptor. The highest affinity was observed when the receptor was bound to an agonist (similar to10 nM); the lowest when receptor was bound to an antagonist (similar to 500 nM); and no binding at all was observed when the receptor was bound to an inverse agonist. We also have found direct evidence for the existence of an additional G-protein binding conformational state that corresponds to the unliganded receptor, which has a G-protein binding affinity of similar to 60 nM. Furthermore, GTP binding to the receptor . G-protein complex was only observed when the agonist was pre-bound. Similar studies were carried out using the individual G-protein subtypes for both the agonist and the unliganded receptor. Significant selectivity toward the different G-protein subtypes was observed. Thus, the unliganded receptor had highest affinity toward the Galpha(o) (K-d similar to 20 nM) and lowest affinity toward the Galpha(i2) (similar to 590 nM) subtypes, whereas the agonist-bound state had highest affinity for the Galpha(o) and Galpha(i2) subtypes (K-d similar to 9 nM and similar to 7 nM, respectively). GTP binding was also highly selective, both with respect to ligand and G-protein subtype. We believe that this methodology provides a powerful new way of investigating transmembrane signaling.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Hruby, VJ (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1306 E Univ Blvd,Old Chem Bldg, Tucson, AZ 85721 USA.		Alves, Isabel D/R-9613-2016	Alves, Isabel D/0000-0003-3193-2436	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013449, P01DA006284] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-13449, DA-06284] Funding Source: Medline; NIGMS NIH HHS [GM59630] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieri C, 1999, NAT BIOTECHNOL, V17, P1105, DOI 10.1038/15090; Breivogel CS, 1998, J BIOL CHEM, V273, P16865, DOI 10.1074/jbc.273.27.16865; Brown GP, 1998, J PHARMACOL EXP THER, V286, P376; Chen SH, 2000, EMBO J, V19, P4265, DOI 10.1093/emboj/19.16.4265; Gazi L, 2003, BRIT J PHARMACOL, V138, P775, DOI 10.1038/sj.bjp.0705116; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; KNAPP RJ, 1994, LIFE SCI, V54, P463; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; Law SF, 1997, J PHARMACOL EXP THER, V281, P1476; Liao SB, 1997, BIOORG MED CHEM LETT, V7, P3049, DOI 10.1016/S0960-894X(97)10145-7; Milligan G, 1997, RECEPTOR CHANNEL, V5, P209; Moon HE, 2001, J NEUROCHEM, V76, P1805, DOI 10.1046/j.1471-4159.2001.00196.x; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Okura T, 2000, EUR J PHARMACOL, V387, pR11, DOI 10.1016/S0014-2999(99)00761-X; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; Quock RM, 1997, EUR J PHARMACOL, V326, P101, DOI 10.1016/S0014-2999(97)83488-7; Quock RM, 1999, PHARMACOL REV, V51, P503; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; Salamon Z, 2000, BIOPHYS J, V79, P2463, DOI 10.1016/S0006-3495(00)76489-7; Salamon Z, 1997, BIOPHYS J, V73, P2791, DOI 10.1016/S0006-3495(97)78308-5; Salamon Z, 2002, J PEPT RES, V60, P322, DOI 10.1034/j.1399-3011.2002.21060.x; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; SALAMON Z, 1991, BIOELECTROCH BIOENER, V26, P321, DOI 10.1016/0302-4598(91)80033-Y; Salamon Z, 1998, BIOPHYS J, V75, P1874, DOI 10.1016/S0006-3495(98)77628-3; Salamon Z, 2000, BIOPHYS J, V78, P1400, DOI 10.1016/S0006-3495(00)76693-8; Salamon Z, 2003, BIOPHYS J, V84, P1796, DOI 10.1016/S0006-3495(03)74987-X; Salamon Z, 1996, BIOPHYS J, V71, P283, DOI 10.1016/S0006-3495(96)79224-X; Salamon Z, 2001, BIOPHYS J, V80, P1557, DOI 10.1016/S0006-3495(01)76128-0; SALAMON Z, 1999, ENCY SPECTROSCOPY SP, V3, P2311; SALAMON Z, 1999, ENCY SPECTROSCOPY SP, V3, P2294; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; TOTA MR, 1990, MOL PHARMACOL, V37, P996	37	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48890	48897		10.1074/jbc.M306866200	http://dx.doi.org/10.1074/jbc.M306866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522991	hybrid			2022-12-25	WOS:000186829000046
J	Csitkovits, VC; Zechner, EL				Csitkovits, VC; Zechner, EL			Extent of single-stranded DNA required for efficient TraI helicase activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER ORIGIN; BIOCHEMICAL-CHARACTERIZATION; MACROMOLECULAR MACHINES; CRYSTAL-STRUCTURE; GENE-PRODUCT; SEX FACTOR; PROTEIN; NICKING; CLEAVAGE	The IncF plasmid protein TraI functions during bacterial conjugation as a site- and strand-specific DNA transesterase and a highly processive 5' to 3' DNA helicase. The N-terminal DNA transesterase domain of TraI localizes the protein to nic and cleaves this site within the plasmid transfer origin. In the cell the C-terminal DNA helicase domain of TraI is essential for driving the 5' to 3' unwinding of plasmid DNA from nic to provide the strand destined for transfer. In vitro, however, purified TraI protein cannot enter and unwind nicked plasmid DNA and instead requires a 5' tail of single-stranded DNA at the duplex junction. In this study we evaluate the extent of single-stranded DNA adjacent to the duplex that is required for efficient TraI-catalyzed DNA unwinding in vitro. A series of linear partial duplex DNA substrates containing a central stretch of single-stranded DNA of defined length was created and its structure verified. We found that substrates containing greater than or equal to 27 nucleotides of single-stranded DNA 5' to the duplex were unwound efficiently by TraI, whereas substrates containing 20 or fewer nucleotides were not. These results imply that during conjugation localized unwinding of > 20 nucleotides at nic is necessary to initiate unwinding of plasmid DNA strands.	Karl Franzens Univ Graz, Inst Mol Biol Biochem & Mikrobiol, A-8010 Graz, Austria	University of Graz	Zechner, EL (corresponding author), Karl Franzens Univ Graz, Inst Mol Biol Biochem & Mikrobiol, Univ Pl 2, A-8010 Graz, Austria.	ellen.zechner@uni-graz.at		Zechner, Ellen L./0000-0003-2035-1898				ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P667, DOI 10.1016/S0022-2836(77)80083-1; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; [Anonymous], 1996, ESCHERICHIA COLI SAL; BRASCH MA, 1986, J BACTERIOL, V167, P703, DOI 10.1128/jb.167.2.703-710.1986; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; Byrd DR, 2002, J BIOL CHEM, V277, P42645, DOI 10.1074/jbc.M205984200; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; DATTA S, 2003, IN PRESS STRUCTURE, V11; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FRANCIA VM, 2003, IN PRESS FEMS MICROB; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GRANDOSO G, 1994, EUR J BIOCHEM, V226, P403, DOI 10.1111/j.1432-1033.1994.tb20065.x; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; HOWARD MT, 1995, J BIOL CHEM, V270, P28381; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P838, DOI 10.1093/oxfordjournals.jbchem.a124604; Karl W, 2001, J BACTERIOL, V183, P909, DOI 10.1128/JB.183.3.909-914.2001; KLINE BC, 1971, BIOCHEMISTRY-US, V10, P4975, DOI 10.1021/bi00802a022; Konieczny I, 2003, EMBO REP, V4, P37, DOI 10.1038/sj.embor.embor703; KUHN B, 1979, J BIOL CHEM, V254, P1343; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; Linden RM, 1996, P NATL ACAD SCI USA, V93, P11288, DOI 10.1073/pnas.93.21.11288; Llosa M, 1996, J MOL BIOL, V264, P56, DOI 10.1006/jmbi.1996.0623; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; MATSON SW, 1991, J BIOL CHEM, V266, P16232; Matson SW, 2001, J BIOL CHEM, V276, P2372, DOI 10.1074/jbc.M008728200; Miller J. H., 1972, EXPT MOL GENETICS, P433; Moncalian G, 1997, J MOL BIOL, V270, P188, DOI 10.1006/jmbi.1997.1082; Moncalian G, 1999, MOL MICROBIOL, V31, P1643, DOI 10.1046/j.1365-2958.1999.01288.x; NELSON WC, 1995, J BIOL CHEM, V270, P28374; OWENS RA, 1993, J VIROL, V67, P997, DOI 10.1128/JVI.67.2.997-1005.1993; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; Perwez T, 1996, J BACTERIOL, V178, P5762, DOI 10.1128/jb.178.19.5762-5767.1996; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; SCHERZINGER E, 1992, NUCLEIC ACIDS RES, V20, P41, DOI 10.1093/nar/20.1.41; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Stern JC, 2001, BIOCHEMISTRY-US, V40, P11586, DOI 10.1021/bi010877q; Street LM, 2003, BBA-PROTEINS PROTEOM, V1646, P86, DOI 10.1016/S1570-9639(02)00553-8; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLIAMS MMR, 1979, ANN NUCL ENERGY, V6, P145, DOI 10.1016/0306-4549(79)90082-3; Zechner E. L., 2000, HORIZONTAL GENE POOL, P87; Zechner EL, 1997, P NATL ACAD SCI USA, V94, P7435, DOI 10.1073/pnas.94.14.7435; Zhang SY, 1997, MOL MICROBIOL, V25, P509, DOI 10.1046/j.1365-2958.1997.4861849.x; Zhou XH, 1999, J VIROL, V73, P1580, DOI 10.1128/JVI.73.2.1580-1590.1999; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279	56	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48696	48703		10.1074/jbc.M310025200	http://dx.doi.org/10.1074/jbc.M310025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506243	hybrid			2022-12-25	WOS:000186829000024
J	Kim, TK; Lee, P; Colman, RF				Kim, TK; Lee, P; Colman, RF			Critical role of Lys(212) and Tyr(140) in porcine NADP-dependent isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PIG-HEART; ESCHERICHIA-COLI; CHEMICAL RESCUE; BINDING-SITE; ACTIVE-SITE; SUBSTRATE-BINDING; BRONSTED ANALYSIS; CRYSTAL-STRUCTURE; EXOGENOUS AMINES	Lys(212) and Tyr(140) are close to the enzyme-bound isocitrate in the recently determined crystal structure of porcine NADP-specific isocitrate dehydrogenase (Ceccarelli, C., Grodsky, N. B., Ariyaratne, N., Colman, R. F., and Bahnson, B. J. ( 2002) J. Biol. Chem. 277, 43454 43462). We have constructed mutant enzymes in which Lys(212) is replaced by Gln, Tyr, and Arg, and Tyr(140) is replaced by Phe, Thr, Glu, and Lys. Wild type and mutant enzymes were each expressed in Escherichia coli and purified to homogeneity. At pH 7.4, the specific activity is decreased in K212Q, K212Y, and K212R, respectively, to 0.01 - 9% of wild type. The most striking change is in the pH-V-max curves. Wild type depends on the deprotonated form of a group of pK(aes) 5.7, whereas this pK(aes) is increased to 7.4 in neutral K212Q and to 8.3 in K212Y. In contrast, the positive K212R has a pK(aes) of 5.9. These results indicate that ( by electrostatic repulsion) a positively charged residue at position 212 lowers the pK of the nearby ionizable group in the enzyme-substrate complex. Lys(212) may also stabilize the carbanion formed initially on substrate decarboxylation. The Tyr(140) mutants have specific activities at pH 7.4 that are reduced to 0.2 - 0.5% of those of wild type, whereas their K-m values for isocitrate and NADP are not increased. Most notable are the altered pH-V-max profiles. V-max is constant from pH 5.3 to 8 for Y140F and Y140T and increases as pH is decreased for Y140E and Y140K. These results suggest that in wild type enzyme, Tyr(140) is the general acid that protonates the substrate after decarboxylation and that the carboxyl and ammonium forms of Y140E and Y140K provide partial substitutes. Relative to wild type, the Y140T enzyme is specifically activated 106-fold by exogenous addition of acetic acid and 88-fold by added phenol; and the K212Q enzyme is activated 4-fold by added ethylamine. These chemical rescue experiments support the conclusion that Tyr(140) and Lys(212) are required for the catalytic activity of porcine NADP-dependent isocitrate dehydrogenase.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.				NHLBI NIH HHS [R01 HL67774] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067774] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, BIOCHEMISTRY-US, V24, P5367, DOI 10.1021/bi00341a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; COLMAN RF, 1973, J BIOL CHEM, V248, P8137; COLMAN RF, 1972, J BIOL CHEM, V247, P215; COLMAN RF, 1983, PEPTIDE PROTEIN REV, V1, P41; Duda D, 2001, BIOCHEMISTRY-US, V40, P1741, DOI 10.1021/bi002295z; EHRLICH RS, 1987, BIOCHEMISTRY-US, V26, P3461, DOI 10.1021/bi00386a032; EHRLICH RS, 1976, BIOCHEMISTRY-US, V15, P4034, DOI 10.1021/bi00663a018; Grodsky NB, 2000, BIOCHEMISTRY-US, V39, P2193, DOI 10.1021/bi9919753; HARPEL MR, 1994, BIOCHEMISTRY-US, V33, P5553, DOI 10.1021/bi00184a026; HASELBECK RJ, 1992, BIOCHEMISTRY-US, V31, P6219, DOI 10.1021/bi00142a007; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Huang YC, 2002, BIOCHEMISTRY-US, V41, P5637, DOI 10.1021/bi0200716; JOHANSON RA, 1981, ARCH BIOCHEM BIOPHYS, V207, P9, DOI 10.1016/0003-9861(81)90002-3; Kim TK, 2003, FASEB J, V17, pA984; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Madhusoodanan KS, 2001, BIOCHEMISTRY-US, V40, P1577, DOI 10.1021/bi002336r; ROSE ZB, 1960, J BIOL CHEM, V235, P928; Sakurai M, 2000, BIOCHEMISTRY-US, V39, P16238, DOI 10.1021/bi0020170; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; Soundar S, 2000, J BIOL CHEM, V275, P5606, DOI 10.1074/jbc.275.8.5606; Soundar S, 1996, PROTEIN EXPRES PURIF, V8, P305, DOI 10.1006/prep.1996.0105; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; TONEY MD, 1992, PROTEIN SCI, V1, P107; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VILLAFRANCA JJ, 1972, J BIOL CHEM, V247, P209; Yasutake Y, 2002, STRUCTURE, V10, P1637, DOI 10.1016/S0969-2126(02)00904-8; Zheng RJ, 2000, BIOCHEMISTRY-US, V39, P16244, DOI 10.1021/bi002134v	32	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49323	49331		10.1074/jbc.M303781200	http://dx.doi.org/10.1074/jbc.M303781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512428	hybrid			2022-12-25	WOS:000186829000100
J	Paciga, M; McCudden, CR; Londos, C; DiMattia, GE; Wagner, GF				Paciga, M; McCudden, CR; Londos, C; DiMattia, GE; Wagner, GF			Targeting of big stanniocalcin and its receptor to lipid storage droplets of ovarian steroidogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; BENZODIAZEPINE RECEPTOR; GROWTH-FACTOR; LEYDIG-CELLS; PERILIPIN; MOUSE; EXPRESSION; METABOLISM; PROTEIN; BINDING	Stanniocalcin (STC) is a large polypeptide hormone that is widely distributed in tissues such as kidney, adrenal, and ovary. In most tissues, STC exists as a 50-kDa homodimer (STC50). The ovaries produce a higher molecular weight variant ( big STC) in androgen-producing theca cell and interstitial cell compartments. Luteal cells, which do not express the STC gene, nonetheless contain high levels of STC protein, suggesting they are targeted by and sequester big STC through a receptor-mediated process. Recently, an STC . alkaline phosphatase fusion protein was used to characterize mitochondrial targeting and sequestration of STC50 and its receptor in liver and kidney. The main objective of the present study was to characterize big STC and its receptor in mammalian ovary and determine whether the ovarian STC variant was similarly targeted to luteal cell mitochondria. By in situ ligand binding, we identified large numbers of STC receptors on corpus luteal cells. However, a more detailed analysis of sub-cellular fractions revealed that both STC and its receptor were not preferentially targeted to mitochondria but instead to cholesterol/lipid storage droplets, which was more indicative of a role in steroidogenesis. Functional studies revealed that additions of big STC had concentration-dependent inhibitory effects on both basal and stimulated progesterone output by primary cultured luteal cells. Furthermore, STC receptor levels were upregulated in luteal cells in response to protein kinase A activation. Taken together, these findings indicate that theca cell-derived big STC is targeted to the cholesterol/ lipid storage droplets of luteal cells to regulate steroidogenesis. This constitutes the first reported description of polypeptide hormone and receptor targeting to cholesterol/ lipid droplets and the first biological role for the big STC variant.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biol, London, ON N6A 5B7, Canada; NIDDK, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; London Reg Canc Ctr, Dept Obstet Gynecol, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Wagner, GF (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.			McCudden, Christopher/0000-0002-4172-4641	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015505, ZIADK015505] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brown RC, 2001, INT REV NEUROBIOL, V46, P117; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; Culty M, 1999, J STEROID BIOCHEM, V69, P123, DOI 10.1016/S0960-0760(99)00056-4; Deol HK, 2000, ENDOCRINOLOGY, V141, P3412, DOI 10.1210/en.141.9.3412; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Forsten KE, 2000, J THEOR BIOL, V205, P215, DOI 10.1006/jtbi.2000.2064; GASS GH, 1996, HDB ENDOCRINOLOGY, P101; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; HILDPETITO SA, 1989, BIOL REPROD, V40, P1075, DOI 10.1095/biolreprod40.5.1075; Hixon J E, 1979, Adv Exp Med Biol, V112, P613; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LONDOS C, 1995, BIOCHEM SOC T, V23, P611, DOI 10.1042/bst0230611; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; McCudden CR, 2002, J BIOL CHEM, V277, P45249, DOI 10.1074/jbc.M205954200; Paciga M, 2002, ENDOCRINOLOGY, V143, P3925, DOI 10.1210/en.2002-220337; Papadopoulos V, 2001, THERAPIE, V56, P549; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SIMMONS KR, 1976, P SOC EXP BIOL MED, V152, P366; SORDOILLET C, 1992, ENDOCRINOLOGY, V130, P1352, DOI 10.1210/en.130.3.1352; Stasko SE, 2001, J ENDOCRINOL, V171, P237, DOI 10.1677/joe.0.1710237; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; WAGNER GF, 1991, MOL CELL ENDOCRINOL, V79, P129, DOI 10.1016/0303-7207(91)90103-Y; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wong CKC, 1998, J ENDOCRINOL, V158, P183, DOI 10.1677/joe.0.1580183; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1	31	46	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49549	49554		10.1074/jbc.M307302200	http://dx.doi.org/10.1074/jbc.M307302200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512426	hybrid			2022-12-25	WOS:000186829000125
J	Tarnow, P; Schoneberg, T; Krude, H; Gruters, A; Biebermann, H				Tarnow, P; Schoneberg, T; Krude, H; Gruters, A; Biebermann, H			Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; DOMINANT RETINITIS-PIGMENTOSA; EARLY-ONSET OBESITY; RECEPTOR GENE; FRAMESHIFT MUTATION; RHODOPSIN MUTATIONS; MORBID-OBESITY; MC4R; DYSFUNCTION; PROTEIN	By screening patients with severe early onset obesity for mutations within the melanocortin 4 receptor (MC4R) gene, we have identified a missense mutation (C271R) that occurs homozygous in two siblings with obesity. In-depth functional characterization of C271R revealed a right-shifted concentration response curve due to lower affinity to natural and synthetic MC4R agonists and a reduced cell surface expression. Cys-271 is located in the third extracellular loop. Here, we provide evidence that Cys-271 forms an intra-loop disulfide bond with Cys-277. Unexpectedly, we found that loss of receptor function is not only caused by the disruption of this disulfide bridge. Our data strongly support a new mechanism in which the receptor malfunction in the C271R mutant is induced by formation of a functionally disastrous disulfide bridge between Cys-277 and a third Cys residue at position 279. Mutational and chemical disruption of this improper disulfide bond was able to restore normal receptor potency. By demonstrating that a loss of a disulfide bond-participating Cys residue can favor a functionally disastrous disulfide bond, we now add a new mechanism of how Cys residues can be involved in G-protein-coupled receptor malfunction.	Humboldt Univ, Otto Heubner Ctr Kinderheilkunde & Jugendmed, D-13353 Berlin, Germany; Univ Leipzig, Inst Biochem, Abt Mol Biochem, D-04103 Leipzig, Germany	Humboldt University of Berlin; Leipzig University	Biebermann, H (corresponding author), Humboldt Univ, Otto Heubner Ctr Kinderheilkunde & Jugendmed, Charite Campus Virchow Klinikum,Augustenburger Pl, D-13353 Berlin, Germany.			Biebermann, Heike/0000-0002-2024-7778				ALMAGHTHEH M, 1993, HUM MUTAT, V2, P249, DOI 10.1002/humu.1380020403; Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; BICHET DG, 1994, AM J HUM GENET, V55, P278; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; Farooqi IS, 2003, NEW ENGL J MED, V348, P1085, DOI 10.1056/NEJMoa022050; Fisher SL, 1999, INT J OBESITY, V23, P54, DOI 10.1038/sj.ijo.0800796; FUCHS S, 1994, HUM MOL GENET, V3, P1203, DOI 10.1093/hmg/3.7.1203; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Kobayashi H, 2002, DIABETES, V51, P243, DOI 10.2337/diabetes.51.1.243; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; MARTIN JL, 1993, J MOL BIOL, V230, P1097, DOI 10.1006/jmbi.1993.1226; Mergen M, 2001, J CLIN ENDOCR METAB, V86, P3448, DOI 10.1210/jc.86.7.3448; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Naville D, 1996, J CLIN ENDOCR METAB, V81, P1442, DOI 10.1210/jc.81.4.1442; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 1998, HUM MUTAT, V12, P196, DOI 10.1002/(SICI)1098-1004(1998)12:3<196::AID-HUMU7>3.0.CO;2-F; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; van der Velden PA, 2001, AM J HUM GENET, V69, P774, DOI 10.1086/323411; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	31	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48666	48673		10.1074/jbc.M309941200	http://dx.doi.org/10.1074/jbc.M309941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504270	hybrid			2022-12-25	WOS:000186829000020
J	Bali, M; Zhang, B; Morano, KA; Michels, CA				Bali, M; Zhang, B; Morano, KA; Michels, CA			The Hsp90 molecular chaperone complex regulates maltose induction and stability of the Saccharomyces MAL gene transcription activator Mal63p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; IN-VIVO; STEROID-RECEPTOR; YEAST; EXPRESSION; COCHAPERONE; KINASE; HEME; CYCLOPHILIN; ENCODES	Induction of the Saccharomyces MAL structural genes encoding maltose permease and maltase requires the MAL activator, a DNA-binding transcription activator. Genetic analysis of MAL activator mutations suggested that protein folding and stability play an important role in MAL activator regulation and led us to explore the role of the Hsp90 molecular chaperone complex in the regulation of the MAL activator. Strains carrying mutations in genes encoding components of the Hsp90 chaperone complex, hsc82Delta hsp82- T101I and hsc82Delta cpr7Delta, are defective for maltase induction and exhibit significantly reduced growth rates on media containing a limiting concentration of maltose (0.05%). This growth defect is suppressed by providing maltose in excess. Using epitope-tagged alleles of the MAL63 MAL activator, we showed that Mal63p levels are drastically reduced following depletion of cellular Hsp90. Overexpression (similar to 3-fold) of Mal63p in the hsc82Delta hsp82-T101I and hsc82Delta cpr7Delta strains suppresses their Mal(-) growth phenotype, suggesting that Mal63p levels are limiting for maltose utilization in strains with abrogated Hsp90 activity. Consistent with this, the half-life of Mal63p is significantly shorter in the hsc82Delta cpr7Delta strain (reduced about 6-fold) and modestly affected in the Hsp90-ts strain (reduced about 2-fold). Most importantly, triple hemagglutinin-tagged Mal63p protein is found in association with Hsp90 as demonstrated by co-immunoprecipitation. Taken together, these results identify the inducible MAL activator as a client protein of the Hsp90 molecular chaperone complex and point to a critical role for chaperone function in alternate carbon source utilization in Saccharomyces cerevisiae.	CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA; CUNY Grad Sch & Univ Ctr, Flushing, NY 11367 USA; Univ Texas, Houston Med Sch, Dept Microbiol & Mol Genet, Houston, TX 77303 USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) Graduate School; University of Texas System; University of Texas Health Science Center Houston	Michels, CA (corresponding author), CUNY Queens Coll, Dept Biol, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	corinne_michels@qc.edu		Morano, Kevin/0000-0002-5992-0253	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHARRON MJ, 1989, GENETICS, V122, P307; Danzi SE, 2000, CURR GENET, V38, P233, DOI 10.1007/s002940000161; DANZI SE, 2003, IN PRESS CURR GENET; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; DUBIN RA, 1988, MOL CELL BIOL, V8, P1027, DOI 10.1128/MCB.8.3.1027; DUBIN RA, 1985, J BACTERIOL, V164, P605, DOI 10.1128/JB.164.2.605-610.1985; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gibson AW, 1997, GENETICS, V146, P1287; HAN EK, 1995, MOL MICROBIOL, V17, P1093, DOI 10.1111/j.1365-2958.1995.mmi_17061093.x; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Hu Z, 1999, CURR GENET, V36, P1, DOI 10.1007/s002940050466; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Lee HC, 2002, J BIOL CHEM, V277, P7430, DOI 10.1074/jbc.M106951200; LEVINE J, 1992, CURR GENET, V22, P181, DOI 10.1007/BF00351724; Liu XD, 1999, J BIOL CHEM, V274, P26654, DOI 10.1074/jbc.274.38.26654; Louvion JF, 1998, MOL BIOL CELL, V9, P3071, DOI 10.1091/mbc.9.11.3071; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NEEDLEMAN RB, 1984, P NATL ACAD SCI-BIOL, V81, P2811, DOI 10.1073/pnas.81.9.2811; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Wang X, 2002, EUKARYOT CELL, V1, P696, DOI 10.1128/EC.1.5.696-703.2002; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819	41	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47441	47448		10.1074/jbc.M309536200	http://dx.doi.org/10.1074/jbc.M309536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500708	hybrid			2022-12-25	WOS:000186731400014
J	Cao, WS; Baniecki, ML; McGrath, WJ; Bao, C; Deming, CB; Rade, JJ; Lowenstein, CJ; Mangel, WF				Cao, WS; Baniecki, ML; McGrath, WJ; Bao, C; Deming, CB; Rade, JJ; Lowenstein, CJ; Mangel, WF			Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo	FASEB JOURNAL			English	Article						S-nitrosylation; antiviral agent; proteinase inhibitor; cysteine proteinase; diethylamine NONOate	CYTOKERATIN NETWORK; SYNTHASE ACTIVITY; VIRUS-PARTICLES; REPLICATION; COFACTOR; PROTEASE; MECHANISM; PEPTIDE; BINDING; PAPAIN	Nitric oxide (NO) is an antiviral effector of the innate immune system, but few of the viral targets of NO have been identified. We now show that NO inhibits adenovirus replication by targeting the adenovirus proteinase (AVP). NO generated from diethylamine NONOate (DEA-NONOate) or spermine NONOate (Sp-NONOate) inhibited the AVP. Inhibition was reversible with dithiothreitol. The equilibrium dissociation constant for reversible binding to the AVP by Sp-NONOate, or K-i, was 0.47 mM, and the first-order rate constant for irreversible inhibition of the AVP by Sp-NONOate, or k(i), was 0.0036 s(-1). Two hallmarks of a successful adenovirus infection were abolished by the NO donors: the appearance of E1A protein and the cleavage of cytokeratin 18 by AVP. Treatment of infectious virus by DEA-NONOate dramatically decreased viral infectivity. These data suggest that NO may be a useful antiviral agent against viruses encoding a cysteine proteinase and in particular may be an antiadenovirus agent.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mangel, WF (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.	Mangel@BNL.Gov		Lowenstein, Charles/0000-0003-0485-7514; McGrath, William/0000-0002-9375-624X				Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Baniecki ML, 2001, BIOCHEMISTRY-US, V40, P12349, DOI 10.1021/bi0109008; BI ZB, 1995, J VIROL, V69, P2208, DOI 10.1128/JVI.69.4.2208-2213.1995; Brown MT, 2002, J BIOL CHEM, V277, P46298, DOI 10.1074/jbc.M202988200; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CAO W, 2003, IN PRESS P NATL ACAD; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HOOPER DC, 1995, P NATL ACAD SCI USA, V92, P5312, DOI 10.1073/pnas.92.12.5312; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Komatsu T, 1996, J NEUROIMMUNOL, V68, P101, DOI 10.1016/0165-5728(96)00083-5; LEYTUS SP, 1984, BIOCHIM BIOPHYS ACTA, V788, P74, DOI 10.1016/0167-4838(84)90299-1; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; McGrath WJ, 1996, VIROLOGY, V217, P131, DOI 10.1006/viro.1996.0100; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P14468, DOI 10.1021/bi011562d; Pang YP, 2001, J COMPUT CHEM, V22, P1750, DOI 10.1002/jcc.1129; Pang YP, 2001, FEBS LETT, V502, P93, DOI 10.1016/S0014-5793(01)02672-2; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; TUCKER PC, 1996, J VIROL, V770, P3971; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBER JM, 1994, METHOD ENZYMOL, V244, P595; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	34	19	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2345	+		10.1096/fj.03-0396fje	http://dx.doi.org/10.1096/fj.03-0396fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525937				2022-12-25	WOS:000186343300009
J	Tsugawa, K; Jones, MK; Akahoshi, T; Moon, WS; Maehara, Y; Hashizume, M; Sarfeh, IJ; Tarnawski, AS				Tsugawa, K; Jones, MK; Akahoshi, T; Moon, WS; Maehara, Y; Hashizume, M; Sarfeh, IJ; Tarnawski, AS			Abnormal PTEN expression in portal hypertensive gastric mucosa: A key to impaired PI 3-kinase/Akt activation and delayed injury healing?	FASEB JOURNAL			English	Article						gastropathy; tumor necrosis factor-alpha (TNF-alpha); early growth response factor-1 (Egr-1)	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE B; TUMOR-SUPPRESSOR; GROWTH-FACTOR; TNF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASED SUSCEPTIBILITY; CELL MIGRATION; EGR-1	Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a dual-specificity phosphatase that has activity toward both phosphorylated peptides and phospholipids. PTEN inhibits activation of Akt, the downstream effector of PI 3-kinase, which is integral to cell proliferation, migration, survival, and angiogenesis essential for tissue injury healing. PTEN expression and activation during injury healing remain unexplored. Portal hypertensive (PHT) gastric mucosa has impaired injury healing, but the underlying mechanisms remain unknown. We investigated whether impaired healing of injured PHT gastric mucosa is due to abnormal PTEN expression/activation that leads to decreased Akt activation. We also investigated the possible involvement of Egr-1, which regulates PTEN in some cells (e.g., fetal kidney epithelial cells), and TNF-alpha, which can induce Egr-1 expression. In PHT gastric mucosa 6 h after injury, PTEN protein levels were increased by 2.7-fold; unphosphorylated PTEN (reflecting activated PTEN) was increased by 2.4-fold; Akt phosphorylation (reflecting Akt activation) was reduced by 2-fold; and Egr-1 expression was increased by 3.3-fold vs. normal gastric mucosa. TNF-alpha neutralization reversed all of the above abnormalities in PHT gastric mucosa, reduced mucosal injury, and enhanced healing. We conclude that, in injured PHT gastric mucosa, overexpressed/activated PTEN leads to the reduced activation of the PI 3-kinase/Akt pathway that results in impaired injury healing.	Univ Calif Irvine, Irvine, CA 92717 USA; Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Disaster & Emergency Med, Fukuoka 812, Japan	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; Kyushu University; Kyushu University	Jones, MK (corresponding author), Univ Calif Irvine, Irvine, CA 92717 USA.	michael.jones4@med.va.gov	Maehara, Yoshihiko/A-4867-2010; Akahoshi, Tomohiko/AAU-4886-2021					Baatar D, 1999, EUR SURG RES, V31, P340, DOI 10.1159/000008711; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferraz JGP, 1997, AM J PHYSIOL-GASTR L, V272, pG809, DOI 10.1152/ajpgi.1997.272.4.G809; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Holst LS, 1998, BIOCHEM BIOPH RES CO, V250, P181, DOI 10.1006/bbrc.1998.9166; ICHIKAWA Y, 1994, GASTROENTEROLOGY, V106, P702, DOI 10.1016/0016-5085(94)90705-6; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kawanaka H, 2002, HEPATOLOGY, V35, P393, DOI 10.1053/jhep.2002.30958; Kawanaka H, 2001, FASEB J, V15, P574; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Liu LS, 1998, DIABETES, V47, P515, DOI 10.2337/diabetes.47.4.515; LOPEZTALAVERA JC, 1995, GASTROENTEROLOGY, V108, P761, DOI 10.1016/0016-5085(95)90449-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ohta M, 1998, HEPATOLOGY, V27, P906, DOI 10.1002/hep.510270403; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Pique JM, 1997, BAILLIERE CLIN GASTR, V11, P257, DOI 10.1016/S0950-3528(97)90039-7; Podolsky Daniel K., 2000, Journal of Gastroenterology, V35, P69; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Rosenzweig T, 2002, DIABETES, V51, P1921, DOI 10.2337/diabetes.51.6.1921; SARFEH IJ, 1988, SURGERY, V104, P79; SARFEH IJ, 1989, DIGEST DIS SCI, V34, P225, DOI 10.1007/BF01536055; SARFEH IJ, 1983, GASTROENTEROLOGY, V84, P987; SARFEH IJ, 1982, SURG GYNECOL OBSTET, V155, P167; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TARNAWSKI AS, 1988, HEPATOLOGY, V8, P1488, DOI 10.1002/hep.1840080604; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tsugawa K, 2002, FRONT BIOSCI-LANDMRK, V7, pE245, DOI 10.2741/tsugawa; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	47	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2316	+		10.1096/fj.02-1107fje	http://dx.doi.org/10.1096/fj.02-1107fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525948				2022-12-25	WOS:000186343300006
J	Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ				Ischenko, I; Petrenko, O; Gu, HH; Hayman, MJ			Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase	ONCOGENE			English	Article						V-SEA; Gab2; transformation	MACROPHAGE-STIMULATING PROTEIN; CELL ANTIGEN RECEPTOR; GROWTH-FACTOR; DOCKING SITE; C-MET; EPITHELIAL MORPHOGENESIS; GENE-PRODUCT; ONCOPROTEIN; ACTIVATION; PATHWAY	Transformation of fibroblasts by V-SEA involves activation of the ERK and phosphatidylinositol 3-kinase (PI3K) pathways. Effector proteins that are key mediators of the ERK and PI3K pathways, namely Grb2, the tyrosine phosphatase, SHP2 and PI3K, interact with the two phosphotyrosines found in the bidentate motif in the carboxy-terminal region of V-SEA. Genetic analysis demonstrated that while Y557 was a primary binding site and thus activator of the PI3K-Akt pathway, Y564 also contributed to the activation of this pathway. Y564 was located within a Grb2-binding motif, this raised the possibility that a protein that associated with Grb2 might be important for this PI3K activation. The scaffolding proteins Gab1 and/or Gab2 were candidates for this role. In this report, we demonstrate that V-SEA preferentially interacts with Gab2. Furthermore by using Gab2 null fibroblasts, we demonstrate that Gab2 is essential for fibroblast transformation by V-SEA. Using mutant forms of Gab2, we show that activation of the PI3K-Akt pathway via Gab2 is required for V-SEA-induced transformation. However, efficient fibroblast transformation also requires the SHP2 interaction site on Gab2.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CROWE AJ, 1993, ONCOGENE, V8, P181; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; CROWE AJ, 1993, CELL GROWTH DIFFER, V4, P403; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; MORIMOTO AM, 1994, J VIROL, V68, P1837, DOI 10.1128/JVI.68.3.1837-1842.1994; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pratt JC, 2000, J IMMUNOL, V165, P4158, DOI 10.4049/jimmunol.165.8.4158; RONSIN C, 1993, ONCOGENE, V8, P1195; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Suda Toshio, 1997, Leukemia (Basingstoke), V11, P451; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wahl RC, 1999, J BIOL CHEM, V274, P26361, DOI 10.1074/jbc.274.37.26361; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943	35	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6311	6318		10.1038/sj.onc.1206742	http://dx.doi.org/10.1038/sj.onc.1206742			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508511				2022-12-25	WOS:000185535300001
J	Pattee, P; Ilie, AE; Benyhe, S; Toth, G; Borsodi, A; Nagalla, SR				Pattee, P; Ilie, AE; Benyhe, S; Toth, G; Borsodi, A; Nagalla, SR			Cloning and characterization of Xen-dorphin prohormone from Xenopus laevis - A new opioid-like prohormone distinct from proenkephalin and prodynorphin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANA-ESCULENTA; METHIONINE-ENKEPHALIN; FUNCTIONAL EXPRESSION; PHYLLOMEDUSA-BICOLOR; BOMBINA-ORIENTALIS; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; RAT-BRAIN; RECEPTOR; PRECURSOR	Opioid-like peptides mediate analgesia and induce behavioral effects such as tolerance and dependence by ligand-receptor-mediated mechanisms. The classical opioid prohormones can generate several bioactive peptides, and these divergent families of prohormones share a common well conserved ancestral opioid motif (Tyr-Gly-Gly-Phe). Evidence from pharmacological and molecular cloning studies indicates the presence of multiple isoforms of opioid ligands and receptors that are as yet uncharacterized. To identify potential new members we used the opioid motif as an anchor sequence and isolated two distinct isoforms (Xen-dorphins A and B) of an opioid prohormone from Xenopus laevis brain cDNA library. Xen-dorphin prohormones can generate multiple novel opioid ligands distinct from the known members of this family. Both isoforms are present in a wide variety of tissues including the brain. Two potential bioactive peptides, Xen-dorphin-1A and -1B, that were chemically synthesized showed opioid agonist activity in frog and rat brain membranes using a [S-35] GTPgammaS assay. Initial radioligand binding experiments demonstrated that Xen-dorphin-1B binds with high affinity to opioid receptor(s) and with potential preference to the kappa-opioid receptor subtype. Cloning of the Xen-dorphin prohormone provides new evidence for the potential presence of other members in the opioid peptide superfamily.	Oregon Hlth Sci Univ, Dept Pediat, Ctr Biomarker Discovery, Portland, OR 97239 USA; Biol Res Ctr, Inst Biochem, H-6701 Szeged, Hungary	Oregon Health & Science University; Hungarian Academy of Sciences; Hungarian Biological Research Center	Nagalla, SR (corresponding author), Oregon Hlth Sci Univ, Dept Pediat, Ctr Biomarker Discovery, Portland, OR 97239 USA.		Benyhe, Sandor/D-1071-2009	Benyhe, Sandor/0000-0002-2235-5334	NIDA NIH HHS [DA1138] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BRADBURY AF, 1976, NATURE, V260, P165, DOI 10.1038/260165a0; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CONE RI, 1982, P NATL ACAD SCI-BIOL, V79, P3345, DOI 10.1073/pnas.79.10.3345; Erspamer V, 1978, Adv Exp Med Biol, V106, P51; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FACCHINETTI F, 1993, J ENDOCRINOL, V137, P49, DOI 10.1677/joe.0.1370049; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KAKIDANI H, 1982, NATURE, V298, P245, DOI 10.1038/298245a0; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KILPATRICK DL, 1983, P NATL ACAD SCI-BIOL, V80, P5772, DOI 10.1073/pnas.80.18.5772; LESLIE LC, 2002, J PHARMACOL EXP THER, V301, P364; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MARTENS GJM, 1984, NATURE, V310, P251, DOI 10.1038/310251a0; MERCHENTHALER I, 1989, J COMP NEUROL, V281, P23, DOI 10.1002/cne.902810104; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; NAGALLA SR, 1992, J BIOL CHEM, V267, P6916; Nagalla SR, 1996, J BIOL CHEM, V271, P7731, DOI 10.1074/jbc.271.13.7731; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; NEGRI L, 1992, P NATL ACAD SCI USA, V89, P7203, DOI 10.1073/pnas.89.15.7203; NEVIN ST, 1994, NEUROPEPTIDES, V26, P261, DOI 10.1016/0143-4179(94)90080-9; NODA M, 1982, NATURE, V295, P202, DOI 10.1038/295202a0; OLSON GA, 1993, PEPTIDES, V14, P1339, DOI 10.1016/0196-9781(93)90195-M; PERT CB, 1973, SCIENCE, V182, P1359, DOI 10.1126/science.182.4119.1359; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON J, 1986, J NEUROCHEM, V46, P695, DOI 10.1111/j.1471-4159.1986.tb13027.x; SIMON J, 1984, J NEUROCHEM, V43, P957, DOI 10.1111/j.1471-4159.1984.tb12830.x; TORIHASHI S, 1993, CELL TISSUE RES, V271, P93, DOI 10.1007/BF00297546; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; ZUKIN RS, 1984, TRENDS NEUROSCI, V7, P160, DOI 10.1016/S0166-2236(84)80128-9	35	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					53098	53104		10.1074/jbc.M306724200	http://dx.doi.org/10.1074/jbc.M306724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14525992	hybrid			2022-12-25	WOS:000187480700134
J	Atkinson, PGP; Coope, HJ; Rowe, M; Ley, SC				Atkinson, PGP; Coope, HJ; Rowe, M; Ley, SC			Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MEMBRANE-PROTEIN 1; IKK-ALPHA; LYMPHOCYTE TRANSFORMATION; ACTIVATED CD40; KINASE ALPHA; MICE LACKING; C-TERMINUS; IN-VIVO; LMP1	Recent studies have identified a limited number of cellular receptors that can stimulate an alternative NF-kappaB activation pathway that depends upon the inducible processing of NF-kappaB2 p100 to p52. Here it is shown that the latent membrane protein (LMP)-1 of Epstein-Barr virus can trigger this signaling pathway in both B cells and epithelial cells. LMP1-induced p100 processing, which is mediated by the proteasome and is dependent upon de novo protein synthesis, results in the nuclear translocation of p52.RelB dimers. Previous studies have established that LMP1 also stimulates the canonical NF-kappaB-signaling pathway that triggers phosphorylation and degradation of IkappaBalpha. Interestingly, LMP1 activation of these two NF-kappaB pathways is shown here to require distinct regions of the LMP1 C-terminal cytoplasmic tail. Thus, C-terminal-activating region 1 is required for maximal triggering of p100 processing but is largely dispensable for stimulation of IkappaBalpha phosphorylation. In contrast, C-terminal-activating region 2 is critical for maximal LMP1 triggering of IkappaBalpha phosphorylation and up-regulation of p100 levels but does not contribute to activation of p100 processing. Because p100 deletion mutants that constitutively produce p52 oncogenically transform fibroblasts in vitro, it is likely that stimulation of p100 processing by LMP1 will play an important role in its transforming function.	Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England; Cardiff Univ, Sect Infect & Immun, Cardiff CF4 4XX, S Glam, Wales	MRC National Institute for Medical Research; Cardiff University	Ley, SC (corresponding author), Natl Inst Med Res, Div Immune Cell Biol, Mill Hill, London NW7 1AA, England.	sley@nimr.mrc.ac.uk	Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Borza CM, 2002, NAT MED, V8, P594, DOI 10.1038/nm0602-594; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; He ZM, 2000, CANCER RES, V60, P1845; Henriquez NV, 1999, J IMMUNOL, V162, P3298; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Mattia E, 1997, ONCOGENE, V15, P489, DOI 10.1038/sj.onc.1201183; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nitsche F, 1997, J VIROL, V71, P6619, DOI 10.1128/JVI.71.9.6619-6628.1997; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROWE M, 1986, INT J CANCER, V37, P367, DOI 10.1002/ijc.2910370307; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	69	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51134	51142		10.1074/jbc.M304771200	http://dx.doi.org/10.1074/jbc.M304771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532284	hybrid			2022-12-25	WOS:000187206300038
J	Kindrachuk, J; Parent, J; Davies, GF; Dinsmore, M; Attah-Poku, S; Napper, S				Kindrachuk, J; Parent, J; Davies, GF; Dinsmore, M; Attah-Poku, S; Napper, S			Overexpression of L-isoaspartate O-methyltransferase in Escherichia coli increases heat shock survival by a mechanism independent of methyltransferase activity*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; PROTEIN REPAIR METHYLTRANSFERASE; HISTIDINE-CONTAINING PROTEIN; CRYSTAL-STRUCTURE; PHOSPHOCARRIER PROTEIN; LIFE-SPAN; HPR; PHOSPHOENOLPYRUVATE; DEAMIDATION; RESIDUES	Over time and under stressing conditions proteins are susceptible to a variety of spontaneous covalent modifications. One of the more commonly occurring types of protein damage is deamidation; the conversion of asparagines into aspartyls and isoaspartyls. The physiological significance of isoaspartyl formation is emphasized by the presence of the conserved enzyme L- isoaspartyl O- methyltransferase ( PIMT), whose physiological function appears to be in preventing the accumulation of deamidated proteins. Seemingly consistent with a repair function, overexpression of PIMT in Drosophila melanogaster extends lifespan under conditions expected to contribute to protein damage. Based on structural information and sequence homology we have created mutants of residues proposed to be involved in co- factor binding in Escherichia coli PIMT. Both mutants retain S- adenosyl L- methionine binding capabilities but demonstrate dramatically reduced kinetic capabilities, perhaps suggestive of catalytic roles beyond co- factor binding. As anticipated, overexpression of the wild type enzyme in E. coli results in bacteria with increased tolerance to thermal stress. Surprisingly, even greater levels of heat tolerance were observed with overexpression of the inactive PIMT mutants. The increased survival capabilities observed with overexpression of PIMT in E. coli, and possibly in Drosophila, are not due to increased isoaspartyl repair capabilities but rather a temperature-independent induction of the heat shock system as a result of overexpression of a misfolding- prone protein. An alternate hypothesis as to the physiological substrate and function of L- isoaspartyl methyltransferase is proposed.	Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada	University of Saskatchewan; University of Saskatchewan	Napper, S (corresponding author), Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada.	napper@sask.usask.ca						ANDERSON JW, 1991, BIOCHEMISTRY-US, V30, P9601, DOI 10.1021/bi00104a006; ASWAD DW, 1995, PROMEGA NOTES, V52, P27; Athiner L, 2002, J BIOL CHEM, V277, P30502, DOI 10.1074/jbc.M205314200; BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; Bussiere DE, 1998, BIOCHEMISTRY-US, V37, P7103, DOI 10.1021/bi973113c; Chavous DA, 2001, P NATL ACAD SCI USA, V98, P14814, DOI 10.1073/pnas.251446498; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CLARKE S, 1992, STABILITY PROTEIN PH, P1; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; GEIGER T, 1987, J BIOL CHEM, V262, P785; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; GROSS R, 1989, MOL MICROBIOL, V3, P1661, DOI 10.1111/j.1365-2958.1989.tb00152.x; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; Kagan RM, 1997, COMP BIOCHEM PHYS B, V117, P379, DOI 10.1016/S0305-0491(96)00333-1; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Knight JA, 2001, ADV CLIN CHEM, V35, P1, DOI 10.1016/S0065-2423(01)35014-X; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Lund PA, 2001, ADV MICROB PHYSIOL, V44, P93, DOI 10.1016/S0065-2911(01)44012-4; MOND JJ, 1991, J BIOL CHEM, V266, P4458; Napper S, 2003, FEBS LETT, V538, P77, DOI 10.1016/S0014-5793(03)00132-7; Napper S, 1999, J BIOL CHEM, V274, P21776, DOI 10.1074/jbc.274.31.21776; Niewmierzycka A, 1999, ARCH BIOCHEM BIOPHYS, V364, P209, DOI 10.1006/abbi.1999.1114; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Ryttersgaard C, 2002, J BIOL CHEM, V277, P10642, DOI 10.1074/jbc.M200229200; SHARMA S, 1993, J BIOL CHEM, V268, P17695; Skinner MM, 2000, STRUCTURE, V8, P1189, DOI 10.1016/S0969-2126(00)00522-0; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Urao T, 2000, TRENDS PLANT SCI, V5, P67, DOI 10.1016/S1360-1385(99)01542-3; Visick JE, 1998, J BACTERIOL, V180, P2623, DOI 10.1128/JB.180.10.2623-2629.1998	37	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50880	50886		10.1074/jbc.M308423200	http://dx.doi.org/10.1074/jbc.M308423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527954	hybrid			2022-12-25	WOS:000187206300007
J	Dou, H; Mitra, S; Hazra, TK				Dou, H; Mitra, S; Hazra, TK			Repair of oxidized bases in DNA bubble structures by human DNA glycosylases NEIL1 and NEIL2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; RNA-POLYMERASE-II; COLI ENDONUCLEASE-VIII; COCKAYNE-SYNDROME; EXCISION-REPAIR; HUMAN NTH1; DHFR GENE; DAMAGE; 8-OXOGUANINE; ELONGATION	Repair of oxidatively damaged bases in the genome via the base excision repair pathway is initiated with excision of these lesions by DNA glycosylases with broad substrate range. The newly discovered human DNA glycosylases, NEIL1 and NEIL2, are distinct in structural features and reaction mechanism from the previously characterized NTH1 and OGG1 but act on many of the same substrates. However, NEIL2 shows a unique preference for excising lesions from a DNA bubble, whereas NTH1 and OGG1 are only active with duplex DNA. NEIL1 also excises efficiently 5-hydroxyuracil, an oxidation product of cytosine, from the bubble and singlestranded DNA but does not have strong activity toward 8-oxoguanine in the bubble. The dichotomy in the activity of NEILs versus NTH1/OGG1 for bubble versus duplex DNA substrates is consistent with higher affinity of the NEILs for the bubble structures of both damaged and undamaged DNA relative to duplex structure. These observations suggest that the NEILs are functionally distinct from OGG1/NTH1 in vivo. OGG1/NTH1-independent repair of oxidized bases in the transcribed sequences supports the possibility that NEILs are preferentially involved in repair of lesions in DNA bubbles generated during transcription and/or replication.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hazra, TK (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Route 1079, Galveston, TX 77555 USA.		Classen, Scott/AAY-8176-2020		NATIONAL CANCER INSTITUTE [P01CA092584, R01CA081063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010514] Funding Source: NIH RePORTER; NCI NIH HHS [CA81063, P01 CA92584] Funding Source: Medline; NIA NIH HHS [AG10514] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; Hanawalt PC, 2001, ENVIRON MOL MUTAGEN, V38, P89, DOI 10.1002/em.1057; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hosfield DJ, 2001, PROG NUCLEIC ACID RE, V68, P315; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Krokan HE, 1997, BIOCHEM J, V325, P1; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nishimura S, 2001, PROG NUCLEIC ACID RE, V68, P107; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; Saparbaev M, 2002, ENVIRON MOL MUTAGEN, V39, P10, DOI 10.1002/em.10041; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Vallone PM, 2000, BIOCHEMISTRY-US, V39, P7835, DOI 10.1021/bi000326k; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	41	270	277	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49679	49684		10.1074/jbc.M308658200	http://dx.doi.org/10.1074/jbc.M308658200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522990	hybrid			2022-12-25	WOS:000187068200006
J	Fukuda, N; Ichihara, M; Morinaga, T; Kawai, K; Hayashi, H; Murakumo, Y; Matsuo, S; Takahashi, M				Fukuda, N; Ichihara, M; Morinaga, T; Kawai, K; Hayashi, H; Murakumo, Y; Matsuo, S; Takahashi, M			Identification of a novel glial cell line-derived neurotrophic factor-inducible gene required for renal branching morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; RET PROTOONCOGENE; KIDNEY DEVELOPMENT; FINGER PROTEIN; BTB-DOMAIN; EXPRESSION; RECEPTOR; DEFECTS; ACTIVATION	In the developing kidney, activation of the rearrangement during transfection by glial cell line-derived neurotrophic factor ( GDNF) is required for normal branching of the ureteric bud epithelium. By differential display analysis we identified a novel GDNF-inducible gene (named GZF1) with a BTB/POZ (broad complex, tramtrack, and bric-a-brac)/(poxvirus and zinc finger) domain and 10 tandemly repeated zinc finger motifs. The up-regulation of the GZF1 gene showed two peaks at 1 h and 24 - 48 h after GDNF stimulation by Northern blotting. The late induction was also found at protein levels by Western blotting with anti-GZF1 antibody. As observed for other proteins with the BTB/POZ domain, the GZF1 protein had strong transcriptional repressive activity. Intriguingly, its expression was detected at high levels in branching ureteric buds and collecting ducts of mouse metanephric kidney in which RET was also expressed. Antisense phosphorothioated oligodeoxynucleotides of the GZF1 gene markedly impaired the ureteric bud branching in the metanephric organ culture, suggesting that the induction of GZF1 expression via the GDNF/RET signaling system is required for renal branching morphogenesis.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neural Dis & Canc, Div Mol Pathol,Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; Kumi, Kawai/I-6275-2014	Takahashi, Masahide/0000-0002-2803-2683; Kumi, Kawai/0000-0002-7772-2605				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Hatini V, 1996, GENE DEV, V10, P1467, DOI 10.1101/gad.10.12.1467; Horowitz H, 1996, DEVELOPMENT, V122, P1859; Kanwar YS, 2002, AM J PHYSIOL-RENAL, V282, pF953, DOI 10.1152/ajprenal.00200.2001; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Miyamoto N, 1997, DEVELOPMENT, V124, P1653; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Piscione TD, 2002, DIFFERENTIATION, V70, P227, DOI 10.1046/j.1432-0436.2002.700602.x; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Sainio K, 1997, DEVELOPMENT, V124, P4077; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Vainio S, 2002, NAT REV GENET, V3, P533, DOI 10.1038/nrg842; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722	34	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50386	50392		10.1074/jbc.M309629200	http://dx.doi.org/10.1074/jbc.M309629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522971	hybrid			2022-12-25	WOS:000187068200089
J	Ip, H; Stratton, K; Zgurskaya, H; Liu, J				Ip, H; Stratton, K; Zgurskaya, H; Liu, J			pH-induced conformational changes of AcrA, the membrane fusion protein of Escherichia coli multidrug efflux system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE MECHANISMS; CRYSTAL-STRUCTURE; T4 LYSOZYME; SPIN; PUMP; PREVALENCE; BINDING; DOMAIN	The multidrug efflux system AcrA-AcrB-TolC of Escherichia coli expels a wide range of drugs directly into the external medium from the bacterial cell. The mechanism of the efflux process is not fully understood. Of an elongated shape, AcrA is thought to span the periplasmic space coordinating the concerted operation of the inner and outer membrane proteins AcrB and TolC. In this study, we used site-directed spin labeling (SDSL) EPR ( electron paramagnetic resonance) spectroscopy to investigate the molecular conformations of AcrA in solution. Ten AcrA mutants, each with an alanine to cysteine substitution, were engineered, purified, and labeled with a nitroxide spin label. EPR analysis of spin-labeled AcrA variants indicates that the side chain mobilities are consistent with the predicted secondary structure of AcrA. We further demonstrated that acidic pH induces oligomerization and conformational change of AcrA, and that the structural changes are reversible. These results suggest that the mechanism of action of AcrA in drug efflux is similar to the viral membrane fusion proteins, and that AcrA actively mediates the efflux of substrates.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Toronto; University of Oklahoma System; University of Oklahoma - Norman	Ip, H (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 4382 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	jun.liu@utoronto.ca	Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733; Zgurskaya, Helen/0000-0001-8929-4727	NIAID NIH HHS [R01 AI052293] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052293] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; Brenwald NP, 1998, ANTIMICROB AGENTS CH, V42, P2032, DOI 10.1128/AAC.42.8.2032; Columbus L, 2002, TRENDS BIOCHEM SCI, V27, P288, DOI 10.1016/S0968-0004(02)02095-9; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DUBOCHET J, 1983, J BACTERIOL, V155, P381, DOI 10.1128/JB.155.1.381-390.1983; GRAHAM LL, 1991, J BACTERIOL, V173, P1623, DOI 10.1128/jb.173.5.1623-1633.1991; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lewis K, 2000, CURR BIOL, V10, pR678, DOI 10.1016/S0960-9822(00)00682-5; Limia A, 1998, Rev Esp Quimioter, V11, P216; MA D, 1993, J BACTERIOL, V175, P6299, DOI 10.1128/JB.175.19.6299-6313.1993; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; NIKAIDO H, 1993, ANTIMICROB AGENTS CH, V37, P1393, DOI 10.1128/AAC.37.7.1393; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 1998, CLIN INFECT DIS, V27, pS32, DOI 10.1086/514920; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Orden B, 1998, PEDIATR INFECT DIS J, V17, P470, DOI 10.1097/00006454-199806000-00006; Salwinski L, 1999, PROTEIN SCI, V8, P562; Shortridge VD, 1999, CLIN INFECT DIS, V29, P1186, DOI 10.1086/313452; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Zgurskaya HI, 2000, J BACTERIOL, V182, P4264, DOI 10.1128/JB.182.15.4264-4267.2000; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; Zgurskaya HI, 2000, MOL MICROBIOL, V37, P219, DOI 10.1046/j.1365-2958.2000.01926.x; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	32	33	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50474	50482		10.1074/jbc.M305152200	http://dx.doi.org/10.1074/jbc.M305152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523004	hybrid			2022-12-25	WOS:000187068200100
J	Perez-Victoria, FJ; Gamarro, F; Ouellette, M; Castanys, S				Perez-Victoria, FJ; Gamarro, F; Ouellette, M; Castanys, S			Functional cloning of the miltefosine transporter - A novel P-type phospholipid translocase from Leishmania involved in drug resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; AMINOPHOSPHOLIPID TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; VISCERAL LEISHMANIASIS; NUCLEOSIDE TRANSPORTER; INWARD TRANSLOCATION; PARASITE LEISHMANIA; 3RD SUBFAMILY; ATPASES; PROTEIN	The antitumor drug miltefosine (hexadecylphosphocholine, MIL) has recently been approved as the first oral agent for the treatment of visceral leishmaniasis. Little is known about the mechanisms of action and uptake of MIL in either parasites or tumor cell lines. We have cloned a putative MIL transporter (LdMT) by functional rescue, using a Leishmania donovani-resistant line defective in the inward-directed translocation of both MIL and glycerophospholipids. LdMT is a novel P-type ATPase belonging to the partially characterized aminophospholipid translocase subfamily. Resistant parasites transfected with LdMT regain their sensitivity to MIL and edelfosine and the ability to normally take up [C-14]MIL and fluorescent-labeled glycerophospholipids. Moreover, LdMT localizes to the plasma membrane, and its overexpression in Leishmania tarentolae, a species non-sensitive to MIL, significantly increases the uptake of [C-14]MIL, strongly suggesting that this protein behaves as a true translocase. Finally, both LdMT-resistant alleles encompass single but distinct point mutations, each of which impairs transport function, explaining the resistant phenotype. These results demonstrate biochemically and genetically the direct involvement of LdMT in MIL and phospholipids translocation in Leishmania and describe for the first time a P-type ATPase involved in MIL uptake and potency in eukaryotic cells.	Consejo Super Invest Cient, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain; Univ Laval, CHUL, Ctr Rech, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Laval University	Castanys, S (corresponding author), Consejo Super Invest Cient, Inst Parasitol & Biomed Lopez Neyra, Ventanilla 11, Granada 18001, Spain.		Ouellette, Marc/K-8694-2017; Castanys, Santiago/Y-3981-2019	Ouellette, Marc/0000-0002-6743-9646; Castanys, Santiago/0000-0002-3460-844X; Gamarro, Francisco/0000-0003-1347-3440				Araujo-Santos JM, 2003, BIOCHEM BIOPH RES CO, V306, P250, DOI 10.1016/S0006-291X(03)00947-1; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; Axelsen KB, 2001, PLANT PHYSIOL, V126, P696, DOI 10.1104/pp.126.2.696; Catty P, 1997, FEBS LETT, V409, P325, DOI 10.1016/S0014-5793(97)00446-8; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Croft SL, 2002, CURR PHARM DESIGN, V8, P319, DOI 10.2174/1381612023396258; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; Gangneux JP, 1999, PRESSE MED, V28, P2057; Ganguly N., 2002, TDR NEWS, V68, P2; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Halleck MS, 1998, GENOME RES, V8, P354, DOI 10.1101/gr.8.4.354; Hanson PK, 2003, J BIOL CHEM, V278, P36041, DOI 10.1074/jbc.M305263200; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hua ZL, 2002, MOL BIOL CELL, V13, P3162, DOI 10.1091/mbc.E02-03-0172; Kato U, 2002, J BIOL CHEM, V277, P37855, DOI 10.1074/jbc.M205564200; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Mollinedo F, 1997, CANCER RES, V57, P1320; MORE B, 2003, POSTGRAD MED J, V49, P101; Mouro I, 1999, BIOCHEM BIOPH RES CO, V257, P333, DOI 10.1006/bbrc.1999.0347; Parodi-Talice A, 2003, BBA-BIOMEMBRANES, V1612, P195, DOI 10.1016/S0005-2736(03)00131-7; Perez-Victoria FJ, 2003, ANTIMICROB AGENTS CH, V47, P2397, DOI 10.1128/AAC.47.8.2397-2403.2003; Perez-Victoria JM, 2001, ANTIMICROB AGENTS CH, V45, P2468, DOI 10.1128/AAC.45.9.2468-2474.2001; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; Pomorski T, 1999, BIOCHEMISTRY-US, V38, P142, DOI 10.1021/bi981244n; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; Sambrook J., 2002, MOL CLONING LAB MANU; Seifert K, 2003, INT J ANTIMICROB AG, V22, P380, DOI 10.1016/S0924-8579(03)00125-0; Small GW, 1997, LIPIDS, V32, P715, DOI 10.1007/s11745-997-0091-3; Sundar S, 2000, CLIN INFECT DIS, V31, P1110, DOI 10.1086/318122; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; WHITE TC, 1988, J BIOL CHEM, V263, P16977; ZHANG ZM, 1994, AM J PHYSIOL, V267, pG80, DOI 10.1152/ajpgi.1994.267.1.G80; ZOELLER RA, 1995, J LIPID RES, V36, P1866	39	181	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49965	49971		10.1074/jbc.M308352200	http://dx.doi.org/10.1074/jbc.M308352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514670	hybrid			2022-12-25	WOS:000187068200039
J	Papin, S; Cazeneuve, C; Duquesnoy, P; Jeru, I; Sahali, D; Amselem, S				Papin, S; Cazeneuve, C; Duquesnoy, P; Jeru, I; Sahali, D; Amselem, S			The tumor necrosis factor alpha-dependent activation of the human Mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP beta and NF kappa B p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIN DOMAIN; TARGETED DISRUPTION; GENE-TRANSCRIPTION; PROTEIN; EXPRESSION; BINDING; NF-IL6; INDUCTION; ADHESION; LIPOPOLYSACCHARIDE	MEFV is a gene expressed specifically in myeloid cells and whose mutations underlie an autosomal recessive auto-inflammatory disease, called familial Mediterranean fever (FMF), characterized by recurrent episodes of serosal inflammation. This gene, which encodes a protein with unclear physiological functions, has been shown to be up-regulated by the pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha). However, the mechanism of this regulation is unknown, and the MEFV promoter is still to be characterized. Here, we show that 243 bp of the 5'-flanking region of the human MEFV gene are sufficient to direct high level expression of MEFV in TNFalpha-treated cells. The TNFalpha-induced expression of MEFV is dependent on both NFkappaB p65 and C/EBPbeta that bind to evolutionarily conserved sites located, in the human promoter, at positions - 163 and - 55, respectively. As shown by a series of transcription and gel shift assays performed with wild-type and mutated promoter sequences, these two transcription factors act differently on the TNFalpha-dependent transcription of MEFV: C/EBPbeta is the key regulatory factor required to confer cell responsiveness to TNFalpha, whereas NFkappaB p65 increases this response by means of a synergistic interaction with C/EBPbeta that is dependent on the integrity of the identified - 55 C/EBP binding site. Given the phenotype of patients with FMF, this C/EBP-NFkappaB interaction may represent a key step in the control of an inflammatory response that is abnormally high in this disease. These data, which shed novel light on the pathophysiology of FMF, represent an unusual example of cross-talk between C/EBP and NFkappaB pathways in TNFalpha signaling.	Hop Henri Mondor, INSERM, U468, F-94010 Creteil, France; Hop Henri Mondor, INSERM, U581, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Amselem, S (corresponding author), Hop Henri Mondor, INSERM, U468, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	serge.amselem@im3.inserm.fr	Sahali, Djillali/Q-5742-2018	Sahali, Djillali/0000-0003-3663-4470; Papin, Stephanie/0000-0003-1358-9988				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Aksentijevich I, 1997, CELL, V90, P797; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Begbie M, 2000, THROMB HAEMOSTASIS, V84, P216; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; BETTS JC, 1993, J BIOL CHEM, V268, P25624; Catron KM, 1998, CELL GROWTH DIFFER, V9, P949; Centola M, 2000, BLOOD, V95, P3223, DOI 10.1182/blood.V95.10.3223; Chae JJ, 2003, MOL CELL, V11, P591, DOI 10.1016/S1097-2765(03)00056-X; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Conway KE, 2000, CANCER RES, V60, P6236; de Menthiere CS, 2003, NUCLEIC ACIDS RES, V31, P282, DOI 10.1093/nar/gkg031; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Gumucio DL, 2002, CLIN EXP RHEUMATOL, V20, pS45; HEILAND S, 1995, MOL CELL BIOL, V15, P6623; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Huszar T, 2001, J BIOTECHNOL, V88, P251, DOI 10.1016/S0168-1656(01)00277-2; KUNSCH C, 1994, J IMMUNOL, V153, P153; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; Richards N, 2001, J BIOL CHEM, V276, P39320, DOI 10.1074/jbc.M104730200; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tidow N, 2000, BLOOD, V95, P1451, DOI 10.1182/blood.V95.4.1451.004k52_1451_1455; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	40	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48839	48847		10.1074/jbc.M305166200	http://dx.doi.org/10.1074/jbc.M305166200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514692	hybrid			2022-12-25	WOS:000186829000041
J	Tam, BYY; Finnson, KW; Philip, A				Tam, BYY; Finnson, KW; Philip, A			Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-beta signaling in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; BINDING-PROTEINS; FUNCTIONAL-CHARACTERIZATION; HETEROMERIC COMPLEX; RECEPTOR EXPRESSION; MEMBRANE-PROTEINS; SKIN DEVELOPMENT; LIGAND-BINDING; SMAD PROTEINS; II RECEPTORS	Glycosylphosphatidylinositol (GPI)-anchored proteins have been demonstrated to bind transforming growth factor-beta (TGF-beta) in certain cell lines. However, the identity of these GPI-anchored proteins and the role they may play in TGF-beta signaling remain unknown. We have previously reported the presence of GPI-anchored TGF-beta-binding proteins on human skin fibroblasts and keratinocytes (Tam, B. Y. Y., and Philip, A. (1998) J. Cell. Physiol. 176, 553 - 564; Tam, B. Y. Y., Germain, L., and Philip, A. (1998) J. Cell. Biochem. 70, 573 - 586). On human keratinocytes, we identified a 150-kDa GPI-anchored TGF-beta1-binding protein (r150) and demonstrated that it can form a heteromeric complex with the type I and II TGF-beta signaling receptors. To explore whether GPI-anchored proteins modulate TGF-beta signaling in keratinocytes, we created keratinocytes defective in GPI anchor biosynthesis ( GPI mutant cells) by chemical mutagenesis of HaCaT cells. Mutant clones were selected by fluorescence-activated cell sorting analysis based on the loss of a CD59 marker. In comparison with parental HaCaT cells, GPI mutant cells demonstrated a significant loss of r150 expression. In contrast, the levels of the type I and II TGF-beta receptors and their ligand affinities, cell morphology, and doubling time remained unchanged. Importantly, GPI mutant cells displayed enhanced gene transcriptional activity and Smad2 and Smad3 activation in response to TGF-beta1 treatment in a dose-dependent manner. Taken together, our results indicate that GPI-anchored protein(s) inhibit TGF-beta signaling and implicate r150 as the GPI-anchored protein responsible for this inhibition in human keratinocytes.	Montreal Gen Hosp, Div Plast Surg, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Philip, A (corresponding author), Montreal Gen Hosp, Div Plast Surg, Rm C9-177,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.			Finnson, Kenneth/0000-0003-2930-0595				Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DUMONT N, 1995, MOL CELL ENDOCRINOL, V111, P57, DOI 10.1016/0303-7207(95)03548-L; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horejsi V, 1998, IMMUNOL LETT, V63, P63, DOI 10.1016/S0165-2478(98)00054-6; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Pasch MC, 1998, J INVEST DERMATOL, V111, P683, DOI 10.1046/j.1523-1747.1998.00358.x; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Screaton RA, 2000, J CELL BIOL, V150, P613, DOI 10.1083/jcb.150.3.613; SEGA GA, 1984, MUTAT RES, V134, P113, DOI 10.1016/0165-1110(84)90007-1; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Stevens VL, 1999, METH MOL B, V116, P13; Stevens VL, 1996, BIOCHEM J, V313, P253, DOI 10.1042/bj3130253; Tam BYY, 1998, J CELL BIOCHEM, V70, P573, DOI 10.1002/(SICI)1097-4644(19980915)70:4<573::AID-JCB13>3.0.CO;2-I; Tam BYY, 2001, J CELL BIOCHEM, V83, P494, DOI 10.1002/jcb.1074; Tam BYY, 1998, J CELL PHYSIOL, V176, P553, DOI 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.3.CO;2-A; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Turner AJ, 1994, ESSAYS BIOCHEM, V28, P113; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; VENNEKER GT, 1994, J PATHOL, V172, P189, DOI 10.1002/path.1711720206; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	49	21	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49610	49617		10.1074/jbc.M308492200	http://dx.doi.org/10.1074/jbc.M308492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504277	hybrid			2022-12-25	WOS:000186829000132
J	Tamura, N; Garbers, DL				Tamura, N; Garbers, DL			Regulation of the guanylyl cyclase-B receptor by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; SMOOTH-MUSCLE-CELLS; EXPRESSION; GENE; CLONING; DIFFERENTIATION; PROLIFERATION; INHIBITION; ACTIVATION; PROTEIN	Guanylyl cyclase-B (GC-B) is a single transmembrane receptor that binds C-type natriuretic peptide (CNP). The ligand/receptor appears critical in the regulation of cell proliferation and differentiation where it acts as an adversary of mitogenic signaling pathways. We have isolated three guanylyl cyclase-B isoforms generated from a single gene by alternative splicing and termed them GC-B1, GC-B2, and GC-B3. GC-B1 is full-length and responds maximally to CNP, GC-B2 contains a 25-amino acid deletion in the protein kinase homology domain, and GC-B3 only retains a part of the extracellular ligand-binding domain. GC-B2 binds CNP, but the ligand fails to activate the cyclase, while GC-B3 fails to bind ligand. When GC-B2 or GC-B3 is expressed coincident with GC-B1, they act as dominant negative isoforms by virtue of blocking formation of active GC-B1 homodimers. Relative expression levels of GC-B1, GC-B2, and GC-B3 vary across tissues and as a function of in vitro culture; the relative amount of GC-B2 to GC-B1 is repressed in cultured smooth muscle cells relative to endogenous ratios in the medial layer cells of the aorta. Thus, GC-B isoform levels can be independently regulated. Given that the splice variants serve as dominant negative forms, these will serve as regulators of the full-length GC-B.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garbers, DL (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Abbey SE, 2003, ENDOCRINOLOGY, V144, P240, DOI 10.1210/en.2002-220702; Abbey SE, 2002, J BIOL CHEM, V277, P42423, DOI 10.1074/jbc.M206686200; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEHRENDS S, 1995, J BIOL CHEM, V270, P21109, DOI 10.1074/jbc.270.36.21109; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Doi K, 2001, ARTERIOSCL THROM VAS, V21, P930, DOI 10.1161/01.ATV.21.6.930; Doi K, 1997, BIOCHEM BIOPH RES CO, V239, P889, DOI 10.1006/bbrc.1997.7576; DUDA T, 1993, FEBS LETT, V335, P309, DOI 10.1016/0014-5793(93)80408-M; Forte LR, 1999, ENDOCRINOLOGY, V140, P1800, DOI 10.1210/en.140.4.1800; FUJIO N, 1994, HYPERTENSION, V23, P908, DOI 10.1161/01.HYP.23.6.908; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GARBERS DL, 1992, CELL, V71, P1; GU YC, 1993, BIOCHEM BIOPH RES CO, V196, P758, DOI 10.1006/bbrc.1993.2314; Gupta G, 1997, J CLIN INVEST, V100, P1488, DOI 10.1172/JCI119670; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; Hasegawa K, 1997, BIOCHEM BIOPH RES CO, V232, P313, DOI 10.1006/bbrc.1997.6281; Hirsch JR, 2003, AM J PHYSIOL-RENAL, V285, pF370, DOI 10.1152/ajprenal.00049.2003; Hirsch JR, 1999, J AM SOC NEPHROL, V10, P472; Itoh H, 1997, ANN NY ACAD SCI, V811, P533, DOI 10.1111/j.1749-6632.1997.tb52037.x; KISHIMOTO I, 1994, J BIOL CHEM, V269, P28300; Koesling D, 1999, METHODS, V19, P485, DOI 10.1006/meth.1999.0891; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KUROO M, 1989, J BIOL CHEM, V264, P18272; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OHYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P743, DOI 10.1016/0006-291X(92)90546-W; OWENS GK, 1995, PHYSIOL REV, V75, P487; Potter LR, 2000, J BIOL CHEM, V275, P31099, DOI 10.1074/jbc.M005506200; Potter LR, 1998, J BIOL CHEM, V273, P15533, DOI 10.1074/jbc.273.25.15533; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; Simpson PJ, 2002, J NEUROSCI, V22, P5536; SUGA SI, 1992, CIRC RES, V71, P34, DOI 10.1161/01.RES.71.1.34; Takahashi Y, 1998, BIOCHEM BIOPH RES CO, V246, P736, DOI 10.1006/bbrc.1998.8693; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695	47	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48880	48889		10.1074/jbc.M308680200	http://dx.doi.org/10.1074/jbc.M308680200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514678	hybrid			2022-12-25	WOS:000186829000045
J	Zhu, HY; Wu, LQ; Maki, CG				Zhu, HY; Wu, LQ; Maki, CG			MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-BODY FORMATION; RING-FINGER DOMAIN; ONCOPROTEIN MDM2; PML; PROTEIN; DEGRADATION; BODIES; EXPRESSION; ACTIVATION; APOPTOSIS	p53 can be regulated through post-translational modifications and through interactions with positive and negative regulatory factors. MDM2 binding inhibits p53 and promotes its degradation by the proteasome, whereas promyelocytic leukemia (PML) activates p53 by recruiting it to multiprotein complexes termed PML-nuclear bodies. We reported previously an in vivo and in vitro interaction between PML and MDM2 that is independent of p53. In the current study, we investigated whether interaction between MDM2 and PML can indirectly affect p53 activity. Increasing amounts of MDM2 inhibited p53 activation by PML but could not inhibit PML-mediated activation of a p53 fusion protein that lacked the MDM2-binding domain. Conversely, increasing amounts of PML could overcome p53 inhibition by MDM2 but could not overcome MDM2-mediated inhibition of a p53 fusion protein that lacked the PML-binding domain. These results demonstrate that MDM2 and PML can antagonize each other through their direct interaction with p53 and suggest the combined effects of MDM2 and PML on p53 function are determined by the relative level of each protein. Furthermore, these results imply that interactions between MDM2 and PML by themselves have little or no effect on p53 activity.	Univ Chicago, Dept Radiat Oncol, Chicago, IL 60611 USA	University of Chicago	Maki, CG (corresponding author), Univ Chicago, Dept Radiat Oncol, 5841 S Maryland Ave,MC1105,Rm G-06, Chicago, IL 60611 USA.							Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CORDONCARDO C, 1994, CANCER RES, V54, P794; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Landers JE, 1997, CANCER RES, V57, P3562; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	26	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49286	49292		10.1074/jbc.M308302200	http://dx.doi.org/10.1074/jbc.M308302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507915	hybrid			2022-12-25	WOS:000186829000095
J	Rhen, T; Grissom, S; Afshari, C; Cidlowski, JA				Rhen, T; Grissom, S; Afshari, C; Cidlowski, JA			Dexamethasone blocks the rapid biological effects of 17 beta-estradiol in the rat uterus without antagonizing its global genomic actions	FASEB JOURNAL			English	Article						17 beta-estradiol; dexamethasone; uterus; microarray	RETINOIC ACID SYNTHESIS; UTERINE GROWTH; MESSENGER-RNA; ESTROUS-CYCLE; MOUSE UTERUS; GLUCOCORTICOID RECEPTOR; ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; STRESS; PROGESTERONE	Estrogens and glucocorticoids have opposing effects on the female reproductive tract, but the molecular basis for this antagonism is poorly understood. We therefore examined the biological and transcriptional programs induced by estrogens and glucocorticoids in the uterus of immature female rats. Estradiol 17beta (E2) rapidly induced morphological changes reminiscent of an acute inflammatory response, including infiltration of eosinophils, edema in the stroma and myometrium, and a decrease in the height of luminal epithelial cells, whereas dexamethasone (Dex) only altered stromal cell morphology. When coadministered with E2, Dex completely blocked the proinflammatory effects of E2. Surprisingly, examination of E2 and Dex effects on gene expression using cDNA microarrays and real-time PCR revealed that these hormones had similar effects on the expression of many genes and that very few genes displayed antagonistic regulation. Together, these results indicate strong discord between the early biologic and genomic actions of estrogens and glucocorticoids and highlight a complex regulatory role for glucocorticoids and GR in the mammalian uterus.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlows1@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES023026, Z01ES023026] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BITMAN J, 1967, ENDOCRINOLOGY, V80, P423, DOI 10.1210/endo-80-3-423; Boehm N, 1997, MOL CELL ENDOCRINOL, V132, P101, DOI 10.1016/S0303-7207(97)00126-3; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chrousos George P., 1998, Annals of Internal Medicine, V129, P229; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DELBENDE C, 1992, BRIT J PSYCHIAT, V160, P24, DOI 10.1192/S0007125000296657; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Galton VA, 1999, J CLIN INVEST, V103, P979, DOI 10.1172/JCI6073; Gibbs RB, 1996, J NEUROSCI, V16, P1049; Gunin AG, 2001, J ENDOCRINOL, V169, P23, DOI 10.1677/joe.0.1690023; Hamadeh HK, 2002, TOXICOL SCI, V67, P219, DOI 10.1093/toxsci/67.2.219; Hilgendorf I, 2001, PANCREATOLOGY, V1, P24, DOI 10.1159/000055788; Huang TJ, 2001, BIOL REPROD, V64, P163, DOI 10.1095/biolreprod64.1.163; Ikeda M, 2001, GENE, V273, P207, DOI 10.1016/S0378-1119(01)00589-3; IZAWA M, 1984, ENDOCRINOL JAPON, V31, P491; Jetten AM, 1996, MOL CELL ENDOCRINOL, V123, P7, DOI 10.1016/0303-7207(96)03871-3; JOHNSON DC, 1980, BIOL REPROD, V22, P1136, DOI 10.1093/biolreprod/22.5.1136; Jonsson P, 1996, PANCREAS, V12, P303; KINYAMU HK, IN PRESS MOL CELL BI; Kuno N, 1998, FEBS LETT, V425, P191, DOI 10.1016/S0014-5793(98)00213-0; Leal-Cerro A, 2001, Pituitary, V4, P111, DOI 10.1023/A:1012903330944; Lobenhofer EK, 2002, MOL ENDOCRINOL, V16, P1215, DOI 10.1210/me.16.6.1215; MARKAVERICH BM, 1981, J STEROID BIOCHEM, V14, P125, DOI 10.1016/0022-4731(81)90164-3; MCGIMSEY WC, 1991, ENDOCRINOLOGY, V129, P3064, DOI 10.1210/endo-129-6-3064; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; MCKAY LI, 2000, CANC MED, P730; MEDLOCK KL, 1991, J RECEPTOR RES, V11, P743, DOI 10.3109/10799899109064677; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Mitch W E, 2000, Trans Am Clin Climatol Assoc, V111, P258; Mizoguchi K, 2001, PSYCHONEUROENDOCRINO, V26, P443, DOI 10.1016/S0306-4530(01)00004-X; PANKO WB, 1981, J RECEPTOR RES, V2, P29, DOI 10.3109/10799898109038796; PFAFF DW, 1994, J STEROID BIOCHEM, V49, P373, DOI 10.1016/0960-0760(94)90282-8; RAMBO CO, 1983, J CELL BIOL, V97, P679, DOI 10.1083/jcb.97.3.679; Reibiger I, 2000, J REPROD FERTIL, V118, P243, DOI 10.1530/reprod/118.2.243; RESNIK R, 1981, AM J OBSTET GYNECOL, V140, P151, DOI 10.1016/0002-9378(81)90102-2; Rumpel E, 1996, ANN ANAT, V178, P337, DOI 10.1016/S0940-9602(96)80089-6; SAPOLSKY RM, 1993, BEHAV BRAIN RES, V57, P175, DOI 10.1016/0166-4328(93)90133-B; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sarrel PM, 1999, HUM REPROD UPDATE, V5, P205, DOI 10.1093/humupd/5.3.205; SZEGO CM, 1988, AM J PHYSIOL, V254, P775; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tibbetts TA, 1999, BIOL REPROD, V60, P1158, DOI 10.1095/biolreprod60.5.1158; Tilbrook AJ, 2000, REV REPROD, V5, P105, DOI 10.1530/revreprod/5.2.105; Twigger S, 2002, NUCLEIC ACIDS RES, V30, P125, DOI 10.1093/nar/30.1.125; Ujioka T, 2000, BIOL REPROD, V63, P1513, DOI 10.1095/biolreprod63.5.1513; VELARDO JT, 1956, ENDOCRINOLOGY, V59, P165, DOI 10.1210/endo-59-2-165; Viau V, 2002, J NEUROENDOCRINOL, V14, P506, DOI 10.1046/j.1365-2826.2002.00798.x; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Whitworth JA, 2001, CLIN EXP PHARMACOL P, V28, P993, DOI 10.1046/j.1440-1681.2001.03584.x; Xiao LJ, 2002, MOL REPROD DEV, V63, P47, DOI 10.1002/mrd.10128; YOSHIKAWA K, 1986, BIOCHEM BIOPH RES CO, V139, P1, DOI 10.1016/S0006-291X(86)80071-7	62	50	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1849	1870		10.1096/fj.02-1099com	http://dx.doi.org/10.1096/fj.02-1099com			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519664				2022-12-25	WOS:000186343300039
J	Wong, FC; Beuning, PJ; Silvers, C; Musier-Forsyth, K				Wong, FC; Beuning, PJ; Silvers, C; Musier-Forsyth, K			An isolated class II aminoacyl-tRNA synthetase insertion domain is functional in amino acid editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC DIFFERENCES; ESCHERICHIA-COLI; MOLECULAR RECOGNITION; PROTEIN-SYNTHESIS; CRYSTAL-STRUCTURE; GENETIC-CODE; IN-VITRO; TRNA(PRO); DISCRIMINATION; CYSTEINE	Aminoacyl-tRNA synthetases are responsible for activating specific amino acids and transferring them onto cognate tRNA molecules. Due to the similarity in many amino acid side chains, certain synthetases misactivate non-cognate amino acids to an extent that would be detrimental to protein synthesis if left uncorrected. To ensure accurate translation of the genetic code, some synthetases therefore utilize editing mechanisms to hydrolyze non-cognate products. Previously class II Escherichia coli proline-tRNA synthetase (ProRS) was shown to exhibit pre- and post-transfer editing activity, hydrolyzing a misactivated alanine-adenylate (Ala-AMP) and a mischarged Ala-tRNA(Pro) variant, respectively. Residues critical for the editing activity (Asp-350 and Lys-279) are found in a novel insertion domain (INS) positioned between motifs 2 and 3 of the class defining aminoacylation active site. In this work, we present further evidence that INS is responsible for editing in ProRS. We deleted the INS from wild-type E. coli ProRS to yield DeltaINS-ProRS. While DeltaINS-ProRS was still capable of misactivating alanine, the truncated construct was defective in hydrolyzing non-cognate Ala-AMP. When the INS domain was cloned and expressed as an independent protein, it was capable of deacylating a mischarged Ala-microhelix(Pro) variant. Similar to full-length ProRS, post-transfer editing was abolished in a K279A mutant INS. We also show that YbaK, a protein of unknown function from Haemophilus influenzae with high sequence homology to the prokaryotic INS domain, was capable of deacylating Ala-tRNA(Pro) and Ala-microhelix(Pro) variants but not cognate Pro-tRNA(Pro). Thus, we demonstrate for the first time that an independently folded class II synthetase editing domain and a previously identified homolog can catalyze a hydrolytic editing reaction.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.				NIGMS NIH HHS [GM49928] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049928, R55GM049928, R01GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Alexander RW, 2001, PROG NUCLEIC ACID RE, V69, P317, DOI 10.1016/S0079-6603(01)69050-0; Augustine J, 1997, BIOCHEMISTRY-US, V36, P3473, DOI 10.1021/bi962395y; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2003, J BIOL CHEM, V278, P45056, DOI 10.1074/jbc.M307080200; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; BUECHTER DD, 1995, BIOCHEMISTRY-US, V34, P6014, DOI 10.1021/bi00018a002; Burke B, 2001, J BIOL CHEM, V276, P20286, DOI 10.1074/jbc.M100456200; Burke B, 2000, BIOCHEMISTRY-US, V39, P15540, DOI 10.1021/bi001835p; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; de Pouplana LR, 2001, J MOL EVOL, V53, P261, DOI 10.1007/s002390010216; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; FERSHT AR, 1981, PROC R SOC SER B-BIO, V212, P351, DOI 10.1098/rspb.1981.0044; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kamtekar S, 2003, P NATL ACAD SCI USA, V100, P1673, DOI 10.1073/pnas.0437911100; LAUGHREA M, 1982, EXP GERONTOL, V17, P305, DOI 10.1016/0531-5565(82)90020-1; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LINCECUM TL, 2000, SAAS B BIOCH BIOTECH, V13, P25; Liu HJ, 1996, J AM CHEM SOC, V118, P2523, DOI 10.1021/ja954062e; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; RAUNIO R, 1970, ACTA CHEM SCAND, V24, P2737, DOI 10.3891/acta.chem.scand.24-2737; Rho SB, 2002, EMBO J, V21, P6874, DOI 10.1093/emboj/cdf671; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; Schimmel P, 2000, TRENDS BIOCHEM SCI, V25, P207, DOI 10.1016/S0968-0004(00)01553-X; Schimmel P, 2001, COLD SPRING HARB SYM, V66, P161, DOI 10.1101/sqb.2001.66.161; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Stehlin C, 1997, BIOCHEMISTRY-US, V36, P2932, DOI 10.1021/bi962295s; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Wolf YI, 1999, GENOME RES, V9, P689; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; YAP LP, 1995, CHEM BIOL, V2, P661, DOI 10.1016/1074-5521(95)90029-2; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y	50	76	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52857	52864		10.1074/jbc.M309627200	http://dx.doi.org/10.1074/jbc.M309627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530268	hybrid			2022-12-25	WOS:000187480700106
J	Koenderink, JB; Geibel, S; Grabsch, E; De Pont, JJHHM; Bamberg, E; Friedrich, T				Koenderink, JB; Geibel, S; Grabsch, E; De Pont, JJHHM; Bamberg, E; Friedrich, T			Electrophysiological analysis of the mutated Na,K-ATPase cation binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5TH TRANSMEMBRANE SEGMENT; NA+-K+ PUMP; ALPHA-SUBUNIT; VOLTAGE-DEPENDENCE; XENOPUS-OOCYTES; NA/K PUMP; RENAL NA,K-ATPASE; ATP-CONCENTRATION; NA,K PUMP; COORDINATING RESIDUES	Na, K-ATPase mediates net electrogenic transport by extruding three Na+ ions and importing two K+ ions across the plasma membrane during each reaction cycle. We mutated putative cation coordinating amino acids in transmembrane hairpin M5-M6 of rat Na, K-ATPase: Asp(776) (Gln, Asp, Ala), Glu(779) (Asp, Gln, Ala), Asp(804) (Glu, Asn, Ala), and Asp(808) (Glu, Asn, Ala). Electrogenic cation transport properties of these 12 mutants were analyzed in two-electrode voltage-clamp experiments on Xenopus laevis oocytes by measuring the voltage dependence of K+-stimulated stationary currents and pre-steady-state currents under electrogenic Na+/Na+ exchange conditions. Whereas mutants D804N, D804A, and D808A hardly showed any Na+/K+ pump currents, the other constructs could be classified according to the [K+] and voltage dependence of their stationary currents; mutants N776A and E779Q behaved similarly to the wild-type enzyme. Mutants E779D, E779A, D808E, and D808N had in common a decreased apparent affinity for extracellular K+. Mutants N776Q, N776D, and D804E showed large deviations from the wild-type behavior; the currents generated by mutant N776D showed weaker voltage dependence, and the current-voltage curves of mutants N776Q and D804E exhibited a negative slope. The apparent rate constants determined from transient Na+/Na+ exchange currents are rather voltage-independent and at potentials above -60 mV faster than the wild type. Thus, the characteristic voltage-dependent increase of the rate constants at hyperpolarizing potentials is almost absent in these mutants. Accordingly, dislocating the carboxamide or carboxyl group of Asn(776) and Asp(804), respectively, decreases the extracellular Na+ affinity.	Univ Nijmegen, Dept Biochem 160, Med Ctr, NL-6500 HB Nijmegen, Netherlands; Max Planck Inst Biophys, Dept Biophys Chem, D-60439 Frankfurt, Germany	Radboud University Nijmegen; Max Planck Society	Koenderink, JB (corresponding author), Univ Nijmegen, Dept Biochem 160, Med Ctr, POB 9101, NL-6500 HB Nijmegen, Netherlands.	J.Koenderink@ncmls.kun.nl	Friedrich, Thomas/AAA-3418-2022; Koenderink, Jan/N-3578-2014					ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P254, DOI 10.1006/abbi.1999.1124; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; BAHINSKI A, 1988, P NATL ACAD SCI USA, V85, P3412, DOI 10.1073/pnas.85.10.3412; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; CLELAND WW, 1989, BIOCHIM BIOPHYS ACTA, V1000, P209; DEWEER P, 1990, NA K PUMP CURRENT GE; FENDLER K, 1985, EMBO J, V4, P3079, DOI 10.1002/j.1460-2075.1985.tb04048.x; Friedrich T, 1997, BIOPHYS J, V73, P186, DOI 10.1016/S0006-3495(97)78059-7; Friedrich T, 1996, BIOPHYS J, V71, P2486, DOI 10.1016/S0006-3495(96)79442-0; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geibel S, 2003, P NATL ACAD SCI USA, V100, P964, DOI 10.1073/pnas.0337336100; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; Hilgemann DW, 1997, ANN NY ACAD SCI, V834, P260, DOI 10.1111/j.1749-6632.1997.tb52257.x; Holmgren M, 2000, NATURE, V403, P898, DOI 10.1038/35002599; HOLMGREN M, 1994, BIOPHYS J, V66, P912, DOI 10.1016/S0006-3495(94)80867-7; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAIRE AV, 1986, J MEMBRANE BIOL, V91, P43, DOI 10.1007/BF01870213; LAUGER P, 1979, BIOCHIM BIOPHYS ACTA, V552, P143, DOI 10.1016/0005-2736(79)90253-0; Lauger P., 1991, ELECTROGENIC ION PUM; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; NAGEL G, 1987, BIOCHIM BIOPHYS ACTA, V901, P239, DOI 10.1016/0005-2736(87)90120-9; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Peluffo RD, 1997, J PHYSIOL-LONDON, V501, P33, DOI 10.1111/j.1469-7793.1997.033bo.x; Peluffo RD, 2000, J GEN PHYSIOL, V116, P47, DOI 10.1085/jgp.116.1.47; Peluffo RD, 2000, J GEN PHYSIOL, V116, P61, DOI 10.1085/jgp.116.1.61; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; RAKOWSKI RF, 1988, J MEMBRANE BIOL, V106, P173, DOI 10.1007/BF01871399; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SCHWARZ W, 1988, BIOCHIM BIOPHYS ACTA, V945, P167, DOI 10.1016/0005-2736(88)90479-8; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; THOMAS RC, 1972, PHYSIOL REV, V52, P563, DOI 10.1152/physrev.1972.52.3.563; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; Vasilets LA, 1998, BBA-BIOMEMBRANES, V1368, P137, DOI 10.1016/S0005-2736(97)00195-8; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; Zillikens S, 2000, BBA-BIOMEMBRANES, V1509, P155, DOI 10.1016/S0005-2736(00)00289-3	55	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51213	51222		10.1074/jbc.M306384200	http://dx.doi.org/10.1074/jbc.M306384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532287	hybrid, Green Published			2022-12-25	WOS:000187206300047
J	Su, WC; Chou, HY; Chang, CJ; Lee, YM; Chen, WH; Huang, KH; Lee, MY; Lee, SC				Su, WC; Chou, HY; Chang, CJ; Lee, YM; Chen, WH; Huang, KH; Lee, MY; Lee, SC			Differential activation of a C/EBP beta isoform by a novel redox switch may confer the lipopolysaccharide-inducible expression of interleukin-6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TRANSCRIPTIONAL INHIBITORY PROTEIN; NF-KAPPA-B; OXIDATIVE STRESS; NUCLEAR FACTOR; THIOREDOXIN; INDUCTION; DOMAIN; MACROPHAGES	C/EBPbeta, a member of the CCAAT/enhancer binding protein (C/EBP) family, is one of the key transcription factors responsible for the induction of a wide array of genes, some of which play important roles in innate immunity, inflammatory response, adipocyte and myeloid cell differentiation, and the acute phase response. Three C/EBPbeta isoforms (i.e. LAP*, LAP, and LIP) were known to arise from differential translation initiation and display different functions in gene regulation. C/EBPbeta is known to induce interleukin (IL)-6 gene when P388D1 cells are treated with lipopolysaccharide (LPS). Exactly how the transcriptional activities of C/EBPbeta isoforms are involved in the regulation of the IL-6 gene remains unclear. Here we report that LPS-induced expression of IL-6 gene in P388D1 cells is mediated by a redox switch-activated LAP*. The intramolecular disulfide bonds of LAP* and LAP have been determined. Among the cysteine residues, amino acid 11 (Cys(11)) of LAP* plays key roles for determining the overall intramolecular disulfide bonds that form the basis for redox switch regulation. The DNA binding activity and transcriptional activity of LAP* are enhanced under reducing condition. LAP and LIP, lacking 21 and 151 amino acids, respectively, in the N-terminal region, are not regulated in a similar redox-responsive manner. Our results indicate that LAP* is the primary isoform of C/EBPbeta that regulates, through a redox switch, the LPS-induced expression of the IL-6 gene.	Natl Taiwan Univ, Inst Mol Med, NTUH, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Inst Clin Med, Coll Med, Taipei 100, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Inst Mol Med, NTUH, Coll Med, 7 Chun Shan S Rd, Taipei 100, Taiwan.		Chang, Ching-Jin/G-4511-2019	Chang, Ching-Jin/0000-0001-7129-8092; Lee, Ming-Yue/0000-0001-7082-1216				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Bradley MN, 2003, MOL CELL BIOL, V23, P4841, DOI 10.1128/MCB.23.14.4841-4858.2003; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Ejima K, 1999, PLACENTA, V20, P561, DOI 10.1053/plac.1999.0415; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lee YM, 1996, MOL CELL BIOL, V16, P4257; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Mancini R, 2000, FASEB J, V14, P769, DOI 10.1096/fasebj.14.5.769; Markus M, 1999, J BIOL CHEM, V274, P1040, DOI 10.1074/jbc.274.2.1040; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Neumann GM, 1999, J BIOL CHEM, V274, P14587, DOI 10.1074/jbc.274.21.14587; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Pope R, 2000, CYTOKINE, V12, P1171, DOI 10.1006/cyto.2000.0691; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Rosenspire AJ, 2002, J IMMUNOL, V169, P5396, DOI 10.4049/jimmunol.169.10.5396; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Toone WM, 2001, ONCOGENE, V20, P2336, DOI 10.1038/sj.onc.1204384; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; Zheng M, 2000, BIOCHEM PHARMACOL, V59, P1, DOI 10.1016/S0006-2952(99)00289-0	43	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51150	51158		10.1074/jbc.M305501200	http://dx.doi.org/10.1074/jbc.M305501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530280	hybrid			2022-12-25	WOS:000187206300040
J	Zhang, HH; Souza, SC; Muliro, KV; Kraemer, FB; Obin, MS; Greenberg, AS				Zhang, HH; Souza, SC; Muliro, KV; Kraemer, FB; Obin, MS; Greenberg, AS			Lipase-selective functional domains of perilipin A differentially regulate constitutive and protein kinase A-stimulated lipolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Diabetes-Association	JUN 13-17, 2003	NEW ORLEANS, LA	Amer Diabet Assoc			HORMONE-SENSITIVE LIPASE; NECROSIS-FACTOR-ALPHA; ADIPOSE-TISSUE; MEDIATED LIPOLYSIS; INSULIN-RESISTANCE; ADIPOCYTE; EXPRESSION; MECHANISM; OBESITY; STORAGE	Perilipin (Peri) A is a lipid droplet-associated phosphoprotein that acts dually as a suppressor of basal ( constitutive) lipolysis and as an enhancer of cyclic AMP-dependent protein kinase (PKA)-stimulated lipolysis by both hormone-sensitive lipase (HSL) and non-HSL(s). To identify domains of Peri A that mediate these multiple actions, we introduced adenoviruses expressing truncated or mutated Peri A and HSL into NIH 3T3 fibroblasts lacking endogenous perilipins and HSL but overexpressing acyl-CoA synthetase 1 and fatty acid transporter 1. We identified two lipase-selective functional domains: 1) Peri A (amino acids 1 - 300), which inhibits basal lipolysis and promotes PKA-stimulated lipolysis by HSL, and 2) Peri A ( amino acids 301 - 517), which inhibits basal lipolysis by non-HSL and promotes PKA-stimulated lipolysis by both HSL and non-HSL. PKA site mutagenesis revealed that PKA-stimulated lipolysis by HSL requires phosphorylation of one or more sites within Peri 1 - 300 (Ser(81), Ser(222), and Ser(276)). PKA-stimulated lipolysis by non-HSL additionally requires phosphorylation of one or more PKA sites within Peri 301 - 517 (Ser(433), Ser(492), and Ser(517)). Peri 301 - 517 promoted PKA-stimulated lipolysis by HSL yet did not block HSL-mediated basal lipolysis, indicating that an additional region( s) within Peri 301 - 517 promotes hormone-stimulated lipolysis by HSL. These results suggest a model of Peri A function in which 1) lipase-specific "barrier" domains block basal lipolysis by HSL and non-HSL, 2) differential PKA site phosphorylation allows PKA-stimulated lipolysis by HSL and non-HSL, respectively, and 3) additional domains within Peri A further facilitate PKA-stimulated lipolysis, again with lipase selectivity.	Tufts Univ, JM USDA HNRCA, Boston, MA 02111 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94305 USA; Stanford Univ, Palo Alto, CA 94305 USA	Tufts University; United States Department of Agriculture (USDA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Greenberg, AS (corresponding author), Tufts Univ, JM USDA HNRCA, Rm 603,711 Washington St, Boston, MA 02111 USA.	andrew.greenberg@tufts.edu	Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050647, P30DK034928] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50647, P30 DK 34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1988, DIABETES METAB REV, V4, P507; Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; BRASAEMLE D, 2000, BIOCHIM BIOPHYS ACTA, P251; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; COPPACK SW, 1994, J LIPID RES, V35, P177; EGAN JJ, 1990, J BIOL CHEM, V265, P18769; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; Gargiulo CE, 1999, J LIPID RES, V40, P881; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; Large V, 1999, J LIPID RES, V40, P2059; LAURENZA A, 1987, MOL PHARMACOL, V32, P133; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; MCGARR JA, 1976, AM J PHYSIOL, V230, P385, DOI 10.1152/ajplegacy.1976.230.2.385; Mottagui-Tabar S, 2003, DIABETOLOGIA, V46, P789, DOI 10.1007/s00125-003-1112-x; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Shen W, 2003, OBES RES, V11, P5, DOI 10.1038/oby.2003.3; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Steinberg D, 1975, Adv Cyclic Nucleotide Res, V5, P549; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; SZTALRYD C, 1994, AM J PHYSIOL, V266, pE179, DOI 10.1152/ajpendo.1994.266.2.E179; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wang XZ, 2000, J VIROL, V74, P11296, DOI 10.1128/JVI.74.23.11296-11303.2000; Zhang HH, 2002, DIABETES, V51, P2929, DOI 10.2337/diabetes.51.10.2929	39	108	116	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51535	51542		10.1074/jbc.M309591200	http://dx.doi.org/10.1074/jbc.M309591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	752ZM	14527948	hybrid			2022-12-25	WOS:000187206300085
J	Bernard, DG; Gabilly, ST; Dujardin, G; Merchant, S; Hamel, PP				Bernard, DG; Gabilly, ST; Dujardin, G; Merchant, S; Hamel, PP			Overlapping specificities of the mitochondrial cytochrome c and c1 heme lyases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOCYTOCHROME-C; IONIC STABILITY; YEAST; IMPORT; BIOGENESIS; MUTANTS; PROTEIN; PATHWAY; GENES; TRANSFORMATION	Heme attachment to the apoforms of fungal mitochondrial cytochrome c and c(1) requires the activity of cytochrome c and c(1) heme lyases (CCHL and CC1HL), which are enzymes with distinct substrate specificity. However, the presence of a single heme lyase in higher eukaryotes is suggestive of broader substrate specificity. Here, we demonstrate that yeast CCHL is active toward the non-cognate substrate apocytochrome c(1), i.e. CCHL promotes low levels of apocytochrome c(1) conversion to its holoform in the absence of CC1HL. Moreover, that the single human heme lyase also displays a broader cytochrome specificity is evident from its ability to substitute for both yeast CCHL and CC1HL. Multicopy and genetic suppressors of the absence of CC1HL were isolated and their analysis revealed that the activity of CCHL toward cytochrome c(1) can be enhanced by: 1) reducing the abundance of the cognate substrate apocytochrome c, 2) increasing the accumulation of CCHL, 3) modifying the substrate-enzyme interaction through point mutations in CCHL or cytochrome c(1), or 4) overexpressing Cyc2p, a protein known previously only as a mitochondrial biogenesis factor. Based on the functional interaction of Cyc2p with CCHL and the presence of a putative FAD-binding site in the protein, we hypothesize that Cyc2p controls the redox chemistry of the heme lyase reaction.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; CNRS, Ctr Genet Mol, F-97198 Gif Sur Yvette, France	University of California System; University of California Los Angeles; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Hamel, PP (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Box 951569, Los Angeles, CA 90095 USA.	hamel@chem.ucla.edu		Bernard, Delphine/0000-0002-9439-5482	NIGMS NIH HHS [GM48350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CLAISSE ML, 1970, EUR J BIOCHEM, V16, P430, DOI 10.1111/j.1432-1033.1970.tb01098.x; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Danin-Kreiselman M, 2003, MOL CELL, V11, P1279, DOI 10.1016/S1097-2765(03)00137-0; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; Dreyfuss BW, 2003, J BIOL CHEM, V278, P2604, DOI 10.1074/jbc.M208652200; DREYFUSS BW, 1999, P 1 INT C PHOT, V4, P3139; DUJARDIN G, 1980, MOL GEN GENET, V179, P469, DOI 10.1007/BF00271736; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, ADV MOL CELL BIOL, P103; DUTTA C, 1990, ANAL BIOCHEM, V184, P96, DOI 10.1016/0003-2697(90)90018-5; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Goldman BS, 2001, RES MICROBIOL, V152, P323, DOI 10.1016/S0923-2508(01)01203-7; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GUELMAN R, 2002, BONE, V30, P23; Hamel P, 1998, GENETICS, V150, P601; Hamel PP, 2003, J BIOL CHEM, V278, P2593, DOI 10.1074/jbc.M208651200; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOWE G, 1994, PHOTOSYNTH RES, V40, P147, DOI 10.1007/BF00019332; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Kranz RG, 2002, RES MICROBIOL, V153, P1, DOI 10.1016/S0923-2508(01)01278-5; KRANZ RG, 1995, ANOXYGENIC PHOTOSYNT, P709; LANG BF, 1982, CURR GENET, V6, P229, DOI 10.1007/BF00390343; LAZ TM, 1984, P NATL ACAD SCI-BIOL, V81, P4475, DOI 10.1073/pnas.81.14.4475; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Lim MLR, 2002, J BIOMED SCI, V9, P488, DOI 10.1159/000064722; MATNER RR, 1982, J BIOL CHEM, V257, P9811; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MINET M, 1992, PLANT J, V2, P417; Nakamoto SS, 2000, BIOCHIMIE, V82, P603, DOI 10.1016/S0300-9084(00)00605-2; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; O'Brian MR, 2002, ADV MICROB PHYSIOL, V46, P257, DOI 10.1016/S0065-2911(02)46006-7; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; Pearce DA, 1998, FEBS LETT, V439, P307, DOI 10.1016/S0014-5793(98)01374-X; Prakash SK, 2002, HUM MOL GENET, V11, P3237, DOI 10.1093/hmg/11.25.3237; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Saint-Georges Y, 2002, J BIOL CHEM, V277, P49397, DOI 10.1074/jbc.M207219200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanchez NS, 2001, ARCH BIOCHEM BIOPHYS, V392, P326, DOI 10.1006/abbi.2001.2465; Schaefer L, 1996, GENOMICS, V34, P166, DOI 10.1006/geno.1996.0261; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schwarz QP, 2002, GENOMICS, V79, P51, DOI 10.1006/geno.2001.6677; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1990, GENETICS, V125, P9; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; STUART RA, 1990, CELL, V60, P31, DOI 10.1016/0092-8674(90)90713-O; STUART RA, 1990, J BIOL CHEM, V265, P20210; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; Thony-Meyer L, 2002, BIOCHEM SOC T, V30, P633; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Tong JC, 1998, J BIOL CHEM, V273, P25695, DOI 10.1074/jbc.273.40.25695; Veloso D., 1984, J BIOL CHEM, V258, P10963; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; Wilks A, 2002, ANTIOXID REDOX SIGN, V4, P603, DOI 10.1089/15230860260220102; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1998, GENETICS, V148, P681; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	81	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49732	49742		10.1074/jbc.M308881200	http://dx.doi.org/10.1074/jbc.M308881200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514677	hybrid			2022-12-25	WOS:000187068200013
J	Bradbury, DA; Newton, R; Zhu, YM; El-Haroun, H; Corbett, L; Knox, AJ				Bradbury, DA; Newton, R; Zhu, YM; El-Haroun, H; Corbett, L; Knox, AJ			Cyclooxygenase-2 induction by bradykinin in human pulmonary artery smooth muscle cells is mediated by the cyclic AMP response element through a novel autocrine loop involving endogenous prostaglandin E-2, E-prostanoid 2 (EP2), and EP4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA STABILITY; PROTEIN-KINASE-C; GENE-EXPRESSION; PROSTANOID RECEPTORS; DEPENDENT ACTIVATION; HUMAN FIBROBLASTS; TNF-ALPHA; IL-1-BETA; INTERLEUKIN-1-BETA	Bradykinin (BK) is an important mediator in several inflammatory and vascular diseases that acts in part via induction of cyclooxygenase-2 (COX-2). The mechanisms involved in BK-mediated COX-2 induction are unclear. Here we characterized the transcriptional mechanisms involved in human pulmonary artery smooth muscle cells. BK stimulated the activity of a transiently transfected 966-bp (-917 to +49) COX-2 promoter luciferase reporter construct. There was no reduction in BK-induced luciferase activity in cells transfected with COX-2 promoter constructs of 674, 407, 239, and 135 bp or constructs with mutated CCAAT/enhancer-binding protein- or NF-kappaB-binding sites. In contrast luciferase activity was reduced in cells transfected with a 407-bp COX-2 promoter fragment containing a mutated cAMP response element (CRE)-binding site, suggesting that the CRE binding site is critical. Electrophoretic mobility shift assays using oligonucleotides specific for the CRE-binding region of the COX-2 promoter and consensus oligonucleotides showed strong specific binding. Furthermore BK increased consensus cAMP-responsive luciferase reporter (p6CRE/luc)-mediated luciferase expression. CRE activation occurred by BK inducing cytosolic phospholipase A(2)-mediated arachidonic acid release and rapid prostaglandin E-2 (PGE(2)) production, thereby increasing cAMP. Indomethacin inhibited BK-induced PGE(2) production, cAMP accumulation, and CRE/luc reporter and COX-2 promoter luciferase activity. Exogenous PGE(2) and EP2 (ONO-AE1 259) and EP4 (ONO-AE1 329) PGE(2) receptor agonists mimicked the effect of BK. Collectively these studies indicate that COX-2 induction by BK in human pulmonary artery smooth muscle cells is mediated by the CRE through a novel autocrine loop involving endogenous PGE(2).	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Imperial College London	Knox, AJ (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.		Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498; Knox, Alan/0000-0002-5906-4143; El-Haroun, Hala/0000-0002-9938-3907				BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bradbury DA, 2002, AM J PHYSIOL-LUNG C, V283, pL717, DOI 10.1152/ajplung.00070.2002; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; Huang ZF, 2000, BIOCHEM PHARMACOL, V59, P187, DOI 10.1016/S0006-2952(99)00312-3; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Maruyama T, 2001, BIOORG MED CHEM LETT, V11, P2033, DOI 10.1016/S0960-894X(01)00365-1; Naraba H, 1998, FEBS LETT, V435, P96, DOI 10.1016/S0014-5793(98)01045-X; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Okada Y, 2000, J CELL BIOCHEM, V78, P197, DOI 10.1002/(SICI)1097-4644(20000801)78:2<197::AID-JCB3>3.0.CO;2-C; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; Pyne NJ, 1997, BIOCHEM J, V328, P689; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Scott MGH, 1999, BRIT J PHARMACOL, V128, P721, DOI 10.1038/sj.bjp.0702829; STEVENS PA, 1994, BIOCHEM J, V297, P233, DOI 10.1042/bj2970233; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Tamura M, 2002, J CLIN ENDOCR METAB, V87, P3263, DOI 10.1210/jc.87.7.3263; Tani K, 2001, BIOORG MED CHEM LETT, V11, P2025, DOI 10.1016/S0960-894X(01)00359-6; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; TRIFILIEFF A, 1993, EUR RESPIR J, V6, P576; Wen FQ, 1998, PROSTAG LEUKOTR ESS, V59, P71, DOI 10.1016/S0952-3278(98)90054-0; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhu YM, 2003, J BIOL CHEM, V278, P29366, DOI 10.1074/jbc.M301785200	32	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49954	49964		10.1074/jbc.M307964200	http://dx.doi.org/10.1074/jbc.M307964200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517215	hybrid			2022-12-25	WOS:000187068200038
J	Dufner-Beattie, J; Langmade, SJ; Wang, FD; Eide, D; Andrews, GK				Dufner-Beattie, J; Langmade, SJ; Wang, FD; Eide, D; Andrews, GK			Structure, function, and regulation of a subfamily of mouse zinc transporter genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DI-LEUCINE; DIETARY ZINC; METALLOTHIONEIN-I; METAL TRANSPORTER; ACRODERMATITIS-ENTEROPATHICA; SACCHAROMYCES-CEREVISIAE; CONFERS RESISTANCE; SYNAPTIC VESICLES; MENKES PROTEIN; ZIP FAMILY	Zinc is an essential metal for all eukaryotes, and cells have evolved a complex system of proteins to maintain the precise balance of zinc uptake, intracellular storage, and efflux. In mammals, zinc uptake appears to be mediated by members of the Zrt/Irt-like protein ( ZIP) superfamily of metal ion transporters. Herein, we have studied a subfamily of zip genes (zip1, zip2, and zip3) that is conserved in mice and humans. These eight-transmembrane domain proteins contain a conserved 12-amino acid signature sequence within the fourth transmembrane domain. All three of these mouse ZIP proteins function to specifically increase the uptake of zinc in transfected cultured cells, similar to the previously demonstrated functions of human ZIP1 and ZIP2 (Gaither, L. A., and Eide, D. J. ( 2000) J. Biol. Chem. 275, 5560 - 5564; Gaither, L. A., and Eide, D. J. ( 2001) J. Biol. Chem. 276, 22258 - 22264). No ZIP3 orthologs have been previously studied. Furthermore, this first systematic comparative study of the in vivo expression and dietary zinc regulation of this subfamily of zip genes revealed that 1) zip1 mRNA is abundant in many mouse tissues, whereas zip2 and zip3 mRNAs are very rare or moderately rare, respectively, and tissue-restricted in their accumulation; and 2) unlike mouse metallothionein I and zip4 mRNAs (Dufner-Beattie, J., Wang, F., Kuo, Y.-M., Gitschier, J., Eide, D., and Andrews, G. K. ( 2003) J. Biol. Chem. 278, 33474 - 33481), the abundance of zip1, zip2, and zip3 mRNAs is not regulated by dietary zinc in the intestine and visceral endoderm, tissues involved in nutrient absorption. These studies suggest that all three of these ZIP proteins may play cell-specific roles in zinc homeostasis rather than primary roles in the acquisition of dietary zinc.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Missouri, Dept Nutr Sci & Biochem, Columbia, MO 65211 USA	University of Kansas; University of Kansas Medical Center; University of Missouri System; University of Missouri Columbia	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Mail Stop 3030,39th & Rainbow Blvd, Kansas City, KS 66160 USA.		Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50181] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; APGAR J, 1985, ANNU REV NUTR, V5, P43, DOI 10.1146/annurev.nu.05.070185.000355; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Cao J, 2001, J LEUKOCYTE BIOL, V70, P559; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; COOKMILLS JM, 1993, BRIT J NUTR, V69, P835, DOI 10.1079/BJN19930084; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Cousins R J, 1989, Adv Exp Med Biol, V249, P3; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; COUSINS RJ, 2000, J NUTR S, V130; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Fraker PJ, 2000, J NUTR, V130, p1399S, DOI 10.1093/jn/130.5.1399S; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Haase H, 2002, BIOCHEM BIOPH RES CO, V296, P923, DOI 10.1016/S0006-291X(02)02017-X; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; HEMPE JM, 1991, J NUTR, V121, P1389, DOI 10.1093/jn/121.9.1389; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kirschke CP, 2003, J BIOL CHEM, V278, P4096, DOI 10.1074/jbc.M207644200; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Krebs NF, 2000, J NUTR, V130, p1374S, DOI 10.1093/jn/130.5.1374S; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lee DK, 2003, J NUTR, V133, P45, DOI 10.1093/jn/133.1.45; Lioumi M, 1999, GENOMICS, V62, P272, DOI 10.1006/geno.1999.5993; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; Petris MJ, 2002, J BIOL CHEM, V277, P46736, DOI 10.1074/jbc.M208864200; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	56	129	133	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50142	50150		10.1074/jbc.M304163200	http://dx.doi.org/10.1074/jbc.M304163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525987	hybrid			2022-12-25	WOS:000187068200059
J	Kim, DY; Kim, KK				Kim, DY; Kim, KK			Crystal structure of ClpX molecular chaperone from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; BINDING SITES; X-RAY; PROTEIN; DOMAIN; PROTEOLYSIS; COMPONENT; ALIGNMENT	ClpX, a heat shock protein 100 chaperone, which acts as the regulatory subunit of the ATP- dependent ClpXP protease, is responsible for intracellular protein remodeling and degradation. To provide a structural basis for a better understanding of the function of the Clp ATPase family, the crystal structures of Helicobacter pylori ClpX, lacking an N- terminal Cys cluster region complexed with ADP, was determined. The overall structure of ClpX is similar to that of heat shock locus U ( HslU), consisting of two subdomains, with ADP bound at the subdomain interface. The crystal structure of ClpX reveals that a conserved tripeptide ( LGF) is located on the tip of ClpP binding loop extending from the N- terminal subdomain. A hexameric model of ClpX suggests that six tripeptides make hydrophobic contacts with the hydrophobic clefts of the ClpP heptmer asymmetrically. In addition, the nucleotide binding environment provides the structural explanation for the hexameric assembly and the modulation of ATPase activity.	Sungkyunkwan Univ, Sch Med, SBRI, Ctr Mol Med,Dept Mol Cell Biol, Suwon 440746, South Korea	Samsung; Sungkyunkwan University (SKKU)	Kim, KK (corresponding author), Sungkyunkwan Univ, Sch Med, SBRI, Ctr Mol Med,Dept Mol Cell Biol, Suwon 440746, South Korea.	kkim@med.skku.ac.kr		Kim, Dong Young/0000-0001-7594-9083				Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joshi SA, 2003, MOL MICROBIOL, V48, P67, DOI 10.1046/j.1365-2958.2003.03424.x; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim DY, 2003, ACTA CRYSTALLOGR D, V59, P1642, DOI 10.1107/S090744490301463X; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; ORUGA T, 2001, GENES CELLS, V6, P575; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramachandran R, 2002, P NATL ACAD SCI USA, V99, P7396, DOI 10.1073/pnas.102188799; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x	38	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50664	50670		10.1074/jbc.M305882200	http://dx.doi.org/10.1074/jbc.M305882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514695	hybrid			2022-12-25	WOS:000187068200122
J	Lim, A; Sengupta, S; McComb, ME; Theberge, R; Wilson, WG; Costello, CE; Jacobsen, DW				Lim, A; Sengupta, S; McComb, ME; Theberge, R; Wilson, WG; Costello, CE; Jacobsen, DW			In vitro and in vivo interactions of homocysteine with human plasma transthyretin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; PROTEIN-BOUND HOMOCYSTEINE; CYSTEINE-MIXED DISULFIDE; ALZHEIMERS-DISEASE; REDOX STATUS; SERUM; INTERMEDIATE; FOLATE; RISK; ACID	Hyperhomocysteinemia is an independent risk factor for cardiovascular disease and an emerging risk factor for cognitive dysfunction and Alzheimer's disease. Greater than 70% of the homocysteine in plasma is disulfide-bonded to protein cysteine residues. The identity and functional consequences of protein homocysteinylation are just now emerging. The amyloidogenic protein transthyretin ( prealbumin), as we now report, undergoes homocysteinylation at its single cysteine residue ( Cys(10)) both in vitro and in vivo. Thus, when human plasma or highly purified transthyretin was incubated with S-35-L-homocysteine followed by SDS-PAGE and PhosphorImaging, two bands corresponding to transthyretin dimer and tetramer were observed. Treatment of the labeled samples with beta-mercaptoethanol prior to SDS-PAGE removed the disulfide-bound homocysteine. Transthyretin-Cys(10)-S-S-homocysteine was then identified in vivo in plasma from normal donors, patients with end-stage renal disease, and homocystinurics by immunoprecipitation and high performance liquid chromatography/electrospray mass spectrometry. The ratios of transthyretin-Cys(10)-S-S-homocysteine and transthyretin-Cys(10)-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine plasma concentrations, whereas the ratio of transthyretin-Cys(10)-S-S-cysteine to that of unmodified transthyretin decreased. The hyperhomocysteinemic burden is thus reflected in the plasma levels of transthyretin-Cys(10)-S-S-homocysteine, which in turn may contribute to the pathological consequences of amyloid disease.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Virginia, Sch Med, Div Pediat, Charlottesville, VA 22908 USA	Cleveland Clinic Foundation; Boston University; University of Virginia	Jacobsen, DW (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, NC-10,9500 Euclid Ave, Cleveland, OH 44195 USA.	jacobsd@ccf.org	McComb, Mark E/I-3193-2014	Costello, Catherine/0000-0003-1594-5122; /0000-0002-4249-485X	NCRR NIH HHS [P41 RR 10888] Funding Source: Medline; NHLBI NIH HHS [R01 HL 52234] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Benson M. D., 2001, METABOLIC MOL BASES, P5345; Bescond A, 1999, BIOCHEM BIOPH RES CO, V263, P498, DOI 10.1006/bbrc.1999.1391; Budy B, 2001, ANAL BIOCHEM, V291, P303, DOI 10.1006/abio.2000.5039; Carmel R., 2001, HOMOCYSTEINE HLTH DI; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; CORNWELL GG, 1983, AM J MED, V75, P618, DOI 10.1016/0002-9343(83)90443-6; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; GREGORY RE, 1984, CHEM-BIOL INTERACT, V49, P55, DOI 10.1016/0009-2797(84)90052-8; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; Hong DP, 2002, J BIOL CHEM, V277, P21554, DOI 10.1074/jbc.M200188200; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Kishikawa M, 1999, AMYLOID, V6, P48, DOI 10.3109/13506129908993287; Kishikawa M, 1996, J MASS SPECTROM, V31, P112, DOI 10.1002/(SICI)1096-9888(199601)31:1<112::AID-JMS246>3.0.CO;2-E; Kishikawa M, 1999, AMYLOID, V6, P183, DOI 10.3109/13506129909007324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Majors AK, 2002, ARTERIOSCL THROM VAS, V22, P1354, DOI 10.1161/01.ATV.0000023899.93940.7C; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; Miller JW, 2000, NUTRITION, V16, P675, DOI 10.1016/S0899-9007(00)00307-5; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Olofsson A, 2001, J BIOL CHEM, V276, P39592, DOI 10.1074/jbc.M103599200; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; REFSUM H, 1985, CLIN CHEM, V31, P624; Robinson K, 1996, CIRCULATION, V94, P2743, DOI 10.1161/01.CIR.94.11.2743; Roda O, 2003, J BIOL CHEM, V278, P5702, DOI 10.1074/jbc.M207605200; Rostom AA, 1998, PROTEINS, P3; Sass JO, 2003, BIOCHEM BIOPH RES CO, V310, P242, DOI 10.1016/j.bbrc.2003.08.089; Schormann N, 1998, AMYLOID, V5, P175, DOI 10.3109/13506129809003843; Sengupta S, 2001, J BIOL CHEM, V276, P30111, DOI 10.1074/jbc.M104324200; Sengupta S, 2001, J BIOL CHEM, V276, P46896, DOI 10.1074/jbc.M108451200; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Suhr OB, 1999, AMYLOID, V6, P187, DOI 10.3109/13506129909007325; Taylor LM, 1999, J VASC SURG, V29, P8, DOI 10.1016/S0741-5214(99)70345-9; Theberge R, 1999, ANAL CHEM, V71, P452, DOI 10.1021/ac980531u; Togawa T, 2000, BIOCHEM BIOPH RES CO, V277, P668, DOI 10.1006/bbrc.2000.3723; Ueland PM, 2000, AM J CLIN NUTR, V72, P324; Undas A, 2001, J BIOL CHEM, V276, P4389, DOI 10.1074/jbc.M004124200; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; WILEY VC, 1988, METABOLISM, V37, P191, DOI 10.1016/S0026-0495(98)90017-8; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	48	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49707	49713		10.1074/jbc.M306748200	http://dx.doi.org/10.1074/jbc.M306748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14507924	hybrid			2022-12-25	WOS:000187068200010
J	Subhi, AL; Diegelman, P; Porter, CW; Tang, BQ; Lu, ZCJ; Markham, GD; Kruger, WD				Subhi, AL; Diegelman, P; Porter, CW; Tang, BQ; Lu, ZCJ; Markham, GD; Kruger, WD			Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SALVAGE PATHWAY; SACCHAROMYCES-CEREVISIAE; KLEBSIELLA-PNEUMONIAE; HISTONE ACETYLTRANSFERASE; HOMOZYGOUS DELETIONS; S-ADENOSYLMETHIONINE; CELL-GROWTH; RAT-LIVER; GENE; 5'-METHYLTHIOADENOSINE	The gene encoding methylthioadenosine phosphorylase (MTAP), the initial enzyme in the methionine salvage pathway, is deleted in a variety of human tumors and acts as a tumor suppressor gene in cell culture (Christopher, S. A., Diegelman, P., Porter, C. W., and Kruger, W. D. (2002) Cancer Res. 62, 6639 - 6644). Overexpression of the polyamine biosynthetic enzyme ornithine decarboxylase (ODC) is frequently observed in tumors and has been shown to be tumorigenic in vitro and in vivo. In this paper, we demonstrate a novel regulatory pathway in which the methionine salvage pathway products inhibit ODC activity. We show that in Saccharomyces cerevisiae the MEU1 gene encodes MTAP and that Meu1Delta cells have an 8-fold increase in ODC activity, resulting in large elevations in polyamine pools. Mutations in putative salvage pathway genes downstream of MTAP also cause elevated ODC activity and elevated polyamines. The addition of the penultimate salvage pathway compound 4-methylthio-2-oxobutanoic acid represses ODC levels in both MTAP-deleted yeast and human tumor cell lines, indicating that 4-methylthio-2-oxobutanoic acid acts as a negative regulator of polyamine biosynthesis. Expression of MTAP in MTAP-deleted MCF-7 breast adenocarcinoma cells results in a significant reduction of ODC activity and reduction in polyamine levels. Taken together, our results show that products of the methionine salvage pathway regulate polyamine biosynthesis and suggest that MTAP deletion may lead to ODC activation in human tumors.	Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA 19111 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Roswell Park Cancer Institute	Kruger, WD (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, 333 Cottman Ave, Philadelphia, PA 19111 USA.	wd_kruger@fccc.edu	kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NCI NIH HHS [CA-22153, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022153, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BACKLUND PS, 1981, J BIOL CHEM, V256, P1533; BACKLUND PS, 1982, J BIOL CHEM, V257, P4196; BACKLUND PS, 1982, BIOCHEM BIOPH RES CO, V108, P687, DOI 10.1016/0006-291X(82)90884-1; BALAKRISHNAN R, 1993, J BIOL CHEM, V268, P24792; BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; Brachmann CB, 1998, YEAST, V14, P115; Chen ZH, 1997, MOL PHARMACOL, V52, P903, DOI 10.1124/mol.52.5.903; Christopher SA, 2002, CANCER RES, V62, P6639; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Cohen SS, 1998, GUIDE POLYAMINES, P296; COHN MS, 1983, METHOD ENZYMOL, V94, P231; CONE MC, 1982, J BACTERIOL, V151, P510, DOI 10.1128/JB.151.1.510-515.1982; Dai Y, 1999, J BIOL CHEM, V274, P1193, DOI 10.1074/jbc.274.3.1193; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DIBNER JJ, 1990, J NUTR, V120, P553, DOI 10.1093/jn/120.6.553; Donoviel MS, 1996, GENETICS, V143, P1137; FERRO AJ, 1981, BIOCHEM BIOPH RES CO, V100, P523, DOI 10.1016/S0006-291X(81)80208-2; FURFINE ES, 1988, J BIOL CHEM, V263, P9598; Garcia-Castellano JM, 2002, CLIN CANCER RES, V8, P782; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gupta R, 2001, P NATL ACAD SCI USA, V98, P10620, DOI 10.1073/pnas.181341298; Harlow E., 1988, ANTIBODIES LAB MANUA; Hobbs CA, 2000, J CELL BIOCHEM, V77, P345, DOI 10.1002/(SICI)1097-4644(20000601)77:3<345::AID-JCB1>3.0.CO;2-P; Hobbs CA, 2002, CANCER RES, V62, P67; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; MARCHITTO KS, 1985, J GEN MICROBIOL, V131, P2153; MEGOSH L, 1995, CANCER RES, V55, P4205; MYERS RW, 1990, J BIOL CHEM, V265, P16913; MYERS RW, 1993, J BIOL CHEM, V268, P24785; NOBORI T, 1991, CANCER RES, V51, P3193; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; OBrien TG, 1997, CANCER RES, V57, P2630; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1981, BIOCHEM J, V194, P79, DOI 10.1042/bj1940079; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; QUASH G, 1995, BIOCHEM J, V305, P1017, DOI 10.1042/bj3051017; Schipper RG, 2000, SEMIN CANCER BIOL, V10, P55, DOI 10.1006/scbi.2000.0308; Schmid M, 1998, ONCOGENE, V17, P2669, DOI 10.1038/sj.onc.1202205; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Stadler WM, 1996, UROL RES, V24, P239, DOI 10.1007/BF00295899; Tang BQ, 2000, CANCER RES, V60, P5543; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; TOOHEY JI, 1978, BIOCHEM BIOPH RES CO, V83, P27, DOI 10.1016/0006-291X(78)90393-5; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; TRACKMAN PC, 1981, BIOCHEM BIOPH RES CO, V103, P1238, DOI 10.1016/0006-291X(81)90255-2; TRACKMAN PC, 1983, J BIOL CHEM, V258, P6717; TYAGI AK, 1983, METHOD ENZYMOL, V94, P135; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WRAY JW, 1995, J BIOL CHEM, V270, P3147, DOI 10.1074/jbc.270.7.3147	53	66	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49868	49873		10.1074/jbc.M308451200	http://dx.doi.org/10.1074/jbc.M308451200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506228	hybrid			2022-12-25	WOS:000187068200028
J	Ren, H; Honse, Y; Peoples, RW				Ren, H; Honse, Y; Peoples, RW			A site of alcohol action in the fourth membrane-associated domain of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED ION CURRENT; ETHANOL INHIBITION; INDUCED NORADRENALINE; HIPPOCAMPAL-NEURONS; H-3 NOREPINEPHRINE; SINGLE-CHANNEL; RELEASE; GLYCINE; DESENSITIZATION; MUTATIONS	The N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptor is an important mediator of the behavioral effects of ethanol in the central nervous system. Although ethanol is known to inhibit NMDA receptors by influencing ion-channel gating, its molecular site of action and the mechanism underlying this effect have not been established. We have previously identified a conserved methionine residue in the fourth membrane-associated domain of the NMDA receptor NR2A subunit (Met(823)) that influences desensitization and gating of the ion channel. Here we report that this residue plays an important role in mediating the effect of ethanol on the NMDA receptor. Ethanol IC50 values among functional substitution mutants at this position varied over the range similar to 130-225 mM. There was a weak correlation between ethanol IC50 and mean open time of NR2A( Met823) mutants that was dependent on inclusion of the value for the tryptophan mutant. In the absence of this value, there was no trend toward a correlation among the remaining mutants. Desensitization appeared to influence the action of ethanol, because ethanol IC50 of the mutants was correlated with the steady-state to peak current ratio. With the exception of tryptophan, ethanol sensitivity was significantly related to the molecular volume and hydrophobicity of the substituent. The relation between ethanol sensitivity and the molecular volume and hydrophobicity at this position suggests that this residue interacts with or forms part of a site of ethanol action and that the presence of a tryptophan residue in this site disrupts its ability to interact with ethanol.	NIAAA, Unit Cellular Neuropharmacol, Mol & Cellular Neurobiol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Peoples, RW (corresponding author), Marquette Univ, Dept Biomed Sci, POB 1881, Milwaukee, WI 53201 USA.	robert.peoples@marquette.edu						BULLER AL, 1995, MOL PHARMACOL, V48, P717; CHU B, 1995, J NEUROCHEM, V65, P140; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; FINK K, 1990, EUR J PHARMACOL, V191, P225, DOI 10.1016/0014-2999(90)94152-N; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; Godden EL, 2001, J PHARMACOL EXP THER, V296, P716; GONZALES RA, 1991, NEUROPHARMACOLOGY, V30, P441, DOI 10.1016/0028-3908(91)90004-U; GONZALES RA, 1990, J PHARMACOL EXP THER, V253, P1138; GOTHERT M, 1989, N-S ARCH PHARMACOL, V340, P516; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOFFMAN PL, 1989, NEUROPHARMACOLOGY, V28, P1239, DOI 10.1016/0028-3908(89)90217-7; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Krasowski MD, 2001, NEUROPHARMACOLOGY, V41, P952, DOI 10.1016/S0028-3908(01)00141-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lewohl JM, 1999, NAT NEUROSCI, V2, P1084, DOI 10.1038/16012; LIMALANDMAN MTR, 1989, FEBS LETT, V247, P61, DOI 10.1016/0014-5793(89)81241-4; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1990, J NEUROSCI, V10, P1372; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MIRSHAHI T, 1995, NEUROPHARMACOLOGY, V34, P347, DOI 10.1016/0028-3908(94)00155-L; Peoples RW, 2000, NEUROPHARMACOLOGY, V39, P1681, DOI 10.1016/S0028-3908(00)00067-8; PEOPLES RW, 1995, P NATL ACAD SCI USA, V92, P2825, DOI 10.1073/pnas.92.7.2825; PEOPLES RW, 1992, BRAIN RES, V571, P342, DOI 10.1016/0006-8993(92)90674-X; Peoples RW, 2002, MOL PHARMACOL, V61, P169, DOI 10.1124/mol.61.1.169; Peoples RW, 1997, BRIT J PHARMACOL, V122, P1035, DOI 10.1038/sj.bjp.0701483; Ren H, 2003, J BIOL CHEM, V278, P276, DOI 10.1074/jbc.M209486200; Ronald KM, 2001, J BIOL CHEM, V276, P44729, DOI 10.1074/jbc.M102800200; Scheller M, 2002, J NEUROSCI, V22, P8411; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; SIMSON PE, 1991, J PHARMACOL EXP THER, V257, P225; Ueno S, 1999, BRIT J PHARMACOL, V127, P377, DOI 10.1038/sj.bjp.0702563; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Wright JM, 1996, BRAIN RES, V738, P249, DOI 10.1016/S0006-8993(96)00780-9; ZILBERTER Y, 1991, MOL PHARMACOL, V40, P337; ZIMMERMAN JM, 1968, J THEOR BIOL, V21, P170, DOI 10.1016/0022-5193(68)90069-6	38	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48815	48820		10.1074/jbc.M302097200	http://dx.doi.org/10.1074/jbc.M302097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506267	hybrid			2022-12-25	WOS:000186829000038
J	Dupuis, L; di Scala, F; Rene, F; de Tapia, M; Oudart, H; Pradat, PF; Meininger, V; Loeffler, JP				Dupuis, L; di Scala, F; Rene, F; de Tapia, M; Oudart, H; Pradat, PF; Meininger, V; Loeffler, JP			Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						mitochondria; neurodegeneration; motor neuron; metabolism	SUPEROXIDE-DISMUTASE GENE; MOTOR-NEURON DISEASE; OXIDATIVE DAMAGE; SKELETAL-MUSCLE; ENERGY-METABOLISM; SPINAL-CORDS; ANIMAL-MODEL; MICE; DEGENERATION; EXPRESSION	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily motor neurons. Growing evidence suggests a mitochondrial defect in ALS. The precise molecular mechanisms underlying those defects are unknown. We studied the expression of mitochondrial uncoupling proteins (UCPs), key regulators of mitochondrial functions, in tissues from a mouse model of ALS (SOD1 G86R transgenic mice) and from muscular biopsies of human sporadic ALS. Surprisingly, in SOD1 G86R mice, UCPs, and particularly UCP3, were upregulated in skeletal muscle but not in spinal cord. Consistent with this pattern of expression, ATP levels were selectively depleted in muscle but not in neural tissues 1 month before disease onset and the respiratory control ratio of isolated mitochondria is decreased. UCP3 up-regulation was not observed in experimentally denervated muscles, suggesting that changes in muscular UCP3 expression are associated with the physiopathological processes of ALS. This is further supported by our observation of increased UCP3 levels in human ALS muscular biopsies. We propose that UCP3 up-regulation in skeletal muscle contributes to the characteristic mitochondrial damage of ALS and to the onset of the disease. Moreover, since skeletal muscle is a key metabolic tissue, our findings suggest that ALS may not solely arise from neuronal events but also from more generalized metabolic defects.	Univ Strasbourg, Fac Med, EA 3433, Lab Signalisat Mol & Neurodegenerescence, F-67085 Strasbourg, France; CNRS, CEPE, F-67087 Strasbourg, France; Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris 13, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Loeffler, JP (corresponding author), Univ Strasbourg, Fac Med, EA 3433, Lab Signalisat Mol & Neurodegenerescence, 11 Rue Humann, F-67085 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020; Dupuis, Luc/A-6981-2012					Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bogdanov M, 2000, FREE RADICAL BIO MED, V29, P652, DOI 10.1016/S0891-5849(00)00349-X; Bonnefont-Rousselot D, 2000, J NEUROL SCI, V178, P57, DOI 10.1016/S0022-510X(00)00365-8; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Brunetti O, 1997, MUSCLE NERVE, V20, P1404, DOI 10.1002/(SICI)1097-4598(199711)20:11<1404::AID-MUS8>3.0.CO;2-E; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Couplan E, 2002, J BIOL CHEM, V277, P43079, DOI 10.1074/jbc.M206726200; Desport JC, 2001, AM J CLIN NUTR, V74, P328; Du G, 1998, FREE RADICAL BIO MED, V25, P1066, DOI 10.1016/S0891-5849(98)00148-8; DUCLERT A, 1990, P NATL ACAD SCI USA, V87, P1391, DOI 10.1073/pnas.87.4.1391; Dupuis L, 2002, ANN NY ACAD SCI, V973, P116, DOI 10.1111/j.1749-6632.2002.tb04618.x; Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; EISEN A, 1995, MUSCLE NERVE, V18, P741, DOI 10.1002/mus.880180711; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hand CK, 2002, MUSCLE NERVE, V25, P135; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Huey KA, 1998, EUR J BIOCHEM, V256, P45, DOI 10.1046/j.1432-1327.1998.2560045.x; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kong JM, 1998, J NEUROSCI, V18, P3241; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x; Windisch A, 1998, J PHYSIOL-LONDON, V510, P623, DOI 10.1111/j.1469-7793.1998.623bk.x; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	52	99	105	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2091	+		10.1096/fj.02-1182fje	http://dx.doi.org/10.1096/fj.02-1182fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500553				2022-12-25	WOS:000185925100011
J	Jungling, K; Nagler, K; Pfrieger, FW; Gottmann, K				Jungling, K; Nagler, K; Pfrieger, FW; Gottmann, K			Purification of embryonic stem cell-derived neurons by immunoisolation	FASEB JOURNAL			English	Article						L1 antibodies; action potentials; glutamatergic synapses; GABAergic synapses; cell replacement	RETINAL GANGLION-CELLS; IN-VITRO; NEURAL PRECURSORS; LINEAGE SELECTION; MOUSE EMBRYOS; CULTURE; DIFFERENTIATION; TRANSPLANTATION; SURVIVAL	The pluripotency and high proliferative capacity of embryonic stem (ES) cells (1-3) makes them an attractive source of different cell types for biomedical research and cell replacement therapies. A major prerequisite for these applications is the availability of a homogeneous population of the desired cell type. However, ES cell-derived material contains, for example, undifferentiated cells, which can cause tumor formation after transplantation into the brain (4). To avoid such unwanted side effects, effective purification of distinct types of cells needs to be developed. Here, we describe an immunoisolation procedure to purify neurons from in vitro differentiated mouse ES cells using an antibody against the neuronal cell adhesion molecule L1 (5, 6). Our procedure yields a pure population of differentiated neurons, which are electrically excitable and form excitatory, glutamatergic, and inhibitory GABAergic synapses. The ability to highly purify ES cell-derived neurons will boost their molecular characterization and the further exploration of their therapeutic potential.	Ruhr Univ Bochum, Dept Cell Physiol, D-44780 Bochum, Germany; Ctr Neurochim, Max Planck CNRS Grp, CNRS, UPR 2356, F-67084 Strasbourg, France	Ruhr University Bochum; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gottmann, K (corresponding author), Ruhr Univ Bochum, Dept Cell Physiol, Univ Str 150, D-44780 Bochum, Germany.	kurt.gottmann@ruhr-uni-bochum.de	Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gomperts SN, 1998, NEURON, V21, P1443, DOI 10.1016/S0896-6273(00)80662-5; HOGAN B, 1994, MANIPULATING MOUSE E, P254; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Malatesta P, 2000, DEVELOPMENT, V127, P5253; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mohrmann R, 1999, J NEUROSCI, V19, P10004; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; RATHJEN FG, 1984, EMBO J, V3, P1; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; ZHANG SC, NAT BIOTECHNOL, V19, P1129	21	33	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2100	+		10.1096/fj.03-0118fje	http://dx.doi.org/10.1096/fj.03-0118fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500547	Green Submitted			2022-12-25	WOS:000185925100005
J	Ramsay, PL; Luo, ZQ; Major, A; Park, MS; Finegold, M; Welty, SE; Kwak, I; Darlington, G; DeMayo, FJ				Ramsay, PL; Luo, ZQ; Major, A; Park, MS; Finegold, M; Welty, SE; Kwak, I; Darlington, G; DeMayo, FJ			Multiple mechanisms for oxygen-induced regulation of the Clara cell secretory protein gene	FASEB JOURNAL			English	Article						CCSP; Nkx2.1; AP-1; C/EBP; hyperoxia exposure	HEPATOCYTE NUCLEAR FACTOR-3; TRANSCRIPTION FACTOR-I; CIS-ACTING ELEMENTS; B GENE; BRONCHIOLAR EPITHELIUM; FAMILY-MEMBERS; 10-KD PROTEIN; C/EBP-ALPHA; MOUSE LUNG; CC10 GENE	The Clara cell secretory protein (CCSP) imparts a protective effect to the lung during oxidant injury. However, exposure to supplemental oxygen, a common therapeutic modality for lung disease, represses the expression of CCSP in the adult mouse lung. We investigated the mechanisms of hyperoxia-induced repression of the mouse CCSP promoter. Deletion experiments in vivo and in vitro indicated that the hyperoxia-responsive elements are localized to the proximal -166 by of the CCSP promoter. Electrophoretic mobility shift and supershift analyses demonstrated increased binding of c-Jun at the activator protein-1 site, increased binding of CCAAT/enhancer binding protein (C/EBP) (3 at the C/EBP sites, and decreased binding at the Nkx2.1 sites. Western analyses revealed that hyperoxia exposure induced an increase in the expression of the C/EBP(3 isoform liver-inhibiting protein (LIP) and an increase in cytoplasmic Nkx2.1. Cotransfection of LIP or c-Jun expression plasmids decreased the transcriptional activity of the proximal -166-by CCSP promoter. These observations suggest that hyperoxia-induced repression of the CCSP gene is mediated, at least in part, at the level of transcription and that multiple mechanisms mediate this repression. Moreover, these novel observations may provide insights for generation of therapeutic interventions for the amelioration of oxidant-induced lung injury.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Ajou Univ, Dept Pediat, Suwon 441749, South Korea; Childrens Res Inst, Columbus, OH 43205 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Ajou University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	fdemayo@bcm.tmc.edu	Welty, Stephen/AAZ-4307-2021; Welty, Stephen/AGS-7454-2022; DeMayo, Francesco/C-6255-2019	Welty, Stephen/0000-0002-6321-8440; DeMayo, Francesco/0000-0002-9480-7336				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Cassel TN, 2002, J BIOL CHEM, V277, P36970, DOI 10.1074/jbc.M201293200; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Daly HE, 1997, TOXICOL APPL PHARM, V142, P303, DOI 10.1006/taap.1996.8056; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; EVANS MJ, 1978, LAB INVEST, V38, P648; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147, DOI 10.1165/ajrcmb.17.2.2676; Kadoya Hirokazu, 2001, Osaka City Medical Journal, V47, P23; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LUM H, 1978, AM REV RESPIR DIS, V118, P335; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Ramsay PL, 2003, AM J PHYSIOL-LUNG C, V284, pL108, DOI 10.1152/ajplung.00186.2002; Ray MK, 1996, J HISTOCHEM CYTOCHEM, V44, P919, DOI 10.1177/44.8.8756763; RAY MK, 1995, J BIOL CHEM, V270, P2689, DOI 10.1074/jbc.270.6.2689; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; STRIPP BR, 1994, GENOMICS, V20, P27, DOI 10.1006/geno.1994.1123; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; TIMBLIN CR, 1995, CANCER RES, V55, P2723; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Zhao BH, 2000, ANN NY ACAD SCI, V923, P346	33	9	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2142	+		10.1096/fj.03-0048fje	http://dx.doi.org/10.1096/fj.03-0048fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500549				2022-12-25	WOS:000185925100009
J	Balasenthil, S; Sahin, AA; Barnes, CJ; Wang, RA; Pestell, RG; Vadlamudi, RK; Kumar, R				Balasenthil, S; Sahin, AA; Barnes, CJ; Wang, RA; Pestell, RG; Vadlamudi, RK; Kumar, R			p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; ESTROGEN-RECEPTOR; ALPHA-PAK; GROWTH; RHO; REORGANIZATION; DOWNSTREAM; CDC42; ORGANIZATION	p21-activated kinase 1 (Pak1) has been shown recently to induce hyperplasia in the mammary epithelium, a phenotype also manifested by overexpression of cyclin D1, a known indicator of the proliferative stage. Here we investigated the role of the Pak1 pathway in the expression of cyclin D1 using tissue culture models and transgenic mice expressing activated Pak1 in mammary glands. We found that hyperplastic mammary glands from catalytically active Pak1 transgenic mice exhibit a 5- to 7-fold increased expression of cyclin D1 as compared with stage-matched wild-type mice. In addition, Pak1 levels were elevated in human breast tumors and also correlated well with increased cyclin D1 expression. Increased expression of Pak1 in breast cancer cells stimulated cyclin D1 promoter activity, elevated levels of cyclin D1 mRNA, protein, and nuclear accumulation of cyclin D1. Conversely, Pak1 inhibition by an autoinhibitory peptide ( amino acids 83 - 149) or Pak1 knockdown by short interference RNA markedly reduced the expression of cyclin D1, suggesting a requirement of a functional Pak1 pathway for optimal expression of cyclin D1. Results from deletion and mutant analysis indicate that Pak1 regulates cyclin D1 transcription by means of an NF-kappaB-dependent pathway. Together, these findings suggest a model wherein Pak1 regulation of cyclin D1 expression might involve an NF-kappaB-dependent pathway and that hyperplasia in the mammary glands of Pak1-TG mice may be associated, at least in part, with the up-regulation of cyclin D1, and that Pak1 is upregulated in human breast tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Georgetown University	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022; Barnes, Christopher/B-1545-2015	Wang, Rui-An/0000-0003-2320-1211; Barnes, Christopher/0000-0001-9682-0748	NATIONAL CANCER INSTITUTE [R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Foryst-Ludwig A, 2000, J BIOL CHEM, V275, P39779, DOI 10.1074/jbc.M007617200; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kumar R, 1996, J CELL BIOCHEM, V62, P102; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	37	170	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1422	1428		10.1074/jbc.M309937200	http://dx.doi.org/10.1074/jbc.M309937200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14530270	hybrid			2022-12-25	WOS:000187722800072
J	Bridges, JP; Wert, SE; Nogee, LM; Weaver, TE				Bridges, JP; Wert, SE; Nogee, LM; Weaver, TE			Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT TYPE-II; PULMONARY SURFACTANT; STRUCTURAL REQUIREMENTS; ENDOPLASMIC-RETICULUM; TERMINAL PROPEPTIDE; SP-B; PROPROTEIN; PNEUMONITIS; EPITHELIUM; SEQUENCES	Surfactant Protein C (SP-C) is a secreted transmembrane protein that is exclusively expressed by alveolar type II epithelial cells of the lung. SP-C associates with surfactant lipids to reduce surface tension within the alveolus, maintaining lung volume at end expiration. Mutations in the gene encoding SP-C (SFTPC) have recently been linked to chronic lung disease in children and adults. The goal of this study was to determine whether a disease-linked mutation in SFTPC causes lung disease in transgenic mice. The SFTPC mutation, designated g.1728 G --> A, results in the deletion of exon4, generating a truncated form of SP-C (SP-C-Deltaexon4). cDNA encoding SP-C-Deltaexon4 was constitutively expressed in type II epithelial cells of transgenic mice. Viable F-0 transgene-positive mice were not generated after two separate rounds of pronuclear injections. Histological analysis of lung tissue harvested from embryonic day 17.5 F-0 transgene-positive fetuses revealed that SP-C-Deltaexon4 caused a dose-dependent disruption in branching morphogenesis of the lung associated with epithelial cell cytotoxicity. Transient expression of SP-C-Deltaexon4 in isolated type II epithelial cells or HEK293 cells resulted in incomplete processing of the mutant proprotein, a dose-dependent increase in BiP transcription, trapping of the proprotein in the endoplasmic reticulum, and rapid degradation via a proteasome-dependent pathway. Taken together, these data suggest that the g.1728 G --> A mutation causes misfolding of the SP-C proprotein with subsequent induction of the unfolded protein response and endoplasmic reticulum-associated degradation pathways ultimately resulting in disrupted lung morphogenesis.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA	Cincinnati Children's Hospital Medical Center; Johns Hopkins University	Weaver, TE (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Bridges, James P./0000-0002-4815-117X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P50HL056387, P01HL061646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61646, HL56387] Funding Source: Medline; NIEHS NIH HHS [P30-ES06096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akinbi HT, 2000, J IMMUNOL, V165, P5760, DOI 10.4049/jimmunol.165.10.5760; Akinbi HT, 1997, J BIOL CHEM, V272, P9640; Amin RS, 2001, J PEDIATR-US, V139, P85, DOI 10.1067/mpd.2001.114545; Beck DC, 2000, J BIOL CHEM, V275, P3371, DOI 10.1074/jbc.275.5.3371; Beers MF, 1995, AM J PHYSIOL-LUNG C, V269, pL744, DOI 10.1152/ajplung.1995.269.6.L744; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Conkright JJ, 2002, AM J RESP CELL MOL, V26, P85, DOI 10.1165/ajrcmb.26.1.4686; Conkright JJ, 2001, J BIOL CHEM, V276, P14658, DOI 10.1074/jbc.M011770200; Davis AJ, 1998, AM J RESP CRIT CARE, V157, P553, DOI 10.1164/ajrccm.157.2.97-08019; Davis AR, 1998, GENE THER, V5, P1148, DOI 10.1038/sj.gt.3300705; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Demayo F, 2002, AM J PHYSIOL-LUNG C, V283, pL510, DOI 10.1152/ajplung.00144.2002; Glasser SW, 2000, AM J PHYSIOL-LUNG C, V278, pL933, DOI 10.1152/ajplung.2000.278.5.L933; Glasser SW, 2003, J BIOL CHEM, V278, P14291, DOI 10.1074/jbc.M210909200; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; HAFNER D, 1995, BRIT J PHARMACOL, V115, P451; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hawgood S, 1996, AM J RESP CRIT CARE, V154, P484, DOI 10.1164/ajrccm.154.2.8756826; JOHANSSON J, 1994, BIOCHEMISTRY-US, V33, P6015, DOI 10.1021/bi00185a042; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Lin S, 1996, BBA-MOL CELL RES, V1312, P177, DOI 10.1016/0167-4889(95)00201-4; Nogee LM, 2002, CHEST, V121, p20S, DOI 10.1378/chest.121.3_suppl.20S; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Ross GF, 1999, AM J PHYSIOL-LUNG C, V277, pL1104, DOI 10.1152/ajplung.1999.277.6.L1104; Russo SJ, 1999, AM J PHYSIOL-LUNG C, V277, pL1034, DOI 10.1152/ajplung.1999.277.5.L1034; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267; Wang WJ, 2002, J BIOL CHEM, V277, P19929, DOI 10.1074/jbc.M201537200; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	38	109	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52739	52746		10.1074/jbc.M309599200	http://dx.doi.org/10.1074/jbc.M309599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14525980	hybrid			2022-12-25	WOS:000187480700092
J	Ma, R; Rundle, D; Jacks, J; Koch, M; Downs, T; Tsiokas, L				Ma, R; Rundle, D; Jacks, J; Koch, M; Downs, T; Tsiokas, L			Inhibitor of myogenic family, a novel suppressor of store-operated currents through an interaction with TRPC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA A431 CELLS; CALCIUM-ENTRY; CA2+ CHANNELS; CATION CHANNEL; CAPACITATIVE CA2+; MOLECULAR-BASIS; DROSOPHILA TRP; HUMAN HOMOLOG; I-CRAC; ACTIVATION	Depletion of intracellular Ca2+ stores leads to the activation of Ca2+ inflow through store-operated Ca2+ channels. Although the identity of these channels is unknown, there is considerable evidence that the transient receptor potential channel 1 (TRPC1) participates in the formation of these channels. We show that TRPC1 physically interacts with the a-isoform of the inhibitor of the myogenic family (I-mfa), a known inhibitor of basic helix-loop-helix transcription factors, in vitro and in vivo. The interaction is mediated by the C-terminal cytoplasmic tail of TRPC1 and the C-terminal cysteine-rich domain of I-mfa. Using the whole cell configuration of the patch clamp technique, we show that ectopic expression of I-mfa in CHO-K1 cells reduces native store-activated Ca2+ currents, whereas knock-down of endogenous I-mfa in A431 cells by RNA interference enhances these currents. Pipette perfusion of purified recombinant I-mfa rescues the effect of I-mfa knock-down on store-operated conductance. Finally, cell dialysis with a monoclonal antibody specific to TRPC1 results in the suppression of store-activated conductance in cells lacking I-mfa, but not in I-mfa expressing cells. We propose that I-mfa functions as a molecular switch to suppress the store dependence of TRPC1.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Tsiokas, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.	leonidas-tsiokas@ouhsc.edu		Tryggestad, Jeanie/0000-0002-5050-0850; Tsiokas, Leonidas/0000-0002-3659-1813	NIDDK NIH HHS [DK59599] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK059599, R01DK059599] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Brough GH, 2001, FASEB J, V15, P1727, DOI 10.1096/fj.01-0108com; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CAMBELL AM, 1984, MONOCLONAL ANTIBODY; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; Clapham DE, 2002, J GEN PHYSIOL, V120, P217, DOI 10.1085/jgp.20028618; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Gailly P, 2001, CELL CALCIUM, V30, P157, DOI 10.1054/ceca.2001.0221; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Gusev K, 2003, J GEN PHYSIOL, V122, P81, DOI 10.1085/jgp.200308815; Harteneck C, 2002, FASEB J, V16, P1668, DOI 10.1096/fj.02-0192fje; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Kaznacheyeva E, 2001, P NATL ACAD SCI USA, V98, P148, DOI 10.1073/pnas.98.1.148; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kraut N, 1998, EMBO J, V17, P6276, DOI 10.1093/emboj/17.21.6276; Kusano S, 2002, MOL CELL BIOL, V22, P6393, DOI 10.1128/MCB.22.18.6393-6405.2002; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; Ma R, 2001, J BIOL CHEM, V276, P25759, DOI 10.1074/jbc.M011241200; Ma R, 2000, AM J PHYSIOL-RENAL, V278, pF954, DOI 10.1152/ajprenal.2000.278.6.F954; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; MOZHAYEVA GN, 1990, FEBS LETT, V277, P233, DOI 10.1016/0014-5793(90)80853-B; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Ong HL, 2002, BIOCHEM J, V364, P641, DOI 10.1042/BJ20020061; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, BIOESSAYS, V21, P38; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2001, BIOCHEM J, V356, P191, DOI 10.1042/0264-6021:3560191; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Thebault S, 2001, CURR PROTEIN PEPT SC, V2, P155, DOI 10.2174/1389203013381143; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vaca L, 2002, J BIOL CHEM, V277, P42178, DOI 10.1074/jbc.M204531200; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983	58	39	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52763	52772		10.1074/jbc.M309610200	http://dx.doi.org/10.1074/jbc.M309610200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530267	hybrid			2022-12-25	WOS:000187480700095
J	Chyung, JH; Selkoe, DJ				Chyung, JH; Selkoe, DJ			Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; IN-VIVO; INTRAMEMBRANE PROTEOLYSIS; LIPID RAFTS; NT2N CELLS; DYNAMIN-I; CLEAVAGE; MEMBRANE	Sequential cleavages of the amyloid beta- protein precursor ( APP) by the beta- and gamma- secretases generate the amyloid beta- protein ( A beta), which plays a central role in Alzheimer's disease. Previous work provided evidence for involvement of both the secretory and endocytic pathways in A beta generation. Here, we used HeLa cells stably expressing a tetracycline- regulated dominant- negative dynamin I ( dyn K44A), which selectively inhibits receptor-mediated endocytosis, and analyzed the effects on the processing of endogenous APP. Upon induction of dyn K44A, levels of mature APP rose at the cell surface, consistent with retention of APP on the plasma membrane. The alpha- secretase cleavage products of APP were increased by dyn K44A, in that alpha- APPs in medium and the C83 C- terminal stub in the membrane both rose. The beta- secretase cleavage of APP, C99, also increased modestly. The use of specific gamma- secretase inhibitors to study the accumulation of alpha- and beta-cleavage products independent of their processing by gamma- secretase confirmed that retention of APP on the plasma membrane results in increased processing by both alpha- and beta- secretases. Unexpectedly, endogenous A beta secretion was significantly increased by dyn K44A, as detected by three distinct methods: metabolic labeling, immunoprecipitation/ Western blotting, and enzyme- linked immunosorbent assay. Levels of p3 ( generated by sequential alpha- and gamma- cleavage) also rose. We conclude that endogenous Abeta can be produced directly at the plasma membrane and that alterations in the degree of APP endocytosis may help regulate its production. Our findings are consistent with a role for the gamma- secretase complex in the processing of numerous single- transmembrane receptors at the cell surface.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Selkoe, DJ (corresponding author), Harvard Univ, Sch Med, Inst Med, 730,77 Ave Louis Pasteur, Boston, MA 02115 USA.				NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG006173, R37AG006173] Funding Source: NIH RePORTER; NIA NIH HHS [AG15379, AG 06173] Funding Source: Medline; NIMH NIH HHS [MH2001] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Berezovska O, 2003, J NEUROSCI, V23, P4560; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jung SS, 1999, NEUROREPORT, V10, P3875, DOI 10.1097/00001756-199912160-00028; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Liu JP, 1997, CLIN EXP PHARMACOL P, V24, P611, DOI 10.1111/j.1440-1681.1997.tb02101.x; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Selkoe DJ, 2000, CURR OPIN NEUROBIOL, V10, P50, DOI 10.1016/S0959-4388(99)00054-9; Sever S, 2002, CURR OPIN CELL BIOL, V14, P463, DOI 10.1016/S0955-0674(02)00347-2; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Tun H, 2002, J MOL NEUROSCI, V19, P31, DOI 10.1007/s12031-002-0007-5; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yao PJ, 2003, NEUROBIOL DIS, V12, P97, DOI 10.1016/S0969-9961(02)00009-8	42	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51035	51043		10.1074/jbc.M304989200	http://dx.doi.org/10.1074/jbc.M304989200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525989	hybrid			2022-12-25	WOS:000187206300026
J	Bu, W; Su, LK				Bu, W; Su, LK			Characterization of functional domains of human EB1 family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-BINDING DOMAIN; TUMOR-SUPPRESSOR PROTEIN; CYTOPLASMIC DYNEIN; ADENOMATOUS POLYPOSIS; DYNACTIN COMPLEX; GENOMIC STRUCTURE; MITOTIC SPINDLE; GENE FAMILY; APC; DYNAMICS	EB1 family proteins are evolutionarily conserved proteins that bind microtubule plus-ends and centrosomes and regulate the dynamics and organization of microtubules. Human EB1 family proteins, which include EB1, EBF3, and RP1, also associate with the tumor suppressor protein adenomatous polyposis coli (APC) and p150(glued), a component of the dynactin complex. The structural basis for interaction between human EB1 family proteins and their associated proteins has not been defined in detail. EB1 family proteins have a calponin homology (CH) domain at their N terminus and an EB1-like C-terminal motif at their C terminus; the functional importance of these domains has not been determined. To better understand functions of human EB1 family proteins and to reveal functional similarities and differences among these proteins, we performed detailed characterizations of interactions between human EB1 family proteins and their associated proteins. We show that amino acids 1 - 133 of EB1 and EBF3 and the corresponding region of RP1, which contain a CH domain, are necessary and sufficient for binding microtubules, thus demonstrating for the first time that a CH domain contributes to binding microtubules. EB1 family proteins use overlapping but different regions that contain the EB1-like C-terminal motif to associate with APC and p150glued. Neither APC nor p150glued binding domain is necessary for EB1 or EBF3 to induce microtubule bundling, which requires amino acids 1 - 181 and 1 - 185 of EB1 and EBF3, respectively. We also determined that the EB1 family protein-binding regions are amino acids 2781 - 2820 and 18 - 111 of APC and p150(glued), respectively.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Su, LK (corresponding author), Cell Press, 1100 Massachusetts Ave, Cambridge, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R29CA070371] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70371, CA 6672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Caruana G, 2002, INT J DEV BIOL, V46, P511; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Charrasse S, 1998, J CELL SCI, V111, P1371; Collin GB, 1998, GENOMICS, V53, P359, DOI 10.1006/geno.1998.5542; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Hayashi I, 2003, J BIOL CHEM, V278, P36430, DOI 10.1074/jbc.M305773200; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Korinek WS, 2000, SCIENCE, V287, P2257, DOI 10.1126/science.287.5461.2257; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Miller RK, 2000, MOL BIOL CELL, V11, P2949, DOI 10.1091/mbc.11.9.2949; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Pancer Z, 1996, CANCER LETT, V109, P155, DOI 10.1016/S0304-3835(96)04440-0; PIERRE P, 1994, J CELL SCI, V107, P1909; Rehberg M, 2002, MOL BIOL CELL, V13, P2301, DOI 10.1091/mbc.E02-01-0054; Renner C, 1997, J IMMUNOL, V159, P1276; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; RON D, 1992, BIOTECHNIQUES, V13, P866; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; Su LK, 2000, AM J HUM GENET, V67, P582, DOI 10.1086/303058; Su LK, 2001, GENOMICS, V71, P142, DOI 10.1006/geno.2000.6428; SU LK, 1995, CANCER RES, V55, P2972; Sun DM, 2001, J CELL SCI, V114, P161; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Tokito MK, 1996, MOL BIOL CELL, V7, P1167, DOI 10.1091/mbc.7.8.1167; Tokito MK, 1998, BBA-GENE STRUCT EXPR, V1442, P432, DOI 10.1016/S0167-4781(98)00195-X; Vaillant AR, 1998, J BIOL CHEM, V273, P13973, DOI 10.1074/jbc.273.22.13973; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Vaughan KT, 1999, J CELL SCI, V112, P1437; Vaughan PS, 2002, J CELL BIOL, V158, P305, DOI 10.1083/jcb.200201029; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WEST RR, 1991, J BIOL CHEM, V266, P21886	55	82	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49721	49731		10.1074/jbc.M306194200	http://dx.doi.org/10.1074/jbc.M306194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514668	hybrid			2022-12-25	WOS:000187068200012
J	Gilchrist, M; Hesslinger, C; Befus, AD				Gilchrist, M; Hesslinger, C; Befus, AD			Tetrahydrobiopterin, a critical factor in the production and role of nitric oxide in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-CYCLOHYDROLASE-I; FEEDBACK REGULATORY PROTEIN; MESSENGER-RNA; SYNTHASE; MODULATION; EXPRESSION; BIOSYNTHESIS; PURIFICATION; SUPEROXIDE; ACTIVATION	Mast cells ( MC) are biologically potent, ubiquitously distributed immune cells with fundamental roles in host integrity and disease. MC diversity and function is regulated by exogenous nitric oxide; however, the production and function of endogenously produced NO in MC is enigmatic. We used rat peritoneal MC ( PMC) as an in vivo model to examine intracellular NO production. Live cell confocal analysis of PMC using the NO- sensitive probe diaminofluorescein showed distinct patterns of intracellular NO formation with either antigen ( Ag)/ IgE ( short term) or interferon-gamma ( IFN-gamma) ( long term). Ag/ IgE- induced NO production is preceded by increased intracellular Ca2+, implying constitutive nitric- oxide synthase ( NOS) activity. NO formation inhibits MC degranulation. NOS has obligate requirements for tetrahydrobiopterin ( BH4), a product of GTP- cyclohydrolase I ( CHI), IFN-gamma- stimulated PMC increased CHI mRNA, protein, and enzymatic activity, while decreasing CHI feedback regulatory protein mRNA, causing sustained NO production. Treatment with the CHI inhibitor, 2,4-diamino- 6- hydroxypyrimidine, inhibited NO in both IFN-gamma and Ag/ IgE systems, increasing MC degranulation. Reconstitution with the exogenous BH4 substrate, sepiapterin, restored NO formation and inhibited exocytosis. Thus, Ag/ IgE and IFN-gamma induced intracellular NO plays a key role in MC mediator release, and alterations in NOS activity via BH4 availability may be critical to the heterogeneous responsiveness of MC.	Univ Alberta, Dept Med, Pulm Res Grp, Glaxo Heritage Asthma Res Lab, Edmonton, AB T6G 2S2, Canada; Goethe Univ Frankfurt, Pharmazentrum, D-60590 Frankfurt, Germany	University of Alberta; Goethe University Frankfurt	Gilchrist, M (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, Glaxo Heritage Asthma Res Lab, Rm 550 HMRC, Edmonton, AB T6G 2S2, Canada.	mark.gilchrist@ualberta.ca	Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Brooks AC, 1999, BRIT J PHARMACOL, V128, P585, DOI 10.1038/sj.bjp.0702838; Coleman JW, 2002, CLIN EXP IMMUNOL, V129, P4, DOI 10.1046/j.1365-2249.2002.01918.x; Dassesse D, 1997, BRAIN RES, V777, P187, DOI 10.1016/S0006-8993(97)01111-6; Delgado-Esteban M, 2002, J NEUROCHEM, V82, P1148, DOI 10.1046/j.1471-4159.2002.01055.x; Gilchrist M, 1997, J IMMUNOL METHODS, V201, P207, DOI 10.1016/S0022-1759(96)00230-X; Gilchrist M, 2002, J LEUKOCYTE BIOL, V71, P618; Giordano A, 2002, FEBS LETT, V514, P135, DOI 10.1016/S0014-5793(02)02245-7; Govers R, 2002, J HISTOCHEM CYTOCHEM, V50, P779, DOI 10.1177/002215540205000604; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; HOGABOAM CM, 1993, J IMMUNOL, V151, P3767; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Kapatos G, 1999, J NEUROCHEM, V72, P669, DOI 10.1046/j.1471-4159.1999.0720669.x; Kasai K, 1997, AM J PHYSIOL-HEART C, V273, pH665, DOI 10.1152/ajpheart.1997.273.2.H665; Kashiwagi S, 2002, CIRC RES, V91, pE55, DOI 10.1161/01.RES.0000047529.26278.4D; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Kulka M, 2002, J LEUKOCYTE BIOL, V71, P54; LEE TDG, 1985, IMMUNOLOGY, V55, P721; Messina A, 2000, LAB INVEST, V80, P423, DOI 10.1038/labinvest.3780047; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Mori S, 2000, ARCH HISTOL CYTOL, V63, P261, DOI 10.1679/aohc.63.261; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; Sullivan R, 2000, CELL CALCIUM, V28, P33, DOI 10.1054/ceca.2000.0127; Suzuki N, 2002, J BIOL CHEM, V277, P47, DOI 10.1074/jbc.M108195200; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Togari A, 1998, FEBS LETT, V428, P212, DOI 10.1016/S0014-5793(98)00531-6; Vann LR, 2000, J BIOL CHEM, V275, P13275, DOI 10.1074/jbc.275.18.13275; Vasquez-Vivar J, 2000, FEBS LETT, V481, P305, DOI 10.1016/S0014-5793(00)02001-9; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Werner ER, 2002, J BIOL CHEM, V277, P10129, DOI 10.1074/jbc.M107326200; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; Williams RM, 1999, BIOPHYS J, V76, P1835, DOI 10.1016/S0006-3495(99)77343-1	38	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50607	50614		10.1074/jbc.M307777200	http://dx.doi.org/10.1074/jbc.M307777200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514683	hybrid			2022-12-25	WOS:000187068200115
J	Owen, D; Lowe, PN; Nietlispach, D; Brosnan, CE; Chirgadze, DY; Parker, PJ; Blundell, TL; Mott, HR				Owen, D; Lowe, PN; Nietlispach, D; Brosnan, CE; Chirgadze, DY; Parker, PJ; Blundell, TL; Mott, HR			Molecular dissection of the interaction between the small G proteins Rac1 and RhoA and protein kinase C-related kinase 1 (PRK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; RAS-BINDING DOMAIN; ALDRICH-SYNDROME PROTEIN; AMINO-TERMINAL REGION; ZIPPER-LIKE SEQUENCES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; KINASE-C; EFFECTOR PROTEINS; NMR-SPECTROSCOPY	PRK1 is a serine/ threonine kinase that belongs to the protein kinase C superfamily. It can be activated either by members of the Rho family of small G proteins, by proteolysis, or by interaction with lipids. Here we investigate the binding of PRK1 to RhoA and Rac1, two members of the Rho family. We demonstrate that PRK1 binds with a similar affinity to RhoA and Rac1. We present the solution structure of the second HR1 domain from the regulatory N- terminal region of PRK1, and we show that it forms an anti- parallel coiled- coil. In addition, we have used NMR to map the binding contacts of the HR1b domain with Rac1. These are compared with the contacts known to form between HR1a and RhoA. We have used mutagenesis to define the residues in Rac that are important for binding to HR1b. Surprisingly, as well as residues adjacent to Switch I, in Switch II, and in helix alpha5, it appears that the C- terminal stretch of basic amino acids in Rac is required for a high affinity interaction with HR1b.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; GlaxoSmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England; London Res Inst, Lincolns Inn Fields Lab, Prot Phosphorylat Lab, London WC2A 3PX, England	University of Cambridge; GlaxoSmithKline	Owen, D (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England.		Mott, Helen/AAV-3873-2020	Mott, Helen/0000-0002-7890-7097; parker, peter/0000-0002-6218-2933; Chirgadze, Dimitri/0000-0001-9942-0993; Nietlispach, Daniel/0000-0003-4364-9291				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dumas JJ, 1999, STRUCTURE, V7, P413, DOI 10.1016/S0969-2126(99)80054-9; EMERSON SD, 1995, BIOCHEMISTRY-US, V34, P6911, DOI 10.1021/bi00021a001; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Gao QS, 2000, J BIOL CHEM, V275, P14824, DOI 10.1074/jbc.275.20.14824; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Hubbard S. J., 1993, NACCESS; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Kawamata T, 1998, J NEUROSCI, V18, P7402; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Kitagawa M, 1998, BIOCHEM BIOPH RES CO, V252, P561, DOI 10.1006/bbrc.1998.9694; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsuzawa K, 1997, BIOCHEM BIOPH RES CO, V234, P621, DOI 10.1006/bbrc.1997.6669; MENETREY J, 1999, PROTEIN-STRUCT FUNCT, V3, P465; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misaki K, 2001, P NATL ACAD SCI USA, V98, P125, DOI 10.1073/pnas.021541498; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Shibata H, 1996, FEBS LETT, V385, P221, DOI 10.1016/0014-5793(96)00385-7; SKINNER RH, 1994, ANAL BIOCHEM, V223, P259, DOI 10.1006/abio.1994.1582; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Takanaga H, 1998, EXP CELL RES, V241, P363, DOI 10.1006/excr.1998.4060; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yoshinaga C, 1999, J BIOCHEM, V126, P475, DOI 10.1093/oxfordjournals.jbchem.a022476; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200	66	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50578	50587		10.1074/jbc.M304313200	http://dx.doi.org/10.1074/jbc.M304313200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514689	hybrid			2022-12-25	WOS:000187068200112
J	Valimaki, S; Hoog, A; Larsson, C; Farnebo, LO; Branstrom, R				Valimaki, S; Hoog, A; Larsson, C; Farnebo, LO; Branstrom, R			High extracellular Ca2+ hyperpolarizes human parathyroid cells via Ca2+-activated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING-RECEPTOR; HORMONE-SECRETION; RELEASE; EXPRESSION	Membrane potential has a major influence on stimulus-secretion coupling in various excitable cells. The role of membrane potential in the regulation of parathyroid hormone secretion is not known. High K+-induced depolarization increases secretion from parathyroid cells. The paradox is that increased extracellular Ca2+, which inhibits secretion, has also been postulated to have a depolarizing effect. In this study, human parathyroid cells from parathyroid adenomas were used in patch clamp studies of K+ channels and membrane potential. Detailed characterization revealed two K+ channels that were strictly dependent of intracellular Ca2+ concentration. At high extracellular Ca2+, a large K+ current was seen, and the cells were hyperpolarized (-50.4 +/- 13.4 mV), whereas lowering of extracellular Ca2+ resulted in a dramatic decrease in K+ current and depolarization of the cells ( - 0.1 +/- 8.8 mV, p < 0.001). Changes in extracellular Ca2+ did not alter K+ currents when intracellular Ca2+ was clamped, indicating that K+ channels are activated by intracellular Ca2+. The results were concordant in cell-attached, perforated patch, whole-cell and excised membrane patch configurations. These results suggest that [Ca2+](o) regulates membrane potential of human parathyroid cells via Ca2+-activated K+ channels and that the membrane potential may be of greater importance for the stimulus-secretion coupling than recognized previously.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Surg Sci, SE-17176 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Farnebo, LO (corresponding author), Karolinska Inst, Karolinska Hosp P9 03, Dept Surg Sci, SE-17176 Stockholm, Sweden.			Branstrom, Robert/0000-0001-6245-7223				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Bauer CK, 1999, MOL CELL ENDOCRINOL, V148, P37, DOI 10.1016/S0303-7207(98)00241-X; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BRUCE BR, 1979, AM J PHYSIOL, V236, pC15, DOI 10.1152/ajpcell.1979.236.1.C15; Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553; CONIGRAVE AD, 1993, CELL CALCIUM, V14, P517, DOI 10.1016/0143-4160(93)90010-4; DEMPSTER DW, 1982, ENDOCRINOLOGY, V111, P191, DOI 10.1210/endo-111-1-191; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; JIA M, 1988, P NATL ACAD SCI USA, V85, P7236, DOI 10.1073/pnas.85.19.7236; KANAZIRSKA MPV, 1995, ENDOCRINOLOGY, V136, P2238, DOI 10.1210/en.136.5.2238; KOMWATANA P, 1994, PFLUG ARCH EUR J PHY, V426, P320, DOI 10.1007/BF00374788; Liu W, 2001, J ENDOCRINOL, V168, P417, DOI 10.1677/joe.0.1680417; MORRISSEY JJ, 1983, AM J PHYSIOL, V245, pE102, DOI 10.1152/ajpendo.1983.245.1.E102; OETTING M, 1987, ENDOCRINOLOGY, V121, P1571, DOI 10.1210/endo-121-4-1571; POSILLICO JT, 1984, ENDOCRINE CONTROL BO, P349; SHERWOOD LM, 1970, NATURE, V225, P1056, DOI 10.1038/2251056a0; SHOBACK D, 1983, ENDOCRINOLOGY, V113, P424, DOI 10.1210/endo-113-1-424; Tse A, 2000, J PHYSIOL-LONDON, V528, P79, DOI 10.1111/j.1469-7793.2000.00079.x; Vassilev PM, 1997, BIOCHEM BIOPH RES CO, V230, P616, DOI 10.1006/bbrc.1996.6017; Ye CP, 2000, BONE, V27, P21, DOI 10.1016/S8756-3282(00)00288-X	22	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49685	49690		10.1074/jbc.M310595200	http://dx.doi.org/10.1074/jbc.M310595200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522972	hybrid			2022-12-25	WOS:000187068200007
J	Bronder, JL; Moran, RG				Bronder, JL; Moran, RG			A defect in the p53 response pathway induced by de novo purine synthesis inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIFOLATE LOMETREXOL DDATHF; CELL-CYCLE ARREST; DNA-DAMAGE; PHASE-I; FOLATE ANTIMETABOLITE; POTENT INHIBITOR; PHOSPHORYLATION; ACETYLATION; PROTEIN; ACID	p53 is believed to sense cellular ribonucleotide depletion in the absence of DNA strand breaks and to respond by imposition of a p21-dependent G(1) cell cycle arrest. We now report that the p53-dependent G(1) checkpoint is blocked in human carcinoma cell lines after inhibition of de novo purine synthesis by folate analogs inhibitory to glycinamide ribonucleotide formyltransferase (GART). p53 accumulated in HCT116, MCF7, or A549 carcinoma cells upon GART inhibition, but, surprisingly, transcription of several p53 targets, including p21(cip1/waf1), was impaired. The mechanism of this defect was examined. The p53 accumulating in these cells was nuclear but was not phosphorylated at serines 6, 15, and 20, nor was it acetylated at lysines 373 or 382. The DDATHF-stabilized p53 bound to the p21 promoter in vitro and in vivo but did not activate histone acetylation over the p53 binding sites in the p21 promoter that is an integral part of the transcriptional response mediated by the DNA damage pathway. We concluded that the robust initial response of the p53 pathway to GART inhibitors is not transcriptionally propagated to target genes due to a defect in p53 post-translational modifications and a failure to open chromatin structure despite promoter binding of this unmodified p53.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Moran, RG (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	rmoran@hsc.vcu.edu		Mason, Julie/0000-0002-5144-175X	NATIONAL CANCER INSTITUTE [R01CA027605, P30CA016059] Funding Source: NIH RePORTER; NCI NIH HHS [CA-27605, P30CA16059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BENIGNI R, 1983, TERATOGEN CARCIN MUT, V3, P481, DOI 10.1002/1520-6866(1990)3:6<481::AID-TCM1770030604>3.0.CO;2-9; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; Bronder JL, 2002, CANCER RES, V62, P5236; Chen VJ, 1998, BRIT J CANCER, V78, P27, DOI 10.1038/bjc.1998.751; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ERBA E, 1994, BRIT J CANCER, V69, P205, DOI 10.1038/bjc.1994.40; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Habeck Lillian L., 1994, Cancer Research, V54, P1021; HARPER JW, 1993, CELL, V75, P805; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Laohavinij S, 1996, INVEST NEW DRUG, V14, P325, DOI 10.1007/BF00194536; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LORICO A, 1988, CANCER RES, V48, P2036; Lu XH, 2000, CLIN CANCER RES, V6, P271; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Matsui S, 1996, CANCER RES, V56, P4715; MORAN RG, 1989, J BIOL CHEM, V264, P21047; OConnor PM, 1997, CANCER RES, V57, P4285; PIZZORNO G, 1991, CANCER RES, V51, P2291; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; Roberts JD, 2000, CANCER CHEMOTH PHARM, V45, P423, DOI 10.1007/s002800051012; Roberts JD, 2000, CANCER CHEMOTH PHARM, V45, P103, DOI 10.1007/s002800050017; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sessa C, 1996, CLIN CANCER RES, V2, P1123; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH SG, 1993, CANCER RES, V53, P5697; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sugars KL, 2001, NUCLEIC ACIDS RES, V29, P4530, DOI 10.1093/nar/29.22.4530; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; TISHLER RB, 1993, CANCER RES, V53, P2212; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yin MB, 1997, MOL PHARMACOL, V51, P630, DOI 10.1124/mol.51.4.630; YOUNG C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P177; YOUNG CW, 1990, P AM ASSOC CANC RES, V9, P285; Zhang CC, 1998, CANCER CHEMOTH PHARM, V41, P223; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	53	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48861	48871		10.1074/jbc.M304844200	http://dx.doi.org/10.1074/jbc.M304844200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14517211	hybrid			2022-12-25	WOS:000186829000043
J	Du, YC; Peddi, SR; Spreitzer, RJ				Du, YC; Peddi, SR; Spreitzer, RJ			Assessment of structural and functional divergence far from the large subunit active site of ribulose-1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLAMYDOMONAS CHLOROPLAST GENE; CO2/O-2 SPECIFICITY; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; THERMAL-STABILITY; COMPLEMENTING SUBSTITUTIONS; SUPPRESSOR MUTATIONS; CO2 FIXATION; OXYGENASE	Despite conservation of three-dimensional structure and active-site residues, ribulose-1,5-bisphosphate carboxylase/ oxygenase ( Rubisco, EC 4.1.1.39) enzymes from divergent species differ with respect to catalytic efficiency and CO2/O-2 specificity. A deeper understanding of the structural basis for these differences may provide a rationale for engineering an improved enzyme, thereby leading to an increase in photosynthetic CO2 fixation and agricultural productivity. By comparing 500 active-site large subunit sequences from flowering plants with that of the green alga Chlamydomonas reinhardtii, a small number of residues were found to differ in regions previously shown by mutant screening to influence CO2/O-2 specificity. When directed mutagenesis and chloroplast transformation were used to change Chlamydomonas Met-42 and Cys-53 to land plant Val-42 and Ala-53 in the large subunit N-terminal domain, little or no change in Rubisco catalytic properties was observed. However, changing Chlamydomonas methyl-Cys- 256, Lys-258, and Ile-265 to land plant Phe-256, Arg-258, and Val-265 at the bottom of the alpha/beta-barrel active site caused a 10% decrease in CO2/O-2 specificity, largely due to an 85% decrease in carboxylation catalytic efficiency (V-max/K-m). Because land plant Rubisco enzymes have greater CO2/O-2 specificity than the Chlamydomonas enzyme, this group of residues must be complemented by other residues that differ between Chlamydomonas and land plants. The Rubisco x-ray crystal structures indicate that these residues may reside in a variable loop of the nuclear-encoded small subunit, more than 20 Angstrom away from the active site.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Spreitzer, RJ (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.							Andersson I, 2003, ARCH BIOCHEM BIOPHYS, V414, P130, DOI 10.1016/S0003-9861(03)00164-4; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1993, PLANT PHYSIOL, V101, P1189, DOI 10.1104/pp.101.4.1189; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Du YC, 2000, P NATL ACAD SCI USA, V97, P14206, DOI 10.1073/pnas.260503997; Du YC, 2000, J BIOL CHEM, V275, P19844, DOI 10.1074/jbc.M002321200; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; Hong SK, 1997, J BIOL CHEM, V272, P11114; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; Kimura MA, 1985, NEUTRAL THEORY MOL E; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; Maeda N, 1999, J MOL BIOL, V293, P57, DOI 10.1006/jmbi.1999.3145; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; PIERCE J, 1986, J BIOL CHEM, V261, P248; READ BA, 1994, ARCH BIOCHEM BIOPHYS, V312, P210, DOI 10.1006/abbi.1994.1301; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Spreitzer RJ, 1999, PHOTOSYNTH RES, V60, P29, DOI 10.1023/A:1006240202051; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; Spreitzer RJ, 2003, ARCH BIOCHEM BIOPHYS, V414, P141, DOI 10.1016/S0003-9861(03)00171-1; Spreitzer RJ, 2002, ANNU REV PLANT BIOL, V53, P449, DOI 10.1146/annurev.arplant.53.100301.135233; Spreitzer RJ, 2001, BIOCHEMISTRY-US, V40, P5615, DOI 10.1021/bi002943e; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; SPREITZER RJ, 1998, MOL BIOL CHLOROPLAST, P515; Sugawara H, 1999, J BIOL CHEM, V274, P15655, DOI 10.1074/jbc.274.22.15655; Taylor TC, 2001, J BIOL CHEM, V276, P48159, DOI 10.1074/jbc.M107765200; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; Uemura K, 1997, BIOCHEM BIOPH RES CO, V233, P568, DOI 10.1006/bbrc.1997.6497; Zhu GH, 1996, J BIOL CHEM, V271, P18494, DOI 10.1074/jbc.271.31.18494; ZHU GH, 1994, J BIOL CHEM, V269, P3952	41	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49401	49405		10.1074/jbc.M309993200	http://dx.doi.org/10.1074/jbc.M309993200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506244	hybrid			2022-12-25	WOS:000186829000108
J	Silverman, N; Zhou, R; Erlich, RL; Hunter, M; Bernstein, E; Schneider, D; Maniatis, T				Silverman, N; Zhou, R; Erlich, RL; Hunter, M; Bernstein, E; Schneider, D; Maniatis, T			Immune activation of NF-kappa B and JNK requires Drosophila TAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN RECOGNITION PROTEIN; GRAM-NEGATIVE BACTERIA; GTP CYCLOHYDROLASE-I; GENE-EXPRESSION; INNATE IMMUNITY; TYROSINE-HYDROXYLASE; SIGNALING PATHWAYS; KINASE COMPLEX; NITRIC-OXIDE; RESPONSES	Stimulation of the Drosophila immune response activates NF-kappaB and JNK signaling pathways. For example, infection by Gram-negative bacteria induces the Imd signaling pathway, leading to the activation of the NF-kappaB-like transcription factor Relish and the expression of a battery of genes encoding antimicrobial peptides. Bacterial infection also activates the JNK pathway, but the role of this pathway in the immune response has not yet been established. Genetic experiments suggest that the Drosophila homolog of the mammalian MAPK kinase kinase, TAK1 ( transforming growth factor beta-activated kinase 1), activates both the JNK and NF-kappaB pathways following immune stimulation. In this report, we demonstrate that Drosophila TAK1 functions as both the Drosophila IkappaB kinase-activating kinase and the JNK kinase-activating kinase. However, we found that JNK signaling is not required for antimicrobial peptide gene expression but is required for the activation of other immune inducible genes, including Punch, sulfated, and malvolio. Thus, JNK signaling appears to play an important role in the cellular immune response and the stress response.	Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02139 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Stanford University	Silverman, N (corresponding author), 364 Plantat Rd,LRB 313, Worcester, MA 01605 USA.			Silverman, Neal/0000-0002-4259-456X	NIGMS NIH HHS [GM59919, GM29379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059919, R01GM029379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIR SS, 2001, SCI STKE; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Boutros M, 2002, DEV CELL, V3, P711, DOI 10.1016/S1534-5807(02)00325-8; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; De Gregorio E, 2001, P NATL ACAD SCI USA, V98, P12590, DOI 10.1073/pnas.221458698; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; Foley E, 2003, GENE DEV, V17, P115, DOI 10.1101/gad.1018503; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Krishnakumar S, 2000, J NEUROGENET, V14, P1, DOI 10.3109/01677060009083474; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MCLEAN JR, 1993, J BIOL CHEM, V268, P27191; MEISTER M, 1994, EMBO J, V13, P5958, DOI 10.1002/j.1460-2075.1994.tb06941.x; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stathakis DG, 1999, GENETICS, V153, P361; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; TOWNSEND JP, 1982, GENOME BIOL; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349	46	194	202	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48928	48934		10.1074/jbc.M304802200	http://dx.doi.org/10.1074/jbc.M304802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14519762	hybrid			2022-12-25	WOS:000186829000052
J	Tu, S; Wu, WJ; Wang, JB; Cerione, RA				Tu, S; Wu, WJ; Wang, JB; Cerione, RA			Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; VAV PROTOONCOGENE PRODUCT; ACTIN STRESS FIBERS; FACTOR RECEPTOR; CELLULAR-TRANSFORMATION; C-SRC; RHO; PHOSPHORYLATION; RAS; FAMILY	Treatment of cells with epidermal growth factor (EGF) promotes the activation of the small GTP-binding protein Cdc42, as well as its phosphorylation in cells. The EGF-dependent phosphorylation of Cdc42 occurs at tyrosine 64 in the Switch II domain and appears to be mediated through the Src tyrosine kinase, because both the expression of a dominant-negative Src mutant ( mouse Src(K297R)) and treatment of cells with the Src kinase inhibitor PP2 blocks the EGF-stimulated phosphorylation of Cdc42, whereas expression of an activated Src mutant ( Src(Y529F)) promotes phosphorylation in the absence of EGF treatment. The EGF-stimulated phosphorylation of Cdc42 is not required for its activation, nor does it directly affect the interactions of activated Cdc42 with target/effector proteins including PAK, ACK, WASP, or IQGAP. However, the EGF-stimulated phosphorylation of Cdc42 is accompanied by an enhancement in the interaction of Cdc42 with the Rho-GDP dissociation inhibitor ( RhoGDI). The EGF-stimulated activation of Cdc42 does require activated Src, as well as the Vav2 protein, a member of the Dbl family of guanine nucleotide exchange factors. Src catalyzes the tyrosine phosphorylation of Vav2, and overexpression of Vav2 together with activated Src ( Src( Y529F)) can completely bypass the need for EGF to promote the activation of Cdc42. Thus, EGF signaling through Src appears to have dual regulatory effects on Cdc42: 1) it leads to the activation of Cdc42 as mediated by the Vav2 guanine nucleotide exchange factor, and 2) it results in the phosphorylation of Cdc42, which stimulates the binding of RhoGDI, perhaps to direct the movement of Cdc42 to a specific cellular site to trigger a signaling response, because Cdc42-RhoGDI interactions are essential for Cdc42-induced cellular transformation.	Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Ctr Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.			Tu, S. Sean/0000-0003-0391-8186	NIGMS NIH HHS [GM40654, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; HART MJ, 1990, J BIOL CHEM, V265, P5990; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin Q, 2003, CURR BIOL, V13, P1469, DOI 10.1016/S0960-9822(03)00613-4; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Wu WJ, 1998, J BIOL CHEM, V273, P16655, DOI 10.1074/jbc.273.27.16655; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200	46	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49293	49300		10.1074/jbc.M307021200	http://dx.doi.org/10.1074/jbc.M307021200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506284	hybrid			2022-12-25	WOS:000186829000096
J	Walia, B; Wang, LX; Merlin, D; Sitaraman, SV				Walia, B; Wang, LX; Merlin, D; Sitaraman, SV			TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: Critical role of SMAD-2	FASEB JOURNAL			English	Article						inflammatory bowel disease; intercellular adhesion molecule-1 (ICAM-1); STAT, Smad	INFLAMMATORY-BOWEL-DISEASE; CYTOKINE MESSENGER-RNA; CROHNS-DISEASE; TRANSFORMING GROWTH-FACTOR-BETA-1; MUCOSAL INFLAMMATION; ADHESION MOLECULE-1; COLONIC-MUCOSA; INTERLEUKIN-6; EXPRESSION; GROWTH	Interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays an important role in the pathogenesis of inflammatory bowel disease. TGF-beta, a multifunctional cytokine, is a potent negative regulator of mucosal inflammation in the intestine. The aim of the present study is to determine possible cross-talk between IL-6 and TGF-beta signaling pathways. Model intestinal epithelial cell lines, Caco2-BBE were used. We show that TGF-beta receptor Type II is predominantly present in the basolateral membrane of intestinal epithelial cells. TGF-beta1 induces a time-dependent phosphorylation of Smad2 and co-immunoprecipitation of SMAD-2 with Smad-4 and its subsequently translocation to the nucleus. We show that pretreatment of cells with TGF-beta1 is associated with a down-regulation of IL-6 induced tyrosine phosphorylation of STAT1 and STAT3 and suppression of ICAM-1 expression. Furthermore, TGF-beta1 pretreatment resulted in a significant inhibition of IL-6 induced ICAM-1 promoter activity. TGF-beta mediated inhibition of IL-6 induced ICAM-1 expression was reversed by transfection with dominant negative Smad2 constructs. In conclusion, we show that: 1) TGF-beta receptor Type II is predominantly located on basolateral membrane and receptor stimulation activates Smad pathway; 2) TGF-beta1 down-regulates IL-6-induced tyrosine phoshorylation of STAT 1 and STAT3 and ICAM-1 expression; and 3) Smad2 is required for the down-regulation of IL-6 signaling by TGF-beta. Collectively, our data demonstrate a cross-talk between TGF-beta and IL-6, and TGF-beta may play a role in the negative regulation of IL-6 signaling in intestinal epithelial cells.	Emory Univ, Div Digest Dis, Atlanta, GA 30322 USA	Emory University	Sitaraman, SV (corresponding author), Emory Univ, Div Digest Dis, Room 201-F,615 Michael St,Whitehead Res Bldg, Atlanta, GA 30322 USA.	ssitar2@emory.edu						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; Bowen-Yacyshyn MB, 2002, J PHARMACOL EXP THER, V302, P908, DOI 10.1124/jpet.102.036053; Burns RC, 2001, GASTROENTEROLOGY, V121, P1428, DOI 10.1053/gast.2001.29568; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Gonnella PA, 1998, J IMMUNOL, V160, P4708; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Hahm KB, 2002, ALIMENT PHARM THERAP, V16, P115, DOI 10.1046/j.1365-2036.16.s2.3.x; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HEINRICH PC, 2003, BIOCH J         0529; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hosokawa T, 1999, J GASTROEN HEPATOL, V14, P987, DOI 10.1046/j.1440-1746.1999.01989.x; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAHIDA YR, 1991, GUT, V32, P1531, DOI 10.1136/gut.32.12.1531; MCCABE RP, 1993, CLIN IMMUNOL IMMUNOP, V66, P52, DOI 10.1006/clin.1993.1007; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; MITSUYAMA K, 1991, DIGESTION, V50, P104, DOI 10.1159/000200747; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Nakabayashi T, 1997, J IMMUNOL, V158, P5527; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.3.CO;2-D; Reinisch W, 1999, AM J GASTROENTEROL, V94, P2156; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Strober W, 2001, ACTA ODONTOL SCAND, V59, P244, DOI 10.1080/00016350152509274; Sun ZW, 1999, J SURG RES, V87, P90, DOI 10.1006/jsre.1999.5746; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takenoshita S, 2002, J GASTROENTEROL, V37, P991, DOI 10.1007/s005350200168; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Whiting CV, 2001, J HISTOCHEM CYTOCHEM, V49, P727, DOI 10.1177/002215540104900606; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	45	60	70	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2130	+		10.1096/fj.02-1211fje	http://dx.doi.org/10.1096/fj.02-1211fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500551				2022-12-25	WOS:000185925100008
J	Funaba, M; Ikeda, T; Murakami, M; Ogawa, K; Tsuchida, K; Sugino, H; Abe, M				Funaba, M; Ikeda, T; Murakami, M; Ogawa, K; Tsuchida, K; Sugino, H; Abe, M			Transcriptional activation of mouse mast cell protease-7 by activin and transforming growth factor-beta is inhibited by microphthalmia-associated transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; SMAD PROTEINS; FACTOR MITF; DEPENDENT DEGRADATION; UBIQUITIN LIGASE; I RECEPTORS; GENE; KINASE; MICE; PHOSPHORYLATION	Previous studies have revealed that activin A and transforming growth factor-beta(1) (TGF-beta(1)) induced migration and morphological changes toward differentiation in bone marrow-derived cultured mast cell progenitors (BMC-MCs). Here we show up-regulation of mouse mast cell protease-7 (mMCP-7), which is expressed in differentiated mast cells, by activin A and TGF-beta(1) in BMCMCs, and the molecular mechanism of the gene induction of mmcp-7. Smad3, a signal mediator of the activin/TGF-beta pathway, transcriptionally activated mmcp-7. Microphthalmia-associated transcription factor ( MITF), a tissue-specific transcription factor predominantly expressed in mast cells, melanocytes, and heart and skeletal muscle, inhibited Smad3-mediated mmcp-7 transcription. MITF associated with Smad3, and the C terminus of MITF and the MH1 and linker region of Smad3 were required for this association. Complex formation between Smad3 and MITF was neither necessary nor sufficient for the inhibition of Smad3 signaling by MITF. MITF inhibited the transcriptional activation induced by the MH2 domain of Smad3. In addition, MITF-truncated N-terminal amino acids could associate with Smad3 but did not inhibit Smad3-mediated transcription. The level of Smad3 was decreased by co-expression of MITF but not of dominant-negative MITF, which resulted from proteasomal protein degradation. The changes in the level of Smad3 protein were paralleled by those in Smad3-mediated signaling activity. These findings suggest that MITF negatively regulates Smad-dependent activin/TGF-beta signaling in a tissue-specific manner.	Azabu Univ, Sch Vet Med, Lab Nutr, Sagamihara, Kanagawa 2298501, Japan; Azabu Univ, Sch Vet Med, Mol Biol Lab, Sagamihara, Kanagawa 2298501, Japan; Azabu Univ, Res Inst Biosci, Sagamihara, Kanagawa 2298501, Japan; RIKEN, Lab Cellular Biochem, Wako, Saitama 3510198, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Azabu University; Azabu University; Azabu University; RIKEN; Tokushima University	Funaba, M (corresponding author), Azabu Univ, Sch Vet Med, Lab Nutr, 1-17-71 Fuchinobe, Sagamihara, Kanagawa 2298501, Japan.		Tsuchida, Kunihiro/A-4501-2012; Funaba, Masayuki/E-4676-2018	Tsuchida, Kunihiro/0000-0002-3983-5756; Funaba, Masayuki/0000-0002-4303-6682				Abe M, 2002, J LEUKOCYTE BIOL, V72, P347; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Friend DS, 1998, J IMMUNOL, V160, P5537; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Funaba M, 2000, MOL ENDOCRINOL, V14, P1583, DOI 10.1210/me.14.10.1583; Funaba M, 2003, J LEUKOCYTE BIOL, V73, P793, DOI 10.1189/jlb.0103012; Funaba M, 2003, CELL SIGNAL, V15, P605, DOI 10.1016/S0898-6568(02)00150-X; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Grinberg AV, 2003, J BIOL CHEM, V278, P11227, DOI 10.1074/jbc.M211734200; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jippo T, 1997, AM J PATHOL, V150, P1373; Kitamura Y, 2000, INT J HEMATOL, V71, P197; Kitamura Y, 2002, INT ARCH ALLERGY IMM, V127, P106, DOI 10.1159/000048178; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Luisi S, 2001, EUR J ENDOCRINOL, V145, P225, DOI 10.1530/eje.0.1450225; Massague J, 2000, GENE DEV, V14, P627; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEKORI YA, 1990, J IMMUNOL, V145, P3719; Miller HRP, 1999, BLOOD, V93, P3473, DOI 10.1182/blood.V93.10.3473.410k01_3473_3486; Miller HRP, 2002, IMMUNOLOGY, V105, P375, DOI 10.1046/j.1365-2567.2002.01375.x; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morii E, 2002, J BIOL CHEM, V277, P8566, DOI 10.1074/jbc.M110392200; Moustakas A, 2001, J CELL SCI, V114, P4359; Murakami M, 2003, BIOCHEM BIOPH RES CO, V311, P4, DOI 10.1016/j.bbrc.2003.09.148; Nadler M J, 2000, Adv Immunol, V76, P325; Oboki K, 2002, BIOCHEM BIOPH RES CO, V290, P1250, DOI 10.1006/bbrc.2002.6332; Ogawa K, 2000, J IMMUNOL, V165, P2997, DOI 10.4049/jimmunol.165.6.2997; Ogihara H, 2001, BLOOD, V97, P645, DOI 10.1182/blood.V97.3.645; Ogihara H, 1999, ONCOGENE, V18, P4632, DOI 10.1038/sj.onc.1202844; PETRAGLIA F, 1991, J CLIN ENDOCR METAB, V72, P496, DOI 10.1210/jcem-72-2-496; RAZIN E, 1984, J IMMUNOL, V132, P1479; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takeda K, 2002, BBA-GENE STRUCT EXPR, V1574, P15, DOI 10.1016/S0167-4781(01)00339-6; Takemoto CM, 2002, J BIOL CHEM, V277, P30244, DOI 10.1074/jbc.M201441200; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	63	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52032	52041		10.1074/jbc.M306991200	http://dx.doi.org/10.1074/jbc.M306991200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527958	hybrid			2022-12-25	WOS:000187480700009
J	Greene, MD; Frasch, WD				Greene, MD; Frasch, WD			Interactions among gamma R268, gamma Q269, and the beta subunit catch loop of Escherichia coli F-1-ATPase are important for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; F1-ATPASE; MUTAGENESIS; RESOLUTION; MECHANISM; ROTATION; ENZYMES; ENERGY	Removal of the ability to form a salt bridge or hydrogen bonds between the beta subunit catch loop (betaY297-D305) and the gamma subunit of Escherichia coli F1Fo-ATP synthase significantly altered the ability of the enzyme to hydrolyze ATP and the bacteria to grow via oxidative phosphorylation. Residues betaT304, betaD305, betaD302, gammaQ269, and gammaR268 were found to be very important for ATP hydrolysis catalyzed by soluble F-1-ATPase, and the latter four residues were also very important for oxidative phosphorylation. The greatest effects on catalytic activity were observed by the substitution of side chains that contribute to the shortest and/or multiple H-bonds as well as the salt bridge. Residue betaD305 would not tolerate substitution with Val or Ser and had extremely low activity as betaD305E, suggesting that this residue is particularly important for synthesis and hydrolysis activity. These results provide evidence that tight winding of the gamma subunit coiled-coil is important to the rate-limiting step in ATP hydrolysis and are consistent with an escapement mechanism for ATP synthesis in which alphabetagamma intersubunit interactions provide a means to make substrate binding a prerequisite of proton gradient-driven gamma subunit rotation.	Arizona State Univ, Sch Life Sci, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Frasch, WD (corresponding author), Arizona State Univ, Sch Life Sci, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA.				NIGMS NIH HHS [GM50202, R01 GM050202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19640; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Chen W, 2001, BIOCHEMISTRY-US, V40, P7729, DOI 10.1021/bi0105779; Frasch WD, 2000, BBA-BIOENERGETICS, V1458, P310, DOI 10.1016/S0005-2728(00)00083-9; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sambrook J., 2002, MOL CLONING LAB MANU; WISE JG, 1990, J BIOL CHEM, V265, P10403; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	14	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51594	51598		10.1074/jbc.M309948200	http://dx.doi.org/10.1074/jbc.M309948200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532272	hybrid			2022-12-25	WOS:000187206300092
J	Mandelboim, M; Barth, S; Biton, M; Liang, XH; Michaeli, S				Mandelboim, M; Barth, S; Biton, M; Liang, XH; Michaeli, S			Silencing of Sm proteins in Trypanosoma brucei by RNA interference captured a novel cytoplasmic intermediate in spliced leader RNA biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; CAP 4 FORMATION; MUTATIONAL ANALYSIS; MESSENGER-RNA; U-SNRNA; RIBOSOMAL-RNA; LA PROTEIN; SL RNA; TRANS; GENE	In Trypanosoma brucei the small nuclear (sn) RNAs U1, U2, U4, and U5, as well as the spliced leader (SL) RNA, bind the seven Sm canonical proteins carrying the consensus Sm motif. To determine the function of these proteins in snRNA and SL RNA biogenesis, two of the Sm core proteins, SmE and SmD1, were silenced by RNAi. Surprisingly, whereas the level of all snRNAs, including U1, U2, U4, and U5 was reduced during silencing, the level of SL RNA was dramatically elevated, but the levels of U6 and spliced leader-associated RNA (SLA1) remained unchanged. The SL RNA that had accumulated in silenced cells lacked modification at the cap4 nucleotide but harbored modifications at the cap1 and cap2 nucleotides and carried the characteristic psi. This SL RNA possessed a longer tail and had accumulated in the cytoplasm in 10 and 50 S particles that were found by in situ hybridization to be present in "speckles." We propose a model for SL RNA biogenesis involving a cytoplasmic phase and suggest that the trypanosome-specific "cap4" nucleotides function as a signal for export and import of SL RNA out and into the nucleus. The SL RNA biogenesis pathway differs from that of U sn ribonucleoproteins (RNPs) in that it is the only RNA that binds Sm proteins that were stabilized under Sm depletion in a novel RNP, which we termed SL RNP-C.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022	Biton, Moshe/0000-0001-8330-1674				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BANGS JD, 1992, J BIOL CHEM, V267, P9805; Bell M, 1999, NUCLEIC ACIDS RES, V27, P3986, DOI 10.1093/nar/27.20.3986; Bell M, 2000, GENE, V247, P77, DOI 10.1016/S0378-1119(00)00118-9; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; Chen YL, 2003, MOL BIOCHEM PARASIT, V126, P275, DOI 10.1016/S0166-6851(02)00276-1; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Darzacq X, 2002, EMBO J, V21, P2746, DOI 10.1093/emboj/21.11.2746; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FREISTADT MS, 1988, J BIOL CHEM, V263, P15071; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Goncharov I, 1999, J BIOL CHEM, V274, P12217, DOI 10.1074/jbc.274.18.12217; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Liang XH, 2003, EUKARYOT CELL, V2, P830, DOI 10.1128/EC.2.5.830-840.2003; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Liu L, 2003, J BIOL CHEM, V278, P18271, DOI 10.1074/jbc.M209215200; Liu L, 2002, J BIOL CHEM, V277, P47348, DOI 10.1074/jbc.M207736200; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; Mair G, 2000, J BIOL CHEM, V275, P28994, DOI 10.1074/jbc.M004193200; Mair G, 2000, RNA, V6, P163, DOI 10.1017/S135583820099229X; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NAKAAR V, 1995, PARASITOL TODAY, V11, P225, DOI 10.1016/0169-4758(95)80085-9; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1994, J BIOL CHEM, V269, P30620; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RYMOND BC, 1993, P NATL ACAD SCI USA, V90, P848, DOI 10.1073/pnas.90.3.848; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Sturm NR, 1999, J BIOL CHEM, V274, P19361, DOI 10.1074/jbc.274.27.19361; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Zeiner GM, 2003, EUKARYOT CELL, V2, P222, DOI 10.1128/EC.2.2.222-230.2003; Zhao XL, 2002, RNA, V8, P1515, DOI 10.1017/S1355838202022537	60	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51469	51478		10.1074/jbc.M308997200	http://dx.doi.org/10.1074/jbc.M308997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532264	hybrid			2022-12-25	WOS:000187206300077
J	Park, HI; Jin, YH; Hurst, DR; Monroe, CA; Lee, S; Schwartz, MA; Sang, QXA				Park, HI; Jin, YH; Hurst, DR; Monroe, CA; Lee, S; Schwartz, MA; Sang, QXA			The intermediate S1 ' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE ELASTASE MMP-12; X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASE-26; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; SWISS-MODEL; COLLAGENASE	Human matrix metalloproteinase-26 (MMP-26/ endometase/ matrilysin-2) is a newly identified MMP and its structure has not been reported. The enzyme active site S-1' pocket in MMPs is a well defined substrate P-1' amino acid residue-binding site with variable depth. To explore MMP-26 active site structure-activity, a series of new potent mercaptosulfide MMP inhibitors (MMPIs) with Leu or homophenylalanine (Homophe) side chains at the P-1' site were selected. The Homephe side chain is designed to probe deep S-1' pocket MMPs. These inhibitors were tested against MMP-26 and several MMPs with known x-ray crystal structures to distinguish shallow, intermediate, and deep S-1' pocket characteristics. MMP-26 has an inhibition profile most similar to those of MMPs with intermediate S-1' pockets. Investigations with hydroxamate MMPIs, including those designed for deep pocket MMPs, also indicated the presence of an intermediate pocket. Protein sequence analysis and homology modeling further verified that MMP-26 has an intermediate S-1' pocket formed by Leu-204, His-208, and Tyr-230. Moreover, residue 233 may influence the depth of an MMP S-1' pocket. The residue at the equivalent position of MMP-26 residue 233 is hydrophilic in intermediate-pocket MMPs (e.g. MMP-2, -8, and -9) and hydrophobic in deep-pocket MMPs (e.g. MMP-3, - 12, and - 14). MMP-26 contains a His-233 that renders the S-1' pocket to an intermediate size. This study suggests that MMPIs, protein sequence analyses, and molecular modeling are useful tools to understand structure-activity relationships and provides new insight for rational inhibitor design that may distinguish MMPs with deep versus intermediate S-1' pockets.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, Chem Res Bldg DLC,Rm 203, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu	Hurst, Douglas R/B-7341-2009	Hurst, Douglas/0000-0002-1296-2210	NCI NIH HHS [CA78646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Bohacek R, 1996, J AM CHEM SOC, V118, P8231, DOI 10.1021/ja950818y; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; Copeland R. A., 2004, ENZYMES PRACTICAL IN; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HURST DR, 2003, BIOCHEM J, DOI DOI 10.1015/BJ20031067; Jin YH, 2002, TETRAHEDRON LETT, V43, P7319, DOI 10.1016/S0040-4039(02)01750-1; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Lang R, 2001, J MOL BIOL, V312, P731, DOI 10.1006/jmbi.2001.4954; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Matter H, 1999, J MED CHEM, V42, P1908, DOI 10.1021/jm980631s; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 2000, CANC DRUG DISC DEV, P39; Nar H, 2001, J MOL BIOL, V312, P743, DOI 10.1006/jmbi.2001.4953; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Pavlovsky AG, 1999, PROTEIN SCI, V8, P1455, DOI 10.1110/ps.8.7.1455; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SCHWARTZ MA, 1995, Patent No. 5455262; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; Uria JA, 2000, CANCER RES, V60, P4745; Zhao YG, 2003, J BIOL CHEM, V278, P15056, DOI 10.1074/jbc.M210975200; ZHAO YG, 2003, IN PRESS CANC RES	50	49	49	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51646	51653		10.1074/jbc.M310109200	http://dx.doi.org/10.1074/jbc.M310109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532275	hybrid			2022-12-25	WOS:000187206300099
J	Tawaramoto, MS; Park, SY; Tanaka, Y; Nureki, O; Kurumizaka, H; Yokoyama, S				Tawaramoto, MS; Park, SY; Tanaka, Y; Nureki, O; Kurumizaka, H; Yokoyama, S			Crystal structure of the human centromere protein B (CENP-B) dimerization domain at 1.65-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST HOMOLOGS; BINDING PROTEIN; NULL MICE; DNA; COMPLEX; ORGANIZATION; KINETOCHORE; DISRUPTION; CONTAINS; JERKY	The human centromere protein B (CENP-B), a centromeric heterochromatin component, forms a homodimer that specifically binds to a distinct DNA sequence (the CENP-B box), which appears within every other alpha-satellite repeat. Previously, we determined the structure of the human CENP-B DNA-binding domain, CENP-B-(1-129), complexed with the CENP-B box DNA. In the present study, we determined the crystal structure of its dimerization domain (CENP-B-(540-599)), another functional domain of CENP-B, at 1.65-Angstrom resolution. CENP- B-(540-599) contains two alpha-helices, which are folded into an antiparallel configuration. The CENP-B-(540-599) dimer formed a symmetrical, antiparallel, four-helix bundle structure with a large hydrophobic patch in which 23 residues of one monomer form van der Waals contacts with the other monomer. In the CENP- B-(540-599) dimer, the N-terminal ends of CENP-B-(540-599) are oriented on opposite sides of the dimer. This CENP- B dimer configuration may be suitable for capturing two distant CENP-B boxes during centromeric heterochromatin formation.	RIKEN, Gen Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Harima Inst SPring8, Sayo, Hyogo 6795148, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan	RIKEN; Yokohama City University; University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; Waseda University	Yokoyama, S (corresponding author), RIKEN, Gen Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kurumizaka, Hitoshi/0000-0001-7412-3722				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baum M, 2000, MOL CELL BIOL, V20, P2852, DOI 10.1128/MCB.20.8.2852-2864.2000; BRUNGER AT, 1996, XPLOR VERSION 3 851; Choo KHA, 2001, DEV CELL, V1, P165, DOI 10.1016/S1534-5807(01)00028-4; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Fowler KJ, 2000, GENOME RES, V10, P30; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fukagawa T, 1997, HUM MOL GENET, V6, P2301, DOI 10.1093/hmg/6.13.2301; Halverson D, 1997, J CELL BIOL, V136, P487, DOI 10.1083/jcb.136.3.487; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hudson DF, 1998, J CELL BIOL, V141, P309, DOI 10.1083/jcb.141.2.309; Ikeno M, 1998, NAT BIOTECHNOL, V16, P431, DOI 10.1038/nbt0598-431; Irelan JT, 2001, GENETICS, V157, P1191; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kipling D, 1997, TRENDS GENET, V13, P141, DOI 10.1016/S0168-9525(97)01098-6; KITAGAWA K, 1995, MOL CELL BIOL, V15, P1602; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JK, 1997, P NATL ACAD SCI USA, V94, P8427, DOI 10.1073/pnas.94.16.8427; Liu WC, 2003, MOL CELL BIOL, V23, P4083, DOI 10.1128/MCB.23.12.4083-4093.2003; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; Murakami Y, 1996, P NATL ACAD SCI USA, V93, P502, DOI 10.1073/pnas.93.1.502; Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Castro AV, 1998, DEV BIOL, V201, P135, DOI 10.1006/dbio.1998.9005; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; Sullivan B, 2001, J CELL BIOL, V154, P683, DOI 10.1083/jcb.200103001; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Tanaka Y, 2001, EMBO J, V20, P6612, DOI 10.1093/emboj/20.23.6612; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; TOTH M, 1995, NAT GENET, V11, P71, DOI 10.1038/ng0995-71; VALDIVIA MM, 1985, J CELL BIOL, V101, P1124, DOI 10.1083/jcb.101.3.1124; Yoda K, 1998, GENES CELLS, V3, P533, DOI 10.1046/j.1365-2443.1998.00210.x	43	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51454	51461		10.1074/jbc.M310388200	http://dx.doi.org/10.1074/jbc.M310388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522975	hybrid			2022-12-25	WOS:000187206300075
J	Woelfle, J; Chia, DJ; Rotwein, P				Woelfle, J; Chia, DJ; Rotwein, P			Mechanisms of growth hormone (GH) action - Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES GROWTH; RAPID CHANGES; TRANSCRIPTION; PROTEINS; TRANSACTIVATION; RECRUITMENT; COFACTOR; ROLES; SERUM; VIVO	Many of the actions of growth hormone (GH) on somatic growth and tissue maintenance are mediated by insulin-like growth factor-I (IGF-I), a secreted protein whose gene expression is rapidly and potently induced by GH by unknown mechanisms. Recent studies implicating Stat5a and Stat5b in the growth response to GH in mice and observations linking Stat5b to control of IGF-I gene transcription in rats have prompted the current investigations into the molecular determinants of a putative regulatory network extending from GH through Stat5b to IGF-I. Here we characterize as critical components of this hormone-activated transcriptional pathway two adjacent Stat5 binding sites in the second intron of the rat IGF-I gene located within a conserved region previously found to undergo acute and reversible changes in chromatin structure after in vivo GH treatment. As assessed by chromatin immunoprecipitation assays, GH rapidly induced binding of Stat5 to this DNA segment in the liver of GH-deficient rats, just prior to the onset of transcription from both major and minor IGF-I gene promoters. Biochemical reconstitution experiments showed that the two intronic Stat5 DNA elements were able to bind Stat5b in vitro after GH treatment could transmit GH- and Stat5b-dependent transcriptional responsiveness to the major IGF-I promoter and to a minimal neutral gene promoter and were required for full stimulation of reporter gene activity by GH. Taken together, these results identify an intronic enhancer as a key mediator of GH- induced IGF-I gene transcription working through Stat5b and provide new insight into the molecular architecture of this transcriptional pathway.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Div Endocrinol, Dept Pediat, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code HTC3, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Woellfe, joachim F/E-9406-2014; Rotwein, Peter/R-5783-2019	, Joachim/0000-0002-9132-6174; Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [R01 DK063073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adamo ML., 1995, DIABETES REV, V3, P2; BERRY SA, 1994, MOL ENDOCRINOL, V8, P1714, DOI 10.1210/me.8.12.1714; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P4741, DOI 10.1210/en.136.11.4741; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pollak M, 2000, GROWTH HORM IGF RES, V10, P21, DOI 10.1016/S1096-6374(00)80005-2; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; ROTWEIN P, 1997, J ANIM SCI, V75, P11; Rotwein Peter, 1999, V17, P19; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yakar S, 2002, J CLIN INVEST, V110, P771, DOI 10.1172/JCI200215463; Ye SK, 2001, IMMUNITY, V15, P813, DOI 10.1016/S1074-7613(01)00230-8; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	33	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51261	51266		10.1074/jbc.M309486200	http://dx.doi.org/10.1074/jbc.M309486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532269	hybrid			2022-12-25	WOS:000187206300052
J	Zhang, R; Xu, YQ; Ekman, N; Wu, ZH; Wu, J; Alitalo, K; Min, W				Zhang, R; Xu, YQ; Ekman, N; Wu, ZH; Wu, J; Alitalo, K; Min, W			Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; NITRIC-OXIDE SYNTHASE; TYROSINE KINASE ETK; KAPPA-B; ACTIVATION; VEGF; FAMILY; ALPHA; EXPRESSION; INHIBITOR	Tumor necrosis factor (TNF), via its receptor 2 (TNFR2), induces Etk (or Bmx) activation and Etk-dependent endothelial cell (EC) migration and tube formation. Because TNF receptor 2 lacks an intrinsic kinase activity, we examined the kinase(s) mediating TNF-induced Etk activation. TNF induces a coordinated phosphorylation of vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) and Etk, which is blocked by VEGFR2-specific inhibitors. In response to TNF, Etk and VEGFR2 form a complex resulting in a reciprocal activation between the two kinases. Subsequently, the downstream phosphatidylinositol 3-kinase (PI3K)-Akt signaling (but not signaling through phospholipase C-gamma) was initiated and directly led to TNF-induced EC migration, which was significantly inhibited by VEGFR2-, PI3K-, or Akt-specific inhibitors. Phosphorylation of VEGFR2 at Tyr-801 and Tyr-1175, the critical sites for VEGF-induced PI3K-Akt signaling, was not involved in TNF-mediated Akt activation. However, TNF induces phosphorylation of Etk at Tyr-566, directly mediating the recruitment of the p85 subunit of PI3K. Furthermore, TNF- but not VEGF-induced activation of VEGFR2, Akt, and EC migration are blunted in EC genetically deficient with Etk. Taken together, our data demonstrated that TNF induces transactivation between Etk and VEGFR2, and Etk directly activates PI3K- Akt angiogenic signaling independent of VEGF-induced VEGFR2- PI3K- Akt signaling pathway.	Yale Univ, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, Sch Med, New Haven, CT 06510 USA; Univ Helsinki, FIN-00014 Helsinki, Finland; Univ Rochester, Rochester, NY 14534 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Yale University; University of Helsinki; University of Rochester	Min, W (corresponding author), Yale Univ, Boyer Ctr Mol Med, Interdept Program Vasc Biol & Transplantat, Sch Med, 295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01HL65978-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cheng N, 2001, J BIOL CHEM, V276, P13771, DOI 10.1074/jbc.M009147200; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee WS, 1998, CIRC RES, V82, P845; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUMOTO T, 2001, SCI STKE; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Qi JH, 2001, EXP CELL RES, V263, P173, DOI 10.1006/excr.2000.5102; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; SARMA V, 1992, J IMMUNOL, V148, P3302; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Walsh DA, 1999, RHEUMATOLOGY, V38, P103, DOI 10.1093/rheumatology/38.2.103; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096	50	119	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51267	51276		10.1074/jbc.M310678200	http://dx.doi.org/10.1074/jbc.M310678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532277	hybrid			2022-12-25	WOS:000187206300053
J	de Mestre, AM; Khachigian, LM; Santiago, FS; Staykova, MA; Hulett, MD				de Mestre, AM; Khachigian, LM; Santiago, FS; Staykova, MA; Hulett, MD			Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; MAMMALIAN HEPARANASE; EXTRACELLULAR-MATRIX; ENDOGLYCOSIDASE HEPARANASE; SULFATE PROTEOGLYCANS; LYMPHOCYTES-T; EXPRESSION; GROWTH; EGR-1; METASTASIS	Cleavage of heparan sulfate by the beta-D-endoglucuronidase heparanase (HPSE) is a fundamental event in a number of important physiological processes including inflammation, wound healing, and angiogenesis. HPSE activity has also been directly correlated with pathological conditions such as tumor growth and metastasis and autoimmune disease. The tight regulation of HPSE expression and function is critical to ensure homeostasis of the normal physiological processes to which it contributes and to prevent imbalance toward pathological situations. Little is known about the transcriptional mechanisms that regulate HPSE expression. In this study we have shown human HPSE gene transcription in Jurkat T cells is induced upon activation. Functional analysis of the HPSE promoter has identified a 280-bp region that is highly inducible. Mutation studies together with supershift experiments have identified a 4-bp motif that binds the transcription factor early growth response-1 (Egr1) and is critical in regulating inducible HPSE gene transcription. Furthermore, the overexpression of Egr1 resulted in the enhanced activation of the HPSE promoter. By using MAPK pathway inhibitors, we have also shown that inducible expression of HPSE mRNA and the activity of the 280-bp HPSE promoter element are dependent on the ERK1/2 (MEK1/2) pathway. This pathway is critical for induction of Egr1 expression at both the mRNA and protein level in T cells, an observation that provides further support to Egr1 playing an important role as a key activator of HPSE expression. In addition, HPSE and Egr1 were shown to co-localize by immunohistochemistry to invading mononuclear leukocytes in actively induced experimental autoimmune encephalomyelitis in rats. These findings provide the first insight into the mechanisms controlling inducible transcription of the HPSE gene, and could represent an important lead into understanding how HPSE expression is deregulated in metastatic tumor cells.	Australian Natl Univ, John Curtin Sch Med Res, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia; Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Canberra Hosp, Neurosci Res Unit, Woden, ACT 2606, Australia	Australian National University; John Curtin School of Medical Research; University of New South Wales Sydney; Australian National University; Canberra Hospital	Hulett, MD (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Canc & Vasc Biol Grp, Acton, ACT 2601, Australia.		Khachigian, Levon/AAZ-7458-2020; Hulett, Mark D/C-4160-2012; de Mestre, Amanda/H-7455-2018	Khachigian, Levon/0000-0003-3446-0323; Hulett, Mark/0000-0003-2072-5968; de Mestre, Amanda/0000-0002-9422-2370				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Baker E, 1999, CHROMOSOME RES, V7, P319, DOI 10.1023/A:1009235132576; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; BRENCHLEY PEC, 2001, ANN RHEUM DIS     S3, V60, P71; CAO XM, 1993, J BIOL CHEM, V268, P16949; Carleton M, 2002, J IMMUNOL, V168, P1649, DOI 10.4049/jimmunol.168.4.1649; Cristillo AD, 1996, DNA CELL BIOL, V15, P561, DOI 10.1089/dna.1996.15.561; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Dzialo-Hatton R, 2001, J IMMUNOL, V166, P4534, DOI 10.4049/jimmunol.166.7.4534; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Fitzgerald M, 1999, ATHEROSCLEROSIS, V145, P97, DOI 10.1016/S0021-9150(99)00019-2; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; FRIDMAN R, 1987, J CELL PHYSIOL, V130, P85, DOI 10.1002/jcp.1041300113; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gohji K, 2001, J UROLOGY, V166, P1286, DOI 10.1016/S0022-5347(05)65754-0; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Hulett MD, 2001, BIOCHEM BIOPH RES CO, V280, P374, DOI 10.1006/bbrc.2000.4088; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; Irony-Tur-Sinai M, 2003, J NEUROL SCI, V206, P49, DOI 10.1016/S0022-510X(02)00318-0; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koliopanos A, 2001, CANCER RES, V61, P4655; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Nadav L, 2002, J CELL SCI, V115, P2179; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; Simizu S, 2003, CANCER LETT, V193, P83, DOI 10.1016/S0304-3835(02)00719-X; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Takaoka M, 2003, LAB INVEST, V83, P613, DOI 10.1097/01.LAB.0000067482.84946.BD; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; Willenborg DO, 1996, J IMMUNOL, V157, P1973; WOOD KV, 1991, CHEMILIUMINESCENCE C, P543; Xi HK, 2003, J IMMUNOL, V170, P315, DOI 10.4049/jimmunol.170.1.315; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	59	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50377	50385		10.1074/jbc.M310154200	http://dx.doi.org/10.1074/jbc.M310154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522979	hybrid			2022-12-25	WOS:000187068200088
J	Song, ES; Juliano, MA; Juliano, L; Hersh, LB				Song, ES; Juliano, MA; Juliano, L; Hersh, LB			Substrate activation of insulin-degrading enzyme (insulysin) - A potential target for drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID BETA-PROTEIN; ONSET ALZHEIMERS-DISEASE; GROWTH FACTOR-ALPHA; EXTRACELLULAR LEVELS; IN-VIVO; DEGRADATION; LINKAGE; LOCUS; CHROMOSOME-10; PROTEOLYSIS	The rate of the insulin-degrading enzyme (IDE)-catalyzed hydrolysis of the fluorogenic substrate 2-aminobenzoyl-GGFLRKHGQ- ethylenediamine-2,4-dinitrophenyl is increased 2-7-fold by other peptide substrates but not by peptide non-substrates. This increased rate is attributed to a decrease in K-m with little effect on V-max. An similar to 2.5-fold increase in the rate of amyloid beta peptide hydrolysis is produced by dynorphin B-9. However, with insulin as substrate, dynorphin B-9 is inhibitory. Immunoprecipitation of differentially tagged IDE and gel filtration analysis were used to show that IDE exists as a mixture of dimers and tetramers. The equilibrium between dimer and tetramer is concentration-dependent, with the dimer the more active form. Bradykinin shifted the equilibrium toward dimer. Activation of substrate hydrolysis is not seen with a mixed dimer of IDE containing one active subunit and one subunit that is catalytically inactive and deficient in substrate binding. On the other hand, a mixed dimer containing one active subunit and one subunit that is catalytically inactive but binds substrate with normal affinity is activated by peptides. These findings suggest that peptides bind to one subunit of IDE and induce a conformational change that shifts the equilibrium to the more active dimer as well as activates the adjacent subunit. The selective activation of IDE toward amyloid beta peptide relative to insulin suggests the potential for development of compounds that increase IDE activity toward amyloid beta peptide as a therapeutic intervention for the treatment of Alzheimer's disease.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil	University of Kentucky; University of Kentucky; Universidade Federal de Sao Paulo (UNIFESP)	Hersh, LB (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Coll Med, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.		Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822	NIA NIH HHS [AG19323] Funding Source: Medline; NIDA NIH HHS [DA02243] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abraham R, 2001, HUM GENET, V109, P646, DOI 10.1007/s00439-001-0614-1; Authier F, 1996, CLIN INVEST MED, V19, P149; Bennett RG, 2000, J BIOL CHEM, V275, P36621, DOI 10.1074/jbc.M006170200; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Camberos MC, 2001, EXP BIOL MED, V226, P334, DOI 10.1177/153537020122600411; Csuhai E, 1999, ANAL BIOCHEM, V269, P149, DOI 10.1006/abio.1999.4033; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Ertekin-Taner N, 2000, SCIENCE, V290, P2303, DOI 10.1126/science.290.5500.2303; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GARCIA JV, 1989, J CELL BIOL, V109, P1301, DOI 10.1083/jcb.109.3.1301; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Ma ZL, 2002, ARCH BIOCHEM BIOPHYS, V401, P198, DOI 10.1016/S0003-9861(02)00020-6; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Mukherjee A, 2000, J NEUROSCI, V20, P8745; MULLER D, 1992, BIOCHEMISTRY-US, V31, P11138; MULLER D, 1991, EUR J BIOCHEM, V202, P285, DOI 10.1111/j.1432-1033.1991.tb16374.x; Myers A, 2000, SCIENCE, V290, P2304, DOI 10.1126/science.290.5500.2304; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200; Vekrellis K, 2000, J NEUROSCI, V20, P1657	27	105	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49789	49794		10.1074/jbc.M308983200	http://dx.doi.org/10.1074/jbc.M308983200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14527953	hybrid			2022-12-25	WOS:000187068200019
J	Zhyvoloup, A; Nemazanyy, I; Panasyuk, G; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Foxon, R; Lyzogubov, V; Usenko, V; Kyyamova, R; Gorbenko, O; Matsuka, G; Filonenko, V; Gout, IT				Zhyvoloup, A; Nemazanyy, I; Panasyuk, G; Valovka, T; Fenton, T; Rebholz, H; Wang, ML; Foxon, R; Lyzogubov, V; Usenko, V; Kyyamova, R; Gorbenko, O; Matsuka, G; Filonenko, V; Gout, IT			Subcellular localization and regulation of coenzyme a synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHESIZING PROTEIN COMPLEX; MITOCHONDRIAL CONTACT SITES; PANTOTHENATE KINASE; RAT-LIVER; COA BIOSYNTHESIS; ACETYL-COA; HEART; MEMBRANE; METABOLISM; CARNITINE	CoA synthase mediates the last two steps in the sequence of enzymatic reactions, leading to CoA biosynthesis. We have recently identified cDNA for CoA synthase and demonstrated that it encodes a bifunctional enzyme possessing 4'-phosphopantetheine adenylyltransferase and dephospho-CoA kinase activities. Molecular cloning of CoA synthase provided us with necessary tools to study subcellular localization and the regulation of this bifunctional enzyme. Transient expression studies and confocal microscopy allowed us to demonstrate that full-length CoA synthase is associated with the mitochondria, whereas the removal of the N-terminal region relocates the enzyme to the cytosol. In addition, we showed that the N-terminal sequence of CoA synthase ( amino acids 1 - 29) exhibits a hydrophobic profile and targets green fluorescent protein exclusively to mitochondria. Further analysis, involving subcellular fractionation and limited proteolysis, indicated that CoA synthase is localized on the mitochondrial outer membrane. Moreover, we demonstrate for the first time that phosphatidylcholine and phosphatidylethanolamine, which are the main components of the mitochondrial outer membrane, are potent activators of both enzymatic activities of CoA synthase in vitro. Taken together, these data provide the evidence that the final stages of CoA biosynthesis take place on mitochondria and the activity of CoA synthase is regulated by phospholipids.	Ludwig Inst Canc Res, London W1W 7BS, England; Inst Mol Biol & Genet, Dept Struct & Funct Nucl Acid, UA-03143 Kiev, Ukraine; Natl Univ Kyiv Mohyla Acad, UA-04070 Kiev, Ukraine; Morphol Lab BIONTEC, UA-94000 Dnepropetrovsk, Ukraine; UCL Royal Free & Univ Coll Med Sch, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Ministry of Education & Science of Ukraine; National University of Kyiv Mohyla Academy; University of London; University College London; UCL Medical School	Gout, IT (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	ivan@ludwig.ucl.ac.uk	Panasyuk, Ganna/A-4133-2018; Panasyuk, Ganna/AAF-4350-2021; Filonenko, Valeriy V/D-5447-2015; Kiyamova, Ramziya G/L-8766-2015	Panasyuk, Ganna/0000-0002-5591-848X; Panasyuk, Ganna/0000-0002-5591-848X; Filonenko, Valeriy V/0000-0003-1839-3335; Rebholz, Heike/0000-0002-0400-7547; Fenton, Tim/0000-0002-4737-8233				ABERHART DJ, 1985, BIOCHEMISTRY-US, V24, P7178, DOI 10.1021/bi00346a024; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; Aghajanian S, 2002, BIOCHEM J, V365, P13, DOI 10.1042/BJ20020569; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Begley TP, 2001, VITAM HORM, V61, P157; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; BRASS EP, 1990, J NUTR, V120, P290, DOI 10.1093/jn/120.3.290; Bucovaz ET, 1997, BIOCHIMIE, V79, P787, DOI 10.1016/S0300-9084(97)86938-6; BUCOVAZ ET, 1980, MOL CELL BIOCHEM, V30, P7, DOI 10.1007/BF00215301; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; CORKEY BE, 1988, J CLIN INVEST, V82, P782, DOI 10.1172/JCI113679; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; FISHER MN, 1985, J BIOL CHEM, V260, P5745; HALVORSEN O, 1982, EUR J BIOCHEM, V124, P211, DOI 10.1111/j.1432-1033.1982.tb05927.x; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; LOPASCHUK GD, 1987, J MOL CELL CARDIOL, V19, P281, DOI 10.1016/S0022-2828(87)80595-3; Massa R, 2000, J MUSCLE RES CELL M, V21, P433, DOI 10.1023/A:1005688901635; MCALLISTER RA, 1988, BRIT J CANCER, V57, P83, DOI 10.1038/bjc.1988.14; MCEVILY AJ, 1986, J BIOL CHEM, V261, P2593; MILLAR AH, 1988, BIOCHEM J, V334, P571; REIBEL DK, 1983, AM J PHYSIOL, V244, pH839, DOI 10.1152/ajpheart.1983.244.6.H839; REIBEL DK, 1981, AM J PHYSIOL, V240, pH606, DOI 10.1152/ajpheart.1981.240.4.H606; ROBISHAW JD, 1982, J BIOL CHEM, V257, P967; Rock CO, 2000, J BIOL CHEM, V275, P1377, DOI 10.1074/jbc.275.2.1377; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SKREDE S, 1979, BIOCHEM BIOPH RES CO, V91, P1536, DOI 10.1016/0006-291X(79)91239-7; SLEBODA J, 1995, BBA-LIPID LIPID MET, V1258, P309, DOI 10.1016/0005-2760(95)00138-3; SMITH CM, 1980, BIOCHEM J, V188, P175, DOI 10.1042/bj1880175; SMITH CM, 1978, J NUTR, V108, P863, DOI 10.1093/jn/108.5.863; TAHILIANI AG, 1991, VITAM HORM, V46, P165; TAHILIANI AG, 1989, J BIOL CHEM, V264, P18426; TAHILIANI AG, 1987, J MOL CELL CARDIOL, V19, P1161, DOI 10.1016/S0022-2828(87)80526-6; Tang PZ, 2001, P NATL ACAD SCI USA, V98, P6581, DOI 10.1073/pnas.121046998; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Zhyvoloup A, 2002, J BIOL CHEM, V277, P22107, DOI 10.1074/jbc.C200195200	41	49	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50316	50321		10.1074/jbc.M307763200	http://dx.doi.org/10.1074/jbc.M307763200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514684	hybrid			2022-12-25	WOS:000187068200080
J	Jiang, FL; Chen, MY; Yi, L; de Gier, JW; Kuhn, A; Dalbey, RE				Jiang, FL; Chen, MY; Yi, L; de Gier, JW; Kuhn, A; Dalbey, RE			Defining the regions of Escherichia coli YidC that contribute to activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INSERTION; PF3 COAT PROTEIN; INNER MEMBRANE; HOMOLOG ALBINO3; OXA1P; INTEGRATION; BIOGENESIS; MACHINERY; COMPONENT; BACTERIAL	The YidC/Oxa1/Alb3 family of proteins catalyzes membrane protein insertion in bacteria, mitochondria, and chloroplasts. In this study, we investigated which regions of the bacterial YidC protein are important for its function in membrane protein biogenesis. In Escherichia coli, YidC spans the membrane six times, with a large 319-residue periplasmic domain following the first transmembrane domain. We found that this large periplasmic domain is not required for YidC function and that the residues in the exposed hydrophilic loops or C-terminal tail are not critical for YidC activity. Rather, the five C-terminal transmembrane segments that contain the three consensus sequences in the YidC/ Oxa1/Alb3 family are important for its function. However, by systematically replacing all the residues in transmembrane segment (TM) 2, TM3, and TM6 with serine and by swapping TM4 and TM5 with unrelated transmembrane segments, we show that the precise sequence of these transmembrane regions is not essential for in vivo YidC activity. Single serine mutations in TM2, TM3, and TM6 impaired the membrane insertion of the Sec-independent procoat-leader peptidase protein. We propose that the five C-terminal transmembrane segments of YidC function as a platform for the translocating substrate protein to support its insertion into the membrane.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Stockholm Univ, Dept Biochem & Biophys, Arrhenius Lab, S-10691 Stockholm, Sweden; Univ Hohenheim, Inst Microbiol & Mol Biol, D-70599 Stuttgart, Germany	University System of Ohio; Ohio State University; Stockholm University; University Hohenheim	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	dalbey@chemistry.ohio-state.edu			NIGMS NIH HHS [GM63862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; GELLER BL, 1985, J BIOL CHEM, V260, P3281; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Koch HG, 2002, J BIOL CHEM, V277, P5715, DOI 10.1074/jbc.C100683200; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Stuart RA, 2002, BBA-MOL CELL RES, V1592, P79, DOI 10.1016/S0167-4889(02)00266-5; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Urbanus ML, 2002, J BIOL CHEM, V277, P12718, DOI 10.1074/jbc.M200311200; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; WHITLEY P, 1993, BIOCHEMISTRY-US, V32, P8534, DOI 10.1021/bi00084a020; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x	26	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48965	48972		10.1074/jbc.M307362200	http://dx.doi.org/10.1074/jbc.M307362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506280	hybrid			2022-12-25	WOS:000186829000057
J	Sheth, P; Basuroy, S; Li, CY; Naren, AP; Rao, RK				Sheth, P; Basuroy, S; Li, CY; Naren, AP; Rao, RK			Role of phosphatidylinositol 3-kinase in oxidative stress-induced disruption of tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; CACO-2 CELL MONOLAYER; EPITHELIAL-CELLS; KINASE-C; OCCLUDIN; ZO-1; INHIBITION; PERMEABILITY; ORGANIZATION; INVOLVEMENT	A recent study (Nusrat, A., Chen, J. A., Foley, C. S., Liang, T. W., Tom, J., Cromwell, M., Quan, C., and Mrsny, R. J. ( 2000) J. Biol. Chem. 275, 29816 - 29822) suggested that phosphatidylinositol 3-kinase ( PI 3-kinase) may interact with occludin; however, there exists no evidence of direct interaction of PI 3-kinase with the tight junctions. Activation of PI 3-kinase by oxidative stress and its role in disruption of tight junctions was examined in Caco-2 cell monolayer. The oxidative stress-induced decrease in electrical resistance, increase in inulin permeability, and redistribution of occludin and ZO-1 were reduced by a PI 3-kinase inhibitor, LY294002. Oxidative stress-induced tyrosine phosphorylation and dissociation from the actin cytoskeleton of occludin and ZO-1 were reduced by LY294002. The regulatory subunit of PI 3-kinase, p85, and the PI 3-kinase activity were co-immunoprecipitated with occludin, which were rapidly increased by oxidative stress. Oxidative stress resulted in increased translocation of p85 from the intracellular compartment into the intercellular junctions. Pair-wise glutathione S-transferase pull-down assay showed that glutathione S-transferase-occludin (C-terminal tail) binds to recombinant p85. This study shows that oxidative stress increases the association of PI 3-kinase with the occludin, and that PI 3-kinase activity is involved in oxidative stress-induced disruption of tight junction.	Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, RK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.				NIAAA NIH HHS [R01-AA12307, R01 AA012307] Funding Source: Medline; NIDDK NIH HHS [R01-DK55532, R01 DK055532] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012307] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Atkinson KJ, 2001, AM J PHYSIOL-GASTR L, V280, pG1280, DOI 10.1152/ajpgi.2001.280.6.G1280; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; HOLLANDER D, 1994, GUT, V26, P1621; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Kale G, 2003, BIOCHEM BIOPH RES CO, V302, P324, DOI 10.1016/S0006-291X(03)00167-0; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Pedram A, 2002, J BIOL CHEM, V277, P44385, DOI 10.1074/jbc.M202391200; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Ries J, 1997, AM J PHYSIOL-CELL PH, V272, pC794, DOI 10.1152/ajpcell.1997.272.3.C794; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TRIER JS, 1978, GASTROINTESTINAL DIS, P1029; Trischitta F, 2001, J COMP PHYSIOL B, V171, P85, DOI 10.1007/s003600000152; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818	26	141	146	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49239	49245		10.1074/jbc.M305654200	http://dx.doi.org/10.1074/jbc.M305654200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500730	hybrid			2022-12-25	WOS:000186829000089
J	Yethon, JA; Epand, RF; Leber, B; Epand, RM; Andrews, DW				Yethon, JA; Epand, RF; Leber, B; Epand, RM; Andrews, DW			Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; BCL-2 FAMILY; CELL-DEATH; PROTEIN; OLIGOMERIZATION; TRANSLOCATION; LOCALIZATION; SUPPRESSES; CYTOSOL	The Bcl-2 family member Bax is an apoptosis-promoting protein that normally resides in an inactive state within the cytoplasm of healthy cells. Upon induction of apoptosis by diverse stimuli, Bax undergoes a conformational change and translocates to mitochondria, where it oligomerizes and forms pores that allow the release of cytochrome c and other cytotoxic factors. Protein-protein interactions between Bax and other Bcl-2 family members are strongly implicated in Bax activation, but a compelling case has recently been made for the involvement of lipids in this process as well. Here we report that purified Bax undergoes a reversible conformational change upon incubation with lipid vesicles in the absence of other proteins. This Bax-liposome interaction does not depend on a specific lipid composition. Changes in Bax conformation were observed by immunoprecipitation with the conformation-specific antibody 6A7, circular dichroism spectroscopy, and differential scanning calorimetry. Although liposomes induced Bax to become 6A7-reactive ( a feature normally associated with the onset of apoptosis), the protein did not insert into membranes, become oligomeric, or form pores, clearly indicating that other triggers are required for Bax to achieve its final pro-apoptotic state. Indeed, the lipid-induced Bax conformational change is shown to be required for tBid-induced Bax oligomerization and pore formation, putting it upstream of tBid activity in this molecular pathway to Bax activation. These data demonstrate that Bax is sensitized to activation by transient interaction with lipid membrane surfaces and provide evidence that Bax activation proceeds in a stepwise fashion, with multiple triggers and potential levels of regulation.	McMaster Univ, Hlth Sci Ctr, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Andrews, DW (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		, Richard/R-2316-2019	, Richard/0000-0002-9602-9558; Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Polster BM, 2003, J NEUROSCI, V23, P2735; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sreerama N, 1999, PROTEIN SCI, V8, P370; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	38	174	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48935	48941		10.1074/jbc.M306289200	http://dx.doi.org/10.1074/jbc.M306289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522999	hybrid			2022-12-25	WOS:000186829000053
J	Babbar, N; Ignatenko, NA; Casero, RA; Gerner, EW				Babbar, N; Ignatenko, NA; Casero, RA; Gerner, EW			Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FAMILIAL ADENOMATOUS POLYPOSIS; ORNITHINE-DECARBOXYLASE GENE; HUMAN PROSTATE-CANCER; CELL-LINES; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; PPAR-GAMMA; ADENOCARCINOMA CELLS; COLORECTAL-CANCER; RECEPTOR-GAMMA	Sulindac, a non-steroidal anti-inflammatory prodrug, is metabolized into pharmacologically active sulfide and sulfone derivatives. Sulindac sulfide, but not sulindac sulfone, inhibits cyclooxygenase (COX) enzyme activities, yet both derivatives have growth inhibitory effects on colon cancer cells. Microarray analysis was used to detect COX-independent effects of sulindac on gene expression in human colorectal cells. Spermidine/spermine N-1-acetyltransferase (SSAT) gene, which encodes a polyamine catabolic enzyme, was induced by clinically relevant sulindac sulfone concentrations. Northern blots confirmed increased SSAT RNA levels in these colon cancer cells. Deletion analysis and mutational studies were done to map the sulindac sulfone-dependent response sequences in the SSAT 5'-flanking sequences. This led us to the identification of two peroxisome proliferator-activated receptor (PPAR) response elements (PPREs) in the SSAT gene. PPRE-2, at +48 bases relative to the transcription start site, is required for the induction of SSAT by sulindac sulfone and is specifically bound by PPARgamma in the Caco-2 cells as shown by transfection and gel shift experiments. PPRE-1, at -323 bases relative to the start site, is not required for the induction of SSAT by sulindac sulfone but can be bound by both PPARdelta and PPARgamma. Sulindac sulfone reduced cellular polyamine contents in the absence but not in the presence of verapamil, an inhibitor of the export of monoacetyl diamines, inhibited cell proliferation and induced apoptosis. The induced apoptosis could be partially rescued by exogenous putrescine. These data suggest that apoptosis induced by sulindac sulfone is mediated, in part, by the COX-independent, PPAR-dependent transcriptional activation of SSAT, leading to reduced tissue polyamine contents in human colon cancer cells.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Biochem Mol & Cellular Biol Grad Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona; Johns Hopkins University; Johns Hopkins Medicine	Gerner, EW (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	egerner@azcc.arizona.edu		Casero, Robert/0000-0001-5653-3306	NCI NIH HHS [CA23074, CA95060, CA51085, CA72008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA095060, P01CA072008, P30CA023074, R01CA051085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi H, 2000, INT J CANCER, V88, P873, DOI 10.1002/1097-0215(20001215)88:6<873::AID-IJC6>3.0.CO;2-B; Bertagnolli MM, 1998, GASTROENTEROLOGY, V115, P1036, DOI 10.1016/S0016-5085(98)70294-X; Boolbol SK, 1996, CANCER RES, V56, P2556; Carbone PP, 1998, CANCER EPIDEM BIOMAR, V7, P907; CELANO P, 1989, BIOCHEM BIOPH RES CO, V165, P384, DOI 10.1016/0006-291X(89)91082-6; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chiu CH, 1997, CANCER RES, V57, P4267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crowley-Weber CL, 2002, CARCINOGENESIS, V23, P2063, DOI 10.1093/carcin/23.12.2063; Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Farriol M, 2001, NUTRITION, V17, P934, DOI 10.1016/S0899-9007(01)00670-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fultz KE, 2002, MOL CARCINOGEN, V34, P10, DOI 10.1002/mc.10043; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Goldberg Y, 1996, ONCOGENE, V12, P893; Goluboff ET, 1999, UROLOGY, V53, P440, DOI 10.1016/S0090-4295(98)00513-5; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hughes A, 2003, BIOCHEM J, V374, P481, DOI 10.1042/BJ20030280; Ignatenko NA, 1996, CELL GROWTH DIFFER, V7, P481; Kohno H, 2001, JPN J CANCER RES, V92, P396, DOI 10.1111/j.1349-7006.2001.tb01108.x; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; Li L, 2001, AM J PHYSIOL-GASTR L, V280, pG992, DOI 10.1152/ajpgi.2001.280.5.G992; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Martinez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100; MEYSKENS FL, 1995, J CELL BIOCHEM, P126; Milovic V, 2000, CANCER LETT, V154, P195, DOI 10.1016/S0304-3835(00)00400-6; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Patten EJ, 1999, CANCER LETT, V147, P95, DOI 10.1016/S0304-3835(99)00282-7; PEGG AE, 1988, CANCER RES, V48, P759; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Piazza GA, 1997, CANCER RES, V57, P2909; Rahman MA, 2000, CANCER RES, V60, P2085; RAO CV, 1995, CANCER RES, V55, P1464; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Scorcioni F, 2001, BIOCHEM J, V354, P217, DOI 10.1042/0264-6021:3540217; SEILER N, 1980, J CHROMATOGR, V221, P227, DOI 10.1016/S0378-4347(00)84307-8; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stoner GD, 1999, ADV EXP MED BIOL, V470, P45; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Taylor MT, 2000, CANCER RES, V60, P6607; Turchanowa L, 2001, EUR J CLIN INVEST, V31, P887, DOI 10.1046/j.1365-2362.2001.00901.x; van Stolk R, 2000, CLIN CANCER RES, V6, P78; Vujcic S, 2000, J BIOL CHEM, V275, P38319, DOI 10.1074/jbc.M003270200; Wang YL, 1999, J BIOL CHEM, V274, P22095, DOI 10.1074/jbc.274.31.22095; Wang YL, 2001, BIOCHEM J, V355, P45, DOI 10.1042/0264-6021:3550045; Wang YL, 1998, J BIOL CHEM, V273, P34623, DOI 10.1074/jbc.273.51.34623; Watts GS, 2001, J PHARMACOL EXP THER, V299, P434; Xie XZ, 1997, J BIOL CHEM, V272, P20484, DOI 10.1074/jbc.272.33.20484	55	108	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47762	47775		10.1074/jbc.M307265200	http://dx.doi.org/10.1074/jbc.M307265200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506281	hybrid			2022-12-25	WOS:000186731400052
J	Xu, XZ; Stern, DF				Xu, XZ; Stern, DF			NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors	FASEB JOURNAL			English	Article						53BP1; gamma-H2AX; MRE11 complex; ATM/ATR substrates; assembly of ionizing radiation-induced foci	BUDDING YEAST RAD9; DAMAGE CHECKPOINT; HISTONE H2AX; EARLY PARTICIPANT; 53BP1; PROTEIN; PHOSPHORYLATION; MEDIATOR; MDC1; CHK2	NFBD1/MDC1 (mediator of DNA damage checkpoint 1) is a nuclear factor with an amino-terminal FHA (forkhead-associated) domain and a tandem repeat of BRCT (breast cancer susceptibility gene-1 carboxyl terminus) domains. We have previously shown that NFBD1 is an early participant in DNA damage signaling pathways and that ionizing radiation-induced nuclear foci (IRIF) of NFBD1 colocalize with several DNA checkpoint signaling and repair factors. We report here that NFBD1 physically associates with ATM, p53, components of the MRE11-RAD50-NBS1 (MRN) complex, and gamma-H2AX. An overexpressed FHA domain-containing fragment of NFBD1 binds to endogenous NFBD1 and components of the MRN complex, but not to gamma-H2AX. This fragment interferes with IRIF formation by endogenous NFBD1, MRE11, or NBS1. A BRCT domain-containing fragment of NFBD1 binds to gamma-H2AX and 53BP1, but not to components of the MRN complex, and abolishes IRIF formation by NFBD1, MRE11, NBS1, 53BP1, CHK2 phospho-T68, gamma-H2AX, and possible ATM/ATR substrates recognized by anti-phospho-SQ/TQ antibody. These results suggest that NFBD1 is an ATM/ATR dependent organizer that recruits DNA checkpoint signaling and repair proteins to the sites of DNA damage.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,BML342, New Haven, CT 06510 USA.	df.stern@yale.edu	xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [R01CA82257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abraham RT, 2002, NAT CELL BIOL, V4, pE277, DOI 10.1038/ncb1202-e277; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bradbury JM, 2003, BIOCHEM SOC T, V31, P40, DOI 10.1042/bst0310040; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jullien D, 2002, J CELL SCI, V115, P71; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Xu XZ, 1999, ONCOGENE, V18, P5554, DOI 10.1038/sj.onc.1203091; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	32	82	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1842	1848		10.1096/fj.03-0310com	http://dx.doi.org/10.1096/fj.03-0310com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519663				2022-12-25	WOS:000186343300038
J	Fukuhara, A; Shimizu, K; Kawakatsu, T; Fukuhara, T; Takai, Y				Fukuhara, A; Shimizu, K; Kawakatsu, T; Fukuhara, T; Takai, Y			Involvement of nectin-activated Cdc42 small G protein in organization of adherens and tight junctions in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; RHO-GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANS-INTERACTIONS; ADHESION; RAC; AFADIN; MOLECULES; POLARITY; DOMAIN	Nectins, Ca2+-independent immunoglobulin-like cell-cell adhesion molecules, trans-interact and form cell-cell adhesion, which increases the velocities of the formation of the E-cadherin-based adherens junctions (AJs) and the claudin-based tight junctions ( TJs) in Madin-Darby canine kidney (MDCK) cells. The trans-interactions of nectins furthermore induce activation of Cdc42 and Rac small G proteins, but the roles of these small G proteins activated in this way remain unknown. We examined here the role and the mode of action of Cdc42 in the organization of AJs and TJs in MDCK cells. We first made the NWASP-Cdc42 and Rac interactive binding ( CRIB) domain, an inhibitor of activated Cdc42, fused to the Ki-Ras CAAX motif (NWASP-CRIB-CAAX; where A is aliphatic amino acid), which was targeted to the cell-cell adhesion sites. We then found that overexpression of NWASP-CRIB-CAAX reduced the velocities of the formation of AJs and TJs. Conversely, overexpression of a constitutively active mutant of Cdc42 ( V12Cdc42) increased their velocities, and the inhibitory effect of NWASP-CRIB-CAAX was suppressed by co-expression with V12Cdc42. The inhibitory effect of NWASP-CRIB-CAAX on the formation of AJs and TJs was suppressed by co-expression of nectin-1 of which trans-interaction activated endogenous Cdc42. Moreover, the formation of the claudin-based TJs required a greater amount of activated Cdc42 than that of the E-cadherin-based AJs. These results indicate that the Cdc42 activated by the trans-interactions of nectins is involved in the organization of AJs and TJs in different mechanisms in MDCK cells.	Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Dept Mol Biol & Biochem, Grad Sch Med, Fac Med, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778				Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Garrard SM, 2003, EMBO J, V22, P1125, DOI 10.1093/emboj/cdg110; GEORGOPOULOS C, 1989, TRENDS GENET, V5, P319, DOI 10.1016/0168-9525(89)90118-2; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung SM, 2000, MOL BIOL CELL, V11, P2131, DOI 10.1091/mbc.11.6.2131; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Takenawa T, 2001, J CELL SCI, V114, P1801; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Yamamoto Y, 2002, ONCOGENE, V21, P2545, DOI 10.1038/sj.onc.1205335; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Yasuda T, 2000, GENES CELLS, V5, P583, DOI 10.1046/j.1365-2443.2000.00349.x	46	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51885	51893		10.1074/jbc.M308015200	http://dx.doi.org/10.1074/jbc.M308015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530286	hybrid			2022-12-25	WOS:000187206300124
J	Kang, SI; Chang, WJ; Cho, SG; Kim, IY				Kang, SI; Chang, WJ; Cho, SG; Kim, IY			Modification of promyelocytic leukemia zinc finger protein (PLZF) by SUMO-1 conjugation regulates its transcriptional repressor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CELL-GROWTH; RAR-ALPHA; IN-VIVO; GENE; FUSION; DOMAIN; LOCALIZATION; ONCOPROTEIN; EXPRESSION	Promyelocytic leukemia zinc finger (PLZF) protein is a sequence-specific DNA-binding protein that represses the transcriptional activity of target genes such as those for cyclin A and the interleukin-3 receptor alpha chain. The PLZF gene becomes fused to the retinoic acid receptor alpha gene as a result of the t(11, 17)(q23;q21) chromosomal translocation that is associated with acute promyelocytic leukemia. We now show that endogenous PLZF in human promyelocytic leukemia HL-60 cells is modified by conjugation with SUMO-1 (small ubiquitin-related modifier-1) and that PLZF colocalizes with SUMO-1 in the nucleus of transfected human embryonic kidney 293T cells. Site-directed mutagenesis identified lysine 242 in the RD2 domain of human PLZF as the sumoylation site. A luciferase reporter gene assay suggested that SUMO-1 modification of this residue is required for transcriptional repression by PLZF, and an electrophoretic mobility shift assay showed that this modification increases the DNA binding activity of PLZF. PLZF-mediated regulation of the cell cycle and transcriptional repression of the cyclin A2 gene were also dependent on sumoylation of PLZF on lysine 242. These results demonstrate that PLZF is modified by SUMO-1 conjugation and that this modification regulates the biological functions of PLZF.	Korea Univ, Sch Life Sci & Biotechnol, Lab Cellular & Mol Biochem, Seoul 136701, South Korea; Konkuk Univ, Dept Anim Biotechnol, Seoul 143701, South Korea; Konkuk Univ, Dept Adv Fus Technol, Seoul 143701, South Korea	Korea University; Konkuk University; Konkuk University	Kim, IY (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Lab Cellular & Mol Biochem, 1-5 Anam Dong, Seoul 136701, South Korea.			Cho, Ssang-Goo/0000-0002-0968-7932				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pandolfi PP, 2001, ONCOGENE, V20, P5726, DOI 10.1038/sj.onc.1204600; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Takahashi S, 2002, LEUKEMIA, V16, P1755, DOI 10.1038/sj.leu.2402682; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	33	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51479	51483		10.1074/jbc.M309237200	http://dx.doi.org/10.1074/jbc.M309237200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527952	hybrid			2022-12-25	WOS:000187206300078
J	Suzuki, M; Hirao, A; Mizuno, A				Suzuki, M; Hirao, A; Mizuno, A			Microfilament-associated protein 7 increases the membrane expression of transient receptor potential vanilloid 4 (TRPV4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLUME REGULATION; CATION CHANNEL; MICE LACKING; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; CYTOSKELETON; INVOLVEMENT; SENSATION; E-MAP-115	The molecular mechanism of the transmission of changes in the shape of the cell surface to ion channels remains obscure. Ca2+ influx induced by cell deformity is inhibited by actin-freezing reagents, suggesting that the actin microfilament couples with an ion channel. Transient receptor potential vanilloid 4 (TRPV4) is a candidate in the calcium-permeable, swelling-activated mechanosensitive channel in heterogeneously expressed cells. To investigate the mechanosensitive molecular complex, we found that microtubule-associated protein 7 (MAP7) is the mouse TRPV4 C-terminal binding protein. MAP7 was coimmunoprecipitated with TRPV4. The results of a pull-down assay demonstrated that the alignment of amino acids 798-809 of TRPV4 was important in this interaction. TRPV4 and MAP7 colocalized in the lung and kidney. The coexpression of these two molecules resulted in the redistribution of TRPV4 toward the membrane and increased its functional expression. The alignment of amino acids 798-809 of TRPV4 was also important in the functional expression. The activated current was abolished by actin-freezing but not by microtubule-freezing reagents. We therefore believe that MAP7 may enhance the membrane expression of TRPV4 and possibly link cytoskeletal microfilaments.	Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Jichi Medical University	Suzuki, M (corresponding author), Jichi Med Sch, Dept Pharmacol, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	macsuz@jichi.ac.jp						Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; ARAKAWA T, 1984, J BIOL CHEM, V259, P1730; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CORNET M, 1987, PFLUG ARCH EUR J PHY, V410, P223, DOI 10.1007/BF00581921; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; DOWNEY GP, 1995, J CELL PHYSIOL, V163, P96, DOI 10.1002/jcp.1041630111; Fabre-Jonca N, 1998, DIFFERENTIATION, V63, P169, DOI 10.1111/j.1432-0436.1998.00169.x; FOSKETT JK, 1985, AM J PHYSIOL, V248, pC27, DOI 10.1152/ajpcell.1985.248.1.C27; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; GUCHARAY F, 1984, J PHYSL, V352, P685; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; JONATHAN GH, 1999, NATURE, V397, P66; KATZ B, 1950, J PHYSIOL-LONDON, V111, P261, DOI 10.1113/jphysiol.1950.sp004479; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; KUZNETSOV SA, 1981, FEBS LETT, V135, P237, DOI 10.1016/0014-5793(81)80790-9; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Lin DH, 2002, J BIOL CHEM, V277, P44278, DOI 10.1074/jbc.M203702200; LINSHAW MA, 1992, AM J PHYSIOL, V262, pF144, DOI 10.1152/ajprenal.1992.262.1.F144; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; MAYER HE, 1995, J BIOL CHEM, V270, P7679; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; OVERNOS JG, 1997, ANNU REV NEUROSCI, V20, P567; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SMALL DL, 1994, AM J PHYSIOL, V267, pC598, DOI 10.1152/ajpcell.1994.267.2.C598; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2003, J BIOL CHEM, V278, P22664, DOI 10.1074/jbc.M302561200; Suzuki M, 2002, FEBS LETT, V517, P219, DOI 10.1016/S0014-5793(02)02627-3; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; SUZUKI M, 1999, J AM SOC NEPHROL, V10, P44; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HS, 2003, J BIOL CHEM, V278, P11520, DOI 10.1074/jbc.M211061200	39	89	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51448	51453		10.1074/jbc.M308212200	http://dx.doi.org/10.1074/jbc.M308212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14517216	hybrid			2022-12-25	WOS:000187206300074
J	Wang, QD; Wang, XF; Evers, BM				Wang, QD; Wang, XF; Evers, BM			Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNCYTIAL VIRUS-INFECTION; NECROSIS-FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; T-CELLS; MEDIATED APOPTOSIS	Activation of protein kinase C (PKC) prevents apoptosis in certain cells; however, the mechanisms are largely unknown. Inhibitors of apoptosis (IAP) family members, including NAIP, cIAP-1, cIAP-2, XIAP/hILP, survivin, and BRUCE, block apoptosis by binding and potently inhibiting caspases. Activation of NF-kappaB contributes to cIAP-2 induction; however, the cellular mechanisms regulating cIAP-2 expression have not been entirely defined. In this study, we examined the role of the PKC and NF-kappaB pathways in the regulation of cIAP-2 in human colon cancers. We found that cIAP-2 mRNA levels were markedly increased in human colon cancer cells by treatment with the phorbol ester, phorbol-12-myristate-13-acetate (PMA), or bryostatin 1. Inhibitors of the Ca2+-independent, novel PKC isoforms, but not inhibitors of MAPK, PI3-kinase, or PKA, blocked PMA-stimulated cIAP-2 mRNA expression, suggesting a role of PKC in PMA-mediated cIAP-2 induction. Pretreatment with the PKCdelta-selective inhibitor rottlerin or transfection with an antisense PKCdelta oligonucleotide inhibited PMA-induced cIAP-2 expression, whereas cotransfection with a PKCdelta plasmid induced cIAP-2 promoter activity, which, taken together, identifies a role for PKCdelta in cIAP-2 induction. Treatment with the proteasome inhibitor, MG132 or inhibitors of NF-kappaB ( e. g. PDTC and gliotoxin), decreased PMA-induced up-regulation of cIAP-2. PMA-induced NF-kappaB activation was blocked by either GF109203x, MG132, PDTC, or gliotoxin. Moreover, overexpression of PKCdelta-induced cIAP-2 promoter activity and increased NF-kappaB transactivation, suggesting regulation of cIAP-2 expression by a PKCdelta/NF-kappaB pathway. In conclusion, our findings demonstrate a role for a PKC/NF-kappaB-dependent pathway in the regulation of cIAP-2 expression in human colon cancer cells. These data suggest a novel mechanism for the anti-apoptotic function mediated by the PKCdelta/NF-kappaB/cIAP-2 pathway in certain cancers.	Univ Texas, Dept Surg, Med Branch, Galveston, TX 77555 USA; Univ Texas, Sealy Ctr Canc Cell Biol, Med Branch, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Dept Surg, Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.				NIA NIH HHS [R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [P01 DK35608, R01 DK48498] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498, P01DK035608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ayad O, 1998, J IMMUNOL, V161, P2594; Baillie G, 2001, MOL PHARMACOL, V60, P1100, DOI 10.1124/mol.60.5.1100; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandt DT, 2003, J BIOL CHEM, V278, P34073, DOI 10.1074/jbc.M211650200; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Chini BA, 1998, J VIROL, V72, P1623, DOI 10.1128/JVI.72.2.1623-1626.1998; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clark AS, 2003, CANCER RES, V63, P780; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fleming RYD, 1998, SURG ONCOL, V7, P125, DOI 10.1016/S0960-7404(99)00034-1; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gorlick R, 1999, SEMIN ONCOL, V26, P606; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Manderscheid M, 2002, KIDNEY INT, V61, P797, DOI 10.1046/j.1523-1755.2002.00223.x; McCracken MA, 2003, MOL CANCER THER, V2, P273; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mochly-Rosen D, 1998, FASEB J, V12, P35; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Page K, 2003, J IMMUNOL, V170, P5681, DOI 10.4049/jimmunol.170.11.5681; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Park SJ, 2002, IMMUNOPHARM IMMUNOT, V24, P211, DOI 10.1081/IPH-120003751; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sade H, 2003, EUR J IMMUNOL, V33, P913, DOI 10.1002/eji.200323782; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shapiro BA, 2002, J PHARMACOL EXP THER, V302, P352, DOI 10.1124/jpet.302.1.352; SHI MM, 1994, J BIOL CHEM, V269, P26512; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Snyder JG, 2002, SHOCK, V17, P304, DOI 10.1097/00024382-200204000-00011; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thomas RP, 2002, SURGERY, V132, P127, DOI 10.1067/msy.2002.124930; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Vancurova I, 2001, J BIOL CHEM, V276, P19746, DOI 10.1074/jbc.M100234200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2000, BIOCHEM BIOPH RES CO, V273, P853, DOI 10.1006/bbrc.2000.3034; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wang QD, 2002, CLIN CANCER RES, V8, P1940; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Yoo J, 2003, AM J PHYSIOL-GASTR L, V284, pG703, DOI 10.1152/ajpgi.00214.2002; Yu LY, 2003, MOL CELL NEUROSCI, V22, P308, DOI 10.1016/S1044-7431(02)00038-6; Zrachia A, 2002, J BIOL CHEM, V277, P23693, DOI 10.1074/jbc.M111658200	71	93	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51091	51099		10.1074/jbc.M306541200	http://dx.doi.org/10.1074/jbc.M306541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527959	hybrid			2022-12-25	WOS:000187206300033
J	Hon, T; Dodd, A; Dirmeier, R; Gorman, N; Sinclair, PR; Zhang, L; Poyton, RO				Hon, T; Dodd, A; Dirmeier, R; Gorman, N; Sinclair, PR; Zhang, L; Poyton, RO			A mechanism of oxygen sensing in yeast - Multiple oxygen-responsive steps in the heme biosynthetic pathway affect Hap1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR HAP1; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-C; MOLECULAR-MECHANISM; CYC1 GENE; SEQUENCE; HYPOXIA; REPRESSION; OXIDASE	Heme plays central roles in oxygen sensing and utilization in many living organisms. In yeast, heme mediates the effect of oxygen on the expression of many genes involved in using or detoxifying oxygen. However, a direct link between intracellular heme level and oxygen concentration has not been vigorously established. In this report, we have examined the relationships among oxygen levels, heme levels, Hap1 activity, and HAP1 expression. We found that Hap1 activity is controlled in vivo by heme and not by its precursors and that heme activates Hap1 even in anoxic cells. We also found that Hap1 activity exhibits the same oxygen dose-response curves as Hap1-dependent aerobic genes and that these dose-response curves have a sharp break at similar to1 muM O-2. The results show that the intracellular signaling heme level, reflected as Hap1 activity, is closely correlated with oxygen concentration. Furthermore, we found that bypass of all heme synthetic steps but ferrochelatase by deuteroporphyrin IX does not circumvent the need for oxygen in Hap1 full activation by heme, suggesting that the last step of heme synthesis, catalyzed by ferrochelatase, is also subjected to oxygen control. Our results show that multiple heme synthetic steps can sense oxygen concentration and provide significant insights into the mechanism of oxygen sensing in yeast.	NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Vet Affairs Med Ctr, Dept Biochem & Pharmacol, White River Jct, VT 05009 USA; Dartmouth Coll Sch Med, White River Jct, VT 05009 USA	New York University; University of Colorado System; University of Colorado Boulder; US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College	Zhang, L (corresponding author), NYU, Sch Med, Dept Biochem, 550 1st Ave, New York, NY 10016 USA.	li.zhang@med.nyu.edu	Zhang, Li/L-5206-2013	Zhang, Li/0000-0001-9242-0763	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063324, R01HL065568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062246, R01GM030228] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65568, HL63324] Funding Source: Medline; NIEHS NIH HHS [ES06263] Funding Source: Medline; NIGMS NIH HHS [GM30228, GM62246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KE, 2001, METABOLIC MOL BASES, P2991; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bruick RK, 2002, SCIENCE, V295, P807, DOI 10.1126/science.1069825; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burke PV, 1997, J BIOL CHEM, V272, P14705, DOI 10.1074/jbc.272.23.14705; Burke PV, 1998, APPL ENVIRON MICROB, V64, P1040; Camadro JM, 1996, J BIOL CHEM, V271, P9120, DOI 10.1074/jbc.271.15.9120; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; CzyzykKrzeska MF, 1997, RESP PHYSIOL, V110, P99, DOI 10.1016/S0034-5687(97)00076-5; Daghman NA, 1999, ANN HEMATOL, V78, P275, DOI 10.1007/s002770050514; Dailey HA, 1990, BIOSYNTHESIS HEME CH, P183; Dann CE, 2002, P NATL ACAD SCI USA, V99, P15351, DOI 10.1073/pnas.202614999; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; Grishin AV, 1998, GENETICS, V149, P879; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Hach A, 1999, MOL CELL BIOL, V19, P4324; Hach A, 2000, J BIOL CHEM, V275, P248, DOI 10.1074/jbc.275.1.248; HALDI M, 1989, J BIOL CHEM, V264, P17107; Hen T, 2000, BIOCHEM BIOPH RES CO, V273, P584, DOI 10.1006/bbrc.2000.2995; Hon T, 2001, MOL CELL BIOL, V21, P7923, DOI 10.1128/MCB.21.23.7923-7932.2001; Hon T, 1999, J BIOL CHEM, V274, P22770, DOI 10.1074/jbc.274.32.22770; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Jiang YD, 2002, EUKARYOT CELL, V1, P481, DOI 10.1128/EC.1.3.481-490.2002; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; Kastaniotis AJ, 2000, MOL CELL BIOL, V20, P7088, DOI 10.1128/MCB.20.19.7088-7098.2000; Kastaniotis AJ, 2000, ADV EXP MED BIOL, V475, P185; Kwast KE, 1999, P NATL ACAD SCI USA, V96, P5446, DOI 10.1073/pnas.96.10.5446; Kwast KE, 1998, J EXP BIOL, V201, P1177; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; Lee HC, 2003, MOL CELL BIOL, V23, P5857, DOI 10.1128/MCB.23.16.5857-5866.2003; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTOON JR, 1979, BIOCH CLIN ASPECTS O, P421; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Mole DR, 2001, IUBMB LIFE, V52, P43; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; Poyton RO, 1999, RESP PHYSIOL, V115, P119, DOI 10.1016/S0034-5687(99)00028-6; Prabhakar NR, 2001, J APPL PHYSIOL, V90, P1986, DOI 10.1152/jappl.2001.90.5.1986; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; SINCLAIR PR, 2000, CURRENT PROTOCOLS TO, V1; SINCLAIR PR, 2002, CURRENT PROTOCOLS TO; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; VOLLAND C, 1984, EUR J BIOCHEM, V142, P551, DOI 10.1111/j.1432-1033.1984.tb08321.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Ward JPT, 2003, J PHYSIOL-LONDON, V548, P664, DOI 10.1113/jphysiol.2003.042168; Wenger RH, 2000, J EXP BIOL, V203, P1253; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718; Zhang L, 1999, CELL MOL LIFE SCI, V56, P415, DOI 10.1007/s000180050442; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZHANG L, 1994, GENETICS, V136, P813; Zhang L, 1998, MOL CELL BIOL, V18, P3819, DOI 10.1128/MCB.18.7.3819; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; Zitomer RS, 1997, KIDNEY INT, V51, P507, DOI 10.1038/ki.1997.71	66	69	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50771	50780		10.1074/jbc.M303677200	http://dx.doi.org/10.1074/jbc.M303677200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14512429	hybrid			2022-12-25	WOS:000187068200133
J	Kawai, Y; Furuhata, A; Toyokuni, S; Aratani, Y; Uchida, K				Kawai, Y; Furuhata, A; Toyokuni, S; Aratani, Y; Uchida, K			Formation of acrolein-derived 2 '-deoxyadenosine adduct in an iron-induced carcinogenesis model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PROTEIN-BOUND ACROLEIN; RENAL-CELL CARCINOMA; LIPID-PEROXIDATION; OXIDATIVE STRESS; FERRIC NITRILOTRIACETATE; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; ALPHA,BETA-UNSATURATED ALDEHYDES; CHEMICAL CARCINOGENESIS; ENDOGENOUS FORMATION	Acrolein is a representative carcinogenic aldehyde found ubiquitously in the environment and formed endogenously through oxidation reactions, such as lipid peroxidation and myeloperoxidase-catalyzed amino acid oxidation. It shows facile reactivity toward DNA to form an exocyclic DNA adduct. To verify the formation of acrolein-derived DNA adduct under oxidative stress in vivo, we raised a novel monoclonal antibody (mAb21) against the acrolein-modified DNA and found that the antibody most significantly recognized an acrolein-modified 2'-deoxyadenosine. On the basis of chemical and spectroscopic evidence, the major antigenic product of mAb21 was the 1, N-6-propano-2'-deoxyadenosine adduct. The exposure of rat liver epithelial RL34 cells to acrolein resulted in a significant accumulation of the acrolein-2'-deoxyadenosine adduct in the nuclei. Formation of this adduct under oxidative stress in vivo was immunohistochemically examined in rats exposed to ferric nitrilotriacetate, a carcinogenic iron chelate that specifically induces oxidative stress in the kidneys of rodents. It was observed that the acrolein-2'-deoxyadenosine adduct was formed in the nuclei of the proximal tubular cells, the target cells of this carcinogenesis model. The same cells were stained with a monoclonal antibody 5F6 that recognizes an acrolein-lysine adduct, by which cytosolic accumulation of acrolein-modified proteins appeared. Similar results were also obtained from myeloperoxidase knockout mice exposed to the iron complex, suggesting that the myeloperoxidase-catalyzed oxidation system might not be essential for the generation of acrolein in this experimental animal carcinogenesis model. The data obtained in this study suggest that the formation of a carcinogenic aldehyde through lipid peroxidation may be causally involved in the pathophysiological effects associated with oxidative stress.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Kyoto 606, Japan; Yokohama City Univ, Kihara Inst Biol Res, Yokohama, Kanagawa 2440813, Japan	Nagoya University; Kyoto University; Yokohama City University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.		Kawai, Yoshichika/G-3231-2011; Toyokuni, Shinya/C-1358-2010; Toyokuni, Shinya/ABE-7714-2021	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Uchida, Koji/0000-0003-3894-5299				ALARCON RA, 1976, CANCER TREAT REP, V60, P327; Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Aratani Y, 1999, INFECT IMMUN, V67, P1828; Aratani Y, 2000, J INFECT DIS, V182, P1276, DOI 10.1086/315843; AWAI M, 1979, AM J PATHOL, V95, P663; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; Calingasan NY, 1999, J NEUROCHEM, V72, P751, DOI 10.1046/j.1471-4159.1999.0720751.x; CHUNG FL, 1988, J ORG CHEM, V53, P14, DOI 10.1021/jo00236a004; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1984, CANCER RES, V44, P990; CLARK RA, 1981, J IMMUNOL, V126, P1295; COHEN SM, 1992, CANCER RES, V52, P3577; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; EBINA Y, 1986, J NATL CANCER I, V76, P107; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fukuda A, 1996, ARCH BIOCHEM BIOPHYS, V329, P39, DOI 10.1006/abbi.1996.0189; Furuhata A, 2002, J BIOL CHEM, V277, P27919, DOI 10.1074/jbc.M202794200; GALLIANI G, 1983, TETRAHEDRON LETT, V24, P4491, DOI 10.1016/S0040-4039(00)85935-3; Girotti AW, 1998, J LIPID RES, V39, P1529; Hashimoto M, 2003, J BIOL CHEM, V278, P5044, DOI 10.1074/jbc.M210129200; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; IZARD C, 1978, Mutation Research, V47, P115, DOI 10.1016/0165-1110(78)90016-7; Kawai Y, 2002, CARCINOGENESIS, V23, P485, DOI 10.1093/carcin/23.3.485; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; LI JL, 1987, CANCER RES, V47, P1867; Li L, 1997, TOXICOL APPL PHARM, V145, P331, DOI 10.1006/taap.1997.8189; London SJ, 1997, CANCER RES, V57, P5001; MCDIARMID MA, 1991, MUTAT RES, V248, P93, DOI 10.1016/0027-5107(91)90091-2; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Okada S., 1982, JPN ARCH INTERN MED, V29, P485; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SMITH RA, 1990, CANCER RES, V50, P3005; SUEOKA NOBORU, 1962, JOUR MOLECULAR BIOL, V4, P161; TERAO J, 1990, MEMBRANE LIPID OXIDA, V1, P219; TOYOKUNI S, 1990, CANCER RES, V50, P5574; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200	50	56	59	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50346	50354		10.1074/jbc.M309057200	http://dx.doi.org/10.1074/jbc.M309057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522963	hybrid			2022-12-25	WOS:000187068200084
J	Kirshner, J; Schumann, D; Shively, JE				Kirshner, J; Schumann, D; Shively, JE			CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN CD66A; HUMAN PROSTATE-CANCER; C-CAM CELL-CAM-105; CALPACTIN-I; IMMUNOGLOBULIN SUPERFAMILY; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODIES; EPITHELIAL-CELLS; DOWN-REGULATION	The epithelial cell adhesion molecule CEACAM1 ( carcinoembryonic antigen cell adhesion molecule-1) is down-regulated in colon, prostate, breast, and liver cancer. Here we show that CEACAM1-4S, a splice form with four Ig-like ectodomains and a short cytoplasmic domain ( 14 amino acids), directly associates with annexin II, a lipid raft-associated molecule, which is also downregulated in many cancers. Annexin II was identified using a glutathione S-transferase pull-down assay in which the cytoplasmic domain of CEACAM-4S was fused to glutathione S-transferase, the fusion protein was incubated with cell lysates, and isolated proteins were sequenced by mass spectrometry. The interaction was confirmed first by reciprocal immunoprecipitations using anti-CEACAM1 and anti-annexin II antibodies and second by confocal laser microscopy showing co-localization of CEACAM1 with annexin II in mammary epithelial cells grown in Matrigel. In addition, CEACAM1 co-localized with p11, a component of the tetrameric AIIt complex at the plasma membrane, and with annexin II in secretory vesicles. Immobilized, oriented peptides from the cytoplasmic domain of CEACAM1-4S were shown to directly associate with bovine AIIt, which is 98% homologous to human AIIt, with average K-D values of about 30 nM using surface plasmon resonance, demonstrating direct binding of functionally relevant AIIt to the cytoplasmic domain of CEACAM1-4S.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Grad Sch, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA.	jshively@coh.org			NCI NIH HHS [CA84202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Babiychuk VS, 2000, ACTA BIOCHIM POL, V47, P579, DOI 10.18388/abp.2000_3980; Beauchemin N, 1999, EXP CELL RES, V252, P243; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BLIKSTAD I, 1992, FEBS LETT, V302, P26, DOI 10.1016/0014-5793(92)80276-M; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BRUMMER J, 1995, ONCOGENE, V11, P1649; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chetcuti A, 2001, CANCER RES, V61, P6331; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; COOPER JA, 1983, J BIOL CHEM, V258, P1108; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; Donda A, 2000, EUR J IMMUNOL, V30, P2593, DOI 10.1002/1521-4141(200009)30:9<2593::AID-IMMU2593>3.0.CO;2-0; Dreier R, 1998, HISTOCHEM CELL BIOL, V110, P137, DOI 10.1007/s004180050275; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; DRZENIEK Z, 1991, CANCER LETT, V56, P173, DOI 10.1016/0304-3835(91)90093-W; DUBOIS T, 1995, BIOCHEM J, V310, P243, DOI 10.1042/bj3100243; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1990, PROG CLIN BIOL RES, V349, P135; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENBERG ME, 1983, J BIOL CHEM, V258, P8497; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; HANDEL SE, 1991, CELL TISSUE RES, V264, P549, DOI 10.1007/BF00319044; HARDER T, 1993, J CELL SCI, V104, P1109; HINODA Y, 1990, INT J CANCER, V45, P875, DOI 10.1002/ijc.2910450516; HOM YK, 1988, J CELL PHYSIOL, V135, P435, DOI 10.1002/jcp.1041350310; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; ISACKE CM, 1986, MOL CELL BIOL, V6, P2745, DOI 10.1128/MCB.6.7.2745; JONES PG, 1992, J BIOL CHEM, V267, P13993; Kammerer R, 2001, J IMMUNOL, V166, P6537, DOI 10.4049/jimmunol.166.11.6537; Kammerer R, 1998, EUR J IMMUNOL, V28, P3664, DOI 10.1002/(SICI)1521-4141(199811)28:11<3664::AID-IMMU3664>3.0.CO;2-D; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KHAN WN, 1993, INT IMMUNOL, V5, P265, DOI 10.1093/intimm/5.3.265; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; Kuo CB, 2002, CELL TISSUE RES, V309, P429, DOI 10.1007/s00441-002-0598-8; Liu JW, 2003, ONCOGENE, V22, P1475, DOI 10.1038/sj.onc.1206196; Liu SH, 2002, AM J PATHOL, V160, P1831, DOI 10.1016/S0002-9440(10)61129-7; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Markel G, 2002, J CLIN INVEST, V110, P943, DOI 10.1172/JCI200215643; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Nakajima A, 2002, J IMMUNOL, V168, P1028, DOI 10.4049/jimmunol.168.3.1028; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; SCHWARTZALBIEZ R, 1993, DIFFERENTIATION, V52, P229, DOI 10.1111/j.1432-0436.1993.tb00635.x; SENDA T, 1994, CELL TISSUE RES, V277, P51; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SMITH PD, 1994, TRENDS GENET, V10, P241, DOI 10.1016/0168-9525(94)90171-6; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; TURBIDE C, 1991, J BIOL CHEM, V266, P309; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Zobiack N, 2002, J CELL SCI, V115, P91; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	88	41	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50338	50345		10.1074/jbc.M309115200	http://dx.doi.org/10.1074/jbc.M309115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522961	hybrid			2022-12-25	WOS:000187068200083
J	Montero, M; Lobaton, CD; Gutierrez-Fernandez, S; Moreno, A; Alvarez, J				Montero, M; Lobaton, CD; Gutierrez-Fernandez, S; Moreno, A; Alvarez, J			Modulation of histamine-induced Ca2+ release by protein kinase C - Effects on cytosolic and mitochondrial [Ca2+] peaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; AMP-DEPENDENT PHOSPHORYLATION; RECONSTITUTED LIPID VESICLES; PANCREATIC ACINAR-CELLS; HELA-CELLS; ENDOPLASMIC-RETICULUM; PHOSPHOINOSITIDE HYDROLYSIS; TRISPHOSPHATE RECEPTOR; CA-2+ RELEASE; H1 RECEPTORS	In HeLa cells, histamine induces production of inositol 1,4,5-trisphosphate (InsP(3)) and release of Ca2+ from the endoplasmic reticulum (ER). Ca2+ release is typically biphasic, with a fast and brief initial phase, followed by a much slower and prolonged one. In the presence of inhibitors of protein kinase C (PKC), including staurosporine and the specific inhibitors GF109203X and Ro-31-8220, the fast phase continued until the ER became fully empty. On the contrary, treatment with phorbol 12,13-dibutyrate inhibited Ca2+ release. Staurosporine had no effect on InsP(3)-induced Ca2+ release in permeabilized cells and did not modify either histamine-induced InsP(3) production. These data suggest that histamine induces Ca2+ release and with a short lag activates PKC to down-regulate it. Consistently, Ca2+ oscillations induced by histamine were increased in amplitude and decreased in frequency in the presence of PKC inhibitors. We show also that mitochondrial [Ca2+] was much more sensitive to changes in ER-Ca2+ release induced by PKC modulation than cytosolic [Ca2+]. PKC inhibitors increased the histamine-induced mitochondrial [Ca2+] peak by 4-fold but increased the cytosolic [Ca2+] peak only by 20%. On the contrary, PKC activation inhibited the mitochondrial [Ca2+] peak by 90% and the cytosolic one by only 50%. Similarly, the combination of PKC inhibitors with the mitochondrial Ca2+ uniporter activator SB202190 led to dramatic increases in mitochondrial [Ca2+] peaks, with little effect on cytosolic ones. This suggests that activation of ER-Ca2+ release by PKC inhibitors could be involved in apoptosis induced by staurosporine. In addition, these mechanisms allow flexible and independent regulation of cytosolic and mitochondrial [Ca2+] during cell stimulation.	Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, Inst Mol Biol & Genet, E-47005 Valladolid, Spain; Consejo Super Invest Cient, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)	Alvarez, J (corresponding author), Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, Inst Mol Biol & Genet, Ramon & Cajal 7, E-47005 Valladolid, Spain.		Alvarez, Javier/K-8210-2014; Lobaton, Carmen D/A-9134-2015; Montero, Mayte/K-8212-2014	Alvarez, Javier/0000-0003-0636-5521; Lobaton, Carmen D/0000-0001-9574-3082; Montero, Mayte/0000-0001-7702-6653; Moreno, Alfredo/0000-0002-7444-5198				Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; ARIASMONTANO JA, 1994, BRIT J PHARMACOL, V111, P598, DOI 10.1111/j.1476-5381.1994.tb14779.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HANJNOCZKY G, 2003, BIOCHEM BIOPH RES CO, V304, P445; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; MATTER N, 1993, J BIOL CHEM, V268, P732; Montero M, 2002, FASEB J, V16, P1955, DOI 10.1096/fj.02-0553fje; Montero M, 2002, BIOCHEM J, V365, P451, DOI 10.1042/BJ20011722; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; NUCIFORA FC, 1995, MOL BRAIN RES, V32, P291, DOI 10.1016/0169-328X(95)00089-B; RAYMOND JR, 1991, J BIOL CHEM, V266, P372; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; SAUVE R, 1991, CELL CALCIUM, V12, P165, DOI 10.1016/0143-4160(91)90018-A; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; WILLEMS PHGM, 1989, J BIOL CHEM, V264, P9762; Zhu DM, 1996, BIOCHEMISTRY-US, V35, P7214, DOI 10.1021/bi952471h	39	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49972	49979		10.1074/jbc.M308378200	http://dx.doi.org/10.1074/jbc.M308378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523015	hybrid			2022-12-25	WOS:000187068200040
J	Tliba, O; Tliba, S; Da Huang, C; Hoffman, RK; DeLong, P; Panettieri, RA; Amrani, Y				Tliba, O; Tliba, S; Da Huang, C; Hoffman, RK; DeLong, P; Panettieri, RA; Amrani, Y			Tumor necrosis factor alpha modulates airway smooth muscle function via the autocrine action of interferon beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ADHESION MOLECULE-1 EXPRESSION; TNF-ALPHA; ENDOTHELIAL-CELLS; ICAM-1 EXPRESSION; UP-REGULATION; RECEPTOR; ACTIVATION; PATHWAY; INFLAMMATION	Current evidence suggests that tumor necrosis factor alpha ( TNF alpha) and the family of interferons ( IFNs) synergistically regulate many cellular responses that are believed to be critical in chronic inflammatory diseases, although the underlying mechanisms of such interaction are complex, cell- specific, and not completely understood. In this study, TNF alpha in a time- dependent manner activated both janus tyrosine kinase 1 and Tyk2 tyrosine kinase and increased the nuclear translocation of interferon- regulatory factor- 1, STAT1, and STAT2 in human airway smooth muscle cells. In cells transfected with a luciferase reporter, TNF alpha stimulated gamma- activated site- dependent gene transcription in a time- and concentration- dependent manner. Using neutralizing antibodies to IFNbeta and TNFalpha receptor 1, we show that TNF alpha- induced secretion of IFN beta mediated gamma- activated site- dependent gene expression via activation of TNF alpha receptor 1. In addition, neutralizing antibody to IFN beta also completely abrogated the activation of interferon stimulation response element-dependent gene transcription induced by TNFalpha. Secreted IFN beta acted as a negative regulator of TNF alpha-induced interleukin- 6 expression, while IFN beta augmented TNF alpha- induced RANTES ( regulated on activation normal T cell expressed and secreted) secretion but had little effect on TNF alpha- induced intercellular adhesion molecule- 1 expression. Furthermore TNFalpha, a modest airway smooth muscle mitogen, markedly induced DNA synthesis when cells were treated with neutralizing anti-IFNbeta. Together these data show that TNFalpha, via the autocrine action of IFN beta, differentially regulates the expression of proinflammatory genes and DNA synthesis.	Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Amrani, Y (corresponding author), Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Dept Med, 421 Curie Blvd,848 BRB 2-3, Philadelphia, PA 19104 USA.		Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Amrani, Yassine/Q-6323-2019	Amrani, Yassine/0000-0002-7042-6926	NHLBI NIH HHS [1P50-HL67663, R01 HL055301, 2R01-HL55301, P50 HL067663] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055301, P50HL067663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Amrani Y, 2003, AM J PHYSIOL-LUNG C, V284, pL1063, DOI 10.1152/ajplung.00363.2002; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Amrani Y, 1999, J IMMUNOL, V163, P2128; Amrani Y, 2000, MOL PHARMACOL, V58, P237, DOI 10.1124/mol.58.1.237; Amrani Y, 2002, CURR OPIN ALLERGY CL, V2, P39, DOI 10.1097/00130832-200202000-00007; Broide DH, 2001, AM J RESP CELL MOL, V24, P304, DOI 10.1165/ajrcmb.24.3.4071; Chehadeh T, 2000, J INFECT DIS, V181, P1929, DOI 10.1086/315516; Cremer I, 2002, FEBS LETT, V511, P41, DOI 10.1016/S0014-5793(01)03276-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Defazio G, 2000, BRAIN RES, V881, P227, DOI 10.1016/S0006-8993(00)02814-6; DhibJalbut S, 1996, J NEUROIMMUNOL, V71, P215, DOI 10.1016/S0165-5728(96)00156-7; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Guo DQ, 1998, J IMMUNOL, V160, P2742; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; HORIKOSHI T, 1995, FEBS LETT, V363, P141, DOI 10.1016/0014-5793(95)00299-O; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hunter I, 2003, MOL PHARMACOL, V63, P714, DOI 10.1124/mol.63.3.714; Kanehiro A, 2002, J IMMUNOL, V169, P4190, DOI 10.4049/jimmunol.169.8.4190; Lahiri T, 2001, AM J PHYSIOL-LUNG C, V280, pL1225, DOI 10.1152/ajplung.2001.280.6.L1225; Lazaar Aili L., 2001, Current Opinion in Pharmacology, V1, P259, DOI 10.1016/S1471-4892(01)00046-7; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LUKACS NW, 1995, J IMMUNOL, V154, P5411; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mukhopadhyay A, 2002, J CELL BIOCHEM, V84, P803, DOI 10.1002/jcb.10097; PALMER H, 1992, LAB INVEST, V66, P715; Panettieri RA, 1998, AM J RESP CRIT CARE, V158, pS133, DOI 10.1164/ajrccm.158.supplement_2.13tac900; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Peschon JJ, 1998, J IMMUNOL, V160, P943; Renzetti LM, 1996, J PHARMACOL EXP THER, V278, P847; Rodel J, 2001, FEMS IMMUNOL MED MIC, V32, P9; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; STEWART AG, 1995, AM J RESP CELL MOL, V12, P110, DOI 10.1165/ajrcmb.12.1.7529028; Takayama A, 2000, INT J MOL MED, V6, P621; Talon J, 2000, J VIROL, V74, P7989, DOI 10.1128/JVI.74.17.7989-7996.2000; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; Thabut G, 2002, J BIOL CHEM, V277, P22814, DOI 10.1074/jbc.M200315200; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Watson ML, 1998, CYTOKINE, V10, P346, DOI 10.1006/cyto.1997.0350	49	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50615	50623		10.1074/jbc.M303680200	http://dx.doi.org/10.1074/jbc.M303680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14519761	hybrid			2022-12-25	WOS:000187068200116
J	Tsao, TS; Tomas, E; Murrey, HE; Hug, C; Lee, DH; Ruderman, NB; Heuser, JE; Lodish, HF				Tsao, TS; Tomas, E; Murrey, HE; Hug, C; Lee, DH; Ruderman, NB; Heuser, JE; Lodish, HF			Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity - Different oligomers activate different signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COMPLEMENT-RELATED PROTEIN; TUMOR-NECROSIS-FACTOR; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; ADIPONECTIN; GLUCOSE; MUSCLE; ACRP30; COLLAGEN	Acrp30/adiponectin is an adipocyte-derived serum protein with important roles in regulation of lipid and glucose metabolism, but which of its isoforms are biologically active remains controversial. We addressed this issue by first characterizing the structure of each individual Acrp30 oligomer and the determinants responsible for multimer formation. Freeze etch electron microscopy showed the trimer to exhibit a ball-and-stick-like structure containing a large globular sphere, an extended collagen stalk, and a smaller sphere on the opposite end of the stalk. The hexamer consists of two adjacent trimeric globular domains and a single stalk composed of collagen domains from two trimers. Although not necessary for trimer formation or stability, two of the three monomers in an Acrp30 trimer are covalently linked by a disulfide bond between cysteine residues at position 22. In contrast, assembly of hexameric and higher molecular weight (HMW) forms of Acrp30 depends upon formation of Cys(22)-mediated disulfide bonds because their reduction with dithiothreitol or substitution of Cys(22) with alanine led exclusively to trimers. HMW and hexamer isoforms of Acrp30 activated NF-kappaB in C2C12 cells, but trimers, either natural, formed by reduction of Acrp30 hexamer, or formed by the C22A mutant, did not. In contrast, incubation of isolated rat extensor digitorum longus with naturally formed Acrp30 trimers or trimeric C22A Acrp30 led to increased phosphorylation of AMP-activated protein kinase-alpha at Thr(172) and its activation. Hexameric and HMW Acrp30 could not activate AMP-activated protein kinase. Thus, trimeric and HMW/hexameric Acrp30 activate different signal transduction pathways, and Acrp30 represents a novel example of the control of ligand signaling via changes in its oligomerization state.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Boston Univ, Sch Med, Diabet Unit, Sect Endocrinol,Boston Med Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA; Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA; Tufts Univ, Dept Chem, Medford, MA 02155 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Boston Medical Center; Boston University; Boston University; Boston University; Harvard University; Boston Children's Hospital; Tufts University; Washington University (WUSTL); Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Heuser, John/H-5940-2012	Tsao, Tsu-Shuen/0000-0002-1041-9687; Ruderman, Neil/0000-0002-6589-6587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047618] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK47618] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Doliana R, 2000, FEBS LETT, V484, P164, DOI 10.1016/S0014-5793(00)02140-2; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Heuser J E, 1989, Prog Clin Biol Res, V295, P71; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KADLER KE, 1987, J BIOL CHEM, V262, P15696; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2; Luo GJ, 2003, AM J PHYSIOL-REG I, V284, pR1249, DOI 10.1152/ajpregu.00490.2002; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; PAJVANI UB, 2002, J BIOL CHEM, V20, P20; Peake PW, 2003, INT J OBESITY, V27, P657, DOI 10.1038/sj.ijo.0802289; PIEZ KA, 1977, J MOL BIOL, V110, P701, DOI 10.1016/S0022-2836(77)80086-7; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; SAHA AK, 1995, AM J PHYSIOL-ENDOC M, V269, pE283, DOI 10.1152/ajpendo.1995.269.2.E283; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yoda M, 2001, INT J OBESITY, V25, P75, DOI 10.1038/sj.ijo.0801482	34	385	411	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50810	50817		10.1074/jbc.M309469200	http://dx.doi.org/10.1074/jbc.M309469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522956	hybrid			2022-12-25	WOS:000187068200137
J	Fraser, DA; Harris, CL; Williams, AS; Mizuno, M; Gallagher, S; Smith, RAG; Morgan, BP				Fraser, DA; Harris, CL; Williams, AS; Mizuno, M; Gallagher, S; Smith, RAG; Morgan, BP			Generation of a recombinant, membrane-targeted form of the complement regulator CD59 - Activity in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; RAT COMPLEMENT; EXPRESSION; PROTEINS; INFLAMMATION; PURIFICATION; ARTHRITIS; EFFICACY; ANTIBODY	Inappropriate activation of complement contributes to pathology in diverse inflammatory diseases. Soluble recombinant forms of the natural cell membrane regulators of complement are effective in animal models and some human diseases. However, their use is limited for reasons related to cost, short half lives, and propensity to cause unwanted systemic effects. Some of these limitations may be overcome by use of bacterial expression systems, specific targeting moieties, and judicious choice of regulator. Here we describe the application of these strategies to the generation of a membrane-targeted form of CD59. A recombinant soluble form of rat CD59, comprising the first 71 residues of the mature protein and missing the membrane-anchoring signal, was expressed in bacteria, purified, and refolded in a fully active form. The protein was coupled through its carboxyl terminus to a short, synthetic address tag that confers membrane binding activity. Attachment of the membrane address tag markedly increased complement-inhibitory activity assessed in vitro in hemolysis assays. Intra-articular administration of the tagged agent markedly suppressed disease in a model of rheumatoid arthritis in Lewis rats. This novel type of agent, termed sCD59-APT542, offers for the first time the prospect of efficient and specific inhibition of membrane attack complex activity in vivo.	Univ Wales Coll Med, Dept Med Biochem, Complement Biol Grp, Cardiff CF4 4XN, S Glam, Wales; Univ Wales Coll Med, Dept Rheumatol, Cardiff CF4 4XN, S Glam, Wales; Adprotech Ltd, Little Chesterford, Essex, England	Cardiff University; Cardiff University	Morgan, BP (corresponding author), UWCM, Dept Med Biochem & Immunol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Mizuno, Masashi/I-7347-2014	Morgan, Paul/0000-0003-4075-7676				ABRAHA A, 1988, BIOCHEM J, V251, P285, DOI 10.1042/bj2510285; DAVIES A, 1993, BIOCHEM J, V295, P889, DOI 10.1042/bj2950889; Dodd I, 1995, PROTEIN EXPRES PURIF, V6, P727, DOI 10.1006/prep.1995.0003; Fitch JCK, 1999, CIRCULATION, V100, P2499, DOI 10.1161/01.CIR.100.25.2499; Fraser DA, 2002, PROTEIN SCI, V11, P2512, DOI 10.1110/ps.0212402; Goodfellow RM, 1997, CLIN EXP IMMUNOL, V110, P45; Harris CL, 2002, BIOCHEM SOC T, V30, P1019, DOI 10.1042/bst0301019; Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x; HUGHES TR, 1992, BIOCHEM J, V284, P169, DOI 10.1042/bj2840169; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; Linton SM, 2000, ARTHRITIS RHEUM-US, V43, P2590, DOI 10.1002/1529-0131(200011)43:11<2590::AID-ANR29>3.0.CO;2-R; MERI S, 1990, IMMUNOLOGY, V71, P1; MOORE FD, 1994, ADV IMMUNOL, V56, P267, DOI 10.1016/S0065-2776(08)60454-X; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; Morgan BP, 1998, BIOCHEM SOC T, V26, P49, DOI 10.1042/bst0260049; Morgan BP., 1999, COMPLEMENT REGULATOR; Quigg RJ, 2000, IMMUNOLOGY, V99, P46, DOI 10.1046/j.1365-2567.2000.00945.x; Rioux P, 2001, Curr Opin Investig Drugs, V2, P364; Rushmere NK, 1997, IMMUNOLOGY, V90, P640, DOI 10.1046/j.1365-2567.1997.00200.x; Smith GP, 2001, MOL IMMUNOL, V38, P249, DOI 10.1016/S0161-5890(01)00047-5; Sugita Y, 1995, IMMUNOTECHNOLOGY, V1, P157, DOI 10.1016/1380-2933(95)00018-6; SUGITA Y, 1993, J BIOCHEM-TOKYO, V114, P473, DOI 10.1093/oxfordjournals.jbchem.a124202; SUGITA Y, 1994, IMMUNOLOGY, V82, P34; Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Zhang HF, 1999, J CLIN INVEST, V103, P55, DOI 10.1172/JCI4607	30	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48921	48927		10.1074/jbc.M302598200	http://dx.doi.org/10.1074/jbc.M302598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14519760	hybrid			2022-12-25	WOS:000186829000051
J	Hummer, A; Delzeith, O; Gomez, SR; Moreno, RL; Mark, MD; Herlitze, S				Hummer, A; Delzeith, O; Gomez, SR; Moreno, RL; Mark, MD; Herlitze, S			Competitive and synergistic interactions of G protein beta(2) and Ca2+ channel beta(1b) Subunits with Ca(V)2.1 channels, revealed by mammalian two-hybrid and fluorescence resonance energy transfer measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; BULLFROG SYMPATHETIC NEURONS; I-II LOOP; N-TYPE; GAMMA-SUBUNITS; ALPHA(1) SUBUNIT; DOMAIN-I; INTRACELLULAR LOOP; COUPLED RECEPTORS; DIRECT BINDING	Presynaptic Ca2+ channels are inhibited by metabotropic receptors. A possible mechanism for this inhibition is that G protein betagamma subunits modulate the binding of the Ca2+ channel beta subunit on the Ca2+ channel complex and induce a conformational state from which channel opening is more reluctant. To test this hypothesis, we analyzed the binding of Ca2+ channel beta and G protein beta subunits on the two separate binding sites, i.e. the loopI - II and the C terminus, and on the full-length P/Q-type alpha(1)2.1 subunit by using a modified mammalian two-hybrid system and fluorescence resonance energy transfer ( FRET) measurements. Analysis of the interactions on the isolated bindings sites revealed that the Ca2+ channel beta(1b) subunit induces a strong fluorescent signal when interacting with the loopI - II but not with the C terminus. In contrast, the G protein beta subunit induces FRET signals on both the C terminus and loopI II. Analysis of the interactions on the full-length channel indicates that Ca2+ channel beta(1b) and G protein beta subunits bind to the alpha(1) subunit at the same time. Coexpression of the G protein increases the FRET signal between alpha(1)/beta(1b) FRET pairs but not for alpha(1)/beta(1b) FRET pairs where the C terminus was deleted from the alpha(1) subunit. The results suggest that the G protein alters the orientation and/or association between the Ca2+ channel beta and alpha(1)2.1 subunits, which involves the C terminus of the alpha(1) subunit and may corresponds to a new conformational state of the channel.	Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University	Herlitze, S (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosci, Rm E604,10900 Euclid Ave, Cleveland, OH 44106 USA.		Mark, Melanie/ABF-9102-2020	Mark, Melanie/0000-0002-2788-6003	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042623] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS42623-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; BOLAND LM, 1993, J NEUROSCI, V13, P516; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Canti C, 2001, BIOPHYS J, V81, P1439, DOI 10.1016/S0006-3495(01)75799-2; Canti C, 1999, J NEUROSCI, V19, P6855, DOI 10.1523/JNEUROSCI.19-16-06855.1999; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Colecraft HM, 2001, J NEUROSCI, V21, P1137; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1999, ANN NY ACAD SCI, V868, P160, DOI 10.1111/j.1749-6632.1999.tb11285.x; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Herlitze S, 2001, P NATL ACAD SCI USA, V98, P4699, DOI 10.1073/pnas.051628998; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Ikeda SR, 1999, ADV SEC MESS PHOSPH, V33, P131; Jarvis SE, 2001, TRENDS PHARMACOL SCI, V22, P519, DOI 10.1016/S0165-6147(00)01800-9; Jones SW, 2002, J PHYSIOL-LONDON, V545, P334, DOI 10.1113/jphysiol.2002.033001; Jones SW, 1997, J MEMBRANE BIOL, V155, P1, DOI 10.1007/s002329900153; Lee HK, 2000, J NEUROSCI, V20, P3115, DOI 10.1523/JNEUROSCI.20-09-03115.2000; Mark MD, 2000, J PHYSIOL-LONDON, V528, P65, DOI 10.1111/j.1469-7793.2000.00065.x; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Page KM, 1997, J NEUROSCI, V17, P1330; Patil PG, 1996, BIOPHYS J, V71, P2509, DOI 10.1016/S0006-3495(96)79444-4; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; Ruiz-Velasco V, 2001, J PHYSIOL-LONDON, V537, P679; Shioda T, 2000, P NATL ACAD SCI USA, V97, P5220, DOI 10.1073/pnas.97.10.5220; Simen AA, 2000, MOL PHARMACOL, V57, P1064; Stephens GJ, 1998, J PHYSIOL-LONDON, V509, P163, DOI 10.1111/j.1469-7793.1998.163bo.x; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wittemann S, 2000, J BIOL CHEM, V275, P37807, DOI 10.1074/jbc.M004653200; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	54	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49386	49400		10.1074/jbc.M306645200	http://dx.doi.org/10.1074/jbc.M306645200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507926	hybrid			2022-12-25	WOS:000186829000107
J	Ziegler, LM; Khaperskyy, DA; Ammerman, ML; Ponticelli, AS				Ziegler, LM; Khaperskyy, DA; Ammerman, ML; Ponticelli, AS			Yeast RNA polymerase II lacking the Rpb9 subunit is impaired for interaction with transcription factor IIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							START SITE SELECTION; N-TERMINAL REGION; TFIIB-DNA COMPLEXES; SACCHAROMYCES-CEREVISIAE; TATA BOX; INITIATION; BINDING; MUTATIONS; PROTEINS; PURIFICATION	Previous studies have shown that transcription factors IIB (TFIIB), IIF (TFIIF), and RNA polymerase II (RNAPII) play important roles in determining the position of mRNA 5'-ends in the yeast Saccharomyces cerevisiae. Yeast strains containing a deletion of the small, nonessential Rpb9 subunit of RNAPII exhibit an upstream shift in the positions of mRNA 5'-ends, whereas mutation of the large subunit of yeast TFIIF (Tfg1) can suppress downstream shifts that are conferred by mutations in TFIIB. In this study, we report an approach for the production of functional recombinant yeast holo-TFIIF (Tfg1- Tfg2 complex) and use of the recombinant protein in both reconstituted transcription assays and gel mobility shifts in order to investigate the biochemical alterations associated with the DeltaRpb9 polymerase. The results demonstrated that upstream shifts in the positions of mRNA 5'-ends could be conferred by the DeltaRpb9 RNAPII in transcription reactions reconstituted with highly purified yeast general transcription factors and, importantly, that these shifts are associated with an impaired interaction between the DeltaRpb9 polymerase and TFIIF. Potential mechanisms by which an altered interaction between the DeltaRpb9 RNAPII and TFIIF confers an upstream shift in the positions of mRNA 5'-ends are discussed.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ponticelli, AS (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA.			Ammerman, Michelle/0000-0002-4272-5822; Khaperskyy, Denys/0000-0003-0583-7179	NIGMS NIH HHS [GM51124] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051124, R01GM051124] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bangur CS, 1999, J BIOL CHEM, V274, P23203, DOI 10.1074/jbc.274.33.23203; Bangur CS, 1997, MOL CELL BIOL, V17, P6784, DOI 10.1128/MCB.17.12.6784; BERROTERAN RW, 1994, MOL CELL BIOL, V14, P226, DOI 10.1128/MCB.14.1.226; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Faitar SL, 2001, MOL CELL BIOL, V21, P4427, DOI 10.1128/MCB.21.14.4427-4440.2001; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GUARENTE L, 1987, ANNU REV GENET, V21, P425, DOI 10.1146/annurev.genet.21.1.425; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; Lee M, 1997, MOL CELL BIOL, V17, P1336, DOI 10.1128/MCB.17.3.1336; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PINTO I, 1994, J BIOL CHEM, V269, P30569; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SMALE ST, 2003, ANNU REV BIOCHEM, V19, P19; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TAN SY, 1994, J BIOL CHEM, V269, P25684; Van Mullem V, 2002, J BIOL CHEM, V277, P10220, DOI 10.1074/jbc.M107207200; WELCH MD, 1993, GENETICS, V135, P265	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48950	48956		10.1074/jbc.M309656200	http://dx.doi.org/10.1074/jbc.M309656200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522989	hybrid			2022-12-25	WOS:000186829000055
J	Fusaro, G; Dasgupta, P; Rastogi, S; Joshi, B; Chellappan, S				Fusaro, G; Dasgupta, P; Rastogi, S; Joshi, B; Chellappan, S			Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; SACCHAROMYCES-CEREVISIAE; REPRESSES TRANSCRIPTION; HISTONE DEACETYLASE; FAMILY PROTEINS; RB; E2F; MITOCHONDRIA; ACTIVATION	Prohibitin, a potential tumor suppressor protein, has been shown to inhibit cell proliferation and repress E2F transcriptional activity. Though prohibitin has potent transcriptional functions in the nucleus, a mitochondrial role for prohibitin has also been proposed. Here we show that prohibitin is predominantly nuclear in two breast cancer cell lines where it co-localizes with E2F1 and p53. Upon apoptotic stimulation by camptothecin, prohibitin is exported to perinuclear regions where it localizes to mitochondria. The data presented here also show that prohibitin is capable of physically interacting with p53 in vivo and in vitro. Prohibitin was found to enhance p53-mediated transcriptional activity and cotransfection of an antisense prohibitin construct reduces p53-mediated transcriptional activation. Prohibitin appears to induce p53-mediated transcription by enhancing its recruitment to promoters, as detected by chromatin immunoprecipitation assays. These results suggest that prohibitin is capable of modulating Rb/E2F as well as p53 regulatory pathways.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	State University System of Florida; University of South Florida; Columbia University	Chellappan, S (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.		Rastogi, Shipra/L-1209-2015; Rastogi, Shipra/F-5109-2012	Rastogi, Shipra/0000-0003-3296-4405; 	NCI NIH HHS [CA77301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HSEIH JK, 1997, GENE DEV, V11, P1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JUPE ER, 1995, EXP CELL RES, V218, P577, DOI 10.1006/excr.1995.1194; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Liu L, 1999, MOL CELL BIOL, V19, P1202; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	38	267	294	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47853	47861		10.1074/jbc.M305171200	http://dx.doi.org/10.1074/jbc.M305171200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500729	hybrid			2022-12-25	WOS:000186731400062
J	Moissoglu, K; Gelman, IH				Moissoglu, K; Gelman, IH			v-Src rescues actin-based cytoskeletal architecture and cell motility and induces enhanced anchorage independence during oncogenic transformation of focal adhesion kinase-null fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; FAMILY KINASES; PROTEIN-KINASE; MORPHOLOGICAL TRANSFORMATION; EXTRACELLULAR-MATRIX; SUBSTRATE P130(CAS); STAT3 ACTIVATION; MAMMALIAN-CELLS; GENE-TRANSFER	The ability of the focal adhesion kinase (FAK) to integrate signals from extracellular matrix and growth factor receptors requires the integrity of Tyr(397), a major autophosphorylation site that mediates the Src homology 2-dependent binding of Src family kinases. However, the precise roles played by FAK in specific Src-induced pathways, especially as they relate to oncogenic transformation, remain unclear. Here, we investigate the role of FAK in v-Src-induced oncogenic transformation by transducing temperature-sensitive v-Src (ts72v-Src) into p53-null FAK +/+ or FAK -/- mouse embryo fibroblasts (MEF). At the permissive temperature ( PT), ts72v-Src induced abundant tyrosine phosphorylation, morphological transformation and cytoskeletal rearrangement in FAK -/- MEF, including the restoration of cell polarity, typical focal adhesion complexes, and longitudinal F-actin stress fibers. v-Src rescued the haptotactic, linear directional, and invasive motility defects of FAK -/- cells to levels found in FAK +/+ or FAK +/+ [ ts72v- Src] cells, and, in the case of monolayer wound healing motility, there was an enhancement. Src activation failed to increase the high basal tyrosine phosphorylation of the Crk-associated substrate, CAS, found in FAK -/- MEF, indicating that CAS phosphorylation alone is insufficient to induce motility in the absence of FAK- or v-Src-induced cytoskeletal remodeling. Compared with FAK +/+ [ts72v-Src] controls, FAK -/- [ts72vSrc] clones exhibited 7 - 10-fold higher anchorage-independent proliferation that could not be attributed to variations in either v-Src protein level or stability. Re-expression of FAK diminished the colony-forming activities of FAK +/+ [ts72v-Src] without altering ts72v-Src expression levels, suggesting that FAK attenuates Src-induced anchorage independence. Our data also indicate that the enhanced Pyk2 level found in FAK -/- MEF plays no role in v-Src-induced anchorage independence. Overall, our data indicate that FAK, although dispensable, attenuates v-Src-induced oncogenic transformation by modulating distinct signaling and cytoskeletal pathways.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Gelman, IH (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.			Moissoglu, Konstadinos/0000-0001-7211-4320	NATIONAL CANCER INSTITUTE [R29CA065787, R55CA094108, R01CA094108] Funding Source: NIH RePORTER; NCI NIH HHS [CA94108, CA65787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Ayaki M, 2001, CLIN CANCER RES, V7, P3106; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Du QS, 2001, J CELL SCI, V114, P2977; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GELMAN IH, 1993, ONCOGENE, V8, P2995; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grignani F, 1998, CANCER RES, V58, P14; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2001, CANCER RES, V61, P7079; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; HUANG QL, 1995, J CELL SCI, V108, P839; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Imai K, 1999, CLIN IMMUNOL, V92, P128, DOI 10.1006/clim.1999.4746; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Ren XD, 2000, J CELL SCI, V113, P3673; Rodina A, 1999, FEBS LETT, V455, P145, DOI 10.1016/S0014-5793(99)00794-2; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang DY, 2000, J CELL SCI, V113, P4221; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	75	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47946	47959		10.1074/jbc.M302720200	http://dx.doi.org/10.1074/jbc.M302720200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500722	hybrid			2022-12-25	WOS:000186731400073
J	Sigurdsson, EM; Brown, DR; Alim, MA; Scholtzova, H; Carp, R; Meeker, HC; Prelli, F; Frangione, B; Wisniewski, T				Sigurdsson, EM; Brown, DR; Alim, MA; Scholtzova, H; Carp, R; Meeker, HC; Prelli, F; Frangione, B; Wisniewski, T			Copper chelation delays the onset of prion disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-PENICILLAMINE TOXICITY; SCRAPIE-INFECTED MICE; PROTEIN BINDS COPPER; CUPRIZONE TOXICITY; METAL-BINDING; BRAIN; CONFORMATION; EXPRESSION; PEPTIDES; SITES	The prion protein (PrP) binds copper and under some conditions copper can facilitate its folding into a more protease resistant form. Hence, copper levels may influence the infectivity of the scrapie form of prion protein (PrPSc). To determine the feasibility of copper-targeted therapy for prion disease, we treated mice with a copper chelator, D-(-)- penicillamine (D-PEN), starting immediately following intraperitoneal scrapie inoculation. D-PEN delayed the onset of prion disease in the mice by about 11 days (p=0.002), and reduced copper levels in brain by 29% (p<0.01) and in blood by 22% (p=0.03) compared with control animals. Levels of other metals were not significantly altered in the blood or brain. Modest correlation was observed between incubation period and levels of copper in brain (p=0.08) or blood (p=0.04), indicating that copper levels are only one of many factors that influence the rate of progression of prion disease. In vitro, copper dose-dependently enhanced the proteinase K resistance of the prion protein, and this effect was counteracted in a dose-dependent manner by co-incubation with D-PEN. Overall, these findings indicate that copper levels can influence the conformational state of PrP, thereby enhancing its infectivity, and this effect can be attenuated by chelator-based therapy.	NYU, Sch Med, Dept Psychiat, Millhauser Labs, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, Millhauser Labs, New York, NY 10016 USA; NYU, Sch Med, Dept Neurol, Millhauser Labs, New York, NY 10016 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; New York State Inst Basic Res Dev Disabil, Dept Virol, Staten Isl, NY 10314 USA	New York University; New York University; New York University; University of Bath; Institute for Basic Research in Developmental Disabilities	Sigurdsson, EM (corresponding author), NYU, Sch Med, Dept Psychiat, Millhauser Labs, Rm HN418,560 1st Ave, New York, NY 10016 USA.		Brown, David/A-4083-2008; Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966; Prelli, Frances/0000-0002-8744-4151; Sigurdsson, Einar/0000-0003-1451-0952	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR002594, R37AR002594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020197, R01AG020245] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 02594] Funding Source: Medline; NIA NIH HHS [AG 20197, R01 AG020197, AG 20245] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aucouturier P, 2001, J CLIN INVEST, V108, P703, DOI 10.1172/JCI200113155; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1999, J NEUROSCI RES, V58, P717; Brown DR, 2002, BIOCHEM SOC T, V30, P742, DOI 10.1042/bst0300742; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; CARP RI, 1984, INTERVIROLOGY, V21, P61, DOI 10.1159/000149503; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; IRINO M, 1982, TOXICOL APPL PHARM, V63, P1, DOI 10.1016/0041-008X(82)90020-5; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kascsak RJ, 1997, IMMUNOL INVEST, V26, P259, DOI 10.3109/08820139709048931; KIMBERLIN RH, 1974, J COMP PATHOL, V84, P263, DOI 10.1016/0021-9975(74)90067-X; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PATTISON IH, 1971, NATURE, V230, P115, DOI 10.1038/230115a0; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rachidi W, 2003, J BIOL CHEM, V278, P14595, DOI 10.1074/jbc.C300092200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; Sigurdsson EM, 2003, NEUROSCI LETT, V336, P185, DOI 10.1016/S0304-3940(02)01192-8; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; Subramanian Indu, 2002, Curr Neurol Neurosci Rep, V2, P317, DOI 10.1007/s11910-002-0007-4; TAKEDA T, 1980, TOXICOL APPL PHARM, V55, P324, DOI 10.1016/0041-008X(80)90094-0; Thackray AM, 2002, BIOCHEM J, V362, P253, DOI 10.1042/0264-6021:3620253; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Weissmann C, 2001, PHILOS T R SOC B, V356, P177, DOI 10.1098/rstb.2000.0763; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wong BS, 2003, CELL MOL LIFE SCI, V60, P1224, DOI 10.1007/s00018-003-3057-0; Wong BS, 2001, J NEUROCHEM, V79, P689, DOI 10.1046/j.1471-4159.2001.00625.x; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x	37	161	172	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46199	46202		10.1074/jbc.C300303200	http://dx.doi.org/10.1074/jbc.C300303200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14519758	hybrid			2022-12-25	WOS:000186569400002
J	Hwang, YYC; Bakr, S; Ellery, CA; Oates, PJ; Ramasamy, R				Hwang, YYC; Bakr, S; Ellery, CA; Oates, PJ; Ramasamy, R			Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium	FASEB JOURNAL			English	Article						SDH; ischemia; reperfusion	ALDOSE REDUCTASE INHIBITION; POLYOL DEHYDROGENASES; RAT HEARTS; GLUCOSE; STIMULATION; METABOLISM; CARNITINE; LIVER; OXIDOREDUCTASES; ALCOHOL	Sorbitol dehydrogenase (SDH) is a polyol pathway enzyme that catalyzes conversion of sorbitol to fructose. Recent studies have demonstrated that activation of aldose reductase, the first enzyme of the polyol pathway, is a key response to ischemia and that inhibition of aldose reductase reduces myocardial ischemic injury. In our efforts to understand the role of pathway in affecting metabolism under normoxic and ischemic conditions, as well as in ischemic injury in myocardium, we investigated the importance of SDH by use of a specific inhibitor (SDI), CP-470,711. SDH inhibition increased glucose oxidation, whereas palmitate oxidation remained unaffected. Global ischemia increased myocardial SDH activity by similar to1.5 fold. The tissue lactate/pyruvate ratio, a measure of cytosolic NADH/NAD(+), was reduced by SDH inhibition under both normoxic and ischemic conditions. ATP was higher in SDI hearts during ischemia and reperfusion. Creatine kinase release during reperfusion, a marker of myocardial ischemic injury, was markedly attenuated in SDH-inhibited hearts. These data indicate that myocardial SDH activation is a component of ischemic response and that interventions that inhibit SDH protect ischemic myocardium. Furthermore, these data identify SDH as a novel target for adjunctive cardioprotective interventions.	Columbia Univ, Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA	Columbia University; Pfizer	Ramasamy, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346				ALVAREZ A, 1993, J INHERIT METAB DIS, V16, P67, DOI 10.1007/BF00711317; Amano S, 2002, BIOCHEM BIOPH RES CO, V299, P183, DOI 10.1016/S0006-291X(02)02584-6; Banfield MJ, 2001, J MOL BIOL, V306, P239, DOI 10.1006/jmbi.2000.4381; BERGMEYER HU, 1995, CARBOHYDRATES, P570; BLAKLEY RL, 1951, BIOCHEM J, V49, P257, DOI 10.1042/bj0490257; Broderick TL, 1995, CARDIOVASC RES, V30, P815, DOI 10.1016/S0008-6363(95)00111-5; BRODERICK TL, 1992, J BIOL CHEM, V267, P3758; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; CHIDA K, 1975, ACTA HISTOCHEM CYTOC, V8, P234, DOI 10.1267/ahc.8.234; Chu-Moyer MY, 2002, J MED CHEM, V45, P511, DOI 10.1021/jm010440g; COHEN RB, 1961, LAB INVEST, V10, P459; ELKUND H, 1985, BIOCHEMISTRY-US, V24, P8005; HOLLMANN S, 1957, J BIOL CHEM, V225, P87; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Johansson K, 2001, CHEM-BIOL INTERACT, V130, P351, DOI 10.1016/S0009-2797(00)00260-X; JOHANSSON K, 2001, CHEM-BIOL INTERACT, P130; KARLSSON C, 1993, EUR J BIOCHEM, V216, P103, DOI 10.1111/j.1432-1033.1993.tb18121.x; Lindstad RI, 1998, BIOCHEM J, V330, P479; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; MARET W, 1991, ADV EXP MED BIOL, V284, P327; MCCORKINDALE J, 1954, BIOCHEM J, V57, P518, DOI 10.1042/bj0570518; Oates PJ, 1997, NEUROSCI RES COMMUN, V21, P33; Park JW, 1998, INT J CARDIOL, V65, P139, DOI 10.1016/S0167-5273(98)00117-X; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH290, DOI 10.1152/ajpheart.2001.281.1.H290; Ramasamy R, 2001, CARDIOVASC RES, V51, P275, DOI 10.1016/S0008-6363(01)00301-7; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Siegel TW, 2000, ANAL BIOCHEM, V280, P329, DOI 10.1006/abio.2000.4531; SMITH MG, 1962, BIOCHEM J, V83, P135, DOI 10.1042/bj0830135; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; TRUBLOOD NA, 2000, AM J PHYSIOL, V279, pH764; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; WALSALL EP, 1978, COMP BIOCHEM PHYS B, V59, P213; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801	37	38	39	4	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2331	+		10.1096/fj.03-0128fje	http://dx.doi.org/10.1096/fj.03-0128fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525943				2022-12-25	WOS:000186343300014
J	Kumar, A; Lnu, S; Malya, R; Barron, D; Moore, J; Corry, DB; Boriek, AM				Kumar, A; Lnu, S; Malya, R; Barron, D; Moore, J; Corry, DB; Boriek, AM			Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma	FASEB JOURNAL			English	Article						mechanotransduction; lung mechanics; nuclear factor-kappaB; activator protein-1; free radicals; stretch-activated channels; asthma; MAP kinases; cyclooxygenase-2	UNIAXIAL CYCLIC STRETCH; TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; B ACTIVATION; TISSUE RESISTANCE; OXIDATIVE STRESS; REDOX REGULATION	We investigated the effects of mechanical stretch and induced stimulation of lung parenchyma on the activation of proinflammatory transcription factors in normal mice and in a mouse model of asthma. Mechanical stretching of lung parenchyma led to increased activation of NF-kappaB and AP-1 transcription factors. Incubation of lung parenchyma with methacholine increased the activation of NF-kappaB, which was further augmented by stretch. Activation of NF-kappaB in response to mechanical stretch was associated with the phosphorylation and degradation of IkappaBalpha and the activation of IkappaB kinase. Stretch-induced activation of NF-kappaB involves activation of stretch-activated (SA) channels and the production of free radicals. Mechanical stretch and/or treatment with methacholine resulted in an increased activation of ERK1/2 and p38 MAP kinase, and the inhibition of the activity of these kinases partially blocked the stretch-induced NF-kappaB and AP-1 activation. A greater level of NF-kappaB and ERK1/2 activity was observed in the asthmatic mice, which was further increased by mechanical stretching. The level of cyclooxygenase-2, an NF-kappaB-regulated enzyme, was also higher in lung parenchyma from asthmatic mice than in normal mice. Our data suggest that mechanical stretching of lung parenchyma activates NF-kappaB and AP-1, at least in part, through the activation of MAP kinase signaling pathways.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848	PHS HHS [63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bennett A, 2000, THORAX, V55, pS54, DOI 10.1136/thorax.55.suppl_2.S54; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Bureau F, 2000, AM J RESP CRIT CARE, V161, P1314, DOI 10.1164/ajrccm.161.4.9907010; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaqour B, 1999, J MOL CELL CARDIOL, V31, P1345, DOI 10.1006/jmcc.1999.0967; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Correa-Meyer E, 2002, AM J PHYSIOL-LUNG C, V282, pL883, DOI 10.1152/ajplung.00203.2001; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; Donovan CE, 1999, J IMMUNOL, V163, P6827; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016; FREDBERG JJ, 1993, J APPL PHYSIOL, V74, P1387, DOI 10.1152/jappl.1993.74.3.1387; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; INGENITO EP, 1993, J APPL PHYSIOL, V75, P2541, DOI 10.1152/jappl.1993.75.6.2541; INGRAM RH, 1990, LUNG, V168, P237, DOI 10.1007/BF02719700; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kato T, 1998, BIOCHEM BIOPH RES CO, V244, P615, DOI 10.1006/bbrc.1998.8335; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; Nelson PJ, 1996, J IMMUNOL, V157, P1139; Oldenhof AD, 2002, AM J PHYSIOL-CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001; Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006-2952(02)01422-3; Scichilone N, 2001, INT ARCH ALLERGY IMM, V124, P262, DOI 10.1159/000053728; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shukla A, 2000, AM J RESP CELL MOL, V23, P182, DOI 10.1165/ajrcmb.23.2.4035; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WIDMER U, 1993, J IMMUNOL, V150, P4996; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	69	76	82	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1800	1811		10.1096/fj.02-1148com	http://dx.doi.org/10.1096/fj.02-1148com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519659				2022-12-25	WOS:000186343300034
J	Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S				Fukushima, T; Suzuki, S; Mashiko, M; Ohtake, T; Endo, Y; Takebayashi, Y; Sekikawa, K; Hagiwara, K; Takenoshita, S			BRAF mutations in papillary carcinomas of the thyroid	ONCOGENE			English	Article						BRAF; RAS; papillary carcinoma of the thyroid; follicular carcinoma of the thyroid; MAP kinase pathway	MOLECULAR-GENETICS; ACTIVATION; ONCOGENES	BRAF is a serine/threonine kinase that receives a mitogenic signal from RAS and transmits it to the MAP kinase pathway. Recent studies have reported that mutations of the BRAF gene were detected with varying frequencies in several cancers, notably more than 60% in melanoma. We analysed mutations of BRAF and RAS genes in 100 cases of thyroid carcinoma to investigate genetic aberrations in the RAS/RAF/MEK/MAP kinase pathway. BRAF mutations were detected exclusively in papillary carcinomas ( 40 in 76 cases: 53%), and were exclusively V599E, a mutation frequently observed in other carcinomas. NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. No mutations were found in KRAS or HRAS. Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.	Fukushima Med Univ, Dept Surg, Fukushima 9601295, Japan; Saitama Med Sch, Dept Resp Med, Moroyama, Saitama 3500495, Japan	Fukushima Medical University; Saitama Medical University	Fukushima, T (corresponding author), Fukushima Med Univ, Dept Surg, 1 Hikarigaoka, Fukushima 9601295, Japan.							Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Lazzereschi D, 1997, J EXP CLIN CANC RES, V16, P325; Learoyd DL, 2000, WORLD J SURG, V24, P923, DOI 10.1007/s002680010164; Ledent C, 1991, Thyroidology, V3, P97; MANENTI G, 1994, EUR J CANCER, V30A, P987, DOI 10.1016/0959-8049(94)90130-9; Naoki K, 2002, CANCER RES, V62, P7001; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sugg SL, 1999, SURGERY, V125, P46, DOI 10.1067/msy.2099.92118; Yuen ST, 2002, CANCER RES, V62, P6451	12	237	249	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6455	6457		10.1038/sj.onc.1206739	http://dx.doi.org/10.1038/sj.onc.1206739			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508525				2022-12-25	WOS:000185535300015
J	Stewart, RA; Li, DM; Huang, H; Xu, T				Stewart, RA; Li, DM; Huang, H; Xu, T			A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila	ONCOGENE			English	Article						CSK; LATS; SRC; tissue size; cell proliferation; genetic modifier	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BREAST-CANCER CELLS; FAMILY KINASES; NEGATIVE REGULATION; EYE DEVELOPMENT; HUMAN HOMOLOG; MICE LACKING; CSK; GROWTH	Disrupting mechanisms that control cell proliferation, cell size and apoptosis can cause changes in animal and tissue size and contribute to diseases such as cancer. The LATS family of serine/threonine kinases control tissue size by regulating cell proliferation and function as tumor suppressor genes in both Drosophila and mammals. In order to understand the role of lats in size regulation, we performed a genetic modifier screen in Drosophila to identify components of the lats signaling pathway. Mutations in the Drosophila homolog of C-terminal Src kinase (dcsk) were identified as dominant modifiers of both lats gain-of-function and loss-of-function phenotypes. Homozygous dcsk mutants have enlarged tissue phenotypes similar to lats and FACS and immunohistochemistry analysis of these tissues revealed that dcsk also regulates cell proliferation during development. Animals having mutations in both dcsk and lats display cell overproliferation phenotypes more severe than either mutant alone, demonstrating these genes function together in vivo to regulate cell numbers. Furthermore, homozygous dcsk phenotypes can be partially suppressed by overexpression of lats, indicating that lats is a downstream mediator of dcsk function in vivo. Finally, we show that dCSK phosphorylates LATS in vitro at a conserved C-terminal tyrosine residue, which is critical for normal LATS function in vivo. Taken together, these results demonstrate a role for dCSK in regulating cell numbers during development by inhibiting cell proliferation and suggest that lats is one of the mediators of the dcsk phenotype.	Howard Hughes Med Inst, Dept Genet, New Haven, CT 06536 USA; Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Dept Genet, Sch Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Howard Hughes Med Inst, Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.		Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOUGERET C, 1993, ONCOGENE, V8, P1241; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cooper JA, 1996, CELL GROWTH DIFFER, V7, P1435; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAY BA, 1994, DEVELOPMENT, V120, P2121; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; Huang H, 1999, DEVELOPMENT, V126, P5365; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Li G, 2002, DEVELOPMENT, V129, P4159; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Lu XY, 1999, DEV BIOL, V208, P233, DOI 10.1006/dbio.1999.9196; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; McCartney BM, 2000, DEVELOPMENT, V127, P1315; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oldham S, 2000, PHILOS T R SOC B, V355, P945, DOI 10.1098/rstb.2000.0630; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Spradling AC, 1999, GENETICS, V153, P135; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stamenovic D, 1999, J THEOR BIOL, V201, P63, DOI 10.1006/jtbi.1999.1014; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Treisman JE, 1998, CURR TOP DEV BIOL, V39, P119, DOI 10.1016/S0070-2153(08)60454-8; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Wolff Tanya, 1993, P1277; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065	68	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6436	6444		10.1038/sj.onc.1206820	http://dx.doi.org/10.1038/sj.onc.1206820			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508523				2022-12-25	WOS:000185535300013
J	Reinecke, K; Lucius, R; Reinecke, A; Rickert, U; Herdegen, T; Unger, T				Reinecke, K; Lucius, R; Reinecke, A; Rickert, U; Herdegen, T; Unger, T			Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT(2) receptor and the transcription factor NF-kappa B	FASEB JOURNAL			English	Article						axonal regeneration; angiotensin receptors; PD 123319; losartan	MICROTUBULE-ASSOCIATED PROTEINS; DORSAL-ROOT GANGLIA; C-JUN; AXONAL REGENERATION; NEURONAL DEATH; GROWTH-FACTOR; CELL-DEATH; EXPRESSION; INJURY; AT(1)	The AT(2) receptor regulates several functions of nerve cells, e.g., ionic fluxes, cell differentiation, and axonal regeneration, but also modulates programmed cell death. We tested the hypothesis that angiotensin II (ANG II) via its AT(2) receptor not only promotes regeneration but also functional recovery after sciatic nerve crush in adult rats. ANG II (10(-7), 10(-9), 10(-11) M) applied locally via osmotic minipumps promoted functional recovery with maximal effects after the lowest concentration. The toe spread distance as a parameter for re-innervation after 20 days was significantly (P<0.01) greater (10.2 +/- 10.27 mm) compared with the control group (8.73 +/- 0.16 mm). The response to local electrical stimulation (return of sensorimotor function) was reduced to 14.6 days vs. 17.9 days in the control group (P<0.01). The AT(2) receptor antagonist PD 123319 administered alone or in combination with ANG II completely prevented the ANG II-induced recovery, whereas the AT(1) receptor antagonist losartan had no effect. Furthermore, ANG II induces, via the AT(2) receptor, activation of the transcription factor NF-kappaB in Schwann cells. Histological criteria, morphometric analyses, and electron microscopy confirmed the functional data. These results are the first to present direct evidence for an involvement of the AT(2) receptor and NF-kappaB in peripheral nerve regeneration.	Humboldt Univ, Charite Hosp, Inst Pharmacol & Toxicol, D-10117 Berlin, Germany; Univ Kiel, Inst Pharmacol, D-24105 Kiel, Germany; Univ Kiel, Inst Anat, D-24098 Kiel, Germany; German Inst High Blood Pressure Res, Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; University of Kiel	Unger, T (corresponding author), Humboldt Univ, Charite Hosp, Inst Pharmacol & Toxicol, Dorotheenstr 94, D-10117 Berlin, Germany.	thomas.unger@charite.de	herdegen, thomas/E-5135-2010; Lucius, Ralph/B-1614-2010					Averill DB, 2000, BRAIN RES BULL, V51, P119, DOI 10.1016/S0361-9230(99)00237-3; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; BLEUEL A, 1995, J NEUROSCI, V15, P750; Book AA, 1996, EXP NEUROL, V138, P214, DOI 10.1006/exnr.1996.0060; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; CHEN YS, 1989, EXP NEUROL, V103, P52, DOI 10.1016/0014-4886(89)90184-2; CULMAN J, 1995, CLIN EXP HYPERTENS, V17, P281, DOI 10.3109/10641969509087071; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELLON AL, 1989, ANN PLAS SURG, V23, P197, DOI 10.1097/00000637-198909000-00002; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dol F, 2001, J CARDIOVASC PHARM, V38, P395, DOI 10.1097/00005344-200109000-00008; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; ESTABLEPUIG JF, 1965, J NEUROPATH EXP NEUR, V24, P531, DOI 10.1097/00005072-196507000-00012; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Gallinat S, 2000, AM J PHYSIOL-ENDOC M, V278, pE357, DOI 10.1152/ajpendo.2000.278.3.E357; Gallinat S, 1997, NEUROSCI LETT, V227, P29, DOI 10.1016/S0304-3940(97)00291-7; Gallinat S, 1998, MOL BRAIN RES, V57, P111, DOI 10.1016/S0169-328X(98)00079-5; Grothe C, 2001, ANAT EMBRYOL, V204, P171, DOI 10.1007/s004290100205; HARE GMT, 1992, PLAST RECONSTR SURG, V89, P251, DOI 10.1097/00006534-199202000-00009; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Kenney AM, 1998, J NEUROSCI, V18, P1318; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; LEAH JD, 1993, NEUROSCIENCE, V57, P53, DOI 10.1016/0306-4522(93)90111-R; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Lucius R, 1999, CELL MOL LIFE SCI, V56, P1008, DOI 10.1007/s000180050490; McKinley MJ, 1996, CLIN EXP PHARMACOL P, V23, pS99, DOI 10.1111/j.1440-1681.1996.tb02821.x; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; OMER GE, 1981, SURG CLIN N AM, V61, P303; RICH KM, 1987, J NEUROCYTOL, V16, P261, DOI 10.1007/BF01795309; RICHARDSON PM, 1994, J NEUROL, V242, pS57, DOI 10.1007/BF00939244; Rosenstiel P, 2002, CNS DRUGS, V16, P145, DOI 10.2165/00023210-200216030-00001; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; STROTH U, 1997, J HYPERTENS, V15, P64; SVENSSON M, 1992, J NEUROCYTOL, V21, P222, DOI 10.1007/BF01194980; TANAKA M, 1995, BIOCHEM BIOPH RES CO, V207, P593, DOI 10.1006/bbrc.1995.1229; TONGE DA, 1993, SEMIN NEUROSCI, V5, P385; Vaudano E, 2001, EUR J NEUROSCI, V13, P1, DOI 10.1046/j.1460-9568.2001.01356.x; von Bohlen und Halbach O, 2001, REGUL PEPTIDES, V99, P209, DOI 10.1016/S0167-0115(01)00258-0; WALKER JL, 1994, RESTOR NEUROL NEUROS, V6, P189, DOI 10.3233/RNN-1994-6303; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Wang MS, 1997, J PHARMACOL EXP THER, V282, P1084; WOODHAMS PL, 1989, NEUROSCIENCE, V28, P49, DOI 10.1016/0306-4522(89)90231-5; Yamauchi F, 1996, NEPHROLOGY, V2, P93, DOI 10.1111/j.1440-1797.1996.tb00071.x	47	104	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2094	+		10.1096/fj.02-1193fje	http://dx.doi.org/10.1096/fj.02-1193fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500552				2022-12-25	WOS:000185925100007
J	Wu, KL; Bottazzi, ME; de la Fuente, C; Deng, LW; Gitlin, SD; Maddukuri, A; Dadgar, S; Li, H; Vertes, A; Pumfery, A; Kashanchi, F				Wu, KL; Bottazzi, ME; de la Fuente, C; Deng, LW; Gitlin, SD; Maddukuri, A; Dadgar, S; Li, H; Vertes, A; Pumfery, A; Kashanchi, F			Protein profile of tax-associated complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 TAX; NF-KAPPA-B; I TAX; RHO GTPASES; IKK-GAMMA; 2-DIMENSIONAL ELECTROPHORESIS; MOLECULAR-INTERACTIONS; MEDIATES INTERACTION; COACTIVATOR CBP; HTLV-1 TAX	Infection with human T-cell leukemia virus type 1 (HTLV-1) results in adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Tax, a 40-kDa protein, regulates viral and cellular transcription, host signal transduction, the cell cycle, and apoptosis. Tax has been shown to modulate cellular CREB and NFkappaB pathways; however, to date, its role in binding to various host cellular proteins involved in tumorigenesis has not been fully described. In this study, we describe the Tax- associated proteins and their functions in cells using several approaches. Tax eluted from a sizing column mostly at an apparent molecular mass of 1800 kDa. Following Tax immunoprecipitation, washes with high salt buffer, two-dimensional gel separation, and mass spectrometric analysis, a total of 32 proteins was identified. Many of these proteins belong to the signal transduction and cytoskeleton pathways and transcription/chromatin remodeling. A few of these proteins, including TXBP151, have been shown previously to bind to Tax. The interaction of Tax with small GTPase-cytoskeleton proteins, such as ras GAP(1m), Rac1, Cdc42, RhoA, and gelsolin, indicates how Tax may regulate migration, invasion, and adhesion in T-cell cancers. Finally, the physical and functional association of Tax with the chromatin remodeling SWI/SNF complex was assessed using in vitro chromatin remodeling assays, chromatin remodeling factor BRG1 mutant cells, and RNA interference experiments. Collectively, Tax is able to bind and regulate many cellular proteins that regulate transcription and cytoskeletal related pathways, which might explain the pleiotropic effects of Tax leading to T-cell transformation and leukemia in HTLV-1-infected patients.	George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; George Washington Univ, Dept Chem, Washington, DC 20052 USA	George Washington University; George Washington University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Michigan System; University of Michigan; George Washington University	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Ross Hall,Rm 552,2300 Eye St NW, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Vertes, Akos/B-7159-2008; wu, kaili/A-1227-2011	Vertes, Akos/0000-0001-5186-5352; Bottazzi, Maria Elena/0000-0002-8429-0476; Li, Hong/0000-0001-5731-5335; Wu, Kaili/0000-0003-3606-683X	NIAID NIH HHS [AI44357, AI43894] Funding Source: Medline; PHS HHS [13969] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI044357, R01AI043894] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asp P, 2002, J CELL SCI, V115, P2735; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Caliendo AM, 1996, J VIROL, V70, P2146, DOI 10.1128/JVI.70.4.2146-2153.1996; Carlier MF, 1999, CHEM BIOL, V6, pR235, DOI 10.1016/S1074-5521(99)80107-0; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Fry CJ, 2002, SCIENCE, V295, P1847, DOI 10.1126/science.1070260; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Maruta H, 1999, MICROSC RES TECHNIQ, V47, P61; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; OConnell KL, 1997, ELECTROPHORESIS, V18, P349, DOI 10.1002/elps.1150180309; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Reddy TR, 1998, P NATL ACAD SCI USA, V95, P702, DOI 10.1073/pnas.95.2.702; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SALVETTI A, 1993, EUR J CELL BIOL, V61, P383; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Trihn D, 1997, J BIOMED SCI, V4, P47, DOI 10.1007/BF02255593; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wang D, 2001, J VIROL, V75, P7266, DOI 10.1128/JVI.75.16.7266-7279.2001; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xu X, 1996, ONCOGENE, V13, P135; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193	59	72	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					495	508		10.1074/jbc.M310069200	http://dx.doi.org/10.1074/jbc.M310069200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14530271	hybrid			2022-12-25	WOS:000187555300060
J	Stock, MF; Chu, J; Hackney, DD				Stock, MF; Chu, J; Hackney, DD			The kinesin family member BimC contains a second microtubule binding region attached to the N terminus of the motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ADP RELEASE; POLYPROLINE-II HELIX; SUPERFAMILY PROTEIN; DROSOPHILA KINESIN; ESCHERICHIA-COLI; HEAD DOMAINS; TAIL DOMAIN; K-LOOP; PROCESSIVITY; EG5	The kinesin family member BimC has a highly positively charged domain of similar to70 amino acids at the N terminus of the motor domain. Motor domain constructs of BimC were prepared with and without this extra domain to determine its influence. The level of microtubules needed for half saturation of the ATPase of BimC motor domain constructs is reduced by similar to7000-fold at low ionic strength upon addition of this extra N-terminal extension. Although the change in microtubule affinity is less at higher salt, addition of the N-terminal domain still produces a 20-fold increase in affinity for microtubules in 200 mM potassium acetate. A fusion protein of the N-terminal domain and thioredoxin binds tightly to MTs at low salt, consistent with the increased affinity of motor domain constructs ( which contain the N-terminal domain) being due to the additional binding of the N-terminal domain to the microtubule. Hydrodynamic analysis indicates that the N-terminal extension is in a highly extended conformation, suggesting that it may be intrinsically disordered. Fusion of the N-terminal extension of BimC onto the motor domain of conventional kinesin produces a similar large increase in microtubule affinity without significant reduction in k(cat) or velocity in an in vitro motility assay, suggesting that the N-terminal extension can act in a modular manner to increase the microtubule affinity of kinesin motor domains without a decrease in velocity.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	Hackney, DD (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.			Chu, Jessica/0000-0002-5763-873X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028562] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28562] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cheng JQ, 1998, BIOCHEMISTRY-US, V37, P5288, DOI 10.1021/bi972742j; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; Creamer TP, 2002, ADV PROTEIN CHEM, V62, P263; Creamer TP, 1998, PROTEINS, V33, P218, DOI 10.1002/(SICI)1097-0134(19981101)33:2<218::AID-PROT6>3.0.CO;2-E; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Griffiths JR, 1979, BIOCHEM SOC T, V7, P429, DOI 10.1042/bst0070429; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; HACKNEY DD, 1995, BIOPHYS J, V68, pS267; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hackney DD, 2003, BIOCHEMISTRY-US, V42, P12011, DOI 10.1021/bi0349118; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kar S, 2003, EMBO J, V22, P70, DOI 10.1093/emboj/cdg001; Karabay A, 1999, BIOCHEMISTRY-US, V38, P1838, DOI 10.1021/bi981850i; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kim AJ, 2000, J CELL SCI, V113, P3681; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Ohsugi M, 2003, EMBO J, V22, P2091, DOI 10.1093/emboj/cdg208; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Rogers KR, 2001, EMBO J, V20, P5101, DOI 10.1093/emboj/20.18.5101; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Shiroguchi K, 2003, J BIOL CHEM, V278, P22460, DOI 10.1074/jbc.M212274200; Sober H. H., 1968, HDB BIOCH; Stock M.F., 2001, METHODS MOL BIOL KIN, P43; STOCK MF, 2001, METHODS MOL BIOL KIN, P65; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WANG DS, 1988, NUCLEIC ACIDS RES, V16, P11369, DOI 10.1093/nar/16.23.11369; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; Yajima J, 2002, CURR BIOL, V12, P301, DOI 10.1016/S0960-9822(01)00683-2; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864	46	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52315	52322		10.1074/jbc.M309419200	http://dx.doi.org/10.1074/jbc.M309419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530265	hybrid			2022-12-25	WOS:000187480700041
J	Moskalenko, S; Tong, C; Rosse, C; Mirey, G; Formstecher, E; Daviet, L; Camonis, J; White, MA				Moskalenko, S; Tong, C; Rosse, C; Mirey, G; Formstecher, E; Daviet, L; Camonis, J; White, MA			Ral GTPases regulate exocyst assembly through dual subunit interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; PLASMA-MEMBRANE; SEC6/8 COMPLEX; PH DOMAINS; EFFECTOR; PATHWAYS; BINDING; SITES; CELLS; RAIA	Ral GTPases have been implicated in the regulation of a variety of dynamic cellular processes including proliferation, oncogenic transformation, actin-cytoskeletal dynamics, endocytosis, and exocytosis. Recently the Sec6/8 complex, or exocyst, a multisubunit complex facilitating post-Golgi targeting of distinct subclasses of secretory vesicles, has been identified as a bona fide Ral effector complex. Ral GTPases regulate exocyst-dependent vesicle trafficking and are required for exocyst complex assembly. Sec5, a membrane-associated exocyst subunit, has been identified as a direct target of activated Ral; however, the mechanism by which Ral can modulate exocyst assembly is unknown. Here we report that an additional component of the exocyst, Exo84, is a direct target of activated Ral. We provide evidence that mammalian exocyst components are present as distinct subcomplexes on vesicles and the plasma membrane and that Ral GTPases regulate the assembly interface of a full octameric exocyst complex through interaction with Sec5 and Exo84.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Inst Curie, Paris, France; Hybrigenics, F-75014 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	White, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Rosse, Carine/L-4775-2017; Mirey, Gladys/H-5676-2019	Mirey, Gladys/0000-0002-0095-1864; Tong, Chao/0000-0001-6521-5465; FORMSTECHER, Etienne/0000-0002-6410-4365	NCI NIH HHS [CA71443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kippenberger AG, 1999, J NEUROCHEM, V73, P1024, DOI 10.1046/j.1471-4159.1999.0731024.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li L, 2003, CELL MOL LIFE SCI, V60, P942, DOI 10.1007/s00018-003-2240-7; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737	27	164	168	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51743	51748		10.1074/jbc.M308702200	http://dx.doi.org/10.1074/jbc.M308702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525976	hybrid, Green Published			2022-12-25	WOS:000187206300109
J	Shimono, Y; Murakami, H; Kawai, K; Wade, PA; Shimokata, K; Takahashi, M				Shimono, Y; Murakami, H; Kawai, K; Wade, PA; Shimokata, K; Takahashi, M			Mi-2 beta associates with BRG1 and RET finger protein at the distinct regions with transcriptional activating and repressing abilities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; CHROMATIN-REMODELING COMPLEX; POLYCOMB; DEACETYLASE; ENHANCER; METHYLATION; INTERACTS; SUBUNIT; FAMILY; DERMATOMYOSITIS	Mi-2beta is the main component of the nucleosome remodeling and deacetylase complex and plays an important role in epigenetic transcriptional repression. Here we show that the amino-terminal and carboxyl-terminal regions of Mi-2beta have distinct transcriptional activities and bind to BRG1, a component of the SWI/SNF complex, and the RET finger protein (RFP), respectively. Analysis by luciferase reporter assay revealed that the amino-terminal region of Mi-2beta has a strong transactivating ability, whereas its carboxyl-terminal region has transcriptional repressive activity. Co-localization and association of Mi- 2, RFP, and histone deacetylase 1 suggested that these proteins cooperate in transcriptional repression. Furthermore, the functional importance of the association of Mi-2beta and RFP was confirmed by using Rfp(-/-) fibroblasts. On the other hand, we demonstrated that Mi- 2 and BRG1 were associated with each other and that the bromodomain region of BRG1 strongly suppressed transactivation by the amino-terminal region of Mi-2beta. The findings that Mi-2beta interacts with both transactivating and repressing proteins and directly associates with another chromatin remodeling protein, BRG1, provide new insight into the formation of multiprotein supercomplex involved in transcriptional regulation.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Neural Dis & Canc, Dept Mol Pathol,Showa Ku, Nagoya, Aichi 4668550, Japan; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Nagoya University; Nagoya University; Nagoya University; Emory University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Kumi, Kawai/I-6275-2014; Wade, Paul A/D-2374-2019; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Kumi, Kawai/0000-0002-7772-2605; Wade, Paul A/0000-0002-6042-357X; Takahashi, Masahide/0000-0002-2803-2683; Shimono, Yohei/0000-0002-6256-4704				Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen AL, 2002, EMBO J, V21, P5797, DOI 10.1093/emboj/cdf560; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Riddihough G, 2001, SCIENCE, V293, P1063, DOI 10.1126/science.293.5532.1063; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Tezel G, 2002, BIOCHEM BIOPH RES CO, V290, P409, DOI 10.1006/bbrc.2001.6161; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	45	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51638	51645		10.1074/jbc.M309198200	http://dx.doi.org/10.1074/jbc.M309198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530259	hybrid			2022-12-25	WOS:000187206300098
J	Borgenstrom, M; Jalkanen, M; Salmivirta, M				Borgenstrom, M; Jalkanen, M; Salmivirta, M			Sulfated derivatives of Escherichia coli K5 polysaccharides as modulators of fibroblast growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; SHIONOGI CARCINOMA-115 CELLS; HEPARAN-SULFATE; HEPARIN/HEPARAN SULFATE; CAPSULAR POLYSACCHARIDE; PENTOSAN POLYSULFATE; CRYSTAL-STRUCTURE; BINDING; RECEPTOR; ANDROGEN	Heparan sulfate (HS) proteoglycans are intimately involved in the regulation of fibroblast growth factor (FGF) signaling. HS and the related glycosaminoglycan heparin interact with FGFs and FGF receptors (FGFRs), and it is believed that both interactions are required for productive FGF signaling. Attempts to inhibit FGF activity have been made with modified heparin preparations, various heparin-like polysaccharide analogues and other polyanionic molecules, which may all act by interfering with the physiological HS-FGF-FGFR interactions on the cell surface. Here, we have studied the potential of sulfated derivatives of a bacterial polysaccharide (capsular polysaccharide from Escherichia coli K5 (K5PS)) in the modulation of FGF-heparin/HS interactions and FGF signaling. We demonstrate that O-sulfated and N, O-sulfated species of K5PS, with high degrees of sulfation, displaced FGF-1, FGF-2, and FGF-8b from heparin. However, only O-sulfated K5PS efficiently inhibited the FGF-induced proliferation of S115 mammary carcinoma cells and 3T3 fibroblasts, whereas N, O-sulfated K5PS had little or no inhibitory effect. Studies with CHO677 cells lacking endogenous HS, as well as with chlorate-treated S115 cells expressing undersulfated HS, indicated that whereas exogenously administered heparin and N, O-sulfated K5PS restored the cellular response toward FGF stimulation, O-sulfated K5PS was largely devoid of such stimulatory activity. Our data suggest that highly O-sulfated species of K5PS may be efficient inhibitors of FGF signaling.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, FIN-20520 Turku, Finland; BioTie Therapies Corp, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; University of Turku; University of Turku	Salmivirta, M (corresponding author), Turku Ctr Biotechnol, POB 123, Turku 20521, Finland.							Ahmad R, 2000, INT J CANCER, V87, P707, DOI 10.1002/1097-0215(20000901)87:5<707::AID-IJC13>3.0.CO;2-W; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Borgenstrom M, 2001, EXP CELL RES, V264, P307, DOI 10.1006/excr.2000.5126; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; Darbre P D, 1988, Cancer Treat Res, V40, P307; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Forsten KE, 2000, J THEOR BIOL, V205, P215, DOI 10.1006/jtbi.2000.2064; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hejna M, 1999, JNCI-J NATL CANCER I, V91, P22, DOI 10.1093/jnci/91.1.22; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; Kaeffer B, 1999, PLANTA MED, V65, P527, DOI 10.1055/s-1999-14009; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KASAYAMA S, 1991, J CELL PHYSIOL, V148, P260, DOI 10.1002/jcp.1041480211; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; Leali D, 2001, J BIOL CHEM, V276, P37900; LEPPA S, 1991, CELL REGUL, V2, P1; Loo BM, 2002, J BIOL CHEM, V277, P32616, DOI 10.1074/jbc.M204961200; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAMURA N, 1989, J STEROID BIOCHEM, V33, P13, DOI 10.1016/0022-4731(89)90351-8; NOGUCHI S, 1989, J STEROID BIOCHEM, V32, P479, DOI 10.1016/0022-4731(89)90379-8; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sciumbata T, 1996, INVAS METAST, V16, P132; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANAKA A, 1990, J STEROID BIOCHEM, V37, P23, DOI 10.1016/0960-0760(90)90368-U; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WALZ DA, 1994, INVAS METAST, V15, P303; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zacharski LR, 1998, THROMB HAEMOSTASIS, V80, P10; ZUGMAIER G, 1992, J NATL CANCER I, V84, P1716, DOI 10.1093/jnci/84.22.1716	55	20	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49882	49889		10.1074/jbc.M304208200	http://dx.doi.org/10.1074/jbc.M304208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514688	hybrid			2022-12-25	WOS:000187068200030
J	Ge, YB; Jensen, TL; Matherly, LH; Taub, JW				Ge, YB; Jensen, TL; Matherly, LH; Taub, JW			Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; UPSTREAM STIMULATORY FACTOR; CYTOSINE-ARABINOSIDE; CELL-LINES; E-BOX; COOPERATIVE INTERACTION; MAMMALIAN-CELLS; MULTIPLE FORMS; DOWN-SYNDROME; IN-VITRO	Deoxycytidine kinase (EC 2.7.1.74, dCK) is central to drug activity of anticancer and antiviral agents such as cytosine arabinoside (araC) and gemcitabine. HepG2 hepatocellular carcinoma cells were used to study the transcriptional regulation of dCK. 5'-Deletion and site-directed mutagenesis of the dCK upstream region (positions -464 to -27) confirmed the importance of two GC-boxes (positions -317 to -309 and -213 to -206) and two E-boxes (positions -302 to -297 and -278 to -273). In vitro electromobility shift assays with HepG2 nuclear extracts and in vivo chromatin immunoprecipitation assays with HepG2 chromatin extracts confirmed the presence of bound Sp1/Sp3 and USF1/2. Co-transfections in HepG2 cells showed that USF1 and USF2a stimulated and Sp1 repressed promoter activity from a dCK-luciferase reporter gene construct. In Sp- and USF-null Drosophila Mel-2 cells, both Sp1 and USF1 stimulated dCK promoter activity in a dose-dependent manner, however, both Sp3 and USF2a were effectively inert. Combined Sp1 and USF1 showed additive transactivation at lower concentrations of Sp1. Sp1 was inhibitory at higher levels. Stimulation by combined USF1/USF2a with Sp1 was similar to that for USF1 alone with Sp1, whereas transactivation by Sp1 and USF2a without USF1 was synergistic. Physical interactions between USF and Sp proteins were confirmed by immunoprecipitations with Sp- and USF-specific antibodies. Domain mapping of USF1 and USF2a localized the functional interactions between USF and Sp proteins to the DNA binding domain of USF. Identifying the physical and functional interactions between Sp and USF proteins may lead to a better understanding of the basis for differential expression of the dCK gene in tumor cells and may foster strategies for up-regulating dCK gene expression and improving chemotherapy with araC and gemcitabine.	Childrens Hosp Michigan, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Children's Hospital of Michigan; Children's Hospital of Michigan; Wayne State University; Wayne State University	Taub, JW (corresponding author), Childrens Hosp Michigan, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 3901 Beaubien Blvd, Detroit, MI 48201 USA.			Ge, Yubin/0000-0002-8748-716X	NCI NIH HHS [R01-CA92308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARNER ESJ, 1988, EXP CELL RES, V178, P335, DOI 10.1016/0014-4827(88)90403-X; CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DURHAM JP, 1969, MOL PHARMACOL, V5, P358; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Ge YB, 2003, BLOOD, V101, P1551, DOI 10.1182/blood-2002-07-2337; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Grant S, 1998, ADV CANCER RES, V72, P197; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Hapke DM, 1996, CANCER RES, V56, P2343; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Howcroft TK, 1999, MOL CELL BIOL, V19, P4788; Kakihara T, 1998, LEUKEMIA LYMPHOMA, V31, P405, DOI 10.3109/10428199809059234; KAWASAKI H, 1992, ANAL BIOCHEM, V207, P193, DOI 10.1016/0003-2697(92)90522-9; KUFE DW, 1985, SEMIN ONCOL, V12, P34; Li N, 1998, J BIOL CHEM, V273, P28170, DOI 10.1074/jbc.273.43.28170; Manome Y, 1996, NAT MED, V2, P567, DOI 10.1038/nm0596-567; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; Moore AW, 2000, P NATL ACAD SCI USA, V97, P10436, DOI 10.1073/pnas.170301897; PAN JL, 1993, J BIOL CHEM, V268, P22600; PIRO LD, 1992, BLOOD, V79, P843; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SONG JJ, 1993, P NATL ACAD SCI USA, V90, P431, DOI 10.1073/pnas.90.2.431; SPASOKOUKOTSKAJA T, 1995, EUR J CANCER, V31A, P202, DOI 10.1016/0959-8049(94)00435-8; Sun P, 2001, J BIOL CHEM, V276, P45462, DOI 10.1074/jbc.M104793200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taub JW, 1999, BLOOD, V94, P1393; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	39	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49901	49910		10.1074/jbc.M305085200	http://dx.doi.org/10.1074/jbc.M305085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514691	hybrid			2022-12-25	WOS:000187068200032
J	Imagawa, T; Kaya, S; Taniguchi, K				Imagawa, T; Kaya, S; Taniguchi, K			The amino acid sequence (442)GDASE(446) in Na/K-ATPase is an important motif in forming the high and low affinity ATP binding pockets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; P-TYPE ATPASES; NA+/K+-ATPASE; ALPHA-SUBUNIT; OLIGOMERIC STRUCTURE; ENERGY TRANSDUCTION; ION-TRANSPORT; ACTIVE-SITE; NA,K-ATPASE; NA+,K+-ATPASE	A highly conserved amino acid sequence (442)GDASE(446) in the ATP binding pocket of rat Na/K-ATPase was mutated, and the resulting proteins, G442A, G442P, D443A, S445A, and E446A, were expressed in HeLa cells to investigate the effect of individual ligands on Na/K-ATPase. The apparent K-m for the high and low affinity ATP effects was estimated by ATP concentration dependence for the formation of the Na-dependent phosphoenzyme (K-m(h)) and Na/K-ATPase activity (K-m(l)). The apparent K-m for p-nitrophenylphosphate (pNPP) for K-dependentpNPPase (K-m(P)) and its inhibition by ATP (K-i,K- 0.5) and the apparent K-m for Mg2+, Na+, K+, and vanadate in Na/K-ATPase were also estimated. For all the mutants, the value for ATP was similar to 2-10-fold larger than that of the wild type. While the turnover number for Na/K-ATPase activity were unaffected or reduced by 20 similar to50% in mutants G442(A/P) and D443A. Although both affinities for ATP effects were reduced as a result of the mutations, the ratio, K-m(l)/ K-m(h), for each mutant was 1.3 similar to 3.7, indicating that these mutations had a greater impact on the low affinity ATP effect than on the high affinity effect. Each K-m P value with the turnover number suggests that these mutations favor the binding of pNPP over that of ATP. These data and others indicate that the sequence 442GDASE446 in the ATP binding pocket is an important motif that it is involved in both the high and low affinity ATP effects rather than in free Mg2+, Na+, and K+ effects.	Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Imagawa, T (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Chem, Kita Ku, Kita 10 Nishi 8, Sapporo, Hokkaido 0600810, Japan.	toshi@sci.hokudai.ac.jp	Imagawa, Toshiaki/A-4255-2012					Abe K, 2002, BIOCHEMISTRY-US, V41, P2438, DOI 10.1021/bi015622r; Askari A, 2000, INT CONGR SER, V1207, P17; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Costa CJ, 2003, J BIOL CHEM, V278, P9176, DOI 10.1074/jbc.M212351200; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; Ettrich R, 2001, J MOL MODEL, V7, P184; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Farley RA, 1997, BIOCHEMISTRY-US, V36, P941, DOI 10.1021/bi962153y; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; Hayashi Y, 2003, ANN NY ACAD SCI, V986, P232, DOI 10.1111/j.1749-6632.2003.tb07167.x; Imagawa T, 1998, JPN J PHARMACOL, V76, P415, DOI 10.1254/jjp.76.415; Ivanov AV, 2002, BIOCHEM J, V364, P293, DOI 10.1042/bj3640293; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; JONG MLH, 1988, SODIUM PUMP, P379; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; Kaya S, 2003, ANN NY ACAD SCI, V986, P278, DOI 10.1111/j.1749-6632.2003.tb07185.x; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2002, BIOCHEMISTRY-US, V41, P11740, DOI 10.1021/bi026334d; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; PETERS WHM, 1981, NATURE, V290, P338, DOI 10.1038/290338a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER W, 2003, SODIUM PUMP STRUCTUR, V278, P14688; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; TANIGUCHI K, 1983, J BIOL CHEM, V258, P6927; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Tao Bernard Y., 1994, P69; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tsuda T, 1998, J BIOCHEM, V123, P169; Tsuda T, 1998, J BIOL CHEM, V273, P24334, DOI 10.1074/jbc.273.38.24334; VILSEN B, 1987, J BIOL CHEM, V262, P10511; WANG K, 1992, J BIOL CHEM, V267, P3577; WEBER K, 1969, J BIOL CHEM, V244, P4406; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792	51	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50283	50292		10.1074/jbc.M309833200	http://dx.doi.org/10.1074/jbc.M309833200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522987	hybrid			2022-12-25	WOS:000187068200076
J	Slessareva, JE; Ma, HZ; Depree, KM; Flood, LA; Bae, HS; Cabrera-Vera, TM; Hamm, HE; Graber, SG				Slessareva, JE; Ma, HZ; Depree, KM; Flood, LA; Bae, HS; Cabrera-Vera, TM; Hamm, HE; Graber, SG			Closely related G-protein-coupled receptors use multiple and distinct domains on G-protein alpha-subunits for selective coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; AMINO-TERMINUS; BETA-GAMMA; BINDING; SPECIFICITY; TRANSDUCIN; ACTIVATION; HELIX; SITE; DETERMINANTS	The molecular basis of selectivity in G-protein receptor coupling has been explored by comparing the abilities of G-protein heterotrimers containing chimeric Galpha subunits, comprised of various regions of G(i1)alpha, G(t)alpha, and G(q)alpha, to stabilize the high affinity agonist binding state of serotonin, adenosine, and muscarinic receptors. The data indicate that multiple and distinct determinants of selectivity exist for individual receptors. While the A1 adenosine receptor does not distinguish between G(i1)alpha and G(t)alpha sequences, the 5-HT1A and 5- HT1B serotonin and M2 muscarinic receptors can couple with G(i1) but not G(t). It is possible to distinguish domains that eliminate coupling and are defined as "critical," from those that impair coupling and are defined as " important." Domains within the N terminus, alpha4-helix, and alpha4-helix-alpha4/beta6-loop of G(i1)alpha are involved in 5- HT and M2 receptor interactions. Chimeric G(i1)alpha/ G(q)alpha subunits verify the critical role of the Galpha C terminus in receptor coupling, however, the individual receptors differ in the C-terminal amino acids required for coupling. Furthermore, the EC50 for interactions with G(i1) differ among the individual receptors. These results suggest that coupling selectivity ultimately involves subtle and cooperative interactions among various domains on both the G-protein and the associated receptor as well as the G-protein concentration.	W Virginia Univ, Sch Med, Dept Mol Pharmacol & Biochem, Morgantown, WV 26506 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	West Virginia University; Northwestern University	Graber, SG (corresponding author), W Virginia Univ, Sch Med, Dept Mol Pharmacol & Biochem, POB 9142 HSN, Morgantown, WV 26506 USA.		Bae, Hyunsu/ABH-6248-2020; Hamm, Heidi E/G-2374-2014	Bae, Hyunsu/0000-0002-0299-3582				Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; Bae H, 1999, J BIOL CHEM, V274, P14963, DOI 10.1074/jbc.274.21.14963; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Blahos J, 2001, J BIOL CHEM, V276, P3262, DOI 10.1074/jbc.M004880200; Christopher NA, 1996, COMPUT CHEM, V20, P339, DOI 10.1016/0097-8485(95)00075-5; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; Grishina G, 2000, MOL PHARMACOL, V57, P1081; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Ho MKC, 2000, MOL PHARMACOL, V58, P993, DOI 10.1124/mol.58.5.993; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Krieger-Brauer HI, 1999, J BIOL CHEM, V274, P28308, DOI 10.1074/jbc.274.40.28308; LEE CH, 1995, MOL PHARMACOL, V47, P218; Natochin M, 1999, J BIOL CHEM, V274, P7865, DOI 10.1074/jbc.274.12.7865; Natochin M, 2000, J BIOL CHEM, V275, P2669, DOI 10.1074/jbc.275.4.2669; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Swift S, 2000, J BIOL CHEM, V275, P2627, DOI 10.1074/jbc.275.4.2627; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8	29	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50530	50536		10.1074/jbc.M304417200	http://dx.doi.org/10.1074/jbc.M304417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525988	Green Published, hybrid			2022-12-25	WOS:000187068200106
J	del Peso, L; Castellanos, MC; Temes, E; Martin-Puig, S; Cuevas, Y; Olmos, G; Landazuri, MO				del Peso, L; Castellanos, MC; Temes, E; Martin-Puig, S; Cuevas, Y; Olmos, G; Landazuri, MO			The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASES; PC12 CELLS; FACTOR-I; HYPOXIA; HIF-1-ALPHA; BINDING; ALPHA; EXPRESSION; INDUCTION	Most of the genes induced by hypoxia are regulated by a family of transcription factors termed hypoxia-inducible factors (HIF). Under normoxic conditions, HIFalpha proteins are very unstable due to hydroxylation by a recently described family of proline hydroxylases termed EGL-Nine homologs (EGLN). Upon hydroxylation, HIFalpha is recognized by the product of the tumor suppressor vhl and targeted for proteosomal degradation. Since EGLNs require oxygen to catalize HIF hydroxylation, this reaction does not efficiently occur under low oxygen tension. Thus, under hypoxia, HIFalpha escapes from degradation and transcribes target genes. The mRNA levels of two of the three EGLNs described to date are induced by hypoxia, suggesting that they might be novel HIF target genes; however, no proof for this hypothesis has been reported. Here we show that the induction of EGLN1 and -3 by hypoxia is found in a wide range of cell types. The basal levels of EGLN3 are always well below those of EGLN1 and EGLN2, and its induction by hypoxia is larger than that found for EGLN1. The inhibitor of transcription, actinomycin D, prevents the increase of EGLN3 mRNA induced by hypoxia, indicating that it is due to enhanced gene expression. Interestingly, EGLN1 and EGLN3 mRNAs were also triggered by EGLN inhibitors, suggesting the involvement of HIFalpha in the control of its transcription. In agreement with this possibility, pVHL-deficient cell lines, which present high HIF activity under normoxia, also showed dramatically increased normoxic levels of EGLN3. Moreover, the overexpression of an oxygen-insensitive mutant form of HIFalpha resulted in increased normoxic levels of EGLN3 mRNA. Finally, hypoxic induction of EGLNs was not observed in cells lacking functional HIFalpha.	Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa	del Peso, L (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Bioquim, Arzobispo Morcillo S-N, E-28029 Madrid, Spain.	lpeso.hlpr@salud.madrid.org	del Peso, Luis/K-9391-2014	del Peso, Luis/0000-0003-4014-5688; Martin-Puig, Silvia/0000-0003-3048-6729; Olmos Centenera, Gemma/0000-0003-4835-0846				Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BANDYOPADHYAY RS, 1995, BBA-GENE STRUCT EXPR, V1264, P72, DOI 10.1016/0167-4781(95)00116-X; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Beitner-Johnson D, 2000, ADV EXP MED BIOL, V475, P143; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conrad PW, 2000, ADV EXP MED BIOL, V475, P293; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gozal E, 1999, J NEUROCHEM, V73, P665, DOI 10.1046/j.1471-4159.1999.0730665.x; Gozal E, 1998, J APPL PHYSIOL, V85, P372, DOI 10.1152/jappl.1998.85.1.372; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Munoz C, 1996, J IMMUNOL, V157, P3587; Naranjo-Suarez S, 2003, J BIOL CHEM, V278, P31895, DOI 10.1074/jbc.M304079200; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Siemeister G, 1996, CANCER RES, V56, P2299; WANG GL, 1993, J BIOL CHEM, V268, P21513; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	37	149	154	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48690	48695		10.1074/jbc.M308862200	http://dx.doi.org/10.1074/jbc.M308862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506252	hybrid			2022-12-25	WOS:000186829000023
J	Huang, YH; Rich, RL; Myszka, DG; Wu, H				Huang, YH; Rich, RL; Myszka, DG; Wu, H			Requirement of both the second and third BIR domains for the relief of X-linked inhibitor of apoptosis protein (XIAP)-mediated caspase inhibition by Smac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; STRUCTURAL BASIS; LIGASE ACTIVITY; IAP PROTEINS; XIAP; ACTIVATION; P35; DEGRADATION; SMAC/DIABLO; PROTEASES	The inhibitor of apoptosis proteins (IAP) are endogenous caspase inhibitors in the metazoan and characterized by the presence of baculoviral IAP repeats (BIR). X-linked IAP ( XIAP) contains three BIR domains and directly inhibits effector caspases such as caspase-7 via a linker_BIR2 fragment and initiator caspases such as caspase-9 via the BIR3 domain. A mitochondrial protein Smac/DIABLO, which is released during apoptosis, antagonizes XIAP-mediated caspase inhibition by interacting directly with XIAP. Here, using glutathione S-transferase pulldown and caspase activity assay, we show that Smac is ineffective in relieving either caspase-7 or caspase-9 inhibition by XIAP domain fragments. In addition, Smac forms a ternary complex with caspase-7 and linker_BIR2, suggesting that Smac/linker_BIR2 interaction does not sterically exclude linker_BIR2/ caspase-7 interaction. However, Smac is effective in removing caspase-7 and caspase-9 inhibition by XIAP fragments containing both the BIR2 and BIR3 domains. Surface plasmon resonance measurements show that Smac interacts with the BIR2 or BIR3 domain in micromolar dissociation constants. On the other hand, Smac interacts with an XIAP construct containing both BIR2 and BIR3 domains in a subnanomolar dissociation constant by the simultaneous interaction of the Smac dimer with the BIR2 and BIR3 domains of a single XIAP molecule. This 2: 1 Smac/XIAP interaction not only possesses enhanced affinity but also sterically excludes XIAP/ caspase-7 interaction, demonstrating the requirement of both BIR2 and BIR3 domains for Smac to relieve XIAP-mediated caspase inhibition.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Univ Utah, Sch Med, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA	Cornell University; Cornell University; Utah System of Higher Education; University of Utah	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, Room Whitney 206,1300 York Ave, New York, NY 10021 USA.				NIAID NIH HHS [AI50872] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050872] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XD, 2001, GENE DEV, V15, P2922; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Xu GZ, 2003, J BIOL CHEM, V278, P5455, DOI 10.1074/jbc.M211607200; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	34	120	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49517	49522		10.1074/jbc.M310061200	http://dx.doi.org/10.1074/jbc.M310061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512414	hybrid			2022-12-25	WOS:000186829000121
J	Kryndushkin, DS; Alexandrov, IM; Ter-Avanesyan, MD; Kushnirov, VV				Kryndushkin, DS; Alexandrov, IM; Ter-Avanesyan, MD; Kushnirov, VV			Yeast [PSI+] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE PROTEIN HSP104; SACCHAROMYCES-CEREVISIAE; GUANIDINE-HYDROCHLORIDE; RELEASE FACTOR; IN-VITRO; PROPAGATION; PSI(+); DETERMINANT; INHERITANCE; EXPRESSION	The yeast [PSI+] determinant is related to formation of large prion-like aggregates of the conformationally altered Sup35 protein. Here, we show that these aggregates are composed of small Sup35 prion polymers and associated proteins. In contrast to other protein complexes of yeast lysates, but similarly to amyloid fibers, these polymers are insoluble in SDS at room temperature. The polymers on average are about 30-fold smaller than the aggregates and comprise from 8 to 50 Sup35 monomers. The size of polymers is characteristic of a given [PSI+] variant and differs between the variants. Blocked expression of Hsp104 chaperone causes gradual increase in the size of prion polymers, while inactivation of Hsp104 by guanidine HCl completely stops their fragmentation, which shows indispensability of Hsp104 for this process.	Russian Acad Med Sci, Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia	National Medical Research Center of Cardiology; Russian Academy of Medical Sciences	Kushnirov, VV (corresponding author), Russian Acad Med Sci, Cardiol Res Ctr, Inst Expt Cardiol, 3rd Cherepkovskaya St 15A, Moscow 121552, Russia.	vita@cardio.ru	Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chacinska A, 2000, MOL CELL BIOL, V20, P7220, DOI 10.1128/MCB.20.19.7220-7229.2000; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Crist CG, 2003, GENES CELLS, V8, P603, DOI 10.1046/j.1365-2443.2003.00661.x; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Derkatch IL, 1996, GENETICS, V144, P1375; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Eaglestone SS, 2000, P NATL ACAD SCI USA, V97, P240, DOI 10.1073/pnas.97.1.240; Fernandez-Bellot E, 2002, EMBO REP, V3, P76, DOI 10.1093/embo-reports/kvf011; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; FRITZ JD, 1993, J MUSCLE RES CELL M, V14, P347, DOI 10.1007/BF00123100; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Greenbaum D, 2002, BIOINFORMATICS, V18, P585, DOI 10.1093/bioinformatics/18.4.585; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jung GM, 2002, P NATL ACAD SCI USA, V99, P9936, DOI 10.1073/pnas.152333299; Jung GM, 2001, CURR MICROBIOL, V43, P7, DOI 10.1007/s002840010251; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; ROSE MD, 1986, METHODS YEAST GENETI, P177; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Serio TR, 2000, TRENDS CELL BIOL, V10, P98, DOI 10.1016/S0962-8924(99)01711-0; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; TUITE MF, 1981, GENETICS, V98, P691; Valouev IA, 2002, CELL MOTIL CYTOSKEL, V52, P161, DOI 10.1002/cm.10040; WANG K, 1982, METHOD ENZYMOL, V85, P264; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	47	352	365	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49636	49643		10.1074/jbc.M307996200	http://dx.doi.org/10.1074/jbc.M307996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507919	hybrid			2022-12-25	WOS:000186829000135
J	Lynch, JR; Tang, W; Wang, HC; Vitek, MP; Bennett, ER; Sullivan, PM; Warner, DS; Laskowitz, DT				Lynch, JR; Tang, W; Wang, HC; Vitek, MP; Bennett, ER; Sullivan, PM; Warner, DS; Laskowitz, DT			APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; APOLIPOPROTEIN-E; MICROGLIAL ACTIVATION; IMMUNOREGULATORY LIPOPROTEIN; CHYLOMICRONS ALTER; ENDOTOXIN; ASSOCIATION; APOPROTEIN; PROTEIN	Human apolipoprotein E is the major apolipoprotein expressed in the brain and exists as three isoforms, designated E2, E3, and E4. Although evidence suggests that apolipoprotein E plays an important role in modifying systemic and brain inflammatory responses, there is little data investigating apoE isoform-specific effects in vivo. In this study, we compared the inflammatory responses of targeted-replacement mice expressing the human APOE3 and APOE4 genes after intravenous administration of lipopolysaccharide. Animals expressing the E4 allele had significantly greater systemic and brain elevations of the pro-inflammatory cytokines TNFalpha and IL-6 as compared with their APOE3 counterparts, suggesting an isoform-specific effect of the immunomodulatory properties of apoE. Furthermore, intravenous administration of a small apoE-mimetic peptide derived from the receptor-binding region of the apoE holoprotein (apoE-( 133 - 149)) similarly suppressed both systemic and brain inflammatory responses in mice after lipopolysaccharide administration. These results suggest that apoE plays an isoform- specific role in mediating the systemic and brain inflammatory responses. Moreover, because exogenous administration of this apoE mimetic peptide is effective at suppressing both systemic and brain inflammation, it may represent a novel therapeutic strategy for diseases characterized by systemic or central nervous system inflammation, such as septic shock, multiple sclerosis, and traumatic brain injury.	Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Bryan Alzheimers Dis Res Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	NIA NIH HHS [1K08-AG022230-01] Funding Source: Medline; NINDS NIH HHS [1R21 NS4487-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG022230] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVILA EM, 1982, J BIOL CHEM, V257, P5900; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CURTISS LK, 1981, J IMMUNOL, V126, P1382; de Bont N, 1999, J LIPID RES, V40, P680; de Bont N, 2000, EUR J CLIN INVEST, V30, P818; Egensperger R, 1998, BRAIN PATHOL, V8, P439; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; Harris HW, 1998, HEPATOLOGY, V27, P1341, DOI 10.1002/hep.510270521; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; MISRA UK, 1994, J BIOL CHEM, V269, P18303; PEPE MG, 1986, J IMMUNOL, V136, P3716; READ TE, 1993, INFECT IMMUN, V61, P3496, DOI 10.1128/IAI.61.8.3496-3502.1993; Roselaar SE, 1998, J LIPID RES, V39, P1740; Schmidt S, 2002, AM J HUM GENET, V70, P708, DOI 10.1086/339269; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; SULLIVAN PM, 1977, J BIOL CHEM, V227, P17972; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249	30	277	291	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48529	48533		10.1074/jbc.M306923200	http://dx.doi.org/10.1074/jbc.M306923200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507923	hybrid			2022-12-25	WOS:000186829000004
J	Roberts, GA; Celik, A; Hunter, DJB; Ost, TWB; White, JH; Chapman, SK; Turner, NJ; Flitsch, SL				Roberts, GA; Celik, A; Hunter, DJB; Ost, TWB; White, JH; Chapman, SK; Turner, NJ; Flitsch, SL			A self-sufficient cytochrome P450 with a primary structural organization that includes a flavin domain and a [2Fe-2S] redox center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOCYTOCHROME P-450 BM3; BACILLUS-MEGATERIUM; ELECTRON-TRANSFER; RHODOCOCCUS SP; P450BM3	P450 RhF from Rhodococcus sp. NCIMB 9784 is the first example of a new class of cytochrome P450 in which electrons are supplied by a novel, FMN- and Fe/S-containing, reductase partner in a fused arrangement. We have previously cloned the gene encoding the enzyme and shown it to comprise an N-terminal P450 domain fused to a reductase domain that displays similarity to the phthalate family of oxygenase reductase proteins. A reductase of this type had never previously been reported to interact with a cytochrome P450. In this report we describe the purification and partial characterization of P450 RhF. We show that the enzyme is self-sufficient in catalyzing the O-dealkylation of 7-ethoxycoumarin. The P450 RhF catalyzed O-dealkylation of 7-ethoxycoumarin is inhibited by several compounds that are known inhibitors of cytochrome P450. Presteady state kinetic analysis indicates that P450 RhF shows a 500-fold preference for NAPDH over NADH in terms of K-d value (6.6 muM versus 3.7 mM, respectively). Potentiometric studies show reduction potentials of - 243 mV for the two-electron reduction of the FMN and - 423 mV for the heme ( in the absence of substrate).	Univ Edinburgh, Sch Chem, Edinburgh Ctr Prot Technol, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh	Flitsch, SL (corresponding author), Univ Edinburgh, Sch Chem, Edinburgh Ctr Prot Technol, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.		Hunter, Dominic/R-8894-2016; Hunter, Dominic/H-7955-2019; Flitsch, Sabine/AAJ-6812-2020; Hunter, Dominic/Q-4226-2019	Hunter, Dominic/0000-0002-1826-6902; Hunter, Dominic/0000-0002-1826-6902; Flitsch, Sabine/0000-0003-3974-646X; Roberts, Gareth/0000-0002-3726-390X; Celik, Ayhan/0000-0003-1355-9252; Turner, Nicholas/0000-0002-8708-0781				CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; De Mot R, 2002, TRENDS MICROBIOL, V10, P502, DOI 10.1016/S0966-842X(02)02458-7; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P305; Grogan G, 2001, J BIOL CHEM, V276, P12565, DOI 10.1074/jbc.M011538200; Kitazume T, 2000, J BIOL CHEM, V275, P39734, DOI 10.1074/jbc.M005617200; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Munro AW, 2002, TRENDS BIOCHEM SCI, V27, P250, DOI 10.1016/S0968-0004(02)02086-8; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; NAGY I, 1995, J BACTERIOL, V177, P676, DOI 10.1128/jb.177.3.676-687.1995; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NERBERT DW, 1987, ANNU REV BIOCHEM, V56, P945; Noble MA, 1999, BIOCHEM J, V339, P371, DOI 10.1042/0264-6021:3390371; OMURA T, 1964, J BIOL CHEM, V239, P2370; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Roberts GA, 2002, J BACTERIOL, V184, P3898, DOI 10.1128/JB.184.14.3898-3908.2002; Sambrook J., 2002, MOL CLONING LAB MANU; Seo JA, 2001, FUNGAL GENET BIOL, V34, P155, DOI 10.1006/fgbi.2001.1299; Yu TW, 2002, P NATL ACAD SCI USA, V99, P7968, DOI 10.1073/pnas.092697199	20	82	90	3	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48914	48920		10.1074/jbc.M309630200	http://dx.doi.org/10.1074/jbc.M309630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514666	hybrid, Green Published			2022-12-25	WOS:000186829000050
J	Schulz, JG; Annaert, W; Vandekerckhove, J; Zimmermann, P; De Strooper, B; David, G				Schulz, JG; Annaert, W; Vandekerckhove, J; Zimmermann, P; De Strooper, B; David, G			Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; TERMINAL FRAGMENT-GAMMA; INTRACELLULAR DOMAIN; TRANSMEMBRANE DOMAIN; ALZHEIMERS-DISEASE; EPITHELIAL-CELLS; CLEAVAGE; NOTCH	The syndecans play critical roles in several signal transduction pathways. The core proteins of these heparan sulfate proteoglycans are characterized by highly conserved transmembrane and intracellular domains which are required for signaling across the membrane and for interaction with cytosolic proteins. However, regulatory mechanisms controlling these functions remain largely unknown. Here we show that, upon ligand-induced primary proteolytic cleavage within the ectodomain, the intracellular domain of syndecan 3 is released by regulated intramembrane proteolysis. The cleavage is mediated by presenilin/gamma-secretase complex and negatively regulates the plasma membrane targeting of the transcriptional cofactor CASK.	Univ Louvain, Dept Human Genet, Neuronal Cell Biol Grp, B-3000 Louvain, Belgium; State Univ Ghent, Dept Med Prot Res, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9052 Ghent, Belgium	Ghent University	De Strooper, B (corresponding author), Univ Louvain, Dept Human Genet, Neuronal Cell Biol Grp, Herestr 49, B-3000 Louvain, Belgium.		de+Strooper, Bart/Z-1638-2019; Zimmermann, Pascale/P-4190-2017; Schulz, Joachim/H-2430-2011; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bredt DS, 2000, NATURE, V404, P241, DOI 10.1038/35005208; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Handler M, 2000, DEVELOPMENT, V127, P2593; Hartmann D, 1999, CURR BIOL, V9, P719, DOI 10.1016/S0960-9822(99)80331-5; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hevner RF, 2001, NEURON, V29, P353, DOI 10.1016/S0896-6273(01)00211-2; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kramer KL, 2002, CELL, V111, P981, DOI 10.1016/S0092-8674(02)01200-X; Kramer KL, 2002, DEV CELL, V2, P115, DOI 10.1016/S1534-5807(01)00107-1; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lin XH, 1999, DEVELOPMENT, V126, P3715; LORIES V, 1992, J BIOL CHEM, V267, P1116; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McLendon C, 2000, FASEB J, V14, P2383; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Vaccarino FM, 1999, NAT NEUROSCI, V2, P246, DOI 10.1038/6350; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200	55	87	90	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48651	48657		10.1074/jbc.M308424200	http://dx.doi.org/10.1074/jbc.M308424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504279	hybrid			2022-12-25	WOS:000186829000018
J	Yang, PR; Qyang, Y; Bartholomeusz, G; Zhou, X; Marcus, S				Yang, PR; Qyang, Y; Bartholomeusz, G; Zhou, X; Marcus, S			The novel Rho GTPase-activating protein family protein, Rga8, provides a potential link between Cdc42/p21-activated kinase and Rho signaling pathways in the fission yeast, Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN PROTEIN; P21-ACTIVATED KINASE; CELL POLARITY; SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; XENOPUS OOCYTES; SHK1; RAS; BINDING; MORPHOGENESIS	The PAK family kinase, Shk1, is an essential regulator of polarized growth in the fission yeast, Schizosaccharomyces pombe. Here we describe the characterization of a novel member of the RhoGAP family, Rga8, identified from a two-hybrid screen for proteins that interact with the Shk1 kinase domain. Although deletion of the rga8 gene in wild type S. pombe cells results in no obvious phenotypic defects under normal growth conditions, it partially suppresses the cold-sensitive growth and morphological defects of S. pombe cells carrying a hypomorphic allele of the shk1 gene. By contrast, overexpression of rga8 is lethal to shk1-defective cells and causes morphological and cytokinesis defects in wild type S. pombe cells. Consistent with a role for Rga8 as a downstream target of Shk1, we show that the Rga8 protein is directly phosphorylated by Shk1 in vitro and phosphorylated in a Shk1-dependent fashion in S. pombe cells. Fluorescence photomicroscopy of the GFP-Rga8 fusion protein indicates that Rga8 is localized to the cell ends during interphase and to the septum-forming region during cytokinesis. In S. pombe cells carrying the orb2-34 allele of shk1, Rga8 exhibits a monopolar pattern of localization, providing evidence that Shk1 contributes to the regulation of Rga8 localization. Although molecular analyses suggest that Rga8 functions as a GAP for the S. pombe Rho1 GTPase, genetic experiments suggest that Rga8 and Rho1 have a positive functional interaction and that gain of Rho1 function, like gain of Rga8 function, is lethal to Shk1-defective cells. Our results suggest that Rga8 is a Shk1 substrate that negatively regulates Shk1-dependent growth control pathway(s) in S. pombe, potentially through interaction with the Rho1 GTPase.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Marcus, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	smarcus@mdacc.tmc.edu			NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alfa C, 1993, EXPT FISSION YEAST L; Allen KM, 1998, NAT GENET, V20, P25, DOI 10.1038/1675; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arellano M, 1996, EMBO J, V15, P4584, DOI 10.1002/j.1460-2075.1996.tb00836.x; Arellano M, 1997, J CELL SCI, V110, P2547; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Bao SL, 2001, J BIOL CHEM, V276, P14549, DOI 10.1074/jbc.C100096200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Calonge TM, 2003, MOL MICROBIOL, V47, P507, DOI 10.1046/j.1365-2958.2003.03312.x; Chang E, 1999, MOL CELL BIOL, V19, P8066; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Glynn JM, 2001, CURR BIOL, V11, P836, DOI 10.1016/S0960-9822(01)00235-4; Hirata D, 1998, J CELL SCI, V111, P149; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Kim H, 2003, J BIOL CHEM, V278, P30074, DOI 10.1074/jbc.M302609200; Kim HW, 2001, MOL CELL, V7, P1095, DOI 10.1016/S1097-2765(01)00248-9; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kozma R, 1996, MOL CELL BIOL, V16, P5069; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MITCHISON JM, 1985, J CELL SCI, V75, P357; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; Nakano K, 1997, GENES CELLS, V2, P679, DOI 10.1046/j.1365-2443.1997.1540352.x; Nakano K, 2001, GENES CELLS, V6, P1031, DOI 10.1046/j.1365-2443.2001.00485.x; NIELSEN O, 1995, SEMIN CELL BIOL, V6, P95, DOI 10.1016/1043-4682(95)90006-3; Ory S, 2000, J CELL SCI, V113, P1177; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Qyang YB, 2002, MOL MICROBIOL, V44, P325, DOI 10.1046/j.1365-2958.2002.02882.x; Rose MD., 1990, METHODS YEAST GENETI; Roumanie O, 2001, FEBS LETT, V506, P149, DOI 10.1016/S0014-5793(01)02906-4; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1998, J BIOL CHEM, V273, P18490, DOI 10.1074/jbc.273.29.18490; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yang PR, 1998, J BIOL CHEM, V273, P18481, DOI 10.1074/jbc.273.29.18481; Yang PR, 1999, J BIOL CHEM, V274, P36052, DOI 10.1074/jbc.274.51.36052; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	66	28	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48821	48830		10.1074/jbc.M306819200	http://dx.doi.org/10.1074/jbc.M306819200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506270	hybrid			2022-12-25	WOS:000186829000039
J	Suschek, CV; Schroeder, P; Aust, O; Sies, H; Mahotka, C; Horstjann, M; Ganser, H; Murtz, M; Hering, P; Schnorr, O; Kroncke, KD; Kolb-Bachofen, V				Suschek, CV; Schroeder, P; Aust, O; Sies, H; Mahotka, C; Horstjann, M; Ganser, H; Murtz, M; Hering, P; Schnorr, O; Kroncke, KD; Kolb-Bachofen, V			The presence of nitrite during UVA irradiation protects from apoptosis	FASEB JOURNAL			English	Article						apoptosis; DNA fragmentation; endothelial cells; lipid peroxidation; nitrite	ENDOTHELIAL-CELLS; OXIDE SYNTHASE; HUMAN SKIN; SODIUM-NITRITE; RELAXATION; EXPRESSION; PHOTOLYSIS; TOXICITY; WATER	Nitrite occurs ubiquitously in biological fluids such as blood and sweat, representing an oxidation product of nitric oxide. Nitrite has been associated with a variety of adverse effects such as mutagenicity, carcinogenesis, and toxicity. In contrast, here we demonstrate that the presence of nitrite, but not nitrate, during irradiation of endothelial cells in culture exerts a potent and concentration-dependent protection against UVA-induced apoptotic cell death. Protection is half-maximal at a concentration of 3 mM, and complete rescue is observed at 10 mM. Nitrite-mediated protection is mediated via inhibition of lipid peroxidation in a similar manner as seen with butylated hydroxytoluene, a known inhibitor of lipid peroxidation. Interestingly, nitrite-mediated protection is completely abolished by coincubation with the NO scavenger cPTIO. Using electron paramagnetic resonance (EPR) spectroscopy or Faraday modulation spectroscopy, we directly prove UVA-induced NO formation in solutions containing nitrite. In conclusion, evidence is presented that nitrite represents a protective agent against UVA-induced apoptosis due to photodecomposition of nitrite and subsequent formation of NO.	Univ Dusseldorf, Dept Immunobiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Laser Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Suschek, CV (corresponding author), Univ Dusseldorf, Dept Immunobiol, Bldg 23-12-02,POB 10 10 07, D-40001 Dusseldorf, Germany.	suschek@uni-duesseldorf.de	Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Sies, Helmut/0000-0002-1000-3198				Bruch-Gerharz D, 1998, ARCH DERMATOL RES, V290, P643, DOI 10.1007/s004030050367; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; Bruch-Gerharz D, 1998, J INVEST DERMATOL, V110, P1, DOI 10.1046/j.1523-1747.1998.00084.x; BruchGerharz D, 1996, J EXP MED, V184, P2007, DOI 10.1084/jem.184.5.2007; Capasso F, 1999, OPT PHOTONICS NEWS, V10, P31, DOI 10.1364/OPN.10.10.000031; DANPURE HJ, 1976, PHOTOCHEM PHOTOBIOL, V23, P171, DOI 10.1111/j.1751-1097.1976.tb07238.x; Darley-Usmar VM, 2000, NITRIC OXIDE BIOL PA, P265; EHRREICH SJ, 1968, NATURE, V218, P682, DOI 10.1038/218682a0; Fan AM, 1996, REGUL TOXICOL PHARM, V23, P35, DOI 10.1006/rtph.1996.0006; FEHSEL K, 1994, J HISTOCHEM CYTOCHEM, V42, P613, DOI 10.1177/42.5.8157933; Fischer M, 1996, J PHYS CHEM-US, V100, P18749, DOI 10.1021/jp961692+; Fukuhara K, 2001, J AM CHEM SOC, V123, P8662, DOI 10.1021/ja0109038; Fukuto JM, 2000, NITRIC OXIDE BIOL PA, P23, DOI DOI 10.1016/B978-012370420-7/50003-4; FURCHGOTT RF, 1991, SEMIN PERINATOL, V15, P11; GRANT D, 1989, FOOD CHEM TOXICOL, V27, P565, DOI 10.1016/0278-6915(89)90015-X; Horstmann A, 2002, NITRIC OXIDE-BIOL CH, V6, P135, DOI 10.1006/niox.2001.0398; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; KULL FC, 1983, APPL BIOCHEM BIOTECH, V8, P97, DOI 10.1007/BF02778090; MIRANDA KM, 2000, NITRIC OXIDE BIOL PA, P41; Noda Y, 1997, RES COMMUN MOL PATH, V96, P115; *NTP, 2001, NATL TOXICOL PROGRAM, V495, P1; ROCHE MG, 1983, NAHRUNG, V27, P837; STREHLOW H, 1982, Z PHYS CHEM NEUE FOL, V132, P151, DOI 10.1524/zpch.1982.132.2.151; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; SUSCHEK C, 1994, AM J PATHOL, V145, P685; Suschek CV, 2001, CELL DEATH DIFFER, V8, P515, DOI 10.1038/sj.cdd.4400839; Suschek CV, 2001, J INVEST DERMATOL, V117, P1200, DOI 10.1046/j.0022-202x.2001.01502.x; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Tsuchiya K, 1999, FREE RADICAL BIO MED, V27, P347, DOI 10.1016/S0891-5849(99)00062-3; Weller R, 1996, J INVEST DERMATOL, V107, P327, DOI 10.1111/1523-1747.ep12363167; WIGILIUS IM, 1990, BIOCHEM BIOPH RES CO, V169, P129, DOI 10.1016/0006-291X(90)91443-V; ZAFIRIOU OC, 1987, PHOTOCHEM PHOTOBIOL, V45, P723, DOI 10.1111/j.1751-1097.1987.tb07873.x	36	40	41	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2342	+		10.1096/fj.03-0359fje	http://dx.doi.org/10.1096/fj.03-0359fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525939				2022-12-25	WOS:000186343300008
J	Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE				Remenyik, E; Wikonkal, NM; Zhang, WG; Paliwal, V; Brash, DE			Antigen-specific immunity does not mediate acute regression of UVB-induced p53-mutant clones	ONCOGENE			English	Article						Rag1; knockout; sunburn cells; apoptosis; epidermal thickness; immune surveillance	MOUSE SKIN CARCINOGENESIS; EARLY ADAPTIVE RESPONSES; ULTRAVIOLET-IRRADIATION; PERSISTENT HYPERPLASIA; INDUCED APOPTOSIS; HAIRLESS MICE; LYMPHOCYTES-T; P53 MUTATIONS; NKT CELLS; CANCER	Chronic irradiation of human or murine epidermis with ultraviolet B (UVB) induces clones of p53-mutant keratinocytes. Clones precede and parallel the induction of carcinomas, suggesting that they are an early stage of UVB carcinogenesis. In the absence of UVB, these clones rapidly regress. For UVB-induced murine skin tumors and papillomas, regression is known to involve antigen-specific immunity. To determine whether antigen-specific immunity influences the creation, expansion, or regression of p53-mutant clones, we studied Rag1 knockout mice deficient in the recombination activating gene 1 required for development of B, alphabetaT, gammadeltaT, and natural killer T cells. Since tissue homeostasis could affect proliferation or persistence of clones, we also examined the effect of Rag1 on UVB-induced hyperplasia and apoptosis. Mice were irradiated with UVB daily for 7-11 weeks to create p53-mutant clones, and then retained in the absence of UV. After UV ended, epidermal thickness decreased and p53-mutant clones observed in the epidermal sheets regressed, with no significant differences between Rag1(-/-) and wild type. During the initial chronic UVB irradiation, increasing irradiation time increased both the number and size of p53-mutant clones, with no significant difference between genotypes. We conclude that antigen-specific immunity is not involved in the initiation, expansion, or acute regression of p53-mutant clones.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT USA; Yale Univ, Yale Canc Ctr, New Haven, CT USA; Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol, H-4012 Debrecen, Hungary; Semmelweis Univ, Sch Med, Dept Dermatol, H-1085 Budapest, Hungary	Yale University; Yale University; Yale University; University of Debrecen; Semmelweis University	Brash, DE (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St,HRT 309, New Haven, CT 06520 USA.	douglas.brash@yale.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA078735] Funding Source: NIH RePORTER; NCI NIH HHS [CA78735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS EJ, 1971, J NATL CANCER I, V47, P653; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1998, CANCER SURV, V32, P69; BURNS FJ, 1976, CANCER RES, V36, P1422; Carnaud C, 1999, J IMMUNOL, V163, P4647; Daugelat S, 1996, IMMUNOL LETT, V50, P81, DOI 10.1016/0165-2478(96)02523-0; DAYNES RA, 1981, J INVEST DERMATOL, V77, P77, DOI 10.1111/1523-1747.ep12479260; DEFABO EC, 1979, PHOTOCHEM PHOTOBIOL, V30, P385, DOI 10.1111/j.1751-1097.1979.tb07372.x; DEGRUIJL FR, 1993, CANCER RES, V53, P53; FISHER MS, 1977, P NATL ACAD SCI USA, V74, P1688, DOI 10.1073/pnas.74.4.1688; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333, DOI 10.1093/jnci/53.5.1333; KRIPKE ML, 1976, J NATL CANCER I, V57, P211, DOI 10.1093/jnci/57.1.211; Lu YP, 1999, CANCER RES, V59, P4591; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moodycliffe AM, 2000, NAT IMMUNOL, V1, P521, DOI 10.1038/82782; NOONAN FP, 1990, PHOTOCHEM PHOTOBIOL, V52, P801, DOI 10.1111/j.1751-1097.1990.tb08685.x; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Rebel H, 2001, CANCER RES, V61, P977; Ren ZP, 1996, ONCOGENE, V12, P765; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; STRICKLAND PT, 1987, CANCER RES, V47, P6294; STRICKLAND PT, 1986, ENVIRON HEALTH PERSP, V68, P131, DOI 10.2307/3430257; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; TODA KI, 1986, J CLIN LAB IMMUNOL, V20, P129; Ullrich SE, 2000, BIOCHEMICAL MODULATION OF SKIN REACTIONS, P281; Ullrich SE, 2002, FRONT BIOSCI-LANDMRK, V7, pD684, DOI 10.2741/ullrich; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	28	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6369	6376		10.1038/sj.onc.1206657	http://dx.doi.org/10.1038/sj.onc.1206657			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508517				2022-12-25	WOS:000185535300007
J	Zhang, HJ; Xu, LJ; Drake, VJ; Xie, LT; Oberley, LW; Kregel, KC				Zhang, HJ; Xu, LJ; Drake, VJ; Xie, LT; Oberley, LW; Kregel, KC			Heat-induced liver injury in old rats is associated with exaggerated oxidative stress and altered transcription factor activation	FASEB JOURNAL			English	Article						free radicals; ROS; aging; hyperthermia; signal transduction	NF-KAPPA-B; FREE-RADICAL GENERATION; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; REDOX REGULATION; GLUTATHIONE; CELLS; AP-1; DIFFERENTIATION; OVEREXPRESSION	A decline in stress tolerance is a hallmark of aging. For instance, older organisms showed extensive hepatic damage, along with increased morbidity and mortality, after environmental heating. We hypothesized that hyperthermic challenge would produce exaggerated oxidative stress in old animals, leading to increased hepatic injury. After a heat-stress protocol, time-course changes in reactive oxygen species (ROS) levels, oxidative damage markers, glutathione (GSH)/glutathione disulfide (GSSG) ratios, and activation of stress-response transcription factors (AP-1 and NF-kappaB) were measured in young and old rats. A small, transient increase in hepatic oxidative damage, with minimal injury, was observed in young rats. However, old rats showed widespread hepatic injury that was manifested over a 24 h period after heating. This pathology was preceded by elevated steady-state levels of ROS, along with large increases in lipid peroxidation products, prolonged hepatic DNA oxidation damage, aberrant GSH/GSSG profiles, and altered activation patterns for AP-1. These data indicate that young animals have an effective oxidation-reduction buffering system in the liver that provides protection from oxidative damage to intracellular macromolecules under stress conditions. In sharp contrast, an environmental challenge in older animals produces exaggerated oxidative stress and alterations in signal transduction pathways, which can contribute to cellular dysfunction and age-related reductions in stress tolerance.	Univ Iowa, Dept Exercise Sci, Integrat Physiol Lab, FH 532, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Kregel, KC (corresponding author), Univ Iowa, Dept Exercise Sci, Integrat Physiol Lab, FH 532, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bejma J, 2000, ACTA PHYSIOL SCAND, V169, P343; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749; Harris AG, 1998, AM J PHYSIOL-HEART C, V274, pH1009, DOI 10.1152/ajpheart.1998.274.3.H1009; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; Headrick JP, 1998, J MOL CELL CARDIOL, V30, P1415, DOI 10.1006/jmcc.1998.0710; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEW M, 1971, T ROY SOC TROP MED H, V65, P325, DOI 10.1016/0035-9203(71)90007-1; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kregel K. C., 1996, J APPL PHYSIOL, V80, P262; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; Kregel KC, 1996, J APPL PHYSIOL, V80, P540, DOI 10.1152/jappl.1996.80.2.540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Li N, 2002, AM J PHYSIOL-RENAL, V282, pF1111, DOI 10.1152/ajprenal.00218.2001; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Miller FJ, 2002, ARTERIOSCL THROM VAS, V22, P560, DOI 10.1161/01.ATV.0000013778.72404.30; Morrison RJ, 1998, TOXICOL APPL PHARM, V148, P229, DOI 10.1006/taap.1997.8339; Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Parola M, 1999, INT J MOL MED, V4, P425; Piette J, 1997, BIOL CHEM, V378, P1237; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Rikans LE, 1999, MECH AGEING DEV, V108, P173, DOI 10.1016/S0047-6374(99)00012-3; RYAN AJ, 1995, J APPL PHYSIOL, V78, P38, DOI 10.1152/jappl.1995.78.1.38; Schafer FQ, 2000, FREE RADICAL BIO MED, V28, P1175, DOI 10.1016/S0891-5849(00)00319-1; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SLATER TF, 1982, BIOCHEM J, V22, P1; Tani M, 1997, J MOL CELL CARDIOL, V29, P3081, DOI 10.1006/jmcc.1997.0533; Tjalkens RB, 1999, ARCH BIOCHEM BIOPHYS, V361, P113, DOI 10.1006/abbi.1998.0946; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 2002, J VIROL, V76, P355, DOI 10.1128/JVI.76.1.355-363.2002; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	50	84	91	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2293	+		10.1096/fj.03-0139fje	http://dx.doi.org/10.1096/fj.03-0139fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500545				2022-12-25	WOS:000185925100013
J	Lisal, J; Kainov, DE; Bamford, DH; Thomas, GJ; Tuma, R				Lisal, J; Kainov, DE; Bamford, DH; Thomas, GJ; Tuma, R			Enzymatic mechanism of RNA translocation in double-stranded RNA Bacteriophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA PACKAGING ENZYME; 3 GENOMIC SEGMENTS; KINETIC CHARACTERIZATION; RAMAN-SPECTROSCOPY; VIBRATIONAL ANALYSIS; DIETHYL PHOSPHATE; NUCLEIC-ACIDS; PROTEIN P4; HELICASE; BINDING	Many complex viruses acquire their genome by active packaging into a viral precursor particle called a procapsid. Packaging is performed by a viral portal complex, which couples ATP hydrolysis to translocation of nucleic acid into the procapsid. The packaging process has been studied for a variety of viruses, but the mechanism of the associated ATPase remains elusive. In this study, the mechanism of RNA translocation in double-stranded RNA bacteriophages is characterized using rapid kinetic analyses. The portal complex of bacteriophage phi8 is a hexamer of protein P4, which exhibits nucleotide triphosphatase activity. The kinetics of ATP binding reveals a two-step process: an initial, fast, second-order association, followed by a slower, first-order phase. The slower phase exhibits a high activation energy and has been assigned to a conformational change. ATP binding becomes cooperative in the presence of RNA. Steady-state kinetics of ATP hydrolysis, which proceeds only in the presence of RNA, also exhibits cooperativity. On the other hand, ADP release is fast and RNA-independent. The steady-state rate of hydrolysis increases with the length of the RNA substrate indicating processive translocation. Raman spectroscopy reveals that RNA binds to P4 via the phosphate backbone. The ATP-induced conformational change affects the backbone of the bound RNA but leaves the protein secondary structure unchanged. This is consistent with a model in which cooperativity is induced by an RNA link between subunits of the hexamers and translocation is effected by an axial movement of the subunits relative to one another upon ATP binding.	Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Missouri, Div Cell Biol & Biophys, Sch Biol Sci, Kansas City, MO 64110 USA	University of Helsinki; University of Helsinki; University of Missouri System; University of Missouri Kansas City	Tuma, R (corresponding author), Univ Helsinki, Viikki Bioctr, POB 65,Viikinkaari 1, FIN-00014 Helsinki, Finland.	roman.tuma@helsinki.fi	Tuma, Roman/AAL-4436-2020; kainov, denis/I-5526-2019	Tuma, Roman/0000-0003-0047-0013; kainov, denis/0000-0001-7716-6955; Bamford, Dennis/0000-0002-6438-8118	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050776] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50776] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benevides JM, 1997, BIOPHYS J, V72, P2748, DOI 10.1016/S0006-3495(97)78917-3; Benevides JM, 1996, BIOCHEMISTRY-US, V35, P5747, DOI 10.1021/bi9529420; Benevides JM, 2002, BIOCHEMISTRY-US, V41, P11946, DOI 10.1021/bi0201623; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; de Haas F, 1999, J MOL BIOL, V294, P357, DOI 10.1006/jmbi.1999.3260; GOTTLIEB P, 1990, J BACTERIOL, V172, P5774, DOI 10.1128/jb.172.10.5774-5782.1990; Gual A, 2000, J BIOL CHEM, V275, P35311, DOI 10.1074/jbc.M004309200; Guan Y, 1996, BIOPHYS J, V71, P2802, DOI 10.1016/S0006-3495(96)79474-2; Guan YF, 1996, BIOPOLYMERS, V39, P813, DOI 10.1002/(SICI)1097-0282(199612)39:6<813::AID-BIP7>3.3.CO;2-C; Guo PX, 2002, PROG NUCLEIC ACID RE, V72, P415, DOI 10.1016/S0079-6603(02)72076-X; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; Ibarra B, 2001, NUCLEIC ACIDS RES, V29, P4264, DOI 10.1093/nar/29.21.4264; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Juuti JT, 1998, J MOL BIOL, V279, P347, DOI 10.1006/jmbi.1998.1772; Kainov DE, 2003, J BIOL CHEM, V278, P48084, DOI 10.1074/jbc.M306928200; Kainov DE, 2003, J MOL BIOL, V328, P791, DOI 10.1016/S0022-2836(03)00322-X; Kim DE, 2002, J MOL BIOL, V321, P807, DOI 10.1016/S0022-2836(02)00733-7; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LI TS, 1992, BIOCHEMISTRY-US, V31, P6673, DOI 10.1021/bi00144a006; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Makeyev EV, 2000, EMBO J, V19, P6275, DOI 10.1093/emboj/19.22.6275; Mindich L, 1999, J BACTERIOL, V181, P4505, DOI 10.1128/JB.181.15.4505-4508.1999; Mindich L, 1999, MICROBIOL MOL BIOL R, V63, P149, DOI 10.1128/MMBR.63.1.149-160.1999; MINDICH L, 1988, ADV VIRUS RES, V35, P137; Moore SD, 2002, J MOL BIOL, V315, P975, DOI 10.1006/jmbi.2001.5275; PAATERO AO, 1995, J VIROL, V69, P6729, DOI 10.1128/JVI.69.11.6729-6734.1995; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pirttimaa MJT, 2000, RNA, V6, P880, DOI 10.1017/S1355838200992598; Poranen MM, 2001, MOL CELL, V7, P845, DOI 10.1016/S1097-2765(01)00228-3; Qiao XY, 1997, P NATL ACAD SCI USA, V94, P4074, DOI 10.1073/pnas.94.8.4074; Sambrook J, 2001, MOL CLONING LAB MANU; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Skordalakes E, 2003, CELL, V114, P135, DOI 10.1016/S0092-8674(03)00512-9; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sun Y, 2003, VIROLOGY, V308, P354, DOI 10.1016/S0042-6822(03)00013-8; Thomas GJ, 1999, ANNU REV BIOPH BIOM, V28, P1, DOI 10.1146/annurev.biophys.28.1.1; THOMAS GJ, 1993, ADV BIOPHYS CHEM, V3, P1; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; Woods L, 1999, BIOCHEMISTRY-US, V38, P14624, DOI 10.1021/bi990866l; Yang Q, 1997, BIOCHEMISTRY-US, V36, P10638, DOI 10.1021/bi970689t	44	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1343	1350		10.1074/jbc.M309587200	http://dx.doi.org/10.1074/jbc.M309587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14530266	hybrid			2022-12-25	WOS:000187722800062
J	Sowa, H; Kaji, H; Iu, MF; Tsukamoto, T; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Iu, MF; Tsukamoto, T; Sugimoto, T; Chihara, K			Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE ACTIVITY; RAT COLLAGENASE-3 PROMOTER; OSTEOGENIC-SARCOMA CELLS; INCREASED BONE-FORMATION; GENE FAMILY MEMBERS; PROTEIN-KINASE-A; C-FOS PROMOTER; FACTOR-I; MESSENGER-RNA; SIGNALING PATHWAYS	Although several studies indicated that parathyroid hormone (PTH) exerted anabolic action on bone, its precise mechanisms have been unknown. On the other hand, transforming growth factor beta (TGF-beta), abundantly stored in bone matrix, stimulates bone formation with a local injection in rodents. Although our previous study suggested that Smad3 is an important molecule for the stimulation of bone formation, no reports have been available about the effects of PTH on Smad3. In this present study, we examined the effects of PTH on Smad3 and the physiological significance in mouse osteoblastic cells. PTH promoted the expression of Smad3 mRNA within 10 min and the protein level in a dose-dependent manner in MC3T3-E1 and rat osteoblastic UMR-106 cells. Protein kinase A (PKA) activator as well as protein kinase C (PKC) activators increased Smad3 protein level, and both PKA and PKC inhibitors antagonized PTH-induced Smad3, indicating that PTH promotes the production of Smad3 through both PKA and PKC pathways. Next, we examined anti-apoptotic effects of PTH and Smad3 in these cells, employing trypan blue, transferase-mediated nick end labeling, and Hoechst staining. Pretreatment with PTH or overexpression of Smad3 decreased the number of apoptotic cells induced by dexamethasone and etoposide. Moreover, a dominant negative mutant, Smad3DeltaC, abrogated PTH-induced anti-apoptotic effects. On the other hand, PTH augmented TGF-beta-induced transcriptional activity. Furthermore, PTH enhanced TGF-beta-induced production of type I collagen, whereas it did not affect TGF-beta-reduced proliferation in MC3T3-E1 cells. These observations indicated that PTH amplified the anabolic effects of TGF-beta by accelerating the transcriptional activity of Smad3. In conclusion, we first demonstrated that PTH-Smad3 axis exerts anti-apoptotic effects in osteoblasts and reinforces the anabolic action by TGF-beta in osteoblasts. Hence, PTH-Smad3 axis might be involved in the bone anabolic action of PTH.	Kobe Univ, Grad Sch Med,Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Sugimoto, T (corresponding author), Kobe Univ, Grad Sch Med,Dept Clin Mol Med, Div Endocrinol Metab Neurol & Hematol Oncol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	sugimot@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BECK LS, 1993, J BONE MINER RES, V8, P753; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; CANALIS E, 1980, J CLIN INVEST, V66, P709, DOI 10.1172/JCI109908; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; D'Alonzo RC, 2002, J BIOL CHEM, V277, P24788, DOI 10.1074/jbc.M202604200; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Finkelstein JS, 1998, JAMA-J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayes SA, 2001, CANCER RES, V61, P2112; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; KANO J, 1993, J BONE MINER RES, V8, P323; Koe RC, 1997, CALCIFIED TISSUE INT, V61, P52, DOI 10.1007/s002239900294; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Lane NE, 1996, J BONE MINER RES, V11, P614; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo-125-3-1484; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; MACDONALD BR, 1986, ENDOCRINOLOGY, V118, P2445, DOI 10.1210/endo-118-6-2445; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, GENE DEV, V14, P627; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1989, CONNECT TISSUE RES, V20, P277, DOI 10.3109/03008208909023897; McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427; Nasu M, 1997, FEBS LETT, V409, P63, DOI 10.1016/S0014-5793(97)00484-5; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; NODA M, 1988, J BIOL CHEM, V263, P18574; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; PARTRIDGE NC, 1985, CALCIFIED TISSUE INT, V37, P519, DOI 10.1007/BF02557835; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121; Ranganathan G, 2002, J BIOL CHEM, V277, P43281, DOI 10.1074/jbc.M202560200; REEVE J, 1976, LANCET, V1, P1035; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957; ROSEN D, 1994, BONE, V15, P355, DOI 10.1016/8756-3282(94)90300-X; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCUTT A, 1994, CALCIFIED TISSUE INT, V55, P208, DOI 10.1007/BF00425877; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; Tomkinson A, 1998, J BONE MINER RES, V13, P1243, DOI 10.1359/jbmr.1998.13.8.1243; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wu YH, 2000, J BONE MINER RES, V15, P879, DOI 10.1359/jbmr.2000.15.5.879; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	86	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52240	52252		10.1074/jbc.M302566200	http://dx.doi.org/10.1074/jbc.M302566200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14517210	hybrid			2022-12-25	WOS:000187480700033
J	Tavor, S; Park, DJ; Gery, S; Vuong, PT; Gombart, AF; Koeffler, HP				Tavor, S; Park, DJ; Gery, S; Vuong, PT; Gombart, AF; Koeffler, HP			Restoration of C/EBP alpha expression in a BCR-ABL(+) cell line induces terminal granulocytic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-ALPHA; CHRONIC MYELOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; DNA-BINDING; TRANSCRIPTION FACTOR; BCR-ABL; C-MYC; PU.1	The transcription factor C/EBPalpha plays a critical role in the process of granulocytic differentiation. Recently, mutations that abrogated transcriptional activation of C/EBPalpha were detected in acute myeloid leukemia patient samples. Moreover, the progression of chronic myelogenous leukemia (CML) to blast crisis in patients was correlated with down-modulation of C/EBPalpha. The KCL22 cell line, derived from BCR-ABL(+) CML in blast crisis, expressed wild-type C/EBPepsilon protein but not a functional C/EBPalpha, -beta, and -delta. Restoration of C/EBPalpha expression in KCL22 cells triggered a profound proliferative arrest, a block in the G(2)/M phase of the cell cycle and a gradual increase in apoptosis. Within 3 days of inducing expression of C/EBPalpha, a remarkable neutrophilic differentiation of the KCL22 blast cells occurred as shown by morphologic changes, induction of expression of CD11b, primary, secondary, and tertiary granule proteins, and granulocyte colony-stimulating factor receptor. Using high density oligonucleotide microarrays, the gene expression profile of KCL22 cells stably transfected with C/EBPalpha was compared with that of empty vector, and we identified genes not previously known to be regulated by C/EBPalpha. These included the up-regulation of those genes important for regulation of hematopoietic stem cell homing, granulocytic differentiation, and cell cycle, whereas down-regulation occurred for genes coding for signaling molecules and transcription factors that are implicated in regulation of proliferation and differentiation of hematopoietic cells. Our study showed that restoration of C/EBPalpha expression in BCR-ABL(+) leukemic cells in blast crisis is sufficient for rapid neutrophil differentiation suggesting a potential therapeutic role for ectopic transfer of C/EBPalpha in acute phase of CML.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Koeffler, HP (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, 8700 Beverly Blvd,Rm 5433, Los Angeles, CA 90048 USA.		Gombart, Adrian/AAV-4738-2020	Gombart, Adrian/0000-0001-7830-0693				Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AIUTI A, 1997, J EXP MED, V185, P11; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; de Vos S, 2003, DIAGN MOL PATHOL, V12, P35, DOI 10.1097/00019606-200303000-00005; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Iwasaki-Arai J, 2002, BLOOD, V100, p61A; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Konopleva M, 2000, BLOOD, V96, p738A; Kumano K, 2001, BLOOD, V98, P3283, DOI 10.1182/blood.V98.12.3283; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; Lodie TA, 1998, BLOOD, V92, p211A; Melo JV, 1996, LEUKEMIA, V10, P751; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	35	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52651	52659		10.1074/jbc.M307077200	http://dx.doi.org/10.1074/jbc.M307077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14517214	hybrid			2022-12-25	WOS:000187480700083
J	Yokoo, T; Toyoshima, H; Miura, M; Wang, YH; Iida, KT; Suzuki, H; Sone, H; Shimano, H; Gotoda, T; Nishimori, S; Tanaka, K; Yamada, N				Yokoo, T; Toyoshima, H; Miura, M; Wang, YH; Iida, KT; Suzuki, H; Sone, H; Shimano, H; Gotoda, T; Nishimori, S; Tanaka, K; Yamada, N			P57(Kip2) regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; LIM DOMAIN PROTEINS; CDK INHIBITOR; NEURONAL DIFFERENTIATION; COFILIN PHOSPHORYLATION; CYTOSKELETAL DYNAMICS; P21; IDENTIFICATION; ACTIVATION	p57(Kip2) is the only cyclin-dependent kinase (Cdk) inhibitor shown to be essential for mouse embryogenesis. The fact suggests that p57 has a specific role that cannot be compensated by other Cdk inhibitors. LIM-kinase 1 (LIMK-1) is a downstream effector of the Rho family of GTPases that phosphorylates and inactivates an actin depolymerization factor, cofilin, to induce the formation of actin fiber. Here we demonstrate that p57 regulates actin dynamics by binding and translocating LIMK-1 from the cytoplasm into the nucleus, which in turn results in a reorganization of actin fiber. The central region of p57, a unique feature among the Cdk inhibitors, and the N-terminal region of LIMK-1, which contains the LIM domains were essential for the interaction. Expression of p57, but not p27(Kip1) or a p57 mutant, with a deletion in the central region was shown to induce marked reorganization of actin filament and a translocation of LIMK-1. Our findings indicate p57 may act as a key regulator in embryogenesis by bearing two distinct functions, the regulation of cell cycle through binding to Cdks and the regulation of actin dynamics through binding to LIMK-1, both of which should be important in developmental procedure.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Tokyo Womens Univ, Ctr Diabet, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138688, Japan	University of Tsukuba; Tokyo Metropolitan Institute of Medical Science	Toyoshima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Shimano, Hitoshi/AAI-5648-2020; Shimano, Hitoshi/V-1761-2019; Sone, Hirohito/ABC-9346-2021	Shimano, Hitoshi/0000-0002-5562-5572; Sone, Hirohito/0000-0003-1263-2817				Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Birkenfeld J, 2001, J NEUROCHEM, V78, P924, DOI 10.1046/j.1471-4159.2001.00500.x; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ezhevsky SA, 1996, MOL BIOL CELL, V7, P553, DOI 10.1091/mbc.7.4.553; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nishimori S, 2001, J BIOL CHEM, V276, P10700, DOI 10.1074/jbc.M007499200; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TURNER CE, 1994, J CELL SCI, V107, P1583; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	45	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52919	52923		10.1074/jbc.M309334200	http://dx.doi.org/10.1074/jbc.M309334200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530263	hybrid			2022-12-25	WOS:000187480700114
J	Hilgendorf, A; Lindberg, J; Ruzsics, Z; Honing, S; Elsing, A; Lofqvist, M; Engelmann, H; Burgert, HG				Hilgendorf, A; Lindberg, J; Ruzsics, Z; Honing, S; Elsing, A; Lofqvist, M; Engelmann, H; Burgert, HG			Two distinct transport motifs in the adenovirus E3/10.4-14.5 proteins act in concert to down-modulate apoptosis receptors and the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE EXPRESSION; CLASS-I; KAPPA-B; MEMBRANE-PROTEINS; SORTING SIGNALS; INVARIANT CHAIN; E3/19K PROTEIN; NUCLEAR FACTOR; EGF RECEPTOR	The adenovirus (Ad) early transcription unit E3 encodes immunosubversive functions. The E3 transmembrane proteins 10.4 and 14.5 form a complex that downregulates the epidermal growth factor receptor and apoptosis receptors from the cell surface by diverting them to endosomes/lysosomes for degradation. The latter process protects infected cells from ligand-induced apoptosis. The mechanism by which 10.4 - 14.5 mediate re-routing remains elusive. We examined the role of putative YXXPhi and dileucine (LL) transport motifs within Ad2 10.4 - 14.5 for target protein modulation. By generating stable E3 transfectants expressing 10.4 - 14.5 proteins with alanine substitutions in these motifs, we show that 3 of the 5 motifs are essential for functional activity. Whereas tyrosine 74 in 14.5 appears to be important for efficient 10.4 - 14.5 interaction, the (122)YXXPhi motif in 14.5 and the dileucine motif Leu(87)-Leu(88) in 10.4 constitute genuine transport motifs: disruption of either motif abolished binding to the cellular adaptor proteins AP-1 and AP-2, as shown by surface plasmon resonance spectroscopy, and caused missorting, dramatically altering cell surface appearance and the intracellular location of viral proteins. Fluorescence-activated cell sorter analysis and immunofluorescence data provide evidence that Tyr(122) in 14.5 is essential for rapid endocytosis of the 10.4 - 14.5 complex, whereas the 10.4LL motif acts downstream and protects 10.4 - 14.5 from extensive degradation by rerouting it into a recycling pathway. Infection of primary cells with adenoviruses carrying the relevant point mutations confirmed the crucial role of these transport motifs for down-regulation of Fas, TRAIL-R1, TRAIL-R2, and epidermal growth factor receptor. Thus, two distinct transport motifs present in two proteins synergize for efficient target removal and immune evasion.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Munich, Gene Ctr, Dept Virol, D-81377 Munich, Germany; Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany; Univ Munich, Inst Immunol, D-80336 Munich, Germany	University of Warwick; University of Munich; University of Gottingen; University of Munich	Burgert, HG (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	H-G.Burgert@warwick.ac.uk	Burgert, Hans-Gerhard/AAE-6668-2020; Ruzsics, Zsolt/D-6284-2014	Burgert, Hans-Gerhard/0000-0002-1650-9878; 				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; Bennett EM, 1999, J IMMUNOL, V162, P5049; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Burgert HG, 2000, VIRUS GENES, V21, P13, DOI 10.1023/A:1008135928310; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; Burgert HG, 1996, TRENDS MICROBIOL, V4, P107, DOI 10.1016/0966-842X(96)81527-7; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Clague MJ, 2001, J CELL SCI, V114, P3075; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; Crooks D, 2000, MOL BIOL CELL, V11, P3559, DOI 10.1091/mbc.11.10.3559; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Diettrich O, 1996, EUR J CELL BIOL, V69, P99; Dimitrov T, 1997, J VIROL, V71, P2830, DOI 10.1128/JVI.71.4.2830-2837.1997; Elsing A, 1998, P NATL ACAD SCI USA, V95, P10072, DOI 10.1073/pnas.95.17.10072; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Friedman JM, 2002, J VIROL, V76, P5515, DOI 10.1128/JVI.76.11.5515-5521.2002; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HOFFMAN P, 1994, MOL CELL BIOL, V14, P3695, DOI 10.1128/MCB.14.6.3695; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; Horwitz MS, 2001, VIROLOGY, V279, P1, DOI 10.1006/viro.2000.0738; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; KORNER H, 1992, P NATL ACAD SCI USA, V89, P11857, DOI 10.1073/pnas.89.24.11857; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; KUIVINEN E, 1993, J CELL BIOL, V120, P1271, DOI 10.1083/jcb.120.5.1271; Lichtenstein DL, 2002, J VIROL, V76, P11329, DOI 10.1128/JVI.76.22.11329-11342.2002; McNees AL, 2002, VIRUS RES, V88, P87, DOI 10.1016/S0168-1702(02)00122-3; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Moise AR, 2002, J VIROL, V76, P1578, DOI 10.1128/JVI.76.4.1578-1587.2002; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Prudenziati M, 2000, INT J CANCER, V88, P943, DOI 10.1002/1097-0215(20001215)88:6<943::AID-IJC17>3.0.CO;2-F; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Sambrook J, 2001, MOL CLONING LAB MANU; SESTER M, 1994, J VIROL, V68, P5423, DOI 10.1128/JVI.68.9.5423-5432.1994; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; STEWART AR, 1995, J VIROL, V69, P172, DOI 10.1128/JVI.69.1.172-181.1995; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; TOLLEFSON AE, 1991, J VIROL, V65, P3095, DOI 10.1128/JVI.65.6.3095-3105.1991; Tollefson AE, 2001, J VIROL, V75, P8875, DOI 10.1128/JVI.75.19.8875-8887.2001; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Windheim M, 2004, CURR TOP MICROBIOL, V273, P29; Windheim M, 2002, J VIROL, V76, P755, DOI 10.1128/JVI.76.2.755-766.2002; Wold W S, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P237; Zaliauskiene L, 2000, MOL BIOL CELL, V11, P2643, DOI 10.1091/mbc.11.8.2643	70	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51872	51884		10.1074/jbc.M310038200	http://dx.doi.org/10.1074/jbc.M310038200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506242	hybrid			2022-12-25	WOS:000187206300123
J	Lagerstrom, MC; Klovins, J; Fredriksson, R; Fridmanis, D; Haitina, T; Ling, MK; Berglund, MM; Schioth, HB				Lagerstrom, MC; Klovins, J; Fredriksson, R; Fridmanis, D; Haitina, T; Ling, MK; Berglund, MM; Schioth, HB			High affinity agonistic metal ion binding sites within the melanocortin 4 receptor illustrate conformational change of transmembrane region 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR DETERMINANTS; ACTIVATION; RHODOPSIN; MUTATIONS; ZINC; MOTIF	We created a molecular model of the human melanocortin 4 receptor (MC4R) and introduced a series of His residues into the receptor protein to form metal ion binding sites. We were able to insert micromolar affinity binding sites for zinc between transmembrane region (TM) 2 and TM3 where the metal ion alone was able to activate this peptide binding G-protein-coupled receptor. The exact conformation of the metal ion interactions allowed us to predict the orientation of the helices, and remodeling of the receptor protein indicated that Glu(100) and Ile(104) in TM2 and Asp(122) and Ile(125) in TM3 are directed toward a putative area of activation of the receptor. The molecular model suggests that a rotation of TM3 may be important for activation of the MC4R. Previous models of G-protein-coupled receptors have suggested that unlocking of a stabilizing interaction between the DRY motif, in the cytosolic part of TM3, and TM6 is important for the activation process. We suggest that this unlocking process may be facilitated through creation of a new interaction between TM3 and TM2 in the MC4R.	Uppsala Univ, Biomed Ctr, Dept Neurosci, S-75124 Uppsala, Sweden; Univ Latvia, Biomed Res & Study Ctr, LV-1067 Riga, Latvia	Uppsala University; Latvian Biomedical Research & Study Centre; University of Latvia	Schioth, HB (corresponding author), Uppsala Univ, Biomed Ctr, Dept Neurosci, Box 593, S-75124 Uppsala, Sweden.	helgis@bmc.uu.se	Schioth, Helgi/AAQ-7239-2020; Klovins, Janis/C-5695-2011; Fredriksson, Robert/AAH-3921-2019; Fridmanis, Davids/I-3292-2017	Fredriksson, Robert/0000-0002-2810-3226; Fridmanis, Davids/0000-0003-0310-0448; Klovins, Janis/0000-0001-8362-5505; Haitina, Tatjana/0000-0002-8754-5534				Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P49, DOI 10.1093/protein/4.1.49; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Elling CE, 1997, ANN NY ACAD SCI, V814, P142, DOI 10.1111/j.1749-6632.1997.tb46152.x; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gaborik Z, 2003, ENDOCRINOLOGY, V144, P2220, DOI 10.1210/en.2002-0135; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; Haskell-Luevano C, 1996, Drug Des Discov, V14, P197; Haskell-Luevano C, 2001, BIOCHEMISTRY-US, V40, P6164, DOI 10.1021/bi010025q; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Kask A, 1998, ENDOCRINOLOGY, V139, P5006, DOI 10.1210/en.139.12.5006; Khorana HG, 2000, J BIOMOL STRUCT DYN, P1; Ling MK, 2003, EUR J BIOCHEM, V270, P1441, DOI 10.1046/j.1432-1033.2003.03506.x; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prusis P, 1997, J MOL GRAPH MODEL, V15, P307, DOI 10.1016/S1093-3263(98)00004-7; Ringholm A, 2002, J NEUROCHEM, V82, P6, DOI 10.1046/j.1471-4159.2002.00934.x; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Scheer A, 2000, MOL PHARMACOL, V57, P219; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schioth HB, 2002, BRAIN RES REV, V38, P340, DOI 10.1016/S0165-0173(01)00159-X; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yang YK, 2002, J BIOL CHEM, V277, P20328, DOI 10.1074/jbc.M201343200; Yeo GSH, 2003, HUM MOL GENET, V12, P561, DOI 10.1093/hmg/ddg057	31	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51521	51526		10.1074/jbc.M307683200	http://dx.doi.org/10.1074/jbc.M307683200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523020	hybrid			2022-12-25	WOS:000187206300083
J	Midura, RJ; Su, XW; Morcuende, JA; Tammi, M; Tammi, R				Midura, RJ; Su, XW; Morcuende, JA; Tammi, M; Tammi, R			Parathyroid hormone rapidly stimulates hyaluronan synthesis by periosteal osteoblasts in the tibial diaphysis of the growing rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; BONE-CELLS; CD44 EXPRESSION; BINDING REGION; ORGAN-CULTURE; ACID; OSTEOPOROSIS; LOCALIZATION; PARATHORMONE; METABOLISM	Short term treatment (3-24 h) with parathyroid hormone (PTH) stimulated the synthesis and accumulation of hyaluronan (HyA) in explant cultures of tibial diaphyses from young rats. PTH increased the overall HyA content of periosteum 5-fold, with the basal cambium layer exhibiting the greatest enhancement (similar to8-fold). PTH increased the HyA content of cortical bone by 2-fold while not affecting the HyA content of bone marrow. PTH treatment greatly enhanced HyA staining throughout all layers of the periosteum, although its most dramatic effect occurred in the basal cambium layer. Here, unlike in the control tissue sections, nearly all cambium-lining osteoblasts stained intensely positive for HyA. PTH treatment enhanced the HyA staining of osteocytes in cortical bone tissue sections to the extent that the lacunocanalicular system became visualized. Three significant findings were revealed in this study. First, mature periosteal osteoblasts, under natural conditions, do not contain much HyA in their surrounding extracellular matrix but dramatically enhance their matrix HyA content when treated with PTH. Second, pre-osteocytes and osteocytes contain more HyA in their natural matrix than mature lining osteoblasts, and they appear to have functional PTH receptors because they responded to PTH treatment with an enhancement of HyA content. Finally, it was observed that the lining cells along the endosteal surface of the diaphysis did not stain strongly positive for HyA either naturally or when exposed to PTH treatment. This indicates that periosteal and endosteal osteoblastic cell populations exhibit metabolic differences in their extracellular matrix responses to PTH.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Univ Iowa, Dept Orthopaed Surg, Iowa City, IA 52242 USA; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Iowa; University of Eastern Finland	Midura, RJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	midura@bme.ri.ccf.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045171] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-45171] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERTOLAMI CN, 1994, CRIT REV ORAL BIOL M, V5, P311, DOI 10.1177/10454411940050030601; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Cosman F, 1998, CALCIFIED TISSUE INT, V62, P475, DOI 10.1007/s002239900464; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; DEMPSTER DW, 1995, ENDOCRINE REV MONOGR, V4, P247; Divieti P, 2001, ENDOCRINOLOGY, V142, P916, DOI 10.1210/en.142.2.916; ECAROTCHARRIER B, 1987, J BIOL CHEM, V262, P5345; FEDARKO NS, 1990, J BIOL CHEM, V265, P12200; Frost HM, 1997, MEDICINA-BUENOS AIRE, V57, P119; Genever PG, 1996, BONE, V18, P429, DOI 10.1016/8756-3282(96)00046-4; Hock JM, 1999, J CLIN INVEST, V104, P371, DOI 10.1172/JCI7991; HUGHES DE, 1994, J BONE MINER RES, V9, P39; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1986, DEV BIOL, V114, P519, DOI 10.1016/0012-1606(86)90215-0; Lane NE, 1998, J CLIN INVEST, V102, P1627, DOI 10.1172/JCI3914; Laurent T.C, 1970, CHEM MOL BIOL INTERC, P703; LAURENT TC, 2002, HYALURONAN CHEM BIOC, V1, P3; LEBLOND CP, 1950, AM J ANAT, V86, P289, DOI 10.1002/aja.1000860205; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LUBEN RA, 1974, ENDOCRINOLOGY, V94, P737, DOI 10.1210/endo-94-3-737; LUBEN RA, 1976, ENDOCRINOLOGY, V98, P413, DOI 10.1210/endo-98-2-413; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; Maleski MP, 1996, CONNECT TISSUE RES, V34, P75, DOI 10.3109/03008209609028895; MARTIN TJ, 1987, CLIN ENDOCRINOLOGY C, P1; MAURER PH, 1952, ARCH BIOCHEM BIOPHYS, V38, P49, DOI 10.1016/0003-9861(52)90008-8; MELICK RA, 1977, CALC TISS RES, V22, P508; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MIDURA RJ, 1994, GLYCOBIOLOGY, V4, P333, DOI 10.1093/glycob/4.3.333; Noonan KJ, 1996, J ORTHOP RES, V14, P573, DOI 10.1002/jor.1100140411; NUTT RF, 1990, ENDOCRINOLOGY, V127, P491, DOI 10.1210/endo-127-1-491; PARTRIDGE NC, 1987, ENDOCRINOLOGY, V120, P1956, DOI 10.1210/endo-120-5-1956; PAVASANT P, 1994, J CELL SCI, V107, P2669; REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340; RIPELLINO JA, 1985, J HISTOCHEM CYTOCHEM, V33, P1060, DOI 10.1177/33.10.4045184; SEVERSON AR, 1983, EXP CELL BIOL, V51, P70; SEVERSON AR, 1973, ENDOCRINOLOGY, V92, P1282, DOI 10.1210/endo-92-4-1282; SLOVIK DM, 1981, J CLIN INVEST, V68, P1261, DOI 10.1172/JCI110372; TAMMI R, 1988, J INVEST DERMATOL, V90, P412, DOI 10.1111/1523-1747.ep12456530; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; THOMAS L, 1993, J INVEST DERMATOL, V100, P115, DOI 10.1111/1523-1747.ep12462776; TOOLE BP, 1971, DEV BIOL, V26, P28, DOI 10.1016/0012-1606(71)90104-7; WANG C, 1992, HISTOCHEMISTRY, V98, P105, DOI 10.1007/BF00717001; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; WONG GL, 1977, SCIENCE, V197, P663, DOI 10.1126/science.195343; WONG GL, 1982, CALCIFIED TISSUE INT, V34, P67, DOI 10.1007/BF02411211; WONG GL, 1984, J BIOL CHEM, V259, P4019; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435	48	39	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51462	51468		10.1074/jbc.M307567200	http://dx.doi.org/10.1074/jbc.M307567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14514685	hybrid			2022-12-25	WOS:000187206300076
J	Petrescu, AD; Payne, HR; Boedecker, A; Chao, H; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB				Petrescu, AD; Payne, HR; Boedecker, A; Chao, H; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB			Physical and functional interaction of acyl-CoA-binding protein with hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; GENE-EXPRESSION; HYPOLIPIDEMIC DRUGS; CIRCULAR-DICHROISM; FATTY-ACIDS; TRANSPORT; ESTERS; TRANSACTIVATION; COENZYME; BETA	Although acyl-CoA-binding protein (ACBP) has been detected in the nucleus, the physiological significance of this observation is unknown. As shown herein for the first time, ACBP in the nucleus physically and functionally interacted with hepatocyte nuclear factor-4alpha (HNF-4alpha), a nuclear binding protein that regulates transcription of genes involved in both lipid and glucose metabolism. Five lines of evidence showed that ACBP bound HNF-4alpha in vitro and in the nucleus of intact cells. (i) ACBP interaction with HNF-4alpha elicited significant changes in secondary structure. (ii) ACBP and HNF-4alpha were coimmunoprecipitated by antibodies to each protein. (iii) Double immunolabeling and laser scanning confocal microscopy (LSCM) of rat hepatoma cells and transfected COS-7 cells significantly colocalized ACBP and HNF-4alpha within the nucleus and in the perinuclear region close to the nuclear membrane. (iv) LSCM fluorescence resonance energy transfer determined an intermolecular distance of 53 Angstrom between ACBP and HNF-4alpha in rat hepatoma cell nuclei. (v) Immunogold electron microscopy detected ACBP within 43 Angstrom of HNF-4alpha. These interactions were specific since ACBP did not interact with Sp1 or glucocorticoid receptor in these assays. The functional significance of ACBP interaction with HNF-4alpha was evidenced by mammalian two-hybrid and transactivation assays. ACBP overexpression in COS-7 or rat hepatoma cells enhanced transactivation of an HNF-4alpha-dependent luciferase reporter plasmid by 3.2- and 1.6-fold, respectively. In contrast, cotransfection with antisense ACBP expression vector inhibited transactivation. LSCM of the individual triple fluorescent-labeled (HNF-4alpha, ACBP, and luciferase) rat hepatoma cells showed a high correlation (r(2), 0.936) between the level of luciferase and the level of ACBP expression. In summary, ACBP physically interacted with HNF-4alpha in vitro and in intact cells, although ACBP expression level directly correlated with HNF-4alpha-mediated transactivation in individual cells.	Texas A&M Univ, Texas Vet Med Ctr, Dept Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Texas Vet Med Ctr, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Hebrew Univ Jerusalem, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Hebrew University of Jerusalem	Kier, AB (corresponding author), Texas A&M Univ, Texas Vet Med Ctr, Dept Pathobiol, College Stn, TX 77843 USA.	Akier@cvm.tamu.edu			NIDDK NIH HHS [DK41402] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abo-Hashema KAH, 1999, BIOCHEMISTRY-US, V38, P15840, DOI 10.1021/bi9912185; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Ceelie H, 2003, J THROMB HAEMOST, V1, P1688, DOI 10.1046/j.1538-7836.2003.00393.x; Chao H, 2003, J LIPID RES, V44, P72, DOI 10.1194/jlr.M200191-JLR200; Chao H, 2002, BIOCHEMISTRY-US, V41, P10540, DOI 10.1021/bi0259498; Chao H., 2002, WILEY ENCY MOL MED, P44; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Elholm M, 2000, J LIPID RES, V41, P538; Elholm M, 2001, J BIOL CHEM, V276, P21410, DOI 10.1074/jbc.M101073200; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; Garuti R, 2002, GENE, V283, P133, DOI 10.1016/S0378-1119(01)00874-5; Gossett RE, 1998, ARCH BIOCHEM BIOPHYS, V350, P201, DOI 10.1006/abbi.1997.0521; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Helledie T, 2000, J LIPID RES, V41, P1740; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; Hertz R, 2003, J BIOL CHEM, V278, P22578, DOI 10.1074/jbc.M212138200; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; Jolly CA, 2000, BBA-MOL CELL BIOL L, V1483, P185, DOI 10.1016/S1388-1981(99)00170-5; Jorgensen C, 2002, ANN NY ACAD SCI, V967, P431; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JW, 2000, J LIPID RES, V41, P1390; LI QL, 1993, J CELL BIOCHEM, V51, P458, DOI 10.1002/jcb.2400510411; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Naiki T, 2002, J BIOL CHEM, V277, P14011, DOI 10.1074/jbc.M105403200; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; ROUSSEL F, 1995, DNA CELL BIOL, V14, P777, DOI 10.1089/dna.1995.14.777; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wadum MCT, 2002, BIOCHEM J, V365, P165, DOI 10.1042/BJ20011727; Warnmark A, 2001, J BIOL CHEM, V276, P45939, DOI 10.1074/jbc.M107875200; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179	50	74	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51813	51824		10.1074/jbc.M303858200	http://dx.doi.org/10.1074/jbc.M303858200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530276	hybrid			2022-12-25	WOS:000187206300117
J	Taverna, S; Ghersi, G; Ginestra, A; Rigogliuso, S; Pecorella, S; Alaimo, G; Saladino, F; Dolo, V; Dell'Era, P; Pavan, A; Pizzolanti, G; Mignatti, P; Presta, M; Vittorelli, ML				Taverna, S; Ghersi, G; Ginestra, A; Rigogliuso, S; Pecorella, S; Alaimo, G; Saladino, F; Dolo, V; Dell'Era, P; Pavan, A; Pizzolanti, G; Mignatti, P; Presta, M; Vittorelli, ML			Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; CAPILLARY ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; TUMOR-CELLS; FACTOR-I; ANGIOGENESIS; EXOSOMES; EXPORT; FGF-2; BFGF	Fibroblast growth factor-2 (FGF-2), a polypeptide with regulatory activity on cell growth and differentiation, lacks a conventional secretory signal sequence, and its mechanism of release from cells remains unclear. We characterized the role of extracellular vesicle shedding in FGF-2 release. Viable cells released membrane vesicles in the presence of serum. However, in serum-free medium vesicle shedding was dramatically downregulated, and the cells did not release FGF-2 activity into their conditioned medium. Addition of serum to serum-starved cells rapidly induced intracellular FGF-2 clustering under the plasma membrane and into granules that colocalized with patches of the cell membrane with typical features of shed vesicle membranes. Shed vesicles carried three FGF-2 isoforms ( 18, 22, 24 kDa). Addition of vesicles to endothelial cells stimulated chemotaxis and urokinase plasminogen activator production, which were blocked by anti-FGF-2 antibodies. Treatment of intact vesicles with 2.0 M NaCl or heparinase, which release FGF-2 from membrane-bound proteoglycans, did not abolish their stimulatory effect on endothelial cells, indicating that FGF-2 is carried inside vesicles. The comparison of the stimulatory effects of shed vesicles and vesicle-free conditioned medium showed that vesicles represent a major reservoir of FGF-2. Thus, FGF-2 can be released from cells through vesicle shedding.	Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90128 Palermo, Italy; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy; Univ Brescia, Dipartimento Sci Biomed & Biotecnol, I-25123 Brescia, Italy; Policlin Palermo, Cattedra Endocrinol, Ist Clin Med, I-90128 Palermo, Italy; NYU, Dept Surg, Sch Med, New York, NY 10016 USA; NYU, Dept Cell Biol, Sch Med, New York, NY 10016 USA; Ctr Oncobiol Sperimentale, I-90128 Palermo, Italy	University of Palermo; University of L'Aquila; University of Brescia; New York University; New York University	Vittorelli, ML (corresponding author), Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90128 Palermo, Italy.	mlvitt@unipa.it	Dell'Era, Patrizia/ABD-5848-2020; Taverna, Simona/AAE-7135-2020; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010; Pizzolanti, Giuseppe/K-7097-2016; Pizzolanti, Giuseppe/I-4547-2019; Dolo, Vincenza/AAB-2885-2021	Dell'Era, Patrizia/0000-0001-6682-6321; Pizzolanti, Giuseppe/0000-0001-6052-8438; Dolo, Vincenza/0000-0003-0424-6676; PRESTA, Marco/0000-0002-4398-8376; Mignatti, Paolo/0000-0002-8157-457X; Ghersi, Giulio/0000-0001-7250-9808; Rigogliuso, Salvatrice/0000-0002-7783-0075				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CHIBA I, 1989, CANCER RES, V49, P3972; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; Dahl JP, 2000, BIOCHEMISTRY-US, V39, P14877, DOI 10.1021/bi001073y; DAINIAK N, 1991, BLOOD, V78, P264; DAINIAK N, 1991, J CLIN INVEST, V87, P213, DOI 10.1172/JCI114974; Denzer K, 2000, J CELL SCI, V113, P3365; Dolo V, 1998, CANCER RES, V58, P4468; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Ginestra A, 1998, ANTICANCER RES, V18, P3433; Giuliani R, 1999, J CELL SCI, V112, P2597; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; Heijnen CJ, 1999, J NEUROIMMUNOL, V100, P197, DOI 10.1016/S0165-5728(99)00194-0; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jorgensen JR, 2001, BIOCHEMISTRY-US, V40, P7301, DOI 10.1021/bi0029503; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; Landriscina M, 2001, J BIOL CHEM, V276, P25549, DOI 10.1074/jbc.M102925200; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MATHEW A, 1995, BIOCHEM J, V308, P823, DOI 10.1042/bj3080823; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; POSTE G, 1980, P NATL ACAD SCI-BIOL, V77, P399, DOI 10.1073/pnas.77.1.399; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; Qu ZH, 1998, J HISTOCHEM CYTOCHEM, V46, P1119, DOI 10.1177/002215549804601004; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SLAVIN J, 1995, CELL BIOL INT, V19, P431, DOI 10.1006/cbir.1995.1087; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; Vittorelli ML, 2003, CURR TOP DEV BIOL, V54, P411, DOI 10.1016/S0070-2153(03)54017-0; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	57	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51911	51919		10.1074/jbc.M304192200	http://dx.doi.org/10.1074/jbc.M304192200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523006	hybrid, Green Published			2022-12-25	WOS:000187206300127
J	Lima, WF; Wu, HJ; Nichols, JG; Prakash, TP; Ravikumar, V; Crooke, ST				Lima, WF; Wu, HJ; Nichols, JG; Prakash, TP; Ravikumar, V; Crooke, ST			Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3 '-DNA/5 '-RNA terminus of the heteroduplex substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING; SUBUNIT; DOMAIN; PURIFICATION; SPECIFICITY	In a previous study, we showed that the RNA-binding domain of human RNase H1 is responsible for the positional preference for cleavage exhibited by the enzyme (Wu, H., Lima, W. F., and Crooke, S. T. (2001) J. Biol. Chem. 276, 23547 - 23553). Here, we identify the substituents on the heteroduplex substrate and the amino acid residues within the RNA-binding domain of human RNase H1 involved in positioning of the enzyme. The human RNase H1 cleavage patterns observed for heteroduplexes with various 3'-DNA/5'-RNA and 5'-DNA/3'-RNA termini indicate that the 5'-most cleavage site on the oligoribonucleotide is positioned 7 bp from the first 3'-DNA/5'-RNA base pair. The presence or absence of phosphate or hydroxyl groups at either the 3'-DNA or 5'-RNA terminus had no effect on the human RNase H1 cleavage pattern. Substitution of the 3'-deoxynucleotide with a ribonucleotide, 2'-methoxyethyl nucleotide, or mismatched deoxyribonucleotide resulted in the ablation of the 5'-most cleavage site on the oligoribonucleotide. Mutants in which Trp(43) and Lys(59)- Lys(60) of the RNA-binding domain were substituted with alanine showed a loss of the positional preference for cleavage. Comparison of the k(cat), K-m, and K-d for the alanine-substituted mutants with those for human RNase H1 suggests that Lys(59) and Lys(60) are involved in binding to the heteroduplex and that Trp43 is responsible for properly positioning the enzyme on the substrate for catalysis. These data suggest that Trp43, Lys59, and Lys60 constitute an extended nucleic binding surface for the RNA-binding domain of human RNase H1, with the entire interaction taking place at the 3'-DNA/5'-RNA pole of the heteroduplex. These results offer further insights into the interaction between human RNase H1 and the heteroduplex substrate as well as approaches to enhance the design of effective antisense oligonucleotides.	ISIS Pharmaceut, Dept Biol Mol & Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Biol Mol & Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; CERRITELLI SM, 1995, RNA, V1, P246; Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1; Crouch R. J., 1982, NUCLEASES, P211; Denisov AY, 2001, NUCLEIC ACIDS RES, V29, P4284, DOI 10.1093/nar/29.21.4284; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; Evans SP, 1999, J MOL BIOL, V291, P661, DOI 10.1006/jmbi.1999.2971; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; Hoffman DW, 1996, J MOL BIOL, V264, P1058, DOI 10.1006/jmbi.1996.0696; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	33	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49860	49867		10.1074/jbc.M306543200	http://dx.doi.org/10.1074/jbc.M306543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506260	hybrid			2022-12-25	WOS:000187068200027
J	Liu, X; Choudhury, S; Roy, R				Liu, X; Choudhury, S; Roy, R			In vitro and in vivo dimerization of human endonuclease III stimulates its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; METHYLPURINE-DNA GLYCOSYLASE; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; SOS MUTAGENESIS; AP-ENDONUCLEASE; LYASE ACTIVITY; BINDING; DAMAGE; ENZYME	Human endonuclease III (hNTH1), a DNA glycosylase with associated abasic lyase activity, repairs various mutagenic and toxic-oxidized DNA lesions, including thymine glycol. We demonstrate for the first time that the full-length hNTH1 positively cooperates in product formation as a function of enzyme concentration. The protein concentrations that caused cooperativity in turnover also exhibited dimerization, independent of DNA binding. Earlier we had found that the hNTH1 consists of two domains: a well conserved catalytic domain, and an inhibitory N-terminal tail. The N-terminal truncated proteins neither undergo dimerization, nor do they show cooperativity in turnover, indicating that the homodimerization of hNTH1 is specific and requires the N-terminal tail. Further kinetic analysis at transition states reveals that this homodimerization stimulates an 11-fold increase in the rate of release of the final product, an AP-site with a 3'-nick, and that it does not affect other intermediate reaction rates, including those of DNA N-glycosylase or AP lyase activities that are modulated by previously reported interacting proteins, YB-1, APE1, and XPG. Thus, the site of modulating action of the dimer on the hNTH1 reaction steps is unique. Moreover, the high intranuclear (2.3 muM) and cytosolic (0.65 muM) concentrations of hNTH1 determined here support the possibility of in vivo dimerization; indeed, in vivo protein cross-linking showed the presence of the dimer in the nucleus of HeLa cells. Therefore, it is likely that the dimerization of hNTH1 involving the N-terminal tail masks the inhibitory effect of this tail and plays a critical role in its catalytic turnover in the cell.	Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Mech Carcinogenesis Program,DNA Repair Lab, Valhalla, NY 10595 USA	American Health Foundation	Roy, R (corresponding author), Amer Hlth Fdn, Ctr Canc, Inst Canc Prevent, Mech Carcinogenesis Program,DNA Repair Lab, 1 Dana Rd, Valhalla, NY 10595 USA.				NATIONAL CANCER INSTITUTE [P30CA017613, R01CA080917] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA17613, R01 CA80917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FERSHT A, 1997, ENZYME STRUCTURE MEC, P121; FRIEDBERG E, 1995, DNA REPAIR MUTAGENES, P5; GERLT JA, 1993, NUCLEASES, V2, P1; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Krokan HE, 1997, BIOCHEM J, V325, P1; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Liu X, 2001, BIOCHEMISTRY-US, V40, P13617, DOI 10.1021/bi011053b; Luby-Phelps K, 2000, INT REV CYTOL, V192, P189; Marenstein DR, 2003, J BIOL CHEM, V278, P9005, DOI 10.1074/jbc.M212168200; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Mitra S, 1997, MOL CELLS, V7, P305; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Monier K, 2000, NAT CELL BIOL, V2, P661, DOI 10.1038/35023615; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pawlyk AC, 2002, P NATL ACAD SCI USA, V99, P11115, DOI 10.1073/pnas.132393599; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Roy R, 1996, J BIOL CHEM, V271, P23690, DOI 10.1074/jbc.271.39.23690; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Sarker AH, 1998, J MOL BIOL, V282, P761, DOI 10.1006/jmbi.1998.2042; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Shekhtman A, 1999, STRUCTURE, V7, P919, DOI 10.1016/S0969-2126(99)80119-1; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sutton MD, 1999, P NATL ACAD SCI USA, V96, P12373, DOI 10.1073/pnas.96.22.12373; Sutton MD, 2002, P NATL ACAD SCI USA, V99, P5307, DOI 10.1073/pnas.082322099; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Wong I, 2003, J BIOL CHEM, V278, P2411, DOI 10.1074/jbc.M209802200; Yang HJ, 2002, J BIOL CHEM, V277, P22271, DOI 10.1074/jbc.M201820200	49	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50061	50069		10.1074/jbc.M309997200	http://dx.doi.org/10.1074/jbc.M309997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522981	hybrid			2022-12-25	WOS:000187068200050
J	Makarova, A; Mikhailenko, I; Bugge, TH; List, K; Lawrence, DA; Strickland, DK				Makarova, A; Mikhailenko, I; Bugge, TH; List, K; Lawrence, DA; Strickland, DK			The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissue-type plasminogen activator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ALPHA-2-MACROGLOBULIN RECEPTOR; VLDL RECEPTOR; MICE LACKING; INCLUSION-BODIES; LIGAND-BINDING; IN-VITRO; INHIBITOR; NEURONS; GENE	Proteases contribute to a variety of processes in the brain; consequently, their activity is carefully regulated by protease inhibitors, such as neuroserpin. This inhibitor is thought to be secreted by axons at synaptic regions where it controls tissue-type plasminogen activator (tPA) activity. Mechanisms regulating neuroserpin are not known, and the current studies were undertaken to define the cellular pathways involved in neuroserpin catabolism. We found that both active neuroserpin and neuroserpin . tPA complexes were internalized by mouse cortical cultures and embryonic fibroblasts in a process mediated by the low density lipoprotein receptor-related protein (LRP). Surprisingly, despite the fact that active neuroserpin is internalized by LRP, this form of the molecule does not directly bind to LRP on its own, indicating the requirement of a cofactor for neuroserpin internalization. Our studies ruled out the possibility that endogenously produced plasminogen activators (i.e. tPA and urokinase-type plasminogen activator) are responsible for the LRP-mediated internalization of active neuroserpin, but could not rule out the possibility that another cell-associated proteases capable of binding active neuroserpin functions in this capacity. In summary, neuroserpin levels appear to be carefully regulated by LRP and an unidentified cofactor, and this pathway may be critical for maintaining the balance between proteases and inhibitors.	Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA; NIDCR, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	American Red Cross; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Strickland, DK (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [HL-55747, HL50784, HL-55374, HL54710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL055747, R01HL055374, R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barker-Carlson K, 2002, J BIOL CHEM, V277, P46852, DOI 10.1074/jbc.M207740200; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Belorgey D, 2002, J BIOL CHEM, V277, P17367, DOI 10.1074/jbc.M200680200; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; Frey U, 1996, J NEUROSCI, V16, P2057; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; Krueger SR, 1997, J NEUROSCI, V17, P8984; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Luthi A, 1997, J NEUROSCI, V17, P4688; Madani R, 2003, MOL CELL NEUROSCI, V23, P473, DOI 10.1016/S1044-7431(03)00077-0; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; Pawlak R, 2003, NAT NEUROSCI, V6, P168, DOI 10.1038/nn998; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; Yepes M, 2002, J CLIN INVEST, V109, P1571, DOI 10.1172/JCI200214308; Yepes M, 2000, BLOOD, V96, P569; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	48	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50250	50258		10.1074/jbc.M309150200	http://dx.doi.org/10.1074/jbc.M309150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522960	hybrid			2022-12-25	WOS:000187068200073
J	Martins, SM; Chapeaurouge, A; Ferreira, RT				Martins, SM; Chapeaurouge, A; Ferreira, RT			Folding intermediates of the prion protein stabilized by hydrostatic pressure and low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PRP(121-231); BUNDLE PROTEIN; NMR STRUCTURE; PRP 27-30; DISEASES; DISSOCIATION; LYSOZYME; DENATURATION; RIBONUCLEASE; ASSOCIATION	Prion diseases are associated with conformational conversion of the cellular prion protein, PrPC, into a misfolded form, PrPSc. We have investigated the equilibrium unfolding of the structured domain of recombinant murine prion protein, comprising residues 121 - 231 (mPrP-(121 - 231)). The equilibrium unfolding of mPrP( 121 - 231) by urea monitored by intrinsic fluorescence and circular dichroism (CD) spectroscopies indicated a two-state transition, without detectable folding intermediates. The fluorescent probe 4,4'-dianilino-1,1'-binaphthyl- 5,5-disulfonic acid (bis-ANS) binds to native mPrP-( 121 - 231), indicating exposure of hydrophobic domains on the protein surface. Increasing concentrations of urea ( up to 4 M) caused the release of bound bis-ANS, whereas changes in intrinsic fluorescence and CD of mPrP took place only above 4 M urea. This indicates the existence of a partially unfolded conformation of mPrP, characterized by loss of bis-ANS binding and preservation of the overall structure of the protein, stabilized at low concentrations of urea. Hydrostatic pressure and low temperatures were also used to stabilize partially folded intermediates that are not detectable in the presence of chemical denaturants. Compression of mPrP to 3.5 kbar at 25 degreesC and pH 7 caused a slight decrease in intrinsic fluorescence emission and an 8-fold increase in bis-ANS fluorescence. Lowering the temperature to - 9 degreesC under pressure reversed the decrease in intrinsic fluorescence and caused a marked (similar to40-fold) increase in bis-ANS fluorescence. The increase in bis-ANS fluorescence at low temperatures was similar to that observed for mPrP at 1 atm at pH 4. These results suggest that pressure-assisted cold denaturation of mPrP stabilizes a partially folded intermediate that is qualitatively similar to the state obtained at acidic pH. Compression of mPrP in the presence of a subdenaturing concentration of urea stabilized another partially folded intermediate, and cold denaturation under these conditions led to complete unfolding of the protein. Possible implications of the existence of such partially folded intermediates in the folding of the prion protein and in the conversion to the PrPSc conformer are discussed.	Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Fundacao Oswaldo Cruz, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Ferreira, RT (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866				Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; BRIDGMAN PW, 1931, PHYS HIGH PRESSURE, P233; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohen FE, 1999, J MOL BIOL, V293, P313, DOI 10.1006/jmbi.1999.2990; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferreira ST, 2001, FEBS LETT, V498, P129, DOI 10.1016/S0014-5793(01)02491-7; GREENE RF, 1974, J BIOL CHEM, V249, P5388; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P537; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jiang X, 2001, BIOCHEMISTRY-US, V40, P11442, DOI 10.1021/bi011194d; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; MANSON J, 1992, DEVELOPMENT, V115, P117; Martins SM, 2002, EUR J BIOCHEM, V269, P5484, DOI 10.1046/j.1432-1033.2002.03248.x; Martins VR, 2002, FEBS LETT, V512, P25, DOI 10.1016/S0014-5793(02)02291-3; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Pace C N, 1986, Methods Enzymol, V131, P266; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Perrett S, 2002, BBA-PROTEIN STRUCT M, V1595, P210, DOI 10.1016/S0167-4838(01)00345-4; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Randolph TW, 2002, BBA-PROTEIN STRUCT M, V1595, P224, DOI 10.1016/S0167-4838(01)00346-6; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; Sasahara K, 1999, PROTEIN SCI, V8, P1469, DOI 10.1110/ps.8.7.1469; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; YORK SS, 1978, BIOCHEMISTRY-US, V17, P4480, DOI 10.1021/bi00614a019; ZHANG J, 1995, BIOCHEMISTRY-US, V34, P8631, DOI 10.1021/bi00027a012	57	70	74	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50449	50455		10.1074/jbc.M307354200	http://dx.doi.org/10.1074/jbc.M307354200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525996	hybrid			2022-12-25	WOS:000187068200097
J	Nikko, E; Marini, AM; Andre, B				Nikko, E; Marini, AM; Andre, B			Permease recycling and ubiquitination status reveal a particular role for Bro1 in the multivesicular body pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASE; DOA4 DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; SYNTAXIN HOMOLOG; DOWN-REGULATION; YEAST VACUOLE; INTRACELLULAR TRAFFICKING; PROTEIN-TRANSPORT; MEMBRANE-PROTEINS	Ubiquitination of the yeast Gap1 permease at the plasma membrane triggers its endocytosis followed by targeting to the vacuolar lumen for degradation. We previously identified Bro1 as a protein essential to this down-regulation. In this study, we show that Bro1 is essential neither to ubiquitination nor to the early steps of Gap1 endocytosis. Bro1 rather intervenes at a late step of the multivesicular body (MVB) pathway, after the core components of the endosome-associated ES-CRT-III protein complex and before or in conjunction with Doa4, the ubiquitin hydrolase mediating protein deubiquitination prior to their incorporation into MVB vesicles. Bro1 markedly differs from other class E vacuolar protein sorting factors involved in MVB sorting as lack of Bro1 leads to recycling of the internalized permease back to the plasma membrane by passing through the Golgi. This recycling seems to be accompanied by deubiquitination of the permease and unexpectedly requires a normal endosome-to-vacuole transport function.	Free Univ Brussels, Lab Physiol Cellulaire, B-6041 Gosselies, Belgium		Andre, B (corresponding author), Free Univ Brussels, Lab Physiol Cellulaire, B-6041 Gosselies, Belgium.		André, Bruno/D-1725-2010					AKASAKI K, 1993, J BIOCHEM-TOKYO, V114, P598, DOI 10.1093/oxfordjournals.jbchem.a124223; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Bryant NJ, 1998, J CELL BIOL, V142, P651, DOI 10.1083/jcb.142.3.651; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Chen LY, 2000, J CELL BIOL, V151, P731, DOI 10.1083/jcb.151.3.731; Coe JGS, 1999, MOL BIOL CELL, V10, P2407, DOI 10.1091/mbc.10.7.2407; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Forsberg H, 2001, GENETICS, V158, P973; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gary JD, 2002, MOL BIOL CELL, V13, P1238, DOI 10.1091/mbc.01-10-0498; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gerrard SR, 2000, TRAFFIC, V1, P259, DOI 10.1034/j.1600-0854.2000.010308.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Holthuis JCM, 1998, MOL BIOL CELL, V9, P3383, DOI 10.1091/mbc.9.12.3383; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; JACOBS P, 1980, J MOL BIOL, V139, P691, DOI 10.1016/0022-2836(80)90055-8; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Losko S, 2001, MOL BIOL CELL, V12, P1047, DOI 10.1091/mbc.12.4.1047; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; Marchal C, 2002, J CELL SCI, V115, P217; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Siniossoglou S, 2002, J BIOL CHEM, V277, P48318, DOI 10.1074/jbc.M209428200; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Springael JY, 1999, J CELL SCI, V112, P1375; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Tsukada M, 1996, J CELL SCI, V109, P2471; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Vincent O, 2003, MOL CELL BIOL, V23, P1647, DOI 10.1128/MCB.23.5.1647-1655.2003; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500	78	80	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50732	50743		10.1074/jbc.M306953200	http://dx.doi.org/10.1074/jbc.M306953200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523026	hybrid			2022-12-25	WOS:000187068200129
J	Potocky, TB; Menon, AK; Gellman, SH				Potocky, TB; Menon, AK; Gellman, SH			Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSDUCTION DOMAINS; PENETRATING PEPTIDES; CELLULAR UPTAKE; MEMBRANE TRANSLOCATION; MOLECULAR TRANSPORTERS; PERMEABLE PEPTIDES; DIPHTHERIA-TOXIN; PLASMA-MEMBRANE; HIV-1; ANTENNAPEDIA	Several short, highly cationic peptides are able to enter the cytoplasm and nucleus of cells from the extracellular medium. The mechanism of entry is unknown. A number of fluorescence-based studies suggested that these molecules cross the plasma membrane by an energy-independent process, directly gaining access to the cytoplasm. Recent reports have questioned this conclusion, attributing the prior observations to artifacts resulting from fixation procedures used to prepare cells for fluorescence microscopy. These studies analyzed live cells and showed that the peptides entered through endocytosis and accumulated in endocytic vesicles, without necessarily entering the cytoplasm. To resolve this controversy and to extend the analyses to non-natural beta-peptide sequences, we studied the cytoplasmic and nuclear delivery of a fluorescein-labeled 9-residue sequence derived from the human immunodeficiency virus transactivator of transcription (TAT) peptide, TAT-(47 - 57), as well as a similarly labeled 12-residue beta-peptide, beta-(VRR)(4), in live cells. Using fluorescence confocal microscopy, we show that when added to cells, both peptides are found in endocytic vesicles containing the transferrin receptor as well as in the cytoplasm and nucleus (TAT-(47 - 57)) or nucleolus (beta-(VRR)(4)). The cells were verified to be intact through all experimental procedures by demonstrating their ability to exclude propidium iodide. Endocytic entry of the peptides was blocked by the energy poisons sodium azide and 2-deoxyglucose, whereas staining of the nucleus ( nucleolus), but not endocytic vesicles, was abrogated by treating the cells with ammonium chloride. Our observations are consistent with the proposal that TAT-(47 -57) and beta-(VRR)(4) enter cells by endocytosis and then exit an endosomal compartment to enter the cytoplasm by means of a mechanism requiring endosome acidification.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Menon, AK (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM56414, GM55427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8; Bogoyevitch MA, 2002, DNA CELL BIOL, V21, P879, DOI 10.1089/104454902762053846; Cheng RP, 2001, CHEM REV, V101, P3219, DOI 10.1021/cr000045i; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Crespo L, 2002, J AM CHEM SOC, V124, P8876, DOI 10.1021/ja020364m; D'Silva PR, 2000, J BIOL CHEM, V275, P11771, DOI 10.1074/jbc.275.16.11771; DeGrado WF, 1999, J PEPT RES, V54, P206, DOI 10.1034/j.1399-3011.1999.00131.x; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Diaz-Griffero F, 2002, J VIROL, V76, P12866, DOI 10.1128/JVI.76.24.12866-12876.2002; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FALNES PO, 1992, J BIOL CHEM, V267, P12284; Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Gademann K, 1999, CURR MED CHEM, V6, P905; Garcia-Echeverria C, 2003, BIOORG MED CHEM LETT, V13, P247, DOI 10.1016/S0960-894X(02)00885-5; Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1; Gellman SH, 1998, ACCOUNTS CHEM RES, V31, P173, DOI 10.1021/ar960298r; Guichard G, 1998, HELV CHIM ACTA, V81, P187, DOI 10.1002/hlca.19980810202; Hakansson S, 2003, BIOCHEMISTRY-US, V42, P8999, DOI 10.1021/bi020715+; Hariton-Gazal E, 2002, BIOCHEMISTRY-US, V41, P9208, DOI 10.1021/bi0201466; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Leifert JA, 2003, MOL THER, V8, P13, DOI 10.1016/S1525-0016(03)00151-5; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450; Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x; Muller A, 1998, SYNTHESIS-STUTTGART, P837, DOI 10.1055/s-1998-2075; Nicola AV, 2003, J VIROL, V77, P5324, DOI 10.1128/JVI.77.9.5324-5332.2003; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Raguse TL, 2002, J AM CHEM SOC, V124, P12774, DOI 10.1021/ja0270423; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rueping M, 2002, CHEMBIOCHEM, V3, P257, DOI 10.1002/1439-7633(20020301)3:2/3<257::AID-CBIC257>3.0.CO;2-S; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Schreiber JV, 2002, CHEMBIOCHEM, V3, P424, DOI 10.1002/1439-7633(20020503)3:5<424::AID-CBIC424>3.0.CO;2-0; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Seebach D., 1997, J CHEM SOC CHEM COMM, V21, P2015; Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X; Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5; Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7; Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109; Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S0006-291X(03)01167-7; Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805	53	192	197	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50188	50194		10.1074/jbc.M308719200	http://dx.doi.org/10.1074/jbc.M308719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517218	hybrid			2022-12-25	WOS:000187068200065
J	Tosello-Trampont, AC; Nakada-Tsukui, K; Ravichandran, KS				Tosello-Trampont, AC; Nakada-Tsukui, K; Ravichandran, KS			Engulfment of apoptotic cells is negatively regulated by Rho-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; FC-GAMMA-R; CYTOSKELETAL REORGANIZATION; CRKII/DOCK180/RAC PATHWAY; KINASE INHIBITORS; FOCAL ADHESIONS; 3T3 FIBROBLASTS; FAMILY GTPASES; SMOOTH-MUSCLE; STRESS FIBERS	The rapid and efficient phagocytosis of apoptotic cells plays a critical role in preventing secondary necrosis, inflammation as well as in tissue remodeling and regulating immune responses. However, the molecular details of engulfment are just beginning to be elucidated. Among the Rho family GTPases, previous studies have implicated a role for Rac and Cdc42 in the uptake of apoptotic cells by phagocytes, yet the role of Rho has remained unclear. Here, we present evidence that Rho-GTP levels decrease during engulfment. RhoA seems to negatively affect basal engulfment, such that inhibition of Rho-mediated signaling in phagocytes enhanced the uptake of apoptotic targets. Activation of endogenous Rho or overexpression of constitutively active forms of Rho also inhibited engulfment. By testing mutants of RhoA that selectively activate downstream effectors, the Rho-kinase seemed to be primarily responsible for this inhibitory effect. Taken together, these data suggest that inhibition of Rho- and Rho-kinase-mediated signaling might be important during engulfment, which could have important implications for several clinical trials involving inhibition of the Rho kinase.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, Bldg MR4,Rm 4072D, Charlottesville, VA 22908 USA.	Ravi@virginia.edu						Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Brown S, 2002, NATURE, V418, P200, DOI 10.1038/nature00811; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fadok VA, 1998, CURR BIOL, V8, pR693, DOI 10.1016/S0960-9822(98)70438-5; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Greenberg S, 2001, J CELL SCI, V114, P1039; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hughes J, 1997, J IMMUNOL, V158, P4389; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Just I, 2001, INT J MED MICROBIOL, V291, P243, DOI 10.1078/1438-4221-00127; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Masumoto A, 2001, HYPERTENSION, V38, P1307, DOI 10.1161/hy1201.096541; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumura F, 2001, CELL STRUCT FUNCT, V26, P639, DOI 10.1247/csf.26.639; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Olazabal IM, 2002, CURR BIOL, V12, P1413, DOI 10.1016/S0960-9822(02)01069-2; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Richard J F, 1999, Int Microbiol, V2, P185; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sawada N, 2000, CIRCULATION, V101, P2030, DOI 10.1161/01.CIR.101.17.2030; Shibata R, 2001, CIRCULATION, V103, P284; Shimokawa H, 2001, CARDIOVASC RES, V51, P169, DOI 10.1016/S0008-6363(01)00291-7; Shimokawa H, 2002, J CARDIOVASC PHARM, V39, P319, DOI 10.1097/00005344-200203000-00001; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Swanson JA, 1999, J CELL SCI, V112, P307; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	63	115	117	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49911	49919		10.1074/jbc.M306079200	http://dx.doi.org/10.1074/jbc.M306079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514696	hybrid			2022-12-25	WOS:000187068200033
J	Carter, RS; Pennington, KN; Ungurait, BJ; Arrate, P; Ballard, DW				Carter, RS; Pennington, KN; Ungurait, BJ; Arrate, P; Ballard, DW			Signal-induced ubiquitination of I kappa B kinase-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAX TRANSFORMING PROTEIN; IKK-BETA; PERSISTENT ACTIVATION; PHOSPHORYLATION; PATHWAYS; COMPLEX; ALPHA	Initiation of the genetic programs for inflammation and immunity involves nuclear mobilization of transcription factor NF-kappaB. This signal-dependent process is controlled in part by the beta-catalytic subunit of IkappaB kinase (IKKbeta), which marks IkappaBalpha and other cytoplasmic inhibitors of NF-kappaB for proteolytic destruction. The catalytic activity of IKKbeta is stimulated by pathologic and physiologic inducers of NF-kappaB, such as the Tax oncoprotein and proinflammatory cytokines. We now report evidence that these NF-kappaB inducers target IKKbeta for conjugation to ubiquitin (Ub) in mammalian cells. The apparent molecular size of modified IKKbeta is compatible with monoubiquitination rather than attachment of a multimeric Ub chain. The modification is contingent upon signal-induced phosphorylation of the activation T loop in IKKbeta at Ser-177/Ser-181. The formation of IKKbeta-Ub conjugates is disrupted in cells expressing YopJ, a Ub-like protein protease that interferes with the NF-kappaB signaling pathway. These findings indicate an important mechanistic link between phosphorylation, ubiquitination, and the biologic action of IKKbeta.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009385, R01CA082556] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052379] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09385, CA082556] Funding Source: Medline; NHLBI NIH HHS [HL68744] Funding Source: Medline; NIAID NIH HHS [AI052379] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Zandi E, 1999, MOL CELL BIOL, V19, P4547	15	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48903	48906		10.1074/jbc.M310686200	http://dx.doi.org/10.1074/jbc.M310686200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514672	hybrid			2022-12-25	WOS:000186829000048
J	Davis, MI; Ronesi, J; Lovinger, DM				Davis, MI; Ronesi, J; Lovinger, DM			A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-DEPENDENT ACTIVATION; SIGNAL-REGULATED KINASE; PROTEIN-KINASE; MAP KINASE; POSITIVE REGULATOR; CYCLIC-AMP; B-RAF; CB1; CYCLASE; GROWTH	Cannabinoids activate several members of the mitogen-activated protein kinase superfamily including p44 and p42 extracellular signal-regulated kinase (ERK). We used N1E-115 neuroblastoma cells and the cannabinoid receptor agonist WIN 55,212-2 (WIN) to examine the signal transduction pathways leading to the activation of ERK. ERK phosphorylation ( activation) was measured by Western blot. The EC50 for stimulation of ERK phosphorylation was 10 nM, and this effect was blocked by pertussis toxin and the CB1 ( cannabinoid) receptor antagonist SR141716A. The MEK inhibitors PD 98059 and U0126 blocked ERK phosphorylation, as did the adenylate cyclase activator forskolin. The phosphatidylinositol (PI) 3-kinase inhibitor LY 294002 and the Src kinase inhibitor PP2 partially occluded the response but also decreased basal levels of phospho-ERK. The PI 3-kinase and Src pathways are known to promote cell survival in many systems; therefore, MTT (1-(4,5-dimethylthiazol-2-yl)- 3,5-diphenylformazan) conversion was used to examine the effects of these inhibitors on cellular viability. LY 294002 decreased the number of viable cells after 18 h of treatment; therefore, the inhibition of ERK by this inhibitor is probably because of cytotoxicity. Forskolin blocked ERK phosphorylation with an EC50 of < 3 mu M, and the protein kinase A (PKA) inhibitor H-89 enhanced ERK phosphorylation. c-Raf phosphorylation at an inhibitory PKA-regulated site (Ser(259)) was also reduced by WIN. This is probably due to constitutive phosphatase activity because WIN did not directly stimulate PP1 or PP2A activity when measured using 6,8-difluoro-4-methylumbelliferyl phosphate as a fluorogenic substrate. These data implicate the inhibition of PKA as the predominant pathway for ERK activation by CB1 receptors in N1E-115 cells. PI 3-kinase and Src appear to contribute to ERK activation by maintaining activation of kinases, which prime the pathway and maintain cellular viability.	NIAAA, Lab Integrat Neurosci, Sect Synapt Pharmacol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Davis, MI (corresponding author), NIAAA, Lab Integrat Neurosci, Sect Synapt Pharmacol, 12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.	midavis@mail.nih.gov	Davis, Margaret/F-4165-2010	Davis, Margaret/0000-0002-0489-8351	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000407, ZIAAA000407] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Croxford JL, 2003, CNS DRUGS, V17, P179, DOI 10.2165/00023210-200317030-00004; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEADWYLER SA, 1993, RECEPTOR CHANNEL, V1, P121; Derkinderen P, 2003, J NEUROSCI, V23, P2371; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FELDER CC, 1992, MOL PHARMACOL, V42, P838; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; GERDEMAN GL, 2003, IN PRESS BR J PHARM; Glass M, 1999, MOL PHARMACOL, V56, P1362, DOI 10.1124/mol.56.6.1362; GOMEZ DP, 2000, BIOCHEM J, V347, P369; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Pan XH, 1996, MOL PHARMACOL, V49, P707; Rhee MH, 1998, J NEUROCHEM, V71, P1525; SEGER R, 1994, J BIOL CHEM, V269, P25699; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; Valjent E, 2001, EUR J NEUROSCI, V14, P342, DOI 10.1046/j.0953-816x.2001.01652.x; WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014-5793(95)00027-7; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhou D, 2001, J NEUROSCI RES, V65, P346, DOI 10.1002/jnr.1160	45	71	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48973	48980		10.1074/jbc.M305697200	http://dx.doi.org/10.1074/jbc.M305697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14517212	hybrid			2022-12-25	WOS:000186829000058
J	Dong, XY; Craig, T; Xing, NZ; Bachman, LA; Paya, CV; Weih, F; McKean, DJ; Kumar, R; Griffin, MD				Dong, XY; Craig, T; Xing, NZ; Bachman, LA; Paya, CV; Weih, F; McKean, DJ; Kumar, R; Griffin, MD			Direct transcriptional regulation of RelB by 1 alpha,25-dihydroxyvitamin D-3 and its analogs - Physiologic and therapeutic implications for dendritic cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VITAMIN-D-RECEPTOR; T-CELLS; 1,25-DIHYDROXYVITAMIN D-3; ANTIGEN PRESENTATION; DOWN-REGULATION; GENE; MATURATION; DIFFERENTIATION; INHIBITION	The nuclear factor-kappaB (NF-kappaB) protein RelB plays a unique role in dendritic cell ( DC) function and, as such, is an important regulator of antigen presentation and immune regulation. In this study, inhibition of RelB expression in DCs exposed to an analog of the active form of vitamin D-3 (1alpha, 25-dihydroxyvitamin D-3 (1alpha, 25( OH)(2)D-3)) was observed and shown to be mediated by the vitamin D receptor (VDR). Potential vitamin D response elements were identified within promoter regions of human and mouse relB genes. In gel shift experiments, these motifs specifically bound VDR . retinoid X receptor-alpha complexes. Reporter assays confirmed that transcriptional activity of human and mouse relB promoters was inhibited by 1alpha,25-(OH)(2)D-3 agonists in a DC-derived cell line. The inhibition was abolished by mutagenesis of the putative vitamin D response elements and was enhanced by overexpression of VDR. Mutagenesis of NF-kappaB response elements within the relB promoter did not affect the magnitude of 1alpha, 25-(OH)(2)D-3 analog-mediated inhibition, ruling out an indirect effect on NF-kappaB signaling. Glucocorticoid caused additional inhibition of relB promoter activity when combined with the 1alpha, 25-(OH)(2)D-3 analog. This effect was dependent on the integrity of the NF-kappaB response elements, suggesting separate regulatory mechanisms for the two steroid pathways on this promoter. We conclude that relB is a direct target for 1alpha, 25-(OH)(2)D-3-mediated negative transcriptional regulation via binding of VDR . retinoid X receptor-alpha to discrete DNA motifs. This mechanism has important implications for the inhibitory effect of 1alpha, 25-(OH)(2)D-3 on DC maturation and for the potential immunotherapeutic use of 1alpha, 25-(OH)(2)D-3 analogs alone or combined with other agents.	Mayo Clin & Mayo Fdn, Dept Internal Med, Div Nephrol, Charlton Transplant Ctr 10, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Proteom Res Ctr, Dept Internal Med, Div Infect Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Helmholtz Association; Karlsruhe Institute of Technology	Griffin, MD (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Div Nephrol, Charlton Transplant Ctr 10, 200 1st St SW, Rochester, MN 55905 USA.	griffin.matthew@mayo.edu	Griffin, Matthew/A-1688-2009	Griffin, Matthew/0000-0002-8701-8056; Kumar, Rajiv/0000-0003-3497-3057	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058546, R01DK059505, R01DK025409, T32DK007013] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59505, T32DK07013, DK58546, R01 DK058546, DK25409, R01 DK025409] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROY I, 1995, MOL CELL BIOL, V15, P5789; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Cantorna MT, 1999, J NUTR, V129, P1966, DOI 10.1093/jn/129.11.1966; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Cippitelli M, 1998, EUR J IMMUNOL, V28, P3017, DOI 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.3.CO;2-Y; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Gregori S, 2001, J IMMUNOL, V167, P1945, DOI 10.4049/jimmunol.167.4.1945; Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198; Griffin MD, 2000, BIOCHEM BIOPH RES CO, V270, P701, DOI 10.1006/bbrc.2000.2490; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382; Hutchings A, 2002, IMMUNOL RES, V26, P143, DOI 10.1385/IR:26:1-3:143; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Martin E, 2003, IMMUNITY, V18, P155, DOI 10.1016/S1074-7613(02)00503-4; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Morelli AE, 2001, SEMIN IMMUNOL, V13, P323, DOI 10.1006/smim.2001.0328; Nguyen TM, 1997, ENDOCRINOLOGY, V138, P5505, DOI 10.1210/en.138.12.5505; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Simmons JD, 2000, GUT, V47, P211, DOI 10.1136/gut.47.2.211; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Takeuchi A, 1998, J IMMUNOL, V160, P209; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; van Etten E, 2000, TRANSPLANTATION, V69, P1932, DOI 10.1097/00007890-200005150-00032; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu YH, 1999, BIOCHEMISTRY-US, V38, P2654, DOI 10.1021/bi981944s; Xing NZ, 2002, BIOCHEM BIOPH RES CO, V297, P645, DOI 10.1016/S0006-291X(02)02262-3; Yoshimura S, 2001, INT IMMUNOL, V13, P675, DOI 10.1093/intimm/13.5.675; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990	42	96	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49378	49385		10.1074/jbc.M308448200	http://dx.doi.org/10.1074/jbc.M308448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507914	hybrid			2022-12-25	WOS:000186829000106
J	Wilhelm, FX; Wilhelm, M; Gabriel, A				Wilhelm, FX; Wilhelm, M; Gabriel, A			Extension and cleavage of the polypurine tract plus-strand primer by Ty1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST RETROTRANSPOSON TY1; MURINE LEUKEMIA-VIRUS; RNASE-H; DNA-SYNTHESIS; MECHANISM; TRANSPOSITION; INITIATION; PARTICLES; SEQUENCE; FIDELITY	Using hybrid RNA/DNA substrates containing the polypurine tract (PPT) plus-strand primer, we have examined the interaction between the Ty1 reverse transcriptase (RT) and the plus-strand initiation complex. We show here that, although the PPT sequence is relatively resistant to RNase H cleavage, it can be cleaved internally by the polymerase-independent RNase H activity of Ty1 RT. Alternatively, this PPT can be used to initiate plus-strand DNA synthesis. We demonstrate that cleavage at the PPT/DNA junction occurs only after at least 9 nucleotidesare extended. Cleavage leaves a nick between the RNA primer and the nascent plus-strand DNA. We show that Ty1 RT has a strand displacement activity beyond a gap but that the PPT is not efficiently re-utilized in vitro for another round of DNA synthesis after a first plus-strand DNA has been synthesized and cleaved at the PPT/U3 junction.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Rutgers State University New Brunswick	Wilhelm, FX (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, CABM 306,679 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutabout M, 2001, NUCLEIC ACIDS RES, V29, P2217, DOI 10.1093/nar/29.11.2217; BURNS NR, 1992, EMBO J, V11, P1155, DOI 10.1002/j.1460-2075.1992.tb05156.x; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Cristofari G, 2000, J BIOL CHEM, V275, P19210, DOI 10.1074/jbc.M001371200; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; KATI WM, 1992, J BIOL CHEM, V267, P25988; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; POCHART P, 1993, NUCLEIC ACIDS RES, V21, P3513, DOI 10.1093/nar/21.15.3513; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Schultz SJ, 2000, J BIOL CHEM, V275, P32299, DOI 10.1074/jbc.M000021200; Schultz SJ, 1999, J BIOL CHEM, V274, P34547, DOI 10.1074/jbc.274.49.34547; Schultz SJ, 2003, J VIROL, V77, P5275, DOI 10.1128/JVI.77.9.5275-5285.2003; Telesnitsky A., 1997, P121; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; Wilhelm M, 1999, NUCLEIC ACIDS RES, V27, P4547, DOI 10.1093/nar/27.23.4547; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wilhelm M, 2001, J BIOL CHEM, V276, P47695, DOI 10.1074/jbc.M106067200; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200	24	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47678	47684		10.1074/jbc.M305162200	http://dx.doi.org/10.1074/jbc.M305162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500728	hybrid			2022-12-25	WOS:000186731400042
J	Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A				Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A			SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo	ONCOGENE			English	Article						pancreas; adenocarcinoma; SEL1L; DPC4/Smad4; TGF beta-pathway	C-ELEGANS SEL-1; NEGATIVE REGULATOR; NEOPLASTIC TRANSFORMATION; HUMAN HOMOLOG; NOTCH-GENE; DPC4 GENE; CELLS; INHIBITION; CANCER; PROLIFERATION	Recent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness. To investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo. In 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival. However, immunohistochemical reactivity for Sel1L and Dpc4/Smad4 was concordant in 69% of cases (chi(2) test P < 0.004). Overexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4. When implanted in nude mice, Suit-2-SEL1L-overexpressing clones displayed a considerably reduced rate of tumor growth. Thus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma. Moreover, our data provide evidence that SEL1L has an impact on the expression of genes involved in regulation of cellular growth, possibly through the TGF-beta signaling pathway.	Univ Verona, Dept Pathol, I-37134 Verona, Italy; CNR, Inst Biomed Technol, Milan, Italy; Univ Verona, Dept Surg & Gastroenterol Sci, I-37100 Verona, Italy; Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Univ Milan, Ctr Excellence, I-20122 Milan, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Verona; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Scarpa, A (corresponding author), Univ Verona, Dept Pathol, Str Grazie 8, I-37134 Verona, Italy.	ida.biunno@ltb.cnr.it; aldo.scarpa@univr.it	Giuseppe, Zamboni/L-6029-2019; Moore, Patrick/GVR-8294-2022; Sorio, Claudio/F-2764-2018; scarpa, aldo/K-6832-2016; Orlandi, Rosaria/C-1182-2017; menard, sylvie mm/C-7940-2011	Giuseppe, Zamboni/0000-0001-7428-4673; Sorio, Claudio/0000-0003-2739-4014; scarpa, aldo/0000-0003-1678-739X; Orlandi, Rosaria/0000-0002-0533-9041; SALVIA, Roberto/0000-0002-3514-8473; /0000-0002-1866-5866; , IDA_2/0000-0002-1068-4763				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Biunno I, 2000, HUM GENET, V106, P227, DOI 10.1007/s004390051032; Biunno I, 1997, GENOMICS, V46, P284, DOI 10.1006/geno.1997.5018; Biunno Ida, 2002, OMICS A Journal of Integrative Biology, V6, P187, DOI 10.1089/153623102760092788; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cattaneo M, 2001, DNA CELL BIOL, V20, P1, DOI 10.1089/10445490150504648; Cattaneo M, 2000, INT J BIOL MARKER, V15, P26, DOI 10.1177/172460080001500105; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; Donoviel DB, 1998, MECH DEVELOP, V78, P203, DOI 10.1016/S0925-4773(98)00146-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Furue M, 2001, BIOCHEM BIOPH RES CO, V282, P745, DOI 10.1006/bbrc.2001.4633; Grant B, 1997, DEVELOPMENT, V124, P637; Grant B, 1996, GENETICS, V143, P237; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harada Y, 1999, J HUM GENET, V44, P330, DOI 10.1007/s100380050171; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kloppel G, 2000, WHO CLASSIFICATION T, P219; Kudawara I, 2001, EUR J CANCER, V37, P1703, DOI 10.1016/S0959-8049(01)00185-X; Lei JY, 1996, ONCOGENE, V13, P2459; Liu QY, 1996, CANCER RES, V56, P1155; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Orlandi R, 2002, CANCER RES, V62, P567; Orlandi R, 2002, INT J BIOL MARKER, V17, P104, DOI 10.1177/172460080201700205; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Rooke HM, 2001, PATHOLOGY, V33, P73; Rozenblum E, 1997, CANCER RES, V57, P1731; Scarpa A, 2002, VIRCHOWS ARCH, V440, P155, DOI 10.1007/s00428-001-0569-6; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; THOMPSON EA, 1989, CANCER RES, V49, pS2259; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612	43	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6359	6368		10.1038/sj.onc.1206665	http://dx.doi.org/10.1038/sj.onc.1206665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508516				2022-12-25	WOS:000185535300006
J	Xiao, S; Sung, SSJ; Fu, SM; Ju, ST				Xiao, S; Sung, SSJ; Fu, SM; Ju, ST			Combining Fas mutation with interleukin-2 deficiency prevents colitis and lupus - Implicating interleukin-2 for auto-reactive T cell expansion and Fas ligand for colon epithelial cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION-INDUCED APOPTOSIS; MURINE LUPUS; B-CELLS; ULCERATIVE-COLITIS; THYMIC SELECTION; MICE; CD4(+); DISEASE; IL-2; GENE	Both the lpr gene defect and interleukin 2-targeted mutation (IL-2 KO) in mice are lethal. Interestingly, mice bearing both mutations live significantly longer than mice with either of the single mutant genes, approximating the life span of normal controls. They do not display the major disease phenotypes of lpr and IL-2 KO mice. Systemic autoimmune response, the accumulation of the abnormal CD4(-)CD8(-)B220(+) double-negative T cells, kidney disease pathology, anemia, colon damage, and lethality are prevented. Our data indicate that IL-2 is mandatory for the expansion of auto-reactive T cells in lpr mice and that CD95 (Fas) is the critical target for the development of anemia and ulcerative colitis in IL-2 KO mice in which CD178 (FasL) on intra-epithelial T cells is the major effector responsible for colon damage and lethality.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Rheumatol & Immunol, Charlottesville, VA 22908 USA; Univ Virginia, Special Ctr Res System Lupus Erythematosus, Charlottesville, VA 22908 USA; Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	University of Virginia; University of Virginia; Boston University	Ju, ST (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Rheumatol & Immunol, POB 800412, Charlottesville, VA 22908 USA.			Fu, Shu Man/0000-0001-5158-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR045222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES010244] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36938] Funding Source: Medline; NIAMS NIH HHS [P50 AR45222] Funding Source: Medline; NIEHS NIH HHS [ES-10244] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almeida ARM, 2002, J IMMUNOL, V169, P4850, DOI 10.4049/jimmunol.169.9.4850; Bassiri H, 2001, J IMMUNOL, V166, P5945, DOI 10.4049/jimmunol.166.10.5945; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; Claesson MH, 1999, J IMMUNOL, V162, P3702; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KRAMER S, 1994, EUR J IMMUNOL, V24, P2317, DOI 10.1002/eji.1830241009; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kung JT, 1998, CELL IMMUNOL, V185, P158, DOI 10.1006/cimm.1998.1282; Lee DS, 1999, IMMUNITY, V10, P83, DOI 10.1016/S1074-7613(00)80009-6; Lin TS, 1998, J CLIN INVEST, V101, P570, DOI 10.1172/JCI896; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MA A, 1995, J EXP MED, V182, P1567, DOI 10.1084/jem.182.5.1567; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Papiernik M, 1998, INT IMMUNOL, V10, P371, DOI 10.1093/intimm/10.4.371; Peng SL, 1996, J IMMUNOL, V156, P4041; Pestano GA, 1999, SCIENCE, V284, P1187, DOI 10.1126/science.284.5417.1187; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; SADLACK B, 1995, EUR J IMMUNOL, V25, P3053, DOI 10.1002/eji.1830251111; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SCHULTZ M, 1999, AM J PHYSIOL, V276, pG1416; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; SHLOMCHIK MJ, 1994, J EXP MED, V180, P1295, DOI 10.1084/jem.180.4.1295; SIMPSON SJ, 1995, EUR J IMMUNOL, V25, P2618, DOI 10.1002/eji.1830250932; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X; Tada Y, 1999, J IMMUNOL, V163, P3153; Vratsanos GS, 2001, J EXP MED, V193, P329, DOI 10.1084/jem.193.3.329; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yin ZN, 2002, J IMMUNOL, V169, P2148, DOI 10.4049/jimmunol.169.4.2148; Yung R, 1996, J CLIN INVEST, V97, P2866, DOI 10.1172/JCI118743; Zheng LX, 1998, J IMMUNOL, V160, P763	39	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52730	52738		10.1074/jbc.M308707200	http://dx.doi.org/10.1074/jbc.M308707200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14525977	hybrid			2022-12-25	WOS:000187480700091
J	Sukotjo, C; Lin, A; Song, K; Ogawa, T; Wu, B; Nishimura, I				Sukotjo, C; Lin, A; Song, K; Ogawa, T; Wu, B; Nishimura, I			Oral fibroblast expression of wound-inducible transcript 3.0 (wit3.0) accelerates the collagen gel contraction in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX REORGANIZATION; GROWTH-FACTOR; WOUND CONTRACTION; ORAL FIBROBLASTS; RESIDUAL RIDGES; MYOSIN ROD; MUSCLE; PROTEIN; MUCOSA; RESORPTION	Wounds of the oral mucosa show faster closure with less scar formation than skin wounds in other areas. A differentially expressed cDNA, wound-inducible transcript 3.0 (wit3.0), was isolated from oral mucosal wound in rats (Sukotjo, C., Abanmy, A. A., Ogawa, T., and Nishimura, I. (2002) J. Dent. Res. 81, 229 - 235). The purpose of this study was to characterize the wit3.0 gene structure and the function of its deduced peptide. Human and rat genome databases revealed that the gene for wit3.0 was located in human chromosome 12p11.23 and rat chromosome 4q44. Its human and rat gene structures were well conserved, composed of 7 exons spread over 20 kb. Exon 5 was alternatively spliced generating two transcripts encoding deduced peptides of 215 and 253 amino acids (wit3.0alpha and wit3.0beta, respectively). The protein families data base of alignments (Pfam) analysis suggested the wit3.0 peptide sequence shared similarity with a portion of the myosin II coiled-coil domain consensus sequence. Fibroblasts isolated from the rat oral wound up-regulated wit3.0 expression and exhibited greater ability to contract collagen gel in vitro than fibroblasts isolated from untreated oral mucosa/gingiva. NIH3T3 and rat oral fibroblasts transfected with expression vector containing the coding sequences of wit3.0alpha or wit3.0beta increased in vitro collagen gel contraction. When treated with TGFbeta-1, NIH3T3 fibroblast expression of wit3.0 showed no significant change, whereas alpha smooth muscle actin was increased in a dose-dependent manner. These data suggest that there may be a novel wound healing pathway involving wit3.0 underlying the favorable early wound closure characteristics of oral mucosa.	Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Bioengn, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Nishimura, I (corresponding author), Univ Calif Los Angeles, Sch Dent, Jane & Jerry Weintraub Ctr Reconstruct Biotechnol, Div Adv Prosthodont Biomat & Hosp Dent, Box 951668,CHS B3-087, Los Angeles, CA 90095 USA.		Sukotjo, Cortino/D-1766-2013					Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Chaussain Miller C, 2002, Clin Oral Investig, V6, P39; Eskin E, 2003, J COMPUT BIOL, V10, P187, DOI 10.1089/106652703321825964; Feliciani C, 1996, CRIT REV ORAL BIOL M, V7, P300, DOI 10.1177/10454411960070040101; Hamosh A, 2002, NUCLEIC ACIDS RES, V30, P52, DOI 10.1093/nar/30.1.52; Hoppe PE, 2003, MOL BIOL CELL, V14, P1677, DOI 10.1091/mbc.E02-11-0728; Ikebe M, 1999, BIOCHEMISTRY-US, V38, P10768, DOI 10.1021/bi990915u; Irwin CR, 1998, J ORAL PATHOL MED, V27, P255; Jahangiri L, 1998, J PROSTHET DENT, V80, P224, DOI 10.1016/S0022-3913(98)70116-7; Lanning DA, 2000, J PEDIATR SURG, V35, P183, DOI 10.1016/S0022-3468(00)90007-1; Lorimier S, 1998, J DENT RES, V77, P1717, DOI 10.1177/00220345980770090801; Marcus SE, 1996, J DENT RES, V75, P684, DOI 10.1177/002203459607502S08; MONTESANO R, 1988, P NATL ACAD SCI USA, V85, P4894, DOI 10.1073/pnas.85.13.4894; Morano I, 2003, J MOL MED-JMM, V81, P481, DOI 10.1007/s00109-003-0451-x; Nedelec B, 2000, HAND CLIN, V16, P289; NISHIMURA I, 1988, J PROSTHET DENT, V60, P381, DOI 10.1016/0022-3913(88)90290-9; NISHIMURA I, 1987, J DENT RES, V66, P1753, DOI 10.1177/00220345870660121101; Ohshima M, 2002, EUR J ORAL SCI, V110, P130, DOI 10.1034/j.1600-0722.2002.11179.x; SCIUBBA JJ, 1978, J ORAL PATHOL MED, V7, P214, DOI 10.1111/j.1600-0714.1978.tb01596.x; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; Stephens P, 1996, J DENT RES, V75, P1358, DOI 10.1177/00220345960750060601; Stephens P, 2001, BRIT J DERMATOL, V144, P229, DOI 10.1046/j.1365-2133.2001.04006.x; Sukotjo C, 2002, J DENT RES, V81, P229, DOI 10.1177/154405910208100402; Szpaderska AM, 2003, J DENT RES, V82, P621, DOI 10.1177/154405910308200810; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; Walsh LJ, 1996, AUST DENT J, V41, P75, DOI 10.1111/j.1834-7819.1996.tb05916.x; Wendel B, 2000, J CELL BIOCHEM, V79, P566, DOI 10.1002/1097-4644(20001215)79:4<566::AID-JCB50>3.0.CO;2-E; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13; Yang J, 1996, AM J PHYSIOL-GASTR L, V270, pG191, DOI 10.1152/ajpgi.1996.270.1.G191	31	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51527	51534		10.1074/jbc.M309616200	http://dx.doi.org/10.1074/jbc.M309616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527947	hybrid			2022-12-25	WOS:000187206300084
J	Comoletti, D; Flynn, R; Jennings, LL; Chubykin, A; Matsumura, T; Hasegawa, H; Sudhof, TC; Taylor, P				Comoletti, D; Flynn, R; Jennings, LL; Chubykin, A; Matsumura, T; Hasegawa, H; Sudhof, TC; Taylor, P			Characterization of the interaction of a recombinant soluble neuroligin-1 with neurexin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOSYLATION; NERVOUS-SYSTEM; BETA-NEUREXINS; ACETYLCHOLINESTERASE; BINDING; EXPRESSION; CHOLINESTERASES; PLASTICITY; RECEPTORS; PROTEINS	Neuroligins, proteins of the alpha/beta-hydrolase fold family, are found as postsynaptic transmembrane proteins whose extracellular domain associates with presynaptic partners, proteins of the neurexin family. To characterize the molecular basis of neuroligin interaction with neurexin-beta, we expressed five soluble and exportable forms of neuroligin-1 from recombinant DNA sources, by truncating the protein before the transmembrane span near its carboxyl terminus. The extracellular domain of functional neuroligin-1 associates as a dimer when analyzed by sedimentation equilibrium. By surface plasmon resonance, we established that soluble neuroligins-1 bind neurexin-1beta, but the homologous alpha/beta-hydrolase fold protein, acetylcholinesterase, failed to associate with the neurexins. Neuroligin-1 has a unique N-linked glycosylation pattern in the neuroligin family, and glycosylation and its processing modify neuroligin activity. Incomplete processing of the protein and enzymatic removal of the oligosaccharides chain or the terminal sialic acids from neuroligin-1 enhance its activity, whereas deglycosylation of neurexin-1beta did not alter its association capacity. In particular, the N-linked glycosylation at position 303 appears to be a major determinant in modifying the association with neurexin-1beta. We show here that glycosylation processing of neuroligin, in addition to mRNA splicing and gene selection, contributes to the specificity of the neurexin-beta/neuroligin-1 association.	Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Jennings, Lori/R-7152-2019	Chubykin, Alexander/0000-0001-8224-9296	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH052804] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM-18360] Funding Source: Medline; NIMH NIH HHS [R37 MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andres C, 1997, P NATL ACAD SCI USA, V94, P8173, DOI 10.1073/pnas.94.15.8173; Bataille S, 1998, EUR J NEUROSCI, V10, P560, DOI 10.1046/j.1460-9568.1998.00065.x; Bigbee JW, 2000, BRAIN RES, V861, P354, DOI 10.1016/S0006-8993(00)02046-1; Bolliger MF, 2001, BIOCHEM J, V356, P581, DOI 10.1042/0264-6021:3560581; Brose N, 1999, NATURWISSENSCHAFTEN, V86, P516, DOI 10.1007/s001140050666; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; Gilbert M, 2001, GLIA, V34, P151, DOI 10.1002/glia.1050; Goslin K., 1998, CULTURING NERVE CELL, P339; Grifman M, 1998, P NATL ACAD SCI USA, V95, P13935, DOI 10.1073/pnas.95.23.13935; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; JONSSON B, 1991, ANAL BIOCHEM, V198, P268; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; Missler M, 1998, J NEUROCHEM, V71, P1339; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Philibert RA, 2000, GENE, V246, P303, DOI 10.1016/S0378-1119(00)00049-4; RANDS E, 1990, J BIOL CHEM, V265, P10759; Rao A, 2000, NAT NEUROSCI, V3, P747, DOI 10.1038/77636; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rudenko G, 2001, TRENDS BIOCHEM SCI, V26, P363, DOI 10.1016/S0968-0004(01)01832-1; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; SHEN L, 1995, J EXP MED, V5, P1773; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Tsigelny I, 2000, PROTEIN SCI, V9, P180; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987	34	97	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50497	50505		10.1074/jbc.M306803200	http://dx.doi.org/10.1074/jbc.M306803200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522992	hybrid			2022-12-25	WOS:000187068200102
J	Doerwald, L; Onnekink, C; van Genesen, ST; de Jong, WW; Lubsen, NH				Doerwald, L; Onnekink, C; van Genesen, ST; de Jong, WW; Lubsen, NH			Translational thermotolerance provided by small heat shock proteins is limited to cap-dependent initiation and inhibited by 2-aminopurine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN STRESS GRANULES; NECROSIS-FACTOR-ALPHA; RIBOSOMAL ENTRY SITE; MESSENGER-RNA; MOLECULAR CHAPERONES; GENE-EXPRESSION; KINASE PKR; CELLULAR ACTIVATOR; SIGNALING PATHWAYS; OXIDATIVE STRESS	Heat shock results in inhibition of general protein synthesis. In thermotolerant cells, protein synthesis is still rapidly inhibited by heat stress, but protein synthesis recovers faster than in naive heat-shocked cells, a phenomenon known as translational thermotolerance. Here we investigate the effect of overexpressing a single heat shock protein on cap-dependent and cap-independent initiation of translation during recovery from a heat shock. When overexpressing alphaB-crystallin or Hsp27, cap-dependent initiation of translation was protected but no effect was seen on cap-independent initiation of translation. When Hsp70 was overexpressed however, both cap-dependent and -independent translation were protected. This finding indicates a difference in the mechanism of protection mediated by small or large heat shock proteins. Phosphorylation of alphaB-crystallin and Hsp27 is known to significantly decrease their chaperone activity; therefore, we tested phosphorylation mutants of these proteins in this system. alphaB-crystallin needs to be in its non-phosphorylated state to give protection, whereas phosphorylated Hsp27 is more potent in protection than the unphosphorylatable form. This indicates that chaperone activity is not a prerequisite for protection of translation by small heat shock proteins after heat shock. Furthermore, we show that in the presence of 2-aminopurine, an inhibitor of kinases, among which is double-stranded RNA-activated kinase, the protective effect of overexpressing alphaB-crystallin is abolished. The synthesis of the endogenous Hsps induced by the heat shock to test for thermotolerance is also blocked by 2-aminopurine. Most likely the protective effect of alphaB-crystallin requires synthesis of the endogenous heat shock proteins. Translational thermotolerance would then be a co-operative effect of different heat shock proteins.	Catholic Univ Nijmegen, Fac Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Lubsen, NH (corresponding author), Catholic Univ Nijmegen, Fac Sci, Dept Biochem 161, POB 9101, NL-6500 HB Nijmegen, Netherlands.	nhl@sci.kun.nl	Lubsen, Nicolette H./B-8426-2011					Arrigo Andre-Patrick, 2002, Prog Mol Subcell Biol, V28, P185; Arrigo Andre-Patrick, 2002, Prog Mol Subcell Biol, V28, P171; BECK SC, 1994, J BIOL CHEM, V269, P21803; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Carper SW, 1997, J CELL BIOCHEM, V66, P153, DOI 10.1002/(SICI)1097-4644(19970801)66:2<153::AID-JCB3>3.3.CO;2-N; CHANG GC, 1994, INT J HYPERTHER, V10, P325, DOI 10.3109/02656739409010276; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Cuesta R, 2000, GENE DEV, V14, P1460; Davidson Sean M, 2002, Prog Mol Subcell Biol, V28, P103; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEMAIO A, 1993, CIRC SHOCK, V40, P177; DEMAIO A, 1993, EUR J BIOCHEM, V218, P413; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gaestel M, 2002, Prog Mol Subcell Biol, V28, P151; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hallberg EM, 1996, CELL STRESS CHAPERON, V1, P70, DOI 10.1379/1466-1268(1996)001<0070:TTISC>2.3.CO;2; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kamei A, 2001, BIOL PHARM BULL, V24, P96, DOI 10.1248/bpb.24.96; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Kato Kanefusa, 2002, Prog Mol Subcell Biol, V28, P129; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431; Kim YK, 2002, BIOCHEM BIOPH RES CO, V297, P224, DOI 10.1016/S0006-291X(02)02154-X; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LASZLO A, 1988, EXP CELL RES, V178, P401, DOI 10.1016/0014-4827(88)90409-0; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Quinlan Roy, 2002, Prog Mol Subcell Biol, V28, P219; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Rubin CM, 2002, NUCLEIC ACIDS RES, V30, P3253, DOI 10.1093/nar/gkf419; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; TOROK I, 1980, NUCLEIC ACIDS RES, V8, P3105, DOI 10.1093/nar/8.14.3105; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; YAMAMOTO N, 1994, KIDNEY INT, V45, P1093, DOI 10.1038/ki.1994.146; Zhao MJ, 2002, J BIOL CHEM, V277, P44539, DOI 10.1074/jbc.M208408200	60	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49743	49750		10.1074/jbc.M302914200	http://dx.doi.org/10.1074/jbc.M302914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523008	hybrid			2022-12-25	WOS:000187068200014
J	Jang, YM; Kim, DW; Kang, TC; Won, MH; Baek, NI; Moon, BJ; Choi, SY; Kwon, OS				Jang, YM; Kim, DW; Kang, TC; Won, MH; Baek, NI; Moon, BJ; Choi, SY; Kwon, OS			Human pyridoxal phosphatase - Molecular cloning, functional expression, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTES; PURIFICATION; 5'-PHOSPHATE; OXIDASE; LIVER; CELLS; CDNA; ACID	Pyridoxal phosphatase catalyzes the dephosphorylation of pyridoxal 5'-phosphate (PLP) and pyridoxine 5'-phosphate. A human brain cDNA clone was identified to the PLP phosphatase on the basis of peptide sequences obtained previously. The cDNA predicts a 296-amino acid protein with a calculated M-r of 31698. The open reading frame is encoded by two exons located on human chromosome 22q12.3, and the exon-intron junction contains the GT/AG consensus splice site. In addition, a full-length mouse PLP phosphatase cDNA of 1978 bp was also isolated. Mouse enzyme encodes a protein of 292 amino acids with M-r of 31512, and it is localized on chromosome 15.E1. Human and mouse PLP phosphatase share 93% identity in protein sequence. A BLAST search revealed the existence of putative proteins in organism ranging from bacteria to mammals. Catalytically active human PLP phosphatase was expressed in Escherichia coli, and characteristics of the recombinant enzyme were similar to those of erythrocyte enzyme. The recombinant enzyme displayed K-m and k(cat) values for pyridoxal of 2.5 muM and 1.52 s(-1), respectively. Human PLP phosphatase mRNA is differentially expressed in a tissue-specific manner. A single mRNA transcript of 2.1 kb was detected in all human tissues examined and was highly abundant in the brain. Obtaining the molecular properties for the human PLP phosphatase may provide new direction for investigating metabolic pathway involving vitamin B-6.	Hallym Univ, Div Life Sci, Dept Genet Engn, Chunchon 200702, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 702701, South Korea; Hallym Univ, Coll Med, Dept Anat, Chunchon 200702, South Korea; Kyung Hee Univ, Grad Sch Biotechnol, Suwon 449701, South Korea; Kyung Hee Univ, Plant Metab Res Ctr, Suwon 449701, South Korea	Hallym University; Kyungpook National University; Hallym University; Kyung Hee University; Kyung Hee University	Choi, SY (corresponding author), Hallym Univ, Div Life Sci, Dept Genet Engn, Chunchon 200702, South Korea.	sychoi@hallym.ac.kr; oskwon@knu.ac.kr	Baek, Nam-In/AAK-7447-2020					ANDERSON BB, 1974, NATURE, V250, P502, DOI 10.1038/250502a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bull H, 2002, J CLIN PATHOL-MOL PA, V55, P65; BUSS DD, 1980, J NUTR, V110, P1665; FONDA ML, 1992, J BIOL CHEM, V267, P15978; FONDA ML, 1995, ARCH BIOCHEM BIOPHYS, V320, P345, DOI 10.1016/0003-9861(95)90018-7; GAO GJ, 1994, ARCH BIOCHEM BIOPHYS, V313, P166, DOI 10.1006/abbi.1994.1373; GAO GJ, 1994, J BIOL CHEM, V269, P8234; GAO GJ, 1994, J BIOL CHEM, V269, P7163; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hanna MC, 1997, J BIOL CHEM, V272, P10756; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; KWOK F, 1992, CHEM BIOCH FLAVOENZY, V3, P1; KWON O, 1991, J BIOL CHEM, V266, P22136; LI TK, 1974, BIOCHEM BIOPH RES CO, V61, P677, DOI 10.1016/0006-291X(74)91010-9; LUMENG L, 1975, J BIOL CHEM, V250, P8126; Lumeng L, 1980, VITAMIN B6 METABOLIS, P27; MCCORMICK D, 1961, J BIOL CHEM, V236, P2076; MCCORMICK DB, 1980, VITAMIN B6 METABOLIS, P1; MEISTER A, 1990, ANN NY ACAD SCI, V585, P13, DOI 10.1111/j.1749-6632.1990.tb28038.x; Ngo EO, 1998, BIOCHEMISTRY-US, V37, P7741, DOI 10.1021/bi972983r; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROSE ZB, 1981, ARCH BIOCHEM BIOPHYS, V208, P602, DOI 10.1016/0003-9861(81)90549-X; SCHWARTZ R, 1951, BIOCHEM J, V48, P333, DOI 10.1042/bj0480333; Snell E. E., 1970, COMPREHENSIVE BIOCH, V21, P47; SNELL EE, 1990, ANN NY ACAD SCI, V585, P1, DOI 10.1111/j.1749-6632.1990.tb28037.x; STANULOVIC M, 1976, ENZYME, V21, P357, DOI 10.1159/000458879; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	28	60	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50040	50046		10.1074/jbc.M309619200	http://dx.doi.org/10.1074/jbc.M309619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522954	hybrid			2022-12-25	WOS:000187068200047
J	Lennon, NJ; Kho, A; Bacskai, BJ; Perlmutter, SL; Hyman, BT; Brown, RH				Lennon, NJ; Kho, A; Bacskai, BJ; Perlmutter, SL; Hyman, BT; Brown, RH			Dysferlin interacts with Annexins A1 and A2 and mediates sarcolemmal wound-healing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MYOPATHY; MICROARRAY ANALYSIS; MIYOSHI MYOPATHY; MEMBRANE REPAIR; GENE; EXPRESSION; MUTATIONS; BINDING; PROTEIN; 2B	Mutations in the dysferlin gene cause limb girdle muscular dystrophy type 2B and Miyoshi myopathy. We report here the results of expression profile analyses and in vitro investigations that point to an interaction between dysferlin and the Ca2+ and lipid-binding proteins, annexins A1 and A2, and define a role for dysferlin in Ca2+-dependent repair of sarcolemmal injury through a process of vesicle fusion. Expression profiling identified a network of genes that are co-regulated in dysferlinopathic mice. Co-immunofluorescence, co-immunoprecipitation, and fluorescence lifetime imaging microscopy revealed that dysferlin normally associates with both annexins A1 and A2 in a Ca2+ and membrane injury-dependent manner. The distribution of the annexins and the efficiency of sarcolemmal wound-healing are significantly disrupted in dysferlin-deficient muscle. We propose a model of muscle membrane healing mediated by dysferlin that is relevant to both normal and dystrophic muscle and defines the annexins as potential muscular dystrophy genes.	Massachusetts Gen Hosp, Day Neuromuscular Res Lab, MGH E, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA; Childrens Hosp, Informat Program, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Brown, RH (corresponding author), Massachusetts Gen Hosp, Day Neuromuscular Res Lab, MGH E, 114 16th St, Charlestown, MA 02129 USA.	rhbrown@partners.org	Bacskai, Brian/AAE-9583-2021	Siao, Michelle/0000-0002-3600-9483	NIA NIH HHS [AG08487, AG020570] Funding Source: Medline; NIBIB NIH HHS [EB00768] Funding Source: Medline; NINDS NIH HHS [5PO1NS40828-02, P01 NS040828] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS040828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG008487, R01AG008487, R01AG020570] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Aoki M, 2001, NEUROLOGY, V57, P271, DOI 10.1212/WNL.57.2.271; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BISCHOFF R, 1994, DEV DYNAM, V201, P41, DOI 10.1002/aja.1002010105; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Butte A J, 2001, Pac Symp Biocomput, P6; Butte AJ, 2000, P NATL ACAD SCI USA, V97, P12182, DOI 10.1073/pnas.220392197; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Davis DB, 2002, J BIOL CHEM, V277, P22883, DOI 10.1074/jbc.M201858200; Ge H, 2001, NAT GENET, V29, P482, DOI 10.1038/ng776; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; Ho MF, 2002, ANN NEUROL, V51, P129, DOI 10.1002/ana.10080; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Kostek CA, 2002, AM J PATHOL, V160, P833, DOI 10.1016/S0002-9440(10)64906-1; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Matsuda C, 1999, NEUROLOGY, V53, P1119, DOI 10.1212/WNL.53.5.1119; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Vafiadaki E, 2001, NEUROREPORT, V12, P625, DOI 10.1097/00001756-200103050-00039; Weiler T, 1999, HUM MOL GENET, V8, P871, DOI 10.1093/hmg/8.5.871; Weller AH, 1997, MUSCLE NERVE, V20, P72, DOI 10.1002/(SICI)1097-4598(199701)20:1<72::AID-MUS10>3.0.CO;2-3; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7	37	292	304	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50466	50473		10.1074/jbc.M307247200	http://dx.doi.org/10.1074/jbc.M307247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506282	hybrid			2022-12-25	WOS:000187068200099
J	Yang, JY; Swaminathan, CP; Huang, Y; Guan, RJ; Cho, SW; Kieke, MC; Kranz, DM; Mariuzza, RA; Sundberg, EJ				Yang, JY; Swaminathan, CP; Huang, Y; Guan, RJ; Cho, SW; Kieke, MC; Kranz, DM; Mariuzza, RA; Sundberg, EJ			Dissecting cooperative and additive binding energetics in the affinity maturation pathway of a protein-protein interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-RECEPTOR RECOGNITION; MUTATIONAL ANALYSIS; PEPTIDE-MHC; HOT-SPOTS; RIBONUCLEASE INHIBITOR; THERMODYNAMIC ANALYSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RATIONAL DESIGN; SURFACE DISPLAY	When two proteins associate they form a molecular interface that is a structural and energetic mosaic. Within such interfaces, individual amino acid residues contribute distinct binding energies to the complex. In combination, these energies are not necessarily additive, and significant positive or negative cooperative effects often exist. The basis of reliable algorithms to predict the specificities and energies of protein-protein interactions depends critically on a quantitative understanding of this cooperativity. We have used a model protein-protein system defined by an affinity maturation pathway, comprising variants of a T cell receptor Vbeta domain that exhibit an overall affinity range of similar to 1500-fold for binding to the superantigen staphylococcal enterotoxin C3, in order to dissect the cooperative and additive energetic contributions of residues within an interface. This molecular interaction has been well characterized previously both structurally, by x-ray crystallographic analysis, and energetically, by scanning alanine mutagenesis. Through analysis of group and individual maturation and reversion mutations using surface plasmon resonance spectroscopy, we have identified energetically important interfacial residues, determined their cooperative and additive energetic properties, and elucidated the kinetic and thermodynamic bases for molecular evolution in this system. The summation of the binding free energy changes associated with the individual mutations that define this affinity maturation pathway is greater than that of the fully matured variant, even though the affinity gap between the end point variants is relatively large. Two mutations in particular, both located in the complementarity determining region 2 loop of the Vbeta domain, exhibit negative cooperativity.	Univ Maryland, Inst Biotechnol, WM Keck Lab Struct Biol, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University System of Maryland; University of Maryland Baltimore; University of Illinois System; University of Illinois Urbana-Champaign	Sundberg, EJ (corresponding author), Univ Maryland, Inst Biotechnol, WM Keck Lab Struct Biol, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	sundberg@umbi.umd.edu	Kieke, Michele (Shellie) C/GSJ-0910-2022	Sundberg, Eric/0000-0003-0478-3033; YANG, JIANYING/0000-0001-8197-5413	NIAID NIH HHS [AI49564] Funding Source: Medline; NIGMS NIH HHS [GM52801] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049564] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; Brooijmans N, 2002, PROTEINS, V48, P645, DOI 10.1002/prot.10139; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; Churchill HRO, 2000, J EXP MED, V191, P835, DOI 10.1084/jem.191.5.835; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Goldman ER, 1997, BIOCHEMISTRY-US, V36, P49, DOI 10.1021/bi961769k; Green NS, 1998, BIOESSAYS, V20, P227, DOI 10.1002/(SICI)1521-1878(199803)20:3<227::AID-BIES6>3.0.CO;2-O; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; Holler PD, 2003, IMMUNITY, V18, P255, DOI 10.1016/S1074-7613(03)00019-0; JIN L, 1994, PROTEIN SCI, V3, P2351, DOI 10.1002/pro.5560031219; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Kieke MC, 2001, J MOL BIOL, V307, P1305, DOI 10.1006/jmbi.2001.4560; Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997; Lavigne P, 2000, PROTEIN SCI, V9, P252; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; Luque I, 2002, PROTEINS, V49, P181, DOI 10.1002/prot.10208; Ma BY, 2001, CURR OPIN STRUC BIOL, V11, P364, DOI 10.1016/S0959-440X(00)00216-5; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; Reiser JB, 2003, NAT IMMUNOL, V4, P241, DOI 10.1038/ni891; Reiser JB, 2002, IMMUNITY, V16, P345, DOI 10.1016/S1074-7613(02)00288-1; Romesberg FE, 1998, SCIENCE, V279, P1929, DOI 10.1126/science.279.5358.1929; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Shapiro R, 2000, J MOL BIOL, V302, P497, DOI 10.1006/jmbi.2000.4075; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Sundberg EJ, 2003, STRUCTURE, V11, P1151, DOI 10.1016/S0969-2126(03)00187-4; Sundberg EJ, 2000, BIOCHEMISTRY-US, V39, P15375, DOI 10.1021/bi000704l; Sundberg EJ, 2000, STRUCTURE, V8, pR137, DOI 10.1016/S0969-2126(00)00167-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Teufel DP, 2003, BIOCHEMISTRY-US, V42, P1451, DOI 10.1021/bi026852o; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Wodak SJ, 2003, ADV PROTEIN CHEM, V61, P9; Yang PL, 1999, J MOL BIOL, V294, P1191, DOI 10.1006/jmbi.1999.3197	54	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50412	50421		10.1074/jbc.M306848200	http://dx.doi.org/10.1074/jbc.M306848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514664	hybrid			2022-12-25	WOS:000187068200092
J	Abdel-Ghany, M; Cheng, HC; Elble, RC; Lin, HQ; DiBiasio, J; Pauli, BU				Abdel-Ghany, M; Cheng, HC; Elble, RC; Lin, HQ; DiBiasio, J; Pauli, BU			The interacting binding domains of the beta(4) integrin and calcium-activated chloride channels (CLCAs) in metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY-DETERMINING LOOP; ALPHA-6-BETA-4 INTEGRIN; CELL-ADHESION; LIGAND-BINDING; ALPHA(6)BETA(4) INTEGRIN; BETA(4) INTEGRIN; BREAST-CANCER; EXPRESSION; LUNG; SUBUNIT	CLCA (chloride channel, calcium-activated) proteins are novel pulmonary vascular addresses for bloodborne, lung-metastatic cancer cells. They facilitate vascular arrest of cancer cells via adhesion to beta(4) integrin and promote early, intravascular, metastatic growth. Here we identify the interacting binding domains of endothelial CLCA proteins (e.g. hCLCA2, mCLCA5, mCLCA1, and bCLCA2) and beta(4) integrin. Endothelial CLCAs share a common beta(4)-binding motif (beta(4)BM) in their 90- and 35-kDa subunits of the sequence F(S/N) R(I/L/ V)(S/T) S, which is located in the second extracellular domain of the 90-kDa CLCA and near the N terminus of the 35-kDa CLCA, respectively. Using enzyme-linked immunosorbent, pull-down, and adhesion assays, we showed that glutathione S-transferase fusion proteins of beta(4)BMs from the 90- and 35-kDa CLCA subunits bind to the beta(4) integrin in a metal ion-dependent manner. Fusion proteins from fibronectin and the integrins beta(1) and beta(3) served as negative controls. beta(4)BM fusion proteins competitively blocked the beta(4)/CLCA adhesion and prevented lung colonization of MDA-MB-231 breast cancer cells. A disrupted beta(4)BM in hCLCA1, which is not expressed in endothelia, failed to interact with beta(4) integrin. The corresponding CLCA-binding domain of the beta(4) integrin is localized to the specific determining loop (SDL). Again enzyme-linked immunosorbent, pull-down, and adhesion assays were used to confirm the interaction with CLCA proteins using a glutathione S-transferase fusion protein representing the C-terminal two-thirds of beta(4) SDL (amino acids 184 - 203). A chimeric beta(4) integrin in which the indicated SDL sequence had been replaced with the corresponding sequence from the beta(1) integrin failed to bind hCLCA2. The dominance of the CLCA ligand in beta(4) activation and outside-in signaling is discussed in reference to our previous report that beta(4)/CLCA ligation elicits selective signaling via focal adhesion kinase to promote metastatic growth.	Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA; Yale Univ, Sch Med, Div Biostat, New Haven, CT 06520 USA	Cornell University; Yale University	Pauli, BU (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.	bup1@cornell.edu		Lin, Haiqun/0000-0002-3114-9671	NCI NIH HHS [CA47668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Bustin SA, 2001, DNA CELL BIOL, V20, P331, DOI 10.1089/10445490152122442; Cheng HC, 2003, J BIOL CHEM, V278, P24600, DOI 10.1074/jbc.M303424200; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Davis MJ, 2002, CELL BIOCHEM BIOPHYS, V36, P41, DOI 10.1385/CBB:36:1:41; Davis TL, 2001, PROSTATE, V46, P240; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Fuller CM, 2001, PFLUG ARCH EUR J PHY, V443, pS107, DOI 10.1007/s004240100655; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gruber A. D., 2000, Current Genomics, V1, P201, DOI 10.2174/1389202003351526; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 2002, CURR TOP MEMBR, V53, P367; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; HENIKOFF S, 1995, GENE-COMBIS, V163, pGC17, DOI 10.1016/0378-1119(95)00486-P; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Khanna C, 2001, CANCER RES, V61, P3750; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Kitajiri S, 2002, PATHOL INT, V52, P438, DOI 10.1046/j.1440-1827.2002.01379.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Pauli BU, 2002, CURR TOP MEMBR, V53, P415, DOI 10.1016/S1063-5823(02)53044-1; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; PAULI BU, 1997, ENCY CANC, P464; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Putz E, 1999, CANCER RES, V59, P241; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Tani T, 1996, AM J PATHOL, V149, P781; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsuruta D, 2003, J BIOL CHEM, V278, P38707, DOI 10.1074/jbc.M301637200; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	49	49	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49406	49416		10.1074/jbc.M309086200	http://dx.doi.org/10.1074/jbc.M309086200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512419	hybrid			2022-12-25	WOS:000186829000109
J	Baitinger, C; Burdett, V; Modrich, P				Baitinger, C; Burdett, V; Modrich, P			Hydrolytically deficient MutS E694A is defective in the MutL-dependent activation of MutH and in the mismatch-dependent assembly of the MutS center dot MutL center dot heteroduplex complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTS; REPAIR PROTEIN MUTS; DNA MISMATCH; TRANSLOCATION MECHANISM; ATP HYDROLYSIS; SLIDING CLAMP; HMUTS-ALPHA; HELICASE II; IN-VIVO; BINDING	The roles of ATP binding and hydrolysis by MutS in mismatch repair are poorly understood. MutS E694A, in which Glu-694 of the Walker B motif is substituted with alanine, is defective in hydrolysis of bound ATP and has been reported to support MutL-dependent activation of the MutH d(GATC) endonuclease in a trans DNA activation assay (Junop, M. S., Obmolova, G., Rausch, K., Hsieh, P., and Yang, W. ( 2001) Mol. Cell 7, 1 - 12). Because the MutH trans activation assay used in these previous studies was characterized by high background and low efficiency, we have re-evaluated the activities of MutS E694A. In contrast to native MutS, which can be isolated in a nucleotide-free form, purified MutS E694A contains 1.0 mol of bound ATP per dimer equivalent, and substoichiometric levels of bound ADP ( 0.08 - 0.58 mol/dimer), consistent with the suggestion that the ADP . MutS . ATP complex comprises a significant fraction of the protein in solution (Bjornson, K. P. and Modrich, P. ( 2003) J. Biol. Chem. 278, 18557 - 18562). In the presence of Mg2+, endogenous ATP is hydrolyzed with a rate constant of 0.12 min(-1) at 30 degreesC, and hydrolysis yields a protein that displays increased specificity for heteroduplex DNA. As observed with wild type MutS, ATP can promote release of MutS E694A from a mismatch. However, the mutant protein is defective in the methyl-directed, mismatch- and MutL-dependent cis activation of MutH endonuclease on a 6.4-kilobase pair heteroduplex, displaying only 1 to 2% of the activity of wild type MutS. The mutant protein also fails to support normal assembly of the MutS . MutL . DNA ternary complex. Although a putative ternary complex can be observed in the presence of MutS E694A, assembly of this structure displays little if any dependence on a mismatched base pair.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM23719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Bjornson KP, 2003, J BIOL CHEM, V278, P34667, DOI 10.1074/jbc.M305513200; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lamers MH, 2003, EMBO J, V22, P746, DOI 10.1093/emboj/cdg064; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LU AL, 1984, COLD SPRING HARB SYM, V49, P589, DOI 10.1101/SQB.1984.049.01.066; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; REENAN RAG, 1992, GENETICS, V132, P975; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	42	18	18	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49505	49511		10.1074/jbc.M308738200	http://dx.doi.org/10.1074/jbc.M308738200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506224	hybrid			2022-12-25	WOS:000186829000119
J	Chen, XX; Li, Y; Wei, KH; Li, L; Liu, WL; Zhu, YP; Qiu, ZY; He, FC				Chen, XX; Li, Y; Wei, KH; Li, L; Liu, WL; Zhu, YP; Qiu, ZY; He, FC			The potentiation role of hepatopoietin on activator protein-1 is dependent on its sulfhydryl oxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; HEPATIC STIMULATOR SUBSTANCE; REGENERATION ALR GENE; LIVER-REGENERATION; COP9 SIGNALOSOME; EGG-WHITE; C-JUN; REDOX REGULATION; GROWTH-FACTOR; AP-1 ACTIVITY	Hepatopoietin (HPO) is a novel hepatotrophic growth factor that stimulates hepatocyte proliferation by two pathways. In the first, intracellular HPO specifically modulates the activator protein-1 (AP-1) pathway through JAB1 (Jun activation domain-binding protein 1), whereas in the second, extracellular HPO triggers the mitogen-activated protein kinase pathway by binding its specific receptor on the cell surface. In this report we demonstrate that HPO is a flavin-linked sulfhydryl oxidase, and the invariant CXXC (Cys-Xaa-Xaa-Cys) motif in HPO is essential for the enzyme activity of HPO but not for its dimerization nor for its binding ability with JAB1. Two intramolecular disulfides were identified in HPO by mass spectrometry, one of which is formed by the redox CXXC cysteine residues. HPO site-directed mutants (Cys/Ser) at active sites, which lost sulfhydryl oxidase activity, could not increase c-Jun phosphorylation and failed to potentiate JAB1-mediated AP-1 activation. However, the mutants still have mitogenic stimulation and mitogen-activated protein kinase activation effects on HepG2 cells. Thus, it can be concluded that the potentiation role of HPO on AP-1 is dependent on its sulfhydryl oxidase activity.	Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Syst Biol, Beijing 100850, Peoples R China; Chongqing Univ Med Sci, Dept Clin Biochem, Chongqing 400016, Peoples R China; Natl Ctr Biomed Anal China, Beijing 100850, Peoples R China; Tsing Hua Univ, Coll Life Sci & Technol, Beijing 100084, Peoples R China	Academy of Military Medical Sciences - China; Chongqing Medical University; Tsinghua University	He, FC (corresponding author), Chinese Natl Human Genome Ctr Beijing, Beijing Inst Radiat Med, Dept Syst Biol, Beijing 100850, Peoples R China.			Liu, Wanli/0000-0003-0395-2800; Li, Li/0000-0003-2342-3658				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Benayoun B, 2001, J BIOL CHEM, V276, P13830, DOI 10.1074/jbc.M010933200; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chopra S, 2002, J BIOL CHEM, V277, P32413, DOI 10.1074/jbc.C200311200; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; Gerber J, 2001, J BIOL CHEM, V276, P23486, DOI 10.1074/jbc.M100134200; Giorda R, 1996, MOL MED, V2, P97, DOI 10.1007/BF03402206; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofhaus G, 2003, EUR J BIOCHEM, V270, P1528, DOI 10.1046/j.1432-1033.2003.03519.x; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; LABRECQUE DR, 1991, DIGEST DIS SCI, V36, P669, DOI 10.1007/BF01297036; LABRECQUE DR, 1975, J PHYSIOL-LONDON, V248, P273, DOI 10.1113/jphysiol.1975.sp010973; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; Lee JE, 2000, FEBS LETT, V477, P62, DOI 10.1016/S0014-5793(00)01767-1; Li Y, 2001, DNA CELL BIOL, V20, P791, DOI 10.1089/104454901753438606; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; LI Y, 2002, EUR J BIOCHEM, V269, P1; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; Lu CR, 2002, FASEB J, V16, P90, DOI 10.1096/fj.01-0506fje; MASSEY V, 1995, FASEB J, V9, P473, DOI 10.1096/fasebj.9.7.7737454; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Senkevich TG, 2002, P NATL ACAD SCI USA, V99, P6667, DOI 10.1073/pnas.062163799; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Wang G, 1999, J BIOL CHEM, V274, P11469, DOI 10.1074/jbc.274.17.11469; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; Wu CK, 2003, PROTEIN SCI, V12, P1109, DOI 10.1110/ps.0238103; Yang XM, 1998, WORLD J GASTROENTERO, V4, P100; Yang XM, 1997, ACTA BIOCH BIOPH SIN, V29, P414; YANG XM, 1997, ACTA PHYSL SINICA, V49, P599; YANG XM, 1997, ACTA PHYSL SINICA, V49, P557	52	25	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49022	49030		10.1074/jbc.M304057200	http://dx.doi.org/10.1074/jbc.M304057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500725	hybrid			2022-12-25	WOS:000186829000064
J	Mamet, J; Lazdunski, M; Voilley, N				Mamet, J; Lazdunski, M; Voilley, N			How nerve growth factor drives physiological and inflammatory expressions of acid-sensing ion channel 3 in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLIA; EXPERIMENTAL TISSUE ACIDOSIS; MAMMALIAN DEGENERIN MDEG; SIGNAL-REGULATED KINASE; GENE-RELATED PEPTIDE; N-TERMINAL KINASE; GATED NA+ CHANNEL; ION CHANNELS; SODIUM-CHANNELS; TRANSCRIPTION FACTORS	Nerve growth factor (NGF) is a key element of inflammatory pain. It induces hyperalgesia by up-regulating the transcription of genes encoding receptors, ion channels, and neuropeptides. Acid-sensing ion channel 3 (ASIC3), a depolarizing sodium channel gated by protons during tissue acidosis, is specifically expressed in sensory neurons. It has been associated to cardiac ischemic and inflammatory pains. We previously showed that low endogenous NGF was responsible for ASIC3 basal expression and high NGF during inflammation increased ASIC3 expression parallely to the development of neuron hyperexcitability associated with hyperalgesia. NGF is known to activate numerous signaling pathways through trkA and p75 receptors. We now show that (i) NGF controls ASIC3 basal expression through constitutive activation of a trkA/phospholipase C/protein kinase C pathway, (ii) high inflammatory-like NGF induces ASIC3 overexpression through a trkA/JNK/ p38MAPK pathway and a p75-dependent mechanism as a transcriptional switch, and (iii) NGF acts through AP1 response elements in ASIC3 encoding gene promoter. These new data indicate potential targets that could be used to develop new treatments against inflammatory pain.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Voilley, N (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.	voilley@ipmc.cnrs.fr						Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Baskey JC, 2002, J NEUROCHEM, V80, P501, DOI 10.1046/j.0022-3042.2001.00730.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bennett DLH, 2001, NEUROSCIENTIST, V7, P13, DOI 10.1177/107385840100700105; Benson CJ, 1999, CIRC RES, V84, P921; BEVAN S, 1995, J NEUROSCI, V15, P4918; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Buschmann T, 1998, NEUROSCIENCE, V84, P163, DOI 10.1016/S0306-4522(97)00487-9; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Delcroix JD, 1999, J NEUROSCI, V19, part. no.; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Fjell J, 1999, J NEUROSCI RES, V57, P39, DOI 10.1002/(SICI)1097-4547(19990701)57:1<39::AID-JNR5>3.0.CO;2-M; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Gould HJ, 2000, BRAIN RES, V854, P19, DOI 10.1016/S0006-8993(99)02216-7; Grunder S, 2000, NEUROREPORT, V11, P1607; HAAS CA, 1991, EUR J NEUROSCI, V3, P708, DOI 10.1111/j.1460-9568.1991.tb00856.x; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Issberner U, 1996, NEUROSCI LETT, V208, P191, DOI 10.1016/0304-3940(96)12576-3; JACOBUS WE, 1977, NATURE, V265, P756, DOI 10.1038/265756a0; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; JOHANSON SO, 1995, BRAIN RES, V690, P55, DOI 10.1016/0006-8993(95)00587-G; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; Latchman DS, 1996, INT J BIOCHEM CELL B, V28, P965, DOI 10.1016/1357-2725(96)00039-8; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; LEWIN GR, 1994, J NEUROPHYSIOL, V71, P941, DOI 10.1152/jn.1994.71.3.941; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mamet J, 2002, J NEUROSCI, V22, P10662; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; McMahon SB, 1996, PHILOS T R SOC B, V351, P431, DOI 10.1098/rstb.1996.0039; Mendell LM, 1999, MICROSC RES TECHNIQ, V45, P252, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<252::AID-JEMT9>3.0.CO;2-N; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; MURASE K, 1992, J NEUROSCI RES, V33, P282, DOI 10.1002/jnr.490330211; NOGUCHI K, 1988, MOL BRAIN RES, V4, P31, DOI 10.1016/0169-328X(88)90015-0; Okuse K, 1997, MOL CELL NEUROSCI, V10, P196, DOI 10.1006/mcne.1997.0657; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; PATERSON JM, 1995, NEUROSCIENCE, V66, P921, DOI 10.1016/0306-4522(95)00041-G; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quinn JP, 2000, NEUROPEPTIDES, V34, P292, DOI 10.1054/npep.2000.0833; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; Schmelz M, 1996, NEUROSCI LETT, V214, P72; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; STEEN KH, 1993, NEUROSCI LETT, V154, P113, DOI 10.1016/0304-3940(93)90184-M; Steen KH, 1996, PAIN, V66, P163, DOI 10.1016/0304-3959(96)03034-5; STEEN KH, 1995, NEUROSCI LETT, V199, P29, DOI 10.1016/0304-3940(95)12002-L; STEEN KH, 1992, J NEUROSCI, V12, P86; STEEN KH, 1995, J NEUROSCI, V15, P3982; Szallasi A, 1999, PHARMACOL REV, V51, P159; TONUSSI CR, 1994, EUR J PHARMACOL, V251, P173, DOI 10.1016/0014-2999(94)90398-0; VEDDER H, 1993, NEUROPEPTIDES, V24, P351, DOI 10.1016/0143-4179(93)90006-V; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; Woolf CJ, 1996, PHILOS T ROY SOC B, V351, P441, DOI 10.1098/rstb.1996.0040; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; WRIGHT DE, 1995, J COMP NEUROL, V351, P329, DOI 10.1002/cne.903510302; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000	80	110	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48907	48913		10.1074/jbc.M309468200	http://dx.doi.org/10.1074/jbc.M309468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522957	hybrid			2022-12-25	WOS:000186829000049
J	Graf, GA; Yu, LQ; Li, WP; Gerard, R; Tuma, PL; Cohen, JC; Hobbs, HH				Graf, GA; Yu, LQ; Li, WP; Gerard, R; Tuma, PL; Cohen, JC; Hobbs, HH			ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER RESISTANCE PROTEIN; EYE PIGMENT PRECURSORS; DROSOPHILA-WHITE GENE; DIETARY-CHOLESTEROL; SUBCELLULAR-LOCALIZATION; MULTIDRUG TRANSPORTER; STEROL ABSORPTION; HUMAN HOMOLOG; SITOSTEROLEMIA; MELANOGASTER	ABCG5 (G5) and ABCG8 (G8) are ATP-binding cassette (ABC) transporters that limit intestinal absorption and promote biliary excretion of neutral sterols. Mutations in either ABCG5 or ABCG8 result in an identical clinical phenotype, suggesting that these two half-transporters function as heterodimers. Expression of both G5 and G8 is required for either protein to be transported to the plasma membrane of cultured cells. In this paper we used immunofluorescence microscopy to confirm, in vivo, that G5 is localized to the apical membranes of mouse enterocytes and hepatocytes. Other ABC half-transporters function as homodimers or as heterodimers with other subfamily members. To determine whether G5 or G8 complex with other ABCG half-transporters, we co-expressed G1, G2, and G4 with either G5 or G8 in cultured cells. G1, G2, and G4 co- immunoprecipitated with G5, and G4 co- immunoprecipitated with G8, but the putative dimers were retained in the endoplasmic reticulum ( ER). Adenovirus-mediated expression of either G5 or G8 in the liver of G5G8 null mice resulted in ER retention of the expressed proteins and no increase in biliary cholesterol. In contrast, co- expression of G5 and G8 resulted in transit of the proteins out of the ER and a 10-fold increase in biliary cholesterol concentration. Finally, adenoviral expression of G2 in the presence or absence of G5 or G8 failed to promote sterol excretion into bile. These experiments indicate that G5 and G8 function as obligate heterodimers to promote sterol excretion into bile.	Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Catholic University of America	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Helen.Hobbs@UTSouthwestern.edu	Eckhardt, Erik/G-1567-2010	Graf, Gregory/0000-0002-0130-9929	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL072304, R37HL072304] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, HL72304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Annilo T, 2001, CYTOGENET CELL GENET, V94, P196, DOI 10.1159/000048816; BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Chen HM, 1996, AM J HUM GENET, V59, P66; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Engel T, 2001, BIOCHEM BIOPH RES CO, V288, P483, DOI 10.1006/bbrc.2001.5756; EWART GD, 1994, J BIOL CHEM, V269, P10370; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Hoekstra M, 2003, J BIOL CHEM, V278, P25448, DOI 10.1074/jbc.M301189200; Ikeda S, 2000, BIOCHEM BIOPH RES CO, V273, P1063, DOI 10.1006/bbrc.2000.3071; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LUTJOHANN D, 1995, J LIPID RES, V36, P1763; Mackenzie SM, 2000, GENETICA, V108, P239, DOI 10.1023/A:1004115718597; Maliepaard M, 2001, CANCER RES, V61, P3458; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; Moreau RA, 2002, PROG LIPID RES, V41, P457, DOI 10.1016/S0163-7827(02)00006-1; Oldfield S, 2002, BBA-MOL CELL RES, V1591, P175, DOI 10.1016/S0167-4889(02)00269-0; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1992, J LIPID RES, V33, P945; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Suzuki M, 2003, J BIOL CHEM, V278, P22644, DOI 10.1074/jbc.M212399200; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; Trappe R, 1999, BBA-GENE STRUCT EXPR, V1446, P341, DOI 10.1016/S0167-4781(99)00107-4; Tuma P.L., 1999, CURRENT PROTOCOLS CE, P321; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; YOSHIKAWA M, 2002, GENE, V26, P67; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	44	340	358	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48275	48282		10.1074/jbc.M310223200	http://dx.doi.org/10.1074/jbc.M310223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504269	hybrid			2022-12-25	WOS:000186731400112
J	Holowaty, MN; Sheng, Y; Nguyen, T; Arrowsmith, C; Frappier, L				Holowaty, MN; Sheng, Y; Nguyen, T; Arrowsmith, C; Frappier, L			Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; NUCLEAR ANTIGEN-1; TRANS ACTIVATION; RING FINGER; SH3 DOMAIN; IN-VITRO; PATHWAY; DEGRADATION; EXPRESSION	USP7 or HAUSP is a ubiquitin-specific protease in human cells that regulates the turnover of p53 and is bound by at least two viral proteins, the ICP0 protein of herpes simplex type 1 and the EBNA1 protein of Epstein-Barr virus. We have overexpressed and purified USP7 and shown that the purified protein is monomeric and is active for cleaving both a linear ubiquitin substrate and conjugated ubiquitin on EBNA1. Using partial proteolysis of USP7 coupled with matrix-assisted laser desorption ionization time-of-flight mass spectrometry, we showed that USP7 comprises four structural domains; an N-terminal domain known to bind p53, a catalytic domain, and two C-terminal domains. By passing a mixture of USP7 domains over EBNA1 and ICP0 affinity columns, we showed that the N-terminal p53 binding domain was also responsible for the EBNA1 interaction, while the ICP0 binding domain mapped to a C-terminal domain between amino acids 599-801. Tryptophan fluorescence assays showed that an EBNA1 peptide mapping to residues 395-450 was sufficient to bind the USP7 N-terminal domain and did so with a dissociation constant of 0.9-2 muM, whereas p53 peptides spanning the USP7-binding region gave dissociation constants of 9-17 muM in the same assay. In keeping with these relative affinities, gel filtration analyses of the complexes showed that the EBNA1 peptide efficiently competed with the p53 peptide for USP7 binding, suggesting that EBNA1 could affect p53 function in vivo by competing for USP7.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Frappier, L (corresponding author), 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; Frappier L, 2003, BIOL PLASMIDS; GRAY DA, 1995, ONCOGENE, V10, P2179; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Holowaty MN, 2003, J BIOL CHEM, V278, P29987, DOI 10.1074/jbc.M303977200; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Maxwell KL, 1998, BIOCHEMISTRY-US, V37, P16172, DOI 10.1021/bi981788p; MEREDITH M, 1994, VIROLOGY, V200, P457, DOI 10.1006/viro.1994.1209; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Park KC, 1997, ARCH BIOCHEM BIOPHYS, V347, P78, DOI 10.1006/abbi.1997.0311; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; YATES JL, 1988, CANCER CELL, V6, P197; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	43	131	139	0	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47753	47761		10.1074/jbc.M307200200	http://dx.doi.org/10.1074/jbc.M307200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506283	hybrid			2022-12-25	WOS:000186731400051
J	White, KA; Yore, MM; Warburton, SL; Vaseva, AV; Rieder, E; Freemantle, SJ; Spinella, MJ				White, KA; Yore, MM; Warburton, SL; Vaseva, AV; Rieder, E; Freemantle, SJ; Spinella, MJ			Negative feedback at the level of nuclear receptor coregulation - Self-limitation of retinoid signaling by RIP140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EMBRYONAL CARCINOMA; INTERACTING PROTEIN 140; TRANSCRIPTIONAL ACTIVATION; GENE ACTIVATION; ACID; COREPRESSOR; BINDING; TRANSACTIVATION; DIFFERENTIATION; ACETYLATION	Nuclear receptor-mediated gene expression is proposed to be regulated by the ordered recruitment of large protein complexes in which activity depends on mutual interactions and posttranslational modifications. In contrast, relatively little attention has been given to mechanisms regulating the expression of the coregulator proteins themselves. Previously we have shown that the ligand-dependent corepressor, RIP140, is a direct transcriptional target of all-trans retinoic acid (RA). Here we demonstrate that RA induction of RIP140 constitutes a rate-limiting step in the regulation of retinoic acid receptor signaling. Silencing of the RA induction of RIP140 dramatically enhances and accelerates retinoid receptor transactivation, endogenous expression of other RA target genes, and RA-induced neuronal differentiation and cell cycle arrest in human embryonal carcinoma cells. The data suggest that RA induction of RIP140 constitutes a functional negative feedback loop that limits activation of retinoid receptors in the continued presence of RA and that acutely regulated expression of coregulators may be a general regulatory mechanism in hormonal signaling.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [K01-CA75154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Mangelsdorf David J., 1994, P319; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyata KS, 1998, MOL CELL ENDOCRINOL, V146, P69; Parker M, 2003, FEBS LETT, V546, P149, DOI 10.1016/S0014-5793(03)00564-7; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Teyssier C, 2003, MOL ENDOCRINOL, V17, P287, DOI 10.1210/me.2002-0324; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200	30	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43889	43892		10.1074/jbc.C300374200	http://dx.doi.org/10.1074/jbc.C300374200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	14506269	hybrid			2022-12-25	WOS:000186306700002
J	Mehats, C; Jin, SLC; Wahlstrom, J; Law, E; Umetsu, DT; Conti, M				Mehats, C; Jin, SLC; Wahlstrom, J; Law, E; Umetsu, DT; Conti, M			PDE4D plays a critical role in the control of airway smooth muscle contraction	FASEB JOURNAL			English	Article						cyclic AMP; metabolism; second messengers; trachea	PROTEIN-KINASE-A; PHOSPHODIESTERASE ISOZYMES; CYCLIC-AMP; AUTORADIOGRAPHIC LOCALIZATION; RYANODINE RECEPTOR; MICE; IDENTIFICATION; ROLIPRAM; INVOLVEMENT; RELAXATION	The airways of mice deficient in the cAMP phosphodiesterase PDE4D gene are refractory to muscarinic cholinergic stimulation. This study was undertaken to determine whether altered smooth muscle contractility causes the PDE4D(-/-) phenotype. A major disruption in contractility was observed in isolated PDE4D(-/-) tracheas, with a 60% reduction in maximal tension and a fivefold decrease in sensitivity to muscarinic cholinergic agonists. Conversely, responses to KCl or arginine vasopressin were unaffected. PDE4D is the predominant PDE4 form in tracheal extracts and PDE4D mRNA is expressed in smooth muscle where muscarinic binding sites are most abundant. Cyclic AMP accumulation in response to acute Gsalpha-coupled receptor stimulation was increased up to fourfold in the airway of PDE4D(-/-) mice when compared with wild-type. This increase in cAMP was associated with an increased sensitivity to PGE(2)-induced relaxation of the PDE4D(-/-) tracheas. Furthermore, a blockade of prostanoid accumulation in PDE4D(-/-) tracheas restored the response to muscarinic cholinergic stimulation in vitro and in vivo. These results demonstrate that PDE4D plays a key role in balancing relaxant and contracting cues in airway smooth muscle, suggesting that natural mutations in the PDE4D gene have profound effects on airway tone.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Stanford University; Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, 300 Pasteur Dr,Room A344, Stanford, CA 94305 USA.	marco.conti@stanford.edu	Mehats, Celine/D-8650-2017; Law, Evelyn C/AAM-4083-2020	Law, Evelyn C/0000-0003-4683-7220; Mehats, Celine/0000-0002-3677-2024	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067674, P50HL067674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67674] Funding Source: Medline; NICHD NIH HHS [R01 HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdel-Latif AA, 2001, EXP BIOL MED, V226, P153, DOI 10.1177/153537020122600302; BARNES PJ, 1992, BRIT MED BULL, V48, P149, DOI 10.1093/oxfordjournals.bmb.a072531; BARNES PJ, 1982, EUR J PHARMACOL, V86, P103, DOI 10.1016/0014-2999(82)90405-8; Birnbaumer M, 2000, TRENDS ENDOCRIN MET, V11, P406, DOI 10.1016/S1043-2760(00)00304-0; Bymaster FP, 2001, LIFE SCI, V68, P2473, DOI 10.1016/S0024-3205(01)01041-4; Catalli A, 2002, AM J PHYSIOL-LUNG C, V283, pL1151, DOI 10.1152/ajplung.00038.2002; Cheng JB, 1997, J PHARMACOL EXP THER, V280, P621; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Fortner CN, 2001, AM J PHYSIOL-LUNG C, V281, pL469, DOI 10.1152/ajplung.2001.281.2.L469; GARSSEN J, 1990, J PHARMACOL METHOD, V24, P209, DOI 10.1016/0160-5402(90)90031-F; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kapiloff MS, 2001, J CELL SCI, V114, P3167; KARIM SMM, 1967, BRIT J PHARM CHEMOTH, V31, P340, DOI 10.1111/j.1476-5381.1967.tb02003.x; Kohyama T, 2002, AM J RESP CELL MOL, V26, P694, DOI 10.1165/ajrcmb.26.6.4743; Kung TT, 2000, BRIT J PHARMACOL, V130, P457, DOI 10.1038/sj.bjp.0703308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li L, 1998, BRIT J PHARMACOL, V123, P1337, DOI 10.1038/sj.bjp.0701741; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Matsui M, 2003, J PHARMACOL EXP THER, V305, P106, DOI 10.1124/jpet.102.044701; RABE KF, 1993, AM J PHYSIOL, V264, pL458, DOI 10.1152/ajplung.1993.264.5.L458; Richter M, 2000, EUR J PHARMACOL, V389, P225, DOI 10.1016/S0014-2999(99)00878-X; Rousseau E, 1995, CAN J PHYSIOL PHARM, V73, P1784, DOI 10.1139/y95-243; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Underwood DC, 1997, J PHARMACOL EXP THER, V280, P210; WAMSLEY JK, 1981, J NEUROSCI, V1, P176	39	110	111	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1831	1841		10.1096/fj.03-0274com	http://dx.doi.org/10.1096/fj.03-0274com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519662				2022-12-25	WOS:000186343300037
J	Fernandez, N; Renedo, M; Alonso, S; Crespo, MS				Fernandez, N; Renedo, M; Alonso, S; Crespo, MS			Release of arachidonic acid by stimulation of opsonic receptors in human monocytes - The Fc gamma R and the complement receptor 3 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING LECTIN SITE; PLATELET-ACTIVATING-FACTOR; BETA-GLUCAN RECEPTOR; CR3 CD11B/CD18; DENDRITIC CELLS; IMMUNE-COMPLEXES; ARTHUS REACTION; PROTEIN-KINASE; CROSS-LINKING; DECTIN-1	The role of the opsonic receptors FcgammaR and CR3 on the release of arachidonic acid (AA) by human monocytes was studied using IgG-ovalbumin (OVA) equivalence immune complexes (IC), anti-OVA IgG bound to OVA-coupled latex beads, and C3bi-bound IC. Release of AA was produced by IC and latex-OVA beads bound to IgG, whereas binding of C3bi to IC inhibited the ability of IC to release AA. In contrast, coating of zymosan particles with C3bi enhanced AA release as compared with that produced by non-coated particles. Masking of C3bi on C3bi-bound IC by incubation with anti-C3 IgG resulted in the recovery of their ability to release AA, thereby suggesting that binding of C3b by IC reduces their flogogenic effects, whereas opsonization of microbial walls by complement may enhance their proinflammatory potential. The binding/uptake of opsonized zymosan particles was inhibited by anti-CR3 Ab and C3bi-bound IC, but not by beta-glucan, mannan, and anti-Toll-like receptor 2 Ab. These findings show that cooperative engagement of CR3 on both the lectin-like site involved in beta-glucan binding and the I-domain involved in C3bi binding, as it can be observed in the innate immune response, produces AA release, whereas the unique interaction of C3bi-bound IC with the I-domain of CR3, as it may occur in the adaptive immune response, diverts the IC lattice from a productive interaction with FcgammaR linked to AA release.	CSIC, Inst Mol Biol & Genet, Fac Med, Valladolid 47005, Spain; Hosp Clin Univ, Unidad Invest, Valladolid 47005, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de la Laguna	Crespo, MS (corresponding author), CSIC, Inst Mol Biol & Genet, Fac Med, Valladolid 47005, Spain.	mscres@ibgm.uva.es	Fernández, Nieves/N-5426-2018	Fernández, Nieves/0000-0002-9141-3956				ALCOLEA JM, 1987, COMPLEMENT INFLAMMAT, V4, P21, DOI 10.1159/000463004; Alonso A, 1996, EUR J IMMUNOL, V26, P2165, DOI 10.1002/eji.1830260931; Banki Z, 2003, J IMMUNOL, V170, P3963, DOI 10.4049/jimmunol.170.8.3963; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Choi IW, 2003, J EXP MED, V198, P145, DOI 10.1084/jem.20022129; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; EDEN A, 1973, CELL IMMUNOL, V7, P459, DOI 10.1016/0008-8749(73)90210-4; Fernandez N, 2002, EUR J IMMUNOL, V32, P383, DOI 10.1002/1521-4141(200202)32:2<383::AID-IMMU383>3.0.CO;2-9; Fernandez N, 2002, J IMMUNOL, V169, P3321, DOI 10.4049/jimmunol.169.6.3321; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Grewal S, 2002, J CELL SCI, V115, P4533, DOI 10.1242/jcs.00146; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; MARSH CB, 1995, J IMMUNOL, V155, P3161; Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987; MILLER GW, 1975, P NATL ACAD SCI USA, V72, P418, DOI 10.1073/pnas.72.2.418; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Romani L, 2002, TRENDS MICROBIOL, V10, P508, DOI 10.1016/S0966-842X(02)02460-5; Sabroe I, 2003, J IMMUNOL, V171, P1630, DOI 10.4049/jimmunol.171.4.1630; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; STEIL AA, 1995, BRIT J PHARMACOL, V114, P895, DOI 10.1111/j.1476-5381.1995.tb13288.x; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; Taborda CP, 2002, IMMUNITY, V16, P791, DOI 10.1016/S1074-7613(02)00328-X; TAKAHASHI M, 1978, J CLIN INVEST, V62, P349, DOI 10.1172/JCI109135; TAKATA Y, 1984, J IMMUNOL, V132, P2531; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Thornton BP, 1996, J IMMUNOL, V156, P1235; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Vidarte L, 2001, J BIOL CHEM, V276, P38217; Vivanco F, 1999, MOL IMMUNOL, V36, P843, DOI 10.1016/S0161-5890(99)00105-4; Xia Y, 1999, J IMMUNOL, V162, P7285; Xia Y, 1999, J IMMUNOL, V162, P2281; Zelle-Rieser C, 2002, FEBS LETT, V511, P123, DOI 10.1016/S0014-5793(01)03326-9	43	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52179	52187		10.1074/jbc.M310905200	http://dx.doi.org/10.1074/jbc.M310905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14532278	hybrid			2022-12-25	WOS:000187480700026
J	Fu, J; Jin, Y; Arend, LJ				Fu, J; Jin, Y; Arend, LJ			Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; PROMOTES CELL-DEATH; SERINE-PROTEASE; IAP PROTEINS; CASPASE ACTIVATION; LIGASE ACTIVITY; CYTOCHROME-C; BIR DOMAIN; IN-VITRO; XIAP	X-linked inhibitor of apoptosis protein (XIAP), the most potent member of the inhibitor of apoptosis protein (IAP) family, plays a crucial role in the regulation of apoptosis. XIAP is structurally characterized by three baculovirus IAP repeat (BIR) domains that mediate binding to and inhibition of caspases and a RING domain that confers ubiquitin ligase activity. The caspase inhibitory activity of XIAP can be eliminated by the second mitochondria-derived activator of caspases (Smac)/direct IAP-binding protein with low pI (DIABLO) during apoptosis. Here we report the identification and characterization of a novel isoform of Smac/DIABLO named Smac3, which is generated by alternative splicing of exon 4. Smac3 contains an NH2-terminal mitochondrial targeting sequence required for mitochondrial targeting of Smac3 and an IAP-binding motif essential for Smac3 binding to XIAP. Smac3 is released from mitochondria into the cytosol in response to apoptotic stimuli, where it interacts with the second and third BIR domains of XIAP. Smac3 disrupts processed caspase-9 binding to XIAP, promotes caspase-3 activation, and potentiates apoptosis. Strikingly, Smac3, but not Smac/DIABLO, accelerates XIAP auto-ubiquitination and destruction. Smac3-stimulated XIAP ubiquitination is contingent upon the physical association of XIAP with Smac3 and an intact RING domain of XIAP. Smac3-accelerated XIAP destabilization is, at least in part, attributed to its ability to enhance XIAP ubiquitination. Our study demonstrates that Smac3 is functionally additive to, but independent of, Smac/DIABLO.	Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA	University of Rochester	Arend, LJ (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	lois_arend@urmc.rochester.edu	Arend, Lois/ABE-2002-2020	Arend, Lois/0000-0001-5434-7630				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deshpande R, 2000, J INVEST DERMATOL, V115, P477, DOI 10.1046/j.1523-1747.2000.00078.x; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang HK, 2000, J BIOL CHEM, V275, P26661; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Ng CP, 2002, MOL CANCER THER, V1, P1051; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qi M, 1998, HUM MOL GENET, V7, P465, DOI 10.1093/hmg/7.3.465; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	64	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52660	52672		10.1074/jbc.M308036200	http://dx.doi.org/10.1074/jbc.M308036200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14523016	hybrid			2022-12-25	WOS:000187480700084
J	Mironova, R; Niwa, T; Dimitrova, R; Boyanova, M; Ivanov, I				Mironova, R; Niwa, T; Dimitrova, R; Boyanova, M; Ivanov, I			Glycation and post-translational processing of human interferon-gamma expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIALYSIS-RELATED AMYLOIDOSIS; THURINGIENSIS SUBSP ISRAELENSIS; HAMSTER OVARY CELLS; HUMAN IFN-GAMMA; NONENZYMATIC GLYCOSYLATION; N-GLYCOSYLATION; END-PRODUCT; PROTEIN GLYCOSYLATION; GEL-ELECTROPHORESIS; GLYCOPROTEIN TOXIN	Until recently, nonenzymatic glycosylation (glycation) was thought to affect the proteins of long living eukaryotes only. However, in a recent study (Mironova, R., Niwa, T., Hayashi, H., Dimitrova, R., and Ivanov, I. (2001) Mol. Microbiol. 39, 1061-1068), we have shown that glycation takes place in Escherichia coli as well. In the present study, we demonstrate that the post-translational processing (proteolysis and covalent dimerization) observed with cysteineless recombinant human interferon-gamma (rhIFN-gamma) is tightly associated with its in vivo glycation. Our results show that, at the time of isolation, rhIFN-gamma contained early (but not advanced) glycation products. Using reverse phase high performance liquid chromatography in conjunction with fluorescence measurements, enzyme-linked immunosorbent assay, and mass spectrometry, we found that advanced glycation end products arose in rhIFN-gamma during storage. The latter were identified mainly in the Arg/Lys-rich C terminus of the protein, which was also the main target of proteolysis. Mass spectral analysis and N-terminal sequencing revealed four major (Arg(140) down arrow Arg(141), Phe(137) down arrow Arg(138), Met(135) down arrow Leu(136), and Lys(131) down arrow Arg(132)) and two minor (Lys(109) down arrow Ala(110) and Arg(90) down arrow Asp(91)) cleavage sites in this region. Tryptic peptide mapping indicated that the covalent dimers of rhIFN-gamma originating during storage were formed mainly by lateral cross-linking of the monomer subunits. Antiviral assay showed that proteolysis lowered the antiviral activity of rhIFN-gamma, whereas covalent dimerization completely abolished it.	Bulgarian Acad Sci, Inst Mol Biol, Dept Gene Regulat, BU-1113 Sofia, Bulgaria; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668560, Japan	Bulgarian Academy of Sciences; Medical University Sofia; Nagoya University	Mironova, R (corresponding author), Bulgarian Acad Sci, Inst Mol Biol, Dept Gene Regulat, BU-1113 Sofia, Bulgaria.		Mironova, Roumyana/D-7413-2013	Tsekovska, Rositsa/0000-0001-5431-5743				ARAI K, 1987, J BIOL CHEM, V262, P16969; ARAKAWA T, 1986, J INTERFERON RES, V6, P687, DOI 10.1089/jir.1986.6.687; BAFFI RA, 1992, DEV BIOLOGICALS, V74, P181; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; BHATTACHARYA M, 1993, APPL ENVIRON MICROB, V59, P2666, DOI 10.1128/AEM.59.8.2666-2672.1993; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUDE IA, 1984, BIOCHEMISTRY-US, V23, P5603, DOI 10.1021/bi00318a034; BULLEID NJ, 1990, BIOCHEM J, V268, P777, DOI 10.1042/bj2680777; CURLING EMA, 1990, BIOCHEM J, V272, P333, DOI 10.1042/bj2720333; DELAMAZA LM, 1987, INFECT IMMUN, V55, P2727, DOI 10.1128/IAI.55.11.2727-2733.1987; DEVOS R, 1982, NUCLEIC ACIDS RES, V10, P2487, DOI 10.1093/nar/10.8.2487; DEVOS R, 1984, J INTERFERON RES, V4, P461, DOI 10.1089/jir.1984.4.461; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; EBLE AS, 1983, J BIOL CHEM, V258, P9406; Familletti P C, 1981, Methods Enzymol, V78, P387; FLUCKIGER R, 1984, METHOD ENZYMOL, V106, P77; Goldman MH, 1997, CYTOTECHNOLOGY, V23, P103, DOI 10.1023/A:1007947130709; GOMI K, 1985, JPN J CANCER RES, V76, P224; Harmon BJ, 1996, ANAL CHEM, V68, P1465, DOI 10.1021/ac951229d; Hooker A, 1998, J INTERF CYTOK RES, V18, P287, DOI 10.1089/jir.1998.18.287; Hooker AD, 2000, MOL BIOTECHNOL, V14, P241, DOI 10.1385/MB:14:3:241; IBERG N, 1986, J BIOL CHEM, V261, P3542; ISLAM KN, 1995, J BIOCHEM-TOKYO, V118, P1054, DOI 10.1093/jb/118.5.1054; IVANOV I, 1987, GENE, V59, P223, DOI 10.1016/0378-1119(87)90330-1; James DC, 1996, PROTEIN SCI, V5, P331; JAMES DC, 1995, BIO-TECHNOL, V13, P592, DOI 10.1038/nbt0695-592; KELKER HC, 1984, J BIOL CHEM, V259, P4301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larkin J, 2001, J INTERF CYTOK RES, V21, P341, DOI 10.1089/107999001750277817; LAUREN SL, 1993, ARCH BIOCHEM BIOPHYS, V306, P350, DOI 10.1006/abbi.1993.1522; LUK SKS, 1990, J BIOL CHEM, V265, P13314; Mironova R, 2001, MOL MICROBIOL, V39, P1061, DOI 10.1046/j.1365-2958.2001.02304.x; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; MONNIER VM, 1989, MAILLARD REACTION AG, P1; Mortz E, 1996, ELECTROPHORESIS, V17, P925, DOI 10.1002/elps.1150170514; MUTHUKUMAR G, 1987, APPL ENVIRON MICROB, V53, P2650, DOI 10.1128/AEM.53.11.2650-2655.1987; Niwa T, 1997, J CLIN INVEST, V99, P1272, DOI 10.1172/JCI119285; Niwa T, 1996, KIDNEY INT, V50, P1303, DOI 10.1038/ki.1996.442; Niwa T, 1997, KIDNEY INT, V51, P187, DOI 10.1038/ki.1997.23; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; PFANNENSTIEL MA, 1987, J BACTERIOL, V169, P796, DOI 10.1128/jb.169.2.796-801.1987; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAKAGUCHI M, 1988, FEBS LETT, V230, P201, DOI 10.1016/0014-5793(88)80671-9; SARENEVA T, 1995, BIOCHEM J, V308, P9, DOI 10.1042/bj3080009; Sareneva T, 1996, EUR J BIOCHEM, V242, P191, DOI 10.1111/j.1432-1033.1996.0191r.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; SHILTON BH, 1991, J BIOL CHEM, V266, P5587; SLODOWSKI O, 1991, EUR J BIOCHEM, V202, P1133, DOI 10.1111/j.1432-1033.1991.tb16481.x; VARESIO L, 1984, CANCER RES, V44, P4465; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; Wiame E, 2002, J BIOL CHEM, V277, P42523, DOI 10.1074/jbc.M200863200; WOLFF SP, 1989, MAILLARD REACTION AG, P259; Zhang JF, 1998, J CHROMATOGR B, V712, P73, DOI 10.1016/S0378-4347(98)00131-5; ZHANG Z, 1992, J CHROMATOGR, V604, P143, DOI 10.1016/0021-9673(92)85539-6	56	38	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51068	51074		10.1074/jbc.M307470200	http://dx.doi.org/10.1074/jbc.M307470200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525998	hybrid			2022-12-25	WOS:000187206300030
J	Pattridge, KA; Weber, CH; Friesen, JA; Sanker, S; Kent, C; Ludwig, ML				Pattridge, KA; Weber, CH; Friesen, JA; Sanker, S; Kent, C; Ludwig, ML			Glycerol-3-phosphate cytidylyltransferase - Structural changes induced by binding of CDP-glycerol and the role of lysine residues in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; KMSKS SIGNATURE SEQUENCE; MONONUCLEOTIDE ADENYLYLTRANSFERASE; CRYSTAL-STRUCTURES; TRANSITION-STATE; DOMAIN MOTIONS; CTP; MECHANISM; ENZYME	The bacterial enzyme, glycerol-3-phosphate cytidylyltransferase (GCT), is a model for mammalian cytidylyl-transferases and is a member of a large superfamily of nucleotidyltransferases. Dimeric GCT from Bacillus subtilis displays unusual negative cooperativity in substrate binding and appears to form products only when both active sites are occupied by substrates. Here we describe a complex of GCT with the product, CDP-glycerol, in a crystal structure in which bound sulfate serves as a partial mimic of the second product, pyrophosphate. Binding of sulfate to form a pseudo-ternary complex is observed in three of the four chains constituting the asymmetric unit and is accompanied by a backbone rearrangement at Asp(11) and ordering of the C-terminal helix. Comparison with the CTP complex of GCT, determined previously, reveals that in the product complex the active site closes around the glycerol phosphate moiety with a concerted motion of the segment 37 - 47 that includes helix B. This rearrangement allows lysines 44 and 46 to interact with the glycerol and cytosine phosphates of CDP-glycerol. Binding of CDP-glycerol also induces smaller movements of residues 92 - 100. Roles of lysines 44 and 46 in catalysis have been confirmed by mutagenesis of these residues to alanine, which decreases V-max(app) and has profound effects on the K-m(app) for glycerol-3-phosphate.	Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ludwig, ML (corresponding author), Univ Michigan, Div Biophys Res, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	mlludwig@umich.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060510] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK2072] Funding Source: Medline; NIGMS NIH HHS [GM16429, GM60510, GM19286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Austin J, 2002, J BIOL CHEM, V277, P20243, DOI 10.1074/jbc.M201923200; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; BORGFORD TJ, 1987, BIOCHEMISTRY-US, V26, P7246, DOI 10.1021/bi00397a008; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CHAN KW, 1995, FEBS LETT, V363, P33, DOI 10.1016/0014-5793(95)00274-D; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; FIRST EA, 1995, BIOCHEMISTRY-US, V34, P5030, DOI 10.1021/bi00015a014; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 1999, PROTEINS, V36, P425, DOI 10.1002/(SICI)1097-0134(19990901)36:4<425::AID-PROT6>3.3.CO;2-J; Helmink BA, 2003, BIOCHEMISTRY-US, V42, P5043, DOI 10.1021/bi027431+; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; Izard T, 2002, J MOL BIOL, V315, P487, DOI 10.1006/jmbi.2001.5272; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kwak BY, 2002, J BIOL CHEM, V277, P4343, DOI 10.1074/jbc.M109163200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li RS, 1996, BIOORG CHEM, V24, P251, DOI 10.1006/bioo.1996.0023; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MECHULAM Y, 1991, J MOL BIOL, V217, P465, DOI 10.1016/0022-2836(91)90750-Z; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PARK YS, 1993, J BIOL CHEM, V268, P16648; Sanker S, 1998, FASEB J, V12, pA1287; Sanker S, 2001, J BIOL CHEM, V276, P37922; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; SCHMITT E, 1994, J MOL BIOL, V242, P566, DOI 10.1006/jmbi.1994.1601; SEGEL LH, 1975, ENZYME KINETICS BEHA; Stevens SY, 2001, NAT STRUCT BIOL, V8, P947, DOI 10.1038/nsb1101-947; Tari LW, 1997, NAT STRUCT BIOL, V4, P990, DOI 10.1038/nsb1297-990; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Zhang H, 2002, STRUCTURE, V10, P69, DOI 10.1016/S0969-2126(01)00693-1	37	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51863	51871		10.1074/jbc.M306174200	http://dx.doi.org/10.1074/jbc.M306174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506262	hybrid			2022-12-25	WOS:000187206300122
J	Rist, W; Jorgensen, TJD; Roepstorff, P; Bukau, B; Mayer, MP				Rist, W; Jorgensen, TJD; Roepstorff, P; Bukau, B; Mayer, MP			Mapping temperature-induced conformational changes in the Escherichia coli heat shock transcription factor sigma(32) by amide hydrogen exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDING DOMAINS; MASS-SPECTROMETRY; PROTEIN-STRUCTURE; SWISS-MODEL; DEGRADATION; KINETICS; FTSH; DNAK	Stress conditions such as heat shock alter the transcriptional profile in all organisms. In Escherichia coli the heat shock transcription factor, sigma(32), out-competes upon temperature up-shift the housekeeping sigma-factor, sigma(70), for binding to core RNA polymerase and initiates heat shock gene transcription. To investigate possible heat-induced conformational changes in sigma(32) we performed amide hydrogen (H/D) exchange experiments under optimal growth and heat shock conditions combined with mass spectrometry. We found a rapid exchange of around 220 of the 294 amide hydrogens at 37 degreesC, indicating that sigma(32) adopts a highly flexible structure. At 42 degreesC we observed a slow correlated exchange of 30 additional amide hydrogens and localized it to a helix-loop-helix motif within domain sigma(2) that is responsible for the recognition of the -10 region in heat shock promoters. The correlated exchange is shown to constitute a reversible unfolding with a half-life of about 30 min due to a temperature-dependent decrease in stabilization energy. We propose that this gradual decrease in stabilization energy of domain sigma(2) with increasing temperatures facilitates the unfolding of sigma(32) by the AAA+ protease FtsH thereby decreasing its half-life. Taken together our data show that the sigma(2) domain of sigma(32) can act as a thermosensor, which might be important for the heat shock regulation.	Heidelberg Univ, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	Ruprecht Karls University Heidelberg; University of Southern Denmark	Bukau, B (corresponding author), Heidelberg Univ, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	bukau@zmbh.uni-heidelberg.de; M.Mayer@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112; Rist, Wolfgang/0000-0002-0626-3544; Jorgensen, Thomas J.D./0000-0002-7149-316X; Bukau, Bernd/0000-0003-0521-7199				Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Chattopadhyay R, 2002, J BIOL CHEM, V277, P33641, DOI 10.1074/jbc.M203197200; Chiba S, 2002, J BACTERIOL, V184, P4775, DOI 10.1128/JB.184.17.4775-4782.2002; Chiba S, 2000, EMBO REP, V1, P47, DOI 10.1093/embo-reports/kvd005; Deng YH, 1998, BIOCHEMISTRY-US, V37, P6256, DOI 10.1021/bi972711o; Eaton WA, 2000, ANNU REV BIOPH BIOM, V29, P327, DOI 10.1146/annurev.biophys.29.1.327; Engen JR, 2001, ANAL CHEM, V73, p256A, DOI 10.1021/ac012452f; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; FERSHT A, 2002, STRUCTURE MECH PROTE, P540; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Herman C, 2003, MOL CELL, V11, P659, DOI 10.1016/S1097-2765(03)00068-6; Hoofnagle AN, 2001, P NATL ACAD SCI USA, V98, P956, DOI 10.1073/pnas.98.3.956; Huyghues-Despointes B M, 2001, Methods Mol Biol, V168, P69; Kanemori M, 1999, J BIOL CHEM, V274, P22002, DOI 10.1074/jbc.274.31.22002; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; Morita M, 1999, J BACTERIOL, V181, P401, DOI 10.1128/JB.181.2.401-410.1999; Morita MT, 1999, GENE DEV, V13, P655, DOI 10.1101/gad.13.6.655; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Tatsuta T, 2000, FEBS LETT, V478, P271, DOI 10.1016/S0014-5793(00)01869-X; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Tomoyasu T, 2001, J BACTERIOL, V183, P5911, DOI 10.1128/JB.183.20.5911-5917.2001; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; Wang LT, 2002, MOL CELL PROTEOMICS, V1, P132, DOI 10.1074/mcp.M100009-MCP200; Yang HJ, 1997, BIOCHEMISTRY-US, V36, P14992, DOI 10.1021/bi9717183; Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; Zhang ZQ, 1996, PROTEIN SCI, V5, P1282; Zhang ZQ, 1998, J AM SOC MASS SPECTR, V9, P225, DOI 10.1016/S1044-0305(97)00284-5; [No title captured]	35	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51415	51421		10.1074/jbc.M307160200	http://dx.doi.org/10.1074/jbc.M307160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14504287	hybrid			2022-12-25	WOS:000187206300070
J	Haendeler, J; Yin, GY; Hojo, Y; Saito, Y; Melaragno, M; Yan, C; Sharma, VK; Heller, M; Aebersold, R; Berk, BC				Haendeler, J; Yin, GY; Hojo, Y; Saito, Y; Melaragno, M; Yan, C; Sharma, VK; Heller, M; Aebersold, R; Berk, BC			GIT1 mediates Src-dependent activation of phospholipase C gamma by angiotensin II and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; STIMULATES TYROSINE PHOSPHORYLATION; PAXILLIN KINASE LINKER; MAP KINASE; SIGNAL-TRANSDUCTION; CARDIAC MYOCYTES; AT(1) RECEPTOR; LD4 MOTIF; PROTEIN; FAMILY	Critical events for vasoconstrictor and growth factor signal transduction include stimulation of phospholipase Cgamma (PLCgamma) and elevation of intracellular calcium. c-Src has been proposed as a common mediator for these signals activated by both G protein-coupled receptors (GPCRs) and tyrosine kinase-coupled receptors (TKRs). Here we show that the GPCR kinase-interacting protein-1 (GIT1) is a substrate for c-Src that undergoes tyrosine phosphorylation in response to angiotensin II (AngII) and EGF in vascular smooth muscle and 293 cells. GIT1 associates with PLCgamma via the PLCgamma Src homology 2 and 3 domains constitutively, and the interaction is unaltered by AngII and EGF. GIT1 interaction with PLCgamma is required for PLCgamma activation based on inhibition of tyrosine phosphorylation and calcium mobilization after GIT1 knockdown with antisense GIT1 oligonucleotides. GIT1 interacts with PLCgamma via a novel Spa homology domain (SHD) and a coiled-coil domain. Deletion mutation analysis showed that GIT1(SHD) is required for AngII- and EGF-mediated PLCgamma activation (measured by phosphorylation of Tyr(783) and inositol 1,4,5-trisphosphate formation). We propose that GIT1 is a novel regulator of PLCgamma function that mediates PLCgamma activation by c-Src and integrates signal transduction by GPCRs and TKRs.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA	University of Rochester; University of Rochester; University of Rochester; University of Washington; University of Washington Seattle	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.			Heller, Manfred/0000-0002-6364-7325; Yan, Chen/0000-0002-1397-6358; Yin, Guoyong/0000-0002-7268-5374; Berk, Bradford/0000-0002-2767-4115; Haendeler, Judith/0000-0001-8507-4540	NHLBI NIH HHS [R01 HL49192, R01 HL59975] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; ARKINSTALL S, 1995, MOL CELL BIOL, V15, P1431; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cook B, 2000, NAT CELL BIOL, V2, P296, DOI 10.1038/35010571; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Haendeler J, 2000, CIRC RES, V86, P729, DOI 10.1161/01.RES.86.7.729; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Ishida M, 1998, CIRC RES, V82, P7; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Melaragno MG, 1998, CIRC RES, V83, P697, DOI 10.1161/01.RES.83.7.697; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Paris S, 2002, INT J BIOCHEM CELL B, V34, P826, DOI 10.1016/S1357-2725(02)00008-0; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SABRI A, 1997, CIRCULATION, V96, P46; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Samarel AM, 2001, J MOL CELL CARDIOL, V33, P1637, DOI 10.1006/jmcc.2001.1427; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; Schmitz U, 1997, CIRC RES, V81, P550, DOI 10.1161/01.RES.81.4.550; SCHORB W, 1994, J BIOL CHEM, V269, P19626; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Shu LM, 2003, J BIOL CHEM, V278, P31419, DOI 10.1074/jbc.M303783200; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; van Drogen F, 2002, CURR BIOL, V12, P1698, DOI 10.1016/S0960-9822(02)01186-7; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	62	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49936	49944		10.1074/jbc.M307317200	http://dx.doi.org/10.1074/jbc.M307317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523024	hybrid			2022-12-25	WOS:000187068200036
J	Inman, CK; Shore, P				Inman, CK; Shore, P			The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HA-RAS; DIFFERENTIATION; PROMOTER; PROTEIN; ACTIVATION; GROWTH; CBFA1; ASSOCIATION; PROLACTIN	Targeted deletion of the Runx2 gene in mice has demonstrated that Runx2 is a master regulator of osteoblast differentiation. Runx2 has therefore largely been regarded as a bone-specific transcription factor. Runx2(-/-) mice die shortly after birth and therefore the role of Runx2 in later developing tissues remains unclear. Here we show that the Runx2 protein is expressed in several mammary epithelial cell lines and in primary mammary epithelial cells. In addition, we have also found that it has a functionally important role in gene regulation. Osteopontin (OPN) is expressed in mammary epithelial cells during pregnancy and lactation and has been shown to have a role in mammary gland differentiation. Here we show that a Runx2 site in the OPN promoter is required for activation of the promoter in mammary epithelial cells. Moreover, dominant-negative Runx proteins can inhibit both activation of an OPN promoter reporter in transient transfections and expression of the endogenous OPN gene in mammary epithelial cells. Our data suggest, for the first time, that the osteoblast transcription factor Runx2 has a role in the normal regulation of gene expression in mammary epithelial cells.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Shore, P (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Shore, Paul/0000-0002-1832-5976				BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Baeckstrom D, 2000, ONCOGENE, V19, P4592, DOI 10.1038/sj.onc.1203792; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Barnes GL, 2003, CANCER RES, V63, P2631; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Escaleira MTF, 1999, BREAST CANCER RES TR, V54, P123, DOI 10.1023/A:1006198107805; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PREVOST G, 1991, ENDOCRINOLOGY, V129, P323, DOI 10.1210/endo-129-1-323; Pullan S, 1996, J CELL SCI, V109, P631; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Sun LX, 2001, CANCER RES, V61, P4994; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Uchida H, 1997, J IMMUNOL, V158, P2251; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F	34	116	120	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48684	48689		10.1074/jbc.M308001200	http://dx.doi.org/10.1074/jbc.M308001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506237	hybrid			2022-12-25	WOS:000186829000022
J	Petrel, C; Kessler, A; Maslah, F; Dauban, P; Dodd, RH; Rognan, D; Ruat, M				Petrel, C; Kessler, A; Maslah, F; Dauban, P; Dodd, RH; Rognan, D; Ruat, M			Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; PROTEIN-COUPLED RECEPTORS; HUMAN CA2+ RECEPTOR; BETA-ADRENERGIC-RECEPTOR; CALCIMIMETIC COMPOUND; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; TERMINAL DOMAIN; CELL-SURFACE; IDENTIFICATION	A model of the Ca2+-sensing receptor (CaSR) seven transmembrane domains was constructed based on the crystal structure of bovine rhodopsin. This model was used for docking (1S, 2S, 1'R)- N-1-(4-chlorobenzoyl)- N-2-[1( 1-naphthyl) ethyl]-1,2-diaminocyclohexane (Calhex 231), a novel potent negative allosteric modulator that blocks (IC50 = 0.39 muM) increases in [H-3] inositol phosphates elicited by activating the human wild-type CaSR transiently expressed in HEK293 cells. In this model, Glu-837(7.39) plays a pivotal role in anchoring the two nitrogen atoms of Calhex 231 and locating the aromatic moieties in two adjacent hydrophobic pockets delineated by transmembrane domains 3, 5, and 6 and transmembrane domains 1, 2, 3, and 7, respectively. To demonstrate its validity, we have mutated selected residues and analyzed the biochemical and pharmacological properties of the mutant receptors transfected in HEK293 cells. Two receptor mutations, F684A(3.32) and E837A(7.39), caused a loss of the ability of Calhex 231 to inhibit Ca2+-induced accumulation of [H-3] inositol phosphates. Three other mutations, F688A(3.36), W818A(6.48), and I841A(7.43), produced a marked increase in the IC50 of Calhex 231 for the Ca2+ response, whereas L776A(5.42) and F821A(6.51) led to a decrease in the IC50. Our data validate the proposed model for the allosteric interaction of Calhex 231 with the seven transmembrane domains of the CaSR. Interestingly, the residues at the same positions have been shown to delimit the antagonist-binding cavity of many diverse G-protein-coupled receptors. This study furthermore suggests that the crystal structure of bovine rhodopsin exhibits sufficient mimicry to the ground state of a very divergent class 3 receptor to predict the interaction of antagonists with the heptahelical bundle of diverse G-protein-coupled receptors.	Neurobiol Cellulaire & Mol Lab, CNRS, Unite Propre Rech 9040, F-91198 Gif Sur Yvette, France; Inst Chim Subst Nat, CNRS, UPR 2301, F-91198 Gif Sur Yvette, France; Inst Alfred Fessard, Inst Federat Rech 2118, CNRS, F-91198 Gif Sur Yvette, France; Lab Pharmacochim Commun Cellulaire, CNRS, Unite Mixte Rec 7081, F-67401 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS)	Ruat, M (corresponding author), Neurobiol Cellulaire & Mol Lab, CNRS, Unite Propre Rech 9040, Batiment 32-33,1 Ave Terrasse, F-91198 Gif Sur Yvette, France.		Ruat, Martial/E-5544-2016; Rognan, Didier/B-9939-2014					Attwood TK, 2001, TRENDS PHARMACOL SCI, V22, P162, DOI 10.1016/S0165-6147(00)01658-8; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Bukoski RD, 1998, AM J HYPERTENS, V11, P1117, DOI 10.1016/S0895-7061(97)00499-8; Chattopadhyay N, 1998, GLIA, V24, P449, DOI 10.1002/(SICI)1098-1136(199812)24:4<449::AID-GLIA10>3.3.CO;2-0; Dauban P, 2000, BIOORG MED CHEM LETT, V10, P2001, DOI 10.1016/S0960-894X(00)00382-6; Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697; FAURE H, 2002, INT OST FDN WORLD C, V731; Ferry S, 1997, BIOCHEM BIOPH RES CO, V238, P866, DOI 10.1006/bbrc.1997.7401; Ferry S, 2000, EUR J NEUROSCI, V12, P872, DOI 10.1046/j.1460-9568.2000.00980.x; Freichel M, 1996, ENDOCRINOLOGY, V137, P3842, DOI 10.1210/en.137.9.3842; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h; Jensen AA, 2000, J BIOL CHEM, V275, P29547, DOI 10.1074/jbc.M910023199; Jingami H, 2003, CURR OPIN NEUROBIOL, V13, P271, DOI 10.1016/S0959-4388(03)00067-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006-291X(02)02133-2; Mirzadegan T, 2000, J BIOL CHEM, V275, P25562, DOI 10.1074/jbc.M000692200; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Reyes-Cruz G, 2001, J BIOL CHEM, V276, P32145, DOI 10.1074/jbc.M102977200; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Rognan D, 2001, J COMPUT AID MOL DES, V15, P103, DOI 10.1023/A:1008145813315; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Ruppert J, 1997, PROTEIN SCI, V6, P524; Schwalbe H, 2002, CHEMBIOCHEM, V3, P915, DOI 10.1002/1439-7633(20021004)3:10<915::AID-CBIC915>3.0.CO;2-L; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1989, J BIOL CHEM, V264, P13572; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Traiffort E, 2001, EUR J NEUROSCI, V14, P839, DOI 10.1046/j.0953-816x.2001.01708.x; Ye CP, 1997, J NEUROSCI RES, V47, P547, DOI 10.1002/(SICI)1097-4547(19970301)47:5<547::AID-JNR10>3.0.CO;2-V	50	113	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49487	49494		10.1074/jbc.M308010200	http://dx.doi.org/10.1074/jbc.M308010200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506236	hybrid			2022-12-25	WOS:000186829000117
J	Qin, H; Raught, B; Sonenberg, N; Goldstein, EG; Edelman, AM				Qin, H; Raught, B; Sonenberg, N; Goldstein, EG; Edelman, AM			Phosphorylation screening identifies translational initiation factor 4GII as an intracellular target of Ca2+/Calmodulin-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION MOTIFS; ELONGATION FACTOR-II; RAT-BRAIN; DEPENDENT TRANSLATION; CDNA CLONING; ACTIVATION; CELLS; CASCADE; PURIFICATION; LOCALIZATION	CaMKI is a Ca2+/calmodulin-dependent protein kinase that is widely expressed in eukaryotic cells and tissues but for which few, if any, physiological substrates are known. We screened a human lung cDNA expression library for potential CaMKI substrates by solid phase in situ phosphorylation ("phosphorylation screening"). Multiple overlapping partial length cDNAs encoding three proteins were detected. Two of these proteins are known: 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase and eukaryotic translation initiation factor (eIF) 4GII. To determine whether CaMKI substrates identified by phosphorylation screening represent authentic physiological targets, we examined the potential for [Ca2+](i)- and CaMKI-dependent phosphorylation of eIF4GII in vitro and in vivo. Endogenous eIF4GII immunoprecipitated from HEK293T cells was phosphorylated by CaMKI, in vitro as was a recombinant fragment of eIF4GII encompassing the central and C-terminal regions. The latter phosphorylation occurred with favorable kinetics (K-m = 1 muM; k(cat) = 1.8 s(-1)) at a single site, Ser(1156), located in a segment of eIF4GII aligning with the phosphoregion of eIF4GI. Phosphopeptide mapping and back phosphorylation experiments revealed [Ca2+](i)- dependent, CaMKI site-specific, eIF4GII phosphorylation in vivo. This phosphorylation was blocked by kinase-negative CaMKI consistent with a requirement for endogenous CaMKI for in vivo eIF4GII phosphorylation. We conclude that phosphorylation screening is an effective method for searching for intracellular targets of CaMKI and may have identified a new role of Ca2+ signaling to the translation apparatus.	SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; McGill University; McGill University	Edelman, AM (corresponding author), SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA.		Raught, Brian/A-5619-2008		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-24738] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; BU X, 1993, J BIOL CHEM, V268, P4975; CHIN KV, 1987, J BIOL CHEM, V262, P16509; Corcoran EE, 2003, J BIOL CHEM, V278, P10516, DOI 10.1074/jbc.M210642200; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; Doutheil J, 1997, BRAIN RES, V775, P43, DOI 10.1016/S0006-8993(97)00899-8; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hook SS, 1999, J BIOL CHEM, V274, P20215, DOI 10.1074/jbc.274.29.20215; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KENNEDY MB, 1981, P NATL ACAD SCI-BIOL, V78, P1293, DOI 10.1073/pnas.78.2.1293; KUMAR RV, 1989, J CELL BIOL, V108, P2107, DOI 10.1083/jcb.108.6.2107; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lukas TJ, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P65; Marin P, 1997, J NEUROSCI, V17, P3445; MATTHEWS MB, 1996, TRANSLATIONAL CONTRO, P1; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Pyronnet S, 2001, CURR OPIN GENET DEV, V11, P13, DOI 10.1016/S0959-437X(00)00150-7; Rasmussen CD, 2000, J BIOL CHEM, V275, P685, DOI 10.1074/jbc.275.1.685; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Suizu F, 2002, BIOCHEM J, V367, P335, DOI 10.1042/BJ20020536; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6	71	24	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48570	48579		10.1074/jbc.M308781200	http://dx.doi.org/10.1074/jbc.M308781200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507913	hybrid, Green Published			2022-12-25	WOS:000186829000009
J	Tominaga, K; Leung, JK; Rookard, P; Echigo, J; Smith, JR; Pereira-Smith, OM				Tominaga, K; Leung, JK; Rookard, P; Echigo, J; Smith, JR; Pereira-Smith, OM			MRGX is a novel transcriptional regulator that exhibits activation or repression of the B-myb promoter in a cell type-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMO-DOMAIN; IN-VIVO; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; INDEFINITE DIVISION; GENETIC-ANALYSIS; LYSINE 9; FAMILY; DROSOPHILA; COMPLEX	MRGX is a novel transcription factor that is a member of the mortality factor 4 (MORF4)-related gene family. MRG15, a closely related family member, is in a complex with the retinoblastoma tumor suppressor protein Rb and activates the B-myb promoter, which is tightly controlled by Rb/E2F through the E2F binding site. In this study we investigated the effect of MRGX on the B-myb promoter. Interestingly, MRGX repressed the B-myb promoter in EJ cells ( human bladder carcinoma cells), which have a functional Rb, but activated B-myb in HeLa cells ( human cervical carcinoma cells), which express a lower amount of Rb. This repression and activation was dependent on the helix-loop-helix and leucine zipper regions of the MRGX protein but not the N-terminal region. MRGX interacts with Rb through the helix-loop-helix and leucine zipper regions. Using a treatment of trichostatin A, which is a potent inhibitor of histone deacetylase ( HDAC), we determined that the repression of the B-myb promoter by MRGX in EJ cells was dependent on HDAC activity. We confirmed the association of MRGX with HDAC1 by immunoprecipitation/ Western analysis and determined that MRGX complexes had HDAC activity. The data indicate that MRGX can repress or activate the B-myb promoter depending on the cell type studied, suggesting that there may be tissue-specific functions of this protein.	Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Ctr Longev & Aging Studies, San Antonio, TX 78245 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Berkeley	Pereira-Smith, OM (corresponding author), Univ Texas, Hlth Sci Ctr, Sam & Ann Barshop Ctr Longev & Aging Studies, STCBM Bldg,15355 Lambda Dr, San Antonio, TX 78245 USA.		Tominaga, Kaoru/AAL-4250-2020	Tominaga, Kaoru/0000-0001-8799-528X	NATIONAL INSTITUTE ON AGING [P01AG020752, R37AG005333] Funding Source: NIH RePORTER; NIA NIH HHS [P01AG20752, R37AG05333] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bertram MJ, 2001, GENE, V266, P111, DOI 10.1016/S0378-1119(01)00372-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Leung JK, 2001, J BIOL CHEM, V276, P39171, DOI 10.1074/jbc.M103435200; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; Pardo PS, 2002, J BIOL CHEM, V277, P50860, DOI 10.1074/jbc.M203839200; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PEREIRASMITH OM, 1982, SOMAT CELL GENET, V8, P731, DOI 10.1007/BF01543015; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Takahashi Y, 2000, GENE DEV, V14, P804; Tominaga K, 2002, MECH AGEING DEV, V123, P927, DOI 10.1016/S0047-6374(02)00030-1; Tominaga K, 2002, GENE, V294, P215, DOI 10.1016/S0378-1119(02)00787-4; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	31	16	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49618	49624		10.1074/jbc.M309192200	http://dx.doi.org/10.1074/jbc.M309192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506250	hybrid			2022-12-25	WOS:000186829000133
J	Trujillo, KM; Roh, DH; Chen, L; Van Komen, S; Tomkinson, A; Sung, P				Trujillo, KM; Roh, DH; Chen, L; Van Komen, S; Tomkinson, A; Sung, P			Yeast Xrs2 binds DNA and helps target Rad50 and Mre11 to DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; INDUCED REPLICATION; REPAIR; RECOMBINATION; COMPLEX; NBS1; DISRUPTION; PROTEIN; LETHALITY	Saccharomyces cerevisiae Rad50, Mre11, and Xrs2 proteins are involved in homologous recombination, nonhomologous end-joining, DNA damage checkpoint signaling, and telomere maintenance. These proteins form a stable complex that has nuclease, DNA binding, and DNA end recognition activities. Of the components of the Rad50 . Mre11 . Xrs2 complex, Xrs2 is the least characterized. The available evidence is consistent with the idea that Xrs2 recruits other protein factors in reactions that pertain to the biological functions of the Rad50 . Mre11 . Xrs2 complex. Here we present biochemical evidence that Xrs2 has an associated DNA-binding activity that is specific for DNA structures. We also define the contributions of Xrs2 to the activities of the Rad50 . Mre11 . Xrs2 complex. Importantly, we demonstrate that Xrs2 is critical for targeting of Rad50 and Mre11 to DNA ends. Thus, Xrs2 likely plays a direct role in the engagement of DNA substrates by the Rad50 . Mre11 . Xrs2 complex in various biological processes.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,Sterling Hall Med C130A, New Haven, CT 06422 USA.				NATIONAL CANCER INSTITUTE [T32CA086800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM047251] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA86800, P30CA54175] Funding Source: Medline; NIEHS NIH HHS [R01ES07061] Funding Source: Medline; NIGMS NIH HHS [R01GM47251, R01GM57814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Anderson DE, 2001, J BIOL CHEM, V276, P37027, DOI 10.1074/jbc.M106179200; Bender CF, 2002, GENE DEV, V16, P2237, DOI 10.1101/gad.1007902; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Nakada D, 2003, GENE DEV, V17, P1957, DOI 10.1101/gad.1099003; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	27	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48957	48964		10.1074/jbc.M309877200	http://dx.doi.org/10.1074/jbc.M309877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14522986	hybrid			2022-12-25	WOS:000186829000056
J	Tucker, KA; Reggiori, F; Dunn, WA; Klionsky, DJ				Tucker, KA; Reggiori, F; Dunn, WA; Klionsky, DJ			Atg23 is essential for the cytoplasm to vacuole targeting pathway and efficient autophagy but not pexophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; VESICLE FORMATION; AMINOPEPTIDASE I; YEAST VACUOLE; CVT PATHWAY; PROTEIN; TRANSPORT; COMPLEX; MUTANTS; INDUCTION	Cells must regulate both biosynthesis and degradation to ensure proper homeostasis of cellular organelles and proteins. This balance is demonstrated in a unique way in the yeast Saccharomyces cerevisiae, which possesses two distinct, yet mechanistically related trafficking routes mediating the delivery of proteins from the cytoplasm to the vacuole: the biosynthetic cytoplasm to vacuole targeting (Cvt) and the degradative autophagy pathways. Several components employed by these two transport routes have been identified, but their mechanistic interactions remain largely unknown. Here we report a novel gene involved in these pathways, which we have named ATG23. Atg23 localizes to the pre-autophagosomal structure but also to other cytosolic punctate compartments. Our characterization of the Atg23 protein indicates that it is required for the Cvt pathway and efficient autophagy but not pexophagy. In the absence of Atg23, cargo molecules such as prApe1 are correctly recruited to a pre-autophagosomal structure that is unable to give rise to Cvt vesicles. We also demonstrate that Atg23 is a peripheral membrane protein that requires the presence of Atg9/Apg9 to be specifically targeted to lipid bilayers. Atg9 transiently interacts with Atg23 suggesting that it participates in the recruitment of this protein.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Klionsky, DJ (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.		Reggiori, Fulvio/U-8327-2019	Reggiori, Fulvio/0000-0003-2652-2686	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396, R01 GM053396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hutchins MU, 1999, J CELL SCI, V112, P4079; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; KLIONSKY DJ, 2004, AUTOPHAGY, P1; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Nice DC, 2002, J BIOL CHEM, V277, P30198, DOI 10.1074/jbc.M204736200; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Reggiori F, 2003, J BIOL CHEM, V278, P5009, DOI 10.1074/jbc.M210436200; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Shintani T, 2002, DEV CELL, V3, P825, DOI 10.1016/S1534-5807(02)00373-8; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Stromhaug PE, 2001, TRAFFIC, V2, P524, DOI 10.1034/j.1600-0854.2001.20802.x; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200	47	68	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48445	48452		10.1074/jbc.M309238200	http://dx.doi.org/10.1074/jbc.M309238200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504273	hybrid, Green Accepted			2022-12-25	WOS:000186731400130
J	Toth-Zsamboki, E; Oury, C; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF				Toth-Zsamboki, E; Oury, C; Cornelissen, H; De Vos, R; Vermylen, J; Hoylaerts, MF			P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; P2X(1) ION-CHANNEL; SHAPE CHANGE; PROTEIN-KINASE; TYROSINE KINASE; ANGIOTENSIN-II; PHOSPHORYLATION; CALCIUM; INVOLVEMENT; RHO	The ATP-gated P2X(1) ion channel is the only P2X subtype expressed in human platelets. Via transmission electron microscopy, we found that P2X(1) mediates fast, reversible platelet shape change, secretory granule centralization, and pseudopodia formation. In washed human platelets, the stable P2X(1) agonist alpha,beta-methylene ATP (alpha,beta-meATP) causes rapid, transient (2-5 s), and dose-dependent myosin light chain (MLC) phosphorylation, requiring extracellular Ca2+. Phosphorylation was inhibited by the calmodulin (CaM) inhibitor W-7, but not by the Rho kinase inhibitor HA-1077, i.e. it is exclusively regulated by Ca2+/CaM-dependent MLC kinase. Correspondingly, the P2X(1)-induced platelet shape change was inhibited by W-7 and by the MLC kinase inhibitor ML-7 but not by HA-1077. W-7, ML-7, the protein kinase C inhibitor GF109203- X, and the Src family kinase inhibitor PP1 inhibited the collagen and convulxin-induced early platelet degranulation, shape change, and subsequent aggregation, indicating a role for Ca2+/CaM and MLC kinase in these glycoprotein VI-related platelet responses. The secreted ATP-mediated P2X(1)-dependent ERK2 activation induced by low collagen concentrations contributes to MLC kinase activation since P2X1 desensitization or blockade of ERK2 phosphorylation by U0126 strongly attenuated MLC phosphorylation, degranulation, and aggregation. We therefore conclude that at low doses of collagen, glycoprotein VI activation leads to early protein kinase C- and MLC kinase-dependent degranulation. Rapidly released ATP triggers P2X(1)-mediated Ca2+ influx, activating ERK2, in turn amplifying platelet secretion by reinforcing the early MLC kinase phosphorylation. Hence, the P2X(1)-ERK2-MLC axis contributes to collagen-induced platelet activation by enhancing platelet degranulation.	Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Univ Louvain, Lab Morphol & Mol Pathol, B-3000 Louvain, Belgium		Hoylaerts, MF (corresponding author), Univ Louvain, Ctr Mol & Vasc Biol, Herestr 49, B-3000 Louvain, Belgium.	marc.hoylaerts@med.kuleuven.ac.be		Oury, Cecile/0000-0002-7561-0132; Hoylaerts, Marc/0000-0002-6474-3933				Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; FOX JEB, 1982, J BIOL CHEM, V257, P4120; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; IKEBE M, 1994, J BIOL CHEM, V269, P28173; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Mustard J.F., 2002, PLATELETS THROMBOTIC, V2002, P3, DOI [10.1017/cbo9780511545283.002, DOI 10.1017/CBO9780511545283.002]; NISHIKAWA M, 1982, J CLIN INVEST, V69, P1348, DOI 10.1172/JCI110574; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; NODA M, 1995, FEBS LETT, V367, P246, DOI 10.1016/0014-5793(95)00573-R; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Oury C, 2003, BLOOD, V101, P3969, DOI 10.1182/blood-2002-10-3215; Oury C, 2002, BLOOD, V100, P2499, DOI 10.1182/blood-2002-03-0812; Oury C, 2001, THROMB HAEMOSTASIS, V86, P1264; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rolf MG, 2002, THROMB HAEMOSTASIS, V88, P495; Rolf MG, 2001, THROMB HAEMOSTASIS, V85, P303, DOI 10.1055/s-0037-1615684; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; STARK F, 1991, J CELL BIOL, V112, P903, DOI 10.1083/jcb.112.5.903; Sun B, 1998, J BIOL CHEM, V273, P11544, DOI 10.1074/jbc.273.19.11544; Vial C, 1997, THROMB HAEMOSTASIS, V78, P1500; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276	33	58	59	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46661	46667		10.1074/jbc.M308452200	http://dx.doi.org/10.1074/jbc.M308452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14500714	Green Published, hybrid			2022-12-25	WOS:000186569400055
J	Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D				Loo, JCY; Liu, L; Hao, AH; Gao, LZ; Agatep, R; Shennan, M; Summers, A; Goldstein, AM; Tucker, MA; Deters, C; Fusaro, R; Blazer, K; Weitzel, J; Lassam, N; Lynch, H; Hogg, D			Germline splicing mutations of CDKN2A predispose to melanoma	ONCOGENE			English	Article						splice site mutations; melanoma; genetic predisposition	HAPLOTYPE ANALYSIS; PRONE FAMILIES; P16(INK4A); FOUNDER	Coding mutations of the CDKN2A gene on chromosome 9p21 cosegregate with 25-60% of familial melanoma cases, but there remains a number of 9p21-linked kindreds that lack germline coding mutations of CDKN2A. W e sequenced CDKN2A exons 1alpha, 2, 3, and the adjacent intronic regions in 167 melanoma-prone families ( at least two affected first-degree relatives), and detected four splice site variations, three of which cosegregate with the disease. RT-PCR experiments verified that these three variants, including an AGgt to ATgt mutation that demonstrates a founder effect, do affect splicing. While an exon 1alpha splice donor site mutation incompletely abolishes splicing, the correctly spliced mRNA yields a protein (Q50P) that cannot effectively interact with CDK4. We also performed RT-PCR on mRNA from 16 melanoma-prone kindreds to search for cryptic splice sites deep within introns, but identified no splice variants. Meanwhile, we screened 139 affected families using allele specific PCR for the recently discovered IVS2-105A >G mutation, but found only one family that possesses this alteration. We conclude that splice site mutations do predispose to disease in a subset of melanoma-prone kindreds. Characterization of additional splice site variants and other noncoding alterations of CDKN2A should allow us to detect a wider range of mutations in at-risk patients.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; City Hope Comprehens Canc Ctr, Dept Clin Canc Genet, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA; NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; N York Gen Hosp, Dept Genet, Toronto, ON M2K 1E1, Canada	University of Toronto; University of Toronto; City of Hope; City of Hope; Beckman Research Institute of City of Hope; Creighton University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; North York General Hospital	Hogg, D (corresponding author), Univ Toronto, Dept Med Biophys, Room 7368,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	david.hogg@utoronto.ca	Blazer, Kathleen/ABC-8530-2021; Tucker, Margaret A/B-4297-2015	Loo, Joanne Chung Yan/0000-0001-8429-6109				Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; Colitt R, 1999, LAT TRADE, V7, P22; Goldstein AM, 2001, BRIT J CANCER, V85, P527, DOI 10.1054/bjoc.2001.1944; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; Harland M, 2001, HUM MOL GENET, V10, P2679, DOI 10.1093/hmg/10.23.2679; Hashemi J, 2001, GENE CHROMOSOME CANC, V31, P107, DOI 10.1002/gcc.1124; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Hogg D, 1998, J Cutan Med Surg, V2, P172; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Li JN, 1999, BIOCHEMISTRY-US, V38, P2930, DOI 10.1021/bi982286e; LIU L, 1995, ONCOGENE, V11, P405; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Liu L, 1997, GENE CHROMOSOME CANC, V19, P52, DOI 10.1002/(SICI)1098-2264(199705)19:1<52::AID-GCC8>3.3.CO;2-S; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; Lynch HT, 2002, CANCER-AM CANCER SOC, V94, P84, DOI 10.1002/cncr.10159; MacKie RM, 1998, J INVEST DERMATOL, V111, P269, DOI 10.1046/j.1523-1747.1998.00267.x; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Moskaluk C A, 1998, Hum Mutat, V12, P70; Petronzelli F, 2001, GENE CHROMOSOME CANC, V31, P398, DOI 10.1002/gcc.1159; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUTTER JL, IN PRESS ONCOGENE; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shennan MG, 2000, ONCOGENE, V19, P1849, DOI 10.1038/sj.onc.1203507	27	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6387	6394		10.1038/sj.onc.1206736	http://dx.doi.org/10.1038/sj.onc.1206736			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508519				2022-12-25	WOS:000185535300009
J	Osman, AA; Saito, M; Makepeace, C; Permutt, MA; Schlesinger, P; Mueckler, M				Osman, AA; Saito, M; Makepeace, C; Permutt, MA; Schlesinger, P; Mueckler, M			Wolframin expression induces novel ion channel activity in endoplasmic reticulum membranes and increases intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; WFS1 GENE; CA2+; PROTEIN; CELL; APOPTOSIS; BAX; MUTATIONS; FAMILY; P64	Wolfram syndrome is an autosomal recessive neurodegenerative disorder associated with juvenile onset non-autoimmune diabetes mellitus and progressive optic atrophy. The disease has been attributed to mutations in the WFS1 gene, which codes for a protein predicted to possess 9-10 transmembrane segments. Little is known concerning the function of the WFS1 protein (wolframin). Endoglycosidase H digestion, immunocytochemistry, and subcellular fractionation studies all indicated that wolframin is localized to the endoplasmic reticulum in rat brain hippocampus and rat pancreatic islet beta-cells, and after ectopic expression in Xenopus oocytes. Reconstitution of wolframin from oocyte membranes into planar lipid bilayers demonstrated that the protein induced a large cation-selective ion channel that was blocked by Mg2+ or Ca2+. Inositol triphosphate was capable of activating channels in the fused bilayers that were similar to channel components induced by wolframin expression. Expression of wolframin also increased cytosolic calcium levels in oocytes. Wolframin thus appears to be important in the regulation of intracellular Ca2+ homeostasis. Disruption of this function may place cells at risk to suffer inappropriate death decisions, thus accounting for the progressive beta-cell loss and neuronal degeneration associated with the disease.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Schlesinger, P (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	paul@cellbio.wustl.edu	Schlesinger, Paul H/C-6049-2012; Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746, R37DK016746, R01DK038495] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR46539] Funding Source: Medline; NIDDK NIH HHS [DK38495, DK16746] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awata T, 2000, BIOCHEM BIOPH RES CO, V268, P612, DOI 10.1006/bbrc.2000.2169; Baran I, 2003, BIOPHYS J, V84, P1470, DOI 10.1016/S0006-3495(03)74960-1; Barrett TG, 2000, J MED GENET, V37, P463, DOI 10.1136/jmg.37.6.463; Barrientos A, 1996, AM J HUM GENET, V58, P963; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bespalova IN, 2001, HUM MOL GENET, V10, P2501, DOI 10.1093/hmg/10.22.2501; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; BU XD, 1993, LANCET, V342, P598, DOI 10.1016/0140-6736(93)91416-J; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Eller P, 2001, J MED GENET, V38, DOI 10.1136/jmg.38.11.e37; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Franco-Obregon A, 2000, BIOPHYS J, V79, P202, DOI 10.1016/S0006-3495(00)76284-9; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Gerbitz KD, 1999, DIABETOLOGIA, V42, P627, DOI 10.1007/s001250051205; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Hajnoczky G, 2000, J PHYSIOL-LONDON, V529, P69, DOI 10.1111/j.1469-7793.2000.00069.x; Hardy C, 1999, AM J HUM GENET, V65, P1279, DOI 10.1086/302609; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hille B., 2001, ION CHANNELS EXCITAB, P269; HILLE B, 2001, ION CHANNELS EXCITAB, P405; Hofmann S, 2003, HUM MOL GENET, V12, P2003, DOI 10.1093/hmg/ddg214; HUMASON GL, 1997, ANIMAL TISSUE TECHNI, P361; Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441; KARASIK A, 1989, DIABETES CARE, V12, P135, DOI 10.2337/diacare.12.2.135; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Minton JAL, 2002, DIABETES, V51, P1287, DOI 10.2337/diabetes.51.4.1287; Moraru II, 1999, J GEN PHYSIOL, V113, P837, DOI 10.1085/jgp.113.6.837; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pollock NS, 1998, BIOPHYS J, V75, P1759, DOI 10.1016/S0006-3495(98)77617-9; POLYMEROPOULOS MH, 1994, NAT GENET, V8, P95, DOI 10.1038/ng0994-95; RAITI S, 1963, BRIT MED J, P1625; RANDO TA, 1992, NEUROLOGY, V42, P1220, DOI 10.1212/WNL.42.6.1220; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SHINODA K, 1992, J COMP NEUROL, V322, P360, DOI 10.1002/cne.903220306; Shuai JW, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.068102; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STORM HK, 1998, HUM MOL GENET, V7, P2021; Swift RG, 1998, MOL PSYCHIATR, V3, P86, DOI 10.1038/sj.mp.4000344; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Takeda K, 2001, HUM MOL GENET, V10, P477, DOI 10.1093/hmg/10.5.477; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299	53	136	143	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52755	52762		10.1074/jbc.M310331200	http://dx.doi.org/10.1074/jbc.M310331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527944	hybrid			2022-12-25	WOS:000187480700094
J	Ullas, KS; Rao, MRS				Ullas, KS; Rao, MRS			Phosphorylation of rat spermatidal protein TP2 by sperm-specific protein kinase A and modulation of its transport into the haploid nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; CATALYTIC SUBUNIT; LOCALIZATION SIGNAL; RIBOSOMAL-PROTEINS; SOMATIC HISTONES; MAMMALIAN-CELLS; IMPORTIN-BETA; II SITE; C-GAMMA; CHROMATIN	Transition protein 2 (TP2), which is expressed during stages 12-15 of mammalian spermiogenesis, has been shown to undergo phosphorylation immediately after its synthesis. We reported earlier that TP2 is phosphorylated in vitro at threonine 101 and serine 109 by the salt extract of sonication-resistant (elongating and elongated) spermatid nuclei and the protein kinase phosphorylating TP2 was identified to be protein kinase A (PKA). We now report that the cytosol from haploid spermatids but not from premeiotic germ cells is able to phosphorylate recombinant TP2 in vitro at threonine 101 and serine 109. The kinase present in the haploid spermatid cytosol that phosphorylates TP2 has been identified to be the sperm-specific isoform of protein kinase A (Cs-PKA). Reverse transcription-PCR analysis indicated that Cs-PKA was present in the haploid spermatids and absent from premeiotic germ cells. The rat Cs-PKA transcript was amplified and sequenced using the isoform-specific primers. The sequence of rat Cs-PKA at the N terminus differs from mouse and human by one amino acid. Western blot analysis using specific anti-Calpha1 antibodies revealed that Calpha1-PKA is absent in haploid spermatid cytosol. We have also established an in vitro nuclear transport assay for the haploid round spermatids. Using this assay, we have found that the cytoplasmic factors and ATP are absolutely essential for translocation of TP2 into the nucleus. Phosphorylation was found to positively modulate the NLS dependent import of TP2 into the nucleus.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, MRS (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	mrsrao@biochem.iisc.ernet.in						ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20662; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GREEN GR, 1994, MOL REPROD DEV, V37, P255, DOI 10.1002/mrd.1080370303; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Kurz M, 1997, J CELL BIOCHEM, V64, P573; Meetei AR, 2000, J BIOL CHEM, V275, P38500, DOI 10.1074/jbc.M002734200; Meetei AR, 2002, BIOCHEMISTRY-US, V41, P185, DOI 10.1021/bi0117652; Mei XH, 1997, EUR J BIOCHEM, V246, P425, DOI 10.1111/j.1432-1033.1997.t01-1-00425.x; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Moss SB, 1999, BIOL REPROD, V61, P335, DOI 10.1095/biolreprod61.2.335; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; Pittoggi C, 1999, J CELL SCI, V112, P3537; Reinton N, 1998, GENOMICS, V49, P290, DOI 10.1006/geno.1998.5240; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; San Agustin JT, 2001, BIOL REPROD, V65, P151, DOI 10.1095/biolreprod65.1.151; San Agustin JT, 2000, MOL BIOL CELL, V11, P3031, DOI 10.1091/mbc.11.9.3031; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SUDHAKAR L, 1990, J BIOL CHEM, V265, P22526; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; USCHEWA A, 1982, FEBS LETT, V138, P50, DOI 10.1016/0014-5793(82)80392-X; Varmuza S, 1999, DEV BIOL, V205, P98, DOI 10.1006/dbio.1998.9100; Wooten MW, 2002, SCI STKE, V2002, ppl15; Wouters-Tyrou D, 1998, BIOCHIMIE, V80, P117, DOI 10.1016/S0300-9084(98)80018-7; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001	44	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52673	52680		10.1074/jbc.M308365200	http://dx.doi.org/10.1074/jbc.M308365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14514679	hybrid			2022-12-25	WOS:000187480700085
J	MacDonald, MJ; Fahien, LA; Buss, JD; Hasan, NM; Fallon, MJ; Kendrick, MA				MacDonald, MJ; Fahien, LA; Buss, JD; Hasan, NM; Fallon, MJ; Kendrick, MA			Citrate oscillates in liver and pancreatic beta cell mitochondria and in INS-1 insulinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRIC-ACID CYCLE; RAT-HEART MITOCHONDRIA; PYRUVATE-DEHYDROGENASE; METHYL SUCCINATE; FREE CA2+; IN-VIVO; SECRETION; ISLETS; PHOSPHOFRUCTOKINASE; ANAPLEROSIS	Oscillations in citric acid cycle intermediates have never been previously reported in any type of cell. Here we show that adding pyruvate to isolated mitochondria from liver, pancreatic islets, and INS-1 insulinoma cells or adding glucose to intact INS-1 cells causes sustained oscillations in citrate levels. Other citric acid cycle intermediates measured either did not oscillate or possibly oscillated with a low amplitude. In INS-1 mitochondria citrate oscillations are in phase with NAD(P) oscillations, and in intact INS-1 cells citrate oscillations parallel oscillations in ATP, suggesting that these processes are co-regulated. Oscillations have been extensively studied in the pancreatic beta cell where oscillations in glycolysis, NAD(P)/NAD(P)H and ATP/ADP ratios, plasma membrane electrical activity, calcium levels, and insulin secretion have been well documented. Because the mitochondrion is the major site of ATP synthesis and NADH oxidation and the only site of citrate synthesis, mitochondria need to be synchronized for these factors to oscillate. In suspensions of mitochondria from various organs, most of the citrate is exported from the mitochondria. In addition, citrate inhibits its own synthesis. We propose that this enables citrate itself to act as one of the cellular messengers that synchronizes mitochondria. Furthermore, because citrate is a potent inhibitor of the glycolytic enzyme phosphofructokinase, the pacemaker of glycolytic oscillations, citrate may act as a metabolic link between mitochondria and glycolysis. Citrate oscillations may coordinate oscillations in mitochondrial energy production and anaplerosis with glycolytic oscillations, which in the beta cell are known to parallel oscillations in insulin secretion.	Univ Wisconsin, Sch Med, Childrens Diabet Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	MacDonald, MJ (corresponding author), Med Sci Ctr, Rm 3459,1300 Univ Ave, Madison, WI 53706 USA.		Fallon, Mike/ABG-6993-2020		NIDDK NIH HHS [DK28348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK028348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ATKINSON DE, 1969, CITRIC ACID CYCLE CO, P137; BOBYLEVA V, 1993, J BIOENERG BIOMEMBR, V25, P313, DOI 10.1007/BF00762592; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; Deeney JT, 2001, J BIOL CHEM, V276, P36946, DOI 10.1074/jbc.M105056200; Denton RM, 1996, ADV ENZYME REGUL, V36, P183, DOI 10.1016/0065-2571(95)00020-8; FAHIEN LA, 1993, J BIOL CHEM, V268, P17935; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; HANSFORD RG, 1977, J BIOL CHEM, V252, P1552; HARBER MJ, 1982, CLIN BIOCH LUMINESCE, P189; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Jung SK, 2000, J BIOL CHEM, V275, P6642, DOI 10.1074/jbc.275.9.6642; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; Krebs H. A., 1969, ENERGY LEVEL METABOL, P329; LANOUE K, 1970, J BIOL CHEM, V245, P102; LARDY HA, 1966, HARVEY LECT, P272; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MacDonald MJ, 2003, BBA-GEN SUBJECTS, V1619, P77, DOI 10.1016/S0304-4165(02)00443-9; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; Malaisse WJ, 1996, ACTA DIABETOL, V33, P173; MCCLURE WR, 1971, J BIOL CHEM, V246, P3591; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; PARMEGGIANI A, 1963, BIOCHEM BIOPH RES CO, V12, P268, DOI 10.1016/0006-291X(63)90294-8; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PASSONNEAU JV, 1963, BIOCHEM BIOPH RES CO, V13, P372, DOI 10.1016/0006-291X(63)90350-4; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; RANDLE PJ, 1970, BIOCHEM J, V117, P677, DOI 10.1042/bj1170677; TORNHEIM K, 1991, J BIOL CHEM, V266, P15675; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; UNDERWOOD AH, 1965, BIOCHEM J, V95, P868, DOI 10.1042/bj0950868; WALTER P, 1966, J BIOL CHEM, V241, P2523; Walter P, 1976, GLUCONEOGENESIS ITS, P239; WILLIAMSON JR, 1980, FEBS LETT, V117, pK73, DOI 10.1016/0014-5793(80)80572-2; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285	43	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51894	51900		10.1074/jbc.M309038200	http://dx.doi.org/10.1074/jbc.M309038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522964	hybrid			2022-12-25	WOS:000187206300125
J	Chen, XQ; Ernst, SA; Williams, JA				Chen, XQ; Ernst, SA; Williams, JA			Dominant negative Rab3D mutants reduce GTP-bound endogenous Rab3D in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GDP-DISSOCIATION INHIBITOR; VESICLE TRAFFICKING; VESICULAR TRANSPORT; SECRETORY PROTEINS; BINDING; MEMBRANE; EXOCYTOSIS; ASSOCIATION; RECEPTOR	Two dominant negative mutants of Rab3D, N135I and T36N were recently reported to inhibit the early phase of regulated amylase secretion from mouse pancreatic acini (Chen, X., Edwards, J. A., Logsdon, C. D., Ernst, S. A., and Williams, J. A. (2002) J. Biol. Chem. 277, 18002 18009). Immunocytochemical studies showed that while the wild-type Rab3D localized to zymogen granules, the two dominant negative mutants did not localize to granules and were primarily in the basolateral regions of the cell. The present study, therefore, evaluated the potential mechanisms by which the dominant negative mutants might act. An affinity precipitation assay based on the property of the Rab3 effector Rim1 to interact only with GTP-bound Rab3D was developed. 78.9 +/- 4.5% of total endogenous Rab3D was found in the GTP-bound form. Overexpression of HA-tagged Rab3D, and its Q81L, N135I, and T36N mutants had no effect on the total amount of endogenous Rab3D. However, the dominant negative mutants, T36N and N135I, reduced GTP-bound endogenous Rab3D by 70.0 +/- 3.5% and 72.7 +/- 1.2%, respectively, while the wild-type Rab3D and Q81L mutant had no effect. Triton X-114 phase separation and cell fractionation studies showed that dominant negative Rab3D mutants did not alter isoprenylation or membrane association of endogenous Rab3D. The dominant negative Rab3D did not affect the amount of endogenous Rab3D on purified zymogen granules as assessed by either Western blotting or immunocytochemistry, but reduced the GTP-bound form by 78.6 +/- 3.3%. The two dominant negative Rab3D mutants, therefore, interfere with endogenous Rab3D function by blocking the GDP/GTP exchange but not zymogen granule targeting of endogenous Rab3D.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chen, XQ (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 7734 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.	xuequnc@umich.edu; jawillms@umich.edu		Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [DK41122, P60 DK20572, P30 DK34933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041122, R01DK041122, P60DK020572, P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BURNHAM DB, 1985, BIOCHEM J, V227, P743, DOI 10.1042/bj2270743; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; Chen XQ, 2002, J BIOL CHEM, V277, P18002, DOI 10.1074/jbc.M201248200; Chou JH, 2000, J BIOL CHEM, V275, P9433, DOI 10.1074/jbc.275.13.9433; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Coppola T, 2002, BIOCHEM J, V362, P273, DOI 10.1042/0264-6021:3620273; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Gerez L, 2000, MOL BIOL CELL, V11, P2201, DOI 10.1091/mbc.11.7.2201; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; JAMIESON JD, 1967, J CELL BIOL, V34, P597, DOI 10.1083/jcb.34.2.597; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; LI GP, 1994, J BIOL CHEM, V269, P14631; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Luan P, 1999, J BIOL CHEM, V274, P14806, DOI 10.1074/jbc.274.21.14806; Mohrmann K, 2002, J BIOL CHEM, V277, P32029, DOI 10.1074/jbc.M203064200; NOVICK P, 1994, NATURE, V369, P18, DOI 10.1038/369018a0; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Riedel D, 2002, MOL CELL BIOL, V22, P6487, DOI 10.1128/MCB.22.18.6487-6497.2002; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; STAHL B, 1994, J BIOL CHEM, V269, P24770; Sun L, 2001, J BIOL CHEM, V276, P12911, DOI 10.1074/jbc.M011110200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; WAGNER ACC, 1994, J BIOL CHEM, V269, P9099; Wagner W, 2002, EMBO J, V21, P6397, DOI 10.1093/emboj/cdf650; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; Wang W, 2000, J CELL BIOL, V151, P289, DOI 10.1083/jcb.151.2.289; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760	55	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50053	50060		10.1074/jbc.M309910200	http://dx.doi.org/10.1074/jbc.M309910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522985	hybrid			2022-12-25	WOS:000187068200049
J	Shao, JS; Cheng, SL; Charlton-Kachigian, N; Loewy, AP; Towler, DA				Shao, JS; Cheng, SL; Charlton-Kachigian, N; Loewy, AP; Towler, DA			Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIAL ARTERIAL CALCIFICATION; BONE MORPHOGENETIC PROTEIN-2; STAGE RENAL-DISEASE; SMOOTH-MUSCLE-CELLS; MATRIX GLA PROTEIN; CARDIOVASCULAR COMPLICATIONS; POSTMENOPAUSAL WOMEN; HIGH GLUCOSE; IN-VIVO; OSTEOPONTIN	Cardiovascular calcification is a common consequence of diabetes. High fat diets induce diabetes and arterial calcification in male low density lipoprotein receptor (LDLR) -/- mice; calcification occurs via Msx2 signaling that promotes the osteogenic differentiation of arterial myofibroblasts. We studied regulation of arterial osteogenesis by human parathyroid hormone (PTH) ( 1 - 34) ( also called teriparatide) in LDLR-/- mice fed diabetogenic diets for 4 weeks. LDLR-/- mice were treated with vehicle or 0.4 mg/kg of PTH( 1 - 34) subcutaneously five times/week. Gene expression was determined from single aortas and hind limb RNA by fluorescence reverse transcription-PCR. Valve calcification was determined by histological staining of cardiac sections using image analysis to quantify valve leaflet mineralization. PTH( 1 - 34) increased bone mineral content ( by dual energy x-ray absorptiometry) in LDLR -/- mice, with induction of osseous osteopontin (OPN) expression and serum OPN levels (> 150 nM); PTH( 1 - 34) did not significantly change serum glucose, lipids, body weight, or fat mass. PTH( 1 - 34) suppressed aortic OPN and Msx2 expression > 50% and decreased cardiac valve calcification 80% (8.3 +/- 1.5% versus 1.4 +/- 0.5%; p < 0.001). Of the known circulating regulators of vascular calcification ( OPN, osteoprotegerin, and leptin), PTH( 1 - 34) regulated only serum OPN. We therefore studied actions of PTH( 1 - 34) and OPN in vitro on cells induced to mineralize with Msx2. OPN ( 5 - 50 nM) reversed Msx2-induced mineralization. PTH( 1 - 34) inhibited mineralization by 40% and down-regulated Msx2 in aortic myofibroblasts. PTH( 1 - 34) inhibits vascular calcification and aortic osteogenic differentiation via direct actions and potentially via circulating OPN. PTH( 1 - 34) exerts beneficial actions at early stages of macrovascular disease responses to diabetes and dyslipidemia.	Washington Univ, Sch Med, Div Bone & Mineral Dis, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Sch Med, Div Bone & Mineral Dis, Dept Med, Barnes Jewish Hosp N Campus,Box 8301,7th Floor St, St Louis, MO 63110 USA.			Towler, Dwight/0000-0003-2107-7923	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069229] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69229] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002-020334; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Chantelau E, 1997, EXP CLIN ENDOCR DIAB, V105, P11, DOI 10.1055/s-0029-1211786; CHANTELAU E, 1995, DIABETES RES CLIN PR, V29, P169, DOI 10.1016/0168-8227(95)01126-9; CHEN NX, 2003, CURR DIAB REP, V3, P285; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; Davies MR, 2001, KIDNEY INT, V60, P472, DOI 10.1046/j.1523-1755.2001.060002472.x; Demer LL, 2002, CURR OPIN NEPHROL HY, V11, P437, DOI 10.1097/00041552-200207000-00011; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Fitzpatrick LA, 2003, ENDOCRINOLOGY, V144, P2214, DOI 10.1210/en.2002-0170; Hale LV, 2000, CALCIFIED TISSUE INT, V67, P80, DOI 10.1007/s00223001101; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Huang ZY, 2003, J CARDIOVASC PHARM, V42, P89, DOI 10.1097/00005344-200307000-00014; Ihara H, 2001, J BIOL CHEM, V276, P13065, DOI 10.1074/jbc.M010938200; Iribarren C, 2000, JAMA-J AM MED ASSOC, V283, P2810, DOI 10.1001/jama.283.21.2810; Isoda K, 2002, CIRC RES, V91, P77, DOI 10.1161/01.RES.0000025268.10302.0C; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Langub MC, 2003, ENDOCRINOLOGY, V144, P1135, DOI 10.1210/en.2002-221026; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978; Matsui Y, 2003, ARTERIOSCL THROM VAS, V23, P1029, DOI 10.1161/01.ATV.0000074878.29805.D0; McMahon R, 2000, J BIOL CHEM, V275, P9901, DOI 10.1074/jbc.275.14.9901; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; NISKANEN L, 1994, DIABETES CARE, V17, P1252, DOI 10.2337/diacare.17.11.1252; NISKANEN LK, 1990, ATHEROSCLEROSIS, V84, P61, DOI 10.1016/0021-9150(90)90009-8; Nitta K, 2001, NEPHRON, V89, P455, DOI 10.1159/000046119; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parhami F, 1997, CURR OPIN LIPIDOL, V8, P312, DOI 10.1097/00041433-199710000-00010; Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975; Price PA, 2002, CIRC RES, V91, P547, DOI 10.1161/01.RES.0000033987.22436.50; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102; Rosenhek R, 2000, NEW ENGL J MED, V343, P611, DOI 10.1056/NEJM200008313430903; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; SHIKATA A, 1993, PEDIATR RADIOL, V23, P100, DOI 10.1007/BF02012395; Sodhi CP, 2001, AM J PHYSIOL-RENAL, V280, pF667, DOI 10.1152/ajprenal.2001.280.4.F667; Speer MY, 2002, J EXP MED, V196, P1047, DOI 10.1084/jem.20020911; Steitz SA, 2002, AM J PATHOL, V161, P2035, DOI 10.1016/S0002-9440(10)64482-3; Takemoto M, 2000, ARTERIOSCL THROM VAS, V20, P624, DOI 10.1161/01.ATV.20.3.624; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; Tsuchihashi K, 2000, NEPHRON, V84, P13, DOI 10.1159/000045533; Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31; VIRCHOW R, 1989, NUTR REV, V47, P23; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200	56	137	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50195	50202		10.1074/jbc.M308825200	http://dx.doi.org/10.1074/jbc.M308825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14504275	hybrid			2022-12-25	WOS:000187068200066
J	Zhang, W; Bogdanov, M; Pi, J; Pittard, AJ; Dowhan, W				Zhang, W; Bogdanov, M; Pi, J; Pittard, AJ; Dowhan, W			Reversible topological organization within a polytopic membrane protein is governed by a change in membrane phospholipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; LACTOSE PERMEASE; INNER MEMBRANE; CONFORMATIONAL FLEXIBILITY; TRANSMEMBRANE SEGMENTS; TOPOGENIC SIGNALS; LIPIDS STIMULATE; TRANSPORT-SYSTEM; CHARGED RESIDUES	Once inserted, transmembrane segments of polytopic membrane proteins are generally considered stably oriented due to the large free energy barrier to topological reorientation of adjacent extramembrane domains. However, the topology and function of the polytopic membrane protein lactose permease of Escherichia coli are dependent on the membrane phospholipid composition, revealing topological dynamics of transmembrane domains after stable membrane insertion (Bogdanov, M., Heacock, P. N., and Dowhan, W. ( 2002) EMBO J. 21, 2107 - 2116). In this study, we show that the high affinity phenylalanine permease PheP shares many similarities with lactose permease. PheP assembled in a mutant of E. coli lacking phosphatidylethanolamine ( PE) exhibited significantly reduced active transport function and a complete inversion in topological orientation of the N terminus and adjoining transmembrane hairpin loop compared with PheP in a PE-containing strain. Introduction of PE following the assembly of PheP triggered a reorientation of the N terminus and adjacent hairpin to their native orientation associated with regain of wild-type transport function. The reversible orientation of these secondary transport proteins in response to a change in phospholipid composition might be a result of inherent conformational flexibility necessary for transport function or during protein assembly.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia	University of Texas System; University of Texas System; University of Melbourne	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin St,Suite 6-200,POB 20708, Houston, TX 77030 USA.	William.Dowhan@uth.tmc.edu	Bogdanov, Mikhail/J-3695-2017		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM020478, GM20487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Bogdanov M, 1999, J BIOL CHEM, V274, P12339, DOI 10.1074/jbc.274.18.12339; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Kruijff B, 1997, CURR OPIN CHEM BIOL, V1, P564, DOI 10.1016/S1367-5931(97)80053-1; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Dogovski C, 2003, J BACTERIOL, V185, P6225, DOI 10.1128/JB.185.21.6225-6232.2003; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Facey SJ, 2003, EUR J BIOCHEM, V270, P1724, DOI 10.1046/j.1432-1033.2003.03531.x; Guo DP, 1996, J BIOL CHEM, V271, P30829, DOI 10.1074/jbc.271.48.30829; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JACKSON RW, 1965, J BACTERIOL, V90, P1420, DOI 10.1128/JB.90.5.1420-1425.1965; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jockel P, 1999, BIOCHEMISTRY-US, V38, P13461, DOI 10.1021/bi990303+; Kanki T, 2002, BIOCHEMISTRY-US, V41, P13973, DOI 10.1021/bi026619q; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; Nakamura H, 2000, BIOSCI BIOTECH BIOCH, V64, P167, DOI 10.1271/bbb.64.167; Opekarova M, 2002, BBA-BIOMEMBRANES, V1564, P9, DOI 10.1016/S0005-2736(02)00455-8; Pi J, 1996, J BACTERIOL, V178, P2650, DOI 10.1128/jb.178.9.2650-2655.1996; Pi J, 2002, J BACTERIOL, V184, P5842, DOI 10.1128/JB.184.21.5842-5847.2002; PI J, 1991, J BACTERIOL, V173, P3622, DOI 10.1128/JB.173.12.3622-3629.1991; Pirch T, 2003, J BIOL CHEM, V278, P42942, DOI 10.1074/jbc.M308253200; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Ridder ANJA, 2001, EMBO REP, V2, P403; Rutz C, 1999, J BIOL CHEM, V274, P33757, DOI 10.1074/jbc.274.47.33757; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Smirnova IN, 2003, BIOCHEMISTRY-US, V42, P3025, DOI 10.1021/bi027329c; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Wang XY, 2002, EMBO J, V21, P5673, DOI 10.1093/emboj/cdf571; Weinglass AB, 1999, P NATL ACAD SCI USA, V96, P11178, DOI 10.1073/pnas.96.20.11178; WILSON DM, 1985, MEMBRANE BIOCHEM, V5, P269, DOI 10.3109/09687688509150282; WOOKEY PJ, 1984, J BACTERIOL, V160, P169, DOI 10.1128/JB.160.1.169-174.1984; Zhang JT, 1998, MOL BIOL CELL, V9, P853, DOI 10.1091/mbc.9.4.853; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	52	90	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50128	50135		10.1074/jbc.M309840200	http://dx.doi.org/10.1074/jbc.M309840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525982	hybrid			2022-12-25	WOS:000187068200057
J	Zhou, CZ; de La Sierra-Gallay, IL; Quevillon-Cheruel, S; Collinet, B; Minard, P; Blondeau, K; Henckes, G; Aufrere, R; Leulliot, N; Graille, M; Sorel, I; Savarin, P; de la Torre, FO; Poupon, A; Janin, JL; van Tilbeurgh, H				Zhou, CZ; de La Sierra-Gallay, IL; Quevillon-Cheruel, S; Collinet, B; Minard, P; Blondeau, K; Henckes, G; Aufrere, R; Leulliot, N; Graille, M; Sorel, I; Savarin, P; de la Torre, FO; Poupon, A; Janin, JL; van Tilbeurgh, H			Crystal structure of the yeast Phox homology (PX) domain protein Grd19p complexed to phosphatidylinositol-3-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SORTING NEXINS; BINDING; SIGNAL; LOCALIZATION; 3-PHOSPHATE/; REFINEMENT; RETENTION; MOLECULES; RECEPTORS	Phox homology (PX) domains have been recently identified in a number of different proteins and are involved in various cellular functions such as vacuolar targeting and membrane protein trafficking. It was shown that these modules of about 130 amino acids specifically binding to phosphoinositides and that this interaction is crucial for their cellular function. The yeast genome contains 17 PX domain proteins. One of these, Grd19p, is involved in the localization of the late Golgi membrane proteins DPAP A and Kex2p. Grd19p consists of the PX domain with 30 extra residues at the N-terminal and is homologous to the functionally characterized human sorting nexin protein SNX3. We determined the 2.0 Angstrom crystal structure of Grd19p in the free form and in complex with D-myo-phosphatidylinositol 3-phosphate (diC(4)PtdIns(3) P), representing the first case of both free and ligand-bound conformations of the same PX module. The ligand occupies a well defined positively charged binding pocket at the interface between the beta-sheet and alpha-helical parts of the molecule. The structure of the free and bound protein are globally similar but show some significant differences in a region containing a polyproline peptide and a putative membrane attachment site.	Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, F-91405 Orsay, France; Lab Enzymol & Biochim Struct, CNRS, UPR 9063, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, CNRS, UMR 8621, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, CNRS, UMR 8619, Bat 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	Janin, Joel/I-2958-2012; GRAILLE, Marc/D-3242-2014; Leulliot, Nicolas/AAA-7160-2019; Zhou, Cong-Zhao/E-9174-2011; Minard, Philippe/GRS-4797-2022	GRAILLE, Marc/0000-0002-7853-5852; Leulliot, Nicolas/0000-0003-0283-4298; Zhou, Cong-Zhao/0000-0002-6881-7151; Minard, Philippe/0000-0002-3256-528X; Poupon, Anne/0000-0003-0617-0935; Li de la Sierra-Gallay, Ines/0000-0003-2770-7439				Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu J, 2002, BIOCHEMISTRY-US, V41, P5956, DOI 10.1021/bi020050b; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P45, DOI 10.1107/S0907444902018048; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200	33	56	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50371	50376		10.1074/jbc.M304392200	http://dx.doi.org/10.1074/jbc.M304392200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514667	hybrid, Green Published			2022-12-25	WOS:000187068200087
J	Garcia-Gimeno, MA; Munoz, I; Arino, J; Sanz, P				Garcia-Gimeno, MA; Munoz, I; Arino, J; Sanz, P			Molecular characterization of Ypi1, a novel Saccharomyces cerevisiae type 1 protein phosphatase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; CATALYTIC SUBUNIT; WALL INTEGRITY; SALT TOLERANCE; YEAST; PPZ1; GLC7; EXPRESSION; BINDING; GENES	The Saccharomyces cerevisiae open reading frame YFR003c encodes a small (155-amino acid) hydrophilic protein that we identified as a novel, heat-stable inhibitor of type 1 protein phosphatase (Ypi1). Ypi1 interacts physically in vitro with both Glc7 and Ppz1 phosphatase catalytic subunits, as shown by pull-down assays. Ypi1 inhibits Glc7 but appears to be less effective toward Ppz1 phosphatase activity under the conditions tested. Ypi1 contains a (RHNVRW53)-R-48 sequence, which resembles the characteristic consensus PP1 phosphatase binding motif. A W53A mutation within this motif abolishes both binding to and inhibition of Glc7 and Ppz1 phosphatases. Deletion of YPI1 is lethal, suggesting a relevant role of the inhibitor in yeast physiology. Cells overexpressing Ypi1 display a number of phenotypes consistent with an inhibitory role of this protein on Glc7, such as decreased glycogen content and an increased growth defect in a slt2/mpk1 mitogen-activated protein kinase-deficient background. Taking together, these results define Ypi1 as the first inhibitory subunit of Glc7 identified in budding yeast.	CSIC, Inst Biomed, Valencia 46010, Spain; Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Autonomous University of Barcelona	Sanz, P (corresponding author), CSIC, Inst Biomed, Jaime Roig 11, Valencia 46010, Spain.	sanz@ibv.csic.es	Arino, Joaquin/D-3756-2011; García-Gimeno, María Adelaida/K-9855-2014; Zhang, Ning/F-1387-2014; Sanz, Pascual/K-2751-2014	Arino, Joaquin/0000-0002-6774-2987; García-Gimeno, María Adelaida/0000-0002-6483-3912; Sanz, Pascual/0000-0002-2399-4103; Arino Carmona, Joaquin/0000-0002-0390-4270; Munoz Munoz, Ivan/0000-0002-1606-5445				Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andrews PD, 2000, J CELL SCI, V113, P507; Arino J, 1998, METH MOL B, V93, P305; Arino J, 2002, EUR J BIOCHEM, V269, P1072, DOI 10.1046/j.0014-2956.2002.02753.x; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; CANNON JF, 1994, GENETICS, V136, P485; Chang JS, 2002, J BIOL CHEM, V277, P48002, DOI 10.1074/jbc.M208471200; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Clotet J, 1999, MOL CELL BIOL, V19, P2408; Clotet J, 1996, J BIOL CHEM, V271, P26349, DOI 10.1074/jbc.271.42.26349; CLOTET J, 1991, CURR GENET, V19, P339, DOI 10.1007/BF00309593; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; de la Torre-Ruiz MA, 2002, J BIOL CHEM, V277, P33468, DOI 10.1074/jbc.M203515200; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; Dignam SS, 1998, ARCH BIOCHEM BIOPHYS, V357, P58, DOI 10.1006/abbi.1998.0780; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARDY TA, 1993, J BIOL CHEM, V268, P23799; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; Nigavekar SS, 2002, ARCH BIOCHEM BIOPHYS, V404, P71, DOI 10.1016/S0003-9861(02)00231-X; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Peggie MW, 2002, J CELL SCI, V115, P195; PENG ZY, 1990, J BIOL CHEM, V265, P13871; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Ramaswamy NT, 1998, GENETICS, V149, P57; ROSE MD, 1990, METHODS YEAST GENETI, P164; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; Simon E, 2001, J BIOL CHEM, V276, P29740, DOI 10.1074/jbc.M101992200; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; Tachikawa H, 2001, J CELL BIOL, V155, P797, DOI 10.1083/jcb.200107008; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; Venturi GM, 2000, GENETICS, V155, P69; Vissi E, 2001, YEAST, V18, P115, DOI 10.1002/1097-0061(20010130)18:2<115::AID-YEA653>3.0.CO;2-G; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wakula P, 2003, J BIOL CHEM, V278, P18817, DOI 10.1074/jbc.M300175200; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Williams-Hart T, 2002, GENETICS, V160, P1423; Yenush L, 2002, EMBO J, V21, P920, DOI 10.1093/emboj/21.5.920; Zhang J, 1998, BIOCHEMISTRY-US, V37, P16728, DOI 10.1021/bi981169g; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368; Zheng JH, 2000, J BIOL CHEM, V275, P18070, DOI 10.1074/jbc.M000918200; Zolnierowicz Stanislaw, 2000, EMBO (European Molecular Biology Organization) Journal, V19, P483, DOI 10.1093/emboj/19.4.483	65	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47744	47752		10.1074/jbc.M306157200	http://dx.doi.org/10.1074/jbc.M306157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506263	hybrid			2022-12-25	WOS:000186731400050
J	Rappoport, JZ; Taha, BW; Lemeer, S; Benmerah, A; Simon, SM				Rappoport, JZ; Taha, BW; Lemeer, S; Benmerah, A; Simon, SM			The AP-2 complex is excluded from the dynamic population of plasma membrane-associated clathrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL-REFLECTION FLUORESCENCE; COATED PITS; MEDIATED ENDOCYTOSIS; TYROSINE KINASE; LIVING CELLS; PROTEIN; RECEPTORS; RECRUITMENT; CYTOSKELETON; MICROSCOPY	Numerous biologically relevant substrates are selectively internalized via clathrin-mediated endocytosis. At the plasma membrane the AP-2 complex plays a major role in clathrin coat formation, interacting with both cargo and clathrin. Utilizing simultaneous dual-channel total internal reflection fluorescence microscopy we have analyzed components of the AP-2 complex (alpha- and beta2-adaptin) during clathrin-mediated endocytosis. Although in static images enhanced green fluorescent protein-tagged AP-2 markers significantly co-localized with clathrin and other components of clathrin-coated pits, AP-2 did not seem to be present in clathrin spots that appeared to undergo internalization or motility parallel to the plane of the plasma membrane. Two populations of clathrin at the plasma membrane seem to exist, the dynamic and the static, and AP-2 appears to be only found within the latter. These results suggest that colocalized clathrin/AP-2 puncta may represent loci for coated pit production and that previous models that assumed AP-2 was retained within clathrin coats during endocytosis may need to be re-evaluated.	Rockefeller Univ, Lab Cellular Biophys, New York, NY 10021 USA; Univ Paris 05, CNRS, UMR 8104,INSERM,U567, Inst Cochin,Dept Infect Dis, F-75014 Paris, France	Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Simon, SM (corresponding author), Rockefeller Univ, Lab Cellular Biophys, 1230 York Ave,Box 304, New York, NY 10021 USA.	simon@rockefeller.edu	benmerah, alexandre/H-3742-2017; Lemeer, Simone/I-4363-2016	benmerah, alexandre/0000-0003-0188-8016; Simon, Sanford/0000-0002-8615-4224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM069200] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM069200-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Conrad ME, 1999, AM J MED SCI, V318, P213, DOI 10.1097/00000441-199910000-00002; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; HOPKINS CR, 1985, J CELL SCI, P173; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Licht SS, 2003, BIOCHEMISTRY-US, V42, P2916, DOI 10.1021/bi026059v; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; Rappoport JZ, 2003, TRAFFIC, V4, P460, DOI 10.1034/j.1600-0854.2003.00100.x; Rappoport JZ, 2003, J CELL SCI, V116, P847, DOI 10.1242/jcs.00289; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schmoranzer J, 2000, J CELL BIOL, V149, P23, DOI 10.1083/jcb.149.1.23; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sorkina T, 2002, J BIOL CHEM, V277, P27433, DOI 10.1074/jbc.M201595200; STEER CJ, 1982, J BIOL CHEM, V257, P8533; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353	33	57	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47357	47360		10.1074/jbc.C300390200	http://dx.doi.org/10.1074/jbc.C300390200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14530274	hybrid			2022-12-25	WOS:000186731400002
J	Wang, Q; Pfeiffer, GR; Gaarde, WA				Wang, Q; Pfeiffer, GR; Gaarde, WA			Activation of SRC tyrosine kinases in response to ICAM-1 ligation in pulmonary microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; EPIDERMAL-GROWTH-FACTOR; PHOSPHATASE 1B; C-SRC; BIOMECHANICAL PROPERTIES; PHOSPHORYLATION; P38; EXPRESSION; CORTACTIN; EZRIN	Previous studies demonstrated that ICAM-1 ligation on human pulmonary microvascular endothelial cells (ECs) sequentially induces activation of xanthine oxidase and p38 MAPK. Inhibition of these signaling events reduces neutrophil migration to the EC borders. This study examined the role of SRC tyrosine kinases in ICAM-1-initiated signaling within these ECs. Cross-linking ICAM-1 on tumor necrosis factor-alpha-pretreated ECs induced an increase in the activity of SRC tyrosine kinases. This increase was inhibited by allopurinol (a xanthine oxidase inhibitor), Me2SO (a hydroxyl radical scavenger), or deferoxamine (an iron chelator). Phenylarsine oxide, a tyrosine phosphatase inhibitor, reduced the base-line activity of SRC as well as the increase in SRC activity induced by ICAM-1 cross-linking. Specific inhibition of the protein expression of the SRC homology 2-containing protein-tyrosine phosphatase-2 (SHP-2) by an antisense oligonucleotide prevented the induced SRC activation but had no effect on the basal SRC activity. Activation of SRC tyrosine kinases was accompanied by tyrosine phosphorylation of ezrin at Tyr-146, which was inhibited by PP2, an SRC tyrosine kinase inhibitor. Moreover, PP2 completely inhibited p38 activation, suggesting a role for SRC tyrosine kinases in p38 activation. These data demonstrate that ICAM-1 ligation activates SRC tyrosine kinases and that this activation requires SHP-2 as well as production of reactive oxygen species generated from xanthine oxidase. Activation of SRC tyrosine kinases in turn leads to tyrosine phosphorylation of ezrin, as well as activation of p38, a kinase previously identified to be required for cytoskeletal changes induced by ICAM-1 ligation and for neutrophil migration along the EC surface.	Rainbow Babies & Childrens Hosp, Dept Pediat, Div Integrat Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Isis Pharmaceuticals Inc	Wang, Q (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, Div Integrat Biol, Rm 787,11100 Euclid Ave, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL07009, HL48160] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048160, R01HL048160] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; Autero M, 2003, FEBS LETT, V535, P82, DOI 10.1016/S0014-5793(02)03861-9; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Blaber R, 2003, J AM SOC NEPHROL, V14, P116, DOI 10.1097/01.ASN.0000040595.35207.62; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Egan C, 1999, ONCOGENE, V18, P1227, DOI 10.1038/sj.onc.1202233; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Holland J, 1997, J BIOL CHEM, V272, P9108; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; PENG ZY, 1995, ONCOGENE, V11, P1955; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; Sans E, 2001, J IMMUNOL, V166, P544, DOI 10.4049/jimmunol.166.1.544; Serrador JM, 2002, J BIOL CHEM, V277, P10400, DOI 10.1074/jbc.M110694200; Shaw AS, 2001, IMMUNITY, V15, P683, DOI 10.1016/S1074-7613(01)00237-0; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Tilghman RW, 2002, FASEB J, V16, P1257, DOI 10.1096/fj.01-0969fje; Tilghman RW, 2002, FEBS LETT, V525, P83, DOI 10.1016/S0014-5793(02)03070-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Wang Q, 2000, J IMMUNOL, V164, P6487, DOI 10.4049/jimmunol.164.12.6487; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Wang Q, 2001, BLOOD, V97, P660, DOI 10.1182/blood.V97.3.660; Wu YX, 2000, J CELL BIOCHEM, V79, P311, DOI 10.1002/1097-4644(20001101)79:2<311::AID-JCB140>3.0.CO;2-Z; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	48	63	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47731	47743		10.1074/jbc.M308466200	http://dx.doi.org/10.1074/jbc.M308466200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504278	hybrid			2022-12-25	WOS:000186731400049
J	Stijlemans, B; Conrath, K; Cortez-Retamozo, V; Van Xong, H; Wyns, L; Senter, P; Revets, H; De Baetselier, P; Muyldermans, S; Magez, S				Stijlemans, B; Conrath, K; Cortez-Retamozo, V; Van Xong, H; Wyns, L; Senter, P; Revets, H; De Baetselier, P; Muyldermans, S; Magez, S			Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies - African trypanosomes as paradigm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; PROTEIN-PROTEIN INTERACTIONS; HEAVY-CHAIN ANTIBODIES; BETA-LACTAMASE; ANTIGENIC VARIATION; ENTEROBACTER-CLOACAE; FLAGELLAR ADHESION; MEMBRANE ANCHOR; IN-VIVO; BRUCEI	Antigen variation is a successful defense system adopted by several infectious agents to evade the host immune response. The principle of this defense strategy in the African trypanosome paradigm involves a dense packing of variant surface glycoproteins (VSG) exposing only highly variable and immuno-dominant epitopes to the immune system, whereas conserved epitopes become inaccessible for large molecules. Reducing the size of binders that target the conserved, less-immunogenic, cryptic VSG epitopes forms an obvious solution to combat these parasites. This goal was achieved by introducing dromedary Heavy-chain antibodies. We found that only these unique antibodies recognize epitopes common to multiple VSG classes. After phage display of their antigen-binding repertoire, we isolated a single domain antibody fragment with high specificity for the conserved Asn-linked carbohydrate of VSG. In sharp contrast to labeled concanavalin-A that stains only the flagellar pocket where carbohydrates are accessible because of less dense VSG packing, the single domain binder stains the entire surface of viable parasites, irrespective of the VSG type expressed. This corroborates the idea that small antibody fragments, but not larger lectins or conventional antibody fragments, are able to penetrate the dense VSG coat to target their epitope. The diagnostic potential of this fluorescently labeled binder was proven by the direct, selective, and sensitive detection of parasites in blood smears. The employment of this binder as a molecular recognition unit in immunotoxins designed for trypanosomosis therapy becomes feasible as well. This was illustrated by the specific trypanolysis induced by an antibody:: beta-lactamase fusion activating a prodrug.	Free Univ Brussels VIB, Dept Cellular & Mol Interact, B-1050 Brussels, Belgium; Seattle Genet, Bothell, WA 98021 USA	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Seattle Genetics	Muyldermans, S (corresponding author), Free Univ Brussels VIB, Dept Cellular & Mol Interact, Pleinlaan 2, B-1050 Brussels, Belgium.	svmuylde@vub.ac.be	De Baetselier, Patrick/D-3866-2014; Magez, Stefan/AAC-5682-2021; Muyldermans, Serge/AAC-7374-2019; Stijlemans, Benoit/AAD-9122-2021; Magez, Stefan/D-9497-2014; Muyldermans, Serge V/C-6418-2016	Magez, Stefan/0000-0003-3760-7968; Muyldermans, Serge/0000-0002-3678-3575; Stijlemans, Benoit/0000-0003-0082-9751; Magez, Stefan/0000-0003-3760-7968; Muyldermans, Serge V/0000-0002-3678-3575				BANGS JD, 1988, J BIOL CHEM, V263, P17697; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BERGOGNEBEREZIN E, 1994, PRESSE MED, V23, P1376; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; CARROLL M, 1987, COMP BIOCHEM PHYS B, V88, P7, DOI 10.1016/0305-0491(87)90069-1; CLARKE MW, 1987, MOL IMMUNOL, V24, P707, DOI 10.1016/0161-5890(87)90052-6; Conrath KE, 2001, ANTIMICROB AGENTS CH, V45, P2807, DOI 10.1128/AAC.45.10.2807-2812.2001; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2002, J BIOL CHEM, V277, P23645, DOI 10.1074/jbc.M202327200; Desquesnes M, 1996, Rev Elev Med Vet Pays Trop, V49, P322; Donelson JE, 1998, MOL BIOCHEM PARASIT, V91, P51, DOI 10.1016/S0166-6851(97)00209-0; FREEMAN DA, 1975, STAIN TECHNOL, V50, P279, DOI 10.3109/10520297509117071; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; GRAHAM MN, 1989, BIOCHEM J, V260, P705, DOI 10.1042/bj2600705; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; Magez S, 2001, J BIOL CHEM, V276, P33458, DOI 10.1074/jbc.M103412200; Mehlert A, 1998, MOL BIOCHEM PARASIT, V91, P145, DOI 10.1016/S0166-6851(97)00187-4; MILLER EN, 1984, MOL BIOCHEM PARASIT, V13, P67, DOI 10.1016/0166-6851(84)90102-6; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Radwanska M, 2002, J CLIN MICROBIOL, V40, P4295, DOI 10.1128/JCM.40.11.4295-4297.2002; REINITZ DM, 1992, MOL BIOCHEM PARASIT, V51, P119, DOI 10.1016/0166-6851(92)90207-Z; RICHARDS FF, 1984, J PROTOZOOL, V31, P60, DOI 10.1111/j.1550-7408.1984.tb04290.x; Staalsoe T, 2002, J INFECT DIS, V186, P719, DOI 10.1086/342390; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; VICKERMAN K, 1969, J CELL SCI, V5, P163; VRUDHULA VM, 1993, BIOCONJUGATE CHEM, V4, P334, DOI 10.1021/bc00023a005; Wang HR, 2002, J MOL EVOL, V54, P465, DOI 10.1007/s00239-001-0037-6; Wehrman T, 2002, P NATL ACAD SCI USA, V99, P3469, DOI 10.1073/pnas.062043699; Wouters J, 2001, ACTA CRYSTALLOGR D, V57, P162, DOI 10.1107/S0907444900016413	43	214	289	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1256	1261		10.1074/jbc.M307341200	http://dx.doi.org/10.1074/jbc.M307341200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14527957	hybrid			2022-12-25	WOS:000187722800051
J	Vishnivetskiy, SA; Hosey, MM; Benovic, JL; Gurevich, VV				Vishnivetskiy, SA; Hosey, MM; Benovic, JL; Gurevich, VV			Mapping the arrestin-receptor interface - Structural elements responsible for receptor specificity of arrestin proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT CHANGES; INDUCED CONFORMATIONAL-CHANGES; CYSTEINE SUBSTITUTION MUTANTS; 3RD INTRACELLULAR LOOP; VISUAL ARRESTIN; CRYSTAL-STRUCTURE; BETA-ARRESTIN; CYTOPLASMIC END; TRANSDUCIN ACTIVATION; SULFHYDRYL REACTIVITY	Arrestins selectively bind to phosphorylated activated forms of their cognate G protein-coupled receptors. Arrestin binding prevents further G protein activation and often redirects signaling to other pathways. The comparison of the high-resolution crystal structures of arrestin2, visual arrestin, and rhodopsin as well as earlier mutagenesis and peptide inhibition data collectively suggest that the elements on the concave sides of both arrestin domains most likely participate in receptor binding directly, thereby dictating its receptor preference. Using comparative binding of visual arrestin/arrestin2 chimeras to the preferred target of visual arrestin, light-activated phosphorylated rhodopsin (P-Rh*), and to the arrestin2 target, phosphorylated activated m2 muscarinic receptor (P-m2 mAChR*), we identified the elements that determine the receptor specificity of arrestins. We found that residues 49 - 90 (beta-strands V and VI and adjacent loops in the N-domain) and 237 - 268 (beta-strands XV and XVI in the C-domain) in visual arrestin and homologous regions in arrestin2 are largely responsible for their receptor preference. Only 35 amino acids ( 22 of which are nonconservative substitutions) in the two elements are different. Simultaneous exchange of both elements between visual arrestin and arrestin2 fully reverses their receptor specificity, demonstrating that these two elements in the two domains of arrestin are necessary and sufficient to determine their preferred receptor targets.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Vanderbilt University; Northwestern University; Jefferson University	Gurevich, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.	Vsevolod.Gurevich@mcmail.vanderbilt.edu	Vishnivetskiy, Sergey/AAJ-8661-2020; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351; Hosey, Marie Therese/0000-0003-1178-4106	NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM63097, GM47417, GM44944] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R01GM063097, R01GM047417, R37GM047417] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7931, DOI 10.1021/bi9900121; Altenbach C, 1999, BIOCHEMISTRY-US, V38, P7945, DOI 10.1021/bi990014l; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Cai K, 1999, BIOCHEMISTRY-US, V38, P12893, DOI 10.1021/bi9912443; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Kishi H, 2002, J BIOL CHEM, V277, P21939, DOI 10.1074/jbc.M110894200; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; Kobilka BK, 2002, METHOD ENZYMOL, V343, P170; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krishnamurthy H, 2003, MOL CELL ENDOCRINOL, V204, P127, DOI 10.1016/S0303-7207(03)00088-1; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Langen R, 1999, BIOCHEMISTRY-US, V38, P7918, DOI 10.1021/bi990010g; Lee KB, 2000, J BIOL CHEM, V275, P35767, DOI 10.1074/jbc.M002225200; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2002, J CELL SCI, V115, P455; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200; Shilton BH, 2002, EUR J BIOCHEM, V269, P3801, DOI 10.1046/j.1432-1033.2002.03071.x; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; Smith WC, 2000, INVEST OPHTH VIS SCI, V41, P2445; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836	55	103	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1262	1268		10.1074/jbc.M308834200	http://dx.doi.org/10.1074/jbc.M308834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14530255	hybrid			2022-12-25	WOS:000187722800052
J	Speidel, D; Varoqueaux, F; Enk, C; Nojiri, M; Grishanin, RN; Martin, TFJ; Hofmann, K; Brose, N; Reim, K				Speidel, D; Varoqueaux, F; Enk, C; Nojiri, M; Grishanin, RN; Martin, TFJ; Hofmann, K; Brose, N; Reim, K			A family of Ca2+-dependent activator proteins for secretion - Comparative analysis of structure, expression, localization, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE VESICLE EXOCYTOSIS; PLASMA-MEMBRANE; CAPS; FUSION; BRAIN; CLEAVAGE; SYNTAXIN; CALCIUM; UNC-13	Ca2+-dependent activator protein for secretion (CAPS) 1 is an essential cytosolic component of the protein machinery involved in large dense-core vesicle (LDCV) exocytosis and in the secretion of a subset of neurotransmitters. In the present study, we report the identification, cloning, and comparative characterization of a second mammalian CAPS isoform, CAPS2. The structure of CAPS2 and its function in LDCV exocytosis from PC12 cells are very similar to those of CAPS1. Both isoforms are strongly expressed in neuroendocrine cells and in the brain. In subcellular fractions of the brain, both CAPS isoforms are enriched in synaptic cytosol fractions and also present on vesicular fractions. In contrast to CAPS1, which is expressed almost exclusively in brain and neuroendocrine tissues, CAPS2 is also expressed in lung, liver, and testis. Within the brain, CAPS2 expression seems to be restricted to certain brain regions and cell populations, whereas CAPS1 expression is strong in all neurons. During development, CAPS2 expression is constant between embryonic day 10 and postnatal day 60, whereas CAPS1 expression is very low before birth and increases after postnatal day 0 to reach a plateau at postnatal day 21. Light microscopic data indicate that both CAPS isoforms are specifically enriched in synaptic terminals. Ultrastructural analyses show that CAPS1 is specifically localized to glutamatergic nerve terminals. We conclude that at the functional level, CAPS2 is largely redundant with CAPS1. Differences in the spatial and temporal expression patterns of the two CAPS isoforms most likely reflect as yet unidentified subtle functional differences required in particular cell types or during a particular developmental period. The abundance of CAPS proteins in synaptic terminals indicates that they may also be important for neuronal functions that are not exclusively related to LDCV exocytosis.	Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; Deutsch Forschungsgemeinsch Ctr Mol Physiol Brain, D-37075 Gottingen, Germany; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; MEMOREC Stoffel GmbH, Bioinformat Grp, D-50829 Cologne, Germany	Max Planck Society; University of Wisconsin System; University of Wisconsin Madison	Reim, K (corresponding author), Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Varoqueaux, Frederique/AAC-1834-2021; Hofmann, Kay/D-6714-2011	Varoqueaux, Frederique/0000-0002-3614-3121; Hofmann, Kay/0000-0002-2289-9083	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Avery Leon, 1993, Genetics, V134, P455; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BEAN AJ, 1994, FASEB J, V8, P630, DOI 10.1096/fasebj.8.9.8005390; Berwin B, 1998, NEURON, V21, P137, DOI 10.1016/S0896-6273(00)80521-8; Betz A, 1997, J BIOL CHEM, V272, P2520; Brandstatter JH, 1996, J COMP NEUROL, V370, P1, DOI 10.1002/(SICI)1096-9861(19960617)370:1<1::AID-CNE1>3.0.CO;2-7; BROSE N, 1993, J BIOL CHEM, V268, P22663; Cisternas FA, 2003, GENOMICS, V81, P279, DOI 10.1016/S0888-7543(02)00040-X; Elhamdani A, 1999, J NEUROSCI, V19, P7375, DOI 10.1523/JNEUROSCI.19-17-07375.1999; Garner CC, 2002, TRENDS NEUROSCI, V25, P243, DOI 10.1016/S0166-2236(02)02152-5; Grishanin RN, 2002, J BIOL CHEM, V277, P22025, DOI 10.1074/jbc.M201614200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLMSTEDT JB, 1987, METHOD ENZYMOL, V137, P467; Renden R, 2001, NEURON, V31, P421, DOI 10.1016/S0896-6273(01)00382-8; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rupnik M, 2000, P NATL ACAD SCI USA, V97, P5627, DOI 10.1073/pnas.090359097; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tandon A, 1998, NEURON, V21, P147, DOI 10.1016/S0896-6273(00)80522-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	28	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52802	52809		10.1074/jbc.M304727200	http://dx.doi.org/10.1074/jbc.M304727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14530279	hybrid			2022-12-25	WOS:000187480700099
J	Fromme, JC; Verdine, GL				Fromme, JC; Verdine, GL			DNA lesion recognition by the bacterial repair enzyme MutM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVELY DAMAGED DNA; COLI ENDONUCLEASE-VIII; ESCHERICHIA-COLI; FPG PROTEIN; CRYSTAL-STRUCTURE; SUBSTRATE RECOGNITION; AMINO-ACID; GLYCOSYLASE; 8-OXOGUANINE; 7,8-DIHYDRO-8-OXOGUANINE	MutM is a bacterial DNA glycosylase that removes the mutagenic lesion 8-oxoguanine (oxoG) from duplex DNA. The means of oxoG recognition by MutM (also known as Fpg) is of fundamental interest, in light of the vast excess of normal guanine bases present in genomic DNA. The crystal structure of a recognition-competent but catalytically inactive version of MutM in complex with oxoG-containing DNA reveals the structural basis for recognition. MutM binds the oxoG nucleoside in the syn glycosidic configuration and distinguishes oxoG from guanine by reading out the protonation state of the N7 atom. The segment of MutM principally responsible for oxoG recognition is a flexible loop, suggesting that conformational mobility influences lesion recognition and catalysis. Furthermore, the structure of MutM in complex with DNA containing an alternative substrate, dihydrouracil, demonstrates how MutM is able to recognize lesions other than oxoG.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University; Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 12 Oxford St, Cambridge, MA 02138 USA.			Fromme, J. Christopher/0000-0002-8837-0473	NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bhagwat M, 1996, BIOCHEMISTRY-US, V35, P659, DOI 10.1021/bi9522662; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; Fowler RG, 2003, DNA REPAIR, V2, P159, DOI 10.1016/S1568-7864(02)00193-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P157; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 2003, CARCINOGENESIS, V24, P155, DOI 10.1093/carcin/24.2.155; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Lavrukhin OV, 2000, BIOCHEMISTRY-US, V39, P15266, DOI 10.1021/bi001587x; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Norman DPG, 2003, BIOCHEMISTRY-US, V42, P1564, DOI 10.1021/bi026823d; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; O'Connor T R, 1989, Ann Ist Super Sanita, V25, P27; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Serre L, 2002, EMBO J, V21, P2854, DOI 10.1093/emboj/cdf304; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; UESUGI S, 1977, J AM CHEM SOC, V99, P3250, DOI 10.1021/ja00452a008; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	44	162	164	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51543	51548		10.1074/jbc.M307768200	http://dx.doi.org/10.1074/jbc.M307768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525999	hybrid, Green Published			2022-12-25	WOS:000187206300086
J	Murata, H; Ihara, Y; Nakamura, H; Yodoi, J; Sumikawa, K; Kondo, T				Murata, H; Ihara, Y; Nakamura, H; Yodoi, J; Sumikawa, K; Kondo, T			Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC OXIDATIVE STRESS; GLYCOGEN-SYNTHASE KINASE-3; DISULFIDE BOND FORMATION; PROTEIN PHOSPHATASE 2A; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; MUSCLE-CELLS; ACTIVATION; THIOLTRANSFERASE	Glutaredoxin (GRX) is a small dithiol protein involved in various cellular functions, including the redox regulation of certain enzyme activities. GRX functions via a disulfide exchange reaction by utilizing the active site Cys-Pro-Tyr-Cys. Here we demonstrated that overexpression of GRX protected cells from hydrogen peroxide (H2O2)-induced apoptosis by regulating the redox state of Akt. Akt was transiently phosphorylated, dephosphorylated, and then degraded in cardiac H9c2 cells undergoing H2O2-induced apoptosis. Under stress, Akt underwent disulfide bond formation between Cys-297 and Cys-311 and dephosphorylation in accordance with an increased association with protein phosphatase 2A. Overexpression of GRX protected Akt from H2O2-induced oxidation and suppressed recruitment of protein phosphatase 2A to Akt, resulting in a sustained phosphorylation of Akt and inhibition of apoptosis. This effect was reversed by cadmium, an inhibitor of GRX. Furthermore an in vitro assay revealed that GRX reduced oxidized Akt in concert with glutathione, NADPH, and glutathione-disulfide reductase. Thus, GRX plays an important role in protecting cells from apoptosis by regulating the redox state of Akt.	Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Anesthesiol, Nagasaki 8528523, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan	Nagasaki University; Nagasaki University; Kyoto University	Ihara, Y (corresponding author), Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.		Murata, Hiroaki/AAA-8374-2020; Yodoi, Junji/F-6189-2011	Murata, Hiroaki/0000-0002-6185-5059; Yodoi, Junji/0000-0001-6849-4914				Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BJONSTEDT M, 1994, J BIOL CHEM, V269, P29382; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; DEGROOT RP, 1993, ONCOGENE, V8, P841; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GAN ZR, 1986, J BIOL CHEM, V261, P996; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Gostick DO, 1998, MICROBIOL-SGM, V144, P705, DOI 10.1099/00221287-144-3-705; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kang JG, 1999, EMBO J, V18, P4292, DOI 10.1093/emboj/18.15.4292; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Krysan K, 2002, INVEST OPHTH VIS SCI, V43, P1876; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura T, 1999, FREE RADICAL RES, V31, P357, DOI 10.1080/10715769900300931; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Pham FH, 2000, CIRC RES, V86, P1252, DOI 10.1161/01.RES.86.12.1252; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Song JJ, 2003, BIOCHEM J, V373, P845, DOI 10.1042/BJ20030275; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Takagi Y, 1999, BIOCHEM BIOPH RES CO, V258, P390, DOI 10.1006/bbrc.1999.0646; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	44	226	233	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50226	50233		10.1074/jbc.M310171200	http://dx.doi.org/10.1074/jbc.M310171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522978	hybrid			2022-12-25	WOS:000187068200070
J	Oshiumi, H; Sasai, M; Shida, K; Fujita, T; Matsumoto, M; Seya, T				Oshiumi, H; Sasai, M; Shida, K; Fujita, T; Matsumoto, M; Seya, T			TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to Toll-like receptor 4 TICAM-1 that induces interferon-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; DOUBLE-STRANDED-RNA; NF-KAPPA-B; DOMAIN-CONTAINING ADAPTER; BACILLUS-CALMETTE-GUERIN; SIGNAL-TRANSDUCTION; ANTIVIRAL RESPONSE; VIRUS-INFECTION; CELL ACTIVATION; DENDRITIC CELLS	Lipopolysaccharide (LPS) is an agonist for Toll-like receptor (TLR) 4 and expresses many genes including NF-kappaB- and interferon regulatory factor (IRF)-3/IFN-inducible genes in macrophages and dendritic cells (DCs). TICAM-1/TRIF was identified as an adapter that facilitates activation of IRF-3 followed by expression of interferon (IFN)-beta genes in TLR3 signaling, but TICAM-1 does not directly bind TLR4. Although MyD88 and Mal/TIRAP adapters functions downstream of TLR4, DC maturation and IFN-beta induction are independent of MyD88 and Mal/ TIRAP. In this investigation, we report the identification of a novel adapter, TICAM-2, that physically bridges TLR4 and TICAM-1 and functionally transmits LPS-TLR4 signaling to TICAM-1, which in turn activates IRF-3. In its structural features, TICAM-2 resembled Mal/ TIRAP, an adapter that links TLR2/4 and MyD88. However, TICAM-2 per se exhibited minimal ability to activate NF-kappaB and the IFN-beta promoter. Hence, in LPS signaling TLR4 recruits two types of adapters, TIRAP and TICAM-2, to its cytoplasmic domain that are indirectly connected to two effective adapters, MyD88 and TICAM-1, respectively. We conclude that for LPS-TLR4-mediated activation of IFN-beta, the adapter complex of TICAM-2 and TICAM-1 plays a crucial role. This results in the construction of MyD88-dependent and - independent pathways separately downstream of the two distinct adapters.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Nara Inst Sci & Technol, Dept Mol Immunol, Nara 6310101, Japan; Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1000013, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Nara Institute of Science & Technology; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST)	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, 1-3-2 Nakamichi, Osaka 5378511, Japan.		Seya, Tsukasa/A-4336-2012; Oshiumi, Hiroyuki/G-1645-2012; 美佐子, 松本/A-4497-2012	Oshiumi, Hiroyuki/0000-0003-1567-8722; Sasai, Miwa/0000-0001-6440-3958				Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BEGUM NA, 2004, IN PRESS INFECT IMMU; Bin LH, 2003, J BIOL CHEM, V278, P24526, DOI 10.1074/jbc.M303451200; Doyle SE, 2003, J IMMUNOL, V170, P3565, DOI 10.4049/jimmunol.170.7.3565; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fuku A, 2001, J BIOL CHEM, V276, P47143, DOI 10.1074/jbc.M103902200; Hardiman G, 1996, ONCOGENE, V13, P2467; Hirano A, 2002, J BIOCHEM, V132, P83, DOI 10.1093/oxfordjournals.jbchem.a003203; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; James P, 1996, GENETICS, V144, P1425; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kaiser P, 2000, MICROBIOL-UK, V146, P3217, DOI 10.1099/00221287-146-12-3217; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KAWAMURA I, 2002, P JPN SOC IMMUNOL, V32, P123; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Oshiumi H, 2003, IMMUNOGENETICS, V54, P791, DOI 10.1007/s00251-002-0519-8; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; SEYA T, 2003, IN PRESS ANTICANCER, V23; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SHERMAN F, 1986, METHODS YEAST GENETI, P22; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	55	303	327	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49751	49762		10.1074/jbc.M305820200	http://dx.doi.org/10.1074/jbc.M305820200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14519765	hybrid			2022-12-25	WOS:000187068200015
J	Sharon, R; Bar-Joseph, I; Mirick, GE; Serhan, CN; Selkoe, DJ				Sharon, R; Bar-Joseph, I; Mirick, GE; Serhan, CN; Selkoe, DJ			Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT FRONTAL-CORTEX; PARKINSONS-DISEASE; SEROTONINERGIC NEUROTRANSMISSION; HYDROGEN-PEROXIDE; AGGREGATION; MEMBRANE; MUTATIONS; PROTEASOME; INDUCTION; RESPONSES	alpha-Synuclein (alphaS) is an abundant neuronal protein that accumulates in insoluble inclusions in Parkinson's disease (PD) and the related disorder, dementia with Lewy bodies (DLB). A central question about the role of alphaS in the pathogenesis of PD and DLB concerns how this normally soluble protein assembles into insoluble aggregates associated with neuronal dysfunction. We recently detected highly soluble oligomers of alphaS in normal brain supernatants and observed their augmentation in PD and DLB brains. Further, we found that polyunsaturated fatty acids (PUFAs) enhanced alphaS oligomerization in intact mesencephalic neuronal cells. We now report the presence of elevated PUFA levels in PD and DLB brain soluble fractions. Higher PUFA levels were also detected in the supernatants and high-speed membrane fractions of neuronal cells over-expressing wild-type or PD-causing mutant alphaS. This increased PUFA content in the membrane fraction was accompanied by increased membrane fluidity in the alphaS overexpressing neurons. In accord, membrane fluidity and the levels of certain PUFAs were decreased in the brains of mice genetically deleted of alphaS. Together with our earlier observations, these results suggest that alphaS-PUFA interactions help regulate neuronal PUFA levels as well as the oligomerization state of alphaS, both normally and in human synucleinopathies.	Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Anaesthesiol, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, 77 Ave Louis Pasteur,HIM 730, Boston, MA 02115 USA.	dselkoe@rics.bwh.harvard.edu						BRAUNBECK T, 1991, ECOTOX ENVIRON SAFE, V21, P109, DOI 10.1016/0147-6513(91)90014-G; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chalon S, 1998, J NUTR, V128, P2512, DOI 10.1093/jn/128.12.2512; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Delion S, 1996, J NEUROCHEM, V66, P1582; DELION S, 1994, J NUTR, V124, P2466, DOI 10.1093/jn/124.12.2466; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell B, 2000, FREE RADICALS BIOL M; JENNER P, 1991, ACTA NEUROL SCAND, V84, P6, DOI 10.1111/j.1600-0404.1991.tb05013.x; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kim KS, 2002, FREE RADICAL BIO MED, V32, P544, DOI 10.1016/S0891-5849(02)00741-4; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; MCMURCHIE EJ, 1998, PHYSIOL REGULATION M; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; Mostofsky DI, 2001, FATTY ACIDS PHYSL BE; MOURITSEN OG, 1993, ANNU REV BIOPH BIOM, V22, P145, DOI 10.1146/annurev.bb.22.060193.001045; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; OWENS SP, 1998, J NUTR, V129; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Poschl JMB, 1999, LIPIDS, V34, P467, DOI 10.1007/s11745-999-0386-4; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; STUBBS CD, 1990, BIOCHEM SOC T, V18, P779, DOI 10.1042/bst0180779; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Williams EE, 2000, MOL MEMBR BIOL, V17, P157; Yehuda S, 2002, NEUROBIOL AGING, V23, P843, DOI 10.1016/S0197-4580(02)00074-X; Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7; Zimmer L, 2000, J LIPID RES, V41, P32; Zimmer L, 2000, NEUROSCI LETT, V284, P25, DOI 10.1016/S0304-3940(00)00950-2	44	139	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49874	49881		10.1074/jbc.M309127200	http://dx.doi.org/10.1074/jbc.M309127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14507911	hybrid			2022-12-25	WOS:000187068200029
J	Naro, F; De Arcangelis, V; Sette, C; Ambrosio, C; Komati, H; Molinaro, M; Adamo, S; Nemoz, G				Naro, F; De Arcangelis, V; Sette, C; Ambrosio, C; Komati, H; Molinaro, M; Adamo, S; Nemoz, G			A bimodal modulation of the cAMP pathway is involved in the control of myogenic differentiation in L6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SKELETAL-MUSCLE CELLS; CYCLIC-AMP; SMOOTH-MUSCLE; INDEPENDENT PATHWAYS; ADENYLATE-CYCLASE; VASOPRESSIN; PHOSPHODIESTERASE; TRANSDUCTION; EXPRESSION	We have previously shown that myogenesis induction by Arg(8)-vasopressin (AVP) in L6 rat myoblasts involves a sustained stimulation of type 4 cAMP-phosphodiesterase. In this model, we observed that a transient cAMP generation occurs in the minutes following AVP addition. Evidence suggests that cAMP generation is due to the prostaglandins produced in response to AVP binding to V1a receptors and subsequent activation of phospholipase A2. The early cAMP increase was effective in activating cAMP-dependent protein kinase (PKA) and increasing phosphorylation of CREB transcription factor. Inhibition of PKA by compound H89 prior to AVP addition led to a significant reduction of expression of the differentiation marker creatine kinase, whereas H89 added 1 - 5 h after AVP had no significant effect. Furthermore, PKA inhibition 24 h after the beginning of AVP treatment potentiated differentiation. This shows that both an early activation and a later down-regulation of the cAMP pathway are required for AVP induction of myogenesis. Because phosphodiesterase PDE4D3 overexpressed in L6 cells lost its ability to potentiate AVP-induced differentiation when mutated and rendered insensitive to PKA phosphorylation and activation, we hypothesize that the early cAMP increase is required to trigger the down-regulation of cAMP pathway through stimulation of phosphodiesterase.	Univ Roma La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy; Inst Natl Sci Appl, INSERM, U585, F-69621 Villeurbanne, France; Univ Roma Tor Vergata, Sez Anat, Dipartimento Sanita Pubbl & Biol Cellulare, I-00173 Rome, Italy; Ist Super Sanita, Dipartimento Farmacol, I-00161 Rome, Italy	Sapienza University Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS)	Naro, F (corresponding author), Univ Roma La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy.		Adamo, Sergio/E-9058-2012; ambrosio, caterina/M-7952-2017	Adamo, Sergio/0000-0002-1409-0452; Sette, Claudio/0000-0003-2864-8266; ambrosio, caterina/0000-0002-0807-9003				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; Chen WC, 1999, ENDOCRINOLOGY, V140, P1639, DOI 10.1210/en.140.4.1639; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Arcangelis V, 2003, MOL BIOL CELL, V14, P1392, DOI 10.1091/mbc.E02-03-0156; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; HASSID A, 1986, J PHARMACOL EXP THER, V239, P334; Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085; HU JS, 1988, J BIOL CHEM, V263, P19670; Inoue T, 2001, CARDIOVASC RES, V51, P470, DOI 10.1016/S0008-6363(01)00248-6; LAGORD C, 1993, BIOCHEM BIOPH RES CO, V191, P928, DOI 10.1006/bbrc.1993.1306; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; MARCHAL S, 1995, EXP CELL RES, V220, P1, DOI 10.1006/excr.1995.1285; Minotti S, 1998, CELL GROWTH DIFFER, V9, P155; Naro F, 1999, MOL BIOL CELL, V10, P4355, DOI 10.1091/mbc.10.12.4355; Naro F, 1997, J CELL PHYSIOL, V171, P34, DOI 10.1002/(SICI)1097-4652(199704)171:1<34::AID-JCP5>3.0.CO;2-I; NERVI C, 1995, CELL GROWTH DIFFER, V6, P81; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Pyne NJ, 1997, BIOCHEM J, V328, P689; RICHMAN RA, 1980, J CELL PHYSIOL, V103, P63, DOI 10.1002/jcp.1041030110; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Siow NL, 2002, J BIOL CHEM, V277, P36129, DOI 10.1074/jbc.M206498200; STEVENS PA, 1994, BIOCHEM J, V297, P233, DOI 10.1042/bj2970233; TETI A, 1993, AM J PHYSIOL, V265, pC113, DOI 10.1152/ajpcell.1993.265.1.C113; WAKELAM MJO, 1987, FEBS LETT, V210, P181, DOI 10.1016/0014-5793(87)81333-9; WINTER B, 1993, J BIOL CHEM, V268, P9869; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZALIN RJ, 1975, EXP CELL RES, V93, P55, DOI 10.1016/0014-4827(75)90422-X; ZALIN RJ, 1976, BIOCHEM SOC T, V4, P1066, DOI 10.1042/bst0041066; ZALIN RJ, 1987, EXP CELL RES, V172, P265, DOI 10.1016/0014-4827(87)90386-7	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49308	49315		10.1074/jbc.M306941200	http://dx.doi.org/10.1074/jbc.M306941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506285	hybrid			2022-12-25	WOS:000186829000098
J	Pillet, NA; Storling, J; Oberson, A; Roduit, R; Negri, S; Sauser, C; Nicod, P; Beckmann, JS; Schorderet, DF; Mandrup-Poulsen, T; Bonny, C				Pillet, NA; Storling, J; Oberson, A; Roduit, R; Negri, S; Sauser, C; Nicod, P; Beckmann, JS; Schorderet, DF; Mandrup-Poulsen, T; Bonny, C			Calcium- and proteasome-dependent degradation of the JNK scaffold protein islet-brain 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL DEATH; SIGNAL-TRANSDUCTION PATHWAY; CYTOKINE-INDUCED APOPTOSIS; INSULIN-SECRETING CELLS; TRANSCRIPTION FACTOR; DIABETES-MELLITUS; KINASE; UBIQUITINATION; INHIBITION; PHOSPHORYLATION	In models of type 1 diabetes, cytokines induce pancreatic beta-cell death by apoptosis. This process seems to be facilitated by a reduction in the amount of the islet-brain 1/JNK interacting protein 1 (IB1/JIP1), a JNK-scaffold with an anti-apoptotic effect. A point mutation S59N at the N terminus of the scaffold, which segregates in diabetic patients, has the functional consequence of sensitizing cells to apoptotic stimuli. Neither the mechanisms leading to IB1/JIP1 down-regulation by cytokines nor the mechanisms leading to the decreased capacity of the S59N mutation to protect cells from apoptosis are understood. Here, we show that IB1/JIP1 stability is modulated by intracellular calcium. The effect of calcium depends upon JNK activation, which primes the scaffold for ubiquitination-mediated degradation via the proteasome machinery. Furthermore, we observe that the S59N mutation decreases IB1/JIP1 stability by sensitizing IB1/ JIP1 to calcium- and proteasome-dependent degradation. These data indicate that calcium influx initiated by cytokines mediates ubiquitination and degradation of IB1/ JIP1 and may, therefore, provide a link between calcium influx and JNK-mediated apoptosis in pancreatic beta-cells.	CHU Vaudois, Serv Med Genet, Mol Genet Unit, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Med Genet, CH-1011 Lausanne, Switzerland; CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland; Steno Diabet Ctr, DK-2820 Gentofte, Denmark; Karolinska Inst, Dept Mol Med, SE-17177 Stockholm, Sweden	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Steno Diabetes Center; Karolinska Institutet	Pillet, NA (corresponding author), CHU Vaudois, Serv Med Genet, Mol Genet Unit, CH-1011 Lausanne, Switzerland.		Roduit, Raphael/AAC-3890-2021; Beckmann, Jacques S/A-9772-2008	Roduit, Raphael/0000-0001-7440-2799; Beckmann, Jacques S/0000-0002-9741-1900; Mandrup-Poulsen, Thomas/0000-0002-3215-9273; Storling, Joachim/0000-0002-7529-4264				Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chen L, 2003, MOL PHARMACOL, V64, P334, DOI 10.1124/mol.64.2.334; Delaney CA, 1997, ENDOCRINOLOGY, V138, P2610, DOI 10.1210/en.138.6.2610; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Donath MY, 2003, J MOL MED-JMM, V81, P455, DOI 10.1007/s00109-003-0450-y; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Dunger A, 1996, DIABETES, V45, P183, DOI 10.2337/diabetes.45.2.183; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Iwahashi H, 1996, DIABETOLOGIA, V39, P530, DOI 10.1007/s001250050475; Kim IJ, 1999, J NEUROCHEM, V72, P1335, DOI 10.1046/j.1471-4159.1999.721335.x; Kim TW, 1997, J BIOL CHEM, V272, P11006; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; Mathis D, 2001, NATURE, V414, P792, DOI 10.1038/414792a; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Mizuno N, 1998, ENDOCRINOLOGY, V139, P1429, DOI 10.1210/en.139.3.1429; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nihalani D, 2003, J BIOL CHEM, V278, P28694, DOI 10.1074/jbc.M304212200; Oikawa T, 1998, BIOCHEM BIOPH RES CO, V246, P243, DOI 10.1006/bbrc.1998.8604; Pietropaolo M, 2000, DIABETES, V49, P32, DOI 10.2337/diabetes.49.1.32; RABINOVITCH A, 1994, DIABETOLOGIA, V37, P733, DOI 10.1007/BF00404328; Rabinovitch A, 2001, ENDOCRINOLOGY, V142, P3649, DOI 10.1210/en.142.8.3649; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; Shah SA, 2001, SURG ONCOL, V10, P43, DOI 10.1016/S0960-7404(01)00018-4; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Wang L, 1999, ENDOCRINOLOGY, V140, P1200, DOI 10.1210/en.140.3.1200; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548	51	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48720	48726		10.1074/jbc.M306745200	http://dx.doi.org/10.1074/jbc.M306745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507925	hybrid			2022-12-25	WOS:000186829000027
J	Szmola, R; Kukor, Z; Sahin-Toth, M				Szmola, R; Kukor, Z; Sahin-Toth, M			Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATIONIC TRYPSINOGEN; REACTIVE-SITE; CATHEPSIN-B; ACTIVATION; PANCREATITIS; ZYMOGEN; EXPRESSION; RESISTANCE; MUTATIONS; ISOFORM	Mesotrypsin is an enigmatic minor human trypsin isoform, which has been recognized for its peculiar resistance to natural trypsin inhibitors such as soybean trypsin inhibitor (SBTI) or human pancreatic secretory trypsin inhibitor (SPINK1). In search of a biological function, two conflicting theories proposed that due to its inhibitor-resistant activity mesotrypsin could prematurely activate or degrade pancreatic zymogens and thus play a pathogenic or protective role in human pancreatitis. In the present study we ruled out both theories by demonstrating that mesotrypsin was grossly defective not only in inhibitor binding, but also in the activation or degradation of pancreatic zymogens. We found that the restricted ability of mesotrypsin to bind inhibitors or to hydrolyze protein substrates was solely due to a single evolutionary mutation, which changed the serine-protease signature glycine 198 residue to arginine. Remarkably, the same mutation endowed mesotrypsin with a novel and unique function: mesotrypsin rapidly hydrolyzed the reactive-site peptide bond of the Kunitz-type trypsin inhibitor SBTI, and irreversibly degraded the Kazal-type temporary inhibitor SPINK1. The observations suggest that the biological function of human mesotrypsin is digestive degradation of trypsin inhibitors. This mechanism can facilitate the digestion of foods rich in natural trypsin inhibitors. Furthermore, the findings raise the possibility that inappropriate activation of mesotrypsinogen in the pancreas might lower protective SPINK1 levels and contribute to the development of human pancreatitis. In this regard, it is noteworthy that the well known pathological trypsinogen activator cathepsin B exhibited a preference for the activation of mesotrypsinogen of all three human trypsinogen isoforms, suggesting a biochemical mechanism for mesotrypsinogen activation in pancreatic acinar cells.	Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA	Boston University	Sahin-Toth, M (corresponding author), 715 Albany St,EVANS 4, Boston, MA 02118 USA.	miklos@bu.edu		Sahin-Toth, Miklos/0000-0003-4513-9922	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58088, R01 DK058088] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Chen JM, 2003, NATURE ENCY HUMAN GE, V5, P645; ESTELL DA, 1980, BIOCHEMISTRY-US, V19, P124, DOI 10.1021/bi00542a019; ESTELL DA, 1980, BIOCHEMISTRY-US, V19, P131, DOI 10.1021/bi00542a020; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; Fukuoka S, 2002, BBA-MOL BASIS DIS, V1588, P106, DOI 10.1016/S0925-4439(02)00153-9; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Katona G, 2002, J MOL BIOL, V315, P1209, DOI 10.1006/jmbi.2001.5305; KIKUCHI N, 1989, J BIOCHEM-TOKYO, V106, P1059, DOI 10.1093/oxfordjournals.jbchem.a122964; Kukor Z, 2002, J BIOL CHEM, V277, P21389, DOI 10.1074/jbc.M200878200; Kukor Z, 2003, EUR J BIOCHEM, V270, P2047, DOI 10.1046/j.1432-1033.2003.03581.x; Kukor Z, 2002, J BIOL CHEM, V277, P6111, DOI 10.1074/jbc.M110959200; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; LASKOWSKI M, 1953, J BIOL CHEM, V204, P797; LEMARECHAL C, 2003, IN PRESS HUM MUT; Lengyel Z, 1998, PROTEIN EXPRES PURIF, V12, P291, DOI 10.1006/prep.1997.0837; LUTHY JA, 1973, J BIOL CHEM, V248, P1760; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; Pfutzer RH, 2000, GASTROENTEROLOGY, V119, P615, DOI 10.1053/gast.2000.18017; RINDERKNECHT H, 1979, GUT, V20, P886, DOI 10.1136/gut.20.10.886; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; RINDERKNECHT H, 1985, DIGEST DIS SCI, V30, P65, DOI 10.1007/BF01318373; RINDERKNECHT H, 1978, CLIN RES, V26, pA112; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 1999, J BIOL CHEM, V274, P29699, DOI 10.1074/jbc.274.42.29699; SCHNEIDE.SL, 1974, J BIOL CHEM, V249, P2009; SCHNEIDER SL, 1973, J BIOL CHEM, V248, P7207; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088	32	110	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48580	48589		10.1074/jbc.M310301200	http://dx.doi.org/10.1074/jbc.M310301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507909	Green Accepted, hybrid			2022-12-25	WOS:000186829000010
J	Yu, JH; Liu, XW; Kim, HRC				Yu, JH; Liu, XW; Kim, HRC			Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21(WAF1/CIP1) promoter activity independent of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED G(1) ARREST; FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; INHIBITOR P21(WAF1/CIP1); P21(CIP1/WAF1) GENE; PROTEIN-KINASE; HUMAN CANCER; CELL-GROWTH; EXPRESSION; P21	Platelet-derived growth factor ( PDGF) is a potent mitogen for mesenchymal cells. PDGF AA functions as a "competent factor" that stimulates cell cycle entry but requires additional ( progression) factors in serum to transit the cell cycle beyond the G(1)/S checkpoint. Unlike PDGF AA, PDGF B-chain (c-sis) homodimer ( PDGF BB) and its viral counterpart v-sis can serve as both competent and progression factors. PDGF BB activates alpha- and beta-receptor subunits (alpha-PDGFR and beta-PDGFR) and induces phenotypic transformation in NIH 3T3 cells, whereas PDGF AA activates alpha-PDGFR only and fails to induce transformation. We showed previously that alpha-PDGFR antagonizes beta-PDGFR-mediated transformation through activation of stress-activated protein kinase-1/c-Jun NH2-terminal kinase-1, whereas both alpha-PDGFR and beta-PDGFR induce mitogenic signals. These studies revealed a striking feature of PDGF signaling; the specificity and the strength of the PDGF growth signal is modulated by alpha-PDGFR-mediated simultaneous activation of growth stimulatory and inhibitory signals, whereas beta-PDGFR mainly induces a growth-promoting signal. Here we demonstrate that PDGF BB activation of beta-PDGFR alone results in more efficient cell cycle transition from G(1) to S phase than PDGF BB activation of both alpha-PDGFR and beta-PDGFR. PDGF AA activation of alpha-PDGFR or PDGF BB activation of both alpha- and beta-PDG-FRs up-regulates expression of p21(WAF1/CIP1), an inhibitor of cell cycle-dependent kinases and a downstream mediator of the tumor suppressor gene product p53. However, beta-PDGFR activation alone fails to induce p21(WAF1/CIP1) expression. We also demonstrate that alpha-PDGFR-activated JNK-1 is a critical signaling component for PDGF induction of p21(WAF1/CIP1) promoter activity. The ability of PDGF/JNK-1 to induce p21(WAF1/CIP1) promoter activity is independent of p53, although the overall p21(WAF1/CIP1) promoter activities are greatly reduced in the absence of p53. These results provide a molecular basis for differential regulation of the cell cycle and transformation by alpha- and beta-PDGFRs.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 540 E Canfield, Detroit, MI 48201 USA.				NCI NIH HHS [CA64139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064139, R01CA064139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; BEJCEK BE, 1993, BIOCHEM BIOPH RES CO, V196, P69, DOI 10.1006/bbrc.1993.2217; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARPER JW, 1993, CELL, V75, P805; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM HRC, 1994, J BIOL CHEM, V269, P30604; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; Kwun HJ, 2001, J GEN VIROL, V82, P2235, DOI 10.1099/0022-1317-82-9-2235; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MICHIELI P, 1994, CANCER RES, V54, P3391; Min W, 1997, J IMMUNOL, V159, P3508; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKEEFE EJ, 1983, MOL CELL ENDOCRINOL, V31, P167, DOI 10.1016/0303-7207(83)90147-8; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; PLEDGER WJ, 1981, P NATL ACAD SCI-BIOL, V78, P4358, DOI 10.1073/pnas.78.7.4358; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pozas E, 1997, J NEUROBIOL, V33, P232, DOI 10.1002/(SICI)1097-4695(199709)33:3<232::AID-NEU3>3.3.CO;2-Y; RIDDLE VGH, 1979, P NATL ACAD SCI USA, V76, P1298, DOI 10.1073/pnas.76.3.1298; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Simm A, 1998, EXP CELL RES, V244, P379, DOI 10.1006/excr.1998.4200; SIMM A, 1992, EXP CELL RES, V201, P192, DOI 10.1016/0014-4827(92)90363-D; SINGH JP, 1983, J CELL BIOL, V96, P1497, DOI 10.1083/jcb.96.5.1497; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; Tarunina M, 1996, ONCOGENE, V13, P589; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yokote K, 1996, J BIOL CHEM, V271, P5101; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622	58	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49582	49588		10.1074/jbc.M309986200	http://dx.doi.org/10.1074/jbc.M309986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506245	hybrid			2022-12-25	WOS:000186829000129
J	Gagneux, P; Cheriyan, M; Hurtado-Ziola, N; van der Linden, ECMB; Anderson, D; McClure, H; Varki, A; Varki, NM				Gagneux, P; Cheriyan, M; Hurtado-Ziola, N; van der Linden, ECMB; Anderson, D; McClure, H; Varki, A; Varki, NM			Human-specific regulation of alpha 2-6-linked sialic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; INFLUENZA-A VIRUS; RECEPTOR SPECIFICITY; FUNCTIONAL-ANALYSIS; SURFACE PROTEIN; HUMAN-EVOLUTION; SIALYLTRANSFERASE; RECOGNITION; GENE; GLYCOPROTEIN	Many microbial pathogens and toxins recognize animal cells via cell surface sialic acids (Sias) that are alpha2-3-or alpha2-8-linked to the underlying glycan chain. Human influenza A/B viruses are unusual in preferring alpha2-6-linked Sias, undergoing a switch from alpha2-3 linkage preference during adaptation from animals to humans. This correlates with the expression of alpha2-6-linked Sias on ciliated human airway epithelial target cells and of alpha2-3- linked Sias on secreted soluble airway mucins, which are unable to inhibit virus binding. Given several known differences in Sia biology between humans and apes, we asked whether this pattern of airway epithelial Sia linkages is also human-specific. Indeed, we show that since the last common ancestor with apes, humans underwent a concerted bidirectional switch in alpha2-6-linked Sia expression between airway epithelial cell surfaces and secreted mucins. This can explain why the chimpanzee appears relatively resistant to experimental infection with human Influenza viruses. Other tissues showed additional examples of human-specific increases or decreases in alpha2-6-linked Sia expression and only one example of a change specific to certain great apes. Furthermore, while human and great ape leukocytes both express alpha2-6-linked Sias, only human erythrocytes have markedly up-regulated expression. These cell type-specific changes in alpha2-6-Sia expression during human evolution represent another example of a human-specific change in Sia biology. Because the data set involves multiple great apes, we can also conclude that Sia linkage expression patterns can be conserved during millions of years of evolution within some vertebrate taxa while undergoing sudden major changes in other closely related ones.	Univ Calif San Diego, Dept Med, Glyocobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glyocobiol Res & Training Ctr, La Jolla, CA 92093 USA; Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Emory University	Varki, NM (corresponding author), Univ Calif San Diego, Dept Med, Glyocobiol Res & Training Ctr, La Jolla, CA 92093 USA.	nvarki@ucsd.edu			NCRR NIH HHS [RR00165] Funding Source: Medline; NIDDK NIH HHS [5T32DK07022] Funding Source: Medline; NIGMS NIH HHS [R01-GM323373] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007022] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; Angata T, 2001, J BIOL CHEM, V276, P40282, DOI 10.1074/jbc.M105926200; Baum J, 2002, MOL BIOL EVOL, V19, P223, DOI 10.1093/oxfordjournals.molbev.a004075; BAUM LG, 1990, ACTA HISTOCHEM, P35; Bossuyt X, 1997, CYTOMETRY, V30, P124; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; Brinkman-Van der Linden ECM, 2002, ANAL BIOCHEM, V303, P98, DOI 10.1006/abio.2001.5539; Chanock R. M., 1992, CHIMPANZEE CONSERVAT, P21; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Chou HH, 1998, P NATL ACAD SCI USA, V95, P11751, DOI 10.1073/pnas.95.20.11751; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Dalziel M, 1999, GLYCOBIOLOGY, V9, P1003, DOI 10.1093/glycob/9.10.1003; Ellies LG, 2002, BLOOD, V100, P3618, DOI 10.1182/blood-2002-04-1007; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Gagneux P, 2001, AM J PHYS ANTHROPOL, V115, P99, DOI 10.1002/ajpa.1061; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; GOODMAN M, 1994, AM J PHYS ANTHROPOL, V94, P3, DOI 10.1002/ajpa.1330940103; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Ito T, 1997, J VIROL, V71, P3357, DOI 10.1128/JVI.71.4.3357-3362.1997; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; JAMIESON JC, 1993, COMP BIOCHEM PHYS B, V105, P29, DOI 10.1016/0305-0491(93)90165-2; KALTER SS, 1978, P SOC EXP BIOL MED, V159, P414; Kaludov N, 2001, J VIROL, V75, P6884, DOI 10.1128/JVI.75.15.6884-6893.2001; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; KUNKEL F, 1993, VIROLOGY, V195, P195, DOI 10.1006/viro.1993.1360; LAMBLIN G, 1984, BIOCHEM SOC T, V12, P599, DOI 10.1042/bst0120599; LEIGH MW, 1995, VACCINE, V13, P1468, DOI 10.1016/0264-410X(95)00004-K; Liu CK, 1998, J VIROL, V72, P4643, DOI 10.1128/JVI.72.6.4643-4649.1998; Lo NW, 1999, GLYCOBIOLOGY, V9, P907, DOI 10.1093/glycob/9.9.907; Lo NW, 1996, BIOCHEM BIOPH RES CO, V228, P380, DOI 10.1006/bbrc.1996.1670; Martin LT, 2002, J BIOL CHEM, V277, P32930, DOI 10.1074/jbc.M203362200; Muchmore EA, 1998, AM J PHYS ANTHROPOL, V107, P187, DOI 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.3.CO;2-M; NELSON J, 1993, VIRUS RES, V29, P155, DOI 10.1016/0168-1702(93)90056-S; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; Satta Y, 2000, MOL PHYLOGENET EVOL, V14, P259, DOI 10.1006/mpev.2000.0704; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SNYDER MH, 1986, J INFECT DIS, V154, P370, DOI 10.1093/infdis/154.2.370-a; Subbarao K, 1995, VIRUS RES, V39, P105, DOI 10.1016/0168-1702(95)00082-8; Takashima S, 2002, J BIOL CHEM, V277, P45719, DOI 10.1074/jbc.M206808200; Traving C, 1998, CELL MOL LIFE SCI, V54, P1330, DOI 10.1007/s000180050258; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Varki A, 2001, YEARB PHYS ANTHROPOL, V44, P54, DOI 10.1002/ajpa.10018; Vines A, 1998, J VIROL, V72, P7626, DOI 10.1128/JVI.72.9.7626-7631.1998; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735	53	140	143	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48245	48250		10.1074/jbc.M309813200	http://dx.doi.org/10.1074/jbc.M309813200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500706	hybrid			2022-12-25	WOS:000186731400108
J	Illarionov, B; Haase, I; Bacher, A; Fischer, M; Schramek, N				Illarionov, B; Haase, I; Bacher, A; Fischer, M; Schramek, N			Presteady state kinetic analysis of riboflavin synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; LIGAND-BINDING; LUMAZINE SYNTHASE; CRYSTAL-STRUCTURE; XYLENE RING; BIOSYNTHESIS; MECHANISM; PURIFICATION; PTERIDINES; COMPLEX	Riboflavin synthase catalyzes a mechanistically complex dismutation affording riboflavin and 5-amino-6-ibitylamino-2,4(1H,3H)-pyrimidinedione from 6,7-dimethyl-8-ribityllumazine. The kinetics of the enzyme from Escherichia coli were studied under single turnover conditions. Stopped flow as well as quenched flow experiments documented the transient formation of a pentacyclic reaction intermediate. No other transient species were sufficiently populated to allow detection. The data are best described by a sequence of one second order and one first order reaction.					Fischer, Markus/AFT-1856-2022; Fischer, Markus/H-2870-2012; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; 				BACHER A, 1980, J BIOL CHEM, V255, P632; Bacher A, 1997, METHOD ENZYMOL, V280, P389; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BEACH R, 1969, Tetrahedron Letters, V40, P3489; BEACH RL, 1971, J ORG CHEM, V36, P3937, DOI 10.1021/jo00824a020; BEACH RL, 1970, J AM CHEM SOC, V92, P2913, DOI 10.1021/ja00712a052; BEACH RL, 1970, BIOCHEMISTRY-US, V9, P760, DOI 10.1021/bi00806a009; BOWN DH, 1986, J ORG CHEM, V51, P2461, DOI 10.1021/jo00363a011; CUSHMAN M, 1991, J ORG CHEM, V56, P4603, DOI 10.1021/jo00015a009; Gerhardt S, 2002, STRUCTURE, V10, P1371, DOI 10.1016/S0969-2126(02)00864-X; HARVEY RA, 1966, J BIOL CHEM, V241, P2120; Illarionov B, 2001, P NATL ACAD SCI USA, V98, P7224, DOI 10.1073/pnas.131610698; Illarionov B, 2001, J BIOL CHEM, V276, P11524, DOI 10.1074/jbc.M008931200; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Liao DI, 2001, STRUCTURE, V9, P399, DOI 10.1016/S0969-2126(01)00600-1; OTTO MK, 1981, EUR J BIOCHEM, V115, P511; PATERSON T, 1972, J CHEM SOC PERK T 1, P1051, DOI 10.1039/p19720001051; PATERSON T, 1969, CHEM COMMUN, P290; PLAUT GWE, 1963, J BIOL CHEM, V238, P2225; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; Plaut GWE, 1971, METHODS ENZYMOL B, V18, P515; ROWAN T, 1963, P CHEM SOC LONDON, P21; ROWAN T, 1968, J CHEM SOC C, P452, DOI 10.1039/j39680000452; Scheuring J, 1996, BIOCHEMISTRY-US, V35, P9637, DOI 10.1021/bi9600916; Scheuring J, 2001, J ORG CHEM, V66, P3811, DOI 10.1021/jo001739u; SCHOTT K, 1990, J BIOL CHEM, V265, P4204; Schramek N, 2003, J AM CHEM SOC, V125, P4460, DOI 10.1021/ja028226k; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; Truffault V, 2001, J MOL BIOL, V309, P949, DOI 10.1006/jmbi.2001.4683	29	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47700	47706		10.1074/jbc.M305050200	http://dx.doi.org/10.1074/jbc.M305050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504292	hybrid			2022-12-25	WOS:000186731400045
J	Bezard, E; Baufreton, J; Owens, G; Crossman, AR; Dudek, H; Taupignon, A; Brotchie, JM				Bezard, E; Baufreton, J; Owens, G; Crossman, AR; Dudek, H; Taupignon, A; Brotchie, JM			Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus	FASEB JOURNAL			English	Article						patched; Parkinson's disease; basal ganglia; rat; macaque	NEURONS IN-VITRO; PRIMATE MODELS; BASAL GANGLIA; HIGH-AFFINITY; PATCHED GENE; CELLS; EXPRESSION; RECEPTORS; INDUCTION; TRANSPORT	It is well established that members of the hedgehog family are involved in tissue patterning during development. We herein show that sonic hedgehog signaling molecules are differentially regulated by dopamine depletion in the basal ganglia of adult animals and specifically that sonic hedgehog levels are reduced in an animal model of Parkinson's disease. In addition, we show that sonic hedgehog protein inhibits electrical activity in the subthalamic nucleus, a key element of basal ganglia, within minutes of application. As the subthalamic nucleus is overactive in parkinsonism, we suggest that enhancement of sonic hedgehog signaling in the subthalamic nucleus may be of therapeutic value in Parkinson's disease.	Univ Victor Segalen, Basal Gang, F-33076 Bordeaux, France; Univ Victor Segalen, CNRS, UMR 5543, F-33076 Bordeaux, France; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester Movement Disorder Lab, Manchester M13 9PT, Lancs, England; Motac Neurosci Ltd, Manchester M15 6SE, Lancs, England; Curis Inc, Cambridge, MA USA; Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada	UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Manchester; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Bezard, E (corresponding author), Univ Victor Segalen, Basal Gang, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	erwan.bezard@umr5543.u-bordeaux2.fr	Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021	Bezard, Erwan/0000-0002-0410-4638; Brotchie, Jonathan/0000-0003-2337-0816; Baufreton, Jerome/0000-0002-2623-6375; Taupignon, Anne/0000-0002-4662-7971				Baufreton J, 2001, J NEUROPHYSIOL, V86, P75, DOI 10.1152/jn.2001.86.1.75; Baufreton J, 2003, J NEUROSCI, V23, P816; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Bevan MD, 2002, J NEUROPHYSIOL, V87, P1348, DOI 10.1152/jn.00582.2001; Bevan MD, 2000, J NEUROPHYSIOL, V83, P3169, DOI 10.1152/jn.2000.83.5.3169; Bevan MD, 2002, TRENDS NEUROSCI, V25, P525, DOI 10.1016/S0166-2236(02)02235-X; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NEUROSCIENCE, V103, P117, DOI 10.1016/S0306-4522(00)00546-7; Bezard E., 2001, FASEB J, DOI [10.1096: fj.00-0637fje, DOI 10.1096FJ.00-0637FJE]; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Emond P, 1997, J MED CHEM, V40, P1366, DOI 10.1021/jm960795d; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gross CE, 1999, PROG NEUROBIOL, V59, P509, DOI 10.1016/S0301-0082(99)00015-5; Guerineau NC, 1997, J PHYSIOL-LONDON, V500, P487, DOI 10.1113/jphysiol.1997.sp022035; Guilloteau D, 1998, NUCL MED BIOL, V25, P331, DOI 10.1016/S0969-8051(97)00224-2; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Henry B, 1999, EXP NEUROL, V155, P204, DOI 10.1006/exnr.1998.6996; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Magill PJ, 2000, J NEUROSCI, V20, P820, DOI 10.1523/JNEUROSCI.20-02-00820.2000; MANEUF YP, 1995, BRAIN RES, V683, P102, DOI 10.1016/0006-8993(95)00358-W; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Miao NN, 1997, J NEUROSCI, V17, P5891; MITCHELL IJ, 1989, NEUROSCIENCE, V32, P213, DOI 10.1016/0306-4522(89)90120-6; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Traiffort E, 2001, EUR J NEUROSCI, V14, P839, DOI 10.1046/j.0953-816x.2001.01708.x; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wallace VA, 1999, DEVELOPMENT, V126, P2901; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184	42	24	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2337	+		10.1096/fj.03-0291fje	http://dx.doi.org/10.1096/fj.03-0291fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525941				2022-12-25	WOS:000186343300011
J	Mata, NL; Moghrabi, WN; Lee, JS; Bui, TV; Radu, RA; Horwitz, J; Travis, GH				Mata, NL; Moghrabi, WN; Lee, JS; Bui, TV; Radu, RA; Horwitz, J; Travis, GH			Rpe65 is a retinyl ester binding protein that presents insoluble substrate to the isomerase in retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ETHYLENE GLYCOL)-MEDIATED FUSION; VITAMIN-A; VISUAL CYCLE; UNILAMELLAR VESICLES; RPE65-DEFICIENT MICE; MEMBRANE-RECEPTOR; BETA-CAROTENE; IDENTIFICATION; RETINOIDS; EYE	Photon capture by a rhodopsin pigment molecule induces 11-cis to all-trans isomerization of its retinaldehyde chromophore. To restore light sensitivity, the all-trans-retinaldehyde must be chemically re-isomerized by an enzyme pathway called the visual cycle. Rpe65, an abundant protein in retinal pigment epithelial (RPE) cells and a homolog of beta-carotene dioxygenase, appears to play a role in this pathway. Rpe65(-/-) knockout mice massively accumulate all-trans-retinyl esters but lack 11-cis-retinoids and rhodopsin visual pigment in their retinas. Mutations in the human RPE65 gene cause a severe recessive blinding disease called Leber's congenital amaurosis. The function of Rpe65, however, is unknown. Here we show that Rpe65 specifically binds all-trans-retinyl palmitate but not 11-cis-retinyl palmitate by a spectral-shift assay, by co-elution during gel filtration, and by co-immunoprecipitation. Using a novel fluorescent resonance energy transfer ( FRET) binding assay in liposomes, we demonstrate that Rpe65 extracts all-trans-retinyl esters from phospholipid membranes. Assays of isomerase activity reveal that Rpe65 strongly stimulates the enzymatic conversion of all-trans-retinyl palmitate to 11-cis-retinol in microsomes from bovine RPE cells. Moreover, we show that addition of Rpe65 to membranes from rpe65(-/-) mice, which possess no detectable isomerase activity, restores isomerase activity to wild-type levels. Rpe65 by itself, however, has no intrinsic isomerase activity. These observations suggest that Rpe65 presents retinyl esters as substrate to the isomerase for synthesis of visual chromophore. This proposed function explains the phenotype in mice and humans lacking Rpe65.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Travis, GH (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, 100 Stein Plaza Rm BH-667, Los Angeles, CA 90095 USA.		Radu, Roxana A./K-8924-2019; Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Radu, Roxana/0000-0002-5064-6403				BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; Bhattacharya SK, 2002, FASEB J, V16, pA14; BOK D, 1984, INVEST OPHTH VIS SCI, V25, P877; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; Ekesten B, 2001, VISION RES, V41, P2425, DOI 10.1016/S0042-6989(01)00140-7; Evans KO, 2002, BIOCHEMISTRY-US, V41, P1241, DOI 10.1021/bi011508x; FUTTERMAN S, 1964, J BIOL CHEM, V239, P81; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Haque ME, 2001, BIOCHEMISTRY-US, V40, P14243, DOI 10.1021/bi011308l; Haque ME, 2001, BIOCHEMISTRY-US, V40, P4340, DOI 10.1021/bi002030k; HO MTP, 1989, J BIOL CHEM, V264, P17759; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P6159, DOI 10.1021/bi034002i; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; Malinin VS, 2001, BIOCHEMISTRY-US, V40, P8292, DOI 10.1021/bi010570r; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Narfstrom K, 2003, INVEST OPHTH VIS SCI, V44, P1663, DOI 10.1167/iovs.02-0595; Newcomer ME, 2000, BBA-PROTEIN STRUCT M, V1482, P57, DOI 10.1016/S0167-4838(00)00150-3; NICOTRA CMA, 1994, MOL CELL BIOCHEM, V132, P45, DOI 10.1007/BF00925674; POOLE RK, 1987, SPECTROPHOTOMETRY SP, P23; Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679; RANDO RR, 1982, BIOCHEM BIOPH RES CO, V104, P430, DOI 10.1016/0006-291X(82)90655-6; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; REDMOND TM, 1985, BIOCHEMISTRY-US, V24, P787, DOI 10.1021/bi00324a038; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; RODRIGUEZ KA, 1989, AM J PHYSIOL, V256, pR255, DOI 10.1152/ajpregu.1989.256.1.R255; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; SAARI JC, 1987, J BIOL CHEM, V262, P7618; Simon A, 1999, J CELL SCI, V112, P549; Thomas RM, 2002, BIOCHEMISTRY-US, V41, P1591, DOI 10.1021/bi011555p; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	50	103	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					635	643		10.1074/jbc.M310042200	http://dx.doi.org/10.1074/jbc.M310042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14532273	hybrid			2022-12-25	WOS:000187555300077
J	Chan, FKM; Shisler, J; Bixby, JG; Felices, M; Zheng, LX; Appel, M; Orenstein, J; Moss, B; Lenardo, MJ				Chan, FKM; Shisler, J; Bixby, JG; Felices, M; Zheng, LX; Appel, M; Orenstein, J; Moss, B; Lenardo, MJ			A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN KINASE; NF-KAPPA-B; CELL-DEATH; TNF RECEPTORS; FACTOR-ALPHA; RIP; APOPTOSIS; INNATE; REQUIREMENT; PATHWAY	Members of the tumor necrosis factor (TNF) receptor (TNFR) superfamily are potent regulators of apoptosis, a process that is important for the maintenance of immune homeostasis. Recent evidence suggests that TNFR-1 and Fas and TRAIL receptors can also trigger an alternative form of cell death that is morphologically distinct from apoptosis. Because distinct molecular components including the serine/threonine protein kinase receptor-interacting protein ( RIP) are required, we have referred to this alternative form of cell death as "programmed necrosis." We show that TNFR-2 signaling can potentiate programmed necrosis via TNFR-1. When cells were pre-stimulated through TNFR-2 prior to subsequent activation of TNFR-1, enhanced cell death and recruitment of RIP to the TNFR-1 complex were observed. However, TNF-induced programmed necrosis was normally inhibited by caspase-8 cleavage of RIP. To ascertain the physiological significance of RIP and programmed necrosis, we infected Jurkat cells with vaccinia virus (VV) and found that VV-infected cells underwent programmed necrosis in response to TNF, but deficiency of RIP rescued the infected cells from TNF-induced cytotoxicity. Moreover, TNFR-2(-/-) mice exhibited reduced inflammation in the liver and defective viral clearance during VV infection. Interestingly, death effector domain-containing proteins such as MC159, E8, K13, and cellular FLIP, but not the apoptosis inhibitors Bcl-x(L), p35, and XIAP, potently suppressed programmed necrosis. Thus, TNF-induced programmed necrosis is facilitated by TNFR-2 signaling and caspase inhibition and may play a role in controlling viral infection.	Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Sch Med, Div Diabet, Worcester, MA 01655 USA; George Washington Univ, Dept Pathol, Washington, DC 20037 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Massachusetts System; University of Massachusetts Worcester; George Washington University	Chan, FKM (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, Rm S2-125,55 Lake Ave N, Worcester, MA 01655 USA.	francis.chan@umassmed.edu	Chan, Francis Ka-Ming/E-9647-2014; Chan, Francis/ABB-1895-2021	Chan, Francis Ka-Ming/0000-0002-4803-8353; Shisler, Joanna/0000-0003-4833-1557; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000539, ZIAAI000539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benedict CA, 2002, NAT IMMUNOL, V3, P1013, DOI 10.1038/ni1102-1013; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Cusson N, 2002, J EXP MED, V196, P15, DOI 10.1084/jem.20011470; Elzey BD, 2001, J IMMUNOL, V167, P3049, DOI 10.4049/jimmunol.167.6.3049; Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hornef MW, 2002, NAT IMMUNOL, V3, P1033, DOI 10.1038/ni1102-1033; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li M, 2000, J VIROL, V74, P7470, DOI 10.1128/JVI.74.16.7470-7477.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Shisler JL, 2001, SEMIN IMMUNOL, V13, P67, DOI 10.1006/smim.2000.0297; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weiss T, 1997, J IMMUNOL, V158, P2398; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	33	332	347	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51613	51621		10.1074/jbc.M305633200	http://dx.doi.org/10.1074/jbc.M305633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532286	hybrid			2022-12-25	WOS:000187206300095
J	Imai, Y; Soda, M; Murakami, T; Shoji, M; Abe, K; Takahashi, R				Imai, Y; Soda, M; Murakami, T; Shoji, M; Abe, K; Takahashi, R			A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses pael receptor-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; DISEASE; IDENTIFICATION; CHAPERONIN; MUTATION; TUBULIN; COMPLEX; STRESS	Parkin, a RING-type ubiquitin ligase, is the product of the gene responsible for autosomal recessive juvenile parkinsonism. A reverse strand gene located upstream of the parkin gene in the human genome has been identified. The gene product, termed Glup/PACRG, forms a large molecular chaperone complex containing heat shock proteins 70 and 90 and chaperonin components. Glup suppressed cell death induced by accumulation of unfolded Pael receptor (Pael-R), a substrate of Parkin. On the other hand, Glup facilitated the formation of inclusions consisting of Pael-R, molecular chaperones, protein degradation molecules, and Glup itself, when proteasome is inhibited. Glup knockdown attenuated the formation of Pael-R inclusions, which resulted in the promotion of cell death with extensive vacuolization. Moreover, Glup turned out to be a component of Lewy bodies in Parkinson's disease cases. These data suggest that Glup may play an important role in the formation of Lewy bodies and protection of dopaminergic neurons against Parkinson's disease.	RIKEN, Lab Motor Syst Neurodegenerat, Brain Sci Inst, Saitama 3510198, Japan; Okayama Univ, Dept Neurol, Grad Sch Med & Dent, Okayama 7008558, Japan	RIKEN; Okayama University	Takahashi, R (corresponding author), RIKEN, Lab Motor Syst Neurodegenerat, Brain Sci Inst, Saitama 3510198, Japan.	ryosuke@brain.riken.go.jp	Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Shoji, Mikio/0000-0003-1027-1712				Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Junn E, 2002, J BIOL CHEM, V277, P47870, DOI 10.1074/jbc.M203159200; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; McNaught KSP, 2002, EUR J NEUROSCI, V16, P2136, DOI 10.1046/j.1460-9568.2002.02301.x; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; West A, 2001, J NEUROCHEM, V78, P1146, DOI 10.1046/j.1471-4159.2001.00512.x; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	31	57	74	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51901	51910		10.1074/jbc.M309655200	http://dx.doi.org/10.1074/jbc.M309655200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532270	hybrid			2022-12-25	WOS:000187206300126
J	Jin, YJ; Gallagher, PJ				Jin, YJ; Gallagher, PJ			Antisense depletion of death-associated protein kinase promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DAP-KINASE; CATALYTIC ACTIVITY; MORPHOLINO; EXPRESSION; IDENTIFICATION; OLIGOMERS; CLONING	Death-associated protein kinases (DAPK) are serine/ threonine protein kinases that have an important role in regulating cell death. In this study two antisense approaches were employed to down-regulate expression of the endogenous DAPK-alpha and DAPK-beta proteins. Transient expression of an antisense DAPK cDNA or antisense morpholino oligonucleotides in HeLa, 3T3, or primary human vascular smooth muscle cells demonstrate that decreased DAPK expression promotes a spontaneous, caspase-mediated apoptosis as evidenced by increased activities of caspases-3 and -9. Clonal HeLa cell lines with attenuated levels of DAPK expression, obtained following selection in the presence of antisense DAPK cDNA, are more sensitive to tumor necrosis factor-induced caspase-mediated apoptosis, and their sensitivity is inversely related to DAPK expression. In contrast, HeLa cells with reduced DAPK expression are moderately resistant to cell death induced by interferon-gamma. This finding is consistent with previous studies showing that DAPK has a role in promoting caspase-independent cell death. Together, these studies demonstrate that the cellular activities of DAPK are critical for antagonizing caspase-dependent apoptosis to promote cell survival under normal cell growth conditions.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, MS 2065,635 Barnhill Dr, Indianapolis, IN 46202 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054118, R01 HL054118-05A2, HL54118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; JIN Y, 2001, J BIOL CHEM, V30, P30; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Morcos PA, 2001, GENESIS, V30, P94, DOI 10.1002/gene.1039; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Sakagami H, 1997, MOL BRAIN RES, V52, P249, DOI 10.1016/S0169-328X(97)00268-4; Schumacher AM, 2002, BBA-PROTEINS PROTEOM, V1600, P128, DOI 10.1016/S1570-9639(02)00453-3; Shohat G, 2002, EUR CYTOKINE NETW, V13, P398; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; TIAN JH, 2003, J BIOL CHEM; Yamamoto M, 1999, J NEUROSCI RES, V58, P674, DOI 10.1002/(SICI)1097-4547(19991201)58:5<674::AID-JNR8>3.0.CO;2-3	21	38	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51587	51593		10.1074/jbc.M309165200	http://dx.doi.org/10.1074/jbc.M309165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530257	Green Accepted, hybrid			2022-12-25	WOS:000187206300091
J	Mohapatra, DP; Nau, C				Mohapatra, DP; Nau, C			Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; RAT SENSORY NEURONS; DIRECT PHOSPHORYLATION; THERMAL HYPERALGESIA; MOLECULAR MECHANISM; PAIN; CHANNEL; CALCIUM; SITES; NOCICEPTION	Proinflammatory prostaglandin E2 is known to sensitize sensory neurons to noxious stimuli. This sensitization is mediated by the cAMP-dependent protein kinase (PKA) signal pathway. The capsaicin receptor TRPV1, a non-selective cation channel of sensory neurons involved in the sensation of inflammatory pain, is a target of PKA-mediated phosphorylation. Our goal was to investigate the influence of PKA on Ca2+-dependent desensitization of capsaicin-activated currents. By using site-directed mutagenesis, we created point mutations at PKA consensus sites and studied wild-type and mutant channels transiently expressed in HEK293t cells under whole-cell voltage clamp. We found that forskolin, a stimulator of adenylate cyclase, decreased desensitization of TRPV1. The selective PKA inhibitor H89 inhibited this effect. Mimicking phosphorylation at PKA consensus sites by replacing Ser-6, Ser-116, Thr-144, Thr-370, Ser-502, Ser-774, or Ser-820 with aspartate resulted in five mutations (S116D, T144D, T370D, S774D, and S820D) that exhibited decreased desensitization as well. However, disrupting phosphorylation by replacing respective sites with alanine resulted in four mutations (S6A, T144A, T370A, and S820A) with desensitization properties resembling those of the aspartate mutations. Significant changes in relative permeabilities for Ca2+ over Na+ or in capsaicin sensitivity could not explain changes in desensitization properties of mutant channels. In mutations S116A, S116D, T370A, and T370D, pretreatment of cells with forskolin did not reduce desensitization as compared with wild-type and other mutant channels. We conclude that Ser-116 and possibly Thr-370 are the most important residues involved in the mechanism of PKA-dependent reduction of desensitization of capsaicin-activated currents.	Univ Erlangen Nurnberg, Dept Anesthesiol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Nau, C (corresponding author), Univ Erlangen Nurnberg, Dept Anesthesiol, Krankenhausstr 12, D-91054 Erlangen, Germany.		Mohapatra, Durga/M-2133-2017; Durga, Mohapatra/B-3620-2008	Mohapatra, Durga/0000-0001-5016-1281; 				Beck EJ, 1998, J GEN PHYSIOL, V112, P71, DOI 10.1085/jgp.112.1.71; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Cantrell AR, 2002, MOL CELL NEUROSCI, V21, P63, DOI 10.1006/mcne.2002.1162; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; Docherty RJ, 1996, PFLUG ARCH EUR J PHY, V431, P828, DOI 10.1007/BF02332166; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Jung J, 2002, J BIOL CHEM, V277, P44448, DOI 10.1074/jbc.M207103200; Koplas PA, 1997, J NEUROSCI, V17, P3525; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Malmberg AB, 1997, J NEUROSCI, V17, P7462; McHugh D, 2000, P NATL ACAD SCI USA, V97, P12334, DOI 10.1073/pnas.210384297; Mohapatra DP, 2003, MOL CELL NEUROSCI, V23, P314, DOI 10.1016/S1044-7431(03)00054-X; Numazaki M, 2002, J BIOL CHEM, V277, P13375, DOI 10.1074/jbc.C200104200; Piper AS, 1999, J PHYSIOL-LONDON, V518, P721, DOI 10.1111/j.1469-7793.1999.0721p.x; Rathee PK, 2002, J NEUROSCI, V22, P4740, DOI 10.1523/JNEUROSCI.22-11-04740.2002; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	25	201	210	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50080	50090		10.1074/jbc.M306619200	http://dx.doi.org/10.1074/jbc.M306619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506258	hybrid			2022-12-25	WOS:000187068200052
J	Moorehead, RA; Hojilla, CV; De Belle, I; Wood, GA; Fata, JE; Adamson, ED; Watson, KLM; Edwards, DR; Khokha, R				Moorehead, RA; Hojilla, CV; De Belle, I; Wood, GA; Fata, JE; Adamson, ED; Watson, KLM; Edwards, DR; Khokha, R			Insulin-like growth factor-II regulates PTEN expression in the mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; NEGATIVE REGULATION; BREAST; RECEPTOR; NEOPLASIA; SURVIVAL; MOUSE; CELLS; MORPHOGENESIS; TRANSCRIPTION	The tumor suppressor PTEN is altered in many cancers, including breast cancer, but only a handful of factors are known to control its expression. PTEN plays a vital role in cell survival and proliferation by regulating Akt phosphorylation, a key component of the phosphatidylinositol 3 kinase (PI3K) pathway. Here we show that insulin-like growth factor-II (IGF-II), which signals through PI3K, regulates PTEN expression in the mammary gland. IGF-II injection into mouse mammary gland significantly increased PTEN expression. Transgenic IGF-II expression also increased mammary PTEN protein, leading to reductions in Akt phosphorylation, epithelial proliferation, and mammary morphogenesis. IGF-II induced PTEN promoter activity and protein levels and this involved the immediate early gene egr-1. Thus, we have identified a novel negative feedback loop within the PI3K pathway where IGF-II induces PTEN expression to modulate its physiologic effects.	Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Burnham Inst, La Jolla, CA 92037 USA; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Sanford Burnham Prebys Medical Discovery Institute; University of East Anglia	Khokha, R (corresponding author), Univ Toronto, Univ Hlth Network, Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rkhokha@uhnres.utoronto.ca	Wood, Geoffrey/ABB-2052-2021; Edwards, Dylan R/B-4734-2009	Wood, Geoffrey/0000-0003-1756-8607; Edwards, Dylan R/0000-0002-3292-2064; , Roger/0000-0001-9539-6295; Khokha, Rama/0000-0002-6028-1524				Bae SK, 1999, CANCER RES, V59, P5989; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Ball SM, 1998, ANAT REC, V250, P459, DOI 10.1002/(SICI)1097-0185(199804)250:4<459::AID-AR9>3.0.CO;2-S; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dunbar ME, 1998, DEV BIOL, V203, P75, DOI 10.1006/dbio.1998.9029; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Fata JE, 2001, BIOL REPROD, V65, P680, DOI 10.1095/biolreprod65.3.680; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Mutter GL, 2000, J CLIN ENDOCR METAB, V85, P2334, DOI 10.1210/jc.85.6.2334; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Petrocelli T, 2001, BREAST CANCER RES, V3, P356, DOI 10.1186/bcr322; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RUSSO IH, 1994, SURG PATHOL, V5, P307; Shyamala G, 1997, TRENDS ENDOCRIN MET, V8, P34, DOI 10.1016/S1043-2760(96)00207-X; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stambolic V, 2000, CANCER RES, V60, P3605; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wall SJ, 2002, J INVEST DERMATOL, V119, P91, DOI 10.1046/j.1523-1747.2002.01779.x; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545	39	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50422	50427		10.1074/jbc.M306894200	http://dx.doi.org/10.1074/jbc.M306894200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517213	hybrid			2022-12-25	WOS:000187068200093
J	Thrower, EC; Choe, CU; So, SH; Jeon, SH; Ehrlich, BE; Yoo, SH				Thrower, EC; Choe, CU; So, SH; Jeon, SH; Ehrlich, BE; Yoo, SH			A functional interaction between chromogranin B and the inositol 1,4,5-trisphosphate receptor/Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING REGION; SECRETORY GRANULES; CHROMAFFIN GRANULES; STORAGE PROTEIN; CA2+; CALCIUM; RELEASE; IDENTIFICATION; SCHIZOPHRENIA; LOCALIZATION	Chromogranins A and B (CGA and CGB) are high capacity, low affinity calcium (Ca2+) storage proteins found in many cell types most often associated with secretory granules of secretory cells but also with the endoplasmic reticulum ( ER) lumen of these cells. Both CGA and CGB associate with inositol 1,4,5-trisphosphate receptor (InsP(3)R) in a pH-dependent manner. At an intraluminal pH of 5.5, as found in secretory vesicles, both CGA and CGB bind to the InsP(3)R. When the intraluminal pH is 7.5, as found in the ER, CGA totally dissociates from InsP(3)R, whereas CGB only partially dissociates. To investigate the functional consequences of the interaction between the InsP(3)R and CGB monomers or CGA/ CGB heteromers, purified mouse InsP(3)R type I were fused to planar lipid bilayers and activated by 2 muM InsP(3). In the presence of luminal CGB monomers or CGA/ CGB heteromers the InsP(3)R/Ca2+ channel open probability and mean open time increased significantly. The channel activity remained elevated when the pH was changed to 7.5, a reflection of CGB binding to the InsP3R even at pH 7.5. These results suggest that CGB may play an important modulatory role in the control of Ca2+ release from the ER. Furthermore, the difference in the ability of CGA and CGB to regulate the InsP(3)R/Ca2+ channel and the variability of CGA/ CGB ratios could influence the pattern of InsP(3)-mediated Ca2+ release.	Yale Univ, Dept Pharmacol & Cellular & Mol Physiol, New Haven, CT 06520 USA; Inha Univ, Coll Med, Dept Biochem, Natl Creat Res Initiat Ctr Secretory Granule Res, Inchon 400712, South Korea	Yale University; Inha University	Ehrlich, BE (corresponding author), Yale Univ, Dept Pharmacol & Cellular & Mol Physiol, New Haven, CT 06520 USA.	barbara.ehrlich@yale.edu; shyoo@inha.ac.kr	/AAX-8408-2021	/0000-0001-9657-9704	NIGMS NIH HHS [GM63496] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063496] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHEN M, 1992, J NEUROCHEM, V58, P1691, DOI 10.1111/j.1471-4159.1992.tb10042.x; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GORR SU, 1989, AM J PHYSIOL, V257, P247; Huh YH, 2003, J BIOL CHEM, V278, P40581, DOI 10.1074/jbc.M304942200; Johenning FW, 2002, J NEUROSCI, V22, P5344; Kang YK, 1997, FEBS LETT, V404, P87, DOI 10.1016/S0014-5793(97)00099-9; Lamberts SWJ, 2001, FRONT NEUROENDOCRIN, V22, P309, DOI 10.1006/frne.2001.0218; Landen M, 1999, EUR NEUROPSYCHOPHARM, V9, P311, DOI 10.1016/S0924-977X(98)00042-X; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; MAHATA SK, 1992, MOL BRAIN RES, V16, P1, DOI 10.1016/0169-328X(92)90187-G; Marksteiner J, 2002, J MOL NEUROSCI, V18, P53, DOI 10.1385/JMN:18:1-2:53; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WEILER R, 1990, BRAIN RES, V532, P87, DOI 10.1016/0006-8993(90)91746-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; YOO SH, 1994, J BIOL CHEM, V269, P12001; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Yoo SH, 2002, J BIOL CHEM, V277, P16011, DOI 10.1074/jbc.M105594200; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; Yoo SH, 2001, J BIOL CHEM, V276, P45806, DOI 10.1074/jbc.M107532200; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0; Zhang BF, 2002, NEUROSCI LETT, V323, P229, DOI 10.1016/S0304-3940(02)00145-3	32	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49699	49706		10.1074/jbc.M309307200	http://dx.doi.org/10.1074/jbc.M309307200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506248	hybrid			2022-12-25	WOS:000187068200009
J	Lichtenthaler, SF; Dominguez, D; Westmeyer, GG; Reiss, K; Haass, C; Saftig, P; De Strooper, B; Seed, B				Lichtenthaler, SF; Dominguez, D; Westmeyer, GG; Reiss, K; Haass, C; Saftig, P; De Strooper, B; Seed, B			The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS BETA-SECRETASE; GAMMA-SECRETASE; CLEAVAGE; DISEASE; PRESENILIN; INHIBITOR; PSGL-1; SITE; GENERATION	The aspartyl protease BACE1 cleaves the amyloid precursor protein and the sialyltransferase ST6Gal I and is important in the pathogenesis of Alzheimer's disease. The normal function of BACE1 and additional physiological substrates have not been identified. Here we show that BACE1 acts on the P-selectin glycoprotein ligand 1 (PSGL-1), which mediates leukocyte adhesion in inflammatory reactions. In human monocytic U937 and human embryonic kidney 293 cells expressing endogenous or transfected BACE1, PSGL-1 was cleaved by BACE1 to generate a soluble ectodomain and a C-terminal transmembrane fragment. No evidence of the cleavage fragment was seen in primary cells derived from mice deficient in BACE1. By using deletion constructs and enzymatic deglycosylation of the C-terminal PSGL-1 fragments, the cleavage site in PSGL-1 was mapped to the juxtamembrane region within the ectodomain. In an in vitro assay BACE1 catalyzed the formation of the PSGL-1 products seen in vivo. The cleavage occurred at a Leu-Ser peptide bond as identified by mass spectrometry using a synthetic peptide. We conclude that PSGL-1 is an additional substrate for BACE1.	Univ Munich, A Butenandt Inst, D-80336 Munich, Germany; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Munich; Harvard University; Harvard Medical School; Massachusetts General Hospital; KU Leuven; University of Kiel	Lichtenthaler, SF (corresponding author), Univ Munich, A Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	Stefan.Lichtenthaler@pbm.med.uni-muenchen.de	de+Strooper, Bart/Z-1638-2019; Reiss, Karina/B-3175-2010; De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010; Lichtenthaler, Stefan F/B-6587-2016	De Strooper, Bart/0000-0001-5455-5819; Lichtenthaler, Stefan F/0000-0003-2211-2575; Westmeyer, Gil Gregor/0000-0001-7224-8919	NIAID NIH HHS [AI27849, AI46731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027849, R01AI027849, R01AI046731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 2002, J BIOL CHEM, V277, P5637, DOI 10.1074/jbc.M109119200; Chamoun F, 2000, FRONT BIOSCI, V5, pE103, DOI 10.2741/chamoun; Citron M, 2002, NAT NEUROSCI, V5, P1055, DOI 10.1038/nn940; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Davenpeck KL, 2000, J IMMUNOL, V165, P2764, DOI 10.4049/jimmunol.165.5.2764; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herman C, 1998, J IMMUNOL, V160, P2478; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Hussain I, 2001, J BIOL CHEM, V276, P23322, DOI 10.1074/jbc.M101069200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lefer DJ, 2000, ANNU REV PHARMACOL, V40, P283, DOI 10.1146/annurev.pharmtox.40.1.283; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schlondorff J, 1999, J CELL SCI, V112, P3603; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	40	221	228	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48713	48719		10.1074/jbc.M303861200	http://dx.doi.org/10.1074/jbc.M303861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507929	hybrid			2022-12-25	WOS:000186829000026
J	Tang, WG; Pavlish, OA; Spiegelman, VS; Parkhitko, AA; Fuchs, SY				Tang, WG; Pavlish, OA; Spiegelman, VS; Parkhitko, AA; Fuchs, SY			Interaction of Epstein-Barr virus latent membrane protein 1 with SCFHOS/beta-TrCP E3 ubiquitin ligase regulates extent of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN 1; P105 REQUIRES PHOSPHORYLATION; SIGNAL-INDUCED UBIQUITINATION; HUMAN EPITHELIAL-CELLS; BETA-TRCP; NASOPHARYNGEAL CARCINOMA; 30-BP DELETION; BNLF-1 GENE; IN-VIVO; FUNCTIONAL DIFFERENCES	The Epstein-Barr virus latent membrane protein 1 (LMP1) is pivotal in the transforming activity of this virus. We found that the common LMP1-95-8 variant interacts with Homologue of Slimb (HOS), a receptor for the SCFHOS/betaTrCP ubiquitin-protein isopeptide ligase (E3) via one canonical and one cryptic HOS recognition site. These sites are mutated or deleted in the tumor-derived LMP1-Cao variant, which did not bind to HOS. Mutations within these sites on LMP1-95-8 abrogated HOS binding and increased transforming activity of LMP1. HOS did not regulate stability of LMP1-95-8 unless it was mutated to bear additional lysine residues near the cryptic motif. LMP1 proteins that could not bind to HOS exhibited an increased ability to induce IkappaB degradation and NF-kappaB-mediated transcription without further increase in activation of IkappaB kinases. Expression of LMP1-95-8 reduced the levels of endogenous HOS available to interact with phosphorylated IkappaBalpha. Degradation of IkappaBalpha and dose dependence of NF-kappaB activation by LMP1-95-8 were promoted by co-expression of HOS. Our data suggest that LMP1-95-8 is a pseudo-substrate of SCFHOS/betaTrCP E3 ubiquitin ligase and that interaction between LMP1 and HOS restricts the extent of LMP1-induced NF-kappaB signaling. We discuss the potential role of this mechanism in transforming and cytostatic effects of LMP1 variants in cells and Epstein-Barr virus-associated tumors.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Russian Acad Med Sci, Canc Res Ctr, Viral Carcinogenesis Lab, Moscow 115478, Russia; AMC Canc Ctr, Lakewood, CO 80214 USA	University of Pennsylvania; Russian Academy of Medical Sciences; AMC Cancer Research Center	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Rm 161E, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu		Parkhitko, Andrey/0000-0001-9852-8329; Spiegelman, Vladimir S/0000-0003-4847-155X	NCI NIH HHS [CA92900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Blake SMS, 2001, VIROLOGY, V282, P278, DOI 10.1006/viro.2001.0828; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; CHEN ML, 1992, ONCOGENE, V7, P2131; Coffin WF, 2003, J VIROL, V77, P3749, DOI 10.1128/JVI.77.6.3749-3758.2003; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Edwards RH, 1999, VIROLOGY, V261, P79, DOI 10.1006/viro.1999.9855; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hahn P, 2001, INT J CANCER, V91, P815, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1122>3.0.CO;2-W; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; He ZM, 2000, CANCER RES, V60, P1845; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Johnson RJ, 1998, J VIROL, V72, P4038, DOI 10.1128/JVI.72.5.4038-4048.1998; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Li SN, 1996, ONCOGENE, V12, P2129; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Pai S, 2001, SEMIN CANCER BIOL, V11, P455, DOI 10.1006/scbi.2001.0412; Prokova V, 2002, J BIOL CHEM, V277, P9342, DOI 10.1074/jbc.M109099200; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Sandvej K, 1997, BLOOD, V90, P323; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Sung NS, 1998, INT J CANCER, V76, P207, DOI 10.1002/(SICI)1097-0215(19980413)76:2&lt;207::AID-IJC7&gt;3.0.CO;2-0; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Walling DM, 1999, J INFECT DIS, V179, P763, DOI 10.1086/314672; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xin BZ, 2001, J VIROL, V75, P3010, DOI 10.1128/JVI.75.6.3010-3015.2001; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang XS, 2002, CANCER LETT, V176, P65, DOI 10.1016/S0304-3835(01)00733-9; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	70	32	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48942	48949		10.1074/jbc.M307962200	http://dx.doi.org/10.1074/jbc.M307962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14523018	hybrid			2022-12-25	WOS:000186829000054
J	di San Filippo, CA; Wang, YH; Longo, N				di San Filippo, CA; Wang, YH; Longo, N			Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION/CARNITINE TRANSPORTER; TISSUE DISTRIBUTION PATTERN; CATION TRANSPORTER; ANION TRANSPORTER; IDENTIFICATION; RECOGNITION; PHENOTYPE; MUTATIONS; FAMILY; ROAT3	Primary carnitine deficiency is an autosomal recessive disorder of fatty acid oxidation characterized by hypoketotic hypoglycemia and skeletal and cardiac myopathy. It is caused by mutations in the Na+-dependent organic cation transporter, OCTN2. To define the domains involved in carnitine recognition, we evaluated chimeric transporters created by swapping homologous domains between OCTN1, which does not transport carnitine, and OCTN2. Substitution of the C terminus of OCTN2 ( amino acid residues 342-557) with the corresponding residues of OCTN1 completely abolished carnitine transport. The progressive substitution of the N terminus of OCTN2 with OCTN1 resulted in a decrease in carnitine transport associated with a progressive increase in the Km toward carnitine from 3.9 +/- 0.5 to 141 +/- 19 muM. The largest drop in carnitine transport ( and increase in Km toward carnitine) was observed with the substitution of residues 341-454 of OCTN2. An additional chimeric transporter (CHIM-9) in which only residues 341-454 of OCTN2 were substituted by OCTN1 had markedly reduced carnitine transport, with an elevated Km toward carnitine (63 +/- 5 muM). Site-directed mutagenesis and introduction of residues nonconserved between OCTN1 and OCTN2 in the OCTN2 cDNA indicated that the R341A, L409W, L424Y, and T429I substitutions significantly decreased carnitine transport. Single substitutions did not increase the Km toward carnitine. By contrast, the combination of three of these substitutions (R341W + L409W + T429I) greatly decreased carnitine transport and increased the Km toward carnitine (20.2 +/- 4.5 muM). The Arg-341, Leu-409, and Thr-429 residues are all located in predicted transmembrane domains. Involvement of these residues in carnitine transport was further supported by the partial restoration of carnitine transport by the introduction of these OCTN2 residues in the OCTN1 portion of CHIM-9. These studies indicate that multiple domains of the OCTN2 transporter are required for carnitine transport and identify transmembrane residues important for carnitine recognition.	Univ Utah, Dept Pediat, Div Med Genet, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Emory Univ, Dept Pediat, Div Med Genet, Atlanta, GA 30222 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Emory University	Longo, N (corresponding author), Univ Utah, Dept Pediat, Div Med Genet, 2C 412 SOM,50 N Med Dr, Salt Lake City, UT 84132 USA.			Longo, Nicola/0000-0002-3677-1216	NIDDK NIH HHS [DK 53824] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053824] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Enomoto A, 2002, J BIOL CHEM, V277, P36262, DOI 10.1074/jbc.M203883200; Feng B, 2002, BIOCHEMISTRY-US, V41, P8941, DOI 10.1021/bi0200615; Feng B, 2001, BIOCHEMISTRY-US, V40, P5511, DOI 10.1021/bi002841o; Meyer-Wentrup F, 1998, BIOCHEM BIOPH RES CO, V248, P673, DOI 10.1006/bbrc.1998.9034; Nakanishi T, 2001, J PHYSIOL-LONDON, V532, P297, DOI 10.1111/j.1469-7793.2001.0297f.x; Ohashi R, 2002, J PHARMACOL EXP THER, V302, P1286, DOI 10.1124/jpet.102.036004; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; Scaglia F, 1999, ARCH BIOCHEM BIOPHYS, V364, P99, DOI 10.1006/abbi.1999.1118; Scaglia F, 1999, SEMIN PERINATOL, V23, P152, DOI 10.1016/S0146-0005(99)80047-0; Segel, 1975, ENZYME KINETICS BEHA, P274; Seth P, 1999, J BIOL CHEM, V274, P33388, DOI 10.1074/jbc.274.47.33388; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 2000, J BIOL CHEM, V275, P40064, DOI 10.1074/jbc.M005340200; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Wagner CA, 2000, AM J PHYSIOL-RENAL, V279, pF584, DOI 10.1152/ajprenal.2000.279.3.F584; Wang YH, 2000, HUM MUTAT, V16, P401, DOI 10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J; Wang YH, 2000, HUM MUTAT, V15, P238, DOI 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3; Wang YH, 2000, J BIOL CHEM, V275, P20782, DOI 10.1074/jbc.M000194200; Wang YH, 2001, GENET MED, V3, P387, DOI 10.1097/00125817-200111000-00002; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482; Yabuuchi H, 1999, J PHARMACOL EXP THER, V289, P768	23	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47776	47784		10.1074/jbc.M307911200	http://dx.doi.org/10.1074/jbc.M307911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506273	hybrid			2022-12-25	WOS:000186731400053
J	Huang, L; Zhao, A; Lew, JL; Zhang, T; Hrywna, Y; Thompson, JR; de Pedro, N; Royo, I; Blevins, RA; Pelaez, F; Wright, SD; Cui, JS				Huang, L; Zhao, A; Lew, JL; Zhang, T; Hrywna, Y; Thompson, JR; de Pedro, N; Royo, I; Blevins, RA; Pelaez, F; Wright, SD; Cui, JS			Farnesoid X receptor activates transcription of the phospholipid pump MDR3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; FAMILIAL INTRAHEPATIC CHOLESTASIS; ORPHAN NUCLEAR RECEPTOR; P-GLYCOPROTEIN GENE; MULTIDRUG-RESISTANCE; ACID RECEPTOR; BILE-ACIDS; HEPATOCYTE CULTURES; EXPRESSION; LIVER	The human multidrug resistance gene MDR3 encodes a P-glycoprotein that belongs to the ATP-binding cassette transporter family (ABCB4). MDR3 is a critical trans-locator for phospholipids across canalicular membranes of hepatocytes, evidenced by the fact that human MDR3 deficiencies result in progressive familial intrahepatic cholestasis type III. It has been reported previously that MDR3 expression is modulated by hormones, cellular stress, and xenobiotics. Here we show that the MDR3 gene is trans-activated by the farnesoid X receptor (FXR) via a direct binding of FXR/retinoid X receptor alpha heterodimers to a highly conserved inverted repeat element (a FXR response element) at the distal promoter (-1970 to -1958). In FXR trans-activation assays, both the endogenous FXR agonist chenodeoxycholate and the synthetic agonist GW4064 activated the MDR3 promoter. Deletion or mutation of this inverted repeat element abolished FXR-mediated MDR3 promoter activation. Consistent with these data, MDR3 mRNA was significantly induced by both chenodeoxycholate and GW4064 in primary human hepatocytes in time- and dose-dependent fashions. In conclusion, we demonstrate that MDR3 expression is directly up-regulated by FXR. These results, together with the previous report that the bile salt export pump is a direct FXR target, suggest that FXR coordinately controls secretion of bile salts and phospholipids. Results of this study further support the notion that FXR is a master regulator of lipid metabolism.	Merck Res Labs, Dept Artherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Bioinformat, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Profiling, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Madrid 28027, Spain	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Cui, JS (corresponding author), Merck Res Labs, Dept Artherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.		Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Green RM, 2000, GENE, V241, P117, DOI 10.1016/S0378-1119(99)00460-6; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PIEKARZ RL, 1993, J BIOL CHEM, V268, P7613; SMIT JJM, 1995, BBA-GENE STRUCT EXPR, V1261, P44, DOI 10.1016/0167-4781(94)00214-N; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Willson TM, 2001, MED RES REV, V21, P513, DOI 10.1002/med.1023; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	28	188	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51085	51090		10.1074/jbc.M308321200	http://dx.doi.org/10.1074/jbc.M308321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527955	hybrid			2022-12-25	WOS:000187206300032
J	Sampath, V; Rekha, N; Srinivasan, N; Sadhale, P				Sampath, V; Rekha, N; Srinivasan, N; Sadhale, P			The conserved and non-conserved regions of Rpb4 are involved in multiple phenotypes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SUBUNIT RPB4; TRANSCRIPTIONAL REGULATION; NONESSENTIAL SUBUNIT; HIGH-TEMPERATURE; STRESS SURVIVAL; POL-II; YEAST; GENE; INITIATION	Rpb4, the fourth largest subunit of RNA polymerase II in Saccharomyces cerevisiae, is required for many phenotypes, including growth at high and low temperatures, sporulation, pseudohyphal growth, activated transcription of a subset of genes, and efficient carbon and energy metabolism. We have used deletion analysis to delineate the domains of the protein involved in these multiple phenotypes. The scRpb4 protein is conserved at the N and C termini but possesses certain non-conserved regions in the central portion. Our deletion analysis and molecular modeling results show that the Nand C-terminal conserved regions of Rpb4 are involved in interaction with Rpb7, the Rpb4 interacting partner in the RNA polymerase II. We further show that the conserved N terminus is required for efficient activated transcription from the INO1 promoter but not the GAL10- or the HSE-containing promoters. The N terminus is not required for any of the stress responses tested: growth at high temperatures, sporulation, and pseudohyphal growth. The conserved C-terminal 23 amino acids are not required for the role of Rpb4 in the pseudohyphal growth phenotype but might play a role in other stress responses and activated transcription. From the deletion analysis of the non-conserved regions, we report that they influence phenotypes involving both the N and C termini ( interaction with Rpb7 and transcription from the INO1 promoter) but not any of the stress-responsive phenotypes tested suggesting that they might be involved in maintaining the two conserved domains in an appropriate conformation for interaction with Rpb7 and other proteins. Taken together, our results allow us to assign phenotype-specific roles for the different conserved and non-conserved regions of Rpb4.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Sadhale, P (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		Sadhale, PArag/A-7799-2009					Archambault J, 1996, GENETICS, V142, P737; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLUNDELL T, 1988, EUR J BIOCHEM, V172, P513, DOI 10.1111/j.1432-1033.1988.tb13917.x; Bolotin-Fukuhara M, 2000, FEBS LETT, V487, P66, DOI 10.1016/S0014-5793(00)02282-1; Bourbonnais Y, 2001, MOL GEN GENET, V264, P763, DOI 10.1007/s004380000365; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; Khazak V, 1998, MOL CELL BIOL, V18, P1935, DOI 10.1128/MCB.18.4.1935; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; Larkin RM, 1998, J BIOL CHEM, V273, P5631, DOI 10.1074/jbc.273.10.5631; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; Miyao T, 2001, J BIOL CHEM, V276, P46408, DOI 10.1074/jbc.M107012200; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; Pillai B, 2003, J BIOL CHEM, V278, P3339, DOI 10.1074/jbc.M112180200; Pillai B, 2001, J BIOL CHEM, V276, P30641, DOI 10.1074/jbc.M010952200; Rekha Nambudiry, 2003, BMC Struct Biol, V3, P4, DOI 10.1186/1472-6807-3-4; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rosenheck S, 1998, J BACTERIOL, V180, P6187; RUET A, 1980, J BIOL CHEM, V255, P6450; Sadhale P, 1998, J BIOSCIENCE, V23, P331, DOI 10.1007/BF02936125; Sakurai H, 1999, MOL CELL BIOL, V19, P7511; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; Sharma N, 1999, J GENET, V78, P149, DOI 10.1007/BF02934460; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; Sherman F., 1983, METHODS YEAST GENETI; Shpakovski GV, 2000, J MOL BIOL, V295, P1119, DOI 10.1006/jmbi.1999.3399; Siaut M, 2003, MOL CELL BIOL, V23, P195, DOI 10.1128/MCB.23.1.195-205.2003; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SRINIVASAN N, 1993, PROTEIN ENG, V6, P501, DOI 10.1093/protein/6.5.501; Tan Q, 2000, MOL CELL BIOL, V20, P8124, DOI 10.1128/MCB.20.21.8124-8133.2000; Tan Q, 2003, MOL CELL BIOL, V23, P3329, DOI 10.1128/MCB.23.9.3329-3338.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Werner F, 2000, NUCLEIC ACIDS RES, V28, P4299, DOI 10.1093/nar/28.21.4299; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	46	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51566	51576		10.1074/jbc.M305863200	http://dx.doi.org/10.1074/jbc.M305863200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530281	Green Submitted, hybrid			2022-12-25	WOS:000187206300089
J	Westover, EJ; Covey, DF; Brockman, HL; Brown, RE; Pike, LJ				Westover, EJ; Covey, DF; Brockman, HL; Brown, RE; Pike, LJ			Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects - Studies with cholesterol enantiomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; INTERFACIAL ELASTICITY; BILAYER-MEMBRANES; CAVEOLAE MEMBRANE; CRYSTAL-STRUCTURE; MODEL MEMBRANES; CHAIN STRUCTURE; PHASE-BEHAVIOR; LIGAND-BINDING; DOMAINS	In A431 cells, depletion of cholesterol with methyl-beta-cyclodextrin induced an increase in both basal and epidermal growth factor (EGF)-stimulated EGF receptor phosphorylation. This increase in phosphorylation was site-specific, with significant increases occurring at Tyr(845), Tyr(992), and Tyr(1173), but only minor changes at Tyr(1045) and Tyr(1068). The elevated level of receptor phosphorylation was associated with an increase in the intrinsic kinase activity of the EGF receptor kinase, possibly as a result of the cyclodextrin-induced enhancement of the phosphorylation of Tyr845, a site in the kinase activation loop known to be phosphorylated by pp60(src). Cholesterol and its enantiomer (ent-cholesterol) were used to investigate the molecular basis for the modulation of EGF receptor function by cholesterol. Natural cholesterol (nat-cholesterol) was oxidized substantially more rapidly than ent-cholesterol by cholesterol oxidase, a protein that contains a specific binding site for the sterol. By contrast, the ability of nat- and ent-cholesterol to interact with sphingomyelins and phosphatidylcholine and to induce lipid condensation in a monolayer system was the same. These data suggest that, whereas cholesterol-protein interactions may be sensitive to the absolute configuration of the sterol, sterol-lipid interactions are not. nat- and ent-cholesterol were tested for their ability to physically reconstitute lipid rafts following depletion of cholesterol. nat- and ent-cholesterol reversed to the same extent the enhanced phosphorylation of the EGF receptor that occurred following removal of cholesterol. Furthermore, the enantiomers showed similar abilities to reconstitute lipid rafts in cyclodextrin-treated cells. These data suggest that cholesterol most likely affects EGF receptor function because of its physical effects on membrane properties, not through direct enantioselective interactions with the receptor.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Washington University (WUSTL); Washington University (WUSTL); University of Minnesota System	Pike, LJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave,POB 8231, St Louis, MO 63110 USA.			Brown, Rhoderick/0000-0002-7337-3604	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045928, R01GM064491, P01GM047969] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045928-08, P01 GM047969, GM45928, GM64491, R01 GM045928-07, R01 GM045928, R01 GM064491, R01 GM045928-09, R01 GM045928-11, GM47969, R01 GM045928-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ARNETT EM, 1982, J AM CHEM SOC, V104, P636, DOI 10.1021/ja00366a054; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATZER AG, 1994, J BIOL CHEM, V269, P31310; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown RE, 1998, J CELL SCI, V111, P1; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Chen Z, 1997, BIOPHYS J, V73, P267, DOI 10.1016/S0006-3495(97)78067-6; Crowder CM, 2001, J BIOL CHEM, V276, P44369, DOI 10.1074/jbc.C100535200; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GHOSH D, 1971, CHEM PHYS LIPIDS, V7, P173, DOI 10.1016/0009-3084(71)90030-2; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; GUYER W, 1983, CHEM PHYS LIPIDS, V33, P313, DOI 10.1016/0009-3084(83)90025-7; HERMETTER A, 1982, CHEM PHYS LIPIDS, V31, P283, DOI 10.1016/0009-3084(82)90063-9; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Jones DH, 1998, BIOCHEMISTRY-US, V37, P16780, DOI 10.1021/bi981520y; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li XM, 2001, BIOCHEMISTRY-US, V40, P5954, DOI 10.1021/bi002791n; Li XM, 2002, BIOPHYS J, V83, P1535, DOI 10.1016/S0006-3495(02)73923-4; Luker GD, 2000, BIOCHEMISTRY-US, V39, P7651, DOI 10.1021/bi9928593; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mannock DA, 2003, BIOPHYS J, V84, P1038, DOI 10.1016/S0006-3495(03)74920-0; McMullen TPW, 1996, CURR OPIN COLLOID IN, V1, P83, DOI 10.1016/S1359-0294(96)80048-3; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MOMSEN WE, 1990, J COLLOID INTERF SCI, V135, P547, DOI 10.1016/0021-9797(90)90025-J; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; OKABAYASHI Y, 1994, J BIOL CHEM, V268, P23634; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P10315, DOI 10.1021/bi025943i; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Ringerike T, 2002, J CELL SCI, V115, P1331; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMABY JM, 1994, BIOCHEMISTRY-US, V33, P9135, DOI 10.1021/bi00197a016; SMABY JM, 1991, CHEM PHYS LIPIDS, V58, P249, DOI 10.1016/0009-3084(91)90099-W; Smaby JM, 1997, BIOPHYS J, V73, P1492, DOI 10.1016/S0006-3495(97)78181-5; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Westover EJ, 2003, STEROIDS, V68, P159, DOI 10.1016/S0039-128X(02)00174-5; Zajchowski LD, 2002, EUR J BIOCHEM, V269, P737, DOI 10.1046/j.0014-2956.2001.02715.x	53	118	119	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51125	51133		10.1074/jbc.M304332200	http://dx.doi.org/10.1074/jbc.M304332200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530278	hybrid, Green Accepted			2022-12-25	WOS:000187206300037
J	Li, CL; Norris, PS; Ni, CZ; Havert, ML; Chiong, EM; Tran, BR; Cabezas, E; Reed, JC; Satterthwait, AC; Ware, CF; Ely, KR				Li, CL; Norris, PS; Ni, CZ; Havert, ML; Chiong, EM; Tran, BR; Cabezas, E; Reed, JC; Satterthwait, AC; Ware, CF; Ely, KR			Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VIRUS TRANSFORMING PROTEIN; CELL-DEATH; HUMAN TRAF2; HOT-SPOTS; TNF; ACTIVATION; BINDING; PATHWAYS; LIGAND	Lymphotoxin-beta receptor (LTbetaR) and CD40 are members of the tumor necrosis factor family of signaling receptors that regulate cell survival or death through activation of NF-kappaB. These receptors transmit signals through downstream adaptor proteins called tumor necrosis factor receptor-associated factors (TRAFs). In this study, the crystal structure of a region of the cytoplasmic domain of LTbetaR bound to TRAF3 has revealed an unexpected new recognition motif, (388)IPEEGD(393), for TRAF3 binding. Although this motif is distinct in sequence and structure from the PVQET motif in CD40 and PIQCT in the regulator TRAF-associated NF-kappaB activator ( TANK), recognition is mediated in the same binding crevice on the surface of TRAF3. The results reveal structurally adaptive "hot spots" in the TRAF3-binding crevice that promote molecular interactions driving specific signaling after contact with LTbetaR, CD40, or the downstream regulator TANK.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; La Jolla Institute for Immunology	Ely, KR (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA69381] Funding Source: Medline; NIAID NIH HHS [R01AI03368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Benedict CA, 2003, CURR OPIN IMMUNOL, V15, P59, DOI 10.1016/S0952-7915(02)00018-3; Benedict CA, 2001, IMMUNITY, V15, P617, DOI 10.1016/S1074-7613(01)00222-9; BHAT TN, 1984, J APPL CRYSTALLOGR, V17, P244, DOI 10.1107/S0021889884011456; Bishop GA, 2001, IMMUNOL RES, V24, P97, DOI 10.1385/IR:24:2:097; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chung JY, 2002, J CELL SCI, V115, P679; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Ely KR, 2002, J MOL RECOGNIT, V15, P286, DOI 10.1002/jmr.589; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Force WR, 2000, J BIOL CHEM, V275, P11121, DOI 10.1074/jbc.275.15.11121; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li CL, 2002, STRUCTURE, V10, P403, DOI 10.1016/S0969-2126(02)00733-5; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Najmanovich R, 2000, PROTEINS, V39, P261, DOI 10.1002/(SICI)1097-0134(20000515)39:3<261::AID-PROT90>3.0.CO;2-4; Nakano H, 1997, GENOMICS, V42, P26, DOI 10.1006/geno.1997.4697; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; Ni CZ, 2002, ACTA CRYSTALLOGR D, V58, P1340, DOI 10.1107/S0907444902008958; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P55; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Rooney IA, 2000, J BIOL CHEM, V275, P14307, DOI 10.1074/jbc.275.19.14307; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; VanArsdale TL, 1997, P NATL ACAD SCI USA, V94, P2460, DOI 10.1073/pnas.94.6.2460; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; [No title captured]	44	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50523	50529		10.1074/jbc.M309381200	http://dx.doi.org/10.1074/jbc.M309381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517219	hybrid			2022-12-25	WOS:000187068200105
J	Schlaeppi, AC; Malherbe, T; Buetikofer, P				Schlaeppi, AC; Malherbe, T; Buetikofer, P			Coordinate expression of GPEET procyclin and its membrane-associated kinase in Trypanosoma brucei procyclic forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC REPETITIVE PROTEIN; BLOOD-STREAM FORMS; ECTOPROTEIN KINASE; SURFACE PROTEIN; TSETSE-FLY; LEISHMANIA-MAJOR; CELL-SURFACE; EXTRACELLULAR PHOSPHORYLATION; TRICHINELLA-SPIRALIS; INFECTIVE LARVAE	GPEET procyclin is a major glycosylphosphatidylinositol-anchored protein of procyclic (insect stage) trypanosomes in culture and is heavily phosphorylated in the GPEET pentapeptide repeat. The phosphorylation reaction is a late event and occurs during maturation and transport of GPEET or on the parasite surface by an ecto-protein kinase. Initial biochemical characterization of the GPEET kinase activity now shows that it depends on bivalent cations for maximal activity, is stimulated by sulfhydryl group reagents, and is specific for ATP as phosphoryl donor. No kinase activity is detected in bloodstream form trypanosomes in culture, whereas strong phosphorylation is observed in early procyclic forms. In addition, the GPEET kinase activity is absent from procyclic trypanosomes that have repressed GPEET synthesis but can be induced in these same stocks by conditions, which also induce GPEET expression. However, the presence of an active kinase does not depend on the presence of (functional) GPEET because it can be detected in parasites expressing a non-phosphorylatable GPEET mutant protein and in procyclin null mutant trypanosomes. Interestingly, the presence of the glycosylphosphatidylinositol lipid moiety seems necessary for GPEET to become phosphorylated. Together, the results demonstrate that GPEET and its kinase are expressed during the same life cycle stages and that factors that induce the expression of GPEET in vitro also induce the expression of the GPEET kinase.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	University of Bern	Buetikofer, P (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	peter.buetikofer@mci.unibe.ch						Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; Arden SR, 1997, MOL BIOCHEM PARASIT, V90, P111, DOI 10.1016/S0166-6851(97)00145-X; Babinska A, 2000, AM J PHYSIOL-HEART C, V278, pH2008, DOI 10.1152/ajpheart.2000.278.6.H2008; Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; Bandyopadhyay D, 1997, MOL CELL BIOCHEM, V167, P73, DOI 10.1023/A:1006815504302; BARBONI E, 1995, J CELL SCI, V108, P487; Berredo-Pinho M, 2001, ARCH BIOCHEM BIOPHYS, V391, P16, DOI 10.1006/abbi.2001.2384; BRAUNBRETON C, 1988, BIOL CELL, V64, P223, DOI 10.1016/0248-4900(88)90081-0; BREWIS IA, 1994, BIOCHEM J, V303, P633, DOI 10.1042/bj3030633; BRUN R, 1979, ACTA TROP, V36, P289; Butikofer P, 1997, BIOCHEM J, V326, P415; Butikofer P, 2003, MOL BIOCHEM PARASIT, V126, P287, DOI 10.1016/S0166-6851(02)00286-4; Butikofer P, 1999, J CELL SCI, V112, P1785; Butikofer P, 2001, FASEB J, V15, P545, DOI 10.1096/fj.00-0415hyp; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CROSS GAM, 1973, PARASITOLOGY, V67, P315, DOI 10.1017/S0031182000046540; DELAUW MF, 1985, EMBO J, V4, P989, DOI 10.1002/j.1460-2075.1985.tb03728.x; Ehrlich YH, 1998, ADV EXP MED BIOL, V446, P51; EMES CH, 1982, BIOCHIM BIOPHYS ACTA, V717, P98, DOI 10.1016/0304-4165(82)90385-3; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1992, J BIOL CHEM, V267, P5324; HERMOSO T, 1994, ACTA TROP, V56, P1, DOI 10.1016/0001-706X(94)90034-5; HERMOSO T, 1991, EMBO J, V10, P4061, DOI 10.1002/j.1460-2075.1991.tb04982.x; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; Kubler D, 2001, BIOCHEM J, V360, P579, DOI 10.1042/0264-6021:3600579; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERAY D, 1977, ANN SOC BELG MED TR, V57, P369; LESTER DS, 1990, BIOCHIM BIOPHYS ACTA, V1052, P293, DOI 10.1016/0167-4889(90)90224-2; Letho MT, 1998, BIOCHEM J, V332, P101, DOI 10.1042/bj3320101; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; MOTION RL, 1984, BIOCHEMISTRY-US, V23, P6851, DOI 10.1021/bi00321a088; MULLER G, 1994, ARCH BIOCHEM BIOPHYS, V308, P504, DOI 10.1006/abbi.1994.1071; Nickel V, 1998, J BIOL CHEM, V273, P23668, DOI 10.1074/jbc.273.37.23668; Paas Y, 1999, IMMUNOPHARMACOLOGY, V42, P175, DOI 10.1016/S0162-3109(99)00027-2; Park JH, 2002, MOL BIOCHEM PARASIT, V119, P97, DOI 10.1016/S0166-6851(01)00407-8; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PIROTTON S, 1992, BIOCHEM J, V285, P585, DOI 10.1042/bj2850585; Redegeld FA, 1999, TRENDS PHARMACOL SCI, V20, P453, DOI 10.1016/S0165-6147(99)01399-1; Redegeld FA, 1997, BBA-BIOMEMBRANES, V1328, P151, DOI 10.1016/S0005-2736(97)00082-5; Riordan J F, 1972, Methods Enzymol, V25, P449, DOI 10.1016/S0076-6879(72)25040-6; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; Sacerdoti-Sierra N, 1997, J BIOL CHEM, V272, P30760, DOI 10.1074/jbc.272.49.30760; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; Smith VP, 2000, FEBS LETT, V483, P104, DOI 10.1016/S0014-5793(00)02094-9; Teshima R, 1999, IMMUNOL LETT, V68, P369, DOI 10.1016/S0165-2478(99)00086-3; TOMAVO S, 1992, PARASITOL RES, V78, P541, DOI 10.1007/BF00936449; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; VANSTEVENINCK J, 1965, J GEN PHYSIOL, V48, P617, DOI 10.1085/jgp.48.4.617; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P91, DOI 10.1016/0166-6851(96)02727-2; Vassella E, 2000, GENE DEV, V14, P615; Vassella E, 2001, J MOL BIOL, V312, P597, DOI 10.1006/jmbi.2001.5004; Vassella E, 2003, MOL BIOL CELL, V14, P1308, DOI 10.1091/mbc.E02-10-0694; VELICK SF, 1953, J BIOL CHEM, V203, P563; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; Vieira LL, 2002, INT J PARASITOL, V32, P1085, DOI 10.1016/S0020-7519(02)00067-X; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Wang X, 1996, BIOCHEMISTRY-US, V35, P16305, DOI 10.1021/bi961098q; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; Yakubov LA, 1998, FEBS LETT, V431, P45, DOI 10.1016/S0014-5793(98)00721-2	70	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49980	49987		10.1074/jbc.M309548200	http://dx.doi.org/10.1074/jbc.M309548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517220	hybrid			2022-12-25	WOS:000187068200041
J	Xiao, GG; Wang, MY; Li, N; Loo, JA; Nel, AE				Xiao, GG; Wang, MY; Li, N; Loo, JA; Nel, AE			Use of proteomics to demonstrate a hierarchical oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLERGIC AIRWAY INFLAMMATION; EPITHELIAL-CELLS; IN-VIVO; CYTOCHROME-P450 1A1; CYTOKINE PRODUCTION; CARBOXYPEPTIDASE-H; POLLUTION PARTICLE; RAGWEED ALLERGEN; OXYGEN RADICALS; PROTEIN	Epidemiological studies demonstrate an association between short term exposure to ambient particulate matter (PM) and cardiorespiratory morbidity and mortality. Although the biological mechanisms of these adverse effects are unknown, emerging data suggest a key role for oxidative stress. Ambient PM and diesel exhaust particles (DEP) contain redox cycling organic chemicals that induce pro-oxidative and pro-inflammatory effects in the lung. These responses are suppressed by N-acetylcysteine (NAC), which directly complexes to electrophilic DEP chemicals and exert additional antioxidant effects at the cellular level. A proteomics approach was used to study DEP-induced responses in the macrophage cell line, RAW 264.7. We demonstrate that in the dose range 10-100 mug/ml, organic DEP extracts induce a progressive decline in the cellular GSH/GSSG ratio, in parallel with a linear increase in newly expressed proteins on the two-dimensional gel. Using matrix-assisted laser desorption ionization time-of-flight mass spectrometry and electrospray ionization-liquid chromatography/ mass spectrometry/mass spectrometry analysis, 32 newly induced/NAC-suppressed proteins were identified. These include antioxidant enzymes (e. g. heme oxygenase-1 and catalase), pro-inflammatory components (e. g. p38(MAPK) and Rel A), and products of intermediary metabolism that are regulated by oxidative stress. Heme oxygenase-1 was induced at low extract dose and with minimal decline in the GSH/GSSG ratio, whereas MAP kinase activation required a higher chemical dose and incremental levels of oxidative stress. Moreover, at extract doses >50 mug/ml, there is a steep decline in cellular viability. These data suggest that DEP induce a hierarchical oxidative stress response in which some of these proteins may serve as markers for oxidative stress during PM exposures.	Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biochem & Biol Chem, Keck Funct Prote Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Nel, AE (corresponding author), Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, David Geffen Sch Med, Box 951680,52-175 CHS, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Nel, Andre E/J-2808-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012053, R01ES010553] Funding Source: NIH RePORTER; NIAID NIH HHS [P0-1 AI50495] Funding Source: Medline; NIEHS NIH HHS [R0-1 ES12053, R0-1 ES10553] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Bernstein C, 2002, PHARMACOLOGY, V65, P2, DOI 10.1159/000056179; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515, DOI 10.1165/ajrcmb.25.4.4515; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; COHEN AJ, 1998, AIR POLLUTION HLTH, V32; Conrad CC, 2001, PROTEOMICS, V1, P829, DOI 10.1002/1615-9861(200107)1:7<829::AID-PROT829>3.0.CO;2-R; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dimayuga FO, 2003, J NEUROIMMUNOL, V136, P67, DOI 10.1016/S0165-5728(03)00003-1; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Eaton P, 2002, J MOL CELL CARDIOL, V34, P1549, DOI 10.1006/jmcc.2002.2108; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fernandez Virginia, 1996, Biological Research, V29, P177; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Ghio AJ, 1999, INHAL TOXICOL, V11, P37, DOI 10.1080/089583799197258; Gillissen A, 1998, RESP MED, V92, P609, DOI 10.1016/S0954-6111(98)90506-6; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; GRUNFELD C, 1991, CANCER RES, V51, P2803; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Hoang VM, 2001, BIOCHEMISTRY-US, V40, P4077, DOI 10.1021/bi0023910; HOOK VYH, 1988, CELL MOL NEUROBIOL, V8, P49, DOI 10.1007/BF00712911; HOOK VYH, 1988, FEBS LETT, V238, P338, DOI 10.1016/0014-5793(88)80508-8; Ito Y, 1996, AM J PHYSIOL-HEART C, V270, pH81, DOI 10.1152/ajpheart.1996.270.1.H81; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jungblut P, 1997, MASS SPECTROM REV, V16, P145, DOI 10.1002/(SICI)1098-2787(1997)16:3<145::AID-MAS2>3.0.CO;2-H; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Laan M, 2003, EUR RESPIR J, V21, P387, DOI 10.1183/09031936.03.00303503; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Li N, 2000, J IMMUNOL, V165, P3393, DOI 10.4049/jimmunol.165.6.3393; LI N, 2003, IN PRESS CLIN IMMUNO; Loo JA, 1999, MED RES REV, V19, P307, DOI 10.1002/(SICI)1098-1128(199907)19:4<307::AID-MED4>3.0.CO;2-2; Luo JD, 2003, CURR MED CHEM, V10, P1593, DOI 10.2174/0929867033457205; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McQueen KL, 1998, IMMUNOGENETICS, V48, P174, DOI 10.1007/s002510050421; Miyabara Y, 1998, INT ARCH ALLERGY IMM, V116, P124, DOI 10.1159/000023935; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138, DOI 10.1164/ajrccm.157.4.9708066; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Naismith James H., 1995, Journal of Inflammation, V47, P1; National Research Council, 1998, RES PRIOR AIRB PART; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; Ohsawa I, 2001, J NEUROCHEM, V76, P1411, DOI 10.1046/j.1471-4159.2001.00144.x; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; POPE CA, 1998, AIR POLLUTION HLTH, V31, P673; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Saldiva PHN, 2002, AM J RESP CRIT CARE, V165, P1610, DOI 10.1164/rccm.2106102; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SCHUETZLE D, 1981, INT J ENVIRON AN CH, V9, P93, DOI 10.1080/03067318108071903; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Takano H, 2002, ARCH TOXICOL, V76, P146, DOI 10.1007/s00204-002-0323-0; Takano H, 2000, LAB INVEST, V80, P371, DOI 10.1038/labinvest.3780041; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Webster KA, 2001, ANTIOXID REDOX SIGN, V3, P535, DOI 10.1089/15230860152542916; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Whitelegge JP, 2000, PROTEIN SCI, V9, P1618, DOI 10.1110/ps.9.9.1618; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	77	312	332	6	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50781	50790		10.1074/jbc.M306423200	http://dx.doi.org/10.1074/jbc.M306423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522998	hybrid			2022-12-25	WOS:000187068200134
J	Hirakawa, T; Galet, C; Kishi, M; Ascoli, M				Hirakawa, T; Galet, C; Kishi, M; Ascoli, M			GIPC binds to the human lutropin receptor (hLHR) through an unusual PDZ domain binding motif, and it regulates the sorting of the internalized human choriogonadotropin and the density of cell surface hLHR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; PROTEIN-COUPLED RECEPTORS; HUMAN CHORIO-GONADOTROPIN; LEYDIG TUMOR-CELLS; HUMAN LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; FOLLITROPIN RECEPTOR; MEDIATED ENDOCYTOSIS; CYTOPLASMIC DOMAIN; TRANSFECTED CELLS	By using a yeast two-hybrid screen we identified GIPC (GAIP-interacting protein C terminus), a protein with a type I PDZ domain as a novel human lutropin receptor (hLHR) binding partner. Pull-down and immunoprecipitation assays confirmed this interaction and showed that it is dependent on the PDZ domain of GIPC and the C-terminal tetrapeptide of the hLHR. To characterize the functional consequences of the GIPC-hLHR interaction, we used a small interfering RNA against GIPC to generate a clonal cell line that is deficient in GIPC. Studies with this cell line reveal that GIPC is partially responsible for the recycling of the hormone that is internalized by the hLHR and also for maintaining a relatively constant level of hLHR at the cell surface during hormone internalization.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pharmacol, 2-319B BSB,51 Newton Rd, Iowa City, IA 52242 USA.		galet, colette/AAG-2464-2020	galet, colette/0000-0002-5931-2143	NCI NIH HHS [CA 40629] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; Awan A, 2002, BIOCHEM BIOPH RES CO, V290, P1030, DOI 10.1006/bbrc.2001.6288; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Cai HB, 1999, J NEUROSCI, V19, P6519; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kishi H, 2002, J BIOL CHEM, V277, P21939, DOI 10.1074/jbc.M110894200; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Kishi M, 2000, MOL ENDOCRINOL, V14, P926, DOI 10.1210/me.14.6.926; Krishnamurthy H, 2003, MOL CELL ENDOCRINOL, V204, P127, DOI 10.1016/S0303-7207(03)00088-1; Liu TF, 2001, J BIOL CHEM, V276, P35768, DOI 10.1074/jbc.M103585200; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; Lou XJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134918; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Tani TT, 2001, J BIOL CHEM, V276, P36535, DOI 10.1074/jbc.M105785200; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; WANG H, 1991, J BIOL CHEM, V266, P780; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200	55	64	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49348	49357		10.1074/jbc.M306557200	http://dx.doi.org/10.1074/jbc.M306557200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14507927	hybrid			2022-12-25	WOS:000186829000103
J	Abe, M; Ho, CH; Kamm, KE; Grinnell, F				Abe, M; Ho, CH; Kamm, KE; Grinnell, F			Different molecular motors mediate platelet-derived growth factor and lysophosphatidic acid-stimulated floating collagen matrix contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; RHO-RHO-KINASE; FIBROBLAST CONTRACTION; EXTRACELLULAR-MATRIX; ACTIN POLYMERIZATION; WOUND CONTRACTION; FORCE GENERATION; FOCAL ADHESIONS; RETROGRADE FLOW; STRESS FIBERS	Fibroblast-collagen matrix contraction has been used as a model system to study how cells organize connective tissue. Previous work showed that lysophosphatidic acid (LPA)-stimulated floating collagen matrix contraction is independent of Rho kinase, whereas platelet-derived growth factor (PDGF)-stimulated contraction is Rho kinase-dependent. The current studies were carried out to learn more about the molecular motors responsible for LPA- and PDGF-stimulated contraction. We found that neither PDGF nor LPA- dependent contractile mechanisms require myosin II regulatory light chain kinase or increased phosphorylation of myosin II regulatory light chain (measured as diphosphorylation). Low concentrations of the specific myosin II inhibitor blebbistatin blocked PDGF-stimulated matrix contraction and LPA- stimulated retraction of fibroblast dendritic extensions but not LPA- stimulated matrix contraction. These data suggest that PDGF- and LPA-stimulated floating matrix contraction utilize myosin II-dependent and -independent mechanisms, respectively. LPA- dependent, Rho kinase-independent force generation also was detected during fibroblast spreading on collagen-coated coverslips.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031321, R37GM031321] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31321] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ai S, 2001, ATHEROSCLEROSIS, V155, P321, DOI 10.1016/S0021-9150(00)00585-2; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Beningo KA, 2002, TRENDS CELL BIOL, V12, P79, DOI 10.1016/S0962-8924(01)02205-X; Berry DP, 1998, PLAST RECONSTR SURG, V102, P124, DOI 10.1097/00006534-199807000-00019; Brown RA, 1998, J CELL PHYSIOL, V175, P323, DOI 10.1002/(SICI)1097-4652(199806)175:3<323::AID-JCP10>3.0.CO;2-6; Caspi A, 2001, BIOPHYS J, V81, P1990, DOI 10.1016/S0006-3495(01)75849-3; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Diefenbach TJ, 2002, J CELL BIOL, V158, P1207, DOI 10.1083/jcb.200202028; EHRLICH HP, 1991, J CELL PHYSIOL, V146, P1, DOI 10.1002/jcp.1041460102; Fukata Y, 2001, TRENDS PHARMACOL SCI, V22, P32, DOI 10.1016/S0165-6147(00)01596-0; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Grinnell F, 2003, TRENDS CELL BIOL, V13, P264, DOI 10.1016/S0962-8924(03)00057-6; Grinnell F, 2003, MOL BIOL CELL, V14, P384, DOI 10.1091/mbc.E02-08-0493; Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918; GROSS J, 1995, P NATL ACAD SCI USA, V92, P5982, DOI 10.1073/pnas.92.13.5982; Henson JH, 2002, MOL BIOL CELL, V13, P1001, DOI 10.1091/mbc.01-04-0167; Henson JH, 1999, MOL BIOL CELL, V10, P4075, DOI 10.1091/mbc.10.12.4075; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; Inoue S, 1997, J STRUCT BIOL, V118, P87, DOI 10.1006/jsbi.1996.3839; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Katoh K, 2001, AM J PHYSIOL-CELL PH, V280, pC1669, DOI 10.1152/ajpcell.2001.280.6.C1669; Kolodney MS, 1999, J PHYSIOL-LONDON, V515, P87, DOI 10.1111/j.1469-7793.1999.087ad.x; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; Lee DJ, 2003, EXP CELL RES, V289, P86, DOI 10.1016/S0014-4827(03)00254-4; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Nobe H, 2003, AM J PHYSIOL-CELL PH, V284, pC599, DOI 10.1152/ajpcell.00188.2002; OBARA K, 1995, J BIOL CHEM, V270, P18734, DOI 10.1074/jbc.270.32.18734; Parizi M, 2000, EXP CELL RES, V254, P210, DOI 10.1006/excr.1999.4754; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Shreiber DI, 2001, EXP CELL RES, V266, P155, DOI 10.1006/excr.2001.5208; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Takayama Y, 2001, FEBS LETT, V508, P111, DOI 10.1016/S0014-5793(01)03041-1; Tamariz E, 2002, MOL BIOL CELL, V13, P3915, DOI 10.1091/mbc.E02-05-0291; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Totsukawa G, 2000, J CELL BIOL, V150, P797, DOI 10.1083/jcb.150.4.797; Tranquillo RT, 1999, BIOCHEM SOC SYMP, V65, P27; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Wakatsuki T, 2003, BIOPHYS CHEM, V100, P593, DOI 10.1016/S0301-4622(02)00308-3; Yanase M, 2000, BIOCHEM BIOPH RES CO, V277, P72, DOI 10.1006/bbrc.2000.3634; Ye LH, 1999, P NATL ACAD SCI USA, V96, P6666, DOI 10.1073/pnas.96.12.6666	49	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47707	47712		10.1074/jbc.M306228200	http://dx.doi.org/10.1074/jbc.M306228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14504290	hybrid			2022-12-25	WOS:000186731400046
J	Lu, YF; Goldenberg, I; Bei, L; Andrejic, J; Eklund, EA				Lu, YF; Goldenberg, I; Bei, L; Andrejic, J; Eklund, EA			HoxA10 represses gene transcription in undifferentiated myeloid cells by interaction with histone deacetylase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING PROTEIN; DNA-BINDING; MAMMALIAN MEMBER; ONECUT CLASS; IN-VITRO; EXPRESSION; DIFFERENTIATION; GP91(PHOX); LEUKEMIA; PU.1	The homeodomain proteins, HoxA10 and Pbx1a, interact with negative cis elements to repress gene transcription in undifferentiated myeloid cells. The CYBB and NCF2 genes, which encode the gp91(PHOX) and p67(PHOX) proteins, are two such HoxA10-Pbx1a target genes. In previous studies, we found that HoxA10-Pbx1a represses transcription of these genes by two mechanisms: competition for DNA binding with transcriptional activators and endogenous repression activity. In these studies, we identify a novel molecular mechanism of endogenous transcriptional repression by HoxA-10Pbx1a. Endogenous repression activity of other Hox-Pbx1a complexes requires recruitment of transcriptional co-repressor proteins by Pbx1a. In contrast, our investigations have determined that HoxA10 has Pbx1a-independent endogenous repression activity. We find that this transcriptional repression activity is abrogated by histone deacetylase inhibitors, suggesting involvement of co-repressor proteins. Consistent with this, we identify HoxA10 amino acids 224 - 249 as a Pbx1-independent repression domain, which interacts with histone deacetylase 2. We have determined that this HoxA10 domain is not conserved with other Abd Hox proteins, although homology exists with other transcription factors and co-repressors. Understanding the roles different Hox proteins play in myeloid differentiation is a challenging problem. Our results suggest that insight into this problem can be obtained from biochemical characterization of the various molecular mechanisms of Hox protein function.	Northwestern Univ, Fineberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Chicago Lakeside Vet Affairs Hosp, Chicago, IL 60611 USA; Birmingham Vet Affairs Hosp, Birmingham, AL 35294 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Eklund, EA (corresponding author), Northwestern Univ, Sch Med, Dept Med Hematol Oncol, Rm 8527,710 N Fairbanks Ct,Olson Pavil, Chicago, IL 60611 USA.	e-eklund@northwestern.edu			NCI NIH HHS [CA95266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Asahara H, 1999, MOL CELL BIOL, V19, P8219; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 2002, J BIOL CHEM, V277, P36878, DOI 10.1074/jbc.M203917200; Eklund EA, 1996, J IMMUNOL, V157, P2418; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Ferrara FF, 2001, CANCER RES, V61, P2; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kautz B, 2001, J BIOL CHEM, V276, P37868; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LARRICK JW, 1980, J IMMUNOL, V125, P6; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Saleh M, 2000, MOL CELL BIOL, V20, P8623, DOI 10.1128/MCB.20.22.8623-8633.2000; SAMBROOK H, 1989, MOL CLONING LAB MANU, P125; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Vanhorenbeeck V, 2002, BIOCHEM BIOPH RES CO, V292, P848, DOI 10.1006/bbrc.2002.6760; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200	38	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47792	47802		10.1074/jbc.M305885200	http://dx.doi.org/10.1074/jbc.M305885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14512427	hybrid			2022-12-25	WOS:000186731400055
J	Necula, M; Chirita, CN; Kuret, J				Necula, M; Chirita, CN; Kuret, J			Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; LEWY BODIES; NEURODEGENERATIVE DISORDERS; PRECURSOR PROTEIN; FATTY-ACIDS; MEMBRANE INTERACTIONS	Parkinson's disease is characterized by the aggregation of alpha-synuclein into filamentous forms within affected neurons of the basal ganglia. Fibrillization of purified recombinant alpha-synuclein is inefficient in vitro but can be enhanced by the addition of various agents including glycosaminoglycans and polycations. Here we report that fatty acids and structurally related anionic detergents greatly accelerate fibrillization of recombinant alpha-synucleinat low micromolar concentrations with lag times as short as 11 min and apparent first order growth rate constants as fast as 10.4 h(-1). All detergents and fatty acids were micellar at active concentrations because of an alpha-synuclein-dependent depression of their critical micelle concentrations. Other anionic surfaces, such as those supplied by anionic phospholipid vesicles, also induced alpha-synuclein fibrillization, with resultant filaments originating from their surface. These data suggest that anionic surfaces presented as micelles or vesicles can serve to nucleate alpha-synuclein fibrillization, that this mechanism underlies the inducer activity of anionic surfactants, and that anionic membranes may serve this function in vivo.	Ohio State Univ, Coll Med & Publ Hlth, Ctr Biotechnol, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Biophys Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Ctr Biotechnol, Dept Mol & Cellular Biochem, 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu			NIA NIH HHS [AG 14452] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Antony T, 2003, J BIOL CHEM, V278, P3235, DOI 10.1074/jbc.M208249200; Arai Y, 2001, BRAIN RES, V888, P287, DOI 10.1016/S0006-8993(00)03082-1; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; Bales BL, 2001, J PHYS CHEM B, V105, P6798, DOI 10.1021/jp004576m; BERGERON C, 1989, Alzheimer Disease and Associated Disorders, V3, P197, DOI 10.1097/00002093-198900000-00002; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CORRIN ML, 1947, J AM CHEM SOC, V69, P683, DOI 10.1021/ja01195a065; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DICKSON DW, 2000, NEURODEGENERATIVE DE, P247; DUFFY PE, 1965, J NEUROPATH EXP NEUR, V24, P398, DOI 10.1097/00005072-196507000-00003; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GUNNARSSON G, 1980, J PHYS CHEM-US, V84, P3114, DOI 10.1021/j100460a029; Hagihara Y, 2002, BIOCHEMISTRY-US, V41, P1020, DOI 10.1021/bi015693q; Huibers PDT, 1997, J COLLOID INTERF SCI, V187, P113, DOI 10.1006/jcis.1996.4680; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAGER WAD, 1969, ARCH NEUROL-CHICAGO, V21, P615; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; KING MD, 1987, BIOCHEMISTRY-US, V26, P1224, DOI 10.1021/bi00379a004; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Mukaetova-Ladinska EB, 2000, J NEUROPATH EXP NEUR, V59, P408, DOI 10.1093/jnen/59.5.408; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Naiki H, 1999, METHOD ENZYMOL, V309, P305; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Pertinhez TA, 2002, FEBS LETT, V529, P193, DOI 10.1016/S0014-5793(02)03333-1; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ranganathan R, 2000, J PHYS CHEM B, V104, P2260, DOI 10.1021/jp993917x; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Spillantini MG, 1999, ACTA NEUROPATHOL, V97, P585, DOI 10.1007/s004010051034; Takeda A, 1998, AM J PATHOL, V152, P367; TESSARI M, 1993, BIOPOLYMERS, V33, P1877, DOI 10.1002/bip.360331213; Trojanowski JQ, 2000, ANN NY ACAD SCI, V924, P62; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wilson DM, 1997, AM J PATHOL, V150, P2181; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yamabe T, 1999, J COLLOID INTERF SCI, V215, P58, DOI 10.1006/jcis.1999.6215; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2002, J BIOL CHEM, V277, P50914, DOI 10.1074/jbc.M207225200	80	178	182	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46674	46680		10.1074/jbc.M308231200	http://dx.doi.org/10.1074/jbc.M308231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14506232	hybrid			2022-12-25	WOS:000186569400057
J	Chen-Konak, L; Guetta-Shubin, Y; Yahav, H; Salit-Salit, A; Zilberman, M; Binah, O; Resnick, N				Chen-Konak, L; Guetta-Shubin, Y; Yahav, H; Salit-Salit, A; Zilberman, M; Binah, O; Resnick, N			Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells	FASEB JOURNAL			English	Article						vascular endothelium; biomechanical forces; vascular restructuring; shear stress response element	TYROSINE KINASE TIE; SIGNALING PATHWAYS; GENE-EXPRESSION; BLOOD-VESSELS; GROWTH; ARTERIOGENESIS; SURVIVAL; ROLES; VEGF; FLOW	The interaction between the vascular endothelium and hemodynamic forces (and more specifically, fluid shear stress), induced by the flow of blood, plays a major role in vascular remodeling and in new blood vessels formation via a process termed arteriogenesis. Tiel is an orphan tyrosine kinase receptor expressed almost exclusively in endothelial cells and is required for normal vascular development and maintenance. The present study demonstrates that Tiel expression is rapidly down-regulated in endothelial cells exposed to shear stress, and more so to shear stress changes. This down-regulation is accompanied by a rapid cleavage of Tiel and binding of the cleaved Tiel 45 kDa endodomain to Tie2. The rapid cleavage of Tiel is followed by a transcriptional down-regulation in response to shear stress. The activity of the Tiel promoter is suppressed by shear stress and by tumor necrosis factor a,. Shear stress-induced transcriptional suppression of Tiel is mediated by a negative shear stress response element, localized in a region of 250 by within the promoter. The rapid down-regulation of Tiel by shear stress changes and its rapid binding to Tie2 may be required for destabilization of endothelial cells in order to initiate the process of vascular restructuring.	Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Anat & Cell Biol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Interdepartmental Program Biotechnol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Physiol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Resnick, N (corresponding author), Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Anat & Cell Biol, POB 9697, IL-31096 Haifa, Israel.	nresnick@rics.bwh.harvard.edu		Binah, Ofer/0000-0002-0468-8530				Ando J, 1996, BIOCHEM BIOPH RES CO, V225, P347, DOI 10.1006/bbrc.1996.1178; ANDO J, 1994, AM J PHYSIOL, V267, pC679, DOI 10.1152/ajpcell.1994.267.3.C679; ANDO J, 1995, ANN NY ACAD SCI, V748, P148; ANDO J, 1995, ANN NY ACAD SCI, V748, P156; Boutet SC, 2001, BIOCHEM J, V360, P23, DOI 10.1042/0264-6021:3600023; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Calvert JT, 1999, HUM MOL GENET, V8, P1279, DOI 10.1093/hmg/8.7.1279; Carmeliet, 1999, Curr Interv Cardiol Rep, V1, P322; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT BIOTECHNOL, V19, P1019, DOI 10.1038/nbt1101-1019; Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Clark ER, 1918, AM J ANAT, V23, P37, DOI 10.1002/aja.1000230103; Davies PF, 1997, J VASC RES, V34, P208, DOI 10.1159/000159224; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Egginton S, 2001, CARDIOVASC RES, V49, P634, DOI 10.1016/S0008-6363(00)00282-0; Fujikawa K, 1999, J VASC RES, V36, P272, DOI 10.1159/000025655; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Herzog S, 2002, AM J PHYSIOL-HEART C, V283, pH2012, DOI 10.1152/ajpheart.00257.2002; Iljin K, 2002, FASEB J, V16, P1764, DOI 10.1096/fj.01-1043com; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Jones N, 2001, EMBO REP, V2, P438, DOI 10.1093/embo-reports/kve093; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LANGILLE BL, 1986, ARTERIOSCLEROSIS, V6, P146, DOI 10.1161/01.ATV.6.2.146; Loughna S, 2001, MATRIX BIOL, V20, P319, DOI 10.1016/S0945-053X(01)00149-4; Loughna S, 2001, MOL CELL, V7, P233, DOI 10.1016/S1097-2765(01)00171-X; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Marron MB, 2000, ADV EXP MED BIOL, V476, P35; McCarthy MJ, 1999, LAB INVEST, V79, P889; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Meeson A, 1996, DEVELOPMENT, V122, P3929; Meeson AP, 1999, DEVELOPMENT, V126, P1407; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; Puri MC, 1999, DEVELOPMENT, V126, P4569; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; REMUZZI A, 1984, BIORHEOLOGY, V21, P617; Resnick N, 2000, CURR OPIN LIPIDOL, V11, P167, DOI 10.1097/00041433-200004000-00010; RESNICK N, 2003, IN PRESS PROG BIOPHY; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaper W, 1999, CARDIOVASC RES, V43, P835, DOI 10.1016/S0008-6363(99)00191-1; Schaper W, 2001, CIRCULATION, V104, P1994, DOI 10.1161/circ.104.17.1994; Scholz Dimitri, 2001, Angiogenesis, V4, P247, DOI 10.1023/A:1016094004084; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Tsiamis AC, 2002, MICROVASC RES, V63, P149, DOI 10.1006/mvre.2001.2377; van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; van Royen N, 2001, J NUCL CARDIOL, V8, P687, DOI 10.1067/mnc.2001.118924; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715	71	43	44	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2121	+		10.1096/fj.02-1151fje	http://dx.doi.org/10.1096/fj.02-1151fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500555				2022-12-25	WOS:000185925100004
J	Ali, S; Nouhi, Z; Chughtai, N; Ali, S				Ali, S; Nouhi, Z; Chughtai, N; Ali, S			SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JANUS TYROSINE KINASE; SIGNAL-TRANSDUCTION; SOCS BOX; PROTEIN; PHOSPHATASE; JAK2; PHOSPHORYLATION; INHIBITION; ACTIVATION; SUPPRESSORS	The protein tyrosine phosphatase SHP-2 is an important regulator of the Janus kinase-2 (Jak2)/signal transducer and activator of transcription (Stat) pathway downstream of the cytokine/prolactin receptor family. We report that SHP-2 dephosphorylates tyrosine (Tyr-1007) of Jak2 kinase, a critical recruitment site for the ubiquitin ligase-associated inhibitory protein suppressor of cytokine signaling-1 (SOCS-1), thereby contributing to Jak2 stability. Inactivation of SHP-2 function by blocking receptor/SHP-2 association or by using a catalytically inactive mutant of SHP-2 led to a marked increase in Jak2 ubiquitination/degradation, Jak2 phosphorylation on Tyr-1007, and Jak2/SOCS-1 association. Furthermore, functional studies indicate that modulating the interaction of Jak2/SOCS-1 by SHP-2 is essential for prolactin/Stat5-mediated signaling. Together our results provide a novel function for SHP-2 as a positive regulator of cytokine receptor signaling by regulating ubiquitination/degradation pathways.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Dept Med, Div Hematol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ali, S (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, H5-81,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	suhad.ali@muhc.mcgill.ca						Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; Ali S, 2000, J BIOL CHEM, V275, P39073, DOI 10.1074/jbc.M007478200; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Lindeman GJ, 2001, GENE DEV, V15, P1631, DOI 10.1101/gad.880801; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pezet A, 1999, J BIOL CHEM, V274, P24497, DOI 10.1074/jbc.274.35.24497; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Tomic S, 1999, MOL CELL ENDOCRINOL, V158, P45, DOI 10.1016/S0303-7207(99)00180-X; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	37	62	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52021	52031		10.1074/jbc.M306758200	http://dx.doi.org/10.1074/jbc.M306758200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14522994	hybrid			2022-12-25	WOS:000187480700008
J	Cui, Q; Tong, YF; Xue, H; Huang, L; Feng, YG; Wang, JF				Cui, Q; Tong, YF; Xue, H; Huang, L; Feng, YG; Wang, JF			Two conformations of archaeal Ssh10b - The origin of its temperature-dependent interaction with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEBACTERIUM SULFOLOBUS-ACIDOCALDARIUS; BINDING PROTEINS; CHEMICAL-SHIFTS; CHROMATIN PROTEIN; CRYSTAL-STRUCTURE; COMPLEXES; SHIBATAE; N-15; ACETYLATION; ALBA	The DNA- binding protein Ssh10b from the hyperthermophilic archaeon Sulfolobus shibatae is a member of the Sac10b family, which has been speculated to be involved in the organization of the chromosomal DNA in Archaea. Ssh10b affects the DNA topology in a temperature dependent fashion that has not been reported for any other DNA- binding proteins. Heteronuclear NMR and site- directed mutagenesis were used to analyze the structural basis of the temperature- dependent Ssh10b-DNA interaction. The data analysis indicates that two forms of Ssh10b homodimers co- exist in solution, and the slow cis- trans isomerization of the Leu(61)- Pro(62) peptide bond is the key factor responsible for the conformational heterogeneity of the Ssh10b homodimer. The T- form dimer, with the Leu(61)- Pro(62) bond in the trans conformation, dominates at higher temperature, whereas population of the C- form dimer, with the bond in the cis conformation, increases on decreasing the temperature. The two forms of the Ssh10b dimer show the same DNA binding site but have different conformational features that are responsible for the temperature-dependent nature of the Ssh10b- DNA interaction.	Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Microbiol, State Key Lab Microbial Resources, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS	Wang, JF (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.		Tong, Yufeng/D-2785-2011; Feng, Yingang/B-6304-2008	Tong, Yufeng/0000-0001-7740-1812; Feng, Yingang/0000-0002-0879-1316				Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Bell SD, 2002, SCIENCE, V296, P148, DOI 10.1126/science.1070506; Cierpicki T, 2001, J BIOMOL NMR, V21, P249, DOI 10.1023/A:1012911329730; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DIJK J, 1986, BACTERIAL CHROMATIN; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Forterre P, 1999, MOL MICROBIOL, V32, P669, DOI 10.1046/j.1365-2958.1999.01366.x; GROTE M, 1986, BIOCHIM BIOPHYS ACTA, V873, P405, DOI 10.1016/0167-4838(86)90090-7; Jones JA, 1997, J BIOMOL NMR, V10, P199, DOI 10.1023/A:1018304117895; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; LURZ R, 1986, EMBO J, V5, P3715, DOI 10.1002/j.1460-2075.1986.tb04705.x; Mai VQ, 1998, J BACTERIOL, V180, P2560, DOI 10.1128/JB.180.9.2560-2563.1998; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Ogura K, 2002, J BIOMOL NMR, V22, P37, DOI 10.1023/A:1013868731495; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; PAWBO CO, 1992, ANNU REV BIOCHEM, V61, P1053; Permi P, 2000, J BIOMOL NMR, V16, P29, DOI 10.1023/A:1008343926502; SAMBROOK J, 1989, MOL CLONING LABORATO, V3, pB23; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Tong YF, 2002, J BIOMOL NMR, V22, P385, DOI 10.1023/A:1014932202874; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; Wardleworth BN, 2002, EMBO J, V21, P4654, DOI 10.1093/emboj/cdf465; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Xue H, 2000, J BACTERIOL, V182, P3929, DOI 10.1128/JB.182.14.3929-3933.2000	27	25	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51015	51022		10.1074/jbc.M308510200	http://dx.doi.org/10.1074/jbc.M308510200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523014	hybrid			2022-12-25	WOS:000187206300024
J	Jonassen, T; Davis, DE; Larsen, PL; Clarke, CF				Jonassen, T; Davis, DE; Larsen, PL; Clarke, CF			Reproductive fitness and quinone content of Caenorhabditis elegans clk-1 mutants fed coenzyme Q isoforms of varying length	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN LENGTH; ELEGANS CLK-1 MUTANTS; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; DIPHOSPHATE SYNTHASE; ESCHERICHIA-COLI; LIFE-SPAN; GENE; MEMBRANES; MITOCHONDRIA	Caenorhabditis elegans clk-1 mutants lack coenzyme Q(9) and accumulate the biosynthetic intermediate demethoxy-Q(9). A dietary source of ubiquinone (Q) is required for larval growth and development of the gonad and germ cells. We considered that uptake of the shorter Q(8) isoform present in the Escherichia coli food may contribute to the Clk phenotypes of slowed development and reduced brood size observed when the animals are fed Q-replete E. coli. To test the effect of isoprene tail length, N2 and clk-1 animals were fed E. coli engineered to produce Q(7), Q(8), Q(9), or Q(10). Wild-type nematodes showed no change in reproductive fitness regardless of the Q(n) isoform fed. clk-1(e2519) fed the Q(9) diet showed increased egg production; however, this diet did not improve reproductive fitness of the clk-1(qm30) animals. Furthermore, animals with the more severe clk-1(qm30) allele become sterile and their progeny inviable when fed Q(7)-containing bacteria. The content of Q(7) in the mitochondria of clk-1 animals was decreased relative to Q(8), suggesting less effective transport of Q(7) to the mitochondria, impaired retention, or decreased stability. Additionally, regardless of E. coli diet, clk-1(qm30) animals contain a dysfunctional dense form of mitochondria. The gonads of clk-1(qm30) worms fed Q(7)-containing food were severely shrunken and disordered. The differential fertility of clk-1 mutant nematodes fed Q isoforms may result from changes in Q localization, altered recognition by Q-binding proteins, and/or potential defects in mitochondrial function resulting from the mutant CLK-1 polypeptide itself.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Texas, Hlth Sci Ctr, Dept Cell & Struct Biol, San Antonio, TX 78229 USA	University of California System; University of California Los Angeles; University of Texas System; University of Texas Health San Antonio	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIA NIH HHS [AG 19777] Funding Source: Medline; NIGMS NIH HHS [GM 45952] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG019777, R01AG019777] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Battino M, 2002, FREE RADICAL RES, V36, P479, DOI 10.1080/10715760290021351; BRENNER S, 1974, GENETICS, V77, P71; Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063; Di Bernardo S, 1998, FEBS LETT, V426, P77, DOI 10.1016/S0014-5793(98)00313-5; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Hihi AK, 2003, J BIOL CHEM, V278, P41013, DOI 10.1074/jbc.M305034200; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jemiota-Rzeminska M, 2001, CHEM PHYS LIPIDS, V110, P85, DOI 10.1016/S0009-3084(00)00227-9; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Jonassen T., 2000, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; Kwong LK, 2002, FREE RADICAL BIO MED, V33, P627, DOI 10.1016/S0891-5849(02)00916-4; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lenaz G, 1999, BIOFACTORS, V9, P87, DOI 10.1002/biof.5520090202; LENAZ G, 1992, BIOCHEM CELL BIOL, V70, P504, DOI 10.1139/o92-078; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Okada K, 1996, BBA-LIPID LIPID MET, V1302, P217, DOI 10.1016/0005-2760(96)00064-1; Okada K, 1998, FEBS LETT, V431, P241, DOI 10.1016/S0014-5793(98)00753-4; Okada K, 1997, J BACTERIOL, V179, P5992, DOI 10.1128/jb.179.19.5992-5998.1997; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Ren JX, 1997, BIOCHEM J, V324, P951, DOI 10.1042/bj3240951; SAMORI B, 1992, J MEMBRANE BIOL, V128, P193; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Sanz MA, 2003, J BIOL CHEM, V278, P32091, DOI 10.1074/jbc.M304877200; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; WONG A, 1995, GENETICS, V139, P1247	39	27	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51735	51742		10.1074/jbc.M308760200	http://dx.doi.org/10.1074/jbc.M308760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530273	hybrid			2022-12-25	WOS:000187206300108
J	Weng, YH; Yang, G; Weiss, S; Dennery, PA				Weng, YH; Yang, G; Weiss, S; Dennery, PA			Interaction between heme oxygenase-1 and-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CRYSTAL-STRUCTURE; DEVELOPMENTAL EXPRESSION; OXIDATIVE STRESS; RAT-LIVER; FORMS; BRAIN; IRON; HO-1; HEMOPROTEIN	The three isoforms of heme oxygenase ( HO), the rate-limiting enzyme in heme degradation, are the products of different genes that show marked differences in regulation and expression. Why is there redundancy in the heme degradation pathway, and why are there differences in tissue expression of HO isoenzymes are unanswered questions? An interaction between HO- 1 and HO- 2 is suspected by the co- localization of these enzymes in the lung and regions of the brain. Using multiple models and assays, we demonstrated an interaction between HO- 1 and HO- 2 at amino acids 0 - 45 of HO- 2 and amino acids 58 - 80 of HO- 1. The latter corresponds to a highly conserved, hydrophilic, and exposed region of the protein. Furthermore, the observed activity of the HO- 1 . HO- 2 complex was lower than that expected from the sum of HO- 1- and HO- 2-derived activities, suggesting that this interaction serves to limit HO enzymatic activity. We speculate that this HO- 1 . HO- 2 protein interaction may promote non- enzymatic functions of HO.	Stanford Univ, Dept Pediat, Stanford, CA 94304 USA	Stanford University	Dennery, PA (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Dennery, Phyllis/GQG-9113-2022; Weis, Sebastian/P-9016-2014	Weis, Sebastian/0000-0003-3201-2375; Dennery, Phyllis/0000-0001-5745-1855	NHLBI NIH HHS [2R01 HL058757] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPLEGATE LA, 1991, CANCER RES, V51, P974; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dennery PA, 2003, PEDIATR RES, V53, P42, DOI 10.1203/01.PDR.0000042442.08111.56; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; Kone BC, 2001, CARDIOVASC RES, V51, P429, DOI 10.1016/S0008-6363(01)00327-3; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, P1508, DOI 10.1164/ajrccm.164.8.2011083; MAINES MD, 1977, J BIOL CHEM, V252, P5900; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; Marks GS, 1997, J CARDIOVASC PHARM, V30, P1, DOI 10.1097/00005344-199707000-00001; McCoubrey WK, 1997, J BIOL CHEM, V272, P12568, DOI 10.1074/jbc.272.19.12568; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEHTA JL, 1995, J LAB CLIN MED, V125, P370; RODGERS PA, 1990, CLIN PERINATOL, V17, P275, DOI 10.1016/S0095-5108(18)30568-2; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; SUN Y, 1990, J BIOL CHEM, V265, P8212; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VINCENT SR, 1994, NEUROSCIENCE, V63, P223, DOI 10.1016/0306-4522(94)90018-3; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Weng YH, 2000, AM J PHYSIOL-LUNG C, V278, pL1273, DOI 10.1152/ajplung.2000.278.6.L1273; XU OL, 2003, CANCER RES, V63, P980	32	37	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50999	51005		10.1074/jbc.M307644200	http://dx.doi.org/10.1074/jbc.M307644200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14514669	hybrid			2022-12-25	WOS:000187206300022
J	Melzer, N; Biela, A; Fahlke, C				Melzer, N; Biela, A; Fahlke, C			Glutamate modifies ion conduction and voltage-dependent gating of excitatory amino acid transporter-associated anion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; RAT-BRAIN; PERMEATION; EXPRESSION; CURRENTS; FLUX; CLONING; CARRIER; EAAC1; CELLS	Excitatory amino acid transporters (EAATs) mediate two distinct transport processes, a stoichiometrically coupled transport of glutamate, Na+, K+, and H+, and a pore-mediated anion conductance. We studied the anion conductance associated with two mammalian EAAT isoforms, hEAAT2 and rEAAT4, using whole-cell patch clamp recording on transfected mammalian cells. Both isoforms exhibited constitutively active, multiply occupied anion pores that were functionally modified by various steps of the Glu/Na+/H+/K+ transport cycle. Permeability and conductivity ratios were distinct for cells dialyzed with Na+- or K+-based internal solution, and application of external glutamate altered anion permeability ratios and the concentration dependence of the anion influx. EAAT4 but not EAAT2 anion channels displayed voltage-dependent gating that was modified by glutamate. These results are incompatible with the notion that glutamate only increases the open probability of the anion pore associated with glutamate transporters and demonstrate unique gating mechanisms of EAAT-associated anion channels.	Rhein Westfal TH Aachen, Inst Physiol, D-52057 Aachen, Germany; Ctr Estudios Cient, Valdivia, Chile	RWTH Aachen University	Fahlke, C (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Pauwelsstr 30, D-52057 Aachen, Germany.		Fahlke, Christoph/G-3635-2013; Melzer, Nico/HGE-2991-2022	Fahlke, Christoph/0000-0001-8602-9952; Melzer, Nico/0000-0002-2420-701X				ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Auger C, 2000, NEURON, V28, P547, DOI 10.1016/S0896-6273(00)00132-X; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; Bergles DE, 2002, J NEUROSCI, V22, P10153; Billups B, 1996, J NEUROSCI, V16, P6722; DANI JA, 1989, J NEUROSCI, V9, P884; DEFELICE LJ, 1981, INTRO MEMBRANE NOISE, P291; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; Fahlke C, 1997, J GEN PHYSIOL, V110, P551, DOI 10.1085/jgp.110.5.551; Fahlke C, 2001, AM J PHYSIOL-RENAL, V280, pF748, DOI 10.1152/ajprenal.2001.280.5.F748; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Hebeisen S, 2003, BIOPHYS J, V84, P2306, DOI 10.1016/S0006-3495(03)75036-X; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1994, J EXP BIOL, V196, P237; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Lin CLG, 1998, MOL BRAIN RES, V63, P174, DOI 10.1016/S0169-328X(98)00256-3; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Otis TS, 1998, J NEUROSCI, V18, P7099; Palmer MJ, 2003, J NEUROSCI, V23, P4831; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; Rychkov GY, 1998, J GEN PHYSIOL, V111, P653, DOI 10.1085/jgp.111.5.653; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Takahashi M, 1997, J EXP BIOL, V200, P401; Trotti D, 1999, NAT NEUROSCI, V2, P427, DOI 10.1038/8091; Voets T, 1997, J GEN PHYSIOL, V110, P313, DOI 10.1085/jgp.110.3.313; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2001, FEBS LETT, V503, P121, DOI 10.1016/S0014-5793(01)02715-6; Watzke N, 2001, J GEN PHYSIOL, V117, P547, DOI 10.1085/jgp.117.6.547; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	39	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50112	50119		10.1074/jbc.M307990200	http://dx.doi.org/10.1074/jbc.M307990200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506254	hybrid			2022-12-25	WOS:000187068200055
J	Schilling, S; Niestroj, AJ; Rahfeld, JU; Hoffmann, T; Wermann, M; Zunkel, K; Wasternack, C; Demuth, HU				Schilling, S; Niestroj, AJ; Rahfeld, JU; Hoffmann, T; Wermann, M; Zunkel, K; Wasternack, C; Demuth, HU			Identification of human glutaminyl cyclase as a metalloenzyme - Potent inhibition by imidazole derivatives and heterocyclic chelators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; ENZYME HIGHLY RESISTANT; PLANT ENZYME; PYROGLUTAMYL-PEPTIDES; DEGRADING ECTOENZYME; CYCLOTRANSFERASE; AMINOPEPTIDASE; PURIFICATION; SPECIFICITY; EXPRESSION	Human glutaminyl cyclase (QC) was identified as a metalloenzyme as suggested by the time-dependent inhibition by the heterocyclic chelators 1,10-phenanthroline and dipicolinic acid. The effect of EDTA on QC catalysis was negligible. Inactivated enzyme could be fully restored by the addition of Zn2+ in the presence of equimolar concentrations of EDTA. Little reactivation was observed with Co2+ and Mn2+. Other metal ions such as K+, Ca2+, and Ni2+ were inactive under the same conditions. Additionally, imidazole and imidazole derivatives were identified as competitive inhibitors of QC. An initial structure activity-based inhibitor screening of imidazole-derived compounds revealed potent inhibition of QC by imidazole N-1 derivatives. Subsequent data base screening led to the identification of two highly potent inhibitors, 3-[3-(1H-imidazol-1-yl) propyl]-2- thioxoimidazolidin-4-one and 1,4-bis-(imidazol-1-yl)methyl- 2,5-dimethylbenzene, which exhibited respective K-i values of 818 +/- 1 and 295 +/- 5 nM. The binding properties of the imidazole derivatives were further analyzed by the pH dependence of QC inhibition. The kinetically obtained pK(a) values of 6.94 +/- 0.02, 6.93 +/- 0.03, and 5.60 +/- 0.05 for imidazole, methylimidazole, and benzimidazole, respectively, match the values obtained by titrimetric pK(a) determination, indicating the requirement for an unprotonated nitrogen for binding to QC. Similarly, the pH dependence of the kinetic parameter K-m for the QC-catalyzed conversion of H-Gln-7-amino-4-methylcoumarin also implies that only N-terminally unprotonated substrate molecules are bound to the active site of the enzyme, whereas turnover is not affected. The results reveal human QC as a metal-dependent transferase, suggesting that the active site-bound metal is a potential site for interaction with novel, highly potent competitive inhibitors.	Probiodrug Aktiengesell, D-06120 Halle Saale, Germany; Leibniz Inst Plant Biochem, D-06120 Halle Saale, Germany	Leibniz Institut fur Pflanzenbiochemie	Demuth, HU (corresponding author), Probiodrug Aktiengesell, Weinbergweg 22, D-06120 Halle Saale, Germany.							AOYAGI T, 1991, J ANTIBIOT, V44, P573, DOI 10.7164/antibiotics.44.573; BAKER JO, 1983, BIOCHEMISTRY-US, V22, P5322, DOI 10.1021/bi00292a011; Bateman RC, 2001, BIOCHEMISTRY-US, V40, P11246; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CZEKAY G, 1993, BIOCHEM J, V290, P921, DOI 10.1042/bj2900921; Dahl SW, 2000, PROTEIN EXPRES PURIF, V20, P27, DOI 10.1006/prep.2000.1273; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; GOLOLOBOV MY, 1994, ARCH BIOCHEM BIOPHYS, V309, P300, DOI 10.1006/abbi.1994.1117; Gololobov MY, 1996, BIOL CHEM H-S, V377, P395; Huntington KM, 1999, BIOCHEMISTRY-US, V38, P15587, DOI 10.1021/bi991283e; Kelly JA, 2000, J BIOL CHEM, V275, P16746, DOI 10.1074/jbc.M910386199; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; MESSER M, 1963, NATURE, V197, P1299, DOI 10.1038/1971299a0; Oberg KA, 1998, EUR J BIOCHEM, V258, P214, DOI 10.1046/j.1432-1327.1998.2580214.x; POHL T, 1991, P NATL ACAD SCI USA, V88, P10059, DOI 10.1073/pnas.88.22.10059; RICHTER K, 1984, EMBO J, V3, P617, DOI 10.1002/j.1460-2075.1984.tb01857.x; Schilling S, 2002, BIOCHEMISTRY-US, V41, P10849, DOI 10.1021/bi0260381; Schilling S, 2002, ANAL BIOCHEM, V303, P49, DOI 10.1006/abio.2001.5560; SCHILLING S, 2003, IN PRESS BIOL CHEM, V384; Temple Jeffrey S., 1998, Korean Journal of Biological Sciences, V2, P243; TSURU D, 1978, J BIOCHEM, V84, P467, DOI 10.1093/oxfordjournals.jbchem.a132148; Wouters MA, 2001, J MOL BIOL, V314, P1191, DOI 10.1006/jmbi.2000.5161; Zerhouni S, 1998, BBA-PROTEIN STRUCT M, V1387, P275, DOI 10.1016/S0167-4838(98)00140-X	24	71	79	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49773	49779		10.1074/jbc.M309077200	http://dx.doi.org/10.1074/jbc.M309077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522962	hybrid			2022-12-25	WOS:000187068200017
J	Kaplun, L; Ivantsiv, Y; Bakhrat, A; Raveh, D				Kaplun, L; Ivantsiv, Y; Bakhrat, A; Raveh, D			DNA damage response-mediated degradation of Ho endonuclease via the ubiquitin system involves its nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; RING-FINGER DOMAIN; BUDDING YEAST; SUBCELLULAR-LOCALIZATION; HOMING ENDONUCLEASES; PROTEIN-DEGRADATION; LIGASE COMPLEX; PHOSPHORYLATION; CHECKPOINT; PROTEASOME	Yeast mating switch Ho endonuclease is rapidly degraded by the ubiquitin system and this depends on the DNA damage response functions, MEC1, RAD9, and CHK1. A PEST sequence marks Ho for degradation. Here we show that the novel F-box receptor, Ufo1, recruits phosphorylated Ho for degradation. Mutation of PEST residue threonine 225 stabilizes Ho, yet HoT225A still binds Ufo1 in vitro. Stable HoT225A accumulates within the nucleus, whereas HoT225E is degraded. Deletion of the nuclear exportin Msn5 traps native Ho in the nucleus and extends its half-life. These experiments suggest that Ho is degraded in the cytoplasm. In mec1 mutants stable Ho accumulates within the nucleus; Ho produced in mec1 cells does not bind Ufo1. Thus the MEC1 pathway has functions both in phosphorylation of Thr-225 for nuclear export and in additional phosphorylations for binding Ufo1. Cells with HO under its genomic promoter, but stabilized by deletion of the Msn5 exportin, proliferate, but are multibudded. These experiments elucidate some of the links between the DNA damage response and degradation of Ho by the ubiquitin system.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Raveh, D (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.		Raveh, Dina/A-7166-2012					Adams A, 1997, METHODS YEAST GENETI; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BAKHRAT A, IN PRESS GENETICS; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Berset G, 2002, MOL CELL BIOL, V22, P4463, DOI 10.1128/MCB.22.13.4463-4476.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Cagney G, 2001, PHYSIOL GENOMICS, V7, P27, DOI 10.1152/physiolgenomics.2001.7.1.27; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Damelin M, 2002, METHOD ENZYMOL, V351, P587; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Enenkel C, 1999, MOL BIOL REP, V26, P131, DOI 10.1023/A:1006973803960; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; James P, 1996, GENETICS, V144, P1425; Kaplun L, 2000, P NATL ACAD SCI USA, V97, P10077, DOI 10.1073/pnas.97.18.10077; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Liu QH, 2000, METHOD ENZYMOL, V328, P530, DOI 10.1016/S0076-6879(00)28417-6; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lustgarten V, 1999, MOL CELL BIOL, V19, P4480; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Paciotti V, 2000, GENE DEV, V14, P2046; Paciotti V, 2001, MOL CELL BIOL, V21, P3913, DOI 10.1128/MCB.21.12.3913-3925.2001; Paulovich AG, 1997, GENETICS, V145, P45; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; RAVEH D, 1989, MOL GEN GENET, V220, P33; Russell SJ, 1999, J BIOL CHEM, V274, P21943, DOI 10.1074/jbc.274.31.21943; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VALLEN EA, 1992, J CELL BIOL, V117, P1277, DOI 10.1083/jcb.117.6.1277; Wilkinson CRM, 1998, EMBO J, V17, P6465, DOI 10.1093/emboj/17.22.6465; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu XH, 1996, MOL CELL BIOL, V16, P657; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48727	48734		10.1074/jbc.M308671200	http://dx.doi.org/10.1074/jbc.M308671200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506225	hybrid			2022-12-25	WOS:000186829000028
J	Peng, BH; Lee, JC; Campbell, GA				Peng, BH; Lee, JC; Campbell, GA			In vitro protein complex formation with cytoskeleton-anchoring domain of occludin identified by limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; ZO-1; SEQUENCE; BINDING; CELLS; CLAUDIN; MEMBER; ACTIN	Occludin is an essential membrane protein component of cellular tight junctions, participating in both cell-cell adhesion in the paracellular space and anchoring of the junctional complex to the cytoskeleton. The latter function is accomplished through binding of the C-terminal cytoplasmic region to scaffolding proteins that mediate binding to cytoskeletal actin. We isolated a structural domain from both the bacterial-expressed C-terminal cytoplasmic region of human occludin and native cellular occludin, extracted from epithelial (Madin-Darby canine kidney) or endothelial ( human brain) cells, by limited proteolysis with trypsin. This human occludin domain contains the last 119 amino acids as identified by N-terminal sequencing and peptide mass fingerprinting using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Based on the sequence and secondary structure prediction, this domain contains 4 of 5 alpha-helices in the C-terminal region and is linked to the fourth membrane-spanning region by a loosely structured tethering polypeptide. Comparison of circular dichroism spectra of recombinant proteins corresponding to the entire C-terminal region versus only the binding domain region also supports the interpretation that the helical structural elements are concentrated in that domain. Co-immunoprecipitation of this domain with ZO-2 demonstrated preservation of the specificity of the scaffolding protein-binding function, and binding studies with immobilized ZO-2 suggest the presence of multiple ZO-2 binding sites in this domain. These results provide a basis for development of a structural model of the ZO-binding site that can be used to investigate regulation of tight junction anchoring by intracellular signaling events.	Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Campbell, GA (corresponding author), Univ Texas, Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009	Campbell, Gerald/0000-0002-7123-6884				AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Belova GI, 2002, J BIOL CHEM, V277, P4959, DOI 10.1074/jbc.M110131200; Cheng XD, 1998, BIOCHEMISTRY-US, V37, P51, DOI 10.1021/bi9719455; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; *JAND SCI SOFTW, 1995, SIGMAGEL WIND REL 1; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; Maniatis T., 1989, MOL CLONING LABORATO, P21; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Morita K, 1999, J CELL BIOL, V145, P579, DOI 10.1083/jcb.145.3.579; Niimi T, 2001, MOL CELL BIOL, V21, P7380, DOI 10.1128/MCB.21.21.7380-7390.2001; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275; RAMZAN MA, 1991, BIOCHEM SOC T, V19, pS296, DOI 10.1042/bst019296s; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rubin Lee L., 1992, Current Opinion in Cell Biology, V4, P830, DOI 10.1016/0955-0674(92)90107-N; Scheler C, 1998, ELECTROPHORESIS, V19, P918, DOI 10.1002/elps.1150190607; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49644	49651		10.1074/jbc.M302782200	http://dx.doi.org/10.1074/jbc.M302782200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512431	hybrid			2022-12-25	WOS:000186829000136
J	Schrauwen, P; Hoeks, J; Schaart, G; Kornips, E; Binas, B; van de Vusse, GJ; van Bilsen, M; Luiken, JJFP; Coort, SLM; Glatz, JFC; Saris, WHM; Hesselinkt, MKC				Schrauwen, P; Hoeks, J; Schaart, G; Kornips, E; Binas, B; van de Vusse, GJ; van Bilsen, M; Luiken, JJFP; Coort, SLM; Glatz, JFC; Saris, WHM; Hesselinkt, MKC			Uncoupling protein 3 as a mitochondrial fatty acid anion exporter	FASEB JOURNAL			English	Article						UCP3; fatty acid transport; mitochondria; high-fat diet	MESSENGER-RNA EXPRESSION; HUMAN SKELETAL-MUSCLE; BINDING PROTEIN; WEIGHT-REDUCTION; UP-REGULATION; MICE LACKING; UCP3; METABOLISM; OXIDATION; OBESITY	In contrast to UCP1, the primary function of UCP3 is not the dissipation of energy. Rather, several lines of evidence suggest that UCP3 is related to cellular long-chain fatty acid homeostasis. If long-chain fatty acids enter the mitochondrial matrix in their non-esterified form, they cannot be metabolized and may exert deleterious effects. To test the feasibility that UCP3 exports fatty acid anions, we systematically interfered at distinct steps in the fatty acid metabolism pathway, thereby creating conditions in which the entry of (non-esterified) fatty acids into the mitochondrial matrix is enhanced. First, reducing the cellular fatty acid binding capacity, known to increase cytosolic concentrations of non-esterified fatty acids, up-regulated UCP3 5.3-fold. Second, inhibition of mitochondrial entry of esterified long-chain fatty acids up-regulated UCP3 by 1.9-fold. Third, high-fat diets, to increase mitochondrial supply of nonesterified long-chain fatty acids exceeding oxidative capacity, up-regulated UCP3 twofold. However, feeding a similar amount of medium-chain fatty acids, which can be oxidized inside the mitochondrial matrix and therefore do not need to be exported from the matrix, did not affect UCP3 protein levels. These data are compatible with a physiological function of UCP3 in facilitating outward transport of long-chain fatty acid anions, which cannot be oxidized, from the mitochondrial matrix.	Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Movement Sci, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, CARIM, Dept Physiol, NL-6200 MD Maastricht, Netherlands; Max Delbruck Ctr Mol Med, Dept Hypertens Res, Berlin, Germany	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Schrauwen, P (corresponding author), Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht, POB 616, NL-6200 MD Maastricht, Netherlands.	p.schrauwen@hb.unimaas.nl	Coort, Susan/ABF-1021-2021; van Bilsen, Marc/E-8342-2016	Hoeks, Joris/0000-0002-0265-0870; schrauwen, patrick/0000-0002-0973-847X				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; GREENBERGER NJ, 1969, NEW ENGL J MED, V280, P1045, DOI 10.1056/NEJM196905082801906; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hesselink MKC, 2003, J CLIN INVEST, V111, P479, DOI 10.1172/JCI16653; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liang P, 1997, DIABETES, V46, P920, DOI 10.2337/diabetes.46.5.920; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; SCHOLTE HR, 1979, J NEUROL SCI, V40, P39, DOI 10.1016/0022-510X(79)90007-8; Schrauwen P, 2000, DIABETOLOGIA, V43, P1408, DOI 10.1007/s001250051547; Schrauwen P, 1999, INT J OBESITY, V23, P966, DOI 10.1038/sj.ijo.0801026; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schrauwen P, 2001, INT J OBESITY, V25, P449, DOI 10.1038/sj.ijo.0801566; Schrauwen P, 2002, AM J PHYSIOL-ENDOC M, V282, pE11, DOI 10.1152/ajpendo.2002.282.1.E11; Skulachev VP, 1999, J BIOENERG BIOMEMBR, V31, P431, DOI 10.1023/A:1005492205984; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; VANDERVUSSE GJ, 1995, J APPL PHYSIOL, V78, P1839, DOI 10.1152/jappl.1995.78.5.1839; VEERKAMP JH, 1993, MOL CELL BIOCHEM, V123, P101, DOI 10.1007/BF01076480; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VONDERVUSSE GJ, 1996, HDB PHYSL INTEGRATIO, P952; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298	36	98	99	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2272	+		10.1096/fj.03-0515fje	http://dx.doi.org/10.1096/fj.03-0515fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525936	Green Submitted			2022-12-25	WOS:000186343300015
J	Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P				Lynch, J; Keller, M; Guo, RJ; Yang, D; Traber, P			Cdx1 inhibits the proliferation of human colon cancer cells by reducing cyclin D1 gene expression	ONCOGENE			English	Article						homeobox; cyclin D1; antiproliferative; colon cancer	HOMEODOMAIN PROTEIN CDX2; INTESTINAL EPITHELIAL-CELLS; HOMEOBOX GENE; COLORECTAL-CANCER; DOWN-REGULATION; CARCINOMA CELLS; DIFFERENTIATION; TRANSCRIPTION; TRANSACTIVATION; LINE	The transcription factor Cdx1 regulates intestine-specific gene expression and enterocyte differentiation. It has been hypothesized to play a role in regulating intestinal cell proliferation; however, the mechanism for this effect remains elusive. In a prior study, we demonstrated that Cdx1 expression reduced the proliferation of a nontransformed intestinal cell line. This study tests the hypothesis that Cdx1 expression inhibits colon cancer cell proliferation by reducing cyclin D1 gene expression. Cdx1 expression markedly reduced cancer cell proliferation and DNA synthesis and induced an accumulation of cells in G0/G1. A transcriptionally inactive Cdx1 mutant could not elicit this effect, suggesting that it required Cdx1 transcriptional activity. Cdx1 expression increased the hypophosphorylation of the retinoblastoma (pRb) and p130 proteins. Reductions in G1 cyclin-dependant kinase (cdk) activity accompanied this effect. Cyclin D1 mRNA and protein levels were diminished by Cdx1 expression. Restoration of cyclin D1 expression reversed the G0/G1 block and induced pRb hyperphosphorylation. Lastly, Cdx1 expression did not alter cyclin D1 mRNA stability but did reduce cyclin D1 promoter activity, suggesting that Cdx1 acts to diminish cyclin D1 gene transcription. We conclude that Cdx1 reduces the proliferation of human colon cancer cells by reducing cyclin D1 gene transcription.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Lynch, J (corresponding author), Univ Penn, Dept Med, Div Gastroenterol, 415 Curie Blvd,660 CRB, Philadelphia, PA 19104 USA.	lynchj@mail.med.upenn.edu		Keller, Matthew/0000-0003-1884-487X	NIDDK NIH HHS [P01-DK49210, DK02695-02, P30-DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, P01DK049210, K08DK002695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kaestner KH, 1997, GENE DEV, V11, P1583, DOI 10.1101/gad.11.12.1583; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2002, HEMATOL ONCOL CLIN N, V16, P775, DOI 10.1016/S0889-8588(02)00029-1; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mariadason JM, 2001, CANCER RES, V61, P3465; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Naishiro Y, 2001, CANCER RES, V61, P2751; Oh EJ, 2002, INT J ONCOL, V20, P23; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; Sherr CJ, 2000, CANCER RES, V60, P3689; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Akker E, 2002, DEVELOPMENT, V129, P2181; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	51	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6395	6407		10.1038/sj.onc.1206770	http://dx.doi.org/10.1038/sj.onc.1206770			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508520				2022-12-25	WOS:000185535300010
J	Hurtado, O; De Cristobal, J; Sanchez, V; Lizasoain, I; Cardenas, A; Pereira, MP; Colado, MI; Leza, JC; Lorenzo, P; Moro, MA				Hurtado, O; De Cristobal, J; Sanchez, V; Lizasoain, I; Cardenas, A; Pereira, MP; Colado, MI; Leza, JC; Lorenzo, P; Moro, MA			Inhibition of glutamate release by delaying ATP fall accounts for neuroprotective effects of antioxidants in experimental stroke	FASEB JOURNAL			English	Article						cerebral infarct; MCAO; reactive oxygen species	MITOCHONDRIAL RESPIRATORY-CHAIN; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; RAT FOREBRAIN SLICES; HIPPOCAMPAL SLICES; BRAIN ISCHEMIA; HYDROGEN-PEROXIDE; FREE-RADICALS; GERBIL BRAIN; NITRIC-OXIDE	Excitotoxic neuronal injury related to excessive glutamate release is believed to play a key role in the pathogenesis of focal cerebral ischemia. Reversal of neuronal glutamate transporters caused by ATP fall and subsequent imbalance of membrane ionic gradients accounts for most glutamate release after cerebral ischemia. ATP synthesis from oxidative phosphorylation derives from the coupled functioning of the mitochondrial respiratory chain (MRC) and the ATP synthase; interestingly, the MRC is one of the main sites of cellular reactive oxygen species (ROS) generation even in physiological circumstances. Hence, we have studied the effect of the antioxidants glutathione, superoxide dismutase, and alpha-tocopherol on infarct outcome, brain ATP, and glutamate levels after permanent middle cerebral artery occlusion (MCAO) in Fischer rats; we have also characterized the actions of antioxidants on MRC complexes. Our results show that intraperitoneal administration of antioxidants 2 h before MCAO enhances ATP synthesis and causes a neuroprotective effect concomitant to inhibition of ischemia-induced increase in brain glutamate. Antioxidants also increased mitochondrial ATP and MRC complex I-III activity and respiration, suggesting that these actions are due to removal of the inhibition caused by endogenous ROS on MRC. These findings may possess important therapeutic repercussions in the management of ischemic stroke.	Univ Complutense Madrid, Fac Med, Dept Farmacol, E-28040 Madrid, Spain	Complutense University of Madrid	Moro, MA (corresponding author), Univ Complutense Madrid, Fac Med, Dept Farmacol, E-28040 Madrid, Spain.	neurona@med.ucm.es	HURTADO, OLIVIA/E-7248-2012; Moro, María Ángeles/K-6396-2014; Pereira, Marta/L-3208-2014; Lizasoain, Ignacio/K-9844-2014; Pereira, Marta/ABF-7999-2020	HURTADO, OLIVIA/0000-0001-5735-7092; Moro, María Ángeles/0000-0003-1010-8237; Pereira, Marta/0000-0002-9347-957X; Lizasoain, Ignacio/0000-0002-6028-7379; Pereira, Marta/0000-0002-9347-957X; LEZA, JUAN CARLOS/0000-0002-9901-0094				ALLEN KL, 1995, J NEUROCHEM, V64, P2222; ALMEIDA A, 1995, J NEUROCHEM, V65, P1698; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; Bickler PE, 1996, J NEUROCHEM, V67, P1463; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Caplan LR, 2002, ARCH NEUROL-CHICAGO, V59, P703, DOI 10.1001/archneur.59.5.703; Cardenas A, 2000, N-S ARCH PHARMACOL, V362, P208, DOI 10.1007/s002100000286; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chamorro A, 2002, STROKE, V33, P1048, DOI 10.1161/hs0402.105927; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DAVALOS A, 1999, CURRENT REV CEREBROV, P149; De Cristobal J, 2002, NEUROREPORT, V13, P217, DOI 10.1097/00001756-200202110-00009; De Cristobal J, 2002, STROKE, V33, P261, DOI 10.1161/hs0102.101299; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; GOLDBERG MP, 2002, STROKE TRIALS DIRECT; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; KASS IS, 1989, J PHYSIOL-LONDON, V413, P1; Keller JN, 1998, J NEUROSCI, V18, P687; KING TE, 1966, ADV ENZYMOL RAMB, V28, P155; KUHN W, 1995, STROKE, V26, P1959; Largeron M, 2001, EUR J PHARMACOL, V424, P189, DOI 10.1016/S0014-2999(01)01152-9; Lees KR, 2000, BRIT MED BULL, V56, P401, DOI 10.1258/0007142001903049; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MADL JE, 1993, J NEUROSCI, V13, P4429; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; Moro MA, 2000, NEUROPHARMACOLOGY, V39, P1309, DOI 10.1016/S0028-3908(99)00226-9; Murakami K, 1998, J NEUROSCI, V18, P205; Oberle S, 1998, CIRC RES, V82, P1016, DOI 10.1161/01.RES.82.9.1016; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PEKOE G, 1982, AGENTS ACTIONS, V12, P232, DOI 10.1007/BF01965152; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RAGAN CI, 1987, MITOCHONDRIA PRACTIC, P153; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Santos MS, 1996, STROKE, V27, P941, DOI 10.1161/01.STR.27.5.941; SCHAPIRA AHV, 1994, MITOCHONDRIA DNA PRO, P241; Skaper SD, 1998, FASEB J, V12, P725, DOI 10.1096/fasebj.12.9.725; VANJAARSVELD H, 1994, RES COMMUN MOL PATH, V86, P287; WHARTON DC, 1968, J BIOL CHEM, V243, P702	56	50	53	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2082	+		10.1096/fj.02-1086fje	http://dx.doi.org/10.1096/fj.02-1086fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500556				2022-12-25	WOS:000185925100003
J	Laurent, M; Martinerie, C; Thibout, H; Hoffman, MP; Verrecchia, F; Le Bouc, Y; Mauviel, A; Kleinman, HK				Laurent, M; Martinerie, C; Thibout, H; Hoffman, MP; Verrecchia, F; Le Bouc, Y; Mauviel, A; Kleinman, HK			NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism	FASEB JOURNAL			English	Article						CCN family; macroarray; metalloprotease; PDGF receptors	TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; ENDOTHELIAL-CELLS; WILMS-TUMORS; FACTOR-BETA; PRODUCT; FAMILY; DOMAIN	Nephroblastoma overexpressed gene (NOV) is highly expressed in the nervous system. We investigated its biological activity by expressing the human NOV gene ( NOVH) in a human glioblastoma cell line that is negative for NOVH and by analyzing four clones with different levels of NOVH expression. There was no difference in cell proliferation between the NOVH-expressing cell lines, but there was increased cell adhesion and migration that correlated with increasing NOVH expression. Gene expression profiling was used to investigate the mechanisms by which NOVH expression regulated cell activity. We identified two induced genes in NOVH-expressing cells that are involved in cell migration: matrix metalloprotease (MMP) 3 and platelet-derived growth factor receptor (PDGFR)-alpha. Our studies show that PDGFR-alpha induced MMP3 gene expression and increased cell proliferation and cell migration upon stimulation by platelet-derived growth factor (PDGF)-AA. We also show that the induction of MMP3 in cells expressing NOVH is potentiated by either cell density, serum, or PDGF-BB. Thus, expression of NOVH in glioblastoma cells triggers a cascade of gene expression resulting in increased cell adhesion and migration.	Hop St Antoine, INSERM,U515, Proliferat Differenciat & Proc Tumoraux Batim, F-75012 Paris, France; NIDCR, NIH, Bethesda, MD 20814 USA; Hop St Louis, INSERM, U32, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laurent, M (corresponding author), Hop St Antoine, INSERM,U515, Proliferat Differenciat & Proc Tumoraux Batim, 184 Rue Fbg St Antoine,Batiment Kourilsky, F-75012 Paris, France.	laurent@st-antoine.inserm.fr	MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Burren CP, 1999, J CLIN ENDOCR METAB, V84, P1096; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chevalier G, 1998, AM J PATHOL, V152, P1563; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; Lafont J, 2002, J BIOL CHEM, V277, P41220, DOI 10.1074/jbc.M204405200; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Mahiou J, 1998, BIOCHEM J, V330, P1051, DOI 10.1042/bj3301051; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Martinerie C, 1997, J CLIN PATHOL-MOL PA, V50, P310, DOI 10.1136/mp.50.6.310; MARTINERIE C, 1994, ONCOGENE, V9, P2729; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; Scholz G, 1996, MOL CELL BIOL, V16, P481; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WENXIN L, 1996, J CLIN PATHOL-MOL PA, V49, pM91; WESTPHAL M, 1987, EXP CELL BIOL, V55, P152; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Woodard AS, 1998, J CELL SCI, V111, P469	45	42	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1919	+		10.1096/fj.02-1023fje	http://dx.doi.org/10.1096/fj.02-1023fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519668				2022-12-25	WOS:000185345100013
J	Edman, K; Royant, A; Larsson, G; Jacobson, F; Taylor, T; van der Spoel, D; Landau, EM; Pebay-Peyroula, E; Neutze, R				Edman, K; Royant, A; Larsson, G; Jacobson, F; Taylor, T; van der Spoel, D; Landau, EM; Pebay-Peyroula, E; Neutze, R			Deformation of helix C in the low temperature L-intermediate of bacteriorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROTONATED SCHIFF-BASE; PROTEIN PHOTOCYCLE INTERMEDIATE; TIME-RESOLVED CRYSTALLOGRAPHY; 1.8 ANGSTROM RESOLUTION; LIPIDIC CUBIC PHASES; SENSORY RHODOPSIN-II; X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; CONFORMATIONAL-CHANGES; RETINAL PROTEINS	X-ray and electron diffraction studies of specific reaction intermediates, or reaction intermediate analogues, have produced a consistent picture of the structural mechanism of light-driven proton pumping by bacteriorhodopsin. Of central importance within this picture is the structure of the L-intermediate, which follows the retinal all-trans to 13-cis photoisomerization step of the K-intermediate and sets the stage for the primary proton transfer event from the positively charged Schiff base to the negatively charged Asp-85. Here we report the structural changes in bacteriorhodopsin following red light illumination at 150 K. Single crystal microspectrophotometry showed that only the L-intermediate is populated in three-dimensional crystals under these conditions. The experimental difference Fourier electron density map and refined crystallographic structure were consistent with those previously presented (Royant, A., Edman, K., Ursby, T., Pebay-Peyroula, E., Landau, E. M., and Neutze, R. ( 2000) Nature 406, 645 - 648; Royant, A., Edman, K., Ursby, T., Pebay- Peyroula, E., Landau, E. M., and Neutze, R. ( 2001) Photochem. Photobiol. 74, 794 - 804). Based on the refined crystallographic structures, molecular dynamic simulations were used to examine the influence of the conformational change of the protein that is associated with the K-to-L transition on retinal dynamics. Implications regarding the structural mechanism for proton pumping by bacteriorhodopsin are discussed.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA; Chalmers Univ Technol, Dept Chem & Biosci, S-40530 Gothenburg, Sweden; Univ Grenoble 1, CEA, CNRS, UMR 5075,Inst Biol Struct, F-38027 Grenoble 1, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Swedish Univ Agr Sci, Dept Mol Biol, Ctr Biomed, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Chalmers University of Technology; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Synchrotron Radiation Facility (ESRF); Stockholm University; Swedish University of Agricultural Sciences; Uppsala University; University of Texas System; University of Texas Medical Branch Galveston	Landau, EM (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA.	emlandau@utmb.edu; pebay@godot.ibs.fr; neutze@molbiotech.chalmers.se	Neutze, Richard/A-7573-2010; van der Spoel, David/A-5471-2008; Royant, Antoine/G-3684-2012; van der Spoel, David/AAD-9820-2019	Neutze, Richard/0000-0003-0986-6153; van der Spoel, David/0000-0002-7659-8526; Royant, Antoine/0000-0002-1919-8649; van der Spoel, David/0000-0002-7659-8526				ALBECK A, 1992, J AM CHEM SOC, V114, P2400, DOI 10.1021/ja00033a015; Aqvist J, 2000, NATURE, V404, P881, DOI 10.1038/35009114; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; Balashov SP, 2001, PHOTOCHEM PHOTOBIOL, V73, P453, DOI 10.1562/0031-8655(2001)073<0453:TASIOT>2.0.CO;2; BALASHOV SP, 1988, PHYSICOCHEMICAL BIOL, V8, P1; Baudry J, 2001, J PHYS CHEM B, V105, P905, DOI 10.1021/jp000898e; BECHER B, 1978, BIOCHEMISTRY-US, V17, P2293, DOI 10.1021/bi00605a006; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bourgeois D, 2002, J APPL CRYSTALLOGR, V35, P319, DOI 10.1107/S0021889802003837; BRAIMAN M, 1982, P NATL ACAD SCI-BIOL, V79, P403, DOI 10.1073/pnas.79.2.403; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANG CH, 1988, PHOTOCHEM PHOTOBIOL, V47, P261, DOI 10.1111/j.1751-1097.1988.tb02724.x; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; DOIG SJ, 1991, J PHYS CHEM-US, V95, P6372, DOI 10.1021/j100169a054; Edman K, 2002, STRUCTURE, V10, P473, DOI 10.1016/S0969-2126(02)00736-0; Edman K, 1999, NATURE, V401, P822, DOI 10.1038/44623; Essen LO, 2002, CURR OPIN STRUC BIOL, V12, P516, DOI 10.1016/S0959-440X(02)00356-1; Facciotti MT, 2001, BIOPHYS J, V81, P3442, DOI 10.1016/S0006-3495(01)75976-0; FRIEDMAN N, 1994, BIOCHEMISTRY-US, V33, P1971, DOI 10.1021/bi00174a001; Gai F, 1998, SCIENCE, V279, P1886, DOI 10.1126/science.279.5358.1886; GAT Y, 1993, J AM CHEM SOC, V115, P3772, DOI 10.1021/ja00062a052; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gergely C, 1997, J PHYS CHEM B, V101, P9390, DOI 10.1021/jp971381e; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Haupts U, 1997, BIOCHEMISTRY-US, V36, P2, DOI 10.1021/bi962014g; Hayashi S, 2002, BIOPHYS J, V83, P1281, DOI 10.1016/S0006-3495(02)73900-3; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HENDERSON R, 1971, ACTA CRYSTALL B-STRU, VB 27, P1414, DOI 10.1107/S0567740871004060; Hendrickson FM, 1998, BIOPHYS J, V75, P1446, DOI 10.1016/S0006-3495(98)74063-9; Herzfeld J, 2000, BBA-BIOENERGETICS, V1460, P95, DOI 10.1016/S0005-2728(00)00132-8; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; Hu JGG, 1997, BIOCHEMISTRY-US, V36, P9316, DOI 10.1021/bi970416y; Kandori H, 2002, BIOCHEMISTRY-US, V41, P6026, DOI 10.1021/bi025585j; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Kandori H, 2001, P NATL ACAD SCI USA, V98, P1571, DOI 10.1073/pnas.98.4.1571; KHORANA HG, 1993, P NATL ACAD SCI USA, V90, P1166, DOI 10.1073/pnas.90.4.1166; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Kolbe M, 2000, SCIENCE, V288, P1390, DOI 10.1126/science.288.5470.1390; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Lanyi JK, 2003, J MOL BIOL, V328, P439, DOI 10.1016/S0022-2836(03)00263-8; Lanyi JK, 2002, J MOL BIOL, V321, P727, DOI 10.1016/S0022-2836(02)00682-4; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; Lanyi JK, 2000, J PHYS CHEM B, V104, P11441, DOI 10.1021/jp0023718; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Luecke H, 2000, BBA-BIOENERGETICS, V1460, P133, DOI 10.1016/S0005-2728(00)00135-3; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 2000, J MOL BIOL, V300, P1237, DOI 10.1006/jmbi.2000.3884; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; MAEDA A, 1994, BIOCHEMISTRY-US, V33, P1713, DOI 10.1021/bi00173a013; Maeda A, 1997, J BIOCHEM-TOKYO, V121, P399; MARTI T, 1991, J BIOL CHEM, V266, P18674; Matsui Y, 2002, J MOL BIOL, V324, P469, DOI 10.1016/S0022-2836(02)01110-5; MCMASTER E, 1988, BIOCHEM BIOPH RES CO, V156, P86, DOI 10.1016/S0006-291X(88)80808-8; Murata K, 2000, BIOPHYS J, V79, P982, DOI 10.1016/S0006-3495(00)76352-1; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Nollert P, 1998, BIOCHEM SOC T, V26, P709, DOI 10.1042/bst0260709; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; ORMOS P, 1991, P NATL ACAD SCI USA, V88, P473, DOI 10.1073/pnas.88.2.473; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Petkova AT, 1999, BIOCHEMISTRY-US, V38, P1562, DOI 10.1021/bi981968z; Reat V, 1998, P NATL ACAD SCI USA, V95, P4970, DOI 10.1073/pnas.95.9.4970; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Ren Z, 2001, BIOCHEMISTRY-US, V40, P13788, DOI 10.1021/bi0107142; Rouhani S, 2001, J MOL BIOL, V313, P615, DOI 10.1006/jmbi.2001.5066; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Royant A, 2002, ACTA CRYSTALLOGR D, V58, P784, DOI 10.1107/S090744490200392X; Royant A, 2001, PHOTOCHEM PHOTOBIOL, V74, P794, DOI 10.1562/0031-8655(2001)074<0794:SCOBSL>2.0.CO;2; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Schobert B, 2002, J MOL BIOL, V321, P715, DOI 10.1016/S0022-2836(02)00681-2; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Srajer V, 2001, BIOCHEMISTRY-US, V40, P13802, DOI 10.1021/bi010715u; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Tajkhorshid E, 1999, J PHYS CHEM B, V103, P5581, DOI 10.1021/jp983742b; TAKEI H, 1994, J BIOL CHEM, V269, P7387; Tittor J, 2002, J MOL BIOL, V319, P555, DOI 10.1016/S0022-2836(02)00307-8; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VARO G, 1991, BIOCHEMISTRY-US, V30, P5008, DOI 10.1021/bi00234a024; Vonck J, 2000, EMBO J, V19, P2152, DOI 10.1093/emboj/19.10.2152; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F	103	66	67	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					2147	2158		10.1074/jbc.M300709200	http://dx.doi.org/10.1074/jbc.M300709200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14532280	hybrid			2022-12-25	WOS:000188005700071
J	Ren, Z; Riley, NJ; Needleman, LA; Sanders, JM; Swanson, GT; Marshall, J				Ren, Z; Riley, NJ; Needleman, LA; Sanders, JM; Swanson, GT; Marshall, J			Cell surface expression of GluR5 kainate receptors is regulated by an endoplasmic reticulum retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; LIGAND-INDUCED ENDOCYTOSIS; AMPA RECEPTOR; HIGH-AFFINITY; HIPPOCAMPAL-NEURONS; GLUTAMATE RECEPTORS; PROTEIN-SYNTHESIS; SYNAPTIC PLASTICITY; ALPHA-SUBUNIT; ION CHANNELS	Kainate receptors (KARs) are mediators of excitatory neurotransmission in the mammalian central nervous system, and their efficient targeting and trafficking is critical for normal synaptic function. A key step in the delivery of KARs to the neuronal plasma membrane is the exit of newly assembled receptors from the endoplasmic reticulum (ER). Here we report the identification of a novel ER retention signal in the alternatively spliced C-terminal domain of the GluR5-2b subunit, which controls receptor trafficking in both heterologous cells and neurons. The ER retention motif consists of a critical arginine (Arg-896) and surrounding amino acids, disruption of which promotes ER exit and surface expression of the receptors, as well as altering their physiological properties. The Arg-896-mediated ER retention of GluR5 is regulated by a mutation that mimics phosphorylation of Thr-898, but not by PDZ interactions. Furthermore, two positively charged residues (Arg-900 and Lys-901) in the C terminus were also found to regulate ER export of the receptors. Taken together, our results identify novel trafficking signals in the C-terminal domain of GluR5-2b and demonstrate that alternative splicing is an important mechanism regulating KAR function.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	Brown University; Brown University; University of Texas System; University of Texas Medical Branch Galveston	Marshall, J (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Box G-B4, Providence, RI 02912 USA.				NCRR NIH HHS [RR15578] Funding Source: Medline; NIMH NIH HHS [MH065289] Funding Source: Medline; NINDS NIH HHS [NS39063, NS44322, NS39309] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH065289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039063, R01NS039309, R01NS044322] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BAHN S, 1994, J NEUROSCI, V14, P5525; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Cho K, 2003, J PHYSIOL-LONDON, V548, P723, DOI 10.1113/jphysiol.2003.040188; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cui CH, 1999, J NEUROSCI, V19, P8281; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; GOOD PF, 1993, BRAIN RES, V624, P347, DOI 10.1016/0006-8993(93)90102-S; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; Hirbec H, 2003, NEURON, V37, P625, DOI 10.1016/S0896-6273(02)01191-1; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Horton AC, 2003, J NEUROSCI, V23, P6188; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kacharmina JE, 2000, P NATL ACAD SCI USA, V97, P11545, DOI 10.1073/pnas.97.21.11545; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Keller SH, 2001, J BIOL CHEM, V276, P18384, DOI 10.1074/jbc.M100691200; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Okabe S, 1999, J NEUROSCI, V19, P7781; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Paternain AV, 2000, J NEUROSCI, V20, P196, DOI 10.1523/JNEUROSCI.20-01-00196.2000; Pemberton KE, 1998, J PHYSIOL-LONDON, V510, P401, DOI 10.1111/j.1469-7793.1998.401bk.x; Ren Z, 2003, J NEUROSCI, V23, P6608; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; SOMMER B, 1992, EMBO J, V11, P1651, DOI 10.1002/j.1460-2075.1992.tb05211.x; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Swanson GT, 1996, J PHYSIOL-LONDON, V492, P129, DOI 10.1113/jphysiol.1996.sp021295; Swanson GT, 1998, J PHYSIOL-LONDON, V513, P639, DOI 10.1111/j.1469-7793.1998.639ba.x; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Temkin R, 1997, MOL BRAIN RES, V52, P38, DOI 10.1016/S0169-328X(97)00249-0; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; Torre ER, 1996, J NEUROSCI, V16, P5967; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; WISDEN W, 1993, J NEUROSCI, V13, P3582; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou JS, 2002, CIRC RES, V91, P540, DOI 10.1161/01.RES.0000033598.00903.27; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	61	54	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52700	52709		10.1074/jbc.M309585200	http://dx.doi.org/10.1074/jbc.M309585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14527949	hybrid			2022-12-25	WOS:000187480700088
J	Bendahhou, S; Donaldson, MR; Plaster, NM; Tristani-Firouzi, M; Fu, YH; Ptacek, LJ				Bendahhou, S; Donaldson, MR; Plaster, NM; Tristani-Firouzi, M; Fu, YH; Ptacek, LJ			Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PERIODIC PARALYSIS; SULFONYLUREA RECEPTOR; ER EXPORT; MUTATIONS; GENE; PIP2; ACTIVATION; SUBUNIT	Andersen-Tawil syndrome is a skeletal and cardiac muscle disease with developmental features caused by mutations in the inward rectifier K+ channel gene KCNJ2. Patients harboring these mutations exhibit extremely variable expressivities. To explore whether these mutations can be correlated with a specific patient phenotype, we expressed both wild-type (WT) and mutant genes cloned into a bi-cistronic vector. Functional expression in human embryonic kidney 293 cells showed that none of the mutant channels express current when present alone. When co-expressed with WT channels, only construct V302M-WT yields inward current. Confocal microscopy fluorescence revealed three patterns of channel expression in the cell: 1) mutations D71V, N216H, R218Q, and pore mutations co-assemble and co-localize to the membrane with the WT and exert a dominant-negative effect on the WT channels; 2) mutation V302M leads to channels that lose their ability to co-assemble with WT and traffic to the cell surface; 3) deletions Delta95-98 and Delta314-315 lead to channels that do not traffic to the membrane but retain their ability to co-assemble with WT channels. These data show that the Andersen-Tawil syndrome phenotype may occur through a dominant-negative effect as well as through haplo-insufficiency and reveal amino acids critical in trafficking and conductance of the inward rectifier K+ channels.	Univ Utah, Dept Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Div Pediat Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bendahhou, S (corresponding author), Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038616] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00064] Funding Source: Medline; NINDS NIH HHS [NS38616] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN ED, 1971, ACTA PAEDIATR SCAND, V60, P559, DOI 10.1111/j.1651-2227.1971.tb06990.x; Bendahhou S, 1999, J NEUROSCI, V19, P4762; Chen L, 2002, P NATL ACAD SCI USA, V99, P8430, DOI 10.1073/pnas.122682899; Donaldson MR, 2003, NEUROLOGY, V60, P1811, DOI 10.1212/01.WNL.0000072261.14060.47; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hille B., 1992, IONIC CHANNELS EXCIT; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; LESAGE F, 1995, GENOMICS, V29, P808, DOI 10.1006/geno.1995.9928; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Preisig-Muller R, 2002, P NATL ACAD SCI USA, V99, P7774, DOI 10.1073/pnas.102609499; RAABGRAHAM KF, 1994, NEUROREPORT, V5, P2501, DOI 10.1097/00001756-199412000-00024; SAKURA H, 1995, FEBS LETT, V367, P193, DOI 10.1016/0014-5793(95)00498-X; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Sansone V, 1997, ANN NEUROL, V42, P305, DOI 10.1002/ana.410420306; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Soom M, 2001, FEBS LETT, V490, P49, DOI 10.1016/S0014-5793(01)02136-6; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; STOFFEL M, 1994, GENOMICS, V21, P254, DOI 10.1006/geno.1994.1253; TAWIL R, 1994, ANN NEUROL, V35, P326, DOI 10.1002/ana.410350313; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; Tristani-Firouzi M, 2002, J CLIN INVEST, V110, P381, DOI 10.1172/JCI200215183; TUCKER SJ, 1995, GENOMICS, V28, P127, DOI 10.1006/geno.1995.1121; Umigai N, 2003, J BIOL CHEM, V278, P40373, DOI 10.1074/jbc.M307451200; Wischmeyer E, 1996, P NATL ACAD SCI USA, V93, P5819, DOI 10.1073/pnas.93.12.5819; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; YANO H, 1994, MOL PHARMACOL, V45, P854; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	43	117	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51779	51785		10.1074/jbc.M310278200	http://dx.doi.org/10.1074/jbc.M310278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522976	hybrid			2022-12-25	WOS:000187206300113
J	Chang, Y; Tesco, G; Jeong, WJ; Lindsley, L; Eckman, EA; Eckman, CB; Tanzi, RE; Guenette, SY				Chang, Y; Tesco, G; Jeong, WJ; Lindsley, L; Eckman, EA; Eckman, CB; Tanzi, RE; Guenette, SY			Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; ADAPTER PROTEIN; DISTINCT SITES; SECRETASE; CLEAVAGE; NOTCH; DEGRADATION	Members of the FE65 family of adaptor proteins, FE65, FE65L1, and FE65L2, bind the C-terminal region of the amyloid precursor protein (APP). Overexpression of FE65 and FE65L1 was previously reported to increase the levels of alpha-secretase-derived APP (APPsalpha). Increased beta-amyloid (Abeta) generation was also observed in cells showing the FE65-dependent increase in APPsalpha. To understand the mechanism for the observed increase in both Abeta and APPsalpha given that alpha-secretase cleavage of a single APP molecule precludes Abeta generation, we examined the effects of FE65L1 overexpression on APP C-terminal fragments (APP CTFs). Our data show that FE65L1 potentiates gamma-secretase processing of APP CTFs, including the amyloidogenic CTF C99, accounting for the ability of FE65L1 to increase generation of APP C-terminal domain and Abeta40. The FE65L1 modulation of these processing events requires binding of FE65L1 to APP and APP CTFs and is not because of a direct effect on gamma-secretase activity, because Notch intracellular domain generation is not altered by FE65L1. Furthermore, enhanced APP CTF processing can be detected in early endosome vesicles but not in endoplasmic reticulum or Golgi membranes, suggesting that the effects of FE65L1 occur at or near the plasma membrane. Finally, although FE65L1 increases APP C-terminal domain production, it does not mediate the APP-dependent transcriptional activation observed with FE65.	Harvard Univ, MassGen Inst Neurodegenerat Dis, Massachusetts Gen Hosp E,Sch Med, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Harvard University; Mayo Clinic	Guenette, SY (corresponding author), Harvard Univ, MassGen Inst Neurodegenerat Dis, Massachusetts Gen Hosp E,Sch Med, Genet & Aging Res Unit, 114 16th St, Charlestown, MA 02129 USA.	guenette@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019; Eckman, Elizabeth/AAL-7316-2021	Tanzi, Rudolph/0000-0002-7032-1454; Eckman, Elizabeth/0000-0002-5391-4960	NIA NIH HHS [AG/NS14713, AG15903] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014713, R01AG015903] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Daugherty BL, 2001, TRAFFIC, V2, P908, DOI 10.1034/j.1600-0854.2001.21206.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Guenette SY, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P591; Guenette SY, 2002, J NEUROCHEM, V82, P755, DOI 10.1046/j.1471-4159.2002.01009.x; HAASS C, 1993, J BIOL CHEM, V268, P3021; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; McLendon C, 2000, FASEB J, V14, P2383; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nunan J, 2001, EUR J BIOCHEM, V268, P5329, DOI 10.1046/j.0014-2956.2001.02465.x; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Roncarati R, 2001, NEUROSCIENCE, V104, P253, DOI 10.1016/S0306-4522(01)00066-5; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Tanahashi H, 2002, BIOCHEM J, V367, P687, DOI 10.1042/BJ20020562; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Van Gassen G, 2000, NEUROBIOL DIS, V7, P135, DOI 10.1006/nbdi.2000.0306; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yankner BA, 2002, NEUROBIOL AGING, V23, pS283; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	51	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51100	51107		10.1074/jbc.M309561200	http://dx.doi.org/10.1074/jbc.M309561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527950	hybrid			2022-12-25	WOS:000187206300034
J	Fux, L; Nussbaum-Shochat, A; Amster-Choder, O				Fux, L; Nussbaum-Shochat, A; Amster-Choder, O			A fraction of the BglG transcriptional antiterminator from Escherichia coli exists as a compact monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; PHOSPHORYLATION; PROTEIN; DOMAIN; OPERON; SACY; SITE; LICT	Expression of the bgl operon in Escherichia coli, induced by beta- glucosides, is positively regulated by BglG, a transcriptional antiterminator. In the presence of inducer, BglG dimerizes and binds to the bgl transcript to prevent premature termination of transcription. The dimeric state of BglG is determined by BglF, a membrane-bound enzyme II of the phosphoenolpyruvate- dependent phosphotransferase system ( PTS), which reversibly phosphorylates BglG according to beta- glucoside availability. BglG is composed of an RNA- binding domain followed by two homologous PTS regulation domains ( PRD1 and PRD2). The predicted structure of dimeric LicT, a BglG homologue from Bacillus subtilis, suggests that the two PRDs adopt a similar structure and that the interactions within the dimer are PRD1- PRD1 and PRD2- PRD2. We have shown recently that the PRD1 and PRD2 domains of BglG can form a stable heterodimer. We report here, based on in vitro and in vivo cross- linking experiments, that a fraction of BglG is present in the cell in a compact form in which PRD1 and PRD2 are in close proximity. The compact form is present mainly in the BglG monomers. Our results imply that the monomer- dimer transition involves a conformational change. The possible role of the compact form in preventing untimely induction of the bgl operon is discussed.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.	amster@cc.huji.ac.il						AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, J BIOL CHEM, V272, P17263, DOI 10.1074/jbc.272.28.17263; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Declerck N, 2001, J MOL BIOL, V314, P671, DOI 10.1006/jmbi.2001.5185; Declerck N, 1999, J MOL BIOL, V294, P389, DOI 10.1006/jmbi.1999.3256; Fux L, 2003, J BIOL CHEM, V278, P46203, DOI 10.1074/jbc.M306506200; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Idelson M, 1998, J BACTERIOL, V180, P660, DOI 10.1128/JB.180.3.660-666.1998; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; Stulke J, 2002, ARCH MICROBIOL, V177, P433, DOI 10.1007/s00203-002-0407-5; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; van Montfort BA, 2002, J BIOL CHEM, V277, P14717, DOI 10.1074/jbc.M201533200; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; vanTilbeurgh H, 1997, EMBO J, V16, P5030, DOI 10.1093/emboj/16.16.5030; VILLAFRANCA JE, 1987, BIOCHEMISTRY-US, V26, P2182, DOI 10.1021/bi00382a017; Yang YS, 2002, EMBO J, V21, P1987, DOI 10.1093/emboj/21.8.1987	32	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50978	50984		10.1074/jbc.M308085200	http://dx.doi.org/10.1074/jbc.M308085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14514681	hybrid			2022-12-25	WOS:000187206300020
J	Goetz, CA; O'Neil, JJ; Farrar, MA				Goetz, CA; O'Neil, JJ; Farrar, MA			Membrane localization, oligomerization, and phosphorylation are required for optimal Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; KINASE; SERINE; RECRUITMENT; C-RAF-1; DOMAIN	Activation of the serine/threonine kinase c-Raf-1 requires membrane localization, phosphorylation, and oligomerization. To study these mechanisms of Raf activation more precisely, we have used a membrane-localized fusion protein, myr-Raf-GyrB, which can be activated by coumermycin-induced oligomerization in NIH3T3 transfectants. By introducing a series of point mutations into the myr-Raf-GyrB kinase domain (S338A, S338A/Y341F, Y340F/Y341F, and T491A/S494A) we can separately study the role that membrane localization, phosphorylation, and oligomerization play in the process of Raf activation. We find that phosphorylation of Ser-338 plays a critical role in Raf activation and that this requires membrane localization but not oligomerization of Raf. Mutation of Tyr-341 had a limited effect, whereas mutation of both Ser-338 and Tyr-341 resulted in a synergistic loss of Raf activation following coumermycin-induced dimerization. Importantly, we found that membrane localization and phosphorylation of Ser-338 were not sufficient to activate Raf in the absence of oligomerization. Thus, our studies suggest that three key steps are required for optimal Raf activation: recruitment to the plasma membrane by GTP-bound Ras, phosphorylation via membrane-resident kinases, and oligomerization.	Univ Minnesota, Ctr Immunol, Ctr Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Farrar, MA (corresponding author), Univ Minnesota, Ctr Immunol, Ctr Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.		Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366	NIAID NIH HHS [2T32-AI07313] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007313] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; Farrar MA, 2000, J BIOL CHEM, V275, P31318, DOI 10.1074/jbc.M003399200; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mineo C, 1997, J BIOL CHEM, V272, P10345; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Weber CK, 2001, CANCER RES, V61, P3595; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	25	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51184	51189		10.1074/jbc.M309183200	http://dx.doi.org/10.1074/jbc.M309183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530258	hybrid			2022-12-25	WOS:000187206300044
J	Marumoto, T; Honda, S; Hara, T; Nitta, M; Hirota, T; Kohmura, E; Saya, H				Marumoto, T; Honda, S; Hara, T; Nitta, M; Hirota, T; Kohmura, E; Saya, H			Aurora-a kinase maintains the fidelity of early and late mitotic events in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; SPINDLE ASSEMBLY CHECKPOINT; PROTEIN-KINASE; CENTROSOME AMPLIFICATION; CHROMOSOME SEGREGATION; BREAST-CANCER; IN-SITU; CYCLE; METAPHASE; KINETOCHORES	Aurora-A, a member of the Aurora/Ipl1-related kinase family, is overexpressed in various types of cancer and considered to play critical roles in tumorigenesis. To better understand the pathological effect of Aurora-A activation, it is first necessary to elucidate the physiological functions of Aurora-A. Here, we have investigated the roles of Aurora-A in mitotic progression with the small interfering RNA, antibody microinjection, and time lapse microscopy using human cells. We demonstrated that suppression of Aurora-A by small interfering RNA caused multiple events to fail in mitosis, such as incorrect separation of centriole pairs, misalignment of chromosomes on the metaphase plate, and incomplete cytokinesis. Antibody microinjection of Aurora-A into late G(2) cells induced dose-dependent failure in separation of centriole pairs at prophase, indicating that Aurora-A is essential for proper separation of centriole pairs. When we injected anti-Aurora-A antibodies into prometaphase cells that had separated their centriole pairs, chromosomes were severely misaligned on the metaphase plate, indicating that Aurora-A is required for proper movement of chromosomes on the metaphase plate. Furthermore, inhibition of Aurora-A at metaphase by microinjected antibodies prevented cells from completing cytokinesis, suggesting that Aurora-A also has important functions in late mitosis. These results strongly suggest that Aurora-A is essential for many crucial events during mitosis and that the phosphorylation of a series of substrates by Aurora-A at different stages of mitosis may promote diverse critical events in mitosis to maintain chromosome integrity in human cells.	Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, Kumamoto 860, Japan; Kobe Univ, Grad Sch Med, Dept Neurosurg, Kobe, Hyogo 6500017, Japan	Kumamoto University; Kobe University	Saya, H (corresponding author), Kumamoto Univ, Dept Tumor Genet & Biol, Grad Sch Med Sci, 1-1-1 Honjo, Kumamoto 860, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Bockmuhl U, 1996, LARYNGO RHINO OTOL, V75, P408, DOI 10.1055/s-2007-997605; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; CHAN CSM, 1993, GENETICS, V135, P677; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Courjal F, 1996, BRIT J CANCER, V74, P1984, DOI 10.1038/bjc.1996.664; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; IWABUCHI H, 1995, CANCER RES, V55, P6172; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larramendy ML, 1997, AM J PATHOL, V151, P1153; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Paoletti A, 1996, J CELL SCI, V109, P3089; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; Roghi C, 1998, J CELL SCI, V111, P557; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SolinasToldo S, 1996, CANCER RES, V56, P3803; STEFFEN W, 1986, J CELL BIOL, V102, P1679, DOI 10.1083/jcb.102.5.1679; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; Tirkkonen M, 1997, CANCER RES, V57, P1222; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Wojcik C, 1996, EUR J CELL BIOL, V70, P172; YASEEN NY, 1990, CANCER GENET CYTOGEN, V44, P83, DOI 10.1016/0165-4608(90)90201-K; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	59	298	309	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51786	51795		10.1074/jbc.M306275200	http://dx.doi.org/10.1074/jbc.M306275200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14523000	hybrid			2022-12-25	WOS:000187206300114
J	Pickett, JS; Bowers, KE; Fierke, CA				Pickett, JS; Bowers, KE; Fierke, CA			Mutagenesis studies of protein farnesyltransferase implicate aspartate beta 352 as a magnesium ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; CRYSTAL-STRUCTURE; ISOPRENOID BIOSYNTHESIS; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; GERANYLGERANYLTRANSFERASE; ENZYME; YEAST; TRANSFERASE; SUBUNIT	Protein farnesyltransferase (FTase) catalyzes the addition of a farnesyl chain onto the sulfur of a C-terminal cysteine of a protein substrate. Magnesium ions enhance farnesylation catalyzed by FTase by several hundredfold, with a K-Mg value of 4 mM. The magnesium ion is proposed to coordinate the diphosphate leaving group of farnesyldiphosphate (FPP) to stabilize the developing charge in the farnesylation transition state. Here we further investigate the magnesium binding site using mutagenesis and biochemical studies. Free FPP binds Mg2+ with a K-d of 120 muM. The 10-fold weaker affinity for Mg2+ observed for the FTase.FPP.peptide ternary complex is probably caused by the positive charges in the diphosphate binding pocket of FTase. Furthermore, mutation of aspartate beta352 to alanine (Dbeta352A) or lysine (Dbeta352K) in FTase drastically alters the Mg2+ dependence of FTase catalysis without dramatically affecting the rate constant of farnesylation minus magnesium or the binding affinity of either substrate. In Dbeta352A FTase, the K-Mg increases 28-fold to 110 +/- 30 mM, and the farnesylation rate constant at saturating Mg2+ decreases 27-fold to 0.30 +/- 0.05 s(-1). Substitution of a lysine for Asp-beta352 removes the magnesium activation of farnesylation catalyzed by FTase but does not significantly enhance the rate constant for farnesylation in the absence of Mg2+. In wild type FTase, Mg2+ can be replaced by Mn2+ with a 2-fold lower K-Mn (2 mM). These results suggest both that Mg2+ coordinates the side chain carboxylate of Asp-beta352 and that the role of magnesium in the reaction includes positioning the FPP prior to catalysis.	Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fierke, CA (corresponding author), 930 N Univ Ave, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [F32CA084757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040602, R29GM040602] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA84757] Funding Source: Medline; NIGMS NIH HHS [GM40602, GM08597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK CB, 1994, COORDIN CHEM REV, V135, P165, DOI 10.1016/0010-8545(94)80068-5; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Cowan J. A., 1995, P1; Cowan JA, 2002, BIOMETALS, V15, P225, DOI 10.1023/A:1016022730880; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DAWSON RMC, 1986, DATA BIOCH RES, P414; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; Dolence JM, 1997, BIOCHEMISTRY-US, V36, P9246, DOI 10.1021/bi970039p; Dunten P, 1998, BIOCHEMISTRY-US, V37, P7907, DOI 10.1021/bi980531o; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Hightower KE, 1998, BIOCHEMISTRY-US, V37, P15555, DOI 10.1021/bi981525v; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Huang CC, 1997, J BIOL CHEM, V272, P20; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; Legler PM, 2002, BIOCHEMISTRY-US, V41, P10834, DOI 10.1021/bi020362e; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Pickett JS, 2003, BIOCHEMISTRY-US, V42, P9741, DOI 10.1021/bi0346852; POPOVYCH O, 1960, SPECTROCHIM ACTA, V16, P49, DOI 10.1016/0371-1951(60)80070-7; REISS Y, 1992, J BIOL CHEM, V267, P6403; Rellick LM, 1997, BIOPOLYMERS, V42, P191, DOI 10.1002/(SICI)1097-0282(199708)42:2<191::AID-BIP8>3.0.CO;2-I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rozema DB, 1999, BIOCHEMISTRY-US, V38, P13138, DOI 10.1021/bi990794y; Saderholm MJ, 2000, BIOCHEMISTRY-US, V39, P12398, DOI 10.1021/bi0011781; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Sebti SM, 2001, CANC DRUG DISC DEV, V8, P197; SOROKA K, 1987, ANAL CHEM, V59, P629, DOI 10.1021/ac00131a019; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Wendt KU, 1998, STRUCTURE, V6, P127, DOI 10.1016/S0969-2126(98)00015-X; Witter DJ, 1996, BIOCHEMISTRY-US, V35, P10454, DOI 10.1021/bi960500y; Wu Z, 1999, PROTEIN ENG, V12, P341, DOI 10.1093/protein/12.4.341; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zhang FL, 1996, BIOCHEM J, V320, P925, DOI 10.1042/bj3200925; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zimmerman KK, 1998, PROTEIN EXPRES PURIF, V14, P395, DOI 10.1006/prep.1998.0979	51	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51243	51250		10.1074/jbc.M309226200	http://dx.doi.org/10.1074/jbc.M309226200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532266	hybrid			2022-12-25	WOS:000187206300050
J	Claydon, TW; Makary, SY; Dibb, KM; Boyett, MR				Claydon, TW; Makary, SY; Dibb, KM; Boyett, MR			The selectivity filter may act as the agonist-activated gate in the G protein-activated Kir3.1/Kir3.4 K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER POTASSIUM CHANNELS; BETA-GAMMA-SUBUNITS; ION SELECTIVITY; PORE REGION; OPEN STATE; INWARD RECTIFICATION; BA2+ BLOCK; PERMEATION; MUTATIONS; RESIDUES	The Kir3.1/ Kir3.4 channel is activated by Gbetagamma subunits released on binding of acetylcholine to the M-2 muscarinic receptor. A mechanism of channel opening, similar to that for the KcsA and Shaker K (+) channels, has been suggested that involves translocation of pore lining transmembrane helices and the opening of an intracellular gate at the " bundle crossing" region. However, in the present study, we show that an extracellular gate at the selectivity filter is critical for agonist activation of the Kir3.1/ Kir3.4 channel. Increasing the flexibility of the selectivity filter, by disrupting a salt bridge that lies directly behind the filter, abolished both selectivity for K (+) and agonist activation of the channel. Other mutations within the filter that altered selectivity also altered agonist activation. In contrast, mutations within the filter that did not affect selectivity had little if any effect on agonist activation. Interestingly, mutation of bulky side chain phenylalanine residues at the bundle crossing also altered both agonist activation and selectivity. These results demonstrate a significant correlation between agonist activation and selectivity, which is determined by the selectivity filter, and suggests, therefore, that the selectivity filter may act as the agonist-activated gate in the Kir3.1/ Kir3.4 channel.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Boyett, MR (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.		Dibb, Katharine/G-8764-2015; Makary, Samy/C-6298-2018	Dibb, Katharine/0000-0002-9309-3853; Makary, Samy/0000-0003-3166-0151; Claydon, Tom/0000-0002-5143-7451; Boyett, Mark/0000-0003-3931-2020				Alagem N, 2003, BIOPHYS J, V85, P300, DOI 10.1016/S0006-3495(03)74475-0; Alagem N, 2001, J PHYSIOL-LONDON, V534, P381, DOI 10.1111/j.1469-7793.2001.00381.x; Berneche S, 2000, BIOPHYS J, V78, P2900, DOI 10.1016/S0006-3495(00)76831-7; Bruening-Wright A, 2002, J NEUROSCI, V22, P6499; Capener CE, 2003, BIOPHYS J, V84, P2345, DOI 10.1016/S0006-3495(03)75040-1; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Choe H, 1999, BIOPHYS J, V76, P1988, DOI 10.1016/S0006-3495(99)77357-1; Claydon TW, 2003, BIOPHYS J, V84, p80A; Claydon TW, 2002, J PHYSIOL-LONDON, V544, p11P; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Dibb K, 2003, BIOPHYS J, V84, p80A; Dibb KM, 2001, BIOPHYS J, V80, p624A; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Guo L, 1998, RECEPTOR CHANNEL, V5, P273; Hackos DH, 1999, J GEN PHYSIOL, V113, P799, DOI 10.1085/jgp.113.6.799; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jin TH, 2002, MOL CELL, V10, P469, DOI 10.1016/S1097-2765(02)00659-7; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; KUO A, 2003, SCIENCE; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Lu T, 2001, NAT NEUROSCI, V4, P239, DOI 10.1038/85080; Makary S. Y., 2002, Pfluegers Archiv European Journal of Physiology, V443, pS170; Makary SY, 2003, BIOPHYS J, V84, p314A; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Phillips LR, 2003, NEURON, V37, P953, DOI 10.1016/S0896-6273(03)00155-7; Proks P, 2001, J GEN PHYSIOL, V118, P341, DOI 10.1085/jgp.118.4.341; Sackin H, 2003, BIOPHYS J, V84, P910, DOI 10.1016/S0006-3495(03)74908-X; Sadja R, 2001, NEURON, V29, P669, DOI 10.1016/S0896-6273(01)00242-2; Silverman SK, 1998, BIOPHYS J, V75, P1330, DOI 10.1016/S0006-3495(98)74051-2; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	44	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50654	50663		10.1074/jbc.M308183200	http://dx.doi.org/10.1074/jbc.M308183200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14525972	hybrid			2022-12-25	WOS:000187068200121
J	Gobin, S; Thuillier, L; Jogl, G; Faye, A; Tong, L; Chi, M; Bonnefont, JP; Girard, J; Prip-Buus, C				Gobin, S; Thuillier, L; Jogl, G; Faye, A; Tong, L; Chi, M; Bonnefont, JP; Girard, J; Prip-Buus, C			Functional and structural basis of carnitine palmitoyltransferase 1A deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA SENSITIVITY; N-TERMINAL DOMAIN; CATALYTIC-ACTIVITY; MOLECULAR-BASIS; I DEFICIENCY; IDENTIFICATION; MUTATION; RESIDUES; BINDING; MODEL	Carnitine palmitoyltransferase 1A (CPT1A) is the key regulatory enzyme of hepatic long-chain fatty acid beta-oxidation. Human CPT1A deficiency is characterized by recurrent attacks of hypoketotic hypoglycemia. We presently analyzed at both the functional and structural levels five missense mutations identified in three CPT1A-deficient patients, namely A275T, A414V, Y498C, G709E, and G710E. Heterologous expression in Saccharomyces cerevisiae permitted to validate them as disease-causing mutations. To gain further insights into their deleterious effects, we localized these mutated residues into a three-dimensional structure model of the human CPT1A created from the crystal structure of the mouse carnitine acetyltransferase. This study demonstrated for the first time that disease-causing CPT1A mutations can be divided into two categories depending on whether they affect directly ( functional determinant) or indirectly the active site of the enzyme ( structural determinant). Mutations A275T, A414V, and Y498C, which exhibit decreased catalytic efficiency, clearly belong to the second class. They are located more than 20 Angstrom away from the active site and mostly affect the stability of the protein itself and/or of the enzyme-substrate complex. By contrast, mutations G709E and G710E, which abolish CPT1A activity, belong to the first category. They affect Gly residues that are essential not only for the structure of the hydrophobic core in the catalytic site, but also for the chain-length specificity of CPT isoforms. This study provides novel insights into the functionality of CPT1A that may contribute to the design of drugs for the treatment of lipid disorders.	Univ Paris 05, Inst Cochin, Dept Endocrinol, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Hop Necker Enfants Malad, INSERM, U393, F-75743 Paris 15, France; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Columbia University	Prip-Buus, C (corresponding author), Univ Paris 05, Inst Cochin, Dept Endocrinol, CNRS,UMR 8104,INSERM,U567, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		PRIP-BUUS, Carina/P-9084-2017; Jogl, Gerwald/AAJ-5783-2021	Jogl, Gerwald/0000-0002-5465-5315; BONNEFONT, Jean-Paul/0000-0002-4235-1197; Prip-Buus, Carina/0000-0002-2153-7857; Tong, Liang/0000-0002-0563-6468				Bonnefont JP, 1999, MOL GENET METAB, V68, P424, DOI 10.1006/mgme.1999.2938; BOUGNERES PF, 1980, NEW ENGL J MED, V302, P123; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Brown NF, 2001, J LIPID RES, V42, P1134; BROWN NF, 1994, J BIOL CHEM, V269, P26438; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Gobin S, 2002, HUM GENET, V111, P179, DOI 10.1007/s00439-002-0752-0; Ijlst L, 1998, J CLIN INVEST, V102, P527, DOI 10.1172/JCI2927; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jogl G, 2003, CELL, V112, P113, DOI 10.1016/S0092-8674(02)01228-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Morillas M, 2003, J BIOL CHEM, V278, P9058, DOI 10.1074/jbc.M209999200; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Ogawa E, 2002, J HUM GENET, V47, P342, DOI 10.1007/s100380200047; Pan Y, 2002, J BIOL CHEM, V277, P47184, DOI 10.1074/jbc.M208055200; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Prip-Buus C, 2001, MOL GENET METAB, V73, P46, DOI 10.1006/mgme.2001.3176; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAUDUBRAY JM, 1982, PEDIATR RES, V16, P877, DOI 10.1203/00006450-198210000-00015; Schaefer J, 1997, J NEUROL NEUROSUR PS, V62, P169, DOI 10.1136/jnnp.62.2.169; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Treber M, 2003, J BIOL CHEM, V278, P11145, DOI 10.1074/jbc.M210566200; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	38	41	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50428	50434		10.1074/jbc.M310130200	http://dx.doi.org/10.1074/jbc.M310130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14517221	hybrid			2022-12-25	WOS:000187068200094
J	Gimeno, RE; Hirsch, DJ; Punreddy, S; Sun, Y; Ortegon, AM; Wu, H; Daniels, T; Stricker-Krongrad, A; Lodish, HF; Stahl, A				Gimeno, RE; Hirsch, DJ; Punreddy, S; Sun, Y; Ortegon, AM; Wu, H; Daniels, T; Stricker-Krongrad, A; Lodish, HF; Stahl, A			Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ADIPOSE-TISSUE; YOLK-SAC; MICE; CLONING; GENE; EXPRESSION; BINDING; DISRUPTION	Fatty acid transport protein-4 (FATP4) is the major FATP in the small intestine. We previously demonstrated, using in vitro antisense experiments, that FATP4 is required for fatty acid uptake into intestinal epithelial cells. To further examine the physiological role of FATP4, mice carrying a targeted deletion of FATP4 were generated. Deletion of one allele of FATP4 resulted in 48% reduction of FATP4 protein levels and a 40% reduction of fatty acid uptake by isolated enterocytes. However, loss of one FATP4 allele did not cause any detectable effects on fat absorption on either a normal or a high fat diet. Deletion of both FATP4 alleles resulted in embryonic lethality as crosses between heterozygous FATP4 parents resulted in no homozygous offspring; furthermore, no homozygous embryos were detected as early as day 9.5 of gestation. Early embryonic lethality has been observed with deletion of other genes involved in lipid absorption in the small intestine, namely microsomal triglyceride transfer protein and apolipoprotein B, and has been attributed to a requirement for fat absorption early in embryonic development across the visceral endoderm. In mice, the extraembryonic endoderm supplies nutrients to the embryo prior to development of a chorioallantoic placenta. In wild-type mice we found that FATP4 protein is highly expressed by the epithelial cells of the visceral endoderm and localized to the brush-border membrane of extraembryonic endodermal cells. This localization is consistent with a role for FATP4 in fat absorption in early embryogenesis and suggests a novel requirement for FATP4 function during development.	Palo Alto Med Fdn, Palo Alto, CA 94301 USA; Stanford Univ, Sch Med, Palo Alto, CA 94301 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Palo Alto Medical Foundation Research Institute; Stanford University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Stahl, A (corresponding author), Palo Alto Med Fdn, Palo Alto, CA 94301 USA.							Binnert C, 2000, AM J PHYSIOL-ENDOC M, V279, pE1072, DOI 10.1152/ajpendo.2000.279.5.E1072; Chiu HC, 2001, J CLIN INVEST, V107, P813, DOI 10.1172/JCI10947; CLANDININ MT, 1979, FEBS LETT, V102, P173, DOI 10.1016/0014-5793(79)80953-9; Coburn CT, 2001, J MOL NEUROSCI, V16, P117, DOI 10.1385/JMN:16:2-3:117; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Dutta-Roy AK, 2000, AM J CLIN NUTR, V71, p315S, DOI 10.1093/ajcn/71.1.315s; Eldridge A L, 2002, Obes Rev, V3, P17, DOI 10.1046/j.1467-789X.2002.00050.x; Farese RV, 1996, J LIPID RES, V37, P347; Fitscher BA, 1998, BBA-GENE STRUCT EXPR, V1443, P381, DOI 10.1016/S0167-4781(98)00231-0; Gimeno RE, 2003, J BIOL CHEM, V278, P16039, DOI 10.1074/jbc.M211412200; GORE J, 1993, J NUTR, V123, P66, DOI 10.1093/jn/123.1.66; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Innis SM, 1999, LIPIDS, V34, P139, DOI 10.1007/s11745-999-0348-x; Jequier E, 2002, INT J OBESITY, V26, pS12, DOI 10.1038/sj.ijo.0802123; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; Keating GM, 2001, DRUGS, V61, P2107, DOI 10.2165/00003495-200161140-00011; Lewis SE, 2001, J BIOL CHEM, V276, P37042, DOI 10.1074/jbc.M105556200; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Richards MR, 2003, J BIOL CHEM, V278, P10477, DOI 10.1074/jbc.M212469200; ROBERTSON EJ, 1987, TERATOCARINOMAS EMBR; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Sternby B, 2002, CLIN NUTR, V21, P395, DOI 10.1054/clnu.2002.0565; STREMMEL W, 1988, J CLIN INVEST, V82, P2001, DOI 10.1172/JCI113820; STREMMEL W, 1989, J HEPATOL, V9, P374, DOI 10.1016/0168-8278(89)90148-7; STREMMEL W, 1989, MOL CELL BIOCHEM, V88, P23; Stuhlsatz-Krouper SM, 1999, PROSTAG LEUKOTR ESS, V60, P285, DOI 10.1016/S0952-3278(99)80001-5; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; Stump DD, 2001, J LIPID RES, V42, P509; Watkins PA, 1999, PROSTAG LEUKOTR ESS, V60, P323, DOI 10.1016/S0952-3278(99)80007-6; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	40	102	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49512	49516		10.1074/jbc.M309759200	http://dx.doi.org/10.1074/jbc.M309759200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512415	hybrid			2022-12-25	WOS:000186829000120
J	Henriksen, K; Karsdal, M; Delaisse, JM; Engsig, MT				Henriksen, K; Karsdal, M; Delaisse, JM; Engsig, MT			RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING-FACTOR; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ENDOCHONDRAL BONE-FORMATION; TNF FAMILY-MEMBER; IN-VITRO; C-SRC; OSTEOPROTEGERIN LIGAND; SIGNAL-TRANSDUCTION; MATURE OSTEOCLASTS	Development of bone depends on a continuous supply of bone-degrading osteoclasts. Although several factors such as the matrix metalloproteinases and the integrins have been shown to be important for osteoclast recruitment, the mechanism of action remains poorly understood. In this study we investigated the molecular mechanisms homing osteoclasts to their future site of resorption during bone development. We show that RANKL and VEGF, two cytokines known to be present in bone, possess chemotactic properties toward osteoclasts cultured in modified Boyden chambers. Furthermore, in ex vivo cultures of embryonic murine metatarsals, a well established model of osteoclast recruitment, antagonists of RANKL and VEGF reduced calcium release, showing that both cytokines play roles during bone development. In cultures of purified osteoclasts both RANKL and VEGF induced phosphorylation of ERK1/2 MAP kinase. M-CSF, a well-known chemoattractant of osteoclast, also induced activation of ERK1/2, although this activation followed a kinetic pattern differing from that of RANKL and VEGF. RANKL and VEGF-induced, but not M-CSF-induced, osteoclast invasion was completely blocked by the specific inhibitor of ERK1/2 phosphorylation, PD98059. In addition, PD98059 was able to inhibit calcium release in cultures of embryonic metatarsals. In contrast, PD98059 was unable to abrogate the RANKL-induced calcium release in the tibia model, demonstrating that only some of the RANKL functions on osteoclast physiology are regulated through the ERK1/2 pathway. Taken together, these results show that RANKL and VEGF, in addition to their role in osteoclast differentiation and activation of resorption, are important components of the processes regulating osteoclast chemotaxis.	Nord Biosci AS, DK-2730 Herlev, Denmark	Nordic Bioscience	Henriksen, K (corresponding author), Nord Biosci AS, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.			Karsdal, Morten/0000-0001-5026-8740; Delaisse, Jean-Marie/0000-0001-7370-1500				AKATSU T, 1992, J BONE MINER RES, V7, P1297; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BLAVIER L, 1995, J CELL SCI, V108, P3649; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Carlevaro MF, 2000, J CELL SCI, V113, P59; Chikazu D, 2000, J BIOL CHEM, V275, P31444, DOI 10.1074/jbc.M910132199; CORBOZ VA, 1992, ENDOCRINOLOGY, V130, P437, DOI 10.1210/en.130.1.437; DIEUDONNE SC, 1991, J BONE MINER RES, V6, P479; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; FELIX R, 1990, J BONE MINER RES, V5, P781; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Insogna K, 1997, MOL REPROD DEV, V46, P104; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014-5793(00)02231-6; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; OWENS J, 1993, BIOCHEM BIOPH RES CO, V195, P1401, DOI 10.1006/bbrc.1993.2199; Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sato T, 1998, J BONE MINER RES, V13, P59, DOI 10.1359/jbmr.1998.13.1.59; Sato T, 1997, J CELL SCI, V110, P589; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Taddei L, 1999, BIOCHEM BIOPH RES CO, V263, P340, DOI 10.1006/bbrc.1999.1342; Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WEIR EC, 1993, J BONE MINER RES, V8, P1507; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	44	126	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48745	48753		10.1074/jbc.M309193200	http://dx.doi.org/10.1074/jbc.M309193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506249	hybrid			2022-12-25	WOS:000186829000030
J	Overton, MC; Chinault, SL; Blumer, KJ				Overton, MC; Chinault, SL; Blumer, KJ			Oligomerization, biogenesis, and signaling is promoted by a glycophorin A-like dimerization motif in transmembrane domain 1 of a yeast G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; ALPHA-FACTOR RECEPTOR; C5A RECEPTOR; TRAFFICKING; RHODOPSIN; SEGMENT; ACTIVATION; INHIBITION; EXPRESSION; INTERFACE	G protein-coupled receptors (GPCRs) can form dimeric or oligomeric complexes in vivo. However, the functions and mechanisms of oligomerization remain poorly understood for most GPCRs, including the alpha-factor receptor (STE2 gene product) of the yeast Saccharomyces cerevisiae. Here we provide evidence indicating that alpha-factor receptor oligomerization involves a GXXXG motif in the first transmembrane domain (TM1), similar to the transmembrane dimerization domain of glycophorin A. Results of fluorescence resonance energy transfer, fluorescence microscopy, endocytosis assays of receptor oligomerization in living cells, and agonist binding assays indicated that amino acid substitutions affecting the glycine residues of the GXXXG motif impaired alpha-factor receptor oligomerization and biogenesis in vivo but did not significantly impair agonist binding affinity. Mutant receptors exhibited signaling defects that were not due to impaired cell surface expression, indicating that oligomerization promotes alpha-factor receptor signal transduction. Structure-function studies suggested that the GXXXG motif in TM1 of the alpha-factor receptor promotes oligomerization by a mechanism similar to that used by the GXXXG dimerization motif of glycophorin A. In many mammalian GPCRs, motifs related to the GXXXG sequence are present in TM1 or other TM domains, suggesting that similar mechanisms are used by many GPCRs to form dimers or oligomeric arrays.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	kblumer@cellbio.wustl.edu	Blumer, Kendall J/C-5268-2012		NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brosig B, 1998, PROTEIN SCI, V7, P1052; Chang FS, 2003, CURR BIOL, V13, P455, DOI 10.1016/S0960-9822(03)00131-3; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; ENGELMAN DM, 1993, SOC GEN PHY, V48, P11; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Floyd DH, 2003, J BIOL CHEM, V278, P35354, DOI 10.1074/jbc.M305607200; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Martin NP, 2002, J MOL BIOL, V317, P765, DOI 10.1006/jmbi.2002.5444; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Overton MC, 2002, METHODS, V27, P324, DOI 10.1016/S1046-2023(02)00090-7; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrish W, 2002, GENETICS, V160, P429; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Shah A, 1996, BIOCHEM BIOPH RES CO, V226, P242, DOI 10.1006/bbrc.1996.1340; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Smith SO, 2001, BIOCHEMISTRY-US, V40, P6553, DOI 10.1021/bi010357v; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Stefan CJ, 1999, J BIOL CHEM, V274, P1835, DOI 10.1074/jbc.274.3.1835; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Torres J, 2002, J MOL BIOL, V316, P375, DOI 10.1006/jmbi.2001.5268; Xie HB, 2000, BIOCHEMISTRY-US, V39, P15462, DOI 10.1021/bi001432p; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873	67	117	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49369	49377		10.1074/jbc.M308654200	http://dx.doi.org/10.1074/jbc.M308654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506226	hybrid			2022-12-25	WOS:000186829000105
J	Suzuki, H; Tashiro, S; Sun, JY; Doi, H; Satomi, S; Igarashi, K				Suzuki, H; Tashiro, S; Sun, JY; Doi, H; Satomi, S; Igarashi, K			Cadmium induces nuclear export of Bach1, a transcriptional repressor of heme oxygenase-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAF RECOGNITION ELEMENT; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; FACTOR NF-E2; EPITHELIAL-CELLS; FACTOR NRF2; ACTIVATION; INDUCTION; BINDING; FAMILY	The export of certain nuclear proteins is involved in the regulation of various nuclear functions, including transcription. In some cases, the export of target proteins is induced upon environmental or cellular cues, resulting in conditional gene expression. The small Maf proteins appear to be critical regulators of heme oxygenase (HO)-1, an anti-oxidant defense enzyme that degrades heme into iron, carbon monoxide, and biliverdin. Although ho-1 is repressed by Bach1/small Maf heterodimers, it is activated by Nrf2/small Maf heterodimers, indicating that Bach1 and Nrf2 compete with each other. We anticipated that the nuclear concentration of Bach1 might be regulated to ensure that the entire system effectively responds to various stimuli. We carried out detailed domain analysis of Bach1 in an effort to understand how various inducers of HO-1 inactivate Bach1. We show here that cadmium, a strong inducer of HO-1, activates the nuclear export of Bach1. This cadmium-induced export of Bach1 was mediated in trans by its C-terminal region that is conserved between Bach1 and Bach2. The nuclear export of Bach2 was also induced by cadmium, indicating that the cadmium responsibility is shared between Bach1 and Bach2. The nuclear export of Bach1 was dependent on Crm1/Exportin1 as well as the extracellular signal-regulated kinase1/ 2 (ERK1/2) activity. These results indicate that the nuclear export of Bach1 constitutes an important regulatory mechanism to relieve the Bach1-mediated repression of genes such as ho-1.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomed Chem, Hiroshima 7348551, Japan; Tohoku Univ, Grad Sch Med, Div Adv Surg Sci & Technol, Sendai, Miyagi 9808575, Japan	Hiroshima University; Tohoku University	Igarashi, K (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biomed Chem, Hiroshima 7348551, Japan.			Igarashi, Kazuhiko/0000-0002-2470-2475				Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Alam J, 2003, AM J PHYSIOL-RENAL, V284, pF743, DOI 10.1152/ajprenal.00376.2002; ALAM J, 1989, J BIOL CHEM, V264, P6371; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Katsuoka F, 2003, MOL CELL BIOL, V23, P1163, DOI 10.1128/MCB.23.4.1163-1174.2003; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; SARDANA MK, 1982, J BIOL CHEM, V257, P4806; Shibahara S, 2002, ANTIOXID REDOX SIGN, V4, P593, DOI 10.1089/15230860260220094; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Stewart D, 2003, J BIOL CHEM, V278, P2396, DOI 10.1074/jbc.M209195200; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; TAKETANI S, 1989, FEBS LETT, V245, P173, DOI 10.1016/0014-5793(89)80215-7; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; TENHUNEN R, 1970, J LAB CLIN MED, V75, P410; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x	43	132	133	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49246	49253		10.1074/jbc.M306764200	http://dx.doi.org/10.1074/jbc.M306764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504288	hybrid			2022-12-25	WOS:000186829000090
J	Wang, ZM; Li, XN; Cocklin, RR; Wang, MH; Wang, M; Fukase, K; Inamura, S; Kusumoto, S; Gupta, D; Dziarski, R				Wang, ZM; Li, XN; Cocklin, RR; Wang, MH; Wang, M; Fukase, K; Inamura, S; Kusumoto, S; Gupta, D; Dziarski, R			Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; INNATE IMMUNITY; CELL-WALLS; DROSOPHILA; PURIFICATION; ACTIVATION; LYSOZYME; BINDING; FAMILY; GENE	Peptidoglycan recognition proteins (PGRPs) are pattern recognition molecules coded by up to 13 genes in insects and 4 genes in mammals. In insects PGRPs activate antimicrobial pathways in the hemolymph and cells, or are peptidoglycan (PGN)-lytic amidases. In mammals one PGRP is an antibacterial neutrophil protein. We report that human PGRP-L is a Zn2+-dependent N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28), an enzyme that hydrolyzes the amide bond between MurNAc and L-Ala of bacterial PGN. The minimum PGN fragment hydrolyzed by PGRP-L is MurNAc-tripeptide. PGRP-L has no direct bacteriolytic activity. The other members of the human PGRP family, PGRP-Ialpha, PGRP-Ibeta, and PGRP-S, do not have the amidase activity. The C-terminal region of PGRP-L, homologous to bacteriophage and bacterial amidases, is required and sufficient for the amidase activity of PGRP-L, although its activity ( in the N-terminal Delta1-343 deletion mutant) is reduced. The Zn2+ binding amino acids ( conserved in PGRP-L and T7 amidase) and Cys-419 ( not conserved in T7 amidase) are required for the amidase activity of PGRP-L, whereas three other amino acids, needed for the activity of T7 amidase, are not required for the activity of PGRP-L. These amino acids, although required, are not sufficient for the amidase activity, because changing them to the "active'' configuration does not convert PGRP-S into an active amidase. In conclusion, human PGRP-L is an N-acetylmuramoyl-L-alanine amidase and this function is conserved in prokaryotes, insects, and mammals.	Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan	Indiana University System; Indiana University Northwest; Indiana University System; Indiana University-Purdue University Indianapolis; Osaka University	Dziarski, R (corresponding author), Indiana Univ, Sch Med, NW Ctr Med Educ, 3400 Broadway, Gary, IN 46408 USA.	rdziar@iun.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056395] Funding Source: NIH RePORTER; NIAID NIH HHS [AI56395, AI2879] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; DEPAUW P, 1995, PROTEIN EXPRES PURIF, V6, P371, DOI 10.1006/prep.1995.1049; Doyle R.J., 2001, MOL MED MICROBIOLOGY, P137; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Dziarski R. A., 2000, GLYCOMICROBIOLOGY, P145; ELLOUZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317, DOI 10.1016/0006-291X(74)90458-6; Ganz T, 2003, BLOOD, V101, P2388, DOI 10.1182/blood-2002-07-2319; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gupta D, 1999, J BIOL CHEM, V274, P14012, DOI 10.1074/jbc.274.20.14012; Heymer B., 1985, IMMUNOLOGY BACTERIAL, P11; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoijer MA, 1997, EUR CYTOKINE NETW, V8, P375; Hoijer MA, 1997, BLOOD, V90, P1246, DOI 10.1182/blood.V90.3.1246.1246_1246_1254; Hoijer MA, 1996, BBA-GEN SUBJECTS, V1289, P57, DOI 10.1016/0304-4165(95)00136-0; INAMURA S, 2003, THESIS OSAKA U OSAKA; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kibardin A V, 2000, Dokl Biochem, V372, P103; Kibardin AV, 2003, J MOL BIOL, V326, P467, DOI 10.1016/S0022-2836(02)01401-8; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; KOTANI S, 1975, Z IMMUNITATSFORSCH, V149, P302; KUSUMOTO S, 1976, B CHEM SOC JPN, V49, P533, DOI 10.1246/bcsj.49.533; LADESIC B, 1981, BIOCHIM BIOPHYS ACTA, V678, P12, DOI 10.1016/0304-4165(81)90042-8; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Majcherczyk PA, 1999, J BIOL CHEM, V274, P12537, DOI 10.1074/jbc.274.18.12537; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MOLLNER S, 1984, ARCH MICROBIOL, V140, P171, DOI 10.1007/BF00454921; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Skubitz KM, 1999, WINTROBES CLIN HEMAT, P300; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; VALINGER Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P63, DOI 10.1016/0167-4838(82)90313-2; VANDERWINKEL E, 1990, BIOCHIM BIOPHYS ACTA, V1039, P331, DOI 10.1016/0167-4838(90)90267-J; VANDERWINKEL E, 1995, BIOCHEM MOL MED, V54, P26, DOI 10.1006/bmme.1995.1004; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	58	182	199	5	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49044	49052		10.1074/jbc.M307758200	http://dx.doi.org/10.1074/jbc.M307758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14506276	hybrid			2022-12-25	WOS:000186829000066
J	Han, XY; Boyd, PJ; Colgan, S; Madri, JA; Haas, TL				Han, XY; Boyd, PJ; Colgan, S; Madri, JA; Haas, TL			Transcriptional up-regulation of endothelial cell matrix metalloproteinase-2 in response to extracellular cues involves GATA-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 PROMOTER; GELATINASE-A EXPRESSION; GENE-EXPRESSION; PHENOTYPIC MODULATION; BINDING-PROTEIN; SKELETAL-MUSCLE; ACTIVATION; GROWTH; YB-1; COFACTOR	Matrix metalloproteinase-2 (MMP-2) plays a critical role in endothelial cells during the processes of angiogenesis and vascular remodeling. Endothelial cell production of MMP-2 is greatly enhanced when cells are cultured within a three-dimensional type I collagen matrix coinciding with the increased invasive and migratory phenotype of the cells. To define the transcriptional regulation of MMP-2 in rat microvascular endothelial cells, we performed promoter-reporter assays with a series of promoter truncations. Activity of the full promoter was significantly greater in cells cultured within three-dimensional type I collagen compared with cells cultured as a monolayer (two-dimensional) on type I collagen. Truncation of the region encompassing base pairs - 1562 to - 1375 ( relative to the start codon) of the MMP-2 promoter resulted in loss of this differential activity of the MMP-2 promoter. Analysis of this region indicated two putative GATA-2 binding domains between - 1437 and - 1387. Southwestern blot analysis and electrophoretic mobility shift assays confirmed the binding of GATA-2 to this region of the MMP-2 promoter. Overexpression of GATA-2 in COS-7 cells significantly increased the activity of the full-length MMP-2 promoter-luciferase construct. Endothelial cells expressed greater levels of GATA-2 protein in three-dimensional compared with two-dimensional cultures, and activity of the - 1437/ - 1387 region of the MMP-2 promoter was significantly greater in three-dimensional cultured endothelial cells. Together, these results indicate GATA-2 regulation of the MMP-2 promoter in endothelial cells and that the GATA-2 binding domain is sufficient to drive increased activity of the MMP-2 promoter in response to an extracellular matrix stimulus.	York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	York University - Canada; Yale University	Haas, TL (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, Rm 341,Farquharson Bldg,4700 Keele St, N York, ON M3J 1P3, Canada.		Haas, Tara/F-6788-2013	Haas, Tara/0000-0001-8559-9574				Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bottles KD, 1999, BBA-GEN SUBJECTS, V1428, P147, DOI 10.1016/S0304-4165(99)00059-8; Cheng SF, 2002, BIOCHEM J, V366, P807, DOI 10.1042/BJ20020202; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; Haas TL, 2002, CAN J APPL PHYSIOL, V27, P491, DOI 10.1139/h02-027; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HUDLICKA O, 1992, PHYSIOL REV, V72, P369, DOI 10.1152/physrev.1992.72.2.369; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; Nagase H, 1998, Cell Res, V8, P179; Nguyen M, 2001, INT J BIOCHEM CELL B, V33, P960, DOI 10.1016/S1357-2725(01)00007-3; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; ORKIN SH, 1992, BLOOD, V80, P575; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thum T, 2000, FASEB J, V14, P740, DOI 10.1096/fasebj.14.5.740; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11; Wung BS, 1999, CIRC RES, V84, P804; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	38	45	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47785	47791		10.1074/jbc.M309482200	http://dx.doi.org/10.1074/jbc.M309482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14512418	hybrid			2022-12-25	WOS:000186731400054
J	Kjaer, S; Ibanez, CF				Kjaer, S; Ibanez, CF			Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; GDNF FAMILY LIGANDS; NEUROTROPHIC FACTOR; CELL-ADHESION; ACTIVATION; CALCIUM; MECHANISMS; PROTOONCOGENE; SPECIFICITY; GFR-ALPHA-1	The RET receptor tyrosine kinase is activated by binding to a ligand complex formed by a member of the glial cell line-derived neurotrophic factor (GDNF) family of neurotrophic factors bound to its cognate GDNF-family receptor-alpha (GFRalpha) glycosylphosphatidylinositol-linked co-receptor. Molecular modeling studies of the extracellular domain of RET (RETECD) have revealed the existence of four cadherin-like domains (CLD1-4) followed by a cysteine-rich domain. Cross-linking experiments have indicated that the RETECD makes direct contacts with both the GDNF ligand and GFRalpha1 molecule in the complex, although it has low or no detectable affinity for either component alone. We have exploited sequence and functional divergences between the ectodomains of mammalian and amphibian RET molecules to map binding determinants in the human RETECD responsible for its interaction with the GDNF-GFRalpha1 complex by homologue-scanning mutagenesis. We found that Xenopus RETECD was unable to bind to GDNF-GFRalpha-1 or neurturin (NTN)-GFRalpha-2 complexes of mammalian origin. However, a chimeric molecule containing CLD1, - 2, and - 3 from human RETECD, but neither domain alone, had similar binding activity as compared with wild type human RETECD, suggesting the existence of an extended ligand binding surface within the three N-terminal cadherin-like domains of human RETECD. Subsequent loss-of-function experiments at higher resolution identified three small subsets of residues, mapping on the same face of the molecular model of RET CLD1, that were required for the interaction of human RETECD with the GDNF-GFRalpha1 complex. Additional experiments demonstrated that N-linked glycosylation of human RETECD was not required for ligand binding. Based on these observations, we propose a model for the assembly and architecture of the GDNF-GFRalpha1-RET complex.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden.			Kjaer, Susanne/0000-0002-8347-1398				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gash DM, 1998, ANN NEUROL, V44, pS121, DOI 10.1002/ana.410440718; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kjaer S, 2003, HUM MOL GENET, V12, P2133, DOI 10.1093/hmg/ddg227; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Steen M, 2002, J BIOL CHEM, V277, P50022, DOI 10.1074/jbc.M205609200; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	36	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47898	47904		10.1074/jbc.M309772200	http://dx.doi.org/10.1074/jbc.M309772200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14514671	hybrid			2022-12-25	WOS:000186731400067
J	Perron, MJ; Blouse, GE; Shore, JD				Perron, MJ; Blouse, GE; Shore, JD			Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1)-PROTEINASE INHIBITOR; TRYPTOPHAN ANALOGS; STAPHYLOCOCCAL NUCLEASE; CONFORMATIONAL-CHANGE; ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; MECHANISM; SUBSTRATE; SITE; BINDING	Plasminogen activator inhibitor-1 ( PAI-1) is a typical member of the serpin family that kinetically traps its target proteinase as a covalent complex by distortion of the proteinase domain. Incorporation of the fluorescently silent 4-fluorotryptophan analog into PAI-1 permitted us to observe changes in the intrinsic tryptophan fluorescence of two-chain tissue-type plasminogen activator (tPA) and the proteinase domain of tPA during the inhibition reaction. We demonstrated three distinct conformational changes of the proteinase that occur during complex formation and distortion. A conformational change occurred during the initial formation of the noncovalent Michaelis complex followed by a large conformational change associated with the distortion of the proteinase catalytic domain that occurs concurrently with the formation of stable proteinase-inhibitor complexes. Following distortion, a very slow structural change occurs that may be involved in the stabilization or regulation of the trapped complex. Furthermore, by comparing the inhibition rates of two-chain tPA and the proteinase domain of tPA by PAI-1, we demonstrate that the accessory domains of tPA play a prominent role in the initial formation of the non-covalent Michaelis complex.	Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Henry Ford Hospital; Wayne State University	Blouse, GE (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, 1 Ford Pl,5-D, Detroit, MI 48202 USA.	gblouse1@hfhs.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054390, R56HL054390] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54390] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blouse GE, 2003, BIOCHEMISTRY-US, V42, P12260, DOI 10.1021/bi034737n; Blouse GE, 2002, BIOCHEMISTRY-US, V41, P11997, DOI 10.1021/bi025967p; Bousquet JA, 2003, BIOCHEM J, V370, P345, DOI 10.1042/BJ20020890; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; Dekker RJ, 1999, J MOL BIOL, V293, P613, DOI 10.1006/jmbi.1999.3178; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; EVANS SA, 1982, J BIOL CHEM, V257, P3014; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KANEKO M, 1991, BIOCHEM BIOPH RES CO, V178, P1160, DOI 10.1016/0006-291X(91)91014-4; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; Mellet P, 1998, J BIOL CHEM, V273, P9119, DOI 10.1074/jbc.273.15.9119; Minks C, 1999, BIOCHEMISTRY-US, V38, P10649, DOI 10.1021/bi990580g; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; Ross JBA, 1997, METHOD ENZYMOL, V278, P151; Tew DJ, 2001, FEBS LETT, V494, P30, DOI 10.1016/S0014-5793(01)02305-5; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; VAUGHAN DE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P221, DOI 10.1016/0167-4838(93)90008-F; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WILHELM OG, 1990, J BIOL CHEM, V265, P14606; Wind T, 2002, BIOL CHEM, V383, P21, DOI 10.1515/BC.2002.003; Wong CY, 1997, PROTEIN SCI, V6, P689; Wong CY, 1998, BIOCHEMISTRY-US, V37, P8938, DOI 10.1021/bi971862o; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	35	13	13	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48197	48203		10.1074/jbc.M306184200	http://dx.doi.org/10.1074/jbc.M306184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500731	hybrid			2022-12-25	WOS:000186731400102
J	Tai, CH; Boraud, T; Bezard, E; Bioulac, B; Gross, C; Benazzouz, A				Tai, CH; Boraud, T; Bezard, E; Bioulac, B; Gross, C; Benazzouz, A			Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata	FASEB JOURNAL			English	Article						Parkinson's disease; extracellular recordings; basal ganglia; cytochrome oxidase	DEEP BRAIN-STIMULATION; ADVANCED PARKINSONS-DISEASE; MPTP-TREATED MONKEY; GLOBUS-PALLIDUS; ELECTRICAL-STIMULATION; PARS RETICULATA; DOPAMINE NEURONS; STN STIMULATION; BASAL GANGLIA; CELL-BODIES	High-frequency stimulation (HFS) of the subthalamic nucleus (STN) has been shown to produce a dramatic alleviation of motor symptoms in patients with advanced Parkinson's disease. Its functional mechanism, however, remains obscure. We used extracellular recording and in situ cytochrome oxidase (Col) mRNA hybridization to investigate the effects of HFS of the STN on neuronal activity of the STN and the substantia nigra reticulata (SNr) in normal rats and rats with 6-hydroxydopamine (6-OHDA) lesion of the substantia nigra compacta (SNc). To allow detection of spikes and analysis of firing activity, artifacts recorded during stimulation were scaled down using a template subtraction method. In both normal and lesioned rats, the activity of a majority of STN neurons was inhibited during stimulation. In the SNr, HFS also induced an inhibition of the activity of a majority of neurons in normal and lesioned rats. In situ hybridization histochemistry confirmed these results in that it showed a significant decrease in levels of Col mRNA expression in the STN and SNr in both normal and lesioned rats during stimulation. These data afford an interesting insight into the functional mechanism of deep brain stimulation and support the hypothesis that HFS exerts an inhibitory influence on STN neuronal firing.	Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, F-33076 Bordeaux, France; Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10018, Taiwan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Benazzouz, A (corresponding author), Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Abdelhamid.Benazzouz@umr5543.u-bordeaux2.fr	Bezard, Erwan/A-8173-2008; Boraud, Thomas/A-6260-2008; Benazzouz, Abdelhamid/E-5050-2016; Bezard, Erwan/ABD-5153-2021	Bezard, Erwan/0000-0002-0410-4638; Tai, Chun-Hwei/0000-0002-3493-8879				ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; Benazzouz A, 2000, NEUROREPORT, V11, P1593, DOI 10.1097/00001756-200005150-00043; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; Benazzouz A, 2000, NEUROLOGY, V55, pS13; Benazzouz A, 1996, MOVEMENT DISORD, V11, P627, DOI 10.1002/mds.870110606; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; Bevan MD, 1999, J NEUROSCI, V19, P7617, DOI 10.1523/JNEUROSCI.19-17-07617.1999; Bezard E, 1999, EUR J NEUROSCI, V11, P2167, DOI 10.1046/j.1460-9568.1999.00627.x; BEZARD E, 2001, FASEB J, V10, P1096; Boraud T, 1996, NEUROSCI LETT, V215, P17, DOI 10.1016/S0304-3940(96)12943-8; Boraud T, 1998, BRAIN RES, V787, P157, DOI 10.1016/S0006-8993(97)01563-1; BURBAUD P, 1995, EXP BRAIN RES, V105, P48; CANTERAS NS, 1990, BRAIN RES, V513, P43, DOI 10.1016/0006-8993(90)91087-W; Dostrovsky JO, 2000, J NEUROPHYSIOL, V84, P570, DOI 10.1152/jn.2000.84.1.570; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; FUJIMOTO K, 1993, BRAIN RES, V609, P185, DOI 10.1016/0006-8993(93)90872-K; Gao GM, 1997, NEUROREPORT, V8, P2601, DOI 10.1097/00001756-199707280-00036; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; HAMMOND C, 1978, BRAIN RES, V151, P235, DOI 10.1016/0006-8993(78)90881-8; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1990, BRAIN RES, V533, P203, DOI 10.1016/0006-8993(90)91341-D; Kaneoke Y, 1996, J NEUROSCI METH, V68, P211, DOI 10.1016/0165-0270(96)00081-7; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Levy R, 2001, BRAIN, V124, P2105, DOI 10.1093/brain/124.10.2105; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LIMOUSIN P, 1995, MOVEMENT DISORD, V10, P672, DOI 10.1002/mds.870100523; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MILLER WC, 1987, ADV BEHAV BIOL, V32, P415; Moro E, 2002, NEUROLOGY, V59, P706, DOI 10.1212/WNL.59.5.706; Mouroux M, 1997, NEUROSCIENCE, V81, P387, DOI 10.1016/S0306-4522(97)00110-3; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Ni ZG, 2001, SYNAPSE, V40, P145, DOI 10.1002/syn.1036.abs; Nowak LG, 1998, EXP BRAIN RES, V118, P477, DOI 10.1007/s002210050304; Nowak LG, 1998, EXP BRAIN RES, V118, P489, DOI 10.1007/s002210050305; Paxinos G., 1996, RAT BRAIN STEREOTAXI; ROBLEDO P, 1990, BRAIN RES, V518, P47, DOI 10.1016/0006-8993(90)90952-8; Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002; Tehovnik EJ, 1996, J NEUROSCI METH, V65, P1, DOI 10.1016/0165-0270(95)00131-X; Vila M, 2000, EUR J NEUROSCI, V12, P337, DOI 10.1046/j.1460-9568.2000.00901.x; Windels F, 2000, EUR J NEUROSCI, V12, P4141, DOI 10.1046/j.1460-9568.2000.00296.x; WINDELS F, 2002, SOC NEUROSCIENCE WAS	50	195	202	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1820	1830		10.1096/fj.03-0163com	http://dx.doi.org/10.1096/fj.03-0163com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519661				2022-12-25	WOS:000186343300036
J	Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C				Motiwala, T; Ghoshal, K; Das, A; Majumder, S; Weichenhan, D; Wu, YZ; Holman, K; James, SJ; Jacob, ST; Plass, C			Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas	ONCOGENE			English	Article						DNA methylation; DNA amplification; folate deficiency; hepatocellular carcinoma; PTPRO; 5-azacytidine	ACUTE MYELOID-LEUKEMIA; RNA POLYMERASE-I; RAT HEPATOMA; P53 GENE; DNA; CANCER; EXPRESSION; DEFICIENT; FOLATE; METHYLTRANSFERASE	A diet lacking folic acid and choline and low in methionine (folate/methyl deficient diet, FMD diet) fed to rats is known to produce preneoplastic nodules (PNNs) after 36 weeks and hepatocellular carcinomas (tumors) after 54 weeks. FMD diet-induced tumors exhibit global hypomethylation and regional hypermethylation. Restriction landmark genome scanning analysis with methylation-sensitive enzyme NotI (RLGS-M) of genomic DNA isolated from control livers, PNNs and tumor tissues was performed to identify the genes that are differentially methylated or amplified during multistage hepatocarcinogenesis. Out of the 1250 genes analysed, 2 to 5 genes were methylated in the PNNs, whereas 5 to 45 genes were partially or completely methylated in the tumors. This analysis also showed amplification of 3 to 12 genes in the primary tumors. As a first step towards identifying the genes methylated in the PNNs and primary hepatomas, we generated a rat NotI-EcoRV genomic library in the pBluescriptKS vector. Here, we describe identification of one methylated and downregulated gene as the rat protein tyrosine phosphatase receptor type O ( PTPRO) and one amplified gene as rat C-MYC. Methylation of PTPRO at the NotI site located immediate upstream of the trancription start site in the PNNs and tumors, and amplification of C-MYC gene in the tumors were confirmed by Southern blot analyses. Bisulfite genomic sequencing of the CpG island encompassing exon 1 of the PTPRO gene revealed dense methylation in the PNNs and tumors, whereas it was methylation free in the livers of animals on normal diet. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed significant decrease in the expression of PTPRO in the tumors and in a transplanted rat hepatoma. The expression of PTPRO mRNA in the transplanted hepatoma after demethylation with 5-azacytidine, a potent inhibitor of DNA methyltransferases, further confirmed the role of methylation in PTPRO gene expression. These results demonstrate alteration in methylation pro. le and expression of specific genes during tumor progression in the livers of rats in response to folate/methyl deficiency, and further implicate the potential role of PTPRO as a novel growth regulatory gene at least in the hepatocellular carcinomas.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Med Univ Lubeck, Inst Biol, D-23538 Lubeck, Germany; Ohio State Univ, Coll Med, Div Human Canc Genet, Columbus, OH 43210 USA; US FDA, Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA	University System of Ohio; Ohio State University; University of Lubeck; University System of Ohio; Ohio State University; US Food & Drug Administration (FDA)	Jacob, ST (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA.	jacob.42@osu.edu	Motiwala, Tasneem/AAB-9067-2021; Das, Anindita/K-8003-2013; Plass, Christoph/H-7192-2014; Jacob, Samson/H-3135-2011	Das, Anindita/0000-0003-4422-7277; 	NCI NIH HHS [CA86978, R01 CA086978-01A2, R01 CA086978] Funding Source: Medline; NIEHS NIH HHS [ES10874, R01 ES010874-01, R01 ES010874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; BUTTERWORTH C, 1991, AM J CLIN NUTR, V94, P2; Canzian F, 1996, CANCER RES, V56, P3331; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; CAVE H, 1995, BLOOD, V86, P3869, DOI 10.1182/blood.V86.10.3869.bloodjournal86103869; Chen YQ, 2002, CARCINOGENESIS, V23, P1811, DOI 10.1093/carcin/23.11.1811; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; CRAVO ML, 1992, CANCER RES, V52, P5002; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; GHOSHAL AK, 1987, CANCER LETT, V36, P289, DOI 10.1016/0304-3835(87)90022-X; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; HAYASHI K, 1984, JPN J CANCER RES, V75, P475; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HAYASHIZAKI Y, 1992, GENOMICS, V14, P733, DOI 10.1016/S0888-7543(05)80176-4; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; JAMES SJ, 1989, CARCINOGENESIS, V10, P1209, DOI 10.1093/carcin/10.7.1209; JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; LASHNER BA, 1989, GASTROENTEROLOGY, V97, P255, DOI 10.1016/0016-5085(89)90058-9; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 1999, ONCOGENE, V18, P6287, DOI 10.1038/sj.onc.1203004; Majumder S, 2002, J BIOL CHEM, V277, P16048, DOI 10.1074/jbc.M111662200; Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Melnyk S, 1999, CANCER LETT, V146, P35, DOI 10.1016/S0304-3835(99)00213-X; MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; ROGERS AE, 1993, CARCINOGENESIS, V14, P2205, DOI 10.1093/carcin/14.11.2205; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; ROSE KM, 1981, J BIOL CHEM, V256, P7468; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROSENBERG IH, 1989, GASTROENTEROLOGY, V97, P502, DOI 10.1016/0016-5085(89)90091-7; Rush LJ, 2002, BLOOD, V99, P1874, DOI 10.1182/blood.V99.5.1874; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SEIMIYA H, 1995, ONCOGENE, V10, P1731; Seimiya H, 1998, J BIOL CHEM, V273, P21187, DOI 10.1074/jbc.273.33.21187; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; SUCHY BK, 1989, CANCER RES, V49, P6781; Tagawa M, 1997, BIOCHEM J, V321, P865, DOI 10.1042/bj3210865; Takeuchi S, 1996, CANCER RES, V56, P738; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Van den Veyver IB, 2002, ANNU REV NUTR, V22, P255, DOI 10.1146/annurev.nutr.22.010402.102932; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WAINFAN E, 1992, CANCER RES, V52, pS2071; WAINFAN E, 1988, CARCINOGENESIS, V9, P861, DOI 10.1093/carcin/9.5.861; WAINFAN E, 1989, CANCER RES, V49, P4094; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wilkens L, 2000, AM J CLIN PATHOL, V114, P867, DOI 10.1309/BMTT-JBPD-D13H-1UVD; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	70	95	104	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6319	6331		10.1038/sj.onc.1206750	http://dx.doi.org/10.1038/sj.onc.1206750			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508512	Green Accepted			2022-12-25	WOS:000185535300002
J	Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ				Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ			Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain	ONCOGENE			English	Article						MEN1; menin; TAP; nonmuscle myosin; cytokinesis	ENDOCRINE NEOPLASIA TYPE-1; MOLD PHYSARUM-POLYCEPHALUM; MESSENGER-RNAS; NONHISTONE PROTEINS; NUCLEAR-ENVELOPE; GENE-PRODUCT; EXPRESSION; INTERACTS; DROSOPHILA; MORPHOGENESIS	MEN1 is a likely tumor suppressor gene that encodes a novel protein, menin. Menin is a 610 amino-acid residue protein with as yet unknown function(s). We have used tandem affinity purification and mass spectroscopy to isolate and identify proteins associating with menin from cultured HeLa cell extracts. This strategy has resulted in the isolation and identification of nonmuscle myosin type II-A heavy chain (NMHC II-A) as a menin interacting protein. This interaction was confirmed by glutathione-S-transferase pulldown assays, by coimmunoprecipitation, and by actin selection of myosin. We have further identified the amino-terminal region of menin and the head domain of NMHC II-A to be regions required for this interaction. Moreover menin was seen to colocalize with this myosin isoform in the cleavage furrow of dividing cells by indirect immunofluoresence. These data indicate that menin through binding to NMHC II-A could participate in cell division and in other processes that involve NMHC II-A.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obungu, VH (corresponding author), Eli Lilly & Co, Lilly Res Lab, Lilly Corp Ctr, DC 1505, Indianapolis, IN 46285 USA.	Obunguvi@lilly.com	Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004218, Z01HL004218] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAYR SM, 1992, SHORT PROTOCOLS MOL; Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUVAS AS, 1975, P NATL ACAD SCI USA, V72, P3902, DOI 10.1073/pnas.72.10.3902; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Huang SC, 1999, LAB INVEST, V79, P301; JOCKUSCH BM, 1971, J BACTERIOL, V108, P705, DOI 10.1128/JB.108.2.705-714.1971; JOCKUSCH BM, 1970, J BACTERIOL, V103, P356, DOI 10.1128/JB.103.2.356-363.1970; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LESTOURGEON WM, 1975, BIOCHIM BIOPHYS ACTA, V379, P529, DOI 10.1016/0005-2795(75)90160-9; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marx SJ, 2001, METABOLIC MOL BASES, P943; MAUPIN P, 1994, J CELL SCI, V107, P3077; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; OHNISHI T, 1963, J BIOCHEM, V54, P298, DOI 10.1093/oxfordjournals.jbchem.a127789; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; STRAND D, 1995, ONCOGENE, V11, P291; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; Suphapeetiporn K, 2001, AM J HUM GENET, V69, P206; Tonini R, 1999, FASEB J, V13, P1395, DOI 10.1096/fasebj.13.11.1395; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	55	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6347	6358		10.1038/sj.onc.1206658	http://dx.doi.org/10.1038/sj.onc.1206658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508515				2022-12-25	WOS:000185535300005
J	Chen, CA; Cowan, JA				Chen, CA; Cowan, JA			Characterization of the soluble domain of the ABC7 type transporter Atm1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SIDEROBLASTIC ANEMIA; ATP-BINDING SUBUNIT; SECONDARY STRUCTURE; HISTIDINE PERMEASE; SWISS-MODEL; MITOCHONDRIAL; PROTEIN; IRON; MUTATION; ATAXIA	Atm1 is an ABC transporter that is located in yeast mitochondria and has previously been implicated in the maturation of cytosolic iron-sulfur cluster proteins. The soluble nucleotide binding domain of Atm1 (Atm1-C) has been overexpressed in Escherichia coli, purified, and characterized. Dissociation constants (K-D) for Atm1-C binding of ATP (K-D similar to97 muM, pH 7.3, and similar to102 muM, pH 10.0) and ADP (K-D similar to43 muM, pH 7.3, and 92 muM, pH 10.0) were measured by fluorimetry. The higher binding affinity for ADP suggests that the transmembrane-spanning domain may be required to promote a structural change in the nucleotide binding domain to facilitate substrate export and ADP release. ADP also had an inhibitory effect on Atm1-C with an IC50 of 10 mM. The Michaelis-Menten constants V-max, K-M, and k(cat) of Atm1-C were measured as 1.822 muM min(-1), 513 muM, and 0.055 min(-1), respectively. The metal dependence of Atm1-C ATPase demonstrated a reactivity order of Mn2+ > Mg2+ > Co2+, while Mg2+ and Co2+ were both found to be inhibitory at higher concentrations. The pH profile and structural comparison with HisP are consistent with a role for His and Lys in promoting the ATPase activity. Structural analysis of Atm1-C by CD spectroscopy suggested a similarity of secondary structure to that found for a prokaryotic homologue (HisP), whereas modeling of the Atm1-C tertiary structure using HisP as a template is also consistent with a similarity in tertiary structure. Atm1-C tends to form a dimer or higher aggregation state at higher concentration; however, the concentration dependence of Atm1-C on ATPase activity and the results of a Hill analysis (n(app) = 1.1) demonstrated that there was essentially no cooperativity in ATP hydrolysis, in contrast to observations for the prokaryotic HisP transporter, which demonstrated full cooperativity for both full-length and the soluble domains. Accordingly, any cooperative response must be mediated through the transmembrane domain in the case of the eukaryotic Atm1 transporter.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.	cowan@chemistry.ohio-state.edu						Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Bekri S, 2000, BLOOD, V96, P3256; BLACK CB, 1994, INORG CHEM, V33, P5805, DOI 10.1021/ic00103a030; Braibant M, 2000, FEMS MICROBIOL REV, V24, P449, DOI 10.1111/j.1574-6976.2000.tb00550.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; ENCINAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1162, P195, DOI 10.1016/0167-4838(93)90147-J; FRESHT A, 1997, ENZYME KINETICS, P107; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lange H, 2001, EMBO REP, V2, P715, DOI 10.1093/embo-reports/kve161; LEHRER SS, 1978, METHOD ENZYMOL, V49, P4406; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2001, RES MICROBIOL, V152, P331, DOI 10.1016/S0923-2508(01)01204-9; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Maguire A, 2001, BRIT J HAEMATOL, V115, P910, DOI 10.1046/j.1365-2141.2001.03015.x; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Schueck ND, 2001, MITOCHONDRION, V1, P51, DOI 10.1016/S1567-7249(01)00004-6; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597	40	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52681	52688		10.1074/jbc.M306472200	http://dx.doi.org/10.1074/jbc.M306472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14514697	hybrid			2022-12-25	WOS:000187480700086
J	Chavan, M; Rekowicz, M; Lennarz, W				Chavan, M; Rekowicz, M; Lennarz, W			Insight into functional aspects of Stt3p, a subunit of the oligosaccharyl transferase - Evidence for interaction of the N-terminal domain of Stt3p with the protein kinase C cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY IN-VIVO; SACCHAROMYCES-CEREVISIAE; YEAST OLIGOSACCHARYLTRANSFERASE; GENE ENCODES; ENDOPLASMIC-RETICULUM; KILLER TOXIN; GLYCOSYLATION; COMPLEX; STAUROSPORINE; MUTANTS	Over a decade ago, the gene STT3 was identified in a staurosporine and temperature sensitivity screen of yeast. Subsequently the product of this gene was shown to be a subunit of the endoplasmic reticulum-localized oligosaccharyl transferase (OT) complex. Although stt3 mutants are known to be staurosporine-sensitive, we found that mutants of other OT subunits (except ost4Delta) are staurosporine-resistant, which indicates that this phenotype of stt3 mutants is not simply a consequence of their defect in glycosylation, as previously speculated. Staurosporine sensitivity was found to be an allele-specific phenotype restricted to cells harboring mutations in highly conserved residues in the N-terminal domain of the STT3 protein. Cells bearing mutations in one of the cytosolic-oriented loops (amino acids 158 168) in the N terminus of Stt3p were found to be specifically susceptible to staurosporine. Staurosporine is a specific inhibitor of Pkc1p, and a genetic link had previously been suggested between PKC1 and STT3. It is known that overexpression of PKC1 suppresses the staurosporine sensitivity of the stt3 mutants in an allele-specific manner, which is typical of mutants of Pkc1p cascade. It has been shown that the pkc1 null mutant exhibits lowered OT activity. Our results combined with these previous observations indicate that the N-terminal domain of Stt3p may interact with members of the Pkc1p cascade and consequently mutations in this domain result in staurosporine sensitivity. We further speculate that the Pkc1p regulates OT activity through the N-terminal domain of Stt3p, the C-terminal domain of which possesses the recognition and/or catalytic site of the OT complex.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, W (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, 450A,Life Sci Bldg, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033185, R01GM033185] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33185] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BROWN JL, 1993, MOL CELL BIOL, V13, P6346, DOI 10.1128/MCB.13.10.6346; CHAVAN M, 2003, IN PRESS P NATL ACAD; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; Dempski RE, 2002, CURR OPIN CHEM BIOL, V6, P844, DOI 10.1016/S1367-5931(02)00390-3; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; HASILIK A, 1978, EUR J BIOCHEM, V91, P567, DOI 10.1111/j.1432-1033.1978.tb12710.x; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; Kim H, 2003, P NATL ACAD SCI USA, V100, P7460, DOI 10.1073/pnas.1332735100; Kimura T, 1999, APPL MICROBIOL BIOT, V51, P176, DOI 10.1007/s002530051379; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Kukuruzinska MA, 1999, BBA-GEN SUBJECTS, V1426, P359, DOI 10.1016/S0304-4165(98)00136-6; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; Nilsson I, 2003, J CELL BIOL, V161, P715, DOI 10.1083/jcb.200301043; Page N, 2003, GENETICS, V163, P875; Park H, 2000, GLYCOBIOLOGY, V10, P737, DOI 10.1093/glycob/10.7.737; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Spirig U, 1997, MOL GEN GENET, V256, P628, DOI 10.1007/s004380050611; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Wacker M, 2002, SCIENCE, V298, P1790, DOI 10.1126/science.298.5599.1790; WATANABE M, 1994, J BIOL CHEM, V269, P16829; Yan G, 2002, J BIOL CHEM, V277, P47692, DOI 10.1074/jbc.M208136200; Yan Q, 2002, P NATL ACAD SCI USA, V99, P15994, DOI 10.1073/pnas.212637999; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1995, GENE, V164, P167, DOI 10.1016/0378-1119(95)00431-5; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	42	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51441	51447		10.1074/jbc.M310456200	http://dx.doi.org/10.1074/jbc.M310456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530272	hybrid			2022-12-25	WOS:000187206300073
J	Ikonomov, OC; Sbrissa, D; Mlak, K; Deeb, R; Fligger, J; Soans, A; Finley, RL; Shisheva, A				Ikonomov, OC; Sbrissa, D; Mlak, K; Deeb, R; Fligger, J; Soans, A; Finley, RL; Shisheva, A			Active PIKfyve associates with and promotes the membrane attachment of the late endosome-to-trans-Golgi network transport factor Rab9 effector p40	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; PROTEIN-KINASE; LIPID KINASE; DOMAINS; FAB1P; ORGANIZATION; RECEPTORS; ROAD	PIKfyve, a kinase that displays specificity for phosphatidylinositol ( PtdIns), PtdIns 3- phosphate ( 3- P), and proteins, is important in multivesicular body/ late endocytic function. Enzymatically inactive PIKfyve mutants elicit enormous dilation of late endocytic structures, suggesting a role for PIKfyve in endosome- to- trans- Golgi network ( TGN) membrane retrieval. Here we report that p40, a Rab9 effector reported previously to bind Rab9- GTP and stimulate endosome- to- TGN transport, interacts with PIKfyve as determined by yeast two- hybrid assays, glutathione S- transferase ( GST) pull- down assays, and co- immunoprecipitation in doubly transfected HEK293 cells. The interaction engages the PIKfyve chaperonin domain and four out of the six C- terminally positioned kelch repeats in p40. Differential centrifugation in a HEK293 cell line, stably expressing PIKfyve(WT), showed the membrane-associated immunoreactive p40 co- sedimenting with PIKfyve in the high speed pellet ( HSP) fraction. Remarkably, similar analysis in a HEK293 cell line stably expressing dominant- negative kinase- deficient PIKfyve(K1831E) demonstrated a marked depletion of p40 from the HSP fraction. GST- p40 failed to specifically associate with the PIKfyve lipid products PtdIns 5- P and PtdIns 3,5- P-2 in a liposome binding assay but was found to be an in vitro substrate of the PIKfyve serine kinase activity. A band with the p40 electrophoretic mobility was found to react with a phosphoserine- specific antibody mainly in the PIKfyve(WT)- containing fractions obtained by density gradient sedimentation of total membranes from PIKfyve(WT) -expressing HEK293 cells. Together these results identify the Rab9 effector p40 as a PIKfyve partner and suggest that p40- PIKfyve interaction and the subsequent PIKfyve-catalyzed p40 phosphorylation anchor p40 to discrete membranes facilitating late endosome- to- TGN transport.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@med.wayne.edu		Finley, Russ/0000-0003-1144-6887	NIDDK NIH HHS [DK58058] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Ikonomov OC, 2003, MOL BIOL CELL, V14, P4581, DOI 10.1091/mbc.E03-04-0222; Ikonomov OC, 2002, ENDOCRINOLOGY, V143, P4742, DOI 10.1210/en.2002-220615; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Itin C, 1999, MOL BIOL CELL, V10, P2191, DOI 10.1091/mbc.10.7.2191; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kolonin MG, 2000, METHOD ENZYMOL, V328, P26, DOI 10.1016/S0076-6879(00)28388-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Sbrissa D, 2002, J BIOL CHEM, V277, P6073, DOI 10.1074/jbc.M110194200; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623	31	52	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					50863	50871		10.1074/jbc.M307260200	http://dx.doi.org/10.1074/jbc.M307260200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530284	hybrid			2022-12-25	WOS:000187206300005
J	Pratt, PF; Bokemeyer, D; Foschi, M; Sorokin, A; Dunn, MJ				Pratt, PF; Bokemeyer, D; Foschi, M; Sorokin, A; Dunn, MJ			Alterations in subcellular localization of p38 MAPK potentiates endothelin-stimulated COX-2 expression in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; DUAL-SPECIFICITY PHOSPHATASES; MESSENGER-RNA STABILITY; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHATASES; IN-VIVO; CYCLOOXYGENASE-2 EXPRESSION; DIFFERENTIAL REGULATION; CATALYTIC ACTIVATION	Endothelin-1 (ET-1) is a potent vasoconstrictor peptide with mitogenic actions linked to activation of tyrosine kinase signaling pathways. ET-1 induces cyclooxygenase-2 (COX-2), an enzyme that converts arachidonic acid to pro-inflammatory eicosanoids. Activation of each of the three major mitogen-activated protein kinase ( MAPK) pathways, ERK1/2, JNK/SAPK, and p38 MAPK ( p38), have been shown to enhance the expression of COX-2. Negative regulation of MAPK may occur via a family of dual specificity phosphatases referred to as mitogen-activated protein kinase phosphatases (MKP). The goal of this work was to test the hypothesis that wild type MKP-1 regulates the expression of ET-1-induced COX-2 expression by inhibiting the activation of p38 in cultured glomerular mesangial cells (GMC). An adenovirus expressing both wild type and a catalytically inactive mutant of MKP-1 (MKP-1/CS) were constructed to study ET-1-regulated MAPK signaling and COX-2 expression in cultured GMC. ET-1 stimulated the phosphorylation of ERK and p38alpha MAPK and induced the expression of COX-2. Expression of COX-2 was partially blocked by U0126, a MEK inhibitor, and SB 203580, a p38 MAPK inhibitor. Adenoviral expression of MKP-1/CS augmented basal and ET-1-induced phosphorylation of p38alpha MAPK with less pronounced effects on ERK1/2 phosphorylation. Ectopic expression of wild type MKP- 1 blocked the phosphorylation of p38alpha MAPK by ET-1 but increased the phosphorylation of p38gamma MAPK. Co-precipitation studies demonstrated association of MKP- 1 with p38alpha MAPK and ERK1/2. Immunofluorescent image analysis demonstrated trapping of phospho-p38 MAPK in the cytoplasm by MKP-1/CS/green fluorescent protein. ET-1-stimulated expression of COX-2 was increased in MKP-1/CS versus LacZ or green fluorescent protein-infected control cells. These results indicate that MKP- 1 demonstrates a relative selectivity for p38alpha MAPK versus p38gamma MAPK in GMC and is likely to indirectly regulate the expression of COX-2.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Dunn, MJ (corresponding author), Med Coll Wisconsin, Dept Med, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdunn@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL 22563, HL 10165] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010165, R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bokemeyer D, 1997, J AM SOC NEPHROL, V8, P40; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cheng HF, 2002, J BIOL CHEM, V277, P45638, DOI 10.1074/JBC.m206040200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guan ZH, 1999, J BIOL CHEM, V274, P36200, DOI 10.1074/jbc.274.51.36200; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; KESTER M, 1994, J BIOL CHEM, V269, P22574; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSEN TA, 1994, KIDNEY INT, V45, P336, DOI 10.1038/ki.1994.43; McGinty A, 2000, BIOCHEM J, V352, P419, DOI 10.1042/0264-6021:3520419; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Noble SL, 2000, AM FAM PHYSICIAN, V61, P3669; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1991, LAB INVEST, V64, P1; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sohaskey ML, 2002, MOL BIOL CELL, V13, P454, DOI 10.1091/mbc.01-11-0553; Sugimoto T, 2001, J AM SOC NEPHROL, V12, P1359, DOI 10.1681/ASN.V1271359; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Volmat V, 2001, J CELL SCI, V114, P3433; WANG YZ, 1993, J CARDIOVASC PHARM, V22, pS164, DOI 10.1097/00005344-199322008-00044; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/s0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8]; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9	51	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51928	51936		10.1074/jbc.M309256200	http://dx.doi.org/10.1074/jbc.M309256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530261	hybrid			2022-12-25	WOS:000187206300129
J	Sulistijo, ES; Jaszewski, TM; MacKenzie, KR				Sulistijo, ES; Jaszewski, TM; MacKenzie, KR			Sequence-specific dimerization of the transmembrane domain of the "BH3-only" protein BNIP3 in membranes and detergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; PROGRAMMED CELL-DEATH; TERMINAL HYDROPHOBIC REGION; GLYCOPHORIN-A DIMERIZATION; PRO-APOPTOTIC ACTIVITY; HUMAN INSULIN-RECEPTOR; BH3 DOMAIN; ALPHA-HELICES; GXXXG MOTIF; MITOCHONDRIAL-MEMBRANE	Mitochondria-mediated apoptosis is regulated by proteins of the Bcl-2 superfamily, most of which contain a C-terminal hydrophobic domain that plays a role in membrane targeting. Experiments with BNIP3 have implicated the transmembrane (TM) domain in its proapoptotic function, homodimerization, and interactions with Bcl-2 and Bcl-x(L). We show that the BNIP3 TM domain self-associates strongly in Escherichia coli cell membranes and causes reversible dimerization of a soluble protein in the detergent SDS when expressed as an in-frame fusion. Limited mutational analysis identifies specific residues that are critical for BNIP3 TM self-association in membranes, and these residues are also important for dimerization in SDS micelles, suggesting that the self-association observed in membranes is preserved in detergent. The effects of sequence changes at positions Ala(176) and Gly(180) suggest that the BNIP3 TM domain associates using a variant of the GXXXG motif previously shown to be important in the dimerization of glycophorin A. The importance of residue His(173) in BNIP3 TM domain dimerization indicates that polar residues, which have been implicated in self-association of model TM peptides, can act in concert with the AXXXG motif to stabilize TM domain interactions. Our results demonstrate that the hydrophobic C-terminal TM domain of the pro-apoptotic BNIP3 protein dimerizes tightly in lipidic environments, and that this association has a strong sequence dependence but is independent of the identity of flanking regions. Thus, the transmembrane domain represents another region of the Bcl-2 superfamily of proteins that is capable of mediating strong and specific protein-protein interactions.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Rice University	MacKenzie, KR (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 Main St, Houston, TX 77005 USA.				NIGMS NIH HHS [R01 GM067850] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Bouillet P, 2002, J CELL SCI, V115, P1567; Bowen ME, 2002, BIOCHEMISTRY-US, V41, P15861, DOI 10.1021/bi0269411; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brosig B, 1998, PROTEIN SCI, V7, P1052; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fisher LE, 1999, J MOL BIOL, V293, P639, DOI 10.1006/jmbi.1999.3126; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FUJII J, 1989, J BIOL CHEM, V264, P12950; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; IMAGAWA T, 1986, J BIOCHEM-TOKYO, V99, P41, DOI 10.1093/oxfordjournals.jbchem.a135478; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; MacKenzie KR, 1998, P NATL ACAD SCI USA, V95, P3583, DOI 10.1073/pnas.95.7.3583; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; McClain MS, 2001, INFECT IMMUN, V69, P1181, DOI 10.1128/IAI.69.2.1181-1184.2001; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Shaw W V, 1975, Methods Enzymol, V43, P737; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Watanabe Y, 2002, J PROTEIN CHEM, V21, P169, DOI 10.1023/A:1015372600277; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	71	86	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51950	51956		10.1074/jbc.M308429200	http://dx.doi.org/10.1074/jbc.M308429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532263	hybrid			2022-12-25	WOS:000187206300131
J	Thouzeau, C; Le Maho, Y; Froget, G; Sabatier, L; Le Bohec, C; Hoffmann, JA; Bulet, P				Thouzeau, C; Le Maho, Y; Froget, G; Sabatier, L; Le Bohec, C; Hoffmann, JA; Bulet, P			Spheniscins, avian beta-defensins in preserved stomach contents of the king penguin, Aptenodytes patagonicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; GASTROINTESTINAL-TRACT; HOST-DEFENSE; ANTIBACTERIAL PEPTIDE; INNATE IMMUNITY; INSECT DEFENSIN; AEDES-AEGYPTI; FOOD; ECOPHYSIOLOGY; EXPRESSION	During the last part of egg incubation in king penguins, the male can preserve undigested food in the stomach for several weeks. This ensures survival of the newly hatched chick, in cases where the return of the foraging female from the sea is delayed. In accordance with the characterization of stress-induced bacteria, we demonstrate the occurrence of strong antimicrobial activities in preserved stomach contents. We isolated and fully characterized two isoforms of a novel 38-residue antimicrobial peptide (AMP), spheniscin, belonging to the beta-defensin subfamily. Spheniscin concentration was found to strongly increase during the period of food storage. Using a synthetic version of one of two spheniscin isoforms, we established that this peptide has a broad activity spectrum, affecting the growth of both pathogenic bacteria and fungi. Altogether, our data suggest that spheniscins and other, not yet identified, antimicrobial substances may play a role in the long term preservation of stored food in the stomach of king penguins.	CNRS, Ctr Ecol & Physiol Energet, F-67087 Strasbourg 2, France; CNRS, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Thouzeau, C (corresponding author), CNRS, Ctr Ecol & Physiol Energet, 23 Rue Becquerel, F-67087 Strasbourg 2, France.	cecile.thouzeau@c-strasbourg.fr	LE BOHEC, CELINE/AAD-3589-2022; BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bals R, 2000, Respir Res, V1, P141, DOI 10.1186/rr25; Bevins C L, 2003, Contrib Microbiol, V10, P106; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; Boulanger N, 2002, J BIOL CHEM, V277, P49921, DOI 10.1074/jbc.M206296200; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; Duke G.E., 1986, P289; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; Gauthier-Clerc M, 2000, NATURE, V408, P928, DOI 10.1038/35050163; Gauthier-Clerc M, 2002, MAR ECOL PROG SER, V237, P291, DOI 10.3354/meps237291; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; Hetru C, 1997, Methods Mol Biol, V78, P35; Hwang PM, 1998, BIOCHEM CELL BIOL, V76, P235, DOI 10.1139/bcb-76-2-3-235; Lamberty M, 1999, J BIOL CHEM, V274, P9320, DOI 10.1074/jbc.274.14.9320; Lamberty M, 2001, J BIOL CHEM, V276, P4085, DOI 10.1074/jbc.M002998200; Le Maho Y, 2002, NATURE, V416, P21, DOI 10.1038/416021a; Lencer WI, 1997, P NATL ACAD SCI USA, V94, P8585, DOI 10.1073/pnas.94.16.8585; Lowenberger C, 1999, J BIOL CHEM, V274, P20092, DOI 10.1074/jbc.274.29.20092; LOWENBERGER C, 1995, INSECT BIOCHEM MOLEC, V25, P867, DOI 10.1016/0965-1748(95)00043-U; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Munks RJL, 2001, INSECT MOL BIOL, V10, P561, DOI 10.1046/j.0962-1075.2001.00296.x; Ouellette AJ, 2001, INFLAMM BOWEL DIS, V7, P43, DOI 10.1097/00054725-200102000-00007; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799; Stevens CE, 1998, PHYSIOL REV, V78, P393, DOI 10.1152/physrev.1998.78.2.393; Thouzeau C, 2003, POLAR BIOL, V26, P115, DOI 10.1007/s00300-002-0451-2; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083; White WB, 1996, NATURE, V380, P699, DOI 10.1038/380699a0; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zhao CQ, 2001, INFECT IMMUN, V69, P2684, DOI 10.1128/IAI.69.4.2684-2691.2001	31	65	99	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51053	51058		10.1074/jbc.M306839200	http://dx.doi.org/10.1074/jbc.M306839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525994	hybrid			2022-12-25	WOS:000187206300028
J	Yeh, BI; Sun, TJ; Lee, JZ; Chen, HH; Huang, CL				Yeh, BI; Sun, TJ; Lee, JZ; Chen, HH; Huang, CL			Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CA2+ CHANNEL; CELLULAR CALCIUM-TRANSPORT; POTASSIUM CHANNEL; INWARD RECTIFICATION; CAPSAICIN RECEPTOR; STONE-FORMATION; DISTAL NEPHRON; PORE; KIDNEY; SODIUM	The transient receptor potential type 5 ( TRPV5) channel is present in kidney and intestine and important for transepithelial ( re) absorption of calcium in these tissues. We report that in whole- cell patch clamp recording extracellular acidification inhibited rabbit TRPV5 with apparent pKa similar to 6.55. The two extracellular loops between the fifth and sixth transmembrane segments of TRPV5 presumably form part of the outer opening of the pore and likely are important in binding and regulation by external protons. We found that mutation of glutamate 522 to glutamine ( E522Q) decreased the sensitivity of the channel to extracellular acidification. Mutations of other titratable amino acids within the two extracellular loops to non- titratable amino acids had no effect on pH sensitivity. Substitutions of aspartate or other titratable amino acids for glutamate 522 conferred an increase in pH sensitivity. The pH sensitivity mediated by glutamate 522 was independent of extracellular or intracellular Mg2+. Single channel analysis revealed that extracellular acidification reduced single channel conductance as well as open probability of the wild type channel. In contrast to wild type channel, extracellular acidification did not reduce open probability for E522Q mutant. Methanethiosulfonate reagents inhibited the activity of glutamine 522 to cysteine mutant channel with a reaction rate constant approaching that with free thiols in solution, suggesting that glutamate 522 is located on the surface of the channel. These data suggest that glutamate 522 of the rabbit TRPV5 is a " pH sensor," and extracellular protons inhibit TRPV5 likely by altering conformation of the channel protein.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Mineral Metab & Clin Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NIDDK NIH HHS [DK-20543, DK-59530, DK-54368] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK020543, R01DK059530, R01DK054368] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cui YJ, 2002, J BIOL CHEM, V277, P10523, DOI 10.1074/jbc.M109118200; DUBOSE TD, 1978, J CLIN INVEST, V62, P338, DOI 10.1172/JCI109134; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; HOENDEROP JG, 2003, EMBO J, V22, P1; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Khan A, 2002, J PHYSIOL-LONDON, V543, P71, DOI 10.1113/jphysiol.2002.021014; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; Lu T, 1999, P NATL ACAD SCI USA, V96, P9926, DOI 10.1073/pnas.96.17.9926; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; Peng JB, 2000, J BIOL CHEM, V275, P28186; Peng JB, 2002, CURR OPIN NEPHROL HY, V11, P555, DOI 10.1097/00041552-200209000-00012; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Phillips LR, 2003, NEURON, V37, P953, DOI 10.1016/S0896-6273(03)00155-7; Reddy ST, 2002, AM J KIDNEY DIS, V40, P265, DOI 10.1053/ajkd.2002.34504; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; ROBERTSON WG, 1979, CLIN SCI, V57, P285, DOI 10.1042/cs0570285; SAKHAEE K, 1983, KIDNEY INT, V24, P348, DOI 10.1038/ki.1983.165; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P19; VANOS CH, 1987, BIOCHIM BIOPHYS ACTA, V906, P195, DOI 10.1016/0304-4157(87)90012-8; Vennekens R, 2001, PFLUG ARCH EUR J PHY, V442, P237, DOI 10.1007/s004240100517; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V283, pF630, DOI 10.1152/ajprenal.00378.2001	41	89	93	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51044	51052		10.1074/jbc.M306326200	http://dx.doi.org/10.1074/jbc.M306326200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525991	hybrid			2022-12-25	WOS:000187206300027
J	Gines, S; Ivanova, E; Seong, IS; Saura, CA; MacDonald, ME				Gines, S; Ivanova, E; Seong, IS; Saura, CA; MacDonald, ME			Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MODELS; BETA-CATENIN; MICE; TRANSCRIPTION; DYSFUNCTION; PHENOTYPES; PATHWAY; REPEAT; TRACTS; GENE	Huntington's disease features the loss of striatal neurons that stems from a disease process that is initiated by mutant huntingtin. Early events in the disease cascade, which predate overt pathology in Hdh CAG knock-in mouse striatum, implicate enhanced N-methyl-D-aspartate ( NMDA) receptor activation, with excitotoxity caused by aberrant Ca2+ influx. Here we demonstrate in precise genetic Huntington's disease mouse and striatal cell models that these early phenotypes are associated with activation of the Akt pro-survival signaling pathway. Elevated levels of activated Ser(P)(473)-Akt are detected in extracts of Hdh(Q111/Q111) striatum and cultured mutant STHdh(Q111/Q111) striatal cells, compared with their wild type counterparts. Akt activation in mutant striatal cells is associated with increased Akt signaling via phosphorylation of GSK3beta at Ser(9). Consequent decreased turnover of transcription co-factor beta-catenin leads to increased levels of beta-catenin target gene cyclin D1. Akt activation is phosphatidylinositol 3-kinase dependent, as demonstrated by increased levels of Ser(P)(241)-PDK1 kinase and decreased Ser(P)(380)-PTEN phosphatase. Moreover, Akt activation can be normally stimulated by treatment with insulin growth factor-1 and blocked by treatment with the phosphatidylinositol 3-kinase inhibitor LY294002. However, in contrast to wild type cells, Akt activation in mutant striatal cells can be blocked by the addition of the NMDA receptor antagonist MK-801. Akt activation in mutant striatal cells is Ca2+-dependent, because treatment with EGTA reduces levels of Ser(P)(473)Akt. Thus, consistent with excitotoxicity early in the disease process, activation of the Akt pro-survival pathway in mutant knock-in striatal cells predates overt pathology and reflects mitochondrial dysfunction and enhanced NMDA receptor signaling.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Gines, S (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.		Saura, Carlos A/D-2727-2011; Saura, Carlos A/AFM-9239-2022; Gines, Silvia/L-1943-2015	Saura, Carlos A/0000-0003-3692-5657; Gines, Silvia/0000-0002-9479-8185; Ivanova, Elena/0000-0002-5069-4974	NINDS NIH HHS [NS16367, NS32765] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032765, P50NS016367, P01NS016367] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cepeda C, 2001, J NEUROSCI RES, V66, P525, DOI 10.1002/jnr.1244; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fossale E, 2002, HUM MOL GENET, V11, P2233, DOI 10.1093/hmg/11.19.2233; Gines S, 2003, HUM MOL GENET, V12, P497, DOI 10.1093/hmg/ddg046; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Menalled L, 2000, EXP NEUROL, V162, P328, DOI 10.1006/exnr.1999.7327; Menalled LB, 2002, J NEUROSCI, V22, P8266; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Panov AV, 2003, ARCH BIOCHEM BIOPHYS, V410, P1, DOI 10.1016/S0003-9861(02)00585-4; Penney JB, 1997, ANN NEUROL, V41, P689, DOI 10.1002/ana.410410521; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sun Y, 2001, J BIOL CHEM, V276, P24713, DOI 10.1074/jbc.M103501200; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369; Wheeler VC, 2000, HUM MOL GENET, V9, P503, DOI 10.1093/hmg/9.4.503; Wheeler VC, 2002, HUM MOL GENET, V11, P633, DOI 10.1093/hmg/11.6.633; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	27	117	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50514	50522		10.1074/jbc.M309348200	http://dx.doi.org/10.1074/jbc.M309348200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522959	hybrid			2022-12-25	WOS:000187068200104
J	Liu, CL; Chen, JC; Sutton, S; Roland, B; Kuei, C; Farmer, N; Sillard, R; Lovenberg, TW				Liu, CL; Chen, JC; Sutton, S; Roland, B; Kuei, C; Farmer, N; Sillard, R; Lovenberg, TW			Identification of relaxin-3/INSL7 as a ligand for GPCR142	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTORS GPR7; INSULIN-LIKE PEPTIDE; PHARMACOLOGICAL CHARACTERIZATION; HUMAN RELAXIN; FAMILY; MOUSE; GENE; CLONING; TESTIS; MEMBER	We have recently identified the insulin-like peptide relaxin-3 (aka INSL7) as the endogenous ligand for an orphan G-protein-coupled receptor, GPCR135 (aka somatostatin- and angiotensin-like peptide receptor). Analysis of possible receptors related to GPCR135 revealed a single orphan receptor, GPCR142. Thus, we tested whether GPCR142 could also respond to relaxin-3 or related insulin-like molecules. Surprisingly, GPCR142 was activated by nanomolar concentrations of relaxin-3 but was completely unresponsive to all other known insulin-like peptides. We evaluated by reverse transcriptase-PCR the expression of GPCR142 mRNA in a variety of human tissues and found expression in brain, kidney, testis, thymus, placenta, prostate, salivary gland, thyroid, and colon. In an analysis of other species, we were able to find a full-length mouse homolog of GPCR142, but were unable to detect any complete GPCR142 transcripts in rat. With respect to intracellular signaling, GPCR142 is similar to GPCR135 in that it potently inhibits adenylate cyclase and stimulates S-35-GTPgammaS incorporation in response to relaxin-3. However, whereas GPCR135 signaling could be converted to calcium mobilization using a G(qi5) or Galpha(16) G-proteins, GPCR142 was only capable of functioning in the presence of Galpha(16). In the accompanying article (Liu, C., Eriste, E., Sutton, S., Chen, J., Roland, B., Kuei, C., Farmer, N., Jornvall, H., Sillard, R., and Lovenberg, T. W. (2003) J. Biol. Chem. 278, 50754-50764), we present the case that relaxin-3, which has previously been shown to bind to the relaxin receptor LGR7, is most likely the endogenous ligand for GPCR135. In this report, we show an additional receptor, GPCR142, which is also selectively activated by relaxin-3. However, the anatomical localization of GPCR142 suggests that GPCR142 may have different physiological functions.	Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Johnson & Johnson; Johnson & Johnson USA; Karolinska Institutet	Liu, CL (corresponding author), Johnson & Johnson Pharmaceut Res & Dev LLC, San Diego, CA 92121 USA.							ADHAM IM, 1993, J BIOL CHEM, V268, P26668; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; Brezillon S, 2003, J BIOL CHEM, V278, P776, DOI 10.1074/jbc.M206396200; Chen JC, 2003, EUR J PHARMACOL, V467, P57, DOI 10.1016/S0014-2999(03)01635-2; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Goto M, 2001, J COMP NEUROL, V438, P86, DOI 10.1002/cne.1303; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; Koman A, 1996, J BIOL CHEM, V271, P20238, DOI 10.1074/jbc.271.34.20238; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; Liu CL, 2001, MOL PHARMACOL, V59, P420, DOI 10.1124/mol.59.3.420; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; Lok S, 2000, BIOL REPROD, V62, P1593, DOI 10.1095/biolreprod62.6.1593; Matsumoto M, 2000, GENE, V248, P183, DOI 10.1016/S0378-1119(00)00123-2; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Shimomura Y, 2002, J BIOL CHEM, V277, P35826, DOI 10.1074/jbc.M205337200; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200	23	180	198	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50765	50770		10.1074/jbc.M308996200	http://dx.doi.org/10.1074/jbc.M308996200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522967	hybrid			2022-12-25	WOS:000187068200132
J	Trakselis, MA; Roccasecca, RM; Yang, JS; Valentine, AM; Benkovic, SJ				Trakselis, MA; Roccasecca, RM; Yang, JS; Valentine, AM; Benkovic, SJ			Dissociative properties of the proteins within the bacteriophage T4 replisome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; DNA-REPLICATION FORK; COORDINATED LEADING-STRAND; POLYMERASE-III HOLOENZYME; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; SLIDING CLAMP; PRIMER SYNTHESIS; PRIMASE DOMAINS; ATP HYDROLYSIS	DNA replication is a highly processive and efficient process that involves the coordination of at least eight proteins to form the replisome in bacteriophage T4. Replication of DNA occurs in the 5' to 3' direction resulting in continuous replication on the leading strand and discontinuous replication on the lagging strand. A key question is how a continuous and discontinuous replication process is coordinated. One solution is to avoid having the completion of one Okazaki fragment to signal the start of the next but instead to have a key step such as priming proceed in parallel to lagging strand replication. Such a mechanism requires protein elements of the replisome to readily dissociate during the replication process. Protein trapping experiments were performed to test for dissociation of the clamp loader and primase from an active replisome in vitro whose template was both a small synthetic DNA minicircle and a larger DNA substrate. The primase, clamp, and clamp loader are found to dissociate from the replisome and are continuously recruited from solution. The effect of varying protein concentrations ( dilution) on the size of Okazaki fragments supported the protein trapping results. These findings are in accord with previous results for the accessory proteins but, importantly now, identify the primase as dissociating from an active replisome. The recruitment of the primase from solution during DNA synthesis has also been found for Escherichia coli but not bacteriophage T7. The implications of these results for RNA priming and extension during the repetitive synthesis of Okazaki fragments are discussed.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 414 Wartik Lab, University Pk, PA 16802 USA.		Trakselis, Michael/V-3806-2019	Trakselis, Michael/0000-0001-7054-8475	NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; Alley SC, 1999, J BIOL CHEM, V274, P24485, DOI 10.1074/jbc.274.35.24485; Alley SC, 2000, BIOCHEMISTRY-US, V39, P3076, DOI 10.1021/bi992377r; Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Kato M, 2003, MOL CELL, V11, P1349, DOI 10.1016/S1097-2765(03)00195-3; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kusakabe T, 1998, EMBO J, V17, P1542, DOI 10.1093/emboj/17.5.1542; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MOK M, 1987, J BIOL CHEM, V262, P2304; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; RUSH J, 1989, J BIOL CHEM, V264, P10943; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; STRACK B, 1992, J BIOL CHEM, V267, P13062; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; Trakselis MA, 2003, J MOL BIOL, V326, P435, DOI 10.1016/S0022-2836(02)01330-X; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yang JS, 2003, J BIOL CHEM, V278, P49828, DOI 10.1074/jbc.M307406200; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49839	49849		10.1074/jbc.M307405200	http://dx.doi.org/10.1074/jbc.M307405200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14500719	hybrid			2022-12-25	WOS:000187068200025
J	Villemaire, J; Dion, I; Abou Elela, S; Chabot, B				Villemaire, J; Dion, I; Abou Elela, S; Chabot, B			Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEINS; HNRNP A/B PROTEINS; SR PROTEINS; IN-VIVO; TELOMERIC REPEATS; SILENCER ELEMENT/; GENE-EXPRESSION; A1; EXON	Alternative pre-messenger RNA splicing is a major contributor to proteomic diversity in higher eukaryotes and represents a key step in the control of protein function in a large variety of biological systems. As a means of artificially altering splice site choice, we have investigated the impact of positioning proteins in the vicinity of 5' splice sites. We find that a recombinant GST-MS2 protein interferes with 5' splice site use, most efficiently when it binds upstream of that site. To broaden the use of proteins as steric inhibitors of splicing, we have tested the activity of antisense oligonucleotides carrying binding sites for the heterogeneous nuclear ribonucleoprotein A1/A2 proteins. In a HeLa cell extract, tailed oligonucleotides complementary to exonic sequences elicit strong shifts in 5' splice site selection. In four different human cell lines, an interfering oligonucleotide carrying A1/A2 binding sites also shifted the alternative splicing of the Bcl-x pre-mRNA more efficiently than oligonucleotides acting through duplex formation only. The use of protein-binding oligonucleotides that interfere with U1 small nuclear ribonucleoprotein binding therefore represents a novel and powerful approach to control splice site selection in cells.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, RNA RNP Grp, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Chabot, B (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, RNA RNP Grp, 3001,12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.		Chabot, Benoit/A-8943-2008	Chabot, Benoit/0000-0003-0994-0042				Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Blanchette M, 1997, RNA, V3, P405; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; Chabot B., 1994, RNA PROCESSING PRACT, VI, P1; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; Damgaard CK, 2002, RNA, V8, P1401, DOI 10.1017/S1355838202023075; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hou VC, 2002, EMBO J, V21, P6195, DOI 10.1093/emboj/cdf625; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Karras JG, 2001, BIOCHEMISTRY-US, V40, P7853, DOI 10.1021/bi010263l; Kole R, 2001, CURR OPIN MOL THER, V3, P229; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; KRAMER A, 1987, J MOL BIOL, V196, P559, DOI 10.1016/0022-2836(87)90032-5; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Matter N, 2000, J BIOL CHEM, V275, P35353, DOI 10.1074/jbc.M004692200; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Mercatante DR, 2002, BBA-MOL BASIS DIS, V1587, P126, DOI 10.1016/S0925-4439(02)00075-3; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; PATRY D, 2003, IN PRESS CANC RES; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Rooke N, 2003, MOL CELL BIOL, V23, P1874, DOI 10.1128/MCB.23.6.1874-1884.2003; Sazani P, 2003, Prog Mol Subcell Biol, V31, P217; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SIEBEL CW, 1994, GENE DEV, V8, P1713, DOI 10.1101/gad.8.14.1713; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; Sierakowska H, 1999, RNA, V5, P369, DOI 10.1017/S135583829998130X; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; Tange TO, 2001, EMBO J, V20, P5748; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079	49	58	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50031	50039		10.1074/jbc.M308897200	http://dx.doi.org/10.1074/jbc.M308897200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522969	hybrid			2022-12-25	WOS:000187068200046
J	Strahl, T; Grafelmann, B; Dannenberg, J; Thorner, J; Pongs, O				Strahl, T; Grafelmann, B; Dannenberg, J; Thorner, J; Pongs, O			Conservation of regulatory function in calcium-binding proteins - Human frequenin (neuronal calcium sensor-1) associates productively with yeast phosphatidylinositol 4-kinase isoform, Pik1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT MEMBRANE ASSOCIATION; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEIN; BOVINE NEUROCALCIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CHROMAFFIN CELLS; CA2+ SENSOR-1; 4-OH KINASE	Frequenin, also known as neuronal calcium sensor-1 (NCS-1), is an N-myristoylated Ca2+-binding protein that has been conserved in both sequence and three-dimensional fold during evolution. We demonstrate using both genetic and biochemical approaches that the observed structural conservation between Saccharomyces cerevisiae frequenin (Frq1) and human NCS-1 is also reflected at the functional level. In yeast, the sole essential target of Frq1 is the phosphatidylinositol 4-kinase isoform, Pik1; both FRQ1 and PIK1 are indispensable for cell viability. Expression of human NCS-1 in yeast, but not a close relative ( human KChIP2), rescues the inviability of frq1 cells. Furthermore, in vitro, Frq1 and NCS-1 ( either N-myristoylated or unmyristoylated) compete for binding to a small 28-residue motif near the N terminus of Pik1. Site-directed mutagenesis indicates that the binding determinant in Pik1 is a hydrophobic alpha-helix and that frequenins bind to one side of this alpha-helix. We propose, therefore, that the function of NCS-1 in mammals may closely resemble that of Frq1 in S. cerevisiae and, hence, that frequenins in general may serve as regulators of certain isoforms of phosphatidylinositol 4-kinase.	Univ Hamburg, Zentrum Mol Neurobiol, Inst Neurale Signalverarbeitung, D-20251 Hamburg, Germany; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of California System; University of California Berkeley	Pongs, O (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Inst Neurale Signalverarbeitung, Falkenried 94, D-20251 Hamburg, Germany.		Strahl, Thomas/E-4315-2010; THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Bartlett SE, 2000, J NEUROSCI RES, V62, P216, DOI 10.1002/1097-4547(20001015)62:2<216::AID-JNR6>3.0.CO;2-A; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Chong L, 2001, SCIENCE, V292, P446, DOI 10.1126/science.1060677; COX JA, 1994, J BIOL CHEM, V269, P32807; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Guthrie C, 1991, METHODS ENZYMOL, V194; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HENDRICKS KB, 1999, THESIS U CALIFORNIA; Hilfiker S, 2003, BIOCHEM SOC T, V31, P828, DOI 10.1042/BST0310828; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Huttner IG, 2003, J BIOL CHEM, V278, P4862, DOI 10.1074/jbc.M207920200; Iacovelli L, 1999, FASEB J, V13, P1; Kabbani N, 2002, J NEUROSCI, V22, P8476; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koizumi S, 2002, J BIOL CHEM, V277, P30315, DOI 10.1074/jbc.M201132200; LADANT D, 1995, J BIOL CHEM, V270, P3179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Pan CY, 2002, J NEUROSCI, V22, P2427, DOI 10.1523/JNEUROSCI.22-07-02427.2002; PONGS O, 1970, BIOCHEMISTRY-US, V9, P2316, DOI 10.1021/bi00813a015; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rajebhosale M, 2003, J BIOL CHEM, V278, P6075, DOI 10.1074/jbc.M204702200; SAMBOROK J, 2001, MOL CLONING LAB MANU; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F, 1986, LAB COURSE MANUAL ME; Spilker C, 2000, NEUROSCIENCE, V96, P121, DOI 10.1016/S0306-4522(99)00536-9; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Taverna E, 2002, J CELL SCI, V115, P3909, DOI 10.1242/jcs.00072; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	57	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49589	49599		10.1074/jbc.M309017200	http://dx.doi.org/10.1074/jbc.M309017200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512421	hybrid			2022-12-25	WOS:000186829000130
J	Yokoyama, N; Miller, WT				Yokoyama, N; Miller, WT			Biochemical properties of the Cdc42-associated tyrosine kinase ACK1 - Substrate specificity, autophosphorylation, and interaction with Hck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; CELL-ADHESION; RHO GTPASES; GENE HCK; FAMILY; SRC; CDC42; TARGET; IDENTIFICATION; ACTIVATION	ACK1 (activated Cdc42-associated kinase 1) is a nonreceptor tyrosine kinase and the only tyrosine kinase known to interact with Cdc42. To characterize the enzymatic properties of ACK, we have expressed and purified active ACK using the baculovirus/Sf9 cell system. This ACK1 construct contains (from N to C terminus) the kinase catalytic domain, SH3 domain, and Cdc42-binding Cdc42/Rac interactive binding (CRIB) domain. We characterized the substrate specificity of ACK1 using synthetic peptides, and we show that the specificity of the ACK1 catalytic domain most closely resembles that of Abl. Purified ACK1 undergoes autophosphorylation, and autophosphorylation enhances kinase activity. We identified Tyr(284) in the activation loop of ACK1 as the primary autophosphorylation site using mass spectrometry. When expressed in COS-7 cells, the Y284F mutant ACK1 showed dramatically reduced levels of tyrosine phosphorylation. Although the SH3 and CRIB domains of purified ACK1 are able to bind ligands (a polyproline peptide and Cdc42, respectively), the addition of ligands did not stimulate tyrosine kinase activity. To characterize potential interacting partners for ACK1, we screened several SH2 and SH3 domains for their ability to bind to full-length ACK1 or to the catalytic-SH3-CRIB construct. ACK1 interacts most strongly with the SH3 domains of Src family kinases (Src or Hck) via its C-terminal proline-rich domain. Co-expression of Hck with kinase-inactive ACK1(K158R) in mammalian cells resulted in tyrosine phosphorylation of ACK1, suggesting that ACK1 is a substrate for Hck. Our data suggest that Hck is a novel binding partner for ACK1 that can regulate ACK1 activity by phosphorylation.	SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Sch Med, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Atherton E., 1990, SOLID PHASE PEPTIDE; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kato-Stankiewicz J, 2001, BIOCHEM BIOPH RES CO, V284, P470, DOI 10.1006/bbrc.2001.5004; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nair KS, 2001, CELL IMMUNOL, V208, P96, DOI 10.1006/cimm.2001.1772; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Suen PW, 1999, J CELL SCI, V112, P4067; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4461, DOI 10.1021/bi00388a041; TILL JH, 1994, J BIOL CHEM, V269, P7423; Worby CA, 2002, J BIOL CHEM, V277, P9422, DOI 10.1074/jbc.M110172200; Xu B, 1996, MOL CELL BIOCHEM, V158, P57; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Yokoyama N, 2003, ARCH BIOCHEM BIOPHYS, V417, P87, DOI 10.1016/S0003-9861(03)00333-3; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	57	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47713	47723		10.1074/jbc.M306716200	http://dx.doi.org/10.1074/jbc.M306716200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506255	hybrid			2022-12-25	WOS:000186731400047
J	Zahabi, A; Picard, S; Fortin, N; Reudelhuber, TL; Deschepper, CF				Zahabi, A; Picard, S; Fortin, N; Reudelhuber, TL; Deschepper, CF			Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; INDUCED CARDIAC-HYPERTROPHY; NITRIC-OXIDE; RECEPTOR; PRESSURE; NOREPINEPHRINE; MYOCYTES; MICE	Evidence from several rodent models has suggested that a reduction of either atrial natriuretic peptide or its receptor in the heart affects cardiac remodeling by promoting the onset of cardiac hypertrophy. The atrial natriuretic peptide receptor mediates signaling at least in part via the generation of intracellular cyclic GMP. To directly test whether accumulation of intracellular cyclic GMP conveys protection against cardiac hypertrophy, we engineered transgenic mice that overexpress a catalytic fragment of constitutively active guanylate cyclase domain of the atrial natriuretic peptide receptor in a cardiomyocyte-specific manner. Expression of the transgene increased the intracellular concentration of cyclic GMP specifically within cardiomyocytes and had no detectable effect on cardiac performance under basal conditions. However, expression of the transgene attenuated the effects of the pharmacologic hypertrophic agent isoproterenol on cardiac wall thickness and prevented the onset of the fetal gene expression program normally associated with cardiac hypertrophy. Likewise, expression of the transgene inhibited the hypertrophic effects of abdominal aortic constriction, since it abolished its effects on ventricular wall thickness and greatly attenuated its effects on cardiomyocyte size. Altogether, our results suggest that cyclic GMP is a cardioprotective agent against hypertrophy that acts via a direct local effect on cardiomyocytes.	Inst Rech Clin Montreal, Expt Cardiovasc Biol Unit, Canadian Inst Hlth Res, Montreal, PQ H2W 1R7, Canada; Inst Rech Clin Montreal, Mol Biochem Hypertens Res Unit, Canadian Inst Hlth Res, Multidisciplinary Res Grp Hypertens, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Institute for Work & Health; Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Institute for Work & Health; Universite de Montreal	Deschepper, CF (corresponding author), Inst Rech Clin Montreal, Expt Cardiovasc Biol Unit, Canadian Inst Hlth Res, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	deschec@ircm.qc.ca	Deschepper, Christian/J-4783-2015	Deschepper, Christian/0000-0001-6234-4667	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069122] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69122] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; Boutin-Ganache I, 2002, PHYSIOL GENOMICS, V12, P61, DOI 10.1152/physiolgenomics.00121.2002; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Deschepper CF, 2001, CIRC RES, V88, P223; DESCHEPPER CF, 1994, J NEUROCHEM, V62, P1974; DESCHEPPER CF, 2002, AM J PHYSIOL, V82, pH149; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; KLINGER JR, 1993, J APPL PHYSIOL, V75, P198, DOI 10.1152/jappl.1993.75.1.198; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; KOHNO M, 1992, HYPERTENSION, V19, P320, DOI 10.1161/01.HYP.19.4.320; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Masciotra S, 1999, CIRC RES, V84, P1453; Mazzetti L, 2001, BRIT J PHARMACOL, V134, P596, DOI 10.1038/sj.bjp.0704275; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; Ozaki M, 2002, CIRC J, V66, P851, DOI 10.1253/circj.66.851; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; Tsoporis JN, 1998, J CLIN INVEST, V102, P1609, DOI 10.1172/JCI3077; Wedel BJ, 1998, TRENDS ENDOCRIN MET, V9, P213, DOI 10.1016/S1043-2760(98)00061-7; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	35	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47694	47699		10.1074/jbc.M309661200	http://dx.doi.org/10.1074/jbc.M309661200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500707	hybrid			2022-12-25	WOS:000186731400044
J	Zlot, C; Ingle, G; Hongo, J; Yang, SY; Sheng, Z; Schwall, R; Paoni, N; Wang, F; Peale, FV; Gerritsen, ME				Zlot, C; Ingle, G; Hongo, J; Yang, SY; Sheng, Z; Schwall, R; Paoni, N; Wang, F; Peale, FV; Gerritsen, ME			Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; FACTOR SCATTER FACTOR; IN-VITRO; EXPRESSION; ASSOCIATION; RECEPTOR; MUSCLE; MODEL; FAK	Stanniocalcin 1 (STC1) is a secreted glycoprotein originally described as a hormone involved in calcium and phosphate homeostasis in bony fishes. We recently identified the mammalian homolog of this molecule to be highly up-regulated in an in vitro model of angiogenesis, as well as focally and intensely expressed at sites of pathological angiogenesis (e.g. tumor vasculature). In the present study, we report that STC1 is a selective modulator of hepatocyte growth factor (HGF)-induced endothelial migration and morphogenesis, but not proliferation. STC1 did not inhibit proliferative or migratory responses to vascular endothelial growth factor or basic fibroblast growth factor. The mechanism of STC1 inhibitory effects on HGF-induced endothelial migration seem to occur secondary to receptor activation because STC1 did not inhibit HGF-induced c-met receptor phosphorylation, but did block HGF-induced focal adhesion kinase activation. In the mouse femoral artery ligation model of angiogenesis, STC1 expression closely paralleled that of the endothelial marker CD31, and the peak level of STC1 expression occurred after an increase in HGF expression. We propose that STC1 may play a selective modulatory role in angiogenesis, possibly serving as a "stop signal" or stabilizing factor contributing to the maturation of newly formed blood vessels. HGF is a mesenchyme-derived pleiotropic factor with mitogenic, motogenic, and morphogenic activities on a number of different cell types. HGF effects are mediated through a specific tyrosine kinase, c-met, and aberrant HGF and c-met expression are frequently observed in a variety of tumors. Recent studies have shown HGF to be a potent growth factor implicated in wound healing, tissue regeneration, and angiogenesis.	Genentech Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gerritsen, ME (corresponding author), 541 Parrott Dr, San Mateo, CA 94402 USA.	meg570@comcast.net						BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; FREUND YR, 1982, J IMMUNOL, V129, P2826; Gerritsen ME, 2002, EXP NEPHROL, V10, P114; Hayashi S, 1999, CIRCULATION, V100, P301; HONGO JAS, 1995, HYBRIDOMA, V14, P253, DOI 10.1089/hyb.1995.14.253; ILLC D, 1995, NATURE, V377, P539; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; JENNISCHE E, 1993, AM J PHYSIOL, V265, pC122, DOI 10.1152/ajpcell.1993.265.1.C122; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; McCudden CR, 2002, J BIOL CHEM, V277, P45249, DOI 10.1074/jbc.M205954200; Morishita R, 2002, ENDOCR J, V49, P273, DOI 10.1507/endocrj.49.273; Paciga M, 2002, ENDOCRINOLOGY, V143, P3925, DOI 10.1210/en.2002-220337; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; Taylor JM, 2001, MOL CELL BIOL, V21, P1565, DOI 10.1128/MCB.21.5.1565-1572.2001; To CTT, 1998, ONCOL REP, V5, P1013; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; WAGNER GF, 1992, MOL CELL ENDOCRINOL, V90, P7, DOI 10.1016/0303-7207(92)90095-N; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8	31	50	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47654	47659		10.1074/jbc.M301353200	http://dx.doi.org/10.1074/jbc.M301353200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500721	hybrid			2022-12-25	WOS:000186731400039
J	Chen, SJ; Paul, P; Price, BD				Chen, SJ; Paul, P; Price, BD			ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response	ONCOGENE			English	Article						leucine zipper; ATM; kinase; radiosensitivity; ataxia telangiectasia	ATAXIA-TELANGIECTASIA GENE; S-PHASE CHECKPOINT; FUNCTIONAL-LINK; BREAST-CANCER; DEPENDENT PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; MISSENSE MUTATIONS; ALLELIC VARIANTS; P53; RADIATION	The ATM protein kinase regulates the DNA damage response by phosphorylating proteins involved in cell cycle checkpoints and DNA repair. We report here on the function of the predicted leucine zipper (LZ) motif, and sequences adjacent to this, in regulating ATM activity. The predicted LZ sequence was deleted from ATM, generating ATMDeltaLZ, and expressed in an ATM-negative AT cell line. ATM increased cell survival following exposure to ionizing radiation, whereas expression of ATMDeltaLZ failed to increase cell survival. ATMDeltaLZ retained in vitro kinase activity, but was unable to phosphorylate p53 in vivo. Leucine zippers mediate homo- and heterodimerization of proteins. However, the predicted LZ of ATM did not mediate the formation of ATM dimers. We examined if the predicted LZ of ATM was a dominant-negative inhibitor of ATM function in SW480 cells. Expression of amino acids 769-1436 of ATM, including the predicted LZ, sensitized SW480 cells to ionizing radiation, but did not inhibit ATM's kinase activity or its ability to phosphorylate Brca1. Further, this dominant-negative activity was not dependent on the predicted LZ domain. The central region of the ATM protein therefore contains multiple sequences which regulate cell survival following DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Price, BD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St,JF513, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA093602, R01CA064585] Funding Source: NIH RePORTER; NCI NIH HHS [CA93602, CA64585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Luo CM, 1996, J BIOL CHEM, V271, P4497; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Price BD, 1996, CANCER RES, V56, P246; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Turenne GA, 2001, ONCOGENE, V20, P5100, DOI 10.1038/sj.onc.1204665; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Wang Y, 2000, GENE DEV, V14, P927; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	39	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6332	6339		10.1038/sj.onc.1206760	http://dx.doi.org/10.1038/sj.onc.1206760			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508513				2022-12-25	WOS:000185535300003
J	Holmes, WF; Soprano, DR; Soprano, KJ				Holmes, WF; Soprano, DR; Soprano, KJ			Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway	ONCOGENE			English	Article						retinoids; apoptosis; CD437; MAP kinase; TR3; MEF-2	SYNTHETIC RETINOID CD437; ACID RECEPTOR-GAMMA; LUNG-CANCER CELLS; CYTOCHROME-C RELEASE; PROTEIN-KINASE; CASPASE ACTIVATION; TRANSCRIPTION FACTORS; INDEPENDENT PATHWAY; SELECTIVE RETINOIDS; MELANOMA-CELLS	Retinoids have great potential in the areas of cancer therapy and chemoprevention. 6-[3-(1-admantyl)]-4-hydroxyphenyl]2-naphthalene carboxylic acid (CD437) is a conformationally restricted synthetic retinoid that has been reported to induce growth arrest and apoptosis in ovarian tumor cell lines but the entire mechanism for apoptotic induction has not been fully defined. We set out to identify the early events of CD437-induced apoptosis of the CA-OV-3 cell line and determine if these occur in a CA-OV-3 cell line resistant to CD437 (CA-CD437R). Using inhibitors for the MAP kinase cascade, we determined that MEK and p38 inhibitors could block CD437-induced apoptosis of the CA-OV-3 cell line. Moreover, treatment of CA-OV-3 and CA-CD437R cells with CD437 resulted in increased phosphorylation and activity of p38 independent of caspase-3 activation. Furthermore, p38 induced the phosphorylation of MEF2 in both CA-OV-3 and CA-CD437R cells after CD437 treatment. Finally, GFP-TR3 protein translocated to the cytosol and associated with mitochondria in both cell lines in response to CD437 treatment. This leads to depolarization of mitochondria and subsequent induction of apoptosis only in CA-OV-3 cells. These results identify a number of initial molecular events in the induction of apoptosis by CD437 in CA-OV-3 cells and demonstrate that the alteration in CA-CD437R cells, which results in resistance to CD437 maps downstream of these early events after TR3 translocation but prior to mitochondrial depolarization.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIAID NIH HHS [AI 07101] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Bild AH, 2002, ONCOGENE, V21, P6649, DOI 10.1038/sj.onc.1205819; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Dawson MI, 2001, CANCER RES, V61, P4723; DE LUCA LM, 1991, FASEB J, V5, P2924; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gudas Lorraine J., 1994, P443; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kumar A, 2001, CANCER RES, V61, P7552; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Liu WF, 2001, EUR J IMMUNOL, V31, P1757, DOI 10.1002/1521-4141(200106)31:6<1757::AID-IMMU1757>3.0.CO;2-J; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; Moon Richard C., 1994, P573; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Sakaue M, 2001, CELL DEATH DIFFER, V8, P411, DOI 10.1038/sj.cdd.4400818; Sanchez-Perez I, 2002, MOL BIOL CELL, V13, P2933, DOI 10.1091/mbc.E02-01-0022; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 2002, CANCER RES, V62, P2430; Sun SY, 1997, CANCER RES, V57, P4931; Sun SY, 2000, CANCER RES, V60, P7149; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; Widschwendter M, 1997, INT J CANCER, V71, P497; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zhang YX, 2002, BLOOD, V100, P2917, DOI 10.1182/blood.V100.8.2917; Zhao M, 2000, ACTA BIOCH BIOPH SIN, V32, P258; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	56	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6377	6386		10.1038/sj.onc.1206694	http://dx.doi.org/10.1038/sj.onc.1206694			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508518				2022-12-25	WOS:000185535300008
J	Liu, ZJ; Snyder, R; Soma, A; Shirakawa, T; Ziober, BL; Fairman, RM; Herlyn, M; Velazquez, OC				Liu, ZJ; Snyder, R; Soma, A; Shirakawa, T; Ziober, BL; Fairman, RM; Herlyn, M; Velazquez, OC			VEGF-A and alpha(V)beta(3) integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; VEGF-A; alpha(V)beta(3) integrin; N-Ras; PI3-K	GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; HUMAN-MELANOMA; ACTIVATION; TRANSDUCTION; PATHWAY; BINDING; RAF-1; AKT	We recently showed that normal fibroblasts mediate capillary-like differentiation of human microvascular endothelial cells (HMVEC) in a 3-D angiogenesis model. Here, we show that a collaborative effect of VEGF-A and alpha(v)beta(3) integrin is critical in fibroblast-mediated angiogenesis because enhancement of both VEGF production by fibroblasts and beta(3) integrin expression in HMVEC can rescue capillary-like endothelial differentiation under reduced serum conditions. To investigate the downstream signaling mechanisms, we compared N-Ras and Rho/Rac/Cdc42, as well as phosphatidylinositol 3-kinase (PI3-K) and Akt, for their involvement in the capillary-like network formation. The dominant-negative mutant of N-Ras (N-Ras(N17)), but not the mutants of Rho/Rac/Cdc42, suppressed network formation. Overexpression of a constitutively active form of PI3-K rescued the network formation, which was inhibited by a dominant-negative beta(3) integrin; however, an active form of Akt failed to rescue the inhibition but induced a phenotypic change in HMVEC. Moreover, PI3-K is a downstream target of N-Ras because it could be coimmunoprecipitated with N-Ras, and its active form could rescue the inhibitory effect of N-Ras (N17). Thus, our data indicate the existence of N-Ras- and PI3-K-dependent but Rho/Rac/Cdc42- and Akt-independent signaling mechanisms for the synergistic effect of VEGF-A and alpha(v)beta(3) on fibroblast-mediated microvascular network formation.	Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Velazquez, OC (corresponding author), Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA.	omaida.velazquez@uphs.upenn.edu						Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu ZJ, 1998, MOL CELL BIOL, V18, P3445, DOI 10.1128/MCB.18.6.3445; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	60	29	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1931	+		10.1096/fj.02-1171fje	http://dx.doi.org/10.1096/fj.02-1171fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519669				2022-12-25	WOS:000185345100008
J	Huang, QQ; Fisher, SA; Brozovich, FV				Huang, QQ; Fisher, SA; Brozovich, FV			Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE I-ALPHA; SIGNAL-TRANSDUCTION; TARGETING SUBUNIT; NITRIC-OXIDE; CYCLIC-GMP; CGMP; PHOSPHORYLATION; ISOFORMS; EXPRESSION; TELOKIN	Recently, it has been hypothesized that myosin light chain (MLC) phosphatase is activated by cGMP-dependent protein kinase (PKG) via a leucine zipper-leucine zipper (LZ-LZ) interaction through the C-terminal LZ in the myosin-binding subunit (MBS) of MLC phosphatase and the N-terminal LZ of PKG (Surks, H. K., Mochizuki, N., Kasai, Y., Georgescu, S. P., Tang, K. M., Ito, M., Lincoln, T. M., and Mendelsohn, M. E. ( 1999) Science 286, 1583 - 1587). Alternative splicing of a 3'-exon produces a LZ(+) or LZ(-) MBS, and the sensitivity to cGMP-mediated smooth muscle relaxation correlates with the relative expression of LZ(+)/LZ(-) MBS isoforms (Khatri, J. J., Joyce, K. M., Brozovich, F. V., and Fisher, S. A. ( 2001) J. Biol. Chem. 276, 37250 - 37257). In the present study, we determined the effect of LZ(+)/LZ(-) MBS isoforms on cGMP-induced MLC20 dephosphorylation. Four avian smooth muscle MBS-recombinant adenoviruses were prepared and transfected into cultured embryonic chicken gizzard smooth muscle cells. The expressed exogenous MBS isoforms were shown to replace the endogenous isoform in the MLC phosphatase holoenzyme. The interaction of type I PKG (PKGI) with the MBS did not depend on the presence of cGMP or the MBS LZ. However, direct activation of PKGI by 8-bromo-cGMP produced a dose-dependent decrease in MLC20 phosphorylation ( p < 0.05) only in smooth muscle cells expressing a LZ(+) MBS. These results suggest that the activation of MLC phosphatase by PKGI requires a LZ(+) MBS, but the binding of PKGI to the MBS is not mediated by a LZ- LZ interaction. Thus, the relative expression of LZ(+)/LZ(-) MBS isoforms could explain differences in tissue sensitivity to NO-mediated vasodilatation.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med Cardiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Brozovich, FV (corresponding author), Case Western Reserve Univ, Dept Physiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	fxb9@cwru.edu	fisher, steven/G-2630-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066171, R01HL064137, R01HL069894] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64137, HL69894, HL66171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772; Etter EF, 2001, J BIOL CHEM, V276, P34681, DOI 10.1074/jbc.M104737200; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GONG MC, 1992, J BIOL CHEM, V267, P14662; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P432; Hayashi K, 1998, J BIOL CHEM, V273, P28860, DOI 10.1074/jbc.273.44.28860; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang QQ, 1999, J BIOL CHEM, V274, P35095, DOI 10.1074/jbc.274.49.35095; Jin JP, 1996, BIOCHEM CELL BIOL, V74, P187, DOI 10.1139/o96-019; Kashiwada K, 1997, J BIOL CHEM, V272, P15396, DOI 10.1074/jbc.272.24.15396; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Langsetmo K, 2001, J BIOL CHEM, V276, P34318, DOI 10.1074/jbc.M103255200; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Somlyo A P, 1999, Rev Physiol Biochem Pharmacol, V134, P201; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Walker LA, 2001, J BIOL CHEM, V276, P24519, DOI 10.1074/jbc.M103560200; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	31	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2004	279	1					597	603		10.1074/jbc.M308496200	http://dx.doi.org/10.1074/jbc.M308496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	757GU	14530290	hybrid			2022-12-25	WOS:000187555300072
J	Feigelson, SW; Grabovsky, V; Shamri, R; Levy, S; Alon, R				Feigelson, SW; Grabovsky, V; Shamri, R; Levy, S; Alon, R			The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTEGRIN ACTIVATION; T-CELLS; ALPHA-4 INTEGRIN; MAJOR CD9; BINDING; LFA-1; SUPERFAMILY; COMPLEXES; LIGAND	Leukocyte integrins must rapidly strengthen their binding to target endothelial sites to arrest rolling adhesions under physiological shear flow. We demonstrate that the integrin-associated tetraspanin, CD81, regulates VLA-4 and VLA-5 adhesion strengthening in monocytes and primary murine B cells. CD81 strengthens multivalent VLA-4 contacts within subsecond integrin occupancy without altering intrinsic adhesive properties to low density ligand. CD81 facilitates both VLA-4-mediated leukocyte rolling and arrest on VCAM-1 under shear flow as well as VLA-5-dependent adhesion to fibronectin during short stationary contacts. CD81 also augments VLA-4 avidity enhancement induced by either chemokine-stimulated G(i) proteins or by protein kinase C activation, although it is not required for Gi protein or protein kinase C signaling activities. In contrast to other proadhesive integrin-associated proteins, CD81-promoted integrin adhesiveness does not require its own ligand occupancy or ligation. These results provide the first demonstration of an integrin-associated trans-membranal protein that facilitates instantaneous multivalent integrin occupancy events that promote leukocyte adhesion to an endothelial ligand under shear flow.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Stanford Univ, Dept Oncol, Stanford, CA 94305 USA	Weizmann Institute of Science; Stanford University	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Deng J, 2000, J IMMUNOL, V165, P5054, DOI 10.4049/jimmunol.165.9.5054; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Henderson RB, 2001, J EXP MED, V194, P219, DOI 10.1084/jem.194.2.219; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KOLESNIKOVA TV, 2002, FASEB C ADV TETR RES; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Lammerding J, 2003, P NATL ACAD SCI USA, V100, P7616, DOI 10.1073/pnas.1337546100; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Liu L, 2002, J BIOL CHEM, V277, P40893, DOI 10.1074/jbc.M206208200; Lub M, 1997, MOL BIOL CELL, V8, P341, DOI 10.1091/mbc.8.2.341; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shibagaki N, 1999, EUR J IMMUNOL, V29, P4081, DOI 10.1002/(SICI)1521-4141(199912)29:12<4081::AID-IMMU4081>3.3.CO;2-9; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; VanCompernolle SE, 2001, EUR J IMMUNOL, V31, P823, DOI 10.1002/1521-4141(200103)31:3<823::AID-IMMU823>3.3.CO;2-4; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; YAUCH RL, 1997, J EXP MED, V186, P1; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	57	78	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51203	51212		10.1074/jbc.M303601200	http://dx.doi.org/10.1074/jbc.M303601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532283	hybrid			2022-12-25	WOS:000187206300046
J	Hamdane, D; Kiger, L; Dewilde, S; Green, BN; Pesce, A; Uzan, J; Burmester, T; Hankeln, T; Bolognesi, M; Moens, L; Marden, MC				Hamdane, D; Kiger, L; Dewilde, S; Green, BN; Pesce, A; Uzan, J; Burmester, T; Hankeln, T; Bolognesi, M; Moens, L; Marden, MC			The redox state of the cell regulates the ligand binding affinity of human neuroglobin and cytoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXACOORDINATE HEMOGLOBIN; TRUNCATED HEMOGLOBINS; MOUSE NEUROGLOBIN; GLOBIN; PROTEIN; IDENTIFICATION; PLANTS; BRAIN; EXPRESSION; SEQUENCES	Neuroglobin and cytoglobin reversibly bind oxygen in competition with the distal histidine, and the observed oxygen affinity therefore depends on the properties of both ligands. In the absence of an external ligand, the iron atom of these globins is hexacoordinated. There are three cysteine residues in human neuroglobin; those at positions CD7 and D5 are sufficiently close to form an internal disulfide bond. Both cysteine residues in cytoglobin, although localized in other positions than in human neuroglobin, may form a disulfide bond as well. The existence and position of these disulfide bonds was demonstrated by mass spectrometry and thiol accessibility studies. Mutation of the cysteines involved, or the use of reducing agents to break the S-S bond, led to a decrease in the observed oxygen affinity of human neuroglobin by an order of magnitude. The critical parameter is the histidine dissociation rate, which changes by about a factor of 10. The same effect is observed with human cytoglobin, although to a much lesser extent ( less than a factor of 2). These results suggest a novel mechanism for the regulation of oxygen binding; contact with an appropriate electron donor would provoke the release of oxygen. Hence the oxygen affinity would be directly linked to the redox state of the cell.	INSERM, U473, F-94276 Le Kremlin Bicetre, France; Univ Antwerp, Dept Biomed Sci, B-2610 Wilrijk, Belgium; Micromass UK Ltd, Waters Corp, Manchester M22 5PP, Lancs, England; Univ Genoa, INFM Adv Biotechnol Ctr, Dept Phys, I-16146 Genoa, Italy; Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Univ Mainz, Inst Mol Genet Biosafety Res & Consulting, D-55099 Mainz, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Antwerp; Waters UK; University of Genoa; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Marden, MC (corresponding author), INSERM, U473, 84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.		Bolognesi, Martino/B-7924-2017; Burmester, Thorsten/I-7225-2013; Pesce, Alessandra/A-3660-2015; Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Kiger, Laurent/Q-1686-2018	Bolognesi, Martino/0000-0002-9253-5170; Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385; 				Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Du WH, 2003, J AM CHEM SOC, V125, P8080, DOI 10.1021/ja034584r; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; HAGLER L, 1979, J BIOL CHEM, V254, P6505; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hogg PJ, 2003, TRENDS BIOCHEM SCI, V28, P210, DOI 10.1016/S0968-0004(03)00057-4; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Kwon M, 2002, J BIOL CHEM, V277, P10903, DOI 10.1074/jbc.M111219200; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Milev Y, 1999, ARCH BIOCHEM BIOPHYS, V361, P120, DOI 10.1006/abbi.1998.0963; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Sowa AW, 1999, ACTA BIOCHIM POL, V46, P431, DOI 10.18388/abp.1999_4175; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Van Doorslaer S, 2003, J BIOL CHEM, V278, P4919, DOI 10.1074/jbc.M210617200; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; Watts RA, 2001, P NATL ACAD SCI USA, V98, P10119, DOI 10.1073/pnas.191349198; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wild BJ, 2001, BLOOD CELL MOL DIS, V27, P691, DOI 10.1006/bcmd.2001.0430; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360	37	233	247	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51713	51721		10.1074/jbc.M309396200	http://dx.doi.org/10.1074/jbc.M309396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14530264	hybrid			2022-12-25	WOS:000187206300106
J	Jelezarova, E; Luginbuehl, A; Lutz, HU				Jelezarova, E; Luginbuehl, A; Lutz, HU			C3b(2)-IgG complexes retain dimeric C3 fragments at all levels of inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE COMPLEMENT PATHWAY; COVALENT-BINDING REACTION; ESTER LINKAGE FORMATION; IMMUNE-COMPLEXES; ACQUIRED-IMMUNITY; IMMUNOGLOBULIN-G; C5 CONVERTASE; PROTEINS C3; FACTOR-H; IGG	C3b(2)-IgG complexes are formed during complement activation in serum by attachment of two C3b molecules (the proteolytically activated form of C3) to one IgG heavy chain (IgG HC) via ester bonds. Because of the presence of two C3b molecules, these complexes are very efficient activators of the alternative complement pathway. Likewise, dimeric C3b is known to enhance complement receptor 1-dependent phagocytosis, and dimeric C3d (the smallest thioester-containing fragment of C3) linked to a protein antigen facilitates CR2-dependent B-cell proliferation. Because the efficiency of all these interactions depends on the number of C3 fragments, we investigated whether C3b(2)-IgG complexes retained dimeric structure upon physiological inactivation. We used two-dimensional SDS-PAGE and Western blot to study the arrangement of the C3b molecules by analyzing the fragmentation pattern after cleavage of the ester bonds. Upon inactivation with factors H and I, a 185-kDa band was generated under reducing conditions. It released IgG HC and the 65-kDa fragment of C3b alpha' chain after hydrolysis of the ester bonds with hydroxylamine. The two C3b molecules were not 65-kDa-to-40-kDa linked, because neither ester-bonded 65 kDa HC nor 65 kDa-40 kDa fragments were observed, nor was a 40-kDa peptide released after hydroxylamine cleavage. Factor I and CR1 cleaved the C3b(2)-IgG molecule to its final physiological product, C3dg(2)-IgG, which migrated as a 133-kDa fragment in reduced form. This fragment released exclusively C3dg (the final physiological product of C3b inactivation by factor I) and IgG HC. C3dg(2)-HC appeared as a double band on SDS-PAGE only at low gel porosity, suggesting the presence of two conformers of the same composition. Our results suggest that, upon physiological inactivation, C3b(2)-IgG complexes retain dimeric inactivated C3b and C3dg, which allows bivalent binding to the corresponding complement receptors.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	ETH Zurich	Jelezarova, E (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, HPM D14, CH-8093 Zurich, Switzerland.							Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ANTON LC, 1989, BIOCHEM J, V257, P831, DOI 10.1042/bj2570831; ANTON LC, 1994, EUR J IMMUNOL, V24, P599, DOI 10.1002/eji.1830240316; ARNAOUT MA, 1983, IMMUNOLOGY, V48, P229; BARRIO E, 1991, EUR J IMMUNOL, V21, P343, DOI 10.1002/eji.1830210215; BURGER R, 1982, J IMMUNOL, V129, P2042; Clemenza L, 2000, J IMMUNOL, V165, P3839, DOI 10.4049/jimmunol.165.7.3839; CORNACOFF JB, 1983, J CLIN INVEST, V71, P236, DOI 10.1172/JCI110764; DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Dodds AW, 1998, IMMUNOL REV, V166, P15; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FRIES LF, 1984, J EXP MED, V160, P1640, DOI 10.1084/jem.160.6.1640; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; Gadjeva M, 1998, J IMMUNOL, V161, P985; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; IIDA K, 1983, J EXP MED, V158, P1021, DOI 10.1084/jem.158.4.1021; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4471; Jelezarova E, 2000, BIOCHEM J, V349, P217, DOI 10.1042/0264-6021:3490217; Jelezarova E, 2001, J IMMUNOL METHODS, V251, P45, DOI 10.1016/S0022-1759(01)00295-2; Jelezarova E, 1999, MOL IMMUNOL, V36, P837, DOI 10.1016/S0161-5890(99)00104-2; KIM YU, 1992, J BIOL CHEM, V267, P4171; KIMBERLY RP, 1989, J CLIN INVEST, V84, P962, DOI 10.1172/JCI114259; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KULICS J, 1983, MOL IMMUNOL, V20, P805, DOI 10.1016/0161-5890(83)90076-7; Law SKA, 1997, PROTEIN SCI, V6, P263; LUTZ HU, 1993, J BIOL CHEM, V268, P17418; Lutz HU, 1996, BLOOD, V88, P184; LUTZ HU, 2004, IN PRESS BLOOD; MERI S, 1990, EUR J IMMUNOL, V20, P2555, DOI 10.1002/eji.1830201205; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; Munoz E, 1998, INT IMMUNOL, V10, P97, DOI 10.1093/intimm/10.2.97; MYONES BL, 1988, J CLIN INVEST, V82, P640, DOI 10.1172/JCI113643; PASCUAL M, 1992, IMMUNOPHARMACOLOGY, V24, P101, DOI 10.1016/0162-3109(92)90016-6; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x; Rawal N, 2001, INT IMMUNOPHARMACOL, V1, P415, DOI 10.1016/S1567-5769(00)00039-4; SAHU A, 1994, J BIOL CHEM, V269, P28997; SCHIFFERLI JA, 1988, J IMMUNOL, V140, P899; SHOHET JM, 1991, J BIOL CHEM, V266, P18520; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; Sutterwala FS, 1996, J LEUKOCYTE BIOL, V59, P883, DOI 10.1002/jlb.59.6.883; TACK BF, 1983, SPRINGER SEMIN IMMUN, V6, P259, DOI 10.1007/BF02116276; Tedder TF, 1997, IMMUNITY, V6, P107, DOI 10.1016/S1074-7613(00)80418-5; van den Elsen JMH, 2002, J MOL BIOL, V322, P1103, DOI 10.1016/S0022-2836(02)00854-9; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777	45	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51806	51812		10.1074/jbc.M304613200	http://dx.doi.org/10.1074/jbc.M304613200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14527961	hybrid			2022-12-25	WOS:000187206300116
J	Yoon, YS; Byun, HO; Cho, H; Kim, BK; Yoon, G				Yoon, YS; Byun, HO; Cho, H; Kim, BK; Yoon, G			Complex II defect via down-regulation of iron-sulfur subunit induces mitochondrial dysfunction and cell cycle delay in iron chelation-induced senescence-associated growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINATE-DEHYDROGENASE; MESSENGER-RNA; RIBONUCLEOTIDE REDUCTASE; DROSOPHILA-MELANOGASTER; ENERGY-METABOLISM; OXIDATIVE STRESS; IN-VIVO; AGE; SUPEROXIDE; MUTATIONS	Mitochondria play a pivotal role as an ATP generator in aerobically growing cells, and their defects have long been implicated in the cellular aging process, although its detailed underlying mechanisms remain unclear. Recently, we found that, in the cellular senescent process of Chang cells induced by desferroxamine mesylate, an iron chelator, a significant decrease of intracellular ATP level was accompanied by decline in complex II activity, which preceded acquisition of the senescent phenotype. In the present study, we investigated the mechanism of how the mitochondrial ATP productivity was damaged by iron chelation and how complex II defect was involved in the senescent arrest. The ATP loss was irreversible and accompanied by sustained collapse of mitochondrial membrane potential (DeltaPsim), but the ATP loss itself did not seem to be essential in progression to the senescent arrest. The DeltaPsim disruption was due to decreased mitochondrial respiration, which was primarily associated with the defective complex II activity. Furthermore, we found that the declined activity of complex II was mainly due to down-regulation of protein expression of the iron-sulfur subunit, which was associated with the irreversibility of the arrest. Finally, we demonstrated that specific inhibition of complex II with 2-thenoyltrifluoroacetone induced overall delay of the cell cycle, suggesting that the delayed arrest by desferroxamine mesylate might be in part due to inhibition of complex II activity. Taken together, our results suggest that complex II might be considered as one of the primary factors to regulate mitochondrial respiratory function by responding to the cellular iron level, thereby influencing cellular growth.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 442721, South Korea	Ajou University	Yoon, G (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 442721, South Korea.	ypeace@ajou.ac.kr		Cho, Hyeseong/0000-0002-4672-8887				ANDERSON GR, 1988, BIOCHEMISTRY-US, V27, P2187, DOI 10.1021/bi00406a056; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Benn DE, 2003, ONCOGENE, V22, P1358, DOI 10.1038/sj.onc.1206300; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; BYRNE E, 1991, REV NEUROL, V147, P532; Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eguchi Y, 1997, CANCER RES, V57, P1835; Esposti MD, 2001, METHOD CELL BIOL, V65, P75; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FURUKAWA T, 1992, LIFE SCI, V50, P2059, DOI 10.1016/0024-3205(92)90572-7; Gadaleta MN, 1998, BIOCHIMIE, V80, P863, DOI 10.1016/S0300-9084(00)88881-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUERRIERI F, 1992, ANN NY ACAD SCI, V671, P395, DOI 10.1111/j.1749-6632.1992.tb43813.x; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; LEDERMAN HM, 1984, BLOOD, V64, P748; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Melefors O, 1996, BIOCHEM BIOPH RES CO, V221, P437, DOI 10.1006/bbrc.1996.0613; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Mikulits W, 1999, MUTAT RES-REV MUTAT, V437, P219, DOI 10.1016/S1383-5742(99)00085-X; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; NICHOLLS DG, 1992, BIOENERGETICS, V2, P107; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; Oexle H, 1999, BBA-BIOENERGETICS, V1413, P99, DOI 10.1016/S0005-2728(99)00088-2; PALL ML, 1990, MECH AGEING DEV, V52, P287, DOI 10.1016/0047-6374(90)90132-Y; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Sastre J, 1996, HEPATOLOGY, V24, P1199, DOI 10.1002/hep.510240536; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Xu D, 2002, BIOCHEM BIOPH RES CO, V294, P245, DOI 10.1016/S0006-291X(02)00464-3; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Zhang JG, 2001, ARCH BIOCHEM BIOPHYS, V393, P87, DOI 10.1006/abbi.2001.2486; Zielke H R, 1974, Methods Cell Biol, V8, P107, DOI 10.1016/S0091-679X(08)60447-1	42	63	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51577	51586		10.1074/jbc.M308489200	http://dx.doi.org/10.1074/jbc.M308489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14512425	hybrid			2022-12-25	WOS:000187206300090
J	Sunters, A; de Mattos, SF; Stahl, M; Brosens, JJ; Zoumpoulidou, G; Saunders, CA; Coffer, PJ; Medema, RH; Coombes, RC; Lam, EWF				Sunters, A; de Mattos, SF; Stahl, M; Brosens, JJ; Zoumpoulidou, G; Saunders, CA; Coffer, PJ; Medema, RH; Coombes, RC; Lam, EWF			FoxO3a transcriptional regulation of bim controls apoptosis in paclitaxel-treated breast cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAX-DEPENDENT APOPTOSIS; BCL-2 RELATIVE BIM; FAMILY-MEMBER BIM; KINASE-B; NUCLEAR EXCLUSION; OXIDATIVE STRESS; 3-KINASE PATHWAY; CARCINOMA CELLS; FACTOR FKHR-L1; PHOSPHORYLATION	Paclitaxel is used to treat breast cancers, but the mechanisms by which it induces apoptosis are poorly understood. Consequently, we have studied the role of the FoxO transcription factors in determining cellular response to paclitaxel. Western blotting revealed that in a panel of nine breast cancer cell lines expression of FoxO1a and FoxO3a correlated with the expression of the pro-apoptotic FoxO target Bim, which was associated with paclitaxel-induced apoptosis. In MCF-7 cells, which were paclitaxel-sensitive, the already high basal levels of FoxO3a and Bim protein increased dramatically after drug treatment, as did Bim mRNA, which correlated with apoptosis induction. This was not observed in MDA-231 cells, which expressed low levels of FoxOs and Bim. Gene reporter experiments demonstrated that in MCF-7 cells maximal induction of Bim promoter was dependent on a FoxO binding site, suggesting that FoxO3a is responsible for the transcriptional up-regulation of Bim. Gene silencing experiments showed that small interference RNA ( siRNA) specific for FoxO3a reduced the levels of FoxO3a and Bim protein as well as inhibited apoptosis in paclitaxel-treated MCF-7 cells. Furthermore, siRNA specific for Bim reduced the levels of Bim protein and inhibited apoptosis in paclitaxel-treated MCF-7 cells. This is the first demonstration that up-regulation of FoxO3a by paclitaxel can result in increased levels of Bim mRNA and protein, which can be a direct cause of apoptosis in breast cancer cells.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Dept Canc Med,Canc Res UK Labs, London W12 0NN, England; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Inst Reprod & Dev Biol, Sch Med, London W12 0NN, England; Univ Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Cancer Research UK; Imperial College London; Netherlands Cancer Institute; Imperial College London; Utrecht University; Utrecht University Medical Center	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Dept Canc Med,Canc Res UK Labs, Cyclotron Bldg,Du Cane Rd, London W12 0NN, England.		Lam, Eric W-F/AAW-8566-2020; Medema, Rene H/E-2981-2013; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020; Medema, Rene H/G-5415-2011; de Mattos, Silvia Fernández/K-5153-2014	Lam, Eric W-F/0000-0003-1274-3576; de Mattos, Silvia Fernández/0000-0003-4144-3687; Medema, Rene/0000-0002-6754-0381; Coombes, Raoul Charles/0000-0002-4811-1100; Brosens, Jan/0000-0003-0116-9329				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chiarle R, 2001, BREAST CANCER RES, V3, P91; Clark AS, 2002, MOL CANCER THER, V1, P707; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engstrom M, 2003, EXP HEMATOL, V31, P316, DOI 10.1016/S0301-472X(03)00002-X; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leivonen M, 2001, BREAST CANCER RES TR, V67, P15, DOI 10.1023/A:1010623326118; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Nohara T, 2001, ONCOLOGY-BASEL, V60, P94, DOI 10.1159/000055303; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Page C, 2000, INT J ONCOL, V17, P23; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Radisavljevic Z, 2003, CANCER, V97, P1358, DOI 10.1002/cncr.10081; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Samatar AA, 2002, J BIOL CHEM, V277, P28118, DOI 10.1074/jbc.M203686200; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Symmans WF, 2001, DRUG RESIST UPDATE, V4, P297, DOI 10.1054/drup.2001.0218; Tanabe K, 2003, INT J ONCOL, V22, P875; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Williams CD, 1997, BLOOD, V90, P194; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	52	413	432	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49795	49805		10.1074/jbc.M309523200	http://dx.doi.org/10.1074/jbc.M309523200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14527951	Green Submitted, hybrid			2022-12-25	WOS:000187068200020
J	Dibb, KM; Rose, T; Makary, SY; Claydon, TW; Enkvetchakul, D; Leach, R; Nichols, CG; Boyett, MR				Dibb, KM; Rose, T; Makary, SY; Claydon, TW; Enkvetchakul, D; Leach, R; Nichols, CG; Boyett, MR			Molecular basis of ion selectivity, block, and rectification of the inward rectifier Kir3.1/Kir3.4 K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; PORE; PERMEATION; CONDUCTION; RESIDUES; KCSA; STABILIZATION; COORDINATION; MECHANISM; MODELS	The glycine-tyrosine-glycine (GYG) sequence in the p-loop of K+ channel subunits lines a narrow pore through which K+ ions pass in single file intercalated by water molecules. Mutation of the motif can give rise to nonselective channels, but it is clear that other structural features are also required for selectivity because, for instance, a recently identified class of cyclic nucleotide-gated pacemaker channels has the GYG motif but are poorly K+ selective. We show that mutation of charged glutamate and arginine residues behind the selectivity filter in the Kir3.1/Kir3.4K(+) channel reduces or abolishes K+ selectivity, comparable with previously reported effects in the Kir2.1 K+ channel. It has been suggested that a salt bridge exists between the glutamate-arginine residue pair. Molecular modeling indicates that the salt bridge does exist, and that it acts as a "bowstring" to maintain the rigid bow-like structure of the selectivity filter and restrict selectivity to K+. The modeling shows that relaxation of the bowstring by mutation of the residue pair leads to enhanced flexibility of the p-loop, allowing permeation of other cations, including polyamines. In experiments, mutation of the residue pair can also abolish polyamine-induced inward rectification. The latter effect occurs because polyamines now permeate rather than block the channel, to the remarkable extent that large polyamine currents can be measured.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem, St Louis, MO 63110 USA	University of Leeds; Washington University (WUSTL); Washington University (WUSTL)	Boyett, MR (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	m.r.boyett@leeds.ac.uk	Makary, Samy/C-6298-2018; Dibb, Katharine/G-8764-2015; Nichols, Colin/D-6336-2012	Makary, Samy/0000-0003-3166-0151; Dibb, Katharine/0000-0002-9309-3853; ROSE, Thierry/0000-0001-8863-0207; Boyett, Mark/0000-0003-3931-2020; Claydon, Tom/0000-0002-5143-7451	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054171] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Berneche S, 2001, NATURE, V414, P73, DOI 10.1038/35102067; Berneche S, 2002, BIOPHYS J, V82, P772, DOI 10.1016/S0006-3495(02)75439-8; Cho HC, 2000, BIOCHEMISTRY-US, V39, P4649, DOI 10.1021/bi992469g; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; ENKVETCHAKUL D, 2003, IN PRESS J PHYSL; Guo DL, 2000, J GEN PHYSIOL, V115, P799, DOI 10.1085/jgp.115.6.799; GUY HR, 1995, SOC GEN PHY, V50, P1; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KORN SJ, 1995, SCIENCE, V269, P410, DOI 10.1126/science.7618108; Kubo Y, 2001, J PHYSIOL-LONDON, V531, P645, DOI 10.1111/j.1469-7793.2001.0645h.x; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LeMasurier M, 2001, J GEN PHYSIOL, V118, P303, DOI 10.1085/jgp.118.3.303; LOPATIN AN, 1995, J GEN PHYSIOL, V106, P923, DOI 10.1085/jgp.106.5.923; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Olson WK, 2001, J MOL BIOL, V313, P229, DOI 10.1006/jmbi.2001.4987; PARKER I, 1988, PROC R SOC SER B-BIO, V234, P45, DOI 10.1098/rspb.1988.0037; Pearson WL, 1998, J GEN PHYSIOL, V112, P351, DOI 10.1085/jgp.112.3.351; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; Wischmeyer E, 2000, FEBS LETT, V466, P115, DOI 10.1016/S0014-5793(99)01769-X; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	35	57	58	6	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49537	49548		10.1074/jbc.M307723200	http://dx.doi.org/10.1074/jbc.M307723200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14504281	hybrid			2022-12-25	WOS:000186829000124
J	Szeltner, Z; Rea, D; Renner, V; Juliano, L; Fulop, V; Polgar, L				Szeltner, Z; Rea, D; Renner, V; Juliano, L; Fulop, V; Polgar, L			Electrostatic environment at the active site of prolyl oligopeptidase is highly influential during substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEPTIDASE INHIBITORS; CATALYSIS; ENZYME; TEMPERATURE; RESIDUES; PHASES; PLOTS; MAPS	The positive electrostatic environment of the active site of prolyl oligopeptidase was investigated by using substrates with glutamic acid at positions P2, P3, P4, and P5, respectively. The different substrates gave various pH rate profiles. The pK(a) values extracted from the curves are apparent parameters, presumably affected by the nearby charged residues, and do not reflect the ionization of a simple catalytic histidine as found in the classic serine peptidases like chymotrypsin and subtilisin. The temperature dependence of k(cat)/K-m did not produce linear Arrhenius plots, indicating different changes in the individual rate constants with the increase in temperature. This rendered it possible to calculate these constants, i.e. the formation (k(1)) and decomposition (k(-1)) of the enzyme-substrate complex and the acylation constant (k(2)), as well as the corresponding activation energies. The results have revealed the relationship between the complex Michaelis parameters and the individual rate constants. Structure determination of the enzyme-substrate complexes has shown that the different substrates display a uniform binding mode. None of the glutamic acids interacts with a charged group. We conclude that the specific rate constant is controlled by k(1) rather than k(2) and that the charged residues from the substrate and the enzyme can markedly affect the formation but not the structure of the enzyme-substrate complexes.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest 112, Hungary; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Warwick; Universidade Federal de Sao Paulo (UNIFESP)	Polgar, L (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest 112, Hungary.	polgar@enzim.hu	Fulop, Vilmos/AAZ-7720-2021; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822				ATACK JR, 1991, EUR J PHARMACOL, V205, P157, DOI 10.1016/0014-2999(91)90814-7; Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; Cornish-Bowden A, 1995, FUNDAMENTALS ENZYME, p[44, 108, 139]; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan YX, 2000, BIOCHEMISTRY-US, V39, P4692, DOI 10.1021/bi9921586; Fulop V, 2000, EMBO REP, V1, P277, DOI 10.1093/embo-reports/kvd048; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; LIN LN, 1983, BIOCHEMISTRY-US, V22, P4480, DOI 10.1021/bi00288a020; MAES M, 1994, BIOL PSYCHIAT, V35, P545, DOI 10.1016/0006-3223(94)90101-5; MASSEY V, 1966, J BIOL CHEM, V241, P2347; MENTLEIN R, 1988, FEBS LETT, V234, P251, DOI 10.1016/0014-5793(88)80092-9; MIURA N, 1995, NEUROSCI LETT, V196, P128, DOI 10.1016/0304-3940(95)11821-D; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; POLGAR L, 1999, LAB MANUAL PROTEOLYT, P148; Polgar Laszlo, 2002, Current Medicinal Chemistry - Central Nervous System Agents, V2, P251, DOI 10.2174/1568015023357860; Portevin B, 1996, J MED CHEM, V39, P2379, DOI 10.1021/jm950858c; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; Szeltner Z, 2002, J BIOL CHEM, V277, P42613, DOI 10.1074/jbc.M208043200; Szeltner Z, 2000, PROTEIN SCI, V9, P353; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELCHES WR, 1993, LIFE SCI, V52, P1461, DOI 10.1016/0024-3205(93)90108-F; WILK S, 1983, LIFE SCI, V33, P2149, DOI 10.1016/0024-3205(83)90285-0; Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734; YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730	39	34	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48786	48793		10.1074/jbc.M309555200	http://dx.doi.org/10.1074/jbc.M309555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514675	hybrid			2022-12-25	WOS:000186829000035
J	Zou, YL; Lim, S; Lee, K; Deng, XB; Friedman, E				Zou, YL; Lim, S; Lee, K; Deng, XB; Friedman, E			Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell migration and is negatively regulated by the Met adaptor Ran-binding protein M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; MAP KINASE; TRANSCRIPTIONAL ACTIVATOR; TYROSINE KINASE; INVASIVE GROWTH; COLON-CANCER; RECEPTOR; SPECIFICITY; EXPRESSION; DIFFERENTIATION	Minibrain-related kinase (Mirk)/Dyrk1B is an arginine-directed serine/threonine kinase that is active in skeletal muscle development but is also expressed in various carcinomas. In the current study, the Met adaptor protein Ran-binding protein M ( RanBPM) was identified as a Mirk-binding protein by yeast two-hybrid analysis. The Mirk-RanBPM association was confirmed by glutathione S-transferase pull-down assays, co-immunoprecipitation studies, and in vivo cross-linking. Met plays an important role in tumor cell invasion and cell migration. RanBPM has been reported to bind to the tyrosine kinase domain of the hepatocyte growth factor (HGF) receptor Met, enhance Met downstream signaling, and enhance HGF-induced A704 kidney carcinoma cell invasion (Wang, D., Li, Z., Messing, E. M., and Wu, G. (2002) J. Biol. Chem. 277, 36216 - 36222). We made a stable Mirk-inducible subline from nontransformed Mv1Lu lung epithelial cells and now demonstrate that induction of Mirk inhibited the migration of these cells in wounding experiments and inhibited their invasion through polycarbonate Transwell filters. Furthermore the ability of Mirk to inhibit Mv1Lu cell migration was attenuated when cells were exposed to HGF or to elevated levels of transiently expressed RanBPM. RanBPM inhibited the kinase activity of Mirk/Dyrk1B and Dyrk1A. In addition, RanBPM and HGF inhibited the function of Mirk as a transcriptional coactivator. Our findings suggest that Mirk plays a role in modulating cell migration through opposing the action of the Met signaling cascade adaptor protein RanBPM.	Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Friedman, E (corresponding author), Upstate Med Univ, Dept Pathol, 2303 Weiskotten Hall,750 E Adams St, Syracuse, NY 13210 USA.			Lim, Seunghwan/0000-0001-8920-0890	NATIONAL CANCER INSTITUTE [R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; Birchmeier C, 1997, CIBA F SYMP, V212, P169; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cabane C, 2003, AM J PHYSIOL-CELL PH, V284, pC658, DOI 10.1152/ajpcell.00078.2002; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; Halverson DO, 1999, CELL BIOL INT, V23, P257, DOI 10.1006/cbir.1999.0346; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jeffers M, 1996, ONCOGENE, V13, P853; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Leder S, 1999, BIOCHEM BIOPH RES CO, V254, P474, DOI 10.1006/bbrc.1998.9967; Lee K, 2000, CANCER RES, V60, P3631; Lim S, 2002, J BIOL CHEM, V277, P49438, DOI 10.1074/jbc.M206840200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lorenzato A, 2002, CANCER RES, V62, P7025; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Paciucci R, 1998, AM J PATHOL, V153, P201, DOI 10.1016/S0002-9440(10)65561-7; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Ponta H, 1998, INT J BIOCHEM CELL B, V30, P299, DOI 10.1016/S1357-2725(97)00152-0; Rao MA, 2002, J BIOL CHEM, V277, P48020, DOI 10.1074/jbc.M209741200; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SMITH DJ, 1997, NAT GENET, V16, P8; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang Y, 2002, BIOCHEM BIOPH RES CO, V297, P148, DOI 10.1016/S0006-291X(02)02020-X; Webb CP, 1998, ONCOGENE, V17, P2019, DOI 10.1038/sj.onc.1202135; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	48	58	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49573	49581		10.1074/jbc.M307556200	http://dx.doi.org/10.1074/jbc.M307556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500717	hybrid			2022-12-25	WOS:000186829000128
J	Noble, B; Kallal, LA; Pausch, MH; Benovic, JL				Noble, B; Kallal, LA; Pausch, MH; Benovic, JL			Development of a yeast bioassay to characterize G protein-coupled receptor kinases - Identification of an NH2-terminal region essential for receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SST2A SOMATOSTATIN RECEPTOR; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; SELECTIVE REGULATION; G-ALPHA; DESENSITIZATION; GRK5; EXPRESSION; TERMINUS; BINDING	G protein-coupled receptor kinases (GRKs) specifically bind and phosphorylate the agonist-occupied form of G protein-coupled receptors. To further characterize the mechanism of GRK/receptor interaction, we developed a yeast-based bioassay using strains engineered to functionally express the somatostatin receptor subtype 2 and exhibit agonist-dependent growth. Here, we demonstrate that agonist-promoted growth was effectively inhibited by co-expression with either wild type GRK2 or GRK5, whereas catalytically inactive forms of these kinases were without effect. In an effort to identify residues involved in receptor interaction, we generated a pool of GRK5 mutants and then utilized the bioassay to identify mutants selectively deficient in inhibiting agonist-promoted growth. This resulted in the identification of a large number of mutants, several of which were expressed, purified, and characterized in more detail. Two of the mutants, GRK5-L3Q/K113R and GRK5-T10P, were defective in receptor phosphorylation and also exhibited a partial defect in phospholipid binding and phospholipid-stimulated autophosphorylation of the kinase. In contrast, these mutants had wild type activity in phosphorylating the non-receptor substrate tubulin. To further characterize the function of the NH2-terminal region of GRK5, we generated a deletion mutant lacking residues 2 - 14 and found that this mutant was also severely impaired in receptor phosphorylation and phospholipid-promoted autophosphorylation. In addition, an NH2-terminal 14-amino acid peptide from GRK5 selectively inhibited receptor phosphorylation by GRK5 but had minimal effect on GRK2 activity. Based on these findings, we propose a model whereby the extreme NH2 terminus of GRK5 mediates phospholipid binding and is required for optimal receptor phosphorylation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Wyeth Neurosci Discovery Res, Princeton, NJ 08543 USA	Jefferson University; Pfizer	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; Dowell SJ, 2002, RECEPTOR CHANNEL, V8, P343, DOI 10.1080/10606820214647; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Iaccarino G, 1999, P ASSOC AM PHYSICIAN, V111, P399, DOI 10.1111/paa.1999.111.5.399; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Levay K, 1998, BIOCHEMISTRY-US, V37, P13650, DOI 10.1021/bi980998z; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sallese M, 2000, BBA-MOL CELL RES, V1498, P112, DOI 10.1016/S0167-4889(00)00088-4; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STJEAN A, 1991, NUCLEIC ACIDS RES, V20, P1425; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; Usui K, 2000, INT J MOL MED, V5, P335; Wittenberg C, 1996, CURR OPIN CELL BIOL, V8, P223, DOI 10.1016/S0955-0674(96)80069-X; Yu QM, 1999, J NEUROCHEM, V73, P1222, DOI 10.1046/j.1471-4159.1999.0731222.x	44	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47466	47476		10.1074/jbc.M308257200	http://dx.doi.org/10.1074/jbc.M308257200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14507916	hybrid			2022-12-25	WOS:000186731400017
J	Bellini, MH; Peroni, CN; Bartolini, P				Bellini, MH; Peroni, CN; Bartolini, P			Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes	FASEB JOURNAL			English	Article						gene therapy; retroviral vector; in vivo secretion; GH circulatory level	HUMAN EPIDERMAL-CELLS; GENE-THERAPY; STEM-CELLS; CULTURED EPITHELIUM; RETROVIRAL VECTORS; ESCHERICHIA-COLI; IN-VITRO; EXPRESSION; PROSPECTS; PROTEINS	Primary human keratinocytes, stably transduced with the human growth hormone (hGH) gene (under control of the retroviral LTR promoter) and selected via geneticin secreted as much as 7 mug hGH/10(6) cells/day. Their grafting onto immunodeficient dwarf mice (lit/scid) led to hGH levels in the circulation that did not go below 0.2-0.3 ng/ml during a 12 day period (peak value, 1.5 ng/ml at 4 h). This phenomenon was associated with a body weight increase of the grafted animals (0.060 g/animal/day) significantly higher (P<0.01) than that of controls (0.023 g/animal/day). This is the first report describing successful utilization of immunodeficient dwarf mice (lit/scid) in keratinocyte-based hGH gene therapy.	Univ Sao Paulo, IPEN CNEN, Dept Biotechnol, BR-05508900 Sao Paulo, Brazil	Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade de Sao Paulo	Bartolini, P (corresponding author), Univ Sao Paulo, IPEN CNEN, Dept Biotechnol, Ave Professor Lineu Prestes 2242,Cidade Univ, BR-05508900 Sao Paulo, Brazil.	pbartoli@ipen.br	Peroni, Cibele/D-5020-2012					BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; BELLINI MH, 1993, ENDOCRINOLOGY, V132, P2051, DOI 10.1210/en.132.5.2051; Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Deitel K, 2002, J SURG ONCOL, V81, P75, DOI 10.1002/jso.10136; DELUCA M, 1989, BURNS, V15, P303, DOI 10.1016/0305-4179(89)90007-7; DeLuca M, 1997, GENE THER, V4, P381, DOI 10.1038/sj.gt.3300434; FENJVES ES, 1994, HUM GENE THER, V5, P1241, DOI 10.1089/hum.1994.5.10-1241; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; He X, 1998, GENE THER, V5, P537, DOI 10.1038/sj.gt.3300622; JENSEN UB, 1994, J INVEST DERMATOL, V103, P391, DOI 10.1111/1523-1747.ep12395402; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; Krueger GG, 1999, P ASSOC AM PHYSICIAN, V111, P198, DOI 10.1046/j.1525-1381.1999.99225.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPKER JH, 1983, GENE, V24, P281, DOI 10.1016/0378-1119(83)90088-4; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGAN JR, 1987, SCIENCE, V237, P1476; OCONNOR NE, 1981, LANCET, V1, P75; PEETERS S, 1977, ENDOCRINOLOGY, V101, P1164, DOI 10.1210/endo-101-4-1164; Pellegrini G, 1998, MED BIOL ENG COMPUT, V36, P778, DOI 10.1007/BF02518885; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RIBELA MTCP, 1993, J IMMUNOL METHODS, V159, P269, DOI 10.1016/0022-1759(93)90166-5; Taichman LB, 1999, P ASSOC AM PHYSICIAN, V111, P206, DOI 10.1046/j.1525-1381.1999.99226.x; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219	31	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2322	+		10.1096/fj.03-0018fje	http://dx.doi.org/10.1096/fj.03-0018fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525947				2022-12-25	WOS:000186343300001
J	Berger, P; Girodet, PO; Begueret, H; Ousova, O; Perng, DW; Marthan, R; Walls, AF; de Lara, JMT				Berger, P; Girodet, PO; Begueret, H; Ousova, O; Perng, DW; Marthan, R; Walls, AF; de Lara, JMT			Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis	FASEB JOURNAL			English	Article						asthma; protease-activated receptor; transforming growth factor beta 1; stem cell factor	GROWTH-FACTOR-BETA; BRONCHOALVEOLAR LAVAGE FLUID; HUMAN-LUNG FIBROBLASTS; BRONCHIAL-ASTHMA; T-HELPER-2 CYTOKINES; ACTIVATED RECEPTOR-2; MESSENGER-RNA; EXPRESSION; RELEASE; CORTICOSTEROIDS	Asthmatic patients have higher numbers of mast cells in the smooth muscle layer of airways than normal subjects. Human airway smooth muscle cells (HASMCs) are a source of various cytokines including transforming growth factor beta1 (TGF-beta1), which is chemotactic for mast cells. We have thus examined the potential for interaction between HASMCs and mast cells and have investigated, in particular, the hypothesis that after stimulation, HASMCs can induce mast cell chemotaxis through the production of cytokines. Supernatants of HASMCs treated with the major mast cell product tryptase had increased chemotactic activity for the HMC-1 mast cell line. The effect depended on an intact catalytic site for tryptase and could be induced by a peptide agonist for protease activated receptor 2. Chemotactic activity was related to the synthesis of TGF-beta1 by HASMCs and, to a lesser extent, to stem cell factor. The number of mast cells within the smooth muscle layer of asthmatic patients was closely related to TGF-beta1 expression by smooth muscle. HASMCs may thus be able to stimulate the accumulation of mast cells, and these cells may, in turn, stimulate the secretion of chemotactic factors by HASMCs.	Univ Bordeaux 2, Lab Physiol Cellulaire Resp, INSERM, E0356, F-33076 Bordeaux, France; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England; CHU Bordeaux, Hop Haut Leveque, Serv Malad Resp, F-33604 Pessac, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Southampton; CHU Bordeaux	de Lara, JMT (corresponding author), Univ Bordeaux 2, Lab Physiol Cellulaire Resp, INSERM, E0356, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	manuel.tunondelara@u-bordeaux2.fr	Berger, Patrick/D-8779-2012	Berger, Patrick/0000-0003-4702-0343; Marthan, Roger/0000-0001-5412-5712; Walls, Andrew/0000-0003-4803-4595; Girodet, Pierre-Olivier/0000-0002-9298-9711				Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Berger P, 1999, EUR RESPIR J, V14, P1394, DOI 10.1183/09031936.99.14613949; Berger P, 2001, J APPL PHYSIOL, V91, P995, DOI 10.1152/jappl.2001.91.2.995; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROWN JK, 1995, CHEST, V107, pS95, DOI 10.1378/chest.107.3_Supplement.95S; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; Coutts A, 2001, AM J PHYSIOL-LUNG C, V280, pL999, DOI 10.1152/ajplung.2001.280.5.L999; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; He S, 1998, J PHARMACOL EXP THER, V286, P289; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kim YK, 1997, J ALLERGY CLIN IMMUN, V100, P389, DOI 10.1016/S0091-6749(97)70254-9; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; MATTOLI S, 1995, BIOCHEM BIOPH RES CO, V209, P316, DOI 10.1006/bbrc.1995.1505; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; NILSSON G, 1994, J IMMUNOL, V153, P3717; Olsson N, 2000, J LEUKOCYTE BIOL, V67, P350, DOI 10.1002/jlb.67.3.350; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	44	135	140	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2139	+		10.1096/fj.03-0041fje	http://dx.doi.org/10.1096/fj.03-0041fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500550				2022-12-25	WOS:000185925100012
J	Chaloupkova, R; Sykorova, J; Prokop, Z; Jesenska, A; Monincovaa, M; Pavlova, M; Tsuda, M; Nagata, Y; Damborsky, J				Chaloupkova, R; Sykorova, J; Prokop, Z; Jesenska, A; Monincovaa, M; Pavlova, M; Tsuda, M; Nagata, Y; Damborsky, J			Modification of activity and specificity of haloalkane dehalogenase from Sphingomonas paucimobilis UT26 by engineering of its entrance tunnel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXACHLOROCYCLOHEXANE-DEGRADING BACTERIUM; CATALYTIC MECHANISM; SUBSTRATE CLASS; ENZYMES; DESIGN; SITE; 1,2-DICHLOROETHANE; EXPRESSION; EVOLUTION; RANGE	Structural comparison of three different haloalkane dehalogenases suggested that substrate specificity of these bacterial enzymes could be significantly influenced by the size and shape of their entrance tunnels. The surface residue leucine 177 positioned at the tunnel opening of the haloalkane dehalogenase from Sphingomonas paucimobilis UT26 was selected for modification based on structural and phylogenetic analysis; the residue partially blocks the entrance tunnel, and it is the most variable pocket residue in haloalkane dehalogenase-like proteins with nine substitutions in 14 proteins. Mutant genes coding for proteins carrying all possible substitutions in position 177 were constructed by site-directed mutagenesis and heterologously expressed in Escherichia coli. In total, 15 active protein variants were obtained, suggesting a relatively high tolerance of the site for the introduction of mutations. Purified protein variants were kinetically characterized by determination of specific activities with 12 halogenated substrates and steady-state kinetic parameters with two substrates. The effect of mutation on the enzyme activities varied dramatically with the structure of the substrates, suggesting that extrapolation of one substrate to another may be misleading and that a systematic characterization of the protein variants with a number of substrates is essential. Multivariate analysis of activity data revealed that catalytic activity of mutant enzymes generally increased with the introduction of small and nonpolar amino acid in position 177. This result is consistent with the phylogenetic analysis showing that glycine and alanine are the most commonly occurring amino acids in this position among haloalkane dehalogenases. The study demonstrates the advantages of using rational engineering to develop enzymes with modified catalytic properties and substrate specificities. The strategy of using site-directed mutagenesis to modify a specific entrance tunnel residue identified by structural and phylogenetic analyses, rather than combinatorial screening, generated a high percentage of viable mutants.	Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 9808577, Japan; Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic	Tohoku University; Masaryk University Brno	Nagata, Y (corresponding author), Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 9808577, Japan.	aynaga@ige.tohoku.ac.jp; jiri@chemi.muni.cz	Fortova, Andrea/D-9397-2012; Damborsky, Jiri/H-3799-2012; Chaloupkova, Radka/M-5565-2016; Tsuda, Masataka/AAC-3657-2019; Prokop, Zbynek/H-5707-2012	Damborsky, Jiri/0000-0002-7848-8216; Chaloupkova, Radka/0000-0002-3539-7445; Tsuda, Masataka/0000-0002-5388-663X; Prokop, Zbynek/0000-0001-9358-4081				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arnold FH, 1998, NAT BIOTECHNOL, V16, P617, DOI 10.1038/nbt0798-617; Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Bohac M, 2002, BIOCHEMISTRY-US, V41, P14272, DOI 10.1021/bi026427v; Bosma T, 2002, APPL ENVIRON MICROB, V68, P3582, DOI 10.1128/AEM.68.7.3582-3587.2002; Capila I, 2002, BBA-PROTEIN STRUCT M, V1597, P260, DOI 10.1016/S0167-4838(02)00304-7; Damborsky J, 1997, J CHEM INF COMP SCI, V37, P562, DOI 10.1021/ci960483j; Damborsky J, 1999, PROTEIN ENG, V12, P989, DOI 10.1093/protein/12.11.989; Damborsky J, 1997, BIOTECHNOL APPL BIOC, V26, P19; Damborsky J, 2001, ENVIRON TOXICOL CHEM, V20, P2681, DOI 10.1002/etc.5620201205; Damborsky J, 1998, PROTEIN ENG, V11, P21, DOI 10.1093/protein/11.1.21; Devi-Kesavan LS, 2003, J AM CHEM SOC, V125, P1532, DOI 10.1021/ja026955u; Dravis BC, 2001, BIOTECHNOL BIOENG, V75, P416, DOI 10.1002/bit.10035; Dravis BC, 2000, BIOTECHNOL BIOENG, V69, P235, DOI 10.1002/1097-0290(20000805)69:3<235::AID-BIT1>3.0.CO;2-D; Gray KA, 2001, ADV SYNTH CATAL, V343, P607, DOI 10.1002/1615-4169(200108)343:6/7<607::AID-ADSC607>3.3.CO;2-D; Holloway P, 1998, BIOTECHNOL BIOENG, V59, P520, DOI 10.1002/(SICI)1097-0290(19980820)59:4<520::AID-BIT16>3.0.CO;2-D; Huang XY, 2000, BIOCHEMISTRY-US, V39, P3240, DOI 10.1021/bi9926173; Hynkova K, 1999, FEBS LETT, V446, P177, DOI 10.1016/S0014-5793(99)00199-4; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; Jesenska A, 2002, APPL ENVIRON MICROB, V68, P3724, DOI 10.1128/AEM.68.8.3724-3730.2002; Lau EY, 2000, P NATL ACAD SCI USA, V97, P9937, DOI 10.1073/pnas.97.18.9937; Lewandowicz A, 2001, J AM CHEM SOC, V123, P4550, DOI 10.1021/ja003503d; Lightstone FC, 1998, J AM CHEM SOC, V120, P5611, DOI 10.1021/ja980162j; Marek J, 2000, BIOCHEMISTRY-US, V39, P14082, DOI 10.1021/bi001539c; Marvanova S, 2001, J MICROBIOL METH, V44, P149, DOI 10.1016/S0167-7012(00)00250-5; Nagata Y, 1999, PROTEIN EXPRES PURIF, V17, P299, DOI 10.1006/prep.1999.1143; Nagata Y, 2003, APPL ENVIRON MICROB, V69, P2349, DOI 10.1128/AEM.69.4.2349-2355.2003; Nagata Y, 1999, J IND MICROBIOL BIOT, V23, P380, DOI 10.1038/sj.jim.2900736; Nagata Y, 1997, APPL ENVIRON MICROB, V63, P3707, DOI 10.1128/AEM.63.9.3707-3710.1997; Newman J, 1999, BIOCHEMISTRY-US, V38, P16105, DOI 10.1021/bi9913855; Oakley AJ, 2002, BIOCHEMISTRY-US, V41, P4847, DOI 10.1021/bi015734i; Otyepka M, 2002, PROTEIN SCI, V11, P1206, DOI 10.1110/ps.ps3830102; Pikkemaat MG, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.8.e35; Schanstra JP, 1997, PROTEIN ENG, V10, P53, DOI 10.1093/protein/10.1.53; Schanstra JP, 1996, BIOCHEMISTRY-US, V35, P13186, DOI 10.1021/bi961151a; Schindler JF, 1999, BIOCHEMISTRY-US, V38, P5772, DOI 10.1021/bi982853y; Schmitt J, 2002, PROTEIN ENG, V15, P595, DOI 10.1093/protein/15.7.595; Shurki A, 2002, J AM CHEM SOC, V124, P4097, DOI 10.1021/ja012230z; STUCKI G, 1995, ENVIRON SCI TECHNOL, V29, P2339, DOI 10.1021/es00009a028; Swanson PE, 1999, CURR OPIN BIOTECH, V10, P365, DOI 10.1016/S0958-1669(99)80066-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9	43	98	105	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	2003	278	52					52622	52628		10.1074/jbc.M306762200	http://dx.doi.org/10.1074/jbc.M306762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	756LX	14525993	hybrid			2022-12-25	WOS:000187480700080
J	Nagano, Y; Yamashita, H; Takahashi, T; Kishida, S; Nakamura, T; Iseki, E; Hattori, N; Mizuno, Y; Kikuchi, A; Matsumoto, M				Nagano, Y; Yamashita, H; Takahashi, T; Kishida, S; Nakamura, T; Iseki, E; Hattori, N; Mizuno, Y; Kikuchi, A; Matsumoto, M			Siah-1 facilitates ubiquitination and degradation of synphilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; PROTEIN LIGASE; BETA-CATENIN; LEWY BODIES; INTERACTING PROTEIN; MAMMALIAN HOMOLOGS; PROTEASOME PATHWAY; DROSOPHILA EYE; GENE-PRODUCT	Parkinson's disease is a common neurodegenerative disorder characterized by loss of dopaminergic neurons and appearance of Lewy bodies, cytoplasmic inclusions that are highly enriched with ubiquitin. Synphilin-1, alpha-synuclein, and Parkin represent the major components of Lewy bodies and are involved in the pathogenesis of Parkinson's disease. Synphilin-1 is an alpha-synuclein-binding protein that is ubiquitinated by Parkin. Recently, a mutation in the synphilin-1 gene has been reported in patients with sporadic Parkinson's disease. Although synphilin-1 localizes close to synaptic vesicles, its function remains unknown. To investigate the proteins that interact with synphilin-1, the present study performed a yeast two-hybrid screening and identified a novel interacting protein, Siah-1 ubiquitin ligase. Synphilin-1 and Siah-1 proteins were endogenously expressed in the central nervous system and were found to coimmunoprecipitate each other in rat brain homogenate. Confocal microscopic analysis revealed colocalization of both proteins in cells. Siah-1 was found to interact with the N terminus of synphilin-1 through its substrate-binding domain and to specifically ubiquitinate synphilin-1 via its RING finger domain. Siah-1 facilitated synphilin-1 degradation via the ubiquitin-proteasome pathway more efficiently than Parkin. Siah-1 was found to not facilitate ubiquitination and degradation of wild type or mutant alpha-synuclein. Synphilin-1 inhibited high K+-induced dopamine release from PC12 cells. Siah-1 was found to abrogate the inhibitory effects of synphilin-1 on dopamine release. Such findings suggest that Siah-1 might play a role in regulation of synphilin-1 function.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima 7348551, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Hiroshima 7348551, Japan; Yokohama City Univ, Dept Psychiat, Yokohama, Kanagawa 2360004, Japan; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1130033, Japan	Hiroshima University; Hiroshima University; Yokohama City University; Juntendo University	Yamashita, H (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hattori, Nobutaka/ACR-0069-2022	NAGANO, YOSHITO/0000-0002-7974-4824; kishida, shosei/0000-0003-0405-851X				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Galvin J E, 1999, Adv Neurol, V80, P313; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Holloway AJ, 1997, GENOMICS, V41, P160, DOI 10.1006/geno.1997.4642; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; ITO T, 2003, J BIOL CHEM; Kammermeier PJ, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-15; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Marx FP, 2003, HUM MOL GENET, V12, P1223, DOI 10.1093/hmg/ddg134; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nagano Y, 2001, NEUROSCI LETT, V316, P103, DOI 10.1016/S0304-3940(01)02330-8; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; Neufeld TP, 1998, GENETICS, V148, P277; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Ribeiro CS, 2002, J BIOL CHEM, V277, P23927, DOI 10.1074/jbc.M201115200; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Susini L, 2001, P NATL ACAD SCI USA, V98, P15067, DOI 10.1073/pnas.261571998; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Takahashi T, 1996, BRAIN RES BULL, V41, P363, DOI 10.1016/S0361-9230(96)00211-0; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	53	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51504	51514		10.1074/jbc.M306347200	http://dx.doi.org/10.1074/jbc.M306347200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14506261	hybrid			2022-12-25	WOS:000187206300081
J	Croci, C; Sticht, H; Brandstatter, JH; Enz, R				Croci, C; Sticht, H; Brandstatter, JH; Enz, R			Group I metabotropic glutamate receptors bind to protein phosphatase 1C-Mapping and modeling of interacting sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; CATALYTIC SUBUNIT; KINASE-C; IMMUNOHISTOCHEMICAL LOCALIZATION; RAT; PHOSPHORYLATION; EXPRESSION; MGLUR5; GLUTAMATE-RECEPTOR-7; DESENSITIZATION	The modulation of neurotransmitter receptors by kinases and phosphatases represents a key mechanism in controlling synaptic signal transduction. However, molecular determinants involved in the specific targeting and interactions of these enzymes are largely unknown. Here, we identified both catalytic gamma-isoforms of protein phosphatase 1C (PP1gamma1 and PP1gamma2) as binding partners of the group I metabotropic glutamate receptors type 1a, 5a, and 5b in yeast cells and pull-down assays, using recombinant and native protein preparations. The tissue distribution of interacting proteins was compared, and protein phosphatase 1C was detected in dendrites of retinal bipolar cells expressing the respective interacting glutamate receptors. We mapped interacting domains within binding partners and identified five amino acids in the intracellular C termini of the metabotropic glutamate receptors type 1a, 5a, 5b, and 7b being both necessary and sufficient to bind protein phosphatase 1C. Furthermore, we show a dose-dependent competition of these C termini in binding the enzyme. Based on our data, we investigated the structure of the identified amino acids bound to protein phosphatase 1C by homology-based molecular modeling. In summary, these results provide a molecular description of the interaction between protein phosphatase 1C and metabotropic glutamate receptors and thereby increase our understanding of glutamatergic signal transduction.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Max Planck Inst Hirnforsch, Abt Neuroanat, D-60528 Frankfurt, Germany	University of Erlangen Nuremberg; Max Planck Society	Enz, R (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	ralf.enz@biochem.unierlangen.de		Sticht, Heinrich/0000-0001-5644-045X				ABE T, 1992, J BIOL CHEM, V267, P13361; Airas JM, 2001, FEBS LETT, V494, P60, DOI 10.1016/S0014-5793(01)02311-0; Alagarsamy S, 2001, CURR OPIN NEUROBIOL, V11, P357, DOI 10.1016/S0959-4388(00)00219-1; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brandstatter JH, 1996, J NEUROSCI, V16, P4749; Ciruela F, 2001, J NEUROCHEM, V76, P750, DOI 10.1046/j.1471-4159.2001.00099.x; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Croci C, 2003, J BIOL CHEM, V278, P6128, DOI 10.1074/jbc.M205162200; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; Enz R, 2002, J NEUROCHEM, V81, P1130, DOI 10.1046/j.1471-4159.2002.00922.x; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; ENZ R, 2003, BIOCHEM J, V15, P183; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; Kinoshita A, 1998, J COMP NEUROL, V393, P332; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Koulen P, 1997, J NEUROSCI, V17, P2200; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lopez-Bendito G, 2002, CEREB CORTEX, V12, P625, DOI 10.1093/cercor/12.6.625; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NUSSER Z, 1994, NEUROSCIENCE, V61, P421, DOI 10.1016/0306-4522(94)90421-9; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; Petralia RS, 1997, J CHEM NEUROANAT, V13, P77, DOI 10.1016/S0891-0618(97)00023-9; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Saugstad JA, 2002, J NEUROCHEM, V80, P980, DOI 10.1046/j.0022-3042.2002.00778.x; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; Strack S, 1999, J COMP NEUROL, V413, P373; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TANABE Y, 1993, J NEUROSCI, V13, P1372; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Vardi N, 2000, J COMP NEUROL, V423, P402, DOI 10.1002/1096-9861(20000731)423:3<402::AID-CNE4>3.0.CO;2-E; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766	51	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50682	50690		10.1074/jbc.M305764200	http://dx.doi.org/10.1074/jbc.M305764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14519764	hybrid			2022-12-25	WOS:000187068200124
J	Ham, YM; Choi, JS; Chun, KH; Joo, SH; Lee, SK				Ham, YM; Choi, JS; Chun, KH; Joo, SH; Lee, SK			The c-jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PKC-DELTA; STRESS; JNK; P21(WAF1/CIP1); PATHWAY; GROWTH; INHIBITION; SURVIVAL; LACKING	We show here that JNK1 activity is rapidly up-regulated and prolonged by specific mechanisms during apoptosis induced by paclitaxel- or ginsenoside-Rh2 in SK-HEP-1 cells. The early phase of JNK1 activation is prevented in cells expressing the dominant negative SEK1 mutant, although this JNK1 perturbation does not prevent apoptotic cell death. The later phase of JNK1 activation, which is temporally coincided with caspase-dependent cleavage of JNK1-associated p21(WAF1/CIP1), is efficiently prevented by expressing p21D112N, an uncleavable mutant of p21(WAF1/CIP1) and this perturbation of JNK1 activation results in prevention of apoptosis. The later JNK1 activation and apoptotic progression are also prevented by co-treatments of cells with rottlerin, a PKC-delta inhibitor or z-VAD-fmk, a pan caspase inhibitor. We also provide evidence that apoptotic cell death is significantly promoted in cells expressing JNK1, while this apoptotic cell death is effectively suppressed in cells expressing the dominant negative JNK1 mutant (DN-JNK1) or JBD, a JNK inhibitor protein. Thus, the later phase of JNK1 activation, which is linked to a caspase-dependent mechanism that requires PKC-delta activity, is associated with the induction of apoptosis, while the early JNK1 activation that is associated with a SEK1-mediated mechanism is not directly involved in apoptotic progression.	Seoul Natl Univ, Coll Pharm, Div Pharmaceut Biosci, Pharmaceut Sci Res Inst, Seoul 151742, South Korea	Seoul National University (SNU)	Lee, SK (corresponding author), Seoul Natl Univ, Coll Pharm, Div Pharmaceut Biosci, Pharmaceut Sci Res Inst, San 56-1,Shillim Dong, Seoul 151742, South Korea.	sklcrs@plaza.snu.ac.kr						Barrett CM, 2002, MOL CANCER THER, V1, P469; Butterfield L, 1999, BIOCHEM J, V338, P681, DOI 10.1042/0264-6021:3380681; Cataldi A, 2002, J CELL BIOCHEM, V86, P553, DOI 10.1002/jcb.10251; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; Engedal N, 2002, ONCOGENE, V21, P1017, DOI 10.1038/sj.onc.1205167; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Mc Gee MM, 2002, J BIOL CHEM, V277, P18383, DOI 10.1074/jbc.M112058200; Mitsutake N, 2001, ONCOGENE, V20, P989, DOI 10.1038/sj.onc.1204179; Nishina H, 1998, J IMMUNOL, V161, P3416; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; Patel R, 1998, J CELL SCI, V111, P2247; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	34	35	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50330	50337		10.1074/jbc.M302997200	http://dx.doi.org/10.1074/jbc.M302997200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514687	hybrid			2022-12-25	WOS:000187068200082
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-BINDING SITE; STIMULATED ATPASE ACTIVITY; CYSTEINE-SCANNING MUTAGENESIS; HIV-1 PROTEASE INHIBITORS; DISULFIDE CROSS-LINKING; MULTIDRUG-RESISTANCE; TRANSMEMBRANE SEGMENTS; FUNCTIONAL CONSEQUENCES; COVALENT MODIFICATION; TRANSPORTER	The human multidrug resistance P-glycoprotein (P-gp, ABCB1) actively extrudes a broad range of potentially cytotoxic compounds out of the cell. Key steps in understanding the transport process are binding of drug substrates in the transmembrane domains, initiation of ATPase activity, and subsequent drug efflux. We used cysteine-scanning mutagenesis of the transmembrane segment residues and reaction with the thiol-reactive drug substrate analog of rhodamine, methanethiosulfonate-rhodamine (MTS-rhodamine), to test whether P-gp could be trapped in an activated state with high levels of ATPase activity. The presence of such an activated P-gp could be used to further investigate P-gp-drug substrate interactions. Single cysteine mutants (149) were treated with MTS-rhodamine, and ATPase activities were determined after removal of unreacted MTS-rhodamine. One mutant, F343C(TM6), showed a 5.8-fold increase in activity after reaction with MTS-rhodamine. Pre-treatment of mutant F343C with rhodamine B protected it from activation by MTS-rhodamine, indicating that residue Cys-343 contributes to the rhodamine-binding site. The ATPase activity of MTS-rhodamine-treated mutant F343C, however, was not stimulated further by colchicine or calcein-AM. By contrast, verapamil and Hoechst 33342 stimulated and inhibited, respectively, the ATPase activity of the MTS-rhodamine-treated mutant F343C. These results indicate that the MTS-rhodamine binding site overlaps that of colchicine and calcein-AM but not that of verapamil and Hoechst 33342 within the common drug-binding pocket.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Room 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; Garrigues A, 2002, MOL PHARMACOL, V62, P1288, DOI 10.1124/mol.62.6.1288; Golin J, 2003, J BIOL CHEM, V278, P5963, DOI 10.1074/jbc.M210908200; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Maki N, 2003, J BIOL CHEM, V278, P18132, DOI 10.1074/jbc.M210413200; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; Qu Q, 2002, BIOCHEMISTRY-US, V41, P4744, DOI 10.1021/bi0120897; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762	59	79	80	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50136	50141		10.1074/jbc.M310448200	http://dx.doi.org/10.1074/jbc.M310448200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14522974	hybrid			2022-12-25	WOS:000187068200058
J	Mouslim, C; Latifi, T; Groisman, EA				Mouslim, C; Latifi, T; Groisman, EA			Signal-dependent requirement for the co-activator protein RcsA in transcription of the RcsB-regulated ugd gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CAPSULAR POLYSACCHARIDE SYNTHESIS; COLANIC ACID; SALMONELLA-TYPHIMURIUM; 2-COMPONENT SYSTEM; MOLECULAR CHARACTERIZATION; SWARMING BEHAVIOR; ERWINIA-AMYLOVORA; PROMOTER REGION; IDENTIFICATION	The RcsC/ YojN/ RcsB phosphorelay system controls gene expression in response to a variety of signals, including changes in temperature, osmolarity, and overproduction of membrane proteins. Transcription of certain RcsB- activated genes, such as the capsule synthesis cps operon, requires the co- activator protein RcsA, whereas expression of other RcsB- activated genes is RcsA- independent. We have established previously that a tolB mutation induces transcription of the Salmonella UDP- glucose dehydrogenase ugd gene in an RcsA- and RcsB- dependent manner. This induction is independent of the two- component systems PhoP/ PhoQ and PmrA/ PmrB, which are required for ugd expression in response to low Mg2+. We now report that the RcsC/ YojN/ RcsB system is activated in a pmrA mutant experiencing Fe3+ and low Mg2+, resulting in expression of both cps and ugd genes. However, whereas cps transcription remained RcsA- dependent, ugd transcription became RcsA- independent but dependent on the PhoP protein. S1 mapping experiments demonstrated that RcsA- dependent and - independent transcription of the ugd gene use the same promoter. DNase footprinting analysis identified a PhoP- binding site in the ugd promoter. Yet, PhoP- mediated ugd transcription required either the RcsC/ YojN/ RcsB or the PmrA/ PmrB systems.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	Groisman, EA (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, Campus Box 8230,660 S Euclid, St Louis, MO 63110 USA.	groisman@borcim.wustl.edu			NIAID NIH HHS [AI42336, AI49561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguirre A, 2000, J BACTERIOL, V182, P3874, DOI 10.1128/JB.182.13.3874-3876.2000; Belas R, 1998, J BACTERIOL, V180, P6126; Bernadac A, 1998, J BACTERIOL, V180, P4872, DOI 10.1128/JB.180.18.4872-4878.1998; Cano DA, 2002, GENETICS, V162, P1513; Carballes F, 1999, MOL MICROBIOL, V34, P442, DOI 10.1046/j.1365-2958.1999.01605.x; Chamnongpol S, 2002, MOL MICROBIOL, V45, P711, DOI 10.1046/j.1365-2958.2002.03041.x; Chen MH, 2001, BIOSCI BIOTECH BIOCH, V65, P2364, DOI 10.1271/bbb.65.2364; Clarke DJ, 1997, MOL MICROBIOL, V25, P933, DOI 10.1111/j.1365-2958.1997.mmi528.x; Costa CS, 2001, FEMS MICROBIOL LETT, V200, P201, DOI 10.1111/j.1574-6968.2001.tb10716.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davalos-Garcia M, 2001, J BACTERIOL, V183, P5870, DOI 10.1128/JB.183.20.5870-5876.2001; Davis R., 1980, ADV BACTERIAL GENETI; Ebel W, 1999, J BACTERIOL, V181, P577, DOI 10.1128/JB.181.2.577-584.1999; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FOGNINILEFEBVRE N, 1987, MOL GEN GENET, V209, P391, DOI 10.1007/BF00329670; Francez-Charlot A, 2003, MOL MICROBIOL, V49, P823, DOI 10.1046/j.1365-2958.2003.03601.x; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; GOTTESMAN S, 1985, J BACTERIOL, V162, P1111, DOI 10.1128/JB.162.3.1111-1119.1985; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; GOTTESMAN S, 1995, 2 COMPONENT SIGNAL T, P253; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; Kox LFF, 2000, EMBO J, V19, P1861, DOI 10.1093/emboj/19.8.1861; MACIAN F, 1994, GENE, V145, P17, DOI 10.1016/0378-1119(94)90317-4; Majdalani N, 2002, MOL MICROBIOL, V46, P813, DOI 10.1046/j.1365-2958.2002.03203.x; Minagawa S, 2003, J BACTERIOL, V185, P3696, DOI 10.1128/JB.185.13.3696-3702.2003; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; Pristovsek P, 2003, J BIOL CHEM, V278, P17752, DOI 10.1074/jbc.M301328200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; Stout V, 1996, J BACTERIOL, V178, P4273, DOI 10.1128/jb.178.14.4273-4280.1996; STOUT V, 1994, RES MICROBIOL, V145, P389, DOI 10.1016/0923-2508(94)90086-8; Sturny R, 2003, J BACTERIOL, V185, P4298, DOI 10.1128/JB.185.15.4298-4304.2003; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Virlogeux I, 1996, J BACTERIOL, V178, P1691, DOI 10.1128/jb.178.6.1691-1698.1996; Wehland M, 1999, J BIOL CHEM, V274, P3300, DOI 10.1074/jbc.274.6.3300; Wehland M, 2000, J BIOL CHEM, V275, P7013, DOI 10.1074/jbc.275.10.7013; Wosten MMSM, 2000, CELL, V103, P113, DOI 10.1016/S0092-8674(00)00092-1; Wosten MMSM, 1999, J BIOL CHEM, V274, P27185, DOI 10.1074/jbc.274.38.27185; ZUBER M, 1995, J BACTERIOL, V177, P4238, DOI 10.1128/jb.177.15.4238-4244.1995	45	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50588	50595		10.1074/jbc.M309433200	http://dx.doi.org/10.1074/jbc.M309433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14514676	hybrid			2022-12-25	WOS:000187068200113
J	Sengle, G; Kobbe, B; Morgelin, M; Paulsson, M; Wagener, R				Sengle, G; Kobbe, B; Morgelin, M; Paulsson, M; Wagener, R			Identification and characterization of AMACO, a new member of the von Willebrand factor A-like domain protein superfamily with a regulated expression in the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MATRIX PROTEIN; COLLAGEN-VI; I-DOMAIN; HUMAN-COMPLEMENT; GENE STRUCTURES; BINDING; PREDICTION; CLEAVAGE; ADHESION	The genes coding for human and mouse AMACO, an extracellular matrix protein containing VWA-like domains related to those in MAtrilins and COllagens, were detected in databases, the cDNAs were cloned, and the primary structures were deduced from the nucleotide sequences. The genes consist of 14 exons and have a similar exon/intron organization. The protein consists of a signal peptide sequence, an N-terminal VWA domain connected to two additional, tandem VWA domains by a cysteine-rich sequence and an epidermal growth factor (EGF)-like domain. The C terminus is made up of another EGF-like domain followed by a unique sequence present in mouse, but absent in human. The predicted molecular weight of the proteins is 79,485 in human and 83,024 in mouse. Full-length AMACO was expressed in 293-EBNA cells, purified by use of an affinity tag and subjected to biochemical characterization. Both monomers and aggregates of AMACO were recovered, as shown by electron microscopy and SDS-PAGE. AMACO was found in the media of a variety of established cell lines of both fibroblast and epithelial origin. In the matrix formed by 293-EBNA cells overexpressing the protein, AMACO was deposited in patchy structures that were often cell-associated. Affinity-purified antibodies detect expression in cartilage and expression associated with certain basement membranes. In the kidney of adult mice, a second promoter located in intron 4 is active. If the resulting transcript is translated it could not yield a secreted protein because of the lack of a signal peptide sequence. The developmental switch from an AMACO mRNA, expressed by the newborn kidney, to the truncated transcript found in the adult kidney indicates an unusual regulation of AMACO expression.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Lund Univ, BMC, Dept Cell & Mol Biol, S-22184 Lund, Sweden	University of Cologne; Lund University	Wagener, R (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de						Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cruz MA, 2000, J BIOL CHEM, V275, P19098, DOI 10.1074/jbc.M002292200; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; DEBLOCK M, 1993, ANAL BIOCHEM, V215, P86, DOI 10.1006/abio.1993.1558; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Smyth N, 2000, METH MOL B, V139, P49; Storz G, 2002, SCIENCE, V296, P1260, DOI 10.1126/science.1072249; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; Williams SC, 1999, BIOCHEM J, V342, P625, DOI 10.1042/0264-6021:3420625; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701	33	19	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50240	50249		10.1074/jbc.M307794200	http://dx.doi.org/10.1074/jbc.M307794200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14506275	hybrid			2022-12-25	WOS:000187068200072
J	Martins, LM; Turk, BE; Cowling, V; Borg, A; Jarrell, ET; Cantley, LC; Downward, J				Martins, LM; Turk, BE; Cowling, V; Borg, A; Jarrell, ET; Cantley, LC; Downward, J			Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS PROTEINS; CASPASE ACTIVITY; IAP PROTEINS; INHIBITOR; OMI/HTRA2; XIAP; IDENTIFICATION; MITOCHONDRIA; EXPRESSION; CHAPERONE	Inhibitor of apoptosis proteins (IAPs) prevent apoptosis through direct inhibition of caspases. The serine protease HtrA2/Omi has an amino-terminal IAP interaction motif like that found in Reaper, which displaces IAPs from caspases, leading to enhanced caspase activity. The cell death-promoting properties of HtrA2/Omi are not only exerted through its capacity to oppose IAP inhibition of caspases but also through its integral serine protease activity. We have used peptide libraries to determine the optimal substrate sequence for cleavage by HtrA2 and also the preferred binding sequence for its PDZ domain. Using these peptides, we show that the PDZ domain of HtrA2/Omi suppresses the proteolytic activity unless it is engaged by a binding partner. Subjecting HtrA2/Omi to heat shock treatment also increases its protease activity. Unexpectedly, binding of X-linked inhibitor of apoptosis protein ( XIAP) to the Reaper motif of HtrA2/Omi results in a marked increase in proteolytic activity, suggesting a new role for IAPs. When HtrA2/Omi is released from mitochondria following an apoptotic stimulus, binding to IAPs may switch their function from caspase inhibition to serine protease activation. Thus although IAP overexpression can suppress caspase activation, it could have the opposite effect on HtrA2/Omi-dependent cell death. This, together with the ability of HtrA2/Omi to degrade IAPs, may limit the overall cellular protection that can be provided by these proteins.	Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Canc Res UK London Res Inst, Prot Isolat & Cloning Lab, London WC2A 3PX, England; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Dept Cell Biol, Boston, MA 02215 USA	Cancer Research UK; Cancer Research UK; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012; Martins, Miguel/AAH-3971-2019; Cantley, Lewis C/D-1800-2014	Martins, Miguel/0000-0002-3019-4809; Cantley, Lewis C/0000-0002-1298-7653; Downward, Julian/0000-0002-2331-4729; Cowling, Victoria/0000-0001-7638-4870	NIGMS NIH HHS [GM56203, R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verhagen AM, 2001, GENOME BIOL, V2; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	21	106	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49417	49427		10.1074/jbc.M308659200	http://dx.doi.org/10.1074/jbc.M308659200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512424	hybrid			2022-12-25	WOS:000186829000110
J	Miao, M; Bellingham, CM; Stahl, RJ; Sitarz, EE; Lane, CJ; Keeley, FW				Miao, M; Bellingham, CM; Stahl, RJ; Sitarz, EE; Lane, CJ; Keeley, FW			Sequence and structure determinants for the self-aggregation of recombinant polypeptides modeled after human elastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-FIBRIL; HUMAN TROPOELASTIN; SECONDARY STRUCTURE; BINDING PROTEIN; MOLECULAR-BASIS; FIBER FORMATION; ALPHA-ELASTIN; COACERVATION; TRANSITIONS; DOMAINS	Elastin is a polymeric structural protein that imparts the physical properties of extensibility and elastic recoil to tissues. The mechanism of assembly of the tropoelastin monomer into the elastin polymer probably involves extrinsic protein factors but is also related to an intrinsic capacity of elastin for ordered assembly through a process of hydrophobic self-aggregation or coacervation. Using a series of simple recombinant polypeptides based on elastin sequences and mimicking the unusual alternating domain structure of native elastin, we have investigated the influence of sequence motifs and domain structures on the propensity of these polypeptides for coacervation. The number of hydrophobic domains, their context in the alternating domain structure of elastin, and the specific nature of the hydrophobic domains included in the polypeptides all had major effects on self-aggregation. Surprisingly, in polypeptides with the same number of domains, propensity for coacervation was inversely related to the mean Kyte-Doolittle hydropathy of the polypeptide. Point mutations designed to increase the conformational flexibility of hydrophobic domains had the unexpected effect of suppressing coacervation and promoting formation of amyloid-like fibers. Such simple polypeptides provide a useful model system for understanding the relationship between sequence, structure, and mechanism of assembly of polymeric elastin.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Keeley, FW (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	fwk@sickkids.on.ca						Bellingham CM, 2001, BBA-PROTEIN STRUCT M, V1550, P6, DOI 10.1016/S0167-4838(01)00262-X; BELLINGHAM CM, 2003, IN PRESS BIOPOLYMERS; Bochicchio B, 2002, CHIRALITY, V14, P782, DOI 10.1002/chir.10153; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; Debelle L, 1998, EUR J BIOCHEM, V258, P533, DOI 10.1046/j.1432-1327.1998.2580533.x; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; JAMIESON AM, 1972, BIOCHIM BIOPHYS ACTA, V271, P34, DOI 10.1016/0005-2795(72)90130-4; JEFFREY GA, 1991, HYDROGEN BONDING BIO, P479; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; Keeley FW, 2002, PHILOS T R SOC B, V357, P185, DOI 10.1098/rstb.2001.1027; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kozel BA, 2003, J BIOL CHEM, V278, P18491, DOI 10.1074/jbc.M212715200; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee TAT, 2000, ADV MATER, V12, P1105, DOI 10.1002/1521-4095(200008)12:15<1105::AID-ADMA1105>3.0.CO;2-1; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li B, 2001, J AM CHEM SOC, V123, P11991, DOI 10.1021/ja010363e; Li B, 2002, J MUSCLE RES CELL M, V23, P561, DOI 10.1023/A:1023474909980; Li B, 2001, J MOL BIOL, V305, P581, DOI 10.1006/jmbi.2000.4306; McMillan RA, 2000, MACROMOLECULES, V33, P4809, DOI 10.1021/ma9921091; MORELLI MAC, 1993, J BIOMOL STRUCT DYN, V11, P181; Muiznieks LD, 2003, ARCH BIOCHEM BIOPHYS, V410, P317, DOI 10.1016/S0003-9861(02)00719-1; PARTRIDGE SM, 1955, BIOCHEM J, V61, P11, DOI 10.1042/bj0610011; PODRAZKY V, 1976, COLLECT CZECH CHEM C, V41, P2296, DOI 10.1135/cccc19762296; Raucher D, 2001, CANCER RES, V61, P7163; Reiersen H, 1998, J MOL BIOL, V283, P255, DOI 10.1006/jmbi.1998.2067; ROBSON P, 1993, J BIOL CHEM, V268, P1440; Ross R, 1977, Adv Exp Med Biol, V79, P7; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; TAMBURRO AM, 1977, BIOCHIM BIOPHYS ACTA, V492, P370, DOI 10.1016/0005-2795(77)90088-5; Toonkool P, 2001, J BIOL CHEM, V276, P44575, DOI 10.1074/jbc.M107920200; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Tycko R, 2000, CURR OPIN CHEM BIOL, V4, P500, DOI 10.1016/S1367-5931(00)00123-X; Urry D W, 1977, Adv Exp Med Biol, V79, P685; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1992, BIOPOLYMERS, V32, P1243, DOI 10.1002/bip.360320913; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; URRY DW, 1974, BIOCHIM BIOPHYS ACTA, V371, P597, DOI 10.1016/0005-2795(74)90057-9; Urry DW, 1998, J BIOMAT SCI-POLYM E, V9, P1015, DOI 10.1163/156856298X00316; URRY DW, 1983, POLYM BIOMATERIALS, P17; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wright ER, 2002, ADV FUNCT MATER, V12, P149, DOI 10.1002/1616-3028(20020201)12:2<149::AID-ADFM149>3.0.CO;2-N; Wu WJ, 1999, EUR J BIOCHEM, V266, P308, DOI 10.1046/j.1432-1327.1999.00891.x; Yaminsky VV, 2001, CURR OPIN COLLOID IN, V6, P342, DOI 10.1016/S1359-0294(01)00104-2; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x	53	133	138	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48553	48562		10.1074/jbc.M308465200	http://dx.doi.org/10.1074/jbc.M308465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14500713	hybrid			2022-12-25	WOS:000186829000007
J	Sorlie, M; Gorren, ACF; Marchal, S; Shimizu, T; Lange, R; Andersson, KK; Mayer, B				Sorlie, M; Gorren, ACF; Marchal, S; Shimizu, T; Lange, R; Andersson, KK; Mayer, B			Single-turnover of nitric-oxide synthase in the presence of 4-amino-tetrahydrobiopterin - Proposed role for tetrahydrobiopterin as a proton donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-TEMPERATURE; HEME DOMAIN; ELECTRON-TRANSFER; RESONANCE RAMAN; INSECT CELLS; REDOX ROLE; OXYGEN; EPR; COMPLEXES; BINDING	Tetrahydrobiopterin (BH4) is an essential cofactor of nitric-oxide synthase (NOS) that serves as a one-electron donor to the oxyferrous . heme complex. 4-Aminotetrahydrobiopterin (4-amino-BH4) is a potent inhibitor of NO synthesis, although it mimics all allosteric and structural effects of BH4 and exhibits comparable redox properties. We studied the reaction of reduced endothelial NOS oxygenase domain with O-2 in the presence of 4-amino-BH4 at - 30 degreesC by optical and electron paramagnetic resonance (EPR) spectroscopy. With Arg as the substrate, we observed a trihydropteridine radical with a corresponding heme species that was oxyferrous, with a Soret maximum at 428 nm and no EPR signal. With N-G-hydroxy-L-arginine (NHA) no pterin radical appeared, whereas an axial ferrous heme . NO complex was formed. The corresponding optical spectra, with Soret bands at 417/423 nm, suggest that the proximal sulfur ligand is protonated. Accordingly, 4-amino-BH4 serves as a one-electron donor to Fe(II) . O-2 with both Arg and NHA, but the reaction cycle cannot be completed with either substrate. We propose that protonation of Fe( II) O-2(-) is inhibited in the presence of 4-amino-BH4. With Arg, dissociation of O-2(-) and binding of O-2 yields Fe(II) . O-2 and a pteridine radical; with NHA, reaction of the substrate with heme-bound O-2(-) eventually yields Fe(II) . NO and reduced 4-amino-BH4. These results suggest that BH4 donates a proton to Fe(II) . O-2(-) during catalysis and that inhibition by 4-amino-BH4 may be due to its inability to support this essential protonation step.	Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, A-8010 Graz, Austria; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; CNRS, IFR122, INSERM, U128, F-34293 Montpellier 5, France; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	University of Graz; Norwegian University of Life Sciences; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Tohoku University; University of Oslo	Gorren, ACF (corresponding author), Karl Franzens Univ Graz, Inst Pharmakol & Toxikol, Univ Pl 2, A-8010 Graz, Austria.	antonius.gorren@uni-graz.at	Mayer, Bernd/B-9391-2008; Andersson, K Kristoffer/F-9624-2010; MARCHAL, stéphane/M-4324-2017	MARCHAL, stéphane/0000-0002-1101-7890; Gorren, Antonius Cornelis Franciscus/0000-0003-3476-6162; Mayer, Bernd/0000-0002-2921-3494				Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Du M, 2003, J BIOL CHEM, V278, P6002, DOI 10.1074/jbc.M209606200; Galli C, 1996, J MAGN RESON SER B, V110, P284, DOI 10.1006/jmrb.1996.0044; Gorren ACF, 2000, BIOCHEM J, V347, P475, DOI 10.1042/0264-6021:3470475; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Gorren ACF, 1998, BIOCHEM J, V331, P801, DOI 10.1042/bj3310801; Gorren ACF, 2002, METHOD ENZYMOL, V353, P114; Gorren ACF, 2002, CURR DRUG METAB, V3, P133, DOI 10.2174/1389200024605154; Gorren ACF, 2001, NITRIC OXIDE-BIOL CH, V5, P176, DOI 10.1006/niox.2001.0332; Harris D, 1998, J AM CHEM SOC, V120, P4308, DOI 10.1021/ja974110q; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2002, BIOCHEMISTRY-US, V41, P3439, DOI 10.1021/bi012002h; Leber A, 1999, J BIOL CHEM, V274, P37658, DOI 10.1074/jbc.274.53.37658; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; Moali C, 2001, CHEM RES TOXICOL, V14, P202, DOI 10.1021/tx0001068; MORSE RH, 1980, J BIOL CHEM, V255, P7876; Newcomb M, 2003, ARCH BIOCHEM BIOPHYS, V409, P72, DOI 10.1016/S0003-9861(02)00445-9; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; Patel KB, 2002, FREE RADICAL BIO MED, V32, P203, DOI 10.1016/S0891-5849(01)00777-8; Perera R, 2003, P NATL ACAD SCI USA, V100, P3641, DOI 10.1073/pnas.0737142100; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; SCHOLLER DM, 1979, J BIOL CHEM, V254, P4072; Sjodin T, 2001, BIOCHEMISTRY-US, V40, P6852, DOI 10.1021/bi002510b; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Voegtle HL, 2003, BIOCHEMISTRY-US, V42, P2475, DOI 10.1021/bi0271502; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wei CC, 2003, BIOCHEMISTRY-US, V42, P1969, DOI 10.1021/bi026898h; Wei CC, 2002, J INORG BIOCHEM, V91, P618, DOI 10.1016/S0162-0134(02)00432-4; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531	54	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48602	48610		10.1074/jbc.M305682200	http://dx.doi.org/10.1074/jbc.M305682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14514694	hybrid			2022-12-25	WOS:000186829000012
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; SIGNAL-TRANSDUCTION PATHWAYS; FOCAL ADHESION KINASE; SRC FAMILY KINASES; C-SRC; EGF RECEPTOR; MITOGENIC RESPONSIVENESS; MEDIATED ADHESION; EPITHELIAL-CELLS; REGULATORY ROLE	The epidermal growth factor receptor ( EGFR) can be activated by both direct ligand binding and cross-talk with other molecules, such as integrins. This integrin-mediated cross-talk with growth factor receptors participates in regulating cell proliferation, survival, migration, and invasion. Previous studies have shown that ligand-dependent EGFR activation is inhibited by GM3, the predominant ganglioside of epithelial cells, but the effect of GM3 on ligand-independent, integrin-EGFR cross-talk is unknown. Using a squamous carcinoma cell line we show that endogenous accumulation of GM3 disrupts the ligand-independent association of the integrin beta(1) subunit with EGFR and results in inhibition of cell proliferation. Consistently, endogenous depletion of GM3 markedly increases the association of EGFR with tyrosine-phosphorylated integrin beta(1) and promotes cell proliferation. The ligand-independent stimulation of EGFR does not require focal adhesion kinase phosphorylation or cytoskeletal rearrangement. Stimulation of EGFR and mitogen-activated protein kinase signaling by GM3 depletion involves the phosphorylation of EGFR at tyrosine residues 845, 1068, and 1148 but not 1086 or 1173. The specific blockade of phosphorylation at Tyr-845 with Src family kinase inhibition and at Tyr-1148 with phosphatidylinositol 3-kinase inhibition suggests that GM3 inhibits integrin-induced, ligand-independent EGFR phosphorylation (cross-talk) through suppression of Src family kinase and phosphatidylinositol 3-kinase signaling.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol 107, 2300 Childrens Plaza, Chicago, IL 60614 USA.			Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; Kassis J, 2002, INT J CANCER, V99, P644, DOI 10.1002/ijc.10382; Kawakami Y, 2002, J BIOL CHEM, V277, P34349, DOI 10.1074/jbc.M200771200; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SASAKI H, 1995, P NATL ACAD SCI USA, V92, P2026, DOI 10.1073/pnas.92.6.2026; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Satoh M, 2001, INT J ONCOL, V19, P723; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SONG WX, 1991, J BIOL CHEM, V266, P10174; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Sung CC, 1998, EXP CELL RES, V239, P311, DOI 10.1006/excr.1997.3897; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wang XQ, 2003, J BIOL CHEM, V278, P25591, DOI 10.1074/jbc.M302211200; Wang XQ, 2002, J BIOL CHEM, V277, P47028, DOI 10.1074/jbc.M208257200; Wang XQ, 2002, J BIOL CHEM, V277, P40410, DOI 10.1074/jbc.M207117200; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Wang YL, 1999, METHOD ENZYMOL, V306, P281; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yu X, 2000, J CELL SCI, V113, P2139; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	68	68	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48770	48778		10.1074/jbc.M308818200	http://dx.doi.org/10.1074/jbc.M308818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14512423	hybrid			2022-12-25	WOS:000186829000033
J	Jia, YZ; Qi, C; Zhang, ZY; Hashimoto, T; Rao, MS; Huyghe, S; Suzuki, Y; Van Veldhoven, PP; Baes, M; Reddy, JK				Jia, YZ; Qi, C; Zhang, ZY; Hashimoto, T; Rao, MS; Huyghe, S; Suzuki, Y; Van Veldhoven, PP; Baes, M; Reddy, JK			Overexpression of peroxisome proliferator-activated receptor-alpha (PPAR alpha)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-oxidation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME PEX5 KNOCKOUT; FATTY ACYL-COENZYME; PPAR-ALPHA; NEURONAL MIGRATION; MOUSE-LIVER; ACID; OXIDASE; IDENTIFICATION; EXPRESSION; INDUCTION	Peroxisomal beta-oxidation system consists of peroxisome proliferator-activated receptor alpha (PPARalpha)-inducible pathway capable of catalyzing straight-chain acylCoAs and a second noninducible pathway catalyzing the oxidation of 2-methyl-branched fatty acyl-CoAs. Disruption of the inducible beta-oxidation pathway in mice at the level of fatty acyl-CoA oxidase (AOX), the first and rate-limiting enzyme, results in spontaneous peroxisome proliferation and sustained activation of PPARalpha, leading to the development of liver tumors, whereas disruptions at the level of the second enzyme of this classical pathway or of the noninducible system had no such discernible effects. We now show that mice with complete inactivation of peroxisomal beta-oxidation at the level of the second enzyme, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE) of the inducible pathway and D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacylCoA dehydrogenase (D-PBE) of the noninducible pathway (L-PBE-/- D-PBE-/-), exhibit severe growth retardation and postnatal mortality with none surviving beyond weaning. L-PBE-/- D-PBE-/- mice that survived exceptionally beyond the age of 3 weeks exhibited overexpression of PPARalpha-regulated genes in liver, despite the absence of morphological evidence of hepatic peroxisome proliferation. These studies establish that peroxisome proliferation in rodent liver is highly correlatable with the induction mostly of the L- and D-PBE genes. We conclude that disruption of peroxisomal fatty acid beta-oxidation at the level of second enzyme in mice leads to the induction of many of the PPARalpha target genes independently of peroxisome proliferation in hepatocytes, raising the possibility that intermediate metabolites of very long-chain fatty acids and peroxisomal beta-oxidation act as ligands for PPARalpha.	Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; Katholieke Univ Leuven, Fac Pharmaceut Sci, Clin Chem Lab, B-3000 Louvain, Belgium; Gifu Univ, Sch Med, Dept Pediat, Gifu 500, Japan	Northwestern University; Feinberg School of Medicine; KU Leuven; Gifu University	Reddy, JK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu	, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564; Baes, Myriam/0000-0002-2525-2269	NATIONAL CANCER INSTITUTE [R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84472] Funding Source: Medline; NIGMS NIH HHS [GM 23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Baes M, 2000, J BIOL CHEM, V275, P16329, DOI 10.1074/jbc.M001994200; Baes M, 2002, J NEUROPATH EXP NEUR, V61, P368, DOI 10.1093/jnen/61.4.368; Baumgart E, 2001, AM J PATHOL, V159, P1477, DOI 10.1016/S0002-9440(10)62534-5; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Cherkaoui-Malki M, 2001, GENE EXPRESSION, V9, P291, DOI 10.3727/000000001783992533; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHU RY, 1995, J BIOL CHEM, V270, P29636; CHU RY, 1995, J BIOL CHEM, V270, P4908, DOI 10.1074/jbc.270.9.4908; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Dadras SS, 2001, GENE EXPRESSION, V9, P173, DOI 10.3727/000000001783992579; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elcombe CR, 1996, ANN NY ACAD SCI, V804, P628, DOI 10.1111/j.1749-6632.1996.tb18649.x; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Fan LQ, 1998, J ENDOCRINOL, V158, P237, DOI 10.1677/joe.0.1580237; Ferdinandusse S, 2000, J LIPID RES, V41, P336; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Johnson EF, 1996, FASEB J, V10, P1241, DOI 10.1096/fasebj.10.11.8836037; Karlsson M, 1997, J BIOL CHEM, V272, P27218, DOI 10.1074/jbc.272.43.27218; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Li XL, 2002, MOL CELL BIOL, V22, P4358, DOI 10.1128/MCB.22.12.4358-4365.2002; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Lopez D, 2003, MOL CELL ENDOCRINOL, V205, P169, DOI 10.1016/S0303-7207(02)00300-3; Meyer K, 2003, CARCINOGENESIS, V24, P975, DOI 10.1093/carcin/bgg040; PANOZZO J, 1991, CARCINOGENESIS, V12, P801, DOI 10.1093/carcin/12.5.801; Qi C, 1999, J BIOL CHEM, V274, P15775, DOI 10.1074/jbc.274.22.15775; Rao MS, 1996, ANN NY ACAD SCI, V804, P573, DOI 10.1111/j.1749-6632.1996.tb18646.x; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1977, BIOCHEM BIOPH RES CO, V77, P824, DOI 10.1016/S0006-291X(77)80052-1; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Takemoto Y, 2003, BRAIN DEV-JPN, V25, P481, DOI 10.1016/S0387-7604(03)00033-0; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; Yu ST, 2001, J BIOL CHEM, V276, P42485, DOI 10.1074/jbc.M106480200; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	56	40	45	1	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47232	47239		10.1074/jbc.M306363200	http://dx.doi.org/10.1074/jbc.M306363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	14500732	hybrid			2022-12-25	WOS:000186569400123
J	Jian, H; Zhao, LJ				Jian, H; Zhao, LJ			Pro-apoptotic activity of HIV-1 auxiliary regulatory protein Vpr is subtype-dependent and potently enhanced by nonconservative changes of the leucine residue at position 64	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CXCR4; CASPASE ACTIVATION; SIGNALING PATHWAYS; LYMPH-NODES; T-CELLS; INDUCTION; DEATH; NEF; MECHANISM	Destruction of CD4(+) T cells, the hallmark of AIDS, is caused in part by HIV-1-induced apoptosis of both infected cells and noninfected "bystander" cells. The HIV-1 auxiliary regulatory protein Vpr has been shown to harbor a pro-apoptotic activity that may contribute to cellular and tissue damage during AIDS pathogenesis. The biochemical mechanism of this Vpr function remains unclear. In this report, substitutions of a single amino acid residue Leu(64) with Pro, Ala, or Arg are shown to dramatically enhance the pro-apoptotic activity of Vpr, as evidenced by the degradation of cellular DNA into fragments of 200-bp increments. Substitutions of Leu(64) with conservative residues have no effect. The pro-apoptotic activity of the VprL64P mutant also requires activation of caspase(s) and is inhibited by the secondary mutation I61A, indicating a high specificity for Vpr-induced apoptosis. Among the three HIV-1 subtypes examined, a subtype B Vpr and an A/G subtype recombinant Vpr have a moderate level of pro-apoptotic activity, whereas a subtype D Vpr has no detectable activity. However, the L64P mutation efficiently enhances the pro-apoptotic potential of the subtype B and subtype D Vpr molecules but not that of the A/G recombinant Vpr. It is hypothesized that Vpr molecules from different HIV-1 subtypes as well as Vpr variants that emerge during HIV-1 infection may have different proapoptotic potentials and contribute to the diversity of AIDS pathogenesis.	St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Zhao, LJ (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailes E, 2003, SCIENCE, V300, P1713, DOI 10.1126/science.1080657; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Gao F, 1998, J VIROL, V72, P5680, DOI 10.1128/JVI.72.7.5680-5698.1998; Geleziunas R, 2001, NATURE, V410, P834, DOI 10.1038/35071111; Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; Lum JJ, 2003, J CLIN INVEST, V111, P1547, DOI 10.1172/JCI200316233; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Muthumani K, 2002, J BIOL CHEM, V277, P37820, DOI 10.1074/jbc.M205313200; Patel CA, 2000, J VIROL, V74, P9717, DOI 10.1128/JVI.74.20.9717-9726.2000; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shostak LD, 1999, EXP CELL RES, V251, P156, DOI 10.1006/excr.1999.4568; Somasundaran M, 2002, P NATL ACAD SCI USA, V99, P9503, DOI 10.1073/pnas.142313699; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Wang LL, 1996, GENE, V178, P7, DOI 10.1016/0378-1119(96)00312-5; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Xu XN, 1999, J EXP MED, V189, P1489, DOI 10.1084/jem.189.9.1489; Yasuda J, 2001, VIROLOGY, V285, P181, DOI 10.1006/viro.2001.0964; Zhang KY, 2003, J VIROL, V77, P6899, DOI 10.1128/JVI.77.12.6899-6912.2003; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7	31	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44326	44330		10.1074/jbc.C300378200	http://dx.doi.org/10.1074/jbc.C300378200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	14506268	hybrid			2022-12-25	WOS:000186306700055
J	Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y				Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y			Expression of the small heat-shock protein Hsp-16-2 in Caenorhabditis elegans is suppressed by Ginkgo biloba extract EGb 761	FASEB JOURNAL			English	Article						GFP reporter; ROS; oxidative stress	OXIDATIVE STRESS; GENE-EXPRESSION; DOUBLE-BLIND; RANDOMIZED-TRIAL; EGB 761(R); ALPHA; HSP27; PHOSPHORYLATION; INTERLEUKIN-1; ACCUMULATION	EGb 761, a standardized extract of Ginkgo biloba leaves, has been shown to have antioxidative properties. We have previously demonstrated that EGb 761 increases stress resistance and mean life span in the model organism Caenorhabditis elegans. In this study, the molecular mechanism of EGb 761 on alleviating effects of oxidative stress is further investigated using transgenic C. elegans expressing a jellyfish green fluorescent protein (GFP)-tagged inducible small heat-shock protein gene (hsp-16-2). The expression of hsp-16-2 induced by the pro-oxidant juglone and by heat shock was significantly suppressed by 86% and 33%, respectively, in the transgenic nematode fed with EGb 761. These effects of EGb 761 correlate with its ability to increase mean survival rate of the nematode in response to acute oxidative and thermal stresses, as well as to attenuate the basal levels of hydrogen peroxide in the organism. Thus, we interpret the suppression of hsp-16-2/GFP expression as an indication that EGb 761 decreases cellular stress resulting from exogenous treatments, therefore leading to a decreased transcriptional induction of the reporter transgene. These results support the hypothesis that EGb 761 augments the natural antistress system of C. elegans, thus increasing stress resistance and life span.	Univ So Mississippi, Dept Biol Sci, Hattiesburg, MS 39406 USA; Beaufour Ipsen, Paris, France; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	University of Southern Mississippi; Ipsen; University of Colorado System; University of Colorado Boulder	Luo, Y (corresponding author), Univ So Mississippi, Dept Biol Sci, 2609 W 4th St, Hattiesburg, MS 39406 USA.	yuan.luo@usm.edu						Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7; Butterfield DA, 1997, P NATL ACAD SCI USA, V94, P674, DOI 10.1073/pnas.94.2.674; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Christen Y, 2002, CELL MOL BIOL, V48, P601; CHRISTEN Y, 2000, OXIDAT STRESS DIS, V5, P411; Curtis-Prior P, 1999, J PHARM PHARMACOL, V51, P535, DOI 10.1211/0022357991772817; DeFeudis F.V., 1998, GINKGO BILOBA EXTRAC; DeFeudis FV, 2002, DRUG DEVELOP RES, V57, P214, DOI 10.1002/ddr.10151; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Ganzera M, 2001, CHEM PHARM BULL, V49, P1170, DOI 10.1248/cpb.49.1170; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Le Bars PL, 2000, DEMENT GERIATR COGN, V11, P230, DOI 10.1159/000017242; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Luo Y, 2001, J ALZHEIMERS DIS, V3, P401, DOI 10.3233/JAD-2001-3407; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Schutte A, 2001, TRANSPLANT P, V33, P3724, DOI 10.1016/S0041-1345(01)02520-9; Smith JV, 2002, CELL MOL BIOL, V48, P699; SMITH JV, 2003, IN PRESS J ALZHEIMER, V4; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Soulie C, 2002, CELL MOL BIOL, V48, P641; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Valdez MM, 2002, EUR J BIOCHEM, V269, P1806, DOI 10.1046/j.1432-1033.2002.02812.x; Wadsworth TL, 2001, BIOCHEM PHARMACOL, V62, P963, DOI 10.1016/S0006-2952(01)00734-1; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Winter JC, 1998, PHYSIOL BEHAV, V63, P425, DOI 10.1016/S0031-9384(97)00464-2; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yatin SM, 1999, NEUROBIOL AGING, V20, P325	46	108	116	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2305	+		10.1096/fj.03-0376fje	http://dx.doi.org/10.1096/fj.03-0376fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525938				2022-12-25	WOS:000186343300010
J	Ylikarppa, R; Eklund, L; Sormunen, R; Kontiola, AI; Utriainen, A; Maatta, M; Fukai, N; Olsen, BR; Pihlajaniemi, T				Ylikarppa, R; Eklund, L; Sormunen, R; Kontiola, AI; Utriainen, A; Maatta, M; Fukai, N; Olsen, BR; Pihlajaniemi, T			Lack of type XVIII collagen results in anterior ocular defects	FASEB JOURNAL			English	Article						anterior eye segment defects; basement membranes; iris; ciliary body	HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE ZONES; INTRAOCULAR-PRESSURE; KNOBLOCH-SYNDROME; DBA/2J MICE; ENDOGENOUS INHIBITOR; TUMOR-GROWTH; IRIS ATROPHY; RIEG1 GENE; PAX6 GENE	Mice lacking type XVIII collagen have defects in the posterior part of the eye, including delayed regression of the hyaloid vasculature and poor outgrowth of the retinal vessels. We report here that these mice also have a fragile iris and develop atrophy of the ciliary body. The irises of Coll8al(-/-) mice can be seen to adhere to the lens and cornea. After the pupils begin to function, the double layer of epithelial cells separates at the apical cell contacts, leading to defoliation of its posterior pigment epithelial cell layer, and extracellular material begins to accumulate in the basement membrane zones of the iris. In contrast to the iris epithelia, where no clear signs of cellular atrophy were detected, the lack of type XVIII collagen resulted in atrophy of the pigmented epithelial cells of the ciliary body, and there were also ultrastructural abnormalities in the basement membrane zones. These changes did not lead to chronically elevated intraocular pressures, however. Our results indicate that type XVIII collagen is needed for the integrity of the epithelial basement membranes of the iris and the ciliary body and that its gene should therefore be taken into account as a new potential cause of anterior segment disorders in the eye.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, Oulu 90014, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland; Univ Oulu, Dept Pathol, Oulu 90014, Finland; Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki, Finland; Univ Helsinki Hosp, Dept Ophthalmol, Helsinki, Finland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	University of Oulu; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Harvard University; Harvard Medical School	Pihlajaniemi, T (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, Oulu 90014, Finland.	taina.pihlajaniemi@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Alward WLM, 2000, AM J OPHTHALMOL, V130, P107, DOI 10.1016/S0002-9394(00)00525-0; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Avila MY, 2001, INVEST OPHTH VIS SCI, V42, P1841; Azuma N, 1999, AM J HUM GENET, V65, P656, DOI 10.1086/302529; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P1138, DOI 10.1167/iovs.02-0553; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Doward W, 1999, J MED GENET, V36, P152; FREDDO TF, 1984, INVEST OPHTH VIS SCI, V25, P1094; Freddo TF, 1996, MICROSC RES TECHNIQ, V33, P369, DOI 10.1002/(SICI)1097-0029(19960401)33:5<369::AID-JEMT1>3.0.CO;2-J; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Gould DB, 1997, AM J HUM GENET, V61, P765; Gould DB, 2002, HUM MOL GENET, V11, P1185, DOI 10.1093/hmg/11.10.1185; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; John SWM, 1997, INVEST OPHTH VIS SCI, V38, P249; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Knobloch WH, 1971, J PEDIATR OPHTHALMOL, V8, P181; Kontiola AI, 2001, EXP EYE RES, V73, P781, DOI 10.1006/exer.2001.1088; Kulak SC, 1998, HUM MOL GENET, V7, P1113, DOI 10.1093/hmg/7.7.1113; Lin YF, 2001, DEVELOPMENT, V128, P1573; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSOSBUENO MR, 1994, AM J MED GENET, V52, P170, DOI 10.1002/ajmg.1320520209; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; Rehn M, 1996, SEMIN CELL DEV BIOL, V7, P673, DOI 10.1006/scdb.1996.0082; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Savinova OV, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-12; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Shields MB., 1987, TXB OF GLAUCOMA; Smith RS, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P217; Sniderman LC, 2000, AM J MED GENET, V90, P146, DOI 10.1002/(SICI)1096-8628(20000117)90:2<146::AID-AJMG11>3.3.CO;2-Q; Sonoda S, 2000, GRAEF ARCH CLIN EXP, V238, P552, DOI 10.1007/s004170000124; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Tomono Y, 2002, CELL STRUCT FUNCT, V27, P9, DOI 10.1247/csf.27.9; Traboulsi E., 1998, GENETIC DIS EYE	41	57	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2257	+		10.1096/fj.02-1001fje	http://dx.doi.org/10.1096/fj.02-1001fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525950				2022-12-25	WOS:000186343300002
J	Lee, MW; Hirai, I; Wang, HG				Lee, MW; Hirai, I; Wang, HG			Caspase-3-mediated cleavage of Rad9 during apoptosis	ONCOGENE			English	Article						caspase-3; Rad9; DNA damage; cell-cycle checkpoint; apoptosis	DNA-DAMAGE; CHECKPOINT COMPLEX; CELL-DEATH; PROTEIN; HRAD9; BCL-2; PHOSPHORYLATION; ACTIVATION; INTERACTS; EVOLUTION	The activation of caspases is a critical event for the execution phase of programmed cell death. Caspases are highly specific in their ability to activate or inhibit many crucial proteins in the cell via cleavage. In this study, we report the identification of several caspase-3-like cleavage sites in the cell-cycle checkpoint protein Rad9. We demonstrate that human Rad9 can be specifically cleaved in cells induced to enter apoptosis by both DNA damage and staurosporine treatment. Indeed, we show that human Rad9 can be effectively cleaved both in vitro and in vivo, which can be inhibited by either a pan-caspase inhibitor or a caspase-3-specific inhibitor. Additionally, no cleavage of Rad9 can be seen in the caspase-3-deficient cell line MCF-7. Site-directed mutagenesis of three of the most conserved cleavage sites dramatically abrogates cleavage of Rad9 by caspase-3 in vitro, and in intact cells after DNA damage. Expression of the cleavage-resistant mutant Rad9 DDD/AAA appears to protect the cell from DNA damage-induced apoptosis. Immunofluorescence studies of Rad9 localization before and after induction of apoptosis show a translocation of Rad9 from the nucleus to the cytosol, concomitant to the appearance of apoptotic morphology. Furthermore, analysis of a truncated Rad9 mutant that corresponds to a putative N-terminal cleavage fragment shows that the N-terminal portion of Rad9 localizes in the cytosol, binds to Bcl-XL, and induces apoptosis. These results support a dual role for cleavage of Rad9: ( 1) the liberation and translocation of the BH3 domain-containing N-terminus of Rad9 to the cytosol, as a means of promoting apoptosis via antagonism of Bcl-XL, and ( 2) the disruption of the Rad9-Rad1-Hus1 DNA damage checkpoint complex.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wang, HG (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER; NCI NIH HHS [CA82197, CA90315] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2002, CURR BIOL, V12, pR105, DOI 10.1016/S0960-9822(02)00673-5; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hayashi K, 2002, PATHOBIOLOGY, V70, P40, DOI 10.1159/000066002; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	27	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6340	6346		10.1038/sj.onc.1206729	http://dx.doi.org/10.1038/sj.onc.1206729			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508514				2022-12-25	WOS:000185535300004
J	Philp, D; Huff, T; Gho, YS; Hannappel, E; Kleinman, HK				Philp, D; Huff, T; Gho, YS; Hannappel, E; Kleinman, HK			The actin binding site on thymosin beta(4) promotes angiogenesis	FASEB JOURNAL			English	Article						beta-thymosin; angiogenic activity; 5 kDa polypeptide; G-actin	DEOXYNUCLEOTIDYL TRANSFERASE-ACTIVITY; ENDOTHELIAL-CELLS; IN-VIVO; PEPTIDE; EXPRESSION; TRANSGLUTAMINASE; METASTASIS; MOTILITY; CANCER; LINES	Thymosin beta(4) is a ubiquitous 43 amino acid, 5 kDa polypeptide that is an important mediator of cell proliferation, migration, and differentiation. It is the most abundant member of the beta-thymosin family in mammalian tissue and is regarded as the main G-actin sequestering peptide. Thymosin beta(4) is angiogenic and can promote endothelial cell migration and adhesion, tubule formation, aortic ring sprouting, and angiogenesis. It also accelerates wound healing and reduces inflammation when applied in dermal wound-healing assays. Using naturally occurring thymosin beta(4), proteolytic fragments, and synthetic peptides, we find that a seven amino acid actin binding motif of thymosin beta(4) is essential for its angiogenic activity. Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta(4) and the actin-binding motif of the peptide display near-identical activity at similar to50 nM, whereas peptides lacking any portion of the actin motif were inactive. Furthermore, adhesion to thymosin beta(4) was blocked by this seven amino acid peptide demonstrating it as the major thymosin beta(4) cell binding site on the molecule. The adhesion and sprouting activity of thymosin beta(4) was inhibited with the addition of 5-50 nM soluble actin. These results demonstrate that the actin binding motif of thymosin beta(4) is an essential site for its angiogenic activity.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany; Kyung Hee Univ, Grad Sch E W Med Sci, Yongin, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Erlangen Nuremberg; Kyung Hee University	Kleinman, HK (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30-433 30 Convent Dr,MSC-4370, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Auerbach R, 2000, CANCER METAST REV, V19, P167, DOI 10.1023/A:1026574416001; Bao L, 1998, CLIN EXP METASTAS, V16, P227, DOI 10.1023/A:1006540824969; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; FFOLKMAN J, 1992, SEMIN CANCER BIOL, P89; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gho YS, 1997, CANCER RES, V57, P3733; Gho YS, 2002, J BIOL CHEM, V277, P9690, DOI 10.1074/jbc.M105526200; Gho YS, 1997, J BIOL CHEM, V272, P24294, DOI 10.1074/jbc.272.39.24294; GMORIANU J, 1993, P NATL ACAD SCI USA, V90, P3815; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU SK, 1981, MOL CELL BIOCHEM, V41, P49; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Huff T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0713com; HUFF T, 1995, EUR J BIOCHEM, V230, P650; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Huff T, 1997, ANAL CHIM ACTA, V352, P239, DOI 10.1016/S0003-2670(97)00133-5; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Koutrafouri V, 2001, BBA-GEN SUBJECTS, V1568, P60, DOI 10.1016/S0304-4165(01)00200-8; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; REICHERT A, 1994, FEBS LETT, V347, P247, DOI 10.1016/0014-5793(94)00551-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SAFER D, 1991, J BIOL CHEM, V266, P4029; Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; XU GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4006, DOI 10.1073/pnas.79.13.4006; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; Young JD, 1999, NAT MED, V5, P1424	40	109	124	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2103	+		10.1096/fj.03-0121fje	http://dx.doi.org/10.1096/fj.03-0121fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500546				2022-12-25	WOS:000185925100014
J	Pannequin, J; Kovac, S; Tantiongco, JP; Norton, RS; Shulkes, A; Barnham, KJ; Baldwin, GS				Pannequin, J; Kovac, S; Tantiongco, JP; Norton, RS; Shulkes, A; Barnham, KJ; Baldwin, GS			A novel effect of bismuth ions - Selective inhibition of the biological activity of glycine-extended gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI ERADICATION; COLON-CANCER CELLS; GROWTH-FACTOR; TRIPLE THERAPIES; TRANSGENIC MICE; FERRIC IONS; CRYPT FOCI; BINDING; PROGASTRIN; ACID	Although bismuth salts have been used for over two centuries for the treatment of various gastrointestinal disorders, the mechanism of their therapeutic action remains controversial. Because gastrins bind two trivalent ferric ions with high affinity, and because ferric ions are essential for the biological activity of glycine-extended gastrin 17, we have investigated the hypothesis that trivalent bismuth ions influence the biological activity of gastrins. Binding of bismuth ions to gastrins was measured by fluorescence quenching and NMR spectroscopy. The effects of bismuth ions on gastrin-stimulated biological activities were measured in inositol phosphate, cell proliferation, and cell migration assays. Fluorescence quenching experiments indicated that both glycine-extended and amidated gastrin 17 bound two bismuth ions. The NMR spectral changes observed on addition of bismuth ions revealed that Glu-7 acted as a ligand at the first bismuth ion binding site. In the presence of bismuth ions the ability of glycine-extended gastrin 17 to stimulate inositol phosphate production, cell proliferation, and cell migration was markedly reduced. In contrast, bismuth ions had little effect on the affinity of the CCK-2 receptor for amidated gastrin 17, or on the stimulation of inositol phosphate production by amidated gastrin 17. We conclude that bismuth ions may act, at least in part, by blocking the effects of glycine-extended gastrin 17 on cell proliferation and cell migration in the gastrointestinal tract. This is the first report of a specific inhibitory effect of bismuth ions on the action of a gastrointestinal hormone.	Univ Melbourne, A&RMC, Dept Surg, Heidelberg, Vic 3084, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3010, Australia	Austin Research Institute; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne; Florey Institute of Neuroscience & Mental Health	Baldwin, GS (corresponding author), Univ Melbourne, A&RMC, Dept Surg, Austin Campus,Studley Rd, Heidelberg, Vic 3084, Australia.	grahamsb@unimelb.edu.au		pannequin, julie/0000-0002-9956-373X; Baldwin, Graham/0000-0002-0944-8747; Norton, Raymond/0000-0001-8893-0584	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065926] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM065926, GM65926-01, R01 GM065926-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, BIOCHEMISTRY-US, V40, P10741, DOI 10.1021/bi010016h; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Barnham KJ, 1999, BBA-PROTEIN STRUCT M, V1435, P127, DOI 10.1016/S0167-4838(99)00214-9; BIERER DW, 1990, REV INFECT DIS, V12, pS3; Briand GG, 1999, CHEM REV, V99, P2601, DOI 10.1021/cr980425s; Chen D, 2000, GASTROENTEROLOGY, V119, P756, DOI 10.1053/gast.2000.16480; Chowers MY, 1999, GASTROENTEROLOGY, V117, P1113, DOI 10.1016/S0016-5085(99)70396-3; Chowers MY, 2002, FEMS MICROBIOL LETT, V217, P231, DOI 10.1111/j.1574-6968.2002.tb11480.x; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; Fine KD, 1998, GASTROENTEROLOGY, V114, P29, DOI 10.1016/S0016-5085(98)70629-8; Fox JG, 2001, NEW ENGL J MED, V345, P829, DOI 10.1056/NEJM200109133451111; GALLEYRAND JC, 1994, INT J PEPT PROT RES, V44, P348; Gillen D, 1998, GASTROENTEROLOGY, V114, P50, DOI 10.1016/S0016-5085(98)70632-8; GORBACH SL, 1990, GASTROENTEROLOGY, V99, P863, DOI 10.1016/0016-5085(90)90983-8; Higashide S, 1996, AM J PHYSIOL-GASTR L, V270, pG220, DOI 10.1152/ajpgi.1996.270.1.G220; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; Karelina Y, 2001, J GASTROEN HEPATOL, V16, P169, DOI 10.1046/j.1440-1746.2001.02429.x; Katelaris PH, 2002, GASTROENTEROLOGY, V123, P1763, DOI 10.1053/gast.2002.37051; Kermorgant S, 2001, BIOCHEM BIOPH RES CO, V285, P136, DOI 10.1006/bbrc.2001.5132; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Lambert JR, 1997, ALIMENT PHARM THERAP, V11, P27, DOI 10.1046/j.1365-2036.11.s1.13.x; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; Malby S, 2001, BIOCHEMISTRY-US, V40, P2555, DOI 10.1021/bi002322l; MATHEWS C, 1995, BIOCHEMISTRY-US, P383; Pannequin J, 2002, J BIOL CHEM, V277, P48602, DOI 10.1074/jbc.M208440200; QIAN JM, 1993, AM J PHYSIOL, V264, pG718, DOI 10.1152/ajpgi.1993.264.4.G718; ROKKAS T, 1988, SCAND J GASTROENTERO, V23, P82, DOI 10.3109/00365528809091719; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Stepan VM, 1999, MOL MED, V5, P147, DOI 10.1007/BF03402058; SUMMERS SP, 1994, INORG CHEM, V33, P88, DOI 10.1021/ic00079a017; Sun HZ, 2001, J BIOL CHEM, V276, P8829, DOI 10.1074/jbc.M004779200; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; van Oijen AHAM, 2000, ALIMENT PHARM THERAP, V14, P991, DOI 10.1046/j.1365-2036.2000.00798.x; VANHOE H, 1993, CLIN CHIM ACTA, V219, P79, DOI 10.1016/0009-8981(93)90199-E; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P28; Yang CH, 2001, INT J BIOCHEM CELL B, V33, P1071, DOI 10.1016/S1357-2725(01)00077-2; Zhang L, 2001, BIOCHEMISTRY-US, V40, P13281, DOI 10.1021/bi010579t	45	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	2004	279	4					2453	2460		10.1074/jbc.M309806200	http://dx.doi.org/10.1074/jbc.M309806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	764MU	14530269	hybrid, Green Published			2022-12-25	WOS:000188211300016
J	Mesquita, P; Jonckheere, N; Almeida, R; Ducourouble, MP; Serpa, J; Silva, E; Pigny, P; Silva, FS; Reis, C; Silberg, D; Van Seuningen, I; David, L				Mesquita, P; Jonckheere, N; Almeida, R; Ducourouble, MP; Serpa, J; Silva, E; Pigny, P; Silva, FS; Reis, C; Silberg, D; Van Seuningen, I; David, L			Human MUC2 mucin gene is transcriptionally regulated by Cdx homeodomain proteins in gastrointestinal carcinoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; GASTRIC CARCINOMAS; INTESTINAL METAPLASIA; 5'-FLANKING REGION; PROMOTER ACTIVITY; MONOCLONAL-ANTIBODIES; COLON-CANCER; EXPRESSION; ACTIVATION; MUC5AC	In intestinal metaplasia and 30% of gastric carcinomas, MUC2 intestinal mucin and the intestine-specific transcription factors Cdx-1 and Cdx-2 are aberrantly expressed. The involvement of Cdx-1 and Cdx-2 in the intestinal development and their role in transcription of several intestinal genes support the hypothesis that Cdx-1 and/or Cdx-2 play important roles in the aberrant intestinal differentiation program of intestinal metaplasia and gastric carcinoma. To clarify the mechanisms of transcriptional regulation of the MUC2 mucin gene in gastric cells, pGL3 deletion constructs covering 2.6 kb of the human MUC2 promoter were used in transient transfection assays, enabling us to identify a relevant region for MUC2 transcription in all gastric cell lines. To evaluate the role of Cdx-1 and Cdx-2 in MUC2 transcription we performed co-transfection experiments with expression vectors encoding Cdx-1 and Cdx-2. In two of the four gastric carcinoma cell lines and in all colon carcinoma cell lines we observed transactivation of the MUC2 promoter by Cdx-2. Using gel shift assays we identified two Cdx-2 binding sites at - 177/ - 171 and - 191/ - 187. Only simultaneous mutation of the two sites resulted in inhibition of Cdx-2-mediated transactivation of MUC2 promoter, implying that both Cdx-2 sites are active. Finally, stable expression of Cdx-2 in a gastric cell line initially not expressing Cdx-2, led to induction of MUC2 expression. In conclusion, this work demonstrates that Cdx-2 activates the expression of MUC2 mucin gene in gastric cells, inducing an intestinal transdifferentiation phenotype that parallels what is observed both in intestinal metaplasia and some gastric carcinomas.	Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; INSERM, U560, F-59045 Lille, France; Univ Penn, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Porto, Fac Med, P-4200 Oporto, Portugal	Universidade do Porto; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Pennsylvania; Universidade do Porto	Mesquita, P (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, Rua Dr Roberto Frias S-N, P-4200 Oporto, Portugal.	pmesquita@ipatimup.pt	Serpa, Jacinta/A-4772-2013; Jonckheere, Nicolas/J-6028-2013; Serpa, Jacinta/AAD-1861-2020; Almeida, Raquel/B-9647-2012; VAN SEUNINGEN, Isabelle/N-6176-2016; da Silva Moura, Elisabete Ferreira/L-9184-2014; Serpa, Jacinta/GLV-1532-2022; REIS, Celso A/B-9969-2008; Santos-Silva, Filipe/J-4535-2013; David, Leonor/A-4829-2008	Jonckheere, Nicolas/0000-0002-0496-0661; Serpa, Jacinta/0000-0002-1548-5907; Almeida, Raquel/0000-0002-5622-1633; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; da Silva Moura, Elisabete Ferreira/0000-0002-6736-3469; REIS, Celso A/0000-0002-0286-6639; Santos-Silva, Filipe/0000-0001-7143-1025; David, Leonor/0000-0003-4207-9258; Mesquita, Patricia/0000-0002-4766-9831	NIDDK NIH HHS [R01 DK059539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida R, 2003, J PATHOL, V199, P36, DOI 10.1002/path.1246; Aslam F, 2001, CANCER RES, V61, P570; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; DEVINE PL, 1993, BRIT J CANCER, V67, P1182, DOI 10.1038/bjc.1993.223; Divine JK, 2003, AM J PHYSIOL-GASTR L, V285, pG62, DOI 10.1152/ajpgi.00074.2003; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Florence B, 1997, DEVELOPMENT, V124, P839; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; GAMBUS G, 1993, GASTROENTEROLOGY, V104, P3; Gartner F, 1996, VIRCHOWS ARCH, V428, P91; Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hanski C, 1997, LAB INVEST, V77, P685; HO SB, 1993, CANCER RES, V53, P641; HO SB, 1995, CANCER RES, V55, P2681; Isshiki S, 2003, J BIOL CHEM, V278, P36611, DOI 10.1074/jbc.M302681200; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Martin MG, 2000, AM J PHYSIOL-GASTR L, V278, pG591, DOI 10.1152/ajpgi.2000.278.4.G591; Mesquita P, 2003, CANCER LETT, V189, P129, DOI 10.1016/S0304-3835(02)00549-9; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Ookawa K, 2002, J BIOL CHEM, V277, P48270, DOI 10.1074/jbc.M207986200; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Pinto-de-Sousa J, 2002, VIRCHOWS ARCH, V440, P304, DOI 10.1007/s00428-001-0548-y; Reis CA, 2000, J HISTOCHEM CYTOCHEM, V48, P377, DOI 10.1177/002215540004800307; Reis CA, 1999, CANCER RES, V59, P1003; Reis CA, 1998, GLYCOCONJUGATE J, V15, P51, DOI 10.1023/A:1006939432665; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; Van Seuningen I, 2000, BIOCHEM J, V348, P675; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; VANSEUNINGEN I, 2001, FRONT BIOSCI, V6, pD1234; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P2697; Velcich A, 1997, J BIOL CHEM, V272, P7968, DOI 10.1074/jbc.272.12.7968; XING PX, 1992, J NATL CANCER I, V84, P699, DOI 10.1093/jnci/84.9.699; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Yussa M, 2001, MECH DEVELOP, V107, P39, DOI 10.1016/S0925-4773(01)00448-8	49	123	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51549	51556		10.1074/jbc.M309019200	http://dx.doi.org/10.1074/jbc.M309019200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14525978	Green Published, hybrid			2022-12-25	WOS:000187206300087
J	Ohta, E; Misumi, Y; Sohda, M; Fujiwara, T; Yano, A; Ikehara, Y				Ohta, E; Misumi, Y; Sohda, M; Fujiwara, T; Yano, A; Ikehara, Y			Identification and characterization of GCP16, a novel acylated Golgi protein that interacts with GCP170	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; BREFELDIN-A; MOLECULAR CHARACTERIZATION; SECRETORY PROTEINS; MATRIX PROTEIN; COMPLEX; GM130; TRANSPORT; P115; CONTAINS	GCP170, a member of the golgin family associated with the cytoplasmic face of the Golgi membrane, was found to have a Golgi localization signal at the NH2-terminal region ( positions 137 - 237). Using this domain as bait in the yeast two-hybrid screening system, we identified a novel protein that interacted with GCP170. The 2.0-kilobase mRNA encoding a 137-amino acid protein of 16 kDa designated GCP16 was ubiquitously expressed. Immunofluorescence microscopy showed that GCP16 was co-localized with GCP170 and giantin in the Golgi region. Despite the absence of a hydrophobic domain sufficient for participating in membrane localization, GCP16 was found to be tightly associated with membranes like an integral membrane protein. Labeling experiments with [H-3] palmitic acid and mutational analysis demonstrated that GCP16 was acylated at Cys(69) and Cys(72), accounting for its tight association with the membrane. A mutant without potential acylation sites (C69A/C72A) was no longer localized to the Golgi, indicating that the acylation is prerequisite for the Golgi localization of GCP16. Although the mutant GCP16, even when overexpressed, had no effect on protein transport, overexpression of the wild type GCP16 caused an inhibitory effect on protein transport from the Golgi to the cell surface. Taken together, these results indicate that GCP16 is the acylated membrane protein, associated with GCP170, and possibly involved in vesicular transport from the Golgi to the cell surface.	Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140180, Japan	Fukuoka University	Ikehara, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140180, Japan.	yikehara@fukuoka-u.ac.jp						Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Bascom RA, 1999, J BIOL CHEM, V274, P2953, DOI 10.1074/jbc.274.5.2953; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FRITZLER MJ, 1984, J IMMUNOL, V132, P2904; Fujiwara T, 1998, J BIOL CHEM, V273, P3068, DOI 10.1074/jbc.273.5.3068; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Linstedt AD, 2000, J BIOL CHEM, V275, P10196, DOI 10.1074/jbc.275.14.10196; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Miller J.H., 1992, SHORT COURSE BACTERI, P74; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Misumi Y, 1997, J BIOL CHEM, V272, P23851, DOI 10.1074/jbc.272.38.23851; Mollenhauer HH, 1998, HISTOCHEM CELL BIOL, V109, P533, DOI 10.1007/s004180050253; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Philpott KL, 1996, EUR J NEUROSCI, V8, P1906, DOI 10.1111/j.1460-9568.1996.tb01334.x; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Sesso A, 1999, TISSUE CELL, V31, P357, DOI 10.1054/tice.1999.0042; Sohda M, 2001, J BIOL CHEM, V276, P45298, DOI 10.1074/jbc.M108961200; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; TAKAMI N, 1988, J BIOL CHEM, V263, P3016; Toki C, 1997, CELL STRUCT FUNCT, V22, P565, DOI 10.1247/csf.22.565; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; WEISZ OA, 1992, J BIOL CHEM, V267, P22282	48	40	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51957	51967		10.1074/jbc.M310014200	http://dx.doi.org/10.1074/jbc.M310014200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14522980	hybrid			2022-12-25	WOS:000187206300132
J	Stange, M; Xu, L; Balshaw, D; Yamaguchi, N; Meissner, G				Stange, M; Xu, L; Balshaw, D; Yamaguchi, N; Meissner, G			Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; DEPENDENT PROTEIN-KINASE; JUNCTIONAL SARCOPLASMIC-RETICULUM; HEART-FAILURE; DEFECTIVE REGULATION; ADENINE-NUCLEOTIDE; CALMODULIN; FKBP12.6; MODULATION; BINDING	Phosphorylation of the skeletal muscle (RyR1) and cardiac muscle (RyR2) ryanodine receptors has been reported to modulate channel activity. Abnormally high phosphorylation levels ( hyperphosphorylation) at Ser-2843 in RyR1 and Ser-2809 in RyR2 and dissociation of FK506-binding proteins from the receptors have been implicated as one of the causes of altered calcium homeostasis observed during human heart failure. Using site-directed mutagenesis, we prepared recombinant RyR1 and RyR2 mutant receptors mimicking constitutively phosphorylated and dephosphorylated channels carrying a Ser/Asp (RyR1-S2843D and RyR2-S2809D) and Ser/ Ala (RyR1-S2843A and RyR2-S2809A) substitution, respectively. Following transient expression in human embryonic kidney 293 cells, the effects of Ca2+, Mg2+, and ATP on channel function were determined using single channel and [H-3] ryanodine binding measurements. In both assays, neither the skeletal nor cardiac mutants showed significant differences compared with wild type. Similarly essentially identical caffeine responses were observed in Ca2+ imaging measurements. Co-immunoprecipitation and Western blot analysis showed comparable binding of FK506-binding proteins to wild type and mutant receptors. Finally metabolic labeling experiments showed that the cardiac ryanodine receptor was phosphorylated at additional sites. Taken together, the results did not support the view that phosphorylation of a single site (RyR1-Ser-2843 and RyR2-Ser-2809) substantially changes RyR1 and RyR2 channel function.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [HL27430, HL73051] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430, R01HL073051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Bandyopadhyay A, 2000, BIOCHEM J, V352, P61, DOI 10.1042/0264-6021:3520061; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; DAMIANI E, 1995, BIOCHEM BIOPH RES CO, V209, P457, DOI 10.1006/bbrc.1995.1524; Dulhunty AF, 2001, BIOPHYS J, V81, P3240, DOI 10.1016/S0006-3495(01)75959-0; FABIATO A, 1983, AM J PHYSIOL, V245, P1; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Franzini-Armstrong C, 1999, BIOPHYS J, V77, P1528, DOI 10.1016/S0006-3495(99)77000-1; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; GUO W, 1994, J BIOL CHEM, V269, P28359; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Li YX, 2002, CIRC RES, V90, P309, DOI 10.1161/hh0302.105660; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Marx SO, 2001, CIRC RES, V88, P1151, DOI 10.1161/hh1101.091268; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Narayanan N, 1997, BASIC RES CARDIOL, V92, P25, DOI 10.1007/BF00794065; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Rodriguez P, 2003, J BIOL CHEM, V278, P38593, DOI 10.1074/jbc.C301180200; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; Sutko JL, 1997, PHARMACOL REV, V49, P53; Szegedi C, 1999, BIOCHEM J, V337, P19, DOI 10.1042/0264-6021:3370019; Temsah RM, 2000, J PHARMACOL EXP THER, V293, P15; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; Uehara A, 2002, PFLUG ARCH EUR J PHY, V444, P202, DOI 10.1007/s00424-002-0791-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; Wehrens XHT, 2003, CELL, V113, P829, DOI 10.1016/S0092-8674(03)00434-3; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Yano M, 2000, CIRCULATION, V102, P2131, DOI 10.1161/01.CIR.102.17.2131; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5	48	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 19	2003	278	51					51693	51702		10.1074/jbc.M310406200	http://dx.doi.org/10.1074/jbc.M310406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	752ZM	14532276	Green Published, hybrid			2022-12-25	WOS:000187206300104
J	Kokoska, RJ; McCulloch, SD; Kunkel, TA				Kokoska, RJ; McCulloch, SD; Kunkel, TA			The efficiency and specificity of apurinic/apyrimidinic site bypass by human DNA polymerase eta and Sulfolobus solfataricus Dpo4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; PRONE LESION BYPASS; ERROR-PRONE; XERODERMA-PIGMENTOSUM; Y-FAMILY; THYMINE DIMER; ABASIC SITE; POL-ETA; A-RULE; FIDELITY	One of the most common DNA lesions arising in cells is an apurinic/ apyrimidinic ( AP) site resulting from base loss. Although a template strand AP site impedes DNA synthesis, translesion synthesis ( TLS) DNA polymerases can bypass an AP site. Because this bypass is expected to be highly mutagenic because of loss of base coding potential, here we quantify the efficiency and the specificity of AP site bypass by two Y family TLS enzymes, Sulfolobus solfataricus DNA polymerase 4 ( Dpo4) and human DNA polymerase eta ( Pol eta). During a single cycle of processive DNA synthesis, Dpo4 and Pol eta bypass synthetic AP sites with 13 - 30 and 10 - 13%, respectively, of the bypass efficiency for undamaged bases in the same sequence contexts. These efficiencies are higher than for the A family, exonuclease- deficient Klenow fragment of Escherichia coli DNA polymerase I. We then determined AP site bypass specificity for complete bypass, requiring insertion or misalignment at the AP site followed by multiple incorporations using the aberrant primer templates. Although Dpo4, Pol eta, and Klenow polymerase have different fidelity when copying undamaged DNA, bypass of AP sites lacking A or G by all three polymerases is nearly 100% mutagenic. The majority ( 70 - 80%) of bypass events made by all three polymerases are insertion of dAMP opposite the AP site. Single base deletion errors comprise 10 - 25% of bypass events, with other base insertions observed at lower rates. Given that mammalian cells contain five polymerases implicated in TLS, and given that a large number of AP sites are generated per mammalian cell per day, even moderately efficient AP site bypass could be a source of substitution and frameshift mutagenesis in vivo.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Boudsocq F, 2001, NUCLEIC ACIDS RES, V29, P4607, DOI 10.1093/nar/29.22.4607; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Gruz P, 2003, NUCLEIC ACIDS RES, V31, P4024, DOI 10.1093/nar/gkg447; Haracska L, 2001, J BIOL CHEM, V276, P6861, DOI 10.1074/jbc.M008021200; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Matsuda T, 2003, J BIOL CHEM, V278, P25947, DOI 10.1074/jbc.C300170200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nakamura J, 1999, CANCER RES, V59, P2522; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; STRAUSS BS, 1985, CANCER SURV, V4, P493; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Taylor JS, 2002, MUTAT RES-FUND MOL M, V510, P55, DOI 10.1016/S0027-5107(02)00252-X; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Washington MT, 2001, P NATL ACAD SCI USA, V98, P8355, DOI 10.1073/pnas.121007298; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WASHINGTON MT, 2000, P NATL ACAD SCI US; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138	43	106	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50537	50545		10.1074/jbc.M308515200	http://dx.doi.org/10.1074/jbc.M308515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523013	hybrid			2022-12-25	WOS:000187068200107
J	Liu, SL; Premont, RT; Kontos, CD; Huang, JH; Rockey, DC				Liu, SL; Premont, RT; Kontos, CD; Huang, JH; Rockey, DC			Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein beta gamma subunit signaling to protein kinase B/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; ET(B) RECEPTOR; COUPLED RECEPTORS; TUMOR-SUPPRESSOR; JUN KINASE; RAT-LIVER; AKT; PATHWAY	Endothelin-1 has dual vasoactive effects, mediating vasoconstriction via ETA receptor activation of vascular smooth muscle cells and vasorelaxation via ETB receptor activation of endothelial cells. Although it is commonly accepted that endothelin-1 binding to endothelial cell ETB receptors stimulates nitric oxide (NO) synthesis and subsequent smooth muscle relaxation, the signaling pathways downstream of ETB receptor activation are unknown. Here, using a model in which we have utilized isolated primary endothelial cells, we demonstrate that ET-1 binding to sinusoidal endothelial cell ETB receptors led to increased protein kinase B/Akt phosphorylation, endothelial cell nitric-oxide synthase (eNOS) phosphorylation, and NO synthesis. Furthermore, eNOS activation was not dependent on tyrosine phosphorylation, and pretreatment of endothelial cells with pertussis toxin as well as overexpression of a dominant negative G-protein-coupled receptor kinase construct that sequesters betagamma subunits inhibited Akt phosphorylation and NO synthesis. Taken together, the data elucidate a G-protein-coupled receptor signaling pathway for ETB receptor-mediated NO production and call attention to the absolute requirement for heterotrimeric G-protein betagamma subunits in this cascade.	Duke Univ, Med Ctr, Ctr Liver, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Rockey, DC (corresponding author), Duke Univ, Med Ctr, Ctr Liver, Rm 336,Sands Bldg,Box 3083, Durham, NC 27710 USA.			Premont, Richard/0000-0002-8053-5026; Kontos, Christopher/0000-0002-8056-3115	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057830, R01DK050574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03557] Funding Source: Medline; NIDDK NIH HHS [R01 DK057830, R01-DK-50574, R01-DK-57830] Funding Source: Medline; NIGMS NIH HHS [R01-GM-59989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS46; ANGGARD E, 1989, J CARDIOVASC PHARM, V13, pS74; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; BODENHEIMER HC, 1988, HEPATOLOGY, V8, P1667, DOI 10.1002/hep.1840080633; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; Coffer PJ, 1998, BIOCHEM J, V335, P1; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fahimi-Vahid M, 2002, J MOL CELL CARDIOL, V34, P441, DOI 10.1006/jmcc.2002.1525; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; GALRON R, 1991, FEBS LETT, V283, P11, DOI 10.1016/0014-5793(91)80542-B; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HilalDandan R, 1997, AM J PHYSIOL-HEART C, V272, pH130, DOI 10.1152/ajpheart.1997.272.1.H130; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; HIRATA Y, 1995, CIRCULATION, V91, P1229, DOI 10.1161/01.CIR.91.4.1229; HIRATA Y, 1988, FEBS LETT, V239, P13, DOI 10.1016/0014-5793(88)80536-2; HOUSSET C, 1993, P NATL ACAD SCI USA, V90, P9266, DOI 10.1073/pnas.90.20.9266; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Krugmann S, 1998, CURR BIOL, V8, pR828; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; LUSCHER TF, 1990, CIRC RES, V66, P1088, DOI 10.1161/01.RES.66.4.1088; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Murakoshi N, 2002, CIRCULATION, V106, P1991, DOI 10.1161/01.CIR.0000032004.56585.2A; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Ribas C, 2002, METHOD ENZYMOL, V344, P140; Robin P, 2002, AM J PHYSIOL-CELL PH, V283, pC251, DOI 10.1152/ajpcell.00601.2001; ROCKEY DC, 1994, J INVEST MED, V42, P660; Rockey DC, 1998, GASTROENTEROLOGY, V114, P344, DOI 10.1016/S0016-5085(98)70487-1; ROSE PM, 1995, FEBS LETT, V361, P243, DOI 10.1016/0014-5793(95)00164-5; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Su XH, 1999, AM J PHYSIOL-GASTR L, V276, pG853, DOI 10.1152/ajpgi.1999.276.4.G853; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WANG YZ, 1994, AM J PHYSIOL-CELL PH, V267, pC1130, DOI 10.1152/ajpcell.1994.267.4.C1130; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOKOI Y, 1984, HEPATOLOGY, V4, P709, DOI 10.1002/hep.1840040425	70	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49929	49935		10.1074/jbc.M306930200	http://dx.doi.org/10.1074/jbc.M306930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14523027	hybrid			2022-12-25	WOS:000187068200035
J	Yang, JS; Trakselis, MA; Roccasecca, RM; Benkovic, SJ				Yang, JS; Trakselis, MA; Roccasecca, RM; Benkovic, SJ			The application of a minicircle substrate in the study of the coordinated T4 DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; PROTEIN-PROTEIN INTERACTIONS; POLYMERASE-III HOLOENZYME; OKAZAKI FRAGMENT SIZE; RNA PRIMER SYNTHESIS; LEADING-STRAND; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SLIDING CLAMP; BACTERIOPHAGE-T4 PROTEINS	A reconstituted in vitro bacteriophage T4 DNA replication system was studied on a synthetic 70-mer minicircle substrate. This substrate was designed so that dGMP and dCMP were exclusively incorporated into the leading and the lagging strand, respectively. This design allows the simultaneous and independent measurement of the leading and lagging strand synthesis. In this paper, we report our results on the characterization of the 70-mer minicircle substrate. We show here that the minicircle substrate supports coordinated leading and lagging strand synthesis under the experimental conditions employed. The rate of the leading strand fork movement was at an average of similar to 150 nucleotides/s. This rate decreased to less than 30 nucleotides/s when the helicase was omitted from the reaction. These results suggest that both the holoenzyme and the primosome can be simultaneously assembled onto the minicircle substrate. The lagging strand synthesized on this substrate is of an average of 1.5 kb, and the length of the Okazaki fragments increased with decreasing [rNTPs]. The proper response of the Okazaki fragment size toward the change of the priming signal further indicates a functional replisome assembled on the minicircle template. The effects of various protein components on the leading and lagging strand synthesis were also studied. The collective results indicate that coordinated strand synthesis only takes place within certain protein concentration ranges. The optimal protein levels of the proteins that constitute the T4 replisome generally bracket the concentrations of the same proteins in vivo. Omission of the primase has little effect on the rate of dNMP incorporation or the rate of the fork movement on the leading strand within the first 30 s of the reaction. This inhibition only becomes significant at later times of the reaction and may be associated with the accumulation of single- stranded DNA leading to the collapse of active replisomes.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 414 Wartik Lab, University Pk, PA 16802 USA.		Trakselis, Michael/V-3806-2019	Trakselis, Michael/0000-0001-7054-8475	NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1977, NATURE, V269, P655, DOI 10.1038/269655a0; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Alley SC, 2000, BIOCHEMISTRY-US, V39, P3076, DOI 10.1021/bi992377r; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BURKE RL, 1985, J BIOL CHEM, V260, P1711; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HINTON DM, 1985, J BIOL CHEM, V260, P2858; HUANG CC, 1981, J BIOL CHEM, V256, P4087; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kolesky SE, 2002, J MOL BIOL, V321, P767, DOI 10.1016/S0022-2836(02)00732-5; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; LIU CC, 1981, J BIOL CHEM, V256, P2813; MAKI H, 1988, J BIOL CHEM, V263, P6570; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MORRIS CF, 1975, P NATL ACAD SCI USA, V72, P4800, DOI 10.1073/pnas.72.12.4800; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; ROTH AC, 1982, J BIOL CHEM, V257, P1267; RUSH J, 1989, J BIOL CHEM, V264, P10943; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; Trakselis MA, 2003, J BIOL CHEM, V278, P49839, DOI 10.1074/jbc.M307405200; Trakselis MA, 2003, J MOL BIOL, V326, P435, DOI 10.1016/S0022-2836(02)01330-X; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	57	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					49828	49838		10.1074/jbc.M307406200	http://dx.doi.org/10.1074/jbc.M307406200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	14500718	hybrid			2022-12-25	WOS:000187068200024
J	Donaldson, LW; Wojtyra, U; Houry, WA				Donaldson, LW; Wojtyra, U; Houry, WA			Solution structure of the dimeric zinc binding domain of the chaperone ClpX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONES; SWISS-MODEL; PROTEINS; DEGRADATION; RECOGNITION; COMPLEX; TRANSLOCATION	ClpX (423 amino acids), a member of the Clp/Hsp100 family of molecular chaperones and the protease, ClpP, comprise a multimeric complex supporting targeted protein degradation in Escherichia coli. The ClpX sequence consists of an NH2-terminal zinc binding domain (ZBD) and a COOH-terminal ATPase domain. Earlier, we have demonstrated that the zinc binding domain forms a constitutive dimer that is essential for the degradation of some ClpX substrates such as lambdaO and MuA but is not required for the degradation of other substrates such as green fluorescent protein-SsrA. In this report, we present the NMR solution structure of the zinc binding domain dimer. The monomer fold reveals that ZBD is a member of the treble clef zinc finger family, a motif known to facilitate protein-ligand, protein-DNA, and protein-protein interactions. However, the dimeric ZBD structure is not related to any protein structure in the Protein Data Bank. A trimer-of-dimers model of ZBD is presented, which might reflect the closed state of the ClpX hexamer.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	York University - Canada; University of Toronto	Donaldson, LW (corresponding author), York Univ, Dept Biol, 4700 Keele St W,049 Farquharson, N York, ON M3J 1P3, Canada.	logand@yorku.ca						Banecki B, 2001, J BIOL CHEM, V276, P18843, DOI 10.1074/jbc.M007507200; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gonzalez M, 2000, EMBO J, V19, P5251, DOI 10.1093/emboj/19.19.5251; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Grishin NV, 2001, NUCLEIC ACIDS RES, V29, P1703, DOI 10.1093/nar/29.8.1703; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones JM, 1998, J BIOL CHEM, V273, P459, DOI 10.1074/jbc.273.1.459; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Neher SB, 2003, GENE DEV, V17, P1084, DOI 10.1101/gad.1078003; Neuwald AF, 1999, GENOME RES, V9, P27; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schmidt M, 1999, CURR OPIN CHEM BIOL, V3, P584, DOI 10.1016/S1367-5931(99)00013-7; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wojtyra UA, 2003, J BIOL CHEM, V278, P48981, DOI 10.1074/jbc.M307825200; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	59	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48991	48996		10.1074/jbc.M307826200	http://dx.doi.org/10.1074/jbc.M307826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	14525985	hybrid			2022-12-25	WOS:000186829000060
J	Jiang, F; Li, PF; Fornace, AJ; Nicosia, SV; Bai, WL				Jiang, F; Li, PF; Fornace, AJ; Nicosia, SV; Bai, WL			G(2)/M arrest by 1,25-dihydroxyvitamin D-3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; DECREASED DNA-REPAIR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; ANDROGEN RECEPTOR; GENE-EXPRESSION; PROSTATE-CANCER; KINASE-ACTIVITY; ANALOG EB1089; GROWTH; PHOSPHORYLATION	1,25-Dihydroxyvitamin D-3 suppresses the growth of multiple human cancer cell lines by inhibiting cell cycle progression and inducing cell death. The present study showed that 1,25-dihydroxyvitamin D-3 causes cell cycle arrest at the G(2)/M transition through p53-independent induction of GADD45 in ovarian cancer cells. Detailed analyses have established GADD45 as a primary target gene for 1,25-dihydroxyvitamin D-3. A DR3-type vitamin D response element was identified in the fourth exon of GADD45 that forms a complex with the vitamin D receptor . retinoid X receptor heterodimer in electrophoresis mobility shift assays and mediates the dose-dependent induction of luciferase activity by 1,25-dihydroxyvitamin D-3 in reporter assays. Chromatin immunoprecipitation assays have shown that the vitamin D receptor is recruited in a ligand-dependent manner to the exonic enhancer but not to the GADD45 promoter regions. In ovarian cancer cells expressing GADD45 antisense cDNA or GADD45-null mouse embryo fibroblasts, 1,25-dihydroxyvitamin D-3 failed to induce G(2)/M arrest. Taken together, these results identify GADD45 as an important mediator for the tumor-suppressing activity of 1,25-dihydroxyvitamin D-3 in human ovarian cancer cells.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Drug Discovery, Tampa, FL 33612 USA; NCI, NIH, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bai, WL (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	wbai@hsc.usf.edu	Bai, Wenlong/A-8977-2013; Fornace, Albert J/A-7407-2008	Bai, Wenlong/0000-0002-9536-0556; Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Ahonen MH, 2000, INT J CANCER, V86, P40, DOI 10.1002/(SICI)1097-0215(20000401)86:1<40::AID-IJC6>3.0.CO;2-E; Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BAI WL, 1991, ONCOGENE, V6, P1715; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; CHIDA K, 1985, CANCER RES, V45, P5426; DELUCA HF, 1990, METABOLISM, V39, P3, DOI 10.1016/0026-0495(90)90263-C; DEVASA DJ, 1999, NIH PUBLICATION, P226; DODD RC, 1983, P NATL ACAD SCI-BIOL, V80, P7538, DOI 10.1073/pnas.80.24.7538; DOKOH S, 1983, ENDOCRINOLOGY, V112, P200, DOI 10.1210/endo-112-1-200; EISMAN JA, 1989, P SOC EXP BIOL MED, V191, P221; EISMAN JA, 1987, CANCER RES, V47, P21; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feldman D, 1995, Adv Exp Med Biol, V375, P53; Gonzalez EA, 2002, KIDNEY INT, V61, P1627, DOI 10.1046/j.1523-1755.2002.00327.x; Hansen CM, 2000, CURR PHARM DESIGN, V6, P803, DOI 10.2174/1381612003400371; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JAMES SY, 1994, J ENDOCRINOL, V141, P555, DOI 10.1677/joe.0.1410555; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Johnson JA, 1996, HISTOCHEM CELL BIOL, V105, P7, DOI 10.1007/BF01450873; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; LEFKOWITZ ES, 1994, INT J EPIDEMIOL, V23, P1133, DOI 10.1093/ije/23.6.1133; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MANGELSDORF DJ, 1987, P NATL ACAD SCI USA, V84, P354, DOI 10.1073/pnas.84.2.354; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUIR CS, 1987, IARC SCI PUBLICATION, V88; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Prudencio J, 2001, J NATL CANCER I, V93, P745, DOI 10.1093/jnci/93.10.745; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; SATO T, 1982, TOHOKU J EXP MED, V138, P445, DOI 10.1620/tjem.138.445; SAUNDERS DE, 1992, GYNECOL ONCOL, V44, P131, DOI 10.1016/0090-8258(92)90028-H; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; Smith ML, 1996, ONCOGENE, V13, P2255; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WATERHOUSE J, 1976, CANC INCIDENCE 5 CON, V15; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yamamoto H, 2003, J BIOL CHEM, V278, P31756, DOI 10.1074/jbc.M304737200; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang XH, 2003, ONCOGENE, V22, P4166, DOI 10.1038/sj.onc.1206599	56	111	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48030	48040		10.1074/jbc.M308430200	http://dx.doi.org/10.1074/jbc.M308430200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14506229	hybrid			2022-12-25	WOS:000186731400082
J	Seo, YW; Shin, JN; Ko, KH; Cha, JH; Park, JY; Lee, BR; Yun, CW; Kim, YM; Seol, DW; Kim, DW; Yin, XM; Kim, TH				Seo, YW; Shin, JN; Ko, KH; Cha, JH; Park, JY; Lee, BR; Yun, CW; Kim, YM; Seol, DW; Kim, DW; Yin, XM; Kim, TH			The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; BCL-2 FAMILY; APOPTOSIS; P53; BAK; PATHWAYS; MEMBER	Genotoxic stresses stabilize the p53 tumor suppressor protein which, in turn, transactivates target genes to cause apoptosis. Although Noxa, a "BH3-only" member of the Bcl-2 family, was shown to be a target of p53-mediated transactivation and to function as a mediator of p53-dependent apoptosis through mitochondrial dysfunction, the molecular mechanism by which Noxa causes mitochondrial dysfunction is largely unknown. Here we show that two domains (BH3 domain and mitochondrial targeting domain) in Noxa are essential for the release of cytochrome c from mitochondria. Noxa-induced cytochrome c release is inhibited by permeability transition pore inhibitors such as CsA or MgCl2, and Noxa induces an ultra-structural change of mitochondria yielding "swollen" mitochondria that are unlike changes induced by tBid. This indicates that Noxa may activate the permeability transition-related pore to release cytochrome c from mitochondria into cytosol. Moreover, Bak-oligomerization, which is an essential event for tBid-induced cytochrome c release in the extrinsic death signaling pathway, is not associated with Noxa-induced cytochrome c release. This finding suggests that the pathway of Noxa-induced mitochondrial dysfunction is distinct from the one of tBid-induced mitochondrial dysfunction. Thus, we propose that there are at least two different pathways of mitochondrial dysfunction; one mediated through Noxa in response to genotoxic stresses and the other through tBid in response to death ligands.	Chosun Univ, Sch Med, Dept Biochem, Kwangju 501759, South Korea; Chonnam Natl Univ, Korea Basic Sci Inst, Gwangju Branch, Kwangju 500757, South Korea; Pukyong Natl Univ, Dept Microbiol, Pusan 608737, South Korea; Kangwon Natl Univ, Vasc Syst Res Ctr, Chunchon 200701, Kangwon Do, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02478 USA	Chosun University; Chonnam National University; Korea Basic Science Institute (KBSI); Pukyong National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; McLean Hospital	Kim, TH (corresponding author), Chosun Univ, Sch Med, Dept Biochem, Room 2205,New Med Bldg,2nd Floor,375 Seosuk Dong, Kwangju 501759, South Korea.							Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	17	101	109	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48292	48299		10.1074/jbc.M308785200	http://dx.doi.org/10.1074/jbc.M308785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	14500711	hybrid			2022-12-25	WOS:000186731400114
J	Kupershmidt, S; Yang, ICH; Hayashi, K; Wei, J; Chanthaphaychith, S; Petersen, CI; Johns, DC; George, AL; Roden, DM; Balser, JR				Kupershmidt, S; Yang, ICH; Hayashi, K; Wei, J; Chanthaphaychith, S; Petersen, CI; Johns, DC; George, AL; Roden, DM; Balser, JR			I-Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines	FASEB JOURNAL			English	Article						HERG; potassium channel; gating; pharmacology; arrhythmia; electrophysiology	RECTIFIER K+-CURRENT; LONG QT SYNDROME; OPEN-CHANNEL BLOCK; POTASSIUM CHANNEL; HERG; DOFETILIDE; CURRENTS; RECTIFICATION; ARRHYTHMIA; INACTIVATION	The cardiac potassium channel encoded by the human ether-a-go-go related gene (HERG) is blocked by a diverse array of common therapeutic compounds. Even transient exposure to such agents may provoke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals. Although the molecular and genetic factors predicting such wide variability in drug response remain unclear, known sequence variations within the coding region of HERG do not explain the adverse drug response in many cases. Although other proteins can modulate HERG function, no studies have identified protein partners capable of limiting the pharmacological sensitivity of HERG. Here we show that KCR1, a protein identified previously in rat cerebellum, is a plasma membrane-associated protein expressed at the RNA level in the human heart and can be immunoprecipitated with HERG. Functionally, KCR1 reduces the sensitivity of HERG to classic proarrhythmic HERG blockers (sotalol, quinidine, dofetilide) in both cardiac and noncardiac cell lines. We propose that KCR1, when coupled to HERG, may limit the sensitivity of HERG to proarrhythmic drug blockade and may be a rational target for modifying the proarrhythmic effects of otherwise clinically useful compounds.	Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Johns Hopkins University	Kupershmidt, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, 554 Preston Res Bldg, Nashville, TN 37232 USA.	sabina.kupershmidt@vanderbilt.edu	Kupershmidt, Sabina/AAO-5464-2021; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; 				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Fiset C, 1996, J MOL CELL CARDIOL, V28, P1085, DOI 10.1006/jmcc.1996.0100; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hoshi N, 1998, J BIOL CHEM, V273, P23080, DOI 10.1074/jbc.273.36.23080; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; RODEN DM, 1993, AM J CARDIOL, V72, pB44, DOI 10.1016/0002-9149(93)90040-J; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Teschemacher AG, 1999, BRIT J PHARMACOL, V128, P479, DOI 10.1038/sj.bjp.0702800; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; Weinshenker D, 1999, J NEUROSCI, V19, P9831; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Yang T, 1997, CIRC RES, V80, P782; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	42	40	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2263	+		10.1096/fj.02-1057fje	http://dx.doi.org/10.1096/fj.02-1057fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525949				2022-12-25	WOS:000186343300005
J	Luquet, S; Lopez-Soriano, J; Holst, D; Fredenrich, A; Melki, J; Rassoulzadegan, M; Grimaldi, PA				Luquet, S; Lopez-Soriano, J; Holst, D; Fredenrich, A; Melki, J; Rassoulzadegan, M; Grimaldi, PA			Peroxisome proliferator-activated receptor delta controls muscle development and oxydative capability	FASEB JOURNAL			English	Article						muscle development; lipid metabolism; hyperplasia; fiber typing; Cre-Lox transgenesis	SKELETAL-MUSCLE; PPAR-DELTA; TRANSGENE EXPRESSION; FATTY-ACIDS; STEM-CELLS; MICE; GAMMA; ADIPOSE; GROWTH; MOUSE	Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors exerting several functions in development and metabolism. The physiological functions of PPARdelta remain elusive. By using a CRE-Lox recombination approach, we generated an animal model for muscle-specific PPARdelta overexpression to investigate the role of PPARdelta in this tissue. Muscle-specific PPARdelta overexpression results in a profound change in fiber composition due to hyperplasia and/or shift to more oxidative fiber and, as a consequence, leads to the increase of both enzymatic activities and genes implicated in oxidative metabolism. These changes in muscle are accompanied by a reduction of body fat mass, mainly due to a large reduction of adipose cell size. Furthermore, we demonstrate that endurance exercise promotes an accumulation of PPARdelta protein in muscle of wild-type animals. Collectively, these results suggest that PPARdelta plays an important role in muscle development and adaptive response to environmental changes, such as training exercise. They strongly support the idea that activation of PPARdelta could be beneficial in prevention of metabolic disorders, such as obesity or type 2 diabetes.	Univ Nice, Ctr Biochim, INSERM, U470, F-06108 Nice 2, France; Hop Louis Pasteur, Serv Diabetol Endocrinol, F-06002 Nice, France; Genopole, INSERM, EMI 9913, F-91057 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Genopole; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Grimaldi, PA (corresponding author), Univ Nice, Ctr Biochim, INSERM, U470, Parc Valrose, F-06108 Nice 2, France.	grimaldi@unice.fr	Luquet, serge/AAT-1809-2021; Rassoulzadegan, Minoo/O-7939-2016; Lopez-Soriano, Joaquin/AAB-7459-2019	Luquet, serge/0000-0001-8668-6645; Lopez-Soriano, Joaquin/0000-0002-5374-2222				Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Giuili G, 2002, EMBO REP, V3, P753, DOI 10.1093/embo-reports/kvf149; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; ISHIHARA A, 1991, EUR J APPL PHYSIOL, V62, P211, DOI 10.1007/BF00643744; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Kelley G, 1996, J APPL PHYSIOL, V81, P1584, DOI 10.1152/jappl.1996.81.4.1584; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; McCall GE, 1996, J APPL PHYSIOL, V81, P2004, DOI 10.1152/jappl.1996.81.5.2004; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SEELBACH JD, 1985, INT J OBESITY, V9, P11; Spiegelman BM, 2000, INT J OBESITY, V24, pS8, DOI 10.1038/sj.ijo.0801492; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200	38	413	435	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2299	+		10.1096/fj.03-0269fje	http://dx.doi.org/10.1096/fj.03-0269fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525942				2022-12-25	WOS:000186343300012
